<SEC-DOCUMENT>0000950170-24-026275.txt : 20240305
<SEC-HEADER>0000950170-24-026275.hdr.sgml : 20240305
<ACCEPTANCE-DATETIME>20240305171717
ACCESSION NUMBER:		0000950170-24-026275
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		100
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240305
DATE AS OF CHANGE:		20240305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IO Biotech, Inc.
		CENTRAL INDEX KEY:			0001865494
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				870909276
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41008
		FILM NUMBER:		24722300

	BUSINESS ADDRESS:	
		STREET 1:		OLE MAALOES VEH 3
		CITY:			COPENHAGEN
		STATE:			G7
		ZIP:			2200
		BUSINESS PHONE:		4570702980

	MAIL ADDRESS:	
		STREET 1:		OLE MAALOES VEH 3
		CITY:			COPENHAGEN
		STATE:			G7
		ZIP:			2200
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>iobt-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:iobt="http://www.iobiotech.com/20231231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_8d9f799b-97bc-4727-8d6f-a3a18ad85239" name="dei:DocumentFiscalPeriodFocus" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07">FY</ix:nonNumeric><ix:nonNumeric id="F_a5359254-18bb-4a55-aae0-90d76b590981" name="dei:AmendmentFlag" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_52e49ca8-9bcd-46f3-b15d-915a079cf977" name="dei:EntityCentralIndexKey" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07">0001865494</ix:nonNumeric><ix:nonFraction id="F_522691ef-a049-4d10-a8f6-eb2141bf9945" name="us-gaap:CommitmentsAndContingencies" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_5e0b0588-b270-4242-937d-c044a120045f" name="us-gaap:CommitmentsAndContingencies" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_c1641a20-794d-4ed3-aacb-528b63397b4c" name="us-gaap:PreferredStockValue" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_bcd4aa41-7f61-41fa-affb-30d04105e5e8" name="us-gaap:PreferredStockValue" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_50d1f921-ea74-4d65-b53b-2d642b4f270d" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Member</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="iobt-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_f4208fa4-bfe6-48ee-94c0-37e910003209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-09</xbrli:startDate><xbrli:endDate>2023-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0cd7c29-89c5-48ee-ae9e-0dbf0ed84a0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc58b312-a405-4ae4-8b50-2ef63fe4fbd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:LaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cfd6318-0a41-4064-a4cb-7e43fe8305a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b417c094-4b8b-413a-b777-f37fa824d616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1dcc1f3e-ab3f-4d97-8c1b-44559a31ab42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2537fee5-7e0b-4dba-8a7b-1ae868729ba1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49c77671-362e-4825-93e3-6d0010545188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbedcb5d-67e0-47f1-96ac-c9bcc05daf23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0307f33c-16a4-4f72-98f6-13168e29e650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-09</xbrli:startDate><xbrli:endDate>2023-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f69509c-a54b-452b-9c95-a1abe33fe007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:OfficeAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f734c8a-b5ea-4a27-879c-88db0c526af2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:OfficeAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37d816e8-ef70-4e8e-b59e-b1a42f867be6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8dd0b70-be88-4ed9-9abb-fff49a8e9151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_921dd2b2-b1d9-4630-914d-9162f5d60817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ea23d1e-bc0a-42c8-afab-71532c2b7804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8a83503-acc7-4b7b-80a3-5d4810b2d5de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iobt:PreferredClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57eb6f8c-679a-491b-8e02-004bcdd10820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1bf34e5-9771-45f8-8bae-3cab72620d3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:OfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4753ff1-8839-464e-bba4-852e1ac3dc55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DividendsAxis">us-gaap:DividendPaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f7c3011-7c33-440c-af08-6ace8d509cd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2021-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ae0c7b5-ef8e-4cb0-93ba-4ebe49f60bd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iobt:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57a8bc27-67ad-49ea-8c7d-a4bc7bcdaabb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe4a2a0a-b6ee-4598-80ca-db97232d35b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43f3828a-2a64-44ee-9ffc-49729d49c629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7a68159-256a-4ce2-b281-a534093c1329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iobt:AtTheMarketEquityProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b46bf404-a97b-4035-a273-403e9d7a9848"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eff12647-8a9c-4060-a740-40ce3f445548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61743499-6fd4-4641-8e5f-157d373726ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75385bc1-6f5b-43da-a2b7-ac643558b468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4610fd3b-ca44-4e94-a210-d0913cb10978"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58193eaa-01f7-4f8a-933b-82502af9abe4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_589be980-c3a1-445b-9010-4a1c2db1e2ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdcfe8ca-1864-4dc3-9e85-2db43b36cb88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1089e4d9-f1b0-4539-bd02-0c5b3cebf7f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-07</xbrli:startDate><xbrli:endDate>2023-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08166775-fe5a-4472-96b3-587d9d04a349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iobt:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b343bb6c-f4f5-4b19-844e-c92494b10a7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cca131d2-c4bc-4848-b12f-0a7cefd61f16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_229bed5d-8df9-47a3-bf23-b8454739ccb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0939c61-54dc-4cc6-bd3a-04cc2fcd2c13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ccc9ec90-8753-446d-ad46-4614b4157e4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iobt:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea391396-42d3-4eff-9bdc-69880686eb48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77688354-ad09-4f13-a478-c216dd6f48f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0c8c506-94c5-4204-b3e9-4087e11e4d77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58b5fcb9-88bf-4c8f-a0dc-fb732ca6c6a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95e6310f-8da5-48b8-9242-a4b89a5ea523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85d6429e-66de-40ef-8389-98da77aaac70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_735c9fc1-57ba-400b-99d6-3730bae07801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed65f1e2-5595-4174-b58c-577f2a1fce62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1c118ba-3d68-42c8-9af6-0389748a393e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6fcc15a-463e-4377-ad07-b2311c2c2577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_deb3bb46-923f-471e-bc2a-d3f58a8d1640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65b6ebb1-4040-4de5-b896-f3c903f4135b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a3ed7cd-93dc-4db4-bb66-a7f11ce29791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aba91903-9247-448c-a45a-f748af1aed15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">iobt:PeriodExpireInTwentyTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7f56205-a6d1-42a7-bef6-62ddf1cf7159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DividendsAxis">us-gaap:DividendDeclaredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec32ec8b-699d-4395-8839-904cf311de78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:OfficeAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_605c651a-ab13-4d27-8446-969fb0785085"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_785d9f06-9d6a-47bd-8cd0-ef70f3e4eef7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2af36d65-e5e9-4e90-8479-0c3a9a9006ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_546c8f6d-7b20-49cd-8a0e-b394348d36fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8883698-bb05-40fe-9155-b8dada03facc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandTwentyThreeInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce55bd70-3918-4ae0-9cad-0dfde777548f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a179b419-8f22-455d-a4ab-2a0aa92c018a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2898211-1ef9-46ec-9a67-2298c6e5e1c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-09</xbrli:startDate><xbrli:endDate>2023-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f628d94-953f-4311-9f9c-e89296efa0d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4193a798-b6e0-487a-bf56-e3158437f049"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09c04cd1-1667-4969-a0bf-6219d9198637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4842f3fa-8b43-4d85-86bd-f8d28ee08613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_203b870a-e8de-4c48-bb69-1f143a5d1919"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41282bac-d510-44e1-bcd8-e9ad005dc1b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6976c5c1-5909-47d1-9d43-69c889de3121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iobt:PreferredClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5265fdb7-64e2-41ae-bedb-28fa9d99cc76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-09</xbrli:startDate><xbrli:endDate>2023-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83696999-4b34-4804-9e55-9bcb95f224d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a27d25f7-5479-49f8-a811-d80dec1dc3d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62f128f9-8dcd-483d-9972-ffa3ab6dd713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_204fa06a-ebbb-41fd-82ba-760913723921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86125bde-a241-4410-b61b-886b4c205d56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iobt:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4aa5700b-45ac-4ba7-aecb-189135584209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bfe21b8-29be-4452-8c6e-25ec17762b3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eaf8786d-c5b6-4a4a-8524-1e92c7607db8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2021-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7888a195-a9c8-438b-8292-c9c9a460c8d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-07</xbrli:startDate><xbrli:endDate>2023-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93ef2e83-0050-441a-9dc6-7635a9140a67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">iobt:PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75c24bfc-711a-4d8f-a9f1-617a36085040"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c457cad7-3e0c-4a59-b4de-aa28ef642dbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1bdcb713-0037-4abc-ba55-93260da29f6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">iobt:PeriodTwentyTwentyThroughTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_856ab70f-a3ef-4cca-b917-88f71a19dda0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6520b4d-f760-4dd3-8633-eeeaeb10c4af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_adf457e8-e0ad-4c0c-aaa7-41e091effa59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1525e770-dbb6-4a8a-b414-dae67b1c0c72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05adc53f-1ee4-4206-b227-537d28cde4b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af6f9339-383a-4c92-83a8-eb2b5990df31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d68d18d7-93d7-49d5-ac79-3f37468692f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77b4e90b-4f57-4362-beca-0e8dcbcfba19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a8a956b-e82c-4de3-b66b-515c278c6057"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2bad730b-2375-4c64-b7fb-4fb30c1b1ef9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd5861a4-c39b-4313-99f5-dd1a1dc0195b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-09</xbrli:startDate><xbrli:endDate>2023-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7201268-1a27-4850-b9eb-b381cbd53051"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a06c72c9-9013-4145-a984-c7a878870eb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-09</xbrli:startDate><xbrli:endDate>2023-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a5e0744-7a0e-42a8-87f6-2990329c4ad7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b50e362-cf80-4463-9c3a-8766edfaa5cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d4b831b-94cf-4ac9-aae8-23f925e98a73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Lease"><xbrli:measure>iobt:Lease</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>iobt:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="U_DKK"><xbrli:measure>iso4217:DKK</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cbe2983a-89bc-455e-b4e6-084a64f2b15f" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_0d94e257-55b6-4526-935c-259e8abf4b58" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c11307dc-e7fd-4847-9f6a-4b28c0762ecd" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a285ca7b-57fd-4839-8b3b-a935d6bf1320" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f927126a-4ca2-4619-8653-77144b43f59c" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_fc005415-4a02-4d97-93a8-069425a956e4" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25c03e7e-1147-4683-8bd2-3de3b9b706e8" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-41008</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_64db9e25-0013-4512-a89b-347679563501" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;min-width:fit-content;">IO BIOTECH, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f8966c0f-87b3-4cd3-ab1f-73667617016e" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_36d54fd8-a985-44c6-9346-1772eb023353" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">87-0909276</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5912c1bb-2d7b-4c40-9e53-d5f8c3b6abb3" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Ole Maal&#248;es Vej 3</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6a65f8c2-1f11-40c8-9e1f-dc96f1e373b4" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">DK-2200</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_c755f249-d301-4730-be7a-6784256381f5" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Copenhagen N</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_42f9bcc3-56cc-4248-9e83-451fecd8b6dc" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Denmark</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">NA</span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7345082b-78c9-4a93-8f12-793d9acae192" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">+45</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9bb64d2-b51f-44c5-8c5d-18883dce2c01" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">7070 2980</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40%;"/>
    <td style="width:1%;"/>
    <td style="width:16%;"/>
    <td style="width:1%;"/>
    <td style="width:42%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_dc9b1de5-1df6-4414-94df-b6256530b0c0" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_9ba12d4a-c1a7-4c64-8d2b-0c11a825e2ba" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">IOBT</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_d2021763-5d3f-4cc4-be24-e8227718b256" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">None</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744;     </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67c5767e-bf1e-450c-bea2-dab242d74507" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &#9744;     </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70288302-dd85-4135-8796-62e1843f2f36" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_52db3cc7-3b17-46fb-b70c-c3ef13848972" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;     No &#9744;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2ef0c796-320f-40cf-8c37-b5bff887c308" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;     No &#9744;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.116%;"/>
    <td style="width:1%;"/>
    <td style="width:55.649%;"/>
    <td style="width:1%;"/>
    <td style="width:20.316%;"/>
    <td style="width:1%;"/>
    <td style="width:1.92%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_e77f18c5-a6bc-4720-81d4-3129ead0ff0a" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_429cad14-acde-47f5-af88-3c90f4f88773" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_61b35504-9a27-4b5a-9dfb-3b379eb0514a" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0508648-4b93-4b16-a103-efc324e55dc2" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d882888-20f2-47e7-9f3a-c2e2ed49cf9a" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c98e3421-6651-4638-8107-f65716fd141a" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  &#9744;<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744;     No </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0afead0-9ab9-4b0a-bd8d-a06915b4668b" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2023, the last day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abf25739-a82c-4f09-9f16-2cc925df2438" contextRef="C_eff12647-8a9c-4060-a740-40ce3f445548" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">31.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">The number of shares of Registrant&#8217;s Common Stock, par value $0.001 per share, outstanding as of February 28, 2024 was </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b8c1b9a-d8a2-4c4e-9d64-d85e27418239" contextRef="C_9b50e362-cf80-4463-9c3a-8766edfaa5cf" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_7ad46f1f-5ea4-49af-837a-705447d57347" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Portions of the registrant&#8217;s proxy statement relating to its 2024 Annual Meeting of Stockholders have been incorporated by reference herein in response to Part III, as specifically set forth in Part III.</span></p></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11%;"/>
    <td style="width:82%;"/>
    <td style="width:7%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART I</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity Risk Management, Strategy and Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1D.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1c_10b51"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Section 16 Officers and Directors Rule 10b5-1 Plans</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART II</span></a></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#market_for_registrants_common_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">(Reserved)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#management_discussion_analysis"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">126</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#quantitative_and_qualitative_disclosure"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#financial_statements_and_supplymentary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">139</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#changes_and_disagreement_accountants"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">161</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">162</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART III</span></a></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">164</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#directors_executive_officers_corporate"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">164</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">164</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#security_ownership_of_certain_beneficial"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">164</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#certain_relationship_and_related"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">164</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#principal_accounting_fees_and_services"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">164</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">165</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibits_financial_statements_schedules"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">165</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0.01in;text-indent:12pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#form_10_k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">166</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">i</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of the Material and Other Risks Associated with Our Business</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is subject to numerous material and other risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of our product candidates are in clinical development or in preclinical development. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance in clinical trials, including IO102-IO103, may not achieve favorable results in later clinical trials, if any, or receive marketing approval.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have experienced, and may in the future experience, delays or difficulties in clinical trial site activation and the enrollment and/or retention of patients in clinical trials, which could delay or prevent our receipt of necessary regulatory approvals.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent, delay or limit the scope of regulatory approval of our product candidates, limit their commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success and commercial opportunity largely depends on the success of our limited number of product candidates. If any of these candidates fail in clinical trials or are not approved for commercialization, our ability to generate revenue and achieve profitability could be impacted if we fail to develop additional product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third-party contract manufacturing organizations (CMOs) to manufacture our product candidates, which can be complex. Our CMOs may encounter difficulties in production, particularly with respect to process development or scale-up of our product candidates. If our CMOs encounter difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will need to obtain substantial additional funding to complete the development and commercialization of our product candidates. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than we do.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Public health emergencies, geopolitical conflicts or other significant domestic and international events could have a material adverse impact on our business, financial condition and results of operations, including the execution of our clinical trials.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The proposals to revise the European Union (EU) legislation on pharmaceutical products could lead to uncertainties over the regulatory framework that will be applicable to medicinal products in the EU, including orphan and pediatric medicinal products. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The price of our common stock may be volatile or may decline regardless of our operating performance and you may lose all or part of your investment.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to a variety of privacy and data security laws, and our failure to comply with them could harm our business.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our internal information technology systems, or those of our third-party contract research organizations (CROs) or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our product candidates&#8217; development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business. Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this Annual Report on Form 10-K, including statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;could,&#8221; &#8220;intends,&#8221; &#8220;target,&#8221; &#8220;projects,&#8221; &#8220;contemplates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this Annual Report on Form 10-K are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of risks, uncertainties and assumptions described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Some of the key factors that could cause actual results to differ from our expectations include:<br/><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing, progress and the success of our clinical trials of IO102-IO103, IO112, IO170 and any other product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether the results of our trials will be sufficient to support domestic or foreign regulatory approvals for IO102-IO103, IO112, IO170 or any other product candidates we may develop;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory actions with respect to our product candidates or our competitors&#8217; products and product candidates;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain, including on an expedited basis, and maintain regulatory approval of IO102-IO103, IO112, IO170 or any other product candidates we may develop;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the outcomes of our preclinical studies;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to enroll patients in our clinical trials at the pace that we project;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and conduct our clinical programs on our expected timelines;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of development of any of our product candidates or clinical development programs;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectation about the period of time over which our existing capital resources will be sufficient to fund our operating expenses and capital expenditures;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential attributes and clinical benefits of the use of IO102-IO103, IO112, IO170 or any other product candidate, if approved by the relevant regulatory bodies;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to successfully commercialize IO102-IO103, IO112, IO170 or any other product candidates we may identify and pursue, if approved by the relevant regulatory bodies;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to successfully establish or maintain collaborations or strategic relationships for our product candidates;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the rate and degree of market acceptance of IO102-IO103, IO112, IO170 or any other product candidates we may identify and pursue;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain orphan drug designation, Breakthrough Therapy Designation (BTD), accelerated or other approval for any of our product candidates we may identify;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding government and third-party payor coverage and reimbursement;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iv</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to manufacture, including through CMOs, IO102-IO103, IO112, IO170 or any other product candidate in conformity with the Food and Drug Administration's (FDA&#8217;s) requirements and the requirements of other applicable regulatory authorities;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to successfully build a sales force and commercial infrastructure;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to compete with companies currently producing or engaged in the clinical development of treatments for the disease indications that we pursue and treatment modalities that we develop;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reliance on third parties to conduct our clinical trials;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reliance on third-party CMOs to manufacture and supply our product candidates for us;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to retain and recruit key personnel;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain intellectual property protection for IO102-IO103, IO112, IO170 or any other product candidates we may identify and pursue;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the time during which we will be an emerging growth company (EGC) under the Jumpstart Our Business Startups Act (JOBS Act);</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our financial performance;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of the COVID-19 pandemic, including mitigation efforts and economic effects, and other significant public health emergencies or geopolitical events on any of the foregoing or any other aspects of our business operations;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of laws and regulations, including legislative developments; and</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments and projections relating to our competitors or our industry.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These statements relate to future events or to future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those set forth in Part II, Item 1A - &#8220;Risk Factors&#8221; below and those described elsewhere in this Annual Report on Form 10-K. Any forward-looking statement in this Annual Report on Form 10-K reflects our current view with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, industry, and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K also contains estimates, projections, and other information concerning our industry, our business, and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates, and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections, or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by third parties, industry, medical and general publications, government data, and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except where the context otherwise requires, in this Annual Report on Form 10-K, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;IO Biotech,&#8221; and &#8220;the Company&#8221; refer to IO Biotech, Inc. and, where appropriate, its consolidated subsidiaries.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">v</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Trademarks<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have applied for various trademarks that we use in connection with the operation of our business. This Annual Report on Form 10-K includes trademarks, service marks, and trade names owned by us or other companies. All trademarks, service marks, and trade names included in this Annual Report on Form 10-K are the property of their respective owners. Solely for convenience, the trademarks and trade names in this report may be referred to without the &#174; and &#153; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">vi</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RT I</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Bu</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">siness.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on our T-win&#174; platform. Our T-win product candidates are designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating the activation and expansion of T cells against IDO+ and/or PD-L1+ target positive cells, resulting in the modulation of the TME, creating a more pro-inflammatory environment, and the potentiation of anti-tumor activity by unleashing the tumor killing by effector T cells. We believe this could represent a paradigm shift in the management of cancer and that our product candidates have the potential to advance the oncology treatment paradigm, amplifying treatment effects across the spectrum of melanoma and other tumor types. Our lead therapeutic cancer vaccine candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by indoleamine 2,3-dioxygenase (IDO) and programmed death ligand 1 (PD-L1). In a single-arm Phase 1/2 clinical trial of 30 patients with metastatic melanoma, IO102-IO103 in combination with nivolumab, an anti-programmed cell death 1 (PD-1) checkpoint inhibitor, demonstrated proof of concept by increasing the overall response rate (ORR) of what is reported with an anti-PD-1 antibody alone. The combination induced meaningful tumor regression and achieved rapid, deep and durable responses with a favorable tolerability profile without adding systemic toxicity to what is seen with an anti-PD-1 monotherapy in this patient population. Safety was the primary endpoint of this trial, immune response was the secondary endpoint and clinical efficacy was the tertiary endpoint. The clinical efficacy endpoints in this trial included objective response (OR), progression free survival (PFS) and overall survival (OS). In this trial, we observed a confirmed ORR of 73% as per RECIST 1.1, a complete response rate (CRR) of 50% and 25.5 months of PFS. Based on these results, IO102-IO103, in combination with pembrolizumab, was granted BTD by the FDA for treatment of unresectable/metastatic melanoma and we initiated a global Phase 3 trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enrolled the first patient in a potentially registrational Phase 3 trial for IO102-IO103 in combination with pembrolizumab as a potential first-line treatment in advanced melanoma, the IOB-013/KN-D18 trial, in May of 2022. We randomized 225 patients in June 2023 and fully enrolled the trial in November 2023. On June 14, 2023, we announced that we amended the protocol and increased the number of patients to be enrolled in the Phase 3 trial from original 300 patients to revised 380 patients, which could potentially accelerate the time to reach the primary endpoint of PFS, which is an event-based driven analysis and will be assessed when 226 events (progression or death) are registered in the trial. The primary endpoint is powered at 89% to detect a hazard ratio of 0.65. The Phase 3 trial protocol has a planned interim analysis of ORR to be conducted 12 months after 225 patients have been randomized; if the investigational arm demonstrates a highly statistically significant improvement in ORR compared to the control arm, with a p-value&lt;0.005, then the interim analysis could allow for potential submission of a Biologics License Application (BLA) for accelerated approval in the United States. When we designed the interim analysis, we assumed that patients treated with IO102-IO103 in combination with pembrolizumab would show an ~18-point improvement in ORR compared to the patients treated with pembrolizumab alone. The trial design and discussions with FDA are aimed at potentially pursuing accelerated approval, if the trial data are favorable, based on the interim analysis of ORR, supported by other data. If the data are supportive, we also plan to file a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) based on the primary endpoint of PFS after the data are available, which is expected to occur in the second half of 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our T-win platform is a novel approach to cancer vaccines designed to activate pre-existing T cells to target immunosuppressive mechanisms. Our T-win product candidates are designed to employ a dual mechanism of action: (1) direct killing of immunosuppressive cells, including both tumor cells and genetically stable cells in the TME, that express IDO and/or PD-L1 (in the case of IO102-IO103), Arginase 1 (in the case of IO112) or TGF&#946;1 (in the case of IO170), and (2) modulation of the TME into a more pro-inflammatory, anti-tumor environment. Our T-win platform is built upon our team&#8217;s deep understanding of both the TME and a tumor&#8217;s ability to evade surveillance and destruction by the immune system. Our approach is in contrast to previous methods that have sought to either block singular immunosuppressive pathways or to direct the immune system against specific identified antigens expressed by tumor cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing a pipeline of product candidates that leverage our T-win platform to address targets within the TME. In addition to melanoma, we are currently evaluating IO102-IO103 in multiple solid tumor indications to potentially expand the market opportunity for IO102-IO103. We are also focusing on additional targets that play key roles in immunosuppression and that are expressed in a broad range of solid tumors. Our current pipeline of product candidates and expected upcoming milestones are summarized in the tables below.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_0.jpg" alt="img134051827_0.jpg" style="width:672px;height:334px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:1.067%;text-indent:-3.487%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">* In combination with pembrolizumab</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:1.067%;text-indent:-3.487%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">NSCLC = non-small cell lung cancer, SCCHN = squamous cell carcinoma of the head and neck</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lead product candidate, IO102-IO103, combines our two fully-owned, novel immune-modulating vaccines, IO102 and IO103, which are designed to target IDO+ and PD-L1+ target cells, respectively. IDO and PD-L1 are often dysregulated and over-expressed in a wide range of solid tumors, and result in the inhibition of the body&#8217;s natural pro-inflammatory anti-tumor response within the TME. IO102-IO103 is designed to employ our novel dual mechanism of action approach. This is in contrast to previous approaches which have sought to block singular immunosuppressive pathways or to direct the immune system against specific identified antigens expressed by tumor cells. By combining IO102 and IO103 in a single treatment regimen, we also aim to provide a synergistic therapeutic effect on tumors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 14, 2020, the FDA granted us BTD for the IO102-IO103 cancer vaccine in combination with pembrolizumab for the treatment of patients with unresectable or metastatic melanoma based on data from the Phase 1/2 clinical trial, MM1636. A BTD enables us to solicit more frequent and intensive guidance from the FDA as to how to conduct an efficient development program for IO102-IO103. The MM1636 trial was an investigator-initiated, single-arm Phase 1/2 trial of 30 anti PD-1/PD-L1 na&#239;ve patients with metastatic melanoma receiving IO102-IO103 and nivolumab, an anti-PD-1 monoclonal antibody. In this trial, investigators initially observed an ORR of 80% (24 out of 30 patients) and confirmed best ORR of 73% based on RECIST 1.1. 50% of patients achieved a complete response (CR), or complete elimination of their tumors. Overall tolerability of the combination was favorable, with no significant added systemic toxicity from what has been reported with nivolumab alone. While a total of five patients (17%) experienced a treatment-related high-grade adverse event (grade 3-5), and 17% discontinued treatment with both nivolumab and IO102-IO103, data from this trial suggests a manageable tolerability profile for patients. In addition, we have observed treatment-induced infiltration of CD3+/CD8+ T cells into the tumor site in responding patients and detected IO102 and/or IO103-specific T cells in tumors after treatment in correlative biomarker data where this was analyzed. Consistent with the earlier reported data, with an additional 15 months of patient follow-up, results from the January 5, 2023 data cut as published in the May 2023 Journal for ImmunoTherapy of Cancer from this study continue to be encouraging. As of that data cut-off date, 30 PD-1 na&#239;ve patients were enrolled with a minimum follow-up time of 49.8 months. Median OS was not reached, median PFS was 25.5 months, and 50% of patients (15/30) achieved a CR, or complete disappearance of their tumors, and the ORR was 80% (73% confirmed ORR per RECIST 1.1). Patients who were anti-PD-1 antibody therapy resistant and enrolled in cohort B in this study had no response to therapy, which we believe shows that our vaccine works best in front-line metastatic melanoma patients, as we expected in this setting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, we fully enrolled a Phase 3 potentially registrational trial for IO102-IO103, the IOB-013/KN-D18 trial, in combination with pembrolizumab in anti PD-1/PD-L1 treatment na&#239;ve patients with unresectable or metastatic melanoma. While the MM1636 trial investigated IO102-IO103 in combination with nivolumab, we have made the commercial decision to investigate IO102-IO103 in combination with pembrolizumab in the Phase 3 trial. Nivolumab and pembrolizumab are both immunoglobulan G4 (IgG4) subclass antibodies that target the PD-1 receptor. In a comparative data analysis by Moser (Annals of Oncology 2020), researchers found no difference between the effectiveness of frontline pembrolizumab and nivolumab in patients with advanced melanoma. The Phase 3 trial also includes a concurrent evaluation of the initial participants to allow for an assessment of safety (a safety run-in) for the combination of IO102-IO103 and pembrolizumab. The pembrolizumab for this trial is being supplied by Merck pursuant to a Clinical Trial Collaboration and Supply Agreement that we entered into in September 2021. The independent data monitoring committee (IDMC) for the IOB-013/KN-D18 trial convened its third meeting in September 2023 and the IDMC recommended that the trial continue without modifications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also investigating the IO102-IO103 cancer vaccine in several other solid tumor indications. We are conducting a Phase 2 basket trial, the IOB-022 trial (KN-D38), which will enable us to investigate multiple first-line solid tumor indications treatment na&#239;ve patients for metastatic disease. This basket trial is designed to investigate the safety and efficacy of IO102-IO103 in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC), adenocarcinoma histology, with PD-L1 TPS &#8805; 50% (cohort A) or recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) with CPS &#8805; 20 (cohort B). We initiated the IOB-022 trial in April 2022 and as of August 21, 2023, 42 patients were enrolled (28 in cohort A and 14 in cohort B). Consistent with the earlier reported data, preliminary results from the IOB-022/KN-D38 Phase 1/2 study of IO102-IO103 in combination with pembrolizumab in metastatic NSCLC or recurrent and/or metastatic SCCHN continue to be encouraging as presented at the European Society for Medical Oncology (ESMO) conference held in October 2023. Of the 28 patients enrolled in cohort A, 18 were efficacy evaluable per protocol having received at least two full cycles of treatment. Among the 18 evaluable patients, 10 patients had a partial response as their best overall response while 5 had stable disease and 3 patients had progressive disease. Of the 14 patients enrolled in cohort B, 6 were efficacy evaluable per protocol having received at least two full cycles of treatment. Among the 6 evaluable patients, 3 patients had a partial response as their best overall response while 3 patients had progressive disease. The safety profile observed to date in this study is consistent with prior clinical experience with IO102-IO103.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to first-line cancer indications, we have initiated a trial to investigate IO102-IO103 in combination with pembrolizumab in a perioperative setting and used before or after surgery as a neo-adjuvant/adjuvant therapy. In April 2023, the FDA cleared the Company&#8217;s Investigational New Drug (IND) application for the evaluation of IO102-IO103 in combination with pembrolizumab, given before (neo-adjuvant) and after (adjuvant) surgery in patients with resectable melanoma and squamous cell carcinoma of the head and neck, the IOB-032 trial (PN-E40). We anticipate that the study will enroll approximately 15 patients with melanoma and 15 patients with SCCHN, each of whom will be a candidate for surgical resection with curative intent and will not have experienced prior systemic therapy for the tumor under study. We expect that patients entering the study will begin neoadjuvant treatment 4-9 weeks prior to surgery for their respective tumor indication. During the 4-9 week neoadjuvant period, patients will receive IO102-IO103 in combination with pembrolizumab every 3 weeks (Q3W) for 3 cycles (melanoma) or 2-3 cycles (SCCHN). After patients recover from surgery, they will receive adjuvant treatment with IO102-IO103 in combination with pembrolizumab Q3W for up to 15 cycles. The primary endpoint will be major pathologic response (MPR) in the resected tumor tissue after neoadjuvant treatment; secondary endpoints will be pathological CR and ORR; and other endpoints will be disease-free survival (DFS), event-free survival (EFS), and safety. We announced in a press release issued on December 21, 2023 that the first patient in the IOB-032 trial was enrolled and dosed. In addition, we also filed a protocol amendment with the FDA in December 2023 to initiate enrollment of 30 new patients with resectable melanoma in a randomized cohort C study in the IOB-032 trial. Patients in cohort C will be randomized 1:1 to receive the neoadjuvant treatment of either IO102-IO103 in combination with pembrolizumab or pembrolizumab alone, and will continue with the same regimen in the post-surgery phase. We are currently awaiting response from the FDA and, if the amendment is approved, we project that we will commence with the amended protocol in the second quarter of 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our development of the IO102-IO103 combination is based on our prior separate development of IO102 and IO103. IO102 is our fully owned novel product candidate containing a single IDO-derived peptide sequence designed to engage and activate IDO-specific human T cells. IDO small molecule inhibitors have shown clinical potential in combination with PD-1 antibodies in early clinical trials, but have not been able to demonstrate the same level of efficacy in later-stage clinical trials. Our Phase 1 non-randomized trial of IO101, our first-generation IDO therapy, in NSCLC resulted in proof of concept for our approach, with 47% of patients displaying clinical benefit and an OS of 26 months in the treatment arm compared to 8 months in the group receiving standard of care. There were no grade 3 or higher adverse events (AEs).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IO112 is our fully owned, novel product candidate containing a single Arginase 1-derived peptide designed to engage and activate Arginase 1-specific human T cells. IO112 is designed to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells (MDSCs) including colorectal, breast, prostate and pancreatic and ovarian cancers. Arginase overexpression is a well-documented tumor escape mechanism. IO112 was tested in a single arm first-in-human Phase 1 trial in patients with Arginase-positive solid tumors conducted in an investigator-initiated trial at the University of Copenhagen. We plan to continue IND-enabling activities for IO112 in 2024 and expect to initiate an IND filing in 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to IO102, IO103 and IO112, we are evaluating additional product candidates that we believe have potential for use in solid tumors. All our compounds in preclinical development are designed to target well-documented immunosuppressive molecules that are known to be overexpressed in the TME across a wide range of tumors. These targets provide additional opportunities across multiple cancer indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that targeting transforming growth factor beta 1 (TGF&#946;1) expressing cells in the TME via a vaccine approach presents a novel and attractive way to modulate the pathway and drive therapeutic benefit in the cancer setting. We are developing and characterizing TGF&#946;1-selective peptide vaccines capable of inducing strong immune responses. Preliminary evidence in mouse models showed that treatment with a TGF&#946;1 vaccine drives T cell infiltration in the TME and might promote in vivo targeted cell killing. We are currently conducting further experimental work to elucidate the cellular and molecular mechanisms of a TGF&#946;1 vaccine to support further development of a TGF&#946;1 vaccine (IO170) to modulate the TME for therapeutic benefit in a wide range of cancer indications. We plan to continue pre-clinical studies for IO170 in 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To achieve our goals, we aim to leverage our T-win&#174; platform to transform cancer treatments by creating a broad portfolio of cancer vaccines focused on targets within the TME.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The key elements of our strategy are to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Advance our lead product candidate, IO102-IO103, toward approval in combination with anti-PD-1 therapy in first-line treatment of advanced melanoma. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were granted BTD by the FDA based on a confirmed ORR of 73% as per RECIST and CRR of 50% in MM1636, the Phase 1/2 clinical trial of IO102-IO103 in combination with nivolumab in first-line treatment of patients with melanoma. We enrolled the first patient in the IOB-013/KN-D18 trial in May of 2022, randomized 225 patients as of June 2023, at which time we also increased the total number of patients to be enrolled to 380 patients, and subsequently fully enrolled and randomized the trial in November 2023. The Phase 3 trial protocol has a planned interim analysis of ORR 12 months after 225 patients have been randomized. The trial design and discussions with the FDA are aimed at pursuing accelerated approval in the event the investigational arm demonstrates a highly statistically significant improvement in ORR compared to the control arm, with a p-value&lt;0.005, as further supported by other data. In addition, if the data is supportive, we also plan to file an MAA with the EMA based on the primary endpoint of PFS, once data related to this endpoint is available, which we expect in the second half of 2025;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Broaden clinical development of IO102-IO103 into other solid tumor settings through basket trials in the first line metastatic and neo-adjuvant / adjuvant treatment settings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We are executing a Phase 2 basket trial, the IOB-022 trial, of IO102-IO103 in combination with pembrolizumab in the first line solid tumor setting. This basket trial enrolls PD-1/PD-L1 treatment na&#239;ve patients with metastatic disease, including NSCLC (cohort A) and SCCHN (cohort B). We enrolled the first patient in our Phase 2 basket trial in solid tumors in 2022 and released encouraging preliminary initial data from the 42 patients enrolled in the IOB-022 study in August 2023. Of the 28 patients enrolled in cohort A, 18 were efficacy evaluable per protocol having received at least two full cycles of treatment. Among the 18 evaluable patients, 10 patients had a partial response as their best overall response while 5 had stable disease and 3 patients had progressive disease. Of the 14 patients enrolled in cohort B, 6 were efficacy evaluable per protocol having received at least two full cycles of treatment. Among the 6 evaluable patients, 3 patients had a partial response as their best overall response while 3 patients had progressive disease. The safety profile observed to date in this study is consistent with prior clinical experience with IO102-IO103 with no added systemic toxicity. We expect to report additional data from this study in 2024. Additionally, in April 2023, the FDA cleared the Company&#8217;s IND for the evaluation of IO102-IO103 in the neo-adjuvant/adjuvant treatment of solid tumors in the IOB-032 trial. As with our targeted first-line cancer indications, we are conducting this Phase 2 basket trial to investigate IO102-IO103 in combination with pembrolizumab in multiple solid tumor indications in anti PD-1/PD-L1 na&#239;ve settings focused initially on melanoma and SCCHN. In this trial, combination therapy will be used before and after surgical resection with curative intent. We expect to report initial data from this study in 2025. These two basket trials build on the data that we have generated from prior trials of our single epitope product candidates, IO102 and IO103, including the anti-tumor activity that we have observed with the use of our first-generation IDO compound in NSCLC; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leverage our T-win platform to design and advance a portfolio of novel immune-modulating cancer vaccine product candidates, including IO112 and additional future product candidates. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, our T-win platform has allowed us to rapidly identify and develop multiple pipeline candidates. Our product candidate, IO112, targets Arginase 1, which is over-expressed in solid tumors where MDSCs are known to play key roles in immune resistance. IO112 is currently being tested in a single arm first-in-human Phase 1 trial in patients with Arginase-positive solid tumors conducted in an investigator-initiated trial at the University of Copenhagen. We plan to continue IND-enabling activities for IO112 in 2024 and expect to initiate an IND filing in 2025. We are continuing to evaluate other targets within the TME, including TGF&#946;1 and intend to leverage our T-win&#174; platform to bring additional product candidates into the clinic over time which could be used alone or in combination with other candidates. We believe that targeting TGF&#946;1 expressing cells in the TME via a vaccine approach presents a novel and attractive way to modulate the pathway and drive therapeutic benefit in cancer setting. We are currently developing and characterizing TGF&#946;1-selective peptide vaccines capable of inducing strong immune responses. We plan to continue pre-clinical studies of a TGF&#946;1 vaccine in 2024;</span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Strengthen our position in the immunotherapy field through the continuous innovation and expansion of our T-win platform.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We have extensive knowledge about the characterization of immunosuppressive mechanisms in the TME and pharmacology. We plan to continue investing in our platform in order to stay at the forefront of developments in the immunotherapy space. Our platform is supported by a strong patent portfolio consisting of 17 different families, filed in all major markets. We plan to continue investing in intellectual property to support our platform and product candidates; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Maximize the value of our product candidates and pipeline by selectively entering into strategic collaborations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We hold worldwide development and commercial rights to our pipeline of compounds, and we intend to commercialize our product candidates, if approved, in key geographies. We have entered, and may enter in the future, into collaborations that grant us access to certain compounds owned by third parties to enable therapeutic combinations that could enhance the clinical and commercial potential of four product candidates. For example, we have entered into a non-exclusive, clinical supply agreement with MSD International GmbH (MSDIG)/Merck, to evaluate IO102-IO103 in combination with pembrolizumab plus chemotherapy and as a neo-adjuvant/adjuvant therapy; and </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Build a leading immune-modulating therapeutic cancer vaccine company while maintaining a strong culture of innovation, valuing diversity and putting patients at the center of everything we do.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We will continue to apply our deep understanding of the TME to the discovery and development of novel immune-modulating therapeutic cancer vaccines that have the potential to provide breakthroughs for cancer patients who are currently underserved by available therapies. We place a high value on the diversity of our team &#8211; including gender, background and expertise &#8211; to foster this culture of innovation. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Approach to Therapeutic Cancer Vaccines</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. We believe this represents a paradigm shift in the management of cancer and that our product candidates have the potential to become cornerstones of the treatment regimens of multiple solid tumors. Our T-win platform is built upon our team&#8217;s deep understanding of both the TME and a tumor&#8217;s ability to evade surveillance and destruction by the immune system.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Role of the Immune System in Fighting Cancer</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Immune System</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The immune system is a dynamic and self-regulating network of cells and molecules that cooperate to help the body fight disease. It is able to detect pathogens and can distinguish abnormal cells, such as tumor cells, from healthy tissue. The immune system has evolved to detect such dangers to the body through the detection of molecules or molecular structures called antigens. When exposed to pathogens or abnormal cells, the immune system responds by recognition of antigens and becomes activated to defend against them. The first line of biological defense is a general, rapid response by the innate immune system which is essential for immediate recognition and attack of pathogens as well as tumor cells. This innate response then activates and triggers a more targeted response by the adaptive immune system. Through such adaptive immune responses, the body can develop long-term immunity, or immunologic memory, to specific pathogens and other threats. Immunologic memory is established through generation of specific B cells and T cells, equipping the body to recognize, counteract and neutralize pathogens and other threats, such as cancer cells.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The intricate system of how immune cells interact and propagate a signal to elicit an immune response in cancer is known as tumor immune regulation. Successful antitumor immunity requires optimal interactions between immune and non-immune constituents of the TME. The immune system is comprised of both activating and suppressing functions built up by a myriad of different cell types. These various immune cells function to activate or suppress immune activity. We have described some of the key cellular factors contributing to anti-tumor immunity below and have classified them as immune activators or immune suppressors. However, many of these cell types can differentiate and acquire distinct functions in response to changing circumstances, known as cellular plasticity, which allows cells to switch from being immune activating to immune suppressing, or the reverse, based on certain immune triggers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Key Immune Activators and Suppressors in Anti-tumor Responses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.293%;"/>
    <td style="width:33.353%;"/>
    <td style="width:33.353%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-bottom:0.056in;border-bottom:0.75pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cell types</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;border-bottom:0.75pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Immune Activators</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;border-bottom:0.75pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Immune Suppressors</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:3.25pt;padding-left:0.02in;vertical-align:top;padding-right:0.02in;text-align:right;"><p style="margin-left:3.25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.10277777777777779in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Antigen Presenting Cells (APCs</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p><p style="margin-left:3.25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.10277777777777779in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">A group of immune cell types that mediate cellular immune responses by processing and presenting antigens to lymphocytes.</span></p></td>
    <td style="text-indent:2.95pt;padding-left:0.02in;vertical-align:top;padding-right:0.02in;text-align:right;"><p style="margin-left:2.95pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1076388888888889in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Macrophages and Dendritic cells</span></p><p style="margin-left:2.95pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.1076388888888889in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Both termed professional APCs, because of their ability to initiate a T cell response to novel antigens.</span></p></td>
    <td style="text-indent:3.25pt;padding-left:0.02in;vertical-align:top;padding-right:0.02in;"><p style="margin-left:3.25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.10277777777777779in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Tumor-associated macrophages (TAMs), tolerogenic dendritic cells (DCs) and myeloid-derived suppressor cells (MDSCs)</span></p><p style="margin-left:3.25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.10277777777777779in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">These are part of the heterogeneous population of APCs that inhibits T cell functions.</span></p><p style="margin-left:3.25pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.10277777777777779in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:1.45pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="border-top:0.75pt solid #000000;text-indent:3.25pt;padding-left:0.02in;vertical-align:middle;padding-right:0.02in;"><p style="margin-left:3.25pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.10277777777777779in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.75pt solid #000000;text-indent:2.95pt;padding-left:0.02in;vertical-align:middle;padding-right:0.02in;"><p style="margin-left:2.95pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1076388888888889in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.75pt solid #000000;text-indent:3.25pt;padding-left:0.02in;vertical-align:middle;padding-right:0.02in;"><p style="margin-left:3.25pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.10277777777777779in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="text-indent:3.25pt;padding-left:0.02in;vertical-align:top;border-bottom:0.75pt solid #000000;padding-right:0.02in;"><p style="margin-left:3.25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.10277777777777779in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">T cells / T lymphocytes</span></p><p style="margin-left:3.25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.10277777777777779in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Specialized white blood cells that recognize and destroy infected or unhealthy cells, such as tumor cells.</span></p></td>
    <td style="text-indent:2.95pt;padding-left:0.02in;vertical-align:top;border-bottom:0.75pt solid #000000;padding-right:0.02in;"><p style="margin-left:2.95pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1076388888888889in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Effector T cells</span></p><p style="margin-left:2.95pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1076388888888889in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Effector T cells consists of two main groups:</span></p><p style="margin-left:2.95pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1076388888888889in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:2.95pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1076388888888889in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">CD4</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-style:italic;position:relative;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">&#160;T Cells</span></p><p style="margin-left:2.95pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1076388888888889in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Also known as helper T cells, CD4</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-style:italic;position:relative;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">&#160;T cells produce cytokines and help maximize the expansion of the CD8</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-style:italic;position:relative;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">&#160;T cell population in a primary immune response and facilitate the generation of specific memory CD8</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-style:italic;position:relative;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">&#160;T cells; and</span></p><p style="margin-left:2.95pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1076388888888889in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:2.95pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1076388888888889in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">CD8+ T Cells</span></p><p style="margin-left:2.95pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1076388888888889in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Also known as cytotoxic T cells, CD8</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-style:italic;position:relative;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">&#160;T cells kill tumor cells, as well as infected and damaged cells. They express T cell receptors (TCRs), which recognize and bind to specific antigens expressed by cancer cells and infected cells which are presented on the surface of the cells.</span></p></td>
    <td style="text-indent:3.25pt;padding-left:0.02in;vertical-align:top;border-bottom:0.75pt solid #000000;padding-right:0.02in;"><p style="margin-left:3.25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.10277777777777779in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Regulatory T cells (Tregs)</span></p><p style="margin-left:3.25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;margin-right:0.10277777777777779in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tregs suppress activation, proliferation and cytokine production of CD4</span><span style="color:#000000;top:-3.9865pt;white-space:pre-wrap;font-size:5.695pt;position:relative;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and CD8</span><span style="color:#000000;top:-3.9865pt;white-space:pre-wrap;font-size:5.695pt;position:relative;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;T cells and APCs.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The immune system has the capacity to detect tumor cells and employ a variety of biological mechanisms, or immune effector functions, to specifically target and destroy these cells. However, tumors are adept at undermining the normal immune system functions that allow cancer cells to evade such detection and destruction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Tumor Microenvironment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tumors can generate signals that promote tumor growth and suppress immune system functions. The TME is an immunosuppressive environment that surrounds a tumor and includes blood vessels, immune cells, and signaling molecules. A significant portion of the immune reaction against tumors occurs within the TME. There is constant interplay between the TME and the tumor itself, as signals from the tumor can facilitate immunosuppression and tumor growth. In recent years, growing understanding of this interplay has led to the successful development of therapies that modulate specific immunosuppressive mechanisms within the TME to activate the immune system against cancer cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Within the TME, several molecules have been identified that play critical roles in regulating immune functions. These include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PD-1/PD-L1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: PD-1 and its ligand, PD-L1, are critical regulators of the immune system, known as immune checkpoints. The interactions between PD-1 with its ligand PD-L1 inhibit T cell effector functions against tumor cells. Tumor cells can upregulate PD-L1 to evade the attack of the immune system and PD-L1 expression is correlated with increased tumor aggressiveness and poor patient prognosis. PD-L1 expression has been reported for both hematological cancer and solid tumors; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IDO</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: IDO is a metabolic enzyme that regulates immune function through depletion of tryptophan, which is essential for T cell effector function, as well as production of immunosuppressive metabolites such as kynurenine. Such depletion of tryptophan and production of kynurenine is also known as canonical immune suppression. IDO also suppresses immunity through non-enzymic effects, known as non-canonical immunosuppression. IDO has been demonstrated to be a critical cellular factor contributing to the suppression of anti-cancer immunity. IDO is expressed in many solid tumors and hematological malignancies and its activity has been shown to correlate with poor prognoses and reduced rates of survival;  </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Arginase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Arginase is an enzyme that contributes to immune regulation by catabolizing and limiting the availability of arginine, which is essential for immune effector cell survival and growth. Arginase overproduction by immunosuppressive cells such as MDSCs is a well-documented tumor escape mechanism. Arginase is highly expressed in difficult-to-treat cancers, including colorectal, breast, prostate, pancreatic and ovarian cancers, and it is associated with high levels of MDSCs; and</span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TGFI&#946;1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: TGF&#946;1 is one of the key molecules that contribute to immunosuppression and it is produced in large amounts in the TME not only by cancer cells but also by suppressive and regulatory cells. We believe targeting TGF&#946;1 expressing cells in the TME via a vaccine approach presents a novel and attractive way to modulate the pathway and drive therapeutic benefit in cancer setting. Preliminary evidence in mouse models showed that treatment with a TGF&#946;1 vaccine drives CD4+ T cell infiltration in the TME and might promote in vivo targeted cell killing.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These immune markers are often dysregulated and over-expressed in a wide range of cancers. The figure below shows the role of these molecules in immunosuppression within the TME:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 1: Selected Drivers of Immunosuppression in the TME</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_1.jpg" alt="img134051827_1.jpg" style="width:467px;height:303px;"/>&#160;</p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Engaging the Immune System to Fight Cancer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In recent years, rapidly growing understanding of the interaction between cancer and the immune system, known as immuno-oncology, has led to the development of a number of therapeutic approaches that aim to counter the tumor-driven immunosuppression in the TME, to allow the immune system to fight cancer. These approaches include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Checkpoint Inhibitors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Checkpoint inhibitors include PD-1, PD-L1 antibodies and cytotoxic T-lymphocyte associated protein 4 (CTLA-4), among others. PD-1 and PD-L1 antibodies block the immunoregulatory functions of PD-1 and PD-L1, respectively, allowing T cell-mediated immune responses against tumor cells. PD-1 and PD-L1 antibody therapies have shown significant clinical efficacy resulting in broad commercial success. However, while such therapies are highly effective in certain subsets of patients with specific types of tumor, there are a significant number of cancer patients for whom these therapies are not effective.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IDO Inhibitors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: IDO inhibitors aim to alleviate the immunosuppressive effects of the IDO protein by blocking one of its well-established biological functions: its enzymatic activity responsible for converting tryptophan (a desirable T cell metabolite) into kynurenine (a non-desirable T cell metabolite contributing to a hostile tumor microenvironment). This is often referred to as the canonical immune suppressive function of IDO. However, there is also evidence demonstrating that the protein induces immune suppression of T cells via a mechanism independent of tryptophan conversion, often referred to as the non-canonical immune suppressive function of IDO. Hence, blocking the immune suppressive activity of IDO will likely require blocking all its related functions. IDO inhibitors have shown clinical potential in combination with anti-PD1 antibodies in early-stage trials but have not been able to demonstrate the same level of efficacy in late-stage clinical trials. </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Peptide immunotherapies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: These therapies are based on peptides which represent tumor antigens, pieces of a key protein, or surface markers on the cancer cell, and whose presentation to the adaptive immune system leads to a specific immunological response directed at their target. Their aim is to direct immune system effector functions, including CD8+ T cells, against antigens expressed on tumor cells. Although previous peptide immunotherapies have demonstrated attractive safety and tolerability profiles, they have only demonstrated modest clinical efficacy to date, likely reflecting (i) the ability of tumors to escape immune recognition by loss of antigens and (ii) the ability of tumors to orchestrate an immunosuppressive microenvironment. Collectively, these abilities are referred to as tumor immune escape.  </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These immuno-oncology approaches typically block a single immunosuppressive pathway employed by tumors or direct the immune system against antigens or neoantigens expressed by tumors cells. We believe that, by directing the immune system against both tumor cells and other healthy cells within the TME that express immunosuppressive molecules such as PD-1 or IDO, we have the potential to drive significant benefits for patients by transforming the immune balance within the TME.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Approach: Targeting The TME With Our T-win</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Platform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our T-win platform is a novel approach to cancer vaccines designed to activate pre-existing T cells to target immunosuppressive mechanisms. Our T-win product candidates are designed to employ a dual mechanism of action: (1) direct killing of immunosuppressive cells, including both tumor cells and genetically stable cells in the TME, that express key immunosuppressive proteins such as IDO and PD-L1 and (2) modulation of the TME into a more pro-inflammatory, anti-tumor environment. This is in contrast to previous methods that have sought either to only block singular immunosuppressive pathways or to direct the immune system against specific identified antigens expressed only by tumor cells. We believe that our dual mechanism approach has the potential to induce tumor regression, establish lasting and durable antitumor response, and achieve manageable tolerability for patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our T-win platform is based on our discovery of naturally occurring, pro-inflammatory T cells which can be used against immunosuppressive mechanisms mediated by key immunosuppressive proteins, such as IDO and PD-L1, that are present in the periphery and among tumor-infiltrating lymphocytes of cancer patients and, to a lesser degree, in healthy individuals (Figure 2 below). When isolated and cultured </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the self-reactive IDO- or PD-L1-specific T cells demonstrated proinflammatory and cytotoxic responses against IDO- or PD-L1-expressing target cells (Figure 3 below).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_2.jpg" alt="img134051827_2.jpg" style="width:209px;height:204px;"/>&#160;</p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_3.jpg" alt="img134051827_3.jpg" style="width:266px;height:206px;"/>&#160;</p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Key Components of Our T-win&#174; Platform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on this discovery, we created our T-win platform to direct the immune system against, both tumor cells and genetically stable cells, within the TME that express immunosuppressive proteins, with the goal of transforming the immune balance within the TME.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The key elements of our T-win platform are:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Target selection</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: We select targets based on well-documented immunosuppressive proteins that are known to be overexpressed in the TME across a wide range of tumors. Our target selection relies on the identification of T cell immunity against these key immune resistance pathways in the TME; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Epitope selection</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: After a target is selected, the ability of the immune system to attack cells overexpressing immunosuppressive molecules is confirmed by examination of intrinsic T cell immunity. The initial epitope selection process involves screening peptide antigens, which are designed using both an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in silico</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> algorithm and our know-how for T cell reactivity in peripheral blood mononuclear cells derived from cancer patients across several indications. Upon identification of an immunogenic peptide antigen, the functionality of reactive T cells is then subjected to further testing to evaluate whether activation leads to a favorable pro-inflammatory or anti-tumorigenic phenotype. Every T-win platform product candidate is designed to contain both CD4</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and CD8</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> T cell epitopes that can be recognized over a wide range of patient population; and </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adjuvant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: T-win peptide product candidates are administered together with an adjuvant, such as Montanide. This provides protection to and facilitates effective release of our T-win peptide product candidates upon injection. </span></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">T-win Platform Mechanism of Action</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are designed to drive the activation and expansion of T cells reactive to immunosuppressive antigens. Upon trafficking these T cells into the tumor site, effective anti-tumor response is induced by a dual mode of action:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recognition and elimination of tumor cells; and </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recognition and elimination of immunosuppressive cells. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our T-win platform offers a novel approach that targets both tumor cells as well as genetically stable host immunosuppressive cells, in order to avoid immune escape. By attracting pro-inflammatory cells against immunosuppression within the TME, T-win product candidates are designed to alter the immunologically unfavorable TME environment into a pro-inflammatory milieu, thereby enhancing effective anti-tumor T cell responses. We believe that our T-win platform is the only existing platform that utilizes the intrinsic ability of cancer patients&#8217; own T cells to target immunosuppression in the TME.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Administration of our T-win product candidates via subcutaneous injection (Figure 4, step 1) selectively activates and expands pre-existing CD4</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and CD8</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> T cell responses against the T-win product candidate targeted antigens, such as those derived from IDO, in the draining lymph nodes (Figure 4, step 2). The resulting T cells migrate to the tumor sites, where target cells with elevated expression of T-win product candidate targeted antigens are found in the TME. Upon recognition and engagement of the targeted cells, the T cells either directly eliminate the cells by cytotoxic lysis or respond by the release of proinflammatory cytokines (Figure 4, step 3). Elimination of immunosuppressive target cells and concomitant immune modulation of the TME into an inflamed environment results in net enhancement of T effector infiltration and enhanced anti-tumor responses (Figure 4, step 4).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 4: Illustration of T-win&#174; Platform Mechanism of Action</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_4.jpg" alt="img134051827_4.jpg" style="width:672px;height:344px;"/>&#160;</p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Advantages of the T-win Platform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our T-win platform has the potential to pave the way for novel cancer vaccines with increased therapeutic effect and limited additional tolerability concerns. Potential advantages of our T-win platform include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Durability of response</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: T-win product candidates are designed to target not only tumor cells but also genetically stable healthy immunosuppressive cells, with the aim of avoiding immune escape. We believe that our approach of killing direct and indirect targets may lead to immune memory, and thus sustained anti-tumor effect over time; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dual and Multi-Epitope Design</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: In our product candidates, we often seek to include dual or multiple epitopes. The rationale behind this approach is based on the complexity of cancer, where individual patients suffering from the same cancer indication may have a different expression of immunoregulatory antigens and as a result may not respond to a single epitope treatment. We believe that an approach of targeting separate immune resistant pathways in the TME will enable our product candidates to address a larger pool of patients than therapies that are currently available are able to reach; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tolerability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Therapies based on subcutaneously injected peptides have been observed to be well-tolerated in over 200 clinical trials. If T-win product candidates based on subcutaneously injected peptides are similarly well-tolerated, our product candidates could have the potential to be used as components of combination therapy in early treatment settings; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Versatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Our product candidates based on our T-win platform have the potential to be used in combination with existing therapies such as checkpoint inhibitors, including the PD-1 monoclonal antibodies, pembrolizumab and nivolumab. As our product candidates target a range of immunosuppressive mechanisms mediated by proteins highly expressed among several cancer indications and the mechanism of action can potentially provide supplementary effect across different checkpoint inhibitors, we believe that the number of cancer indications and combination opportunities of our product candidates are extensive; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Well-understood manufacturing process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The compounds necessary for the production of product candidates based on T-win platform are manufactured through a well-known synthetic chemistry process. We believe this enables us to reproduce high quality product at an anticipated low cost of goods; and </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Time to Treatment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: T-win product candidates are designed to be readily available, off-the shelf vaccines with the potential to provide immediate treatment compared to personalized approaches.  </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current Trials</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Proposed Registrational Trial in Melanoma Under BTD by FDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the results of the MM1636 trial, we recruited for a multicenter, international, open-label, randomized, two-arm Phase 3 potentially registrational trial of IO102-IO103, the IOB-013/KN-D18 trial, in combination with pembrolizumab as first-line treatment for patients with previously untreated unresectable or metastatic (advanced) melanoma. The Phase 3 trial initially had a target enrollment of 300 patients randomized into either the experimental arm of IO102-IO103 in combination with pembrolizumab or the pembrolizumab control arm. As of June 2023, we had randomized 225 patients. In addition, on June 14, 2023, we announced that we increased enrollment in the IOB-013/KN-D18 study to 380 randomized patients; the trial reached full enrollment in November 2023. All patients will receive pembrolizumab 200 mg intravenously every three weeks for a maximum of 35 cycles, corresponding to approximately two years of treatment. Patients randomized to the experimental arm will also be given IO102-IO103 every three weeks with an additional dose given during the induction period on Day 8 of cycles 1 and 2. IO102-IO103 will thereafter be administered subcutaneously every three weeks during the maintenance period. Each patient can be treated for a maximum of 37 administrations in total, corresponding to approximately two years of treatment. The Phase 3 trial protocol has a planned interim analysis based on ORR that will be conducted 12 months after 225 patients have been randomized; if the investigational arm demonstrates a highly statistically significant improvement in ORR compared to the control arm, with a p-value&lt;0.005, then the interim analysis could allow for potential submission of a BLA for accelerated approval in the United States. When we designed the interim analysis, we assumed that patients treated with IO102-IO103 in combination with pembrolizumab would show an ~18-point improvement in ORR compared to the patients treated with pembrolizumab alone. The trial design and discussions with FDA are aimed at potentially pursuing accelerated approval, if the trial data are favorable, based on the interim analysis of ORR, supported by other data. If the data are supportive, we also plan to file an MAA with the EMA based on the primary endpoint of PFS after the data are available, which is expected to occur in the second half of 2025. The Phase 3 trial also includes a concurrent evaluation of the initial participants to allow for an assessment of safety, or safety run in.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Development in First-Line Indications</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the IOB-013/KN-D18 trial discussed above, we are executing a Phase 2 basket trial, the IOB-022 trial, which will enable us to investigate multiple solid first-line tumor indications in anti PD-1/PD-L1 treatment na&#239;ve patients with metastatic disease, such as NSCLC and SCCHN. In the NSCLC portion of the trial we are investigating IO102-IO103 in patients expressing PD-L1 &#8805;50%, a patient population similar to Cohort A in our Phase 1/2 trial of IO102 in combination with pembrolizumab as first line treatment for patients with metastatic NSCLC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our IOB-022 trial is a non-comparative, open label, unblinded trial and investigates the safety and efficacy of IO102-IO103 in combination with pembrolizumab, intended to investigate each of the following metastatic first-line indications:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NSCLC with PD-L1 TPS &#8805;50% </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SCCHN (HPV +/-) with PD-L1 CPS &#8805;20% </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trial is ongoing in three countries (the United States, Spain and the United Kingdom) at 20 active sites.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Encouraging preliminary initial data was reported on August 21, 2023 for the first time from 28 lung cancer patients and 14 head and neck cancer patients in the Company&#8217;s Phase 2 basket study (IOB-022/KN-D38) evaluating IO102-IO103 in combination with pembrolizumab in patients with non-small cell lung cancer and head and neck cancer as presented at the ESMO conference held in October 2023. Of the 28 patients enrolled in cohort A, 18 were efficacy evaluable per protocol having received at least two full cycles of treatment. Among the 18 evaluable patients, 10 patients had a partial response as their best overall response while 5 had stable disease and 3 patients had progressive disease. Of the 14 patients enrolled in cohort B, 6 were efficacy evaluable per protocol, having received at least two full cycles of treatment. Among the 6 evaluable patients, 3 patients had a partial response as their best overall response while 3 patients had progressive disease. The UBC cohort was closed in fiscal year 2023 in response to challenges in recruiting patients into the trial as a result of changes in standards of care associated with UBC. The safety profile observed to date in this study is consistent with prior clinical experience with IO102-IO103. We anticipate reporting additional data from this study in 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Decisions regarding further clinical development and larger study plans will be made based on evaluation of data from the ongoing NSCLC and SCCHN cohorts. The primary endpoints of the Phase 2 trial will be dual target of either ORR according to RECIST 1.1. or PFS at six months by investigator assessment. Secondary outcome measures will include PFS, duration of response, CRR, disease control rate, OS, time to response and safety reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 5: Schematic Clinical Development Diagram: IOB-022 Trial</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_5.jpg" alt="img134051827_5.jpg" style="width:654px;height:283px;"/>&#160;</p>
  <p style="margin-left:1.067%;text-indent:-3.487%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">* KEYNOTE-042 (pembro alone in 1L NSCLC PD-L1 &#8805; 50%): ORR 39% (Mok et al. Lancet 2019)</span></p>
  <p style="margin-left:1.067%;text-indent:-3.487%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">** KEYNOTE-48 (pembro alone in 1L SCCHN CPS PD-L1 &#8805; 20%): ORR 23% (Burtness et al. Lancet 2019) EudraCT No. 2021-003026-69; ClinicalTrials.gov No. NCT05077709</span></p>
  <p style="margin-left:4.4%;text-indent:4.742%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the IOB-022 trial, we have initiated a Phase 2 basket trial, the IOB-032 trial, to investigate IO102-IO103 in combination with pembrolizumab in a perioperative setting and used before or after surgery as a neo-adjuvant/adjuvant therapy in multiple solid tumor indications in anti-PD-1/PD-L1 na&#239;ve settings, focused initially on melanoma and SCCHN. In April 2023, the FDA cleared our IND application for the IOB-032 trial. We anticipate the study will initially enroll up to 15 patients with melanoma, and 15 patients with SCCHN.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.4%;text-indent:4.742%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trial is currently enrolling patients in five countries (Australia, the United States, France, Denmark, and Spain) at 14 active sites. Enrolling patients for the following cohorts are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Melanoma (n=10-15)</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SCCHN (n=15-20)</span></div></div>
  <p style="margin-left:4.4%;text-indent:2.371%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The primary endpoint of the study will be the percentage of patients with major pathologic response (MPR) in the resected tumor tissue after neoadjuvant treatment; secondary endpoints will be pathological CR and ORR; and other endpoints will be disease-free survival (DFS), event-free survival (EFS), and safety. We announced in a press release issued on December 21, 2023 that the first patient in the IOB-032 trial was enrolled and dosed. In addition, we also filed a protocol amendment with the FDA in December 2023 to initiate enrollment of 30 new patients with resectable melanoma in a randomized cohort C study in the IOB-032 trial. Patients in cohort C will be randomized 1:1 to receive the neoadjuvant treatment of either IO102-IO103 in combination with pembrolizumab or pembrolizumab alone, and will continue with the same regimen in the post-surgery phase. We are currently awaiting response from the FDA and, if the amendment is approved, we project that we will commence with the amended protocol in the second quarter of 2024.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 6: Schematic Clinical Development Diagram: IOB-032 Trial</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_6.jpg" alt="img134051827_6.jpg" style="width:672px;height:340px;"/>&#160;</p>
  <p style="margin-left:1.067%;text-indent:-3.487%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">*  Recovery &#8804; 12 weeks</span></p>
  <p style="margin-left:1.067%;text-indent:-3.487%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">** If required</span></p>
  <p style="margin-left:1.067%;text-indent:-3.487%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ECOG PS = Eastern Cooperative Oncology Group performance status; SCCHN, squamous cell carcinoma of the head and neck; ClinicalTrials.gov No. NCT05280314</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing a pipeline of product candidates that leverage our T-win&#174; platform to address targets within the TME. We are currently investigating IO102-IO103 in the IOB-013/KN-D18 trial, the IOB-022 trial and the IOB-032 trial. We are also developing earlier stage product candidates that target additional immunosuppression-related targets that are expressed in a broad range of solid tumors, which include our next product candidate, IO112, that targets Arginase 1 and the further development of a TGF&#946;1 vaccine, IO170. We expect to use these earlier stage product candidates in combination with our existing pipeline candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Melanoma</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IO102-IO103 is currently being tested in the IOB-013/KN-D18 in treatment-na&#239;ve patients with unresectable or metastatic (advanced) melanoma.  Unresectable, metastatic melanoma is a serious and life-threatening disease with a clear unmet medical need. According to the International Agency for Research on Cancer of the World Health Organization, it was estimated that 325,000 patients were diagnosed with, and about 57,000 people would die from, melanoma worldwide in 2020. The agency further estimated that, approximately 510,000 patients will be diagnosed with, and about 96,000 people will die from, melanoma, worldwide by 2040, representing an approximately 57% increase in new patients diagnosed with melanoma and an approximately 68% increase in melanoma related deaths. The incidence of cutaneous melanoma is also increasing, and advanced melanoma (unresectable or metastatic) is fatal if left untreated. According to Ascierto (JAMA Oncology 2019), Robert (New England Journal of Medicine 2019), Larkin (New England Journal of Medicine 2019), and research conducted by the Melanoma Research Alliance, the median OS in patients with stage IV melanoma (untreated) regardless of BRAF mutation status is between 37 to 39 months and five-year OS is approximately 22.5%. Anti-PD-1 monotherapy leads to a five-year OS of approximately 43-51%, while anti-CTLA-4 and anti-PD-1 combination therapy can increase five-year OS to approximately 52%, but is associated with considerable toxicity. Accordingly, we believe there is a clear, unmet need for improved combination therapies with the potential to enhance anti-PD-1 efficacy without a significant increase in toxicity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Historical and Current Standard of Care</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Historically, chemotherapy, with or without interferon-alpha (IFN-&#945;) or interleukin 2 (IL-2), was offered to patients with advanced melanoma, with limited results. Although in the last decade the treatment of advanced melanoma has improved with the regulatory approval of many novel agents, the current standard of care does not work for many patients. Before the availability of these treatments, according to Maio (Journal of Clinical Oncology 2015) and Garbe (The Oncologist 2011), patients with advanced melanoma had a median survival time of approximately 10 months. According to Robert (New England Journal of Medicine 2019) and Larkin (New England Journal of Medicine 2019), the current long-term survival is at least 37 to 39 months for patients with advanced melanoma (regardless of BRAF mutational status) based on current standard of care.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The currently approved novel agents can be divided into two main categories:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immunotherapies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Immune checkpoint inhibitors targeting CTLA-4, such as ipilimumab, and PD-1, such as nivolumab and pembrolizumab, indirectly activate the immune system. The immune system plays an important role in the regulation of melanoma, and intravenously administered immunotherapies help overcome immune suppression; and </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Targeted agents</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Orally administered selective inhibitors of mitogen-activated protein kinase (MAPK) directly inhibit the oncogene BRAF and MAPK pathway. According to Drummer (Lancet 2018), around 35-50% of advanced melanoma patients have a targetable BRAF mutation, and in approximately 90% of these cases, the mutation consists of valine substituted with glutamic acid at amino acid 600 (BRAF V600). </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recommended first-line treatment options for the treatment of unresectable or metastatic melanoma and for patients with or without BRAF-mutant advanced melanoma are summarized below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Anti-PD-1 monotherapy (nivolumab or pembrolizumab); </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab) combination therapy; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Anti PD-1 (nivolumab) and LAG-3 (relatlimab) combination therapy;</span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dabrafenib/trametinib combination targeted therapy if the activating BRAF-V600 mutation is present; and </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vemurafenib/cobimetinib + atezolizumab combination targeted therapy and immunotherapy if the activating BRAF-V600 mutation is present. </span></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Table 1a: Certain Currently Approved Immunotherapies and Targeted Agents</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><img src="img134051827_7.jpg" alt="img134051827_7.jpg" style="width:672px;height:306px;"/></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.6%;"/>
    <td style="width:93.4%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">ORR:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Overall response rate</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">CRR:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Complete response rate</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">PFS:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Progression free survival</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">OS:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Overall survival</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">mDoR</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Median duration of response</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.6%;"/>
    <td style="width:93.4%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">mo:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">months</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">y:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">years</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">NR</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Not reached</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">N/A:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Not available</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">TRAE:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Treatment-related adverse events</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Table 1b: Selected Phase 3 Trial Update - American Society of Clinical Oncology (ASCO) 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_8.jpg" alt="img134051827_8.jpg" style="width:672px;height:283px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For patients with tumors harboring a BRAF V600 mutation, treatment choices are between MAPK or checkpoint inhibitor therapy. Cross trial comparisons indicate that combined MAPK or BRAF plus MAPK kinase (MEK) has proven to have higher response rates than checkpoint inhibitor therapies. Data from cross trial comparisons suggest that the responses to checkpoint inhibitor therapies are slower in onset but more durable. For patients who are candidates for both treatments, standard of care guidelines recommend that checkpoint inhibitor therapies should be chosen as first-line therapy. Patients whose tumors are not progressing quickly and are not immediately threatening an important organ function, should be considered for checkpoint inhibitor therapies first, preserving MAPK for subsequent lines. However, American Society of Clinical Oncology guidelines do not recommend a specific order of therapies for patients with BRAF wild-type (WT) unresectable and metastatic cutaneous melanoma.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As combination therapy with ipilimumab/nivolumab is associated with more severe toxicity, physicians must make a treatment decision between combination therapy and single agent anti-PD-1 antibody therapy after thorough evaluation regarding clinical activity and potential severe toxicity. Accordingly, we believe novel anti-PD-1 combinations with improved overall outcomes are needed for patients with advanced melanoma.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing IO102-IO103 for potential treatment of patients with anti PD-1 na&#239;ve in the advanced setting advanced melanoma who are candidates for CI monotherapy, regardless of PD-L1 expression and BRAF mutation status, except for patients with rapidly progressing disease. We also plan to test IO102-IO103 as a neo-adjuvant used before surgery, followed by adjuvant therapy after surgery, in patients with melanoma, in a basket trial, the IOB-032 trial, with multiple solid tumor indications. We announced that the first patient in the IOB-032 trial was enrolled and dosed in a press release issued on December 21, 2023.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Development of Dual Epitope IO102-IO103 in the First-line Setting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MM1636 trial evaluated IO102-IO103 in combination with an anti-PD-1 monoclonal antibody, nivolumab, in 30 anti-PD-1 na&#239;ve, first-line metastatic melanoma patients. A brief summary of the MM1636 trial is below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30 patients from Herlev University Hospital in Denmark included in cohort A; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Baseline characteristics were largely comparable with benchmark trials with the majority of patients having one or more poor prognostic factors, such as negative tumor expression, M1c stage/visceral metastases and high lactate dehydrogenase (LDH); </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investigators initially observed an ORR of 80% (24 out of 30 patients); however, two of 24 patients in which a response was observed progressed before subsequent radiological confirmation, which resulted in a confirmed ORR of 73%. CRR was 50% with duration of response not yet reached at a median follow up time of 49.8 months as of January 5, 2023; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Median PFS was 25.5 months and median OS had not yet been reached as of January 5, 2023;</span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Correlative biomarker data from the MM1636 trial support the mechanism of action of IO102-IO103 in treated patients, based on the following observations; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Induction of systemic therapy (IO102+IO103)-specific T cell response in blood; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treatment-induced increased infiltration of CD3+/CD8+ T cells into the tumor site with enhanced immune effector signature in responding patients; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Detection of IO102-IO103-specific T cells in tumors post treatment; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10 patients (patients with anti-PD-1 de-novo refractory disease) from Herlev University Hospital in Denmark included in cohort B; and</span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4 of 10 patients were enrolled into cohort C (patients with acquired anti-PD-1 resistance, meaning those who progressed after anti-PD-1 therapy), with enrollment completed in January 2023.  <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">MM1636 Cohort A Trial Design and Patient Characteristics</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MM1636 trial consists of 3 cohorts &#8211; cohorts A, B and C. Within each cohort, the trial was a Phase 1/2 single arm, single center trial with the primary objective to investigate safety and feasibility, secondary objective to investigate immunogenicity and tertiary objective to investigate clinical efficacy. While the size of the trial was deemed sufficient to evaluate safety, as a single arm trial, the MM1636 trial was not designed to provide statistically significant results in respect of its clinical efficacy endpoints. The MM1636 trial patients were treated with IO102-IO103 in combination with nivolumab for up to 47 weeks and thereafter continued with nivolumab treatment according to usual guidelines. Treatment consisted of 100 &#181;g IDO long, 100 &#181;g PD-L1 long1, 25 &#181;l dimethyl sulfoxide (DMSO), 475 &#181;l phosphate-buffered saline (PBS) and 500 &#181;l Montanide. The treatment was administered biweekly for 6 weeks and then every 4 weeks for 41 weeks. Patients were given a maximum of 15 treatments during one year or until progression or undue adverse events. Nivolumab was administered according to the approved label for melanoma (3 mg/kg bi-weekly for up to two years). Because of the preclinical data on IO102-IO103, which provided support for the combination effect of our IDO and PD-L1 targeted candidates, IO102 and IO103, the MM1636 trial was not designed to evaluate the individual contributions of each component antigen.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A review of patient baseline characteristics presented in table 2 for the 30 anti PD-1 na&#239;ve metastatic melanoma patients prior to treatment included in cohort A of the MM1636 trial shows that the majority of patients had one or more poor prognostic factors: 43% were  PD-L1 negative, 60% with visceral metastatic disease (M1c) and 37% with high LDH. The frequency of these poor prognostic factors indicates that the patient population was not subject to specific selection of good prognosis patients, as the baseline characteristics are largely similar to those in other trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Table 2: MM1636 Cohort A&#8212;Patient Characteristics</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_9.jpg" alt="img134051827_9.jpg" style="width:514px;height:271px;"/>&#160;</p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Tolerability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the MM1636 trial cohort A, 77% of patients developed Common Terminology Criteria for Adverse Events (CTCAE) grade 1 and 2 injection site reactions that typically manifested as transient adverse events; 77% experienced injection site tenderness, 63% experienced granulomas, 23% experienced redness, 13% experienced pain, 13% experienced pruritus, and 3% experienced myalgia at the injection site. The injection site reactions that manifested were most likely related to the adjuvant Montanide. Two patients discontinued treatment after eight and 11 injections, respectively, due to granulomas, tenderness and pain that limited instrumental activities of daily living. Other CTCAE grade 1-2 AEs have included rash (47%), fatigue (47%), arthralgia (30%), diarrhea (30%), nausea (23%), amylase increase (20%), dry skin (27%), pruritus (27%), infusion reaction (17%), xerostomia (17%) and myalgia (17%).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A total of five patients (17%) experienced a high-grade adverse event (grade 3-5); four patients (13%) experienced CTCAE grade 3-4 AEs, one patient experienced a grade 3 maculopapular rash, one patient had a grade 3 adrenal insufficiency and two patients had a grade 3 arthralgia. One patient died (CTCAE grade 5) due to urosepsis with multi-organ failure and severe hyponatremia. In addition, the patient had experienced multiple AEs, including grade 3 colitis, grade 2 pneumonitis, grade 3 arthralgia, grade 2 vasculitis and grade 2 nivolumab induced infusion allergic reaction. The patient had symptoms of myocarditis at time of death with highly elevated troponin I. Bedside echocardiography showed an ejection fraction of 15%, which at baseline was 60%. The myocarditis was never confirmed pathologically. All the AEs leading to treatment discontinuation were considered by the investigator to be related to nivolumab. The rate of treatment-related adverse events leading to discontinuation of both nivolumab and IO102-IO103 was 17%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Response Rate in Cohort A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results from the MM1636 trial, with a cut-off date of January 5, 2023, showed an ORR of 80% (95% confidence interval (CI); 62.7-90.5%). Two of the 24 responding patients progressed before subsequent radiological confirmation, therefore the confirmed ORR was 73.3% (95% CI; 54.1% to 87.7%). The CRR was 50.0% (95% CI; 31.3% to 68.7%).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Table 3: Objective Response Rate by Investigator Review</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.113%;"/>
    <td style="width:1.4%;"/>
    <td style="width:1%;"/>
    <td style="width:31.486%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of data cut-off:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">January 5, 2023</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Median follow-up</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49.8 months</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Evaluable patients</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Responders (including unconfirmed responses)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80.0% (N = 24)</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Confirmed responders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Best Overall (confirmed) Response Rate (Clopper Pearson Exact 95% CI)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73.3% (N=22/30) 54.1% to 87.7%</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Complete Response Rate (Clopper Pearson Exact 95% CI)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0% (N=15/30) 31.3% to 68.7%</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Partial Response Rate (Clopper Pearson Exact 95% CI)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.3% (N=7/30) 9.9% to 42.3%</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Best overall (confirmed) response rate by PD-L1 status (PD-L1&lt;1% vs &#61619;1%)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PD-L1 positive patients (Clopper Pearson Exact 95% CI)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88.2% (N=15/17) 63.6% to 98.5%</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PD-L1 negative patients (Clopper Pearson Exact 95% CI)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53.8% (N=7/13) 25.1% to 80.8%</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Independent External Radiology Review</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To substantiate the investigator assessed evaluation of efficacy, clinical response data was validated by blind independent external review. This was performed at an earlier cut-off date (January 2020) where an ORR of 76.7% (CI: 57.7%-90.1%) was reported with 50.0% achieving CR, 26.7% partial response (PR), and 3.3% stable disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison With Contemporary anti PD-1 Treated Patients from the National Danish Metastatic Melanoma Database (DAMMED)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To address potential trial bias regarding treatment effect through post-hoc exploratory analysis, patients in the MM1636 trial were matched with patients from the Danish Melanoma Database (DAMMED), which is a population-based database that retrospectively collects data on patients with metastatic melanoma in Denmark.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Data regarding 938 patients who were treated with a PD-1 monotherapy contemporaneously (January 2015 to October 2019) was extracted. 218 of these patients were eligible for comparison and matching (all parameters available). 60 DAMMED patients were found to match; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients were matched on age (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">&#61603;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70, &gt; 70), gender, LDH (normal, elevated), M-stage (M1a, M1b, M1c), BRAF status (Wildtype, mutated) and PD-L1 status (&lt;1, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">&#61619;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 1). An exact matching algorithm was used where patients in the MM1636 trial were matched with patients from DAMMED with the exact same combination of variables; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29 patients from the MM1636 trial were matched with the exact combinations of the six variables. One patient could not be matched. To secure a balance of the calculations, control patients were weighted according to the number of patients for each MM1636 patient. Estimates for treatment effects were calculated by weighted logistic regression analyses and weighted Cox proportional hazard model. A weighted binary logistic regression model was used for comparing response rates in the two matched cohorts; and </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Matched controls were identified for 29 patients and the ORR of 79.3% (95 CI: 61.0-90.4%) observed in the MM1636 trial was found to be significantly higher (p&lt;0.0012) compared to the matched control group where an ORR of 41.7% (95% CI: 31.0% to 53.3%) was reached. Furthermore, of the 29 patients in the MM1636 trial, a significantly (p&lt;0.0017) higher percentage of 41.4% (CI: 25.2% to 59.6%) patients achieved CR in the MM1636 trial, compared to 12% (CI: 6.3% to 21.6%) in the matched historical control group. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ORR was significantly higher in the patients from the MM1636 trial than in the historical controls, suggesting that the high response rate and the long durability of response observed with the combination therapy approach are unlikely to be due to patient selection bias.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Tumor Shrinkage in Individual Patients in Cohort A</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Data showing the percent change in target lesions from the baseline is shown in Figure 6. The effect was binary, as patients either responded (24 out of 30) or experienced disease progression (six out of 30). No patients showed stable disease (SD). The icons describe melanoma risk factors. Green bars indicating CR that are not at 100% tumor reduction are in patients with lymph node metastases, as lymph nodes do not disappear but normalize in size. Blue and green bars at 100% indicate the disappearance of target lesions, whereas some non-target lesions may remain based on RECIST 1.1. definitions. Six of the 30 patients experienced disease progression (orange bars).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 6: MM1636 Cohort A&#8212;Waterfall Plot Showing Best Percentage Change in Target Lesion Size</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_10.jpg" alt="img134051827_10.jpg" style="width:518px;height:293px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CR = complete response, PR = partial response, PD = progressive disease</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Timing and Durability of Response in Individual Patients in Cohort A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The swimmer plot in Figure 7 below presents individual patient-level data, including onset of PR, CR, PD and death. In addition, patients with ongoing responses as of the January 5, 2023 cut-off date are marked with an arrow. As of the January 5, 2023 cut-off date, response was still ongoing in 10 patients. The majority of patients achieving a CR had one or more high risk factors (marked with icons) such as PD-L1 negative tumor expression, M1c stage/visceral metastases and high LDH as an indication severe disease.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CRs were observed more than 15 months after initial treatment, and as of the January 5, 2023 cutoff date, the CRR had improved to 50% for the latest included patients with a minimum follow-up of 30 months. We believe these data indicate good quality responses with a deep and durable response in most of the patients (Figure 8).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The median duration of response (DOR) was 27 months as of the January 5, 2023 cut-off date in the MM1636 trial, and 20 of the 22 patients with a radiologically confirmed response (at 12 weeks after the first response) had a response lasting greater than 182 days providing a durable response rate of 66.7% (20/30) (Figures 7 and 8). <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 7: MM1636 Cohort A&#8212;Durability and Deepening Responses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><img src="img134051827_11.jpg" alt="img134051827_11.jpg" style="width:475px;height:379px;"/></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CR = complete response, PR = partial response, PD = progressive disease</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 8: MM1636 Cohort A&#8212;Duration of Response</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><img src="img134051827_12.jpg" alt="img134051827_12.jpg" style="width:451px;height:325px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Tumor Shrinkage and Durability of Response in Individual Patients Over Time in Cohort A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The rapid onset of response, deepening of responses over time and durability of responses in the MM1636 trial are shown in the spider plot for individual patients. Green, blue and red lines respectively indicate CR, PR and PD. Only six out of 30 patients experienced progressive disease at the first imaging timepoint (12 weeks) marked with red lines (Figure 8).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 9: MM1636 Cohort A&#8212;Change in Target Lesions from Baseline Over Time</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><img src="img134051827_13.jpg" alt="img134051827_13.jpg" style="width:556px;height:304px;"/></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Progression Free Survival (PFS) in Patients from Cohort A</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At a median duration of follow-up of 49.8 months (Figure 10), the median PFS was 25.5 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 10: MM1636 Cohort A&#8212;Progression Free Survival</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_14.jpg" alt="img134051827_14.jpg" style="width:417px;height:307px;"/>&#160;</p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">+ Censored; dotted lines show 95% Confidence Limits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overall Survival (OS)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At a median duration of follow-up of 49.8 months, the median OS had still not yet been reached (Figure 11).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 11: MM1636 Cohort A&#8212;Overall Survival</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_15.jpg" alt="img134051827_15.jpg" style="width:417px;height:292px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Censored; dotted lines show 95% Confidence Limits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1/2 Correlative Data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Correlative biomarker data from the MM1636 trial support the mechanism of action of IO102-IO103 in treated patients, based on the following observations:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Induction of systemic therapy (IO102+IO103)-specific T cell response in blood was confirmed in over 96% of treated patients (Table 4); </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Confirmation of IO102-IO103-specific T cell clones homing into TME (Figure 12); and </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treatment-induced increased infiltration T cells into TME with enhanced immune effector signature in responding patients (Figure 13). </span></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Table 4: Treatment-specific T cell Responses to IO102 (IDO) and/or IO103 (PD-L1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:14.883%;"/>
    <td style="width:1.62%;"/>
    <td style="width:14.883%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">T-win&#174; antigen-<br/>specific response<br/>at BASELINE</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">T-win antigen-<br/>specific response<br/>ON-TREATMENT</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Response against IO102</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10/30 (33.3%)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27/30 (90%)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Response against IO103</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8/30 (26.7%)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25/30 (83.3%)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Response against IO102 and/or IO103</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14/30 (46.7%)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29/30 (96.7%)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 12: Increased Frequency of IO102-IO103-expanded T cell Clones Detected in TME After Treatment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_16.jpg" alt="img134051827_16.jpg" style="width:208px;height:201px;"/>&#160;</p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cumulative frequencies of IO102-IO103-specific TCR rearrangements pre- and post-treatment in one CR patient are shown.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 13: Treatment-induced Increased Infiltration T cells into TME with Enhanced Immune Effector Signature in Responding Patients</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_17.jpg" alt="img134051827_17.jpg" style="width:274px;height:239px;"/>&#160;</p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_18.jpg" alt="img134051827_18.jpg" style="width:276px;height:239px;"/>&#160;</p></td>
   </tr>
  </table>
  <p style="margin-left:9.08%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(A) In a CR patient (PD-L1 negative, LDH high, BRAF WT, M1c), immunohistochemistry (IHC) analysis of tumor sections before vs on-treatment revealed more than three-folds increase in infiltrating T cells (left), majority of which were antigen-experienced (positive for PD-1/LAG-3/T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), &#8220;Ag</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> CD8</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8221;) CD8</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> T cells (right). (B) This was accompanied by increased signature of effector T cell activation with concomitant reduction in pro-tumorigenic genes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">MM1636 Cohort B</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ten patients with metastatic melanoma with progressive disease on anti-PD-1 therapy were enrolled from May 2019 to September 2022. A review of patient baseline characteristics for the 10 patients with refractory (to an anti PD-1 therapy) melanoma who were included in cohort B of the MM1636 trial shows all patients to have BRAF wild-type tumors, and 50% with available PD-L1 status (n=8) were PD-L1&lt;1%. Nine of the patients had normal LDH levels and two patients had disease stage M1c. The mean age was 68.5 years.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the January 5, 2023 data cutoff, all patients were off trial treatment due to progressive disease. The most frequently reported adverse events as considered related to nivolumab were CTCAE grade 1-2 fatigue (30%), nausea (30%) and dry skin (30%). Local injection site reactions were seen in 40% of the patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In terms of efficacy, the best overall response was stable disease in 2 (20%) patients and eight were progressive disease. The mOS was 16.7 months and the mPFS was 2.4 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In summary, patients who were PD-1 refractory and enrolled in cohort B in this study had no response to therapy, which we believe shows that our vaccine works best in front-line metastatic melanoma patients, as we expected in this setting.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Potential Opportunities for Dual Epitope IO102-IO103</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lung Cancer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lung cancer is the leading cause of cancer death according to the American Cancer Society (ACS). The two main types of lung cancer are NSCLC and small cell lung cancer (SCLC). Worldwide, lung cancer is the second most diagnosed cancer and NSCLC is estimated to account for 85% of all lung cancer diagnoses. According to the International Agency for Research on Cancer of the World Health Organization, it was estimated that 1,875,000 patients were diagnosed with, and about 1,526,000 people would die from, NSCLC worldwide in 2020. The agency further estimated that, by 2040, approximately 3,084,000 patients will be diagnosed with, and about 2,557,000 people will die from, NSCLC, representing a 64% and 68% increase in new patients diagnosed with NSCLC and NSCLC related deaths, respectively. According to the organization, the five-year survival rate for patients suffering from highly advanced, metastatic (Stage IV) lung cancers is estimated to be 28%. The NSCLC market was expected to generate $45.5 billion in revenue in 2022, growing to $81.4 billion in 2028 with a compounded annual growth rate (CAGR) of 10%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is a large unmet need for improved combination therapies enhancing anti-PD-1 efficacy without a significant increase in toxicity. Until recently, the standard of care for patients with metastatic NSCLC was platinum-based chemotherapy. Recently, anti-PD-1 therapy, such as pembrolizumab, with or without chemotherapy, has changed the standard practice in first-line treatment of metastatic NSCLC. According to Mok (Lancet 2019) and Gandhi (New England Journal of Medicine 2018) the ORR for patients with previously untreated metastatic NSCLC and a PD-L1 expression of 50% or higher who were treated with pembrolizumab monotherapy was 39% and pembrolizumab in combination with chemotherapy 61%. In high PD-L1, approximately 40% of patients are alive after 30 months on pembrolizumab monotherapy. In low PD-L1, approximately 45% of patients are alive at 24 months on pembrolizumab plus chemotherapy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Observations from a Phase 1 trial of our first generation IDO compound, IO101, provided us foundational support for our IO102-IO103 development strategy. We have initiated development of IO102-IO103 plus anti PD-1 in first-line treatment of metastatic solid tumors with high PD-L1 expression. NSCLC is one of the indications in our IOB-022 basket trial. Consistent with the earlier reported data and as presented at the ESMO conference in October 2023, preliminary results from the IOB-022/KN-D38 Phase 1/2 study of IO102-IO103 in combination with pembrolizumab in metastatic NSCLC continue to be encouraging. As of August 21, 2023, of the 28 patients enrolled in cohort A, 18 were efficacy evaluable per protocol having received at least two full cycles of treatment. Among the 18 evaluable patients, 10 patients had a partial response as their best overall response while 5 had stable disease and 3 patients had progressive disease.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">First Generation IDO Compound</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LU1006 was an investigator-initiated Phase 1 single-arm, first-in-human trial with the primary objective of investigating safety, the secondary objective of investigating immunogenicity, and the tertiary objective of investigating clinical benefits in patients with heavily pretreated human leukocyte antigen-A2 (HLAA2) positive stage III to IV NSCLC. Patients had stable disease after standard therapy comprising of chemotherapy and targeted therapy. The trial was a non-randomized comparison against patients who had standard of care, chemotherapy, at the site and were HLAA2 negative. 15 patients were treated with IO101 as subcutaneous injections formulated in 900 microliters Montanide and imiquimod ointment. The mean treatment duration was 7.9 months (95% CI: 4.6 &#8211;11.3).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Tolerability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 90% of the patients in the LU1006 trial, CTCAE grade 1 to 2, short-term, local injection site reactions (i.e., redness, swelling, or itching) were observed. Local treatments with steroid ointments removed the symptoms. High frequencies of fatigue, shortness of breath, coughing and hemoptysis were present at baseline in the 15 NSCLC patients. These were considered to probably be related to the underlying lung cancer. Nausea and headache were observed in relation to the development of brain metastases, whereas dyspepsia, abdominal pain and diarrhea could be related to the treatment, as IDO is expressed in the epithelial cells in the gastrointestinal tract (Table 5). No grade 3 or higher AEs were observed in the 15 patients treated with IO101 monotherapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Table 5: Adverse Event Frequency by CTCAE Grade</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_19.jpg" alt="img134051827_19.jpg" style="width:296px;height:279px;"/>&#160;</p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Benefit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical benefit was defined as OR or SD for a minimum of 8.5 months after treatment initiation, corresponding to at least nine injections and demonstration of SD on at least three consecutive CT scans. Based on this definition, seven of 15 (47%) patients had clinical benefit. One patient achieved a PR after 15 months treatment (ORR of 7%), and six patients obtained SD (40%).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Survival</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Progression-free survival (PFS) is shown in Figure 14 below. &#8220;Censored&#8221; represents patients who are surviving without progression of disease. The median PFS was 5.2 months. Overall survival was 26 months in the 15 patients treated with IO101, compared to eight months in patients who received the hospitals standard of care, which included chemotherapy and targeted therapies. These observations provided us foundational support for our IO102-IO103 development strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SCCHN includes cancers of the oral cavity, oropharynx, hypopharynx and larynx, and is the sixth most diagnosed cancer worldwide. According to the International Agency for Research on Cancer of the World Health Organization, it was estimated that 744,000 patients were diagnosed with, and about 364,000 people would die from, SCCHN worldwide in 2020. The agency estimated that, approximately 1,109,000 patients will be diagnosed with, and about 556,000 people will die from, SCCHN by 2040, representing a 49% and 52% increase in new patients diagnosed with SCCHN and SCCHN related deaths, respectively. According to the organization, the five-year survival rate for patients suffering from SCCHN was estimated to be 50%. Locoregional SCCHN is treated with curative intent, but at a cost of functional impairment and locoregional recurrence or metastatic disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Standard first-line treatment for recurrent or metastatic (R/M) disease that is not amenable to local therapy was for more than a decade, cetuximab, an anti-epidermal growth factor receptor (EGFR) antibody, plus chemotherapy with platinum and 5-fluorouracil (the EXTREME regimen), which provides a mOS of about 10 months and is associated with substantial adverse events, according to Vermorken (New England Journal of Medicine 2008).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to Burtness (Lancet 2019), in the KN-048 Phase 3 clinical trial, mOS with pembrolizumab was 12.3 months in patients with combined positive score (CPS) &gt; 1% and 14.9 months in CPS &gt; 20% versus 10.7 months and 10.3 months with the EXTREME regimen. In the overall population, the mOS with pembrolizumab plus chemotherapy was 12.3 months versus 10.7 months with EXTREME. Based on the above, pembrolizumab plus platinum and 5-fluorouracil is an appropriate first-line treatment for R/M SCCHN and pembrolizumab monotherapy is an appropriate first-line treatment for PD-L1-positive recurrent or metastatic SCCHN. Pembrolizumab with or without chemotherapy did not improve the ORR versus EXTREME. ORR ranged from 17 to 23% with pembrolizumab versus 35-36% with EXTREME, pending the CPS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A significant number of cancer patients fail to respond to immunomodulatory agents regardless of PD-L1 expression, presumably because of tumor resistance mechanisms against immune attacks. According to Burtness (Lancet 2019), the two year OS in first-line R/M SCCHN ranged from 38% to 27%, pending on the CPS. Consequently, there is a large unmet need for improved combination therapies enhancing anti-PD1 efficacy without an increase in toxicity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Besides anti-PD-1, investigations into the immune landscape of SCCHN provide a strong rationale to test agents targeting other immunomodulatory pathways such as IDO and arginase, either as a monotherapy or in combination with other therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the head and neck cancer market was expected to generate $2.9 billion in revenue in 2022 and is expected to grow to $4.7 billion by 2028, reflecting a CAGR of 8%.</span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the IOB-032 trial, we commenced another development track in curative settings with neo-adjuvant (before surgery or radiotherapy)/adjuvant treatment (after surgery or radiotherapy). SCCHN is one of these indications. </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also investigating the dual epitope strategy in first-line setting of previously untreated solid tumors. R/M SCCHN is one of these indications. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ongoing and planned investigator-initiated trials will provide learnings that we can use in our own development of IO102-IO103. See &#8220;&#8212;Additional trials in other first-line indications and neo-adjuvant and adjuvant settings&#8221; for additional details on these trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Development in Neo-Adjuvant / Adjuvant Setting, other than the IOB-032 trial</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are multiple potential indication expansion opportunities in various cancer settings with limited anti-PD-1 mAb efficacy or tolerability and toxicity concerns. Both IDO and PD-L1 are highly expressed in numerous other solid tumor indications where anti PD-1-mAb is also approved. Therefore, we believe the potential for the dual epitope IO102-IO103 product candidate in combination with anti PD-1-mAB is significant beyond first-line treatment of advanced melanoma&#8212;both as a first-line treatment, but also as a neo-adjuvant (before surgery)/adjuvant (after surgery) therapy. A series of investigator-initiated trials has been completed and others are ongoing that will inform our own development. Safety data from these trials is included in the tables below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Table 9: Adverse Events Summary of Completed Investigator Initiated Trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes adverse events reported by the clinical investigators:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_20.jpg" alt="img134051827_20.jpg" style="width:672px;height:560px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_21.jpg" alt="img134051827_21.jpg" style="width:672px;height:642px;"/>&#160;</p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Table 10: Ongoing Investigator Initiated Trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><img src="img134051827_22.jpg" alt="img134051827_22.jpg" style="width:672px;height:274px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical trials listed in Table 10 above are investigator-initiated trials and accordingly we do not have control over the timing of such trials.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">IO112 (Arginase 1)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IO112 is our fully-owned, novel product candidate containing a single Arginase 1-derived peptide designed to engage and activate Arginase 1-specific human T cells. IO112 is designed to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of MDSCs including colorectal, breast, prostate and pancreatic and ovarian cancers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Arginase 1 contributes to immune regulation by catabolizing and limiting the availability of arginine, an essential amino acid for immune effector cell survival and growth. Arginase overproduction by immune suppressive cells like myeloid derived suppressor cells and tolerogenic dendritic cells is a well-documented tumor escape mechanism. Increased levels of arginase have been detected on tumor and immune cells in several solid tumor types.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IO112 is designed to selectively engage and activate cancer patients&#8217; own T cells to attack Arginase 1-expressing target cells. Upon activation, T cells secrete proinflammatory cytokines such as IFN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">&#61543;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and TNF</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">&#61537;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, thereby contributing to immune modulation of microenvironment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immunotherapeutic activity of murine Arginase 1 peptide therapy (mIO112) has been observed in multiple Arginase 1-expressing tumor models. Arginase 1 treatment resulted in a concomitant reduction of Arginase 1+ cells and an increased influx of T cells into the TME. The treatment approach enhanced the anti-tumor effect of an anti-PD-1 antibody treatment in a colon adenocarcinoma model, MC38.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure 13: Arginase 1 Therapy in Mouse Colon Cancer Model</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img134051827_23.jpg" alt="img134051827_23.jpg" style="width:499px;height:344px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Treatment combining Arginase 1 therapy and aPD-1 treatment results in synergistic response in a mouse colon cancer model, MC38 (A). In this model, mIO112 treatment (and in combination with aPD-1) results in increased influx of immune cells into TME while promoting enrichment of M1 macrophages (B). In another model (fibrosarcoma, MCA205), increased influx of T cells (CD3 staining) and reduction of Arginase 1-expressing cells in the TME was observed in mice treated with Arginase 1 therapy (ovalbumin (OVA) used as irrelevant peptide control) (C).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Development of IO112</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The next indications that we look to explore are difficult to treat cancers, and therefore Arginase 1 was tested in a single-arm first-in-human Phase 1 trial in patients with arginase-positive solid tumors conducted in an investigator-initiated trial at the University of Copenhagen.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Longer term, we are considering investigating our product candidates in difficult to treat tumors which often express high levels of arginase, such as colorectal, breast, prostate, pancreatic and ovarian cancer. These are all large indications with significant unmet medical need and large commercial potential.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Compounds</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to IO102, IO103 and IO112, we are evaluating additional potential targets that we believe have potential for use in solid tumors. All our compounds in preclinical development target well-documented immunosuppressive molecules that are known to be overexpressed in the TME across a wide range of tumors. These targets are differentially expressed on tumors compared to normal tissue and cover multiple cancer indications. For example, we are evaluating the potential anti-tumor effect of a novel immune-modulatory cancer therapy using TGF-&#223;-derived peptides (IO170) in murine tumor models. Transforming growth factor-&#223; (TGF-&#223;) is one of the key molecules that contribute to immunosuppression and it is produced in large amounts in the TME by not only cancer cells but also by suppressive and regulatory cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaborations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreements with Herlev University Hospital (Herlev)</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Option Agreements with Herlev</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into a number of agreements with Herlev in Denmark granting us options to acquire certain intellectual property rights related to our programs. The primary agreement governing these rights is Framework Assignment Agreement (the Framework Assignment Agreement) that we entered into with Herlev in May 2016. Under the Framework Assignment Agreement, Herlev grants us options to acquire licenses to data and assignments of patent rights in and to certain inventions related to activating or boosting T cells that react towards regulatory immune cells for the treatment and prevention of cancer (the Field) developed by Drs. Mads Hald Andersen and Inge Marie Svane. We have a period of three months after disclosure by Herlev of any applicable invention to exercise our option with respect to such invention in the Field. Upon exercise of any option, we will negotiate in good faith with Herlev regarding the terms of an assignment agreement for such invention in the Field. If we are unable to agree to terms of such assignment within six months of exercise of the option, Herlev will have no further obligation to continue negotiations with respect to such invention.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Framework Assignment Agreement will continue until termination by either party. Under the Framework Assignment Agreement, either party may terminate the agreement (1) for convenience, upon six months&#8217; prior written notice or (2) for the other party&#8217;s uncured material breach. Termination of the Framework Assignment Agreement for any reason will not affect any assignment agreement entered into prior to such termination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have exercised our options granted under the Framework Assignment Agreement, and other option agreements with Herlev, and obtained assignments and licenses related to certain inventions, including inventions related to our lead product candidates, IO102, IO103, IO112 and IO170.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Assignment Agreements with Herlev</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2015, January 2017 and December 2018, respectively, we exercised options granted by Herlev, and acquired Herlev&#8217;s rights and title in and to the patent applications related to Indoleamine 2, 3-dioxygenase based immunotherapies, PD-L1-based immunotherapies and PD-LI peptides for use in cancer vaccines, such as our T-win&#174; product candidates, and Arginase specific T cells. In connection with such acquisitions, Herlev has also granted us non-exclusive licenses under any clinical data related to such patent rights arising at Herlev for the purpose of developing and commercializing the inventions and patent rights. The agreements pursuant to which we have obtained these rights and licenses (the Assignment Agreements) are non-terminable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Assignment Agreements and other similar agreements with Herlev, we have paid and are obligated to pay future contingent payments and royalties, including upon achieving potential regulatory milestones and low single digit royalties on net sales from sales of products incorporating the acquired patent rights and other revenues arising from the acquired patent rights. Upon the occurrence of a change of control, stock or asset sale or IPO, certain outstanding milestone payments under such agreements became due immediately in the aggregate of approximately DKK 13.2 million (which is approximately $1.9 million based on the exchange rate of DKK 6.75 to one U.S. dollar on December 31, 2023). This was triggered by our IPO in November 2021, and has subsequently been paid. We have the right to buy-out all remaining payment obligations under the Assignment Agreement at any time by paying DKK 20 million (for each of the PD-L1 technology and IDO technology) or DKK 10 million (for the Arginase technology) to Herlev.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Assignment Agreements, we control all rights to the covered patents and, with respect to the PD-L1 and Arginase technology, are required to use our best reasonable efforts to manage, prosecute, maintain and enforce, and we are not permitted to abandon, the acquired patent rights certain markets, including Denmark and certain other EU countries, the UK, the US, Canada, Japan and China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research Agreements with Herlev</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Framework Assignment Agreement, we entered into a Framework Cooperation Agreement (the Framework Cooperation Agreement) with Herlev in January 2017, and as amended in December 2018, in which we agreed to cooperate with Herlev, either through co-financed research or sponsored research, for certain agreed-upon research programs to develop therapies aimed at activating or boosting T cells that react towards regulatory immune cells for the treatment and prevention of cancer (the Field). Pursuant to the Framework Cooperation Agreement, we will have the option to acquire all intellectual property rights in inventions developed in the course of any research program, under the terms of the Framework Assignment Agreement. The Framework Cooperation Agreement does not have a set expiration date, but may be terminated by either party (1) for convenience, upon six months&#8217; prior written notice, or (2) for the other party&#8217;s uncured material breach.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each research program under the Framework Cooperation Agreement will be conducted under a separate cooperation agreement (each, a Cooperation Agreement). We are currently engaged in six co-financed or sponsored research programs in the Field, each under a separate Cooperation Agreement. Each Cooperation Agreement will continue until the completion of the applicable research program, and either party may terminate such Cooperation Agreement, (1) for convenience, upon three months&#8217; prior written notice, or (2) for the other party&#8217;s uncured material breach.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we have entered into a separate agreement with Herlev pursuant to which we were obligated to pay a cash fee in the amount of DKK 5.0 million (which is approximately $0.7 million based on the exchange rate of DKK 6.75 to one U.S. dollar on December 31, 2023) upon the occurrence of a change of control, stock or asset sale or IPO. This was triggered by our IPO in November 2021, and has subsequently been paid.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreements with MSD International GmbH</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">November 2022 Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2022, we entered into a clinical collaboration with MSDIG, an affiliate of Merck, and MSD International Business GmbH (MSDIB), another affiliate of Merck (collectively, MSD) to evaluate IO102-IO103 in combination with KEYTRUDA&#174; as a neo-adjuvant/adjuvant therapy for patients with metastatic melanoma and SSCHN. Under the terms of the collaboration with MSD, we will conduct an international Phase 2 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA&#174;. We will sponsor the clinical trials and MSD will provide KEYTRUDA&#174; to be used in the clinical trials free of charge. We and MSD will be responsible for our own internal costs and expenses to support the study and we shall bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trials will be shared by us and MSD and we will maintain global commercial rights to IO102-IO103.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">December 2021 Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, we entered into a Clinical Trial Collaboration and Supply Agreement (the CTCSA) with MSD. Under the CTCSA, we will collaborate with MSD regarding the conduct of our international Phase II trial for our compounds, IO102 and IO103, in combination with MSD&#8217;s pembrolizumab, a humanized anti-human PD-1 monoclonal antibody, for the treatment of metastatic NSCLC, SCCHN or UBC (the Trial). Under the CTCSA, we will act as the sponsor of the Trial at our cost, and MSD will supply pembrolizumab for use in the Trial. Neither party will have any obligation to reimburse costs incurred by the other party in connection with the Trial or the supply of pembrolizumab, except upon certain breach or early termination events.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The CTCSA will remain in effect until we provide MSD with top-line results and a final report of the results, promptly after the Trial is completed, unless terminated earlier by either party for the other party&#8217;s material breach if such party fails to cure such breach within the specified cure period, or upon certain other occurrences specified in the CTCSA.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">September 2021 Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, we entered into an additional Clinical Trial Collaboration and Supply Agreement (the MSD Agreement) with MSDIG, and MSDIB to collaborate regarding the conduct of our international Phase 3 trial for the Company&#8217;s compounds, IO102-IO103, in combination with MSD&#8217;s anti-PD-1 therapy, Keytruda, for the treatment of advanced melanoma (the MSD Study). Each party is required to use commercially reasonable efforts to supply its compound, at its own cost, for use in the MSD Study. Under the MSD Agreement, we will act as the sponsor of the MSD Study at our cost (except for the cost of the supply of Keytruda from MSD and certain other internal costs incurred by MSD in conducting the MSD Study).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the MSD Agreement, all clinical data besides the data arising from the arm of the MSD Study involving only Keytruda will be jointly owned by us and MSD. All inventions relating to the combined use of IO102-IO103 and Keytruda arising from the MSD Study will also be jointly owned by us and MSD. We do not have the right under these jointly owned inventions to research, develop or commercialize any PD-1 antagonist and MSD does not have the right under the jointly owned inventions to research, develop or commercialize any peptide vaccine, such as our T-win&#174; product candidates, containing an IDO- or PD-L1-derived peptide. We have the first right to enforce such jointly owned patents. We will own all rights in any inventions or improvements arising from the MSD Study relating solely to or solely covering IO102-IO103 or any a compound that is a peptide vaccine, such as our T-win product candidates, containing an IDO- or PD-L1-derived peptide and MSD will own all rights in any inventions or improvements arising from the MSD Study relating solely to or solely covering Keytruda or any PD-1 antagonist. The parties agreed that positive clinical data from the MSD Study may be used to obtain label changes for each party&#8217;s respective compounds to add an indication for combination therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the MSD Agreement, MSD has a limited time right of first negotiation to enter into a definitive agreement with us to develop and commercialize IO102 or IO103. We will be free to negotiate with third parties regarding rights to IO102 or IO103 if MSD does not exercise its right of first negotiation within the exercise period or if the parties are not able to enter into an agreement during the negotiation period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MSD Agreement will remain in effect until delivery of the MSD Study&#8217;s final analysis by us to MSD, unless terminated earlier by either party: (1) for the other party&#8217;s material breach if such party fails to cure such breach within the specified cure period; (2) upon a good faith determination by the terminating party that there is a patient safety concern regarding the MSD Study; (3) if any regulatory authority takes any action that prevents the terminating party from supplying its compound for the MSD Study; (4) if the terminating party determines to withdraw any regulatory approval for its compound or discontinue development of its compound; or (5) for the other party&#8217;s failure to comply with its anti-corruption obligations. Upon termination by MSD due to our material breach or our failure to perform any obligations related to anti-corruption laws, we are required to reimburse MSD for the direct and indirect manufacturing costs incurred by MSD in delivering its compound for the MSD Study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">February 2018 Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2018, we entered into a Clinical Trial Collaboration and Supply Agreement (the Merck Collaboration Agreement) with MSDIG, an affiliate of Merck, to collaborate regarding the conduct of the Company&#8217;s international Phase 1/2 trial for the Company&#8217;s compound, IO102, in combination with MSDIG&#8217;s anti-PD-1 therapy, Keytruda (pembrolizumab), for the treatment of non-small cell lung cancer (the Study). Each party is required to use commercially reasonable efforts to supply its compound, at its own cost, for use in the Study. Under the Merck Collaboration Agreement, we will act as the sponsor of the Study at our cost (except for the cost of the supply of Keytruda from MSDIG and certain other internal costs incurred by MSDIG in conducting the Study).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Merck Collaboration Agreement, all clinical data arising from the Study and all inventions relating to the combined use of IO102 and Keytruda arising from the Study will be jointly owned by us and MSDIG. We do not have the right under these jointly owned inventions to commercialize any PD-1 antagonist and MSDIG does not have the right under the jointly owned inventions to commercialize any peptide vaccine, such as our T-win&#174; product candidates, containing an IDO-derived peptide. The parties are jointly responsible for prosecuting and maintaining the joint patents, and we have the first right to enforce the joint patents. We will own all rights in any inventions or improvements arising from the Study relating solely to or solely covering IO102 or any a compound that is a peptide vaccine, such as our T-win product candidates, containing an IDO-derived peptide and MSDIG will own all rights in any inventions or improvements arising from the Study relating solely to or solely covering Keytruda or any PD-1 antagonist.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the term of the Merck Collaboration Agreement and for six months thereafter, each party has the option to propose an amendment to the Merck Collaboration Agreement or a new agreement for a registration study for the combination of IO102 and Keytruda for the treatment of non-small cell lung cancer. If either party makes such a proposal, the other party is obligated to negotiate in good faith the terms of such an amendment or agreement. In addition, we are obligated to offer MSDIG the option of participating in a registration study for the treatment of non-small cell lung cancer using IO102 in combination with Keytruda before we enter into an agreement with any third party to conduct a registration study for non-small cell lung cancer for IO102 in combination with a PD-1 antagonist.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Merck Collaboration Agreement will remain in effect until delivery of the final study report for the Study by the Company, unless terminated by either party: (1) for the other party&#8217;s material breach if such party fails to cure such breach within the specified cure period; (2) upon a good faith determination by the terminating party that there is a patient safety concern regarding the Study; (3) if any regulatory authority takes any action that prevents the terminating party from supplying its compound for the Study; (4) if the terminating party determines to withdraw any regulatory approval for its compound or discontinue development of its compound; or (5) for the other party&#8217;s failure to comply with its anti-corruption obligations. Upon termination by MSDIG due to our material breach or our failure to perform any obligations related to anti-corruption laws, we are required to reimburse MSDIG for the direct and indirect manufacturing costs incurred by MSDIG in delivering its compound for the Study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trial Research Agreement with Cliniques Universitaires Saint-Luc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2019, we entered into a Clinical Trial Research Agreement (the Clinical Trial Agreement) with Cliniques Universitaires Saint-Luc (Saint-Luc) in Belgium in order to conduct an investigator-initiated study regarding the activity and safety of peptide-based immunotherapy in the pre-operative setting for patients with squamous-cell carcinoma of the head and neck (the Saint-Luc Study). The Saint-Luc Study is designed as an umbrella trial enabling the testing of multiple of our compounds, including IO102, IO103 and IO112, after initial testing of IO102 in a monotherapy setting. We are responsible for payment of costs associated with the Saint-Luc Study in accordance with an agreed-upon budget.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Saint-Luc is the sponsor of the Saint-Luc Study and owns all inventions arising from, and data and results generated in, the Saint-Luc Study, and has agreed to grant us an exclusive license to all data and results generated during the Saint-Luc Study. In addition, we have the exclusive right to evaluate, prepare, file, prosecute and maintain patent rights related to any inventions, and we will own all such patented inventions. Saint-Luc is required to take all actions necessary to assign rights in any such patents to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Clinical Trial Agreement will continue for the term of the Saint-Luc Study, unless terminated earlier by either party for convenience or the other party&#8217;s material breach, subject to applicable notice and cure periods. In addition, we have the right to terminate the Clinical Trial Agreement for various reasons related to the conduct of the Saint-Luc Study, as specified in the Clinical Trial Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our industry is intensely competitive and subject to rapid and significant technological change. While we believe that our knowledge, experience and scientific resources provide us with competitive advantages, we face substantial competition from major pharmaceutical companies and biotechnology companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and established collaborative arrangements for the research, development, manufacturing and commercialization of cancer immunotherapies. Many of our competitors have significantly greater financial, technical and human resources. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face competition with respect to our current product candidates, and will face competition with respect to future product candidates, from segments of the pharmaceutical, biotechnology and other related markets that pursue immune-oncology treatments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specifically, there are many companies that commercialize or are developing immuno-oncology treatments for cancer including large pharmaceutical and biotechnology companies such as Amgen, AstraZeneca, BMS, Merck, Novartis, Pfizer, Moderna, Regeneron, Roche, and Roche's subsidiary Genentech.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In melanoma specifically, the dominant market players are nivolumab, marketed by BMS and Ono, combination of nivolumab &amp; ipilimumab, marketed by BMS and Ono, combination of nivolumab and relatlimab (LAG-3 blocking antibody) marketed by BMS and pembrolizumab, marketed by Merck. We are also aware of several companies testing their compounds in combination with nivolumab or pembrolizumab. In mid stage development there is Moderna and Merck with an investigational personalized mRNA cancer vaccine, in combination with pembrolizumab. In earlier stage development there are also BioNTech with NEO-PV-01 and Karyopharm with selinexor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are not aware of any human peptides targeting the TME that are currently in late stage development for melanoma, NSCLC,  or other solid tumors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than us in manufacturing and marketing their products. Our competitors may also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, we also face competition more broadly across the market for cost-effective and reimbursable cancer treatments. The most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy, or a combination of such methods. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates, if any are approved, may compete with these existing drug and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product candidates may not be competitive with them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some of our competitors' drugs may be branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic, including branded generic, products. As a result, obtaining market acceptance of, and gaining a significant share of the market for, any of the product candidates that we successfully introduce to the market may pose challenges. In addition, many companies are developing new therapeutics, and we cannot predict what the standard of care will be as our product candidates progress through clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The acquisition or licensing of pharmaceutical products is also very competitive. If we seek to acquire or license products, we may face substantial competition from a number of more established companies, some of which have acknowledged strategies to license or acquire products, and many of which are bigger than us and have more institutional experience and greater cash flows than we have. These more established companies may have competitive advantages over us, as may other emerging companies taking similar or different approaches to product licenses and/or acquisitions. In addition, a number of established research-based pharmaceutical and biotechnology companies may acquire products in late stages of development to augment their internal product lines, which may provide those companies with an even greater competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing and Supply</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our compounds are linear peptides formulated as lyophilized powders to ensure long-term shelf-life and reconstituted with water for injection and emulsified with adjuvant prior to subcutaneously administration. The manufacturing process of our compounds has multiple advantages over other immuno-oncology compounds. The manufacturing process is based on a well-understood process solid state peptide synthesis and data has proven our compounds to be stable for a long period at easy-to-administer temperatures. The cost of goods sold for both trials and commercial use is expected to be relatively low.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently do not own or operate any manufacturing facilities nor do we have any plans to do so in the foreseeable future. We rely on, and expect to continue to rely on, third-party contract development and manufacturing organizations to continue the development and the optimization of our product candidates and to ensure that suitable manufacturing processes are in place for both present scales and future commercial scales of production of our product candidates. This ensures that all products manufactured under our responsibility are done in accordance with relevant regulatory requirements and approval and includes those product materials intended for use in our preclinical and clinical testing, as well as commercial manufacture.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our strategy and workforce allow us to maintain an efficient infrastructure and ensure we do not need to invest in expensive manufacturing facilities and equipment. Our personnel within the organization enable us to focus our expertise and resources on the development of our product candidates and the management of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have obtained active pharmaceutical ingredients (API) from qualified facilities with the relevant expertise to manufacture our drug substances. Likewise, suitably qualified facilities with relevant experience have been used to manufacture our drug products. All third parties are assessed under our quality system and appropriate quality agreements to ensure compliance are in place. We maintain agreements with our manufacturers and ensure that confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates are in place.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are in the process of further optimizing and developing our supply chain for each of our product candidates to ensure continuity of supply and capacity for intended commercial scales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commercialization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We hold worldwide development and commercial rights to our pipeline of therapeutic cancer vaccine programs, and we intend to commercialize our product candidates, if approved, in key geographies. We do not currently have our own marketing, sales, or distribution capabilities. To commercialize IO102-IO103, if approved for commercial sale, we would have to establish marketing and sales capabilities internally or through collaborators.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to receiving marketing approvals, we plan to commence commercialization activities by building a focused marketing and sales organization. The marketing organization would be responsible for creating and implementing marketing strategies and tactics. The sales organization would be responsible for overseeing and supporting the sales force. We may selectively enter into distribution, marketing or other commercial arrangements with third parties for any of our product candidates that obtain marketing approval if we believe these collaborations could maximize the value of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">     </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to our business, including seeking, maintaining, and defending patent rights, whether developed internally or assigned from third parties. We own the issued patents and patent applications relating to all compounds in our portfolio. Our policy includes seeking to protect our proprietary position by, among other methods, filing patent applications, in the United States and in jurisdictions outside of the United States, directed at our proprietary technology, inventions, improvements, and product candidates that are important to the development and implementation of our business. We also rely on trade secrets and know-how relating to our proprietary technology and product candidates, continued innovation, and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of immunotherapy. We also plan to rely on data exclusivity, market exclusivity, and supplementary protection certificates / patent term extensions (SPC/PTE) when available. Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions, and improvements; to preserve the confidentiality of our trade secrets and know-how; to obtain and maintain licenses to use intellectual property owned by third parties; to defend and enforce our proprietary rights, including any patents that we may own in the future; and to operate without infringing, misappropriating or otherwise violating the valid and enforceable patents and other proprietary rights of third parties. For more information, please see &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our patent portfolio is currently comprised of 17 separate patent families.  These are numbered as Families 1 to 17 and are discussed in more detail below. The families are divided into groups based on therapeutic targets. Some of the families span more than one target, particularly with respect to the patents for our lead compounds directed to the target IDO (compound IO102) and target PD-L1 (compound IO103).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IO102 (IDO)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: We own five patent families covering compositions of matter and methods of treatment related to IO102, which were filed between 2009 and 2023. These are Families 1, 2, 3, 13 and 15.</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.0484032491376425%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Family 1 is based on an international (PCT) application filed April 17, 2009. Patents granted from this family will expire April 17, 2029 based on a normal 20 year term. In the United States, a granted patent covering IO102 as a composition of matter will expire October 7, 2029 due to a patent term adjustment of 173 days. A separate granted patent in the United States covers methods of treatment using IO102 and will expire May 28, 2029 due to a patent term adjustment of 41 days. A separate granted patent in the United States application covers nucleotides encoding IO102 and will expire April 17, 2029 (no patent term adjustment). A separate pending United States application covers methods of treatment using nucleotides encoding IO102. In other jurisdictions it is not typically necessary to present claims to compositions of matter separately from methods of treatment and thus both types of claim appear in the same patent. The family includes granted patents in Europe, Hong Kong, China, Japan, Canada, Australia, Israel, New Zealand and South Africa, each of which has claims covering IO102 as a compositions of matter and the local equivalent of methods of treatment using IO102. Each of these patents has the normal 20 year term expiring April 17, 2029. The family also includes a pending application at the European Patent Office (EPO); </span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.0484032491376425%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Family 2 is based on a PCT application filed March 3, 2017.  Patents granted from this family will expire  March 3, 2037 based on a normal 20 year term. A granted patent in Europe covers a combination of IO102, IO103 and an anti-PD1 antibody for use in a method for preventing or treating cancer. A pending application in Japan covers the same subject matter and has received a notice of allowance. Separate pending applications in Europe and Japan will pursue claims which cover administration of IO102 + anti-PD-1 in a separate composition to IO103. The family also includes a pending application in the United States with claims covering a method of treating a PD-L1 expressing cancer by administering IO103 + anti-PD1 and an adjuvant;</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.0484032491376425%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Family 3 is based on a PCT application filed April 23, 2018.  Patents granted from this family will expire April 23, 2038 based on a normal 20 year term. The family includes pending applications in the United States, Europe, Japan and China. Claims are directed to combined uses of IO102, IO103 and a specific category of therapeutic antibody, i.e. those which operate via antibody-dependent cellular cytotoxicity (ADCC) mechanisms of action; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.0484032491376425%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Family 13 is based on a PCT application filed August 31, 2021. Patents granted from this family will expire August 31, 2041 based on a normal 20 year term. The family includes pending applications in the United States, Europe, China, Japan, Republic of Korea, Singapore, Canada, Australia and Israel. Claims are directed to combined uses of IO102, IO103 and anti-PD1 antibody; and </span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.0484032491376425%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Family 15 is based on a PCT application filed February 23, 2023. National phase applications in other jurisdictions will be filed in due course. Patents granted from this family will expire February 23, 2043. Claims are directed to mRNAs encoding all existing candidates in the IO Biotech portfolio, including IO102. </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IO103 (PD-L1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We own five patent families covering compositions of matter and methods of treatment related to IO103, which were filed between 2012 through 2023. These are Families 2, 3, 13 and 15 listed above, plus Family 4 set out below. Family 5 covers alternative PD-L1 compound IO104.1. </span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.0484032491376425%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Family 4 is based on a PCT application filed October 17, 2012. Patents granted from this family will expire October 17, 2032 based on a normal 20 year term. In the United States, a granted patent covering IO103 as a composition of matter and methods of treatment using IO103 will expire May 11, 2033 due to a patent term adjustment of 206 days. The family includes granted patents in Europe, China, Japan, Brazil and Canada, each of which has claims covering IO103 as a composition of matter and the local equivalent of methods of treatment using IO103. The family also includes pending applications in Europe, Hong Kong and China; and</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.0484032491376425%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Family 5 is based on a PCT application filed June 20, 2017. Patents granted from this family will expire June 20, 2037 based on a normal 20 year term. A granted patent in China covers alternative PD-L1 compound IO104.1 as a composition of matter and methods of treatment using IO104.1. We anticipate calculating patent term adjustment in the near future. The family includes pending applications in the United States, Europe, and Japan. IO103 is also disclosed in the application, but the data in the application is primarily concerned with IO104.1, as such prosecution is focused on securing claims to this compound.</span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IO112 (Arginase 1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: We own three patent families covering compositions of matter related to IO112, which were filed between 2017 through 2023. These are Family 15 as listed above, plus Families 6 and 7 set out below. </span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.0484032491376425%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Family 6 is based on a PCT application filed October 6, 2017. Patents granted from this family will expire October 6, 2037 based on a normal 20 year term. In the United States, there is a granted patent with this expiry date which covers IO112 as a composition of matter and methods of treatment using IO112. A separate pending application in the United States covers methods of preparing a pharmaceutical composition comprising IO112 and has received a notice of allowance. A granted patent in Japan covers IO112 as a composition of matter, as well as nucleotides encoding IO112 and methods of treatment using the same. A pending application in Europe covers the same and has received a notice of allowance. The family also includes pending applications in the United States, Hong Kong, China, Australia, Canada, Republic of Korea, and Mexico. Grant is imminent in Singapore and Israel. This family is also relevant to Arginase 2; and </span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.0484032491376425%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Family 7 is based on a PCT application filed September 24, 2019. Patents granted from this family will expire September 24, 2039 based on a normal 20 year term. The family includes pending applications in the  United States, the EPO, China, Japan, Australia, Canada, Israel, Republic of Korea, Mexico, and Singapore. The claims are directed specifically to IO112, and uses thereof. </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have additional patent families relevant to the following targets: </span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.0484032491376425%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TDO</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We own one patent family based on a PCT application filed September 15, 2015. This is Family 8. Patents granted from this family will expire September 15, 2035 based on a normal 20 year term. In the United States, a granted patent covering TDO candidate peptides and methods of treatment using the same will expire March 1, 2036 due to a patent term adjustment of 168 days. A separate granted patent in the United States covers nucleic acids encoding the TDO candidate peptides and will expire February 21, 2037 due to a patent term adjustment of 525 days. The family includes granted patents in Europe, China, Japan, Australia, Canada, Israel and South Africa. The family also includes a pending application in Europe which will pursue alternative claim scope, including nucleic acids encoding TDO candidate peptides. Grant is imminent in New Zealand.  Family 15 listed above is also relevant; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.0484032491376425%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PD-L2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We own one patent family based on a PCT application filed October 13, 2017. This is Family 9. Patents granted from this family will expire October 13, 2037 based on a normal 20 year term. The family includes granted patents in the United States and Japan. The family also includes pending applications in the United States, China, EPO, and Hong Kong. Claims are directed to target candidates, and uses thereof.  Family 15 listed above is also relevant; </span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.0484032491376425%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CCL22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We own one patent family based on a PCT application filed September 16, 2016. This is Family 10. Patents granted from this family will expire September 16, 2036 based on a normal 20 year term. The family includes granted patents in the United States, China, Japan, Israel and Australia. The family also includes pending applications in the United States, China, EPO, Canada, Hong Kong, New Zealand, and South Africa. Claims are directed to target candidates, and uses thereof.  Family 15 listed above is also relevant; </span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.0484032491376425%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Arginase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: We own three patent families relevant to this target. The first is Family 6 as listed under IO112 (Arginase 1) above. The second is Family 11, based on a PCT application filed November 14, 2019. Patents granted from this family will expire November 14, 2039 based on a normal 20 year term The family includes pending applications in the United States, China, EPO, Japan, Australia, Canada, Israel, Republic of Korea, and Singapore.  Claims are directed to target candidates, and uses thereof. The third family is Family 14, based on two first filings made in the United Kingdom on February 24, 2022 and September 13, 2022. A PCT application was filed February 24, 2023. National phase applications in other jurisdictions will be filed in due course. Patents granted from this family will expire February 24, 2043 based on a normal 20 year term. Claims are directed to alternative target candidates, and uses thereof.  Family 15 listed above is also relevant; and</span></div></div>
  <div style="margin-left:10.13%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.0484032491376425%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TGF&#946;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: We own three patent families relevant to this target. The first is Family 12, based on a PCT application filed  June 4, 2020. Patents granted from this family will expire June 4, 2040 based on a normal 20 year term. The family includes pending applications in the United States, China, Hong Kong, EPO, Japan, Australia, Canada, Israel, Republic of Korea, Mexico, and Singapore. Claims are directed to target candidates, and uses thereof. The second is Family 16, based on a PCT application filed November 3, 2023. National phase applications in other jurisdictions will be filed in due course. Patents granted from this family will expire 3 November 4, 2043 based on a normal 20 year term. Claims are directed to alternative target candidates, and uses thereof. The third is Family 17, based on a PCT application filed October 27, 2023. National phase applications in other jurisdictions will be filed in due course. Patents granted from this family will expire October 27, 2043 based on a normal 20 year term. Claims are directed to combined uses of TGF&#946; target candidates with immune checkpoint inhibitors such as anti-PD1 antibody, as well as methods of predicting responsiveness to anti-PD1 treatment based on immune responses to TGF&#946;. Family 15 listed above is also relevant.  </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon receipt of marketing approvals in each country, we will file applications for supplementary protection certificates/patent term extensions (SPC/PTE) as appropriate. These will provide up to an additional 5 years term of protection with respect to each extended patent, although there is no guarantee that we will be able to obtain such SPC/PTE. For more information, please see &#8220;Risk Factors&#8212; If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be harmed.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trademark</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We hold the trademark T-win&#174; in the European Union (Registered no. 017871048), the United States (Registered no. 5754675), China (Registered no. 33152486), Japan (Registered no. 6107125), and the United Kingdom (Registered no. 00917871048). The trademark of T-win is registered in class 5 (including pharmaceuticals and other preparations for medical purposes) and class 42 (including scientific and/or medical research services).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, tracking, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biological products such as those we are developing. We, along with our vendors, collaboration partners, CROs and CMOs, will be required to navigate the various preclinical, clinical, manufacturing and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our product candidates. The process of obtaining regulatory approvals of biological products and ensuring subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, where we are initially focusing our product development, the FDA regulates biologics under the Federal Food, Drugs, and Cosmetics Act, as amended (FDCA) and the Public Health Service Act, as amended (PHSA) and their implementing regulations. Biologics are also subject to other federal, state and local statutes and regulations. Our product candidates are early-stage and have not been approved by the FDA for marketing in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates must be approved for therapeutic indications by the FDA through a BLA before they may be marketed in the United States. The process generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with GLP requirements; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an IND, which must become effective before clinical trials to be conducted in the U.S. may begin and must be updated annually or when significant changes are made; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval by an IRB or independent ethics committee at each clinical trial site before each trial may be initiated; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well-controlled clinical trials in accordance with GCP requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational biologic for each proposed indication; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation and submission to the FDA of a BLA, after completion of all pivotal trials; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment of user fees for FDA review of the BLA; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential review of the product application by an FDA advisory committee, where appropriate and if applicable; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of an FDA advisory committee review, if applicable; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the biologic will be produced to assess compliance with cGMP to assure that the facilities, methods, and controls are adequate to preserve the product&#8217;s identity and continued safety, purity, and potency; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential FDA audit of the preclinical and clinical trial sites that generated the data in support of the BLA; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA review and approval of the BLA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the product in the United States; and </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with any post-approval commitments and / or requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (REMS) or to conduct a post-approval study. </span></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nonclinical and Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nonclinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before testing any biologic product in humans, the product candidate must undergo rigorous nonclinical testing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro and in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Such nonclinical in vitro and in vivo animal studies assess safety and in some cases to establish the rationale for therapeutic use. The conduct of nonclinical studies is subject to federal and state regulations and requirements, including GLP requirements for safety and toxicology studies. The results of the nonclinical studies, together with manufacturing information, a proposed clinical trial protocol, and analytical data must be submitted to the FDA as part of an IND prior to the start of clinical studies in humans. However, some long-term nonclinical testing may continue after the IND is submitted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials to evaluate therapeutic indications to support BLAs for marketing approval are typically conducted in three sequential phases, which may overlap.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1&#8212;Phase 1 clinical trials involve initial introduction of the investigational product into healthy human volunteers or patients with the target disease or condition. These studies are typically designed to test the safety, dosage tolerance, absorption, metabolism, distribution, and excretion of the investigational product in humans, evaluate the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 2&#8212;Phase 2 clinical trials typically involve administration of the investigational product to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Phase 1 trials are sometimes combined with Phase 2 trials. These trials are known as Phase 1/2 trials. Generally, a Phase 1/2 trial is conducted as a single trial that has the characteristics of both a Phase 1 trial (as described above) and a Phase 2 trial. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. Phase 2 trials may be conducted as basket trials where a single investigational drug or drug combination is studied across multiple cancer populations defined by disease stage, histology, number of prior therapies, genetic or other biomarkers, or demographic characteristics; and </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3&#8212;Phase 3 clinical trials typically involve administration of the investigational product to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for approval. Accordingly, these are generally known as registrational trials. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of a BLA. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional information regarding risks, benefits, and optimal use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of a BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investigational New Drug &#8212; Authorization to Conduct Clinical Trials in US</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An IND is a request for authorization from the FDA to administer an investigational biologic product to humans and to ship such products in interstate commerce for use in investigational clinical trials. INDs must become effective before clinical trials in the U.S. may begin. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, carcinogenicity, formulation, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; any available human data or literature to support the use of the investigational product; and a proposed clinical trial protocol.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The IND automatically becomes effective 30 days after receipt of the submission by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and imposes a clinical hold. In such a case, the IND sponsor must resolve any outstanding concerns before the clinical trial can begin. Accordingly, submission of an IND may or may not result in FDA authorization to begin a trial. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development of a product candidate, and the FDA must grant permission, either explicitly or implicitly by not objecting, before each clinical trial can begin.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials involve the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control in accordance with GCP requirements, which include the requirements that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection, and exclusion criteria, and the parameters and criteria to be used in monitoring safety and evaluating effectiveness. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonably related to the anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA, the IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There also are requirements governing the reporting of ongoing clinical trials and completed clinical trials to public registries. Information about applicable clinical trials, including clinical trials results, must be submitted within specific timeframes to the National Institutes of Health (NIH) for publication on the www.clinicaltrials.gov website.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and IND safety reports must be submitted to the FDA and the investigators within fifteen days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse reactions, findings from other studies or animal or in vitro testing that suggest a significant risk for human participants exposed to the drug or biological product, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible, but in no case later than seven calendar days after the sponsor&#8217;s initial receipt of the information.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. The FDA will accept a well-designed and well-conducted foreign clinical study not conducted under an IND if, among other things, the study was conducted in accordance with GCP, and the FDA is able to validate the data through an onsite inspection if deemed necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">FDA Review Process</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assuming successful completion of the required clinical testing, a BLA requesting approval to market the product for one or more indications must be submitted to FDA. A BLA is a request for approval to market a new biological product for one or more specified indications. The BLA must include all relevant data available from pertinent nonclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators not from the company. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety, purity, and potency of the investigational biological product, to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a product may be marketed in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under the Pediatric Research Equity Act (PREA) certain BLAs and certain supplements to a BLA must contain data to assess the safety and effectiveness of the product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, unless the sponsor has received a deferral or waiver. A sponsor who is planning to submit a marketing application for a product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan (iPSP) within 60 days after an End-of-Phase 2 meeting or such other time as agreed upon between FDA and the sponsor.  If no End-of-Phase 2 meeting occurs, the iPSP should be submitted as soon as practicable but before initiation of Phase 3 studies, or within 210 calendar days in advance of a marketing application if a Phase 3 study, or a combined Phase 2 and Phase 3 study, will not be conducted or will be conducted but not under IND. Unless otherwise required by regulation, PREA does not apply to a product for an indication for which orphan designation has been granted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA reviews all submitted BLAs before it accepts them for filing, and may request additional information rather than accepting the BLA for filing. The FDA must make a decision on accepting a BLA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the application. The FDA reviews a BLA to determine, among other things, whether the product is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure continued safety, quality and purity. Under the goals and polices agreed to by the FDA under the Prescription Drug User Fee Act, as amended (PDUFA) the FDA targets ten months, from the filing date, in which to complete its initial review of an original BLA and respond to the applicant, and six months from the filing date of an original BLA filed for priority review. The FDA does not always meet its PDUFA goal dates for standard or priority BLAs, and the review process may be extended by FDA requests for additional information or clarification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, under the PDUFA, each BLA must be accompanied by a user fee and the sponsor of an approved BLA is also subject to an annual program fee. FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions may be available in certain circumstances, including a waiver of the application fee for the first BLA filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product applicant also seeks approval for a non-orphan indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may refer an application for a biologic product to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before approving a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production within required specifications. Additionally, before approving a BLA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP, and other requirements, and the integrity of the clinical data submitted to the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA also may require submission of a Risk Evaluation and Mitigation Strategy (REMS) as a condition for approving the BLA to ensure that the benefits of the product outweigh its risks. The REMS could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk-minimization tools.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After evaluating the application and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter. A Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter will usually describe all of the deficiencies that the FDA has identified in the BLA, except where the FDA determines that the data supporting the application are inadequate to support approval, and the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted production lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if the FDA approves a biologic product, depending on the specific risk(s) to be addressed, the FDA may limit the approved indications for use, require that contraindications, warnings or precautions be included in the approved labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan drug designation (ODD) to a biologic product intended to treat a rare disease or condition, defined as a disease or condition with either a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biological product in the United States will be recovered from sales in the United States of that drug or biological product. ODD must be requested before submitting a BLA. After the FDA grants ODD, the identity of the therapeutic agent and its orphan designation are disclosed publicly by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A product that has received ODD and subsequently is the first FDA approved biologic product for the disease for which it has such designation, is entitled to orphan product exclusivity for the approved indication. The designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process. Orphan exclusivity means that the FDA may not approve any other applications, including a full BLA, to market the same drug or biological product for the same indication for seven years from the date of approval of the BLA, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or if the FDA finds that the holder of the orphan exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the product was approved. Orphan exclusivity does not prevent the FDA from approving a different drug</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or biological product for the same disease or condition, or the same product for a different disease or condition. Among the other benefits of ODD are tax credits for certain research and a waiver of the BLA application user fee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A product that has received ODD may not receive orphan exclusivity if it is approved for a use that is broader than the indication for which it received ODD. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of the patients with the rare disease or condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA maintains several programs intended to facilitate and expedite development and review of new biologic products to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track Designation (FTD), Breakthrough Therapy Designation (BTD), Priority Review (PR) and Accelerated Approval (AA).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A new biologic product is eligible for FTD if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. FTD applies to the biologic product, or combination of drugs and biologic products, and the specific indication for which it is being studied. FTD may provide increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed, meaning that the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. FDA may revoke the FTD if it believes that the designation is no longer supported by data emerging in the clinical trial process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, a new biologic product may be eligible for BTD if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biological product, alone or in combination with or more other biologic products, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. BTD provides all the features of FTD in addition to intensive guidance on an efficient development program beginning as early as Phase 1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review and regulatory staff in a proactive, collaborative, cross-disciplinary review, where appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any biologic product submitted to the FDA for approval, including a product with FTD, or BTD, may also be eligible for priority review. A product is eligible for priority review if it is intended to treat a serious condition, and if approved, would provide a significant improvement in safety or effectiveness. For original BLAs, PR Designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (compared with ten months under standard review).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, biologic products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of such product receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the product may be subject to accelerated withdrawal procedures. Products granted AA must meet the same statutory standards for safety and effectiveness as those granted traditional approval. In addition, the FDA currently requires as a condition for AA pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. FTD, BTD, PR, and AA do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval but may expedite the development or review process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Post-Approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biological products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences with the product, complying with promotion and advertising</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements, which include restrictions on promoting products for unapproved uses or patient populations (off-label use) and limitations on industry-sponsored scientific and educational activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may impose a number of post-approval requirements as a condition of approval of a BLA. For example, the FDA may require post-market testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, product manufacturers and their subcontractors involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP, which imposes certain procedural and documentation requirements upon us and our CMOs. Changes to the manufacturing process are strictly regulated, and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon the sponsor and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. Failure to comply with statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, and civil or criminal penalties. There is also a continuing, annual program fee for any marketed product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mandated modification of promotional materials and labeling and issuance of corrective information; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, warning letters, or untitled letters; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">holds on clinical trials; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation of product approvals; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties; and </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Biosimilars and Reference Product Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010  (collectively, the ACA) includes a subtitle called the Biologics Price Competition and Innovation Act (BPCIA), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product.  The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a clinical study or studies, unless the Secretary of Health and Human Services waives a required element. Interchangeability requires that a product is biosimilar to the reference product, and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biological product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to approval of biosimilar and interchangeable biosimilar products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reference product is granted 12 years of exclusivity from the time of first licensure of the reference product, and an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing that sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the other company&#8217;s product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At this juncture, it is unclear whether products deemed interchangeable by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study, requested by the Secretary, in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study. However, extensions are not applicable if made later than 9 months prior to the expiration of such period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Regulatory Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As further described below, manufacturing, sales, commercialization and promotion of product candidates following product approval and other related activities of the company, where applicable, are subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, which may include the Centers for Medicare and Medicaid Services (CMS), other divisions of the Department of Health and Human Services (HHS), the Department of Justice (DOJ), the Drug Enforcement Administration (DEA), the Consumer Product Safety Commission (CPSC), the Federal Trade Commission (FTC), the Occupational Safety &amp; Health Administration (OSHA), the Environmental Protection Agency (EPA) and state and local governments and governmental agencies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Healthcare Laws</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Physicians, other healthcare providers, and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our business operations and any current or future arrangements with third-party payors, healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we develop, market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include, without limitation:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Anti-Kickback Statute, an intent-based, federal criminal statute which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or arrangement for, or recommendation of, any item or service, for which payment may be made, in whole or in part, by a federal healthcare program such as Medicare or Medicaid. A person or entity need not have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. The term remuneration has been interpreted broadly to include anything of value. Further, courts have found that if any &#8220;one purpose&#8221; of an arrangement involving remuneration is to induce referrals of federal healthcare program business, the federal Anti-Kickback Statute has been violated. Violations may be subject to significant civil and criminal fines and penalties for each violation, imprisonment, and exclusion from participation in federal healthcare programs. The federal Anti-Kickback Statute applies to arrangements between pharmaceutical manufacturers on the one hand and individuals, such as prescribers, patients, purchasers, and formulary managers on the other hand, including, for example, consulting/speaking arrangements, discount and rebate offers, grants, charitable contributions, and patient support offerings, among others. Although there are a number of statutory exceptions and regulatory safe harbors to the federal Anti-Kickback Statute that protect certain common industry activities from prosecution, these exceptions and safe harbors are narrowly drawn. Arrangements that do not fully satisfy all elements of an available exception or safe harbor are evaluated based on the specific facts and circumstances and are typically subject to increased scrutiny; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal civil and criminal false claims laws, including the civil False Claims Act (FCA), which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false, fictitious or fraudulent; knowingly making, using, or causing to be made or used, a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. Additionally, the ACA specified that any claims submitted as a result of a violation of the federal Anti-Kickback Statute constitute false claims and are subject to enforcement under the FCA, and  the government may further assert that a claim that includes items or services resulting from a violation of the FDCA or other law constitutes a false or fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring qui tam actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery or settlement. Violations of the FCA may be subject to significant civil fines and penalties for each false claim, currently ranging from $13,946 - $27,894 per false claim, treble damages, and potential exclusion from participation in federal healthcare programs;</span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal civil monetary penalties laws, which impose significant civil fines against individuals and entities that engage in activities including, among other things, knowingly presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; arranging for or contracting with an individual or entity that is excluded from participation in federal healthcare programs to provide items or services reimbursable by a federal healthcare program; violations of the federal Anti-Kickback Statute; failing to report and return a known overpayment; or offering or transferring any remuneration to a Medicare or Medicaid beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of items or services reimbursable by Medicare or Medicaid, unless an exception applies; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal criminal statutes which impose criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, or to obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program; knowingly and willfully embezzling or stealing from a healthcare benefit program; willfully preventing, obstructing, misleading, or delaying a criminal investigation of a healthcare offense; and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity need not have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Health Insurance Portability and Accountability Act (HIPAA), as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), and their respective implementing regulations, imposes, among other things, specified requirements on covered entities and their business associates relating to the privacy and security of individually identifiable health information including mandatory contractual terms and required implementation of technical safeguards of such information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates in some cases, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. The Department of Health and Human Services Office for Civil Rights (OCR) has recently increased its enforcement efforts on compliance with HIPAA, including its security regulations, and bringing actions against entities an business associates for failure to implement required security measures to protect electronic protected health information or to conduct a thorough risk assessment, among other violations;</span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Physician Payments Sunshine Act, enacted as part of the ACA, which imposes annual tracking and reporting requirements for, among others, certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, of certain payments and &#8220;transfers of value&#8221; provided to U.S.-licensed physicians (defined to include doctors, dentists, optometrists, podiatrists and licensed chiropractors), physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiology assistants, certified nurse midwives, and teaching hospitals, as well as tracking and reporting of ownership and investment interests held by U.S.-licensed physicians and their immediate family members; and </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party-payors, including private insurers, and may be broader in scope than their federal equivalents; state and foreign laws requiring pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state laws and regulations that require disclosures to state agencies and/or commercial purchasers with respect to certain price increases that exceed a certain level as identified in the relevant statutes; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, and restrict marketing practices or require disclosure of marketing expenditures and pricing information; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws that govern the privacy and security of health information in some circumstances and which may differ from each other in significant ways and often are not pre-empted by HIPAA and may therefore complicate compliance efforts. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The full scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have continued to increase their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices, including certain arrangements with physicians who receive stock, warrants, or stock options as compensation for services provided to us, do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other related governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from its business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients and healthcare providers are unlikely to use our products unless third-party payor coverage is provided and reimbursement by such payor is adequate to cover a significant portion of the cost of our products. Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other comparable government authorities. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Medicaid Drug Rebate Statute, we expect to be required to participate in the Medicaid Drug Rebate Program in order for federal payment to be available for our products under Medicaid and Medicare Part B. Medicaid is a government health insurance program for eligible low-income adults, children, families, pregnant women, and people with certain disabilities. It is jointly funded by the federal and state governments, and it is administered by individual states within parameters established by the federal government. As a result, coverage and reimbursement requirements for drugs and biologics vary by state. For example, drugs and biologics may be covered under the medical or pharmacy benefit, and state Medicaid programs may impose different utilization management controls, such as prior authorization, step therapy, or quantity limits on drugs and biologics, subject to federal limitations for such controls. But all state Medicaid programs must generally provide coverage and reimbursement for a manufacturer&#8217;s covered outpatient drugs, as that term is defined by applicable law, if a manufacturer participates in the Medicaid Drug Rebate Program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Medicaid Drug Rebate Program, we would be required to, among other things, pay a rebate to each state Medicaid program for quantities of our products utilized on an outpatient basis (with some exceptions) that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program. Medicaid Drug Rebate Program rebates are calculated using a statutory formula, state-reported utilization data, and pricing data that are calculated and reported by us on a monthly and quarterly basis to CMS. These data include the average manufacturer price and, in the case of single source and innovator multiple source products, the best price for each drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to participating in the Medicaid Drug Rebate Program, federal law requires manufacturers to participate in the Public Health Service&#8217;s 340B drug pricing program in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and Medicare Part B. The 340B drug pricing program requires participating manufacturers to agree to charge statutorily-defined covered entities no more than the 340B &#8220;ceiling price&#8221; for the manufacturer&#8217;s covered outpatient drugs. These 340B covered entities only include health care organizations that have certain federal designations or receive funding from specific federal programs, including Federally Qualified Health Centers, Ryan White HIV/AIDS Program grantees, and certain types of hospitals and specialized clinics, as well as certain hospitals that serve a disproportionate share of low-income patients. The ACA expanded the 340B program to include additional types of covered entities: certain children&#8217;s hospitals, certain free-standing cancer hospitals, critical access hospitals, certain rural referral centers and certain sole community hospitals, each as defined by the ACA. However, &#8220;orphan drugs&#8221; i.e., those designated under section 526 of the FDCA are exempted from the ceiling price requirements for these eligible entities added by the ACA (except for certain children&#8217;s hospitals). The 340B ceiling price is calculated using a statutory formula, which is based on the average manufacturer price and rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate Program, and in general, products subject to the Medicaid Drug Rebate Program are also subject to the 340B ceiling price calculation and discount requirement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, after multiple delays, the final rule implementing civil monetary penalties against manufacturers for instances of overcharging 340B covered entities became effective on January 1, 2019. Accordingly, if we have an approved product, we could be subject to such penalties if the government were to find that we knowingly and intentionally overcharged a 340B covered entity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal law requires that for a company to be eligible to have its products paid for with federal funds under the Medicaid and Medicare Part B programs as well as to be purchased by certain federal agencies and grantees, it also must participate in the Department of Veterans Affairs (VA) Federal Supply Schedule (FSS) pricing program. To participate, we will be required to enter into an FSS contract and other agreements with the VA for our products, which may qualify as &#8220;covered drugs.&#8221; Under these agreements, we would need to make our products available to the &#8220;Big Four&#8221; federal agencies&#8212;the VA, the Department of Defense (DoD), the Public Health Service (including the Indian Health Service), and the Coast Guard&#8212;at prices that are capped pursuant to a statutory federal ceiling price, or FCP, formula set forth in Section 603 of the Veterans Health Care Act of 1992, as amended (VHCA). The FCP is based on a weighted average non-federal average manufacturer price (Non-FAMP), which manufacturers are required to report on a quarterly and annual basis to the VA. Pursuant to the VHCA, knowing provision of false information in connection with a Non-FAMP filing can subject a manufacturer to a penalty for each item of false information and could result in other potential liability as well, including liability under the False Claims Act.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FSS contracts are federal procurement contracts that include standard government terms and conditions, separate pricing for each product, and extensive disclosure and certification requirements. All items on FSS contracts are subject to a standard FSS contract clause that requires FSS contract price reductions under certain circumstances where pricing is reduced to an agreed &#8220;tracking customer.&#8221; Further, in addition to the &#8220;Big Four&#8221; federal agencies, all other federal agencies and some non-federal entities are authorized to purchase off FSS contracts. FSS contractors are permitted to charge FSS purchasers other than the Big Four agencies &#8220;negotiated pricing&#8221; for covered drugs that is not capped by the FCP, and such pricing is negotiated based on a mandatory disclosure of the contractor&#8217;s commercial &#8220;most favored customer&#8221; pricing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, pursuant to regulations issued by the DoD to implement Section 703 of the National Defense Authorization Act for Fiscal Year 2008, each of our covered drugs will be listed on an agreement with the Defense Health Agency (DHA) under which we will agree to honor the &#8220;Big Four&#8221; pricing for our products when they are dispensed to TRICARE beneficiaries by TRICARE retail network pharmacies. More specifically, we will agree to provide rebates (or refunds) on such utilization. Companies are required to enter into a DHA Agreement for &#8220;covered drug&#8221; products in order for the covered drug to be eligible for DoD formulary inclusion and available to TRICARE beneficiaries without preauthorization. The formula for determining the rebate is established in the regulations and our DHA agreement and is based on the difference between the annual Non-FAMP and the FCP (as described above, these price points are required to be calculated by us under the VHCA).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, with commercial payors, coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged for, examining the medical necessity of, and reviewing the cost-effectiveness of medical products and services. They are also increasingly imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. Moreover, for products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. Nonetheless, product candidates may not be considered medically necessary or cost-effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Third-party coverage and reimbursement may not be available to enable us to maintain price levels sufficient to cover our costs, including research, development, manufacture, sale and distribution.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The containment of healthcare costs also has become a priority of federal, state and foreign governments, and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. It is difficult to predict how Medicare coverage and reimbursement policies will be applied to products for which the company receives marketing approval in the future and coverage and reimbursement under different federal healthcare programs is not always consistent. Further, private payors often follow the coverage and reimbursement policies established under Medicare. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products for which we receive marketing approval.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. For example, in March 2010, the United States Congress enacted the ACA, which, among other things, included changes to the coverage and payment for products under government health care programs. The ACA included provisions of importance to our potential product candidate that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">created an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products, apportioned among these entities according to their market share in certain government healthcare programs; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 138% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of &#8220;average manufacturer price,&#8221; or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expanded the types of entities eligible for the 340B drug discount program; and</span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its enactment, there have been judicial, executive and congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law, including the repeal, effective January 1, 2019, of the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states who argued that, without the individual mandate, the entire ACA was unconstitutional. The Supreme Court&#8217;s dismissal of the lawsuit  did not specifically rule on the constitutionality of the ACA. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact the ACA or our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. These changes include the Budget Control Act of 2011, which, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through the first six months of the FY 2032 sequestration order unless additional congressional action is taken, with the exception of a temporary suspension by Congress of the 2% cut in Medicare payments from May 1, 2020 through March 31, 2022, with a 1% cut in Medicare payments in effect from March 31, 2022 to July 1, 2022, due to COVID-19 public health emergency. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, payment methodologies may be subject to changes under new healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. For example, included in the Consolidated Appropriations Act, 2021 were several drug price reporting and transparency measures, such as a new requirement for certain Medicare plans to develop tools to display Medicare Part D prescription drug benefit information in real time and for group and health insurance issuers to report information on pharmacy benefit and drug costs to the Secretaries of HHS, Labor and the Treasury. Moreover, in August 2022, President Biden signed into law the Inflation Reduction Act of 2022 (IRA), which implements substantial changes to the Medicare program, including drug pricing reforms and the creation of new Medicare inflation rebates. Namely, the IRA imposes inflation rebates on drug manufacturers for products reimbursed under Medicare Parts B and D if the prices of those products increase faster than inflation; implements changes to the Medicare Part D benefit that, beginning in 2025, will cap beneficiary annual out-of-pocket spending at $2,000, while imposing new discount obligations for pharmaceutical manufacturers; and, beginning in 2026, establishes a &#8220;maximum fair price&#8221; for a fixed number of high expenditure pharmaceutical and biological products covered under Medicare Parts B and D following a price negotiation process with CMS.  CMS has also taken steps to implement the IRA, including: on June 30, 2023, issuing guidance detailing the requirements and parameters of the first round of price negotiations, to take place during 2023 and 2024, for products subject to the &#8220;maximum fair price&#8221; provision that would become effective in 2026; on August 29, 2023, releasing the initial list of ten drugs subject to price negotiations; on November 17, 2023, releasing guidance outlining the methodology for identifying certain manufacturers eligible to participate in a phase-in period where discounts on applicable products will be lower than those required by the Medicare Part D Manufacturer Discount Program; and on December 14, 2023, releasing a list of 48 Medicare Part B products that had an adjusted coinsurance rate based on the inflationary rebate provisions of the IRA for the period of January 1, 2024 to March 31, 2024.  Additionally, on October 14, 2022, President Biden issued an Executive Order on Lowering Prescription Drug Costs for Americans, which instructed the Secretary of HHS to consider whether to select for testing by the CMS Innovation Center new health care payment and delivery models that would lower drug costs and promote access to innovative drug therapies for beneficiaries enrolled in the Medicare and Medicaid programs. On February 14, 2023, HHS issued a report in response to the October 14, 2022 Executive Order, which, among other things, selects three potential drug affordability and accessibility models to be tested by the CMS Innovation Center. Specifically, the report addresses: (1) a model that would allow Part D Sponsors to establish a &#8220;high-value drug list&#8221; setting the maximum co-payment amount for certain common generic drugs at $2.00; (2) a Medicaid-focused model that would establish a partnership between CMS, manufacturers, and state Medicaid agencies that would result in multi-state outcomes-based agreements or certain cell and gene therapy drugs; and (3) a model that would adjust Medicare Part B payment amounts for Accelerated Approval Program drugs to advance the developments of novel treatments.  In addition on February 2, 2022, the Biden administration signaled its continued commitment to the Cancer Moonshot initiative, which was initially launched in 2016. In its announcement, the administration noted that its new goals under the initiative include addressing inequities in order to ensure broader access to cutting-edge cancer therapeutics and investing in a robust pipeline for new treatments.  In alignment with President Biden&#8217;s Cancer Moonshot initiative, on June 27, 2023, the Center for Medicare Innovation at CMS announced a new model, the Enhancing Oncology Model, that is designed to make high-quality cancer care more affordable to both patients and Medicare. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the extent to which the U.S. federal government covers particular healthcare products and services and could limit the amounts that the U.S. federal government will pay for healthcare products and services. This could result in reduced demand for our product candidates or additional pricing pressures. At the state level, individual states have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize any product that is ultimately approved, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act, but the manufacturer must develop an internal policy and respond to patient requests according to that policy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the United States, ensuring coverage and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval for a product and may require a clinical trial that compares the cost-effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the EU provides options for its EU Member States to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between low-priced and high-priced EU Member States, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compliance with Other Federal and State Laws or Requirements; Changing Legal Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any products that we may develop are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, labeling, packaging, distribution, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws, among other requirements to we may be subject.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, the distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The failure to comply with any of these laws or regulatory requirements may subject us to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, relabeling or repackaging, or refusal to allow a company to enter into supply contracts, including government contracts. Any claim or action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on marketing, sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our sales and manufacturing arrangements; (ii) additions or modifications to product labeling or packaging; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European Union Drug Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, our future products also may be subject to extensive regulatory requirements. As in the United States, medicinal products can only be marketed if a Marketing Authorization (MA) from a competent regulatory authority has been obtained and additionally, the various phases of preclinical and clinical research in the EU are subject to significant regulatory controls.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European Union Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, in the EU, a clinical trial application (CTA) must be submitted to each EU Member State&#8217;s competent authority and an independent ethics committee, similar to the FDA and the IRB, respectively. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. Once the CTA is approved by the EU Member State&#8217;s competent authority and the ethics committee has granted a positive opinion in relation to the conduct of the trial in the relevant Member State(s), in accordance with an EU Member State&#8217;s requirements, clinical trial development may proceed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and EU Member State regulations and the International Conference on Harmonization (ICH) guidelines on GCP, as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. Additional GCP guidelines from the European Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the EU, it must appoint an entity within the EU to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU Member States, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, the Clinical Trials Regulation ((EU) No 536/2014) applied since 31 January 2022, replacing and repealing the Clinical Trials Directive (2001/20/EC). Under the Clinical Trials Regulation  (EU) No 536/2014, there is a centralized application procedure where one EU Member State&#8217;s competent authority takes the lead in reviewing part I of the application, which contains scientific and medicinal product documentation, and the other national authorities only have limited involvement. Part II, which contains the national and patient-level documentation, will be assessed individually by each EU Member State. A clinical trial can only start in an EU Member State once it has been authorized (potentially with conditions) by the concerned EU Member State via the EU Clinical Trials Information System (CTIS). Separately, the sponsor must obtain a positive opinion from the relevant, independent Ethics Committee(s). A transitional period will apply during the transition from Clinical Trials Directive to the Clinical Trials Regulation, During this period, the following applies: (a) from January 31, 2023, clinical trial sponsors will need to use CTIS to apply to start a new clinical trial in the EU/EEA; and (b) from January 31, 2025, any trials approved under the Clinical Trials Directive that continue running will need to comply with the Clinical Trials Regulation and their sponsors must have recorded information on them in the CTIS.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any substantial changes to the trial protocol or other information submitted with the CTA must be notified to or approved by the relevant competent authorities and ethics committees. Medicines used in clinical trials must be manufactured in accordance with GMP. Other national and EU-wide regulatory requirements may also apply.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the development of a medicinal product, the EMA and EU Member States&#8217; competent authorities provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the CHMP. A fee is incurred with each scientific advice procedure. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical trials, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future MAA of the product concerned.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are in the process of applying to renew our status with the EMA as a small and medium-sized enterprise (SME). If we are successful in maintaining our current SME status with the EMA, it will provide access to administrative, regulatory and financial support, including fee reductions for scientific advice and regulatory procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European Union Drug Review and Approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, medicinal products can only be placed on the market after obtaining a MA. To obtain regulatory approval of an investigational biological product in the EU, we must submit an MAA. The application used to file the BLA in the United States is similar to that required in the EU, with the exception of, among other things, country-specific document requirements. The process for doing this depends, among other things, on the nature of the medicinal product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The centralized procedure results in a single MA, issued by the European Commission (based on the opinion of the EMA), which is valid across the entire territory of the EU. The centralized procedure is compulsory for human drugs that are: (1) derived from biotechnology processes, such as genetic engineering, (2) contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">dysfunctions and viral diseases, (3) designated orphan medicines and/or (4) advanced-therapy medicines, such as gene therapy, somatic cell therapy or tissue-engineered medicines. The centralized procedure may, at the request of the applicant, also be used in certain other cases. Therefore, the centralized procedure would be mandatory for the products we are developing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The CAT is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CAT is primarily responsible for the scientific evaluation of ATMPs and prepares a draft opinion on the quality, safety and efficacy of each ATMP for which a MAA is submitted. The CAT&#8217;s opinion is taken into account by the CHMP when giving its final recommendation regarding the authorization of a product in view of the balance of benefits and risks identified. Although the CAT&#8217;s draft opinion is submitted to the CHMP for final approval, the CHMP may depart from the draft opinion, if it provides detailed scientific justification. The CHMP and CAT are also responsible for providing guidelines on ATMPs and have published numerous guidelines, including specific guidelines on gene therapies and cell therapies. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs; the manufacturing and control information that should be submitted in a MAA; and post-approval measures required to monitor patients and evaluate the long term efficacy and potential adverse reactions of ATMPs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the centralized procedure, the maximum timeframe for the evaluation of a MAA by the EMA is 210 days. This excludes so-called clock stops, during which additional written or oral information is to be provided by the applicant in response to questions asked by the EMA. At the end of the review period, the EMA provides an opinion to the European Commission. If this opinion is favorable, the European Commission may then adopt a decision to grant an MA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MAs have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the European Commission or the EU Member States&#8217; competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In exceptional cases, the EMA might perform an accelerated review of an MAA in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the Priority Medicines (PRIME) scheme, which provides incentives similar to BTD in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment but this is however not guaranteed. The benefits of a PRIME designation include the appointment of a rapporteur from the EMA before submission of an MAA, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review earlier in the application process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The European Commission may grant a so-called &#8220;conditional marketing authorization&#8221; prior to obtaining the comprehensive clinical data required for an application for a full MA. Such conditional MAs may be granted for product candidates (including medicines designated as orphan medicinal products), if (1) the risk-benefit balance of the product candidate is positive; (2) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data; (3) the product fulfills an unmet medical need; and (4) the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional MA may contain specific obligations to be fulfilled by the MA holder, including obligations with respect to the completion of ongoing or new studies and the collection of pharmacovigilance data. Conditional MAs are valid for one year, and may be renewed annually if the risk-benefit balance remains positive and after an assessment of the need for additional or modified conditions and/or specific obligations. The MA can be converted into a standard MA once the MA holder fulfils the obligations that were imposed and the complete data confirm that the medicine&#8217;s benefits continue to outweigh its risks. The timelines for the centralized procedure described above also apply with respect to the review by the EMA of applications for a conditional MA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The European Commission may also grant a so-called &#8220;marketing authorization under exceptional circumstances.&#8221; Such MA is intended for products for which the applicant can demonstrate that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized because (1) the indications for which the product in question is intended are encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence; (2) in the present state of scientific knowledge, comprehensive information cannot be provided; or (3) it would be contrary to generally accepted principles of medical ethics to collect such information. Consequently, MAs under exceptional circumstances may be granted subject to certain specific obligations, which may include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the applicant must complete an identified program of studies within a time period specified by the competent authority, the results of which form the basis of a reassessment of the benefit/risk profile; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the medicinal product in question may be supplied on medical prescription only and may in certain cases be administered only under strict medical supervision, possibly in a hospital and in the case of a radio-pharmaceutical, by an authorized person; and </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An MA under exceptional circumstances is subject to annual review to reassess the risk-benefit balance in an annual reassessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the MA being suspended or revoked. The renewal of a MA of a medicinal product under exceptional circumstances, however, follows the same rules as a &#8220;normal&#8221; MA. Thus, a MA under exceptional circumstances is granted for an initial five years, after which the authorization will become valid indefinitely, unless the EMA decides that safety grounds merit one additional five-year renewal. A MA under exceptional circumstances should not be granted when a conditional MA is more appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EU medicines rules expressly permit the EU Member States to adopt national legislation prohibiting or restricting the sale, supply or use of any medicinal product containing, consisting of or derived from a specific type of human or animal cell, such as embryonic stem cells. While the products we have in development do not make use of embryonic stem cells, it is possible that the national laws in certain EU Member States may prohibit or restrict us from commercializing our products, even if they have been granted an MA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European Union Data and Marketing Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EU also provides opportunities for market exclusivity. MAAs for generic medicinal products do not need to include the results of preclinical and clinical trials, but instead can refer to the data included in the MA of a reference product for which regulatory data exclusivity has expired. Upon receiving an MA, new chemical entities generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in the EU from referencing the innovator&#8217;s data to assess a generic or biosimilar application. During the additional two-year period of market exclusivity, a generic marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity. The overall ten-year market exclusivity period may be extended to a maximum of eleven years if, during the first eight years a new therapeutic indication with significant clinical benefit over existing therapies is approved. However, there is no guarantee that a product will be considered by the EU regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 26, 2023, the European Commission published proposals to revise the existing EU legislation on pharmaceutical products (the EU Pharma Law Review). These proposals comprise a new directive and a new regulation (the EU Pharma Law Proposal) that will replace the current legislation concerning medicinal products for human use, including legislation concerning orphan medical products and medicinal products for pediatric use. The EU Pharma Law Review could have a significant impact on the regulatory data exclusivity protection (RDP) for innovative pharmaceutical products in the EU. If adopted in current form, the EU Pharma Law Proposal would reduce the current baseline for data exclusivity from eight to six years, extendable under certain conditions. Such RDP reduction could lead to faster access to the EU market for generics and biosimilars.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European Union Orphan Drug Designation and Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Products receiving orphan drug designation in the EU can receive ten years of market exclusivity once they are authorized as orphan medicines. During the ten-year market exclusivity period, the EMA cannot accept another application for a MA, or grant a MA or accept an application to extend an existing MA, for the same therapeutic indication, in respect of a similar medicinal product. An orphan medicinal product can also obtain an additional two years of market exclusivity in the EU for pediatric studies. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. A medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers. The application for orphan drug designation must be submitted before the MAA. The applicant will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the MA is submitted. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ten-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, a MA may be granted to a similar product for the same indication at any time if:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the holder of the MA for the original orphan medicinal product has given its consent to the second applicant; or </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the holder of the MA for the original orphan medicinal product is unable to supply sufficient quantities of the medicinal product. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EU Pharma Law Review could have a significant impact on the designation of orphan medicinal products in the EU and the incentives offered for the development of these products. If adopted in current form, the EU Pharma Law Proposal would introduce the possibility for the European Commission to derogate by way of delegated acts from the current prevalence criterion and impose specific criteria for certain conditions depending on the characteristics of these conditions or other scientific reasons. The EU Pharma Law Proposal also proposes changes to the current orphan market exclusivity (OME) approach. If adopted in the current form, the EU Pharma Law Proposal would in most cases reduce the duration of the OME, and replace the current system with separate OME periods for each new indication, to a system with a single OME period for each active substance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similar to the United States, both marketing authorization holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the EU Member States&#8217; competent authorities. The holder of an MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, (PSURs).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All new MAAs must include a RMP describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to comply with EU and EU Member State laws that apply to the conduct of clinical trials, manufacturing approval, MAs of medicinal products and marketing of such products, both before and after grant of the MA; manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European Union Drug Marketing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the EU. Although general requirements for advertising and promotion of medicinal products are established under EU Directives, the details are governed by regulations in each EU Member State and can differ from one country to another.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Much like the Anti-Kickback Statue prohibition in the United States, the provision of benefits or advantages to healthcare professionals to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-bribery rules of EU Member States. Infringement of these laws could result in substantial fines and imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payments made to healthcare professionals in certain EU Member States must be publicly disclosed. Moreover, agreements with healthcare professionals often must be the subject of prior notification and approval by the healthcare professional&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative or criminal penalties, including fines, or imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pricing and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if a medicinal product obtains a MA in the EU, there can be no assurance that reimbursement for such product will be secured on a timely basis or at all. Governments influence the price of medicinal products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. EU Member States are free to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of pharmaceutical products for human use. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. EU Member States may approve a specific price or level of reimbursement for the pharmaceutical product, or alternatively adopt a system of direct or indirect controls on the profitability of the company responsible for placing the pharmaceutical product on the market, including volume-based arrangements, caps and reference pricing mechanisms. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials in order to compare the cost-effectiveness of a particular product candidate to currently available therapies. Other EU Member States may allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription medicines, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross border imports from low-priced markets exert a commercial pressure on pricing within a country. In December 2021, Regulation (EU) 2021/2282 on HTA (HTA Regulation) was adopted. The HTA Regulation will apply beginning on January 12, 2025. It replaces the current system based on the voluntary network of national authorities, and the new framework covers joint clinical assessments, joint scientific consultations, the identification of emerging health technologies, and voluntary cooperation for the national authorities. The HTA Regulation aims to provide a transparent and inclusive framework for health technology assessments in the EU, and it will help EU countries determine the effectiveness and value of new technologies and decide on pricing and reimbursement by health insurers or health systems.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European Pediatric Investigation Plan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, MAAs for new medicinal products must generally include the results of studies conducted in the pediatric population in compliance with a pediatric investigation plan (PIP) agreed with the EMA&#8217;s Pediatric Committee (PDCO). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which an MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the medicinal product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when this data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all Member States of the EU and trial results are included in the product information, the product is eligible for six months&#8217; supplementary protection certificate extension.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The EU Pharma Law Review could have a significant impact on pediatric medicinal products. If adopted in the current form, the EU Pharma Law Proposal would introduce a new evolutionary pediatric investigation plans (PIPs) system for certain types of developments, allowing the submission of an initial high level PIP, to be subsequently completed at precise stages in the development. The greater flexibility granted by this step-wise approach could be offset by the more stringent scrutiny over PIPs by the EMA. In addition, the EU Pharma Law Proposal could introduce the obligation to place medicinal products authorized for a pediatric indication on the market of all EU Member States where the medicinal product is already placed on the market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European Data Collection</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The collection and use of personal data (including health data) in the EEA is governed by the EU General Data Protection Regulations (GDPR) and national implementing legislation in EEA States. The EU GDPR applies to any company established in the EEA and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. The EU GDPR establishes stringent requirements applicable to the processing of personal data, including strict requirements relating to the validity of consent of data subjects, expanded disclosures about how personal data is used, requirements to conduct data protection impact assessments for &#8220;high risk&#8221; processing, limitations on retention of personal data, special provisions for the processing of &#8220;special categories of personal data&#8221; including health and genetic information of data subjects, mandatory data breach notification (in certain circumstances), &#8220;privacy by design&#8221; requirements, and direct obligations on service providers acting as processors. The EU GDPR also prohibits the international transfer of personal data from the EEA to countries outside of the EEA unless made to a country deemed to have adequate data privacy laws by the European Commission or a data transfer mechanism has been put in place. Failure to comply with the requirements of the EU GDPR and the related national data protection laws of the EEA States may result in fines up to &#8364;20 million or 4% of a company&#8217;s global annual revenues for the preceding financial year, whichever is higher. Moreover, the EU GDPR affords various data protection rights to individuals (e.g., the right to erasure of personal data) in certain circumstances, and the ability for data subjects to claim material and non-material damages resulting from infringements of the EU GDPR. Given the breadth and depth of changes in data protection obligations, maintaining compliance with the EU GDPR, will require significant time, resources and expense, and we may be required to put in place additional mechanisms ensuring compliance with the evolving data protection rules. This may be onerous and adversely affect our business, financial condition, results of operations and prospects. These requirements and risks are set out in further detail in the section of this annual report titled &#8220;Risk Factors&#8212;Risks Related to Our Industry and Business Operations&#8212;We are subject to a variety of privacy and data security laws, and our failure to comply with them could harm our business.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rest of the World Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For other countries outside of the EU (or in some cases, EEA) and the United States, such as the United Kingdom, countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Additionally, the clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employees and Human Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 68 full-time employees, 22 of whom have Ph.D. or M.D. degrees. Of these full-time employees, 52 employees are engaged in research and development activities and 16 employees are engaged in finance, legal, human resources, investor relations, IT, facilities and general management. We have no collective bargaining agreements with our employees and we have not experienced any work stoppages. We consider our relationship with our employees to be good.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our human capital resources objectives include identifying, recruiting, retaining, incentivizing and integrating our employees. We also place a high value on the diversity of our team, including gender, background and expertise in order to foster a culture of innovation. The principal purposes of our equity incentive plans are to align the interests of our stockholders and those eligible for awards, to retain and incentivize officers, directors, employees, and other service providers, and to encourage them to act in our long-term best interests. We value our employees and regularly evaluate total compensation we provide, including pension contributions paid time off personal leave and other benefits, to ensure we remain competitive and attractive to potential new hires.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Facilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We lease a facility containing approximately 622 square meters of office space for our main office, which is located at Ole Maal&#248;es Vej 3, DK-2200 Copenhagen N, Denmark. The lease expires in December 2027. We also lease lab space at Ole Maal&#248;es Vej 3, DK-2200 Copenhagen N, Denmark. The lease expires in December 2027.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, we lease a facility in New York for office space, located at 430 East 29th Street, New York, New York, and a facility in Maryland for lab space, located at 5640 Fishers Lane, Suite C, Rockville, Maryland. The New York lease expires in January 2027 and the Maryland lease expires in May 2027.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For our UK team, we lease office space located at No 1 Langstone Business Park, Newport, UK. The lease expires in May 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our current facilities are adequate for our current needs and that suitable additional or substitute space at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were incorporated under the laws of the State of Delaware on May 25, 2021 under the name IO Biotech, Inc. We consummated a corporate reorganization in connection with our initial public offering (IPO), pursuant to which all of the issued and outstanding stock of IO Biotech ApS was exchanged for shares of Class A and preferred stock of IO Biotech, Inc. As a result of the corporate reorganization, IO ApS, became a wholly-owned subsidiary of IO Biotech, Inc. We are a holding company. We conduct substantially all of our operations through our subsidiaries. Our subsidiary, IO Biotech ApS, a corporation domiciled in Denmark, was originally incorporated in December 2014, and holds our intellectual property assets. Our executive offices are located at Ole Maal&#248;es Vej 3, DK-2200 Copenhagen N, Denmark, and our telephone number is +45 7070 2980. Our website address is iobiotech.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this Annual Report on Form 10-K, and you should not consider information on our website to be part of this Annual Report on Form 10-K.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">k Factors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business is subject to numerous risks. You should carefully consider the following risks and all other information contained in this Annual Report, as well as general economic and business risks, together with any other documents we file with the SEC. If any of the following events actually occur or risks actually materialize, it could have a material adverse effect on our business, operating results and financial condition and cause the trading price of our common stock to decline.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Limited Operating History, Financial Position and Capital Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company with a limited operating history that may make it difficult to evaluate the success of our business to date and to assess our future viability. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing and optimizing our technology platform, identifying potential product candidates, undertaking research, preclinical studies and clinical trials for our product candidates, establishing and enhancing our intellectual property portfolio, and providing general and administrative support for these operations. IO102-IO103 is in clinical development and IO112 is in preclinical development, and none of our product candidates have been approved for commercial sale. We have never generated any revenue from product sales and have incurred net losses each year since we commenced operations. For the years ended December 31, 2023 and 2022, our net losses were $86.1 million and $71.5 million, respectively. We expect that it will be several years, if ever, before we have a product candidate ready for regulatory approval and commercialization. We expect to incur increasing levels of operating losses over the next several years and for the foreseeable future as we advance our product candidates through clinical development. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; deficit and working capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To become and remain profitable, we must develop and eventually commercialize a product or products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we succeed in commercializing one or more of our product candidates, we may never generate revenue that is significant or large enough to achieve profitability. In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need to obtain substantial additional funding to complete the development and commercialization of our product candidates. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially during the next few years. The development of biopharmaceutical product candidates, especially immune-oncology product candidates, is capital intensive. As our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our clinical, regulatory, quality and manufacturing capabilities. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to marketing, sales, manufacturing and distribution. Furthermore, we expect to incur additional costs associated with operating as a public company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had $143.2 million in cash and cash equivalents. Based upon our current operating plan, we estimate that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025. However, our existing cash and cash equivalents may not be sufficient to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, some of which are outside of our control, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the initiation, design, progress, timing, costs and results of drug discovery, preclinical studies and clinical trials of our product candidates, and in particular the clinical trials for IO102-IO103; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and characteristics of product candidates that we pursue; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of clinical trials needed for regulatory approvals from the FDA, the European Commission (based on recommendation from the EMA), and any other regulatory authority; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the length of our clinical trials, including, among other things, as a result of delays in enrollment, difficulties enrolling sufficient subjects or delays or difficulties in clinical trial site activations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased costs associated with conducting our clinical trials, including, among other things, clinical trial site activations and patient enrollment;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successfully completing ongoing pre-clinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the outcome, timing and costs of seeking regulatory approvals from the FDA, the European Commission, and any other regulatory authority; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of manufacturing our product candidates, in particular for clinical trials in preparation for marketing approval and in preparation for commercialization; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of any third-party products used in our combination clinical trials that are not covered by such third party or other sources; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs associated with hiring additional personnel and consultants as our preclinical, manufacturing and clinical activities increase; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the receipt of marketing approval and revenue received from any commercial sales of any of our product candidates, if approved; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of commercialization activities for any of our product candidates, if approved, including marketing, sales, compliance and distribution costs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the emergence of competing therapies and other adverse market developments; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to establish and maintain strategic collaboration, licensing or other arrangements and the financial terms of such agreements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we in-license or acquire other products and technologies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amount and timing of any payments we may be required to make pursuant to our current or future license agreements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our need and ability to retain key management and hire scientific, technical, business, medical, and compliance personnel; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our implementation of additional internal systems and infrastructure, including operational, financial, compliance and management information systems; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our costs associated with expanding our facilities or building out our laboratory space; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effects of the disruptions to and volatility in the credit and financial markets in the United States and worldwide from public health emergencies, and geopolitical conflict (such as in Ukraine and the Middle East); and  </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of operating as a public company. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will require additional capital to achieve our business objectives. Additional funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. Further, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide. If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our growth strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through equity offerings, debt financings or other capital sources, including potentially grants, collaborations, licenses or other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of our common stock. Additional debt financing, if available, may involve agreements that include covenants further limiting or restricting our ability to take specific actions, such as further limitations on our ability to incur additional debt, make capital expenditures or declare dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we raise funds through collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">All of our product candidates are in clinical development or in preclinical development. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no assurance that clinical trials of IO102-IO103, or any other future clinical trials of our product candidates, will be successful or will generate positive clinical data and we may not receive marketing approval from the FDA, European Commission (based on recommendation from the EMA), or other regulatory authorities for any of our product candidates. We have limited experience submitting INDs to the FDA. There can be no assurance that the FDA will permit any of our future INDs, including any IND for IO112, to go into effect in a timely manner or at all. Without an IND for a product candidate, we will not be permitted to conduct clinical trials in the United States of such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biopharmaceutical development is a difficult, long, time-consuming, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical trials. For example, we have experienced longer than expected lead times in clinical trial site activation and patient enrollment in our clinical trials. Failure to obtain regulatory approval for our product candidates will prevent us from commercializing and marketing our product candidates. The success in the development of our product candidates will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">timely and successful completion of preclinical studies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining and maintaining patent, trademark and trade secret protection and regulatory exclusivity for our product candidates and otherwise protecting our rights in our intellectual property portfolio; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission of INDs and CTAs for and receipt of allowance to proceed with our planned clinical trials or other future clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiating, enrolling, and successfully completing clinical trials, including investigator-initiated clinical trials over which we have limited control; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining positive results from our preclinical studies and clinical trials that support a demonstration of efficacy, safety, and durability of effect for our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receiving approvals for commercialization of our product candidates from applicable regulatory authorities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, European Commission (based on recommendation from the EMA), and other regulatory authorities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing sales, marketing and distribution capabilities and successfully launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining a continued acceptable safety, tolerability and efficacy profile of any approved products; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">setting acceptable prices for our product and obtaining coverage and adequate reimbursement from third-party payors; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing our product candidates at an acceptable cost; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining and growing an organization of scientists, medical and clinical professionals and business professionals who can develop and commercialize our products and technology.  </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of these factors are beyond our control, including the time needed to adequately complete clinical testing, the regulatory submission process and potential threats to our intellectual property rights. It is possible that none of our product candidates will ever obtain regulatory approval, even if we expend substantial time and resources seeking such approval. If we do not achieve one or more of these factors in a timely manner or at all, or any other factors impacting the successful development of biopharmaceutical products, we could experience significant delays or an inability to successfully develop our product candidates, which would materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance in clinical trials, including IO102-IO103, may not achieve favorable results in later clinical trials, if any, or receive marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The research and development of drugs and biological products is extremely risky. Only a small percentage of product candidates that enter the development process ever receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. The outcome of clinical testing is uncertain. We may face unforeseen challenges in our product candidate development strategy, and we can provide no assurances that we will ultimately be successful in our current and future clinical trials or that our product candidates will be able to receive regulatory approval. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. For example, it is not uncommon for product candidates to exhibit unforeseen safety or efficacy issues when tested in humans despite promising results in preclinical animal models. In particular, while IO102-IO103 in combination with an anti-PD-1 monoclonal antibody has been investigated in a Phase 1/2 trial in 30 metastatic melanoma patients at Herlev University Hospital of Copenhagen, we do not know how IO102-IO103 will perform in our ongoing Phase 3 clinical trial combining IO102-IO103 with an anti-PD-1 monoclonal antibody in first line treatment of advanced melanoma patients, nor do we know how candidates in our ongoing Phase 2 basket trial, IOB-022, our ongoing Phase 2 basket trial, IOB-032 or in future clinical trials will perform. Future results of preclinical and clinical testing of our product candidates are also less certain due to the novel and relatively untested nature of the approach of our T-win&#174; platform. In general, clinical trial failure may result from a multitude of factors including flaws in study design, dose selection, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A number of companies in the biopharmaceutical industry, including immune-oncology companies, have suffered setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates are based on novel technologies that target the highly immunosuppressive tumor microenvironment, which makes it difficult to predict the results, timing, and cost of product candidate development and likelihood of obtaining regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have concentrated our research and development efforts on product candidates using our T-win platform, and our future success depends on the successful development of this approach. Our product candidates target the tumor microenvironment which is highly immunosuppressive. We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates based on our platform technologies in clinical trials or in obtaining marketing approval thereafter, and use of our platform technologies may not ever result in marketable products. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners or establishing our own commercial manufacturing capabilities, which may prevent us from completing our clinical trials or commercializing any products on a timely or profitable basis, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the clinical trial requirements of the FDA, and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be less predictable, more expensive and longer than for other, better known or extensively studied pharmaceutical or other product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no assurance that the approaches offered by our products will gain broad acceptance among doctors or patients or that governmental agencies or third-party medical insurers will be willing to provide reimbursement coverage for proposed product candidates. Since our current product candidates and any future product candidates will represent novel approaches to treating various conditions, it may be difficult, in any event, to accurately estimate the potential revenues from these product candidates. Accordingly, we may spend significant capital trying to obtain approval for product candidates that have an uncertain commercial market. The market for any products that we successfully develop will also depend on the cost of the product. We do not yet have sufficient information to reliably estimate what it will cost to commercially manufacture our current product candidates, and the actual cost to manufacture these products could materially and adversely affect the commercial viability of these products. If we do not successfully develop and commercialize products based upon our approach or find suitable and economical sources for materials used in the production of our products, we will not become profitable, which would materially and adversely affect the value of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The oncology industry is also rapidly developing, and our competitors may introduce new technologies improving the immune response to cancer that render our technologies obsolete or less attractive. New technology could emerge at any point in the development cycle of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are investigating IO102-IO103 in clinical trials in melanoma and other solid tumors, and our third product candidate, IO112, targets an immune resistance pathway known as Arginase 1 which is highly expressed in solid cancer indications. If our product candidates do not show any functionality in the solid tumor microenvironment, our development plans, financial position, results of operations and prospects may be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we plan to develop product candidates for use in solid tumors, including IO102-IO103 and IO112, our product candidates may not show any functionality in the solid tumor microenvironment. The cellular environment in which solid tumor cells thrive is generally hostile to T cells due to factors such as the presence of immunosuppressive cells, humoral factors and limited access to nutrients. Our product candidates may not be able to access the solid tumor, and even if they do, they may not be able to exert anti-tumor effects in a hostile tumor microenvironment. In addition, the safety profile of our product candidates may differ in a solid tumor setting. As a result, our product candidates may not demonstrate efficacy in solid tumors. If we are unable to make our product candidates function in solid tumors, our development plans, financial position, results of operations and prospects may be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have experienced, and may in the future experience delays, or difficulties in clinical trial site activations and the enrollment and/or retention of patients in clinical trials, which could delay or prevent our receipt of necessary regulatory approvals.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients. Patient enrollment, which is an important factor in the timing of clinical trials, is affected by many factors, including clinical trial site activation, the size and nature of the patient population and competition for patients eligible for our clinical trials with competitors which may have ongoing clinical trials for product candidates that are under development to treat the same indications as one or more of our product candidates, or approved products for the conditions for which we are developing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. As a result of public health emergencies and resource constraints on CROs, prospective clinical trial sites and others, we may experience longer than expected lead times in clinical trial site activation and patient enrollment in our clinical trials. Furthermore, enrollment for our clinical trials may take longer than anticipated due to other monotherapies and combination therapies being investigated in the first-line setting at this time. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required to adequately power our studies in order to draw meaningful conclusions from them or as may be required by the FDA, European Commission (based on recommendation from the EMA), or comparable foreign regulatory authorities. We cannot predict how successful we will be at enrolling subjects in future clinical trials. Subject enrollment is affected by other factors including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the pace of clinical trial site activation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the severity and difficulty of diagnosing the disease under investigation; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the eligibility and exclusion criteria for the trial in question; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size of the patient population and process for identifying patients; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the design of the trial protocol; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the perceived risks and benefits of the product candidate in the trial, including relating to cell therapy approaches; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of competing commercially available therapies and other competing therapeutic candidates&#8217; clinical trials for the disease or condition under investigation, including for melanoma and other cancers in a first-line setting; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of patients to be enrolled in our clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patient referral practices of physicians; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may also modify or enhance clinical trial requirements, which may affect enrollment and retention of patients. In August 2023, the FDA published a guidance document, &#8220;Informed Consent, Guidance for IRBs, Clinical Investigators, and Sponsors,&#8221; which supersedes past guidance and finalizes draft guidance on informed consent. The FDA&#8217;s new guidance presents evolving requirements for informed consent which may affect recruitment and retention of patients in clinical trials. Effects on recruitment and retention of patients may hinder or delay a clinical trial, which may increase costs and delay clinical programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. Furthermore, we expect to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and we will have limited influence over their performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interim &#8220;top-line&#8221; and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may publish interim top-line or preliminary results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated, and should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA, European Commission (based on recommendation from the EMA), and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain required regulatory approval for our product candidates, our business will be substantially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The time required to obtain approval or other marketing authorizations by the FDA, European Commission (based on recommendation from the EMA), and comparable foreign regulatory authorities is unpredictable, and it typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, and the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate, and it is possible that we may never obtain regulatory approval for any product candidates we may seek to develop in the future. Neither we nor any current or future collaborator is permitted to market any drug product candidates in the United States until we receive regulatory approval of a BLA from the FDA, and we cannot market it in the EU until we receive a MAA from the European Commission (based on recommendation from the EMA), or in the UK until we receive regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) or other required regulatory approval in other countries. To date, we have had only limited discussions with the FDA and EMA regarding clinical development programs or regulatory approval for any product candidate within the United States and EU, respectively. In addition, we have had no discussions with other comparable foreign authorities regarding clinical development programs or regulatory approval for any product candidate outside of those jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to obtaining approval to commercialize any drug product candidate in the United States or abroad, we must demonstrate with evidence from well-controlled clinical trials, and to the satisfaction of the FDA, European Commission (based on recommendation from the EMA), or other foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA, the European Commission (based on recommendations from the EMA), and other comparable foreign regulatory authorities. The FDA or European Commission (based on recommendations from the EMA) may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or after approval, or it may object to elements of our clinical development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, EMA, or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials, or with our interpretation of clinical trial results; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA, EMA, or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA, European Commission (based on recommendation from the EMA), or comparable foreign regulatory authorities for approval; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, European Commission (based on recommendation from the EMA), or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval policies or regulations of the FDA, European Commission, EMA, or comparable foreign authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Of the large number of products in development, only a small percentage successfully complete FDA, European Commission (based on recommendation from the EMA), or foreign regulatory approval processes and are commercialized. The lengthy approval and marketing authorization process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval and marketing authorization to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, the EMA&#8217;s Committee for Advanced Therapies (CAT) is responsible for assessing the quality, safety, and efficacy of advanced therapy medicinal products (ATMPs). ATMPs include gene therapy medicines, somatic-cell therapy medicines and tissue-engineered medicines. The role of the CAT is to prepare a draft opinion on an application for marketing authorization for a gene therapy medicinal candidate that is submitted to EMA&#8217;s Committee for Medicinal Products for Human Use (CHMP) for final adoption. In the EU, the development and evaluation of ATMPs follow relevant EU guidelines. European Commission or EMA may issue new guidelines concerning the development and marketing authorization for ATMPs and require that we comply with these new guidelines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have invested a significant portion of our time and financial resources in the development of our clinical and preclinical product candidates. Our business is dependent on our ability to successfully complete preclinical and clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize IO102-IO103, IO112 and any future product candidates in a timely manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we eventually complete clinical testing and receive approval of a BLA or other comparable foreign marketing application for IO102-IO103, IO112 or any future product candidates, the FDA, European Commission (based on recommendation from the EMA) or other comparable foreign regulatory authorities may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including post-marketing clinical trials. The FDA, European Commission (based on recommendations from the EMA) or other comparable foreign regulatory authorities may also approve or authorize for marketing a product candidate for a more limited indication or patient population than we originally request, and the FDA, European Commission (based on recommendations from the EMA) or other comparable foreign regulatory authorities may not approve or authorize the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval or other marketing authorization would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the FDA, European Commission (based on recommendations from the EMA), or other comparable foreign regulatory authorities and regulatory review committees described above may change their policies, issue additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent, delay or limit the scope of regulatory approval of our product candidates, limit their commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To obtain the requisite regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe and effective for use in each target indication. These trials are expensive and time consuming, and their outcomes are inherently uncertain. Failures can occur at any time during the development process. Preclinical studies and clinical trials often fail to demonstrate safety or efficacy of the product candidate studied for the target indication, and most product candidates that begin clinical trials are never approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may fail to demonstrate with evidence from adequate and well-controlled trials, and to the satisfaction of the FDA, European Commission (based on recommendation from the EMA), or comparable foreign regulatory authorities, that our product candidates are safe and effective for their intended uses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Possible adverse reactions and adverse side effects that could occur with immuno-oncology treatments can be severe. For example, we have reported to FDA some serious and unexpected suspected adverse reactions from the IOB-012 trial to FDA, which involved pulmonary tuberculosis, enterocolitis, hypovolemic shock, and diabetic ketoacidosis. As part of routine safety monitoring and pharmacovigilance evaluation on ongoing and planned trials, we continue to review data and perform additional assessments, depending on an evaluation of the available data, we may decide or be required to perform additional preclinical studies or to halt or delay further clinical development of our product candidates or to limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical trials could also be suspended or terminated and the FDA, European Commission (based on recommendation from the EMA), or comparable foreign regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications. Even if this does not occur, reports of serious reactions could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our product candidates are associated with side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses in which the side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. The FDA, European Commission (based on recommendation from the EMA), an institutional review board (IRB) or ethics committee (EC), which are local institutional boards or committees, as applicable, that review, approve and oversee basic and clinical research conducted as the institution participating in the clinical trial, or comparable foreign regulatory authorities, may also require that we suspend, discontinue, or limit our clinical trials based on safety information, or that we conduct additional animal or human studies regarding the safety and efficacy of our product candidates which we have not planned or anticipated. Such findings could further result in regulatory authorities failing to provide marketing authorization for our product candidates or limiting the scope of the approved indication, if approved. Many product candidates that initially showed promise in early stage testing have later been found to cause side effects that prevented further development of the product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">As an organization, we have never conducted pivotal clinical trials, and we may be unable to do so for any product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will need to successfully complete clinical trials meeting requirements for approval of the FDA or comparable foreign regulatory authorities, known as pivotal trials, to market IO102-IO103, IO112, IO170 or any future product candidate. Conducting and successfully completing pivotal clinical trials is a complicated process. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to BLA submission and approval of IO102-IO103, IO112, IO170 or future product candidates. In order to do so, we will need to expand our clinical development and regulatory capabilities, and we may be unable to recruit and train qualified personnel. We also expect to continue to rely on third parties to conduct our pivotal clinical trials. We also may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in commercializing our product candidates.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Some data for product candidates comes from clinical trials conducted outside the United States, EU and the UK, and the FDA, European Commission (based on recommendation from the EMA), or comparable foreign regulatory authorities may not accept data from such trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we believe that the patient population in the Phase 1/2 trial with IO102-IO103 in combination with an anti-PD-1 monoclonal antibody in 30 metastatic melanoma patients is representative of the population for which we intend to label our IO102-103 product candidate in the United States, the trial was conducted in Europe, our ongoing IOB-013/KN-D18 and IOB-022 trials include sites outside of the United States, and we may conduct additional trials in the future outside of the United States, Europe and the United Kingdom. The acceptance of data from clinical trials conducted outside the United States or another jurisdiction by the FDA may be subject to certain conditions or may not be accepted at all. Similarly, the European Commission (based on recommendation from the EMA), and other equivalent foreign regulatory authorities may not accept data from trials conducted outside their jurisdiction. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (1) the data are applicable to the U.S. population and U.S. medical practice; and (2) the trials were performed by clinical investigators of recognized competence and pursuant to good clinical practice (GCP) regulations; and (3) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In general, the patient population for any clinical trials conducted outside the United States must be representative of the population for whom we intend to label the product candidate in the United States. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements for clinical trials. In addition, such trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, European Commission (based on recommendation from the EMA),  or any comparable foreign regulatory authority will accept data from trials conducted outside of the applicable jurisdiction. If the FDA, European Commission (based on recommendation from the EMA), or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Breakthrough therapy designation by the FDA for any product candidate may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that the product candidate will receive marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IO102-IO103 combined with an anti-PD-1 monoclonal antibody in first line metastatic melanoma patients has been granted BTD from the FDA. We may also, in the future, apply for BTD, or the equivalent thereof in foreign jurisdictions (where available), for our product candidates or programs. A breakthrough therapy is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Product candidates designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BTD is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for BTD, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate, including the breakthrough therapy designation of IO102-IO103 combined with an anti-PD-1 monoclonal antibody in first line metastatic melanoma patients, may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even after a product candidate qualifies as a breakthrough therapy, the FDA may later decide that the product candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may submit a BLA for our product candidates under the Accelerated Approval Pathway. If we are unable to obtain licensure of our biological candidates through the Accelerated Approval Pathway in the United States, we may be required to conduct additional nonclinical and clinical studies and trials beyond those that we currently contemplate, which could increase the expense of obtaining, reduce the likelihood of obtaining and/or delay the timing of obtaining, necessary marketing approval. Even if we receive licensure from the FDA through the Accelerated Approval Program, if any required confirmatory post-marketing trial does not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw the approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek approval under the Accelerated Approval Pathway for our IO102-IO103, IO112 or any other product candidates. For any approval to market a product, we must provide the FDA and foreign regulatory authorities with clinical data that adequately demonstrate the safety, efficacy, purity and potency of the product for the indication applied for in the BLA, or other respective regulatory filings. The Accelerated Approval Pathway is one of several approaches used by the FDA to make prescription drugs and biologics more rapidly available for the treatment of serious or life-threatening diseases. Section 506(c) of the FDCA provides that the FDA may grant accelerated approval to &#8220;a product for a serious or life-threatening condition upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.&#8221; Approval through the Accelerated Approval Pathway is typically subject, however, to the requirement that the applicant conduct additional post-marketing clinical trials to verify and describe the product&#8217;s clinical benefit. Typically, clinical benefit is verified when post-marketing clinical trials show that the product provides a clinically meaningful positive therapeutic effect, that is, an effect on how a patient feels, functions, or survives. If such confirmatory post-marketing trial fails to confirm the product&#8217;s clinical profile or risks and benefits, the FDA may withdraw its approval of the product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has broad discretion with regard to approval through the Accelerated Approval Pathway, and even if we believe that the Accelerated Approval Pathway is appropriate for our product candidates, we cannot assure you that the FDA will ultimately agree. Furthermore, even if we do obtain approval through the Accelerated Approval Pathway, we may not experience a faster development process, review or approval compared to conventional FDA procedures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we receive approval for one or more of our product candidates through the Accelerated Approval Pathway, we will be subject to rigorous post-marketing requirements, possibly including the completion of one or more confirmatory post- marketing trials as the FDA may require, to verify the clinical benefit of the product, and submission to the FDA of all promotional materials prior to their dissemination. The FDA could seek to withdraw the approval for multiple reasons, including if we fail to conduct any required confirmatory post-marketing trial with due diligence, our confirmatory post-marketing trial does not confirm the predicted clinical benefit, other evidence shows that the product is not safe, effective, pure or potent under the conditions of use, or we disseminate promotional materials that are found by the FDA to be false and misleading.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, Congress has recently enacted changes to the Accelerated Approval Pathway that could impact our ability to obtain Accelerated Approval, or increase the burdens associated with post-marketing requirements in the event we do obtain Accelerated Approval. In particular, the FDA must specify certain conditions for required post-approval studies for products that receive Accelerated Approval, which may include enrollment targets and milestones, including the target date for study completion, by the time the biologic is licensed. FDA may also require post-approval studies to be underway at the time of Accelerated Approval or within a specified time period following Accelerated Approval for such biologics.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any delay in obtaining, or inability to obtain, approval or licensure through the Accelerated Approval Pathway, or any issues in maintaining approval or licensure granted under the Accelerated Approval Pathway, would delay or prevent commercialization of our products, and could materially adversely affect our business, financial condition, results of operations, cash flows and prospects.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions, and even recall or market withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA, the European Commission (based on recommendation from the EMA), or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, storage, advertising, promotion, import, export, recordkeeping, monitoring, and reporting for our product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and listing, as well as continued compliance with current Good Manufacturing Practice requirements (cGMPs) and GCP requirements for any clinical trials that we conduct post-approval. Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">revision to the labeling, including limitations on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imposition of a REMS, which may include distribution or use restrictions; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements to conduct additional post-market clinical trials to assess the safety of the product; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, warning letters or other regulatory enforcement action; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties; </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, the European Commission (based on recommendation from the EMA) will require an equivalent risk management plan (RMP). The FDA&#8217;s, European Commission&#8217;s, EMA&#8217;s, and other comparable foreign regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We anticipate that our current product candidates and any future product candidates will be used in combination with third-party drugs or biologics, some of which are still in development, and we have limited or no control over the supply, regulatory status, or regulatory approval of such drugs or biologics.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our T-win&#174; platform targets both immune suppressive host and tumor cells in the TME initiating a dynamic process of activating the host immune system, which response can be further exploited by concurrent or subsequent therapies as checkpoint inhibitors such as the dominant PD-1 monoclonal antibodies, pembrolizumab and nivolumab. Accordingly, it is expected that our product candidates, if approved, would be used in combination with third-party drugs or biologics. For example, IO102-IO103 in combination with an anti-PD-1 monoclonal antibody was investigated in a Phase 1/2 trial in 30 metastatic melanoma patients at Herlev University Hospital of Copenhagen, and we are conducting a Phase 3 clinical trial, the IOB-013/KN-D18 trial, combining IO102-IO103 with an pembrolizumab in first line advanced melanoma patients. Our ability to develop and ultimately commercialize our current product candidates and any future product candidates used in combination with pembrolizumab, nivolumab, or any other checkpoint inhibitor immunotherapies will depend on our ability to access such drugs or biologics on commercially reasonable terms for the clinical trials and their availability for use with the commercialized product, if approved. We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of such drugs or biologics on commercially reasonable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any failure to maintain or enter into new successful commercial relationships, or the expense of purchasing checkpoint inhibitor immunotherapies or other comparator therapies in the market, may delay our development timelines, increase our costs and jeopardize our ability to develop our current product candidates and any future product candidates as commercially viable therapies. If any of these occur, our business, financial condition, results of operations, stock price and prospects may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the development of product candidates for use in combination with another product or product candidate may present challenges that are not faced for single agent product candidates. We are currently developing IO102-IO103 and IO112 and may develop other future product candidates for use in combination with checkpoint inhibitors and other therapies. The FDA, EMA, or comparable foreign regulatory authorities may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. It is possible that the results of such trials could show that any positive previous trial results are attributable to the combination therapy and not our current product candidates and any future product candidates. It is also possible that trial results for our product candidates may differ significantly if our product candidates are investigated with different combination therapies in different trials - for example, if we were to investigate our product candidates with one anti-PD-1 monoclonal antibody in one trial and a different anti-PD-1 monoclonal antibody in another. Moreover, following product approval, the FDA, EMA, or comparable foreign regulatory authorities may require that products used in conjunction with each other be cross labeled for combined use. To the extent that we do not have rights to the other product, this may require us to work with a third party to satisfy such a requirement. Moreover, developments related to the other product may impact our clinical trials for the combination as well as our commercial prospects should we receive marketing approval. Such developments may include changes to the other product&#8217;s safety or efficacy profile, changes to the availability of the approved product, quality, manufacturing and supply issues, and changes to the standard of care.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event that any of our collaborators or suppliers cannot continue to supply their products on commercially reasonable terms, we would need to identify alternatives for accessing such checkpoint inhibitor immunotherapies. Additionally, should the supply of products from any collaborator or supplier be interrupted, delayed or otherwise be unavailable to us, our clinical trials may be delayed. In the event we are unable to source an alternative supply, or are unable to do so on commercially reasonable terms, our business, financial condition, results of operations, stock price and prospects may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we have limited financial and managerial resources, we must prioritize our research programs and will need to focus our discovery and development on select product candidates and indications. Correctly prioritizing our research and development activities is particularly important for us due to the breadth of potential product candidates and indications that we believe could be pursued using our platform technologies. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may also relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our success largely depends on the success of our limited number of product candidates. If any of these candidates fail in clinical trials or are not approved for commercialization, our ability to generate revenue and achieve profitability could be impacted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect initially to focus on the development of our lead dual epitope IO102-IO103. We also expect to continue to develop our other product candidates, IO112 and IO170. A key part of our strategy, however, is to continue to pursue clinical development of additional product candidates utilizing our T-win&#174; platform. Developing, obtaining marketing approval for, and commercializing any future product candidates will require substantial additional funding and will be subject to the risks of failure inherent in drug product development. We cannot assure you that we will be able to successfully advance any future product candidates through the development process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain approval from the FDA, European Commission (based on recommendation from the EMA) or comparable foreign regulatory authorities to market any future product candidates for the treatment of tumors, we cannot assure that any such product candidates will be successfully commercialized, widely accepted in the marketplace, or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional product candidates our commercial opportunity may be limited and our business, financial condition, results of operations, stock price and prospects may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Difficulty in enrolling patients could delay or prevent clinical trials of our current product candidates and any future product candidates. We may find it difficult to enroll patients in our ongoing clinical trials or any subsequent trials we may conduct and our receipt of necessary regulatory approvals could be delayed or prevented. For example, we have experienced longer than expected lead times in clinical trial site activation and patient enrollment in our clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identifying and qualifying patients to participate in clinical studies of our current product candidates and any future product candidates is critical to our success. The timing of completion of our clinical trials depends in part on the speed at which we can recruit patients to participate in testing our current product candidates and any future product candidates, and we may experience delays in our clinical trials if we encounter difficulties in enrollment or patient retention due to other unforeseen factors. We may not be able to initiate or continue clinical trials for our current product candidates and any future product candidates if we are unable to locate and enroll and retain a sufficient number of eligible patients to participate in these trials as required by the FDA, EMA, or comparable foreign regulatory authorities outside the United States. For example, COVID-19 impacted our ability to initiate clinical sites and recruit, enroll and retain patients, or similar public health emergencies may divert healthcare resources away from clinical trials. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our current product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates or future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the competitive trial environment, the eligibility criteria of our planned clinical trials will further limit the pool of available study participants as we will require that patients have specific characteristics that we can measure to assure their cancer is either severe enough or not too advanced to include them in a study. Additionally, the process of finding patients may prove costly. We also may not be able to identify, recruit and enroll a sufficient number of patients to complete our clinical studies because of the perceived risks and benefits of the product candidates under study, the availability and efficacy of competing therapies and clinical trials, the proximity and availability of clinical trial sites for prospective patients, and the patient referral practices of physicians. If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of potential products may be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The enrollment of patients further depends on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size of the patient population and process for identifying patients; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the eligibility criteria for the clinical trial in question; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of an appropriate screening test, as necessary; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the perceived risks and benefits of the product candidate under study; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the design of the clinical trial; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain patient consents; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reporting of the preliminary results of any of our clinical trials; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the clinical trials before clinical trial completion. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our current product candidates and any future product candidates, and this competition may reduce the number and types of patients available to us because some patients who might have opted to enroll in our clinical trials may instead opt to enroll in a clinical trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which may reduce the number of patients who are available for our clinical trials at such clinical trial sites. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we experience delays in the completion of, or termination of, any clinical trial of our current product candidates and any future product candidates, the commercial prospects of our current product candidates and any future product candidates will be harmed, and our ability to generate product revenue from such product candidates could be delayed or prevented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future growth depends, in part, on our ability to penetrate multiple markets in which we would be subject to additional regulatory burdens and other risks and uncertainties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future profitability will depend, in part, on our ability to commercialize our product candidates, if approved, in markets in the United States, Europe, the United Kingdom, and other countries where we maintain commercialization rights. As we begin to commercialize our product candidates, if approved, in multiple markets, we are subject to additional risks and uncertainties, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign currency exchange rate fluctuations and currency controls; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic weakness, including inflation, or political instability in particular economies and markets; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potentially adverse and/or unexpected tax consequences, including penalties due to the failure of tax planning or due to the challenge by tax authorities on the basis of transfer pricing and liabilities imposed from inconsistent enforcement; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the burden of complying with complex and changing regulatory, tax, accounting and legal requirements, many of which vary between countries; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">different medical practices and customs in multiple countries affecting acceptance of drugs in the marketplace; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tariffs, trade barriers, import or export licensing requirements or other restrictive actions; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">workforce uncertainty in countries where labor unrest is common; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced or loss of protection of intellectual property rights in some foreign countries, and related prevalence of generic alternatives to therapeutics; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">becoming subject to the different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These and other risks associated with international operations may adversely affect our ability to attain or maintain profitable operations. Future sales of our products or our product candidates, if they are approved, will be dependent on purchasing decisions of and reimbursement from government health administration authorities, distributors and other organizations. As a result of adverse conditions affecting the global economy and credit and financial markets, including disruptions due to political instability, geopolitical conflict or otherwise, these organizations may defer purchases, may be unable to satisfy their purchasing or reimbursement obligations, or may affect milestone payments or royalties for our products or any of our product candidates that are approved for commercialization in the future. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Manufacturing and Commercialization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The manufacture of our product candidates is complex and we may encounter difficulties in production, particularly with respect to process development or scale-up of our manufacturing capabilities. If we encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not yet manufactured or processed our product candidates on a commercial scale and may not be able to do so for any of our product candidates. We may encounter difficulties in production, particularly in scaling up or out, validating the production process, and assuring high reliability of the manufacturing process. These problems may include delays or break-downs in logistics and shipping, difficulties with production costs and yields, quality control, and product testing, operator error, lack of availability of qualified personnel, as well as failure to comply with strictly enforced federal, state and foreign regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, if contaminations are discovered in our supply of product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any of these or other issues relating to the manufacture of our product candidates will not occur in the future. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to begin new clinical trials at additional expense or terminate clinical trials completely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing facilities also require commissioning and validation activities to demonstrate that they operate as designed, and are subject to government inspections by the FDA, EU Member States (coordinated by the EMA) and other comparable foreign regulatory authorities. If we are unable to reliably produce products to specifications acceptable to the regulatory authorities, we may not obtain or maintain the approvals we need to manufacture our products. Further, manufacturing facilities may fail to pass government inspections prior to or after the commercial launch of our product candidates, which would cause significant delays and additional costs required to remediate any deficiencies identified by the regulatory authorities. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in product candidate manufacturing or formulation may result in additional costs or delay.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As product candidates are developed through preclinical studies to later-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Any of these changes could cause our current product candidates or any future product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changes may also require additional testing, or notification to, or approval by the FDA, European Commission, EMA, or a comparable foreign regulatory authority. This could delay completion of clinical trials, require the conduct of bridging clinical trials or studies, require the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our current product candidates and any future product candidates and/or jeopardize our ability to commence product sales and generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain marketing approvals from the FDA, European Commission (based on recommendation from the EMA), or other comparable foreign regulatory agencies and are able to initiate commercialization of our clinical-stage product candidates or any other product candidates we develop, the product candidate may not achieve market acceptance among physicians, patients, hospitals, including pharmacy directors, cancer treatment centers, and third-party payors and, ultimately, may not be commercially successful. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which our product candidates are approved; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">physicians, hospitals, cancer treatment centers, and patients considering our product candidates as a safe and effective treatment; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential and perceived advantages of our product candidates over alternative treatments; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any side effects; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product labeling or product insert requirements of the FDA, European Commission, EMA, or other comparable foreign regulatory authorities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limitations or warnings contained in the labeling approved by the FDA, European Commission, EMA, or other comparable foreign regulatory authorities; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of our product candidates as well as competitive products; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of treatment in relation to alternative treatments; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amount of upfront costs or training required for physicians to administer our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of coverage from, adequate reimbursement from, and our ability to negotiate pricing with, third-party payors and government authorities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of comprehensive coverage and reimbursement by third-party payors and government authorities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of our sales and marketing efforts and distribution support. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits of our product candidates, if approved, may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our product candidates. Because we expect sales of our product candidates, if approved, to generate substantially all of our product revenue for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing. Even if our product candidates, if approved, achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to successfully commercialize our product candidates, if approved, due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell our product candidates profitably.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process, with uncertain results, that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. There may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may not be available, or may be more limited than the purposes for which the product is approved by the FDA or other comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost products and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors, by any future laws limiting drug prices and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, there is no uniform policy among third-party payors for coverage and reimbursement. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Therefore, one third-party payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a covered benefit under its health plan; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safe, effective and medically necessary; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">appropriate for the specific patient; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cost-effective; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neither experimental nor investigational. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be sure that reimbursement will be available for any product that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement will be. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reimbursement may impact the demand for, and the price of, any product for which we obtain marketing approval. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with those medications. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement are critical to a new product&#8217;s acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, CMS, the federal agency responsible for administering the Medicare program, revises the reimbursement amounts paid to health care providers, including the Medicare Physician Fee Schedule and Hospital Outpatient Prospective Payment System, which may result in reduced Medicare payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription medicines, medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the successful commercialization of new products. Further, the adoption and implementation of any future governmental cost containment or other health reform initiative may result in additional downward pressure on the price that we may receive for any approved product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside of the United States, many countries require approval of the sale price of a product before it can be marketed, and the pricing review period only begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some of these countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if such product candidates obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reimbursement and healthcare payment systems vary significantly by country outside the United States, and many countries have instituted price ceilings on specific products and therapies. In the EU and the United Kingdom, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU, United Kingdom or at an EU Member State level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU Member States and the United Kingdom have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products in these countries, these restrictions on pricing and reimbursement could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States, the EU, United Kingdom or any other jurisdiction. If we, or any third parties we may engage, are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the regulatory authorities in such jurisdictions set prices or make reimbursement criteria that are not commercially attractive for us or our collaborators, our revenues and the potential profitability of our products in those countries would be negatively affected.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the market opportunities for any of our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are focused on the development of treatments for cancer. Our projections of addressable patient populations that have the potential to benefit from treatment with our product candidates are based on estimates, including estimated incidence rates of specific forms of cancer. If any of our estimates are inaccurate, the market opportunities for any of our product candidates could be significantly diminished and have an adverse material impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If any of our product candidates are approved for marketing and commercialization and we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize our product candidates if and when they are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have no sales, marketing or distribution capabilities or experience. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization, which would be expensive and time consuming, or outsource these functions to other third parties. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. Factors that may inhibit our efforts to commercialize future products on our own include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability of sales personnel to compliantly obtain access to physicians or educate adequate numbers of physicians on the benefits of prescribing any future products; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product portfolios; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of the product revenue to us are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of third parties and we cannot assure you that such third parties will establish adequate sales and distribution capabilities or devote the necessary resources and attention to sell and market any future products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If granted, regulatory approval by the FDA, European Commission (based on recommendations from the EMA) or comparable foreign regulatory authorities is limited to those specific indications and conditions for which approval has been granted, and we may be subject to substantial fines, criminal penalties, injunctions, or other enforcement actions if we are determined to be promoting the use of our products for unapproved or off-label uses, or in a manner inconsistent with the approved labeling, resulting in damage to our reputation and business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We must comply with requirements concerning advertising and promotion for any product candidates for which we obtain marketing approval. Promotional communications with respect to therapeutics are subject to a variety of legal and regulatory restrictions and continuing review by the FDA or comparable foreign regulatory and governmental authorities, Department of Justice, HHS Office of Inspector General, state attorneys general, members of Congress, and the public. When the FDA or comparable foreign regulatory authorities issue regulatory approval for a product candidate, the regulatory approval is limited to those specific uses and indications for which the product has been approved. If we are not able to obtain FDA or comparable foreign regulatory authority approval for desired uses or indications for our current product candidates and any future product candidates, we may not market or promote them for those indications and uses, referred to as off-label uses, and our business, financial condition, results of operations, stock price and prospects will be materially harmed. We also must sufficiently substantiate any claims that we make for our products, including claims comparing our products to other companies&#8217; products, and must abide by the FDA or a comparable foreign regulatory or governmental authority&#8217;s strict requirements regarding the content of promotion and advertising.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While physicians may choose to prescribe products for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, we and any third parties engaged on our behalf are prohibited from marketing and promoting the products for indications and uses that are not specifically approved by the FDA or comparable foreign regulatory authorities. Regulatory authorities in the United States generally do not restrict or regulate the behavior of physicians in their choice of treatment within the practice of medicine. Regulatory authorities do, however, restrict communications by biopharmaceutical companies concerning off-label uses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are found to have impermissibly promoted any of our current product candidates and any future product candidates, we may become subject to significant liability and government fines. The FDA and other agencies actively enforce the laws and regulations regarding product promotion, particularly those prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted a product may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, engaging in the impermissible promotion of our products, following approval, for off-label uses can also subject us to false claims and other litigation under federal and state statutes. These include fraud and abuse and consumer protection laws, which can lead to civil and criminal penalties and fines, and agreements with governmental authorities that materially restrict the manner in which we promote or distribute therapeutic products and conduct our business. These restrictions could include corporate integrity agreements, suspension or exclusion from participation in federal and state healthcare programs, and suspension and debarment from government contracts and refusal of orders under existing government contracts. These FCA lawsuits against manufacturers of drugs and biologics have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements pertaining to certain sales practices and promoting off-label uses. In addition, FCA lawsuits may expose manufacturers to follow-on claims by private payors based on fraudulent marketing practices. This growth in litigation has increased the risk that a biopharmaceutical company will have to defend a false claim action, pay settlement fines or restitution, as well as criminal and civil penalties, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid, or other federal and state healthcare programs. If we do not lawfully promote our approved products, if any, we may become subject to such litigation and, if we do not successfully defend against such actions, those actions may have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the promotion of biopharmaceutical products are subject to additional FDA requirements and restrictions on promotional statements. If after one or more of our current or future product candidates obtains marketing approval the FDA determines that our promotional activities violate its regulations and policies pertaining to product promotion, it could request that we modify our promotional materials or subject us to regulatory or other enforcement actions, including issuance of warning letters or untitled letters, suspension or withdrawal of an approved product from the market, requests for recalls, payment of civil fines, disgorgement of money, imposition of operating restrictions, injunctions or criminal prosecution, and other enforcement actions. Similarly, industry codes in foreign jurisdictions may prohibit companies from engaging in certain promotional activities and regulatory agencies in various countries may enforce violations of such codes with civil penalties. If we become subject to regulatory and enforcement actions our business, financial condition, results of operations, stock price and prospects will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, the use of our products for indications other than those approved by the FDA or comparable foreign regulatory authorities may not effectively treat such conditions. Any such off-label use of our product candidates could harm our reputation in the marketplace among physicians and patients. There may also be increased risk of injury to patients if physicians attempt to use our products for these uses for which they are not approved, which could lead to product liability suits that that might require significant financial and management resources and that could harm our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we obtain FDA or European Commission (based on recommendations from the EMA) approval of any of our product candidates in the United States or EU, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Approval by the FDA in the United States or the European Commission (based on recommendations from the EMA) in the EU does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Reliance on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Some of our product candidates may be studied in clinical trials sponsored by organizations or agencies other than us, or in investigator-initiated clinical trials, which means we will have minimal or no control over the conduct of such trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have supplied and may continue to supply and otherwise support third party research, including investigator-initiated clinical trials. Investigator-initiated clinical trials pose similar risks as those set forth elsewhere in this &#8220;Risk Factor&#8221; section relating to our internally-sponsored clinical trials, but because we may not be the sponsors of these trials, we have less control over the protocols, administration or conduct of these trials, including follow-up with patients and ongoing collection of data after treatment. The conduct or findings of these trials may have a negative impact on our development programs notwithstanding that we have little involvement or control over these trials. As a result, we are subject to additional risks associated with the way investigator-initiated trials are conducted. In particular, we may be named in lawsuits that would lead to increased costs associated with legal defense. Additional risks include difficulties or delays in communicating with investigators or administrators, procedural delays and other timing issues and difficulties or differences in interpreting data. Third-party investigators may design clinical trials with clinical endpoints that are more difficult to achieve, or in other ways that increase the risk of negative clinical trial results compared to clinical trials that we may design on our own. Negative results in investigator-initiated clinical trials could have a material adverse effect on our efforts to obtain regulatory approval for our product candidates and the public perception of our product candidates. As a result, our lack of control over the conduct and timing of and communications with the FDA and other regulatory authorities regarding investigator-sponsored trials may expose us to additional risks and uncertainties, many of which are outside our control, and the occurrence of which could adversely affect the commercial prospects for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third parties to conduct, supervise, and monitor our clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs which may have an adverse effect on our business and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have the ability to conduct all aspects of our preclinical testing or clinical trials ourselves. As a result, we are and expect to remain dependent on third parties to conduct our current and future preclinical studies and clinical trials. CROs that manage our preclinical studies and clinical trials as well as clinical investigators, including in investigator-initiated clinical trials, and consultants play a significant role in the conduct of our preclinical studies and clinical trials and the subsequent collection and analysis of data. The timing of the initiation and completion of these studies and trials will therefore be partially controlled by such third parties and may result in delays to our development programs. Nevertheless, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal requirements, and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with Good Laboratory Practice (GLP) and GCP requirements, which are regulations and guidelines enforced by the FDA, the EMA, and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GLP and GCP requirements through periodic inspections of preclinical study sites, trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our CROs or clinical trial sites, including clinical trial sites in investigator-initiated clinical trials, fail to comply with applicable GLP or GCP requirements, the data generated in our preclinical studies and clinical trials may be deemed unreliable, and the FDA, EMA, or comparable foreign regulatory authorities may require us to perform additional preclinical or clinical trials before approving our marketing applications.   Further, requirements regarding clinical trial data may evolve. In June 2023, the FDA published a draft guidance, &#8220;E6(R3) Good Clinical Practice (GCP),&#8221; which seeks to unify standards for clinical trial data for ICH member countries and regions. Changes to data requirements may cause the FDA or other foreign regulatory authorities to disagree with data from preclinical studies or clinical trials, and may require further studies. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to stop and/or repeat clinical trials, which would delay the marketing approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no guarantee that any such CROs, clinical trial investigators or other third parties on which we rely will devote adequate time and resources to our development activities or perform as contractually required. If any of these third parties fails to meet expected deadlines, fails to adhere to our clinical protocols or meet regulatory requirements, otherwise performs in a substandard manner, or terminates its engagement with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in such clinical trials unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult or impossible. In addition, clinical trial investigators for our clinical trials or investigator-initiated clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or any comparable foreign regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application we submit by the FDA or any comparable foreign regulatory authority. Any such delay or rejection could prevent us from commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may be unable to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and may be unable to, or may be delayed in our efforts to, successfully commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third parties to manufacture our product candidates, and we expect to continue to rely on third parties for the clinical as well as any future commercial supply of our product candidates and other future product candidates. The development of our current and future product candidates, and the commercialization of any approved products, could be stopped, delayed or made less profitable if any such third party fails to provide us with sufficient clinical or commercial quantities of such product candidates or products, fails to do so at acceptable quality levels or prices or fails to achieve or maintain satisfactory regulatory compliance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not currently have, and we do not plan to build, the infrastructure or capability internally to manufacture current product candidates or any future product candidates for use in the conduct of our clinical trials or, if approved, for commercial supply. We rely on, and expect to continue to rely on, CMOs. Reliance on third-party providers may expose us to more risk than if we were to manufacture our product candidates ourselves. We do not control the manufacturing processes of the CMOs we contract with and are dependent on those third parties for the production of our product candidates in accordance with relevant applicable regulations such as cGMP, which includes, among other things, quality control, quality assurance and the maintenance of records and documentation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In complying with the manufacturing regulations of the FDA and other comparable foreign regulatory authorities, we and our third-party suppliers must spend significant time, money and effort in the areas of design and development, testing, production, record-keeping and quality control to assure that the products meet applicable specifications and other regulatory requirements. The failure to comply with these requirements could result in an enforcement action against us, including the seizure of products and shutting down of production. We and any of these third-party suppliers may also be subject to inspections by the FDA, EU Member States (coordinated by the EMA), or comparable foreign regulatory authorities. If any of our third-party suppliers fails to comply with cGMP or other applicable manufacturing regulations, our ability to develop and commercialize our product candidates could suffer significant interruptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any disruption, such as a fire, natural hazards or vandalism at our CMOs, or any impacts on our CMOs due to COVID-19, could significantly interrupt our manufacturing capability. We currently do not have alternative production plans in place or disaster-recovery facilities available. In case of a disruption, we will have to establish alternative manufacturing sources. This would require substantial capital on our part, which we may not be able to obtain on commercially acceptable terms or at all. Additionally, we would likely experience months of manufacturing delays as we build facilities or locate alternative suppliers and seek and obtain necessary regulatory approvals. If this occurs, we may be unable to satisfy manufacturing needs on a timely basis, if at all. If changes to CMOs occur, then there also may be changes to manufacturing processes inherent in the setup of new operations for our product candidates and any products that may obtain approval in the future. Any such changes could require the conduct of bridging studies before we can use any materials produced at new facilities or under new processes in clinical trials or, for any products reaching approval, in our commercial supply. Further, business interruption insurance may not adequately compensate us for any losses that may occur and, in that case, we would have to bear the additional cost of any disruption. For these reasons, a significant disruptive event of any CMOs could have drastic consequences, including placing our financial stability at risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates and any drugs that we may develop may compete with other product candidates and drugs for access to manufacturing facilities. There are no assurances we would be able to enter into similar commercial arrangements with other manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we were to experience an unexpected loss of supply of or if any supplier were unable to meet our clinical or commercial demand for any of our product candidates, we could experience delays in our planned clinical studies or commercialization. For example, future public health emergencies may impact our ability to procure sufficient supplies for the development of our current and future product candidates, and the extent of such impacts will depend on the severity and duration of and the actions undertaken to contain such public health crisis or treat its effects. We could be unable to find alternative suppliers of acceptable quality and experience that can produce and supply appropriate volumes at an acceptable cost or on favorable terms. Moreover, our suppliers are often subject to strict manufacturing requirements and rigorous testing requirements, which could limit or delay production. The long transition periods necessary to switch manufacturers and suppliers, if necessary, could significantly delay our clinical trials and, for any product candidates that reach approval, the commercialization of our products, which would materially adversely affect our business, financial condition and results of operation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend on third-party suppliers for materials that are necessary for the conduct of preclinical studies and manufacture of our product candidates for clinical trials, and the loss of these third-party suppliers or their inability to supply us with sufficient quantities of adequate materials, or to do so at acceptable quality levels and on a timely basis, could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing our product candidates requires many reagents, which are substances used in our manufacturing processes to bring about chemical or biological reactions, and other specialty materials and equipment, some of which are manufactured or supplied by small companies with limited resources and experience to support commercial biologics production. We currently depend on a limited number of vendors for certain materials and equipment used in the manufacture of our product candidates. For example, we currently use facilities and equipment at external CMOs, as well as supply sources internal to the collaboration for vector supply. Our use of CMOs increases the risk of delays in production or insufficient supplies as we transfer our manufacturing technology to these CMOs and as they gain experience with our supply requirements. Some of these suppliers may not have the capacity to support clinical trials and commercial products manufactured under cGMP by biopharmaceutical firms or may otherwise be ill-equipped to support our needs. We also do not have supply contracts with many of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key materials and equipment to support clinical or commercial manufacturing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For some of these reagents, equipment, and materials, we rely and may in the future rely on sole source vendors or a limited number of vendors. The supply of the reagents and other specialty materials and equipment that are necessary to produce our product candidates could be reduced or interrupted at any time. In such case, identifying and engaging an alternative supplier or manufacturer could result in delay, and we may not be able to find other acceptable suppliers or manufacturers on acceptable terms, or at all. Switching suppliers or manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. If we change suppliers or manufacturers for commercial production, applicable regulatory agencies may require us to conduct additional studies or trials. If key suppliers or manufacturers are lost, or if the supply of the materials is diminished or discontinued, we may not be able to develop, manufacture and market our product candidates in a timely and competitive manner, or at all. An inability to continue to source product from any of these suppliers, which could be due to a number of issues, including regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we continue to develop and scale our manufacturing process, we expect that we will need to obtain rights to and supplies of certain materials and equipment to be used as part of that process. We may not be able to obtain rights to such materials on commercially reasonable terms, or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such materials or find a suitable substitute, it would have a material adverse effect on our business. Even if we are able to alter our process so as to use other materials or equipment, such a change may lead to a delay in our clinical development and/or commercialization plans. If such a change occurs for a product candidate that is already in clinical testing, the change may require us to perform both ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. These factors could cause the delay of studies or trials, regulatory submissions, required approvals or commercialization of product candidates that we develop, cause us to incur higher costs and prevent us from commercializing our product candidates successfully.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our reliance on third parties requires us to share certain of our trade secrets, which increases the possibility that a competitor will discover them or that such trade secrets will be misappropriated or disclosed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we rely on third parties to research and develop and to manufacture our product candidates, we must share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s independent discovery of our trade secrets or other unauthorized use or disclosure could impair our competitive position and may have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with will likely expect to be granted rights to publish data arising out of such collaboration and any joint research and development programs may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets could impair our competitive position and have an adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may form or seek partnerships, collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such partnerships, collaborations, alliances or licensing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may form or seek partnerships or strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. For example, we have entered into collaborative agreements with Merck pursuant to which they provide the pembrolizumab used in certain of our trials. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, share the data with such collaborators, restrict our ability to utilize certain data arising out of these collaboration arrangements, issue securities that dilute our existing stockholders or take actions that disrupt our management and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy and obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, collaborations involving our product candidates are subject to numerous risks, which may include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization of our product candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes, including contract disputes, may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result, if we enter into additional collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Industry and Business Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The outbreak of COVID-19, or similar public health emergencies, could have a material adverse impact on our business, financial condition and results of operations, including the execution of our planned clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, a novel strain of coronavirus, SARS-CoV-2, was identified. This virus spread globally, including within the United States and, while the COVID-19 public health emergency expired on May 11, 2023 and cases and hospitalization are currently on the decline in the United States, there can be no assurances they will not continue at the current rate or increase in the future especially in light of the number of variants that are emerging across the world. Governments in the United States and elsewhere have historically taken and may in the future take severe measures to slow the spread of COVID-19, including by requiring that certain businesses close or conduct only the minimum necessary operations. The pandemic and government measures taken in response had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages occurred, supply chains were disrupted, facilities were closed, production was suspended, and demand for certain goods and services, such as medical services and supplies, spiked, while demand for other goods and services, such as travel, fell. The extent to which COVID-19 and similar public health emergencies may impact our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and similar public health emergencies and government measures taken in response.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Site activation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis for our planned clinical trials may be delayed due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to COVID-19 or similar public health emergencies. Additionally, some participants and clinical investigators may not be able to comply with clinical trial protocols in light of future restrictions imposed by the U.S. and other foreign governments. For example, quarantines or other travel limitations (whether voluntary or required) may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and we may be unable to conduct its planned clinical trials. If the global effort to control public health emergencies such as COVID-19 continues for an extended period of time, we risk a delay in activating sites and enrolling subjects as previously projected. For example, during COVID-19, we experienced longer than expected lead times in clinical trial site activation and patient enrollment in our clinical trials. Any delays to our planned clinical trials for IO102-IO103 and any future clinical trials and increased cost associated with the conducting of our clinical trials could impact the use and sufficiency of our existing cash reserves, and we may be required to raise additional capital earlier than it had previously planned. We may be unable to raise additional capital if and when needed, which may result in further delays or suspension of our development plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, infections and deaths related to COVID-19 and similar public health emergencies have disrupted, and may disrupt in the future, certain healthcare and healthcare regulatory systems globally. Such disruptions could divert healthcare resources away from, or materially delay review by, the FDA and comparable foreign regulatory agencies. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially adversely affect the development and study of its product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently utilize third parties to, among other things, manufacture raw materials and our product candidates, components, parts, and consumables, and to perform quality testing. If either we or any third-party in the supply chain for materials used in the production of its product candidates are adversely impacted by restrictions resulting from the COVID-19 or similar public health emergencies, our supply chain may be disrupted, limiting our ability to manufacture product candidates for its clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In response to COVID-19, we complied with applicable regulation and limited required on-site staff to essential workers, with the balance of its employees continuing their work primarily outside of our offices. Due to shelter-in-place orders or other mandated local travel restrictions, third parties conducting clinical or manufacturing activities were not be able to access laboratory or manufacturing space, and, should future public health emergencies necessitate similar action, our core activities may be significantly limited or curtailed, possibly for an extended period of time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While the potential economic impact brought by and the duration of public health emergencies may be difficult to assess or predict, COVID-19 caused, and may in the future cause, significant disruption of global financial markets and the trading prices of biopharmaceutical companies was highly volatile as a result of COVID-19 pandemic, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the global effort to control future public health emergencies could materially and adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ultimate impact of the COVID-19, or any other health epidemic, is highly uncertain and subject to change. Potential delays or impacts on our business, our planned clinical trials, healthcare systems or the global economy as a whole could have a material adverse impact on our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disruptions at the FDA, EMA, SEC and other government agencies and regulatory authorities caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal governmental functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA, EMA, and other comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at regulatory authorities and government agencies have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disruptions at the FDA and other agencies such as the EMA following its post-Brexit relocation and resulting staff changes may also slow the time necessary for new products to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs in the future, it could significantly impact the ability of the FDA to review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since March 2020, when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring, and pre-approval inspections on a prioritized basis.  Since April 2021, the FDA has conducted limited inspections and employed remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates. Travel restrictions and other uncertainties may continue to impact oversight operations both domestic and abroad. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the agency has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed.  On February 2, 2022, the FDA announced that it would resume domestic surveillance inspections across all product areas on February 7, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 11, 2023, the COVID-19 public health emergency declared under the Public Health Service (PHS) Act expired. It is unclear how the FDA&#8217;s policies and guidance will impact any inspections of our facilities, including our clinical trial sites. During the COVID-19 public health emergency, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. Regulatory authorities outside of the United States may adopt similar restrictions or other policy measures in response to COVID-19 and may experience delays in their regulatory activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a prolonged government shutdown occurs, or if global health concerns impact regular inspections, reviews, or other regulatory activities of the FDA or other regulatory authorities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be exposed to significant foreign exchange risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have operations in Denmark and we incur portions of our expenses, and may in the future derive revenues, in a variety of currencies. As a result, we are exposed to foreign currency exchange risk as our results of operations and cash flows are subject to fluctuations in foreign currency exchange rates. Fluctuations in currency exchange rates have had, and will continue to have, an impact on our results as expressed in U.S. dollars. We currently do not engage in hedging transactions to protect against uncertainty in future exchange rates between particular foreign currencies and the U.S. dollar. We cannot predict the impact of foreign currency fluctuations, and foreign currency fluctuations in the future may adversely affect our financial condition, results of operations and cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and other comparable foreign regulatory authorities, provide accurate information to the FDA and other comparable foreign regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States, EU, United Kingdom and in other jurisdictions, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impairment of our business reputation; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs due to related litigation; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">distraction of management&#8217;s attention from our primary business; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to patients or other claimants; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize our product candidates; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for our product candidates, if approved for commercial sale. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our product liability insurance coverage is sufficient in light of our current clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claims or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients with cancer and other diseases targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to, or perceived to be related to, our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may divide the attention of our management team, interrupt our sales efforts, delay our regulatory approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future success depends on our ability to retain key members of senior management and to attract, retain and motivate qualified personnel.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to compete in the highly competitive biopharmaceutical industry depends upon our ability to attract and retain highly qualified management, research and development, clinical, financial and business development personnel. We are highly dependent on our management, scientific and medical personnel, including Mai Britt Zocca, Ph.D., our Chief Executive Officer, Amy Sullivan, M.B.A., our Chief Financial Officer and Qasim Ahmad, M.D., our Chief Medical Officer. Our senior management may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recruiting and retaining qualified scientific and clinical personnel and, if we progress the development of any of our product candidates, commercialization, manufacturing and sales and marketing personnel, will be critical to our success. The loss of the services of members of our senior management or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing members of our senior management and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product candidates. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers, as well as junior, mid-level and senior scientific and medical personnel. Competition to hire from this limited candidate pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high-quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We expect to expand our clinical development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 we had 68 full-time employees. As our development progresses, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical product development, regulatory affairs, manufacturing and, if any of our product candidates receives marketing approval, compliance, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development and commercialization of new products is highly competitive. We expect to compete in the segments of the pharmaceutical, biotechnology and other related markets that pursue oncology treatments. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain regulatory approval from the FDA or other comparable foreign regulatory authorities for their products more rapidly than we may obtain approval for ours, if ever, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. Moreover, with the proliferation of new drugs and therapies into oncology, we expect to face increasingly intense competition as new technologies become available. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. The highly competitive nature of and rapid technological changes in the biotechnology and pharmaceutical industries could render our product candidates or our technology obsolete, less competitive or uneconomical.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other products in a similar class as some of our product candidates have already been approved and other products in the same class are further along in development. As more product candidates within a particular class of biopharmaceutical products proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Consequently, the results of our clinical trials for product candidates in those classes will likely need to show a risk benefit profile that is competitive with or more favorable than those products and product candidates in order to obtain marketing approval or, if approved, a product label that is favorable for commercialization. If the risk benefit profile is not competitive with those products or product candidates, we may have developed a product that is not commercially viable, that we are not able to sell profitably or that is unable to achieve favorable pricing or reimbursement. In such circumstances, our future product revenue and financial condition would be materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specifically, there are many companies that have commercialized or are developing immuno-oncology treatments for cancer including large pharmaceutical and biotechnology companies such as Amgen Inc. (Amgen), AstraZeneca plc (AstraZeneca), Bristol-Myers Squibb Company (BMS), Merck, Novartis AG (Novartis), Pfizer Inc. (Pfizer), Moderna, Regeneron, and F. Hoffman-La Roche AG (Roche), and Roche's subsidiary Genentech, Inc. (Genentech).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In melanoma specifically, the dominant market players are nivolumab, marketed by BMS and Ono, combination of nivolumab &amp; ipilimumab, marketed by BMS and Ono, combination of nivolumab and relatlimab (LAG-3 blocking antibody) marketed by BMS and pembrolizumab, marketed by Merck. We are also aware of several companies testing their compounds in combination with nivolumab or pembrolizumab. In mid stage development there is Moderna and Merck with an investigational personalized mRNA cancer vaccine, in combination with pembrolizumab and Regeneron testing their fianlimab anti-LAG3 in combination cmiplimab Anti-PD-1 in first line melanoma. In earlier stage development there are also BioNTech with NEO-PV-01 and Karyopharm with selinexor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing and marketing than we do. Future collaborations and mergers and acquisitions may result in further resource concentration among a smaller number of competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors will also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or that maybe necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety, and convenience. If we are not successful in developing, commercializing and achieving higher levels of reimbursement than our competitors, we will not be able to compete against them and our business would be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The tax authorities in the jurisdictions in which we operate may challenge our transfer pricing procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a multinational business that operates in Denmark and other tax jurisdictions, and the tax laws of those jurisdictions generally require that royalty and other payments between affiliated companies in different jurisdictions be the same as those between unrelated companies dealing at arm&#8217;s length, and that such prices are supported by contemporaneous documentation. While we believe that we operate in compliance with applicable transfer pricing laws and intend to continue to do so, our transfer pricing procedures are not binding on applicable tax authorities. If tax authorities in any of these jurisdictions were to successfully challenge our transfer prices as not reflecting arm&#8217;s length transactions, they could require us to adjust our transfer prices and thereby reallocate our income or deductions to reflect these revised transfer prices, which could result in a higher overall tax liability to us and possibly interest and penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, tax authorities in the jurisdictions in which we operate may challenge our treatment of our corporate reorganization. No assets (either physical or intangible) were transferred from Denmark to the U.S. pursuant to our corporate reorganization, nor were any existing business functions or units operating from Denmark transferred from IO Biotech ApS to IO Biotech, Inc. as part of the corporate reorganization to form part of our U.S. operations. Accordingly, we did not intend to treat the corporate reorganization as a deemed sale of all or part of our business by IO Biotech ApS to IO Biotech, Inc. If Danish tax authorities were to disagree with our position and treat the corporate reorganization or any of our activities thereafter as a deemed sale, in whole or in part, of intellectual property rights and/or other assets owned by IO Biotech ApS to IO Biotech, Inc., we could be subject to a Danish tax, the current rate of which is 22%, on the gain realized calculated as the difference between the fair market value and the tax value of the assets, at the time of the deemed sale of the assets from Denmark as determined by the Danish tax authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Finally, the nature of our operations can produce conflicting claims from tax authorities in different countries as to the profits to be taxed in the individual countries. The jurisdictions in which we operate have double tax treaties with other jurisdictions, which provide a framework for mitigating the impact of double taxation on our revenues and capital gains. However, mechanisms developed to resolve such conflicting claims are largely untested, can be expected to be very lengthy, and do not always contain a mandatory dispute resolution clause. In recent years, tax authorities around the world have increased their scrutiny of company tax filings, and have become more rigid in exercising any discretion they may have.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, tax reform efforts, including with respect to transfer pricing, will require us to continually assess our organizational structure and could lead to an increased risk of international tax disputes, an increase in our effective tax rate and an adverse effect on our financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have net operating losses to be carried forward, which may become devalued if we do not generate sufficient future taxable income, applicable corporate tax rates are reduced or if we experience an ownership change.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our total gross deferred tax assets as of December 31, 2023 were $58.4 million. Total gross deferred tax assets is comprised of $53.3 million, $4.5 million and $0.6 million relating to IO Biotech ApS, IO Bio US, Inc. and IO Biotech, Inc., respectively. Our anticipated activities are also expected to result in future significant net operating losses in Denmark resulting in additional deferred tax assets. Utilization of most deferred tax assets is dependent on generating sufficient future taxable income in the appropriate jurisdiction and/or entity. The company has provided a valuation allowance of ($53.1) million, $(4.3) million and $(0.5) million on our net deferred tax assets in IO Biotech ApS, IO Bio US, Inc. and IO Biotech, Inc., respectively, as of December 31, 2023. Based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. Additionally, most of our deferred tax assets are determined by reference to applicable corporate income tax rates in Denmark and the United States. Accordingly, in the event of a reduction of any such corporate income tax rates, the carrying value of certain of our deferred tax assets would decrease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, our ability to use our net operating losses and other deferred tax assets to offset future taxable income in Denmark and the U.S. may be limited if we experience an ownership change. We may experience ownership changes in the future as a result of our IPO or subsequent shifts in our stock ownership, some of which are outside the Company&#8217;s control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For Danish income tax purposes, an ownership change will generally occur when one, or several shareholders together, at once or successively, acquire shares representing more than 50 percent of the share capital or voting power. Although such an ownership change entails no reduction of the amount of net operating losses to be carried forward, the utilization is restricted to exclude offsetting against positive net capital income (e.g. income from interest, dividend and royalty) on net operating losses incurred in a previous income year, where the ownership differs by 50 percent (under section 12D of the Danish Corporate Tax Act). The restriction may limit future offsetting against net operating profits, when the ownership change is due to the listing on an exchange.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For U.S. federal income tax purposes, an ownership change will generally occur when the percentage of our stock (by value) owned by one or more &#8220;5% shareholders&#8221; (as defined in the U.S. Internal Revenue Code of 1986, as amended) has increased by more than 50% over the lowest percentage owned by such shareholders at any time during the prior three years (calculated on a rolling basis). We anticipate that we will incur losses in the United States in the foreseeable future related to our research and development activities. Due to potential ownership changes under Section 382 of the Code, we may be limited in our ability to realize a tax benefit from the use of such losses, whether or not we attain profitability in future years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our ability to utilize any future net operating losses may be limited by Pub. L. 115-97, enacted in 2017 and commonly known as the Tax Cuts and Jobs Act of 2017 (TCJA). Under the TCJA, the amount of our net operating losses that we are permitted to deduct in any taxable year is limited to 80% of our taxable income in such year, where taxable income is determined without regard to the net operating loss deduction itself, while allowing unused net operating losses to be carried forward indefinitely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For these reasons, a material devaluation in our deferred tax assets due to insufficient taxable income, lower corporate income tax rates or ownership change would have an adverse effect on our results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to current taxation on some of the income of our foreign subsidiaries even absent any cash distributions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we hold directly or indirectly all of the shares of our foreign subsidiaries, including IO Biotech ApS, such subsidiaries are treated as controlled foreign corporations (CFC) for U.S. federal income tax purposes. For U.S. federal income tax purposes, IO Biotech, Inc. will therefore need to include in its taxable income each year its &#8220;global intangible low-taxed income&#8221; and IO Biotech ApS&#8217;s &#8220;subpart F income,&#8221; if any, even if no distributions are made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our foreign subsidiaries may directly become subject to U.S. federal income tax and be subject to a branch profits tax in the United States, which could reduce our after-tax returns and the value of our shares.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently intend to conduct substantially all of our businesses and operations in a manner such that our foreign subsidiaries will not be treated as engaged in a trade or business in the United States and will not be subject to additional U.S. income tax or branch profits tax. However, it is not entirely clear when a foreign subsidiary is treated as being engaged in a trade or business in the United States for U.S. federal income tax purposes. Accordingly, we cannot assure you that the Internal Revenue Service (IRS) will not contend, perhaps successfully, that our foreign subsidiaries were engaged in a trade or business in the United States or are subject to more U.S. income tax than they currently incur. A foreign corporation deemed to be so engaged would be subject to U.S. federal income tax on its income that is treated as effectively connected with the conduct of that trade or business, as well as to branch profits tax on its &#8220;dividend equivalent amount,&#8221; unless the corporation is entitled to relief under an applicable tax treaty, which is determined on an annual basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, transparency laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Although we do not currently have any products on the market, our operations and current and future arrangements with investigators, healthcare professionals, customers and third-party payors, may be subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal civil and criminal false claims laws and the Physician Payments Sunshine Act and regulations. These laws may impact, among other things, our current business operations, including our clinical research activities, and proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers and other parties through which we may market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to additional healthcare, statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. See Part I, Item 1, &#8220;Government Regulations &#8211; Other Regulatory Matters &#8211; Other Healthcare Laws&#8221; for additional detail.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including certain arrangements with physicians who receive stock, warrants or stock options as compensation for services provided to us, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the delay, reduction, termination or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our current product candidates and any future product candidates, restrict or regulate post-approval activities and affect our ability</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to profitably sell a product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (1) changes to our manufacturing arrangements; (2) additions or modifications to product labeling; (3) the recall or discontinuation of our products; or (4) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjected biological products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and biologics that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations, and established annual fees and taxes on manufacturers of certain branded prescription drugs and biologics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. See Part I, Item 1, &#8220;Government Regulation &#8211; Healthcare Reform&#8221; for additional detail on recent challenges to the ACA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that the ACA, new laws, and other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates, if approved. We cannot predict the initiatives that may be adopted in the future. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Upcoming changes in the pharmaceutical product legislation in certain jurisdictions may have an adverse effect on the data and market exclusivity available for our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EU Pharma Law Review initiated by the European Commission on April 6, 2023 could have a significant impact on the RDP available for innovative medicinal products in the EU.  If adopted in current form, the EU Pharma Law Proposal would reduce the current baseline for data exclusivity from eight to six years, extendable under certain conditions.  Such RDP reduction could lead to faster access to the EU market for generics and biosimilars.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EU Pharma Law Proposal also proposes changes the current orphan market exclusivity approach.  If adopted in the current form, the EU Pharma Law Proposal would in most cases reduce the duration of orphan market exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to a variety of privacy and data security laws, and our failure to comply with them could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain a large quantity of sensitive information, including confidential business and personal information in connection with the conduct of our clinical trials and related to our employees, and we are subject to laws and regulations governing the privacy and security of such information. In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws, and federal and state consumer protection laws. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues, including with respect to regulatory enforcement and private litigation, which may affect our business and is expected to increase our compliance costs and exposure to liability. In the United States, numerous federal and state laws and regulations could apply to our operations or the operations of our partners, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations (e.g., Section 5 of the Federal Trade Commission (FTC) Act), that govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that may be subject to privacy and security requirements under HIPAA, as amended by HITECH and regulations promulgated thereunder. Depending on the facts and circumstances, we could be subject to significant penalties if we obtain, use, or disclose, or are subject to an actual or alleged data breach regarding, individually identifiable health information in a manner that is not authorized or permitted by HIPAA. In 2023, the SEC finalized rules requiring enhanced disclosures regarding cybersecurity risk management, strategy, and governance, as well as the timely reporting of material cybersecurity incidents. These rules mandate disclosures about our processes for identifying, assessing, and managing cybersecurity risks, the role of management and the board of directors in overseeing these risks, and specific incidents that materially affect us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EEA, we are subject to the EU GDPR, which took effect in May 2018. The EU GDPR governs the collection, use, disclosure, transfer or other processing of personal data (i.e., data which identifies an individual or from which an individual is identifiable), including clinical trial data, and grants individuals various data protection rights (e.g., the right to erasure of personal data). The EU GDPR imposes a number of obligations on companies, including inter alia: (1) accountability and transparency requirements, and enhanced requirements for obtaining valid consent; (2) obligations to consider data protection as any new products or services are developed and to limit the amount of personal data processed; (3) obligations to implement appropriate technical and organizational measures to safeguard personal data and to report certain personal data breaches to the supervisory authority without undue delay (and no later than 72 hours where feasible); and (4) additional, more onerous requirements around the processing of special categories of personal data (including health data and genetic data). In addition, the EU GDPR prohibits the transfer of personal data from the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws unless a data transfer mechanism has been put in place. In July 2020, the Court of Justice of the EU (CJEU) in the Schrems II decision limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the EU-US Privacy Shield for purposes of international transfers and imposing further restrictions on use of the standard contractual clauses (SCCs), including a requirement for companies to carry out a transfer impact assessment, which among other things, assesses laws governing access to personal data in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under SCCs will need to be implemented to ensure an essentially equivalent level of data protection to that afforded in the EEA. The European Commission subsequently issued new SCCs in June 2021 to account for the decision of the CJEU and recommendations made by the European Data Protection Board and which are in turn relatively more onerous. At present, there are few, if any, viable alternatives to the SCCs. However, on October 7, 2022, the Biden administration introduced an Executive Order to facilitate a new Trans-Atlantic Data Privacy Framework which will act as a successor to the invalidated EU-US Privacy Shield. On December 13, 2022, the European Commission also published its draft adequacy decision to reflect its view that the new Executive Order and Trans-Atlantic Data Privacy Framework, is able to meet the concerns raised in Schrems II. If the draft adequacy decision is approved and implemented, the agreement will facilitate the transatlantic flow of personal data and provide additional safeguards to data transfer mechanisms (including SCCs and Binding Corporate Rules) for companies transferring personal data from the EU to the US. However, before parties rely on the new framework, there are still legislative and regulatory steps that must be undertaken both in the US and in the EU. The EU GDPR imposes substantial fines for breaches and violations (up to the greater of &#8364;20 million or 4% of consolidated annual worldwide gross revenue), and confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the EU GDPR. The EU GDPR increases our responsibility and liability in relation to personal data that we process, and additional mechanisms put in place to address compliance with the EU GDPR must be kept under review as the legislative and regulatory landscape for data protection in the EU continues to evolve.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Relatedly, following Brexit, the EU GDPR has been implemented in the United Kingdom (as the UK GDPR). The UK GDPR sits alongside the UK Data Protection Act 2018 which implements certain derogations in the EU GDPR into UK law. Under the UK GDPR, companies not established in the UK but that process personal data in relation to the offering of goods or services to individuals in the UK, or to monitor their behavior will be subject to the UK GDPR &#8211; the requirements of which are (at this time) largely aligned with those under the EU GDPR and as such, may lead to similar compliance and operational costs with potential fines of up to &#163;17.5 million or 4% of global turnover. The UK Government has published its own form of SCCs, known as the International Data Transfer Agreement (IDTA) and International Data Transfer Addendum (UK Addendum) to the EU SCCs. The UK Information Commissioner&#8217;s Office (ICO) has also published its own version of the transfer impact assessment and recently revised guidance on international transfers, although entities may choose to adopt either the EU or UK style transfer impact assessment. In terms of international data transfers between the UK and US, it is understood that the UK and the US are also negotiating an adequacy agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to devote additional resources to and put in place additional mechanisms ensuring compliance with the new data protection and disclosure rules. Despite our efforts to comply with these laws and regulations, the inherent complexity of data security and cyber threats, and the newness of some of these requirements, such as the SEC&#8217;s cybersecurity disclosure requirements, present a risk of non-compliance or insufficient disclosure, which could invite regulatory scrutiny and affect our operational and financial performance. Furthermore, the laws are not consistent, and compliance in the event of a widespread data breach is costly. In addition, states are constantly adopting new laws or amending existing laws, requiring attention to frequently changing regulatory requirements. For example, California enacted the California Consumer Privacy Act (the CCPA), which took effect on January 1, 2020, became enforceable by the California Attorney General on July 1, 2020, and was the first comprehensive state privacy law in the United States. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights Act (the CPRA), which further amended the CCPA, went into effect on January 1, 2023. The CCPA, as amended by the CPRA, imposes additional data protection obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions went into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. Although the CCPA currently exempts certain health-related information, including clinical trial data, the CCPA (as amended by the CPRA) may increase our compliance costs and potential liability. Similar laws have been adopted in other states or proposed in other states and at the federal level, and if passed, such laws may have potentially conflicting requirements that would make compliance challenging. For example, the Nevada Privacy of Information Collected on the Internet from Consumers Act went into effect on October 1, 2021, the Virginia Consumer Data Protection Act went into effect on January 1, 2023, the Colorado Privacy Act went into effect on July 1, 2023, the Connecticut Data Privacy Act went into effect July 1, 2023, and the Utah Consumer Privacy Act went into effect December 31, 2023.  Additionally, newly introduced state laws related to health privacy may result in additional compliance costs. For example, the state of Washington recently passed the &#8220;My Health My Data&#8221; Act, which will regulate &#8220;consumer health data,&#8221; defined as &#8220;personal information that is linked or reasonably linkable to a consumer and that identifies a consumer&#8217;s past, present, or future physical or mental health.&#8221;  The &#8220;My Health My Data&#8221; Act provides exemptions for personal data used or shared in research, including data subject to 45 C.F.R. Parts 46, 50, and 56.  Additionally, Nevada recently enacted a consumer health data privacy bill, and other states could adopt health-specific privacy laws that could impact our business.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Federal Trade Commission (FTC) and many state attorneys general are interpreting existing federal and state consumer protection laws to impose evolving standards for the collection, use, dissemination and security of health-related and other personal information. For instance, the FTC has promulgated standards for fair information practices, which concern consumer notice, choice, security and access, and also require notice of certain health information breaches outside the HIPAA context. Privacy laws require us to publish statements that describe how we handle personal information and choices individuals may have about the way we handle their personal information. Violating individuals&#8217; privacy rights, publishing false or misleading information about security practices, or failing to take appropriate steps to keep individuals&#8217; personal information secure may constitute unfair or deceptive acts or practices in violation of Section 5 of the FTC Act. Additionally, the FTC published an advance notice of proposed rulemaking on commercial surveillance and data security in 2022 and may implement new trade regulation rules or other regulatory alternatives concerning the ways in which companies (1) collect, aggregate, protect, use, analyze, and retain consumer data, as well as (2) transfer, share, sell, or otherwise monetize that data in ways that are unfair or deceptive in the coming years. Federal regulators, state attorneys general and plaintiffs&#8217; attorneys have been and will likely continue to be active in this space, and if we do not comply with existing or new laws and regulations related to patient health information, we could be subject to criminal or civil sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any actual or perceived failure by us to comply with applicable privacy and data security laws and regulations could result in regulatory investigations, reputational damage, orders to cease/ change our processing of our data, enforcement notices, and/ or assessment notices (for a compulsory audit). We may also face civil claims including representative actions and other class action type litigation (where individuals have suffered harm), potentially amounting to significant compensation or damages liabilities, as well as associated costs, diversion of internal resources, and reputational harm.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely upon a combination of patents, know-how and confidentiality agreements to protect the intellectual property related to our products and technologies and to prevent third parties from copying and surpassing our achievements, thus eroding our competitive position in our market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain patent protection for our T-win&#174; platform, product candidates and their uses, as well as our ability to operate without infringing the proprietary rights of others. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business. We cannot guarantee that our pending and future patent applications will result in patents being issued or that issued patents will afford sufficient protection of our product candidates or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or that they will effectively prevent others from commercializing competitive technologies, products or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining and enforcing patents is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications or maintain and/or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Composition of matter patents for biological and pharmaceutical product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. However, we cannot be certain that the claims in our pending patent applications directed to composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (USPTO) or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal, scientific, and factual questions and has in recent years been the subject of much litigation, resulting in court decisions, including United States Supreme Court decisions, which have increased uncertainties as to the ability to enforce patent rights in the future. The standards that the USPTO and its foreign counterparts use to grant patents are not always applied predictably or uniformly. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. For example, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or their intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. Patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, inventorship, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending patent applications may be challenged in patent offices in the United States and abroad. The issuance of a patent is not conclusive as to its inventorship, ownership, scope, validity or enforceability. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. For example, our pending patent applications may be subject to third-party pre-issuance submissions of prior art to the USPTO or our issued patents may be subject to post-grant review (PGR) proceedings, oppositions, derivations, reexaminations, interference or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. Any failure to obtain or maintain patent protection with respect to our product candidates or their uses could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. We may also rely on trade secret protection as temporary protection for concepts that may be included in a future patent filing. However, trade secret protection will not protect us from innovations that a competitor develops independently of our proprietary know how. If a competitor independently develops a technology that we protect as a trade secret and files a patent application on that technology, then we may not be able to patent that technology in the future, may require a license from the competitor to use our own know-how, and if the license is not available on commercially-viable terms, then we may not be able to launch our product. Although we require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, and this scenario could materially adversely affect our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may be able to make product candidates that are the same as or similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that noncompliance with the USPTO and foreign governmental patent agencies requirement for a number of procedural, documentary, fee payment and other provisions during the patent process can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that our pending patent applications will not lead to issued patents; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued patents that we own or have exclusively licensed may be revoked, modified, or held invalid or unenforceable, as a result of legal challenges by our competitors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we cannot predict the scope of protection of any patent issuing based on our patent applications, including whether the patent applications that we own or in-license will result in issued patents with claims that directed to our product candidates or uses thereof in the United States or in other foreign countries; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the claims of any patent issuing based on our patent applications may not provide protection against competitors or any competitive advantages, or may be challenged by third parties; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if enforced, a court may not hold that our patents are valid, enforceable and infringed; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may fail to adequately protect and police our trademarks and trade secrets; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by our patents and patent applications. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should any of these or similar events occur, they could significantly harm our business, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations imposed by any intellectual property licenses with third parties that we may need in the future, we could lose rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may in the future require licenses to third-party technology and materials. Such licenses may not be available in the future or may not be available on commercially reasonable terms, or at all, which could have a material adverse effect on our business and financial condition. We may rely on third parties from whom we license proprietary technology to file and prosecute patent applications and maintain patents and otherwise protect the intellectual property we license from them. We may have limited control over these activities or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by these licensors will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We may have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that may be licensed to us. It is possible that the licensors&#8217; infringement proceeding or defense activities may be less vigorous than if we conduct them ourselves. Even if we acquire the right to control the prosecution, maintenance and enforcement of the licensed and sublicensed intellectual property relating to our product candidates, we may require the cooperation of our licensors and any upstream licensor, which may not be forthcoming. Therefore, we cannot be certain that the prosecution, maintenance and enforcement of these patent rights will be in a manner consistent with the best interests of our business. If we or our licensor fail to maintain such patents, or if we or our licensor lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be adversely affected. In addition to the foregoing, the risks associated with patent rights that we license from third parties will also apply to patent rights we may own in the future. Further, if we fail to comply with our diligence, development and commercialization timelines, milestone payments, royalties, insurance and other obligations under our license agreements, we may lose our patent rights with respect to such agreement, which would affect our patent rights worldwide.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Termination of our current or any future license agreements would reduce or eliminate our rights under these agreements and may result in our having to negotiate new or reinstated agreements with less favorable terms or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology. Any of the foregoing could prevent us from commercializing our other product candidates, which could have a material adverse effect on our operating results and overall financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, intellectual property rights that we may in-license in the future may be sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize our product candidates may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In the future, we may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently own intellectual property directed to our product candidates and other proprietary technologies, including our T-win&#174; platform. Other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. From time to time, in order to avoid infringing these third-party patents, we may be required to license technology from additional third parties to further develop or commercialize our product candidates. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our product candidates, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if we are able to obtain a license under such intellectual property rights, any such license may be non-exclusive, which may allow our competitors to access the same technologies licensed to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, some of our owned and in-licensed patents or patent applications or future patents may be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Furthermore, our owned and in-licensed patents maybe subject to a reservation of rights by one or more third parties. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates without infringing the intellectual property and other proprietary rights of third parties. Third parties may allege that we have infringed, misappropriated or otherwise violated their intellectual property. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">105</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our product candidates. We cannot be certain that our product candidates and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. Third parties may assert infringement claims against us based on existing or future intellectual property rights. If we are found to infringe a third party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing candidate product or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing candidate product or product. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our investigational products or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including but not limited to the identification of relevant patents, analysis of the scope of relevant patent claims or determination of the expiration of relevant patents, are complete or thorough. We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing our product candidates, might assert are infringed by our current or future product candidates, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates and other proprietary technologies we may develop, could be found to be infringed by our product candidate. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. . Our determination of the expiration date of any patent in the United States, Europe or elsewhere that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates. The pharmaceutical and biotechnology industries have produced a considerable number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents, and there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may choose to challenge the enforceability or validity of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex-parte </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">re-exam, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the European Patent Office (EPO), or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors or other third parties may infringe our patents, trademarks or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or insufficient written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention, or decide that the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1). An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We employ and may employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our future patents. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. There is no guarantee of success in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">107</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs, and may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act), signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review, and derivation proceedings. Further, because of a lower evidentiary standard in these USPTO post-grant proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After March 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before we file an application covering the same invention, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates and other proprietary technologies we may develop or (ii) invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention where the other party can show that they used the invention in commerce before our filing date. Thus the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the 2013 case </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Assoc. for Molecular Pathology v. Myriad Genetics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">108</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of any individual patent depends on applicable law in the country where the patent is granted. In the United States, provided all maintenance fees are timely paid, a patent generally has a term of 20 years from its application filing date or earliest claimed non-provisional filing date. Extensions may be available under certain circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. Even if we or our licensors obtain patents covering our product candidates, when the terms of all patents covering a product expire, our business may become subject to competition from competitive medications or vaccines, including generic medications or vaccines. Given the amount of time required for the development, testing and regulatory review and approval of new product candidates, patents protecting such candidates may expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, a patent that covers an FDA-approved drug or biologic may be eligible for a term extension designed to restore the period of the patent term that is lost during the premarket regulatory review process conducted by the FDA. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, as amended (the Hatch-Waxman Act), which permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. In Europe, our product candidates may be eligible for term extensions based on similar legislation. In either jurisdiction, however, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Even if we are granted such extension, the duration of such extension may be less than our request. If we are unable to obtain a patent term extension, or if the term of any such extension is less than our request, the period during which we can enforce our patent rights for that product will be in effect shortened and our competitors may obtain approval to market competing products sooner. The resulting reduction of years of revenue from applicable products could be substantial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive, and even in countries where we have sought protection for our intellectual property, such protection can be less extensive than in the United States. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. In-licensing patents covering our product candidates in all countries throughout the world may similarly be prohibitively expensive, if such opportunities are available at all. And in-licensing or filing, prosecuting and defending patents even in only those jurisdictions in which we develop or commercialize our product candidates may be prohibitively expensive or impractical. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection or licensed patents to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but where enforcement is not as strong as that in the United States or Europe. These products may compete with our product candidates, and our or our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">109</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or regulations in the United States and Europe, and many companies have encountered significant difficulties in protecting and defending proprietary rights in such jurisdictions. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets or other forms of intellectual property, particularly those relating to biotechnology products, which could make it difficult for us to prevent competitors in some jurisdictions from marketing competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, are likely to result in substantial costs and divert our efforts and attention from other aspects of our business, and additionally could put our or our licensors&#8217; patents at risk of being invalidated or interpreted narrowly, could increase the risk of our or our licensors&#8217; patent applications not issuing, or could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, while damages or other remedies may be awarded to the adverse party, which may be commercially significant. If we prevail, damages or other remedies awarded to us, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition in those jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some jurisdictions, including certain European countries, compulsory licensing laws compel patent owners to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties under patents relevant to our business, or if we or our licensors are prevented from enforcing patent rights against third parties, our competitive position may be substantially impaired in such jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may rely on trade secret and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to seeking patents for some of our technology and current product candidates or any future product candidates, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Elements of our current product candidates or any future product candidates, including processes for their preparation and manufacture, as well as our T-win&#174; platform, may involve proprietary know-how, information, or technology that is not covered by patents, and thus for these aspects we may consider trade secrets and know-how to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Trade secrets and know-how can be difficult to protect. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We enter into written agreements that include confidentiality and intellectual property obligations to protect each party&#8217;s property, potential trade secrets, proprietary know-how, and information. We further seek to protect our potential trade secrets, proprietary know-how, and information in part, by entering into non-disclosure and confidentiality agreements with parties who are given access to them, such as our corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we may in-license in the future. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and tradenames to third parties, such as distributors. Although these license agreements may provide guidelines for how our trademarks and tradenames may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">111</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The stock price of our common stock may be volatile or may decline regardless of our operating performance and you may lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report on Form 10-K, these factors include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">overall performance of the equity markets; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our operating performance and the performance of other similar companies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">published opinions and third-party valuations by banking and market analysts; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">results from our ongoing clinical trials and future clinical trials with our current and future product candidates or of our competitors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse results or delays in clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to commercialize our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unanticipated serious safety concerns related to immuno-oncology or related to the use of our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory or legal developments in the United States and other countries; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of expenses related to future product candidates or clinical development programs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our failure to achieve product development goals in the timeframe we announce; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements of acquisitions, strategic alliances or significant agreements by us or by our competitors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the economy as a whole and market conditions in our industry; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trading activity by a limited number of stockholders who together beneficially own a majority of our outstanding common stock; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the expiration of market standoff or contractual lock-up agreements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size of our public float; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">political uncertainty and/or instability in the United States and throughout the world; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any other factors discussed in this Annual Report on Form 10-K. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many immuno-oncology companies. Stock prices of many immuno-oncology companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. The trading prices for common stock of other biopharmaceutical companies have also been highly volatile as a result of the high inflation environment and geopolitical conflict in Ukraine and the Middle East. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">112</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our executive officers, directors, 5% stockholders and their affiliates beneficially owned approximately 93.7% of our voting stock. Therefore, these stockholders will have the ability to influence us through their ownership positions. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If there are substantial sales of shares of our common stock, the price of our common stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The price of our common stock could decline if there are substantial sales of our common stock, particularly sales by our directors, executive officers and significant stockholders, or if there is a large number of shares of our common stock available for sale and the market perceives that sales will occur. As of December 31, 2023, we had 65,880,914 shares of common stock outstanding. Substantially all of our outstanding shares of common stock are currently able to be sold freely in the public market, subject to certain restrictions that may apply to shares of our common stock held by our affiliates and by certain participants in our August 2023 private placement. The market price of our common stock could decline as a result of the sale of a substantial number of shares of our common stock in the public market or the perception in the market that the holders of a large number of shares intend to sell their shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delaware law and provisions in our amended and restated certificate of incorporation and bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation and bylaws contain provisions that could depress the trading price of our common stock by acting to discourage, delay or prevent a change of control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a classified board of directors so that not all members of our board of directors are elected at one time; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">permit the board of directors to establish the number of directors and fill any vacancies and newly-created directorships; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that directors may only be removed for cause and only by the affirmative vote of the holders of at least a majority of the voting power of all then outstanding shares of our capital stock; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require super-majority voting to amend some provisions in our amended and restated certificate of incorporation and bylaws; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board of directors could use to implement a stockholder rights plan; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prohibit stockholders from calling special meetings of stockholders; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that the board of directors is expressly authorized to make, alter or repeal our bylaws; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrict the forum for certain litigation against us to Delaware; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon by stockholders at annual stockholder meetings. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any provision of our amended and restated certificate of incorporation or bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation designates a state or federal court located within the state of Delaware as the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to choose the judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">113</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf under Delaware law; (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders; (3) any action arising pursuant to any provision of the Delaware General Corporation Law (DGCL), our amended and restated certificate of incorporation or bylaws; (4) any other action asserting a claim that is governed by the internal affairs doctrine; or (5) any other action asserting an &#8220;internal corporate claim,&#8221; as defined in Section 115 of the DGCL, shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) in all cases subject to the court having jurisdiction over indispensable parties named as defendants. These exclusive-forum provisions do not apply to claims under the Securities Act or the Securities Exchange Act of 1934, as amended (the Exchange Act).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. However, our amended and restated certificate of incorporation contains a federal forum provision which provides that unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to this provision. This exclusive forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum of its choosing for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find the exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner, we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the IO Biotech, Inc. 2021 Equity Incentive Plan (the 2021 Equity Plan), we are  authorized to grant stock options and other equity-based awards to our employees, directors and consultants. In addition, pursuant to the IO Biotech, Inc. 2023 Inducement Award Plan (2023 Inducement Plan), we are eligible to grant stock options and other equity-based awards to employees as an inducement for them to join us. Equity-based awards granted under the 2021 Equity Plan and the 2023 Inducement Plan would cause dilution to our stockholders. The number of shares of our common stock reserved for issuance under the 2021 Equity Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, by an amount equal to the lesser of (1) 4% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of each automatic increase; or (2) a lesser number of shares determined by our board of directors prior to the applicable January 1st. If our board of directors elects to increase the number of shares available for future grant by the maximum amount each year, our stockholders may experience additional dilution, which could cause our stock price to fall. The maximum number of shares reserved for issuance under the 2023 Inducement Plan is 1,976,427 shares.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common shares less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">114</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act (the JOBS Act), and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced disclosure obligations regarding executive compensation; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not being required to hold a non-binding advisory vote on executive compensation or obtain stockholder approval of any golden parachute payments not previously approved. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as an &#8220;emerging growth company&#8221; the JOBS Act allows us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies, unless we later irrevocably elect not to avail ourselves of this exemption. We have elected to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult. We will remain an emerging growth company until the earliest of (1) the end of the fiscal year following the fifth anniversary of our initial public offering; (2) the last day of the fiscal year during which our annual gross revenues are $1.235 billion or more; (3) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt securities; and (4) the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700.0 million as of the end of the second quarter of that fiscal year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also a &#8220;smaller reporting company meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements in our Annual Report on Form 10-K, and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held by non-affiliates exceeds $250 million as of the end of that year&#8217;s second fiscal quarter and our annual revenues exceeds $100 million during such completed fiscal year, or (ii) the market value of our common stock held by non-affiliates exceeds $700 million, regardless of our annual revenue, as of the end of that year&#8217;s second fiscal quarter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investors may find our common stock less attractive to the extent we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">115</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We incur significantly increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002, as amended (the Sarbanes-Oxley Act), as well as rules subsequently implemented by the SEC and Nasdaq, have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the Dodd-Frank Act) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;Say on Pay&#8221; and proxy access. Recent legislation permits smaller &#8220;emerging growth companies&#8221; to implement many of these requirements over a longer period and up to five years from the pricing of our IPO. We have taken advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costlier than when we were a private company. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure to build our finance infrastructure and improve our accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company, we operate in an increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act, the regulations of Nasdaq, the rules and regulations of the SEC, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud. Commencing with our fiscal year ending December 31, 2022, we must perform system and process evaluation and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Form 10-K filing for that and each subsequent year, as required by Section 404 of the Sarbanes-Oxley Act. Prior to our IPO, we were not required to test our internal controls within a specified period and, as a result, we may experience difficulty in meeting these reporting requirements. For example, in connection with the audit of our financial statements for the years ended December 31, 2021 and 2020, we and our independent registered public accounting firm identified a material weakness in our internal control over financial reporting. This material weakness was not previously remediated, and in connection with the preparation of our consolidated financial statements for the year ended December 31, 2021, the Company identified an error, which resulted in a restatement as disclosed in our Current Report on Form 8-K filed on December 17, 2021. For the year ended December 31, 2022, this material weakness was remediated and no additional material weaknesses were identified for the year ended December 31, 2023, but we could experience further difficulty with internal control over financing reporting in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence in our reported financial information and we could be subject to sanctions or investigations by Nasdaq, the SEC or other authorities.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">116</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our reported financial position or results of operations. Financial accounting standards in the United States are constantly under review and new pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future. As a result, we may be required to make changes in our accounting policies. Those changes could affect our financial condition and results of operations or the way in which such financial condition and results of operations are reported. We intend to invest resources to comply with evolving standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from business activities to compliance activities. See the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Recent Accounting Pronouncements.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New income, sales, use, or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted, changed, modified, or applied adversely to us. For example, the TCJA enacted many significant changes to the U.S. tax laws. Future guidance from the IRS and other tax authorities with respect to the TCJA may affect us, and certain aspects of the TCJA could be repealed or modified in future legislation. For example, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) modified certain provisions of the TCJA. In addition, it is uncertain if and to what extent various states will conform to the TCJA or any newly enacted federal tax legislation. For example, the U.S. government recently enacted the IRA which, among other things, significantly changes the taxation of certain business entities, including by imposing a 1% excise tax on certain share buybacks, effective for tax years beginning in 2023. If and when applicable, it is possible that the 1% excise tax on share buybacks could result in an additional tax liability over the regular federal corporate tax liability in a given year. Any resulting tax liability could adverse impact our business, financial condition, results of operation, and liquidity. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the TCJA or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one time charges, and could increase our future U.S. tax expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, recent and upcoming presidential and congressional elections in the United States could also result in significant changes in, and uncertainty with respect to, tax legislation, regulation and government policy directly affecting us and our business. For example, the United States government may enact significant changes to the taxation of business entities including, among others, a permanent increase in the corporate income tax rate, an increase in the tax rate applicable to the global intangible low-taxed income and elimination of certain exemptions, and the imposition of minimum taxes or surtaxes on certain types of income. The likelihood of these changes being enacted or implemented is unclear.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">117</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The global credit and financial markets have recently experienced extreme volatility and disruptions, including as a result of recent developments in the U.S. banking sector and geopolitical conflict in Ukraine and the Middle East, leading to increased inflation, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, and uncertainty about economic and bank-system stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our drug-candidate-development goals on schedule and on budget.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will have broad discretion in the use of our existing cash and cash equivalents and may not use them effectively or in ways that increase the value of our share price.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot specify with any certainty the particular uses of our existing cash and cash equivalents. We will have broad discretion in the application of our existing cash and cash equivalents, including working capital and other general corporate purposes, and you and other stockholders may disagree with how we spend or invest our cash and cash equivalents. The failure by our management to apply these funds effectively could adversely affect our business and financial condition. Pending their use, we may invest our cash and cash equivalents in a manner that does not produce income or that loses value. These investments may not yield a favorable return to our investors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our internal information technology systems, or those of our third-party CROs or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our product candidates&#8217; development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have also outsourced elements of our operations to third parties, and as a result we manage a number of third-party contractors who have access to our confidential information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the implementation of security measures, given their size and complexity and the increasing amounts of confidential information that they maintain, our internal information technology systems and those of our third-party CROs and other contractors and consultants are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, extortion, account takeover attacks, degradation of service attacks, denial-of-service attacks, &#8220;phishing,&#8221; or social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure or lead to data leakage. We have technology security initiatives and disaster recovery plans in place to mitigate our risk to these vulnerabilities, but these measures may not be adequately designed or implemented to ensure that our operations are not disrupted or that data security breaches do not occur. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and reputational damage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Hackers and data thieves are increasingly sophisticated and operate large-scale and complex automated attacks which may remain undetected until after they occur. We cannot assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. Like all businesses we may be increasingly subject to ransomware or other malware that could significantly disrupt our business operations, or disable or interfere with necessary access to essential data or processes. Numerous recent attacks of this nature have also involved exfiltration and disclosure of sensitive or confidential personal or proprietary information, or intellectual property, when victim companies have not paid the cyber criminals substantial ransom payments. For example, any such event that leads to unauthorized access, use, disclosure, unavailability, or compromised integrity of personal or other sensitive or essential information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, increase the costs we incur to protect against such information security breaches, such as increased investment in technology, render key personnel unable to perform duties or communicate throughout the organization and otherwise subject us to fines and other liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The costs of mitigating cybersecurity risks are significant and are likely to increase in the future. These costs include, but are not limited to, retaining the services of cybersecurity providers; compliance costs arising out of existing and future cybersecurity, data protection and privacy laws and regulations; and costs related to maintaining redundant networks, data backups and other damage-mitigation measures. We also cannot be certain that our existing insurance coverage will continue to be available on acceptable terms or in amounts sufficient to cover the potentially significant losses that may result from a security incident or breach or that the insurer will not deny coverage of any future claim.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operations as a global company subject us to various risks, and our failure to manage these risks could adversely affect our business, results of operations, cash flows, financial condition and/or prospects.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face significant operational risks as a result of doing business globally, such as:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fluctuations in currency exchange rates (in particular, between U.S. dollars, Euros and Danish Kroner);</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potentially adverse tax consequences, including the complexities of foreign value-added tax systems, tax inefficiencies related to our corporate structure, and potential restrictions on the repatriation of earnings;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">export restrictions, trade regulations and foreign tax laws;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customs clearance and shipping delays;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the burdens of complying with a wide variety of foreign laws and different legal standards; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased financial accounting and reporting burdens and complexities.  </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If one or more of these risks are realized, it could have a material adverse effect on our business, results of operations, cash flows, financial condition and/or prospect.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Global economic and political instability and conflicts, such as the conflict in Russia and Ukraine and conflicts in the Middle East, could adversely affect our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">119</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business could be adversely affected by unstable economic and political conditions within the United States and foreign jurisdictions and geopolitical conflicts, such as the conflict in Ukraine and conflicts in the Middle East. While we do not have any operations in Russia or Ukraine at this time, the current military conflict, and related sanctions, as well as export controls or actions that may be initiated by nations and regions including the United States, the EU or Russia (e.g., potential cyberattacks, disruption of energy flows, disruptions to supply chains, etc.) and other potential uncertainties could adversely affect our business. Certain of our clinical trial sites are located in Israel and conflicts in the Middle East may delay, limit or hinder ongoing, planned or future trials and affect enrollment and retention of patients. Inability to enroll or retain patients and limitations or delays in clinical trials could increase costs and cause setbacks in product development. In the event geopolitical tensions fail to abate or deteriorate further, additional governmental sanctions may be enacted adversely impacting the global economy, which could adversely affect our business, financial condition or results of operations.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters and/or terrorism and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevent us from using all or a significant portion of our headquarters or other facilities, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur substantial expenses as a result of the absence or limited nature of our internal or third-party service provider disaster recovery and business continuity plans, which could have a material adverse effect on our business. In addition, the long-term effects of climate change on general economic conditions and the pharmaceutical manufacturing and distribution industry in particular are unclear, and changes in the supply, demand or available sources of energy and the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including raw materials and other natural resources, necessary to run our business.  Furthermore, certain parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our ability to conduct our clinical trials, our development plans and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for any violations of such laws.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, Trade Laws) prohibit, among other things, companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect to continue our non-U.S. activities, which may increase over time. We expect to rely on third parties for research, preclinical studies, and clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We, and the third parties with whom we share our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Each of our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us or the third parties with whom we share our facilities, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">120</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. Although we maintain general liability insurance, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials, and our general liability insurance may not probe sufficient coverage against any potential liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research and development. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We could be subject to securities class action litigation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no or only very few securities analysts commence coverage of us, or if industry analysts cease coverage of us, the trading price for our common stock could be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure to meet investor and stakeholder expectations regarding environmental, social and corporate governance, or &#8220;ESG&#8221; matters may damage our reputation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is an increasing focus from certain investors, employees and other stakeholders concerning ESG matters. Additionally, public interest and legislative pressure related to public companies&#8217; ESG practices continue to grow. If our ESG practices fail to meet investor, employee or other stakeholders&#8217; evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, Board of Directors and employee diversity, human capital management, corporate governance and transparency, our reputation, brand, appeal to investors and employee retention may be negatively impacted, which could have a material adverse effect on our business or financial condition.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">121</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1B. Unre</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">solved Staff Comments.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="toc_page"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C. Cybersecurity Risk Management, Strategy and Governance</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Management and Strategy</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We regularly assess risks from cybersecurity threats, monitor our information systems for potential vulnerabilities, and test those systems pursuant to our information and cybersecurity policies, processes, and practices. We maintain a Cybersecurity Incident Response Plan that establishes an incident response team led by our Head of Information Technology and describes our response protocol for cybersecurity incidents. To help protect our information systems from cybersecurity threats, we use various security tools that are designed to help identify, escalate, investigate, resolve, and recover from security incidents in a timely manner. Assessment of cybersecurity threats is included as part of our overall risk management processes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have engaged consultants and other third parties to assist in our assessment of risks from cybersecurity threats and to evaluate our cybersecurity prevention and response systems and processes. At times, we may engage third parties to assist in the management and mitigation of a particular threat.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are requiring each of our significant third-party service providers to agree that it will implement and maintain appropriate security measures that are consistent with applicable law, implement and maintain reasonable security measures in connection with their work with us, and promptly report any suspected breach of its security measures that may affect our company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governance</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our board of directors, as a whole and through the Audit Committee, is responsible for the oversight of risk management, including oversight of risks from cybersecurity threats, and discusses with management our major risk exposures, including from cybersecurity threats, their potential impact on us, and the steps we take to manage them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Head of Information Technology, reporting to our Chief Financial Officer, has day-to-day responsibility for preventing, detecting, mitigating and remediating cybersecurity risks. The individual currently serving in this role has over twenty years of experience in information technology and cybersecurity. Our Head of Information Technology leads an incident response team that includes members of executive management, including members of our legal team, and is charged with assessing and managing material cybersecurity risks, and with notifying our executive management committee and disclosure committee of potential material cybersecurity incidents. Executive management provides updates on our cybersecurity risk profile to our Audit Committee on at least a quarterly basis.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cybersecurity Threats</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the date of this report, we have not identified cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially affected us, including our business strategy, results of operations or financial condition. We and our third-party service providers have, however, been the target of cybersecurity threats and we expect these threats to continue. For additional information regarding risks from cybersecurity threats, please refer to Item 1A, &#8220;Risk Factors,&#8221; in this annual report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item1c_10b51"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1D. Section 16 Officers and Directors Rule 10b5-1 Plan.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">perties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We lease a facility containing approximately 622 square meters of office space for our main office, which is located at COBIS, Ole Maal&#248;es Vej 3, DK-2200 Copenhagen N, Denmark. The lease expires in December 2027. We also lease lab space at COBIS, Ole Maal&#248;es Vej 3, DK-2200 Copenhagen N, Denmark. The lease expires in December 2027.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, we lease office space in New York, located at 430 East 29th Street, New York, New York, and lab space in Maryland, located at 5640 Fishers Lane, Suite C, Rockville, Maryland. The New York lease expires in January 2027 and the Maryland lease expires in May 2027.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">122</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For our UK team, we lease office space located at No 1 Langstone Business Park, Newport, UK. The lease expires in May 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our current facilities are adequate for our current needs and that suitable additional or substitute space at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Legal Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">oceedings.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may be a party to litigation or subject to claims incidental to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material adverse effect on our business. Regardless of the outcomes, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. We are not currently a party to any material legal proceedings.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Safe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ty Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not Applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">123</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T II</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="market_for_registrants_common_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Mark</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">et for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information for Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;IOBT.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid any dividends on our common stock. We anticipate that we will retain all of our</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future earnings, if any, for use in the operation and expansion of our business and do not anticipate paying cash dividends</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stockholders</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 26, 2024, we had 65,880,914 shares of common stock outstanding held by 13 holders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity Compensation Plans</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table details information regarding our existing equity compensation as of December 31, 2023:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.04%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:15.94%;"/>
    <td style="width:1%;"/>
    <td style="width:1.14%;"/>
    <td style="width:1%;"/>
    <td style="width:15.14%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:19.74%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Plan Category</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Securities to be Issued Upon Exercise of Outstanding Options and Warrants <br/>(in thousands)<br/>(a)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average Exercise Price of Outstanding Options and Warrants<br/>(b)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Securities Remaining Available for Issuance Under Equity Compensation Plans (Excluding Securities reflected in Column (a))<br/>(in thousands)<br/>&#160;(c)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity compensation plans approved by security holders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,504</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.53</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">593</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity compensation plans not approved by security holders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">348</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.86</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,976</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,852</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.20</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,570</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See &#8220;Item 8. Financial Statements and Supplementary Data - Notes to the Consolidated Financial Statements - Note 11. Equity-Based Compensation&#8221; for additional information on compensation plans under which equity securities of the registrant are authorized for issuance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Proceeds</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 9, 2023, we completed a private placement transaction (the Private Placement) in which we issued and sold (i) an aggregate of 37,065,647 shares of the Company&#8217;s common stock, $0.001 par value (the Common Stock), and (ii) 37,065,647 warrants to purchase up to 37,065,647 shares of Common Stock, $0.001 par value, to the Purchasers (the Warrants). The offer and sale of securities in the Private Placement were exempt from registration under Section 4(a)(2) of the Securities Act as transactions by an issuer not involving a public offering. The Purchasers acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in the Private Placement. Each of the Purchasers was an accredited person and had adequate access to information about the Company. The co-placement agents in connection with the Private Placement were Morgan Stanley &amp; Co. LLC &amp; Piper Sandler &amp; Co.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We raised $71.9 million in net proceeds from the Private Placement after deducting underwriting discounts, commissions and other issuance costs of $3.2 million. No underwriting discounts and commissions or offering expenses were paid directly or indirectly to any of our directors of officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">124</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Proceeds From Registered Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 9, 2021, we completed our IPO in which we issued and sold 8,222,500 shares of common stock, $0.001 par value per share, including 1,072,500 shares of common stock sold pursuant to the underwriters&#8217; exercise of their option to purchase additional shares of common stock. The offer and sale of the shares in the IPO was registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-260301), which was filed with the SEC on October 15, 2021 and subsequently amended and declared effective on November 4, 2021, and the prospectus included therein (the Prospectus). The underwriters of the IPO were Morgan Stanley &amp; Co. LLC, Jefferies LLC, Cowen and Company, LLC and Kempen &amp; Co U.S.A, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We raised $103.3 million in net proceeds from the IPO after deducting underwriting discounts and commissions of $8.0 million and other offering expenses of $3.8 million payable by us. No underwriting discounts and commissions or offering expenses were paid directly or indirectly to any of our directors of officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been no material change in the planned use of proceeds from our IPO, as described in the Prospectus.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Parties</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. [</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eserved].</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">125</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="management_discussion_analysis"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. Manag</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ement&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the consolidated financial statements and the related notes to those statements included later in this Annual Report. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, beliefs and expectations that involve risks and uncertainties. Our actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report, particularly in Part I, Item 1A. &#8220;Risk Factors,&#8221; and &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on our T-win&#174; platform. Our T-win product candidates are designed to kill both tumor cells and immune-suppressive cells in the TME by stimulating the activation and expansion of T cells against IDO+ and/or PD-L1+ target positive cells, resulting in the modulation of the TME, creating a more pro-inflammatory environment, and the potentiation of anti-tumor activity by unleashing the tumor killing by effector T cells. We believe this could represent a paradigm shift in the management of cancer and that our product candidates have the potential to advance the oncology treatment paradigm, amplifying treatment effects across the spectrum of melanoma and other tumor types. Our lead therapeutic cancer vaccine candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by IDO and PD-L1. In a single-arm Phase 1/2 clinical trial of 30 patients with metastatic melanoma, IO102-IO103 in combination with nivolumab, an anti-PD-1 checkpoint inhibitor, demonstrated proof of concept by increasing the ORR of what is reported with an anti-PD-1 antibody alone. The combination induced meaningful tumor regression and achieved rapid, deep and durable responses with a favorable tolerability profile without adding systemic toxicity to what is seen with an anti-PD-1 monotherapy in this patient population. Safety was the primary endpoint of this trial, immune response was the secondary endpoint and clinical efficacy was the tertiary endpoint. The clinical efficacy endpoints in this trial included OR, PFS and OS. In this trial, we observed a confirmed ORR of 73% as per RECIST 1.1, a CRR of 50% and 25.5 months of PFS. Based on these results, IO102-IO103, in combination with pembrolizumab, was granted BTD by the FDA for treatment of unresectable/metastatic melanoma and we initiated a global Phase 3 trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enrolled the first patient in a potentially registrational Phase 3 trial for IO102-IO103 in combination with pembrolizumab as a potential first-line treatment in advanced melanoma, the IOB-013/KN-D18 trial, in May of 2022. We randomized 225 patients in June 2023 and fully enrolled the trial in November 2023. On June 14, 2023, we announced that we amended the protocol and increased the number of patients to be enrolled in the Phase 3 trial from original 300 patients to revised 380 patients, which could potentially accelerate the time to reach the primary endpoint of PFS, which is an event-based driven analysis and will be assessed when 226 events (progression or death) are registered in the trial.  The primary endpoint is powered at 89% to detect a hazard ratio of 0.65. The Phase 3 trial protocol has a planned  interim analysis of ORR to be conducted 12 months after 225 patients have been randomized; if the investigational arm demonstrates a highly statistically significant improvement in ORR compared to the control arm, with a p-value&lt;0.005, then the interim analysis could allow for potential submission of a BLA for accelerated approval in the United States. When we designed the interim analysis, we assumed that patients treated with IO102-IO103 in combination with pembrolizumab would show an ~18-point improvement in ORR compared to the patients treated with pembrolizumab alone. The trial design and discussions with FDA are aimed at potentially pursuing accelerated approval, if the trial data are favorable, based on the interim analysis of ORR, supported by other data. If the data are supportive, we also plan to file a MAA with the EMA based on the primary endpoint of PFS after the data are available, which is expected to occur in the second half of 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Our operations to date have been financed primarily by aggregate net proceeds of $360.6 million from the issuance of convertible preference shares, convertible notes, ordinary shares, our IPO and our Private Placement. On August 9, 2023, we completed the Private Placement, pursuant to which we raised $71.9 million in net proceeds after deducting offering expenses of $3.2 million. Since inception, we have had significant operating losses. Our net loss was $86.1 million and $71.5 million for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $263.8 million and $143.2 million in cash and cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">126</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued expenses. We expect to continue to incur net losses for the foreseeable future, and we expect to continue to incur significant research and development expenses and general and administrative expenses. In particular, we expect our expenses to increase as we continue our development of, and seek regulatory approvals for, our product candidates, as well as hire additional personnel, pay fees to outside consultants, lawyers and accountants, and incur other increased costs associated with being a public company. In addition, if and when we seek and obtain regulatory approval to commercialize any product candidate, we will also incur increased expenses in connection with commercialization and marketing of any such product. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based upon our current operating plan, we believe that our existing cash and cash equivalents of $143.2 million as of December 31, 2023, will be sufficient to continue funding our development activities into the fourth quarter of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. To finance our operations beyond that point we will need to raise additional capital, which, though we were successful in raising additional capital through the Private Placement, cannot be assured and which we may not be able to pursue successfully again in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have not had any products approved for sale and, therefore, have not generated any product revenue. We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution, and associated regulatory and compliance costs. As a result, until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies, including our research and development activities. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Components of Operating Results</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operating expenses since inception have consisted primarily of research and development expenses and general and administrative costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and development expenses consist primarily of costs incurred for the development of our product candidates and our drug discovery efforts, which include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">personnel costs, which include salaries, benefits and equity-based compensation expense; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses incurred under agreements with outside consultants and advisors, including their fees and related travel expenses; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses incurred under agreements with third parties, including CROs that conduct research, preclinical activities and clinical trials on our behalf as well as CMOs that manufacture our product candidates for use in our preclinical and clinical trials and perform chemistry, manufacturing and control activities; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory and vendor expenses related to the execution of preclinical studies and planned and ongoing clinical trials; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses related to research conducted by institutions, universities and hospitals as part of collaborations; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">filing and maintenance of patents and intellectual property rights, including payment to third parties for assignment of patent rights and licensing fees and milestone payments incurred under product license agreements where no alternative future use exists; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory supplies and equipment used for internal research and development activities; and </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">127</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expense all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we obtain grants from public and private funds for our research and development projects. The grant income for a given period is recognized as a cost reimbursement and is typically based on the time and the costs that we have spent on the specific project during that period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have historically met the requirements to receive a tax credit in Denmark of up to 5.5 million Danish Kroner per year for tax losses resulting from research and development costs of up to 25 million Danish Kroner per year. The tax credit is presented as a reduction to research and development expense in the consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use our personnel and infrastructure resources across multiple research and development programs directed toward identifying and developing product candidates. We generally have not tracked our research and development expenses on a program-by-program basis. Substantially all of our direct research and development expenses in the years ended December 31, 2023 and 2022 were on IO102-IO103 and consisted primarily of external costs, such as consultants, third-party contract organizations that conduct research and development activities on our behalf, costs related to production of preclinical and clinical materials, including fees paid to contract manufacturers, and laboratory and vendor expenses related to the execution of our ongoing and planned preclinical studies and clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to incur significant research and development expenses for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, including investments in conducting clinical trials, manufacturing and otherwise advancing our programs. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with product development and the current stage of development of our product candidates and programs, we cannot reasonably estimate or know the nature, timing and estimated costs necessary to complete the remainder of the development of our product candidates or programs. We are also unable to predict if, when, or to what extent we will obtain approval and generate revenues from the commercialization and sale of our product candidates. The duration, costs and timing of preclinical studies and clinical trials and development of our product candidates will depend on a variety of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful completion of preclinical studies and of clinical trials for IO102-IO103, IO112, IO170, and our other current product candidates and any future product candidates; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful enrollment and completion of our Phase 3 clinical trial for IO102-IO103, Phase 2 basket trials, and any clinical trials for future product candidates; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">data from our clinical programs that support an acceptable risk-benefit profile of our product candidates in the intended patient populations; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance by the FDA, regulatory authorities in Europe, or other regulatory agencies of the IND applications, clinical trial applications and/or other regulatory filings for IO102-IO103, our other current product candidates and any future product candidates; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expansion and maintenance of a workforce of experienced scientists and others to continue to develop our product candidates; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful application for and receipt of marketing approvals from applicable regulatory authorities; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtainment and maintenance of intellectual property protection and regulatory exclusivity for our product candidates; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">arrangements with third-party manufacturers for, or establishment of, commercial manufacturing capabilities; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishment of sales, marketing and distribution capabilities and successful launch of commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">effective competition with other therapies; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtainment and maintenance of coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">128</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintenance, enforcement, defense and protection of our rights in our intellectual property portfolio; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">avoidance of infringement, misappropriation or other violations with respect to others&#8217; intellectual property or proprietary rights; and </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintenance of a continued acceptable safety profile of our products following receipt of any marketing approvals. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our preclinical studies and clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. A change in the outcome of any of these factors could mean a significant change in the costs and timing associated with the development of our current and future preclinical and clinical product candidates. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our preclinical studies or clinical trials, we could be required to expend significant additional financial resources and time on the completion of preclinical and clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development activities account for a significant portion of our operating expenses. We expect to incur significant research and development expenses for the foreseeable future as we continue to implement our business strategy, which includes advancing IO102-IO103 through clinical development and other product candidates further into clinical development, expanding our research and development efforts, including hiring additional personnel to support our research and development efforts, and seeking regulatory approvals for our product candidates that successfully complete clinical trials. In addition, product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect our research and development expenses to increase as our product candidates advance into later stages of clinical development. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our general and administrative expenses consist primarily of personnel costs, depreciation expense and other expenses for outside professional services, including legal fees relating to patent and corporate matters, human resources, audit and accounting services and facility-related fees not otherwise included in research and development expenses. Personnel costs consist of salaries, benefits and equity-based compensation expense, for our personnel in executive, finance and accounting, business operations and other administrative functions. We expect to continue to incur significant general and administrative expenses to support our continued research and development activities, manufacturing activities, and to continue to operate as a public company. These costs will likely include retaining key personnel, fees to outside consultants, lawyers and accountants, and costs associated with being a public company such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC requirements, director and officer insurance premiums and investor relations costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense), Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our other income (expense), net is comprised of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foreign exchange</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The functional currency of our subsidiaries operating in Denmark and United Kingdom is the Euro and  the British Pound, respectively. Transactions denominated in currencies other than the Euro and the British Pound result in exchange gains and losses that are recorded in our consolidated statements of operations.</span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest expense</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: For the year ended December 31, 2022, we incurred interest expense on account balances with banks and vendors. We did not incur interest expense for the year ended December 31, 2023. </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: For the years ended December 31, 2023 and 2022, we recognized interest income on account balances invested in money market funds and on account balances with banks.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">129</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following sets forth our results of operations:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.57%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:9.242%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:9.242%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:8.882%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.702%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Percent</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,829</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,986</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,843</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,614</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,438</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(824</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,443</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,424</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,019</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28.0</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(91,443</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(71,424</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(20,019</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28.0</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,212</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,239</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,973</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">401.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income tax expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(85,231</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(70,185</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(15,046</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">852</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,273</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(421</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(33.1</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(86,083</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(71,458</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(14,625</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20.5</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses were comprised of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.57%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:9.242%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:9.242%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:8.882%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.702%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Percent</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preclinical studies and clinical trial-related activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,716</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,910</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,806</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69.3</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chemistry, manufacturing and control</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,865</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,354</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,511</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58.9</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,276</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,101</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,175</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Consultants and other costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,972</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,621</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(649</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(24.8</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,829</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,986</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,843</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses were $67.8 million for the year ended December 31, 2023, compared to $47.0 million for the year ended December 31, 2022. The increase of $20.8 million was primarily related to an increase in preclinical studies and clinical trial-related activities for our IO102-IO103 therapeutic vaccine candidate, including the continued execution of our Phase 3 clinical trial, of $13.8 million, an increase in costs for chemistry, manufacturing and control activities of $5.5 million related to manufacturing activities of our IO102-IO103 therapeutic product candidate and an increase in personnel costs of $2.2 million primarily related to a one time charge in equity-based compensation that were offset by a decrease in consultants and other costs of $0.6 million.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were comprised of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.57%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:9.242%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:9.242%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:8.882%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.702%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Percent</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,294</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,260</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,034</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41.8</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional services</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,469</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,167</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(698</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(13.5</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Consultants and other costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,851</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,011</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,160</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(26.3</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total general and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,614</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,438</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(824</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were $23.6 million for the year ended December 31, 2023, compared to $24.4 million for the year ended December 31, 2022. The decrease of $0.8 million was primarily due to an increase in personnel costs of $3.0 million related to an increase in head count that were offset by a decrease in consultants and other costs of $3.2 million primarily related to a decrease in consultant spend and insurance premiums and a decrease of professional services costs of $0.7 million primarily related to less professional service spend related to legal and accounting costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">130</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense), Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income (expense), net was comprised of:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.41%;"/>
    <td style="width:1.32%;"/>
    <td style="width:1%;"/>
    <td style="width:9.082%;"/>
    <td style="width:1%;"/>
    <td style="width:1.32%;"/>
    <td style="width:1%;"/>
    <td style="width:9.082%;"/>
    <td style="width:1%;"/>
    <td style="width:1.32%;"/>
    <td style="width:1%;"/>
    <td style="width:8.922%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.542%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Percent</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Currency exchange gain, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">331</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">201</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154.6</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,881</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,411</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,470</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">316.8</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(302</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">302</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(100.0</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,212</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,239</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,973</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">401.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income (expense), net was $6.2 million for the year ended December 31, 2023 compared to $1.2 million for the year ended December 31, 2022. The increase of $5.0 million was primarily due to an increase in interest income recognized on our money market fund.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations to date have been financed primarily by aggregate net proceeds of $360.6 million from the issuance of convertible preference shares, convertible notes, ordinary shares, our IPO and our Private Placement. On August 9, 2023, we completed the Private Placement, pursuant to which we raised $71.9 million in net proceeds after deducting offering expenses of $3.2 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 9, 2021, we completed an IPO of our common stock and issued and sold 8,222,500 shares of common stock at a public offering price of $14.00 per share, including 1,072,500 shares of common stock sold pursuant to the underwriters&#8217; exercise of their option to purchase additional shares of common stock, resulting in net proceeds of $103.3 million after deducting underwriting discounts and commissions and estimated offering expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 7, 2023, the Company entered into the Purchase Agreement, pursuant to which the Company agreed to sell and issue (i) 37,065,647 shares of the Company&#8217;s Common Stock, and (ii) 37,065,647 Warrants in the Private Placement. Each Purchaser&#8217;s Warrant is exercisable for a number of shares of Common Stock equal to one hundred percent of the aggregate number of shares of Common Stock purchased by such Purchaser. The purchase price for each share of Common Stock and Warrant was $2.025. The Warrants are exercisable at an exercise price of $2.47 per share, subject to adjustment as set forth therein. The Warrants are exercisable until the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an acquisition, as defined in the Warrants. The Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the Warrants. The Private Placement closed on August 9, 2023. The Company received $75.1 million in gross proceeds from the Private Placement, before deducting offering expenses of $3.2 million. The Company intends to use the net proceeds of $71.9 million from the Private Placement for general corporate purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In addition, on February 15, 2023, we filed a new prospectus supplement with the SEC with respect to the offer and sale of shares of our common stock, par value $0.001 per share, with an aggregate offering price of up to $19,500,000, establishing an at-the-market equity program. On February 15, 2023, we also entered into a Sales Agreement by and between the Company and Cowen and Company, LLC for shares with an aggregate offering price of up to $75,000,000 through which we may, from time to time, sell shares through Cowen and Company, LLC, acting as agent and/or principal. Any shares offered and sold through the at-the-market equity program will be issued pursuant to the Company&#8217;s Registration Statement on Form S-3 (File No. 333-269569), which was declared effective on February 10, 2023, the prospectus supplement related to the offering that forms a part of the registration statement, and any applicable prospectus supplements that may form a part of the registration statement in the future. The aggregate market value of shares eligible for sale under the prospectus supplement and under the Sales Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3, to the extent required under such instruction. We have not currently issued any shares pursuant to our at-the-market equity program as of December 31, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, we have had significant operating losses. Our net loss was $86.1 million and $71.5 million for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $263.8 million and $143.2 million in cash and cash equivalents. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">131</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently expect that our cash and cash equivalents of $143.2 million as of December 31, 2023 will be sufficient to fund our operating expenses and capital requirements into the fourth quarter of 2025. However, additional funding will be necessary to fund our future clinical and pre-clinical activities. If we are unable to obtain funding, we could be forced to delay, reduce or eliminate our research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect our business prospects and our ability to continue operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our cash flows for the periods indicated:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(71,737</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(59,729</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(323</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(690</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,860</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(200</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(60,419</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Cash Used in Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash used in operating activities of $71.7 million during the year ended December 31, 2023 was primarily attributable to our net loss of $86.1 million, partially offset by an increase of $5.9 million in our working capital accounts and an increase in non-cash items of $8.5 million primarily due to equity-based compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash used in operating activities of $59.7 million during the year ended December 31, 2022 was primarily attributable to our net loss of $71.5 million, partially offset by an increase of $4.2 million in our working capital accounts and an increase in  non-cash items of $7.5 million primarily due to equity-based compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Cash Used in Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash used in investing activities of $0.3 million and $0.7 million for the years ended December 31, 2023 and 2022, respectively, was related to the purchase of property and equipment.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Cash Provided by Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by financing activities of $71.9 million for the year ended December 31, 2023 was related to the net proceeds obtained from the issuance of common stock and warrants as part of the August 2023 private placement. We had no cash provided by financing activities for the year ended December 31, 2022.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">132</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses; costs related to third-party clinical research, manufacturing and development services; costs relating to the build-out of our headquarters and our other offices, laboratories and manufacturing facility; license payments or milestone obligations that may arise; laboratory expenses and costs for related supplies; clinical costs; manufacturing costs; legal and other regulatory expenses; and general overhead costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based upon our current operating plan, we believe that our existing cash and cash equivalents of $143.2 million as of December 31, 2023 will be sufficient to continue funding our development activities through the fourth quarter of 2025. To finance our operations beyond that point we will need to raise additional capital, which, though we were successful in raising additional capital through the Private Placement, cannot be assured and which we may not be able to pursue successfully again in the future. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, potentially including collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we may need to delay, reduce or terminate planned activities to reduce costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the progress, costs and results of our ongoing and planned clinical trials of IO102-IO103, as well as our planned trials for our other product candidates; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, results and costs of discovery research, preclinical development, laboratory testing and clinical trials for our product candidates, including our ongoing clinical trials of IO102-IO103; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of, and development requirements for, other product candidates that we pursue; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to enter into contract manufacturing arrangements for supply of API, and manufacture of our product candidates and the terms of such arrangements;</span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the payment or receipt of milestones and receipt of other collaboration-based revenues, if any; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of any future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our product candidates for which we may receive marketing approval; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amount and timing of revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property-related claims; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or in-license other products, product candidates, technologies or data referencing rights; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the enrollment and completion of our Phase 3 clinical trial for IO102-IO103, Phase 2 basket trials, and any clinical trials for future product candidates; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">133</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to receive additional non-dilutive funding, including grants from organizations, public institutions and foundations; </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addition of operational, financial and management information systems and personnel, including personnel to support our drug development, any future commercialization efforts and our transition to a public company; and </span></div></div>
  <div style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.805787706420075%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of operating as a public company. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, our operating plans may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development activities. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contractual Obligations and Commitments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, we entered into a lease for our office space in Copenhagen, Denmark that was amended in September 2022 and is set to expire in December 2027.  The lease for our office space in Copenhagen, Denmark is terminable upon six months&#8217; notice. In January 2023, we entered into a lease for laboratory space in Copenhagen, Denmark that expires in December 2027. In August 2021, we entered into a lease for laboratory facilities and office space in Rockville, Maryland that expires in May 2027. In October 2021, we entered into a lease for office space in New York, New York that expires in January 2027. In June 2023, we entered into a lease for office space in Newport, United Kingdom that expires in May 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enter into contracts in the ordinary course of business with third-party service providers for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice of 30 to 90 days, and therefore, we believe that our non-cancelable obligations under these agreements are not material and we cannot reasonably estimate whether they will occur. However, in the event of a termination of any contracts with CROs or other institutions and with respect to active patients enrolled in our clinical trials, we may be financially obligated for a period beyond the contractual termination notice periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also enter into additional research, manufacturing, supplier, lease and other agreements in the future, which may require up-front payments and even long-term commitments of cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our evaluation of our ability to continue as a going concern requires us to evaluate our future sources and uses of cash sufficient to fund our currently expected operations in conducting research and development activities. We evaluate the probability associated with each source and use of cash resources in making our going concern determination. The research and development of pharmaceutical products is inherently subject to uncertainty. We currently expect that our cash and cash equivalents of $143.2 million as of December 31, 2023 will be sufficient to fund our operating expenses and capital requirements for at least 12 months from the date the financial statements are issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">134</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We incur substantial expenses associated with clinical trials. Accounting for clinical trials relating to activities performed by CMO&#8217;s, CRO&#8217;s and other external vendors requires management to exercise significant estimates in regard to the timing and accounting for these expenses. We estimate costs of research and development activities conducted by service providers, which include costs associated with the conduct of sponsored research, preclinical studies, contract manufacturing activities and pass-through costs. The diverse nature of services being provided under CRO and other arrangements, the different compensation arrangements that exist for each type of service and the lack of timely information related to certain clinical activities complicates the estimation of accruals for services rendered by CROs and other vendors in connection with clinical trials. We record the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and allocate these costs in the accrued and other current liabilities or prepaid expenses on the balance sheets and within research and development expense on the statements of operations. In estimating the duration of a clinical study, we evaluate the start-up treatment and wrap-up periods, compensation arrangements and services rendered attributable to each clinical trial. Fluctuations are regularly tested against payment plans and trial completion assumptions. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We estimate these costs based on factors such as estimates of the work completed and budget provided and in accordance with agreements established with our collaboration partners and third-party service providers. We make significant judgments and estimates in determining the accrued liabilities and prepaid expense balances in each reporting period. As actual costs become known, we adjust our accrued liabilities or prepaid expenses. We have not experienced any material differences between accrued costs and actual costs incurred since our inception. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our expenses related to clinical trials are based on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions, CMOs and CROs that may be used to conduct and manage clinical trials, chemistry and testing and manufacturing services on our behalf. We generally accrue expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, we modify our estimates of accrued expenses accordingly on a prospective basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We issued stock-based compensation awards through the granting of warrants and stock options, which generally vest over a four-year period. We issued 2,171,841 options with a weighted average exercise price of $2.02 to certain employees, board members and advisors during the year ended December 31, 2023. We issued 1,211,155 options with a weighted average exercise price of $5.34 to certain employees, board members and advisors during the year ended December 31, 2022. In July 2023, we issued 348,153 options with a weighted average exercise price of $1.86 as separate inducement grants distinct from the 2023 Inducement Award Plan.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for equity-based compensation in accordance with ASC 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation-Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASC 718). In accordance with ASC 718, compensation cost is measured at estimated fair value and is included as compensation expense over the vesting period during which service is provided in exchange for the award on a straight-line basis. Vesting of the awards depend solely on service conditions required of the employee. The Company reverses any previously recognized compensation cost associated with forfeited awards in the period of the forfeiture occurs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use a Black-Scholes option pricing model to determine fair value of our warrants and options. The Black-Scholes option pricing model includes various assumptions, including the fair value of common shares, expected life of warrants and options, the expected volatility and the expected risk-free interest rate. These assumptions reflect our best estimates, but they involve inherent uncertainties based on market conditions generally outside our control. As a result, if other assumptions had been used, equity-based compensation cost could have been materially impacted. Furthermore, if we use different assumptions for future grants, share-based compensation cost could be materially impacted in future periods. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will continue to use judgment in evaluating the assumptions utilized for our equity-based compensation expense calculations on a prospective basis. In addition to the assumptions used in the Black-Scholes model, the amount of equity-based compensation expense we recognize in our financial statements includes warrant forfeitures as they occurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">135</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the level of historical operating results and projections for the taxable income for the future, we have determined that it is more likely than not that our net deferred tax assets will not be realized. Accordingly, we have recorded a full valuation allowance to reduce our net deferred tax assets in IO Biotech ApS, IO Bio US, Inc and IO Biotech, Inc. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize tax benefits from uncertain tax positions only if, based on the technical merits of the position, it is more likely than not that the tax positions will be sustained on examination by the tax authority. The tax benefits recognized in the financial statements from such positions are measured based on the largest amount that is more than 50% likely to be realized upon ultimate settlement. We recognize interest and penalties related to unrecognized tax benefits within the provision for taxes in our statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We operate in Denmark and may be subject to audits from various tax authorities. Management&#8217;s judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities, liabilities for uncertain tax positions, and any valuation allowance recorded against our net deferred tax assets. We will monitor the extent to which our deferred tax assets may be realized and adjust the valuation allowance accordingly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrants Issued in Connection with Sale of Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for warrants issued as a separable unit in connection with sale of common stock as either liability or equity in accordance with Accounting Standards Codification (ASC) 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (ASC 480-10) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (ASC 815-40). Under ASC 480-10, warrants are considered liabilities if they are mandatorily redeemable and they require settlement in cash or other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as liability or equity. If warrants do not require liability classification under ASC 815-40 or other applicable generally accepted accounting principles in the United States of America (U.S. GAAP) the warrants should be classified as equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The proceeds received from the sale of equity classified warrants and shares of common stock in a bundled transaction are allocated based on the relative fair values of warrants and shares with no changes in fair value of warrants recognized after the issuance date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 2, &#8220;Summary of Significant Accounting Policies,&#8221; in the accompanying notes to our financial statements for the years ended December 31, 2023 and 2022 appearing elsewhere in this Annual Report on Form 10-K for a discussion of recently issued accounting standards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Off-Balance Sheet Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As an EGC under the Jumpstart Our Business Startups (the JOBS Act), we may delay the adoption of certain accounting standards until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (1) are no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">136</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other exemptions and reduced reporting requirements under the JOBS Act for EGCs include presentation of only two years of audited financial statements in a registration statement for an IPO and in an Annual Report on Form 10-K, an exemption from the requirement to provide an auditor&#8217;s report on internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board (PCAOB) regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may remain classified as an EGC until December 31, 2026, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of June 30 of any year before that time, or if we have annual gross revenues of $1.235 billion or more in any fiscal year, we would cease to be an EGC as of December 31 of the applicable year. We also would cease to be an EGC if we issue more than $1.0 billion of non-convertible debt over a three-year period.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">137</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="quantitative_and_qualitative_disclosure"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A. Quantitat</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ive and Qualitative Disclosures About Market Risk.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a smaller reporting company as defined by Item 10 of Regulation S-K and are not required to provide the information otherwise required under this item.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">138</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="financial_statements_and_supplymentary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. Financial</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Statements and Supplementary Data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="financialstatements_tableofcontents"><span id="item8_financialstatement_index"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IO Biotech, Inc.</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:90%;"/>
    <td style="width:10%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#reportofindependentregisteredpublic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(PCAOB ID </span><span><ix:nonNumeric id="F_557963e3-43e8-4504-98f7-db8643c54d94" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1757</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Audited Financial Statements as of and for the years ended December 31, 2023 and 2022</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:36pt;vertical-align:top;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:36pt;vertical-align:top;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_operations_and_comp"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:36pt;vertical-align:top;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_convertible_deficit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:36pt;vertical-align:top;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">144</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:36pt;vertical-align:top;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_the_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to the Consolidated Financial Statements</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">145</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">139</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="reportofindependentregisteredpublic"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Shareholders and the Board of Directors of IO Biotech, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of IO Biotech, Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f46650b0-c57e-4fcc-b144-9abc2128382f" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EY Godkendt Revisionspartnerselskab </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2015.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a386937-fd15-4b8e-92c4-884f02391865" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Copenhagen, Denmark</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 5, 2024</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">140</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">io biotech, inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance Sheets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b50542f7-464a-49a6-bd2b-696b327a455b" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,193</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2af1651d-0c9d-4cb4-969e-5e05ec68a2dc" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,590</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5e5c760-adcc-4fd1-b7f4-1c4d5be72ce7" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,062</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc231335-a2be-4da4-ad08-f39e7920ce60" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,629</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6c9048f-8476-4e0e-9b29-444d2d172edc" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,255</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50285101-f9e5-4f05-a997-28c140d93325" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148,219</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e818f17-8ac7-4842-8bac-fbd0276ebbc2" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dec3a5f0-f739-4105-bb53-c438b6a113f2" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_070ca81a-cfcd-43ef-82fd-744a0256eabc" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">847</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfd471f2-0add-49a0-99fd-ed4ea4f80889" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">741</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right of use lease asset</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8496d72-a362-4573-af67-3e4f30bb7b2e" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,259</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_638578a7-e024-44ca-b207-86826e0f2f5d" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,493</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40149936-5e92-4702-b3cb-bdac2fead226" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6af1eef-d5a5-447d-bf8e-dd5b49f95957" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total non-current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aec8394c-bfb6-4a70-a3b5-f79d9f020259" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,463</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db0a1afb-ac45-448e-9e72-32fc6f3b40dc" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,586</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20075a61-6952-4be0-b3ad-315af7e63f70" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,718</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4302ac14-cd96-4432-aaac-864c5b690f8c" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">151,805</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Liabilities and stockholders&#8217; equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d28ba28d-7c15-4b85-b16d-82564a4cf522" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,878</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f04bda4-5eae-482b-88d1-3a1d4a374120" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,004</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability - current</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80f130f6-66b5-46ee-b8dd-9b49c106bf24" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">655</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91df7cf0-2bb2-4dfa-af34-f63a247fab17" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">515</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27278b3f-5acd-4918-9d37-c6e285fab65c" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,184</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c94c28e-6532-4d00-851b-b160108b06d6" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,157</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66210287-c28d-46e5-85d3-f15ffe114ddd" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,717</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29aed86c-44e8-45be-ba1f-cf3fcdeea527" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,676</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability - non-current</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_712b108c-248f-4182-ab29-0f47cf680e98" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,839</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_764e4dfe-f4b3-4599-b88d-9bf558a9de4e" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,275</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total non-current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1a9cee1-4023-460e-a444-df1a0cf6795f" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,839</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e33d759a-5b85-476b-b88f-a8e2382faafe" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,275</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6fca4f4-3bbc-492f-b41d-0b18337cc186" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,556</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_722688e1-cdeb-4f44-ae08-5ee26aec6314" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,951</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_522691ef-a049-4d10-a8f6-eb2141bf9945;"><span style="-sec-ix-hidden:F_5e0b0588-b270-4242-937d-c044a120045f;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies</span></span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(Note 9)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, par value of $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78407ba2-b9d3-4c84-8f70-62d60493c5d4" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e0a6fc11-752b-451e-8cfb-a5d174cdbdfd" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;per share; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a239d80-1568-4acc-9196-18646044760c" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6b2f2439-3711-4411-a6e4-70eb91dbeeb4" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized,<br/></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9936a930-57e7-4b5e-b73b-2d0932b7457c" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d1d87d13-4526-4c2d-be38-e918a514881e" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d34bf874-532a-4587-a6ec-8dc4d9b6abc5" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_716d9865-072c-4a8d-8a37-a6c3982ebc89" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding as of December 31, 2023 and 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_c1641a20-794d-4ed3-aacb-528b63397b4c;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_bcd4aa41-7f61-41fa-affb-30d04105e5e8;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, par value of $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c90c96d-9646-48e6-a528-e15a241f6bd8" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bd0dbce2-ce77-428f-971f-630ff5020ace" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;per share; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f5c68f4-5364-4a89-96fb-0a8b100bbfd5" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ca3ec0ee-34bb-431b-9c4d-fbd9d248bc46" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized at December 31, 2023 and December 31, 2022; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f8387ee-56f5-4ce5-aaf6-8a5bfb3edacc" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_af9078af-0501-400e-b330-0103137280ec" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b34d6a2-88d7-4d2c-a10b-65c4ae5fd395" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0f6ad70f-e07d-49a9-b9c7-979f81344d61" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">28,815,267</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f577b68-7616-4253-a33d-0dc11605c2cc" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05c18bf9-4aef-417e-ad57-e82178fa3cb2" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c68cc6e-7779-450d-8a33-165d6c42a280" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">406,587</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e48b28b-c91d-4704-b6ee-236ecba3f59b" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">326,705</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_feef3c00-3c22-486a-8a64-b2327906a7c3" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">263,822</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b3cefaf-b622-4675-85fd-5172f5baaab5" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">177,739</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a444eea-600a-4970-aa4f-f8f22112f6a6" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,669</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90eb34b9-0ed2-49b1-acbd-6f097ae8d6a4" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,141</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41504297-7d16-4940-a7a9-f4c8347eb461" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,162</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d22112c4-7aee-42ec-b5df-4d72e16595ff" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,854</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffc1be2e-bb14-4f8c-8b9f-4ef0efb755af" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,718</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a6fee04-d7fe-404f-9231-838fb50b7b67" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">151,805</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">141</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">io biotech, inc</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_of_operations_and_comp"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Statements of Operations and Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.926%;"/>
    <td style="width:1.58%;"/>
    <td style="width:1%;"/>
    <td style="width:12.458%;"/>
    <td style="width:1%;"/>
    <td style="width:1.58%;"/>
    <td style="width:1%;"/>
    <td style="width:12.458%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e599c28d-3a55-4acf-b258-7d33051a44c8" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,829</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e8be449-fa1a-4d49-89cb-cc5347436b40" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,986</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41b121f2-fe2e-413d-a860-33bcc1c396f3" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,614</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebaef840-11fb-44e6-a17b-7695bc0cf69c" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,438</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_293e027e-3513-4d38-94d5-513ccf07be00" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,443</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_268216a6-9a09-453e-9e2f-ab5b0efc3c30" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,424</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_802df391-4e39-45ec-bd68-43f285abaefc" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">91,443</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6402ba3d-7359-4ed2-b511-00845eade1bc" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,424</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Currency exchange gain, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c504422-e3ba-43cf-a652-7db367ea9cb1" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">331</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8812a9b-a432-4a4c-a5de-59d1bf8efe77" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab4fb823-b965-4e46-b56c-e18507e23cc3" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,881</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf794e5e-2fc8-4e9c-8517-40535b225cc7" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,411</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c6db8ed-4042-465e-8e58-33dbe20b1f33" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">302</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c9442ac-7e93-463c-a677-6ab4b3af0c1c" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,212</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5484512a-d3f7-4313-b982-3bad1b9b90e3" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,239</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income tax expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8626d2be-28e6-4e13-8f7f-9704d19b6b37" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,231</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58a8afa0-f5fc-445c-900e-20f993b2d64e" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">70,185</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de820c4d-2587-4b12-8807-913474b67ee6" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">852</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8052753-01d5-4b15-bfcf-33f31f57200f" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,273</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a73d8b68-20e7-46a4-9652-4631bc0286e8" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,083</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_191a1eda-587f-466a-81f3-17c7bfe0e761" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,458</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to common shareholders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50dea70e-bd78-402b-ae8f-eeedfb4e13e9" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,083</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c5bf734-2927-4309-be19-cef0d72677cc" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,458</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8532c0b-1780-4aea-99e2-e8942c570158" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0e5ebd78-2e47-45ac-9fac-4e69aa1a6d41" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.98</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec6c9257-c781-4db4-8421-433125882836" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a4c28836-7b21-464b-b6fa-a1c920cf103c" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.48</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of shares used in computing net loss per common share, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b85ad78c-1945-4124-9a08-f19187ede66f" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b07622ca-4041-4ac0-9b75-469189c97d15" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">43,539,976</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38968f9a-9994-4102-ba46-dbaa6663738b" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0c308d94-9f46-45e7-afaa-0fc4cc796cac" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">28,815,267</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8d9ad01-1e64-47ca-8fc5-3c0facbadb50" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,083</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7181e693-6f2d-48cb-bbe3-91aad70f34b7" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,458</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ce33051-aae7-4ae5-aa36-fd408a2155f8" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">472</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7695dde-d5d7-4b07-8c96-27d28ae13b0e" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,652</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b4167ef-72ec-44d3-bdef-1dab8cb2d9f1" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,611</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbaa94af-6212-4973-89ed-7b2df5c0cb3a" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,110</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">142</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IO BIOTECH, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_of_convertible_deficit"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Statements of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.713%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.838%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:7.359%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:7.359%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:7.878%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:7.878%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:7.878%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated Other<br/>Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Loss</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, January 1, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7a33282-432e-4e68-b56f-f1ee0f2717c6" contextRef="C_b417c094-4b8b-413a-b777-f37fa824d616" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">28,815,267</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28769005-1b80-47b2-8988-bea541aba61c" contextRef="C_b417c094-4b8b-413a-b777-f37fa824d616" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fc9bfb1-f151-4197-a595-e0633189fe18" contextRef="C_41282bac-d510-44e1-bcd8-e9ad005dc1b8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">319,665</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bf1e437-cab6-4edc-b915-4e005cbf7b3a" contextRef="C_d6fcc15a-463e-4377-ad07-b2311c2c2577" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,489</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc43b766-df5c-4228-bdad-10a569131534" contextRef="C_2af36d65-e5e9-4e90-8479-0c3a9a9006ed" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">106,281</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39897e10-3bdc-4fda-9e2a-e773556fedcd" contextRef="C_203b870a-e8de-4c48-bb69-1f143a5d1919" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">211,924</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c794076e-b430-4d0f-bc8f-67a09683d1a1" contextRef="C_58193eaa-01f7-4f8a-933b-82502af9abe4" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,040</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc875605-eb30-4245-8716-ae10bac8c49a" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,040</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa03c31c-ba82-49de-b42a-6a6d875e4918" contextRef="C_4193a798-b6e0-487a-bf56-e3158437f049" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,652</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c302390a-9959-4ac8-8be9-70c5db3e00c9" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,652</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbbec681-0c42-42d5-86fd-b92d76c53b3a" contextRef="C_a27d25f7-5479-49f8-a811-d80dec1dc3d7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,458</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2134c7d-2700-401e-bc39-e84ce22a17c4" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,458</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c62058f-401d-4568-adb4-1af787041dd3" contextRef="C_83696999-4b34-4804-9e55-9bcb95f224d2" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">28,815,267</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f548597d-82a2-4a57-b17f-955cbac11120" contextRef="C_83696999-4b34-4804-9e55-9bcb95f224d2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_507bcec1-62aa-45ae-95a1-5a00250ec35a" contextRef="C_af6f9339-383a-4c92-83a8-eb2b5990df31" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">326,705</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7ae6289-dd47-4a7d-b2e7-4ff7284a2721" contextRef="C_4aa5700b-45ac-4ba7-aecb-189135584209" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,141</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efe3f25b-8e65-4466-b27a-f4ba5b115cd1" contextRef="C_fe4a2a0a-b6ee-4598-80ca-db97232d35b5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">177,739</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db194839-3793-46bb-9cd9-07a407d79643" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,854</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ed645ed-cae3-41a3-bf82-4d4bf3dc07b9" contextRef="C_546c8f6d-7b20-49cd-8a0e-b394348d36fc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,059</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebc94958-5f4c-420f-8b8c-17a284ed86f2" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,059</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24a7aa6b-68b9-4146-82e0-cb1f63020835" contextRef="C_b46bf404-a97b-4035-a273-403e9d7a9848" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">472</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f44845bd-ad1b-495f-a599-19049fdbb15b" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">472</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common shares and warrants in private placement, net of issuance costs of $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c8fdf4c-54f4-42a6-bf38-36bcb5e667ec" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="iobt:PaymentsOfStockAndWarrantIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,198</ix:nonFraction></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa89d5a5-7ff4-4cff-bfce-2922f15af1de" contextRef="C_4610fd3b-ca44-4e94-a210-d0913cb10978" name="iobt:StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a912b45-8dec-4e84-ab08-7302e7a2b2a6" contextRef="C_4610fd3b-ca44-4e94-a210-d0913cb10978" name="iobt:StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41dac33e-3a8c-459d-b011-fe8bb8eec6ab" contextRef="C_546c8f6d-7b20-49cd-8a0e-b394348d36fc" name="iobt:StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,823</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_937ca690-97d1-4af6-ad2d-d175df0ff596" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="iobt:StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,860</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11d6d1ec-1d0f-4171-8af9-4c4046ea5129" contextRef="C_6bfe21b8-29be-4452-8c6e-25ec17762b3a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,083</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5598bfa3-1f27-44ef-971f-137dee31a0ac" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,083</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03f5f6ed-e088-4c33-8099-44986d590cc7" contextRef="C_785d9f06-9d6a-47bd-8cd0-ef70f3e4eef7" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3df412ed-0195-4081-a365-abb6744a8c16" contextRef="C_785d9f06-9d6a-47bd-8cd0-ef70f3e4eef7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_561330f4-a0c9-44f4-993a-3fe9a5dc4300" contextRef="C_d68d18d7-93d7-49d5-ac79-3f37468692f2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">406,587</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62efd84b-05e5-407c-aecc-c98e8a7d0fad" contextRef="C_8a8a956b-e82c-4de3-b66b-515c278c6057" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,669</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ddec3d2-6c6f-47fe-b25c-c6b25939ca63" contextRef="C_cca131d2-c4bc-4848-b12f-0a7cefd61f16" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">263,822</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d9c3d31-d2d1-485c-81fc-b61f4ae2ff58" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,162</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">143</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">io biotech, inc.</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Statements of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ce1484f-81d5-42cd-87ac-fa0c470223d5" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,083</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10b3b84a-3f94-484a-832d-cec5a700604c" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,458</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustment to reconcile net loss to net cash used in operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c269b96-f005-49a2-8ece-daceff7be8e8" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39e079d7-58f7-48fa-9f76-72a1e7efbca2" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_867e51ba-aaac-4113-bcfd-270f18e30ed0" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,059</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8eb29c5d-6835-467f-8ab6-d62d21686872" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,040</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of right of use lease asset</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf1b005a-615a-4f7a-b466-210bf7ace20d" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">541</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cae8798-5c9a-4118-80fa-721d451efc9b" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">436</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency gain</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95dd0a2f-7fec-4a33-8f9c-56dee8291d26" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">331</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5db59ee2-78b3-4c1b-bd16-d607ee644177" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for deferred tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f19f7b58-873f-4454-a172-7439a4cfff68" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cee8e88-1d25-46a3-bc87-ee571e0d5c14" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,568</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7dae1bbd-820c-4ee7-a03c-d7647d28d471" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,578</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e6b77db-219b-4273-920f-1f86413f9274" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56008a38-82ff-41bc-af15-6a1eb9c1bdfa" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8de3d88-21ec-4888-8fd8-31a153eda914" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">126</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f89936df-5459-45f2-9d4b-9ec586e46da4" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff69b4a6-a73a-4055-a6cc-8e5b0b11bcc4" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="iobt:IncreaseDecreaseInLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">604</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2327f35e-16b0-4cd0-9c90-69ca481366a0" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="iobt:IncreaseDecreaseInLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">139</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb417c1e-b403-44e5-b72e-4331b34159ee" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,028</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29bc10f4-691b-4111-8a9d-96eec860ea39" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">280</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:40pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c53a4de-923f-430e-88db-7eaf92656a1b" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,737</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_283b291a-f5dc-4758-95a8-c97bb2d2f987" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,729</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2b4b34e-bc17-4985-9afb-cdfec7696380" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">323</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5b7f14b-27bf-499b-95d7-549180e4cff2" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">690</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:40pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a00672f0-19d7-452a-ad3e-2f3a4fd82141" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">323</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0bc1b9f-06e7-4c08-92be-86f62c30ab5c" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">690</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common shares and warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ed7f53f-2efa-415b-a589-dece5a54494b" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="iobt:ProceedsFromIssuanceOfCommonStockAndWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,058</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common shares and warrants issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5de0fd86-640a-4953-ab1e-7b8c3a86ef9e" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="iobt:PaymentsOfStockAndWarrantIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,198</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:40pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_909c609e-1855-44fc-88f6-197500ac028f" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,860</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66308c1e-3da4-4cd7-81dd-19f53952047d" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13080fed-d48e-4c71-a691-657209ef0fb4" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">60,419</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58036804-0283-44a1-9722-7b8e5efece37" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">803</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a47f7446-5a94-4cfc-80c4-a6ad9c3fdf83" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,522</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash, beginning of year</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae426bfb-a51c-4979-882a-ca6fafaa519a" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,858</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31552093-2984-4043-91b4-6aea147ad6d2" contextRef="C_203b870a-e8de-4c48-bb69-1f143a5d1919" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">211,799</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash, end of year</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81fdabb0-f19e-42c2-905f-92f4a1cc0cae" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,461</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ed39c3b-82f2-4d37-8566-3a4e8a75ac45" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,858</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Components of cash, cash equivalents, and restricted cash</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d65acc5-1cca-4b6b-9d8b-e41ef67fffe9" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,193</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f8a25f4-b71c-49b4-8ee5-b75ea5525e16" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,590</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24e6560a-7d9c-41a1-9f1e-7939887fdcbd" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_862d43c4-e338-4456-908d-544ea7426c24" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total cash, cash equivalents, and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce361ff0-9a26-4b01-8ec5-0a5564e151bc" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,461</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52c352e7-3399-424d-847c-809cdbc35bc1" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,858</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">144</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">io biotech, inc.</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_the_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to the Consolidated Financial Statements</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0566469f-20a8-4148-835c-5ceee5e6bb55" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Description of Business, Organization and Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on our T-win&#174; platform. As used in these financial statements, unless the context otherwise requires, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to IO Biotech, Inc. and its subsidiaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Corporate reorganization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IO Biotech ApS was incorporated in Denmark in December 2014. In November 2021, we completed a corporate reorganization whereby IO Biotech ApS became a wholly-owned subsidiary of the Company. In connection with the corporate reorganization, each issued and outstanding Class A ordinary share ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39243a8f-6f0d-45f7-8c37-30589dcefbcb" contextRef="C_ce55bd70-3918-4ae0-9cad-0dfde777548f" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value) was exchanged on a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9eb2d5b-c0e7-4de3-a872-0f97159cc2eb" contextRef="C_deb3bb46-923f-471e-bc2a-d3f58a8d1640" name="us-gaap:CommonStockConversionBasis"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one-for-one</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> basis into shares of common stock of the Company ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0fe3949-ec3d-4c9b-bee3-c6a5698bffdb" contextRef="C_6976c5c1-5909-47d1-9d43-69c889de3121" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_271c1361-70c9-4291-83f8-7bc86ca36240" contextRef="C_1525e770-dbb6-4a8a-b414-dae67b1c0c72" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value). Each Class B and Class C preference share of IO Biotech ApS was exchanged on a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8fafe75b-7666-46ab-a506-611ad0145f42" contextRef="C_204fa06a-ebbb-41fd-82ba-760913723921" name="us-gaap:CommonStockConversionBasis"><ix:nonNumeric id="F_ab1bf50e-5af6-41ff-b532-b35619d14aab" contextRef="C_e8a83503-acc7-4b7b-80a3-5d4810b2d5de" name="us-gaap:CommonStockConversionBasis"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one-for-one</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> basis into shares of Class B and Class C preferred stock of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IO Bio US, Inc., a wholly owned subsidiary of IO Biotech ApS, was incorporated in Delaware in May 2021. IO Biotech Limited, a wholly owned subsidiary of IO Biotech ApS, was incorporated in the UK in August 2021. In November 2021, the Company engaged in a series of transactions, referred to collectively as the Corporate Reorganization. As a result of the Corporate Reorganization, IO Biotech ApS became a wholly-owned subsidiary of IO Biotech, Inc.  IO Biotech, Inc. is a holding company formed in October 2021, which, prior to our IPO, had nominal assets and no liabilities, contingencies, or commitments, and which has not conducted any operations prior to our IPO other than acquiring the entire issued and outstanding stock of IO Biotech ApS. The Company, IO Biotech ApS, and the holders of all of the issued and outstanding equity interests of IO Biotech ApS have entered into a Share Contribution and Exchange Agreement, dated as of October 29, 2021, pursuant to which the Corporate Reorganization was effected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial Public Offering (IPO)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, we completed our IPO, selling an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9137bbdd-0811-4fec-87b4-fe8596be9773" contextRef="C_58b5fcb9-88bf-4c8f-a0dc-fb732ca6c6a9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,222,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at a price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34b223a3-187f-43bd-b07d-fd5a013a4750" contextRef="C_09c04cd1-1667-4969-a0bf-6219d9198637" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">14.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53dcc3e8-3480-4d9b-abce-ddee9a45e3d2" contextRef="C_a0939c61-54dc-4cc6-bd3a-04cc2fcd2c13" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,072,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock sold pursuant to the underwriters&#8217; exercise of their option to purchase additional shares of common stock. We received net proceeds from the IPO, after deducting underwriting discounts and commissions and other offering costs, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f47554fb-f914-487c-9a1d-fa52d7e353f1" contextRef="C_1dcc1f3e-ab3f-4d97-8c1b-44559a31ab42" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">103.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately prior to the consummation of the IPO, all outstanding shares of our Class A ordinary shares and Class B and Class C convertible preference shares were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d40b09ba-b701-4000-bb75-39ae9801c93d" contextRef="C_a0cd7c29-89c5-48ee-ae9e-0dbf0ed84a0c" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,592,413</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. Upon the closing of the IPO on November 9, 2021, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8790969e-b5a2-4fee-a5c9-92d0121f78a4" contextRef="C_a0cd7c29-89c5-48ee-ae9e-0dbf0ed84a0c" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_94c786a3-f51b-41b5-8d58-b3ae5c970aad" contextRef="C_a0cd7c29-89c5-48ee-ae9e-0dbf0ed84a0c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">28,815,267</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were issued and outstanding. Our common stock began trading on the Nasdaq Global Market on November 5, 2021 under the symbol &#8220;IOBT.&#8221;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 9, 2021, we amended and restated the certificate of incorporation of IO Biotech, Inc. to authorize the issuance of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e550a670-8d34-4a89-82f0-a745e857a90b" contextRef="C_a0cd7c29-89c5-48ee-ae9e-0dbf0ed84a0c" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ffea1b6-caaa-4fa9-837b-1c17e93f6471" contextRef="C_ccc9ec90-8753-446d-ad46-4614b4157e4b" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock. The shares of preferred stock are currently undesignated.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">August 2023 Private Placement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 9, 2023, the Company completed a private placement transaction (the Private Placement), pursuant to which we sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3858e6a-cd85-4170-a3f5-67e53ce0eff2" contextRef="C_e2898211-1ef9-46ec-9a67-2298c6e5e1c8" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc6d2eb7-0d3d-4b79-8ef8-779afd1438e8" contextRef="C_49c77671-362e-4825-93e3-6d0010545188" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e79eb01e-d9f7-4fe4-84c7-2ec74d74411b" contextRef="C_e2898211-1ef9-46ec-9a67-2298c6e5e1c8" name="iobt:WarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24330d7f-547b-4aae-b99a-0402fe05a737" contextRef="C_dd5861a4-c39b-4313-99f5-dd1a1dc0195b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (the Warrants) to certain institutional investors and existing shareholders (the Purchasers). Each Purchaser&#8217;s Warrant is exercisable for a number of shares of common stock equal to one hundred percent of the aggregate number of shares of common stock purchased by such Purchaser. The purchase price per share of common stock and Warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ce58918-dc95-4c64-8564-cd49cf52ea99" contextRef="C_e2898211-1ef9-46ec-9a67-2298c6e5e1c8" name="iobt:PurchasePricePerShareOfCommonStockAndWarrant" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.025</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the Purchase Price). The Company received net proceeds from the Private Placement, after deducting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f56a5044-64b9-4250-b296-3787a926b474" contextRef="C_e2898211-1ef9-46ec-9a67-2298c6e5e1c8" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in underwriting discounts and commissions and other offering costs, of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6f90595-ecde-474e-b61b-ca8a8c30abfa" contextRef="C_5265fdb7-64e2-41ae-bedb-28fa9d99cc76" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">71.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Refer to Note 2, &#8220;Summary of Significant Accounting Policies,&#8221; and Note 10, "Stockholders' Equity" in the accompanying notes to our consolidated financial statements for the years ended December 31, 2023 and 2022 for additional information on the Private Placement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">145</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">At-The-Market Equity Program</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 15, 2023, we filed a new prospectus supplement with the U.S. Securities and Exchange Commission (the SEC) with respect to the offer and sale of shares of our common stock, with an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1ea159a-b2fd-45ac-85d5-cc8c7dbb54e5" contextRef="C_08166775-fe5a-4472-96b3-587d9d04a349" name="iobt:CommonStockMaximumAggregateOfferingAmount" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">19,500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, establishing an at-the-market equity program. On February 15, 2023, we also entered into a common stock sales agreement, dated February 15, 2023 (the &#8220;Sales Agreement&#8221;) by and between the Company and Cowen and Company, LLC for shares with an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1d7abc8-59cc-4e42-a9a2-b742abcb16f4" contextRef="C_f7a68159-256a-4ce2-b281-a534093c1329" name="iobt:CommonStockMaximumAggregateOfferingAmount" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">75,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through which we may, from time to time, sell shares through Cowen and Company, LLC, acting as agent and/or principal. Any shares offered and sold through the at-the-market equity program will be issued pursuant to the Company&#8217;s Registration Statement on Form S-3 (File No. 333-269569), which was declared effective on February 10, 2023, the prospectus supplement related to the offering that forms a part of the registration statement, and any applicable prospectus supplements that may form a part of the registration statement in the future. The aggregate market value of shares eligible for sale under the prospectus supplement and under the Sales Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3, to the extent required under such instruction. We have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4be51fb2-3972-416e-ae90-7fdeaa3f3e39" contextRef="C_86125bde-a241-4410-b61b-886b4c205d56" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t issued any shares pursuant to our at-the-market equity program as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance reporting capabilities.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are in preclinical research and clinical development. There can be no assurance that our research and development will be successfully completed, that adequate protection for our intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if our product development efforts are successful, it is uncertain when, if ever, we will generate significant revenue from product sales. We operate in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, we are dependent upon the services of our employees and consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity Considerations and Going Concern Basis of Accounting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, we have devoted substantially all of our efforts to business planning, conducting research and development, recruiting management and technical staff, and raising capital. We have financed our operations primarily through the issuance of convertible preference shares, convertible notes, our IPO and the Private Placement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our continued discovery and development of product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if our product development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de53d405-1482-4e6c-9916-dfbbb18ac87f" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">263.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. We have incurred losses and negative cash flows from operations since inception, including net losses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5efab89b-3e15-4383-a524-652ad78f09e9" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">86.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9e3d1fa-fc44-4907-abff-584f370050cf" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">71.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023 and 2022, respectively. We expect that our operating losses and negative cash flows will continue for the foreseeable future as we continue to develop our product candidates. We currently expect that our cash and cash equivalents of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2b96b36-9c8c-4fd0-bb08-7b130a15d73d" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">143.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 will be sufficient to fund our operating expenses and capital requirements for at least 12 months from the date the financial statements are issued. On this basis the financial statements are prepared on a going concern basis of accounting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. However, additional funding will be necessary to fund future discovery research, pre-clinical and clinical activities. We will seek additional funding through public financings, debt financings, collaboration agreements, strategic alliances and licensing arrangements. Although we have been successful in raising capital in the past, there is no assurance that we will be successful in obtaining such additional financing on acceptable terms, or at all, and we may not be able to enter into collaborations or other arrangements. If we are unable to obtain funding, we could be forced to delay, reduce or eliminate our research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect our business prospects, even our ability to continue operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">146</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_495d6598-26f6-4bfd-9e30-89acdaea1561" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b32e0bf-410e-44b0-9c21-003dd5b02a5f" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e90741b1-8ebc-454a-bc14-4921473b5bbd" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements include the accounts of its subsidiaries IO Biotech ApS, IO Bio US, Inc. and IO Biotech Limited. IO Bio US, Inc. is a wholly owned subsidiary of IO Biotech ApS. IO Biotech Limited is a wholly owned subsidiary of IO Biotech ApS. All intercompany transactions and balances have been eliminated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66bcb947-5797-4ba8-b081-697fcb5cef3d" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:UseOfEstimates" escape="true" continuedAt="F_66bcb947-5797-4ba8-b081-697fcb5cef3d_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_66bcb947-5797-4ba8-b081-697fcb5cef3d_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant items subject to such estimates and assumptions include contract research organization accruals, the fair value of stock-based compensation awards, the fair value of Warrants issued as part of the Private Placement and valuation of the Company&#8217;s deferred tax assets. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8cc4a8f7-d309-43b2-8395-d5b716eebd61" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true" continuedAt="F_8cc4a8f7-d309-43b2-8395-d5b716eebd61_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Currency and Currency Translation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_8cc4a8f7-d309-43b2-8395-d5b716eebd61_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The financial statements are presented in U.S. Dollars, our reporting currency. The functional currency of IO Biotech ApS and IO Biotech Limited is the Euro and the British Pound, respectively. The functional currency of IO Bio US, Inc. and IO Biotech, Inc. is the U.S. Dollar. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the functional currency are included in other income and expense in the consolidated statements of operations. Assets and liabilities recorded in our Euro and British Pound functional currencies are translated into the U.S. dollar reporting currency at the exchange rate on the balance sheet date. Our expenses in the Euro and the British Pound functional currencies are translated into the U.S. Dollar reporting currency at the average exchange rate prevailing each month. Resulting translation adjustments are recorded to other comprehensive income (loss) (OCI).</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb455bd7-a8b5-4013-8afc-4a87d22d7e11" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true" continuedAt="F_eb455bd7-a8b5-4013-8afc-4a87d22d7e11_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_eb455bd7-a8b5-4013-8afc-4a87d22d7e11_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents, which consist of money market accounts, are stated at fair value. As of December 31, 2023 and 2022 we had money market funds of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a5ec556-952d-4085-a9ee-9cc9283e9b48" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">131.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25629bb1-65c1-491e-8d98-16c4d24e4a64" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">88.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, which are included in cash and cash equivalents and reported at fair value (Note 3).</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37a0f9f1-7517-42c8-8ec6-62cc9a443b9a" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain our cash in bank deposit and checking accounts that at times exceed insured limits. We have not experienced any losses in such accounts and believe we are not exposed to any significant credit risk, however, we are exposed to the potential loss of uninsured deposits should a financial institution we maintain our cash deposits with fail.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79e8f6d3-ef92-487a-8997-b35b39ef4ee1" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true" continuedAt="F_79e8f6d3-ef92-487a-8997-b35b39ef4ee1_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the price we would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The three levels of the fair value hierarchy are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">liabilities;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">147</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are observable, either directly or indirectly; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_79e8f6d3-ef92-487a-8997-b35b39ef4ee1_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We monitor the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, our policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, the Company only held Level 1 financial instruments, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_933976ff-0867-4b14-b824-4b507dc1a18c" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consists of laboratory equipment, computer hardware and office furniture and are recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset by asset basis, which generally consists of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b331dba7-d4e7-4cd2-b9d4-9a1aba3b4027" contextRef="C_a179b419-8f22-455d-a4ab-2a0aa92c018a" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for computer hardware, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a279fa7c-0505-47dd-92b2-24df9fa809b7" contextRef="C_c457cad7-3e0c-4a59-b4de-aa28ef642dbf" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for office furniture and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1992e3c0-7279-4ec9-bd14-d116f7ca7380" contextRef="C_a0c8c506-94c5-4204-b3e9-4087e11e4d77" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for laboratory equipment. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If circumstances require a long-lived asset to be tested for possible impairment, recoverability is measured by comparison of the carrying amount of the assets to estimated future undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset exceeds its estimated future cash flows, then impairment expense is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1fec080-17dc-49d3-9d4b-51d954dfee2c" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_65821b11-8a0d-4991-8640-dc5c8d1d9c92" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment expenses were recognized.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_672de337-3a00-446b-9079-9622c8861064" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_672de337-3a00-446b-9079-9622c8861064_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. The Company&#8217;s research and development expenses consist primarily of costs incurred for the development of its product candidates and include expenses incurred under agreements with contract manufacturing organizations, or CMOs, contract research organizations, or CROs, investigative sites and consultants to conduct clinical trials and preclinical and non-clinical studies, costs to acquire, develop and manufacture supplies for clinical trials and other studies, salaries and related costs, including equity-based compensation, depreciation and other allocated facility-related and overhead expenses and licensing fees and milestone payments incurred under product license agreements where no alternative future use exists.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may obtain grants from public and private funds for our research and development projects. The grant income for a given period is recognized as a cost reimbursement and is typically based on the time and the costs that we have spent on the specific project during that period. During the years ended December 31, 2023 and 2022, we had active cost reimbursement grants with Innovation Fund Denmark. The grants provided partial reimbursement of employment-related costs related to two employees pursuant to Business Ph.D. and Business post-doctoral programs. For the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, research and development expenses in the statements of operations include $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2efc2c14-5ffc-48be-bcc1-db5df1daf5b1" contextRef="C_77b4e90b-4f57-4362-beca-0e8dcbcfba19" name="iobt:GrantIncomeCostReimbursement" unitRef="U_USD" scale="6" decimals="-4" format="ixt:num-dot-decimal">0.02</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d4be2c2-6983-4c21-816f-cfaa01d3fb7c" contextRef="C_c1c118ba-3d68-42c8-9af6-0389748a393e" name="iobt:GrantIncomeCostReimbursement" unitRef="U_USD" scale="6" decimals="-4" format="ixt:num-dot-decimal">0.03</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, of grant income cost reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_672de337-3a00-446b-9079-9622c8861064_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have historically met the requirements to receive a tax credit in Denmark of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e82267e8-b3dd-406f-9492-93db1ad22eef" contextRef="C_2537fee5-7e0b-4dba-8a7b-1ae868729ba1" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_DKK" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million Danish Kroner per year for tax losses resulting from research and development costs of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4e0be7c-bd61-4be5-b748-4e08fa1c4537" contextRef="C_65b6ebb1-4040-4de5-b896-f3c903f4135b" name="iobt:RefundableTaxCredit" unitRef="U_DKK" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million Danish Kroner per year. The tax credit is reported as a reduction to research and development expense in the statements of operations. For the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, research and development expenses include refundable tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8737624c-6bd9-4d05-9f28-2b3263fca278" contextRef="C_61743499-6fd4-4641-8e5f-157d373726ff" name="iobt:RefundableTaxCreditReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ccfeffea-9c01-4f52-8c7b-2b46b2208fc0" contextRef="C_0ea23d1e-bc0a-42c8-afab-71532c2b7804" name="iobt:RefundableTaxCreditReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">148</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56e1a531-e38a-4db2-a257-973b14b9863b" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="iobt:AccruedResearchAndDevelopmentCostsPoliciesTextBlock" escape="true" continuedAt="F_56e1a531-e38a-4db2-a257-973b14b9863b_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_56e1a531-e38a-4db2-a257-973b14b9863b_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantial portions of our pre-clinical and clinical trials are performed by third-party laboratories, medical centers, CMOs, CROs and other vendors. These vendors generally bill monthly for services performed, or bill based upon milestone achievement. For preclinical studies, we accrue expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled, the duration of the study and other investigative costs. We monitor patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to us by the CROs, correspondence with the CROs and clinical site visits. Our estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. We periodically evaluate the estimates to determine if adjustments are necessary or appropriate based on information we receive.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dd8c77a1-5c17-4eed-946c-7d106b9a25e8" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" continuedAt="F_dd8c77a1-5c17-4eed-946c-7d106b9a25e8_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2016, the FASB issued ASU No. 2016-02, Leases (&#8220;ASC 842&#8221;) to enhance the transparency and comparability of financial reporting related to leasing arrangements. Under this lease standard, most leases are required to be recognized on the balance sheet as right-of-use (ROU) assets and lease liabilities. The right-of-use model requires a lessee to recognize a ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement as well as the reduction of the right of use asset. In 2022, the Company adopted the standard effective January 1, 2022 and chose to use the effective date as date of initial application. The standard provides a number of optional practical expedients in transition. Upon adoption, the Company elected to apply the &#8216;package of practical expedients&#8217; which allowed the Company to not reassess (1) whether existing or expired arrangements contain a lease; (2) the lease classification of existing or expired leases; or (3) whether previous initial direct costs would qualify for capitalization under the new lease standard. The Company also elected to apply (1) the practical expedient which allows us to not separate lease and non-lease components, for new leases entered into after adoption and (2) the short-term lease exemption for all leases with an original term of less than 12 months, for purposes of applying the recognition and measurements requirements in the new standard.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_dd8c77a1-5c17-4eed-946c-7d106b9a25e8_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company will utilize the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. As of January 1, 2022, the ASC 842 effective date, the Company&#8217;s incremental borrowing rate was approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_249bfc8b-1560-4135-a3fc-ed10c71696f6" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="iobt:OperatingLeaseIncrementalBorrowingRateOnRemainingLease" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="1" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% based on the remaining lease term of the applicable leases.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f2ee48e3-6c29-4840-b94f-b40ee0c8131b" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for stock options granted in accordance with ASC 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation-Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In accordance with ASC 718, compensation expense is measured at the estimated fair value of the stock options at grant date and is included as compensation expense over the vesting period during which an employee provides service in exchange for the award on a straight-line basis. Vesting of the awards depend solely on service conditions required of the employee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All share-based awards granted are measured based on the fair value on the date of the grant and compensation expense is recognized with respect to those awards over the requisite service period, which is generally the vesting period of the respective award. The Company reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity-based compensation expense is classified in the Company&#8217;s consolidated statements of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes model. The following summarizes the inputs used:</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">149</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies because we lack company-specific historical and implied volatility information due in part to the limited time in which we have operated as a publicly traded company. We expect to continue to do so until such time as we have adequate historical data regarding the volatility of our traded stock price.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected term of the Company&#8217;s stock options has been determined based on the expected time to liquidity. The Company uses the simplified method prescribed by the SEC&#8217;s Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term of options granted because we lack company-specific historical and implied expected term information due in part to the limited time in which we have operated as a publicly traded company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk-free interest rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free interest rate is based on the implied yield on a U.S. Treasury security at a constant maturity with a remaining term equal to the expected term of the option granted.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividends</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected dividend yield is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db0e5d9c-87f6-4af0-83fb-97621707894c" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> because the Company does not pay cash dividends on common shares and does not expect to pay any cash dividends in the foreseeable future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share Price</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The Company's common stock trades on the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nasdaq Global Market under the symbol &#8220;IOBT" and is utilized to determine the fair value of the Company's share price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1dfb2c6-dea7-4174-a9d4-232e9bef6752" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_a1dfb2c6-dea7-4174-a9d4-232e9bef6752_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are established when necessary, to reduce deferred tax assets to the amount expected to be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We follow the provisions of ASC 740-10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Uncertainty in Income Taxes. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not recognized a liability as a result of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae77d6f9-a477-4658-8e27-281df5b02395" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unrecognized benefit since the date of adoption and we have not recognized interest expense or penalties as a result of ASC 740-10. If there were an unrecognized tax benefit, we would recognize interest accrued related to unrecognized tax benefits as income tax expense within our consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_a1dfb2c6-dea7-4174-a9d4-232e9bef6752_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have identified Denmark and the U.S. as our major tax jurisdictions.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5197b6f2-d80c-4355-8fdb-7ebfe6a3995a" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="iobt:WarrantsPolicyPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrants Issued in Connection with Sale of Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for warrants issued as a separable unit in connection with sale of common stock as either liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered liabilities if they are mandatorily redeemable and they require settlement in cash or other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as liability or equity. If warrants do not require liability classification under ASC 815-40 or other applicable U.S. GAAP the warrants should be classified as equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The proceeds received from the sale of equity classified warrants and sh</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ares of common stock in a bundled transaction are allocated based on the relative fair values of warrants and shares of common stock with no changes in fair value of warrants recognized after the issuance date. Based on our analysis of the foregoing, the Company's warrants issued in the Private Placement are classified as equity in our consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_826b38b4-5ff5-4931-8e78-4c636eeaf6fc" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="F_826b38b4-5ff5-4931-8e78-4c636eeaf6fc_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_826b38b4-5ff5-4931-8e78-4c636eeaf6fc_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders  by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method and the as if-converted method, for convertible securities, if inclusion of these instruments is dilutive. Potentially dilutive securities include stock options and warrants to purchase common stock of the Company. In all periods presented, the Company&#8217;s outstanding stock options and warrants were excluded from the calculation of diluted net loss per share because their effects were anti-dilutive.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023 and 2022, both basic and diluted net loss per share are equivalent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">150</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_119d73b2-bdb4-4db4-8dcf-5b39554186d5" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (CODM), in deciding how to allocate resources to an individual segment and in assessing performance. Our CODM is our chief executive officer. The Company has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d75fc19-07a9-4dd2-aa03-6ce39b5aee66" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true" continuedAt="F_7d75fc19-07a9-4dd2-aa03-6ce39b5aee66_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Comprehensive Income (Loss)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_7d75fc19-07a9-4dd2-aa03-6ce39b5aee66_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OCI is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our OCI includes currency translation from the Euro and the British Pound, the functional currency of IO Biotech ApS and IO Biotech Limited, respectively, to the U.S. Dollar, our reporting currency.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e31fbf31-239b-4d32-90f8-1bc1f6ff70f1" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="iobt:EmergingGrowthCompanyStatusPoliciesTextBlock" escape="true" continuedAt="F_e31fbf31-239b-4d32-90f8-1bc1f6ff70f1_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_e31fbf31-239b-4d32-90f8-1bc1f6ff70f1_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (1) are no longer an emerging growth company or (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_92794b0f-205f-4de0-8dc3-749b638aeb5d" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" continuedAt="F_92794b0f-205f-4de0-8dc3-749b638aeb5d_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently adopted accounting standards</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#8212;Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_50d1f921-ea74-4d65-b53b-2d642b4f270d;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASU 2019-04</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fbd59a99-de54-420d-aa86-1aed79344f1b" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the standard effective </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_464c5d34-9e07-4ab9-b842-5f7ee5e4633d" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The adoption of the standard has </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7927560a-b601-49fa-b29f-07ae81b86e67" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t had a material impact on our financial statements or financial statement disclosures.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued Accounting Standards</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity s Own Equity (Subtopic 815-40): Accounting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">being separately recognized from the host contract as compared with current U.S. GAAP. Convertible instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that continue to be subject to separation models are (1) those with embedded conversion features that are not</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the derivatives scope exception for contracts in an entity&#8217;s own equity to reduce form-over-substance-based</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">accounting conclusions. ASU 2020-06 will be effective for us in the interim periods in the fiscal year beginning after December 15, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">interim periods within those fiscal years. We are currently assessing the impact adoption of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASU 2020-06 will have on our financial statements and disclosures, but do not expect a material impact on the financial statements or disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, the FASB issued ASU 2023-06, Accounting Standards Update 2023-06&#8212;Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative. ASU 2023-06 will eliminate disclosure requirements that are redundant, duplicative, overlapping, outdated, or superseded as a result of subsequent changes to SEC disclosure requirements, U.S GAAP or technology. ASU 2023-06 is intended to better align U.S. GAAP requirements with those of the SEC and to facilitate the application of U.S. GAAP. The disclosure requirements would apply prospectively in the financial statements. ASU 2023-06 will be effective for us on the date on which the SEC&#8217;s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, if we are already subject to the SEC&#8217;s current disclosure requirements. For those current disclosure requirements we are not subject to, ASU 2023-06 will become effective two years after the date of such removal by the SEC. We are currently assessing the impact adoption of ASU 2023-06 will have on our financial statements and disclosures.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">151</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 will improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 will also enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment and contain other disclosure requirements. The enhanced segment disclosure requirements apply retrospectively to all prior periods presented in the financial statements. ASU 2023-07 will be effective for us in the annual periods beginning after December 15, 2023. We are currently assessing the impact adoption of ASU 2023-07 will have on our financial statements and disclosures, but do not expect a material impact on the financial statements or disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 will require disclosure of additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate (the rate reconciliation) for federal, state and foreign income taxes. ASU 2023-09 will also require information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold.  ASU 2023-09 will be effective for us in the annual periods beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. We are currently assessing the impact adoption of ASU 2020-06 will have on our financial statements and disclosures.</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_92794b0f-205f-4de0-8dc3-749b638aeb5d_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our consolidated financial statements</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1b2fb2f-73f6-4a6a-a65c-772552cced35" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_a1b2fb2f-73f6-4a6a-a65c-772552cced35_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value are performed in a manner to maximize the use of observable inputs and minimize the use of unobservable inputs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classified its money market funds within Level 1 as the fair value of the funds are based on their quoted market prices in an active market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67ec19b0-6e02-44b0-900e-36da532b1844" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about our financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0af8c9b5-c9b7-4458-bc1d-b4c297735afc" contextRef="C_adf457e8-e0ad-4c0c-aaa7-41e091effa59" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,613</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7ab0217-001f-4dc4-9622-63e6bde1a776" contextRef="C_85d6429e-66de-40ef-8389-98da77aaac70" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,613</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a8dfd89-4902-4a79-86e0-482de63a21b5" contextRef="C_735c9fc1-57ba-400b-99d6-3730bae07801" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,613</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_914e95b9-d693-41e5-8852-4ac9dd46af71" contextRef="C_856ab70f-a3ef-4cca-b917-88f71a19dda0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,613</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90a4a485-8f58-40ef-abc3-1b0e2dc85bd7" contextRef="C_589be980-c3a1-445b-9010-4a1c2db1e2ba" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,971</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43eb5e64-dd5c-4fcb-9254-81d034c04abd" contextRef="C_d7201268-1a27-4850-b9eb-b381cbd53051" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,971</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92c9b7d5-2d39-4aa8-a609-2fa81995d825" contextRef="C_cdcfe8ca-1864-4dc3-9e85-2db43b36cb88" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,971</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bde634ce-5761-457c-bbcc-c9bb53229031" contextRef="C_77688354-ad09-4f13-a478-c216dd6f48f9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,971</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Money market funds with maturities of 90 days or less at the date of purchase are included within cash and cash equivalents in the accompanying consolidated balance sheets and are recognized at fair value.</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company only held Level 1 financial instruments.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a1b2fb2f-73f6-4a6a-a65c-772552cced35_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97586331-a9cb-4d20-9c53-f21fc9aefd8d" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f4e1663f-4627-44b6-98fb-3d3f9c7256ba" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="iobt:FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_44c82a4c-525b-4ab6-bcb1-a242519e6b97" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="iobt:FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0a47edea-5d4b-4422-aae5-f3f96901f84d" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers among Level 1, Level 2 or Level 3 categories in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1af21924-417a-43b0-962f-8c850214cbf2" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="iobt:FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" unitRef="U_USD" scale="3" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_70291045-524f-442d-a7a5-0be955bbdd88" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="iobt:FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" unitRef="U_USD" scale="3" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23 and 2</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_969e7053-7b1e-47dd-bf37-fd87ea439870" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" scale="3" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_58a166e8-43af-425f-a0d0-89ab03b88b54" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" unitRef="U_USD" scale="3" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">152</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f27642b1-1099-47e5-a8d9-a8123dfd7026" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. License and Collaboration Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreements with MSD International GmbH</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2018, we entered into a clinical collaboration with MSD International GmbH (MSDIG) to evaluate IO102 in combination with KEYTRUDA&#174; (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer. Under the terms of the collaboration with MSDIG, we will conduct an international Phase 1/2 study to evaluate a combination therapy of IO102 and KEYTRUDA&#174;. We will sponsor the clinical trials and MSDIG will provide KEYTRUDA&#174; to be used in the clinical trials free of charge. We and MSDIG will be responsible for our own internal costs and expenses to support the study and we shall bear all other costs associated with conducting the study, including costs of providing IO102 for use in the study. The rights to the data from the clinical trials will be shared by us and MSDIG and we will maintain global commercial rights to IO102.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In September 2021, we entered into a clinical collaboration with MSDIG and MSD International Business GmbH (MSDIB), another affiliate of Merck (collectively, &#8220;MSD&#8221;) to evaluate IO102-IO103 in combination with KEYTRUDA&#174; versus KEYTRUDA&#174; alone in treatment of patients with metastatic (advanced) melanoma. Under the terms of the collaboration with MSD, we are conducting an international Phase 3 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA&#174;. We are the sponsor of the clinical trials and MSD will provide KEYTRUDA&#174; to be used in the clinical trials free of charge. We and MSD are responsible for our own internal costs and expenses to support the study and we will bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trials will be shared by us and MSD and we will maintain global commercial rights to IO102-IO103.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In December 2021, we entered into a clinical collaboration with MSD to evaluate IO102-IO103 in combination with KEYTRUDA&#174; in previously untreated patients with three different tumor types&#8212; metastatic non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and urothelial bladder cancer (UBC). Under the terms of the collaboration with MSD, we are conducting an international Phase 2 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA&#174;. We are the sponsor of the clinical trials and MSD will provide KEYTRUDA&#174; to be used in the clinical trials free of charge. We and MSD are responsible for our own internal costs and expenses to support the study and we will bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trials will be shared by us and MSD and we will maintain global commercial rights to IO102-IO103.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  In November 2022, we entered into a clinical collaboration with MSD to evaluate IO102-IO103 in combination with KEYTRUDA&#174; as a neo-adjuvant/adjuvant therapy for patients with metastatic melanoma and SCCHN. Under the terms of the collaboration with MSD, we will conduct an international Phase 2 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA&#174;. We will sponsor the clinical trials and MSD will provide KEYTRUDA&#174; to be used in the clinical trials free of charge. We and MSD will be responsible for our own internal costs and expenses to support the study and we shall bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trials will be shared by us and MSD and we will maintain global commercial rights to IO102-IO103.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c186f951-afcc-47af-9ce3-9a1e1df8257f" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Prepaid Expenses and Other Current Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_498b5976-22b5-4e72-943b-dda9d5d1cbe6" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_038eb1a2-fcf6-4493-beeb-6c34be1e4c5a" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,352</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bb3278a-33cc-4d6f-a9cd-23280bfb378c" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,716</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credit receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17be1b04-b59d-45aa-be0d-1ccdc45ed4b0" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="iobt:ResearchAndDevelopmentTaxCreditReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">814</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0af6859b-072b-418b-a08b-141bfd6cd211" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="iobt:ResearchAndDevelopmentTaxCreditReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">792</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2c2afaa-400c-4ad8-ae07-c2ba95a24a2a" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:PrepaidTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">829</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2406986-66a5-435c-9f1b-15abdb657559" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:PrepaidTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Value-added tax refund receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cf079fb-50ee-48c1-9ad2-5f86c4b1ba11" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:ValueAddedTaxReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">313</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1aad2203-039b-413b-820f-2d55de6a6485" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:ValueAddedTaxReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">741</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid contract research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0aa3130-1472-4790-b288-751f08982c5c" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="iobt:PrepaidContractResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,695</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e62e451-4b42-4baa-ac01-04ac0ae463c8" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">754</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bfb164e-ea37-467f-9f0f-c08e4de762e5" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">561</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13acb106-18fe-4633-b2e2-b684c7a5dc07" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,062</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8dd6ceb-0026-4284-803e-b309c5db10a1" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,629</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">153</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e236b9c-8b1d-4fa9-aa7d-985f315367d0" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_389dc251-8e6b-42ad-b1f6-927bd538f87c" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.527%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:13.057%;"/>
        <td style="width:1%;"/>
        <td style="width:1.74%;"/>
        <td style="width:1%;"/>
        <td style="width:13.057%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a243de8-ff95-4fc7-a811-9c033a1bad8f" contextRef="C_a0c8c506-94c5-4204-b3e9-4087e11e4d77" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">836</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_741c291e-e0f2-4b0f-abc3-119d6de69db0" contextRef="C_ed65f1e2-5595-4174-b58c-577f2a1fce62" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">544</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office furniture</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf646ba5-3c00-4707-a4a1-df2ffeb4fdfa" contextRef="C_c457cad7-3e0c-4a59-b4de-aa28ef642dbf" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">238</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_741cfd48-5fa2-4c74-a67e-3a138ef6015d" contextRef="C_c6520b4d-f760-4dd3-8633-eeeaeb10c4af" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">233</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer hardware</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be7c0658-b204-4f15-8d0e-7b32b1255976" contextRef="C_a179b419-8f22-455d-a4ab-2a0aa92c018a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccb5145d-58ea-4b99-817a-6bae61a5e63f" contextRef="C_2bad730b-2375-4c64-b7fb-4fb30c1b1ef9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94893afa-d77d-48c3-9f18-a4d5c63213f1" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">330</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5fe87f0-03ee-450a-9c24-5a58bc475eb7" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c751cef-8825-47f1-aec4-f03ca63fde8a" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">847</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ef14a23-7ec5-4666-a2e6-f2aa065384b5" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">741</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023 and 2022, the Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5e06159-052b-4e72-9737-caf9954de131" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bcbfc4ab-d743-418f-aca3-5938984b7c0a" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of depreciation expense in the consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32e00243-f331-44f3-8d86-20576208c568" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b8411d4-d75f-411a-b64c-999666ea7212" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued contract research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa886c44-88a8-4fd1-938e-5e46d637480a" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="iobt:AccruedContractResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,153</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e485d5be-9933-4f1b-8e11-4d31b03afbfe" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="iobt:AccruedContractResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,936</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee compensation costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_559cb8d4-7bb0-4002-894f-5d38f469e605" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,225</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed51369d-d849-49c7-9c5e-f395c55abae7" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,863</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d00365ba-113c-4b25-9555-17e091a60526" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">243</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9abda506-3fec-4ba4-baa7-557c939a46ae" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">407</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f621ac6c-d6d7-4234-9b67-4c34b9996b63" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">563</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cc3413e-66fb-4abd-84fb-dceca8069c50" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,951</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bea18b3-9747-4222-abea-9b0fb3aa4c13" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,184</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf6cb09a-beef-43db-be54-4eac3af5698d" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,157</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2420de48-a142-4c16-8efa-ba5d886ebadc" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 1, 2022, the Company adopted ASC 842 using the modified retrospective transition approach allowed under ASU 2018-11 which releases companies from presenting comparative periods and related disclosures under ASC 842 and requires a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption (Note 2). The Company had an immaterial cumulative-effect adjustment to the opening balance of accumulated deficit as of January 1, 2022. The Company is party to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f762881-5d5e-4f75-bd7a-6798a3992cd0" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="iobt:NumberOfOperatingLease" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">five</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating leases for laboratory and office space. The Company&#8217;s finance leases are immaterial both individually and in the aggregate. The Company has elected to apply the short-term lease exception to all leases of one year or less. Further, the Company has applied the guidance in ASC 842 to our corporate office and laboratory leases and has determined that these should be classified as operating leases. Consequently, as a result of the adoption of ASC 842 on January 1, 2022, we recognized an ROU lease asset of approximately</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_359ae5e5-a48d-4f8f-8f46-9035f2e64650" contextRef="C_37d816e8-ef70-4e8e-b59e-b1a42f867be6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million with a corresponding lease liability of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_129638e4-c0fb-4749-bb15-b655f468d3f7" contextRef="C_37d816e8-ef70-4e8e-b59e-b1a42f867be6" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million based on the present value of the minimum rental payments of such leases. In accordance with ASC 842, the beginning balance of the ROU lease asset was reduced by the existing deferred rent liability at inception of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33f128c0-faf4-4a18-b142-7d5340eb4abe" contextRef="C_37d816e8-ef70-4e8e-b59e-b1a42f867be6" name="us-gaap:DeferredRentCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In the consolidated balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Company has an ROU asset balance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_073e5c4c-2dab-42de-a589-19f3e478c2e2" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and a current and non-current lease liability of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bbb86be-30ce-47f6-8611-ea53f486b2c1" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a87b2a14-b611-4277-bded-8ec45bbf825d" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, relating to the ROU lease asset. The balance of both the ROU lease asset and the lease liabilities primarily consists of future payments under the Company&#8217;s office leased in New York, New York, Rockville, Maryland and Copenhagen, Denmark. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">154</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is party to an operating lease in Copenhagen, Denmark for office space that commenced in March 2021 with an initial term that expired in January 2025. Base rent for this initial lease was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fd81edc-3af5-4b26-b740-8b497ef5593b" contextRef="C_d1bf34e5-9771-45f8-8bae-3cab72620d3b" name="iobt:OperatingLeaseAnnualBaseRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million annually. The Company amended its operating lease in Copenhagen, Denmark on September 1, 2022 with a new term set to expire in December 2027. The base rent for the amended lease is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf810669-3e51-4214-8e66-38eb81e5690b" contextRef="C_ec32ec8b-699d-4395-8839-904cf311de78" name="iobt:OperatingLeaseAmendedBaseRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million annually. The Company is also party to an operating lease in Copenhagen, Denmark for laboratory space that commenced in January 2023 with the term set to expire in December 2027. The base rent for the lease is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64b3732f-38a7-48e6-89aa-5605adc99321" contextRef="C_fc58b312-a405-4ae4-8b50-2ef63fe4fbd2" name="iobt:OperatingLeaseAnnualBaseRent" unitRef="U_USD" scale="6" decimals="-4" format="ixt:num-dot-decimal">0.04</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million annually. The Company is party to an operating lease in New York, New York for office space that commenced in October 2021 with the initial term set to expire in January 2027. Base rent for this lease is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59cc8263-0865-4e6a-8e8d-6bc6b147cca4" contextRef="C_7f69509c-a54b-452b-9c95-a1abe33fe007" name="iobt:OperatingLeaseAnnualBaseRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million annually. The Company is party to an operating lease in Rockville, Maryland for office and laboratory space that commenced in December 2021 with the initial term set to expire in May 2027. Base rent for this lease is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1573b6d7-3ef9-4ee8-973b-0937c37374c0" contextRef="C_4f734c8a-b5ea-4a27-879c-88db0c526af2" name="iobt:OperatingLeaseAnnualBaseRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million annually. The Company is party to an immaterial operating lease in Newport, United Kingdom that commenced in June 2023. Rent expense for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_428c0fc0-6887-4ba3-972d-3b56a8b45787" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb509a54-4c11-4331-b06a-99ee64b136fa" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_acdaf063-0dc8-403c-8f4e-d4ac5a13ca65" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Quantitative information regarding the Company&#8217;s leases for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2023 is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/><br/><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.974%;"/>
        <td style="width:1.319%;"/>
        <td style="width:1%;"/>
        <td style="width:13.035%;"/>
        <td style="width:1%;"/>
        <td style="width:2.319%;"/>
        <td style="width:1%;"/>
        <td style="width:13.035%;"/>
        <td style="width:1%;"/>
        <td style="width:2.319%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d8cab44-6f5c-4ff0-bce0-f5db80dc4ac6" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">730</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb5e0a29-563a-4775-ab08-d3f5ccf9dd5f" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">755</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating cash flows paid for amounts included in the measurement of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a778271-69de-4127-b2b9-30ad3bbc9956" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">723</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f32e24e-631f-464e-b093-6b977710182b" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">419</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities arising from obtaining right&#8209;of&#8209;use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_822dbe46-9638-4c4a-9a9d-668b80aee624" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63db5dbe-3caa-4018-98fe-421cb28cd42b" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,600</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remaining lease term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_f4ec0d25-df05-4554-a771-f373a008a783" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="iobt:OperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_c46c16fb-b0c5-402c-a143-7ce5131079c9" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="iobt:OperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc461f6c-69cd-4959-8beb-378ab2de9af0" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b319240-9815-4e32-8c84-3147ef122a43" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3fb7fbf8-5689-41d4-bfa7-f08b87dd47d1" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future lease payments (undiscounted) under noncancelable leases are as follows as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Future Lease Payments</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e89589e-36ec-4312-b1c9-716e6c448f0e" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">793</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de8b9a8a-c65e-46be-aa6c-b07538a6fc37" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">792</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78b0ee58-a93b-4fe5-bf57-e032cd22b0e1" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">798</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25e0d9df-0ef0-43c9-9a83-9c32169a3d67" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">403</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2fc7e7c-cb32-4bf7-8798-a1c2ebcf2fb5" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b47026c5-9c39-46f9-b0ae-3109cf5fd227" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24e89747-30f6-4576-bd36-403d6d567cc5" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,786</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s leases do not provide an implicit rate, therefore the Company used its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company used the incremental borrowing rate on January 1, 2022 for operating leases that commenced prior to that date, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb1f8d95-31f0-417b-a328-c5a9b045d286" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may be party to litigation arising in the ordinary course of its business. We were not subject to any material legal proceedings during the years ended December 31, 2023 and 2022, and, to our knowledge, no material legal proceedings are currently pending or threatened.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">155</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contractual Obligations and Commitments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enter into contracts in the ordinary course of business with third-party service providers for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e42f194b-ea27-45c3-9ef9-50c839f76eaa" contextRef="C_b343bb6c-f4f5-4b19-844e-c92494b10a7e" name="iobt:ContractualObligationsTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90a210a8-6a18-4275-87e0-c1b5b3e93bdf" contextRef="C_fbedcb5d-67e0-47f1-96ac-c9bcc05daf23" name="iobt:ContractualObligationsTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days, and therefore, we believe that our noncancelable obligations under these agreements are not material and we cannot reasonably estimate whether they will occur. However, in the event of a termination of any contracts with CROs or other institutions and with respect to active patients enrolled in our clinical trials, we may be financially obligated for a period beyond the contractual termination notice periods. We may also enter into additional research, manufacturing, supplier, lease and other agreements in the future, which may require up-front payments and even long-term commitments of cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enter into certain types of contracts that contingently requires us to indemnify various parties against claims from third parties. These contracts primarily relate to procurement, service, consultancy or license agreements under which we may be required to indemnify vendors, service providers or licensees for certain claims, including claims that may be brought against them arising from our acts or omissions with respect to our products, technology, intellectual property or services. The Company, as permitted under Delaware law and in accordance with its amended and restated certificate of incorporation and amended and restated bylaws and pursuant to indemnification agreements with certain of its officers and directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, which the officer or director is or was serving at the Company&#8217;s request in such capacity.  At the 2023 Annual Meeting of Stockholders, the Company&#8217;s stockholders approved an amendment to, and the Company subsequently amended, its amended and restated certificate of incorporation to extend the indemnification of officers pursuant to recent amendments to the General Corporation Law of the State of Delaware.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may receive indemnification claims under existing contracts in the normal course of business. In the event that one or more of these matters were to result in a claim against us, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on our future business, operating results or financial condition. It is not possible to estimate the maximum amount potentially payable under these contracts since we have no history of prior indemnification claims and the unique facts and circumstances involved in each particular claim will be determinative.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5cf7f29a-3323-4097-ba2d-3a097911b92d" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Stockholders' Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common and Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the closing of our IPO in November 2021, we filed an amended and restated certificate of incorporation, which authorized us to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85d373fa-4c93-4485-aed3-9041f5e2340d" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_289f6d5d-4711-4875-9974-bfa724f8d473" contextRef="C_1ae0c7b5-ef8e-4cb0-93ba-4ebe49f60bd5" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock. The shares of preferred stock are currently undesignated. Common stockholders are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d60fc88-41eb-4489-867c-abb13e119600" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="iobt:NumberOfVotePerShare" unitRef="U_Vote" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings. Common stockholders are entitled to receive dividends, if and when declared by the Company's board of directors (Board). </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_562388c7-807d-44f7-9e84-b0b3b9caa151" contextRef="C_e7f56205-a6d1-42a7-bef6-62ddf1cf7159" name="us-gaap:Dividends" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d05c9d9a-fb26-4f43-84f1-2ed94730b3d2" contextRef="C_c4753ff1-8839-464e-bba4-852e1ac3dc55" name="us-gaap:Dividends" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends have been declared or paid by us through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Private Placement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 7, 2023, the Company entered into the Purchase Agreement, pursuant to which the Company agreed to sell and issue (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b18acab-a048-4ba1-8a99-274cfb78d77c" contextRef="C_1089e4d9-f1b0-4539-bd02-0c5b3cebf7f8" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f332518-9077-4a7b-abab-861fda985c4b" contextRef="C_7888a195-a9c8-438b-8292-c9c9a460c8d3" name="iobt:WarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Warrants in the Private Placement. Each Purchaser&#8217;s Warrant is exercisable for a number of shares of common stock equal to one hundred percent of the aggregate number of shares of common stock purchased by such Purchaser. The Purchase Price for each common stock and Warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c69a1133-e337-44ef-addb-79a2a7e76aee" contextRef="C_7888a195-a9c8-438b-8292-c9c9a460c8d3" name="iobt:PurchasePricePerShareOfCommonStockAndWarrant" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.025</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Warrants are exercisable at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18c1592b-53f5-4bad-bf60-256e62542524" contextRef="C_7888a195-a9c8-438b-8292-c9c9a460c8d3" name="iobt:WarrantsExercisablePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.47</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, subject to adjustment as set forth therein. The Warrants are exercisable until the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an acquisition, as defined in the Warrants. The Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the Warrants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Private Placement closed on August 9, 2023. The Company received </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_512f5fcc-047e-4366-8835-170736ed8f8c" contextRef="C_0307f33c-16a4-4f72-98f6-13168e29e650" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in gross proceeds from the Private Placement, before deducting offering expenses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a12c7c1a-b8ef-4d19-a983-837de65b0899" contextRef="C_0307f33c-16a4-4f72-98f6-13168e29e650" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Of the total proceeds, legal entities of certain related parties contributed $33</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc6d530d-1c00-491b-abb1-e30a752441e2" contextRef="C_a06c72c9-9013-4145-a984-c7a878870eb5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and members of management contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23f3badb-d123-4131-ba36-206a476e6017" contextRef="C_f4208fa4-bfe6-48ee-94c0-37e910003209" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company intends to use the net proceeds of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ce4b024-6542-4342-96bc-19b31b8bc371" contextRef="C_0307f33c-16a4-4f72-98f6-13168e29e650" name="iobt:NetProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">71.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the Private Placement for general corporate purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">156</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in-capital and were recorded at the issuance date using a relative fair value allocation method. The Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. In addition, such Warrants do not provide any guarantee of value or return. The Company valued the Warrants at issuance using the Black-Scholes valuation model and allocated proceeds from the sale proportionately to the common stock and Warrants, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64c17818-280a-449e-9c07-5cdb3e8413a6" contextRef="C_921dd2b2-b1d9-4630-914d-9162f5d60817" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">29.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was allocated to the Warrants and recorded as a component of additional paid-in-capital. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f506c67-530d-4ddc-b51f-481f03c8cef2" contextRef="C_921dd2b2-b1d9-4630-914d-9162f5d60817" name="iobt:WarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants issued and outstanding at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12ec9be6-9065-47ec-a59d-5656c1376c3b" contextRef="C_921dd2b2-b1d9-4630-914d-9162f5d60817" name="iobt:WarrantsExercisablePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.47</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share to purchase shares of the Company's common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the execution of the Purchase Agreement, the Company also entered into a registration rights agreement (the Registration Rights Agreement) with the Purchasers. Under the terms of the Registration Rights Agreement, the Company has filed the Registration Statement with the SEC to register for resale the common stock issued under the Purchase Agreement and the shares of common stock issuable upon conversion of the Warrants issued pursuant to the Purchase Agreement (the Registrable Securities), which Registration Statement was declared effective on September 8, 2023. The Company may be required to pay certain liquidated damages under the terms of the Registration Rights Agreement in the event sales cannot be made pursuant to the Registration Statement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41fd596f-8900-4ab9-a10b-8fdb975ecf8f" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_629b0a50-f279-40cf-a3f1-dd93e9feb07b" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">28,815,267</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares outstanding, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_793610c1-d477-48e8-91b9-58ea208cbec5" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Equity-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Equity Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, our Board adopted, and our stockholders approved, the 2021 Equity Incentive Plan (2021 Equity Plan), which became effective on November 4, 2021. The 2021 Equity Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, awards of restricted stock, restricted stock units and other stock-based awards. The number of shares of our common stock reserved for issuance under the 2021 Equity Plan is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d468d50-b7f8-4a92-b86e-b91eb39b8fc4" contextRef="C_4842f3fa-8b43-4d85-86bd-f8d28ee08613" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,496,934</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, subject to an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022 and continuing until, and including, the fiscal year ending December 31, 2031, equal to the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efc8afa7-c929-4670-9883-3df3fa88311d" contextRef="C_4f7c3011-7c33-440c-af08-6ace8d509cd4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of common stock outstanding on the first day of such fiscal year or (ii) such other amount determined by our Board.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6206ddac-3c44-4319-b31d-891b29024666" contextRef="C_75c24bfc-711a-4d8f-a9f1-617a36085040" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">593,468</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options available for future grant under the 2021 Equity Plan.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, our Board adopted and our stockholders approved the 2021 IO Biotech, Inc. Employee Stock Purchase Plan (2021 ESPP), which became effective on November 4, 2021. The number of shares of our common stock reserved for issuance under the 2021 ESPP is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c88bc158-50f1-49d0-bb36-87fc18f2656e" contextRef="C_605c651a-ab13-4d27-8446-969fb0785085" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">257,272</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, subject to an annual increase, to be added on the first day of each fiscal year, beginning January 1, 2023, equal to the lesser of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3029f9f-8ea1-4f6b-9e0f-b7c752ee108e" contextRef="C_eaf8786d-c5b6-4a4a-8524-1e92c7607db8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of common stock outstanding on the first day of such fiscal year; (2) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_635d54c6-c0e4-4092-a08b-07bf345d7afb" contextRef="C_605c651a-ab13-4d27-8446-969fb0785085" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">257,272</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock; or (3) such other amount as determined by our Board. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Board had not yet approved any offering under the 2021 ESPP.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Inducement Award Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, our Board adopted the 2023 Inducement Award Plan (2023 Inducement Plan), which became effective on September 28, 2023. The 2023 Inducement Plan provides for the grant of non-statutory stock options, stock appreciation rights, awards of restricted stock, restricted stock units and other stock-based awards to eligible employees who satisfy the standards for inducement grants under Nasdaq Global Market rules. The number of shares of our common stock reserved for issuance under the 2023 Inducement Plan is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7756ca39-af68-4693-83a1-4bd3406584d1" contextRef="C_a8883698-bb05-40fe-9155-b8dada03facc" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,976,427</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22876125-f53d-4ff6-ba86-40c47b89a1c7" contextRef="C_a8883698-bb05-40fe-9155-b8dada03facc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,976,427</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for future grant under the 2023 Inducement Plan.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c9be312-a964-432e-9302-36bd91f1a48a" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our stock options activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">157</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:8.942%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Options<br/>&#160;and <br/>Warrants</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>average<br/>exercise<br/>price<br/>per share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75d4ba43-d8c5-4f13-866e-8a9b77d0f5a4" contextRef="C_43f3828a-2a64-44ee-9ffc-49729d49c629" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,071,613</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8220f459-8a4b-48d1-8585-eea811fe93c8" contextRef="C_43f3828a-2a64-44ee-9ffc-49729d49c629" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.12</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8c045dc7-1029-413c-8c19-95358eee5216" contextRef="C_a8dd0b70-be88-4ed9-9abb-fff49a8e9151" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.5</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c59aa5da-4ee8-4442-b1e3-a99de02c0db3" contextRef="C_57a8bc27-67ad-49ea-8c7d-a4bc7bcdaabb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,211,155</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84ce89dc-ad7e-4fc5-a1f4-9a7a387580fa" contextRef="C_57a8bc27-67ad-49ea-8c7d-a4bc7bcdaabb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.34</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled or forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07ff4320-5ec2-416b-95c4-ffc03815dff4" contextRef="C_57a8bc27-67ad-49ea-8c7d-a4bc7bcdaabb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">362,596</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af765631-19da-4bf5-b442-7c5387f9ee4e" contextRef="C_57a8bc27-67ad-49ea-8c7d-a4bc7bcdaabb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.51</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ef49c6a-c04c-440d-9df0-1a6dab26c245" contextRef="C_229bed5d-8df9-47a3-bf23-b8454739ccb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,920,172</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b465f7d-56e4-4ea7-a38d-3d2806bc2c63" contextRef="C_229bed5d-8df9-47a3-bf23-b8454739ccb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.77</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_93527b25-9067-46cf-a6fc-3f6e6f0b4b59" contextRef="C_57a8bc27-67ad-49ea-8c7d-a4bc7bcdaabb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e24df5fe-6bfe-4262-b6d0-494339f404c0" contextRef="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,519,994</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2213174e-2d98-401a-8ed5-6b75f8473bbe" contextRef="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.99</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled or forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5a6268b-b065-4339-bc50-e3d5bc5271ec" contextRef="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">588,243</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_107c6fb8-f5e9-4e67-9b7a-415fe585781d" contextRef="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.74</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cea26d5-9148-4153-880c-7f646f1c9139" contextRef="C_95e6310f-8da5-48b8-9242-a4b89a5ea523" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,851,923</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c66e49d-816a-4295-9ad1-e6425c8a6690" contextRef="C_95e6310f-8da5-48b8-9242-a4b89a5ea523" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_90cd56c1-a4d9-4e03-813e-9aac00b36e2d" contextRef="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3b5fa44-0056-48b5-b0a6-3ae2fa4ec5fb" contextRef="C_95e6310f-8da5-48b8-9242-a4b89a5ea523" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50f3396b-9ddc-4841-bfa8-28d70637d784" contextRef="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba" name="iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,902,547</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03c589ee-c304-4df5-9976-a25eca5be13d" contextRef="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba" name="iobt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.26</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_56459260-fd32-4d5c-a18f-a55076c1e81c" contextRef="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba" name="iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.7</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea665edd-12fc-417a-a06f-314889e74abc" contextRef="C_95e6310f-8da5-48b8-9242-a4b89a5ea523" name="iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All share-based awards granted are measured based on the fair value on the date of the grant and compensation expense is recognized with respect to those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures related to equity-based compensation awards are recognized as they occur, and we reverse any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023 and 2022, we recorded equity-based compensation expense of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40f690af-37ea-464e-bd71-83bf4ac7c3aa" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74e5896e-e696-421b-8d41-30015514413a" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, related to the issuance of stock options and warrants. As of December 31, 2023, there was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57d4e7a2-a939-4c11-98fe-f1b7b74f128a" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized compensation cost related to unvested stock-based compensation arrangements that is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38ef42a9-fd51-4e34-a7fe-964d34d919ff" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ddf26e9-4e11-4077-b37f-e739ad7dd786" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of the options granted were estimated based on the Black-Scholes model, using the following assumptions:<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.553%;"/>
        <td style="width:1.54%;"/>
        <td style="width:16.683%;"/>
        <td style="width:1.54%;"/>
        <td style="width:16.683%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66fb5b28-70d8-4fe4-acc7-e943aa6e144f" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">86.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03238426-cff6-4a80-88d4-c27db584e339" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">102.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a22a916-0ed6-4359-9b9d-ab3e0ab5a191" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">74.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6871d9ca-5fcf-49e1-9303-f255a15badbc" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">77.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28bd7b09-c07b-48e6-909a-ea96c933a907" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6e4bf85-c462-4def-9597-8d449a9c93ea" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8274448-3ce8-4832-8f40-3c4dc383cb2f" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.62</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33896bdd-c98d-490c-ab6c-9f12d79644f6" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b18a5fbd-9b01-4046-b791-f52f7c3216c3" contextRef="C_b343bb6c-f4f5-4b19-844e-c92494b10a7e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">- </span><span><ix:nonNumeric id="F_f179b075-fa8b-47f7-a7b7-ff3ed4ea7484" contextRef="C_fbedcb5d-67e0-47f1-96ac-c9bcc05daf23" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1de6c0d2-23dc-4c3f-ba18-899508c7c323" contextRef="C_ea391396-42d3-4eff-9bdc-69880686eb48" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">- </span><span><ix:nonNumeric id="F_c1601c78-9901-4e31-948d-7876601e05a3" contextRef="C_2a3ed7cd-93dc-4db4-bb66-a7f11ce29791" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fd26216-a4d9-4423-bdfd-c03fccc34711" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd273477-d393-4479-948d-a51533dee5aa" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_510670c5-ebae-4694-9c4d-4d5a9e788cb9" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd79ce97-fd65-45d4-812f-ce3f4ee41f5a" contextRef="C_77b4e90b-4f57-4362-beca-0e8dcbcfba19" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,204</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8139d46-7678-4169-a837-ac0e974db9f8" contextRef="C_c1c118ba-3d68-42c8-9af6-0389748a393e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,859</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4783e6d2-6968-47ea-8b9c-911251476826" contextRef="C_75385bc1-6f5b-43da-a2b7-ac643558b468" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,855</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7855e05-80a6-4556-8363-fc90fec0a540" contextRef="C_6f628d94-953f-4311-9f9c-e89296efa0d6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,181</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total equity-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52e00b28-4380-4ce1-b1a7-78eb2f1b1161" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,059</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75a2e161-2f0f-45b1-b15d-c4c695f52071" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,040</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c08dcced-0ee9-4c95-b6e7-e2a1514bf58b" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a4954dd8-3f3a-4012-8f4a-8e99bde2d1c1" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize any tax benefits for stock-based compensation during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_7021b10c-a4f2-4097-ad0f-c3aa6d9b4a22" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to U.S. federal, state and foreign corporate income taxes. </span><span><ix:nonNumeric id="F_4cade335-6889-4442-bd28-14fa9010205b" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true" continuedAt="F_4cade335-6889-4442-bd28-14fa9010205b_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our loss before provision for income taxes for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022 consisted of the following (in thousands): </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_4cade335-6889-4442-bd28-14fa9010205b_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f319ece-38b4-4ee4-be60-85e8c01555df" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,365</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0488ffd4-c610-4193-86b9-653d096d668c" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,885</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47445d03-4eff-47c8-b6b7-646c360e697d" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">87,596</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_215d28b2-18e2-4e75-a7a1-7acc20908254" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68,300</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_134a4fc0-a125-4692-9e22-184ec1bb05d8" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,231</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d7c122a-9eac-4c51-89f7-4ddef77174b6" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">70,185</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">158</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div></ix:exclude></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed782164-a249-4a7c-ae75-580c412c266f" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our provision for income taxes consists of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_312eeaa7-1d54-49b8-ba21-e580592e0bbf" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">439</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5068468d-25d0-4e28-976c-f8fcba473410" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,059</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6bacdae-a130-4461-b232-06be7969ee22" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">374</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbc94cb8-737e-4390-930e-18e53e6d87dc" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58693a84-59eb-4d41-86c8-801ab9160439" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e90ae96-576b-44de-b498-72a954b435b1" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9cde8d5-de14-462e-a89f-1df8f8592fe7" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">852</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b27c451-a354-43b7-9472-e572ea912c6f" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,197</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0ef86d9-c7db-432b-bcce-70eb78ce4865" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2415e6ad-b1b1-4b3f-9ca9-caa93af575cc" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27474a81-9b7c-4c4e-b307-2decfc286fb8" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">852</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32a06260-589a-4422-be6a-a8dc0a7d3121" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,273</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reconciliation of Effective Tax Rate</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our effective tax rate for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is different from the statutory rate in the U.S. primarily due to the valuation allowance against deferred tax assets as a result of insufficient sources of income. </span><span><ix:nonNumeric id="F_428d1bea-30a0-48e4-a16b-dacd762db2f2" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" continuedAt="F_428d1bea-30a0-48e4-a16b-dacd762db2f2_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The reconciliation of the statutory income tax rate to our effective income tax rate is as follows: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_428d1bea-30a0-48e4-a16b-dacd762db2f2_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.358%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.358%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax benefit at the statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c0e4118-c5fd-4971-b4dd-b6823690452e" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56e41415-ddb9-4548-bdd8-88972c6eca10" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4abe14d9-8d5a-4d89-bc2c-17c045846015" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c429d5d-bb0a-417a-aa17-70bddd1afdf0" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Difference in tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e75b193-f3b5-4f5a-b59d-a90d8700724d" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1980029f-c101-4218-9065-0f49e5fde093" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">R&amp;D Deduction</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc5df299-4233-4df7-866c-3a6f36a81cb3" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="iobt:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d177e287-9742-45e1-b8a6-11ca9b7f7562" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="iobt:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fda7427c-3acf-40ef-9c47-726c81d5651f" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">24.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba7608a9-84ae-49e1-ac21-ce1e9e97edf1" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">27.4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prior period adjustments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b23666a3-757b-47cb-b195-c621fd319b6e" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f90b3d9-c303-4f0b-8087-dde8d28c2597" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44b37494-f6b0-441b-a3b0-3524e8be2daf" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7a02e15-39bf-40e8-b097-a5d585a6740c" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af54fac7-7554-487f-9722-2f82d947028d" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5baa205-db05-4053-a317-426860c00cf0" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is recorded when it is more likely than not</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">159</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">some or all of the deferred tax assets will not be realized. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a36d631e-8a7a-4fac-b2d9-ef3e733d9f5c" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_a36d631e-8a7a-4fac-b2d9-ef3e733d9f5c_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets consisted of the following (in thousands): </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_a36d631e-8a7a-4fac-b2d9-ef3e733d9f5c_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c3cd572-c90b-4464-8f42-f7dcc812857d" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,343</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_098e4a0b-f6f8-4820-beef-07a03bc77d04" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,338</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50277603-138f-4cea-8b3e-718b1cb3fe44" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,602</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec40f5ac-f071-4de0-b36f-451aa2665a44" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,828</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bdd853f-8308-40a7-a513-69f7e1f464b8" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="iobt:DeferredTaxAssetsAccruedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3fa4cd1-33a7-402c-9efe-bb56ad017f47" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="iobt:DeferredTaxAssetsAccruedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ROU Lease Liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd10d748-255b-4a6f-9b26-643e564c18ed" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="iobt:DeferredTaxAssetsRightOFuseLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">526</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ace9f87e-237c-479a-a13f-51dc64488d8f" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="iobt:DeferredTaxAssetsRightOFuseLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">618</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized R&amp;D</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5575cb3f-f49c-4aaa-b347-a022cf41605e" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,348</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fdf3638-5a68-48f9-af16-bff372e37471" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,231</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fec60121-53c5-42b2-b35e-3b174908c129" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">529</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b567c62-dce1-4def-819f-9d4e2da76236" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">529</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a57de5b-db8b-4363-995b-b1752d5ce52f" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,381</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d6dbfe5-1fe8-4380-a898-bbd3183ba246" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,565</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67e1de63-d2ab-4143-a33c-f0781bd895d2" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,902</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e6c54d5-2ab1-4970-8977-f07d61d4f2fe" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,984</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb822042-1f92-421a-b27d-b187b930ba9b" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">479</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c943043a-51a8-42e7-80dd-56ada93b3e09" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">581</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ROU Lease Asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1be31fb7-d64f-4247-93be-56877a838c97" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="iobt:DeferredTaxLiabilitiesRightOfUseLeaseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">441</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5cdb68c-2a52-426c-b5e8-1d099285f77b" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="iobt:DeferredTaxLiabilitiesRightOfUseLeaseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">567</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed Assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3f0accb-2d96-46d8-94dd-75d47bd9cf26" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6dbf9d4d-d448-4478-9289-e4e3a20d6e0e" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other Liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85bab26a-241d-412e-a410-072c42307608" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abeaf71c-c73b-4c22-9062-7214678e5915" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1cd336c0-f289-4ded-84b3-fbfea5302570" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">479</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6d148e9-deda-4696-ae62-4a891d3b56f9" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">581</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax asset (liability)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2017, the U.S. enacted the Tax Cuts and Jobs Act (the 2017 Tax Act), which contained a provision that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022. Previously, these expenses could be deducted in the year incurred. The implementation of this provision increased our deferred tax asset and valuation allowance by approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12b03a91-6726-410c-8ae8-ffaabf939007" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="iobt:ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2f1989d-5bde-488e-beae-941007207642" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="iobt:ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When realization of a deferred tax asset is more likely than not to occur, the benefit related to the deductible temporary differences attributable to operations is recognized as a reduction of income tax expense. Valuation allowances are provided against deferred tax assets when, based on all available evidence, it is considered more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. We cannot be certain that future income in Denmark will be sufficient to realize the Company&#8217;s deferred tax assets. Accordingly, a full valuation allowance has been provided against our net deferred tax assets in Denmark. We have also provided a full valuation allowance against our net deferred tax assets in the U.S. for IO Bio US, Inc. The Company's valuation allowance increased by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e31360c-6ca3-4597-b460-5d9d66073a9b" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fc03aee-c179-4080-b1bf-1069e1630762" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023 and 2022, respectively. The increase for the years ended December 31, 2023 and 2022 is primarily the result of an increase in net operating loss carryforwards (NOL carryforwards) in Denmark.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Available Carryforward Tax Losses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had NOL carryforwards of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dde44f7-063c-418b-8a59-e7e161c3fcc5" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">228.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> that can be carried forward indefinitely according to Danish Tax Authority regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Uncertain Tax Positions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We determine our uncertain tax positions based on whether and how much of a tax benefit taken by us in our tax filings is more likely than not to be sustained upon examination by the relevant income tax authorities. We determine whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not recognition threshold is calculated as the largest amount that is more than 50%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by the Danish Tax Authority. As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e7295d9-0ec2-4df3-bd3b-588a0702e18b" contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_852c9b4a-5026-40e1-8339-e127780d5a63" contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recorded an uncertain tax position liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tax filings in Denmark remain subject to examination by the Danish Tax Authority. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, tax years </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e227eb0-9ecd-4ca9-a554-d71d28ccb093" contextRef="C_62f128f9-8dcd-483d-9972-ffa3ab6dd713" name="us-gaap:OpenTaxYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2020</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and forward were generally open to examination by the Danish Tax Authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">160</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Tax Credits</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023, we have elected to claim a research and development tax credit on the federal income tax return filed for the year ended December 31, 2022. We plan to continue to make this election on the federal income tax return filed for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> based on law currently enacted, and will continue to monitor impacts of proposed or enacted law changes on the cost to benefit of making this election. The Company included $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d61b573-4630-4ff4-96f9-1325fa4be992" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in research and development tax credits in the U.S. provision for income taxes for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2023.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Tax Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes accrued interest related to unrecognized tax benefits and penalties as income tax expense in the statements of operations. The Company does not have any material unrecognized tax benefits which would affect the effective tax rate, if recognized. The Company does not have any unrecognized tax benefits which would reverse within the next twelve months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is eligible for the Danish enhanced research and development tax allowance, providing for an increase in the deductible value of the amount of certain R&amp;D expenditur</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">es. For 2019, the deduction is set at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06ded1ee-a17c-4500-abf8-ad48d841095d" contextRef="C_05adc53f-1ee4-4206-b227-537d28cde4b2" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">101.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. Furthermore, the deduction for R&amp;D expenditures is set at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcb8b67c-7acb-44f4-8985-a071b345189a" contextRef="C_1bdcb713-0037-4abc-ba55-93260da29f6f" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">130</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for 2020 through 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c31542a1-a313-4f71-b576-d147ab13bee0" contextRef="C_93ef2e83-0050-441a-9dc6-7635a9140a67" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">108</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for 2023 through 2025, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25447d21-fd0e-45b3-b621-4bfde7f2e134" contextRef="C_aba91903-9247-448c-a45a-f748af1aed15" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">110</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax allowance is reported as a reduction to research and development expense in the statements of operations. For the years ended December 31, 2023 and 2022, we applied for refundable tax credit of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_345f1e30-1bb1-428b-b015-e525e2ea2cb8" contextRef="C_61743499-6fd4-4641-8e5f-157d373726ff" name="iobt:RefundableTaxCredit" unitRef="U_DKK" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3a0f76dc-8e9b-4a11-8884-e37ad97fccd8" contextRef="C_0ea23d1e-bc0a-42c8-afab-71532c2b7804" name="iobt:RefundableTaxCredit" unitRef="U_DKK" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million DKK for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and a receivable was recorded for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e8bfa8a-64c6-411b-acc3-26d0c140ec90" contextRef="C_0ea23d1e-bc0a-42c8-afab-71532c2b7804" name="iobt:RefundableTaxCreditReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8cb3d96a-6970-4704-bb99-499c7f77c69e" contextRef="C_61743499-6fd4-4641-8e5f-157d373726ff" name="iobt:RefundableTaxCreditReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in each year, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_c04074dd-970a-434e-ba88-3572720297d1" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0cd0ccf-f91f-4dd8-9fe4-45087ce5eb0b" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted net loss per common share is calculated as follows (in thousands except share and per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.389%;"/>
        <td style="width:1.401%;"/>
        <td style="width:1%;"/>
        <td style="width:10.904%;"/>
        <td style="width:1%;"/>
        <td style="width:1.401%;"/>
        <td style="width:1%;"/>
        <td style="width:10.904%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8995d2df-8f82-4177-b764-bda0421919c0" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,083</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65cf6d85-e118-4768-b202-d3745b5ca186" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,458</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to common shareholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09e1dfe9-7d15-4957-b699-57cd50ec4c89" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,083</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdf2ac06-7869-4713-a3f2-2ada396f4b0e" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,458</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9aaaa92-92b0-46f0-bcf0-f0efdbea5bb5" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_888016a0-3c43-4b8e-981e-68a2f9c467e8" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.98</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f48e93d0-f034-46e5-b53d-b8c135f76311" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0161d104-d2a8-4cff-98fd-0557ed0b4b4c" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.48</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of shares used in computing net loss per common share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca09b15f-b5b4-4fb3-b478-2c4fe57eefa7" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e82976c0-1555-404e-b042-7b5df2b5bcb3" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">43,539,976</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a84592d8-b545-43dd-93f0-018c2a18f033" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_77d29725-fb38-4a1a-8819-2f8a56425dc1" contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">28,815,267</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per common share, as their effect is anti-dilutive:</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26056ab7-d242-4edb-addd-0adcaa0b4db8" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_26056ab7-d242-4edb-addd-0adcaa0b4db8_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_26056ab7-d242-4edb-addd-0adcaa0b4db8_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34f6cbfb-0f54-4306-85d1-d486fadd3056" contextRef="C_0d4b831b-94cf-4ac9-aae8-23f925e98a73" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,851,923</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_322a41fb-ea00-4177-b663-9242bb2b5dce" contextRef="C_6a5e0744-7a0e-42a8-87f6-2990329c4ad7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,920,172</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants issued in Private Placement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e850832-54d6-4921-82a6-3c19693306a2" contextRef="C_5cfd6318-0a41-4064-a4cb-7e43fe8305a2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b910fce-6b5e-4e95-b50a-9582cd6478a8" contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have evaluated subsequent events through the date on which the consolidated financial statements were issued. The Company has concluded that no subsequent events have occurred that require disclosure to the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="changes_and_disagreement_accountants"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9. Changes in </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and Disagreements With Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">161</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9A. Contro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ls and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, mean controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company on the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including, our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the evaluation of our disclosure controls and procedures as of December 31, 2023 our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2023. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting as defined under the Exchange Act and by the Public Company Accounting Oversight Board (United States), such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as  defined in Rule 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended. Our internal control over financial reporting is a process designed to provide reasonable assurance to our management and board of directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes policies and procedures that: (1) pertain to the maintenance of  records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with  authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely  detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial  statements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements,  errors or fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute,  assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no  evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control  issues and instances of fraud will be detected. Also, projections of any evaluations of effectiveness to future periods are  subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023 based  on the framework set forth by the Committee of Sponsoring Organizations of the Treadway Commissions in Internal Control-Integrated Framework. Based on that assessment, management has concluded that our internal control over financial  reporting was effective as of December 31, 2023. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Attestation Report of the Registered Public Accounting Firm</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm due to an exemption established by the JOBS Act for &#8220;emerging growth companies.&#8221;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">162</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been no change in our internal control over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act during the year ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Information.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">163</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RT III</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="directors_executive_officers_corporate"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 10. Direc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tors, Executive Officers and Corporate Governance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this item is incorporated herein by reference to the Company&#8217;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#8217;s fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e Compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this item is incorporated herein by reference to the Company&#8217;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#8217;s fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="security_ownership_of_certain_beneficial"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 12. Sec</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">urity Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this item is incorporated herein by reference to the Company&#8217;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#8217;s fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="certain_relationship_and_related"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 13. Certain Rela</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tionships and Related Transactions, and Director Independence.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this item is incorporated herein by reference to the Company&#8217;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#8217;s fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="principal_accounting_fees_and_services"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 14. Principal Acc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ounting Fees and Services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this item is incorporated herein by reference to the Company&#8217;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#8217;s fiscal year ended December 31, 2023.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">164</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> IV</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="exhibits_financial_statements_schedules"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 15. Exhibits, Fin</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ancial Statement Schedules.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a list of the financial statements included herein, see Index to the Consolidated Financial Statements on page </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">139</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of this Annual Report on Form 10-K, incorporated into this Item by reference.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibits:</span></div></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.12%;"/>
    <td style="width:2.02%;"/>
    <td style="width:86.86%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521314634/d180178dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Certificate of Incorporation of IO Biotech, Inc. (filed as an exhibit to our Quarterly Report on Form 10-Q dated August 11, 2023 and incorporated herein by reference)</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1865494/000119312521314634/d180178dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Amended and Restated Bylaws of IO Biotech, Inc. (filed as an exhibit to our Amendment No. 2 to Registration Statement on Form S-1/A dated November 1, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521314634/d180178dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Common Stock Certificate (filed as an exhibit to our Amendment No. 2 to Registration Statement on Form S-1/A dated November 1, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="iobt-ex4_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Capital Stock</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1865494/000119312523024343/d457383dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Indenture (filed as an exhibit to our Registration Statement on Form S-3 dated February 3, 2023 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1865494/000119312523204538/d493270dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Warrant (filed as an exhibit to our Form 8-K dated August 7, 2023 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1&#134;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521314634/d180178dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement (filed as an exhibit to our Amendment No. 2 to Registration Statement on Form S-1/A dated November 1, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2&#134;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521314634/d180178dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of IO Biotech, Inc. 2021 Equity and Incentive Plan and related form agreements (filed as an exhibit to our Amendment No. 2 to Registration Statement on Form S-1/A dated November 1, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3&#134;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521314634/d180178dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of IO Biotech, Inc. 2021 Employee Stock purchase Plan and related form agreements (filed as an exhibit to our Amendment No. 2 to Registration Statement on Form S-1/A dated November 1, 2021 and incorporated herein by reference)</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521308118/d180178dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Option Assignment Agreement, dated as of January 2, 2015, by and between IO Biotech ApS and Herlev Hospital (filed as an exhibit to our Amendment No. 1 to Registration Statement on Form S-1/A dated October 26, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521308118/d180178dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Addendum I to Option Assignment Agreement, dated as of May 2, 2016, by and between IO Biotech ApS and Herlev Hospital (filed as an exhibit to our Amendment No. 1 to Registration Statement on Form S-1/A dated October 26, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521308118/d180178dex106.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Framework Assignment Agreement, dated as of May 2, 2016, by and between IO Biotech ApS and Herlev Hospital (filed as an exhibit to our Amendment No. 1 to Registration Statement on Form S-1/A dated October 26, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521308118/d180178dex107.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Assignment Agreement, dated as of January 2, 2017, by and between IO Biotech ApS and Herlev and Gentofte Hospital (field as an exhibit to our Amendment No. 1 to Registration Statement on Form S-1/A dated October 26, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521308118/d180178dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Option Assignment Agreement, dated as of March 27, 2017, by and between IO Biotech ApS and Herlev and Gentofte Hospital (filed as an exhibit to our Amendment No. 1 to Registration Statement on Form S-1/A dated October 26, 2021 and incorporated herein by reference)</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521308118/d180178dex109.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">1st Amendment to Option Assignment Agreement, dated as of December 7, 2018, by and between IO Biotech ApS and Herlev and Gentofte Hospital (filed as an exhibit to our Amendment No. 1 to Registration Statement on Form S-1/A dated October 26, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521308118/d180178dex1010.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2nd Amendment to Option Assignment Agreement, dated as of December 7, 2018, by and between IO Biotech ApS and Herlev and Gentofte Hospital (filed as an exhibit to our Amendment No. 1 to Registration Statement on Form S-1/A dated October 26, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521308118/d180178dex1011.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Agreement on Payment for Specific Services, dated as of January 27, 2021, by and between IO Biotech ApS and Herlev and Gentofte Hospital (filed as an exhibit to our Amendment No. 1 to Registration Statement on Form S-1/A dated October 26, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">165</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.12%;"/>
    <td style="width:2.02%;"/>
    <td style="width:86.86%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521308118/d180178dex1012.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement, dated September 7, 2021, by and among IO Biotech ApS, MSD International GmbH and MSD International Business GmbH (filed as an exhibit to our Amendment No. 1 to Registration Statement on Form S-1/A dated October 26, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521314634/d180178dex1013.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Investors&#8217; Rights Agreement, dated October 29, 2021, by and among IO Biotech, Inc. and the Investors and Key Holders party thereto (filed as an exhibit to our Amendment No. 2 to Registration Statement on Form S-1/A dated November 1, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14&#134;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521308118/d180178dex1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Service Agreement, dated August 21, 2017, by and between IO Biotech ApS and Mai-Britt Zocca (filed as an exhibit to our Amendment No. 1 to Registration Statement on Form S-1/A dated October 26, 2021 and incorporated herein by reference)</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15&#134;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521308118/d180178dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Addendum to Service Agreement, dated April 1, 2021, by and between IO Biotech ApS and Mai-Britt Zocca (filed as an exhibit to our Amendment No. 1 to Registration Statement on Form S-1/A dated October 26, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16&#134;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521308118/d180178dex1016.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Service Agreement, dated August 21, 2017, by and between IO Biotech ApS and Eva Ehrnrooth (filed as an exhibit to our Amendment No. 1 to Registration Statement on Form S-1/A dated October 26, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17&#134;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521308118/d180178dex1017.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Addendum to Service Agreement, dated April 1, 2021, by and between IO Biotech ApS and Eva Ehrnrooth  (filed as an exhibit to our Amendment No. 1 to Registration Statement on Form S-1/A dated October 26, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521348545/d151067dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement by and among IO Biotech ApS, MSD International GmbH, and MSD International Business GmbH, dated as of November 30, 2021 (filed as an exhibit to our Current Report on Form 8-K dated November 30, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19*&#134;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="iobt-ex10_19.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Letter Agreement, dated as of October 15, 2022, by and between IO Bio US, Inc. and Amy Sullivan.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.20</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1865494/000119312523040254/d264518dex11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Common Stock Sales Agreement, dated as of February 15, 2023, by and between IO Biotech, Inc. and Cowen and Company LLC (filed as an exhibit to our Form 8-K dated February 15, 2023 and incorporated herein by reference).</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1865494/000119312523204538/d493270dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Securities Purchase Agreement, dated as of August 7, 2023, by and among IO Biotech, Inc. and the Purchasers thereto (filed as an exhibit to our Form 8-K dated August 7, 2023 and incorporated herein by reference)</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.22</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1865494/000119312523204538/d493270dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Registration Rights Agreement, dated as of August 7, 2023, by and among IO Biotech, Inc. and the Purchasers thereto (filed as an exhibit to our Form 8-K dated August 7, 2023 and incorporated herein by reference)</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001865494/000119312521308118/d180178dex211.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">List of subsidiaries (filed as an exhibit to our Amendment No. 1 to Registration Statement on Form S-1/A dated October 26, 2021 and incorporated herein by reference)</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="iobt-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of EY Godkendt Revisionspartnerselskab, independent registered public accounting firm</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="iobt-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="iobt-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="iobt-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.2*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="iobt-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="iobt-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Policy on Recoupment of Incentive Compensation, dated September 20, 2023, of IO Biotech Inc.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:80%;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#134; Indicates a management contract or compensatory plan or arrangement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"># Portions of the exhibit have been or will be excluded because it is both not material and is the type of information that the registrant treats as private or confidential.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="form_10_k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 16. Form 10-K </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">166</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.38%;"/>
    <td style="width:2.7%;"/>
    <td style="width:5.54%;"/>
    <td style="width:46.38%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">IO Biotech, Inc.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:  March 5, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Mai-Britt Zocca</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Mai-Britt Zocca, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer and Director</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each person whose signature appears below constitutes and appoints Mai-Britt Zocca and Amy Sullivan, and each of them, his or her true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to file with the Securities and Exchange Commission this Form 10-K and any and all amendments and exhibits thereto, and all documents in connection therewith, granting unto each such attorney-in-fact and agent full power and authority to do and perform each and every act and thing necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his or her substitutes may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.98%;"/>
    <td style="width:1.04%;"/>
    <td style="width:43.3%;"/>
    <td style="width:1.04%;"/>
    <td style="width:21.64%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Mai-Britt Zocca, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer and Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 5, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Mai-Britt Zocca, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(Principal Executive Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Amy Sullivan, M.B.A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Chief Financial Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 5, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amy Sullivan, M.B.A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(Principal Financial Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Peter Hirth, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Chairman of the Board</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 5, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Peter Hirth, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Kathleen Sereda Glaub, M.B.A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 5, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Kathleen Sereda Glaub, M.B.A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Christian Elling, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 5, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Christian Elling, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Helen Collins, MD</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 5, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Helen Collins, MD</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Jack B. Nielsen</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 5, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Jack B. Nielsen</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.98%;"/>
    <td style="width:1.04%;"/>
    <td style="width:43.3%;"/>
    <td style="width:1.04%;"/>
    <td style="width:21.64%;"/>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Heidi Hunter</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 5, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Heidi Hunter</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.98%;"/>
    <td style="width:1.04%;"/>
    <td style="width:43.3%;"/>
    <td style="width:1.04%;"/>
    <td style="width:21.64%;"/>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ David V. Smith, M.B.A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 5, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">David Smith, M.B.A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">167</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>iobt-ex4_2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<html>
 <head>
  <title>EX-4.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 4.2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DESCRIPTION OF CAPITAL STOCK</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following summary describes the capital stock of IO Biotech, Inc. (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d;) and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the investors&#x2019; rights agreement to which we and certain stockholders are parties (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">IRA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201d;) and of the General Corporation Law of the State of Delaware. Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation, amended and restated bylaws, and the IRA, copies of which are incorporated by reference as exhibits to our Annual Report on Form 10-K.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, IO Biotech, Inc. (&#x201c;IO Biotech&#x201d;) had common stock, $0.001 par value per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), and listed on The Nasdaq Global Select Market under the trading symbol &#x201c;IOBT.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation authorizes 300,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of undesignated preferred stock, $0.001 par value per share, the rights, preferences and privileges of which may be designated from time to time by our board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had outstanding 65,880,914 shares of common stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividend Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and only then at the times and in the amounts that our board of directors may determine.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Voting Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holders of our common stock are entitled to one vote per share. Stockholders do not have the ability to cumulate votes for the election of directors. Our amended and restated certificate of incorporation and bylaws provide for a classified board of directors consisting of three classes of approximately equal size, each serving staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Preemptive or Similar Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is not entitled to preemptive rights and is not subject to redemption or sinking fund provisions.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Right to Receive Liquidation Distributions</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preferred Stock</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to our amended and restated certificate of incorporation, our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions, in each case without further vote or action by our stockholders. Our board of directors can also increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control and might adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. We have no current plan to issue any shares of preferred stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants and Options</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had outstanding options and warrants to purchase an aggregate of 42,917,570 shares of common stock, with a weighted-average exercise price of $3.11 per share.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain holders of shares of our common stock, or their permitted transferees, are entitled to rights with respect to the registration of these shares under the Securities Act of 1933, as amended (the &#34;Securities Act&#34;). These shares are referred to as registrable securities. These rights are provided under the terms of our IRA, and are described in additional detail below.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Demand Registration Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holders of registrable securities are entitled to certain demand registration rights. Upon the written request of the holders of a majority of our registrable securities then outstanding that we file a registration statement under the Securities Act covering at least 40% of our registrable securities then outstanding, we are obligated to register the sale of all registrable securities that the holders may request in writing to be registered. We are required to effect no more than one registration statement that is declared or ordered effective. We may postpone the filing of a registration statement for up to 120 days once in a 12-month period if in the good faith judgment of our Board of Directors such registration would be seriously detrimental to us.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Piggyback Registration Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holders of registrable securities are entitled to certain piggyback registration rights.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we register any of our securities for public sale, either for our own account or for the account of other security holders, we will also have to register all registrable securities that the holders of such securities request in writing be registered. This piggyback registration right does not apply to a registration relating to any of our stock plans, stock purchase or similar plan, a transaction under Rule 145 of the Securities Act or a registration related to stock issued upon conversion of debt securities. We, based on consultation with the underwriters of any underwritten offering will have the right to limit the number of shares registered by these holders if the underwriters determine that including all registrable securities will jeopardize the success of the offering.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:16.65pt;font-family:Times New Roman;margin-bottom:16.65pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Form S-3 Registration Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holders of at least 30% of the registrable securities then outstanding are entitled to certain registration rights on Form S-3. The holders of these shares can request that we register all or a portion of their shares on Form S-3 if we are eligible to file a registration statement on Form S-3 and the aggregate price to the public of the shares offered is in excess of $10.0 million. We are required to effect no more than two Form S-3 registration statements that are declared or ordered effective in any 12-month period. We may postpone the filing of a registration statement for up</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to 120 days not more than once in a 12-month period if in the good faith judgment of our Board of Directors such registration would be seriously detrimental to us.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Anti-Takeover Provisions</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provisions of the DGCL, our amended and restated certificate of incorporation and our bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and encourage persons seeking to acquire control of our company to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 203 of the DGCL</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#x201c;business combination&#x201d; with an &#x201c;interested stockholder&#x201d; for a three-year period following the date that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:4%;"></td>
    <td style="width:1%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">before the stockholder became interested, our board of directors approved either the business combination or the transaction, which resulted in the stockholder becoming an interested stockholder;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:4%;"></td>
    <td style="width:1%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">upon consummation of the transaction, which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans in some instances, but not the outstanding voting stock owned by the interested stockholder; or</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:4%;"></td>
    <td style="width:1%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">at or after the time the stockholder became interested, the business combination was approved by our board and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock, which is not owned by the interested stockholder.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 203 defines a business combination to include:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:4%;"></td>
    <td style="width:1%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">any merger or consolidation involving the corporation and the interested stockholder;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:4%;"></td>
    <td style="width:1%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:4%;"></td>
    <td style="width:1%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">subject to exceptions, any transaction that results in the issuance of transfer by the corporation of any stock of the corporation to the interested stockholder;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:4%;"></td>
    <td style="width:1%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:4%;"></td>
    <td style="width:1%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amended and Restated Certificate of Incorporation and Bylaw Provisions</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation and our bylaws include a number of provisions that may have the effect of deterring hostile takeovers, or delaying or preventing changes in control of our management team or changes in our board of directors or our governance or policy, including the following:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board Vacancies</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation and bylaws authorize generally only our board of directors to fill vacant directorships resulting from any cause or created by the expansion of our board of directors. In addition, the number of directors constituting our board of directors may be set only by resolution adopted by a majority vote of our entire board of directors. These provisions prevent a stockholder from increasing the size of our board of directors and gaining control of our board of directors by filling the resulting vacancies with its own nominees.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Classified Board</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation and bylaws provide that our board of directors is classified into three classes of directors. The existence of a classified board of directors could delay a successful tender offeror from obtaining majority control of our board of directors, and the prospect of that delay might deter a potential offeror.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Directors Removed Only for Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation provides that stockholders may remove directors only for cause.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Supermajority Requirements for Amendments of Our Amended and Restated Certificate of Incorporation and Bylaws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation further provides that the affirmative vote of holders of at least two-thirds of the voting power of our outstanding common stock are required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to the classified board, the size of the board of directors, removal of directors, special meetings, actions by written consent and designation of our preferred stock. The affirmative vote of holders of at least two-thirds of the voting power of our outstanding common stock are required to amend or repeal our bylaws, although our bylaws may be amended by a simple majority vote of our board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stockholder Action; Special Meeting of Stockholders</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation provides that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, holders of our capital stock would not be able to amend our bylaws or remove directors without holding a meeting of our stockholders called in accordance with our bylaws. Our amended and restated certificate of incorporation and our bylaws provide that special meetings of our stockholders may be called only by a majority of our board of directors, the chairperson of our board of directors, or our chief executive officer, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders to take any action, including the removal of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Advance Notice Requirements for Stockholder Proposals and Director Nominations</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. To be timely, a stockholder&#x2019;s notice generally must be delivered to us not later than the close of business on the 90</font><font style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> day nor earlier than the close of business on the 120</font><font style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> day prior to the first anniversary of the preceding year&#x2019;s annual meeting of stockholders. Our bylaws also specify certain requirements regarding the form and content of a stockholder&#x2019;s notice. With respect to nominations of persons for election to our board of directors, the notice shall provide information about the nominee, including, among other things, name, age, address, principal occupation,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ownership of our capital stock and whether they meet applicable independence requirements. With respect to the proposal of other business to be considered by our stockholders at an annual meeting, the notice shall provide a brief description of the business desired to be brought before the meeting, the text of the proposal or business, the reasons for conducting such business at the meeting and any material interest in such business by such stockholder and any beneficial owners and associated persons on whose behalf the notice is made, or the proposing persons. In addition, a stockholder&#x2019;s notice must set forth certain information related to the proposing persons, including, among other things:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:4%;"></td>
    <td style="width:1%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">the name and address of the proposing persons;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:4%;"></td>
    <td style="width:1%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">information as to the ownership by the proposing persons of our capital stock and any derivative interest or short interest in any of our securities held by the proposing persons;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:4%;"></td>
    <td style="width:1%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">information as to any material relationships and interest between the proposing persons and us, any of our affiliates and any of our principal competitors;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:4%;"></td>
    <td style="width:1%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">a representation that the stockholder is a holder of record of our stock entitled to vote at that meeting and that the stockholder intends to appear in person or by proxy at the meeting to propose such nomination or business; and</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:4%;"></td>
    <td style="width:1%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">a representation whether the proposing persons intend or are part of a group which intends to deliver a proxy statement or form of proxy to holders of at least the percentage of our outstanding capital stock required to elect the nominee or carry the proposal.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#x2019;s own slate of directors or otherwise attempting to obtain control of our company.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Cumulative Voting</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#x2019;s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation and bylaws do not provide for cumulative voting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issuance of Undesignated Preferred Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our board has the authority, without further action by the stockholders, to issue up to 5,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock enables our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusive Forum</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf under Delaware law, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or bylaws, (4) any other action against us or any of our directors, officers or other employees asserting a claim that is governed by the internal affairs doctrine shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) or (5) any other action asserting an &#x201c;internal corporate claim,&#x201d; as defined in Section 115 of the Delaware General Corporation Law, in all cases subject to the court having jurisdiction over indispensable parties named as defendants. These exclusive-forum provisions do not apply to claims under the Securities Act or the Exchange Act. Any person or entity purchasing or otherwise</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acquiring any interest in our securities shall be deemed to have notice of and consented to this provision. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Transfer Agent and Registrar</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent&#x2019;s address is 150 Royall Street, Canton, Massachusetts 02021, and its telephone number is (800) 962-4284.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>3
<FILENAME>iobt-ex10_19.htm
<DESCRIPTION>EX-10.19
<TEXT>
<html>
 <head>
  <title>EX-10.19</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:42.133%;text-indent:11.521%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.19</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img62367891_0.jpg" alt="img62367891_0.jpg" style="width:62px;height:99px;">&#160;</p>
  <p style="margin-left:46.667%;text-indent:12.5%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:12.5%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3 October 2022</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Ms. Amy Sullivan</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Re:	Offer of Employment</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dear Amy:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">I am pleased to offer you full-time employment with IO Bio US, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), a subsidiary IO Biotech ApS (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">IO Biotech</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), beginning on October 15, 2022 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commencement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). As of the Commencement Date you will be employed in the position of Chief Financial Officer, and report to the Chief Executive Officer of IO Biotech.  You will perform your duties primarily from your home in Massachusetts, but be subject to necessary travel as may be required from time to time, including regular travel to the New York office as appropriate.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">You will receive a base salary at an annual rate of U.S. $425,000</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> less applicable withholdings, which will be paid in accordance with the Company&#x2019;s normal payroll procedures.</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">You will be eligible to earn an annual bonus with a target payout equal to 45% of your annual base salary (prorated for 2022). The final bonus amount will be determined based on your performance and the performance of IO Biotech and its subsidiaries, if any, during the calendar year, as determined by the Company.  The Company will pay this bonus, to the extent earned, by March 15th of the following calendar year.  The bonus is not earned until paid and, except as expressly set forth below, no pro-rated amount will be paid if your employment terminates for any reason prior to the payment date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IO Biotech shall grant to you, upon and subject to Board of Directors approval as soon as administratively practicable after the Commencement Date, a number of options allowing you to subscribe for such number of shares of IO Biotech that represents 1% of the issued and outstanding shares of IO Biotech as of the Commencement Date, at an exercise price equal to the closing price of IO Biotech shares on the date of grant, and such other terms and conditions as determined by the Board of Directors of IO Biotech.  Twenty-five percent of such options will vest on the first anniversary of the Commencement Date, and the remainder will vest on a monthly basis after that over the subsequent 36 months, subject to your continued employment through the applicable vesting date (except as provided below).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">During your employment, you will be eligible to participate in the Company&#x2019;s standard benefit plans maintained by the Company and offered to similarly situated U.S. employees from time to time, subject to the terms of such</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">plans and generally applicable Company policies.  The Company may modify its compensation and benefit plans from time to time in its discretion.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">You will be eligible for vacation to be taken at such times as you may select consistent with the Company&#x2019;s policies.  In addition, you shall be entitled to such national holidays as observed in the United States pursuant to Company policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">As a Company employee, you will be expected to abide by all rules and policies of IO Biotech and its subsidiaries (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">IO Biotech Group</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) in place from time to time. As a condition of employment, you must sign and comply with the attached Employee Confidential Information and Inventions Assignment Agreement (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CIIA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) which prohibits unauthorized use or disclosure of IO Biotech Group proprietary information, among other obligations.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This employment offer is contingent on and subject to the nonexistence of any legally enforceable agreement between you and any other person or entity which would restrict your ability to be employed by the Company.  It is the Company&#x2019;s understanding and your express representation that no noncompetition agreements or other post-employment obligations will prevent you from performing the duties of your position.  You acknowledge and agree that, as of the Commencement Date, you were not engaged in any other employment, occupation, consulting, or other business activity directly related to the business in which the IO Biotech Group is involved.  Moreover, you agree that during the term of your employment with the Company you will not engage in any other employment, occupation, consulting, or other business activity directly related to the business in which the IO Biotech Group is now involved or becomes involved during the term of your employment or in any other activities that materially conflict with your obligations to the IO Biotech Group, provided that you may with prior written approval of the Chief Executive Officer of IO Biotech, not to be unreasonably withheld, serve on advisory boards or board of directors (or similar advisory or governing bodies) of other companies and organizations (whether industry, non-profit, for profit or other, in each case other than competitors of the IO Biotech Group) as long as such activities do not conflict with the interests of the IO Biotech Group or otherwise materially</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">interfere, individually or in the aggregate, with the performance of your duties to the IO Biotech Group.  Similarly, you agree not to utilize any third-party confidential information in performing your duties for the IO Biotech Group.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Your employment relationship with the Company is at-will. You may terminate your employment with the Company at any time and for any reason whatsoever simply by notifying the Chief Executive Officer of IO Biotech in writing at least 30 days prior to the date of such termination.  Likewise, subject to the provisions below related to severance, the Company may terminate your employment at any time by notifying you in writing at least 30 days prior to the date of such termination; provided that the Company may terminate your employment immediately upon written notice if such termination is for Cause, as defined below.  Your employment at-will status can only be modified in a written agreement signed by you and by the Chief Executive Officer of IO Biotech.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Company terminates your employment without Cause or you resign for Good Reason, as such terms are defined below, you shall be entitled to receive:  (i) severance pay in an amount equal to 12 months of your then current base salary, payable in substantially equal installments over the 12-month period following your termination date; (ii) any unpaid bonus for the prior year, as authorized by the Company, payable within 30 days after your termination date; (iii) if you elect to continue your health care benefits under COBRA or any similar state law following your termination date, then during the first 12 months of such coverage your health premiums shall be equal to those paid by similarly situated active employees and (iv) 25% of the number of options that are unvested as of the date of your termination shall become vested and exercisable as of the date of your termination of employment.  In addition, if such termination occurs within 24 months after a Change of Control (as such term is defined in IO Biotech&#x2019;s Articles of Association), then all outstanding options that are unvested immediately prior to such termination shall become fully vested and exercisable upon such termination.  To be eligible to receive any severance benefits hereunder, you must execute a reasonable and customary separation and general</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">release of claims agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Release Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) in a form to be provided by the Company (which will include, at a minimum, a release of all releasable claims, reasonable obligations to cooperate, a non-disparagement obligation, and reaffirmation of your continuing non-compete and other continuing obligations to the IO Biotech Group) within 21 days following your termination and not revoke such Release Agreement within seven days after it has been executed.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this letter agreement:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the occurrence of any of the following events: (i) your willful failure substantially to perform your duties and responsibilities to the IO Biotech Group or your violation of an IO Biotech Group policy; (ii) your commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has caused or is reasonably expected to result in injury to the IO Biotech Group; (iii) your unauthorized use or disclosure of any proprietary information or trade secrets of the IO Biotech Group or any other party to whom you owe an obligation of nondisclosure as a result of your relationship with the IO Biotech Group; or (iv) your breach of any of your obligations under any written agreement or covenant with the IO Biotech Group. The determination that a termination of your employment is either for Cause or without Cause will be made by the Chief Executive Officer of IO Biotech, in her sole discretion.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">means any of the following actions taken by the Company without your consent: (i) the Company&#x2019;s breach of any material obligations to you under this letter agreement or any other material agreement to which you and the Company are parties; (ii) a requirement by the Company that you relocate your principal employment responsibilities to a location that is more than 50 miles from the location at which your principal employment responsibilities are then being performed; (iii) an adverse change in your reporting relationship, authority or areas of responsibility as are commensurate with your position; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, that it shall not be considered &#x201c;Good Reason&#x201d; if, following a Change in Control, either (a) the Company continues as a separate legal entity or business unit and you hold the same position in such legal entity or business unit as you held before such Change in Control, or (b) you hold a position with authority, duties, function or responsibilities comparable (though not necessarily identical, in view of the relative sizes of the Company and the entity involved in the Change in Control) to those that you held prior to such Change in Control; or (iv) a material reduction in your base salary, except in the case of across-the-board salary reductions based on the Company&#x2019;s financial performance and similarly affecting all other executives of the Company at your level of employment; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, that no such action taken by the Company shall constitute Good Reason unless (A) you provide written notice to the Chief Executive Officer of the Company stating your objection to such action not later than 30 days after it initially occurs, (B) the Company shall have failed to remedy such action within 30 days after receipt of such notice and (C) you resign from employment within 60 days after the expiration of such remediation period.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This letter is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), and shall be interpreted and construed consistently with such intent.  The payments to you are also intended to be exempt from Section 409A of the Code to the maximum extent possible, under either the separation pay exemption pursuant to Treasury regulation &#167;1.409A-1(b)(9)(iii) or as short-term deferrals pursuant to Treasury regulation &#167;1.409A-1(b)(4), and for this purpose each payment shall constitute a &#x201c;separately identified&#x201d; amount within the meaning of Treasury Regulation &#167;1.409A-2(b)(2).  In the event the terms of this letter would subject you to taxes or penalties under Section 409A of the Code (&#x201c;409A Penalties&#x201d;), you and the Company shall cooperate diligently to amend the terms of this letter to avoid such 409A Penalties, to the extent possible; provided that in no event shall the Company be responsible for any 409A Penalties that arise in connection with any amounts payable under this letter.  To the extent any amounts under this letter are payable by reference to your &#x201c;termination of employment,&#x201d; such term shall be deemed to refer to your &#x201c;separation from service,&#x201d; within the meaning of Section 409A of the Code.  Notwithstanding any other provision in this letter, if you are a &#x201c;specified employee,&#x201d; as defined in Section 409A of the Code, as of the date of your separation from service, then to the extent any amount payable to you (i) constitutes the payment of nonqualified deferred compensation, within the meaning of Section 409A of the Code, (ii) is payable upon your separation from service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">and (iii) under the terms of this letter would be payable prior to the six-month anniversary of the your separation from service, such payment shall be delayed until the earlier to occur of (a) the first business day following the six-month anniversary of the separation from service and (b) the date of your death.  Any reimbursement or advancement payable to you pursuant to this letter or otherwise shall be conditioned on the submission by you of all expense reports reasonably required by the Company under any applicable expense reimbursement policy, and shall be paid to you within 30 days following receipt of such expense reports, but in no event later than the last day of the calendar year following the calendar year in which you incurred the reimbursable expense.  Any amount of expenses eligible for reimbursement, or in-kind benefit provided, during a calendar year shall not affect the amount of expenses eligible for reimbursement, or in-kind benefit to be provided, during any other calendar year.  The right to any reimbursement or in-kind benefit pursuant to this letter or otherwise shall not be subject to liquidation or exchange for any other benefit.	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of federal immigration law, you will be required to provide to the Company, or the Company&#x2019;s designee, documentary evidence of your identity and eligibility for employment in the United States.  Such documentation must be provided to the Company or its designee within three (3) business days of the Commencement Date, or our employment relationship with you may be terminated and such termination shall be deemed to be for &#x201c;Cause.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To ensure the timely and economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the CIIA enforcement, breach, performance, negotiation, execution, or interpretation of this letter agreement, the CIIA, your employment, or the termination of your employment, including but not limited to all statutory claims, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration by a single arbitrator conducted in the Washington, D.C. metropolitan area by Judicial Arbitration and Mediation Services Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">JAMS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) under the then applicable JAMS rules (at the following web address: https://www.jamsadr.com/rules-employment-arbitration/).  A hard copy of the rules will be provided to you upon request.  </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In addition, all claims, disputes, or causes of action under this provision, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity.  The Arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding.  To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration.  The Company acknowledges that you will have the right to be represented by legal counsel at any arbitration proceeding.  Questions of whether a claim is subject to arbitration under this agreement) shall be decided by the arbitrator.  Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator.  The arbitrator shall:  (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; (b) issue a written arbitration decision, to include the arbitrator&#x2019;s essential findings and conclusions and a statement of the award; and (c) be authorized to award any or all remedies that you or the Company would be entitled to seek in a court of law.  The Company shall pay for JAMS&#x2019; arbitration fees.  Each party is responsible for its own attorneys&#x2019; fees.  Notwithstanding the preceding, the arbitrator is authorized to allocate attorneys&#x2019; fees and expenses and interest to either party considering in part whether the actions or lack of action by either party caused delay or additional costs. Nothing in this letter agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.  Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To indicate your acceptance of the Company&#x2019;s offer, please sign and date this letter in the space provided below and the CIIA.  A duplicate original is enclosed for your records.  This letter, along with the CIIA and any other agreements relating to proprietary rights between you and the Company, set forth the terms of your employment with the Company and supersede any prior representations or agreements, including, but not limited to, any representations made during your interviews or negotiations, whether written or oral.  This letter, including, but not limited to, the at-will employment provision set forth herein, may not be modified or amended except by a written agreement signed by the Chief Executive Officer of the Company and you.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;text-indent:11.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Sincerely,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">							  <br><br>                                                                                        /s/ Mai-Britt Zocca</font></p>
  <table style="margin-left:47.454%;border-spacing:0;table-layout:fixed;width:36.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mai-Britt Zocca, CEO</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">									</font></p>
  <p style="margin-left:13.6%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">                                                            Acknowledged and accepted:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">                                                                                       /s/ Amy Sullivan</font></p>
  <table style="margin-left:47.454%;border-spacing:0;table-layout:fixed;width:36.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amy Sullivan</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">                                                                                      Date: October 3, 2022</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Enclosures</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee Confidential Information and Inventions Assignment Agreement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>iobt-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:30pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.5277777777777778in;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-3 No. 333-269569) of IO Biotech, Inc.,</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-262587) pertaining to the 2021 Equity and Incentive Plan and 2021 Employee Stock Purchase Plan of IO Biotech, Inc., </font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-269597) pertaining to the IO Biotech, Inc. 2021 Equity and Incentive Plan, and </font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration statement (Form S-3 No. 333-274267) of IO Biotech, Inc.;</font></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of our report dated March 5, 2024, with respect to the consolidated financial statements of IO Biotech, Inc. included in this Annual Report (Form 10-K) of IO Biotech, Inc. for the year ended December 31, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">/s/ EY Godkendt Revisionspartnerselskab</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Copenhagen, Denmark</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">March 5, 2024</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>iobt-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Mai-Britt Zocca, certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of IO Biotech, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:4.08%;"></td>
    <td style="width:4.08%;"></td>
    <td style="width:41.84%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:  March 5, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Mai-Britt Zocca</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Mai-Britt Zocca, Ph.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer and Director</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>iobt-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Amy Sullivan, certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of IO Biotech, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:4.08%;"></td>
    <td style="width:4.08%;"></td>
    <td style="width:41.84%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 5, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Amy Sullivan, M.B.A.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amy Sullivan, M.B.A.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>iobt-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report of IO Biotech, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ending December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:3.04%;"></td>
    <td style="width:46.46%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:  March 5, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Mai-Britt Zocca</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Mai-Britt Zocca, Ph.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer and Director</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>iobt-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report of IO Biotech, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ending December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:3.04%;"></td>
    <td style="width:46.46%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:  March 5, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Amy Sullivan, M.B.A.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amy Sullivan, M.B.A.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>9
<FILENAME>iobt-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IO BIOTECH, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Introduction</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of the Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of IO Biotech, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has adopted this Policy on Recoupment of Incentive Compensation (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), which provides for the recoupment of compensation in certain circumstances in the event of a restatement of financial results by the Company.  This Policy shall be interpreted to comply with the requirements of U.S. Securities and Exchange Commission (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) rules and Nasdaq Stock Market (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nasdaq</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) listing standards implementing Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dodd-Frank Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and, to the extent this Policy is in any manner deemed inconsistent with such rules, this Policy shall be treated as retroactively amended to be compliant with such rules.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administration</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be administered by the Compensation Committee.  Any determinations made by the Compensation Committee shall be final and binding on all affected individuals.  The Compensation Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy, in all cases consistent with the Dodd-Frank Act.  The Board or Compensation Committee may amend this Policy from time to time in its discretion.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Covered Executives</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy applies to any current or former &#x201c;executive officer,&#x201d; within the meaning of Rule 10D-1 under the Securities Exchange Act of 1934, as amended, of the Company or a subsidiary of the Company (each such individual, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  This Policy shall be binding and enforceable against all Executives and their beneficiaries, executors, administrators, and other legal representatives.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recoupment Upon Financial Restatement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Financial Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the Compensation Committee shall cause the Company to recoup from each Executive, as promptly as reasonably possible, any erroneously awarded Incentive-Based Compensation, as defined below.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No-Fault Recovery</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recoupment under this Policy shall be required regardless of whether the Executive or any other person was at fault or responsible for accounting errors that contributed to the need for the Financial Restatement or engaged in any misconduct.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compensation Subject to Recovery; Enforcement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy applies to all compensation granted, earned or vested based wholly or in part upon the attainment of any financial reporting measure determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, and any measure that is derived wholly or in part from such</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">measures, whether or not presented within the Company&#x2019;s financial statements or included in a filing with the SEC, including stock price and total shareholder return (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">TSR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), including but not limited to performance-based cash, stock, options or other equity-based awards paid or granted to the Executive (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Compensation that is granted, vests or is earned based solely upon the occurrence of non-financial events, such as base salary, restricted stock or options with time-based vesting, or a bonus awarded solely at the discretion of the Board or Compensation Committee and not based on the attainment of any financial measure, is not subject to this Policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event of a Financial Restatement, the amount to be recovered will be the excess of (i) the Incentive-Based Compensation received by the Executive during the Recovery Period (as defined below) based on the erroneous data and calculated without regard to any taxes paid or withheld, over (ii) the Incentive-Based Compensation that would have been received by the Executive had it been calculated based on the restated financial information, as determined by the Compensation Committee. For purposes of this Policy, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recovery Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the three completed fiscal years immediately preceding the date on which the Company is required to prepare the Financial Restatement, as determined in accordance with the last sentence of this paragraph, or any transition period that results from a change in the Company&#x2019;s fiscal year (as set forth in Section 5608(b)(i)(D) of the Nasdaq Listing Rules).  The date on which the Company is required to prepare a Financial Restatement is the earlier to occur of (A) the date the Board or a Board committee (or authorized officers of the Company if Board action is not required) concludes, or reasonably should have concluded, that the Company is required to prepare a Financial Restatement or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare a Financial Restatement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For Incentive-Based Compensation based on stock price or TSR, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Financial Restatement, then the Compensation Committee shall determine the amount to be recovered based on a reasonable estimate of the effect of the Financial Restatement on the stock price or TSR upon which the Incentive-Based Compensation was received and the Company shall document the determination of that estimate and provide it to Nasdaq.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation is considered to have been received by an Executive in the fiscal year during which the applicable financial reporting measure was attained or purportedly attained, even if the payment or grant of such Incentive-Based Compensation occurs after the end of that period.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company may use any legal or equitable remedies that are available to the Company to recoup any erroneously awarded Incentive-Based Compensation, including but not limited to by collecting from the Executive cash payments or shares of Company common stock from or by forfeiting any amounts that the Company owes to the Executive.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">    </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Indemnification</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company shall not indemnify any Executive or pay or reimburse the premium for any insurance policy to cover any losses incurred by such Executive under this Policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exceptions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The compensation recouped under this Policy shall not include Incentive-Based Compensation received by an Executive (i) prior to beginning service as an Executive or (ii) if he or she did not serve as an Executive at any time during the performance period applicable to the Incentive-Based Compensation in question.  The Compensation Committee (or a majority of independent directors serving on the Board) may determine not to seek recovery from an Executive in whole or part to the extent it determines in its sole discretion that such recovery would be impracticable because (A) the direct expense paid to a third party to assist in enforcing recovery would exceed the recoverable amount (after having made a reasonable attempt to recover the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">erroneously awarded Incentive-Based Compensation and providing corresponding documentation of such attempt to Nasdaq), (B) recovery would violate the home country law that was adopted prior to November 28, 2022, as determined by an opinion of counsel licensed in the applicable jurisdiction that is acceptable to and provided to Nasdaq, or (C) recovery would likely cause the Company&#x2019;s 401(k) plan or any other tax-qualified retirement plan to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Other Remedies Not Precluded</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The exercise by the Compensation Committee of any rights pursuant to this Policy shall be without prejudice to any other rights or remedies that the Company, the Board or the Compensation Committee may have with respect to any Executive subject to this Policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date and Applicability</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy has been adopted by the Compensation Committee on September 20, 2023, and shall apply to any Incentive-Based Compensation that is received by an Executive on or after October 2, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img62367891_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62367891_0.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI8VAA96P@
M4F%I8FQE    !9 #  (    4   0J) $  (    4   0O)*1  (    #.#$
M )*2  (    #.#$  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,3$@,C$Z,#DZ,C$ ,C R,SHP
M,SHQ,2 R,3HP.3HR,0   $T :0!C &@ 80!E &P ( !2 &$ :0!B &P 90
M /_A"R%H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B
M96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X
M;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y
M;G1A>"UN<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A
M9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,]
M(FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D
M,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#(S+3 S+3$Q5#(Q.C Y
M.C(Q+C@P-3PO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ
M,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN
M;W)G+V1C+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^/')D9CIL:3Y-:6-H865L(%)A:6)L93PO<F1F.FQI/CPO<F1F
M.E-E<3X-"@D)"3PO9&,Z8W)E871O<CX\+W)D9CI$97-C<FEP=&EO;CX\+W)D
M9CI21$8^/"]X.GAM<&UE=&$^#0H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(#P_
M>'!A8VME="!E;F0])W<G/S[_VP!#  <%!08%! <&!08(!P<("A$+"@D)"A4/
M$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_VP!#
M 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" !R $@# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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+] >3^9HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img134051827_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_0.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0+X17AI9@  34T *@    @ ! $[  (
M   /   !2H=I  0    !   !6IR=  $    >   "TNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M36EC:&%E;"!286EB;&4    %D ,  @   !0   *HD 0  @   !0   *\DI$
M @    ,Q-@  DI(  @    ,Q-@  ZAP !P   0P   &<     !SJ     0
M
M
M
M
M
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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M=^_9N&<;L#/UP*U:\8\&_$'7++X:Z/\ V!X'O]8L-/L(TN;TW"6ZDJOS^4C
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MQXX7C/J*YV_^*.NZ&JZAXC\ :CIV@EP'O_M<<LD*DX#/"O*CGUH Z7Q5XO\
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M)Q<I;012=T\QP06'<5T*:QKS>$6U&3PO*NKCII OH2Q^8#_6YV8Q\WT&.O%
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M&NOV-_"L]M<WK12QN,AE,2@BO9M-T+2=&M9+;2-+LK""4[I(K6W2)7.,9(4
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MT  X ]J0SR#3?^3N=6_[ Z_^@Q5[)7C>F_\ )W.K?]@=?_08J]DH \K\>_\
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M1+&BDG)PJ@#K6#XHUSQ7I5Y$GAKP>FOV[1@O+_:L=JR/DY7:Z\C !SGOTXH
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M(W'?\17;S_%7P7>_#F:YAUNRB>6Q:-;$2#SU<I@1B+[W7CICWKT8 *H"C '
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M&.Y[4W2_#^C:&'&BZ38Z<)/O_9+9(MWUV@9I 3ZC_P @NZ_ZXO\ ^@FO O\
MFR;_ #_T$:^A6574JX#*PP01D$5G_P#"/:-_8G]C?V18?V7_ ,^/V9/(^]N_
MU>-OWOFZ=>: ,;QA_P D>UW_ + -Q_Z3M1\+_P#DE7AK_L'0_P#H(KI9K6WN
M+.2TN((I;:2,Q/"Z!D=",%2IX((XQ1:VMO8VD5K9016]O"H2.&% B(HZ  <
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M #D5YHFMV'@GX\^(YO%,BV%KX@M;5]/OI^(CY481T+]%.>>?0>HSZPJJBA4
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MZ;8WMS;7%Y96]Q/:,7MY98E9H6/4H2,J?<47VFV.J0I%J=E;WD<<@E1+B)9
MKCHP!!P1ZT <1X[TSP==:_;7VJ^+$\,Z_:P;(KF#4H[>8Q$DA65S\R9SV]:K
M_"3Q-JFNS^(K&^U4:[8:7=)%8ZN(A']I#*2RG'!*X7GON^E=KJ?AK0M;D636
M=%T[4'485KNT24@>Q8&KMK:6UC;);65O%;01C"10H$51[ <"@":BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!JR*[NJG)
M0X88Z'&?Y&G56MO^/N\_ZZ+_ .@+5F@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 0L P7G)Z<<?G2U&X_TF,X_A;G'T]OZ_G4E !1110 4444 %%%%
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MFH8B&YY(7._<&)&X\-SBNPTO1K#1ENAIT!B^V7+W=P2[.9)7QN8EB3V QT
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M.<2>N<?*/<_T^G<RU%$<R3<YP_KT^4>Y_I].Y ):*** "BBB@ HHHH ****
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M4_[Z% #Z*9Y\7_/5/^^A1Y\7_/5/^^A0 ^BF>?%_SU3_ +Z%'GQ?\]4_[Z%
M#Z*9Y\7_ #U3_OH4>?%_SU3_ +Z% #Z*9Y\7_/5/^^A1Y\7_ #U3_OH4 /HI
MGGQ?\]4_[Z%'GQ?\]4_[Z% #Z*9Y\7_/5/\ OH4>?%_SU3_OH4 /HIGGQ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6F8U>AMVW_("/_7-_P"M8M;5M_R 3_US?^M8M..[)GL@HHHJR HHHH ****
M"BBB@ HHHH **** "K6F?\A&+\?Y&JM6M,_Y",7X_P C2>PX[HZ"BBBN<Z@H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *UM
M_P ?=Y_UT7_T!:LU6MO^/N\_ZZ+_ .@+5F@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH C?_ (^8_P#=;^E25&X_TF,X_A;M]/:I* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ J*+_ %DW^_\ ^RBI:BB&))N.K^G^R/;_ !H
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M\81RNI63[5CS V%&1QQC'OF@#"MOC'826MU-<6MNVRP6^MX[*_6X9@SA!%*
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M_(TGL..Z.@HHHKG.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_%?_ $,^L_\ @PE_^*K=^,W_ "5S6O\ MA_Z(CKAJW6QQ2;YF;G_  F_BO\
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MUG_P82__ !58=%%@NS<_X3?Q7_T,^L_^#"7_ .*H_P"$W\5_]#/K/_@PE_\
MBJPZ*+!=FY_PF_BO_H9]9_\ !A+_ /%4?\)OXK_Z&?6?_!A+_P#%5AT46"[-
MS_A-_%?_ $,^L_\ @PE_^*H_X3?Q7_T,^L_^#"7_ .*K#HHL%V;G_";^*_\
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M7_T,^L_^#"7_ .*K#HHL%V;G_";^*_\ H9]9_P#!A+_\51_PF_BO_H9]9_\
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M-I3^4UO^\SN )C\P+EB<!\9]N*J_\(%:/X8G\/3ZIJ4^ENB1P02M$?LJHP9
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M'& P'!]JS[;XBWUKH:BPT*34$L-"M=4N)KG4@'\MXBS MLR\GRYS@!OF)V\
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MWR!-CM$XD!C# #Y6WX(X/- $5O\ $73)TAFDLM0M[6[AFFL;F:) EXL0+'8
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M5:M:9_R$8OQ_D:3V''='04445SG4%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!6MO\ C[O/^NB_^@+5FJUM_P ?=Y_UT7_T
M!:LT %%%% !1110 4444 %%%% !1110 4444 %%%% $;G_28QG^%N,]>GO\
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M\ORO*\S.W;S]_=NYSCY:GT[PHUEJEKJ,U]Y]S')<S7!$.Q97FV?=&X[54(
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M_ORW^% %FBJWVY/^>-Q_WY;_  H^W)_SQN/^_+?X4 6:*K?;D_YXW'_?EO\
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MZ=I+B$PKLF9CEF88PQ/<GK18+G&0V3:9\2+O2?![6VFP2Z3YUU%'!N@MY_,
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MQ_E0!J4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&T(BV*I 0M 3CG^(DU>TKP5;Z5J-E<1:KJ4UOIR21V-E,\?DVT;C&Q<('8
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MJO\ PT+XK_Z!^C?]^)?_ (Y1_P -"^*_^@?HW_?B7_XY7E5%'*@]I+N>J_\
M#0OBO_H'Z-_WXE_^.4?\-"^*_P#H'Z-_WXE_^.5Y511RH/:2[GJO_#0OBO\
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M'Z-_WXE_^.5Y511RH/:2[GJO_#0OBO\ Z!^C?]^)?_CE'_#0OBO_ *!^C?\
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M92C8Z*<^;1[G0T445)J%%%% !4</67_?/\A4E10GF7_?/\A0!+1110 4444
M%%%% !1110 4444 %%%% !1110 5A+]T5NUQ/BS4+G3/!VH7UA+Y=Q##NC?
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ME%R)(IX);<N51<91PI.,\'%6-=U+4].O]-^RI:?8Y[J*WE,@9I&WD@[0,!<
M Y.[.<8&,EBL;E%%% !1110 5:TS_D(Q?C_(U5JUIG_(1B_'^1I/8<=T,\5>
M.--\(7VC6FIP7LLFL70M;<VL'F!6)49;D<?,.!DGG .*Z.BBN<Z@HHHH PK?
M4;J3XA:CICRYLX=+M;B./:/ED>6X5CG&>1&@QG''N:@F\7>3;ZU+]BS_ &7J
M<.GX\W_6^8L!W_=XQY_3G.WKSQ+J/A=[SQ!)K%EKNI:7<RVL=K(+1;=E=$=V
M7(EB?!S*W0CM45SX+MKO4GNI-3U$0SS0W%W9J\8BNIH@H21_DW _NX\A&53L
M&1UR 4[3QM>SWL;SZ/%#ICZI<:9]I%X6E\R)Y5#^7Y>-A\K^]D$]"!DRZ/XN
MO]3O=*,^CQ6VGZS$\]E.+PO+Y87>IDC\L!"RE3@,V.<GCG0B\*6$-M% ))V2
M+4I=3&YE.9)'=V4\?=S(V!UQCFN;\.^'M2@\4:>ZV^KV>D:5%,EO;ZG/:LL8
M<!4CA$&YBH QF5B0 H&<G !-XCU[5S8>(KC2;[["NGW-MI]NWD+)^]=HC)*0
MWW@!*% R/NL>X(EB\5:E>W6EVJ1QVVJ"2X@U"Q)!59DA+H-Q&=C':RL,94CW
M%:-SX4%U=ZM#+)MT[5)8;N01MMDCN(R@XR""K+%'GI@ANN[(LWGA:PN_$UMK
MZM-;ZA;PO")(6 $@((!=2"&*[FVGMN/4'% ',Z;XFDTG2;_4=<U;6;C4;/3)
MKN?2;^QCM4+1J&D\EA"OF!2-N5DD4!P23D&M*\M?$&D^&=2U>_\ $ES->PV$
M\QMHK:!+:.01L1L!C,F%.,;G;..<]*OVWA-/MIN=8U6_UMQ ]NB7ZPA(T?&\
M!8HT!W  9;/ P,9.8H_!Q2QGT]O$.L2Z9-!);BRE:!UCC=2N!(8O-.T'@LY/
M SF@"75-;NM.\$Q:C$J37DL=O''Y@^0RS,D:LP&/E#."0,< XQ5:[TW7M*T.
M\O8_$MYJ%[#!YR0W$%LD+NGS% $B#*K8*\LQ ;.21FK%KX4V:=-I^J:SJ.KV
M,L'D?9[M8$" 8PRM#$CAAC@[N.HY -07'AK5TTBZL[7Q+J%Y]IA^S#[?Y&+=
M&(#2*R0AFD5<XW,03U]: .@L;M+_ $ZVO(<B.XB65,^C $?SJ>HK:WCM+2&V
M@7;%"BQHOHH& *EH **** "BBB@ HHHH **** /E7XS?\E<UK_MA_P"B(ZX:
MO3?BQX8U_4_BEK%SINAZE>6[&$++;VDDB'$$8/(&*X[_ (0CQ7_T+&L_^"^7
M_P")K=;'%)/F9AT5N?\ "$>*_P#H6-9_\%\O_P 31_PA'BO_ *%C6?\ P7R_
M_$T[DV9AT5N?\(1XK_Z%C6?_  7R_P#Q-'_"$>*_^A8UG_P7R_\ Q-%PLS#H
MK<_X0CQ7_P!"QK/_ (+Y?_B:/^$(\5_]"QK/_@OE_P#B:+A9F'16Y_PA'BO_
M *%C6?\ P7R__$T?\(1XK_Z%C6?_  7R_P#Q-%PLS#HK<_X0CQ7_ -"QK/\
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M_P!"QK/_ (+Y?_B:/^$(\5_]"QK/_@OE_P#B:+A9F'16Y_PA'BO_ *%C6?\
MP7R__$T?\(1XK_Z%C6?_  7R_P#Q-%PLS&AADN)DA@C:221@J(@R6)Z "OIW
MX3_#H^"]*>\U$[M6O4'G*#\L*=0GH3ZG\!ZG*^$7PM'A^"/7O$$/_$TE7,$#
MK_QZJ>Y']\_IT]:]8K*4KZ(Z*=.VK"BBBH-PHHHH *CA.3+SG#GO[#W/]*DJ
M.$Y,G.?G/?/I[G^GTH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y;
M5=,AUO1;C3[IY%AN4V.T3#=CV)R/YUU-<SJ%VUEI4]V&M\PQF3==7'E1#'.6
MD^;:/?G\::$RC)X9LY8=1C:6?&HWL=[+AA\KH(@ O'3]RO7)Y//3%9/!UO'J
M44\>I:@MK!>->Q:>&C\A)6W;B/DWX)=CM+8RW &!C,M?B ]]:QBPL;*]NWU(
M:>/LFI"6W+-"90XF"9*X&"-N1S@' S;B\6:A=-!8VNDP-J[RW"20/>%8(UA9
M0S^:(R2#YD>!L!^;G&*8BP/!\$ MFTS4]0TZXMXF@^T0&)FDC9]^UA(C*<,2
M0=H(R>>3E4\'VZ:NEZNI7_DQWK7R668O)69@P9L[-YSO8X+$9/3@8HZ??:S-
M\-?M5D)9-38R?>(ED4>>0VW<<,RIG:#P2 .G%1QZ[)!I$RZ9K%[J6H2W4%LB
MZQ9B!K8R-@.T0BB8KC<1D?,5P".< &K9^%+:T:U'VV\GAL[Q[JV@E,>V$NDJ
M% 0@8KB9OO$G@<]08;?P390*D3WU]/:V\,D-E:RNFRS5U*$)A QPI*C>6P.*
M9?#5?#^F QZU<ZI>7D\-K"U_#"(X6=PI?$2(2 "3@GG &1DFJ^N2:GX6T2.]
MDU[4-19KZSBD\VVA8A&N$60(D408EE8C'S'ICF@#<M="MK2[L;B-Y2]C9-91
MAB,%"8R2>.O[M?0<GBJ<'A46.HW=SI>LZC817<[7,MI%Y+1&1A\S#?&S#)Y(
M# 9R<<USGB7QO<K)??V)+>VJV^@7MY_I6FR0D31M"$8>=&-V S<#(YY[5IQ>
M(K_SM-TV\=(=4AU%+74$1!MFC:*5DD7.<*^P$8Z$,N<J: *\GPWL-/L[BXT:
M:]&IO:W$<TQE0MJ+2 G]^2N&.XY!&W'TJ'1/AO;S>%;&V\2SWUS<C1UL##++
M'BR#(OF+&449.5 RQ;A0 <==W5?$-];ZE<V>CZ7'?FQMUN+LRW7D[0V[:D8V
M-O<A&.#M ^7GGC.F\=3LMU=Z=I4=QIME#!<3W$MWY;M%*@<%$"-N8*22"5'3
M!.3@ &^&VGS//)>ZIJ=U+-]F#22-"I MWWQ@!(P ,\'CD>_-:<GA95U74M1T
M_5]0T^YU)XGG: 0L/W:; H$D;  CD]\CJ!Q46OZEK5IXDT6UTF"TEM[IY!,)
M[DQEL(3CB-L8QG(/)XZ<U GBV]DTS4M1-EIMG9V5U-:K/J&J>0CM'.8BQ(C8
M*IP,9YW';C&&(!!;_"_P[;V_V<+<O;_V6-+,3RY!C$AEWYQG?O8G(./0"I+C
MX>6%_;7::KJ6I7]Q=)!$UW.\?FI'%()%1=J!0"RY/RY.>O3#;'QO-K%O9)HN
MGVUW?73W *_;O]&5(&57D$RHQ927CVX3)W<@8-16WB2[B\8:KH\,/VW4GFAD
M6U-R1%:Q>3'O<N5.%W,0 %RS'H/F( .AM-"MK/7]3U>&2;[1J4<*2JQ!51$&
M"E1C/\9SDGM6>_@V&XBNSJ&JZA>75RD2"[D\E9(A%)YD>T)&J<.=W*G/0Y'%
M='10!AOX4M+BSU2WOKFZN_[5MEMKJ20HK,H0KD;% !(8]!C/:JY\&Q2Q7_VW
M5]2NY[Y8 US*85>,PN7C*!(U4$,V>5(..1USTE% &&OAJ2*^%W;:YJ4$T@C^
MU%! 1=%!@,X:(@$C@[-O 'H*PI] OY?$T4>GV^J6NG)J8OI1/-;?9"02S-&%
MW3;F;G:VU<LQXX![FB@# \.:)]@U#6=2FMOLT^I79;R]X;;$F0G0D#<2\F!W
ME.><U,/#-F-4BO\ S9_-COWOP-PV^8T!@(Z?=VG/KGOCBMFB@#.@TA;2PNK:
MRNKBW:YFEG\]=A>-Y&+';N4KP3QD'\:QHO J0Z=;6L>OZL#:7K7MO-BVWQR,
M) ^/W.T@^<YP0<<8QC%=510!D7.@"_\ #-YHNIZE>7L=Y$\,EQ((EE"L,'&Q
M%7C/'R_G2ZEX<L=3UK3=5G\Q+O3G+1/$V-X*D;7&/F7G([@]#R<ZU% &);^&
MV74H+S4M8U#5#;%F@BNA J1.RE2P$<:9.UF7YB1AC3;'PQ_9K)%8ZSJ46GQY
M$>G$PO"BXQL#-&9 H[#?QP!@ "MVB@#GM*\)+INF)I<VL:AJ.EI:?8Q8W:6Y
MC,6W: 2D2L?EXY;ZYJUIFASZ9.N-=U.ZMD4JEK=&%U4=AO\ +$C8]6<GU)K7
MHH *GL_^/M/Q_E4%3V?_ !]I^/\ *@#4HHHJ2@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KSK->BUYQFMJ?4PJ]#L=*_Y%=?^N<G\VK+
MK3TG_D5E_P"N<G\VK,IQW8I;(RKWPWI=_P#:/M$$@:XG2XD>*XDB;S$4*K!E
M8%2 H'&*DL= TW3X;B."W\S[4,7#W,C3O,,8 =Y"S, "0 20 :T:*H@Q[/PQ
MIFFW"7-G!*\T*E;<7-W+*D.1C$8=F$8QQ\H'''3BGVVC>=X432-=D:^,MMY-
MXYD;]Z6'SX.=P!)..>!BM6B@"MJ&GVVJZ?-8WT9DMYUV2('*Y'U!!'X&JNG>
M'].TNZ:YMHYI+ED\OS[JYEN) F<[0\C,0N0#@$ D UIT4 9VJ:%8ZP\#WHN!
M);EC%);W4L#+N&#\T;*><55N_"6EWT-M%=-J,BVIS$?[4N00V20Q(DRS G@G
M)'0<5MT4 (BA$51DA1@9))_,]:6BB@ HHHH *M:9_P A&+\?Y&JM6M,_Y",7
MX_R-)[#CNAGBKQQIOA"^T:TU."]EDUBZ%K;FU@\P*Q*C+<CCYAP,D\X!Q71T
M45SG4%%%% ')7OBS^ROB#>:;??;I;,:7;3Q16>FS7.V1I9U=B8HV(R$0?-QQ
MQWK A^*)L],5KF2RDN;B\U!HSJUVNFJMO#<NB)\R;C)C: I4'Y6+$'KWT>D0
M1>(;C65>3[1<6L5JZDC8$C>1E(&,YS*V>>P_''_X0BW@D$^F:KJ.G70GN93<
MV[1,S">4RNA62-D*[SQ\NX8Z\G(!GZC\1[6Q;2KA#I;V6IPVT\44NIB*^9)F
M"ADMRF' SD_..C8R1@LUCQ)JE[/;G3[,0:9'KD%BUX+PK-(RSJD@\H)CRR0R
MYWY./NX.:TK_ ,#PZA=RS2:SJ<:W @-W#&80MTT)!5V)BW \#(0JIQTZY=+X
M)MI-2^T)JFHPVOVY=0.GQM%Y!G#!BW*%\%ADKNQDDX!H Q/B+XEO]&U.QMK"
M_OK99H'R;""%_)D+*L<EPTRE8X,DC=P2<XS@XZ2ZUHOX5U:YL[A&O-/@F25X
MXSL2=(\G;N'(!QZCMZTW6_"L>L7K7<.J7VFS2VQM+@V@A87$620K++&XX+/@
M@ _.<YXPND^$=/T7PK<>';&2X7391*L<;,I,"29W*K8R1EF.6W')Y)H YRP\
M6ZJ=#T^TU*98]96\L4FD$:@7EM+(H$RKR!N!*L!]U@<8&TF73_BIIEYK+VSF
MQ6W(N/*\G4%ENAY(9F,L &8P51B/F)X&0I.!NWW@[2]0_L9I_.671I(WMID<
M!V";3L?CYE)121ZJ",8HL?"L=@\L,6J7TFER>8/[+E$+0*)"2P#>7YF,L< O
M@9QT % &#K7BK4+7PU9:YKT$.A6'VVUEWQWS2R>2S982@(H4XQ\JLX))&>!G
M;F\27EKX-O\ 7KW2S:F*-Y;:U:7?)(F/DW@ !&8]5!;''.<@,@\&0QV$5A=Z
MMJ.H65O+$\%O=F%A$(SPFX1AG4C .\L2!USDF9/"-G'X3O/#JW%RVGSQO%"D
MKAC:QL,!(S@':O5=Q)'3.   #$UBYUG3K^WBUC6]6LK!+)&-_I6FQSB6?<WF
M^;F&3RD5=A7Y5&"V6)'%_P _4O$.N75GINN3:?I^GPPYN;2.&26ZDD7?NW.C
MH$"XZ+DENH P;5QH.JZK9Q+J'B&^L7: 17,&G"#RI3R&8,\)D7<#V88[<C)6
MX\(VXGAGT;4+[1)H[=+4M8F,B2)/N*R2HZG;V;&X D9P<4 5,:OJVN7.E6^N
M75A:Z5#"DMS## UQ=S,NXLQ>-HU4+CA4&6;@J!@UXO%1TCQ9J6DZK-J=]%;6
MMJ87@TN6X8L0^]G,$1 +%0<' ZX %:=SX5,MS'>6NMZG8Z@(%@GO+?R=UTJ]
M#(C1M'N!)PRH",D# XJYINB1Z=J%S?&ZN+JZNH88II)]@W^4& ;"*H!.XYP,
M>@% ' 6'C;7C+I6HM(]YIXM+NYO[7[*%E:);KRQ(H #!HU()3'S ,,;L5N2>
M)+]9M5U&WO4N-/L-:MH!&H0K):S6UL258#)(:8R YY&1TQC:TCPG8Z->07-K
M+<.\,$T"B1E(*RS>:Q. .=W ]O7K6;'X#MM/MGT[1V,.FWNJ+J-['))DJ$$>
MV&(8X0F)!@GA<@<$  '74444 %%%% %:V_X^[S_KHO\ Z M6:K6W_'W>?]=%
M_P#0%JS0 4444 %%%% !1110 4444 %%%% !1110 4444 1N?])C&?X6XS]/
M>I*C?_CYC_W6_I4E !1110 4444 %%%% !1110 4444 %%%% !1110 5%$<R
M3<Y^?UZ?*/?_  J6HHO]9-_O_P#LHH EHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *CA.3)SGYSW]A[U)4</63_?/]* )**** "BBB@ HHHH **** "B
MBB@ HHHH **** "N6U;2X=;TB6QN9)$27:?,B(W*RL&5AG(R" ><CUS74UAK
M]T4T)G/VWA"WANDNKG4;Z]N1>K?--.8P7=83" 0B*H7:>@ Y&?7+I_"5N]P+
MFTO[VQO%N)9UN8#&77S0-Z8=&4J=JG!!.5'-;]%,1E6>A#3O#J:38:A>0;,[
M;O,;S EBQ/S(5).2.5[^O-5D\(VDEO>+J=W>:E/>>6'NIW5)4$9+1A#$J!-K
M%F! !R2<UO44 88\,^?8S6FKZQJ.J0R;2HN/)C:%E.Y71H8T8," 0<\$#%-/
MAAYX%AU+7=3U"..X@N$$ZVZ[7BD61>8XE)!*@'.>.F#S6]10!BZYX6LO$#2M
M>2W"&73Y]/;RF48CF*%CR#\P\L8/3KP:DU+PY8ZGK6FZK/YB7>G.6B>)L;P5
M(VN,?,O.1W!Z'DYUJ* ,35?#$6IWLEU%J%]I\D\'V>Z^R,@%S&"<*VY6((W-
MAEVM\QYZ81_"6G-9ZE:QF:*'488X72-@!&B)L4)D<<#OFMRB@#-U;1EU22SF
M6\N;*XLY3)%-;;"W*E64AU92"#Z9]"*IR^$[5M+-G#=W=NPOY-0CN(RADBE>
M1I#C<I4C+L,%3Q[\UO44 <VG@N"&*%K?5M2BOH9IIAJ"M$929<&12#&8RI(4
MXV<%1C&*DF\(6<UV;TW=VNH><DZ7J,@D1EC6-@/EV[75?F4@@YR "%QT%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %3V?\ Q]I^/\J@J>S_
M ./M/Q_E0!J4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5YKFO2J\SS6U/J85NAVFD?\BJO_ %SD_FU9M:6C_P#(J+_USD_FU9M.
M.[%+9!1115$!1110 4444 %%%% !1110 4444 %6M,_Y",7X_P C56K6F?\
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M..Z.AHJM]L/_ #ZW'_? _P :/MA_Y];C_O@?XUSG46:*K?;#_P ^MQ_WP/\
M&C[8?^?6X_[X'^- %FBJWVP_\^MQ_P!\#_&C[8?^?6X_[X'^- %FBJWVP_\
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MXT %M_Q]WG_71?\ T!:LUG6]V1=71^S3G,@X"CCY%]ZL?;#_ ,^MQ_WP/\:
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M%/\ KG)_Z$U9]7]#_P"103_KG)_Z$U4*<=V*6R"BBBJ("BBB@ HHHH ****
M"BBB@ HHHH *M:9_R$8OQ_D:JU:TS_D(Q?C_ "-)[#CNCH****YSJ"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K6W_ !]W
MG_71?_0%JS5:V_X^[S_KHO\ Z M6: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@"-Q_I,9Q_"W;Z>W]:DJ)_^/F/_=;^E2T %%%% !1110 4444 %%%%
M !1110 4444 %%%% !44(Q)/QUD]/]D>W^/]*EJ*'_63_P#73_V44 2T444
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M;Q7,YOKJSDAFM+FTDDM-.$%U<+.1EYI][&1QC@[1R22.>&^(]$UF&RN9]6U
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M"_Z#W_DG/_\ $468<T>YVK_\?,?^ZW]*DK@V^,G@,SHPUW@ Y_T.?V_V*?\
M\+F\!?\ 0>_\DY__ (BBS#FCW.YHKAO^%S> O^@]_P"2<_\ \11_PN;P%_T'
MO_).?_XBBS#FCW.YHKAO^%S> O\ H/?^2<__ ,11_P +F\!?]![_ ,DY_P#X
MBBS#FCW.YHKAO^%S> O^@]_Y)S__ !%'_"YO 7_0>_\ ).?_ .(HLPYH]SN:
M*X;_ (7-X"_Z#W_DG/\ _$4?\+F\!?\ 0>_\DY__ (BBS#FCW.YHKAO^%S>
MO^@]_P"2<_\ \11_PN;P%_T'O_).?_XBBS#FCW.YHKAO^%S> O\ H/?^2<__
M ,11_P +F\!?]![_ ,DY_P#XBBS#FCW.YHKAO^%S> O^@]_Y)S__ !%'_"YO
M 7_0>_\ ).?_ .(HLPYH]SN:BA_UD_\ UT_]E%<7_P +F\!?]![_ ,DY_P#X
MBF1_&3P&'E)UWAGR/]#GZ8'^Q19AS1[G>45PW_"YO 7_ $'O_).?_P"(I\7Q
MB\!S3)&FOJ&=@H+VLRC)]24P![GBBS#FCW.VHI%8,H92"I&00>M+2*"BBB@
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M6 ()4<L<$<*>16?%XPC_ .$?TV\>QN+F_OI#;+I]H%,AG3<)4!=E4!#&^2S
M?+CJ0#9UOPQ:>(M3LI-92"]TZT61AI]Q;B2.29L!9&W9!VKO &/XR<UE#P'_
M &?<F;PU>V^EK%>"[L[<66Z" M%Y4J%%=<HPPV 5(;G)!(KG.HATKQG,+(W.
MJ+.@-UJ&8'MU\Q(X"Q"9#@ @#&?F#>O>M>[\86%G]C\R"Z9;JV2Z#(BD1QM)
M&FYOF[&52<9X!/:N>M_#\R:Y9:/>27%^Q^WW5_>)8O! !<?PJQRA.7("AF8
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M&>O"G_00UG_O_%_\;H_X9Z\*?]!#6?\ O_%_\;I\Z%[*1\XT5]'?\,]>%/\
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MM::I&HQ9![]O8TGL..Z-^BBBN<Z@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** *UM_Q]WG_71?\ T!:LU6MO^/N\_P"NB_\
MH"U9H **** "BBB@ HHHH **** "BBB@ HHHH **** (W'^DQG'\+=OI[5)4
M;C_28SC^%N<=.GM_4?C4E !1110 4444 %%%% !1110 4444 %%%% !1110
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M +_XT?V?!_TU_P"_[_XU9HH K?V?!_TU_P"_[_XT?V?!_P!-?^_[_P"-6:*
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M (^8_P#=;^E2T 5O[/@_Z:_]_P!_\:/[/@_Z:_\ ?]_\:LT4 5O[/@_Z:_\
M?]_\:/[/@_Z:_P#?]_\ &K-% %;^SX/^FO\ W_?_ !H_L^#_ *:_]_W_ ,:L
MT4 5O[/@_P"FO_?]_P#&C^SX/^FO_?\ ?_&K-% %;^SX/^FO_?\ ?_&C^SX/
M^FO_ '_?_&K-% %;^SX/^FO_ '_?_&C^SX/^FO\ W_?_ !JS10!6_L^#_IK_
M -_W_P :/[/@_P"FO_?]_P#&K-% %;^SX/\ IK_W_?\ QJ*+3X/,FXE'S_\
M/9^?E'O_ (_T%ZHH1^\G_P"NGI_LB@"/^SX/^FO_ '_?_&C^SX/^FO\ W_?_
M !JS10!6_L^#_IK_ -_W_P :/[/@_P"FO_?]_P#&K-% %;^SX/\ IK_W_?\
MQH_L^#_IK_W_ '_QJS10!6_L^#_IK_W_ '_QH_L^#_IK_P!_W_QJS10!6_L^
M#_IK_P!_W_QH_L^#_IK_ -_W_P :LT4 5O[/@_Z:_P#?]_\ &C^SX/\ IK_W
M_?\ QJS10!6_L^#_ *:_]_W_ ,:/[/@_Z:_]_P!_\:LT4 5O[/@_Z:_]_P!_
M\:BAT^#,G^M'SG_EL_M[BKU1P\&3_?/]* (O[/@_Z:_]_P!_\:/[/@_Z:_\
M?]_\:LT4 5O[/@_Z:_\ ?]_\:/[/@_Z:_P#?]_\ &K-% %;^SX/^FO\ W_?_
M !H_L^#_ *:_]_W_ ,:LT4 5O[/@_P"FO_?]_P#&C^SX/^FO_?\ ?_&K-% %
M;^SX/^FO_?\ ?_&C^SX/^FO_ '_?_&K-% %;^SX/^FO_ '_?_&C^SX/^FO\
MW_?_ !JS10!6_L^#_IK_ -_W_P :/[/@_P"FO_?]_P#&K-% %;^SX/\ IK_W
M_?\ QK%2TB" ?O!@=/,;_P"M_(5T=8:\**:$R+[+%_M_]_&_QH^RQ?[?_?QO
M\:FHIB(?LL7^W_W\;_&C[+%_M_\ ?QO\:FHH A^RQ?[?_?QO\:/LL7^W_P!_
M&_QJ:B@"'[+%_M_]_&_QH^RQ?[?_ '\;_&IJ* (?LL7^W_W\;_&C[+%_M_\
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M!V!P 67). ,C)K9KSCU3CH_A]%!9R6T&H/L>RM;4M)$&8M#.\S2'! )<R'@
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M** "BBB@ HHHH **** "BBB@ HHHH *XKQ5K%SH/A*_U2QM3=SVT#2(@*D9
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M<56\.^$M2O\ PKIL6M7BQ1V]K*MM;?8C')!))&T9:0ESNPKL  $Z\YH W/\
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M_P#MM'_#-_\ U-7_ )3O_MM>Y44<S#V<.QX;_P ,W_\ 4U?^4[_[;1_PS?\
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M_P \KC_OP_\ A0!9HJM]NC_YY7'_ 'X?_"C[='_SRN/^_#_X4 6:*K?;H_\
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M_P * +-%5OMT?_/*X_[\/_A1]NC_ .>5Q_WX?_"@"S15;[='_P \KC_OP_\
MA1]NC_YY7'_?A_\ "@"S15;[='_SRN/^_#_X4?;H_P#GE<?]^'_PH LT56^W
M1_\ /*X_[\/_ (4?;H_^>5Q_WX?_  H LT56^W1_\\KC_OP_^%'VZ/\ YY7'
M_?A_\* +-%5OMT?_ #RN/^_#_P"%'VZ/_GE<?]^'_P * )7_ ./F/_=;^E25
M2:]0SQGRKC@'_E@WM[5)]NC_ .>5Q_WX?_"@"S15;[='_P \KC_OP_\ A1]N
MC_YY7'_?A_\ "@"S15;[='_SRN/^_#_X4?;H_P#GE<?]^'_PH LT56^W1_\
M/*X_[\/_ (4?;H_^>5Q_WX?_  H LT56^W1_\\KC_OP_^%'VZ/\ YY7'_?A_
M\* +-%5OMT?_ #RN/^_#_P"%'VZ/_GE<?]^'_P * +-%5OMT?_/*X_[\/_A1
M]NC_ .>5Q_WX?_"@"S15;[='_P \KC_OP_\ A1]NC_YY7'_?A_\ "@"S447^
MLF_W_P#V45']NC_YY7'_ 'X?_"HXKU \O[JXY?/^H;^Z/:@"[15;[='_ ,\K
MC_OP_P#A1]NC_P">5Q_WX?\ PH LT56^W1_\\KC_ +\/_A1]NC_YY7'_ 'X?
M_"@"S15;[='_ ,\KC_OP_P#A1]NC_P">5Q_WX?\ PH LT56^W1_\\KC_ +\/
M_A1]NC_YY7'_ 'X?_"@"S15;[='_ ,\KC_OP_P#A1]NC_P">5Q_WX?\ PH L
MT56^W1_\\KC_ +\/_A1]NC_YY7'_ 'X?_"@"S15;[='_ ,\KC_OP_P#A1]NC
M_P">5Q_WX?\ PH LU'#UD_WS_(5%]NC_ .>5Q_WX?_"HXKU 9/W5QRY/^H;_
M  H NT56^W1_\\KC_OP_^%'VZ/\ YY7'_?A_\* +-%5OMT?_ #RN/^_#_P"%
M'VZ/_GE<?]^'_P * +-%5OMT?_/*X_[\/_A1]NC_ .>5Q_WX?_"@"S15;[='
M_P \KC_OP_\ A1]NC_YY7'_?A_\ "@"S15;[='_SRN/^_#_X4?;H_P#GE<?]
M^'_PH LT56^W1_\ /*X_[\/_ (4?;H_^>5Q_WX?_  H LT56^W1_\\KC_OP_
M^%'VZ/\ YY7'_?A_\* +-8:_=%:?VZ/_ )Y7'_?A_P#"L9;A0H&R7_OVW^%-
M"9/14/VE?[DO_?MO\*/M*_W)?^_;?X4Q$U%0_:5_N2_]^V_PH^TK_<E_[]M_
MA0!-14/VE?[DO_?MO\*/M*_W)?\ OVW^% $U%0_:5_N2_P#?MO\ "C[2O]R7
M_OVW^% $U%0_:5_N2_\ ?MO\*/M*_P!R7_OVW^% $U%0_:5_N2_]^V_PH^TK
M_<E_[]M_A0!-14/VE?[DO_?MO\*/M*_W)?\ OVW^% $U%0_:5_N2_P#?MO\
M"C[2O]R7_OVW^% $U%0_:5_N2_\ ?MO\*/M*_P!R7_OVW^% $U%0_:5_N2_]
M^V_PH^TK_<E_[]M_A0!-14/VE?[DO_?MO\*/M*_W)?\ OVW^% $U%0_:5_N2
M_P#?MO\ "C[2O]R7_OVW^% $U%0_:5_N2_\ ?MO\*/M*_P!R7_OVW^% $U%0
M_:5_N2_]^V_PH^TK_<E_[]M_A0!-14/VE?[DO_?MO\*/M*_W)?\ OVW^% $U
M3V?_ !]I^/\ *J7VE?[DO_?MO\*L6$ZO>QJ%D&<]4('0T ;-%%%24%<SK.JZ
MT?&5CH6B36%L+BPGO))[NV>?'ER1(%"K(G7S/7M735S&M>$1K?C.QU2ZED2S
MM=/GMR+:\FMYO,>2)E(:,J=N$8'YNXX/8 S&\9WK^'[1I;NUL-6-Y<6<L<>E
MW&HB=H'9)'BBA<.%RH.3G;D*><$Y$GB3Q%XBL_!-_IU];:9)>:E<6MQ$]I,4
MDDBCN%+,GF(VPF(D1MRI*Y8E>>UG\&Z'-86%H+66WCT\,+5[2ZEMY(PPPW[R
M-E<[NK9)W'DY/-(?!FA_V);Z2EK+%:6MPUS!Y-U+')%*S.S.LBL'!)D?HW1B
M.G% &#JOBNXT23Q 8;&V>\CO+2TBEAM)&,CRQ)^\D1-SN%R<*O)"A<C.X02>
M-]>M_#.J77V*.6ZM+VS@MKBYTVYL(;E9YHXV_=R_.I7<PR"P^Z>^VNLN/"VC
MW=M>P7-IYJ7QC-P7E<LS1J%1@V<JP"KA@0<C.<\TQ?"FE#39+"87MU;R313L
MMWJ%Q<$/&ZNA#2.2 &53@$ XYS0!R?B;6?$UMX?\8:9/J%@E[I^B?VA!?6=I
M+#\CK."H4S$K(#"2KAB!N!V\8-W4]:\3:)H^DF::VE2:-WN]2AT:XN5A 52B
MF".4O\V6)DW;1LY W"NIGT33KJZO+BXM5DDO;5;.X+,2)(5+D(1G'_+1_?GZ
M5GOX*TB33HK%I=6%O$&"HNM7@)#8!!(ERPP. 20.<8R: #6_$$NG^$[?4=.^
MSW]Q>-;06L@)2&22=U1'/)(3+AL9)QQG)S7,>*-2UI?#_C31=;GL+H0^&I;N
M.>SM7@SO29"I5I'Z>7USWKLM7TJ*Y\,S:7:Z;:7$)A$4=G+(;>+:,  ,BL4P
M!D%5R"!C'4<[H/@9EFUJ7Q!"GEZK9K8/:)J5Q>$P@/N+7$N');S&&  % &,D
MT 6#JGB#4=6O-.\.R:9:IIEO#O:_@DE-Q(Z;@HV.OEJ!@;L/DD\?+SCZ=JVI
M^*/%.G:MX?DM-.-]X?CG?[; USL!E/R!4>//)^]N[?=.[(ZO5/!^BZQ<>?>V
M\PE:'R)&M[N:#SH^R2>6Z^8O)X;(Y/J:+[P?HNH74%S);SV\]O;BVBDL;R:T
M9(@<^6#$Z_+G''3@>@H YQ_'%[=Z#ILUM=6MCJ<ZS^=:+I-SJ>XQ2>4S*(&5
MD3>#\S YW#N*KV^MMXCU'PKK$D(@>]\.ZC*T0)(0EK7(!..]=3<>#-"GCLT2
MTDM!90FW@-C=2VI6(X)C)B925RH.#D9YJ>U\+Z/8QV,=K9"-+"VDM+91(^(X
MI"I=>O.?+7D\C'&.: .1T/Q6WAKPIHBZK&K6#^&X+FT:)3YCRQQKOA/4%F#(
M4 P3\PYQ7<Z6U^VDVK:PL*7S1*;A( 0B.1RHR3D#IG/.,UBZGX2BO7\-V$4-
MNNCZ+,MP(I"7?=$FR!5R#P-Q)8G/RJ.<FNEH **** "OF/=7TY7R_NKHH=3E
MQ'0]J\+\_!P_]>EU_P"A25YS7HOA4Y^#?_;I=?\ H4E>=5U8?[7J<>*^SZ!1
M6%=>)X[.ZU*"6V=FLWACC"-EIWE&0H';GWJ5=:GMM0@M-8M8K3[0C-#+'<>8
MA*C+*Q*KM('/<'GFNCGB<O)(V**S;?7M.N[>>>TEDN(X'"/Y4$CG)Z8 7+#!
M!R,C'-,7Q)I;I*PFE!AD6)HVMI%?>W(4(5W,<<X /'-/FCW%R2[&K14%G>V]
M_;">TD\R,DC."""#@@@\@@]C4],G8****8!1110 4444 %;_ ('_ .1RL?\
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MNFMEFC,Z()&B##<JDD!B.N"58 ^Q]*)[B&V17N9HX59UC4R,%!9B%51GN20
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M")Q_I,9QT5N<?3V_J/Q[2U$__'S'Q_"W./I4M !1110 4444 %%%% !1110
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MBOL)MDR 3G!'J.?0UUE_H&CZK###JFDV-[%;C$*7%LDBQ\8^4,#CH.GI4_\
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MD)'N(10N[@$C@]"C6^NWNJ>'!J]]J6FS+?W$<6Y;0RR1B!V5WVJZ;L94[<#
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M<SFU0O.O'RNV,L/E7@^@]*LMI]F_VK=:0-]L&VYS$/WXV[</Q\W''/;BK%%
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M*\-_X275O^?O_P AI_A710DDY>ISXB+DHV['?45P/_"2ZM_S]_\ D-/\*/\
MA)=6_P"?O_R&G^%='.CD]FSOJ9)%',H65%<!@P##."#D'Z@@&N$_X275O^?O
M_P AI_A1_P )+JW_ #]_^0T_PHYT'LY'?45P/_"2ZM_S]_\ D-/\*/\ A)=6
M_P"?O_R&G^%'.@]FSOJ*X'_A)=6_Y^__ "&G^%'_  DNK?\ /W_Y#3_"CG0>
MS9WU%<#_ ,)+JW_/W_Y#3_"C_A)=6_Y^_P#R&G^%'.@]FSOJ*X'_ (275O\
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M (6[XX_Z#?\ Y*0?_$4>PD'UF!]-T5\R?\+=\<?]!O\ \E(/_B*/^%N^./\
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M-_\ DI!_\11_PMWQQ_T&_P#R4@_^(H]A(/K,#Z;HKYD_X6[XX_Z#?_DI!_\
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MK6VM-0.GQFVM?.>=P-Q;:64!=N#U/<?6CXA\)?V#XU3P^;T7!9H5^T"+;CS
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MQ,J\9!+KQUZXX'?.*EU#X=)9KKT$.L">^T.,33Q?9BL;H3D8?=G=MP2-N,G
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M_P"%1>!_^@)_Y-S_ /Q='_"HO __ $!/_)N?_P"+HHHYY=P]G#L'_"HO _\
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MX'_Z G_DW/\ _%T?\*B\#_\ 0$_\FY__ (NBBCGEW#V<.P?\*B\#_P#0$_\
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M?^3<_P#\71_PJ+P/_P! 3_R;G_\ BZ**.>7</9P[!_PJ+P/_ - 3_P FY_\
MXNC_ (5%X'_Z G_DW/\ _%T44<\NX>SAV#_A47@?_H"?^3<__P 71_PJ+P/_
M - 3_P FY_\ XNBBCGEW#V<.P?\ "HO _P#T!/\ R;G_ /BZ/^%1>!_^@)_Y
M-S__ !=%%'/+N'LX=@_X5%X'_P"@)_Y-S_\ Q='_  J+P/\ ] 3_ ,FY_P#X
MNBBCGEW#V<.P?\*B\#_] 3_R;G_^+H_X5%X'_P"@)_Y-S_\ Q=%%'/+N'LX=
M@_X5%X'_ .@)_P"3<_\ \71_PJ+P/_T!/_)N?_XNBBCGEW#V<.P?\*B\#_\
M0$_\FY__ (NC_A47@?\ Z G_ )-S_P#Q=%%'/+N'LX=@_P"%1>!_^@)_Y-S_
M /Q='_"HO __ $!/_)N?_P"+HHHYY=P]G#L'_"HO _\ T!/_ ";G_P#BZ/\
MA47@?_H"?^3<_P#\7111SR[A[.'8/^%1>!_^@)_Y-S__ !='_"HO _\ T!/_
M ";G_P#BZ**.>7</9P[!_P *B\#_ /0$_P#)N?\ ^+H_X5%X'_Z G_DW/_\
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AR+N'=Y<GVB5MN5*GAF(Z$]J**.>7<.2*Z'3T445)9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img134051827_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_1.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1]"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'R:^>70X0DE-! 0      %D< 5H  QLE1QP"   "!_X< E  "')R,S4Y
M,#DS' (% #A-:6-R;W-O9G0@4&]W97)0;VEN=" M(%!R;VIE8W0@26YD:6=O
M("T@1W)A<&AI8W,@9F]R(%,M,0 X0DE-!"4      !#;I.PNPFMTD@[XVCN:
M1O64.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           "N   !"T          0                         !
M          0M   "N                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   "N     !29VAT;&]N9P  !"T    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   K@
M    4F=H=&QO;F<   0M     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    +.$))300,     !2B     0   *    !H   !X
MPP   !2& !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MQLUU5++;;GN<!=!.UK]S0[W;&^WZ3F[%?Z=AY/1[AFX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MGNEH@0R17='CLA\$-@Z_'T>_?U4VY9YX.,>OG]/EYU;CK)Z.NI+;VQ_:.T&
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M8/-8]O/XY8?T,O\ >%>Q?W-GWB[0?U^W_P"6:P6$_P .-6?3V_+ QE?@G?\
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M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M8/\DY_H/='O^/K(_\
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MQ2M8/\DY_H/='GX=]Y&G_P"(LGZOBO[G^WLN%]N/O7$?"Y0_'[:W_P#N=?\
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M2G%*<4K\RKV@>4FV_P!;'65D(R.DKF'4UDN#UQ!.4GJ1,9R'["*T0E;W\D;
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M_CZR/_0:1_[N89VX^]<7E<H?JK?W[G4X[:W'^[)\^H(Y_-6HIFR_W-6/T?\
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M0!H;3C:Y'!(X0Y;WA:9A!L*C7^/=$5.J11C.-]\#_ _GZ[5S5BFX.1C##\(
MC*\R=\8(Y'.]2LT &%CX[UX#NC4U#C\4#XS7*]BQXBD<DAR)^?+%#"*Q2*CG
M.60_O\YZ]ZBS&#(Q.!@>CX?][&!X<\=?=;-15[A[:)%S-<7!2/.WI.RHJ$G8
M+Q,,#8#&-A40=H[IR;8N16,Z%9W--C)1-AUE%'L9( ?)Z"1CRV XSQ!D2K!S
MGR)#2,<P+"#@M<9L=3'HYKEIGRI944X &0",<SC()SOOC ->C^S/8_3NSNGP
M036UG=ZE&YENK^6VB>0SDL0EL95:2.&V!6*-@4,K9EP&;@6*.QMBUVN8-><U
M>>QESRF#!AQC-AM:T"#]Y(23Z15 QK#L8C6!(XKB*U>S$<YE')-W. -F8$['
M<C?)WP2,@^((\*VIV:[.77:2:Y6.X%M#;HK7$S*\C,[DB-$B5E5V '$69EP%
MR 0,U-;HOZJ5RM<?UT" DR%+LY<0;9,MS;C'"'B2K)@2(J$!/J2/ARO='C2*
M\7J$3LY J!+A8WA?@B(R,XXBV6&0",YW(\_9TK3/RQ_)<VD'4.T+S]S-%;0S
M-W<6;+4(TECMW=6PK07BK+&9$+3!QPL> ,&.4SEWKS+3BE6/U7TW:0TKD6P,
MRUKKRCQW,]J9!/R;8F9JDJTR_+;2?-//5MQDUQ(GW1ZR"8[QU%(V:RFIHS1Q
M:N#$ -K$?GI5\.*4XI3BE.*4XI4;.H3H\Z8NJYF-CZC=*X1N >'_ "E]B[,S
M@&L&43KA(J6;ZYK) $ 2:D*(TY&IZCVQQ-\D:U$Y! /, ^NF2.N/;BH];&S'
MIK]EUHF)A^G-;TN*0;RYN[# M18S,F1*R=D$UD1]Y<.6=(LEHZ*._P!TDVY(
M8D$69(:V-$?86)2NL>O:[;Z':=](O>SR<2VUN&"&1QPY+,0>&-.-2[ $C( &
M3D;/^2SY,-7^4_7'L+.0V6EV(CEUC5GB,J6D4C,(X8HP5$UY<F.001LZHH22
M:5A'&<X4LL]H]U>Y/?FNXFT38G&>;SC8_B])11:.$)%[, T=E76DZ6GBB(1\
MZ;*>5W=W=C7(U-3S]LM>FF:1+P6RY]&&&&,(H\/MB,[YVR6;&WF*]X:5^YX^
M2G3;-+.?L[]E9 JB6^U.^OFNYFPV7!MYK:"+)((2")#'A1ELYK)%T->TIO-F
M9=4:>WTE6/(;YZ0<.SRNBBJXUO:HQ5#1Y%7A1L&-/L$8]M;:04B1I<WTJXM>
M*1*CE)F/9CMA)?3QZ=J803R[6]R@$8D<9(BEC "J[ >@Z81B.#'&1GSU\M/[
MGFT[,:5<]K>Q37+:998DU;19Y'N9+.V) -]8W+@32V\1(-U!-WCPQDSI.T2,
MJU5[8YEF[0VMB15>M6/;,9;5&HOAZJXCE#:YQ7)V:C6E]=J(Y>ZE(-J?2G.W
MY0E<Z5:,HRGS]./<[DV]P$\N>2/$^>*MO[DMK4=N]>67A^=-V6F^:%L<7HZK
MIG?A,D$MP%6(4$E%;.!FM2G>-M/)?0Z=Q'LK8]<":,2+^9FD2#2&/,[M\'J-
M M$/R3YBH]41%?W71=Z["0)GT>#('CDD$X]F/+EU-?2O18HS"\S!>\,AC4D@
MLHX$.!GDV2=QN1Y5U>E[*9&RYE>%Y%AV4.6DH*.7T_.,%QPR%;W1$(QXO1\_
M@JM*YG=>Z)R+-G$P3)X2"64YP,#/%C?'3)QUZ[5V:U$C6W>D NKH.+J(VR"-
MN:Y  SL"<Y\=T_V6;+%O1YA*V"%0;\DSU]4AD=W^3%RJQ1OI>?Q]'WQ)JC5O
MS5155OPYZ'[$AQV?M>//\+<\'0<!G<@@>&<C(S]=?*#]TFUJWRM:V+;A#)9:
M,+G@(WN1IL''QXSZ00Q@Y]+89Z5D4YEM:'IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2G%*<4IQ2G%*T>?R0]^F+8=^Q3PO_6/L'FL>WG\<L/Z&7^\*]B_N;/O'V@_K
M]O\ \LU@K)_ASJSM]/Y8&-(G[=Y5I_7_ "+S$-.^^-I_3)_>%;O[8G'9K6<C
M_J-QL/ QMG'E@GV5^JJ#^\!_YH?_ %&\W[7S,;F?6?KKEXJ*<4IQ2G%*P$_D
MBS?AM8]#$'4=).0&2]2>R\>U^2,-6+(=@] P^8YC)1KN[_=G2*G':.4K$[^%
M\C5<C57OC7:N\^::1, W"\Y$*[XSQ9XNHZ>L;'((!K;'R,:#]G.W&G,\?>6V
MFDWTV<D!HB#'D#GD@\R!G R"16./\C1ZK;:;\ZK-TR83O3P+76!:AI9AAN11
MR,RMCY3?QP.5&M]1@<)I'R6HBN:R4!55K2-1;#V$MBJ7MT1]T4A4X'\D9)!'
M+?((/+H.>=F?ND]55[O0]'C8_:8WNI5XB?2<84,,X.$9"#@Y.3GQW$N;#KRW
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5K!_DG/X:>Z//\
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MB+AL'B5GF?A4F0(H8+$"V/J]ZB;34^P:N%60Y2#JY-3;R9P; PE:9IDE"5D
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M%)+'8++)\EC@QOE/UICA_ H8P@E20(JB B,48R/(T#0C:%6#;X.Z7N9$;)W
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M%*E5;$+6U,&RKB,"Z#*LB1T>=7]G&5"1J@:R@-CO5C"%(=+RE^1'Z:\3]&&
MK#H<<_,[;C<5Y'USY([6;6@VGWL&E:<RK\[LE6YO+FVN5+B:&V20HI!41X66
MXQ'(T@#$($/5P^L#9H9[CS:K$+"O5Z.6M%!M*\R,1?[V&R^59JC<K$[*8\&6
MGEW>D=$^9SB+Z8-EEC*GH RD>L\3;8ZXVZBJN7Y)^S3P+%!<ZQ!<!<&Z>YM+
MA"P_E-:_,[?B'0(D\9)YN!DU)#2W46':>06..VF/@QBP'!=8U+!W3K9EE' 5
M@IPG$+657HR8OKQBL&P1&F"0KT\%CD5U7;W:S,R%>!ANHX@0R^7(D\CRY5KK
MMA\GTO9>PM]1@OY=2MWF[B[9['YH;9W5FMW"K<W7%%*(Y%+,X*.%4CTQ4G47
MO\?^S_9WY5UKFG%*\*B+]*(OXTXI7PR*JKE&;(E5L"2=G;P/(AQS&9V[=O$A
M!N>WMV3MV<G;LG;G$HC'+(I/B5!.W+<CI7<EQ<1J4CGFC0[E$E=%)\2JL ?:
M*^YK6M1$:U&HB(B(U$1$1/@B(B?!$1/@B?5SE73SYUYXI3BE8CNOK?FXM$[P
MQR]U5>ACR871_N2XA4.1QKB^P$V73.J/HLP&HR3(<2K;N@;<SZ&ASK*15KV6
ME=/%%L;,$:> ,N3W4V]N0,^QMC[O?[:CCL/KGZU]-46WKK(<MTQG;,0G=:.M
ML6CP]+9'BCV97TW:P;LS#-@7!6[5O6V4/(%'+H,@Q&&*MC/"Z)-K+J'(%('(
MC?RS\>O'3QID9 W\3C'+P]?U^PU]>P.L[KPU63<3RY+I_:!]>[$V+I3&,<HM
M%9/CEOE64LZ$4ZO\(RYI![8R1ROK<KM*[6\C$8<(XL@I:\M@EM"N[!$AR?+X
M]=/#/7ZLD?FS]%=Q!]HIN/>NXL'UKTY[,TJ_$<WRW6&*.V;&P:?LRMJY-STJ
M;8W1GL6$&OSW&:Z=;5V;X'74($+8J"A82QK;*)/G@>P+X^/&GKY[]//X_0.E
MNZ/VI'4;E%ECEC6VN@*7+LKG1JE.F')\>R2MRG#=>VG26N\H'5-E>QGY@AX>
MHHV>$AU]C,D87%QB/B,OY#7*4S=K"$4\SGGCPWSRZ^K'CZJ^<?M:MC8[J#(,
MHRG--8ID1>FO<.1:XM[K%*FGH=D=1VLMK0L/GX;KN=B6T<XQ7:&-UM)9Q90I
M.&9,<UM!\KJ6VD="MX,-Z^?QFG/]O3/+/+'MQ70Y][53J(Q=NY[/&MC=/666
M> 6W5_4WNL0:\O#7FB,;T-F0*C6VT=I6==LTTJ?1YHIAX[-KY=9AHKJ595\K
M&)PCU%RLJ,[CSSX=/;^8^>*G&/$\N1Z?I_0>=5>3VA_6#96F<5NH\BTKOW&=
M;4_5;GF/;.PK5=^6EZCJ#0>N^F7+X&%Z^C4^SK2NJ;:+G&X\NUSD>5U=IET&
M2S&2"KZB/D<*8K&?K]XQG8>/E[?*F-QG/U8^KIOOX^5?'2>TTZ@P8[K;)[O;
M/3#E>#7FXZ+%+3)]6?85F^R\EK[_ ![ 3CQ3'M2UV\1UUA8U.597*C7<7$\U
MR+8]?C%CC,S[!I,Z#?$DS]/QZZ?1S]^>NWAM[<GP'#5]:'4GNC,*G',9L]59
MAOG!MQ[^I,$+B,"TM-+UET#IFW_E>M*"-EF![EF5NQELS8GCU;F5#LBAQW+<
M&E6LB7)Q6MGS\5M8<'XY_3CIZZ;;^  YX\1[L<P?#G7499[57JHMXV'Y]B-?
MI;4>K-N5^SLRT3<;T #$J[/1:T/KW" :SO,ARO/,1%4W>19TNR;Z02@@W>7/
MPN3BDG',5FNJ+LUDW^.GQXXZ<J8Y^6,XW\<GZOT[[;',4A31HQ9 F1SE $A@
M#,DA@2O&UQ!,.C!(=@WJYC3(,:%1J/1C/+Q2:BN?BE.*4XI3BE.*5H\_DA[]
M,6P[]BGA?^L?87-8]O/XY8?T,O\ >%>Q?W-GWC[0?U^W_P"6:P5$5$SK5OW?
ML^QK[OQ3Y=J?A]S\?X.8AIWWPL_#OX_/^6OM]N?9X[P[8[=FM9!(_B%QMMU0
MY&?';Q\@1SK]58']X#_S0_\ J)S?M?,MN9]9^NHMYE)@8@2YDW%@*+7U95)*
ML)+G-:@3^#Q*JIY/<<KI AM8QI"F/V&(;B/:U<:O"EM)*TK@*OINYY\+98'
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MQ'EGD-QY]1BF=\#)8G  !R2>0Y=?V\JC_E&;ER_)!%KWR&TM1'*RL4;#,@S
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MW^?%/>?/X]=>FWNICIYT18TE/NC;F!:XM,D@3+*CK\NNXE9+LJBNL*RML[8
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M1XT>WNBD:/TW]V(O:E4JI)8XP.NQ(QG8D;D>_!SGGF\ ,Q"+G<['!&,<R<=
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MMOG[:-/%J-G]IDOX9([JSGLF99?FY*SP1QN\A25>[@:=6(R'"*6%&X[I+ :
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M@UDSHZ%XF.2H(!1QZ(.>1VV/CC/45;O$.G\]/=P;'(K2!8,@R@RQ5D!2-]9
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M$&P,?S1K!IZ;6H1S!M<5RJI/)%1&XZSM)ODC.&P=\ YVQY8'T^W._FR6Y,6
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M+$J@CF<8)!.2,DG)QN-LDXJS76AVMG&\ES=R)''%++).ZHD'"@9CZ8'$A*J
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M6M;5(3LOCYN%*N/2\OBK4,C$[(].6.^_BPSS[]2#U.4D!('/? XCCHN:VO\
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MM(V8EX5#*OVPA<\/$^<YWR#M@ ;]*F63'[[=5GCKL>V+(2??W%@PN%Y7.M1
MHY<*"R;*C4LIC)E3*K!BEI*J/=@5=DV-"+!;&D/BRC+E9@GU9X7MK^13/+(C
M6TTDT8@=%[QA X'=O&J\4D2JL;\ X"I=&<ZQ6]L^Q]O>1ZAH,12PMHF35M-M
MK64W\,LDD4+7@E$=S!<-($2Z+-<P-+)WID5'CC.6W&ZR12T%+3R[ ]M*JJJN
MKI-G*\ED6)X40,<TXZD>4BEE$&XY/4*5_F]RO(]RJY=DP(T4,4;,7:.-$9V)
M9G*J 6).22Q&3DGGS/.O-=W,ES=W5S'"EO'<7$TR6\>T<"22,Z1(!MPQJ0B[
M#T0-ABN[YVU3TXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE:P7Y)T[II[
MH\_Q]Y&G[N"R?PI]'T_@7M^+F&=M_O7%_68_K%;_ /W.F/WZW&?]67&-L[\+
M_&:U<L=S &.Q)@I8"EC]WRT<%R>HQS0IYM\7*C5:Y!M5%1R+W[HO=O9>:RBF
M6-6#CEDC;/L(]GLQYU[%U'39+R1)8G5&"<+(X^Z'%Q!E/0 YR-]M_7FV]E_3
M B]#W41MX$4SIFT=FUV($EF K5^3L3^26$&PO96D:&;EMHA'#<YB%,WR[.1.
M9QHL;1Z-/<%3FXD<\1&"5SCGT .>9V!((R*\L_*E>"Z[;V6GAU9=+M8QPKG"
MO)&78,#MQ,88Q@<\9!]+!NNQY"(9%9Z/B]S!/<K"(1O@U6F[#=Y-:KG.:K'*
MQ_S%5?%%:O(W]OT?'U>%8\/Y7,@' '/&/ 9WQ[#MMSVASF]K8Y-E=J(\PCH5
M9*/#BB:CT $48GHN48//P0A2-<1[W*YR_6]4:U$JT389Q[.OQUR-_*J61\>9
M^@'.!RQC Z<N0KTIBOJ21FH:5)AB,QYH3I#QB*-7(I1M4:,<%KVHO91*U4>O
MFO=>_<UO&^2PW.^<@<N?3 /JW\M]BW<R+Z#G VQX$G/,=-N77/2I3GUY6V,:
M/-HYIZ]LD(3#9)\K$!0&:(C"^)31I 2^+U^:DIXE1J-]+R<CFT[0)G"Y !
M!!R/'EUY[?GKO2]D R_I;[G)!'3<$X(\>HYYJRKH9T0KB2/*>-3@8=XT>"(=
MCG (L>,KT:C$(UWSE>XI&)XN,K7+RE88)&",;>!P,^'QX5=%;C56(QD X&W,
M>/T^ YBODFV0H\6PDRCNKJZ-7CE+>JZ.H40C2^HHA$4KD)'1@2(TP%819 QB
M0OSDX/0;Y)(^#_ARYU.1XXQSW )Z8&?'Q&X]^+ W.^*/WHPJ_&9%C$>OIDD2
M+(E;[RSQ5GDD4,<_SE:O9KRN0J(B?-:J-1O=W#8!) ..6-\^&V>>.GAUZ=7?
MKRP2!RY?G^/?FJWPG8V+Y<4%9' :ELT1RLK3RCM9)&(3G.9"D1R"8<K4:CG#
M*,95&TCT:Y>ZIP>-EYX*^/NY_3\"N:2*^0/#D0.6?;[=^H\*NJ-(L1XP#1@'
M2R/484\T1[Q!:I?3:JN:WL%OF]/FH]?)W;U'N5W7TV.?/GU\O@5)SRWQC<[=
M<],8QX\L53UOKFPS26Q<8##'D$&!92(SIS1+62(Q'1FS:JVCE[!E4UTU[(]G
M%>\:O>R//CN9,AL>[OA+'*9)0D,=]U(.S*1R8;@'?&2#SH\R0@&3)4L  ",@
M]".7GGIG&<[516'2\EI:9E>V%,M(%>Z/'%$L)(9-U1QRQ0.)73K6"21\L!K3
M.>D"7'K/7E5OHL>]QHA7.JI+>'B FF$$QY83BB=&R>/B!7@WP#S&22!5W73X
M!W<=Y>BRN)NYDC+Q\</S>9$=)&F#J ^^&CQL"IRV^;ATLV-*K!M(QX&"\X:C
MFG?)]5@T1BN23*:PTEA&.\7$.QA'.\T<U6M1SJ.>,0NRI(LRJ-F0GA(VWR>8
M]@.=O70W<26UQ+ D\-RL>XF@8,CK@G !^Y88Y N.G6LB/3KT9P]G8OB^=YAE
M1L;QVTLE=&Q^%0,DDF8[ E)&;))/)8!9#CV2A*@4!53/2JW E!]=\@0@W*RT
MT2K'+-(45B&"A/Y//<D[@\SU&_LPW5^T+V<L]K;0I,\:%>],C*>,C&%4(067
M.V9-R,G K*-!U+A."6\XM-BN.5UA(8OG/K(T8PRQ)*->WW"2U'-%!.UJ*@HW
MHC?X^)1]Q^+;\($A<A456&X=<9PQYKSQX==JPSY[/=1J)99'0'T4D/(\B.'
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MK%;^_<Z_Z:S_ .[9_P"Z_P >NM2?(">C26I4545M=([=O@J.<)6-^/XW(O\
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MF$7.-E3;EC\$<AT]E>,9KA[N>>[E_AKN:>ZF898M+.SS.26)QEF*C& JX&,
M8P?=26Y\PM-NYE7SKRBQ^#C6<+A-94VE#:3BTN.0@M<F62Y++NMCR8V0RU?(
MCM ",/PEBA,ER)5;+9R]V4Y@A&)8(N*<AR]O)(RQ/C$S$2*'5LJ$'" K$X8[
MXM>HZ%9:C<"0V6J:D(])>XCDL]4M8(;F^CE[N72+:W>PN7BGMBS23NSRLK)W
MLD*V\]NU6<IMJ9^:6KWZZNAD#4XO-BQXX%ARSS9MD&/;6@I-C,B!CUT<<EB0
M("O?;"?#/(G(.,KG1Z];VYDXEDLI O<PL$X.$REW59'#DL.[57PH^ZRIR!Q
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M8@7GE2"-  0D5Y"%>OBUK$;]+OI1>ZHB)]*HGQYSW]P^/;OMGV;XK@.?J/N
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MXIUA]*V;04L<<ZA=0RXA-B9+J6.Z9G>/4QIVR,2O)N.WF'UL2ZG5TNTN VD
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M(B10U])&FOAM:R18OA@/%<>GEN!$W#P,^(S(W"5R%SA<*S L6;;"@\(&6QD
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MMQYU]!J;;)V5:P['+9]O71Q8O52+"?=SFNJ8[HY5<<:/;&#VC4EX>)HGX?3
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M/0MKK3=M R[(+*3L'-JXB2:NQGP@U=#2R4149+J:!DF>_P"41(YRCG6-C8/
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MM64]J-?,EHCCV,][41$:^?8&E37M3\Z\[D[KV[\QB:0RRO(1CB.0/ #91[
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MO_C,?[OP^/;X_3_VZH;F/#B&/I_97MM_X-_]@_4I^/*OT7?9-_I:_13W^/\
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MT9)SW<,CQQ(#_)5%(0J!@88-N"3DL<Y5_9X=6^68-DT3)+F9))51;6#0;"C
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M$@84;DX.QV(P#TWK:!]EX>ZH]NKC;2E-$D:GD1K]45SA&E4$S'65\LJIW:I
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M;!L&Q@QHC&#:C&,:B-:UC41K6M:B(B-:B(C6HB(B?!/ARB^/7XD^)/4UL4
M           8  '(#H*]^*FG%*<4IQ2G%*<4IQ2G%*<4IQ2J;M</QB\FML;>
MCKK"<P#8K94J.TADC,>\C0H_NB^FTA'O:U>Z(YRJGT\X,B.0656(Y$C)'MKO
MBNKF!2D,\D2D\15'*@G&,D X.VV]=:NM\$<\;W8K3*\1&E&Y8C55A&JCFO:J
MK\'-<UJHOU=DY'<Q @A%!4Y&PVKM.H7S*RFZG*N.%AWC889S@[U6W.RJ.G%*
M<4JB]D0;&SUWGM;3N>RWL,+RF#5O'W]1MC+HYP(+F=E1?-LD@E;V5%\D3LJ+
MSLB(66-F&5$B$CQ 8$CVBJ#58Y9M+U** D3RV%Y'"5.&$KV\BQD'H>,K@^-:
MF.64\RZPW(*"(_W6?9T,^MCN*JM]*4>$4#!E5?BQ%)^8G55^:USU5/)$[Y+"
MZQ7$3OED29">'<\(D*C Y8V/7 )YG%>+KV![BRN+5"R22VSQKDG*LR >D1C9
MO25O LPP2-\35A G5,Z36V<,\&?#*X$J))&\1@E8O9S7L<GQ^CNQR=V/:B*Q
MSD<G,X$B.H>-@ZL.(,-U(SN3G8'D-AS)&/#3<L4D+O%(CI+&2'1U*E2.8WYG
M/+Q)V.-ZR1])&)Y/BM=13PME1\AR/+\?M<>@(Q6RX\H<^$"C(QG9I&R9LKT3
M#9V:1&K&3\]V1N+:M-'-=<*>DL*,K.#@,<$,H&P]%A@]!RYD&MI]C+.[LXK:
M51(ES=7UM+;(<AU</$MN57!])Y$R/%0,DG&-T$2.0;//MY^#?/M]'EV^=V^"
M?#OWY@YYG'+I7O!<X&>>!GUU[\5-.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE8W.L)D6SZP/9F8]E*-=@)]S;KR9!
MR&M6 ?;6):+R*9J@9U>U1^^1UF9=:4[%=YK9UP#!9ZT<9!*GQ_3Y]/'X\JR1
M\5%67W_N&!HW5V0[ F0V6<J![G!I:AQ_=_E:ZM)0H5?%4J->\8!O(^9-(P;R
M"@1)16,<YB)SN@B[Z54)PN"S'GA5&2:L':778NSNCW.J2)WS1&.." $*9KB9
MUCC0$YPH),DA /#&CM_)-:U6Z-XVF6W,[8.W<Q]>5).9(BSY#FPJT#U<X=/C
M=0QSV1(H1=F,B00J<_BDB:^5+*:27(+>W=RL-M$6QR&,I_MNPPV2>N3C &-L
MCRCKW:"6]N)=3UN_XG=SP&0XBB7)*P6D2KM'&AX0D4;<6[3=Y(SNUM\.V-BV
M52&3</R5AK.L(.8 D,\JNNH!6O[BFQD=[M8QGL)V].9'\%8_Q1A4<B(D#3OL
M9$((K**SMN)V"6T:1PAI'+N0B@+Z3L7; 4,[NY 9F)H8-=75K@W4>I2WE[$8
MV[Z2>4WJ=TO!$RM(4GQ&B\";>A&JQ@\"J!G?Z%.JB_VD^=JG8DKY1RR@HDN*
M#)S/3WS)*:)+#"G1;9J,8,EO4I+K',G-<X]Q%+)E2QI*A2I4RU7ENJ S1KP*
M6"LGX)8$JPZ -PMML!L .>/0WR=]LKG6#)HNJ,9KVUMS/;WA.9+J")UBE2?8
M!IH>.(B5<M.K.[@.C,^27LGT_6GU_P!?Q\MWQ_CXG;G6U:\\FE.*4XI3BE.*
M4XI5&9Y@.-;'Q^3CF3PDE0S(XD:2)4%85<U1$".QJY:(KXLP0S&"Y>SP2XAY
M-?/!+KIDR(?@Z+(I5AD'U@CU$8(.,CU$@Y!(-3:7<]E.D\#<+KL01E'7()1U
M_E*2 >A5@KHRR*K+J)]8>?W5GM_.JF_R*UM<<T_.O=>XNRRD.*RMH<-G2X4P
MD2/YJ*,VTLHTVS;%'Y)!!)B4\5[:NIK(L70O:>_DO-6NUD=V@LGDMH$)RL<<
M+,IX0<8+L"YYDDJI.%&/JA\BO9FQT+L'H4MG;01WW:2TM-=U*>)>%[BZU.$7
M,*2G'$RV=M+#:QD$%^"2>13--([8V)&][19?E'HX#8+7*B!.60Z4]ODJ(KCC
M<P8W*BHJM0)&H[O\7?3S"_G[9/"@*[X](Y('(Y&W(;[?56]QH<93B><A\ GT
M<HIQN .+!WVSZ\;FLL'LT-YVV&]1FJ[*G)(9C^T9H,"RFG]1WIR(M\7W6$1[
M&M4;Y%'D+(,X,A&^3HPYL<;QCG'5<X[&:E);:S9F-SW-\1;3IQ$@F0@*6 R.
M*-E4J>8 88'$37G;]T-V1M-=^3KM";B.,WW9R"37-,N>$=Y%)9%3<1*VS!+N
MR>:.2/)0L(Y"K/$AK++[7;2E[FFL\,V[0!D3FZMEVD+)X$<+BOCXQD[H"/O^
MS55R"J+.M@CF]A/8*%8'G&(*/!*YV==OM.FN;&WOH07^8,_>HHR1#,8U:7(.
M>&,JO'T",SG 4UYB_<K]LK'1>TNJ]EK]T@':B*U;3YY'5$;4=.,S)9EFP ]U
M!--W&&#/-$D"JS3H*U(MO8Q;1<FEW;0'E5EFT!!RA#(0<4@@, ^*96(Y!*BB
M\Q*[Q0@WM1O=R*G-%7L;B5I.$E6&20!@="&Y;C8;X)\"0<?2S2;J'YN("R))
M&6)5F"\0)R&&>9))!'0 'K@5KT]X7D=I=N- K)\R3=NB8_15L6,4LZYM)TP+
M QX49C?4D$<=H0 1K50IY#F,[JQ_*G3K>:1\1([O*!''$BDO([LO JCJ2< ?
M[1Z5;>TFI6-I:2SW5Q#;V]C%->7=S+(J06L$43-,\SD\(54'>,V2.$$]#6]C
MTQZNFZ9T)JO6]H09+G&<2KP7JB[*)E[-]2TNHX7M>]I01;2=*C ,B_FP0C)X
ML\O!OIG1[,Z?IEE9L07A@19".7>'TI /'A8E<]<9P,U\;OE#[1Q=KNVW:7M%
M;JR6NIZK<36@?9S:(1!:NZX' \D$4<KH/N'=EXFQDWXY<JPRG%*@#UT]2^S.
MFX6GYFG8&-;4V3L'-%PC%NEP]?,'G.[SSEA2;.RQ#,X5FH=?Q-9T,6VR?)<C
MR/&KC#DKGMA7=A2RY51)>^/CX]^:D#/D.I\/@U)'I^W?6[_UW&SF'A6PM;V4
M>SLL;RO -H8K8XEF.'Y;1&;&O:&PB31)#M PI*I[CD./S+3';R&0$^HLI48J
M.:J*O:J=_AQ2OA@5L"L&8-?#BPA'E2)I1Q(XHPR2I3_4DR2,$UK7GD%52',Y
M%(4BJ][G.55Y36MG:6*/%9VMO:1R337,D=M#' CW%PYDGG9(U56EFD)DED(+
MR.2SDL2:[9IYKAE>>:69DC2)6ED>1EBC7ACC4N20B* J(,*HV  K[N5-=5.*
M4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI14[HJ?=3MQ2L*75IT
M29?0Y-=[%U%32\GQ.]ER;>XQ2J"Z3>XU82BN//=5UHVK(N*229Q)0HT%IY]:
M0A(Z1#06B*"[V]VDBA92J2!2H9ON9,?<EV.P;H<@C8>S07;7Y/KVWNY]5T6W
M>\LYV>:>R@0-<VDCL[OW,0].>W>1F=53CDA+,O"8E!7'!)UE96UP*+,UW:6>
M01W(T,,^(39ER)S%3Q8.,^M+/8]K^W9B,16N5$[-?V1;@)954@2,JL,$!PJ<
M/3)WP![O7M6JGTF::4(^F2R7"[*C6$TER"" H53$TG,@;IMC>LK/1MT5Y%59
M+2[;V_5I4-I?3L\-PJ6B.LOE=/%T*^R*,G=D#Y+15D5E01SIC;!8TZ:V&2"R
M*>V75TN&CC(9F'"[C< #FJ-_*XL#B;D>F#RW-V#[!74%W!K>MPB 0$2V%A(!
MWQE(/!<728Q%W(;BA@.9!($>18^Z$;9<D3LG;^OT_P!?^U?IY:ZW97GBE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3B
ME17ZP^G63U):?)C6-7X\*VS@N34&U]$[">!93<#W)@D@EEAE[,BM^?.HY!W2
M*+**QBM=9XS;V\)CF&,(HU/CX^-CO5H=3^T(U;8:HV1D744:#T];<Z>(T>)U
M(ZFR6:Z3<85;E(.%67.)A"-]CG>"Y_->%=8Y#C\*<F7.FQ:B",EXTT!JAZ>?
M+X_-^;>NN]I%'EV^@L3N:]LA:NOV+CUI8D> P%' L\>R2J@OE .P1XZOLK:N
MC^G(&,@Y)Q"(P9%[<K]/(,LB]3$<#H2'1B.F^%)QGD<UJ_Y6(I).SEK(@)2#
M5H'E8$X5'M;R!"V.2F:6-"2" 6!R.5:H?55(L'YO3Q3N(E<+'0&KV=^PE,:=
M,;+(WX^/JJHP,>JHKD&T/T+X]\[T,+\UE8 <9EX';()P0I&!SX<YW.#OS(Y>
M-.U[RM?P*V>Z6T!C\ 6=UE8';TBP.<G(&":LSK2RLJK/<4DU;B>]NNH,;TV=
M^YP2I P2 /8WXO&8#R,>U4[?'R[(K6]KA=K');S+(0J"-B3DCENO(#^5CUD\
MN@L6DS30:C9O 2)?G$:C )XE<\+*0#R(.YWVR=N8V./9]U-G8]2U%,@C)[K0
MXMEEI<D:CE8R >".G$(KFIXHIK2SKU8UW9'^D]S47TW=M?W; VSDD9/=H>7W
M?$'( Y[!3DC;<#K7J+Y-8)I>UEL\?$$MK2]EG8# $?=?-@K-C )FGBX03EN$
MLOH@5L )\$3\2<LM>EJ\\4IQ2G%*<4IQ2G%*<4K5-]IUTSWNM]SYQD*0I#M=
M[KEVU]1W@QO>"%D%R)\G)J&8;Q00["-;$EVT$+W-=)J)8$$I'PYCV:/[:Z/)
M9:E<7/#_ )+J#--&_P#)25@#+%G P0Y=P#C((QD U],/W.?RA6/:?L7I6CM,
MBZ[V2@M["]MBV))=.MF,>G7T2'(:$VB16\T@8%+F)U=466(O@LE:VS.+9+6I
M22Y+E+X#E@8KX)1JY$0RR_@(;%:OD]"N8X:([S1.RKS6S6TW%P"-CG."%)'M
MSL "<$L1CF1@UZN74[)X0[2JI(!:,Y#YYE0N,ECR"C<G8;D5G=]DITS9!E6X
M,,S*9",["=+N->W%R\!&P+#,C1I'R%0P9"HC"S(LZ>*^.QJN>"%6#24T?RA%
M\]E]@]&EGU"&[:,_-;#+M+OPM<^F4C0X])E>0R/CT0H'+(!\D_NG?E L-%['
M:EH$<\9USM8$LX;17)F@TD7 DO;Z2+8QQ21P?,8RP'?/<N8P1 Y7:@EQ(L^+
M)@SHP)D*8 L67$DB8>/)C'8X1X\@!6N&4)1N<,@WM<Q['.:YJHJHN[2 P*L
M58$$$9!!&"".H(V(KYM1R212)+$[QRQNLD<B,4='0AE=&4AE96 *L""" 0<U
MBKVO[)'1.<7<F^P;),FU:^:=YY5#6AA7V+C>]RO<M776'NUA6->]SE6..W-"
M$GBR)$C,:K781?=@]*NI6FMY;BR+L7:.,B2+B.-XUDR8Q_W5;A'117I;LO\
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M, U*\;58,;%<YZL8UJO>O=[U:U$\GJB(BN=V[N7LG=57X)]',3SG? &=\ 8
MST Z <L5?!L/'S//VU[\4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*(G;Z.*4XJ,#X^/\*]7^7BO@J([LO953R1%[+V
M543XJB+V541454[_ !3CX-2>1^/JJ([V9=71O=\M;NV)=@DS%F7^)RK*_I9C
MG2S$'*K8%0ZXBQH#PN%[M#/CH'Q M;'.,I6.*[+4^92,3:_85HF5 D%XJ0S)
MA%'"[S"$M)Q \4BSGC;)&!5B87*[2G4%<,P,D)[Q&](D, AE"H5P &B4KRW.
M30&PIU4K! W5$B'>[Q;!VUB]?627JBHG@)&"U[,<]JN1']TD+W7NK%7NJ\CI
ML4HRVC,_#N7TFZ>0#S()U%"",G/%&!DC(P  NY4S_E@&P(%W"%.VQ!'#;'GU
M /3.VYN#!SC9GN[9(JS7V8QG(CFRJ.^MJ'UF*G=%$R1 R6*JJB]T[V*,3Z/4
M3NCN4#Z?IG$5:74;-N16>WBN,'P]%[9R,[?P9.?'854+=W>Q[NWG'C%(Z9&,
MD[K(G3;+^P=>T'M>SB)_;[6N90O@G<M,ZBR>.B_'NJ-K;5EFYOP[HOR6CE3Z
M6-7X+T-I"-_ :E9N#G F$]JX\">]B[L$^4C#D<XKFM_@D26TZ8&28Q',O+?/
M=N7/L0'Q&XKJLLS?2>PL3R/!=F0XY\-RZGL,<RK&-E8E;U=!>4EM')"LZFW#
MD59'JYM=/BE)'D@*4@#!(YKE<QW.IM$U('$<*7.W_5)X+EN6<\,4C,<^' -S
MRV-=JZA:GG(8_P"E1XL'PRX&_7]M5!E&-Z2Z@,*MM?Y=6:ZV]@5N&."XQ6T;
M0Y?C\QD4HY$19-<]TV*A(D@(I$0W@TT4XAF 09!M<E%-:75M@75M/;DC83PR
M0Y]0D49^FJF.:&7>*6.3'6-U?'KX2<&K9SNB'H\LL:P?#Y_31I27BVMI5E+P
M.C-K[''UV+R;F8*PN7U0%@^(?EBP ";;#=YCLY@ R9S#F$-[>C\U=E79I=+Z
MEQO)A9G0:YP^FRP$S+IX<AK:*!#MA3<^-32,VE#F@"PS392?':(MX]'(M@^I
M@+(\_=A>,;<]OC;]E*XZ[26H:C*OLXJ];8; S!,DRW,?LEBT, -TF59]34N.
MYKD/O[ I(^5LIHL;H:B\G>?KV-?3U\60]XHHFM#&^/'Z:5U-)TZ:(QJ@BXKC
M^H\ I\;@W6$Y'#HZ[&JR+61K[6T6HA8!;@AB T(Y^'Q*"EC8]):U"58JN"R*
MX:1Q]II5%S.B[I*L;K#LBG].6G9M[KZ/21,)M96"4$B;C$3&[2==T$2H,6&Y
MT2+3W-E.MZZ.S\QB6<DD\+&RO$K5*J.VZ7>G2^GX_:7.D]:V=EBN7YGGV-SY
MN)U)Y=)FFQ)JV.=Y-72"1E+%N,NL%]^R"8-R$M)C1R92D,(;VJ5\3^DOIC)F
M&![ +H35!,VU=3T./Z\RDF$T3[K#J7%1E%B]=0SG0U-!C8T,YFX^T;O*F]4C
MJYT9SW*JE7(JM9Z[QNVI,AH\,QVIN\:Q2PP:@M:^IBQY]/AMG9UUY8XQ72!#
M0L:FG6]15V4BN"K0&F5\4SF*0+%2#MCVY\AXXZ[X QU-1X <R=L\CY$]/7TY
M\@:T]/:W[]UCU"=3-;D6K;N7>5>*X)#P6\/+I[2E)$R2BR?*5LX38UM$AR"M
MCI)#VD,&X!'*YK'JYCD3S?\ *%JUEJVM12V,K21V]LMI,61XBLT<]SQ@+(JE
M@ PRPR!D<LC/U'_<W=CM>[&]@Y[37[6.UN-1U=]5M%ANK>Z22QO+&Q$$IDMW
M=5),4F48A\]-C6</V-F_=99CTOX1HC'[N5+V3JBGR.USBF?36D>+5PLFV+EE
MA3D%;R(K*R:^5&FQR**'+,4?FYKV-41?#9WR=:M8W6AVVEPRL]YI\4CW47=N
M%C6>[N'B^V%>!B5(^Y8[Y&Y4X\G?NG>QVOZ7\H&J]K;RUCCT+M'=64&DW0N(
M'DGEL-%L(;H-;+*;B())"X#21JK#A()##.87FPZ\U4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE8'?;(X,R/<:8V/'CHU)M?D>%6<AJ=NY()HMW2C>Y/
MCW<.;>>*K]+1^/Q1O;GGWY;M/ ?1-351Z:7%A(V.7 R7$.3U/I38YG'J%:5^
M5FR"RZ1J*C!=)[)R#C)5XIX@1C'W)G&23L< #G4-?9NX2W-.K77CS!4L3$07
MF9R%\5<P9*>M,.N>]?H;VMID#P5?^/X]OC\>8+\EEC\][9:<Q4,EE'<7KY_D
MF*(K$P\Q-)'BL1^3VS^>=I[$E<I:K-=DG?!BC98SOMD321\L;UL<YSTXZAV;
MM+$-N;#Q2%F^28'A678)B=9E08U[B-/5YU;XM<Y/91\6LXTFJ7([$V&8_#2^
M(%\Z-61"P(KP@F2T-Z\QU\/SUZ8\O;]?Z35@\$]G/TYZNR6[N]:_EE8%1Y6V
MP3-M;8ELC(:/6.;OELR:+!?D^(P2BC3&4%/E4_'J:'&/#KV4,#'Z^PB6+<=I
MGPU*^6C]FYTW5&$7>O[%-CYC0WW3%]J!*)FF?6E[:Q=&1KF[NJ/'JRS>./)K
M[+%9%X0&+W\=6VE/&KJA0'=+A)*(^/CX]=,X]^?;M^@5U^0>S(Z7K^1A2I$V
M#1UF$:UT[JB-08[GEI54U]B&A,PEY[JR/DX6"+,LY6/Y9/G7$LX9L,>1R)*_
M9,"X;'AMC*9]77H/CV>[%??9>SXZ7 )9OS#[+KG%)N9[QS<.(YAL*Q/A-'8=
M15/EE3MRMHJTKXOR929*F;9-9NA#F.+!M9PY<24)L& &+S2.25@L4;RL?Y,:
M,[8]2@G<XV_17%G1 2[*@YDL0HV'/?&<"J$P7IDZ0M:YQB.PL<L=K;4VMA>P
MP;*AYQ.R/+]F95<WE9IO-=!8W4Y#D'NCZ:1C.*ZSSW(Z3&Z(LFM@P)<UU[(?
M(M#3YTJY+HNH$<4D4=JI&<WD\-N0/'NI)!,<>"1DGUFJ5M0MAD*[2G'**-Y,
M[\N(+P9SXL,8W(J^VF*!NC=94NJM/:QL:/"\=G9385C]F9O"]^%(S++KW-[H
MQOD$.63) W7N1V1P1Y)H9 QGBB-<Q@4>G:NF6<>T^I"5AC*6-K++S ..\NGM
M%ZXX@'&QQFNIKV5AF.V*Y&09I$'C@\$)F8C(WR5YUV5OGU]ZJQ[_ &YC="5?
MC\BZ^H 65TC?K'[S;&RF9)>J_-1T?'(A%\NR,[I\VXQ:9;@!H-)NIP!_#ZA<
MF*'D/2X$6TC4';8W3@#.^]4;WDS-P/=PQG\"W0/)D')'$WS@YQC [E3G&3O@
M4;?2*IT>#+L\.VIGP[.T@5%>?-K&74TDVSL2^$8:4-_:57F%B,+*D$@X:<0(
M<>1)4*L"K4K;97#R)%>:78&.&6:46*+-/''&,N>^@24*=PB<=\K&1U4'<UTR
MD<(DDAN[@%U13<,T:LS@X CXQD[!B!;X"J<U5^'Q,WN+>[Q."/ ]9)0BK9+8
M-543,GD3JFS ONMG6&5V*5@6-F1Y]<=IJJ;[M+A.5XB!-&>6CO9+*"*"[<WV
MI]^94,LTL=LB2PL \4BCYW-DH4F4B9>-),<6037;;QS2/)"IM[;NRC!$C=V*
M."5=6#Q+@;IZ<) 8$]<5=(.H84E/+)<PS?)7.57/ ^Z;CE?\?_BV0\1BT+G!
M1/AZ<H\I53NCWN[KRU'69!_%K.QMA@@,(#<R8R><EXT^_FJ)Y#K5>-/C.>\F
MN)<G+ R]VI/^S$(]NN"3N-R=\U30ZXP3&2+(HL3HZ^6O;RL!U\<EF14^/D6R
M.PL\SU^MYI#W+]:\H[C4+^Z 6>\N)$&?M9D81@= L:E8U \ N/&N^.TMH3F.
M")3^$$7B/K<@L=^I)/N%5K]'T<I/CXZ>ZJBG%*<4KC03&D>5&M1Y$8CW(U$<
MY!HY&(YR?%R-\U[=^_;NJ)]/%,D@ DD D@9V&3G8>[/CUKDXI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5P
M'BQI0W!DQPR O3L\1Q#,)R?6CAD:YBHJ?!45OQX4LA!5BI!R"I*D>KA(/TU!
M56&& 8>! (]QJWT_3^L+$SI)L(QX$M[O)9M9 '3ST=]*N;/J?<IB.5?CW0_?
MO\4[+RXQ:OJ<0X5OKADY<$K]]'C;;NY0Z8VZKOUJE>PLWR3;0AB<\2($;///
M$G"W,YYUUC]/4H>_R+D^>T"_'LV'E<VU"U>_=/&+E+,@BHUJ_P#$:%K>WP^"
M<[AK-P23-;6%QGGWEJL9)_VK9K=_<U=9TZ'^1)<Q\MEG=@,>"RF11[%JT5R+
M959E%MC>'YE6Y3]CV/ML;5,QQJ&CEN+!'$HL>;88S+QT+)$V( TRPDEAE]PC
M'K3>[2/?%:.[0-ILMM%<WME+;=_.(X39W+8[B,\-Q<-'<K<L51R$C"LO&RR
M$=V>*@F6Y25H8;A)5C0&03Q@\,C[Q(.[* $@$D\/\I0.9KY:S';G/J&JRBPU
MCK3+0SXJ&80,\E3?1#M>X,N :'<XX8<6?"EB/%.Q<A:C) GM5Z(GJ+V275O8
M7,EJFI:E:-&W"08Q/ ZD<2.KPW*%HG7!5C;!L-CAK@EM)<1),UK:2AAD$,$D
M1@<,,20D @@C E !!W\/9M02B_Y&;OPI@^_YKCV03,@K!)V_^+KL?RK)V(Q/
MI9ZE'Z:(B-[)W1JN^CN3DWFB7I(QBZMTMI #MN\]M; MT/#<%L]1@UR[N2(
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MQU3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5C=]JCA2Y1TJVUX(/JR,
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M\%1.5L6J:G!A8K^Z6/K&9Y6C//<QLS1MS/W2GQYDU3O9VLARUO"3^$$56_\
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M._\ 8N?Z:=UJOXU9_P!FD_74^0.HO]<K6:__ -/+9/VO\+OC^/X<?..S6_\
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MY;=_P?\ *U/Z_P KYQV;_P!7:IOR_P XV_\ [+PY>WG4]WJOXU9_V:3]=3Y
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M]FM_\WZI_P"I6^WK_P B_13NM5_&K/\ LTGZZGR!U%_KE:S^GX?^#RV3X?\
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MOXU9_P!FD_7>S]N]/D#J+_7+UG]?_P GEM]'U?\ *Y?Z_N<?..S?33M4\_\
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MU4UV0C".-A@$&8)6-((HGM(,K'HCFO&]BN:]CD5%:YJJBHJ*BJB\4KUD2 1
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M/ ^/B.8K+M"[1Z7VBMVGTZ;B:/'?V\G"MQ 6SPF2,,3P/@]W*O%%)PL$<E6
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MQFN^"G;'&T/>,*6K6K)#'( 1%1?-CT>1'V*?LUIT]Z+PQA6!4\"J N0>@&
M=N0 QS!%9S8_*3VBL=(DTI;AI049$N)&9Y@K C#.S<3LH)",Q+*-@0-JE%'C
M@BA%'C!$  !L$((1L$(0V(C6L&-B-8QC41$1K6HB(B(B?#F0JJJ J@*HV 4
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MQA&P?,;:^1?Y4HOD_P"VTFO=HEO=4LM3L#INH7/$;N^@07%O<PW""=PTJ1O
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MK73G +-<-\ARS[&99%\W"&)BHTTPC6=AM[#:Q%[N154BA%"CD*BZN7NYWN)
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ML.WSC:]([#;D> P ;+RD-CC\@3,DDP=LXOC668%2Y176>.LQBUR_';&H"LJ
M4,;_ !X[]?#V>?.I^/C]GZ<TI!]GWU98G69!78%M.OH8ECB\/'(=</>^ZHQ7
M9; R#J4E46WC9*VHF7D4N,!V?K3)V:J 0N*9!>8W;P;.U8X$6YLI^/CXQ38X
MV&W7R]GJW/7-3QZ:M"[FU'L+8F2[!VE89W0YS63CNK;#*\MR <3*UW)M_)JZ
MUJJG(BR*S%8(M697K[$2U>,^X5WO&*H%8)10HDZ0IOO]'[:FGQ2G%*<4IQ2G
M%*<4KI\B@6=I07E9271<;N;&HL8-3D0(42R/0V4J&8$&X#7SVO@SBUDD@I@X
M<QCHLEX4#(:X3WHJGQX5 36>V^N#4AY."=3/3^;>5/C[!Q*;J6Z;+'$4^SJ
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M_#_;*[^CX_\ I/\ :_K\7[YM<_'W_)6_ZFGV*L/Y@_E9OUE$Z:=)=_C@L/\
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M\VN_C[_DK?\ 45/V*L/YC_BS?K*?:TZ2_4+#_A.\_P!Y_P"W_N?OFUSI?O\
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2*"JFG%*<4IQ2G%*<4IQ2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img134051827_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_2.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2<84&AO=&]S:&]P(#,N,  X0DE-! 0
M    )OR^F8 X0DE-! 0       << @   @   #A"24T$)0      $.CQ7/,O
MP1BAHGMGK<5DU;HX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q >0            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-
M!"8       X             /X   #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _0      !( -0    $ +0    8       $X0DE- _<
M     !P  /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      T$
M   &              00   $)P    8 9P P #$ 80 Q #$    !
M                  $             !"<   00
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   00     %)G:'1L;VYG   $
M)P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   $$     !29VAT;&]N9P  !"<    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P     '64
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M>4\76<6NOR2>%D&OYY*'O4VCLEGU(W,R9IAW&;112**SDDY=8V!EO_W"!A[
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MTRSHK/)6L'CT\(BDSO6"@0PD-GK]2A,Q',[IPK5K3W;\=,/1WFWU;LJS[WH
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MEK1#)XI;YJE6RGG36IM1:/ULL:RT0BI>M=3KU:U*GIFO! T$EB*9J_:.VLP
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M2MBD?7>NO0TK4@^C]7.?X4(I(6T]+)I57]ITM.8<W^]*&;*]3:5(N*- JO\
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MGXF*M(M))@%PSRNDPI\RM'8/JZ%$EXC:'9#8NI<I>[4.'P]^4=G;(9'_ &M
MSO=8FQ=G "U/<IA8%VL1TCYGT2T">SXFI RV\&12\NIT<Q4<3 &J%9E=15._
MC3*U^Z7[3_#UY/A*T)5PMNA-4@H;5RTN:X7MAPS*:RKZHV#_ )4$+@(BQK[
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M]ZJ)@6B7R;^,TIVJ)JXL[ 0,*R_JG2R&R+[?K4JPI#VX:\4/4"XT;3900YV
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M'STC&% Z"OKH720K20%SH02T"IYZVSMS9S&SQ#\JI8UEL39K<Z+X\W>L6;Q
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M')*.PI3SZ#M'PUM-M:]N-:1N-(3IM@N\[8'H$M9DSW=*0]H_>FCF>VS,=-V
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-QQQQQQQQQQQQQS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img134051827_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_3.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2#F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (,J^@Y0X0DE-! 0       << @   @   #A"24T$)0      $.CQ7/,O
MP1BAHGMGK<5DU;HX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q >0            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-
M!"8       X             /X   #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _0      !( -0    $ +0    8       $X0DE- _<
M     !P  /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      T$
M   &              0<   %40    8 9P P #$ 8@ R #(    !
M                  $             !5$   0<
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   0<     %)G:'1L;VYG   %
M40    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   $'     !29VAT;&]N9P  !5$    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     $X0DE-! P     %S,
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MK[-N/]B=[-GJ_K/\RH.ROK: U@Q*"\LDV?F;BT.U;]IW-^SV.]/9N?\ ;?\
M287^$2E865]8'9M3<BIWHDN!#F-:TT!MIJR;; ?T6>^]N-79C?S;*K+/T/\
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M3'(%.-;TVFNG$!OPZ6!C*"8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  "P@ _0%' 0$1 /_$ !X  0 " @,! 0$
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MBMK !T R7]ZM\_+/T<PB:JRL*,FW[51@"E=*>#8_J4<]7^(G.ZU^ >T;,O\
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M<KU[6\>L$\]2U%%OO)7GUCA3CUWFG/C*NONSNL*QIU(ZB5,6<,4Q]Y@O[W*
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MM%RG'4LU\VK,$^+$,/8YA]17DCQR9DZ\R*3X@+*0E<N>G(J4H@BP*B Z*4M
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M<YX1S'E4#7HH@;.DSQ;V(-UHX<.,\YJY)<*E;6=\,)$E7&TKIP^Q,-H,$@&
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M61 C_P!9K59J@XU<BH#JWX;1"A-M#8^[8JZUY)=]LWOX\>/'CQYBS0,*R"B
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M)RZ08\X*8Z$/JCQ&+8UG<*YW-6A=U5V^$IV+LIBL[C]*<XV*\^5"K_<K/+3
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MOY/@=A LN?\ B;MF?AF;1*7L>_)=1$/W.OQ5VO\ =NF\7V,^@7">2;\2!7T
M#?6-.<U#K^Q*2P#3)%B55F?NP=,Z#8"5;%9FO!,JP *U+JDNA!BP$_3\K1$K
:^<EHGQZXK7OX\>/'CQX\>/'CQX\>/'CS_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img134051827_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_4.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0+X17AI9@  34T *@    @ ! $[  (
M   /   !2H=I  0    !   !6IR=  $    >   "TNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M36EC:&%E;"!286EB;&4    %D ,  @   !0   *HD 0  @   !0   *\DI$
M @    ,P,@  DI(  @    ,P,@  ZAP !P   0P   &<     !SJ     0
M
M
M
M
M
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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MU._M/[6_LS['"LN_[-YV_)QC&Y<5Z?;?LM?9[J*;_A,-WEN'Q_9F,X.?^>M
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M6,/&/AEKW[&OB/23=9V^0+Z+?GTV[LUR_P 7/'<7A;P-J9T77;*T\01K"UO
M98GFPTJ D1-G(V%NW3)[4 >@T5R_A+QMHFN:3I, \0Z9=ZO<6D;2V\5W$96D
M\L,_[M3D$88D <8/I4":#X:C^+4FN#6!_P )%)8^0=.-U'_JN#O\O&_MUSB@
M#KZ*9+-';PO+/(L4:#+.[ !1ZDGI6;8>*O#VJW1MM+UW3+V=>L5M>1R,/P4D
MT :M%,FFBMX))KB1(HHU+O([!510,DDGH .]4)?$>AP:7%J<^LZ?'83#,=V]
MT@B?Z.3@_G0!I454T[5=/U>U^TZ3?VU]!G'FVTRR+GZJ2*MT %%%% !1110
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MXFT]2/[6T>ZTR5E[-M(5OJ"Z'_@%>H_##P]_PB_PTT73739,+<33@]1))\[
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MO;.LD4L5N$D5E.0=ZX8\CN:\_P#&[R_#WXWV/CN[MI)="U"U%E?7$:EOLS]
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MZK7D?[.?_(CZW_V'I_\ T7%72S_&#P/%X<.L+X@LY%\KS%M5E'VACC(3R_O
M]N1CWK ^!^B:OIGPFO);B(VMYJMU/>VR.-I0,BJA(/3)3(]B*0Q=>U+X+:!K
M-[#KT6B2:A<3O+=%[,W<@D8DME@K;3DGC(Q7-_#O4-&T[X\76F> ]06;PWJE
M@;EK:)B8XIAUP#RIX/'HWIBI/@;XC\+^&?"^HVGB2^L](\017DOV[^T)!%-)
MTQRW+=^!SG/'.3'X:\0:1XE_:<BO_#L16P_LJ2-)O)\M9RI(+J.,C/&3W4TQ
M&K\1_P#DX+X??\#_ /0C7LE>-_$?_DX+X??\#_\ 0C7LE SP_P"-ME)J?Q0\
M!6$5Y/9&ZEE@-Q;MMD179%;:>QP2,UU'BSX5>"[?X<ZK!::!9P26MC+)#=)&
M//5T0D,9/O'D#.3S6'\5_P#DM/PV_P"OMO\ T9'7I?C#_D1]=_[!UQ_Z+:@#
MS#X.>$M.\8>#;3Q-XS4^(+YMUM NHCS8[>*,[ JH>"3MR6(R<_4F/1[*V\&?
MM.G1O#T0L]-U;3#--:1\1JX#'*KVY3\-Q[5T'[/O_)&]-_Z[3_\ HUJQ]2_Y
M.YTG_L#M_P"@RT",[XI>+-%O/BQ8^&/&.HR67AG3[<7-Y$BR,+N8\HC",$[0
M,'\_:L#XB>(/A-=>%_M/@.YMM.\16#QRV,EA836S,0PR&;RP#QDY)SD#GKGK
MO&5S)\.OCE:^-KV"1]!U6R^PWMQ&A;[.P*X) [?+&??YL<BN\;XG^!ULA='Q
M7I/ED9VB[0O_ -\9W?I0!S'C3XB7NF_ 2U\3V1$.I:G:VZQN!Q%)(H+$?0!\
M>^*N^"_A)X8TSPS;'6-)M-8U.YB$MY=W\2SL\C#+8+9P,G QSZ\U)\7O#<_C
MGX5W,.BJ;BX7R[VU09!EQS@>Y5FP/7 J/P3\7/"VK>&;7^UM7L](U*WB$5W:
M7TRP,DBC#8W$9&1QCGUYI ;FK:'IOAWX:ZWI^BVB6=HMA=.L,>=JED8G&>G)
MZ5YM\"_ .@ZS\/K+6=?M%U>8R31V\-Z/,AMD$AR$C/RY)Y)(S7I&K:]IGB+X
M;Z]?:)>1WMK]ANH_.BSM+"-L@'O]:YS]GW_DC>F_]=I__1K4QF!H]E;>#?VG
MFT;P]"+/3=6TSS9K2/B-7 8@A>W*?AN-=SX\/@&T:TU+X@+IS-"&6V%ZOFD@
MX+;8N=W0=C7&ZE_R=SI/_8';_P!!EJIXFN;'1OVF;34?&QCCTF33=NFW%TN8
M8I!UY/ (._GMN4]P:!'+?$?7/AU_9=IXC^%][9Z=K^G7:,BV5NUJ9$.0?W95
M0>V>.F0>#7H_QXE,_P #[R9A@R/;,0.V9%-<E\?/''A76O")TK1;JWU74?-2
M5I[,"5((P<9:4<#)(& >_/:NJ^./_)![C_MU_P#0UH N^"/ACX8;PC8WVM:;
M#K>HZC:1SW-YJ2"=V+(#A=V=@ .!C' %87P4+:1XV\=>%K1W_LK3KX-:0NQ;
MR<LX(!/LJ_E7I?@__D1]"_[!UO\ ^BUKS3X4?\EI^)/_ %]K_P"C)*0!IO\
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M6D!YI\$V;2/&?CGPK:NYTO3;[=:1.Q/D@LX(&?95_+WKV2O&_A1_R6GXD_\
M7VO_ *,DKV2@9XEX5TVV^+7Q*\1:WXH7[=I6B7)LM-TZ0_NEY.79>A)"@\YY
M;V%6OBUX&TSPSX;/C/P7:PZ%J^CR1R[K%!$DT98*59%PIZ@].1D'.:J>$]4M
MOA-\2O$>A^*3]ATO6KHWNFZA*"(FR3E&;H" P'.,%>>HJ[\6?&^F^)_#9\&>
M"KJ'7=7UF2.(+8N)4AC#!B[.N5'0#KP"2<8IB-;QLFD^+_@C<^)KO2K.:[DT
M0W$$LMNKR6Y:/<0K$$K@^A[4_P"$GA3P\WPY\.:HV@Z8=1^SK+]L-G'YV\$_
M-OQG/OFK?BO1U\/_  !U+2$;>+'0VMR_]XK'@G\2,U;^$?\ R2/PY_UYC^9I
M =E7G'B^]^$VA>(KF[\8QZ/)JUT%,PN;8W<G"A5R@5MORJ.PKT>O"?ACJ^C>
M&?B%XSC\<W=KIVO27[/'<Z@XCWPDM]QVX .0<<9!'7' ,S[#5?"VF_''PW=?
M#"_B73]9#6^HV=L&2/(!P3&P!7J".!RO'4UU?Q?U"]UKQ;X:^'UC=R6=OK3F
M34)8CAVA4_=!]PK_ %P.V0>;\0^*M \4?'SP6_AK;<16MS)'/>QQ;8YI" =J
MM_&5&,GI\P]:Z#XPV=[H/C#PQ\0;.SDO+71W,6H)$,LD1/W@/HS\]CMS3$=C
M'\*? L>EK8#PMIK1!=N]H 93QU\S[^??-<S\=_#^C+\)]9U,:59'4(4MHX[P
MVZF9%\^-<"0C=C!(Z]":Z>'XJ>!9],6^'BG3$B9=VQ[A5E'MY9^;/X5F_&6&
M36?@EK9TQ&N/,@AN$V@Y9%ECD)Q_N@F@9H>!O"GAVR\-Z%J=GH.F6]_]@A?[
M7%9QK+N:(!CO SDY.3GG)KBO^;N?^X/_ .RUU?P]\=>&=5\):!96FM61OVLX
MH/L33J)Q(L8#+LSGC:><8KE/^;N?^X/_ .RT"$\4JWQ&^.B>![Z9UT'1;,7U
M[:HQ7[3(0I )'8>;'_X]Z\=#XQ^$?A;4?"URNCZ1::1J-K$9;.\LHQ"Z2*,K
MDK@L,CG.?7K7.^*)&^''QW3QK?P2-H6MV0LKNZ12PMI!L + #@?NX_K\V.F*
MZ/QA\6_"VG^%KEM'U>TU?4;F(Q6=G92B:221AA00N2HR<G./3K@4 4/!GBNZ
M\8?L^7]_J3F2]AL+JVN)#_RT9(VPQ]RI4GWS7/\ P,\ :%K7@&RUSQ#:KK$Y
M:6&WAOAYL-M&)#\J(<KRV6)QWKH/!OA.Z\'?L^7]AJ2>7>S6%U<W$?\ SS9X
MVPI]PH4'WS4W[/O_ "1O3?\ KM/_ .C6H Y_2;&V\&_M/?V/X=A%EINJZ9YL
M]I'Q&' 8@A>@Y3\-Q]:]LKQO4O\ D[G2?^P.W_H,M=QXH^(ND^%/$FCZ%>VU
M[=7VKN$@2TC1@N6"@MN88!)[9Z&D!UE%%% PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *S-*\-:%H<LDFB:+I^G22#:[6EJD1<>A*@9K3HH *BNK6WO
MK26UO8(KBWF4I)#,@='4]00>"/:I:* .>_X5]X,_Z%'0O_!9#_\ $U);^!O"
M5I=17-IX7T6">%Q)%+%I\2LC Y# A<@@\Y%;M% &7!X8T"UU=M5MM#TV'469
MG:\CM(UF+-G<2X&[)R<G/.36I110!FZKX<T/77C?6]&T_46B!$;7EJDI0'J!
MN!Q5]88D@$"QHL078(PHVA<8QCTQVI]% &9I7AK0M#EDDT31=/TZ20;7:TM4
MB+CT)4#-:=%% &9I7AK0M#EDDT31=/TZ20;7:TM4B+CT)4#-:=%% !69J7AG
M0=:D$FL:)IU^XZ-=6D<I_-@:TZ* *FG:3IVD0>3I-A:V,1Q^[MH5C7\E JW1
M10!F:5X:T+0Y9)-$T73].DD&UVM+5(BX]"5 S5N_T^RU6R>SU2S@O;63&^"X
MB61&P<C*L"#R :L44 4=+T/2=#BDCT32[+3HY&W.EI;I$'/J0H&346E>&M"T
M.6231-%T_3I)!M=K2U2(N/0E0,U/%K&F3:O-I4.HVDFHP)YDMFDZF:->/F9,
M[@/F7DC^(>M7* *,^B:5=:K#J=UIEG-J%NNV&[DMT:6,<\*Y&0.3T/<T:IHF
ME:Y D.M:99ZC%&V]([NW655;&,@,#@X/6KU% $-G9VVGV<=I86T-K;1+MCAA
MC"(@] HX KF_BA_R2KQ+_P!@Z;_T$UU55=4TRTUG2KG3=2B\ZTNHS%-'N*[E
M(P1D$$?@: /+?V:_^252?]A&;_T%*]<K'\.>&-%\&Z.VGZ!:BQLO,:9D,KN
MQ R<N2>@'>KNFZMIVM6ANM'U"UU"W#%#-:S+*FX=1E21GD<4 27MC::E9R6F
MHVL-W;2C$D$\8='&<\J>#R*=:VMO8VD5K9016]O"H2.&% B(HZ  < >U2T4
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MR!KB!9#"W'S*2#M/ Y'I1J6CZ9K,<<>KZ=:7Z1/YD:W4"RA&_O ,#@^]7**
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M&W&,$=J33]-L=(LUL]*LK>QMD)*P6T2QHI)R<*H ZU9I&944LY"JHR23@ 4
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MD&S'U$DCG_@->[T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI'CKQA,]Y?K;2"ZU=F 4J3D;0O/%?05>-_M(?\BWX=_[#"?^@-3 Z'_A4?\
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MK=7MCJ0O+I(VW>1&KQL=V.APCG!]!ZUZ!XE\ >%O&$B2>(]&@O)47:LN6CD
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MY[^&H0^<X2XF1?\ OD.%_2NOT[1=.TC1H])TRTCM;"-65((AA5#$D_F23^-
M'F/[-?\ R2J3_L(S?^@I5?X$?\C)\0?^PP?_ $.6O3?#7A;1O"&E'3?#MG]C
MM#(93'YKR?,0 3ER3V'>FZ#X2T3PS<ZA<:)9?99=2F\^[;S7?S'R3GYB<?>/
M P.:8&%X@^'_ (!\:K+J>IV-E<.P^>_MI_+/ QEG0@'&/XLUR'P(N)H=7\6:
M-I^HS:EX;TVZ2/3KB5MP'+956Z$8"]..AXSSU=W\%?A[>WS7<_AN'S6;<?+N
M)D4G.?NJX7]*ZW2-&TW0=-2PT6R@LK6/E8H$"C/<^Y]SS2 NUXW\"/\ D9/B
M#_V&#_Z'+7LE8V@^$M$\,W.H7&B67V674IO/NV\UW\Q\DY^8G'WCP,#F@#S3
MX4?\EI^)/_7VO_HR2C]I#_D6_#O_ &&$_P#0&KTO2?"6B:'K6I:MI=EY%]JC
M[[R7S7;S6R3G#$@<D] */$GA+1/%UM;V_B&R^V16TPGB7S7CVN 1GY",]3P>
M* -FO/\ XZ123?!77UB0NP6!B ,\">,D_@ 37H%1SP0W5O)!<Q)-#*I22.10
MRNIX((/!'M0!A>!-0M+[X?Z!/:7$<L;6$$8*L/O", K]00<CVKSS_F[G_N#_
M /LM=II/PH\$Z'K\>M:3H4=M?Q,6CD2>7"$C!PA;:.">U:__  B6B?\ "7?\
M)/\ 8O\ B<>3Y'VGS7^YC&-N=OXXS0!ROQX_Y(GKW_;O_P"E,58'B_0[K7OV
M6M+AT^-I9[?2;&Y$:C)94C0MC_@.3^%>HZ]H.F^)]$N-(URV^U6-QM\V+S&3
M=M8,.5((Y4'@U9T^PMM*TRUT^PC\JUM(4@ACW%MB*H51DY)P .3S0!Y[X!LO
MASXS\*V-[8^'/#LESY*BY@^P0&2*0 !@PVYZ]#W&#78Z)H_AC2[JY'AS3M)L
M[A0%N!8011N!S@/L&>QZUB:M\(/ >N7CW6H>'+<S.=SM!))!N/J1&R@FMOPW
MX1T'PC:RV_AS38K".8@R;"27(Z9)))ZF@#9KQO\ :0_Y%OP[_P!AA/\ T!J]
MDK&\2>$M$\76UO;^(;+[9%;3">)?->/:X!&?D(SU/!XH V:\:^-/_)3?A;_V
M&#_Z.MJ]EK&UKPEHGB+4]*U#6++[1=:1-Y]E)YKIY3[E;.%(#<HO!R./K0!P
MWQTT>X_X1W3_ !=I*_\ $R\-7:W2D?Q1;AN!]LA3] WK53X+V\OB76_$7Q&U
M")DDU>X-O8J_5+="!C/_  %5^J&O5[RT@O[&>SO(EFM[B-HI8VZ.C#!!^H-0
M:/I%AH&CVVEZ1;K;65JFR&)23M'7J22?J>: /*/!'_)SOCC_ *]$_P#:5'Q'
M_P"3@OA]_P #_P#0C7I=CX2T33?$]]XALK+R]5U! ES<>:Y\Q1CC:3M'W1T
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M1110 4444 <SX$\":9\/="FTK19[N>":Y:Y9KMU9@Q55P"JJ,80=O6NFHHH
MYGQ9X$TSQE?:/=:G/=Q/H]S]I@%NZJ&;*G#94Y'RCIBNFHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BB@D 9)P* "BJDNI01\*2Y_V?\:IR:I,_^K"H/S-4
MHMF<JD4:]1/=0I]Z5?P.:Q'FDD_UCLWU--S5<ADZW9&NVHPC[NYOH*C.ICM$
M?Q:LW-.JN5$>UF7SJ3=HU'XTG]HR?W4_6J6:7-'*B?:3[EW^T)/[BTX:@W=
M?H:HTH-'*@]I/N: U!>Z'\#4BWD3=25^HK,I0:.5%*M(UEEC;[KJ?QI]8]2)
M-(GW7(]JGD-%6[HU**II>M_&H/TJPEQ')T;!]#4N+1K&I&6Q)1114EA1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ I&944LY"@=2:I7>J16Y*)^\D] >!6//=2W+9E<GT'85:
MBV92JJ.B-2XU=%RMNN\_WCP*SI;F6<YE<D>G:H,U)%%),VV)"Q]JT44CFE.4
MA,TX5H0:0QYN'Q_LK_C5^*T@A^Y&,^IY-)S2+C2D]S'BM9Y?N1MCU/%6DTJ0
M_P"L=5^G-:E%0YLU5&*W*2:9$/O,S?I4RV-NO_+//U)J>BIYF6H170C%M".D
M2?E2^5'_ ,\U_P"^13Z*+LJR&>3'_P \T_[Y%(;>$]8U_ 5)11=A9$!LX#_!
MCZ$U&VGH?N.P^O-6Z*.9DN$7T,]K&5?ND-^E0M&Z??4C\*UJ*KG9FZ,7L9&:
M6M"2UBD_AVGU%5WLW7E#N'ZU:DF92I20R.X>/H<CT-6X[I'X;Y3[UGD$'##!
M]Z7-#BF*-2435HK/BG>/CJOH:N1S)+T.#Z&LW%HZ8U%(DHHHJ30**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI^@[ 4EW=R7EP9)/HJ_W14(R3@<FMXQL<=2HY/38<*V=.TC.);L<=5C/]?\
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MB[5X)P, ]L4:;I-EH\=PFG0^2MS<R74HWLVZ61MSMR3C).<#@=JN44 %%%%
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M3);K D<0(.U8UR!T'.?YFJ7A3X87WA#6[K^S/%$Q\/75Q+<3:.]DA+,Z%?\
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M7@L6 0''7G&:Y'P>VF^*_C;\0Y+:2+4=(O+&WMGFA;?'(#$J,H8<'[K#\#3
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2L+B\N1Y@(CP?E&.N1DX'6NFU/X7:AK$7AOQ%I":/)J%MHT%G<:?KUIYUO(
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M#=<*K;3N\ML'C@$=1GVJE>^&/$6M>&?B-XGET*^LI->6!+'2FB+7#*CKEFC
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M-?>0)&E?>5<X.[9T'X^M>B6=O]CL8+;SI9_)C6/S9VW228&-S'N3C)/K4U%
M!1110 4444 %<KJ5M]EOG4?<;YE^AKJJR=>@WVR3 <QG!^A_^O\ SK:C*TK=
MP,-&9'#H<,IR#Z&NO@E$\"2KT=0?I7'"NAT*??9M$>L;<?0__7S6U>-XW$:=
M%%%<8PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O-/B1\-8]7BEUC080FH+\TT"#BX'<@?W_Y_6O2Z
M*<9.+NAIM'R&T9!((P1U!K<\(^*;[PCK2WEF2\+X6XMR<+*OI[$=CV_,5Z7\
M4/AZ+A9O$&B18E4%[N!1]\=Y%'KZCOUZYSX]LKK34T;IJ2/JC1M8L]>TF#4=
M.D\R"9<C(P5/<$=B#Q5ZOG[X;>,V\+ZO]EO7/]EW; 2^D3= X_D?;Z"OH!6#
M*&4@J1D$'K7-./*S&2LQ:***@D**** "N*\0W'G:S( <B,!!_7]2:[1F"J6;
M@ 9-><SS&>XDE;K(Q8_B:UIK6YA6>EA44O(J+R6. *]#AB$,$<2]$4*/P%<1
MH</GZS;J>BMO/X<_SKNJ*CUL%%:-A11161N%%%% ')^*/B%I/A7Q%H^E7]S9
M(VH2LL[S7J1&T0(6$C*?X21M&<#/?M6[/KVCVVE1ZG<ZK8PZ?* T=W)<HL3@
M]"')P<_6O/OBI8>'XO%W@W4_$-GIPM7OW@N[F\A0JR>2^Q9&8?=W<@'@'FN9
M^(DEO)XX\/C2W\('0%T@_P!G#7=W]GF3S2'\OR_DW!1'UXQTH$>X6MY:WUG'
M=V5S#<VTB[DFAD#HX]0PX(JG9>(]$U.^DLM.UG3[NZC&7@@NDD=/JH.17CEO
M8ZC8?!CQHUAJ.A7,5Q.DH@\+7#2PVT9\L7"J#RI,89MN<<GIG%=[X)_X5GYE
MK_PA/]@?;/)/E_9O*^U[.^[_ ):?7- QGP^\56*^!]%37]>MQJ-WYNQ;V\7S
MIOWS@8W'<W3'X5U]YK&F:?(T=_J-I:NL1G*S3JA$8(!?!/W02!GIDBO&=,\#
M^')_V?-4U>XTFWFU)["]N1>2IOE1XS(4VL>5 VC@8%;5UHVG>(OB=X0@UZSA
MU&$>''F\NY7>K.&CY(/!ZGK0!Z=IVJ:?K%H+K2;ZVOK<DJ)K699$)'4;E)%5
M[?Q)H=WJ;:;:ZSI\]\A(:UCND:52.N4!S^E>8WFE-H5Q\4;'P=:BS8Z5:306
MUHFU4=HY@YC5>C$+V[XK"UP?#(_#*S_X0K^S?^$BQ!_9?V/'V_[3N7;NQ\^<
M]=W'Z4P/48;RY/QDO+(W$QM%T""98-Y\L.;B8%MO3<0 ,]< 5M'Q)H:ZM_93
M:SIXU'.W[&;I/.SZ;,Y_2N0OOMW_  M#6OL6W^T/^$2B\G9T\WSI\8_X%BO/
M8/\ A5I^"Q^T?V=_PD'V(^9OQ_:/V_;SC_EIGS?^ _A0(]XU+5M.T>U^TZO?
MVMA!G'FW4RQ+GTRQ J!/$>B20&:/6-/:)3&#(MTA4&0X09S_ !'IZ]J\KN3I
M1\>Z&/BTUH%7PY ;9=3Q]F-V6_T@G=\N_P"[U[8JUX;T/PUXEOOB'HWALV*Z
M3>):QQO8!?)23RF.Y-O'#@'CN*0SU:ZO;6QC1[VYAMDDD6)&FD"!G8X503U)
M/ '>IJ\J\,:Q<_$'Q#H<&H(1_P (Q"9]50CC^T06A1?PVR2?\"6O3[6]M;Z-
MWLKF&Y2.1HG:&0.%=3AE)'0@\$=J (-3UG2]$@6?6=2L]/B8[5DNYUB4GT!8
MBG'5]-72QJ3:A:BP(!%T9E\K!. =^<=>.O6O,=9_X1;_ (73J7_"Q_L/D_V?
M!_8W]J[?LVSYO.QO^3?NQUYQTKE=5_L__A6_Q._X17;_ ,(OYMM]A\K/E>=E
M//\ +S_#G9TXZXXI@>YV_B#1KO4Y--M-7L9[Z/.^UBN4:5,=<H#D?E1J?B#1
MM%>--8U:QT]I?]6MU<I$7^FXC-<'XK\&^'?#MYX0N]!T>STZYBUZVA$UM$$=
MT8.&5F'+ ^Y-9.GGP0?B#XL_X6/_ &7_ &Q]O_T;^VMGE_8]B^5Y?F?+_>SC
MFD!ZM>ZOINFV(O=1U"UM+1@"+B>=4C.>GS$XJ:TO+:_M([JQN(KFWE&Z.:%P
MZ./4$<&O%/B<Q/Q!T%8&\*#1ETC.GKXBW_8"YDPQ39\F=GE8SQ@\5UOP?L)K
M'3-8)U'P[=6]Q>B6*#PY<-+;6Q**&49^[G ;;G'/:@#M]3UK2]$@6;6=2L]/
MB<[5DNYUB5CZ L13SJ=@&M5-[;@WO%J#*O[_ (W?)S\W'/';FO$OB ;IOC%>
MB^;P?Y2V$ L5\7>8(=AW;S%CY-V_.2>>%QWK5TOP_?0?!Z6YLKW2-1O='U)]
M6TW^Q+AIK:,(V]H$8\X*F1=N3]X4 >MR7MK#>0V<MS"ES<*S0P-( \@7&XJO
M4@9&<=,BJT/B#1KC57TNWU:QEU! 2UHERC2KCKE <C\J\^L[^?Q<_BSQEX?+
MR?9]*?3=#91RSB/S'<#U,A1>/^>=>:^&=/:_L=!73]3^&MC<0W%O+'<Q7,T6
MIEPRDAB_+.W*E2"#D@=J8'T7>Z_H^G>?_:&K6-I]FV&?S[E$\K?G9NR>,[6Q
MGK@^E6+._L]1@,VGW4%U$'9#)!('4,IP5R.X/!%>;KX8T7Q%\=/$+:[IT&H+
M:Z=9M%'<KOC!;?DE#P3QW''/K5;Q#JESX \0:[I6DQXD\31I<:+&HPJWS,L,
MJC'3[T<I^C4@/4[2]M;^W\^PN8;F'<R>9#('7<I(89'<$$$=B*FK-\.Z);^'
M/#=AH]G_ *FSA6(,>KD#EC[DY)]S6E0 5!//Y; +R>]2R.(XRQ_"LXDLQ)ZF
MKC&YC5GRZ(OQ3+*..#Z&I*SHD+R +Q[^E:(X%*22'3FY+4****DU"BBB@ HH
MHH **** "BBO)OBOX\\2:5XRT+P?X0NK#2[S5(VF?4M0QY<8&<*,@C/RGL>J
M@=: /6:*\Y^#'CS5/''AR_&O+ U_I=XUI+<VW^JN,#(9<<?EQT/>O1J "BFK
M+&\CHCJSH<.H.2OU]*=0 4444 %%%<1\8/%&H^#OA=JFLZ+-'#?PF)87D0.!
MNE53P>"<$T =O16;X<U"35?"VE:A.5,MU9Q32%.FYD!./Q-:5 !1110 4444
M %%%% !1110 4444 %%%% !1110!R7Q"O/)T>"U4X-Q+DCU5?_KD5YT*ZCQ_
M=>=XA2 'Y8(0"/0GD_IBN8%>K0CRTT>/B)<U5GH_@"R\C19+IA\UQ)QQ_"O'
M\\UU54](M?L6C6EOT,<2@_7'/ZU<KS:DN:;9ZE./+!(****@T"BBB@"&\O;7
M3[5[J_N8;6WC&7EFD"(OU)X%9\'BOP[=:?<7]MKVF36=MCS[B.\C:.+)P-S
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MHRQ) QZ\CBJOPRU"TT#X@:3X42Q\(ZR[6LGE:[H2*TT85"?WS@'EL8.#_$*
M/5O&VO7>CZ;:6FC[#J^K7265EYB[EC9LEI&'<(@9L=\ =ZT[[6=,T&UA.NZO
M9V>X!1+=SI")&QSC) _ 5SGBXB#XB>!;F?B#[5=P;R>%E>W;9^)VL/QKS?QP
M;I_C%K*Z@W@O8+6W6Q7Q<90HAV98PX^3_6;\GKD"D,]ZCD2:)9(G5XW 964Y
M# ]"#5;4M6T[1[7[3J]_:V$&<>;=3+$N?3+$"N0^&OE>'?AW NK:WHDML+J0
M0SZ?>;[2-7D.V)'?T8[0"2>@R:Q?%9\-GXS0#XA-9C35T@'3%U+'V8RF4^:3
MN^7?C9U[8H ])L=6T[4]W]FW]K>;%5F^SS+)M#?=)P>AP<>N*MUYG\/;CPU:
M>+/'%SX=FTZ#183:R&6T9%MTQ$Q=LCY0 <DGIUKT)M3L$2U=KVW5;U@MJQE7
M$Y(W )S\Q(!/'89H M4444 %%%% !45S"+BUDB/\2D#V/:I:*%H!QA!!P>"*
MT-%F\O4 IZ2*5_K_ $J'4HO)U&9>Q;</QYJ"&0PSI(/X6!KTG[\/41V%%'6B
MO-&%%%% !1110 4444 %%%% !1110 4444 %%%,GGBMH'FN94BBC&YY)&"JH
M]23TH ?17COBGX^VG]HG0_AMILOBC67.U7A4F!#ZY'+@>V!_M5B#X->/O&^=
M;\>>,9M/U5!OL;6SY2T;MG:0!Z?+S[F@#WVBO!8OB%\1?A1,MI\2])?7M&5M
MJ:S9<LH_VCP"?9MI]S7K?A3QQX=\;6'VKPWJ<-V ,R19VR1>S(>1_*@#?HHH
MH **** "BBB@ HHHH **** "BBB@ KPOXF>"?[!U(ZGIT0&G73\HHXAD/)7Z
M'DCTY'I7NE5M1T^VU73IK&^B$MO.NUU/\_8CJ#5PERNXXNS/E?97L?PD\7->
M6Q\/ZC+NFMUW6C,>60=4_#M[?2O-O$6@S^'M<N-.N<GRVS&^,>8A^ZWXC]<U
M3T^]N-+U&"^LG\N>W<.C>X]?;MBNF24HFS5T?4=%9OA_6[?Q#H=OJ-J<"5?G
M3/,;C[RGZ'_&M*N/8P"BBB@"KJ4GE:7<OZ1-C\J\]S7<>(Y/+T*?U;:OZBN&
MK>GL<M;<Z'PE'NOYI#_#'C\S_P#6KK*YSPA'BWN9/[S*OY _XUT=9S^(VI?"
M%%%%0:!1110!6U#3;'5K-K35;*WO;9B"T-S$LB$C_98$5!/H&CW.EQZ9<Z38
MS6$8 2TDMD:) .F$(P/RK0HH IZ=I&FZ/:FVTC3[6P@)R8K6!8E)]<* *AL?
M#>AZ9?27NFZ-I]G=R AY[>U2.1L]<L!DUI44 54TO3X]+;38[&V6P=&C:U6%
M1$RMG<I3&,')R,<Y-*NFV*7<-TEE;K<01>3%,(E#QQ\?(IQD+P.!QQ5FB@"&
M.SMHKR:[BMH4N;A56:98P'D"YVAFZD#)QGIDU2M_#6A6FIMJ-IHNGP7SDEKJ
M*U196)ZY<#/ZU+K6M:?X>TF74]8N/L]G"R*\FQGP7<(O"@GEF Z=ZSO%6NW.
MA_V+]D2)_M^K064OF@G"/NR1@CGCC.1[4 ;(L[87S7HMH1=M&(6G\L>84!)"
M[NNT$DXZ9)JD?#>AG5O[4.BZ>=1SN^V?94\[/KOQG]:TZ* ./\>-JLD5O;6'
M@*R\7VK9:1+N\AB$3#I\LJD'Z@U#X!\/:OHZZQJ^N6EI:7NIO&4TRPQY5K%$
MFU(P>!D\Y[5VU% ')>"-"U+1_#-[=7\$,6OZM<37]TA8%4E<_)&67/"J%7(S
MT)[U?\$^'Y/"_@W3]*NI4FNHD+W4J=))G8O(P) )&YC@D#C' K>HH I:GHNE
MZW L.LZ;9ZA$AW+'=P+*JGU 8&A]&TR723I<FG6CZ<5VFS:!3"1G.-F,8SST
MJ[10!#<6=M>>5]KMXI_)D$L7FH&\MQT89Z$9X(YJIJ?A[1=;>-]9TBPU!HO]
M6UW;)*4^FX'%:-5=4NGLM'O+J(*9(('D4,."54D9_*@!M[H^F:E8K9:CIUI=
MVBXVP3P*\8QT^4C%+IND:;HUL;?1]/M;" G<8K6%8ESZX4 55\+:I-K?@_1M
M5NUC2>^L(+F58@0H9XU8@ DG&3W)K5H I:GHNE:W"L.LZ99ZA$ARJ7=NLJJ?
M4!@:DL=.LM,LUM--L[>SMD^[#;Q+&B_10,59HH K:?IMCI-DEGI5G;V5K&24
M@MHEC1<G)PJ@ 9))JDWA3PZVI_VDV@Z8;[=O^U&SC\W=Z[\9S[YK6HH @2QM
M(KZ6]BM84NIE5)9UC DD5?NAFZD#)P#TS7-W^B7NK_$S3;^\ME72=%M7DMI"
MRDS74ORDXSD!$'<#EN.E=710 445'-)Y<9/<\"@3=E<K7,F^3:.BU#14MO'O
MDR>B\FM]D<.LY%FWB\N/)^\>M2T45BW<[DDE9!1112&%%%% !1110 4444 %
M<WXQ\ >'/'MI#!XFT\7/D$F&17*21YZ@,.<' XKI** /G'Q1IFI? OQSIQ^&
MDHNX/$68!H-R6DS*, ..<XR1SD'J.G2_XG\6?&_P-X=N-:URWT2[LW3:YMDW
M-9,W"L0,9P2/[P]:/C?XB@TCXL^#]0T0-JNM:29'GTR!"[>21G)QG!(W?H:I
M?$;X[Z?XN^'^HZ)X5T75)KNZ@*W;36^%M(^KDX)YP,=@.M 'HOP:\&QZ!X9;
M7;G5)-7U;Q"D=Y>7C.2K9&55<^FX\GG/IP*]'KCOA-=Z5<_"S0DT.^6]M[>T
M2%W'!60#YE8=B#VJQXH^)?A#P:QC\0:Y;V\X&?LZ9DE_[X4$C\<4 =+<3"WM
MI9G!*QH7('4@#-?-Z?'CQK%;Q>,KF#26\+3:B;+^S48?:E &<]<YQWZ9[ $5
MW*_M+?#QYO+:YU!5)QYC69V_H<_I4'A/P-\'?%/BC_A)/"[V]]=))]H^R+.P
M2-\YW>2V".><'CVH 3_AISP9_P! SQ!_X!Q__'*YCP=X?A_: UW6_$_B^]O6
MTBTNC:Z?I<4OEB-<!LMCO@KTZG// %>Q>/O'VD?#WPZ^I:L^^5\K:VB']Y</
M_='MZGM7@*6?Q)^'WAO5OB;:2V.D0ZK<"XNM$DC+!5DD 1MIZ'+],@@?E0!M
M3ZFG[._Q,ATU+S4-0\*:K:M,++(EEMW!(RH) ZCVR#SDBO8/ 7Q%TCXB65W=
M:);7\"6DBQR"]@$9)(R,8)!Z>O'XUR/PT\!:O=Z]#\1?'>JQZGK%Y:+]BBA3
M;':Q.N>.G.#C '&3R2<UZU0 4444 %%%% !1110 4444 %%%% !1110 444$
M@ D]!UH \?\ $=Q]I\2W\F<CSBH/LOR_TJ+2+?[7K-G >1),H/TSS^E5)9#-
M/)*W5V+'\36[X+A$WBFV)Z1AG_\ '3_C7L/W8>B/$C[]3U9ZG1117CGMA111
M0 4444 4]3T?3-:MA;ZSIUIJ$*MN$5U LJ@^N&!&:=8:7I^E6GV72[&VLK?_
M )XVT*QI^2@"K5% &79^&- TZ_:^T_0]-M;ML[KB"TC20YZY8#-<+'X#NK[X
M\ZWK>MZ-;W?A^[TI+>-[D12H\H,/'EDD_P #<D8XKTZB@#AOB=X4N-6^$>I^
M'O">FPB:00BWM(-D*86='.,D*. 36MX4\*:;HVDZ;.VBV-MJ\=E%%<7$=O&)
M=PC 8&11D\@CK71T4 5(M)TZ#59]3@T^UCO[A0DUVD*B650  &<#) P.">PJ
M'5/#NB:XR'6M'L-1,8PAN[5)=OTW XJ+6?$5IH=]I-K=QS.^JW8M(#$H(5]I
M;+9(P,*>F?I7/:Y\4;/1O$MYHD7AOQ'JUS9+&\\FEV GCC$B[ER0X(XSU'8T
M =)<>&=!N].BT^[T33I[*$DQ6TMI&T<9)R=JD8'X4X>'M%&D'2AI%@-./6S^
MS)Y)_P" 8Q^E9WA;QSHGB_[1'I4LL=W:X^T65U$89X<^J'M[C(K/U_XG:1H>
MM2:1:V&K:[J,(!GMM&LS<-!GD;^0 <=LYH Z*PT#1M*M9;;2])L;*"88DBMK
M9(U<>X4 &I;72M.L=,&FV5A:VUB%91:PPJD0#$EAL Q@DG/'.363X4\;Z/XQ
MCN!I;3PW5HP6YLKN(Q3P$]-R'^8R*Z&@"KIVF6&D6:VFDV5O8VRDE8;:)8T!
M/)(50!5&;PCX;N-0-]/X>TJ6\+;C</91F3/KN*YS6Q7.>,?&EIX,M;*6[T_4
MM1>^N/L\%OIL EE9]I;[I89X4],T ='66GA?0(]5_M./0]-6_#;OM:VD8ESZ
M[\9S^-<_H/Q0TC6M=AT:ZT[6-#U&X4M;VVL61MVGP,G:<D'CWJC-\8;"/4K^
MU@\+>*KR+3[N6TGO+331+ 'C;:WS*_3CTSR.* .MU'POX?U>[%UJVA:;?7"]
M)KFSCD<?BP)JQ)HNES2V4LNFV;R:>,6;M I-MP!^[./DX '&.@JCH'B_1O$^
MB2ZIHEU]I@A++*FTK)$RC)5E."#]:L>'-=MO$_AVRUJP2:.VO8A+&LP <#W
M)&?QH D_L'2 UZPTJQW:AC[8?LR9N<9QYG'SXR>N>M-TOP]HNAESHNCV&G&3
M[YM+5(MWUV@9K1K&UOQ$F@ZAI<=[;/\ 8]0G^S&\5OE@E;_5AAZ,<KN[' /6
M@!_B;P_!XFT.2PGE>WD#K-;W,7W[>9#N21?<$=.XR.]2W^@Z9K-K##K^G66J
M>4!S=6J2#=CD@,#C-:-% % :%I(TQ-.&EV0L8V#):BW3RE(.00F, @\].M<]
MX\;59(K>VL/ 5EXOM6RTB7=Y#$(F'3Y95(/U!KL** .'\"^%+^T@UN\\4V6G
MP2:T41M*M4#V]O D>Q8SQAL@G/;FM.]\,S7?C30;Y/LT.D:+;S>3;(,-Y[A4
M7"XP%5-^.>IZ=ZZ6B@ HHHH **** "B@G )/:J?]KV)_Y;_^.G_"FHM[(#,U
MZ/;=1R#^),?E_P#KK+K5UBZM[J.(P2!V4G(P1P?_ -595=]*_(KB.LLG\RQA
M;J2@S]:GK*TR_MX]/2.:559<\'ZU<&H6A( G3)]ZXY0:D]!EFBBBLP"BBB@
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MTIM3;[(W.=OEXR%]@: .U5E=0R$,K#((.012TBJJ*%0!548  P *6D 4444
M%%%% !5.Z?=)M'1:MLVU2Q["LUCN8D]35P6MS"M*RL%7X(_+B'J>35.!/,F
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M20I=ZSI\#CJLETBG\B: -*BJMGJFGZA_QX7UM=?]<)E?^1JU0 4444 %%%%
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MHH *X7XU63:A\&?$<* DK:B7 _V'5_\ V6NZJMJ=A#JNDW>GW(S#=0O#(/\
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MS4/%7C^_0J^M7K1V^>T:L6./;)5?^ 4 >W4444 %%%% !1110 4444 %%%%
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M-&N/LNM6<QZ),I/TSS^E>O+WH>J/%C[E3T9[%1117D'M!1110 4444 %%%%
M!1110 4444 %%%% !114%]-);Z?<30*'ECB9D5NA(&0* )Z*\4\)_$?XJ>)/
M#-OKMAX3T;4[.<L%$-X87^4X((8G'(K5E^*OC'2K=YM?^%^JQ1QJ6D>SN$F"
M@=3Q0!ZM161X7\3Z9XP\.VVM:).)K6X7(_O(W=6'8@]JUZ "BO//$?Q9BTSQ
M3-X=\-Z!?^)M2MHP]TEAC9;$]%9CT-9__"<?%*]?;8?#6.U4]'O=20?H* /4
MZ*\U^''CCQ3X@\9^(M \66&GVLNCI"2+)F;#/DX))YX'M7I5 !1110 4444
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MX82^$(+C7O$TOV[Q3JF7N[AVW&$$Y* ^N>I]L#@5Z90 4444 %%%% !1110
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M1@8QGC@C)K3F^%?@6XU);^7PKIAN%(.1  I(]5'RG\176T4 ?-OQ*T1_A_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4M)HOT445B=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 $X&3P*HZ;JUO
MJOVC[*<K#)LS_>XZ_3K^5<YXP\0[ VF63_,>)W!Z?[/^/Y52\!W?EZK/;,<"
M:/</<J?\":W5%^S<F<KKKVJ@COJ***P.H**** "BBB@ HHHH **** "BBB@
MHHHH Y_Q[K\OA?P!K6M6RAI[.T>2($9&_&%)]LD5Y?X:\,?$W0_#&G>(O#?B
M@:])J%LEY=Z3JK$HS.-_[M\_*<'IP,UZ_P"(=/L-5\-ZC8:PRK87-L\=PS-M
M"H5()SVQUS7B?P<^+=C877_"$ZS?K<65M.UKI&LE2D=PH/RQMGH<8P>_3TR
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MXKM1B2V?B.Z']^(]P>N.?;-5_C=I_AR7PK%J6LZQ'H>K6#^;I5^"?-64<[5
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METD8D\J5 0"4;AAACP:RO#'@35])\7GQ%XA\5RZ]>-8R66&LDMU56D1P5"'
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MA>&M;&I6OD7#?Z5$.<G[Z^OU]:W:Y6FG8[$TU=!1112&%%%% !1110 4444
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MDIW[A1117.=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0*'## ZC)4_AGM7IM% '@WB;QEX>\8^//AY+X7662&UU14DF-F\2(24Q'N8
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MD^M 'KM%>7ZEH6M>#O$'A[58_&.M:HU_JL5E?6M]*IMW20-DI&% 0@@8Q_\
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M %Z]4JII>FP:3IT5G:C"1CJ>K'N35NO.JU/:2OT/6H4E2A;J%%%%9&X4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% ',ZOIWV6;S8A^YD/_?)
M]*SL5VDT*7$+12C*L,&N3O+1[.X:)^G56]17;1J<RL]P-+3KB&_L9=+U%%EB
MEC,9209$B$8*G\#^58>E?"NQT74[:YTWQ)XHAM;617BTW^U6-J I!"%,9*\8
MP3R.*>"58%3@@Y!':NETK4A=Q^5,<3*/^^AZUG6IV]Y 1:=X=M-,\0ZSK-O)
M,UQK#0M<*[ HIBC$:[0!D<#G)//I67=_#S1K[P_>Z3/)>>5=ZC)J8F28)+!.
M[E]T; #&"3C.>.N:ZJBN8#C?#GPTT_P[X@36_P"V=<U74%A>#SM4O?/)1BIQ
M]T8QMXQCJ<YXQF2_!;1))[IH];\16]O>S237EG;ZAY<%RSN6.]0O(YV\8X [
MY)]%K,T#7K7Q%I\EY91S1QQW,UL1,H!W1.48\$\94X]O2@"!O"FF?:M!FMT>
MV302_P!C@A(" -$8L,""2 K<8(Y]:HZAX TK4O#^OZ1/<7BV^OW9N[ID=0Z.
M1&,(2N /W2]0>IYK<_M:R_MS^Q_._P!/^S?:O)V-_JMVW=G&.O&,YK&B\=Z9
M-X?T_6%@NQ;W^I#38E*+O64SF#+#=C;N4G()..V>* -/6="MM<^P?:WE3[!>
MQWL7E$#<Z9P#D'CGG&#[UYA\0IOA]I_C2:?4_$6O:#KLL:?:(]%:>(WH &P,
M50JQQ@<$>AKU2+5[&;6KC28Y]U];0I/+%L;Y4<L%.<8.2K< YXJ[0!Q'PDTV
MXT[P0S7-I<60O+ZXNX8+IBTR122$IO)R=VW!.3GGGFNAM?#MI9^*M0U^*28W
M6H0102HS#RU6/=M*C&<_,<Y)K6HH X/6?A%HFL:M>WJZEK6G1ZBY>^L["^,5
MO=L1@ETP<YQS@C-;Y\'Z6NJZ#?6RR6W]@0RP6<$1 C"2(J$,""3@(,8([YS5
MO^W;;_A*O[ V2_:_L7VW?@>7LW[,9SG.?;&.]:5 '.>+O!%AXQ6R>[O-0T^[
ML)&>VO--N/)FBW## -@\$ 9X[59L/"]KI^L6VIK=7EQ<V^F)IH:XE#F2-6#;
MV.,ER1R<\^E;5% &#+X-TFYDU_[;')=1>("GVR"5AL^2)8P%P 1PH.<DYY&*
MRM!^&T'A_5X;VW\4>*+F* GR[&ZU0R6X!&,;,#(&>YKH=9UVVT/[!]K25_M]
M['91>4 <.^<$Y(XXYQD^U:5 &3H7AVT\/OJC64DSG5+^34)O-8';(X4$+@#"
M_(.#D]>:3Q/X:L/%N@3:1JOFB"4JP>!]DD;*0593V((K7JKJ.J:?H]F;O5[Z
MVL+8$*9KJ98D!/0;F(% ',W/PUTR_P#"L&B:GJ>LWS6]Q]I@U*XO2UY%)V*R
MXXP#C&,5+X:^'NE^&GOKB.\U+4K^_C\J>_U.Y\^<IV4-@  ?3TJU_P +!\&?
M]#=H7_@RA_\ BJWH9HKB".:WD26*10Z2(P974C(((Z@CO0!SO_"":9_PKK_A
M#//N_P"SOLWV;S=Z^=MSG.=NW/\ P&K^I^';35;?3(KB295TR[BNX3&P!9XP
M0H;(.1SSC'UK6HH XO7_ (7Z3KFN3:O;ZEK.BWERH2[?2+TVXN@!@>8,'/''
M:KC?#W0QX6L/#]JDUK96%U%=Q^4XWO(C[\NS YRW7OZ8K5GUZUM_$]GH3QS&
MZO+:6YC<*-@6,J""<YS\XQQZT:!KUKXBT^2\LHYHXX[F:V(F4 [HG*,>">,J
M<>WI0!IUQ&J?"O2K_7[C5[#5]=T.XNW#W2Z1?FW2X;U88/)]L?G7;T4 <EXC
M^'6F>(M0AU%=0U;2=2CB$!OM*O#!+(@Z*YP0W4\XSS4X\#VC^%[?1+S5-6OH
MX+J*Z%U>77G3N\<@D4%V'W<J. !QTQ734V21(HVDD8*JC))[4 94NDV5GXDG
M\2RRRBX>Q2R9"PV;%=G! QG=ESWQTXKG;^\DO[III.G15_NCTJSJNI/J$^%R
ML*GY5]?<UGXKMI4^57>XQ$C:21412S,< #N:[/2M.73[0*>97YD;W]/PJCH&
ME^4HNYU^=A^[![#UK<K*M4N^5""BBBN< HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "D=%D0K(H93U##(-+10!E7'AK2KG)-J(V]8B5_3I65<>"
M(CDVEVZ^@D4']1BNJHJE*2(<(OH<++X.U*/[C02?[KD?S%5)/#VJQ?>LW/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!FWFCQ3Y>#$4GI_"?\ "L.>VEMI-DR%3V]ZZZFR
M1)*FV5%=?0C-;PK..C X_%207$ML^Z&0H>^.AK7NM#4Y:T;:?[C=/SK)GMIK
M=MLT;*??H?QKJC.,T!J6^O'@7,7_  )/\*TH+VWN?]5*I/\ =/!_*N4HJ)4(
MO;0#LJ*Y:'4+J#[DS$>C<C]:N1:]*/\ 71*P]5.*P="2V W:*S$UVW;[Z2(?
MID5.NJV3?\M@/JI%9NG-= +E%0"^M6Z7$?XL!3OM=N?^6\7_ 'V*GE?8"6BH
M3>6PZW$7_?8IC:E9KUN$_ YI\LNP%FBJ#ZU9KT=G_P!U?\:K2:^@_P!5 Q]V
M.*I4YOH!L4C.J+N=@H]2<5SLNM7<F0A6,?[(_P :HR2R3',LC.?]HYK18>74
M#H;C6K6'(C)E;_9Z?G65<ZQ<W *H1$OHG7\ZH8HP3TK>-*,0$HK0M='N+C!<
M>4GJW7\JV;73+:UP57>_]YN31*K&(&/9:--<8>;,4?OU-;UM:PVD>R! OJ>Y
MJ:BN2=24]P"BBBLP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,^[T2RN\DQ^6Y_BCX_3I
M6%>>&;N'+6K+.OI]UORKK:*TC4E$QG1A+H>;S120OMFC:-O1ABHB:]+DC25"
MDJ*ZGJK#(K+N?#>G7 .V(PMZQG'Z=*WC775'-+"R^RSA2::'*-E25(Z$&NGG
M\&ODFWO%([!TQ^HK/G\*ZI%G9'',/]AQ_7%:JI!]3G=&HNA135]0A&([R8 =
M!O)J5?$NK1]+QC_O(I_F*ADT?4H_O6-Q^$9/\JJ26MQ'_K()5^J$55H,GFJ1
M[FK_ ,);JP'^N3_OV*8?%NK]KA1_VS7_  K&.?2FE'/1&/X4_9P["]K4[LU)
M?%.L2<&]8?[J*/Y"J4VL:C-_K+ZX8>GFG%0K:W,IQ%;RN?14)JPF@:M+C9I\
M_/\ >3;_ #IVA'L*]27=F>[L[%G8L3U).:C)KH(/!>LS'YXHX!ZR2#^F:U+?
MX>]#>7_U6)/ZG_"DZM-=1JA5ET.()J2VL[J]DV6=O+.WI&A.*]+L_!NCVC!C
M UPPZ&9MWZ=*VXXHX8PD*+&@Z*HP!64L2E\*-XX.3^)GG6G> =0N2&U!UM(\
M\KG<Y_+@?G77Z9X6TK2MK0VXEE'_ "UF^9OP[#\*V**YIUISW9V4\/3AL@HH
MHK(W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1E#*58!@>H(I:* *$^CV
MLV2@,3?[/3\JS9M$N8R?*VRCV.#^1KH:*UC5G$#D)(983B6-D/N,4RNR(!&"
M,BJ\FGVLOWX$SZ@8_E6RQ"ZH#E:*Z%]#M6^Z9$^C?XU V@+_  7!'U7/]:T5
M: &+16L= D_AG0_4&F_V#/\ \]8_UI^UAW RZ*U1H,W>:/\ (T]= ;^*X ^B
M?_7H]K#N!C8HQ6\N@PC[\SGZ "K$>D6:=8RY_P!IC4NO! <S@DX'-6H=-NY_
MN0L!ZMQ_.NFC@BB_U4:I_NKBGUF\0^B QH-!Z&YE_P" I_C6G!9V]M_J8E4^
MO4_G4U%82J2ENP"BBBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **AN7:.,%#@Y
MQ5;[3+_?_04[7$Y6+]%4/M,O]_\ 04?:9?[_ .@I\K%S(OT50^TR_P!_]!1]
MIE_O_H*.5AS(OT50^TR_W_T%'VF7^_\ H*.5AS(OT50^TR_W_P!!1]IE_O\
MZ"CE8<R+]%4/M,O]_P#04?:9?[_Z"CE8<R+]%4/M,O\ ?_04?:9?[_Z"CE8<
MR+]%4/M,O]_]!1]IE_O_ *"CE8<R+]%4/M,O]_\ 04?:9?[_ .@HY6',B_15
M#[3+_?\ T%'VF7^_^@HY6',B_15#[3+_ '_T%'VF7^_^@HY6',B_15#[3+_?
M_04?:9?[_P"@HY6',B_15#[3+_?_ $%'VF7^_P#H*.5AS(OT50^TR_W_ -!1
M]IE_O_H*.5AS(OT50^TR_P!_]!1]IE_O_H*.5AS(OT50^TR_W_T%'VF7^_\
MH*.5AS(OT50^TR_W_P!!1]IE_O\ Z"CE8<R+]%4/M,O]_P#04?:9?[_Z"CE8
M<R+]%4/M,O\ ?_04?:9?[_Z"CE8<R+]%4/M,O]_]!1]IE_O_ *"CE8<R+]%4
M/M,O]_\ 04?:9?[_ .@HY6',B_15#[3+_?\ T%'VF7^_^@HY6',B_15#[3+_
M '_T%'VF7^_^@HY6',B_15#[3+_?_04?:9?[_P"@HY6',B_15#[3+_?_ $%'
MVF7^_P#H*.5AS(OT50^TR_W_ -!1]IE_O_H*.5AS(OT50^TR_P!_]!1]IE_O
M_H*.5AS(OT50^TR_W_T%'VF7^_\ H*.5AS(OT50^TR_W_P!!1]IE_O\ Z"CE
M8<R+]%4/M,O]_P#04?:9?[_Z"CE8<R+]%4/M,O\ ?_04?:9?[_Z"CE8<R+]%
M4/M,O]_]!1]IE_O_ *"CE8<R+]%4/M,O]_\ 04?:9?[_ .@HY6',B_15#[3+
M_?\ T%'VF7^_^@HY6',B_15#[3+_ '_T%'VF7^_^@HY6',B_15#[3+_?_04?
M:9?[_P"@HY6',B_15#[3+_?_ $%'VF7^_P#H*.5AS(OT50^TR_W_ -!1]IE_
MO_H*.5AS(OT50^TR_P!_]!1]IE_O_H*.5AS(OT50^TR_W_T%'VF7^_\ H*.5
MAS(OT50^TR_W_P!!1]IE_O\ Z"CE8<R+]%4/M,O]_P#04?:9?[_Z"CE8<R+]
M%4/M,O\ ?_04?:9?[_Z"CE8<R+]%4/M,O]_]!1]IE_O_ *"CE8<R+]%4/M,O
M]_\ 04?:9?[_ .@HY6',B_15#[3+_?\ T%'VF7^_^@HY6',B_15#[3+_ '_T
M%'VF7^_^@HY6',B_15#[3+_?_04?:9?[_P"@HY6',B_15#[3+_?_ $%'VF7^
M_P#H*.5AS(OT50^TR_W_ -!1]IE_O_H*.5AS(OT50^TR_P!_]!1]IE_O_H*.
M5AS(OT50^TR_W_T%'VF7^_\ H*.5AS(OT50^TR_W_P!!1]IE_O\ Z"CE8<R+
M]%4/M,O]_P#04?:9?[_Z"CE8<R+]%4/M,O\ ?_04?:9?[_Z"CE8<R+]%4/M,
MO]_]!1]IE_O_ *"CE8<R+]%4/M,O]_\ 04?:9?[_ .@HY6',B_15#[3+_?\
MT%'VF7^_^@HY6',B_15#[3+_ '_T%'VF7^_^@HY6',B_15#[3+_?_04?:9?[
M_P"@HY6',B_15#[3+_?_ $%'VF7^_P#H*.5AS(OT50^TR_W_ -!1]IE_O_H*
M.5AS(OT50^TR_P!_]!1]IE_O_H*.5AS(OT50^TR_W_T%'VF7^_\ H*.5AS(O
MT50^TR_W_P!!1]IE_O\ Z"CE8<R+]%4/M,O]_P#04?:9?[_Z"CE8<R+]%4/M
M,O\ ?_04?:9?[_Z"CE8<R+]%4/M,O]_]!1]IE_O_ *"CE8<R+]%4/M,O]_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEW?OLQDG<<\"2+Y<8W&FZCHFL>$=>T'5$\6ZQJ;7VJ16=[;7LJFW=) V2D8
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MRKY;,&B;L00.!V_*M'PAX-\OXK>*&_X23Q W]FW5G)AK[(NMT(?;-\OS@?=
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M\1?]C#<_^@1UFM'K7B3XY^*?#Z^)]5TS3(;:";RK.;##]U'PA;(CR7))49-
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M4M6+9S\F/4YQG%=_10!S&K^ =)UC2--LI9KVVETN(16E]:3^5<1 *%.' QR
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M)/IU^E=310!A7'A*PN%\1*\MP!XBC\NZPR_(/)$/R<<?*,\YY_*GWOA>RO\
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M7O/]2/\ >JG5R\_U(_WJITX[$RW"BBBJ)"BBB@ HHHH **** "BBB@ HHHH
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ME:V^T1<+YC-G=NV]".]=EIGB7QZ)+2UNOASY$ *1R7']N0-L7@%]H&3@<XH
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M;;6Z':KCYAD$9R.E6/@_X<U7PM\/XM-UZU^RW:W$CF/S%?@G@Y4D?K7)^/\
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M3Z9IU,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 Z+_7)_O"M*LV+_7)_O"M*HD:1*]Y_J1_O
M53JY>?ZD?[U4Z<=B9;A1115$A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=@7(+%N2 !U/I6K10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*C_YYK_WS1S!RF=16CY4?_/-?^^:/*C_ .>:_P#?-','*9U%:/E1_P#/-?\
MOFCRH_\ GFO_ 'S1S!RF=16CY4?_ #S7_OFCRH_^>:_]\T<P<IG45H^5'_SS
M7_OFCRH_^>:_]\T<P<IG45H^5'_SS7_OFCRH_P#GFO\ WS1S!RF=16CY4?\
MSS7_ +YH\J/_ )YK_P!\T<P<IG45H^5'_P \U_[YH\J/_GFO_?-','*9U%:/
ME1_\\U_[YH\J/_GFO_?-','*9U%:/E1_\\U_[YH\J/\ YYK_ -\T<P<IG45H
M^5'_ ,\U_P"^:/*C_P">:_\ ?-','*9U%:/E1_\ /-?^^:/*C_YYK_WS1S!R
MF=16CY4?_/-?^^:/*C_YYK_WS1S!RF=16CY4?_/-?^^:/*C_ .>:_P#?-','
M*9U%:/E1_P#/-?\ OFCRH_\ GFO_ 'S1S!RF=16CY4?_ #S7_OFCRH_^>:_]
M\T<P<IG45H^5'_SS7_OFCRH_^>:_]\T<P<IG45H^5'_SS7_OFCRH_P#GFO\
<WS1S!RE"+_7)_O"M*FB*,'(10?I3JENY25C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img134051827_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_5.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0+X17AI9@  34T *@    @ ! $[  (
M   /   !2H=I  0    !   !6IR=  $    >   "TNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M36EC:&%E;"!286EB;&4    %D ,  @   !0   *HD 0  @   !0   *\DI$
M @    ,X-P  DI(  @    ,X-P  ZAP !P   0P   &<     !SJ     0
M
M
M
M
M
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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M<_\ (>N/^^4_PK4^-/\ R5"]_P"N<?\ Z"*X'O7KTX1<+M'S]:K-5;)G5?\
M"S?&/_0>N/\ OE/\*/\ A9OC'_H/7'_?*?X5RM%:>SAV,O;5.YU7_"S?&/\
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MC_T'KC_OE/\ "C_A9OC'_H/7'_?*?X5RM%'LX=@]M4[G5?\ "S?&/_0>N/\
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M  LWQC_T'KC_ +Y3_"C_ (6;XQ_Z#UQ_WRG^%<K11[.'8/;5.YU7_"S?&/\
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MI>(?AYJFA:'INH;)KA;F RS+Y>/L_3@_G2]Q6T!2JN[3V(O^%F^,O^@[<?\
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M;XQ_Z#UQ_P!\I_A1_P +-\8_]!ZX_P"^4_PKE:*/9P[![:IW.J_X6;XQR/\
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M )Z7?_?T_P"-'_"@O"W_ #TN_P#OZ?\ &N9_X:)N>^A1C_MKG-'_  T3=?\
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M6AY=_P *"\+?\]+O_OZ?\:/^%!>%O^>EW_W]/^->I8HQ4>UGW-/J]+L>6_\
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M/^%!>%O^>EWQ_P!-3_C7J-+67MI]SH^KTET/+?\ A07A;'^LO.N?]:?\:/\
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M2Y:X>TPIT_\ PH+PM_STN_\ OZ?\:/\ A07A;_GI=_\ ?T_XUS'_  T3=?\
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M!>%O^>EW_P!_3_C1_P *"\+?\]+O_OZ?\:YC_AHFZ_Z *?\ ?VC_ (:)NO\
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M  H+PM_STN_^_I_QJGXO^-5QX8\5WFD+I"SK;D 2%R,Y /\ 6L3_ (:)NO\
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M)7#VF%.G_P"%!>%O^>EW_P!_3_C1_P *"\+?\]+O_OZ?\:YC_AHFZ_Z *?\
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MKTGX+"%M<U@7#M'']@;<R<E5[D5%23BKFM&$93L8&K?#K6]%TJ?4+N2P:&$
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MS@DYSWK2G-S5V8U::@[(3)HR:**K0QU#)HR:**- U#)HR:**- U#)HR:**-
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M^%$>+/[]G_W\/^%'MX!["IV/-:*]*_X41XL_OV?_ '\/^%'_  HCQ9_?L_\
MOX?\*/;P#V%3L>;9'0_EZUZ/<_$W2=2M;.+6O"$.H26L*PI)),5^4?A3A\"/
M%H& UGC_ *Z&C_A1/BS^]9_]_#_A43G3DS6%.K'I^!CV?CNUTS4=6N-*T2*T
MM]1M?LX@60XC_P!K.*S=/\5'3_ ^H^'5M5>.^D60S;^5( [8]JZK_A1'BW^]
M9_\ ?P_X4?\ "B?%O]^S_P"_A_PI<U(?+B%LOP*L7Q(L[C3;(:UX=AU+4=/4
M+;W1D*X ]1BNA\#^*3XG^)6L:W+;+&6TM@8LY5MJCC\<5CGX$>+#U:S_ ._A
M_P *LVOP7\;63N]I=6\#.I1S',06!['':I;I6+BJ]]3%U;Q]:'1+W2?#VA)I
M*WKG[9(LFYI,<8''%2:=\1;/^R+*T\3Z!'JTVF "TG,FPCV/!SVJ\?@5XM+;
MB]GGU\P_X4?\*)\68^_9_P#?PT[TB;8CF9EVWQ+OD\67NMWEJLLEQ;&V2%'V
MK$F,#USQ69=>+I)_ D7ALVNU8[HW'G[^N>V,5TY^!'BS'WK/_OX?\*/^%$>+
M/[UG_P!_#_A5*5%"E"N]#F]6\9RZG8^'XH[98GT146-RV[>5Q],=*U==\=Z+
MK]]:W]WX95KU9%:[?S^)U'\/3C-7_P#A1/BTYR]G_P!_#1_PHCQ9@C=9X/7]
MX:7-2'R5W_PQF:OX_LI/#%QH?AO0UTJUNV!N"TYD+8[ 8&*XCL.<C'%>E?\
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MB$E==T:$Q2$\&9 P D'KD8-;^G^!/#_B?X:Z1J.L6IGN8=-VI)N(P 2?YDT
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M:EX3M[P_Z-)JBK(-Y4,,KQQ6;J5E;>&/BMI<7A>-8&N["=KNVM^%8+@J[*.
M<\9]ZV?B#H;ZY?>&[=K22YMEU!6N-AQL7CDGTK:T/P?HOAZ>6?3+8_:)AA[B
M5B[$>F3T% 'CVC>'->\6^%;J[M=.T^2_N+J9AJDETWVB"19& P=V5VX QQTK
MJ;S04UGXLZ=8:_\ OUCT?=+&'(1W!'4 \CZUU=S\.?#ESJ<EZ;5X99&WRB"4
MHLC=R5K:30=.CU>+5$M\7L4'V=)2<G9Z?I0!G>+9I='\ ZH^C1^7):V3B$(N
M/+P,# ]OZ5F^!_#'A^'PSIFJV-M#<7DD(E:^)WR/(>3\YYZY&*[%XA+&\<J;
ME<$%6YR/0BN<T_P!X?TS5AJ-A;R0RJ_F+&)3Y2MZA: .)\*Z'H_B/P7KNL>)
M8UGU.2>?[1/._P ]L5SM"_W,>@Q6?Y3^(O#?P]AUIII5EOI49BY5I$7(3)&#
M@J!]:]#U#X=^'-4U&6]N;-Q),V^94E*I*?5@.M:TV@Z9<2:<S6R@:<VZT"C'
ME'&./PH X);&W\._%R[MM!A6VBFT1Y6MXAM1G4\-CIGD\UCZ-H.AZG\%KK7M
M497U62"2YFU!GQ-%.,D -U7#<;1]*]8;1;%M=75S!B^\DPB7/\&<XQ6)/\./
M#-UJ37KZ>0TC^8\2N1&[9SDKTH XG["/%6O>![?Q!YKK<:;*T\8D9/-P!C=@
MC.1USZU<OO"/AY/C+I-HNDVJV[Z9-)L"  LKQX/X9/YUZ(^BZ=)J=KJ)@ N;
M.-HX'!^XIX( _"J>O^$](\236TFJP$SVQS#)&Y1T]LCL: -J.-8XU2-555 4
M*.P'2G4R&-8H8XT!VQKM&3T XI] !1110 4444 %%%% !1110 ^/[U25'']Z
MI*0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !11FC- !11FC- !11FC- !11FC- !11FC- !129HS0 M%%% !1110 4444
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M_P +? _YA1_[^_\ UJ3XO_=TWZO_ $KS*K43FG-IV1Z;_P +@'_0)_\ (O\
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MB@ HHHH **** "BBB@ H[T4=Z (F^]3:<WWJ;3 ****!!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% "BGQTP4^.@!'^]333G^]330 E17%S#:0F6YE6*,$
M#>YP.:E^E<1\7U#?#/4$<D(S1C(..KCI0!TEOXDT6ZOI[.WU6TDN+==TL2S
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M"K=W"A990,,X'3FLI_ WAU]7;4Y=.1[DR>82[%E+>NWIG\*Z"B@ ^O6BBB@
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M !H_X:+U#_H!0?\ ?9_QKQFBCE0>TEW/9O\ AHO4/^@%!_WV?\:/^&B]0_Z
M4'_?9_QKQFBCE0>TEW/9O^&B]0_Z 4'_ 'V?\:/^&B]0_P"@%!_WV?\ &O&:
M*.5![27<]F_X:+U#_H!0?]]G_&C_ (:+U#_H!0?]]G_&O&:*.5![27<]F_X:
M+U#_ * 4'_?9_P :/^&B]0_Z 4'_ 'V?\:\9HHY4'M)=SV;_ (:+U#_H!0?]
M]G_&C_AHO4/^@%!_WV?\:\9HHY4'M)=SV;_AHO4/^@%!_P!]G_&C_AHO4/\
MH!0?]]G_ !KQFBCE0>TEW/9O^&B]0_Z 4'_?9_QH_P"&B]0_Z 4'_?9_QKQF
MBCE0>TEW/9O^&B]0_P"@%!_WV?\ &C_AHO4/^@%!_P!]G_&O&:*.5![27<]F
M_P"&B]0_Z 4'_?9_QH_X:+U#_H!0?]]G_&O&:*.5![27<]F_X:+U#_H!0?\
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M$(\2?] N7\Q_C1_PA'B3_H%R_F/\:][Q1BGS$^R1X)_PA'B3_H%R_F/\:/\
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M#CP?;7OVN#P_9)-G._R^A]0*Z;-+@^E " ;1@<>U%%% !1110 4444 %%%%
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M^COGO10 4444 %%%% !1110 4444 /C^]4E1Q_>J2D,:RAL@XP>H-0"PM?\
MGWC_ .^15FBB[%9%5K&V XMXP?\ <%4[;P_96]PTYB$DC'.YAP/PK6HQ3YF+
ME5QH ' Z=@*<.E)12*(Y9HXR!(ZKGIN.,TQ;JW/'G1CT&\5XM^T3))&-$,3N
MF3)G:<= *\0-Q/\ \]Y?^^S5J-T8RJ<I]M?:8/\ GO'_ -]BC[3!_P ]X_\
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MM,'_ #WC_P"^Q7Q+]IG_ .>\W_?9H^TS_P#/>;_OLT<@>W78^VOM,'_/>/\
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M_P#06H$]B[%;PQ?ZJ%$V],(!4W:BCM0'06O+/C]_R(,7_7TG\Z]3KRSX_?\
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M!XUL=3UVWTO5M$N-%U?:?(BNHUPX YV.I(_#.: .OGN([6!YIY%CC5=S.W0
M=S[5BWWC;PYI=I97%_JD$,=XF^!FS^\7&<BLGXE3O<:?I&AQEE75[]+>;G_E
MF 21^/%8?Q O;30/B)X4EDL);JW@AF5;>WC#$ (V,#TH [[1_$NC^(D=M&U"
M&[V?>$;<K63<_$OPC:W$L,VN6RS0.4=>258=17*^$6'B[XB#Q7HNEMIFE0VK
MVTKR!%:ZDR>"JDG"Y[X/-9W@W7K[3HM8AMO!UYJZ_P!JSL;N$PA3ENGS.#Q]
M* /6K;5K&ZTI=3@N8S9LF_SLX7;Z\UAV7Q"\,7^I)I]KJ\4L\K[$V X<^@K!
M\=+_ &S<^$M!NHGM+'4[@O=VW'*JN[RSCC!(P17>VNG6EI!'!:VT4440 C55
M "XH BM]6L;N6\CM[J)Y+)MMRH;_ %1Z\_AS6'%\2?"<VH"TBUF!I?,V \[6
M;., ^M<MIVDSZY_PL33+.80RW5UY:N>@)0\'V-.T;Q5'X:TRPT+QIX7ETF"'
M;"MX$22V8C@'Y22,]>0* .JU+XA>%](O9+34-7@MYH3B17SQ^-6M%\8Z!X@O
M9+;1M3CNIE&]D7L*Q_BA:6Q^&^K2^3&9-L9W[>?]8O>MBU2:R\)VTNBV,$UY
M]DC\M&^0$[!C)],T ;E%<5X+UWQ#?^)]<TKQ*UIYEBL3QBV'RKOW9!) )QMK
MI]9FU&WTR1M%MXKF\X$:3/M3KU)]J +CLJJ2Y  Y)]*@TZ_M-4L([O3YDG@D
M&4=#Q7*>!=>UW4]6UZP\2-:M-I]PL:FV4[<% V.0">M1^$2ND?$#Q)X>A&+0
ME+Z",#"QE\[P!VR2/RH [BBE[4E !1110 4444 %%%% !1110 4444 %%%%
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M1+!G&"VTA2?8UMVW@&ZTRY*:'XDU#3].>3S/L:[6523DA21P#Z59U?P,;[Q
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M7W]:*,Y]1[$44 %%%% !1110 4444 %%%% !1110 ^/[U25'']ZI*0PHHHH
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MHL*Z-)4%E\&9)H/O7^IB*8@]51>%/M\QK2N5\/?\*X\,CQ&U\) )C#]D /\
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M_P#W\7_XFM>9'+[*1\YT8KZ+'[/_ (7Z"\O_ ,)5_P#B:7_AGWPS_P _E_\
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MI>%O&-UXEOI"MI!!9C> &F_?J5./F3L#4/AWP9>Z!<10+)IL]E"[-&SVG^D
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M!<;57D^@S7)#..#^N*.@YX_'-%AW"BBBJL(****0!1110 4444  KZE^"O\
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M--M9A+;6%O%(O1TC ([5<H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *.]%'>@"%A\^?\ )I.X-.;[QIM, QV%8'C/PP/%N@C3OMDEBRS+,DL:
M@E67..H([UO_ %'_ ->@MM!ZX ]:!'#)\.)K^YAD\6>)-0UJ&%Q(MI)L2)F!
MR"0B@GGL3BM[Q+X2L/$NEQ6EP9+5X&#VMQ;MM>W8="M75US2WNOLZ:E:F8G
M02C)-6VFCCC:61UC1>2[$ ?K0!RFC^&O$MCJ4+ZAXQN+ZS@/^H:"(&08Q\Q"
M@_EBK>B>#++2+'5K6XD-[;:G<R3RI,!C#]5X[?K6M::UINH2%+'4+>>0=4CD
M!-7>AZ$T 9'AG03X=T@:<MW+=QQN3"TIR40_P^X'O6O2]>OZ=Z3]* "BBB@
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MR;1GGK6IBC%&H61E6GAK2;'4#>6EE%#,23N10.3U-:U)M]:6@84444 %%%%
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M@T5I";Z>(S+&!T0=SZ=ZT?3T/2@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** %%/CI@I\= "/\ >III
MS_>IIH 2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** 'Q_>J2HX_O5)2&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% #X_O5)4<?WJDI#"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *.]
M%'>@")OO4VG-]ZFTP"BBB@04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 H
MI\=,%/CH :_WJ::D8#.32; :5P&44_RQ2^6M.XB.BI/+6CRUI@1T5)Y:T>6M
M $=%2>6M'EK0!'14GEK1Y:T 1T5)Y:T>6M $=%2>6M'EK0!'14GEK1Y:T 1T
M5)Y:T>6M $=%2>6M'EK0!'14GEK1Y:T 1T5)Y:T>6M $=%2>6M'EK0!'14GE
MK1Y:T 1T5)Y:T>6M $=%2>6M'EK0!'14GEK1Y:T 1T5)Y:T! *0Q(QSFI*:
M!3LTAAFC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%%
M !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC
M-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%%
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M!#_SQ>C_ (2"+_GB]%GV"Z[F=YGC7_GAI'_?3T>9XU_YX:1_WV]:'_"01?\
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MM_SPTC_OIZ/,\;?\\-(_[Z>M'_A((O\ GB]'_"01?\\7HY9=@O'N9WF>-O\
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M01?\\7H_X2"+_GB]'++L%X]S.\SQM_SPTC_OIZ/,\;?\\-(_[Z>M'_A((O\
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M_P">+TK/L%UW,WS/&W_/#2/^^GH\SQM_SPTC_OIZTO\ A((O^>+TG_"01?\
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M2"+_ )XO1_PD$7_/%Z+2[!S1[F=YGC7_ )X:1_WV]'F>-?\ GAI'_?;UH_\
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MC!WO( .4XZ4KCY3U:[O+>PM6N+Z=((4&6>0[0*S=+\6^'];N3!I6K6MS,/\
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M)''MVH[\_F3DFBP7N&****'L+J)W_&NLTO\ Y!L/^Z*Y/O\ C76:7_R#8?\
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M]=LKE_AAI%M%;R-+&]N711\R8)YQ[4M0LC:U7Q9'I^K?V78Z?=:I>I&)9D@
M_=)VW$]_;K4?_";Z4?"\VNN)TAMY/*N(F4^9"V[;@KUK--\WA'QQJ][JEM<-
M::HL<D-S!'O"LN<H?S_2L.ZTG4+KP?XBU$V,D)U:_BFM[5AAQ&"HW,/?;G\:
M>HK([W0]<_MV.:==/N;6 ,!&]RFWS1ZA>H_&JVL>([G2;B0)H-]>6T";Y+F
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M.NI+[3X;F>VEM7E7<89<;ESZXJU026PQZGGZ4E4A"T4E+0]A=1._XUUFE_\
M(-A_W17)]_QKK-+_ .0;#_NBLZNR-J.[+=%%%<YU&-XA_P!1%_O'^580K=\0
M_P"HB_WC_*L(5TT]CDJ_& HH%!Z59D@Y(.>X->7^$/$5]I>K79U>XDFTF^U.
M>"&5F_X]I0[ *3V4XX]R*]0Z;CUR#@5Q'A30TO\ PQK>GZO;M''<ZE<$;AR
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ML\<4LID<#A!L?']*=XSTZ^G_ +,U;2(/M%WI5P9O)4\R1G&X#WP*>H:&=?\
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MW)NH+$32H7/E[!R"!ZU+X5NIKC14AO;(65U:'R)8PFU6(_B4>A!!K)>TN/\
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M244 +1244"%HI** %HI**!BT4E% "T4E% "FDHHH$%%%% !_"?I6YX>^[/\
M45A_PGZ5N>'ONS_45G4V-*6Y2UG_ )"<GT%43UJ]K/\ R$Y/H*HGK50V)GN
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ME9 T$@*'YB%'4_-T&/6@6IHTNXX')X.15*SU?3=0EDBL+^UN98?]8D,P8K^
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M*4L2,$G%-HH"XN><Y- 8AMP)SG.:2B@+B[CZT$YZTE% 7';CZ]L4G08[4E%
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M@,3QFJ^HZ.OP\\=>&QX?OKMX]2F\BYMI9V<..?GY)^N:&PY3U0LH&2R@=R6
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MQTF2,K>B[N_-60[2=P^8]\&J/A_PXOB7P]XFO=3U34&:RNYQ;1I<LJQD $'
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M)>*/%.H:%=W,D6O:*JP#>-/D/[QUZX//#8KK-'EU.;3U;6K>*VN1\FR"3S%
M X() _+%</+X.UZ&#7--M;33;B+4Y9)%OIW/F(').W;CMG&<TW<2M?4VK_Q/
M?73Z-9:"D4=[JD'VAI)P2D$8ZG'<]:S-+GO].^(6M3Z^\,\MOI2N7MT(#J"#
MT/0U>NO#6K6B:'J.D?9Y=2TJW^SRPS$A)T/7!['KV-+8>'M7O]?U/4O$*VT2
M:C8?91% Y8Q].^!FEJ5H8'B:^\3:S\-;[5YVL8M-NHMZVA0^8D>>&+9ZXYKH
MFU.>/Q-I6F6D5OYDVEM*ES(N64C:,9].:R;CP]XOG\(R>%@NGFU2,Q1WID.Y
MHP?E!3'7'&<UT T&['C#3-3WIY%K8-;2 'DL=O0>G!IDZ'/_  \;Q!LUB6\N
M[6:VCO;D2J%)8NI;@<\+D=/2K<'BZZ7PAI3Z?:6PU'5+E[>"$+MBC(<@L0.W
M0U;T/2-;T35=3LA#;3:7?SRSK<"4B1"^XXVXYY/K50>#=2B\*:5#:S1)JVDW
M3W$+GE&RY.T_48I:CT+MMK6LZ1XGL])\1R6]W#J*.;:ZMU*['49*L/IG'TK+
M@\2>*]3T34M4L3I]O!ILLRB.123<"-CGG/' Q]:TK71];UKQ/9ZQXDCM[./3
MT86]M;RF3+MQN)(';/&.]2Z/X=O-/\(ZMIDK1F>\DN6C*M\O[PMC/YT:BT%O
M-?GF\*Z?JMOJ-CI'VE SR7Q^4>R\\FLJP\37.N>'/$UE>7%I=RV5G)B\M#F.
M96C)SU.#S2WGA'5H;'PW-:QVM[/I$;)):3N5CD+8^;.#TQZ=ZETSPMJBKXDF
MOH[."76+7RHXK<D+&=N,'C]:-0T-[PB0/!>DY^Z+49(';FN9EUCQ%XC\/ZIJ
MFE/96^F*DL<,,JEGF4 @MG/%=?H-E)IOA^PL;E@TEO"(W*G@_2N3AT'Q-HNF
M7V@:4EC<:?<-)Y%Q+(5:%6_AVX.?S%-W!6)=/O;C3_AGHDMOJ=EI8\A0\U[T
M/LHS4.G^)]4UW1]>LH;JPFO;!01>P9,4D;!N>#P?EI;KPGJEMI_AN2UBL[V?
M1XS'+;7#$1RYS\P.#R,^E6_#GAK4;34M;O=32TM_[4A1%BM2<1XW=3CGJ.:6
MH[H@^'SZV/ -M<7E[9M%]DS;.P;*''5R3R*BTGQC>#Q/8Z;=:MIFL17[,A:S
M;#0L,=1GIS3;3POXA?P-<^%;T6L*0Q!+6ZCD+&8*P(#+@8! QU/6G6?AO6[G
M7-#NKVPTRP@TM_F6V8LT@P!G.!Z=*>HE8[L'@#.>,BBESGD]>])3)"BBBF(*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "EI*6D]@ZB=_QKK-+_Y!
ML/\ NBN3[_C76:7_ ,@V'_=%9U=D;4=V6Z***YSJ,;Q#_J(O]X_RK"%;OB'_
M %$7^\?Y5A"NFGL<E7XPH'% HJS)" 87\#7E7A34X+6/6(I?"L^K-_:LY-Q'
M;*XYD;C.TUZMC@_0U@>$=%NM"L;Z&\:-VGOIKA=IR-KN2!]<&DREH5-4UR__
M +7L/#_AV"&UNI[?[1*9T^6UC],#'/!J.T\2ZG:7&L:5K0MY-0T^U-U%-",)
M.GT]>GYU8U[1=2'B*U\0>'_*DNX83;S6\[;5EC)R/F .""3VJK:>'-4O9]9U
M;6?(BU#4+3[+;PQ,62!/][ R3@=J6H]"YX3O]?UJUM]4U86D%G=0!XK>('>3
MCJ3FN9\6:3/J_P 4(!8SF"_M],,UM*#T<,,*?8C-=SX?L9=*\-V-A.P,MO"J
M,R_=R/2J#Z'<M\0XM<!06R6+6^W/S;B0>GIQ18-#EO$&O)XATGP[=&'R;J#6
M(XKNW(Y@E&00<^^<5<U2SO-$\>:AKMWHCZW874**CQIYCVNW.1LYZY["K'B7
MP3/J'BC3]6TF58E6X22]A8X$FWHP_P!KBM35+OQ;;:E*-(L+"[M&(\MY9RCC
MZC:<BF.YD:OXDT^3X=ZC?^&%6U8R+ Z+'Y3PNS!6W+Q@X)ZUT&C^&=)TK1H+
M6*PMI!Y:EY)8U=I6(R6+-DG)_P#K5DZ5X-D;0]9A\02QR7>M2^=<>0,)&0<J
M%^A-1V@\=Z1:I8QP:;J4<("174DK1L5[;EP>@]Z5@N%R@7XS6(5=JC2G ('^
MT*G^(=Y/!X9BMK65H3?W<5HTB@Y5'8 X/TXJ#6M'\1?\)?9Z[HL5C)(EF;>5
M)Y"H!)!XP#GI5F;2=9\4:+=Z?XJAM+3)5[:6SD+E7!!!Y Q@BGL+<V+'0-)T
MZRCM;73K58XU ^:)68GU)(SG-: X3 (Z=0<UR5K+X\M5CM9++2[TKA!=^>R$
M@<;BNT\X]ZM:7KUYJ?CC6-/C\O\ L[3XT0LHY,IZ_P C1<+%3QS@ZKX6)&?^
M)HG;KTJ'2[2'7/B'KUUJB1W TQDMK2*8!E3.26"GN<#GVK6\2Z)=:Q?:++;.
M@%C>K/(&.,J,=/?BJNJZ%J]EXCEU[PM) 9;E!'>6=QE5G"YVL&&<$9/:@5RA
MXPM8-$US0]9TN*.VN6O5M9A" HF1P1M(Z=\Y/I64MY%9_$SQ*LGAN76M_D_Z
MNW$@C 7H20<5OVVB:WKFMVNI>*_LT%O8DR6]C;,7!D(QN9B!G )XQ5>72?%6
MF^,-7U+0XM/F@U'R_P#CYE*LFT8Z 5-BKH9\.XK6YTW5DEMHXHY+TR#2Y8_^
M/0'/RE6Z'_"ET?2]/;XG>(HWL+,QI;PE4:!=JY"YXQBMCPSH=[IMQJ&I:O-%
M+J6I.K3"%<1H%S@ =^O6G:?HMS:^-M7U:1D-O>11)& ?FRH&<C\*=A7*NI:=
M_8>H:GXK1!<-#9"*VM5CXB4$YQ]<CIZ4WP;K&I:Y$EY=:QIE]"\8:2"U'SP$
M_P )Y[9QS717QN19RM91QRW&W"+*<*Q]S_\ 6KE=%\/:H_C)=>O[.RTM(8&B
M-O9R%_M!/=C@?RHL!F?%J::<:!H0E:&VU*\\NX96QE>/ES^-:7BKP%X<_P"$
M-OH[73(+22U@+P7$:['1EZ'=W_&M'QKX37Q;H\=NDYM;RV?S;2<#/EO]/P%<
MQ>:+\2-=T[^Q=6N]-M[.0!+F[@W&25!VQVS18:9RWB35I-6^#'A>]U13*RWJ
MI(&7<756QT[Y IUS/I'BSQ1I5IX T*6POK*59+NZ$9BV)Z,..M=OXF\"27?A
M?0]&T(QK'IEQ'(3,<;P""3TZU)K_ (/OAXJL?$?A=X8+U (KR*0[4G3\.]39
ME71RGC/4-&T[XU_:=?T]K^S&GC,8@+X.T<XQVJU\.(%U+QYJ'B'PY8/IWAUX
M1$D9X6:3GD#VKJ6\+W4GQ1/B*40-9-9>0T1.6+;<'CTJ'PSX4U/PMXIOEL)8
MG\/7C>:L#,0T$AZ[1W%"0FT3?$+Q+?\ AK2;)M'\HWMY=K;QB5<KR#G^50/>
M^--$T'5]1\3M8E(+-I+?[.G.[!QDU>\8:1X;UM+.W\378@$+-+$/-V9/3.<=
MLUR'@.);[6O%'AR&^GU/P[Y?EQ32-NP67# 'OC)IN]PC:Q@^%-7L=(\-0ZEX
MB\&W%W;WLN^YU>==^23QC(X ]JM>.5A7Q1JTUY827L.K:7''I4B1%U5_EQ@]
MC6F_@?QK)H2^$)+O3VT-9 1<X/G>7G[N.GZUVVNZ1?R^&(-'T&6.$82WDFD'
MS)"  Q7_ &L<4K,=T>;W_B&?4+'1+":T>]L+)H[<P!MOV^Z&#LS_ '5!7/U-
M>F>$?$D?B?39)OLILYK60P3VIYV,.PQVK(\1^"7?0M(@\,>5#=:-,)K?SONR
MGC.XCUQUJ[X'\.W6@:?>/JKQO?7]RUS/Y/W%)SP/;FFDR7:Q)J&HZ_I%W-</
M8IJ6ECG-N?W\(QSD=Q]!6IHNM66OZ;%?Z7+YMNS;0<8^8=1]:S+WPS+K-_(^
MM:E/)IZD>5I\/R)CON/\7/TK;L[2VL+=(+2%((EX"1C 7Z51/0\IM9)-$^(&
MI>((^(5U7['>8' 1\A6/T8K3_B;/_;MQ?"/FQT-$W'J'GDR?T 4_C776GA*0
MV_B6WORABU69I(=ISM[J3[@XK/\ ^$%O(OAM-HB7"2ZE<RB6>X<X#D<=?]T*
M/PJ;%71J^)=4O--2U-MKFEZ9&T>6%X06D/8 9Z5DQ^/;R3X?76LI!!/>V=V+
M9EB.8YOGQN4YZ$59UC0-57Q>FLZ=9V6HI):BW:"[<J(2,?,O!ST]JI1>!]5'
M@G4=)F:V%U=:@+I=A(15W!L>WI18+HC\63ZM#H6G77B:>T7.I0RJD P(DVL?
MF/>MZQ\3W.HQWNM")8?#\$;O S@B2YV\EAZ*<<?A4WBO09]<TS3[2'RV%O=1
MS2"7HRA2"/UJO:>&+BPN-2TNWE#>'K^-]L).'MV8<A?5>3QQBF%T<R/B5=11
M6VJS:EI,MK-*%?387W3Q(3@-G/7UJZ!XD/Q:N8[>^LP/L08*Z,5$>Y>.OWJL
M:3I'B'2HX-.?1M(N[>%MJWA<JY3/==IY ]ZT-4TG6;3QNFN:)%;7,4UL+:>*
M:0H4&0=P(!STZ<4!H3>/M3N-'\ ZK>V;;9TMRJL!T)&,_P"%9'@KP1H!\#V;
M7VGP7T]W#YMQ<3+EW9O?KQ[5U^IZ=;ZOI$^GZ@FZ&YB,<@'N/Z5P%EH7Q$\-
MV7]CZ)=Z=<V"96"XN"1)$I[8&:+ G8R/#YDT_P /?$#PXLS2V6GK)]FWMG:/
M[N:YFVU?PQ=?#FST*V\/23^([F+9!,L!0F0DX8-CGM^5>HZ3X"DTCP3J^G_:
M5NM6U5)&N+AQA6D8'CZ<]:J3?#R>Y^&^EZ2TR0:SIB[K:ZC/"/N)ZXY'2E9E
M71S7Q!LKG2?AWX/MM>5KF:VNHQ<)MWEOE.5]S4#R:3XM\9:1'\/M%ETZ?3[E
M9;V<1F/;'G[K#BNQ\1^%M?\ $NA^'UO7M%U&QNTFNF5CM< $9''7FK.M>$[^
M'QI9^)O"KPV]R2([Z%SM2:/IV'7%*S"ZL8/Q(T_6+S6DL])N[B[-P@N&M7B!
MBC$?\0./O?-ZUUW@9IKCPW%>W=]=7CW1\QOM*!&C8]5  '2NB & 2,'&/I2J
M#VZXP./Y521G?4X3Q5>>/-%AO]9M9M._LRS'F+!(IW.@'<YZU%JOQ"NSX7T"
MYT:T0:GKV%B67.R(XR2:I?$RQ\-ZSI=_>7/B)[>YM8MBVL<N5+C)PR]SS3XK
M+3/%?PVT ^*KE='O H>VF3Y"K =0*3N5I<MV.O\ B:R\3/X5\6"V>[O[1WLK
MJW&T,=IX/XBO/]'NH=&U'0I9+&:UNM%FG?4IS$4R&V[1NQ\V2#ZUN>']--]\
M8K-[/7;G78M,@)GO)AE58@X5?TKOM3\/76M^+K:YU%HO['L5\R&V3K+-ZO[#
MM]:23&VC@;/QE<:;XFO]<U719;RZ2*-IFW8&G6[D;5 _O8(SWZUZ(VLZI/XB
MT^*PT\2Z-=6XFDO2"#&3VKE_%7@37-1U_4Y-$GM?L.NI''>"8D/'M*DE/7.W
M]:L:3K>HO\3D\+Z=.#H^D62"Y4C)9\=S35Q-H[^DI<Y4$]<<^])5F84444 %
M%%% !1110 M%)13 **** "BBBD 4444 %%%% !1110 4M)13 6DHHH /X3]*
MW/#WW9_J*P_X3]*W/#WW9_J*SJ;&E+<I:S_R$Y/H*HGK5[6?^0G)]!5$]:J&
MQ,]PI***HD*6DHI +V.:/IG\Z2BF,6C]/3FDHH$+]<T'G@GBDHI +^GTH/TI
M**8%'6-%L=>TXZ?JD)EMRX<H#M(8=#D5>552)47(5%"J,]A112'<4\?3V-!
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M0 4444 %%%% !1110 4444 %+24M)[!U$[_C76:7_P @V'_=%<GW_&NLTO\
MY!L/^Z*SJ[(VH[LMT445SG48WB'_ %$7^\?Y5A"MWQ#_ *B+_>/\JPA733V.
M2K\8"B@4'H:LR09'K24V5_+B>5@Q"*68(,Y%85SXUTFU\,6^N3O(MK<R*B+C
MY@Q."#].] [7.@'.3V'4TU75UW(RNO\ >!S5"XUNTCU*QLCN>?4(VDB"C@*
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MOOZT<P^74[<JPZ@C\*0C'7@CD5QNF:%<:7X;;5K*^U*^U";3MR03R KO9>N
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ME'S'$VEO,/$G@AVA?;%IY$F%X4^6>#[UAW.BW][X%UN.*"?S$UIIRB?*\D8
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M:W\'].>>REN;&SMS+&A'[T.H^8#'<G(_&KNM> ]4UF\N@/%E]!I]TQ+V<>T
M#^Z#C.*ZC1-'M- T6WTO3T*V\"[0"?O>Y^O6I41J>AYB_@:YE^'>JZA%9F*_
MNH-ME9+UMH!D[!_M-DD_6K?PZA:^\;7&J6.GSV-@FFQV[B6/R]TH(SQWZ'FO
M4L]^_8TGL!@=@*:B#E=!CO1115D!1110 4444 %%%%( _A/TK<\/?=G^HK#[
M'Z5N^'_NS_45%38TI[E?5K6>74':.-F! P15+[#<_P#/%ORKKOXJ2LU-FK@F
M<E]AN?\ GB_Y4?8;G_GBWY5UM%/VC%[-')?8;G_GBWY4?8;G_GBWY5UM%'M&
M'LT<E]AN?^>+?E1]AN?^>+?E76T4>T8>S1R7V&Y_YXM^5'V&Y_YXM^5=;11[
M1A[-')?8;G_GBWY4?8;G_GBWY5UM%'M&'LT<E]AN?^>+?E1]AN?^>+?E76T4
M>T8>S1R7V&Y_YXM^5'V&Y_YXM^5=;11[1A[-')?8;G_GBWY4?8;G_GBWY5UM
M%'M&'LT<E]AN?^>+?E1]AN?^>+?E76T4>T8>S1R7V&Y_YXM^5'V&Y_YXM^5=
M;11[1A[-')?8;G_GBWY4?8;G_GBWY5UM%'M&'LT<E]AN?^>+?E1]AN?^>+?E
M76T4>T8>S1R7V&Y_YXM^5'V&Y_YXM^5=;11[1A[-')?8;G_GBWY4?8;G_GBW
MY5UM%'M&'LT<E]AN?^>+?E1]AN?^>+?E76T4>T8>S1R7V&Y_YXM^5'V&Y_YX
MM^5=;11[1A[-')?8;G_GBWY4?8;G_GBWY5UM%'M&'LT<E]AN?^>+?E1]AN?^
M>+?E76T4>T8>S1R7V&Y_YXM^5'V&Y_YXM^5=;11[1A[-')?8;G_GBWY4?8;G
M_GBWY5UM%'M&'LT<E]AN?^>+?E1]AN?^>+?E76T4>T8>S1R7V&Y_YXM^5'V&
MY_YXM^5=;11[1A[-')?8;G_GBWY4?8;G_GBWY5UM%'M&'LT<E]AN?^>+?E1]
MAN?^>+?E76T4>T8>S1R7V&Y_YXM^5'V&Y_YXM^5=;11[1A[-')?8;G_GBWY4
M?8;G_GBWY5UM%'M&'LT<E]AN?^>+?E1]AN?^>+?E76T4>T8>S1R7V&Y_YXM^
M5'V&Y_YXM^5=;11[1A[-')?8;G_GBWY4?8;G_GBWY5UM%'M&'LT<E]AN?^>+
M?E1]AN?^>+?E76T4>T8>S1R7V&Y_YXM^5'V&Y_YXM^5=;11[1A[-')?8;G_G
MBWY4?8;G_GBWY5UM%'M&'LT<E]AN?^>+?E1]AN?^>+?E76T4>T8>S1R7V&Y_
MYXM^5'V&Y_YXM^5=;11[1A[-')?8;G_GBWY4?8;G_GBWY5UM%'M&'LT<E]AN
M?^>+?E1]AN?^>+?E76T4>T8>S1R7V&Y_YXM^5'V&Y_YXM^5=;11[1A[-')?8
M;G_GBWY4?8;G_GBWY5UM%'M&'LT<E]AN?^>+?E1]AN?^>+?E76T4>T8>S1R7
MV&Y_YXM^5'V&Y_YXM^5=;11[1A[-')?8;G_GBWY4?8;G_GBWY5UM%'M&'LT<
ME]AN?^>+?E1]BN?^>+_E76T4>T8>S1R7V&Y_YXOQ[5TNG(T=C$K@A@O(-6*!
MUJ92YBH146.HHHK,V,G7(9)H8Q$A8ANU8WV&Y_YXO^5==336L9M(PG!,Y/[#
M<_\ /%_RH^PW/_/%ORKK!2T_:,7LT<E]AN?^>+?E1]AN?^>+?E76T4>T8>S1
MR7V&Y_YXM^5'V&Y_YXM^5=;11[1A[-')?8;G_GBWY4?8;G_GBWY5UM%'M&'L
MT<E]AN?^>+?E1]AN?^>+?E76T4>T8>S1R7V&Y_YXM^5'V&Y_YXM^5=;11[1A
M[-')?8;G_GBWY4?8;G_GBWY5UM%'M&'LT<E]AN?^>+?E1]AN?^>+?E76T4>T
M8>S1R7V&Y_YXM^5'V&Y_YXM^5=;11[1A[-')?8;G_GBWY4?8;G_GBWY5UM%'
MM&'LT<E]BN?^>#4?8;G_ )XL?PKK:*/:,/9HY+[#<_\ /%ORH^PW/_/%ORKK
M:*/:,/9HY+[#<_\ /%ORH^PW/_/%ORKK:*/:,/9HY+[#<_\ /%ORH^PW/_/%
MORKK:*/:,/9HY+[#<_\ /%ORH^PW/_/%ORKK:*/:,/9HY+[#<_\ /%_RH^PW
M/_/!_P JZVBCVC#V:.2^PW/_ #Q;\J/L-S_SQ;\JZVBCVC#V:.2^PW/_ #Q;
M\J/L-S_SQ;\JZVBCVC#V:.2^PW/_ #Q;\J/L5UVA<>OO76T4>T8>S1R/V&Y[
M0M^5+]AN?^>+?E76T4>T8>S1R7V&Y_YXO1]BNL_ZEAD\\5UM%'M&'LT<E]AN
M?^>+?E1]AN?^>+?E76T4>T8>S1R7V&Y_YXM^5'V&Y_YXM^5=;11[1A[-')?8
M;G_GBWY4?8;G_GBWY5UM%'M&'LT<E]AN?^>+?E1]AN?^>+?E76T4>T8>S1R7
MV&Y_YXM^5'V&Y_YXM^5=;11[1A[-')?8;G_GBWY4?8;G_GBWY5UM%'M&'LT<
ME]AN?^>+?E1]AN?^>+?E76T4>T8>S1R7V&Y_YXM^5'V&Y_YXM^5=;11[1A[-
M')?8;G_GBWY4?8;G_GBWY5UM%'M&'LT<E]AN?^>+?E1]AN?^>+?E76T4>T8>
MS1R7V&Y_YXM^5'V&Y_YXM^5=;11[1A[-')?8;G_GBWY4?8;G_GBWY5UM%'M&
M'LT<E]AN?^>+?E1]AN?^>+?E76T4>T8>S1R7V&Y_YXM^5'V&Y_YXM^5=;11[
M1A[-')?8;G_GBWY4?8;G_GBWY5UM%'M&'LT<E]AN?^>+T?8;G_GBWY5UM%'M
M&'LT<E]AN?\ GBWY4?8;G_GBWY5UM%'M&'LT<E]AN?\ GBWY4?8;G_GBWY5U
MM%'M&'LT<E]AN?\ GBWY4?8;G_GBWY5UM%'M&'LT<E]AN?\ GBWY4?8;G_GB
MWY5UM%'M&'LT<E]AN?\ GBWY4?8;G_GB_P"5=;11[1A[-')?8;G_ )X/^5;&
7APR1+-YJ%<D8S6J*5>IJ7-M%1@DS_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img134051827_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_6.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0+X17AI9@  34T *@    @ ! $[  (
M   /   !2H=I  0    !   !6IR=  $    >   "TNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M36EC:&%E;"!286EB;&4    %D ,  @   !0   *HD 0  @   !0   *\DI$
M @    ,R.0  DI(  @    ,R.0  ZAP !P   0P   &<     !SJ     0
M
M
M
M
M
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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M">#/!&I:ZZK(]K%^ZC8\/(Q"H/IN(S[9KY^^&/PSN?BS>WOBSQMJ%U+:F<H
MKX>X<<D9/W4&0,#W QB@#VBR^-7P]U"Z6WMO$D/F.0J^;;S1@G_>9 /UK?\
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MGJEI/9747G^9!<1-&Z9GD(RK $9!!^AIGQ5\#S^*-&@U303Y'B/1G^TZ?,F
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M^U^WU&\C:!IM5MO(M8,C!8R9^8#)],T )^SI_P DB@_Z_)OYBL[]GW_F<?\
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M%OA[IWBF;X^ZUXC\3Z#-IB:EI&Y-JLT4?S0!(S)C!<*G(ZY!X%>TT#"BBB@
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M '6O>*** "BBB@ HHHH **** "BL_7M9M_#WA^^UB]25[>Q@:>180"Y51D@
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MYA_#0!TU%5'U;3HM6CTN34+5-1EC\V.S:91,Z<_,$SDCY3SCL?2K= !1110
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M>E3:=8Q1W%U:13SW)7=+*[H&8LYY/)/TI#.NKF?$OQ%\)^$+H6WB+68K.X9
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MMROG;P-XRAN/&7B+Q9JWA+Q%X@OIKUH+2XT[3OM,5G$G2-26&UL$9QVP>YH
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M_BOWMHI)UW^4@CC;Y >%)+G)')XK;^-UU/JFM>$/!:SR06>N7X^VM&<%HU9
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MX9>(KG2OV:3J[-YTVFVEVT._G[C/L4^W0?2D,[/Q'\3/!WA.\^R:]KL%M<@
MM"B/*ZYZ;E0$K^-.M?B3X0OKC3(++7+>YEU61H[1(59R[* 2#@?(?F'WL=:Y
MCX%:!:0> ;?Q%.BW&L:S)+<75[(-TC$R,,;CSCC/U)KG/&^B:;I7[1G@FXTV
MRAM9+QB]P85VB1@2 Q XSCOWI@>Y5C>)/%V@^$;6*X\1ZE%81S$B/>"2Y'7
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MB.P^<'/^]W'/LU%(9X)\6?BGI'C#X>:IH_@ZWO-6B98I+R_6W>.&U194;DN
M220!C'<G/%>Q>#_^1'T+_L'6_P#Z+6MFB@#SSX\?\D3U[_MW_P#2F*L/P=\7
M_#_A_P !:'8>*HK[2;RWT^WCA1[221;I!&NQXV4$$,N#@XP21VK<^/'_ "1/
M7O\ MW_]*8JZ+X??\DR\,?\ 8'M/_1*TQ'#?#S2]5\4?$K5?B+K.GRZ;:S0"
MSTNUN%VR&,8_>,.W _\ 'CV )J_\W<_]P?\ ]EKV2BD,\\^/'_)$]>_[=_\
MTIBK$\3>']2\2_LPZ18Z+&\]TNE6$P@3[TRI&A*@=SCD#N17KU% 'DFC?&_P
MGI_A73[!(-0.LV]O';_V+#9/YWF*H&T<;<9'KG';M4'P >YDD\9O?VQM+I]9
M9IK=CDQ.<EDSWP>*]BHH \YNOC;X%C66TU6XN[>Y!*-87.G2^8QSC& I4Y^M
M8WP5T&Y&J^*_$!TF71]&UFX7[#83)L)0%R6V=AAACMR<<#GU^B@#PSP?K4_P
M3NM3\->,+*]&@M=-<:=JT,!ECV'&0^WIP <=0<]B#7H&A?%;PMXHURVTSP[/
M=ZA)/NS-'92I%%M4M\[.HQTP.O)%=G10 5P7Q/\ BKIOPYT]4>,W>K7*%K:T
M&0,=-[GLN?Q/ZCO:* /G'P-XN\"0^('\9^/_ !:NH^)9QF.-;&X,-BIZ*G[O
MD@$C/0<XR?F/T%I&K66O:1;:II4WGV=TF^&78R[E]<, 1^(JY10 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%?\ H'ZQ_P!^8O\ XY1[&IV#ZQ2_F/4Z*\L_X:#\*_\ 0/UC_OS%_P#'*/\
MAH/PK_T#]8_[\Q?_ !RCV-3L'UBE_,>IT5Y9_P -!^%?^@?K'_?F+_XY1_PT
M'X5_Z!^L?]^8O_CE'L:G8/K%+^8]3HKRS_AH/PK_ - _6/\ OS%_\<H_X:#\
M*_\ 0/UC_OS%_P#'*/8U.P?6*7\QZG17EG_#0?A7_H'ZQ_WYB_\ CE'_  T'
MX5_Z!^L?]^8O_CE'L:G8/K%+^8]3HKRS_AH/PK_T#]8_[\Q?_'*/^&@_"O\
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M'_?F+_XY1[&IV#ZQ2_F/4Z*\L_X:#\*_] _6/^_,7_QRC_AH/PK_ - _6/\
MOS%_\<H]C4[!]8I?S'J=%>6?\-!^%?\ H'ZQ_P!^8O\ XY1_PT'X5_Z!^L?]
M^8O_ (Y1[&IV#ZQ2_F/4Z*\L_P"&@_"O_0/UC_OS%_\ '*/^&@_"O_0/UC_O
MS%_\<H]C4[!]8I?S'J=%>6?\-!^%?^@?K'_?F+_XY1_PT'X5_P"@?K'_ 'YB
M_P#CE'L:G8/K%+^8]3HKRS_AH/PK_P! _6/^_,7_ ,<H_P"&@_"O_0/UC_OS
M%_\ '*/8U.P?6*7\QZG17EG_  T'X5_Z!^L?]^8O_CE'_#0?A7_H'ZQ_WYB_
M^.4>QJ=@^L4OYCU.BO+/^&@_"O\ T#]8_P"_,7_QRC_AH/PK_P! _6/^_,7_
M ,<H]C4[!]8I?S'J=%>6?\-!^%?^@?K'_?F+_P".4?\ #0?A7_H'ZQ_WYB_^
M.4>QJ=@^L4OYCU.BO+/^&@_"O_0/UC_OS%_\<H_X:#\*_P#0/UC_ +\Q?_'*
M/8U.P?6*7\QZG17EG_#0?A7_ *!^L?\ ?F+_ ..4?\-!^%?^@?K'_?F+_P".
M4>QJ=@^L4OYCU.BO+/\ AH/PK_T#]8_[\Q?_ !RC_AH/PK_T#]8_[\Q?_'*/
M8U.P?6*7\QZG17EG_#0?A7_H'ZQ_WYB_^.4?\-!^%?\ H'ZQ_P!^8O\ XY1[
M&IV#ZQ2_F/1].T?3-'25=)TZTL5F?S)1;0+&)&_O':!D^YJY7EG_  T'X5_Z
M!^L?]^8O_CE'_#0?A7_H'ZQ_WYB_^.4>QJ=@^L4OYCU.BO+/^&@_"O\ T#]8
M_P"_,7_QRC_AH/PK_P! _6/^_,7_ ,<H]C4[!]8I?S'J=%>6?\-!^%?^@?K'
M_?F+_P".4?\ #0?A7_H'ZQ_WYB_^.4>QJ=@^L4OYCU.BO+/^&@_"O_0/UC_O
MS%_\<H_X:#\*_P#0/UC_ +\Q?_'*/8U.P?6*7\QZG17EG_#0?A7_ *!^L?\
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MC_AH/PK_ - _6/\ OS%_\<H]C4[!]8I?S'J=%>6?\-!^%?\ H'ZQ_P!^8O\
MXY1_PT'X5_Z!^L?]^8O_ (Y1[&IV#ZQ2_F/4Z*\L_P"&@_"O_0/UC_OS%_\
M'*/^&@_"O_0/UC_OS%_\<H]C4[!]8I?S'J=%>6?\-!^%?^@?K'_?F+_XY1_P
MT'X5_P"@?K'_ 'YB_P#CE'L:G8/K%+^8]3HKRS_AH/PK_P! _6/^_,7_ ,<H
M_P"&@_"O_0/UC_OS%_\ '*/8U.P?6*7\QZG17EG_  T'X5_Z!^L?]^8O_CE'
M_#0?A7_H'ZQ_WYB_^.4>QJ=@^L4OYCU.BO+/^&@_"O\ T#]8_P"_,7_QRC_A
MH/PK_P! _6/^_,7_ ,<H]C4[!]8I?S'J=%>6?\-!^%?^@?K'_?F+_P".4?\
M#0?A7_H'ZQ_WYB_^.4>QJ=@^L4OYCU.BO+/^&@_"O_0/UC_OS%_\<H_X:#\*
M_P#0/UC_ +\Q?_'*/8U.P?6*7\QZG17EG_#0?A7_ *!^L?\ ?F+_ ..4?\-!
M^%?^@?K'_?F+_P".4>QJ=@^L4OYCU.BO+/\ AH/PK_T#]8_[\Q?_ !RC_AH/
MPK_T#]8_[\Q?_'*/8U.P?6*7\QZG17EG_#0?A7_H'ZQ_WYB_^.4?\-!^%?\
MH'ZQ_P!^8O\ XY1[&IV#ZQ2_F/4Z*\L_X:#\*_\ 0/UC_OS%_P#'*/\ AH/P
MK_T#]8_[\Q?_ !RCV-3L'UBE_,>IT5Y9_P -!^%?^@?K'_?F+_XY1_PT'X5_
MZ!^L?]^8O_CE'L:G8/K%+^8]3HKRS_AH/PK_ - _6/\ OS%_\<H_X:#\*_\
M0/UC_OS%_P#'*/8U.P?6*7\QZG17EG_#0?A7_H'ZQ_WYB_\ CE'_  T'X5_Z
M!^L?]^8O_CE'L:G8/K%+^8]3HKRS_AH/PK_T#]8_[\Q?_'*/^&@_"O\ T#]8
M_P"_,7_QRCV-3L'UBE_,>IT5Y9_PT'X5_P"@?K'_ 'YB_P#CE'_#0?A7_H'Z
MQ_WYB_\ CE'L:G8/K%+^8]3HKRS_ (:#\*_] _6/^_,7_P <H_X:#\*_] _6
M/^_,7_QRCV-3L'UBE_,>IT5Y9_PT'X5_Z!^L?]^8O_CE'_#0?A7_ *!^L?\
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ME'L:G8/K%+^8]3HKRS_AH/PK_P! _6/^_,7_ ,<H_P"&@_"O_0/UC_OS%_\
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MG.6/>L#_ (9\\*_]!#6/^_T7_P ;JZ>(A&"3,JN&J3FY(^<Z*^C/^&?/"O\
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M'I?Q+U#1=+6UTK1M"M+A;?[.-0BL<7)&,9+YP3WY')KUK_AGSPK_ -!#6/\
MO]%_\;H_X9\\*_\ 00UC_O\ 1?\ QNE[:C:P_88B][GDND^,-9OK[PQ86]WI
MVEMHAD6TO+@LB .!N\UB2,$+C@#K7H6N^*;/3O NOQZKJ7A>?4=5B\J.'PXN
MXR.<@O*^>>#GG'3N36Q_PSYX5_Z"&L?]_HO_ (W1_P ,^>%?^@AK'_?Z+_XW
M4RJ4FT5&E7BFOU/''\?ZH^I>'[TV]GYF@0)!:@(VUU08!?YN3QVQ6#JFH2ZO
MK%YJ5RJ+->3O/(L8(4,[%B!DDXR?6OH'_AGSPK_T$-8_[_1?_&Z/^&?/"O\
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M%_\ &Z/^&?/"O_00UC_O]%_\;H^LTP^IU3YSHKZ,_P"&?/"O_00UC_O]%_\
M&Z/^&?/"O_00UC_O]%_\;H^LTP^IU3YSHKZ,_P"&?/"O_00UC_O]%_\ &Z/^
M&?/"O_00UC_O]%_\;H^LTP^IU3YSHKZ,_P"&?/"O_00UC_O]%_\ &Z/^&?/"
MO_00UC_O]%_\;H^LTP^IU3YSHKZ,_P"&?/"O_00UC_O]%_\ &Z/^&?/"O_00
MUC_O]%_\;H^LTP^IU3YSHKZ,_P"&?/"O_00UC_O]%_\ &Z/^&?/"O_00UC_O
M]%_\;H^LTP^IU3YSHKZ,_P"&?/"O_00UC_O]%_\ &Z/^&?/"O_00UC_O]%_\
M;H^LTP^IU3YSHKZ,_P"&?/"O_00UC_O]%_\ &Z/^&?/"O_00UC_O]%_\;H^L
MTP^IU3YSHKZ,_P"&?/"O_00UC_O]%_\ &Z/^&?/"O_00UC_O]%_\;H^LTP^I
MU3YSHKZ,_P"&?/"O_00UC_O]%_\ &Z/^&?/"O_00UC_O]%_\;H^LTP^IU3YS
MHKZ,_P"&?/"O_00UC_O]%_\ &Z/^&?/"O_00UC_O]%_\;H^LTP^IU3YSHKZ,
M_P"&?/"O_00UC_O]%_\ &Z/^&?/"O_00UC_O]%_\;H^LTP^IU3YSHKZ,_P"&
M?/"O_00UC_O]%_\ &Z/^&?/"O_00UC_O]%_\;H^LTP^IU3YSHKZ,_P"&?/"O
M_00UC_O]%_\ &Z/^&?/"O_00UC_O]%_\;H^LTP^IU3YSHKZ,_P"&?/"O_00U
MC_O]%_\ &Z/^&?/"O_00UC_O]%_\;H^LTP^IU3YSHKZ,_P"&?/"O_00UC_O]
M%_\ &Z/^&?/"O_00UC_O]%_\;H^LTP^IU3YSHKZ,_P"&?/"O_00UC_O]%_\
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MM>Q5JG-RWU,#_A-O%7_0S:Q_X'R__%4?\)MXJ_Z&;6/_  /E_P#BJT+C1/\
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MO0Z,-*3JJ[_JQ[?1117EGLGB_P 8O'WB7PKXPM;'0=2^R6\E@DS)Y$;Y<R2
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MA=&V?RL>N_&/UHY*?9![2KW?XG4?\+D\>?\ 0=_\DX/_ (BC_A<GCS_H._\
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M3@_^(KAZ*]GV<.R/ ]K4_F?WG<?\+D\>?]!W_P DX/\ XBC_ (7)X\_Z#O\
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M?Q!/=S6L.AZE)<6^!-"EI(7CR,C<,9&1SS3Y*?9"]I5[LZ/_ (7)X\_Z#O\
MY)P?_$4?\+D\>?\ 0=_\DX/_ (BN431]3DOI;*/3KMKJ!2TL"P,7C4=2RXR
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M>!67IFO:1'JOPQ>35;)5L;.=;IC<(!;DQ  /S\I)XYQ7EW_"%^*?^A:UC_P
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MQ9K/]HZEX8U*-UB6&.*#3IECB11PJ@@G&<GKU)K'_P"$+\4_]"UK'_@!+_\
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M%G/I6CW]]"NG(C26UJ\BAO,D.,J",X(X]ZO#-*IJ1BTW2T/&J*W/^$)\5?\
M0LZQ_P" $O\ \31_PA/BK_H6=8_\ )?_ (FO3YH]SR.278PZ[_X=ZC967A7Q
MK%>WEO;R7.EF.!)951I6VO\ *H)^8\C@5SG_  A/BK_H6=8_\ )?_B:/^$)\
M5?\ 0LZQ_P" $O\ \34RY9*URH<T7>QZKX-\<:1K?AR[N/$-Y;VFOV6F36 G
MGE"&\A8 KR3\S H/S)[\7O!7BO0E\ Z);V-YIMK=V&?/M[W69-/^?))8A582
MACS@@CG\*\<_X0GQ5_T+.L?^ $O_ ,31_P (3XJ_Z%G6/_ "7_XFL72@^IO&
MM45M#TZP\16%\OC'3],UG3?#>L7]ZL\-ZEUB"1 %#!9]JGDACG /SDC/-9/C
M?Q59V"^%X3=:;XLU72HIA=W,Z>?;RAQA5;GY\=<YZJ#W-</_ ,(3XJ_Z%G6/
M_ "7_P")H_X0GQ5_T+.L?^ $O_Q-4H03O<EU*C5K?U>YW/@#6]'U;Q#J^H:K
M-8^'[DVT:VMG97LFEVLQ!.[<Z'(/W?7.2<'%=;KGBKPM#\0/!M[)J-G=06T=
MS%+-'=_:/L[D*J%W/S$9SAF]=WO7C/\ PA/BK_H6=8_\ )?_ (FC_A"?%7_0
MLZQ_X 2__$TG3@Y7N.-6<8VY3TZZO'L?!'C"#7/'>G:_/?11FSCBO_,( 9LX
M0\*3D?*N>E:=IKMAH%W\/IM6G%O;7&@O;F=ONQEECP3[9&,^_I7EFC^'/%FC
MZM#?KX.OKPQ9_<7FERR1."I&&7 R.:T/%4/CSQ?=6\NH^%=0@CM8O*@M[72Y
M4BB7V&#[=^PJ735[7T_X%BU4DE>VO_!N;-\--\'?";5-$3Q'INIZA?WT<T']
MF3^9L564Y8C[I^3\\=:U=3\7Z(/"-SXOM+RW'BC5M.CTV6WC8"2*0$B27 .1
ME5&"?[J\\UYG_P (3XJ_Z%G6/_ "7_XFC_A"?%7_ $+.L?\ @!+_ /$U?)%[
MLS]I-;1/:? &J^&-*\/:'+_PD<.1;C[0MYKLD9AE/5!;$["H)/)QC //6N53
MQ+;Z5X%\<#1]8AM+V;6V>T%O<JLCQF106CP<D;<\CM7 ?\(3XJ_Z%G6/_ "7
M_P")H_X0GQ5_T+.L?^ $O_Q-)4X7O<IU9V243U(^-K6+7OA]>3Z^I'V'R]4D
M2YW'<57B;!_O<_-TY-<'\2TG/B22ZF\26FN17$TSVXMKTW MHB^50YX7@_='
M'%9/_"$^*O\ H6=8_P# "7_XFC_A"?%7_0LZQ_X 2_\ Q-5&,8NZ9$YSFK-'
ML_G7-M;^ [M?&%GH=C::5;2W=G<79C:X38N<1]'R 5YZ=17./XSLH?!7C:[\
M/:G'875YJPDLT241S/&Q0,ZK]X9&XY'(YKE=>L?&_B*UTJWO?"FHQII=FEG"
M8=.G!9%  +9SD\=L?2L7_A"?%7_0LZQ_X 2__$U$:<;:O^KFDJLK^ZOZM8]+
MN-9T76=0^'DVM>(O+DBM)1>W4%WB:.3:NT22*=R9.02>>O3J-/Q[J^AW'PUN
M+"UUC39[T7D4D<?]KMJ&WYP-VZ3YL;<Y ! Y]:\A_P"$)\5?]"SK'_@!+_\
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M[6[T.^AO8_E!\023RYR-I2W9"$(/.%('%>-?\(3XJ_Z%G6/_   E_P#B:/\
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M%_Y.3_\ Q==!J_BO1="NUMM5O?(F=!(J^4[94DC.5!'4&J/_  L7PM_T%/\
MR7E_^)JU.:5DV9.-)O5(S?\ A3?@/_H!?^3D_P#\71_PIOP'_P! +_R<G_\
MBZTO^%B^%O\ H*?^2\O_ ,31_P +%\+?]!3_ ,EY?_B:?M*G=BY*/9?@9O\
MPIOP'_T O_)R?_XNC_A3?@/_ * 7_DY/_P#%UI?\+%\+?]!3_P EY?\ XFC_
M (6+X6_Z"G_DO+_\31[2IW8<E'LOP,W_ (4WX#_Z 7_DY/\ _%T?\*;\!_\
M0"_\G)__ (NM+_A8OA;_ *"G_DO+_P#$T?\ "Q?"W_04_P#)>7_XFCVE3NPY
M*/9?@9O_  IOP'_T O\ R<G_ /BZ/^%-^ _^@%_Y.3__ !=:7_"Q?"W_ $%/
M_)>7_P")H_X6+X6_Z"G_ )+R_P#Q-'M*G=AR4>R_ S?^%-^ _P#H!?\ DY/_
M /%T?\*;\!_] +_R<G_^+K2_X6+X6_Z"G_DO+_\ $T?\+%\+?]!3_P EY?\
MXFCVE3NPY*/9?@9O_"F_ ?\ T O_ "<G_P#BZ/\ A3?@/_H!?^3D_P#\76E_
MPL7PM_T%/_)>7_XFC_A8OA;_ *"G_DO+_P#$T>TJ=V')1[+\#-_X4WX#_P"@
M%_Y.3_\ Q='_  IOP'_T O\ R<G_ /BZTO\ A8OA;_H*?^2\O_Q-'_"Q?"W_
M $%/_)>7_P")H]I4[L.2CV7X&;_PIOP'_P! +_R<G_\ BZ/^%-^ _P#H!?\
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MIE/D^]^%,IB"BBLG6?$^EZ#=VEKJ#W)N+U9&MX;:RFN7<)MWG;$C$ ;EZ^M
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M4DRY1L/T?P_J>O/*NDVWVAH0"X\Q5P#T^\1Z5%IFCW^L7_V+3K=IKC!)3(7
M'7)) %=;\.;QM.L?$%[&-S6]JLH7.,[=QQ^E=);VMKH.L2ZU:LK+KE[;169'
M.$D97D_/G\A2N4H)I,\HO;.?3[V6TO(_+GA;:Z9!P?J.*ETO2;W6;LVVFP^=
M,$+E=ZK\HZG)('>O0X_#>G:GXB\2:GJWDR);W.Q(I[@P1YP"69P,CV_&IM#T
MS2-/\<QOH5U;RQ3:?(9(8+CSEA<%<@-U(/OZ&BX<FIY517HOA3PKI]YI-BVL
M:7:[[LL8Y9=1>.61<]4B P<#'?WJM%X>T32['Q'<:C:27RZ7=(D0$QC9E)
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M2VC\V2WETZXCG*=-RQ,@=QD$953SQ5:Q\=:+J.HM8VBZJUPDBQ2*VC7B")F
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M>_[!=M_Z*6OCFOL;P1_R3[P]_P!@NV_]%+6-78RJ;&Y1116!B%%%% !1110
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M^4D4NJ7,T:+TP(WD*C&.,#CM0!RVB>(-6T^^\OQG<ZQ;ZK)!+.FGM;V_V*?
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MJ/\ A-_%?_0SZS_X,)?_ (JCD8>V78^QZ*^./^$W\5_]#/K/_@PE_P#BJ/\
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M)J_">54445J<@4444 %%%:+Z!J<?AN/7GML:9+<?9DG\Q>9,$[=N=W0'G&*
M,ZBNKTKX8>,M:TV._P!/T.5[:1=R/)+'&6'J [ D>^.:YW4-.O-)OY;+4K:2
MUN86VO%*N&4_Y[]Z+CLT5J***!!1110 45J:AX;U?3!IWVRR93JD*3V:HRNT
MR-C:0%).3D<'GVK=D^$WCB.Q-VWA^;RPNX@2QE\?[@;=GVQFE=#Y6<=12LK(
MY5U*LIP01@@TE,04444 %%%% !115K3--N]8U.WT_3HO.NKAPD4>X+N;TR2
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MOQE=Z=>_ G1+C1M+.E6CZL^RU-PT^SY9 ?G8 G)YHY@Y+7N>3T4451F%%%%
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MM=(L7BCN+IBJ-,2$! )Y(!/;THMU"[:L;UG\5_&UA8P6EMKLBPVZA8PT$3D
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MJ.X7':M"#_A%?^$B\-_\*U^Q_;/M/^G?V9C_ (]/+._[5CG.=F/,^;?TYW4
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MQ3_T"_\ R8B_^*KW2BE<ITTSPO\ X5UXI_Z!?_DQ%_\ %4?\*Z\4_P#0+_\
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M=#NR/NT<PW#0\>HHHJC(**** "BBB@#['\$?\D^\/?\ 8+MO_12UN5A^"/\
MDGWA[_L%VW_HI:W*YSO6P5\<^-_^2@^(?^PI<_\ HUJ^QJ^.?&__ "4'Q#_V
M%+G_ -&M6M+<VI[F'117H?A^>>W\%V!\/:CH&GWK33?;1J#6QEE&1Y9_>@D
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MY<"R>3S6MA*WEL^,;BN<9P!S[59'B+6Q<K<#6+\3K!]F$OVI]PBZ^7G.=O\
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M;R.5E0$ L0I) R1S[B@#5HKF]$\>^'?$=Y>V6D:K9R75K*T2QFYC)F"HK&1
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M^-_^2?>(?^P7<_\ HIJQ6Y@]CXXHHHK<X HHHH **** "BBB@ HHHH ****
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MJ* "BBB@ HHHH *DC[U'4D?>@!]%%%(9P7CK_D.0_P#7LO\ Z$U<U72^.O\
MD.0_]>R_^A-7-5U0^%'%4^)A16NWA76E4DV1P/21#_6LEE9&*N"K*<$$8(-4
MFGL2TUN)1113$%%%% !5[3-6FTIIC#%#*)DV.LRE@1],BJ-%+<:=C4O-?N;J
MR-HD-O:P,<LEM'L#?7FJ=[=_;)4?[/!!M0+M@3:#[GWYI+RRN-/N3!>1^7*
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M_A,!X$\:?\)I_:.=EOY7V[.W=]J3=Y6>-O3.SY?N_P"S6)X#6Z.@^(VT#/\
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MH;B2XAMXHYI559)%0!G"YV@GJ0,G'IDU0T31/[);4)YKC[5=ZA=O<SS;-O&
MJ(!DX"HJ+UY()XSBH[/Q;HM\ML8+M@;FZ:S1)8)(W6=5+&-U908VV@D!P"1@
MC.1F_;:E:WEQ>06DAEELI!%.%4@*Y4-MW'@G# \'C(SB@"U17(>#]=U7Q-'%
MJ/\ :^BO:GFXTVVM7:XM"P)$,DIFP'7@-F,9P>!VTG\::"FJG3VO)!(+@6IF
M^RR_9UF_YYF?;Y8?)QMW9W?+UXH W:*YE]5US6=:OK3PX]A96NFR"">\O;=[
M@RS;58HD:O'A5#C+ECDY '&:Z&U6X2TB6]EBFN H$DD,9C1F[D*68@>V3]:
M):*** /G+]H7_DH-C_V"X_\ T;+7E5>J_M"_\E!L?^P7'_Z-EKRJNJ'PHZ8_
M"=]H7B#5;[P/J.EVFDRZBRQB&=K2-8FB@V$1G,8#OALD[MPQP>N:X&NC\*PV
MMM;WVNWG]H,-,,6Q+"80L6<D#=)]Y5XQE03\W4=['B'QM%XF6X.HZ!8).P M
M[J NDT>,8WL2?-X&#N&>XQ3V>@^IRE?8W@C_ ))]X>_[!=M_Z*6OCFOL;P1_
MR3[P]_V"[;_T4M9U=C.IL;E8?C?_ ))]XA_[!=S_ .BFK<K#\;_\D^\0_P#8
M+N?_ $4U8K<P>Q\<4445N< 4444 %%%% !1110 445U4>G:9H'A.PU?5;(:G
M?:MYAM;661TAAB1]I=]A5V9B"% 8  $G/2@:5SE:*UX[2?Q-J?EZ)H]M:&.$
MO)';R.(D1<EI'>:1MH ZDL%Z?CH:5X3NH/%GA^VUNU22PU*^AB$D%PLL4R&4
M*ZB6)B,]00#D9'3BE<+,YBBNE\0>#-4TN;4[I;2-;&SGVNJ74<DENK,1'O0,
M73/ ^8"J]OX*UZZMH)8;)"UQ";B"W-S$MQ-'@G<D);S&!"DC"G(&1FBZ"S,*
MBMBU\*:Q=Z7#J4=O%'8S%UCN;BZBAC9E/*[G8#=Z+U(!(! .+GB?P7<>&K:Q
MGDO;.Y2ZM(KAA'=0ED9\_*%5RSJ,?? VFBX6>YS=%=GX%T'1KJUNM4\5HQTY
MIHM.MRKE")Y2,R @_P#+- 6(/!R*Y;5--N-'U:ZTZ^39<6LK12 =,J<<>WH:
M+A;2Y5HHHIB"BBB@ HHHH **** /5?V>O^2@WW_8+D_]&Q5]'5\X_L]?\E!O
MO^P7)_Z-BKZ.K&6YUTOA(Y/O?A3*?)][\*92- K#U"[MXO&VB6LEQ?I<36UV
MT4,3@6\@7RMQE'4L-PVXZ9?UK<K#U#1;F[\;:)K$;Q"WT^VNXI58G>QE\K;M
M&,8_=G.2.W6@#+A^(]E/IT>IC1]732FF$#ZA)%&L<3&3R^5,F\KN(^959>>O
M!PZ#Q?JDOQ%O= /A^Z-G!;PR+.K097?)(IE;,W,9" @!=_#97I5;_A"]1_X5
M5_PC/G6OVWS-WF;V\O'VGS>NW/W>.G7\ZTIM'U6U^(#ZYIT=G<6EY9PVETD]
MP\4D(CD=MZ81@_$A^4E>0.>> !MQXZLH#+.-.U"72H;C[--JL:1_9T</L;@N
M)"JM\I94*@@\X!(FNO%Z1:_=Z-8:-JFIWMG''+*MJD2H$<'!WR2(N>,8SD]0
M" 2.9L?AT-)GG@_X17PMKEN]W)-%>WX$5RJ.Y;8X\B3>5)(#;AD8&!BNLTW1
M;BS\9:YJTKQ&#4(K5(E4G<IB#AMPQC^,8P3WZ4 8>K?$&9+#PY?^']'NK^UU
MB[2)F(C5E!5\Q /*I$H*=_EX;G.*[.VE>>UBEEMY+9W4,T,I4M&3_"=I*Y'L
M2/>N(C\&:M:>#-"LK:2REU'1]2^W!))76&8;Y,KO"$K\LO7:>1TQS7;6K7#V
ML37L4<5P5!DCBD,B*W<!BJDCWP/I0!+1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5)'WJ.I(^] #Z***0S@O'7_(<A_Z]E_]":N:
MKI?'7_(<A_Z]E_\ 0FKFJZH?"CBJ?$ST.>&R?Q--.GGOJ%O"'6$.%608Z#O^
M?K61IVGVFHVUWJVI)"7EN& CEG,2)WY('7FN??5KZ34EOWG/VE<8D"@8[=,8
MJ6#7M3MIY9H+HH\S;I,(N"?7&,9J>5I%\\6]35&GZ##KLL;W$<MN80\2^=\F
M_P#NEQR.GZU/;^'[6?6I!/;1V]O%;B58UN2RR9)PV_&0./TK%7Q%JJ7;W*W9
M$SJ%9MB\@=.,8[U%_;6H_P!H?;?M3_:-NW?@=/3'3'M3Y9"YH]C<N=$TJYOK
M".RN((S,Y6:*"X\T  $Y!//;'3O4!FTFVUV*VBT=U:*X"[WN&!/. <?7!K+N
M];U&^:)KJY9FA;=&54+M/KP!2WFN:E?Q)'=71=8W#KA54AAT.0,]Z.5]1<T>
MAN:O##J'BW[+#IOF2AQYKF=E$@V \\?+CVINM:+8Q:$U[:1Q1/'(%(@N#,K#
M..IQS61+XBU69XGDO&+0MN0A5&#C'8<\>M-O->U*_MV@N[DR1L02NQ1T^@HY
M9:#<HNYU6I6VG:AXG-C=6,K32Q9%RLA&W ].F/?UK/-B)_#FG6)D&UM0:,N.
MXRPR*R9/$^L2QNCWK;7&#A%!_ @<?A5/^T+K['%:B8B&)_,10 "K>N>O>DHL
M;G%LZ;5M&T:WL[I8WMX)X5S'B[+.Y'8H>GX5R%:<_B/5;FU:WFNR\3KM8;%Y
M'UQFIO$.H6UU]CMK"3S+:UA"*V",MWZ_054;K1DRY7JA]AJMD^CC2M3AG,8D
MW(]NPW9/J#UK6TS3K;1_%EO J-/]HB\R&1VVM%\K9RHZYQ7/6>OZG86X@M+H
MQQ+G"[%.,_45"=4O6U 7QN'-RO20]OZ8]J3BP4DK&Q:VMKJ6M7,B:9&EM"A\
MP2W3(H;<?G+8SV/'2K5[X<L3JVEQ0#R8[L.9%CE+K\HS\K'GG-8O_"1:K]L-
MU]K;SB@C)V+@KG.,8QW-']KW=_?6S:AJ#1"%B5F$8)CSU.!C/046D/FC8UOL
M6DW5CJK0:;);R6:D*SRL<GGG&>O'2KB^']&MK:".^>!7DBW-/)=%'!(_A7H1
M5>]U^!='N8#J<FI33KL7]QY2H.YZ5BV_B/5;2W6""\98T&%!16P/3)%*TF.\
M4]2/34$7B.TC5PZK=H XZ-AQS71'_7>*?]T?^S5R4<\D5TMPC8E1PZMC.&!S
MG\ZL?VM>[KH^=S=C$_R+\_Z<=>U4XMD1DD;UW:_;(?#5N1D2)AA[?+G],U*M
MS]K;Q/+VV!1]%W ?RK%L=>GM;BWDN%^T+:QLD"Y"[,C&<@<_C5*"_N;:&>*&
M7:EPNV48!W#\?K2Y65S+^O0Z*PM!XCT.RB)_>V,PCDYY,1_^L/TIT!36?&4E
MPY5;.Q&0QX4*G3GTSS]*YVRU*[TXR&SF,1D7:^ #D?C38+^YMK6:W@DV13@"
M0!1E@.V>M'*Q<RT.IU^$ZEH;7/VBVN;BTE9B;>3?B-CP#CTX_(UQU6+6_N;)
M95MI-BS)LD!4$,/3!JO515M"92YM3O? O_(#F_Z^6_\ 05KI:YKP+_R YO\
MKY;_ -!6NEKFG\3.NG\*"OG']H7_ )*#8_\ 8+C_ /1LM?1U><?$/X2_\)YX
M@@U3^VOL'DVJV_E?9/-SAW;=G>O]_&,=J(NS%43<;(^8Z*]Q_P"&;_\ J:O_
M "G?_;:/^&;_ /J:O_*=_P#;:TYD<_LY]CPZBO<?^&;_ /J:O_*=_P#;:/\
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MG>*+ZUTB7S;)),PMOW8! .W/?&<9]JR:V/%KZ:_BR_\ [$$8L5DVQ>4,(V
M2OL2"1]:QZ:V&MC[BJAKUC+JGAS4M/MV19;NTE@1G)"AF0J"<9XR:OUEZQXC
MT[0I+6+4&N3+=EA!%;6<UR[[1EOEB5CP/:N,Y#(NO#^JVT^@:CI/V.XO=*LY
M+*6WNI6CCE218]Q60(Q5@T2X.TY!(.*K6?A#4DN;"^NYK7[4=>?5[V.)F\M
MUK) (XR1EL9CR2%S\QP.!6X/%6EOI(U&$WD\/FF%D@T^>2:-QU5X50R(?]Y1
MU'J,QZ)XOTGQ%(%TG[?(IW8EETRYAB)4[6'F/&%R"",9SD'TH Q+;PGK.E)I
M-[8-8W-]IT]_NMYY7CBEBN9C)Q($8JRX3^ _Q#OFH[GP;K,N@:C<V]S90^([
MK5!JMNP9S;VT@18@@;;N8>4I4MM!)8G '%=W5#2-7M];M);FS6011W,UL&<
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M &"[;_T4M?'-?8W@C_DGWA[_ +!=M_Z*6HJ[$5-C<K#\;_\ )/O$/_8+N?\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J2/O4=21]Z 'T444AG!>.O\
MD.0_]>R_^A-7-5TOCK_D.0_]>R_^A-7-5U0^%'%4^)A1115D!1110 4444 %
M36=J]]>16T14/*VU2QX%0UH^'O\ D8;+_KJ*3V&M6-N]'NK+54L)]@ED90C
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M^$LT7_G]_P#(3_X4?\)9HO\ S^_^0G_PHY9=@YH]S8HK'_X2S1?^?W_R$_\
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MMH9$D;#2%4$3!CEF."R\\9[U/J.M^&M6TZ:PU"X\ZVG79+'LD7</3( -6O\
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M7R0LIC_@21\DR%1\H8\X SSDF3_A+-%_Y_?_ "$_^%'_  EFB_\ /[_Y"?\
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MCC: $!#X"@';_"=7S-8B^+VNMHEK8W9_LNR$L=W<O!CYY\$,L;^_!7N.1C!
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M$4L;1RIJCHPPRL)""/I7IE%/VGD+V/F>8_9M>^S^1Y&H^3C'E[)-N/ITJO\
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M-C_V"X__ $;+51W,ZC:CH8?_  N;Q[_T'O\ R3@_^(H_X7-X]_Z#W_DG!_\
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MVYK<[3_A<WCW_H/?^2<'_P 11_PN;Q[_ -![_P DX/\ XBN&HHLA<TNYW/\
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M[US\T,MM<207$;Q31,4DCD4JR,#@@@]"#VIT%I<72RFUMY9A!&993&A;RT!
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MM:[_ ,^FG?\ ?M__ (NC_A;6N_\ /IIW_?M__BZ.5A[6)[!17C__  MK7?\
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MKQ__ (6UKO\ SZ:=_P!^W_\ BZ/^%M:[_P ^FG?]^W_^+HY6'M8GL%%>/_\
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M_P#DGWB'_L%W/_HIJW*P_&__ "3[Q#_V"[G_ -%-6*W,'L?'%%%%;G %%%%
M!1110 4444 *@5I%#ML4D MC.!ZUU_Q/GEB\:7.CQ@PZ=I6(+*U4_)$FU3N
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M0*L=PA>":*5)8I0#@[9$)5L'@X/'>G1:'=2>&[C7&>**SAN%MEWL=TTA&2J
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M:*;?GYRQ8!1P>"0?:O2/$]W9:QK,7A'6G$275A:S:;>,?^/6Z,*C!/\ SS?
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M8\/5BK!E)!!R"#TK2O/$VO:A9FTO];U&ZMFQF&>[D=#@Y'RDXZ@5Z]_PS?\
M]35_Y3O_ +;1_P ,W_\ 4U?^4[_[;1S(/9S/'6U[6'U&'4'U6^:]@39%<FY<
MR1KR,*V<@<G@>IJ--6U&..[CCO[I$O3FZ59F N.2?G&?FY)/.>IKV;_AF_\
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MLK6.VL]<U*WMXN8XHKN143Z ' KUW_AF_P#ZFK_RG?\ VVC_ (9O_P"IJ_\
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M&538W*P_&_\ R3[Q#_V"[G_T4U;E97BFRN-2\':S8V4?F7-S83PQ)N W.T;
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MM:7_ &]<I_9ND/+=6\;P;V$NTE45@I8 R;3@D+G)ZU=_X4SX]_Z /_DY!_\
M%T?\*9\>_P#0!_\ )R#_ .+IW0)270P_">JPV/CS2]5U6<K%%>I/<3%2Q W9
M9L $G\*?KGB[4]3:_M1<0K975P9)/(M8X6N,,2ID9%#/US\Q///6MG_A3/CW
M_H _^3D'_P 71_PIGQ[_ - '_P G(/\ XNE=!:5K6.3U76+[6[M+G4Y_/F2)
M(5;8JX11A1@ #@5H2>-?$,UZMY-J3R7"V)T\2O&C,8"""I)')Y/S'YN>M;G_
M  IGQ[_T ?\ R<@_^+H_X4SX]_Z /_DY!_\ %T[H.69REGJEQ!8S::TY6PNI
M$>=/)24@KG#J&Z, 2,@J2#C.#5WQ7KL6O:RLEE UMI]I EI90N<LD*#"[C_>
M/)/N36]_PIGQ[_T ?_)R#_XNC_A3/CW_ * /_DY!_P#%T70<LK;'#45W/_"F
M?'O_ $ ?_)R#_P"+H_X4SX]_Z /_ ).0?_%T70N678X:BNY_X4SX]_Z /_DY
M!_\ %T?\*9\>_P#0!_\ )R#_ .+HN@Y9=C<_9Z_Y*#??]@N3_P!&Q5]'5XK\
M&_A_XF\*>,;J^U_3/LEM)8/"K_:(GRYDC(&%8GHI_*O:JREN=5--1U(Y/O?A
M3*?)][\*\W^+OP]UCQ_9:3%HFJ16)LKAI)$F9E5\@88;03N7!QT^\>12+/1:
MP]<\4)HNK:=ID>EWVI7FHI,\,=F81A8MFXDR2(!]\8Y/>M6PMY+33;:VFF:X
MDAB2-YFZR$  L?<]:XOQ?:37OQ/\(0VVHW.G/]EU$^?;+&SCB#C$B.N/PH Z
MJQU:2XLY[G4M,NM&C@!9C?20?= R6S'(X '?)%9UEXM?5&BETKP]J]W83,OE
MWX6"*-U./G"RRK)MYZ[.1R,@@FCXRT749/AGK%A%>7VM7+Q;OWJ1B65 5+1
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M_P"$=_ZC&K?^!7_UJ/\ A'?^HQJW_@5_]:BR[A=]C8HK'_X1W_J,:M_X%?\
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M@^(?^PI<_P#HUJTI;G13W,.BBBMS8**** /N*BBBN(Y HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /G+]H7_DH-C_V"X_\ T;+7E5>J_M"_\E!L
M?^P7'_Z-EKRJNJ'PHZ8_"%%%%64%?8W@C_DGWA[_ +!=M_Z*6OCFOL;P1_R3
M[P]_V"[;_P!%+6-78RJ;&Y1116!B%%%% !1110 4444 %%%% !1110 4444
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M,.BBBN@V"BBB@#[BHHHKB.0**** "BBB@ HHHH **** "BBB@ HHHH ****
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MBC_A<W@+_H/?^2<__P 17RK11R(/;2/JK_A<W@+_ *#W_DG/_P#$4?\ "YO
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M%2Z%_P _>H_]_$_^(H_X5+H7_/WJ/_?Q/_B*[JBB[#DCV.%_X5+H7_/WJ/\
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MKM3\1_#LOQ$U/48[N6"R7PZVFVT[Q/F:7<K# 4$KGGDXZ=JY&Z\46<GP4M=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_12UN5A^"/\ DGWA[_L%VW_HI:W*YSO6P4444#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P_&_\
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M'5\X_L]?\E!OO^P7)_Z-BKZ.K&6YUTOA"BBBI-0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *^<?VA?^2@V/_8+C_P#1LM?1U>!_'7P[K>K^
M.;.?2='U"^A73D1I+:U>10WF2'&5!&<$<>XJH[F57X3QBBMS_A"/%?\ T+&L
M_P#@OE_^)H_X0CQ7_P!"QK/_ (+Y?_B:VN<MF8=%;G_"$>*_^A8UG_P7R_\
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M_H6-9_\ !?+_ /$T?\(1XK_Z%C6?_!?+_P#$T7"S,.BMS_A"/%?_ $+&L_\
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M_P#!-=__ !JMJBC0-3%_X2O3_P#GWU?_ ,$UW_\ &J/^$KT__GWU?_P37?\
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M?_P37?\ \:K:HHT#4Q?^$KT__GWU?_P37?\ \:H_X2O3_P#GWU?_ ,$UW_\
M&JVJ*- U,7_A*]/_ .??5_\ P37?_P :H_X2O3_^??5__!-=_P#QJMJBC0-3
M%_X2O3_^??5__!-=_P#QJC_A*]/_ .??5_\ P37?_P :K:HHT#4Q?^$KT_\
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MWU?_ ,$UW_\ &J/^$KT__GWU?_P37?\ \:K:HHT#4Q?^$KT__GWU?_P37?\
M\:H_X2O3_P#GWU?_ ,$UW_\ &JVJ*- U,7_A*]/_ .??5_\ P37?_P :H_X2
MO3_^??5__!-=_P#QJMJBC0-3%_X2O3_^??5__!-=_P#QJC_A*]/_ .??5_\
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M !JC_A*]/_Y]]7_\$UW_ /&JVJ*- U,7_A*]/_Y]]7_\$UW_ /&J/^$KT_\
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M$UW_ /&J/^$KT_\ Y]]7_P#!-=__ !JMJBC0-3%_X2O3_P#GWU?_ ,$UW_\
M&J/^$KT__GWU?_P37?\ \:K:HHT#4Q?^$KT__GWU?_P37?\ \:H_X2O3_P#G
MWU?_ ,$UW_\ &JVJ*- U,7_A*]/_ .??5_\ P37?_P :H_X2O3_^??5__!-=
M_P#QJMJBC0-3%_X2O3_^??5__!-=_P#QJC_A*]/_ .??5_\ P37?_P :K:HH
MT#4Q?^$KT_\ Y]]7_P#!-=__ !JC_A*]/_Y]]7_\$UW_ /&JVJ*- U,7_A*]
M/_Y]]7_\$UW_ /&J/^$KT_\ Y]]7_P#!-=__ !JMJBC0-3%_X2O3_P#GWU?_
M ,$UW_\ &J/^$KT__GWU?_P37?\ \:K:HHT#4Q?^$KT__GWU?_P37?\ \:H_
MX2O3_P#GWU?_ ,$UW_\ &JVJ*- U,7_A*]/_ .??5_\ P37?_P :H_X2O3_^
M??5__!-=_P#QJMJBC0-3%_X2O3_^??5__!-=_P#QJC_A*]/_ .??5_\ P37?
M_P :K:HHT#4Q?^$KT_\ Y]]7_P#!-=__ !JC_A*]/_Y]]7_\$UW_ /&JVJ*-
M U,>/Q/822*BV^J@L0 6TBZ4<^I,>!]36Q111H"OU/G3]H/_ )*!8_\ 8+C_
M /1LM>5UZI^T'_R4"Q_[!<?_ *-EKRNO6H_PT>'B/XL@HHHK8Q"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **]3^"MEHMP
MWB"Y\0V%G=VUI;QR$W<*R"(9;<PW#C@?I6EX,\!V&C?$373K]I#<Z;I]Q%:6
MT=Q&)%D>XD41'##!(5AGCJV:QE546UV-XT'))KJ>-45ZAJFF:S#K7Q!C\+SV
M>G:5:C_3K7RE7S(L-A4 0X_BZ%>M)XF\'/K+>"=/\.:?;175[HD4T[HBQACM
M!:21@.?<G)_&G[1"]B^G]:V/,**Z[5_AMK.F1V,MO<:?JT%]="SCFTZY\U!,
M3@(Q(&"?Z59O_AA=:9>1VE]XG\,PW#2>7)$^H[6@.TM\X*Y XQ]2/6G[2/<G
MV<^QQ%%>C^-OA6-&\2VVF^&K^&^>[D2**RDN5:[4E2Q=E"J G!YK-U?X6ZSI
M6EWE]'?:5J2V'_'Y#877F26X[[U(&,4*I!I:@Z,TVK;'%45WMC\(M:O8=/D_
MM31;<ZE;)<VD<]V4>8,N[:J[<E@,9QQSU-9>C_#W6-6N=3C>6RTZ'2I3#=W=
M_/Y<,<@;;MW8.3D?YR*/:0[A[*?8Y:BNT3X5^(7\2OHY:S39:_;#?-,?LQA_
MO[\=,^V>">G-8'B#0_[ U!+3^T]-U/=&)/.TVX\Z,9)&TM@8;C./0BFIQ;LF
M2X2BKM&5179:+\-;[Q!8PS:9KF@R7,T?F)I_V_\ TD\9P4 X/U-1:+\.M5UG
M1Y]3-YING6UM>-9W#:A<>3Y+JH)+$C&/F ZYSV[T<\>X_9S[')45UUS\-/$%
MOXQM_#:);W%W<0BXCEAES$8CD;]Q ( P>WTSD5U%UX,M- ^#GB"2YFT75+Z.
M\A"7EBZS-"-Z IOP"IZY'O4NI%6\RE2D[WZ'E-%='X7\%:CXLM-0N=/N+*"+
M3O+,[7<WE@*Y;YLXQ@;23DCVS5C6/AUK6DZCI5I&]GJ1U?/V*6PF\R.7&,X8
M@=-P.>F.]5SQO:Y/LY-<UM#E**[+6_AEJVB:7/?O?Z7>P6DJQ7GV*Y,K6A)Q
M^\7:".?3)]JF_P"%3Z]Y^?M.G?V=]C^V_P!J^<WV7R_][;G/MBE[2'<?LIWM
M8X>BO2A\+;&3X=6NMQ^)-+CO)IN9)KT+;;"A;RQE-PFZ94^AKD?"WA/4/%VH
MRVFFM!$((3/-/<N4BB0=V;!]?Y^E"J1:;[ Z<DTK;F'17I7A'X66>K^+GTO4
M_$>EW4$=N)2=)OE=Y"VX )E"#MV988X#+ZUBVWPXU&^UJXL+#5=&NX;6 7%Q
MJ$-YNM85.<!GQP>#QBCVD;VN'LIV3L<?178R_#+6H_$NEZ.MSI\O]K(SV=[#
M.7MY0JECA@N>@].XI=7^&.LZ5HMSJ:7FEZC'9-MNXK"Z\V2V/?>,#&._)_*C
MVD>X>SGV.-HKL=6^&NHZ'I)O-6U?1+6?[.+C^SY+W%R5(Z!,<GJ.#U%<=5*2
MEL3*+CHPHHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** -SP3_P E \/?]A2V_P#1JU]AU\>>"?\ DH'A[_L*6W_HU:^P
MZ\_%_$CU,#\+"BBBN([SQ#]HW_F7/^WK_P!I5X?7N'[1O_,N?]O7_M*O#Z]7
M#_PD>)BOXS_KH%%%%=!SA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 445Z'\&--MM4\5:G%<Z=::DT>E2R00
M7<2R(9 \>WAN!UQGCJ:B4N6-RH1YY*)YY17HWCJP\1K9V%GKG@[P_H NKH"&
MXTZ"-'=L$;24=CM^;)&.P]*CE^#.OQ7%S:+J.BRWUO&9?L27A\Z1!_$$*].V
M3BI52-KMENE*]DCSVBNLT7X>:EK'AY=;EU#2M*L)',<,NI7?DB8C(.W@]P1S
MCH:[#QQ\/7UWXE:I9>&X]-TR"QLHKB1&_<1@$<D;5P/4DXH=2*=@5&;C>QY'
M175ZW\.]8T>'3YXIK'5;;49Q;V]QIMQYL;2G@)D@<GGVX-:%Y\(M?M;6Z:.\
MTF\N[.+S;C3[6[WW$2]>4QZ>_/;-/VD.XO93['"45W5WX>\3ZSI7@S3[S4+.
M2TU 2II49&W[.,KNWD)GD[>[=*9J'PIUJPTO4;O[?I%R^F*7N[2VN]\T*C/+
M+CC@$X)S[4>TCU8>RET1Q%%>E>)?A9::1X3TW4K'Q!ITUU+#(\R->AENF!7:
M+4! 7ZD$$]2*Q/$7PZO_  OILEQJNKZ*MS$J,^G)>9NAN( ^3'/7/!Z FA5(
MO9A*E..Z.0HHHK0S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH W/!/_ "4#P]_V%+;_ -&K7V'7QYX)
M_P"2@>'O^PI;?^C5K[#KS\7\2/4P/PL^=/V@_P#DH%C_ -@N/_T;+7E=?0'Q
M9^'FH^+?%EM?6-]86\<=DD)6Y:0,2'<Y^5&&/F'>N%_X4IKG_07T?_OY/_\
M&JWI5(J"39RUZ<W4;2/.:*]&_P"%*:Y_T%]'_P"_D_\ \:H_X4IKG_07T?\
M[^3_ /QJM?:0[F/LI]CSFBO1O^%*:Y_T%]'_ ._D_P#\:H_X4IKG_07T?_OY
M/_\ &J/:0[A[*?8\YHKT;_A2FN?]!?1_^_D__P :H_X4IKG_ $%]'_[^3_\
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M\HA2K*2/E.0,+QU/K3O^%*:Y_P!!?1_^_D__ ,:H_P"%*:Y_T%]'_P"_D_\
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M]ZUX8S%!'&6W%%"[O7 ZU5M];TJZU"2PM=3LYKR+/F6T=PK2)@X.5!R,&KM
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MJ1@8' Q3H]%TN&]@O(M-LTNK> 6\,ZP*'BB'2-6QD+R?E'% %ZBBB@ HHHH
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M<0LD0DEB0C#D?,>AR0>#TKO**+!<\[M;6[N-;U^XB_MB\AGT7R4N+^Q$#2R
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:U[4XK4WEQIMQ'MM1;ZFEO!&NWE98B,R$GZ=>OI?U#POX@B\(^#&L=.2ZO\
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MSG:K2,Q4$GD#&>,]!6G30F%%%%,04444 %%%% !1110 4444 %%%% !1110
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M<8QC /?.>U4B65/#5_<C2M3GM5O=6T^&YQI99@9KB#RXSE7E9=Z[RX5V;YE
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MSCV#_A'?^GK_ ,A__7H_X1W_ *>O_(?_ ->BBCVD@]G'L'_"._\ 3U_Y#_\
MKT?\([_T]?\ D/\ ^O111[20>SCV#_A'?^GK_P A_P#UZ/\ A'?^GK_R'_\
M7HHH]I(/9Q[!_P ([_T]?^0__KT?\([_ -/7_D/_ .O111[20>SCV#_A'?\
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M?_UZ**/:2#V<>P?\([_T]?\ D/\ ^O1_PCO_ $]?^0__ *]%%'M)![./8/\
MA'?^GK_R'_\ 7H_X1W_IZ_\ (?\ ]>BBCVD@]G'L'_"._P#3U_Y#_P#KT?\
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0]:**  1(#D#]:?110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img134051827_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_7.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0+X17AI9@  34T *@    @ ! $[  (
M   /   !2H=I  0    !   !6IR=  $    >   "TNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M36EC:&%E;"!286EB;&4    %D ,  @   !0   *HD 0  @   !0   *\DI$
M @    ,X-P  DI(  @    ,X-P  ZAP !P   0P   &<     !SJ     0
M
M
M
M
M
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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M'>O#8?&?CJ6".0^,+D%E#$?8K;N/^N=-*Y,I*.Y]&T5\[?\ "8>.?^AQNO\
MP"MO_C='_"8>.?\ H<;K_P  K;_XW3Y63[6)]$T5\[?\)AXY_P"AQNO_  "M
MO_C='_"8>.?^AQNO_ *V_P#C='*P]K$^B:*^=O\ A,/'/_0XW7_@%;?_ !NC
M_A,/'/\ T.-U_P" 5M_\;HY6'M8GT317SM_PF'CG_H<;K_P"MO\ XW1_PF'C
MG_H<;K_P"MO_ (W1RL/:Q/HFBOG;_A,/'/\ T.-U_P" 5M_\;H_X3#QS_P!#
MC=?^ 5M_\;HY6'M8GT317SM_PF'CG_H<;K_P"MO_ (W1_P )AXY_Z'&Z_P#
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M (!6W_QNCE8>UB?1-%?.W_"8>.?^AQNO_ *V_P#C='_"8>.?^AQNO_ *V_\
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M2-@S6-KGYD5O^>?O6?\ \)AXY_Z'&Z_\ K;_ .-TK,/:1/HFBOG;_A,/'/\
MT.-U_P" 5M_\;H_X3#QS_P!#C=?^ 5M_\;I\K#VL3Z)HKYV_X3#QS_T.-U_X
M!6W_ ,;H_P"$P\<_]#C=?^ 5M_\ &Z.5A[6)]$T5\[?\)AXY_P"AQNO_  "M
MO_C='_"8>.?^AQNO_ *V_P#C='*P]K$^B:*^=O\ A,/'/_0XW7_@%;?_ !NC
M_A,/'/\ T.-U_P" 5M_\;HY6'M8GT317SM_PF'CG_H<;K_P"MO\ XW6AH>O^
M-M5U>.TE\:7B*R2,66QM<_*C-_SS]J5F'M(L]YHKYV_X3#QS_P!#C=?^ 5M_
M\;H_X3#QS_T.-U_X!6W_ ,;I\K#VL3Z)HKYV_P"$P\<_]#C=?^ 5M_\ &Z/^
M$P\<_P#0XW7_ (!6W_QNCE8>UB?1-%?.W_"8>.?^AQNO_ *V_P#C='_"8>.?
M^AQNO_ *V_\ C='*P]K$^B:*^=O^$P\<_P#0XW7_ (!6W_QNC_A,/'/_ $.-
MU_X!6W_QNCE8>UB?1-%?.W_"8>.?^AQNO_ *V_\ C='_  F'CG_H<;K_ , K
M;_XW1RL/:Q/HFBOG;_A,/'/_ $.-U_X!6W_QNM"/7_&S^'+C43XTO \5U'"$
M^PVN"&5CG_5_[-+E8>TB>\T5\[?\)AXY_P"AQNO_  "MO_C='_"8>.?^AQNO
M_ *V_P#C=/E8>UB?1-%?.W_"8>.?^AQNO_ *V_\ C='_  F'CG_H<;K_ , K
M;_XW1RL/:Q/HFBOG;_A,/'/_ $.-U_X!6W_QNC_A,/'/_0XW7_@%;?\ QNCE
M8>UB?1-%?.W_  F'CG_H<;K_ , K;_XW1_PF'CG_ *'&Z_\  *V_^-T<K#VL
M3Z)HKYV_X3#QS_T.-U_X!6W_ ,;H_P"$P\<_]#C=?^ 5M_\ &Z.5A[6)]$T5
M\[?\)AXY_P"AQNO_  "MO_C=:&K:_P"-M.^Q>7XTO'^TVD=PVZQM>"V>/]7T
MXI68>TB>\T5\[?\ "8>.?^AQNO\ P"MO_C='_"8>.?\ H<;K_P  K;_XW3Y6
M'M8GT317SM_PF'CG_H<;K_P"MO\ XW1_PF'CG_H<;K_P"MO_ (W1RL/:Q/HF
MBOG;_A,/'/\ T.-U_P" 5M_\;H_X3#QS_P!#C=?^ 5M_\;HY6'M8GT317SM_
MPF'CG_H<;K_P"MO_ (W1_P )AXY_Z'&Z_P# *V_^-T<K#VL3Z)HKYV_X3#QS
M_P!#C=?^ 5M_\;H_X3#QS_T.-U_X!6W_ ,;HY6'M8GT317@6C^(_&^I:W964
MGC.[1+B=(F9;&UR 3C/^KJM/XL\<Q7$D8\971".5!-E;=C_USI68>TB?0U%?
M.W_"8>.?^AQNO_ *V_\ C='_  F'CG_H<;K_ , K;_XW3Y6'M8GT317SM_PF
M'CG_ *'&Z_\  *V_^-T?\)AXY_Z'&Z_\ K;_ .-T<K#VL3Z)HKYV_P"$P\<_
M]#C=?^ 5M_\ &Z/^$P\<_P#0XW7_ (!6W_QNCE8>UB?1-%?.W_"8>.?^AQNO
M_ *V_P#C='_"8>.?^AQNO_ *V_\ C='*P]K$^B:*^=O^$P\<_P#0XW7_ (!6
MW_QNC_A,/'/_ $.-U_X!6W_QNCE8>UB?1-%>#66O^-KK2-3NV\:7BM9I&RJ+
M&UPVYPO/[OWK/_X3#QS_ -#C=?\ @%;?_&Z5F'M(GT317SM_PF'CG_H<;K_P
M"MO_ (W1_P )AXY_Z'&Z_P# *V_^-T^5A[6)]$T5\[?\)AXY_P"AQNO_  "M
MO_C='_"8>.?^AQNO_ *V_P#C='*P]K$^B:*^=O\ A,/'/_0XW7_@%;?_ !NC
M_A,/'/\ T.-U_P" 5M_\;HY6'M8GT317SM_PF'CG_H<;K_P"MO\ XW1_PF'C
MG_H<;K_P"MO_ (W1RL/:Q/HFBOG;_A,/'/\ T.-U_P" 5M_\;H_X3#QS_P!#
MC=?^ 5M_\;HY6'M8GT317@U]K_C:UTC3+M?&EXS7B2,RFQM<+M<KQ^[]JS_^
M$P\<_P#0XW7_ (!6W_QNE9A[2)]$T5\[?\)AXY_Z'&Z_\ K;_P"-T?\ "8>.
M?^AQNO\ P"MO_C=/E8>UB?1-%?.W_"8>.?\ H<;K_P  K;_XW1_PF'CG_H<;
MK_P"MO\ XW1RL/:Q/HFBOG;_ (3#QS_T.-U_X!6W_P ;H_X3#QS_ -#C=?\
M@%;?_&Z.5A[6)]$T5\[?\)AXY_Z'&Z_\ K;_ .-T?\)AXY_Z'&Z_\ K;_P"-
MT<K#VL3Z)HKYV_X3#QS_ -#C=?\ @%;?_&Z/^$P\<_\ 0XW7_@%;?_&Z.5A[
M6)]$T5\[?\)AXY_Z'&Z_\ K;_P"-T?\ "8>.?^AQNO\ P"MO_C='*P]K$^B:
M*^=O^$P\<_\ 0XW7_@%;?_&Z/^$P\<_]#C=?^ 5M_P#&Z.5A[6)]$T5\[?\
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M-&BW1W3+C(V J-V>U3R_#C4XY?(74-+DNS'YBVJW)$KC'92HI?''_(,\,?\
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M_"H;_P#Z"EO_ -^VHN@]G+L>>45Z'_PJ&_\ ^@I;_P#?MJ/^%0W_ /T%+?\
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M//**]#_X5#?_ /04M_\ OVU'_"H;_P#Z"EO_ -^VHN@]G+L>>45Z'_PJ&_\
M^@I;_P#?MJ/^%0W_ /T%+?\ []M1=![.78\\HKT/_A4-_P#]!2W_ ._;4?\
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M  EOI;B20:G;@.Q;'EMQDTKHKDE;8\XHKT/_ (5#?_\ 04M_^_;4?\*AO_\
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MQ7=ZKYNKVT<L<2)';B+Y]N<AU8D$=,8YY-/_ .%0W_\ T%+?_OVU'_"H;_\
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M(NO#,GE7&-)CVS_*OS'C[O//3OBM7_A4-_\ ]!2W_P"_;4?\*AO_ /H*6_\
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MK$@!QB-3C]>WUKT7[._M^='V=_;\ZKZQ5MO^7]=!6.,N/ OGZEX0N_[1V_\
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M]OSH AHJ;[._M^='V=_;\Z (:*F^SO[?G1]G?V_.@"&BIOL[^WYT?9W]OSH
MAHJ;[._M^='V=_;\Z (:*F^SO[?G1]G?V_.@"&BIOL[^WYT?9W]OSH AHJ;[
M._M^='V=_;\Z (:*F^SO[?G1]G?V_.@"&BIOL[^WYT?9W]OSH AHJ;[._M^=
M'V=_;\Z (:*F^SO[?G1]G?V_.@"&BIOL[^WYT?9W]OSH AHJ;[._M^='V=_;
M\Z (:*F^SO[?G1]G?V_.@"&BIOL[^WYT?9W]OSH AHJ;[._M^='V=_;\Z (:
M*F^SO[?G1]G?V_.@"&BIOL[^WYT?9W]OSH AHJ;[._M^='V=_;\Z (:*F^SO
M[?G1]G?V_.@"&BIOL[^WYT?9W]OSH AHJ;[._M^='V=_;\Z (:*F^SO[?G1]
MG?V_.@"&BIOL[^WYT?9W]OSH AHJ;[._M^='V=_;\Z (:*F^SO[?G1]G?V_.
M@"&BIOL[^WYT?9W]OSH AHJ;[._M^='V=_;\Z (:*F^SO[?G1]G?V_.@"&BI
MOL[^WYT?9W]OSH AHJ;[._M^='V=_;\Z (:*F^SO[?G1]G?V_.@"&BIOL[^W
MYT?9W]OSH AHJ;[._M^='V=_;\Z (:*F^SO[?G1]G?V_.@"&BIOL[^WYT?9W
M]OSH AHJ;[._M^='V=_;\Z (:*F^SO[?G1]G?V_.@"&N3^)W_(@W7_7U9_\
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M*;>.4XQ&TX7RU;YE&TL#D@=2*R+3QU:6&N>(;37[R9([/4UAAD%G(T5M$UO
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M1F7+9R?O";&,<8ZG- $NI>,-.TRXU&&:.YD:P6 .8HPWFRS,5C@09R9"=O'
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M:$\E(F$^U22 2Y0L< $X"@ $UGXXL[VZM-FGWZ:??3&"TU-TC^SSN,X PY<
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MJ2.^6R6#H2J\$DLP(XS@9QDZGAO4;W5O"NGZE?01Q75W;K.85RH3<-RJ>I!
M(!]\UB?\++TO_H$>)/\ P1W/_P 11_PLO2_^@1XD_P#!'<__ !% %>ST#Q-J
M6J:A/XKM]+ O+6:RCFL;^1C:0/\ PI&T"Y8D*68OR5&  -M6-*\/Z\UYH0UO
M^SHK?05;RI+.5W>[;RFA4LC(HB&UF)4,_..>.3_A9>E_] CQ)_X([G_XBC_A
M9>E_] CQ)_X([G_XBF!%8:+XGOO$5Q>>*K72S#-#+:PM9:C(390..0B- -[L
M53<Y8<*-H'(8TOPYKD2:!9ZV^FQZ?X<;?%<VTKF2ZV0O"A9&0"(;'+, S\C
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M%%<?_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\
M\++TO_H$>)/_  1W/_Q%'_"R]+_Z!'B3_P $=S_\10!V%%<?_P ++TO_ *!'
MB3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\ \++TO_H$>)/_  1W
M/_Q%'_"R]+_Z!'B3_P $=S_\10!V%%<?_P ++TO_ *!'B3_P1W/_ ,11_P +
M+TO_ *!'B3_P1W/_ ,10!V%%<?\ \++TO_H$>)/_  1W/_Q%'_"R]+_Z!'B3
M_P $=S_\10!V%%<?_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_
M ,10!V%%<?\ \++TO_H$>)/_  1W/_Q%'_"R]+_Z!'B3_P $=S_\10!V%%<?
M_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\ \++T
MO_H$>)/_  1W/_Q%'_"R]+_Z!'B3_P $=S_\10!V%%<?_P ++TO_ *!'B3_P
M1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\ \++TO_H$>)/_  1W/_Q%
M'_"R]+_Z!'B3_P $=S_\10!V%%<?_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_
M *!'B3_P1W/_ ,10!V%%<?\ \++TO_H$>)/_  1W/_Q%'_"R]+_Z!'B3_P $
M=S_\10!V%%<?_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10
M!V%%<?\ \++TO_H$>)/_  1W/_Q%'_"R]+_Z!'B3_P $=S_\10!V%%<?_P +
M+TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\ \++TO_H$
M>)/_  1W/_Q%'_"R]+_Z!'B3_P $=S_\10!V%%<?_P ++TO_ *!'B3_P1W/_
M ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\ \++TO_H$>)/_  1W/_Q%'_"R
M]+_Z!'B3_P $=S_\10!V%%<?_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'
MB3_P1W/_ ,10!V%%<?\ \++TO_H$>)/_  1W/_Q%'_"R]+_Z!'B3_P $=S_\
M10!V%%<?_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%
M<?\ \++TO_H$>)/_  1W/_Q%'_"R]+_Z!'B3_P $=S_\10!V%%<?_P ++TO_
M *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\ \++TO_H$>)/_
M  1W/_Q%'_"R]+_Z!'B3_P $=S_\10!V%%<?_P ++TO_ *!'B3_P1W/_ ,11
M_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\ \++TO_H$>)/_  1W/_Q%'_"R]+_Z
M!'B3_P $=S_\10!V%%<?_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P
M1W/_ ,10!V%%<?\ \++TO_H$>)/_  1W/_Q%'_"R]+_Z!'B3_P $=S_\10!V
M%%<?_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\
M\++TO_H$>)/_  1W/_Q%'_"R]+_Z!'B3_P $=S_\10!V%%<?_P ++TO_ *!'
MB3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\ \++TO_H$>)/_  1W
M/_Q%'_"R]+_Z!'B3_P $=S_\10!V%%<?_P ++TO_ *!'B3_P1W/_ ,11_P +
M+TO_ *!'B3_P1W/_ ,10!V%%<?\ \++TO_H$>)/_  1W/_Q%'_"R]+_Z!'B3
M_P $=S_\10!V%%<?_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_
M ,10!V%%<?\ \++TO_H$>)/_  1W/_Q%'_"R]+_Z!'B3_P $=S_\10!V%%<?
M_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\ \++T
MO_H$>)/_  1W/_Q%'_"R]+_Z!'B3_P $=S_\10!V%%<?_P ++TO_ *!'B3_P
M1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\ \++TO_H$>)/_  1W/_Q%
M'_"R]+_Z!'B3_P $=S_\10!V%%<?_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_
M *!'B3_P1W/_ ,10!V%%<?\ \++TO_H$>)/_  1W/_Q%'_"R]+_Z!'B3_P $
M=S_\10!V%%<?_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10
M!V%%<?\ \++TO_H$>)/_  1W/_Q%'_"R]+_Z!'B3_P $=S_\10!V%%<?_P +
M+TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\ \++TO_H$
M>)/_  1W/_Q%'_"R]+_Z!'B3_P $=S_\10!V%%<?_P ++TO_ *!'B3_P1W/_
M ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\ \++TO_H$>)/_  1W/_Q%'_"R
M]+_Z!'B3_P $=S_\10!V%%<?_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'
MB3_P1W/_ ,10!V%%<?\ \++TO_H$>)/_  1W/_Q%'_"R]+_Z!'B3_P $=S_\
M10!V%%<?_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%
M<?\ \++TO_H$>)/_  1W/_Q%'_"R]+_Z!'B3_P $=S_\10!V%%<?_P ++TO_
M *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\ \++TO_H$>)/_
M  1W/_Q%'_"R]+_Z!'B3_P $=S_\10!V%%<?_P ++TO_ *!'B3_P1W/_ ,11
M_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\ \++TO_H$>)/_  1W/_Q%'_"R]+_Z
M!'B3_P $=S_\10!V%%<?_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P
M1W/_ ,10!V%%<?\ \++TO_H$>)/_  1W/_Q%'_"R]+_Z!'B3_P $=S_\10!V
M%%<?_P ++TO_ *!'B3_P1W/_ ,11_P ++TO_ *!'B3_P1W/_ ,10!V%%<?\
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M#HJYY/7MD9IGBZPU;0/AAIHA\7:E<ZEJ>K6OVC5HKMR")6.?*4':L>#PJX!
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MFPRY)/) .FHKBG\=:DIO+L:#%_95CJ?]G3W!O\3$^:(_,2+R\%1N4D%U/WL
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MBB@ HHJ&>[MK5H1=7$4)GD$40D<+YCD$A5SU. 3@<\&@":BL'4]?O4US^Q]
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M2W&H3R*2(U=28XEP1^\.0YSG"CI\ZD;M !1110 4444 %%%% !1110 4444
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MY0BMXY$8I(C%RY<L &R!\K (,DUZ!+%'/"\4R+)'(I5T<9# \$$=Q6/#X?\
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M9%D? 'F/LSD*<UO _AG4-&\07=Q=:?\ 8P8'CNKG>C?VG,9V=9OE)8X4D9<
M_/@# KO** "BBB@ HHHH XWQZMS'_9=W<7$$FFPZI9$621;+B6;SU"E92Q!
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M>_\ 4W>*O_!G_P#8UV%% ''_ /"O?^IN\5?^#/\ ^QH_X5[_ -3=XJ_\&?\
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M_!G_ /8UV%% ''_\*]_ZF[Q5_P"#/_[&C_A7O_4W>*O_  9__8UV%% ''_\
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M&NPHH X__A7O_4W>*O\ P9__ &-'_"O?^IN\5?\ @S_^QKL** ./_P"%>_\
M4W>*O_!G_P#8T?\ "O?^IN\5?^#/_P"QKL** ./_ .%>_P#4W>*O_!G_ /8T
M?\*]_P"IN\5?^#/_ .QKL** ./\ ^%>_]3=XJ_\ !G_]C1_PKW_J;O%7_@S_
M /L:["B@#C_^%>_]3=XJ_P#!G_\ 8T?\*]_ZF[Q5_P"#/_[&NPHH X__ (5[
M_P!3=XJ_\&?_ -C1_P *]_ZF[Q5_X,__ +&NPHH X_\ X5[_ -3=XJ_\&?\
M]C1_PKW_ *F[Q5_X,_\ [&NPHH X_P#X5[_U-WBK_P &?_V-'_"O?^IN\5?^
M#/\ ^QKL** ./_X5[_U-WBK_ ,&?_P!C1_PKW_J;O%7_ (,__L:["B@#C_\
MA7O_ %-WBK_P9_\ V-'_  KW_J;O%7_@S_\ L:["B@#C_P#A7O\ U-WBK_P9
M_P#V-'_"O?\ J;O%7_@S_P#L:["B@#C_ /A7O_4W>*O_  9__8T?\*]_ZF[Q
M5_X,_P#[&NPHH X__A7O_4W>*O\ P9__ &-'_"O?^IN\5?\ @S_^QKL** ./
M_P"%>_\ 4W>*O_!G_P#8T?\ "O?^IN\5?^#/_P"QKL** ./_ .%>_P#4W>*O
M_!G_ /8T?\*]_P"IN\5?^#/_ .QKL** ./\ ^%>_]3=XJ_\ !G_]C1_PKW_J
M;O%7_@S_ /L:["B@#C_^%>_]3=XJ_P#!G_\ 8T?\*]_ZF[Q5_P"#/_[&NPHH
M X__ (5[_P!3=XJ_\&?_ -C1_P *]_ZF[Q5_X,__ +&NPHH X_\ X5[_ -3=
MXJ_\&?\ ]C1_PKW_ *F[Q5_X,_\ [&NPHH X_P#X5[_U-WBK_P &?_V-'_"O
M?^IN\5?^#/\ ^QKL** ./_X5[_U-WBK_ ,&?_P!C1_PKW_J;O%7_ (,__L:[
M"B@#C_\ A7O_ %-WBK_P9_\ V-'_  KW_J;O%7_@S_\ L:["B@#C_P#A7O\
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M/_[&NPHH X__ (5[_P!3=XJ_\&?_ -C1_P *]_ZF[Q5_X,__ +&NPHH X_\
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MW_J;O%7_ (,__L:["B@#C_\ A7O_ %-WBK_P9_\ V-'_  KW_J;O%7_@S_\
ML:["B@#C_P#A7O\ U-WBK_P9_P#V-'_"O?\ J;O%7_@S_P#L:["B@#C_ /A7
MO_4W>*O_  9__8T?\*]_ZF[Q5_X,_P#[&NPHH X__A7O_4W>*O\ P9__ &-'
M_"O?^IN\5?\ @S_^QKL** ./_P"%>_\ 4W>*O_!G_P#8T?\ "O?^IN\5?^#/
M_P"QKL** ./_ .%>_P#4W>*O_!G_ /8T?\*]_P"IN\5?^#/_ .QKL** ./\
M^%>_]3=XJ_\ !G_]C1_PKW_J;O%7_@S_ /L:["B@#C_^%>_]3=XJ_P#!G_\
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M:DTE_I_E229-M+*(]K@QLP,;9&1M8MP>F3ZU=H **** "BBB@ HHHH ****
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M]_Y@5XZ\@CCD5YQX5\1:-.WBRQ_X3=3!#>K)#>/JD<LB0>3#O=6<L%0R,P)
M"@L0NTXP >FT5P'P\\6Z2_A=XY=>6^>/59K5"UVUU*%DNG2W#-EFPPVA6;@C
MG..:9?I/:^.[^[\30:_'I,]W;0:?=VNIO':PY15_>1Q3!ANE)7+1D<C) )H
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M/F@,<;0E26$B A<-C<1C/?BO2I;B&!HEGFCC,S^7&'8#>V"=HSU. 3CV-24
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MDQ\3_P#8)NO_ $4U:VB_\@&P_P"O:/\ ]!%9/Q$_Y)CXG_[!-U_Z*:M;1?\
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M_DF/B?\ [!-U_P"BFK6T7_D V'_7M'_Z"*R?B)_R3'Q/_P!@FZ_]%-6MHO\
MR ;#_KVC_P#010!FS^(7T_Q3>V.I^5'91Z;_ &A;RJ"&*HQ68-S@[<QD8Q]^
ML/2_'&JWW@FWN[BQM[?79]0CL/LIW&-&=E8$\YXA;>>>QQ3OB)IMOKT5E;1:
MI;64\5S]GNQ,3E[69-LR< XRI!!.%RHR1S4'V2P'Q+&O?VO9C3$48M@#O%[L
M,/F=,;/))7=T_*IYH]S94*S5U%_<SHY_&F@VVI/937D@>.<6\DPMI3;QRG&(
MVG"^6K?,HVE@<D#J15.R\4)9S>))==O-MM9:NEG:J(MS8:W@98U5!N=B\C8
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MY/ <\<<XOBS7[V?P[K6C:YIT-A?I:QW,7V:Z-Q%-%YJJ2&*(0P;@@KW!!/.
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M !1110 4444 %%%9?B+6AH.D-=) ;JYDD2"UM@VTSS.P5$S@X&3DG!P 3VH
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M;I5%EHNG?9[=\C,\SA0[8YP%6, 9Y)=O0$]-10 4444 %%%% !1110 4444
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M+SKME++%&NV.,;54;5!;D@L2Q))K:HHH **** *NIQQS:5=1361U".2%U>T
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M*PV/P0HS_#6Q\1/^28^)_P#L$W7_ **:M;1?^0#8?]>T?_H(H YS_A;'@?\
MZ&&W_P"_;_\ Q-'_  MCP/\ ]##;_P#?M_\ XFNPHH X_P#X6QX'_P"AAM_^
M_;__ !-'_"V/ _\ T,-O_P!^W_\ B:["B@#C_P#A;'@?_H8;?_OV_P#\31_P
MMCP/_P!##;_]^W_^)KL** ./_P"%L>!_^AAM_P#OV_\ \31_PMCP/_T,-O\
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MX'_Z&&W_ ._;_P#Q-'_"V/ __0PV_P#W[?\ ^)KL** ./_X6QX'_ .AAM_\
MOV__ ,31_P +8\#_ /0PV_\ W[?_ .)KL** ./\ ^%L>!_\ H8;?_OV__P 3
M1_PMCP/_ -##;_\ ?M__ (FNPHH X_\ X6QX'_Z&&W_[]O\ _$T?\+8\#_\
M0PV__?M__B:["B@#C_\ A;'@?_H8;?\ []O_ /$T?\+8\#_]##;_ /?M_P#X
MFNPHH X__A;'@?\ Z&&W_P"_;_\ Q-'_  MCP/\ ]##;_P#?M_\ XFNPHH X
M_P#X6QX'_P"AAM_^_;__ !-'_"V/ _\ T,-O_P!^W_\ B:["B@#C_P#A;'@?
M_H8;?_OV_P#\31_PMCP/_P!##;_]^W_^)KL** ./_P"%L>!_^AAM_P#OV_\
M\31_PMCP/_T,-O\ ]^W_ /B:["B@#C_^%L>!_P#H8;?_ +]O_P#$T?\ "V/
M_P#T,-O_ -^W_P#B:["B@#C_ /A;'@?_ *&&W_[]O_\ $T?\+8\#_P#0PV__
M '[?_P")KL** ./_ .%L>!_^AAM_^_;_ /Q-'_"V/ __ $,-O_W[?_XFNPHH
M X__ (6QX'_Z&&W_ ._;_P#Q-'_"V/ __0PV_P#W[?\ ^)KL** ./_X6QX'_
M .AAM_\ OV__ ,31_P +8\#_ /0PV_\ W[?_ .)KL** ./\ ^%L>!_\ H8;?
M_OV__P 31_PMCP/_ -##;_\ ?M__ (FNPHH X_\ X6QX'_Z&&W_[]O\ _$T?
M\+8\#_\ 0PV__?M__B:["B@#C_\ A;'@?_H8;?\ []O_ /$T?\+8\#_]##;_
M /?M_P#XFNPHH X__A;'@?\ Z&&W_P"_;_\ Q-'_  MCP/\ ]##;_P#?M_\
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M_P#?M_\ XFNPHH X_P#X6QX'_P"AAM_^_;__ !-'_"V/ _\ T,-O_P!^W_\
MB:["B@#C_P#A;'@?_H8;?_OV_P#\31_PMCP/_P!##;_]^W_^)KL** ./_P"%
ML>!_^AAM_P#OV_\ \31_PMCP/_T,-O\ ]^W_ /B:["B@#C_^%L>!_P#H8;?_
M +]O_P#$T?\ "V/ _P#T,-O_ -^W_P#B:["B@#C_ /A;'@?_ *&&W_[]O_\
M$T?\+8\#_P#0PV__ '[?_P")KL** ./_ .%L>!_^AAM_^_;_ /Q-'_"V/ __
M $,-O_W[?_XFNPHH X__ (6QX'_Z&&W_ ._;_P#Q-'_"V/ __0PV_P#W[?\
M^)KL** ./_X6QX'_ .AAM_\ OV__ ,31_P +8\#_ /0PV_\ W[?_ .)KL**
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M .)KL** ./\ ^%L>!_\ H8;?_OV__P 31_PMCP/_ -##;_\ ?M__ (FNPHH
MX_\ X6QX'_Z&&W_[]O\ _$T?\+8\#_\ 0PV__?M__B:["B@#C_\ A;'@?_H8
M;?\ []O_ /$T?\+8\#_]##;_ /?M_P#XFNPHH X__A;'@?\ Z&&W_P"_;_\
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M5JX_XJ?\D[N_^OJS_P#2J*@#L**** .<^(G_ "3'Q/\ ]@FZ_P#135K:+_R
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MBBB@ HHHH **** "BBB@ HHHH ***J7NJ6>GSV<-W+LEO9O(MT",S2/M+8P
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MIPRLC ,K#T(!JH?%6EIK*:9,UY!<22F"-KBPGBBDD )VK*R"-B0IQACG'&:
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MDYS(W [U[6*&/Q!XRTS4-.&I"\DAU".T=8V-U$8(XBH$A"G#P$8) &Y<XR*
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MX&2X^$]1A\4VMUI<4.G6T,L1GNXM5G9[N-$V[9+78(F9@ N\L2  1T ':T4
M%%%% !1110 4444 %%%% !7(KX):YT/5+*^N%AGN-5FU&RNK8DO:N7W1N,@?
M,.XZ$$CD$UUU% 'G^F^ ]4GT_0M/\274/V73OM%U<?V==SPO)=/(Q0JR[65%
M5W[YR0.@R=OP_P"&)O#GB+4GL9VDTB_CCF9+FZEGF2Y7Y&;=(6)5D$8Y;C8
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MIJUM%_Y -A_U[1_^@B@#DO%/PZA\6^/+34M7AL[K2(]+FLI89<F42.W#I\N
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MVGZB\0(C:[M4E* ]0-P.*NK:VZSK,L$8E6/RED"#<$SG:#Z9 XJ6B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW<MNC*#D;5"'.<'?@=#0!H445F^(=7_L'0+K4_(^T?9P#Y>_;NRP'7!QU]*
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MWUQJ6E17EU9-8M-ET@D;+JF3L+<#:Q7!*\[22,G&:O4 %%%% !1110 4444
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M9)K%_-/"+J2\T*;-KB(*[P7K 1H@QNV $EBP!RW'I=% !1110 4444 %%%%
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M<6-T;R[M+/39?M,@N&/VA _FMOQO+ !!GRE QBO3Z** "BBB@ HHHH ****
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MA-H;3YR0-HQG]]UH ]"HKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\
M\>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_
M .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\
MQZC'Q'_Z"GAG_P %T_\ \>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_
M  73_P#QZ@#MZ*XC'Q'_ .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WH
MKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\ \>H [>BN(Q\1_P#H*>&?
M_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_ .@IX9_\%T__ ,>HQ\1_
M^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\
M\>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_
M .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\
MQZC'Q'_Z"GAG_P %T_\ \>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_
M  73_P#QZ@#MZ*XC'Q'_ .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WH
MKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\ \>H [>BN(Q\1_P#H*>&?
M_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_ .@IX9_\%T__ ,>HQ\1_
M^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\
M\>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_
M .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\
MQZC'Q'_Z"GAG_P %T_\ \>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_
M  73_P#QZ@#MZ*XC'Q'_ .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WH
MKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\ \>H [>BN(Q\1_P#H*>&?
M_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_ .@IX9_\%T__ ,>HQ\1_
M^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\
M\>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_
M .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\
MQZC'Q'_Z"GAG_P %T_\ \>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_
M  73_P#QZ@#MZ*XC'Q'_ .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WH
MKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\ \>H [>BN(Q\1_P#H*>&?
M_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_ .@IX9_\%T__ ,>HQ\1_
M^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\
M\>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_
M .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\
MQZC'Q'_Z"GAG_P %T_\ \>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_
M  73_P#QZ@#MZ*XC'Q'_ .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WH
MKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\ \>H [>BN(Q\1_P#H*>&?
M_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_ .@IX9_\%T__ ,>HQ\1_
M^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\
M\>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_
M .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\
MQZC'Q'_Z"GAG_P %T_\ \>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_
M  73_P#QZ@#MZ*XC'Q'_ .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WH
MKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\ \>H [>BN(Q\1_P#H*>&?
M_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_ .@IX9_\%T__ ,>HQ\1_
M^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\
M\>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_
M .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\
MQZC'Q'_Z"GAG_P %T_\ \>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_
M  73_P#QZ@#MZ*XC'Q'_ .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WH
MKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\ \>H [>BN(Q\1_P#H*>&?
M_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_ .@IX9_\%T__ ,>HQ\1_
M^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\
M\>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_
M .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\
MQZC'Q'_Z"GAG_P %T_\ \>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_
M  73_P#QZ@#MZ*XC'Q'_ .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WH
MKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\ \>H [>BN(Q\1_P#H*>&?
M_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_ .@IX9_\%T__ ,>HQ\1_
M^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\ QZC'Q'_Z"GAG_P %T_\
M\>H [>BN(Q\1_P#H*>&?_!=/_P#'J,?$?_H*>&?_  73_P#QZ@#MZ*XC'Q'_
M .@IX9_\%T__ ,>HQ\1_^@IX9_\ !=/_ /'J .WHKB,?$?\ Z"GAG_P73_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *Y/XG?\ (@W7_7U9_P#I5%765R?Q._Y$&Z_Z
M^K/_ -*HJ .[HHHH YSXB?\ ),?$_P#V";K_ -%-5C1_^0'8?]>T?_H(JO\
M$3_DF/B?_L$W7_HIJU=& _L&PX'_ ![1_P#H(H 2BKV!Z"C ]!0!1K UKPJ=
M?$\&H:WJ7]G7!42Z?'Y*1.@QE-PC\P XYP^>3R*ZW ]!1@>@JHR<7= 9T$,=
MM;QP0($BB0(B#HJ@8 I]7L#T%&!Z"I HT5>P/048'H* *-%7L#T%&!Z"@"C1
M5[ ]!1@>@H HUE:MX=M-9U32KZZDF272IS/ (V 5F*[<-D'(QZ8KH\#T%&!Z
M"FI.+N@.>\1:%!XET.?2;RXN(+>XPLIMF"LZYR5R0>#T..<=ZT(88[>".&!%
MCBC4(B*,!0!@ 5HX'H*,#T%',[6 HT5>P/048'H*0%&BKV!Z"C ]!0!1HJ]@
M>@HP/04 4:*O8'H*,#T% %&BKV!Z"C ]!0!1HJ]@>@HP/04 4:*O8'H*,#T%
M %&BKV!Z"C ]!0!1HJ]@>@HP/04 4:*O8'H*,#T% %&BKV!Z"C ]!0!1HJ]@
M>@HP/04 4:*O8'H*,#T% %&BKV!Z"C ]!0!1HJ]@>@HP/04 4:*O8'H*,#T%
M %&BKV!Z"C ]!0!1HJ]@>@HP/04 4:*O8'H*,#T% %&BKV!Z"C ]!0!1HJ]@
M>@HP/04 4:*O8'H*,#T% %&BKV!Z"C ]!0!1HJ]@>@HP/04 4:*O8'H*,#T%
M %&BKV!Z"C ]!0!1HJ]@>@HP/04 4:*O8'H*,#T% %&BKV!Z"C ]!0!1HJ]@
M>@HP/04 4:*O8'H*,#T% %&BKV!Z"C ]!0!1HJ]@>@HP/04 4:*O8'H*,#T%
M %&BKV!Z"C ]!0!1HJ]@>@HP/04 4:*O8'H*,#T% %&BKV!Z"C ]!0!1HJ]@
M>@HP/04 4:*O8'H*,#T% %&BKV!Z"C ]!0!1HJ]@>@HP/04 4:*O8'H*,#T%
M %&BKV!Z"C ]!0!1HJ]@>@HP/04 4:*O8'H*,#T% %&BKV!Z"C ]!0!1HJ]@
M>@HP/04 4:*O8'H*,#T% %&BKV!Z"C ]!0!1HJ]@>@HP/04 4:*O8'H*,#T%
M %&BKV!Z"C ]!0!1HJ]@>@HP/04 4:*O8'H*,#T% %&BKV!Z"C ]!0!1HJ]@
M>@HP/04 4:*O8'H*,#T% %&BKV!Z"C ]!0!1HJ]@>@HP/04 4:*O8'H*,#T%
M %&BKV!Z"C ]!0!1HJ]@>@HP/04 4:*O8'H*,#T% %&BKV!Z"C ]!0!1HJ]@
M>@HP/04 4:*O8'H*,#T% %&BKV!Z"C ]!0!1HJ]@>@HP/04 4:Y/XG?\B#=?
M]?5G_P"E45=U@>@KC_BH!_PKN[X_Y>K/_P!*HJ .QHHHH YSXB?\DQ\3_P#8
M)NO_ $4U:VB_\@&P_P"O:/\ ]!%9/Q$_Y)CXG_[!-U_Z*:M;1?\ D V'_7M'
M_P"@B@#!U[Q1?KXPLO"?AR*V.IW%J;Z>YO%9HK6W#A-VQ2I=B<@#<N.I-5M?
M\2:WX?\ [(T??I^HZ_K=T\-K(MN]O;Q(J[G=T\QV;:.P89SVQ4^O>&-1/C2Q
M\6^')+4ZA!:-87%K>,R1W,!<. )%#%&5LD':V?:H-=\-ZYXA_LG6&33]-U[1
M+IYK2-+A[BWF1DVLCL8T9=W3(4XQGG.* 'KXEUC0_&NF:!XG-C=Q:RDGV*^L
M8'@VRQC<T;QL[\%3D,&ZC&WO4_PX\3WOB_P;%JVI1013O<31%;=65<)(RC@D
MG.!ZU OAK6-<\:Z9K_B<6-I%HR2?8K&QG>?=+(-K2/(R)P%& H7J<[NU4O 6
M@>+/!NA0:+-8Z-=6ZW,DCW*:G*KA'D+'$?V?!(!Z;AG'44 6O"OC'4-<\+>(
M=2NX;9)M,O[RVA6)6"LL/W2V6))/?!'X5R.I_%[7=.\/^!]4^PV$B:U#/<ZF
MHC?]W%$4+F+Y^,*S'YMW2N@@\(^)=!L_$.E>'AI5Q8:S=3W44]Y<21R6C3##
MKL6-A(!U'S*3T/K3)/A>4O/!%O#-#<:5X?L[RTO!.2LEPL\ CRJ@$<G)()&
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MBUHMCH[%Q.S.&:25S''D\# VGU)XQ7>T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q_Q4_Y)
MW=_]?5G_ .E45=A7'_%3_DG=W_U]6?\ Z514 =A1110!SGQ$_P"28^)_^P3=
M?^BFK6T7_D V'_7M'_Z"*R?B)_R3'Q/_ -@FZ_\ 135K:+_R ;#_ *]H_P#T
M$4 )>:M;V>J6&GNLDES?%_+2-<[409=V]%&5&?5U'>J>F>+=*UBZ2#3?MTXD
MSY=P--N!;N!DY6<QB,@XX(;!XQG(K/(B/Q4O1=[=AT&+RMQP-OGR^;_[2S^%
M8^A:Y:6&L:/H?A;Q79^)+"0^2UH'CGGLX4C;#B6(@!!M1?WBLQ+??R<4 >@2
M.(XV=LX4$G%5='U2'6]"L-5M%D2"^MH[F)90 P5U# $ D9P>Q-<3X7O]-NKF
MX.L:[.?%)DN5FTN?4I$\L MA5M=X0J(PI#;#D?-DDYJAX0MI-&TCX>7,%_J,
MQU*Q6.YBENG>)D%D9%58L[%*E% *J"0#DDDD@'J-4=1U>#3+K38)TD9]2NOL
ML)0 A7\J23+9/ Q$W3/)'UKRWP[XHGOO&>E/HTJQK?QW7GZ?)X@GOI481ET6
M:&1<6[AEQA6_O#D#AVEWFFWFJ>"7_M^ZU#Q VHE]4M)[YW,$OV2X\P-;EML&
MUR5"A5XXYZT >O45Y'X1U;5;WQ+IC7NM:?!JC7$RZC83Z_*T\JX?,8L6B"QE
M2%*E2,JF<L&)-K15NX]#\/:ZVKZK-?7.M&WF$U](\3Q&66/88B=F  ,';NR
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M3XK'3X5@MH1MBB4G"#.<#/0#L.@' XJS0 4444 %%9/B26PATG=J^M'1K/S
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MU4!S!NWEHV&TH%P,[N@H [&BN0B\:7VJW6F0>'='AN3J&E1ZHKWEZ;=8XW(
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MFPQ4=\US.F_#*YM5U W#Z9&]]9NOF:?;&":*X$HEBD,A)\UE;D.0F"B_*<G
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M=%)*C&<=^N,GC/054?PGI)U9]1B6\MKB243RBUU">".608&YXT<(Y(4 D@Y
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MR&[-NL@D,F 02I*[#G!.1G K:I=W=_>:0--BL+.YB\77$$;^02AQ:W \QU#
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M 2"5""3:%)5<KC:<#(H ;I7B%M3\1:C;B2VCL+>0VMMD_O;F>/F<KSRJ$JF
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M9TR?6$U.X%W/.D@E2.6^G>!' P&$)<Q@CJ"%X/(YYH UJ*** "BBB@ HHHH
M**** .:U'6=:L?&VCV#1V"Z9J,TL(QO>9MD#2;\_*J?,N-N&R.=PS@2IXB:?
MQE/IL<EM'8VB+%-+*<-+=2#>L*'(&1&-S#!)WKC&#3]3\&Z1K&JQZE??V@;J
M)MT30ZK=0K$=NTE%20*I*Y!P!G)SU-8^L_#?3[V_M;K3Y+VW)U3[=>!=6NT5
M\J^XHJOA6)8<@+@ @$#B@#G(K#6/#_C;%EIR)J^HMJ")?.Z,M\))TDBE=5;=
ML@CX.X+SM1/OYKH/A_K*M''I(L#!%) ]Y;W;7'FRWH$I2268; $D9BK8!8?/
MU&,5UZ:=:IJDNHK"/M<L2PM*22=BDD*,\ 98GCKWZ"JFF>&]*T:]N;O3K9HI
MKG.\M,[A06+%45B1&I9B2J@ DYQ0!J4444 %%%% '++JNN6?C:RTF[N]-U""
M[265XK6SDAFM(P#LD=C*X92PV=%R3D="*#JNN67C6PTNYN]-OX+WS7>"VLWA
MFM(54E978RN&4L%C^ZN2V1T(JS9>"-%T[6)M3LQJ$5U<3>?,1JMT4E?&,NAD
MVMQ@8((P .E%KX(T6QUJ?5;0:A%>7$PGG8:K=;97' +)YFU@!P 1C QC% $/
MCOQ)-X9TBRGM[JPLWN[^&T-SJ S#"K9+.PWIT52?O"M#3;N[;PZU[<:CI^IL
MT;30W-A 8X73;E< R/GZAN:26SNM&L3'X7TVSF:6YEGECN[V2%=TCL[L&$<A
M)+L3C  SQTQ4/AC09-(T.:UU!H7FO+B:YGCMP5BC:5BS(G0E1G&[@GDX&<
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MNZ=I\7G75WIT\$,>X+O=HV"C)( Y/4UA6'B+Q=::=;6S?#V_9H8EC)&IVG.
M!_STH T=3L;^V\:QZAI^X)J6GMI\DXA\P6LJ%I(9&7(RGSR@\CG:,_-D9[_"
MGP]_PBJZ?;6=G!JT<"B/6Q9H;D7"X(G+?>+;QN(W<\C-3_\ "5>+/^B>7_\
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MZC<:D)8T>_F6TBEB\MDA0B->, D,49P3R0X[8K+D\,Z_-XR76I]=L)[>%_\
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M9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\
MP9V?_P <H_X2KQ9_T3R__P#!G9__ !R@#L**X_\ X2KQ9_T3R_\ _!G9_P#Q
MRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\ P9V?_P <H_X2KQ9_
MT3R__P#!G9__ !R@#L**X_\ X2KQ9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\
M&=G_ /'* .PHKC_^$J\6?]$\O_\ P9V?_P <H_X2KQ9_T3R__P#!G9__ !R@
M#L**X_\ X2KQ9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^
M$J\6?]$\O_\ P9V?_P <H_X2KQ9_T3R__P#!G9__ !R@#L**X_\ X2KQ9_T3
MR_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\ P9V?
M_P <H_X2KQ9_T3R__P#!G9__ !R@#L**X_\ X2KQ9_T3R_\ _!G9_P#QRC_A
M*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\ P9V?_P <H_X2KQ9_T3R_
M_P#!G9__ !R@#L**X_\ X2KQ9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_
M /'* .PHKC_^$J\6?]$\O_\ P9V?_P <H_X2KQ9_T3R__P#!G9__ !R@#L**
MX_\ X2KQ9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6
M?]$\O_\ P9V?_P <H_X2KQ9_T3R__P#!G9__ !R@#L**X_\ X2KQ9_T3R_\
M_!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\ P9V?_P <
MH_X2KQ9_T3R__P#!G9__ !R@#L**X_\ X2KQ9_T3R_\ _!G9_P#QRC_A*O%G
M_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\ P9V?_P <H_X2KQ9_T3R__P#!
MG9__ !R@#L**X_\ X2KQ9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'*
M .PHKC_^$J\6?]$\O_\ P9V?_P <H_X2KQ9_T3R__P#!G9__ !R@#L**X_\
MX2KQ9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\
MO_\ P9V?_P <H_X2KQ9_T3R__P#!G9__ !R@#L**X_\ X2KQ9_T3R_\ _!G9
M_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\ P9V?_P <H_X2
MKQ9_T3R__P#!G9__ !R@#L**X_\ X2KQ9_T3R_\ _!G9_P#QRC_A*O%G_1/+
M_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\ P9V?_P <H_X2KQ9_T3R__P#!G9__
M !R@#L**X_\ X2KQ9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PH
MKC_^$J\6?]$\O_\ P9V?_P <H_X2KQ9_T3R__P#!G9__ !R@#L**X_\ X2KQ
M9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\
MP9V?_P <H_X2KQ9_T3R__P#!G9__ !R@#L**X_\ X2KQ9_T3R_\ _!G9_P#Q
MRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\ P9V?_P <H_X2KQ9_
MT3R__P#!G9__ !R@#L**X_\ X2KQ9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\
M&=G_ /'* .PHKC_^$J\6?]$\O_\ P9V?_P <H_X2KQ9_T3R__P#!G9__ !R@
M#L**X_\ X2KQ9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^
M$J\6?]$\O_\ P9V?_P <H_X2KQ9_T3R__P#!G9__ !R@#L**X_\ X2KQ9_T3
MR_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\ P9V?
M_P <H_X2KQ9_T3R__P#!G9__ !R@#L**X_\ X2KQ9_T3R_\ _!G9_P#QRC_A
M*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\ P9V?_P <H_X2KQ9_T3R_
M_P#!G9__ !R@#L**X_\ X2KQ9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_
M /'* .PHKC_^$J\6?]$\O_\ P9V?_P <H_X2KQ9_T3R__P#!G9__ !R@#L**
MX_\ X2KQ9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6
M?]$\O_\ P9V?_P <H_X2KQ9_T3R__P#!G9__ !R@#L**X_\ X2KQ9_T3R_\
M_!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\ P9V?_P <
MH_X2KQ9_T3R__P#!G9__ !R@#L**X_\ X2KQ9_T3R_\ _!G9_P#QRC_A*O%G
M_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\ P9V?_P <H_X2KQ9_T3R__P#!
MG9__ !R@#L**X_\ X2KQ9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'*
M .PHKC_^$J\6?]$\O_\ P9V?_P <H_X2KQ9_T3R__P#!G9__ !R@#L**X_\
MX2KQ9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\
MO_\ P9V?_P <H_X2KQ9_T3R__P#!G9__ !R@#L**X_\ X2KQ9_T3R_\ _!G9
M_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\ P9V?_P <H_X2
MKQ9_T3R__P#!G9__ !R@#L**X_\ X2KQ9_T3R_\ _!G9_P#QRC_A*O%G_1/+
M_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\ P9V?_P <H_X2KQ9_T3R__P#!G9__
M !R@#L**X_\ X2KQ9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PH
MKC_^$J\6?]$\O_\ P9V?_P <H_X2KQ9_T3R__P#!G9__ !R@#L**X_\ X2KQ
M9_T3R_\ _!G9_P#QRC_A*O%G_1/+_P#\&=G_ /'* .PHKC_^$J\6?]$\O_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ J.YN([2UEN)VVQ0H9'/H ,FI*PO&UIJ.H>!]6LM$A\
MZ]NK9H(TW*N=_P K'+$ 84D_A05%)R290LOB-HNH^%;/7K1+J2"\O$LD@"+Y
MJRL^T*1NQW!Z]*WUUG2WU9M+74K1M10;FLQ.OG*, Y*9ST(/3H:\_;X>W]AX
M_P!'.F(&\.H\5W=?.J^7<P0M&A"YR=V4S@'D&E\-^$M:6?P_;:G8&T71[RZO
M;N],L;?;I7+A2FUBV"&R2X4X 'T#HE3I6O%_U_7YG5ZYXPLM \1:9IM^]O!%
M>132RW5Q<K$ENJ;0,YX.YF '([UI7FNZ1IRV[:AJEE:K=?\ 'N9[A$$W3[N3
M\W4=/45R/B/P_J^H>(O$&J6^GI,Z:%]@TK=(@+RR;R[#)^7&5&3C(X'>L7_A
M7][%JXM]1M=2O-*ETRRL -/FME CB_UD4ID(D52PW'RCSD]\4 J=-I79Z/>>
M(-&TZ\%IJ&K6-K<E0XAGN41RI. =I.<9XS6;XJ\9Z?X9T^<B6VN]2C$?EZ;]
MI5)9-[J@XY(&6ZX/2N-OO"FNR:I>1-HK7,%QXC@OY;M9X0'LXP@CC4%@V5P0
M00,#.-V:6;PMK\FL-'/HIN()/%(U2XN_.A/F6Z\1*H+ X4 !@0,=@V30.-*F
MFFV>C:QJ]EH6DSZCJDZ06T"%F9V"Y]%&2,D] .YJC9^,=!N_#EIKDFIVEI8W
M04(]S<QH%<C/ED[B-XP<KG(P?2LWQCH&K7W@K7;+3[^ZU*YOT"PV\_D((E+?
M,J%43^$D?.3T'(Y)S-7TO6FU^WU.PT&:XC_L.2QMK>6: &RG9Q\S_/C!4 $H
M6.%(QS09QA!QU>IWT<B2QK)$ZNC@,K*<A@>A!KGO#/C33_$DES"DMM!<QW,T
M45M]J5Y98XW*^;LX(!(/K]:CT?PYJ'ASPU9VUIJEU<R6&GB%;,+"(9I0AYR4
MWC+=/G Z9[UREEX"UF"Q\.6EO#'9R6&DWC2W0D7Y;Z>,)SCDXRQW $<?2@<8
M4VG=^GXGHEMK>E7EU<VUIJ=G/<6F1<117",\.#@[P#E<$8YIEEXBT74A(=.U
MBPNQ''YKF"Z1]B9(W'!X&0>?:O,XO >I-X#N[2/3=3BUE-*BL(OM<]J(A'O#
M31P^2<?-ALO( QXRW6I]2\*:]J</BIX=$:R&H)8PVMOY\.6MHB-\60^ Q&>#
M\O0!C05[&G?XOZT_KY':Z9XOLM9\52Z5I#07MM%8K=/?6]P)$W-(4$?&1GY2
M<Y]L46GCKP_>:[J6E1:C;B73(Q)/*T\8CQ@EL'=D[,?,<87N:H>#]+U"#Q3X
MDU75-)_LX7[VXM5WQM^Y2+:%^1CA@<Y'3)^4L.:P[_PWK]QH?C73X],E^U:U
MJ&Z&Y\Z'RVMR8T_O[@50,2"H]!F@7)3<FK]NOWG83:ZEY>:?'H&JZ/.LETT5
MPLEQO=E1<NL04\R#*D@]!R:LP>)=#NI)([36+"XDB5V>.&Y1V4)][Y02>,C/
MID5ROB7PIJEYJR+H<"6UII^@7%KI[!U54GDP@4#J $0<XQTK#3PSXC\K4&M/
M#YLV3PL-)L%:XASOW'>&*N<,3\P/*X )()(H&J=.2W.UT?QOI=[X=TS4M7NK
M/1Y-2C\R&VNKM S#.!@G&[C'0=\5N3:C96]QY%Q>6\4PB:8QO*JMY:_>?!.=
MH[GH*X-M!UBTU/0)_#VGZC8W5I9VMA<S32VS6QM5(9T9=[/O'(R@'/<CFKWC
MSPSJ.NZKI,FEQYC=)K&_E$@4QVTNS>>2"3A2 !W:@EPIN2ULG<ZE-:TN5K=8
M]2LW:YB,T 6=298QR77GYE'J.*B@\2:'=63WEMK.GS6L<@C>>.Z1D5S@!2P.
M 3D8'N*\TB^'NOR_#_48KB/R]6:WAL;6W$J<6D4@=D#<J#(=QYX^X#CFM*?P
M5-?VMI$-+U#_ $O5[>;5'U26VW-;PH=BA86V!,X4*H!ZY&.:"O94_P"8[B3Q
M-H,4%K-+K>G)%>$BVD:[C"SX(!V'/S8) X]:N7M]::;9O=ZC=0VEM'C?-/($
M1<G RQX') _&O/\ 6_!]YJ/CO5;C4[74KW2=2BM8@+":V51&AR\4ID(D5=P#
M'RC\P)SR,5N>+-,OY]=\-W]II\FI66FW$LD]E#)&K;S&1%(!(RJ=ISWR-V1F
M@CDA=:_U_6AL3>)="M[2VNI]:TZ*WN\_9YGND"38Z["3AOPIU_XAT72IO)U3
M5["REPIV7%RD;?-G'#$==IQ]#Z5Q/B'0=>U+6->DM](:7^W-*@L;:XFFBVZ>
MIW><L@W9_B#?('!('/>JNJ>"-7EL?%2VUD)I[RVL]+L)'DCW-;HJB1\Y^4$E
MC@\G:.#Q04J5/2\OZT_KY'9^*?%^F>%=+NI[NYMFO(K9YX;%KA4EGP#@*#SC
M(Z@''/I5Z/6[%;222^N[6TEMXXWO(I+A?]%+C(#DXQGL2!FO-]<\'Z[/=ZW:
M1:,;RUU#4+)S<B:$?Z'#Y?[I0S [P03@A01N^;)P;FH>%==U'6];LI; _9-8
MU:VGEU#S8S&+2%4.S;NW[\IMQMQSUQ0/V=.RU_K3_@G>76OZ/8WPLKW5K&WN
MV7>+>:Y1)"N"<[2<XX//L:S]%\<:!KMCJ%Y::A EMIT[13RRS1A5 .!)D,<(
MV#M)QG!K/\*6.JZ-J.MP7NE2O+?:C/=)J?FQ&*1#_JE8;_,&!A<;,#''K7+Q
M>$O$+> O#6GR:?>PS:3?FXO((Y;5I)R2[>9'N9HSAWSA\=.G2@2IT]F^W4]'
M?Q#HL>DIJCZO8+I\C;4NS<H(F.2,!\X)R".O8U7\,>(1XET^YO8[?R88[R:W
MA;S-_FK&VW?T&,D'CGZUQS>%M2TV_P!#OM&TB[N5MUO)I(KZXA,JWDV )Y2&
MVD=<E-Q /"]JZ?X?:1/H/@'2=-O;9K6Y@B(FB)4[7+$MRI(P22>#W[=*"9PA
M&%T[O_ASHZ***# **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img134051827_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_8.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0+X17AI9@  34T *@    @ ! $[  (
M   /   !2H=I  0    !   !6IR=  $    >   "TNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M36EC:&%E;"!286EB;&4    %D ,  @   !0   *HD 0  @   !0   *\DI$
M @    ,X.0  DI(  @    ,X.0  ZAP !P   0P   &<     !SJ     0
M
M
M
M
M
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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M *@7_DY_]A1_PN+_ *@7_DY_]A19A[2/<]-HKS+_ (7%_P!0+_R<_P#L*/\
MA<7_ % O_)S_ .PHLP]I'N>FT5YE_P +B_Z@7_DY_P#84?\ "XO^H%_Y.?\
MV%%F'M(]STVBO,O^%Q?]0+_R<_\ L*/^%Q?]0+_R<_\ L*+,/:1[GIM%>9?\
M+B_Z@7_DY_\ 84?\+B_Z@7_DY_\ 8468>TCW/3:*\R_X7%_U O\ R<_^PH_X
M7%_U O\ R<_^PHLP]I'N>FT5YE_PN+_J!?\ DY_]A1_PN+_J!?\ DY_]A19A
M[2/<]-HKS+_A<7_4"_\ )S_["C_A<7_4"_\ )S_["BS#VD>YZ;17F7_"XO\
MJ!?^3G_V%'_"XO\ J!?^3G_V%%F'M(]STVBO-K;XMM<W44":( TKA 3>< DX
M_N4^^^+#6.H7-H^BAFMY6B+"[X)4D9^Y[468_:1[GHU%>9?\+B_Z@7_DY_\
M84?\+B_Z@7_DY_\ 8468O:1[GIM%>9?\+B_Z@7_DY_\ 84?\+B_Z@7_DY_\
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MGIM%>9?\+B_Z@7_DY_\ 84?\+B_Z@7_DY_\ 8468>TCW/3:*\R_X7%_U O\
MR<_^PH_X7%_U O\ R<_^PHLP]I'N>FT5Y]JOQ1?2=4FLI=&5WB(!9;O@Y /]
MSWJG_P +B_Z@7_DY_P#8468_:1[GIM%>9?\ "XO^H%_Y.?\ V%'_  N+_J!?
M^3G_ -A19B]I'N>FT5YE_P +B_Z@7_DY_P#84?\ "XO^H%_Y.?\ V%%F'M(]
MSTVBO,O^%Q?]0+_R<_\ L*/^%Q?]0+_R<_\ L*+,/:1[GIM%>9?\+B_Z@7_D
MY_\ 84?\+B_Z@7_DY_\ 8468>TCW/3:*\R_X7%_U O\ R<_^PH_X7%_U O\
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MO5/_ (7%_P!0+_R<_P#L*+,?M(]STVBO,O\ A<7_ % O_)S_ .PH_P"%Q?\
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M"_\ )S_["C_A<7_4"_\ )S_["BS#VD>YZ;17F7_"XO\ J!?^3G_V%'_"XO\
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MCW/3:*\R_P"%Q?\ 4"_\G/\ ["C_ (7%_P!0+_R<_P#L*+,/:1[GIM%>9?\
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MIVW_ %_)_P"@/36Y$_A9X_1116AQA1110 4444 %%%% !1110 4444 %%%%
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MY]#N)(#%AM5^V@$/C_GGGIVZ=>V.:P='\,Z-#H6NW&M027#Z7>-%OB<JS*I
MQC..3_.E<?LV<%179ZWH^CW/@2W\0:18OI[F?RGA,[2AADCJ?H*XRF0U8***
M*8@HHHH **** "BBB@ HHHH **** +>D_P#(:LO^OB/_ -"%3>(/^1FU3_K\
ME_\ 0S4.D_\ (:LO^OB/_P!"%3>(/^1FU3_K\E_]#-(KH9U%%%,DM:=IUUJV
MH1V6GQ>=<2YV)N"YP"3R2!T!I-0T^ZTN^DL[^$PW$1PZ$@XXSU'!K=^'7_(_
M:=_VU_\ 13UU'B6TA\::=?7%DBKJ^CS212Q@<S1*QQC\!D>X([TKZEJ-XW.
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M'-5T#R?[7M?L_G[O+_>*V[;C/W2?45F5Z;XV1O$W_")+'^Z.H;R"?X WEG]
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MU6/5=+OH;<,\KV]RTA)')&=N,\]S6K=:7X9T7PEI&JWVERW<]U" 8DN&17;
M)9CGC'MZT7'RG 5)! ]S<Q00C,DKA%'J2<"NI\.2^'=2N[+2[GPU+)/,5C>Z
MCO)"<G@OL& !W/H*L:/X=BM?BNFFPN9[>SF\W>V. J[AGZ' HN"C<Y?5]+GT
M75)M/O"AFAQO\LY'(!Z_0U2KL='T^/QC\0+RXNR7L%EDGF8D@>6#A5R.G;\
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M_H%_^3$7_P 51_PKKQ3_ - O_P F(O\ XJG='/RR[',T5TW_  KKQ3_T"_\
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MI_Z!?_DQ%_\ %470<LNQS-%=-_PKKQ3_ - O_P F(O\ XJC_ (5UXI_Z!?\
MY,1?_%470<LNQS-%=-_PKKQ3_P! O_R8B_\ BJ/^%=>*?^@7_P"3$7_Q5%T'
M++L<S173?\*Z\4_] O\ \F(O_BJ/^%=>*?\ H%_^3$7_ ,51=!RR[',T5TW_
M  KKQ3_T"_\ R8B_^*H_X5UXI_Z!?_DQ%_\ %470<LNQS-%=-_PKKQ3_ - O
M_P F(O\ XJC_ (5UXI_Z!?\ Y,1?_%470<LNQS-%=-_PKKQ3_P! O_R8B_\
MBJ/^%=>*?^@7_P"3$7_Q5%T'++L<S173?\*Z\4_] O\ \F(O_BJ/^%=>*?\
MH%_^3$7_ ,51=!RR[',T5TW_  KKQ3_T"_\ R8B_^*H_X5UXI_Z!?_DQ%_\
M%470<LNQS-%=-_PKKQ3_ - O_P F(O\ XJC_ (5UXI_Z!?\ Y,1?_%470<LN
MQB:3_P AJR_Z^(__ $(5-X@_Y&;5/^OR7_T,UO:?\/\ Q-!J=K++IFU(YD9C
M]HB. &!/\52:QX!\2W6NW]Q!IN^*:YD=&\^,94L2#RWI1=#Y96V.,HKIO^%=
M>*?^@7_Y,1?_ !5'_"NO%/\ T"__ "8B_P#BJ+H7++L<S173?\*Z\4_] O\
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MKQ3_ - O_P F(O\ XJC_ (5UXI_Z!?\ Y,1?_%470<LNQS-%=-_PKKQ3_P!
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MNQS-%=-_PKKQ3_T"_P#R8B_^*H_X5UXI_P"@7_Y,1?\ Q5%T'++L<S173?\
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MB+_XJC_A77BG_H%_^3$7_P 51=!RR[',T5TW_"NO%/\ T"__ "8B_P#BJ/\
MA77BG_H%_P#DQ%_\51=!RR[%7QE_R-U]_O+_ .@+6'7=^)O WB+4/$=W=6>G
M>9#(5VMY\8SA0.A;/:LK_A77BG_H%_\ DQ%_\51=#<97V.9HKIO^%=>*?^@7
M_P"3$7_Q5'_"NO%/_0+_ /)B+_XJBZ%RR[',T5TW_"NO%/\ T"__ "8B_P#B
MJ/\ A77BG_H%_P#DQ%_\51=!RR[',T5TW_"NO%/_ $"__)B+_P"*H_X5UXI_
MZ!?_ ),1?_%470<LNQS-%=-_PKKQ3_T"_P#R8B_^*H_X5UXI_P"@7_Y,1?\
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M?_DQ%_\ %470W&5]CF:*Z;_A77BG_H%_^3$7_P 51_PKKQ3_ - O_P F(O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MOFO_ (2GQ!_T'=2_\#)/\:/^$I\0?]!W4O\ P,D_QKP_[8I_RL]?^RY_S(^E
M**^:_P#A*?$'_0=U+_P,D_QH_P"$I\0?]!W4O_ R3_&C^V*?\K#^RY_S(^E*
M*^:_^$I\0?\ 0=U+_P #)/\ &C_A*?$'_0=U+_P,D_QH_MBG_*P_LN?\R/I2
MBOFO_A*?$'_0=U+_ ,#)/\:/^$I\0?\ 0=U+_P #)/\ &C^V*?\ *P_LN?\
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M.!8;6&2XC?;DY=B&X!S@#'84EC=Z-IQU2VM=:TB.PNOGMXENT'E,5PPQT"Y
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MT(RZ]-IT^JFX40/9/"\AB"8?S##\I'$87=\W#8XJN6/O6%=Z'*T445B6>M?
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M?\CW>_\ 8-?_ -&Q5YC7IWP&_P"1[O?^P:__ *-BJ*GP,TI?&CZ!HHHKSSU
MHHHH **** "BBB@!D\$5S;R07,230RJ4DCD4,KJ1@@@\$$=J;:VEO8VD5K8V
M\5M;PJ$CAA0(B*.@ ' %2T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>U44?V5ANS^\/[1K^1XK_P *<\0?\_FF_P#?V3_XBC_A3GB#_G\TW_O[)_\
M$5[511_96&[/[P_M&OY&+X0T:X\/^%+/3+QXGF@W[FB)*G<[,,9 /0^E;5%%
M>E""A%16R.&4G.3D^H44451(4444 %%%% !1110 4444 %%%% 'AW_"E?$7_
M #^Z7_W]D_\ B*/^%*^(O^?W2_\ O[)_\17N-%<']GT#;V\SP[_A2OB+_G]T
MO_O[)_\ $4?\*5\1?\_NE_\ ?V3_ .(KW&BC^SZ >WF>'?\ "E?$7_/[I?\
MW]D_^(H_X4KXB_Y_=+_[^R?_ !%>XT4?V?0#V\SP[_A2OB+_ )_=+_[^R?\
MQ%'_  I7Q%_S^Z7_ -_9/_B*]QHH_L^@'MYG#_#?P5J/@_\ M+^TYK67[5Y6
MS[.[-C;OSG*C^\*[BBBNNG3C3BH1V,Y2<G=A1116A(4444 %%%% !1110 44
M44 %%%% !1110 4444 >._\ "@_^ID_\D/\ [91_PH/_ *F3_P D/_ME>Q45
M?M)&?LX=CQW_ (4'_P!3)_Y(?_;*/^%!_P#4R?\ DA_]LKV*BCVD@]G#L>._
M\*#_ .ID_P#)#_[91_PH/_J9/_)#_P"V5[%11[20>SAV/'?^%!_]3)_Y(?\
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M7\CV'<WJ?SHW-ZG\Z\>_X6UKO_/IIW_?M_\ XNC_ (6UKO\ SZ:=_P!^W_\
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M7.5A5C&,VH.Z-J;DXIR6H4445F:'TU1117Z ?%!1110 4444 %%%% !1110
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M_D;[K_KP?_T9'6V%_CQ)J? SV>BBBOISS@HHHH **** "BBB@ HHHH ****
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M_P"1/L/]UO\ T-JW*P_!G_(GV'^ZW_H;5N4"CL@HHHH&%%%% !1110 4444
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M\ ^)?%/C2VO=!TW[5;QV*0L_GQIAP\A(PS ]&'YUY]_PISQW_P! +_R<@_\
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M_P >'JOS(Q'\&?H_R/?Z***^X/D0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^2Z***^//5"B@'# D \]#WKMM;T?4QIWAVYM_#PM;J0R1M$MAA2WF'R
MU8,#N.T?QY)')SR:TC!R3:Z$MV.)HKJ_%FD7T,NF6L^DM'J1@?[0UM9^5'*P
M8MM4*H5BBD;F48]R!DZ&E:?%)IFGE;"WET:2RF>_OGMU+13#?P9<;D(Q'M4$
M9ST.35JBW)Q_K^NXN=6N<)1116!9K>$_^1TT3_L(0?\ HQ:^GJ^8?"?_ ".F
MB?\ 80@_]&+7T]7MY;\$CCQ&Z"BBBO5.8**** "BBB@ HHHH **** "BBB@
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MM_\ XU4MMI]S!<+)+J][<JN<Q2I"%;COMC!]^#5ZB@+!1110,**** "BBB@
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M4?\ "+>'_P#H!:;_ . <?^%+^QZG\R'_ &I#^5GS717TI_PBWA__ * 6F_\
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M_P */[-G_,'UA=CYAHKZ>_X1/P[_ - #2_\ P#C_ ,*/^$3\._\ 0 TO_P
MX_\ "C^S9_S!]878^8:*^GO^$3\._P#0 TO_ , X_P#"C_A$_#O_ $ -+_\
M ./_  H_LV?\P?6%V/G?PG_R.FB?]A"#_P!&+7T]67%X9T&WF2:#1-.BEC8,
MCI:1AE8'((('!K4KOPN'="+3=[F%2:FPHHHKL,@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^/**^PZ*V]KY'/['S/D.SN(K6X$D]G#>( 1Y4Y<*??Y&
M4_K4^K:K+J]Q%)+%#!'!"L$,,((2)%Z 9))Y).22<D\U]:T4>U\@]CYGQX#A
M@2 0#T/>KFKZI/K.JS7]TL:23$?)&,*@  "@<\  #\*^MZ*/:^0>Q\SX\HK[
M#HH]KY!['S..^$__ "3#2?\ MM_Z.>NQHHK)N[N;I65@HHHI#"BBB@ HHHH
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MMR'DN'V>9C:'#'D9''7!KR.OH/4+K1[_ %'7?,\=:6=,U+3C:6]BUPI6V?8
M''S8X.X_C[5TU-T<5+9GB7B.[T6]U&.3PYILNFVHB"O%+,92SY.6R?8@8]J[
M+X'?\CO>?]@Y_P#T9'7(>)]$M-!U..UL-8M=7C>$2&>U(*J22-IP3SP#^(KK
M_@=_R.]Y_P!@Y_\ T9'3G_#=A4[^T5SVZ/5+"74Y=-BOK9[Z%!)):K,IE13C
M#%,Y Y'..]5[WQ#I&GP:C+=:A !I<8EOD1M[VZE=P+(N6&0,CCGM7DVLZ9J-
MU\:/%&I>'2PUO2;6TNK5,_+<)LQ) P]'!'X@=*BT7Q@;ZX^*?BGP_(UO+_9]
MA/"70%H9%MG!!!!!*L"#D8XKA/2/:K2ZAOK*"[M7\R"XC66-\$;E89!P>1P:
MFKR,_$75O#5KINI>(KP7-CJWAE+VVW1(G^FI&K.@*@??W X/0\  5+-K'C::
M]\,>%/[?ATO5K[3FOK[49[..1RV?]2D> A(S@]\#.?5 >KT5QOPV\2:GX@TK
M4X=;D@NKK2M1EL6O;9=L=R$ .\#H#SR!QTKS^_\ &'CR#PCKOBN'Q!:BTT75
MY+5;!M/0FX3SE0!GXQ@..@R<<G- 'N5%>96WB#Q7X9\<WFE>(]5@UR!]$EU2
M)8;-;?R7C;'EKC)93TRQ)Z=.^-IOC'QE:6/ACQ+J.OZ?J=EX@OHK5M(AM50P
M"0X^1Q\S,O<'H>* /9J*\2U/Q7X[&A>+O$-EXBMH;3P]KEQ:1V3:>CM/&LB@
M*S\8 #C&!D\Y-;E_XB\3^)O&=QI'AW7K3PY;V.FPWKO/:I,]P9%W8PW 0< D
M<CWS0!ZC2.ZQHSNP55&68G  ]:X7PIXE\4^+? >B:OIL6E1W,MP4OS="38\2
M.R,T.W^([<C/'6N@UU5GU+2+6[ -E-.WFHWW9&"$HK>O(SCN5% F]"_#K&F7
M*R-;ZC:2B)"\A2=6V*.I.#P/>K$ES!%;^?+-&D. ?,9@%P>G/3O5+Q%_R*^J
M?]><W_H!K UF74SX)"S6EHD'EPY=+IF;&Y<?+Y8'ZTQ-V.DN=7TVSF,-YJ%K
M;R@9*2SJK8^A-3"\MC9_:Q<1&VV[O.#C9CUW=,5A0O>IXPUC[#;V\V8;;?YT
M[1XX?&,(V>_I4U^OVKQ)I-OJ"((?)EE6+.Y'F&WCGKM!8@D>] 7-&+5]-GAD
MEAU"UDCBQYCI.I5,],G/&:LO/#'-'%)*B22Y$:,P!? R<#O@5C^,<_\ ")7V
M.N%_]#6G:'MFFN9[PDZH#LG1QCR5ZJJ#^X<9#?Q<D\C  OK8U(+NWNM_V6>*
M;RV*/Y;AMK#L<=#[4175O/-+##/%)+"0)41P63/3([?C7#Z1?+X?ENM0E!^R
MW4MRD@_Z;1N[+_WTN1^ J]X91M+OM9FU%L3?9X;FZ;'1F\UV_+./PHL)2N=8
MD\,DTD*2HTL6#(@8%DSTR.V:HGQ#HH.#J]@"/^GE/\:YK3I[FTO[+6+RRN(!
MJ$K+=3NT90K)CR0,,6 7"CD#J?I6S>_\CSI?_7K/_-*+!S:&A-K6EVY03ZE9
MQ%T#J'G5=RGH1D\@^M6H)X;F%9K:5)HGY5XV#*WT(KG6>\3QU>?88()F^Q1;
MA-,8\?,W3"-FMN:ZN((X?] EG=Q^\%NZ%8SQW=E)'N!VZ"@:9:J&ZO+6QB$M
M[<PV\9.T/-($!/ID_2L*>]U"XCU>]M[TVRZ=(R1P>6K))L4,2Y(W?-G'RD8&
M*ABFO=5\2O/:M;0/!8Q/"ES$TFWS,EL ,N.@!/L.*+!S'3QR)-$DL+K)&ZAE
M=3D,#T(/<4ZN6NM3N[CPU'JUO>W-O<7 6.&UB$3(92=H +1DD9YZ]*Z6W26.
MUB2XD\V54 >3 &]L<G Z9-(:=R2BBB@84444 %%%% !1110 4444 *OWA]:5
M_P#6-]32+]X?6E?_ %C?4T -HHHH **XF^\5ZQ!'K&K0'3AI6C79M[BUDC<W
M#JH4N_F!PJ'#[E78V0!R-W&S=>(#'XNATN*2VCMH8A)?33G&UY6V01(<@;V;
M<<'/  Q\P- &[17%WWBB_E\?77AZQUG0],\B"!HH[^!I9KF23>2$431\ *O0
M'[U=I0 4444 ?,M%%%?GY]J%%%:UOHX?PW/J$B3/*TFRVCB'55&Z5V&/NJ"H
MR.YYZ548N6Q,I*.YDT5T<NB6MKX.LM6DLM0N'NEEW3QR!88"'*+N_=G.3VW"
MM\:;H>OW]C)";<60NFB M[<PF3<$\N%CA=S##EF&>".<E:Z(X:4M+ZZ?B8RK
MQ6MM-?P//:*U?$-F+744ECD62*\B6ZC*P"'"OVV D+@@C )&,5E5SRBXR:9M
M&2DKH*]-^#O_ #&?^V'_ +4KS*O3?@[_ ,QG_MA_[4KNRW_>H_/\F<>/_P!V
ME\OS1Z;1117V!\P%%%% !1110 4444 %%%% !1110 4444 %%%% 'RU1171^
M&+:S73=3U*ZELXYK<Q0V[7T+2PJTF_+%%1LD!#C<-N3GKBOD81YG8]1NR.<H
MK6O=+NCXL&FW[6\4\TZ(9($58L/C:ZJH  ((.,#KS@U:UC1]/BLKV;2Q=QOI
M][]DG2Y=7W@[MKC"KMYC8%>>HYJO9O7R%S(Y^OI'PO\ \BAH_P#UX0?^BUKY
MNKZ1\+_\BAH__7A!_P"BUKT<M^.1AB-D:E%%%>V<84444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!\ET445VGGA170>%-(L]:N6M[RRU!D!S
M+?6\RK%:1X^_(&0C P2?F7@5LZ5I*)X:TQ--GTD:IJTLN/M]L96EVL42.,M&
MR)DY.3M))7D 5+92C<X:BM7P_I<&HZC.E\TB0VMM+<RI&0)'$:EBJY! /'4@
MX&3@XI=;TRVM;?3[_3O.6SU"$ND=PP9XV5BCJ6  89&0<#@XQQ3OJ*VES)K6
M\)_\CIHG_80@_P#1BUDUK>$_^1TT3_L(0?\ HQ:'L"W/IZBBBN,[PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /GC]H;_DHEG_V#(__ $;+7E5>
MJ_M#?\E$L_\ L&1_^C9:X[PCI.E:[--8W\-]%*L4L[:A%<*(;6-4R&DC,9)&
MX $[USN '/5'TF'ERX>+?8YNBM^U\.^9X,GU>6*YDN))]EG%",CRXQNGE<;2
M=BY1<@@9)STKJH;+P[X@\,6444MK!%9BU:\D@L_+GA_=NLJ-*5 D>64IL&YL
M $G 4T&TJJ1YM7T5^S]_R(%[_P!A.3_T5%7DGQ#T*#2M62XL&C%G-)-;1PI;
M^3Y+0/Y3+C<V\< [R=S$DD UZW^S]_R(%[_V$Y/_ $5%0<>,DIX?F1ZE1113
M/!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *7@S_D3[#_
M '6_]#:MRL/P9_R)]A_NM_Z&U;E H[(****!A1110 4444 %%%% !1110 5Y
ME\>?^1#L_P#L)1_^BY*]-KS+X\_\B'9_]A*/_P!%R5K1^-&=3X&?/M%%%=QY
M85Z1\#O^1WO/^P<__HR.O-Z](^!W_([WG_8.?_T9'45/@9I2^-'L]OX?TRU\
M07>N06VS4;V-(IY_,8[U7[HVD[1CV%4$\"^'(QK8BTQ4&O#&HA)7 G^]V#?+
M]]ONXZUT%%>>>H85_P""?#VIZ3IFF7^FK-9Z28S9Q-(_[K8NU><Y88XPQ(/?
M-.\2^#?#_C"WBA\1Z;'>K"28R69&3/7#*00#@<9[5MT4 4=&T33?#VEQZ=HM
MG'9VD>=L48XR>I)ZD^YYK.E\#>'9O#]_H<NG;M.U&X-U=0^?)^\D+ARV[=N'
MS*#@$#BM^B@#/DT'39O$$>MR6V[48[8VJS%VXB)W%=N=O7OC-8VE_#/P=HVN
M?VQIF@V\%\&++(&8A#ZJA)5?P KJ:* ,)_!7A^31]5TM[#-GK%T]W?1>=)^^
ME<@LV=V5R5'"D#CI5;7/ASX3\2&U.M:-%<M:1K%"_F.C!%Z*65@6 ]#FNFHH
M X3Q!X0GO_%G@ZST[3XX/#NBRO=S;&55615'DJ$SG@Y.<8YKJM6M[B\C-L-/
ML[RV=?F%Q<,A!]@$;VP<@UHT4".?73;\0SPM80RQSQF*19M9N) 5(P1\R''U
M'-33VVHW6G_8I]*L&M\*NS^T)!PI!'(BSV%;5%,+'/SZ7?7%Y)=-IUO'-(%5
MVAUBXBW =,A8P.,G\Z?-8W]S8I:7.EV4T2$,IDU.5G5AT8.8MP/OG-;M% K'
M/'2[YK2:VETZWFAFQO6;6+B3H<C!:,D?ABK$L&IS7<5T^F6(GB!"R+J,BG!Z
MJ<1<C@<'(K9HH'8Y_P#LNZ-K]F.C:<T/G_:-C:A(?WF[=GF+U[=.U+<Z;>7?
MVK[1I%@WVQ46?_B92C>$SM'$7'4].O>M^B@5C'NX=2OK)[2ZTO3W@< ,@OY%
MZ<CD19'2D:#4GO8;MM+L#/"C)&YU"3A3C(_U7/0=:V:*0['/W&F7UU>M=R:=
M;I.R!&>'6)XLJ.@.V,>IJW!_;%M L4=A9E5Z&34I7;\6:(D_G6K10%CGKG2K
MJ\N6GN-(L6:3;YBC4Y527;TWJ(MK_P# @>.*?>Z??:A()+G2[/S ACWQ:I-&
MQ4]5)6,$CV/%;U%,5CG9-/U9[RP=;#3H[:Q#&*V6\<+OQM#?ZKL"V!CJ<YKH
M(RYB0S*JR%1N56W 'N <#(]\"G44AI6"BBB@84444 %%%% !1110 4444 *O
MWA]:5_\ 6-]32+]X?6E?_6-]30 VBBB@#BO$G@Z3Q1JA6]T+08K=I$$FJ$^=
M>-"IR44&(;"WW=V\[03@$U+XD^'UCJ\KW5DUU!=W&H6MU=,-2N8TD6.2,L=B
MOM#^6F%( ((7!&,CL** .7\1:/K.N6<FAQ6]A#I4AB!OI;N26X55*MD1&/&_
M*X#&0XX;D\5U%%% !1110!\RT5[$_P (]!5R!=ZC_P!_8_\ XBF_\*ET+_G[
MU'_OXG_Q%?)_V5B>R^\^D_M&AYGC]=#HOBRYTVU:TN!'+;QVLT5NIM(G*,X/
M4L,E<GD9/'8]*[__ (5+H7_/WJ/_ '\3_P"(H_X5+H7_ #]ZC_W\3_XBKAEV
M+IN\?S)GCL--6E^1YUIVH:=IEE>21RW4UY=VCVYA,"QQ(7QD[@Y+  <#:.<=
M,5FR:C=R+:J9F46@Q $ 3R^<Y&,<YYSUZ<UZO_PJ70O^?O4?^_B?_$4?\*ET
M+_G[U'_OXG_Q%-Y=BFK*WWB6.PZ=]?N/)+FZN+VX:XO)Y;B9\;I)7+,V!@9)
MYZ#%15[!_P *ET+_ )^]1_[^)_\ $4?\*ET+_G[U'_OXG_Q%0\KQ+=W;[R_[
M0PZ_X8\?KTWX._\ ,9_[8?\ M2M/_A4NA?\ /WJ/_?Q/_B*W?#7A*P\+?:?[
M/EN)/M.S?Y[*<;<XQ@#^\:ZL'E]>C7C.>RO^1S8K&TJM%PCN_P#,W:***^A/
M$"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y:JYI^JWFF>:+1TV3*%EC
MEB25' .1E'!4X/0XXKUU_@YX?5R!>:E_W]C_ /B*;_PI[0/^?S4O^_L?_P 1
M7SZP%=.Z_,[O;0/))]2GO[J:349O,:YE5YI3$K.,9'R],#!^Z"!P!V&-?6?$
M0N]!32XM0U/4<SB:2>_;&T*I"HB;W 'S$DYYXXXKT3_A3V@?\_FI?]_8_P#X
MBC_A3V@?\_FI?]_8_P#XBJ6#Q"3\_,7M:9XQ7TCX7_Y%#1_^O"#_ -%K7*_\
M*>T#_G\U+_O['_\ $5V]A9QZ=IMM90%FCMHDA0N<L0H &<=^*Z\%AJE&3<S*
MK4C-*Q/1117IG.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?)=%>Y/\%/#BN0+W5/^_L?_P ;I/\ A2OAW_G]U3_O['_\173[2)R>RD>3
M^'+K2]-U&WU&_N;Y)[2=98X;:!2)-I! +EP5R>/NGC\J(_%>JVQE%G-' CRR
M2Q@0HQMR_P![RF*EH^,<J1T%>L?\*5\._P#/[JG_ ']C_P#B*/\ A2OAW_G]
MU3_O['_\12YXC]G,\>TV]$5Y;-/>3V"VP;R[BQMU,RDDGJ&0GKU+9 X''%7/
M$^OG6Y;.-)[RYALH/*6>]?=+,Q)9G;DXR3@#)P%'->J_\*5\._\ /[JG_?V/
M_P"(H_X4KX=_Y_=4_P"_L?\ \11SQ#V<[6/#JUO"?_(Z:)_V$(/_ $8M>M_\
M*5\._P#/[JG_ ']C_P#B*L:?\(M!TW4[6^@N]1:6UF29 \L94LK C.$Z<4.I
M&P*E*YW=%%%<YU!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/'
M[0W_ "42S_[!D?\ Z-EKA-+\6ZMH^DS:99/:?8YY!)+%/803AV'0DR(Q..WI
MDXZU](^-?A=HOC;7(]2U6ZOX9HH%@5;:1%4J&9L_,A.<L>]<]_PS]X5_Z"&L
M?]_HO_C=(]FCBZ,:2A/IY'DWAWX@WFE6,UE>K;SVR6%Q;VB?V=;N8WDYY++D
MH6))!)!]#7,2:G=R:5%IK2XLX9&E6)5"@N1@LQ RQP, G.!P,5] ?\,_>%?^
M@AK'_?Z+_P"-T?\ #/WA7_H(:Q_W^B_^-T&BQF&3NOR/G_4-4U#5IDFU2^N;
MV5$$:/<S-(RJ"2%!8G Y/'O7T!^S]_R(%[_V$Y/_ $5%1_PS]X5_Z"&L?]_H
MO_C==GX/\'Z?X)T>73=*FN9H99S.S7+*S!BJKCY5 QA1VIF&*Q5*I2Y(&_11
M10>2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4O!G_(GV
M'^ZW_H;5N5A^#/\ D3[#_=;_ -#:MR@4=D%%%% PHHHH **** "BBB@ HHHH
M *\R^//_ "(=G_V$H_\ T7)7IM>9?'G_ )$.S_["4?\ Z+DK6C\:,ZGP,^?:
M***[CRPKTOX%QF3QQ> $ _V<_7_KI'7FE>G? ;_D>[W_ +!K_P#HV*HJ? S2
ME\:/>/LS^JT?9G]5JS17GGJ%;[,_JM'V9_5:LT4 5OLS^JT?9G]5JS10!6^S
M/ZK1]F?U6K-% %;[,_JM'V9_5:LT4 5OLS^JT?9G]5JS10!6^S/ZK1]F?U6K
M-% %;[,_JM'V9_5:LT4 5OLS^JT?9G]5JS10!6^S/ZK1]F?U6K-% %;[,_JM
M'V9_5:LT4 5OLS^JT?9G]5JS10!6^S/ZK1]F?U6K-% %;[,_JM'V9_5:LT4
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MZK5C<*,@T 5_LS^JT?9G]5JS10!6^S/ZK1]F?U6K-% %;[,_JM'V9_5:LT4
M5OLS^JT?9G]5JS10!6^S/ZK1]F?U6K-% %;[,_JM'V9_5:LT4 0/ S.2"*;]
MF?U6K-% %;[,_JM'V9_5:LT4 5OLS^JT?9G]5JS29 H K_9G]5H^S/ZK5C<*
M7- %;[,_JM'V9_5:LT4 5OLS^JT?9G]5JS10!6^S/ZK1]F?U6K-% %;[,_JM
M'V9_5:LT4 5OLS^JT?9G]5JS10!6^S/ZK1]F?U6K-% %;[,_JM'V9_5:LT4
M5OLS^JT?9G]5JS10!6^S/ZK1]F?U6K-% &'X,_Y%"Q_W6_\ 0VK<K#\&_P#(
MHV/^ZW_H;5N4"CL@HHHH&%%%% !1110 4444 %%%% !7F7QY_P"1#L_^PE'_
M .BY*]-KS+X\_P#(AV?_ &$H_P#T7)6M'XT9U/@9\^T445W'EA7IWP&_Y'N]
M_P"P:_\ Z-BKS&O3O@-_R/=[_P!@U_\ T;%45/@9I2^-'T#17@/CCQ#86WQB
MUVS\3^-_$7A^P@M('LXM+N90K2% 2-BJP]^V?6NCT[XDZIX2^%^B77BNTEO-
M8U":2&TCO)DLVEC4DK),[_+'\NW)/J/7->>>H>MT5XEXJ\=VWCOX8Q745N+2
MYL]?M+>YMUN$G56$@(*R)\KJ0>"/0UTWCCXKR^"->:UNM#@N;&-%=[A=8MTG
M*D<E+8G>V/PZ9Z4 >CT5Y//X^\9-\9!I&E^'_MNDR:4MQ%;?;88]\33 ?;-Y
M7<.#M\K.>,USTVI:;I6D^.+K6-(_M:!?&*[;?[2T&'^7:^Y03P><=#0![S17
MFNM_%;4].U;Q%::9X.N-3A\/$->727R1HL7EAR^&&<@9^4 \#.:GT;XI7.H^
M)-%LK_PO=Z;INOQL^EZA+<QN9]J;_FC7)0$'@D\Y''7 !Z'17FEW\7SIGCM=
M!U;18(;:2_%C'=P:O;SR[F;:CO;J=Z*>#STSZ\5S=AXOU;PEXO\ ']Y8^%Y]
M8T^#4A/?7,5TD7V9%C&2%;ESC)P.@% 'M]%9\&N:=-X=@UQKJ.WTZ:W2Y$]P
MXC58V4,"Q/ X(K&\*?$#1?%=Y?VEG?6'VFVO)8(H8KU)7N(TQB95'.TY[9''
M6@#J:*\F^).H^)K;XH:#%X5OIA-%I\]V-.\UA%?&-LF-ES@DKN ..#BK6C>,
M1XG^+>B3Z3?7']E7GAZ6=K0RD*LHFVG>F<;UY7- 'I]%>3_#GQYIL'A_PEI^
MF^'/['T?5Y;JWMS]N:<6\R.S;"67+;R6(.>#Q6C)\6P= _M&QT&:]DO-6DTW
M2+>&X!:_V$@RY*XC7(/KTH ]'HKBO#_Q#FU+^VK36?#E]IFLZ+!]HGTR-UN7
MF0J2OE,N Y., <<D"N@AU1M3\*-J26MYI[36SR""[C\J:(X/#+GY3^- &K17
M$Z'<_:8='&FSZE)J'EPS7WVF28QF)EPS8E.T@G."G.1QQFI(KBWF\1:U'J4N
MKN(KA5B6T:Z*(OEJ<8BX'/K3L3S'945AK)+'XXAM%FE^SKIC-Y;2$@L)%&XY
M/)QW/-2^*-4_LK09I4E2*:4B"%W;:%=S@$GL!R<GTI#N:]%<UX=G@U73;K39
M=0DO38SE!<PW;;I4/S(QD1LDX.#SU4T>&;-99K^::YOI6MM0FBB$E[,RA%Q@
M%2V#U[@TQ7.EHKC='OKJ'2/#NIW%U-)%,6M;KS)"V=['8YR<9# #/7#59U"[
MN;B+Q+>P7$L<-E9R6T'ER%1YBH6=\?W@2J@]MIHL'-H=317(:_"R>&[2_CNK
MV.YD:V1FCO95!#,H/RAL<@]<>]:6J6$^FV4=YI,MY(]G(97MWN7E^T(0 Z_.
MQYP,KZ$<=30%S=HK!TF\-Y)=:_=730:>R^7:I(^R/R@?]:P..6/3/(&/6K%S
MKT!2U723#J,UW(8X1'.!'\HRQ9QG  ] 3D@8I#NC6HK*M]=3[+?OJ,0M9M.)
M^THK[U V[@RM@9!7V!SD8J:VO+V[T6"[CLHH[F9 XMYIRH4'U8*><>W7CWH"
MZ+]%9.DZM=7^I7UI<V<$/V,HK20W!E5G89V\HO08S]16M0/<**** "BBB@ H
MHHH **** "BN:\0>,9?#HEENO#6KW%JDB1+<V[VI65G8*H56G#DEF QMZU9A
M\56TWBQ=!^Q7\<KPRRQW$L(CBD\ID5PNXAC@R+AMNT@\$T ;E%9]KK-O>:[?
M:7;QRO)8)&9YL#RU=P6$><YW;=K'C&'7GG%:% !1110!\U_\)3X@_P"@[J7_
M (&2?XT?\)3X@_Z#NI?^!DG^-95%?!^UJ?S/[S['V<.R-7_A*?$'_0=U+_P,
MD_QH_P"$I\0?]!W4O_ R3_&LJK<FG2Q:1#J,C(L<\K11H<[WV@$L.,;1D#.>
MOT--5*CV;^\3A371%K_A*?$'_0=U+_P,D_QH_P"$I\0?]!W4O_ R3_&H?[*=
M+6PN+B>***^=E3).Y55MI<CIMSD=?X3747/@2,ZU!;VHNHH LC3K.RF0*CLJ
ME20H_> ?+G@8)R0"1M"->>S?3KW,Y2HQW2_X8YW_ (2GQ!_T'=2_\#)/\:/^
M$I\0?]!W4O\ P,D_QJGJ%G)87\D$L?ED895\U9/E8!E.Y>&RI!R.#5:L74J)
MV;9JH0:NDC4/BKQ /^8[J7_@9)_C7JOPLU/4-4\,7+W=S/=R+>LHEGE+E1L0
MXR3TY/'O7B,F3A5&2> /4U[IXBOQX&\-:9HVD8C9U,8EP-P 'S-TQN8G.?K7
MI8&JZ?-7J-VBOS.#%TU4Y:,%K+]#L"ERO/RM[ TZ&X#G:W##J#VKRNT\3W]C
M(+A+Z60@Y9)9"RO]0:])DG6:"TOHP5$ZJ<>Q7(KUL!F-/&I\J::/,QF!GA+<
MSNF:=%,B.5%/KTS@"BBB@ HHHH **** "BBB@ HHHH **** /F'_ (2SQ%_T
M']4_\#)/\:/^$L\1?]!_5/\ P,D_QK)HKY+VD^YZ?*NQK?\ "6>(O^@_JG_@
M9)_C1_PEGB+_ *#^J?\ @9)_C4=IHDUWI-U?QW-JHMHS*T)DS(RAE4G: <<N
MOWL9SQG!J<>&+DV G^U6HG-J;P699O-,/7=]W;]T;L;LXYQ5_O7U8O=&?\)9
MXB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?XU2L;2&[D99]0M[$*,AKA9"&]AL1
MC^=+J>G3Z3J=Q878436[E&VG(/N#Z'K4\U2U[CM&]BY_PEGB+_H/ZI_X&2?X
MUW?PBUO5=2\6W4.HZG>7<2V+L$GN'=0WF1C.">O)_.O+J]#^"O\ R.EW_P!@
M]_\ T9'6^%G)UHILBHER,]QHHHKZ4\\**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HKG/'_ (@O/"W@34M9TR."2ZM40QK<*2A)=5Y (/?UK&3Q
M_=W%YX8MHK6&&>_OY=/U:"16+6LT<1=D4Y'< @D'*D'O0!WE%>26?Q3U>>Y.
M+O0[NX&MOIPT*W@?[:T0E*>:&\XXPHW$F/& >17HVKZI-:ZAIFG62QFZOYCS
M*"5CB0;I&P""3C"CG@N"<@$4 :M%>?77Q2TZS\*^(;BYU?18=;TV74(K>PEN
M55G:&21808R^XE@B\#&<\8R*;K?CN]T_7M1M%UC0;(V=M#-!87<#M<7S.A8I
M'B8')("C:CG)'!Z$ ]#HK,O];33-&@O;NUG,TYCCCLX@&D>5R (QD@9R>22
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M]*FF2J)&?#'S")RN<?*AP NT<'&*]$HHH **** /E:BN_P#^%.>(/^?S3?\
MO[)_\11_PISQ!_S^:;_W]D_^(KXOZCB?Y&?5_6Z'\R. KK?[6T;4/"EU#-8M
M#<6=I#!; W2'+;\LZ*8\@DDLV"<CC(ZUI?\ "G/$'_/YIO\ W]D_^(H_X4YX
M@_Y_--_[^R?_ !%:4\+BH7M#<SGB,/.UY[&7?:OHVJ>';MC8207,(MH+9&NT
M8JJJXRH\L';GEAGDL.169;^(IK'["MA$L<-H"S12'<)Y&!5V;&#RIV@=AT.<
MD]/_ ,*<\0?\_FF_]_9/_B*/^%.>(/\ G\TW_O[)_P#$54J&,;OR:_+O<E5L
M*E;FT.*U&_?4KS[1)''%A$C2./.U%10J@9)/0#J356N__P"%.>(/^?S3?^_L
MG_Q%'_"G/$'_ #^:;_W]D_\ B*R>"Q3=W!FJQ6'2LI(\ZF!VG'![5[8([;XK
M>![::*<6^I6K8<XX27 W#IT(P>*Y=O@WX@(_X_--_P"_LG_Q%==X/\%7GAS1
MI;:\FB-PUPTJR6SMPI51U(!SP:]' X:JG*G5C[K6IPXO$4VE.G+WD86D?"[6
MVO4&LWL$=JC?-Y1+,XSV]*]!GF2>Z@MK7!A@X)'3., ?A4)T^[F&R>ZF=.A4
MN<'Z^M:%G8);J HQBO8P^$I8:_LUN>97Q-2O;G>Q<B&$%/H Q174<P4444 %
M%%% !1110 4444 %%%% !1110!\ET5Z'_P *5\1?\_NE_P#?V3_XBC_A2OB+
M_G]TO_O[)_\ $5\Q]5K_ ,IZ/M(=SE=&U;3M.L;V&ZL+JXDO(3 [QW:QA4WH
M_ ,;<Y0<YZ'I4_\ PDL'V17.G$ZBM@; 7/G_ +O85*;O+VYW^6=N=V.^*Z/_
M (4KXB_Y_=+_ ._LG_Q%'_"E?$7_ #^Z7_W]D_\ B*T5'$I6Y?R)YZ?<Y+1]
M2TK3=0%S=:5+>A8P(T>Y4!9,<O\ ZL@C/(4@@=#NJEJ5TE[J4]U&)@)G+GSY
M1(Y8\L2P50<G)Z"NZ_X4KXB_Y_=+_P"_LG_Q%'_"E?$7_/[I?_?V3_XBI>'Q
M#7+RC]I"][GGE>A_!7_D=+O_ +![_P#HR.C_ (4KXB_Y_=+_ ._LG_Q%=7\/
M?A[JOA/Q!/?:C<6<L4EJT($#N6W%T/=1Q\IK7#X>K&K%N.A-2I%Q:3/1J***
M^@.$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"\:^&O^$P\&ZA
MH/VO[']M14\_R_,V88-]W(ST]16=JW@&#4?'^E>*+:]:TDLWWW-L(MRW;"-D
M1B<C:RAR,X.1@=A7744 <!'\,'M+."33M9%OJ]IJT^HVM_\ 9-P59F)D@9-X
MW(0<'YAT!XKIM9T^Y?6-(U6RC\Z2RE>*6(,%+0R@*Q&2!E2$;GJ%8#DBMFB@
M#FV\([O!>N:!]M_Y"S7Y\_RO]5]I>1ON[OFV^9CJ,X[9IMUX-BNYM1F>\9);
MK[.]O*D8#VDL*D+(ISR<GD=",J<@FNFHH R=9T>XU;2;>(7J6^H6TL=Q%=+!
ME%E3OY9;E3R"N[.&.&SS46CZ+?:;]HN+C4(+F^OKH3WLHM2B,H0(J1IO)3"J
MG)9^=Q[C&W10!R-KX)GAU*V,NIPR:=9ZC+J4$(L]MQYTA<D/-O(9<RMT0,0%
M!8\[I=,T'7--\07VM:EJEKJYF1@D,>GM%+'&.5AB9IRBC/))7+'&YN!CJ:*
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MR>#D_E3/%UQ#=:Q$\4T<THMHUN'A;='YH'.T],=.G%:__"K=;_Y^K#_OX_\
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M#SWXC?%?_A!/$D6F?V-]O\VU6X\S[5Y6,LRXQL/]S.<]ZY/_ (:,_P"I6_\
M*A_]JK&_:&_Y*)9_]@R/_P!&RUY52/=P^$HSI1E):_,]\T3X]?VQX@T_3/\
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M)O\ %_YGV%#$8*6'IJI)744O31?Y&+HVMVNASK=VEE.UZL94/)=#RR2,9*!
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M4%Y%&_F+'/&'4-@C.#QT8UO"7+),QDN:+1\=T5]:_P#"&^&/^A<TC_P!B_\
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M\];_ /\  ^;_ .*H_P"$/TW_ )ZW_P#X'S?_ !5 :EZBJ/\ PA^F_P#/6_\
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M ,#YO_BJ/^$/TW_GK?\ _@?-_P#%4!J7J*H_\(?IO_/6_P#_  /F_P#BJ/\
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M_"'Z;_SUO_\ P/F_^*H_X0_3?^>M_P#^!\W_ ,50&I>HJC_PA^F_\];_ /\
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MJ U+U%4?^$/TW_GK?_\ @?-_\51_PA^F_P#/6_\ _ ^;_P"*H#4O4A -4O\
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M37.G:<M[--&UY=1MY+(@)61074@/@$98\$8)X)FN_$-U;+8AM8TB*VN(W?\
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M:W+W-G=P7-O(D;6;JC2NSXV!=K%3NS_>XP<XP:MV&KPWUG/.8I;9K9VCGAF
MWQ,HR0=I(/!!X)X(H OT5B0>)XI;*VNY=/O+>"[EACMWD\H^;YOW6 5R0.F<
MX//2GWOB6VLY'B^S74\JWJV(2)%)>5H1*,98#&"!DXP>N!S0!L45D#Q%;B M
M+:W,4PO$LC;LJ[_,;:1T8KC:P;.>@/TIEAXC@GPMQO3*7$@E,81"L,I1AC<Q
MR.#[CGCH #:HK$E\2I!86U_+IE\ME/%'*UQB/$(<X&]=^[C()P#@'ZXFL=2)
MU#5H[VX14AOTM[<.0OWK>)]H]26=CZ\T :M%<]XB\0W&AZIIR);K-:2I-)=D
M F1$0H-RX]-Y)![ X]UN/$3Q2ZF08S!:M:B*1$\S<)2!G[P!Z\$$8Z\]* .@
MHK*3Q!;.( (I_-FO&LQ%M&Y77<23SC;M4MD$\$?2HK#Q/;7]U;1I:W44-YN^
MQW,JKY=SM!/RX8L,J"PW!<@&@#:HK)US6#9>%+S5M,>"X,4!EA<G?&WH<J>1
M]#52+Q)+/'IJ>2D5U)??8KZ!\DPN(G<XYZ$J"#W4Y[\ '0T5C6'B&"XV+/N4
MR"Y=93&$0B&4HPQN8Y'!]QD\<@0'Q?;FW6:#3K^=1:K>3B-$S;Q,"5+@N.2
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M!89(7'49SQ6O%/#.',$J2A'*-L8':PZ@XZ$>E $E%%% !1110 4444 %%%%
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M!,&%PJN5W!&<C:KD<[20?:E_M^P%]):.;E)T5V"/:2KY@3[WEDKB0^RY)[4
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MQE"C+&'(3<">I4 GIUJ[10 4444 %%%% !1110 4444 %%%% !1110 4444
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MM(;Z::,2I-YN0Q"F$' 7$8XSD<@5M:!I;Z='<M/:K;S3R!G(U":[+X4 $O*
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M WN,L03R3C/7VKJJ* ,&#19H/!%OI$T%O>3101Q-&T[Q(Q4CD.%++C&00,Y
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M994BL[21 $LH+R2XC#[B2R[U41CG&U1C\A6_10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 445&TRKU- $E%1"X0]#4@(/2@!:*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK#T7PR
MFG6UD]U>ZA=7T,2B:634KATDDVX9MC.5P3DXQ3%J;E%9U]H5IJ%QY\\M^CX
MQ;ZC<0K_ -\HX'XXJ6]TN"_MHX)Y+I4C(*F"\EA8\8Y9&!/XDT:!J7**IPZ9
M!;Z<]DDET8G!!:2[E>09ZXD9BX]L'CM3-/T:VTV1Y+>6]<N-I%S?SSC\!([
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MK>6_=BI7%QJ$\ZX_W9'(SQUQFFRZ!9RWQNWFU 2%P^U-2N%CS_N!]N/;&*-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR2M(1^!<C\*N4WN);!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
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MN2#GOFH]1\#^']4OKF[NK.59+M52Z6WNYH([H#./-2-PLG!(^8'(XZ<5T%%
M%>2PMI--;3PAAMC%Y(2W<Q;$QC"E""N!TP1CM6'I7A&R\':7)%X,L6# 8BL[
MO5;@6XRV6QN\P(>2<A,D\=\UTE% ',^$?#]]I-WK>HZL;9+K6+W[2UM:.SQ0
M (J !F52S$+DG:.3TXKIJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %9]AH&C:5<-/I>DV-E,R[#);VR1L5R#C*@<9 X]JT** ,UO#>AO?\
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MZ+I]M<IDK-#:HCKD8.& SR"1^-:=%%V%D%%%%(84444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img134051827_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_9.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &F*^9U0X0DE-! 0      #T< 5H  QLE1QP"   "!_X< E  #45V82!%
M:')N<F]O=&@< @4 %U!O=V5R4&]I;G0@4')E<V5N=&%T:6]N #A"24T$)0
M    $&&EJ(I)'RW68LT.O4\3.O\X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q ;:@(
M0         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ ! [_^
M-0 "  $X0DE-!"8       X             /X   #A"24T$#0      !
M %HX0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              ,5   %V          !
M                  $             !=@   ,5
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   ,5     %)G:'1L;VYG   %
MV     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   #%0    !29VAT;&]N9P  !=@    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     @X0DE-! P     #_8
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
M @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@ , P$  A$#$0 _ +SN@Y;LFQEN3BFUUA<T.S<FIY%[WW4^I6*75[_2NQZ:
M_3]E?_">H@W?5[+=6YE6?BTV[AM<[/RG.$GZ#JGT?G?F+N68N>XU7U''<UC!
MZ/JL)<W<QF[](WW-_25_Z^Q$&+G, ],8S3])WL(;N+C[VM:=V[TMGYZD]Z?@
MCA#P6/\ 4CZS9+/4HZC18R2-PR<B)'_647_QO_K;_P!SJ?\ V(R/_22[O$KZ
M@RS],*&52Z64@B23],[OW_I*ZC[\_#[$< ?-O_&_^MO_ '.I_P#8C(_](I__
M !O_ *V_]SJ?_8C(_P#2*](22]^?A]BN /F__C?_ %M_[G4_^Q&1_P"D46GZ
MA_65C?TM]-SMX=N.7DM&T?X/8*=KEZ$9@QSV5 T]9%>UM]9?K[W-[>V- /Z_
M^O\ -KWY^"N /%Y'U#^L]EI?3DT8]< "H962Z"/I.W.I_.5K-Z'U-G0NF8UV
M35ZG3SD#*?9=>*W%[O1J=ZM#?M#_ $K+JW>_8NN:SJ8R-S[*S27#V 1#=K9[
M?O[_ ,]5[G.:V6/KJ<'VP^[5D^M5[7?U_HI>[(]M$\(>+'0+'F*\O&)8"[;^
MT,MQVM!+M[6TM<ZQOY__ )[53_FWU&]UEF/U?'KI!;#7Y.3[0\[&>^VIF[WK
MT+ 96]]H<<:T.8T.=6T;W#W@>K[6M]/9]!7Q56.&-^X=DAFGX*,0^5-^KO4W
M-W#K6,!_*R,EO(!_/J'[RG_S7ZQZSZ/VM2;:W;'L%V42';A7M]M7^D=L7J(I
MJ$0QHCC0)G44.$.K:1KH6@\_2_SDO?GX?8C@CXOF#?JIUMUK:6]5I]1X:6-]
M;*$[PUS-I
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MKVL45S3]%6>/@L-RW7#8B.S0W&YX:,W G*F%8SKD"%B%,]+D,YC/X1!!0/\
M9[-9S7\N33XF<F/2IKA'SE)<J9;"B2XU5S;#,B6*%(8%2ZBNDN46Z2WWB?:(
M(9T,B*)PDZ-+J&7I,%U%#8ML2?0L6%+%M5%L2S95-DBK9'A3O"Y:>MY.@;3W
M?L:@74-B,HG6;7K;7@8O$:FQFYD*0N),HK;BXLV(\S*ARVO+C2XSK;\=UQI:
M59L:Z$-!3Z1 Y9T]JYD1W2039+IU' JPJL,272.5^E"J*BPKLHNVEJ'C-JU9
MD1K+G3YLJ-++8(Y<N%41=E%L6#:5/'M*FT:+^6<\)?[4=B^AFL?N3RC6+H4Y
M'E8P\\_COBT\]7*IA<70E]P?EG/"7^U'8OH9K'[D\:Q="B?]'E=>\7]7'SSV
MM7*IA470E]PL;T^\+'X0C9O;#K1KN[=D+ :IUXWSJ:JVD,NJ:[B-EZ\=O0,:
M8&.R8-/C3&&2$"1(B/.1)#$A+3J\LO-.>2M.77-!NAEI1JLZ;TJ5+GMZ:]G2
M9B3G2W$V6WF1P1I#%/6%5AB1(D146&U-E%*F58J4UXUE3',44$R?*AC2Y@2Z
MABC1%2U(4792U-A;3^[OG\\'Z ?PK]F/"B>$E =QMZ:4U+ORX.Q!G878.NM<
MTT32]?ER"V6;\4 5>MC$OTV41(258Q"&P4.O2)3Z_-(4XZZK*L_T+2=".A6;
M0J>_>TV0D4=,;.G3B-PY@A15;0S9TV.QPD$*;,442HB(B>)+-CX%U5:I"^<-
MY#B-41Q,ERI<,$"K8DR*&&%+8%55V$1-E;?.J[&F;B\(1X:[KXX';W?L'<VK
M,6'TO %^ZZCHP*&97 4A,]H9.F4%$.<_!RZUB9'CON/Q?.M9?;;PXC*O9CH:
MT!5.[6GMF#S2K%F)(>N)D4"1I]%8X4<K%##%8MRJHB+LW*\'E/J-=;7-\3)\
MF[M2%8Y4$**J;=BK!8JI:EJ;-G 16,\+SX5 U"-D@W8:]EAU:@M%+'/&:XU_
M/A5\8_+8'LD3<J+0G6!4%Z?*C0FI<]QB.Y+D,1D.9>>;0JV/05H/EQ2X(Z6V
M@BFQ7$J&-TYABFQHBQ+! D3E(HXKE%B6&&U;E%7:13RAK-7B2)87$R)($NHU
M27 J0PJMEL2I!9"EJHEJV):J);:;!?O"I>%GU>3$!K[V$M5<)GJI6+P)B2:I
MJ.2N95;D)8.5HPA<"J2VFVBHJ2Q+:8>6W,92YAN5'8>2IK'DWT'Z#'D$<;>F
M29L$J=.;QJDY]#<SI$:RYLM;J?"JK!&BHJI:BJEL,2H=IE7K$E4AF.(X8HH(
M9D*+#*V8(TNH8MB':5+%1-M4V]G;T;\LYX2_VH[%]#-8_<GE&L70IR1*QAY_
M!Q^G\SSU<JF%1="7W#,2O"]>%.A!15DF=A[U$KIV23A!#TK7.OHX4S,"YB8,
M1!11VAH@D9(G)"!@FQ$?>=@9FQ,2D->DL^7TAT%:$(HXY4-+;Q39:013):.G
M2S)<,RZN(HX$<W4"1W,5PL2(D5RMS;<K9V6LU9(88U<S$ABM1(EEP)#$L*I=
M(D2P6+9:B+8NQ;L^(P_Y9SPE_M1V+Z&:Q^Y/.^L70I9_=$K:LMT]W;[19;Y[
M+3KJY5,*BZ$ON#\LYX2_VH[%]#-8_<GC6+H4Y'E=>\6SG<?K:-7*IA<70E;/
M_P /T'Y9SPE_M1V+Z&:Q^Y/^W^;C6+H4Y(E=>[_5'%OV[/Y#5RJ87%T)=O\
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MRT>RIJ2XXI$$,<B.!=-67'%L*B1?12*!5BE(JW%EIY]^%5;UK-N6G[3KXAK
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M]_V,4<"6)%'!L*OG12AG/HS.' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M.Q5NMX>:1);2K*V%.-*2ZA+J4Y6WG"TXRG.,\ X8!,:5:7(%D())AI]R,X]
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ME"F]8;'.M.Z--4L.!LK0L=+'UINO[D)B;7=H%GFWD4;)GPA)9@3)FO5FRN*
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M_P!'&. :3+HE'E;$]VLN/&7<B-#DTR9$=E-K9.T^&?B&F<$0CN5-$D #$U[
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MJ"1NKSTB!?\ M&R<VQSVEC.9A2. . . . . . . . . . . . . . . . .
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M]5!,VG#91YZ021BP-P$E<)(/R'WIV/2_\;=?><?\XIUS*@-XX X X X X X
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M-Z8JL0V;(UDN/%#W9\R=+DNAQLN(*)S'7TXF%8<Z2U%@M.MPV )RX X X X
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MK52X@]5WK)(;J)#$?KO8[(^4)AHJ(^+ ;G'&89%TI9I!J1"?@L9#Y&>=G>F
M33IS8FS=HVF[V-\A0A>L*[M#:FJ!].37SBK\J;J^S$:@[9IEO<M/J9?KLN#)
M$6:RW2(^8U=F"Y>#\B2A]M\"S7 ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M ' ' ' ' ' ' ' ' ($[0"B!70&V\C;9;:;*$Z_N5@;*THO[GSCS@.L%R,>
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MX>?<4E"?*SC@&V\ < < < < < < < < < < < < < < < < < < < < < <
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MLY-1!<M#J9T0>8Q&C)*C6I*8!!N+&;EQGFX[*6P,WL?3]9OVIR&I(B6Z<#Q
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M*!6HY32 6&+ W"88#$2]<B2LD)L@U#! 7CX X X X X X X X X X X X X
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M+P,KIF7),S?,1QST@DIU %K=);27N&@Q;D_6IM3F^NK-7R(:4_(FQDSJN?(
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M!)0!DG&F##,562TIU"T, 59+V;>]*HVB[Q:+_P!@(^GAO6V#L'<NPM4C--W
MBQL8C)$VJR&[=!V6'M-R<I@T%,/2(H_7X@DX*%1V(D:+EF&TE($N;RV7>:CM
M#2-AJ.Q-D,46^; U>+)8ETFE2>O4>CV^0D3,C'KDBGR;\.NMLG/CF:9)Q9H
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MYF"/B)8'CHL2!&CQF@-FX X X X X X X X X X X X X X X X X X X X
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M^3G5_O2B^KIWO>J"3NKSTB#V1M^/\.#QEC>9A2. . . . . . . . . . .
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M.2'PHM=?)7L!^RYV/_"WC4ESQU-[6IN="_)7DN,5<Y(?"BUU\E>P'[+G8_\
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M<TR.?A*:2\M &O%E.Y*BV)& +J< < < < < < < < < < < < < < < < <
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MZT"8#8IH,Z8BDB <=*<B#9L"-.?FI:$M1U%9,:$ZM7A7G47*<"<R&B:R[O\
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M>=18G G,A5!KP@@ND[( ZTW71ZG6%P*0,)[)M8@Z[A\):,:*9W29G!=?2!!
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M7A7G46)P)S(/087\SB_T=K^QQ:O"O.HL3@3F0>@POYG%_H[7]CBU>%>=18G
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M:CM-,-K=4M2&6VVDYPA"4X Y^ . . . . . . . . . . . . . . . . .
M. . . . . 5JTY\=G;KYS];?9]U3S5?;PHOHCKWD\)9.[O/O97L\K\OZ\)V=
M*_&EV^^?RH_97ZW\ZO\ >E%]73O>]4.9&[//OX/96WSSEC.9A2. . . . .
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MYME%+&\S"D< < < < < < < < < < < < < < < < < < < < < < < < <
M< < < < < < < KGVD^+.N_/YU8^TSJ7FG2=]3?5U7]UO"5YN4'I#7VF46,Y
MF%17/JO\4Y#Y[.T'VF=N\TZOOR'T"D^ZF1,TW%?OW7M4XJHQTDM=5HFKH5/Q
M7&CFK]^=A=H>Y>O;"O>IQMCJVW+!L*-5H,785*#/V2NV2GT(]40S"$A" =4,
M-/J>'L"'8I1K,_B4FXA^MFRZ99]/$M4@:KJK !0!C8Y^%O'8=[?,4[WRK5?;
MKK@O6;?KI479#1-=M/R*G>"IJI6&JG[2=E0&X@N,@>: ]!N . . . . . .
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M!>#+!&W4R^[YOT)<L76GP>M/, *];=*]3*N?M<C,6K [%3=5A#%EE86EO,8
M,)PHLTS(PXM",LCF)+F%K2G*?*5C&6K]<Y8J>/.<H+P8X(VZF7W2(*4!\%!?
MJW;K@"HG3MBM46X%:-:#)ZH:KKD 4=%D2 Q.7I)J'"9]5F7Q1!^LF,+]6V2#
M%>G!9,V*VMU+5^N<L5/'G.4%X,L#;=1+\?\ [3)DZ-X+D3L;7FK)FK>IV+AM
M6MSK70H[%!UM(&6$+$FPAT=Z&:8'+%K?-S)OF*U%]*S(L;D(HD,W,4-F8::O
MUSEBIX\YR@O!E@;;J)?=\Q)4+K7X/,DT#D#M+]2I[%F#E;#6WH5.U5*:L-?!
M>8]>' ;C$-Q!8.'])C>M2<!4B$/](8]+?9\ZWY37!7>6*GCSG*"\&."-NIE]
MT[--ZP>#^V,)<.Z]T=U2O8-F=(&O&:;2-7V@2T2B8;5*@.$0D&=#1.C)=:S(
MBJ>P^SAUO+C:<+3XVK]<Y8J>/.<H+Q98(VZF7W3;/@1=./99Z_\ U2T?^Y.-
M<%=Y8J>/.<H+P8X(VZF7W1\"+IQ[+/7_ .J6C_W)QK@KO+%3QYSE!>#'!&W4
MR^Z/@1=./99Z_P#U2T?^Y.-7ZYRQ4\><Y07@RP1MU,ONCX$73CV6>O\ ]4M'
M_N3C5^N<L5/'G.4%X,L$;=3+[H^!%TX]EGK_ /5+1_[DXU?KG+%3QYSE!>#+
M!&W4R^Z/@1=./99Z_P#U2T?^Y.-7ZYRQ4\><Y07@RP1MU,ON^=><? BZ<>RS
MU_\ JEH_]R<:OUSEBIX\YR@O!C@C;J9?='P(NG'LL]?_ *I:/_<G&K]<Y8J>
M/.<H+P98(VZF7W1\"+IQ[+/7_P#R_P#JEH_^7_\ !>-7ZYRQ4\><Y07@RP1M
MU,O[/)X-@? BZ<>RSU_^J6C_ -R<:OUSEBIX\YR@O!E@C;J9?='P(NG/LL]?
M_JEH_P#<G&N"N\L5/'G.4%X,L$;=3+[H^!%TX]EGK_\ 5+1_[DXUP5WEBIX\
MYR@O!C@;;J)?='P(NG./XNK/7_ZI:/\ W)QJ_7.6*GCSG*"\&6"-NIE]T? B
MZ<>RSU_^J6C_ -R<:X*[RQ4\><Y07@QP-MU$ONCX$73CV6>O_P!4M'_N3C5^
MN<L5/'G.4%X,L$;=3+[H^!%TX]EGK_\ 5+1_[DXU?KG+%3QYSE!>#+!&W4R^
MZ/@1=./99Z__ %2T?^Y.-7ZYRQ4\><Y07@RP1MU,ONCX$73CV6>O_P!4M'_N
M3C5^N<L5/'G.4%X,L$;=3+[H^!%TY\?C^"UU_P#'\TM'_P G_P""<:OUSEBI
MX\YR@O%E@C;J9?='P(NG'LL]?_JEH_\ <G&N"N\L5/'G.4%X,<#;=1+[H^!%
MTX]EGK_]4M'_ +DXU?KG+%3QYSE!>#'!&W4R^Z/@1=./99Z__5+1_P"Y.-7Z
MYRQ4\><Y07@RP1MU,ONCX$73CV6>O_U2T?\ N3C7!7>6*GCSG*"\&.!MNHE]
MT? BZ<>RSU_^J6C_ -R<:OUSEBIX\YR@O!C@C;J9?=(6WMU2ZR4"JTNW4?K]
MINH6H-V!ZNO"+'6]<U,*;&//]D=5Q'G(),>*CS(JW8LA^.XIEY&5LO.-*SE"
MU8S=3JS5G$YQ)GU-_.DS*;5TCE37<^.7&B4MY$B1013%ABL5+41479V=L\'+
M1K*@EQRV\B".%PUN8H)4"1):XE(MBI#:EJ;"JGB\QZ%\^:-(J;HRUC*'UUOE
MY-HEN!J9L;M[:RZ(#3;\Y8RN]A=T%YZ(3#KT=IZ6J+#=3':<?8;<>RA"WFDY
MRM.G5]^0^@4GW4R)FFXK]^Z]JG&9U]VQU9LR!HLA6&[,M&_W[O J\:>+APYU
M:,ZZ"DS-O WJ(HJMT&8$J$3Q3L6'@NE15G"$N^@N-SU9A23;7+[1KC*,0JC<
MZG:IM>E>@V")7+$'.2@<W*G$8AF(XR9*=&2LJ9=3Z/-0P]Y33B?(\:%8P!MG
M ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' -(O]QGT
M@&V7&4*[[(GOD(X^/6:!'K;QQU3S4A]<MQ^W6:H5R /BM1EYD2R=@@MY=7'B
MQ_/S)4>.Z! \3MY2#=7UZ>I=%VG>SFQX-])C-=UP)68]Z"C]5V!-1V1+LL>S
MW"N5L<BH6UV-6)K4>RSI)4Q+C,5IDXTO+Z0-Z/[_ *?"T1"WW64/6RMV('4R
M5)@,KR*F6@IL D' T>O^5-86L3/.6.P!PCV)D5;@N5*<Q*C*7'<:X!SHW@/(
M[++:TJM$OUV?JA4,"V!<:W'J3='U\;."X)Z,(/D;';Z\8)D8P$J(-%(5, VJ
M4*'EQJR#,=^4B/@"-3O;H13K8U5M@:7W;0F7ZWLRX,6<[#U82K[E6U-7W;';
M#RF:=M:T6>.-1#]7Q8,B56V$O%3809(Q$ED&T) W"L]DJG:)%?#1*Q=8%T.W
MDC1GJ"2BUQ5GK[H,*)LU@LQY8>S&*ZS40M;L%=*3#8\^10J18P%?8:=LY:*%
M4!OFO-EQ+Z3V8"R+D!3>K=A3J$=@29+4KS_C!@;973L5YMMK&85BJ=H!%FV5
M-^7!E2)@QQV0Y 6^X!)G ' *U:<^.SMU\Y^MOL^ZIYJOMX47T1U[R>$LG=WG
MWLKV>5\V;7C\:G9TK\:?;[Y_*C]E?KASJ_WI1?5T[WO5#F1NKSTB#V1M\V^:
MSQ%*.KO@],:TTW%*[(4?/;_%4W>M8IPP[L(A9=>:S]] O:TNJU\$1G *M/V@
M+.$9LQ"+&D3'7'IC:W$YRXWG,_,I-<U'U2[-VP;TPHFX0%0T]1>FX"/(9L%1
MV"W=KYL2\P*$[10DP/&9K$(+3@8U,J89F8(S3DF9)]#A8B.,(=>P!(6Q^N'8
M;7>V.KNS]63[+VE?TTYOO-C7O#:-9J5J=:VK5ZG71$* ?$T1@<X,%+$D)J(_
MJ%R2E;BVW)642&U, ;4:IG9LYW;U%O!>E*M#U[4-4&]6GIV-OBWR;/OBD:/8
M[ ?B"<5AIZ6W39X8H'9'86V[9$,,D6)0U$A,9(''V8T#MZX]G]-;=T[6(L4@
M!CTVM7>\V"V5.?1I^MX%\?LMHJEDU?8*P3/2#D.-G).C6JDF!T]H[.\V3?@1
MAS$EP"MS?4WLO1ZML6AT'4.K(XB=W%N>V(]M"D-4*N5LT_>)=^GAX-3;V%KV
MU5V@V.A>Z :#D+-!RCN:X5L@RJX9:=<]8A\\QU]#='-W:EE=+3%BUMKNYDM5
M!^P^O-F9?LP',NH"MF;3:N%#O=?GOUUIFQ8J$!)&9#$#H84A!EE7&1D<4N7,
MS''/Z['-L_T->U/TM[.0!&F*%M35-&GT31/6SL[H5SU%N!$<GM56U?5V!$MA
MYNLI=HP\R/A,CXLM[UQ/&3?3II6!$CMPFI0X^?E?FW\"_O1/5>Y]0:PLM3V^
MS$AQFKH^K6@R7-J!N]"]>1 0,6(@;&M-$!5ZLVBR17X$J.P5BPGY:@K(UF?/
M??;\U& NWP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P"N?:
M3XLZ[\_G5C[3.I>:=(WU-]75?W4\M_(E>;E!Z0T]IE6?F6,YF%12>@5<M=^H
MFZ*6!;9=.V^P=VZN%:DOIC1W"Q_>.\A0YM^2O^!'97,ELI=?7_!:1E3BOT)S
MS3J^_(?0*3[J9$S3<5^_=>U3B B/3';<+;NKS=++B0% EZQNN;^EHDIDE0-X
M&^OD[3#EPJT-A*$DH=L2Y5YQ?,)V.]%,U"2;6IV18'W4YA233U\TUL*O[ UM
M:;-K2I:D':IZZR]'2X=7L LVG89F8;H!%@U#2('0LQ:?6FJ02=KWNBQ&LCDJ
MYDDN"12&IKA4"]G ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' (.["O[I3KI\?H@-#)74Z5@A)9.29%B)=1K$YJ7Z^M@!!K"116SC6
M&FHU='$7FA[9:?%*D43X R4*G@5M#:KV9K EI:]:MTI']&HFI-F:9*ZI*[+K
MZ3L9-HM%*M@"\N7-YN2&-ND3-5*2KRX\]D]+?L?KEADH0C28,H#K;$U(8U!T
MGU?5);[1^?H2Q]?=A750EB2] )0-:;;IEYV3)&Q5MHENC1PN%8C(J,XQZ2XP
M,ALJ:0\KQH U8AU:V'%WE=[%7:L.97<^RFO=Z!M]1KW)'%JC1A8W7<;86L95
M0;5Z>0E6=FF'J\S%C,O58V!MT:389L>0#:'+ M#6M6'SN[-S;0V>*$3 Q*M"
M=-ZLK3KD0S&QJMJ(V>O!(Q&=0J(U.V/="3T(L*>PM+E<I-2;G^4ORVF@*I3>
MKNX <D9==7CXVO+-9E6>,]7*A:HM<A:LB>N*W,U7#+2H;BX]WK@./'N1S;H:
M,^73>+I:(K;4<]7JQ5U! ++Z$A2B&W^V]\0P\P"L.V:M4@:W6'&&RCFL=75&
ML64O&\YA/GFF[8HW65R$I\ER16'DH6MM",X M5P!P"M6G/CL[=?.?K;[/NJ>
M:K[>%%]$=>\GA+)7]N\\TV5]N]Y7]+/Q.SI7XT^WWZ/_ %]U#]/_ $_^:OUP
M_P"[G5_O2B^KIWO>J',G=7FS_P Q!L<'[HV_7^ UMVGU)M*QB:K7I-L'E+-"
MLY*F.6JCVFL";T/IA) JU2J:<+#(X<]D%*=85/AQ9OK%$1]N>B&N$EY]K,*2
MP&"(_,5V=B?#S"8R[A^9B4QF*SEA64/8=D>7YIO+*\90[A:\9;5C*5^+.,XX
M!H=HVM3:3BPRK?,EUT%6A]2(3K41@2<5I_W:&9H -"&DHZ)&9Y!)*(TU/C,,
M9S!;)#'WE^9DJ6T!LL&SP9YPN";C$6'1+09U)&5$RP',>NHT^6RT!(J7EHJ]
M#9'OJ)-QT^5#\IG*_*2YY20,RY.A,I\IV9%:3Z0B'Y3DAI"?2W,IPW%\:EXQ
MZ0O*DX0Q_P :K*DX2G/CQXP-/V9L -JRAV:_GV9LL=6Q^).!PQMETJ9(29#
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M&L..)C/R6<PSH:2'M(1W#OG)  \*DOM1I#KL9D#?N . . . . . . . . .
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MM=3:UUG<",?*O\&M*KM5K '?<;_0J:$E)SX_(2I0%MN . . . . . . . .
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M5@O^K*38:P/J-UI:Q(JO'!!"T6Y9:VRK'M"^4H9L0T0H]6C5P5>+K HU=PP
MAN6>Q;(N38E5B70R[ &[:Y9V"6[%:+SL!;;NP]>].+'C<TICU=XT6C:%XUBB
MOPIV0F$ _29T[5=^G>2(3@9A\7+6/0F"Y$SE\_/]07OX!7/M)\6==^?SJQ]I
MG4O-.D;ZF^KJO[J>?KM$KS<H/2&OM,HL9S,*BN?5?XIR'SV=H/M,[=YIU??D
M/H%)]U,B9IN*_?NO:IQ8SF84C@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@%:M.?'9VZ^<_6WV?=4\U7V
M\*+Z(Z]Y/"63OAY]Y*]GEG8TK\:?;[Y^ZA]E?KASJ_WI1?5T[WO5#M)W5YZ1
M![(V_D9^M]D-(W"J1;O6=@BC%7F;)B:@9*1(I?.$[)GV2+4853DPW!R"$*?)
M/3H,5EZ;$CP5QIL0KB7ZIDL3EYA03=P!P##R+""B'1=8E%QT>QG!IDP'!O2V
M&RI0579 :*>(P8*EXD2H0>38@+!&0RVIJ(Z8'(?4A4MG"P/FNGQ]I!C;"*01
M0.+1DRXB"X<M7R26E*4G&)@8["'%Q[WC3GQQY\*,_C'B5EOR5)5D#+/,M2&G
M6'VFWV'VULO,O(2XT\TXG*'&G6UX4AQMQ"LH6A:<I6G.4JQG&<XX!"9\-I$5
ML*G5XEKFFS+WL*59C0J2S1J],()15(C!@_:3!)<'$F+&C3R : HHMQZ0X?L
M:/C&5RUOL@3;EQO#B6LK1AU:%N);RI.'%-MJ0EQ:4>/RLH0IQM*U8QE*5.(Q
MG.,K3XP(V'[DU>6V*=U,,NH4AL*L ';/8ZW#==DO @S$J!#?>+SFF5BA\MAX
MJ,4^)E3FBS,4A#G.P40I#4A0&M5[L'I<W7%V&N6AM\1[IZW6&8[5=L0TG/L-
M_P#5I&JMC:].#0311BVQ#T&P"#(\=)%%PDMZQQR#PEB9/9 WZN7VOVBQ7RJ#
M7)+9W7!L6$LL&8QB.XA9NMB+2()0<><7F8'(CBZ6(I!.$-N$AQ@?Y.'QLC&
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MYN&4B$:MJ?.P+19*I R&L4<ILHS--L"2#6IJ4/< E;7TZ^63L;H E>8#8S8
M3II<9VX849I,9L<=OE[U'[G!\R%'?EQH+\LG2+Y)BQ$2I#;"Q99B.\XW'\M8
M%[^ 5S[2?%G7?G\ZL?:9U+S3I&^IOJZK^ZGGS^NP2O-R@](:^TROG]-DL9S,
M*B@PVK'KQT=[#4RK#G"]FMDSO/7*\*:=CL.DC1K=>]!PN V]+=8BM.2YLAEA
M#DA]EA"G,*==;1A2L:=7WY#Z!2?=3(F:;BOW[KVJ<48H72/?&KNSW54E5*NK
M&A'P$C9.R(7K(.A&GMZE.N)K5=_0W"P23)E#KZ656BTEP2P3:P?8).-*BQ,J
M<?S"GA_+Y_U-<UGU][6R*UK6C670EHJ:-+=+NW>A'K#-MU'(0+O?K[&')J"Z
M[&%6.7.:#F&H4-(XJ7;@X<F/367F8D<<B9+ Q!GP;AE=7N3,+13SQ:9X.F@L
MC$+LC;JYG=8=)L>2QEWTBT*9D;#@QW![,>US,J@18TIV*.*ML29;2P^?GY^T
MZ^\NHW8&Z[)W20@==K$?V1LYKJ&QI_L9BZU: WIFS:UJ%';V?:".'K/'L$'/
MG89&$LH%&$IIJ6+D#,HS%?B/2@)RJ?5O<,?N_8=AW^N[2D/8[+D=HTC;E.":
M>EUJ5JF16&A0NCV_8AFV0MO"*P/&*E5DGK(97" .1);BE!C*ENN$6N-FW^G\
M;;/E;!_'Y_#Y3QEI>AW6LII'KN8;+5%-"WO?9VP7+D;G34%2\EQF[7G.MWI\
MR,0)Q<CPU>*CWQ<""XAF)'DN(5';E.2$\Y!032_3;;4C%,!V/KB4H)NJ]?>Q
M-&[-7FQ62G&A_:B^7J!AFB88DB;48+7-"+$VBYMG[I!#Y .H;$,.8PPQY8%K
MG^LMVK_@G'.OE+UND+M\MU]K<$W21#XB 0F[1EC #MK7*(MD&A+IJ44BRW)Q
M'UGYJ0^WE:)2\91G(Y5;55>%;2L.SO!X&AQ#M25U9I21%)16^G%CZV2QUD2T
MX/O0>T#G>P%FK?IUE2D=:'Q @>NSGRB8Y(XVAY,69/=ERTO#@W@)U0VU([HV
MJZ;)J>SB#4WLQ.V94-J5$#IHA6"&H98)L7"H-RV$=ML';8:H0P3TRIG-8C*Z
M1"3U(9G#8SBUX(M@1;7>J^S:%IE>GH'2D02;@]G-@S[]:Y%3U)L!ZVZ_*3=J
M3M56O7E3M&Q*[72R:Z+L .I2Y=\RP[3A95V2'"SIC$IT6.?Y?/BX/];=@[6O
M>KG86M.](2A72=GMFTM;U*GZ_N\?9HO4M\TS5*&,W=<3\XD,L<VZHO6M=I4Z
MIOCIP0[1!YN+8Q6:Q6ELO1AY")@<;?X[/\MC8_H?H;JSLG7.MKEJP)TL"%1V
M>V]L.VNS/U356P,6G3Q6?LB=K,]KBDV?85;KU@DTP>9'5MZ)L+,5BJ#[ Y,%
M"9\Z/+4( [6D.G^U*(<Z,7#:77$C>+!2M<;NU9<YB9U&*F=4V%>['+%HZY&9
M$RS-QY("HU!R:L')K$HQ+!07LPX4/$A42$\'B_AXCMZ>ZQ[>HI7K'*W;U9L.
M] %<ZUT_7M> LV>D93H?<@O:U@L9VT%6#5L@1Q62-?FUZ2J[U91@PPT#2'88
M=SGS61RMGYKS>+A+>>$AT_=MHB-4E-<ZOL.U;S1I]R(52MRZSJ^]::(&#(T4
M+0+W'4]DVBLJBC)\;TA8*^U=R8>H\B*1E0F<2Y\/.1P5,V]U#VI:95[O-PZZ
M,;,6,[TZ=V][AQ,RJSI%KT]&T=4*;LX93<6(Z/B/"W;*.C0U"34P4\29K[3[
MR,-,ID9#Y^?P-BUYU9V\/[@D[_=:1M: ZUV#+[-H>P*<&TJNO-ZDF4Y(H!K*
MV[(FW./M,-708A:Z7-UF)!$ZVF;#AE0ZE-+65; D[I'U8F" V]-6;6T)F'HX
M^U3W*N5W)4=7#]X6P^U,MA$ZU>SVLK+8X=[=I,LI">IFU2F0EQ<E3I#D57D0
M8CL,%^?Z'J31J%3-:5N%4*#6@]3K8]3[L80$@L0(GI,QY<F=.>0RA.91$C+<
M=FDB,G+LTC->>F3'WY+SCJ@-NX X X X X X X X X X X X X X X X X X
M!6K3GQV=NOG/UM]GW5/-5]O"B^B.O>3PED[N\^\E?9O>5\K^!V=*_&EV^^?R
MH_97ZX?[>/\ U?Y.</\ >E$]6SO?%4YSF1NKSTB#FO1MX_MMV/YEC.992=(D
M-'&!\X27@0B@HG$D0"0PC%8FCR$&6TMB5"FPY*'8\J))86MF1'?;<9>:6IMQ
M"D*SC(&M4O76O]<0I0W7M'J-&'SI*9DZ#4*X(KD29+2TEE,J7'#PX;4B0AE"
M&4//)6XEI*6TJPA.$X W+@#@#@&/EB14^6+(3AL"9/!RGYH6;*AQY$L1,E0)
M8J5+&2'6UO0),D9/FCGWXJVG'H,R5%<4IA]UM0&0X X X!CX(@4,>)R!HR /
MD&R'K8R_"AQXKQ8IZ%"&^LB3K#:%SI_JX:/@>ER5.R/0H,.+YSS$9E" ,AP!
MP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#'BQ(H'!:&!1L 0.9<DNLP!D./ A-
M.S)3TV6XU%BMM,-KE3)$B7(4A&%/27WGW,J<<6K(&0X X!CVA(J.3FFF!L!D
MP2B0(!$LU#CMDI\$4Y.>%PIDY#>),F(.=*$W8,=YU;,1PA.7'0VJ6_EP#(<
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MI]OOG\J/V5^N'.K_ 'I1?5T[WO5!(W5YZ1![*V^;?Y%C.9A2. . . . . .
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M--;>2-JCMI8=%6N-'RV4C,#@NCW0FE)NA>H!RQ!S5<$8[1=/R^SP-CG^L2@
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M4;7I !4Q!529,=HS:[S#6AU45>$@5AB%KAJVR@-G0X;%\JABS;!LNJV; #E
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M0%H/EI1B-7SSK\N>- ]+N . . . . . . . . . . . . . . . . . . .
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M-S 80ZIB/BQIK1^IQ")%AKR4DUC@]F,(&MS,N,PI;[4YE&)46,ZT!NW ' '
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M4!>3@%<^TGQ9UWY_.K'VF=2\TZ1OJ;ZNJ_NIX2O-R@](:^TRBQG,PJ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M_EU7UA^OW:W[MG&ET/#*KV:T^*BZ>^*2UQF;F@]>]S_U5]8?'\_NUO\ -_\
MXU_Z?T_Z/T<:71,,JO9K3XJ+I[Q+6STF;Y_JOV;'V[)TB,SM^8'S11;3O50H
M+)Q)$ D,([TV?-'D(,MI;$J'-AR>M#L>7$DL+6S(C/M+9>:6MMQ"D*SC+2Z'
MAE5[-9_%1=/?'):XS-7_ .HA&S&IMOQ0A2M1>H_0N-7#DB!,-@&+U9V0AB6+
M4\X,E%!3?51, A('+D/K@/RV'G8BGWE1U-Y<7E32Z'AE5[-:?%1=/>):XS-S
M0D2&YVW&B6 ([2_5 >#BPDC8H:#O#9L,7%'(:\PB#&@1NL[<5B&AC_ HC--(
M92W_ (-*,)_1QI=$PRJ]FM/BHNGO$M<9FYH196-0;^KE'U[0)VA.IEX#:JBL
MP=?R=@;EN]I+5>%!5AH/'$SI?55'H.0@UJ$&&RXC+,_ P9 3,ES);3LMYI=$
MPRJ]FM/BHNGO$M?/^\S<T-Q?JG8N3;H^P)/6[I:_?(K*(T6[/[4O+UNC1T,J
MCH8CV5SJ[DRRRB.M;"&FYB4)96IK"<(5E.6ET/#*KV:T^*BZ>\2UQF=FAW"
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J#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img134051827_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_10.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI8VAA96P@
M4F%I8FQE    !9 #  (    4   0J) $  (    4   0O)*1  (    #,S8
M )*2  (    #,S8  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,#(@,38Z-3,Z,3@ ,C R,SHP
M,SHP,B Q-CHU,SHQ.    $T :0!C &@ 80!E &P ( !2 &$ :0!B &P 90
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" %2 E8# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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MF#NST_$4 =915'1M8L?$&CVVJ:5-YUI<INC?:0>N""#R""""#T(J]0 4444
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MN_\ ^0E<_P#75OYFND\#_P#+Y_P#^M?%Y?\ [\O5_DSZW'?[D_1?FC%\1?\
M(PW?^^/Y"M#P7_R%Y?\ KB?YBL_Q%_R,-W_OC^0K0\%_\A>7_KB?YBBA_P C
M'_MY_J%;_</^W5^A'XO8C7C@D?NE[_6H?"[,?$5OEB>&[_[)J7QA_P AX_\
M7)?ZU#X7_P"1BM_HW_H)IS_Y&7_;WZBC_N'_ &[^AVU[JMEI\BI>3"-G&5!!
M.1^%0P^(-,N)TAAN@TCG:HVGD_E7/>-O^/\ M?\ KD?YUCZ)_P AVR_Z[+7I
MU\SK4\5[%)6NE_6IY]'+Z4\-[5MWLV>ET445] >&%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV(IFD_\ (Z>(/]RU_P#0&H XV_\ ^0E<_P#75OYFND\#_P#+Y_P#^M<W?_\
M(2N?^NK?S-=)X'_Y?/\ @']:^+R__?EZO\F?6X[_ ')^B_-&+XB_Y&&[_P!\
M?R%:'@O_ )"\O_7$_P Q6?XB_P"1AN_]\?R%:'@O_D+R_P#7$_S%%#_D8_\
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MKP_>R:N;66YT_4)K%KJS!$-T$QB1,]CG'U!I#.RHHHH **** "BBB@ HHHH
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M:"7SK>.4#&]0V/3(I]06/_(.MO\ KDO\A4]?10;<4V>%)6DT@HHHJB0HHHH
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M[+;Q[(TPB@*HR3T'4]237!:IH=\OC>:ZU#4$NELKFX,+^3ME?>2,2-G! ''
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M %XR?^S5=+XT/)?XL_\ #_D>9#H*]2\ ?\BD?^NTG]*\M'05ZEX _P"12/\
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M!T?_ *"M>75]3DW\&7K^B/0QV\/1'J>B_P#)-!_UZ3?^S5\\K]T?2OH;1?\
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MX_X1ZQE,C2O#.\*L&<[B<,<C).:Z:RGM+FQAFTZ6&6U91Y3P,&0K_LD<8^E
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M]]?K7HWQ*_Y ]G_U\?\ LIKSE?OK]:^QRO\ W5?,]/,/]X?R/0?BQ_R3]_\
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MYYN7<\#.X\DJ<>R/=_A/_P B!%_UWE_G7GLG^M?_ 'C_ #KT+X3_ /(@1?\
M7>7^=>>R?ZU_]X_SKW\D^W\OU.BM_NM#T_R/1/AK_P @F]_Z[C_T$5Q&O?\
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MZA3_ .1G_P!O/\QWQ?\ ^1V3_KT3_P!":LSX;_\ )0M,_P!Y_P#T!JT_B_\
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M]7^IV/P6_P"0WJ?_ %[I_P"A5A?%#_DH5]_N1?\ H K=^"W_ "&]3_Z]T_\
M0JPOBA_R4*^_W(O_ $ 4=!U/^15#_%_F6/A+_P C['_U[2?TJ[\9O^1KL_\
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M1W9=_&^1\_2_ZZ3_ 'C_ #KV#X+?\@'4O^OH?^@"O'Y?]=)_O'^=>P?!;_D
MZE_U]#_T 5\BMSR\H_WQ?/\ (\R\5?\ (X:O_P!?DO\ Z$:[CX*?\A35O^N,
M?\S7#^*O^1PU?_K\E_\ 0C7<?!3_ )"FK?\ 7&/^9I+<,#_R,5ZO]3G/B7_R
M4+4O^V?_ * M7_A%_P CP?\ KUD_FM4/B7_R4+4O^V?_ * M7_A%_P CP?\
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M7[H^E?/8K^//U?YG'F_P4?3_ "/<O@__ ,B.W_7W)_):\5O_ /D)77_7=_\
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M_P!?D7_H0HZAC_\ D8/U7Z'LWQ*_Y ]G_P!?'_LIKSE?OK]:]&^)7_('L_\
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MCLG_ %Z)_P"A-69\-_\ DH6F?[S_ /H#4^H5/^1G_P!O+\SJ/C7_ ,?VD?\
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M?\CKK'_7Y)_.CH+$_P#(NH^K_4['X+?\AO4_^O=/_0JPOBA_R4*^_P!R+_T
M5N_!;_D-ZG_U[I_Z%6%\4/\ DH5]_N1?^@"CH.I_R*H?XO\ ,L?"7_D?8_\
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M-=G_ ->8_P#0VHZ!'_D5/_%_D<]X"_Y'[2/^N_\ [*:^BZ^=/ 7_ "/VD?\
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M_P .:E]NTWQ2_G;#'^\T]&&#C_:]JFVI\U'+*ZQGM]+<U_Q.6^+_ /R.R?\
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img134051827_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_11.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI8VAA96P@
M4F%I8FQE    !9 #  (    4   0J) $  (    4   0O)*1  (    #-#(
M )*2  (    #-#(  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,#(@,38Z-38Z-#@ ,C R,SHP
M,SHP,B Q-CHU-CHT.    $T :0!C &@ 80!E &P ( !2 &$ :0!B &P 90
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" '' CH# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M?4OT444R@HHHH ***X?XNSWEOX#+VLMW#:&\@74Y;+/G1V9<><4QSG;Z=LT
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MKU<A57VDY81.UM;[>7S,,*Z%VZ:?X'?:?\"/%>GV@AC2S8YRS&YZG\N*M?\
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M^%+>+O\ GG9?^!/_ -:C_A2WB[_GG9?^!/\ ]:L;_A8WB_\ Z#]W^:_X4?\
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M+\#9_P"%+>+O^>=E_P"!/_UJ/^%+>+O^>=E_X$__ %JQO^%C>+_^@_=_FO\
MA1_PL;Q?_P!!^[_-?\*+X;L_P#FP?:7X&S_PI;Q=_P \[+_P)_\ K4?\*6\7
M?\\[+_P)_P#K5C?\+&\7_P#0?N_S7_"C_A8WB_\ Z#]W^:_X47PW9_@'-@^T
MOP-G_A2WB[_GG9?^!/\ ]:C_ (4MXN_YYV7_ ($__6K&_P"%C>+_ /H/W?YK
M_A1_PL;Q?_T'[O\ -?\ "B^&[/\  .;!]I?@;/\ PI;Q=_SSLO\ P)_^M6EX
M=^#6M1>(K*77[>UDT])"9ECN2&(P>F,'KCO7<^'O&'B2;PWITDG@_4KYGMD)
MN1=6X\X[1\V"X//7I7 ^'?BYXS/B2ZTU=*/B*)+AU"11%98U#$8W*,<>X_&N
MQ4*$6GJ>@L-A8.,M?Z^1W'BGX/Z+JVB-9Z'&NG7#RH6N))99<(#D@*6P35CP
M?\(?#WA&ZBOHVN;W4(^EQ+(5 /LBX'YYKM+"XFN["&>ZM)+*9UR]O(RLT9]"
M5)!_ U8KO5*%^:QZBHT^;FL%%%%:FP4444 %<=\3M?U#P_X4ADTBZ@L;B\O[
M>R^W7"!X[19'VF5@>, >O'-=C7%_%75)]-\$&.UL[&Z>_NX+$_VC'OMHA*X7
MS)%[J/YXH \WA\6:K%KT_B71M5LH-+77H=&M--ALXE_M5-RI-*& W$Y;<"#@
M8KWRO,-,^'OBVTU#2)I]9\-M;Z6^8(H- 5#"C$&18R&^0L!U KT^@ HHHH X
M?QY'X2CU.QF\13W]KJ$\$L,+Z8UP)I8 5+HWD@DIDKU[GBNJT2*PAT&QBT>#
M[/8) @MHO+*;(\?*-IY''8\UQ'CZUT__ (2NSO=37Q- 4TZ6*VO-%,A7>74F
M,B(%PYVJ1GY#C!Z5U/A,:S+X&TQ?$;O%J[V:"Y<!=RR%>I'3=Z]LT 4OB0MH
M_@.\74SMLFFMA<')&(_M$>[ISTS7#?V;\&_^?U?^_P#/6U\3M!U,?#G4@->U
M*^),*BV:*#$I,R #Y8P>OH:\9_X0[Q+_ - #4?\ P&?_  KS\7-QDK13^1Y6
M/J.$HV@I>JN>F?V;\&_^?U?^_P#/7(ZUX4^"[^+]-F'B%K6VD+?:+)/,99CC
M*DN1E 3P?7C&.36 ?!OB8J<:#J(..#]E?C]*\_UGPKXCL-<BLM2TN]%[>-_H
MZ- P:?\ W1CGZ#I7J9%&56M*S5/3HM7_ ,-_7<PPU24I/W%'Y'T8NE_!E%"K
M>(J@8 $\_%+_ &;\&_\ G]7_ +_SUY3IO@CQ;!81QW>B:B\@'_/L_ ],XYJU
M_P (=XE_Z &H_P#@,_\ A7AUIN%245!2L][/7S.>5:2;7LHOY'IG]F_!O_G]
M7_O_ #T?V;\&_P#G]7_O_/7F?_"'>)?^@!J/_@,_^%'_  AWB7_H :C_ . S
M_P"%9>UE_P ^U]Q/MY?\^5]QZ9_9OP;_ .?U?^_\]']F_!O_ )_5_P"_\]>9
M_P#"'>)?^@!J/_@,_P#A1_PAWB7_ * &H_\ @,_^%'M9?\^U]P>WE_SY7W'K
M&F>%OA5K-PT&F/\ :947>RI<39 SC//UJSJ/@7X:Z3:&ZU&-K> ,%+M<2XR>
MG0UR'PTT'5]*\074VI:7>VL;6Q57DMV )W*<=*Z7XAV%YJ?A%[;3[*YN9C-&
MPCC@8G /)Z57M';^&ON+55\M_9+[BI_9OP;_ .?U?^_\]']F_!O_ )_5_P"_
M\]>9_P#"'>)?^@!J/_@,_P#A1_PAWB7_ * &H_\ @,_^%3[67_/M?<1[>7_/
ME?<>F?V;\&_^?U?^_P#/71V?BOX>6%C#:6NLQ)#"@1%)D. /<BO$/^$.\2_]
M #4?_ 9_\*/^$.\2_P#0 U'_ ,!G_P */;2_Y]K[@6(FO^7*^X]5U%?A'JNH
M2WM[J"//,07833#.!CH/856_LWX-_P#/ZO\ W_GKS/\ X0[Q+_T -1_\!G_P
MH_X0[Q+_ - #4?\ P&?_  H]K+_GVON#V\O^?*^X],_LWX-_\_J_]_YZ/[-^
M#?\ S^K_ -_YZ\S_ .$.\2_] #4?_ 9_\*/^$.\2_P#0 U'_ ,!G_P */:R_
MY]K[@]O+_GRON/3/[-^#?_/ZO_?^>C^S?@W_ ,_J_P#?^>O,_P#A#O$O_0 U
M'_P&?_"C_A#O$O\ T -1_P# 9_\ "CVLO^?:^X/;R_Y\K[CTS^S?@W_S^K_W
M_GH_LWX-_P#/ZO\ W_GKS/\ X0[Q+_T -1_\!G_PH_X0[Q+_ - #4?\ P&?_
M  H]K+_GVON#V\O^?*^X],_LWX-_\_J_]_YZ/[-^#?\ S^K_ -_YZ\S_ .$.
M\2_] #4?_ 9_\*/^$.\2_P#0 U'_ ,!G_P */:R_Y]K[@]O+_GRON/3/[-^#
M?_/ZO_?^>C^S?@W_ ,_J_P#?^>O,_P#A#O$O_0 U'_P&?_"C_A#O$O\ T -1
M_P# 9_\ "CVLO^?:^X/;R_Y\K[CTS^S?@W_S^K_W_GH_LWX-_P#/ZO\ W_GK
MS/\ X0[Q+_T -1_\!G_PH_X0[Q+_ - #4?\ P&?_  H]K+_GVON#V\O^?*^X
M],_LWX-_\_J_]_YZ/[-^#?\ S^K_ -_YZ\S_ .$.\2_] #4?_ 9_\*/^$.\2
M_P#0 U'_ ,!G_P */:R_Y]K[@]O+_GRON/3/[-^#?_/ZO_?^>C^S?@W_ ,_J
M_P#?^>O,_P#A#O$O_0 U'_P&?_"C_A#O$O\ T -1_P# 9_\ "CVLO^?:^X/;
MR_Y\K[CTS^S?@W_S^K_W_GH_LWX-_P#/ZO\ W_GKS/\ X0[Q+_T -1_\!G_P
MH_X0[Q+_ - #4?\ P&?_  H]K+_GVON#V\O^?*^X],_LWX-_\_J_]_YZ/[-^
M#?\ S^K_ -_YZ\S_ .$.\2_] #4?_ 9_\*/^$.\2_P#0 U'_ ,!G_P */:R_
MY]K[@]O+_GRON/3/[-^#?_/ZO_?^>C^S?@W_ ,_J_P#?^>O,_P#A#O$O_0 U
M'_P&?_"C_A#O$O\ T -1_P# 9_\ "CVLO^?:^X/;R_Y\K[CTS^S?@W_S^K_W
M_GH_LWX-_P#/ZO\ W_GKS/\ X0[Q+_T -1_\!G_PH_X0[Q+_ - #4?\ P&?_
M  H]K+_GVON#V\O^?*^X],_LWX-_\_J_]_YZ/[-^#?\ S^K_ -_YZ\S_ .$.
M\2_] #4?_ 9_\*/^$.\2_P#0 U'_ ,!G_P */:R_Y]K[@]O+_GRON/3/[-^#
M?_/ZO_?^>C^S?@W_ ,_J_P#?^>O,_P#A#O$O_0 U'_P&?_"C_A#O$O\ T -1
M_P# 9_\ "CVLO^?:^X/;R_Y\K[CTS^S?@W_S^K_W_GH_LWX-_P#/ZO\ W_GK
MS/\ X0[Q+_T -1_\!G_PH_X0[Q+_ - #4?\ P&?_  H]K+_GVON#V\O^?*^X
M],_LWX-_\_J_]_YZ/[-^#?\ S^K_ -_YZ\S_ .$.\2_] #4?_ 9_\*/^$.\2
M_P#0 U'_ ,!G_P */:R_Y]K[@]O+_GRON/3/[-^#?_/ZO_?^>C^S?@W_ ,_J
M_P#?^>O,_P#A#O$O_0 U'_P&?_"C_A#O$O\ T -1_P# 9_\ "CVLO^?:^X/;
MR_Y\K[CTS^S?@W_S^K_W_GH_LWX-_P#/ZO\ W_GKS/\ X0[Q+_T -1_\!G_P
MH_X0[Q+_ - #4?\ P&?_  H]K+_GVON#V\O^?*^X],_LWX-_\_J_]_YZW=*^
M&WP^US3UO=)MWN;9B5$BW,H!(X/4UXM_PAWB7_H :C_X#/\ X5ZU\/O!^OCP
MA#YFOZKHK>;)_H8MXQL^;K\ZD\]:WH2]I*TJ:^XZ<-+VL^6=)?=_F>B:8VF6
M*)HNGW$6ZQB6/[,)0TD:X&W(SGICDU9M;*UL8S'96T-NA8L5B0*"3U/'>O$?
M$'PC\6ZU\0IKRWU0K"B1@:M<2!97(4=%CQR.G;I7KOAG1K[0])6UU/6[K69A
M_P M[A5!'L,<X^I)KT(2DW9QM8]:G.3=G&R1L4445L;A1110 4444 %<9\56
MT3_A!98O$=A<ZG;W%Q%##86LK1R74[-B.,$$=3_*NSKC_BE;Z1+X%GFUS4Y=
M)2TFBN;:]A3?)#<(P,91/XCGC;WS^- 'EVG^&;/PKK6D7?BKP#=Z/8R7D44-
M[;>(IKI;:4L/+$L>X?*6P,\BOH&OG_3->U?Q3XBT?3?B1JVI66FF\CDM(I]
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M)C_YOQ1B_P#"]?$?_/AIW_?#_P#Q5'_"]?$?_/AIW_?#_P#Q5;7_  I30O\
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M\_/P8?5\/_S]_!GC&%]!1A?05[/_ ,+LT/\ Z%=_^^H_\*/^%V:'_P!"N_\
MWU'_ (4>QH_\_/P8?5\/_P _?P9XQA?0487T%>S_ /"[-#_Z%=_^^H_\*/\
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M .^H_P#"C_A=FA_]"N__ 'U'_A1[&C_S\_!A]7P__/W\&>,87T%&%]!7L_\
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MCC<(VW=SEL9 ''7(["N/^(2:0MG8W'B"YO7MHY66+2K-V#:C,RX1-J$,Q')
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M_P#\37 ZW\ _&>G>(+.QM+6.^BOF(6ZA<F.'N?,) V\<Y[]N>*TO^$W\4?\
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MZ_\ \31_PHWQ-_S]:=_W]?\ ^)KD_P#A-_%'_0P:C_X$-1_PF_BC_H8-1_\
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MYX)_W[N*/M7P9_YX)_W[N*\\_P"%?>+O^A>OO^^!_C1_PK[Q=_T+U]_WP/\
M&CVM3_GVON#VU7_GRO\ P$]#^U?!G_G@G_?NXH^U?!G_ )X)_P!^[BO//^%?
M>+O^A>OO^^!_C1_PK[Q=_P!"]??]\#_&CVM3_GVON#VU7_GRO_ 3T/[5\&?^
M>"?]^[BC[5\&?^>"?]^[BO//^%?>+O\ H7K[_O@?XT?\*^\7?]"]??\ ? _Q
MH]K4_P"?:^X/;5?^?*_\!/0_M7P9_P">"?\ ?NXH^U?!G_G@G_?NXKSS_A7W
MB[_H7K[_ +X'^-'_  K[Q=_T+U]_WP/\:/:U/^?:^X/;5?\ GRO_  $]#^U?
M!G_G@G_?NXH^U?!G_G@G_?NXKSS_ (5]XN_Z%Z^_[X'^-'_"OO%W_0O7W_?
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M2?\ "H?"/_0U-_W^BH_X5#X1_P"AJ;_O]%2Y,5_-^(>SQW\WXG-_\+L\6_\
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M#_\ P'/_ ,51_P +L\6_]0__ ,!S_P#%5TG_  J'PC_T-3?]_HJ/^%0^$?\
MH:F_[_14<F*_F_$/9X[^;\3F_P#A=GBW_J'_ /@.?_BJ/^%V>+?^H?\ ^ Y_
M^*KI/^%0^$?^AJ;_ +_14Y/@]X4ED5(_$\CNQPJK+$23Z 4<F*_F_$/9X[^;
M\3(T+XTZW+X@L8=<FL(+"24+/((""J]^<FNU\3_&#0M(T@7>BSPZQ*LJB2W1
MV0B,\%@2O8X_.H]$^#6E:)KEIJ<.I7DLEK()%1PFUB.QXKK/$WA/2_%NEII^
MKQN;99EF*Q-L+%<X!/7'/:NRC"NH-2>IWX>&*C3:F]?O,/PG\6?#/BVXCM+:
M>6TOY.%M;E,,Q]F&0?SKMJS-%\-Z-X=M_)T33;>R3&"8D^9OJW4_B:TZZH<U
MO>W.Z"FH^^]0HHHJRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU7_H)7?_ '^;_&C^V]5_Z"5W_P!_F_QH]GC?^?B^X.?"_P C^\Z+_A6VI_\
M/Y:?FW^%'_"MM3_Y_+3\V_PKG?[;U7_H)7?_ '^;_&C^V]5_Z"5W_P!_F_QH
M]GC?^?B^X.?"_P C^\Z+_A6VI_\ /Y:?FW^%'_"MM3_Y_+3\V_PKG?[;U7_H
M)7?_ '^;_&C^V]5_Z"5W_P!_F_QH]GC?^?B^X.?"_P C^\Z+_A6VI_\ /Y:?
MFW^%'_"MM3_Y_+3\V_PKG?[;U7_H)7?_ '^;_&C^V]5_Z"5W_P!_F_QH]GC?
M^?B^X.?"_P C^\Z+_A6VI_\ /Y:?FW^%'_"MM3_Y_+3\V_PKG?[;U7_H)7?_
M '^;_&C^V]5_Z"5W_P!_F_QH]GC?^?B^X.?"_P C^\Z+_A6VI_\ /Y:?FW^%
M'_"MM3_Y_+3\V_PKG?[;U7_H)7?_ '^;_&C^V]5_Z"5W_P!_F_QH]GC?^?B^
MX.?"_P C^\Z+_A6VI_\ /Y:?FW^%'_"MM3_Y_+3\V_PKG?[;U7_H)7?_ '^;
M_&C^V]5_Z"5W_P!_F_QH]GC?^?B^X.?"_P C^\Z+_A6VI_\ /Y:?FW^%'_"M
MM3_Y_+3\V_PKG?[;U7_H)7?_ '^;_&C^V]5_Z"5W_P!_F_QH]GC?^?B^X.?"
M_P C^\Z(_#74B"#=VA!Z\M_A7*V_[.9_M:.2[UM/L&_=)#'$=^,_=#$X_''X
M5Z/X9U;5F\/VY&F3WWWOW[7* M\Q_O'/M63I_BW7_P"UI[:*U.I(LK#8$PR#
M/3<./SKQ,50KXUN-1I\GFE_7S/<P..67+FH-KG6NE_S_ $/08HTAA2*)=J(H
M50.P'2G5%;22S6R// 8)&&6C+!MOXCBI:\EJSL=5[ZA1112 **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *P/&FE7VL>''M-+T_1]0N#*K"#6HV>W(!Y)"\Y]*WZ\K^*GBW4K&
MSN+"X\-^((].6>)(M4TG48H))G;&U$'+<L=N,<XH P+W2-<\(:EH]]K/@SX?
M0V$NHP6\EW8V3^9;%W 5QG'?&",X.#TKW.OGB.U?3O$&@W'BWPUXVFMI-1A6
MV.L:Y'-;13,P",ZCH0>0#C)XKZ'H *P_$OB*QT2.WMKRUN[Z;4"\4-G90&62
M4!<N<<  #J21UK<KF_&5W<PV<-L-(U#4-.NP\5W+I<Q6YM^ 5*A2&()R"001
MQZT <IJQ^'M_IOANX_L*\U436KP:7#80RF6*&+ =2H8%0IP#GOQ7?:!#:P>'
M[./3[.>RMA$#';W 821@\X8,20?J:\JM?"SVGA_P^GBKPAJ>I16MO=PVXL;C
M$UHC2AHDECC906*!<N"<,.>N:]%\%V&K6O@'3;'Q'/*VI+;;)W,NZ1<YP"_=
M@I +=R,T ,\?M G@RX:\&;<7%J91C.5^T1Y_2L?[?X#_ .?0?]^7J+QYX8,?
M@VX:#4]6N9//M@D4UXS*Y,\8 (/7K7/GPCKN?^0;+^:_XU[&74Z4XRYZCCZ.
MQYN-G4C)<D.;Y7.D^W^ _P#GT'_?EZ\]\:O\&_\ A,=(N-6CGCN/,_TB*WC(
MC=<?*9AUQG'3D]^*W3X1UX@C^SIAQU!7C]:\0\7?"_Q=I/B6*";3[N^;4YBM
MM,%W&5NNUB. 0/7C S7K0H4+Z5G_ .!&&'G4E+WH)?(^DX]0\ &-?*M4\O:-
MNV%\8[8]J7[?X#_Y]!_WY>N!\*?#CQ-H6@16=Y;SW$@^8C<I6//\*\]!6U_P
MB.O?] V7\U_QJ?88?_G\_P#P(QE4K)M*FG_VZ=)]O\!_\^@_[\O1]O\  ?\
MSZ#_ +\O7-_\(CKW_0-E_-?\:/\ A$=>_P"@;+^:_P"-'L,/_P _G_X$3[6O
M_P ^E_X"=)]O\!_\^@_[\O1]O\!_\^@_[\O7-_\ "(Z]_P! V7\U_P :/^$1
MU[_H&R_FO^-'L,/_ ,_G_P"!![6O_P ^E_X"=)]O\!_\^@_[\O1]O\!_\^@_
M[\O7-_\ "(Z]_P! V7\U_P :/^$1U[_H&R_FO^-'L,/_ ,_G_P"!![6O_P ^
ME_X"=)]O\!_\^@_[\O1]O\!_\^@_[\O7-_\ "(Z]_P! V7\U_P :/^$1U[_H
M&R_FO^-'L,/_ ,_G_P"!![6O_P ^E_X"=)]O\!_\^@_[\O1]O\!_\^@_[\O7
M-_\ "(Z]_P! V7\U_P :/^$1U[_H&R_FO^-'L,/_ ,_G_P"!![6O_P ^E_X"
M=)]O\!_\^@_[\O1]O\!_\^@_[\O7-_\ "(Z]_P! V7\U_P :/^$1U[_H&R_F
MO^-'L,/_ ,_G_P"!![6O_P ^E_X"=)]O\!_\^@_[\O1]O\!_\^@_[\O7-_\
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M_P #8?\ "N'%1JMKV;M\SS<;&O*2]E*WSL<K_P +F\8?\_-I_P" PKD]9_:
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M_P#'O)_W[-?3'CS6+.#P?/-%<03/'<VKB-91EL7$9Q^E9O\ PLP_] H?]_\
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M)_W[-'V6;_GWD_[]FOH7_A9A_P"@4/\ O_\ _8T?\+,/_0*'_?\ _P#L:/\
M5O%?U;_,/J^&_P"?OX,^>OLLW_/O)_W[-'V6;_GWD_[]FOH7_A9A_P"@4/\
MO_\ _8T?\+,/_0*'_?\ _P#L:/\ 5O%?U;_,/J^&_P"?OX,^:1J&L6&HHMI<
MWEM,LFZ%(G92#G@@#OTK[$\/2:A+X;TZ365V:@UM&;E<8Q)M&[]:\\M_CEX/
MNM<M[:ZM)XWR$^VM$K1QL?0YW;<]\5ZH"" 0<@]#65"FJ;:4KGZ!CJDW0HTI
MTN2R^_3\/0****Z3R HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%/\ XT?ZRXC^K![;"_\ /M_>>X?\*UO_ /G_ +?_ +Y:C_A6M_\ \_\ ;_\
M?+5X?_PD.M?]!C4/_ I_\:/^$AUK_H,:A_X%/_C1_K+B/ZL'ML+_ ,^W]Y[A
M_P *UO\ _G_M_P#OEJ/^%:W_ /S_ -O_ -\M7AY\0ZUC_D,:A_X%/_C7ONA3
MS2>'=.>261W:UC+,S$DG:.2:I<28E_TBXU,++[#^\I?\*UO_ /G_ +?_ +Y:
MC_A6M_\ \_\ ;_\ ?+5Y1XNUS5H/&.J10:I>QQK<$*B7+@*/8 UC?\)#K7_0
M8U#_ ,"G_P :7^LN(_JQ+JX5/X']Y[A_PK6__P"?^W_[Y:C_ (5K?_\ /_;_
M /?+5X?_ ,)#K7_08U#_ ,"G_P :/^$AUK_H,:A_X%/_ (TO]9<1_5A>VPO_
M #[?WGN'_"M;_P#Y_P"W_P"^6H_X5K?_ //_ &__ 'RU>%W'B77(8&DCU?4"
MR\C_ $I_\:ZKX5?$+Q9??$*RL+S4;G4[:]9EFBF._8,$[Q_=QCZ5M2X@Q%1V
M_1'T&6Y13S##5,3!64.[WTNSTK_A6M__ ,_]O_WRU'_"M;__ )_[?_OEJ]'H
MKN_M7%=_P1C_ &?A^WXGG'_"M;__ )_[?_OEJ1OAG?,I5KZW((P?E:O2**7]
MJXKO^"#^SZ';\3P.#]G.\&MQ_:=9MVTP.&?8C>:5[J!T]LY]\=J]ZC18HUC0
M850% ] *=17DQIQA?E/:Q.,KXKE]J[V"BBBK.0**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *Y/XE:;::AX->:\UB+1'T^XBOK;4)L%()HV!0L#U!/&/>N
MLKC/BEI$NJ^#XY()+$'3;Z"_:+491';SK$^3&['@ ^IXSB@#S#3+*\F\:#PK
MXO\ &'AV)=0UA-:FLM/24RW4I".D>YQM13L5L9W'\:^@J^=K$6FI?9[2;Q#X
M6?5-?\0IJFHW$.JQNUFL<B&&"$=78@;01TR?6OHF@ KC/'UOX7N+C2D\1Z+<
M:S?NTBV%M:HS2_=!D(PR@  #))'8=Z[.N-^(6K>(;&UL[3PQI=Y<27CLMQ?V
ML*RM91@<LJ,P#.<X&3@8).<8(!EVWB#P7;:7H4>CZ/?7QC>>[LK*VMGDFM60
MM'*[*Q^4JS,I!.<G !KO-+U.TUG2K;4=-F6>TNHQ)%(O\2G^7TKRZYT:32[/
M0;SPUHOBC3S!:W%J\EN(7NFW2!BLR2;@=[9?S >#UZUVG@'P]<^'_AQI>B:B
MS+<PVQ6;9(249B6(#CN-V,CTS0 OQ"^S_P#"$W/VY!);>?;><A&=R?:(\C'T
MKG/^+;_] *'_ ,!:M>._"L<?@ZX-M>ZK--Y]LJ1S:C*ZL3/& "K-@]>]8)\&
M:_G_ (\#_P!_%_QKTL%A<)7BWB'9K;5?J>;C95(R7)"_RN:?_%M_^@%#_P"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&  .@KYA<_/)R>ESZW%SP<J=-8>+32UO_6K\QU%%%6><%%%% !1110 4444
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MVD^';#3[JY-W/;6Z12W!7'FL!@MCMDY-:%%%;E!1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/_DJG^-4=4^(/P\TJW2+4;2/+/N6W-DKL/\ ;QR /?KQ6=_P@WB#_GS7_O\
M)_C7*^)O@IXGU>\&H60MED?"/!-, 0 .&!&1CVZ\5YV90HPP]Z$^9W6G-?\
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M %%%% 'S3\=/BQK?]OS>%M&%UI%O9R*9I^8Y;EAR"I[)W&.OZ5Z/\$_B3?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\DCZ\@ACMK>."!!'%$H1$7HJ@8 I] Z<T5]*?&!1110 4444 %%%% !1110
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MP ?F]JM>&_!?B'Q=X1\(0>*[G3TT33[&.>)+17%Q.S6Y1 ^X83:KG.,Y([4
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M:P2M&2 QQ\VT]0,DX[T 1^/)$B\(S23+OC2ZM69<9R!<QY%5O^$AT#_H&?\
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M/MGN&:#O*0@)"#U/>O.5^'7B#1[Z&]&D7NJ?:M&L;:2'3]<:Q:VG@A$95R&
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M-T9<LP., #(&<\YXKA=8\'>-)[>?3X;.X:WFT2VLX?L-]#;1B582CBY;'F2
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MM0FU2&PF@5R#%N;#D'&&*]U!X[XKA_$'@[QOJEUJ,+6%Q(K:RMY#Y%]!!9-
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M8W^]&P.&0^ZL"#]*U*X[X5VDUM\/[6:XB:$WUQ<7R1,,&-)IGD0$=OE85V-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!_L[Q-_T,-G_ ."S_P"VU3MX/%TNK7EM)K%K'! D9BF.EG$I;=N'^M[8'YT
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M_;: -ZBN6B@\6OK-U:OK%JMO%#%)'/\ V6<2,Q<,O^M[!5/_  *K?]G>)O\
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M?ZWWI=3B\6:?8-=6^JVM])&R?Z.NFD%P6 (R).."30!U%%%% !1110 4444
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M M;F8$'<R[=W)4$@$ D<UVO2BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#SCX]?\DAO_\ KZM/_2B.K_Q,U2^T
MQO"7]G7<MM]J\1VMO/Y38\R)@^Y#Z@X'%=#XH\,Z?XOT"71]7\W[+*\;MY3[
M6RCAQS]5%+KWANP\1G3?[1\W_B6WT=_!Y;[?WJ9VY]1R>* /&[X^(M0T'XB>
M(O\ A+]9MG\/:K=KIUK;SA8D$6&PXQ\R\[=IX ^M:7VS7?"VO>#-7G\1ZGJK
M:_;7$FH6=Q(# 66V,P\I  $P>!CM7H8\!:,-$\0:4/M'V;Q#<37%[^]^;?*
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H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img134051827_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_12.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI8VAA96P@
M4F%I8FQE    !9 #  (    4   0J) $  (    4   0O)*1  (    #,#@
M )*2  (    #,#@  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,#(@,38Z-3DZ,#@ ,C R,SHP
M,SHP,B Q-CHU.3HP.    $T :0!C &@ 80!E &P ( !2 &$ :0!B &P 90
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" &6 C0# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M59&C9,E3@\, >M:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7!^+OBMIWA[5&T31]/O/$.O <Z?8(6\K(X,C=%
M'3U-=Y5>VL+.TGGGM+6&&6X??/)'& TC=,L1U/UH \B?6?CQJ[":Q\/Z%H\#
M<K'<2;Y%]F^;K^ I\?C'XP^'/WGBCP79:S9CEY-(EQ*H[G;DY^F!7<>._',/
M@JPLRFGW&J:CJ$_V>RL;;[\SXSU[ #J:YO3/BKK=KKVGZ=X[\%W7AZ+4YQ;V
MMV+A9HS*?NJVWH3TH ZCP9X_T3QS:S-I,DL5U;$"ZLKF,QS6Y/9E/T/-=-5>
M/3[.+4);Z*UA2[F01R3K& [J"2 6ZD#)_.K% !1110 4444 %%%% !169KM[
MJMC8K)HFE+JEP7 ,+7 APOKN(/Y5C^$_%FI:YKFL:5K6C+I5SIHA.U;D3;Q(
MI(.0 .U '5T444 %%%% !1110 4444 %%%% !1110 5\[>$]#TO7?VHO&MOK
M6GVU_"B,ZQW$0<*<IR >]?1->"_#W_DZOQO_ -<F_G'0!Z#K_P &_ NO:5-9
MOX>LK.212$N;2$121GL01Z>AX-<%^SOK&HZ;JOB/P!J\[3G192]JS'.U Y5P
M/09VD#_:->YSSQ6UO)/<2+'%&I=W<X"@<DDUX'\"#_PD7Q:\<^+[>-OL4\AA
MAD[/ODW<?@BG_@0H ]&^''Q*3X@W.NQ)IK6/]D7(MR3-O\W)89Z#'W?UIVO?
M$==$^*6A>#3IIF;5XRXNO.P(L;OX<<_=]>]>?_LV$?VKX]7N-30D?\"EIWCR
M5&_:N\#Q*P+I;$L/3/FX_E0!J^+OCY'X8\;:GX7A\-W6HWUML6V6"7)N'90V
M,!20 #[_ $JPOQQ33?A^?$/BWPW>:3=R7C6=MIN[=)<, "6&X*0H[DC\\BN<
M\.VL5Q^V3XBDE4,UO8;X\C[K&.%<_DQ_.ND^-/B[2/#]QHED_ABU\1^(+J;.
MFPW$8/DG<!N!QG);' ZX]J ,S4/C=XPT>Q&JZM\+[^UT@ ,]PUU\R*>Y79Q^
M./K2?%OQVWB'X$_VCX<TFXO=,UFW/GW0<+]B"NH.\=SN!7\*S?&)^,NH>!=7
MN/$<V@:-I:V;O<10IOD9,<ISN )Z=:SM%.?V)[SV6;_TJH T_!GBZ>/]GRY3
MQ+X-EET72],C*//,/+U%2^...,<'O7<Z!X[\-Z%\%=/\42V::)I'DDPV43;R
MI+L B],DD$_G7)7/_)FJ_P#8&3_T,5YUXW,O_#.?PW1V(LFN)//'8G<V/TW4
M >D)\=?$UQIS:W9_#/4I=! +?;#/ABG][;LZ?CCWKM;3XIZ-JWPPOO&>BH]U
M!90N\MJY"2(ZC)1NN#R.?0UV%K':IIT,=HL?V01*L:IC9Y>.,>V*^6_!A1/"
MWQEAT[_D&+&3%C[H.Z4#'X?R% 'H%E\?M3\1:<D_@WP#J.L21QAKS;+MC@;^
MX&VG<<8/0=:Z_P"&7Q4T_P")%K>)%9S:;J5@P6YLYCDKG(R#QD9!'(!!JA^S
MW;16_P $-$:) K3-/)(0/O-YSC)_  ?A7+_"U%C_ &C_ (B+& JYS@>I<$_J
M: /<Z\H\0_&[RO%<_AOP-X;NO%.HVI(N#!)LBC(ZC=@YQT/09XS7J5V7%G,8
MN'\MMOUQQ7AW[+:0GPWXCFGV'5&U/%RW&\KL!&?;<9/UH Z?PA\:(=9\5CPM
MXJT*Z\-:X_\ J8+AMR2\9P&P.>#CC!]:\B\7^(=8U?\ :&TB]U/P+<S7-M:[
M(=&FD#&X4&7$G3&.2<8_AKL?VB1!'XP\!3VH4:I]OPA7[Q0/'C/?&X\?4U8\
M29_X;"\-9Z_V2/\ VO0![!X<8R>'+*5]*&CR2Q"1[  #R&/)4X &<UQ'Q*^,
M=G\-?$&G:=?Z5->1WL#3&6&0 I@D!0N.22/4=:]*KP+XR6L5[^T%\/+>X4/%
M))&&4C((\[.* .K\(?&*[U>UUB^\6^%KKPSIVF6PN3=7#,0X)PJ@%%)8\],U
MD0_'3Q%JMK+JGAOX;:GJ&B1EO],,VQG4=2%"G/X$U/\ M.O<+\(P(/\ 5O?P
MB;_=PQ'_ (\%JCX:LOC/%X6TQ-#OO"XTX6L?V7;&?]7M&WH/2@#T;P)\0M&\
M?^'7U;27>$0-LNH)^'MVQG#>WO7"Q?''6]?N[I_ 7@"^U[3+:4QM>FX\H.1_
M=&T_7KGVJA\(O"]SH'BSQA=^(];\/W"7L;M?VUA=J1;MO8N73^!1EASTK&T/
MP1\0/!L5Q<_![Q3I^O>'Y)V=;9Y$<%AP1SQN[$JPS0!Z?X ^*MAX[TW5&2PN
M-.U'2?\ C[L;@C<O!Q@^F5(Z#!%<9I'[0]]XHA^S^$_ U[JFJ(6::W2X CB0
M' 8OMZGGC':I_AQ\0'US6/$?A_Q)X8M-"\406LDUU);1!?M   .[J<Y8'J<C
MFH?V68K-?A]JLL(3[6^ILLY_BP$3:#[<MCZF@#J?A_\ %VV\8:[=>'=7TFXT
M#Q!:@E[&X;=N Z[6P,D<'&.AR,U3\5?&J/3?%DGA?P?H%UXGUB'(GCMWV1Q$
M=06P>1WXP.F<US'C@1)^UIX..GX%TULOVK9W7]Y]['^SZ]L5'^S.J/J'C.:^
MV-JYOP)V/WR,N3^&[- '5>&/C6M[XLA\,>-/#UUX7U:X(%NL[[XY2>@#8&,]
M!VSQFCQG\<+/P9X]E\-76BW5W(+9987MFW--(P^6,)COZYKEOVH%MTMO"DT>
MT:DM^PA*_?V_*3[XW;:;>6ZW7[9FF_:XU9DTX2;2,@.(&(/X&@#5;X^:CHFM
M6=OXZ\#7WA^QO7VQ7;S;\#U(VCIG)P<^U==\0_BC:>!CIUG:Z=<:SJVJ'%G9
M6QP7'J3@X'/H:Y3]J"-6^%,+,H+)J$14XZ<,*3XA^"X/%D_A6XT+Q3:Z-XOL
MK5&LXI)@'F3;G( ^88*M@X(/(H >?CIJF@ZE90?$+P->^'K6\D\N.[\\2HON
M?E'3OW]J[+XA_$S1_AYI=O-?I+>7EX2MG96W+S'CGV'(Y_+->2:[XP^)?@:V
MMF^*OAO2O$NB1SJ#=>4C%6[$$# ;&<94?6L[XC7>IZY^T!X3N?#3V<4EQI\$
M^E-?#]T"RLPR/7/ ]\4 =Q+\=-<T,P7?C7X>:EHVD3N%%ZLWF[ >A9=HQ],Y
MKUZPOK;4]/M[ZPF6>VN(UEBD0Y#J1D&O$O%>B_&'5O">HV/B34_"L6ES0E;F
M20% B_WMQ&!CUKO?@[I<VB_"S2M.N-0LM1-OYJK<V,XEB9?,8@!AUQG'X4 =
MQ1110 4444 %%%% !1110 5YWXC^'VMPZ]=>(_ ?B:;2M1N6#W%E=GS;.X8#
M'*_PG@<BO1*^??&]YH]]\7=7L/BEK^J:/I4$,1TB&V=XX)E(^=BR@Y;..OOZ
M4 2^,?$L^J?V=IWQ*MKWP1K>GW/G:;K]FOGV;28Q]X= 1C(/3OBNET+X=:UK
M^I:5K/C#Q]_PD^GV$RW=E#:0)'"\@^ZY9?O8/-97PB>UU?Q#XET32[R[\1>!
MTBC-O+JB&11,?O(I<<KU[=A]3TT'PDC\.^((-3\ ZU=:##]H1[O3<F6UN(]P
MW (?NDC@$4 >CT444 %%>>_$_P"+VC?#G32N^*_UA\>5IZ2?,!_>?'W1_.NW
MM+])]&@U"<K"DENL[EFX0%=QR?04 6Z*\='QNUK6#>ZAX,\!WVM:#8R,DE]Y
MXC,NWJ43!)]<<GU KN?#GQ#T+Q)X#;Q9!.;>PAC=[H3##6Y09=6^GMUXH ZF
MBO&%^.6OW.FR^(=-^'E_<^&(B?\ 3?M 61D!P7"8/ Y]1[UZIX=\0:?XI\/6
MFM:/+YMG=Q[XR1@CL01V(((/TH TZXKP[_R5KQC_ -<;'_T!ZZ+7M L_$5BM
MIJ#W21JX<&VN7@;(_P!I"#CVKC? 6BVN@?$?QA8V+W#PK'9N#<W#S/DHV?F8
MDX_&@#T6BBB@ HHHH **** "BBB@ HHHH **** "O%-9^"?BB7XB:OXI\,^,
MUT:34G)*I;DL%P/E)SSR*]KHH \-N_@9XQ\01_9/%GQ+OKVP8YD@BC8!_J"V
M#^(->K^$?".D^"?#L.C:%!Y5O%\S,QRTKGJS'N36W10!XQJ7P4\0:3XUO_$'
MPW\6#0_[28M<6\L&]02<G'4$9Y&1D>M.T3X%ZAIWQ"T?Q?J7BB35-1MY7EOW
MGB.9R5*J$Y^4 'W_  KV6B@#S_2?AO<:;\:M6\<OJ44D&H6OD+:"(ADXC&2V
M<'[A[=ZC^*7PK_X3^73=2TS5&TG6M+;=;707<,9#8('(P1D$5Z)10!XU?_"/
MQQXPL_L/C[QY]IT\#/V2QMA&)' ^5F/&1GG%;'ASX33Z;\&[_P !:OJR7,=R
MTGE7,$)0QJQ##().2'!/T->FT4 >-:+\'O%EGX UGPCJOB^&\TZZM!;V,?V<
MXMCO#;NN2.HQFNEM_A1877P=L_ GB"?[4EM'A;J%=C)(&+*Z@YP1NQ[C/K7H
M%% 'B,?PF^)EIH__  C]C\2 NB[3$NZV/G)'TVANO3T:NJTWX1:=H'PIU3P?
MHEP4FU*%UGOITW%Y&&-Q [ = *]$HH YGX=>%)? _@'3?#UQ=)>268D!F1"@
M;=(S]"3_ 'L?A61X5^'-QX<^)_B7Q7)J,<\6M?<MUB*M%R#R<\]*[VB@ KR'
M6/@SJVG>,+OQ)\-/$Q\/W%\2UU:R1;X9&)STZ8SD\@XSQBO7J* /)O#'P:OQ
MXTB\6_$/Q"_B'5;;'V:,1[(H2.G'MDD  #//-;>J?#BXU#XU:7XY748TAL;/
M[,UH8B6<_O.=V<#[_IVKOJ* "O/O&'PUN/$_Q,\,^*8M2BMXM$92]NT19I</
MNX.>/2O0:* ,KQ+X<T_Q9X=N]%UB+S+2[3:X'!4]0P/8@X(->46/PD^(_AO3
MWT;PM\1!#HY+"))[;,D"GLIYQ^!'MBO;** .#^'?PHTKP'H-[9O*VIW>I@B_
MNIUYF!!!7'9>3WYS7'V'P<\:^#+JZ@^'?C=;+2;B4R"TO+?S#%GN#@@GWXSC
MFO;** /,?!OPK_X0YM<\0ZWJ\NM^(=1MI$GO'7:H4C)"CW*C\@!BO(?@CX(\
M5:GX9OM?\$>*SHMV;U[6>WEA$D4RJJ,IQSR"[<X_K7U3-$L\$D,F=DBE6P>Q
M&*P?!G@C1O 6CS:9X=CFCMIIS<.)93(=Y4*>3[** .5^'WPD?PSXDNO%/BC6
M)->\1W0*FZ==JQ \':/7  [ #@ 51\1_!O44\:7'BOX=>(V\/:C>9-W"T6^&
M8GJ<>YY.0>>1BO6:* /(=#^"^IWOC*V\3_$OQ(?$%Y9$-:VR1[(8R#D9'H#S
M@ 9/7-;LOPUN)/CE!X^&I1""*U,!L_*.X_NRF=V<=\]*]!HH XGXK> 9OB-X
M/71;:_CL7%PDWFR1EQA0>, CUK*\>_"+_A+%T;4=)U=](\0:/$D<%]&F0P7L
M1G/7)'U/6O2Z* /%;[X/^-_&0MK/XA^.5O-)AE$CVME;",RD="6P.?P.*ZCX
M@?"'2O&FCZ;#9W$FDZAH\8CT^\A&3$J@;5/<@8&.<BO0J* /$M1^$7Q#\46D
M>D>+_B$MSHRL#)';VH628#IN/&?QS7KN@Z'8^&]!L]'TF+RK.SC$<:YR<>I/
M<D\D^IK0HH **** "BBB@ HHHH **** "O,?&?BO5/#6MSGQ=X,CUWPR6W6U
M]8Q">2W&!D2QM[_Q#''K7IU! (P1D&@#SG1OC5\,Y+-(['7+2PBQD0R0M %_
M#&*CU7X^^!+#]U8:A-K-TW^KMM.MVD:0^@/ S^-=3J/P_P#"&K7!GU+PSI5S
M*>LDEHA8_CBK>D^%/#^@Y.BZ+86!/4V]LB'\P* ,;P/KOBOQ'-=ZAX@T*/0M
M+=5%A;2N6N6Y.7D[ $8P.OUKKZ** / /C1\-?#GA?X7>(=:LK9Y]5O;N*26]
MN7WR#=,"57LHYQQVKT#QU<RV?P U*: E7&BJH(]"@!_0FJ?[0%A>:E\'=2MM
M.M)[NX:: K%!&7<XE4G@<UU-SH0U_P"&IT2YS$;S3!;G</N,8P 2/8_RH Q_
M@I:Q6GP8\-I"H >U\QL=V9F8G\S7@]]<2:9\/?B[IUF2ELNMQJBKP%#7'('X
M*!7;>#/B%K'PS\'_ /"(^)_".LW&IZ67CLWL[<R172EBRX<<=^HSQCO5GPQ\
M*M8U7X-^*K?7XUM=<\4W#7WE/QY+A@\:MZ98<^@- 'J/A*QMXOAGH]FD:B Z
M7$I7'&#$,_S->>?LWW+P_#?6HB))(K'6+A(8T&3M"(VU1]2?SK,TKXK:YH'@
M*/PSJ'@W6W\3V=O]BA1+9FAE(&U7WCL!C.,UWGP;\&W?@GX=6UCJH U&YE>[
MNU!SM=\?+]0 H/O0!9_X6,/^A1\4_P#@L/\ C7)Z#XZ\KXE>*KK_ (1GQ$_G
M1V@\I-/)D3:C<LN>,YXKU^N*\.?\E:\8_P#7&Q_] >@"*\^*EEIML;G4_#GB
M.SME95>>?3BJ(68*,G/') KNJ\Q_:$U6?2?A'=/;",F:Z@C;>">-X;CGU45W
M>D:W::EI]G)]LM6N)X4=HXY03N*@D 9S0!IT444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=;P6>\@:5"O<85E.?QKC? 46K0_$CQ@GB"YM;F]V6>9+2%HXRNQL#:Q)S^-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[,'A+7M6_=+)]HL+;?'SGC/J,5RUQ^T=86=Y;6U_X,\16DMT^R%)X%0R'('
M)YZCIZU[#--#86,D]Q)MAMXRSNQZ*HR2?P%>*?"ZRG^)OQ!U+XE:\C-96LIM
M-#MY.5C5>K@'N,]?[Q;TH ]P1M\:M@KN .#U%+17ANOZ[X]UCX]:EX.\+Z\N
MFV1M(YGEDA63[,@4%B@(^\20.?7M0![E17SW_:?Q.T+XFM\.;7Q2FI-J,"SP
M:K>6ZF2T0 L[ =SA2,'(Z=*U](U/QCX$^-NE>%-?\32>(M+UNW>1'N(@KQ,
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M6.=4V^?C<,L!C(&W/8D>_-<UX;U3Q;XN\-)K.B?%N-_$CJ7_ +#E2*--V?\
M5A6[^X7'/6@#Z2HK+\-3:Q/X;LI/$MO%;:J8A]JCA;<@?OCV/6M2@ HHHH *
M*** "J^H6::CIEU93$B.YA>)B.P8$'^=6*I:S<S66A7]U:KOF@MI)(U]6"DC
M]10!\X:AX*\16D>B>!/&WB/P]9>%]-O//CEDNUCGNH]QVKL)R3R1TXSU.*]
M?0]?\:?&>WN-0GTZ#P]X3N"UK!;SK)++(4&TNH)*]1UQTX!SFO)[CPOI-[\$
M;;QW=SOJ7B34=6B-S=R2EC$3,08P.W '7U],5Z/XITNS\*_'OPEJWAZ>2+4=
M?F:+4K-9,B:/:/G*]O\ ZU 'MM%%% !1110 4444 %%%% !7%>'/^2M>,?\
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MIX>^&N@Z<B!#'9HS@#J[#<Q^N2:ZBB@ KQS148?M9:^Y5MITB/#8XZ)7L=%
M'CE\C?\ #7.F/M;;_8KC=CCHU-\=HY_::\!L$8J+67) X'WZ]EHH ^??"7B%
M/@?XM\1:%XSL[N'2M1O6O=/U*&!I(WSU!Q[;>G0@YZYJ[X>NKGXK?'>Q\7Z;
MI]S;>'-!MFB@NKF,I]HD(8?*#_O?@!SUQ7N;HDB%)%5U/56&0:4 *H"@ #@
M=J /'/V=$=-'\4AU93_;4O48I? ".O[2/Q!9E8*8H,$C@\+7L=% 'SY\(O$=
MMX?UOQ;X+U:VN[?5K[4KJX@#0G85\LGD]CA<CUR*ZG]FU&3X52!U93_:=QP1
MC^[7K.T;MV!NQC..:6@#P7P5-K-AXP^+EUX?L4O-2COB]M;S A9B'?(]R1G'
MOBN-U?5OA/XC\+2RZMX;O-&\7^4RR6FG6SQDW&,<+]S:6]0#7U93/*C\[S?+
M7S,8W[1G'UH XGX-VNOV?PLTJ#Q9YPOU5L+<$F18]QV!L\Y QP>E=S110 44
M44 %%%% !4%_=16.G7-W<Y\F")I9,#/RJ"3Q]!4]07L+7.GW$$>S?+$R+YB[
MER1CD=Q[4 >!6/PB\+_%'17\1>"-9U;P]I]_<-))8R1!HO-5N6";ACGIR0.U
M>@>!_@[I?A'7&UZ^U*]U[6BI1;R^;/E*1@[1SCZY-<)X<^$'Q7\(Q2P>'?&^
MF65M)(93;K&SQ*QZ[49"!^%=CX;\.?%RS\1V<_B3QIIE_I<;YN;:*T56D7!X
M!$8QSCN* /3J*** "BBH+V[CL-/N+R<XBMXFE<^BJ,G^5 $]%?/W@>?XR?$'
MPV-?T_QK9:?:S3R)%#-81D[5.,@B,\9R/PKT_3+O7?!/P]U'4OB#J\.L75BL
MMPT]O$(PT87*H  !G(QT[T =E17A>ACXO>-_#)\8Z?XHM=)^T!I;#2%M$=&C
M&<!F()R<<$Y]>*] ^%?CIO'W@M-1NX5M]0MIFM;V%.B2KC./8@@^V<=J .AU
MWQ#IWANQ6\U>9X86<(&2)I#D^R@FN-\!:W8^(/B1XPO]*D>6W9+- SQLA)"-
MGA@#7HM<5X<_Y*UXQ_ZXV/\ Z ] ':T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!Y;\:/$4FB7_@>..W6;SM?BDR6QC:-N/_(GZ5ZE6)XG
M\':#XQM8(/$>GI>);2>;"2[(T;>H92"/S["L;_A4G@[_ )\+K_P97/\ \<H
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MC.6% 'IE%<4GC/Q"L:J?A]K/  _X^+;_ ..4[_A-?$/_ $3[6?\ P(MO_CE
M'7+=V[W!@2>)IEZQAP6'X=:EKYW\/^'/&ND?'+4_'$W@^^DLKSS=MLEQ#YB[
M@ ,Y?'&/6O5?^$U\0_\ 1/M9_P# BV_^.4 =G3(IXIMWDRI)M.&V,#@UQ_\
MPFOB'_HGVM?^!%M_\<K@/A=:>,? @U[^TO!>I7?]IWYNHO)N8/D4YX.YQSSV
MH ]RHKC/^$U\0_\ 1/M9_P# BV_^.4?\)KXA_P"B?:S_ .!%M_\ '* .SHKC
M/^$U\0_]$^UG_P "+;_XY1_PFOB'_HGVM?\ @1;?_'* .PBGBG!,,J2 '!*,
M#@T^O#OA1:^,/A_I>JVNI^"]2O'OKYKE&@N8,*I &#N<<\5WW_":^(?^B?:S
M_P"!%M_\<H [.BN,_P"$U\0_]$^UG_P(MO\ XY1_PFOB'_HGVL_^!%M_\<H
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M.EDQ<72788Q+@\XSSSBO/OAW\0O&'@?PXOA^X^&OB*_L;61_LDJV4J2"-F+
M.-A!(SU%>@^'/BSK.N^(K/3+KX<>(M+BN7V->74#B.$8)RQ*#CC'6@#TVBBB
M@ HHHH **** "BBB@ KBO#G_ "5KQC_UQL?_ $!ZZ+7O#NF>)K%;/6H'G@5Q
M(%29XCN'NC UQO@'0M.\._$?QAI^CP&"V5+-PC2O(=Q1LG<Y)_6@#T6BBB@
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M#]:]%KBO#G_)6O&/_7&Q_P#0'H [6BBB@ HHHH **** "BBB@ HHHH ****
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M10 5Q?Q;_P"28ZE_OP?^CTKM*XOXM_\ ),=2_P!^#_T>E '9I_JU^@I:1/\
M5K]!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB_BW_ ,DQU+_?@_\
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MS\F_^+JSH7P.OM-\::3XAU;QK?ZS)I<A>**ZCSU!! )8X_\ K5Z]10 4444
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M7W]EQQ6QLB]Y.(]Q5O,VG=SSC-;MU\*/"8LYC#I]SYGEMMQ?3YSCC'SUV]%
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M@;@O-=]X6T4^'/">EZ,TXN#86J6YE"[=^T8SCG%:U '&_P#"J/"'_0/G_P#
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M9^;IMSD]J[#1_ 'AW0=334-,LY8KF,$*S74K@ C!X9B.E=)10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %'6=:T_P]H]QJFL726MG;KNDE<\
M?U/M7 :=\?O!E_?VT$QU"PANWV6UY>6ACAE/^_V'O6/^T.3?6WA'0'=A;:KK
M<45PH.-RY Q_X]73?&'0;"]^"^N6IMHECL;,S6P" >48QD;?3@8X[&@#OP00
M".0>AHKC_A+J=QJ_PE\.WEXY>9[-49CU.TE ?R6NPH **** "BBB@ HHHH *
M*** "BBB@ HHHH Y'QG\3/#G@6:WMM9N)9+VZ_U-G:Q&65QZ[1T&>*J>$_BY
MX9\6ZT=&MFNK#50NX6=_ 8788SQGKQSBKT'P]TN+XE7'C:66:?4);;[.D<N"
MD(X&4XR#@8_$^M>8^*;ZV^('[1'ABS\)1K._AR0S:GJ,0^55# [-W?&"/JY'
MK0!Z9XT^)?A[P++;6VKRS37UWS!96D1EF<=,[1T&>/>D\&_$WP[XXN+BTTF:
M:&_M1F:RNXC%*H]=IZCZ5P/@6-=>_:9\;:I?JLLFEQ):VNX9\H<+E?3A3_WT
M:?\ $1$T+]H7P'J]@HBGU$R6EV4&/-7@#/K][]!0![31110 4444 %%%% !1
M110 4444 %%%% !63XF\2Z;X1\/76M:W/Y-I;+EB.68]E4=R3VK5=UCC9Y&"
MHHRS,< #UKYV\;7-Q\88O$.JQ/)'X.\,6LYM"N1]ONU0_/\ [J_X>IH ]T\+
M^([+Q;X9L]=TL2+:7BEHQ*NU@ Q4Y'U!KB]6^//@[2]5NK)#?WZV3%;JYLK4
MRPPD=<M]>*Q_!NI3:1^R2M_:L4G@TBZ:)QU5MTF#^!K8^!&BV5E\%])V01DW
M\;S7&Y0?,+,1SZ\ "@#N="U[3?$VBV^JZ)=)=V=PN4D3]01V([@UHUXQ\!LZ
M9XF\?^&H3BRTW5%>WC[)O,@('H,1K7L] !1110 4444 %%%% !1110 4444
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M#X?Z!+X7^'NBZ-<?Z^TM%649SASRP_ DUT5%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*2/%$[HI'4;@,'\,U8\>ZIHNN_"FXU"'Q0VEZ7<!&75K(&0J-XZ!2#UX([4
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MI>%VA\S?M!&W&1CKUK(\5?"S4KOQM_PE_@GQ"="UF2$0W0>'S8KE0 !D9ZX
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ME6G110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img134051827_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_13.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI8VAA96P@
M4F%I8FQE    !9 #  (    4   0J) $  (    4   0O)*1  (    #.#$
M )*2  (    #.#$  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,#(@,3<Z,#(Z,#8 ,C R,SHP
M,SHP,B Q-SHP,CHP-@   $T :0!C &@ 80!E &P ( !2 &$ :0!B &P 90
M /_A"R%H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B
M96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X
M;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y
M;G1A>"UN<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A
M9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,]
M(FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D
M,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#(S+3 S+3 R5#$W.C R
M.C V+C@Q-#PO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ
M,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN
M;W)G+V1C+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^/')D9CIL:3Y-:6-H865L(%)A:6)L93PO<F1F.FQI/CPO<F1F
M.E-E<3X-"@D)"3PO9&,Z8W)E871O<CX\+W)D9CI$97-C<FEP=&EO;CX\+W)D
M9CI21$8^/"]X.GAM<&UE=&$^#0H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(#P_
M>'!A8VME="!E;F0])W<G/S[_VP!#  <%!08%! <&!08(!P<("A$+"@D)"A4/
M$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_VP!#
M 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" %? H(# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M>^(-0T>]\2VUS'9VNDVUA-)IPA5EN3,B22AF/S# D 7&.1SFO6V;:A;!.!G
M&37,WGP^T*[ODGV7$$6V!);2"8I!<"$YB$B=]N!]0 #D5T] &!J&J1W,MA&M
MO>(3>1_-+;.B]^Y%;]9NL]+'_K]B_F:TJ "BBB@#,\21+/X<O(6+#S4V+M/.
MXD ?J15C2M/32M+@L8G>1(5VAGZGG-1:E^]NK"V[//YC?1!N_P#0MM:%81BG
M5<^J5OU_R.B4Y*A&G?1MO]/\PHHHK<YPHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/O-!
MTG4+@SWVG6UQ*0 7DB#' ]S2V>A:5IUQY]AIUM;RX*[XH@IQZ9%<CXH^,GA;
MPCX@FT?5S>BZA56?RH-R_, 1SGT-3^#_ (L>&_'&L/IFAF[-PD)F/G0[%V@@
M'G/7YA7:\HQ2I?671?+:_-;IWN8<M'GO97&2^"O$.EZCJC^#O$5OIUEJL[7,
MUO=6/GFWF?[[Q,'7&2,X8$9J?PO\.[?PY=:GY][)JEMJ%G;VLB7@WN_EAPS.
MQ)W;MYXP,=*X&]\>7:7'BA[GXB)I=_IVHW,%EI1LX9?,5/\ 5C;MWMN/'!J"
MR^(E]=2ZI)XK\;S^%KN"6-4TZ/3TE$>Z"-R.4))WLPQG/%<1N>K>#?#=QX3T
MB727U%KZQBG8V D0A[>$\B(MD[MO(!XXP.U=#7/^!=0UC5? ^F7OB2W-OJ<T
M69D,?ED\D!BG\)*X..V:Z"@ HHHH **** "BBB@ HHHH JZGJ5GH^F7&HZG<
M);6ELADEE<\*HK#T+X@>'_$-Y!:V%Q,L]R)3#'<6[Q%_*;#@;@.1UQUQSBI?
M'EMIUUX'U)-9U#^S+1$65KS&[R&1@R-C^+#!>._3O7G'P\6.^\96SZCXB?49
M([FZOK:"'0[BT1IIE.]WDD&,!2P"@CKWXH ]HKS?XE:_KECK%O8^'Y;\LFFW
M%X\6FQQM(KJ5$;R>8"/*SN!"_,3TS7I%8FN^$=)\0W$=Q?I<).D30>;;7+PL
M\3?>C8H1N4XZ&@#@+WQ=K=Q8ZMK]GK($.B06#QVUO&OD7GFHCR,VY=V&#X7!
M&,5ZRS;5+8)P,X YKG;CP#X=N+R"X:R:,0I#'Y$4SI#*L7,0>,':^SMD&NCH
M P=1U%;B2PC%K=QYO8_FD@*@=>];U9NL]+'_ *_8OYFM*@ HHHH ST_?>(I&
MZK;6X0?[SG)_15_.M"L&2ZN+;0M5U.S5&G>1WB#]"%P@_1?UK3TI[V32X'U6
M-8KMES*B= <USTJB<N7OK^.AU5J;4>:ZLM/.]M?E<MT445T'*%%%% !1110
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M@M;JY:ZEC7#3-G+G/7FN*BV\1*U[))>7_#GH8A)86#=N9MOSU\^WD7****]
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M1A$$*"*#R=PY/)'/M78T4 97AC2;G0?#5CI5[?"_DLXA"MP(1%N11A<J">0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI<$.HW N;E%Q)*/XCGK76JEY\B7SZ>GJ<+IVIJ;>[VZ^OIT+=%%%:&04444
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M-0#X3Z,K/.NHZO\ V@UXE[_:!NPTZS+&8]P)7'*D@C&/0"@#D8_'GB7Q+?:
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MVB63[0OG2^4!GY]IVYSC.,U>\/:KI>JZ0CZ'.9[6#]R&9&4@J!Q\P!Z8K4H
MQ7?Q/_:D0CATG[#Y3>8S2R>8'R-N/EQC&<TR%_%?^F^?!HXPY^Q[)9>5VC&_
MY>N[/3M6[10!RT%]XPN+-42UT47T$\4=V#-+Y>"JLY3Y<YPW&?2K[/XG_M5
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M:(BR->",R>0RNK*Q7^(!@,CN*\I\*>(]$L?$UO>^*?&NG2I#=7.H6\5MIEQ
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M]?@""N:\?V"ZCX3>"6TU"[B%Q!))'IL@2<*LBMN7(YQ@' Y...:Z6BLAG*>
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MC\O-/X"MJ*7/=[+7[O\ /83V-FSM8K&Q@M+==L,$:QH/15&!_*IJ*0D*I+$
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M64MDC'.>O/NC9*G:0&QP2,XJK+JNGPWT-E-?6T=W.-T4#3*))!ZJN<G\*MT
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M9O\ 8=O_ ,_-_P#^!LO_ ,50=$MP,FZOP/\ K]E_^*IWGV_'_@#YJG\J^_\
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M!X@TUGMWV2C[4@VG&>YY_"IO^$HT#_H.:;_X%Q_XUM[&HM'%_<;71JT5E?\
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M9-P*G"L-V>,>]6&577# ,/0BLN^\,Z/J.S[38Q91Q(&C&PDCU*XS4M32Z/\
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MU>7/S67I97_+\/Q-#^R]*_Z%_4/^^S_\<H_LO2O^A?U#_OL__'*A'BZ[L?\
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MXZ0E]^O_  ?Q'?\ "0:9_P _/_D-O\*/^$@TS_GY_P#(;?X5I45C:IW7W?\
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M6D4A. ,#Y:G_ +)D_P"@I?\ _?:__$UJI3ZQ-E.;6L?Q1HT5G?V3)_T%+_\
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MIMY:!<FZ/.!6U14.$6[M&4J4)2YI+4RO[!7_ *">I_\ @4:/[!7_ *">I_\
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MV#;?M9&W Q^-=!12]A3?03PU)N]C'_X1Q/\ H*ZK_P"!C4?\(XG_ $%=5_\
M QJV**?L:?8?U>EV,?\ X1Q/^@KJO_@8U5Y/":/?0W/]L:L/*5EV_:SSG'?\
M*Z"BDZ%-[H3PU)[HQ_\ A'4_Z"NJ_P#@8U'_  CJ?]!75?\ P,:MBBG[&GV'
M]7I=C'_X1U/^@KJO_@8U5[WPFMY:F$:QJT>64[OM1/0@]/PKH**3H4VK-">&
MI-6:,?\ X1U?^@KJO_@6U'_".K_T%=5_\"VK8HI^QI]BO84NQC_\(ZO_ $%=
M5_\  MJ#X=4C_D*ZK_X&-6Q11[&GV%["EV,"Q\*BSLXX#K&JR%,_,;HC//I5
MC_A'E_Z"FJ?^!9K7HI*A32LD"P])*R1D?\(\O_04U3_P+-'_  CR_P#04U3_
M ,"S6O13]C#L/V%/L8,'A40W=Q/_ &QJK>>5.TW1^7 Q5C^P%_Z"FJ?^!1K6
MHI*C36R$L/22LD9/]@+_ -!35/\ P*-']@+_ -!35/\ P*-:U%/V4.P_84^Q
M@S>%A+>6\_\ ;&JKY.[Y1<GYLC%6/[ 7_H*:I_X%&M:BDJ--=!+#TELC)_L!
M?^@IJG_@4:/[ 7_H*:I_X%&M:BG[*'8?L*?8PKWPL+RSD@_MC5(]X^\+DG'-
M6QHH"@?VCJ!P,9-P?\*TJ*%1@G>PEAZ:=TC-_L8?]!#4/_ @_P"%']C#_H(:
MA_X$'_"M*BG[.'8KV,.QF_V,/^@AJ'_@0?\ "I=)TW^RK$6WVJXNL.S>9</N
9;DYQGTJ[135.*=TAJE",N9+4****LT/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img134051827_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_14.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI8VAA96P@
M4F%I8FQE    !9 #  (    4   0J) $  (    4   0O)*1  (    #-C
M )*2  (    #-C   .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,#(@,3<Z,#0Z,S( ,C R,SHP
M,SHP,B Q-SHP-#HS,@   $T :0!C &@ 80!E &P ( !2 &$ :0!B &P 90
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" &0 B # 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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MBU86DVPV[M(P9FSPOS,0/?% &KI_Q8^)7B/3&UWPU\/X9M%RQB,MUB690<9
MR,].P^F:[/P!\4-/\:^";S7IK=].?3BZWUNYR8BJ[B1TR"/ZBO+]&\!_$KPK
MI45W\*?&%IKF@R9EMK>8@!USV# K]<,O-=7\,OB':^,?"_B72_&.G6>BW&E*
M8]4*8BB9'W*S'^Z05;/)[4 4=-^+?Q#\76\VK>"O <-UHJ2,L4MS=!9)PO7
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M%@LKR*% /18F&: .XU7XG76@_%C1?"FHZ7#%INL0JUM?"4Y#D$;"N,?> '_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% %74],L]9TNXT[5+=;FTN4,<T3YPZGL<5Y#
M\0/"WPB^'6D07FK>$8[B6ZE\JWM;8N9)6[]7X _J*]HKR+XSR#0?%7@OQA?6
MLUUI.D7D@O!&F[RMZX63'L1G\* /+F\7?"I?/S\)+\&VQYV78>5GIN^;C\:]
MJ^"U[I6I>"YKWP]X7;PYI\UTS0PLY?SQ@#S 3[C''I7&2>,=#\&?&O4-7UJ1
MHO#OB[1X+F&Y>%F25@HP"N,\J3U'<9ZUO?L]W#77A'6I;6.2/2'UFX;3%<$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBB@#CO&G@7PQJVFZKJFI:):7-]]CD/VB1,ME4..?;%7OAX<_#7PZ3_T#H/\
MT 5F>-_$&OV=AJUI8>#[O4+3['(/ML=[!&O*'/RLP;CZ5I_#S_DFWAW'/_$N
M@_\ 0!0!T=%%% !1110!!>V5MJ5C-9W\$=Q;3H4EBE7<KJ>H(KEQ\)_ 8&!X
M5TX =A%77T4 >0?".ZMK7XF?$#0M-T^&QL;2[B,4<).U<*4.!VSMS]37K^17
M)7_PM\&ZEJ]SJEWHJ_;;MMT\T5Q+$9#ZD(P%0_\ "I/!?_0)E_\  ^X_^.4
M=GD49%<9_P *D\%_] F7_P #[C_XY1_PJ3P7_P! F7_P/N/_ (Y0!V>117&?
M\*D\%_\ 0)E_\#[C_P".5S7P=U"W'BOQUHMA;2P6FGZF! DD[2[ %V$ L2>2
MA;K_ !4 >L4444 %%%% !14=P2MM*5."$)!_"OG;X::3XV^)^AZA-J/CK5--
MT^RO)(+?[*_[V5\[B6;KM&0 ,^O2@#Z-JGJ]\=+T2^OPGF&UMY)@A.-VU2V,
M_A7@/P]B\>?$N#5-%UCQI>Z?9:!.ULUS9#;<74A8XW/Z*%^O(K8^'VN:\V@?
M$;PIXCU.357T%)X8+N;EV79(.3U/W0><XR: ':%\:O'7B;2UU+0?AL][9LQ1
M9H[T8)'4<BM[PK\9SJ/C&+PKXP\.W?AO5[@9MUG;<DI[ ' ZX.#TXQ7FWP=^
M,^A>"OAU!H^HZ9K%S<)/*Y>TME>,ACD<EAS^%:_VC5_C)\8?#>M:=X=OM)T7
M0)!+)>WL>QI<-OVCZD  #.,DF@#JO%'Q=\0:9\3+WP?X:\(?VW<6L*392YV,
M59%8G!';<!UJ,?$KXGDC/PIGQ_U^K_A7'Z]XBU+PS^U3K=]H_A^[U^=M.BC-
MK:9WA3%'\W / Q^M>@^'OB?XIU?Q#9:??_#36=,MKB39)>3%MD(Q]X_(./QH
M M^._BHOA76K+P]HVC7&N^(;V,2)8P' 1>>6;MT/Y9KFKOXS^+?"DD%Q\0O
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M&0>HH \%O+VZ^-7Q4\.7&B:7>6WAOP[.+J:_O(3'YSY#;5!]=JCUY)KWJ@
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MP*.I!'SMV->=_# ^)])^#7BZ?PUIXEU9-:GDAM[J$_O4VQ[L*<9.,X]37O\
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MB@#C/&WCO0=(T_5=*OI[A;O['(-J6DKK\R''S!2._K6C\/!CX;>'1_U#H/\
MT 5H^(Q_Q2VJ_P#7E-_Z :SOAY_R37P[_P!@V#_T 4 ='1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KSKXK^#M<UO\ L?Q!X-DB&O:#.9K>*4@+
M.I&&3)XYQWP#D\BO1:K7.I65E<0P7EW!!+.2(DED"F3'7&>M 'CLGQ/^*MQ
M;*U^%]Q#J++M\^1SY"L>^3@8_P"!5V?PH\%WW@SPK,FN7"7&KZE=/?7SQG*B
M1^P/?  _'-=Q10 4444 %><_%7X?V?Q!NM"M+WQ"-)^R3M(D*[?,G+;?NY((
M(V\'GK7HU>?_ !1^&LWCA--U+1=0&EZ_H\OFV5TRY4\@[6QR!D YYQSP<T >
M=?$KX3Z9\-?"K>,O E_?:;J>F2H[L]R7$ZLX4@Y[\_0],59O]5?5_CU\--9O
M$\H:AHH<*1@"1@Y('YBM74OAY\2?B!]ETWXAZUI-KH4$JR7$&E!_,NRO3.5
M _EUQ73_ !$^&1\5:7I$GAR]72-9T%P^F7&#L4  ;&QSCY1SSTZ&@#$_:7=%
M^#DX?JU[ %^N2?Y UV\EKXC_ .$7TF'P_=6-K=1P1B<WT#2 @(!@!6&#FO/I
M/AQX]\<Z[IC_ !/U32O['TN83"RTT-_I3CH6R!@'^61@9S7LM 'GFO67Q&'A
MS4C/K'A\Q"TEWA+"4$KL.<?/UQ5GP';>(&^'F@&WU&R2(Z?#L5K5B0-@QD[J
MWO%&IV$'AW58)[VVCF^QR_NWF4-RAQP34'P\_P"2:^'?^P;!_P"@"@"Q]E\2
M?]!2P_\  1O_ (NC[+XD_P"@I8?^ C?_ !=;=% &)]E\2?\ 04L/_ 1O_BZ/
MLOB3_H*6'_@(W_Q=;=% &)]E\2?]!2P_\!&_^+H^R^)/^@I8?^ C?_%UMT4
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M$7,$OQ+\?QQS([K>6I*JV2/W '\P17>T %%%% !1110 4444 %%%% !1110
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MUU32-#M=8@U*6)AF_6 QC!8=5.>OZ5V?_"0^/_\ H1+3_P ':?\ Q%;.D_\
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MA_@'KWK2^'AS\-O#I_ZAT'_H H Z.BBB@ HHHH **** "BBB@ HHHH ****
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M'#$E0.<CZT =917(>,/B#;^$/$?AW2)[&6Y?7;AH(Y$<*(B"HR0>OW_TKKZ
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M?^P;!_Z * .CHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH P])_P"1JU[_ 'H/_1=;E8>D_P#(U:]_O0?^BZW* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M73]6U%M>U^U8V<A^SVFI/%#\J'^ <<]_6M/X>'/PU\.G_J'0?^@"@#HZ***
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MO0?^BZW*P])_Y&K7O]Z#_P!%UN4 %%%% !1110 4444 %%%% !1110 4444
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M:J*!@*!V  Q4M '%_P!B?$/_ *'+2_\ P2'_ ./4?V)\0_\ H<M+_P#!(?\
MX]7:44 <7_8GQ#_Z'+2__!(?_CU']B?$/_H<M+_\$A_^/5VE% '%_P!B?$/_
M *'+2_\ P2'_ ./4?V)\0_\ H<M+_P#!(?\ X]7:44 >7Z5/\0]3\6:_HO\
MPE.E1_V.;<";^R"?-\V/?T\WY<=.IS[5N?V)\0_^ARTO_P $A_\ CU3^'=-O
M+7XD>,KZXMGCM;PV7V>5A\LNR$AL?0\5UM '%_V)\0_^ARTO_P $A_\ CU']
MB?$/_H<M+_\ !(?_ (]7:44 <7_8GQ#_ .ARTO\ \$A_^/4?V)\0_P#H<M+_
M /!(?_CU=I10!Q?]B?$/_H<M+_\ !(?_ (]1_8GQ#_Z'+2__  2'_P"/5VE%
M 'E_B*?XAZ!=Z'#_ ,)3I<_]K:DECG^QROE;D=M_^M.?N8QQUZUN?V)\0_\
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M ZG\1Q4]>%6VF0?"C]H+2=+\/&2#0?$]NPDL=Y*1S+GE<_1?S(KW6@ HHHH
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M&.N<UN? 77M+U'X4:/IUE?0S7MC;D7-NK?/$3(V-P[9JM^T>K-\&+XJ"0MS
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M][/0GO[@UU?@>#P?:_$_4KKP2-<UV[T?3I9#J4UX);=R4($?(R<DX&#U!]*
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&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img134051827_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_15.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI8VAA96P@
M4F%I8FQE    !9 #  (    4   0J) $  (    4   0O)*1  (    #.#
M )*2  (    #.#   .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,#(@,3<Z,#8Z,C0 ,C R,SHP
M,SHP,B Q-SHP-CHR-    $T :0!C &@ 80!E &P ( !2 &$ :0!B &P 90
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" %1 >$# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
M  %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8
M&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)
MRM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$!
M 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$
M!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I
M*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Z1HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\L\2_&*Y7Q9-X6^'O
MAV7Q-JUL<7+K)Y<%N?0MT)'0\@9XSFO2M1ED@TNZEA&9(X79!ZD*2*\B_9CM
MX6^&MYJ7W[V\U*4W,I^\Q 7&3^)/XF@"5_C%XE\)WULGQ0\%OI%A<N$74;*<
M3QQD_P!X#/\ //L:]=M[B*ZMHKBVD66&5 \<B'(92,@@^F*YKXFV%GJ7PO\
M$<&HJI@&GS2989V,B%E;Z@@&O!_#&O:UX8\+_#;Q?+?WG]CB632M0MS,WD^7
MYC"-RN<9 )Y_V%H ^H:*\C^(.JW_ (C^+WA7P3H=_<VL4>=2U22TG:,F(?=0
ME3T.#Q_MK7GS>.-&\>^,=;G\=>.K_P /Z39W#6^G:;I\KQ^8H)_>,RJ0>@Z\
MY/H.0#Z=HKYX\"^/9H]4\6^$;+Q/<>(M+ATB>]TO4YF;SXRJ<H6."2-W7_9X
MZXJ/X5^#/%'B[PAI_C.\\9:LU[;N_P!@LY+EQ"XC8@"0YR0S@Y]O7L ?1=<A
M\3_&\OP]\$3:]!8I?/'-''Y+R% =QQG(!KQBZM?#46DSS_$/XNZ@_B7<[.NE
M:@\D-N^3M5$13[9Z>V.M9NJ>)=3\3?LFW4NLWDE]/:ZLENMS*27D0,"I8GDG
MGJ>: /;K[XAS6GQ.\->%!IR-'K=DUTUP92#$0KMM"XY^YZCK7=5XGK7_ "<C
M\.?^P-+_ .BI:]JD+B)S$ SA3M!. 3VH =17RGHNL:3KEYJ<?Q-\<^)?#OBP
M7,BHOG/#;V_]W: , >QV\=/6NM^(-_XET7X Z')=>*%U"_.JQ(-4TRY8>?$1
M)@%Q@MZ'UP.] 'O]%<#\;;Z[T[X/:U=:?=36MQ&D>R:"0HZ_O%'!'(KS3QK<
M^)-6\2_#71=&\07^FOK&DJEQ-%.V2"H+N1GEMN[D\Y[T ?1-%>!QZ5JGP;^*
MGAI;GQ+JFK>'M;9[*3[?.66&4D;>,XZE>>.-WI70ZYJ>H^*OVA])\.Z7?W-O
MIGAZW-[J0MYF199&P51\'D?<X/8M0!V_@K7M;U_3[Z;Q%H$FB307CP0Q2,3Y
MT8 (DY X))'X5TE?-&D/XE\0? WQ??V&N:G_ &IH^OS7$$BW<FXQHB%H\Y^[
MM+';TR*[3QW\3);OX#:;J>A2LFK^(Q%9VRP.5=)FXDVD'(((8 ^I% 'L=%>*
M^+=#U33(/#>E>(O'W]@^&[2S"WUR-1*7M]<?Q88C)7..YZGCI7(:%XCTKP_\
M:/#NG_#[QIJFN:7J,I@O[6]F>1$)X!4L ">^1R,=>: /9?!WCV7Q3XU\6:%)
M8);)X?N$A2992QFW%QDC Q]SWZUVE>._"3_DL7Q1_P"PA%_Z%+7L5 !1110
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MATVWG'6(R9RP]\#&>V:Y#Q7X?N_@Y#H_BG0_$&L7L*WL5MJUM?71E2ZC?@N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6Y B..OK7I]% ')_:/B%_P! SPU_X,)__C-'VCXA?] SPU_X,)__ (S7644
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M4,/H: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"N3\!,KW'BID8,IUZ?!!R#^[CH Z^BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SCXR> =7\>:3H\>@RVJ3Z=
M?K<LMT[(KJ > 0#S^%9WAWPQX\T#QUXD\1?V;HD_]N-&WD?VE(/)V#'7R><U
MZQ10!XGXU^'WCSQAX]\/>)39Z):?V*Z-Y']H2-YNV3?U\KCTKT#^T/'O_0O:
M)_X-I/\ XS7644 >7_$#0?'GCKP5>^'SI6B6?VHI^^_M.1]NU@W3R1Z5HWFN
M>-O"_A.:\N_#VCRP:79F23R]4?<RQIDX!AZ\>M=_7-_$4X^&/B7/'_$KN/\
MT6U &_:S?:;.&?&WS8U?'ID9J6JNEG.CV9'_ #P3_P!!%6J "BFM+&AP[JIQ
MGDXXI5974,A# ]"#F@!:*** "BBD9E1<NP4>I.* %HI"ZA@I8 GH,]:%=6SM
M8'!P<'I0 M%)O7?MW#=C.,\TM !1110 4444 %%%% !7F'Q<MO#FE6NE:C-X
M:BU;6YM21=.M8D5#=7!4@"4X^9 ,D@^U>GUQ7Q+\):IXETW3;WPU<Q6VMZ+>
M+>V1G'[N1@""C>Q!H \\OD\>>'+&36M=^''@^\TV!?-N;:QA7SXXQRQ!(()
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M@ HHHH **** "BBB@ KF_B'X?N_%7P]UG1-.>-+J]MS'$920N<@\D?2NDHH
MX309_'&B^'=.TMO"FGSFRM8K<R_VUMW[%"[L>2<9QTK0_MKQO_T)VG_^#S_[
M175T4 >"?$?X<>/O'OB*74XM.T_3EDTP6'D_VF9,$2F3?GRQZXQC\:Z[P%I_
MCKP5X)T_P_)X;T^^:S5E-Q_;!3?EBWW?)..N.M>FT4 <I_;7C?\ Z$[3_P#P
M>?\ VBC^VO&__0G:?_X//_M%=710!RG]M>-_^A.T_P#\'G_VBN6^(ND>._'G
M@FZT"+P]I^G-</&WVC^V#)MVL&QCRAUQCK7JE% 'DFJ>'_'>H^/O#7B0:#I\
M2Z'#+$UM_:Y/G[TVYW>5\N.O0T_P-H?COP=/K\DN@:???VOJ4E\H_M<IY(;^
M#_5'./7CZ5ZQ10!YQIOACQ-J/QAA\8ZU:6FF6MOIALA:Q7IN&D8L3NSL4#K7
MH]%% !1110 4444 %%%% !7.>,_%%WX3TR"_M= OM;B,VRX2Q&Z2%-I._;_$
M,@#'O71UR?C_ ,7W_A/3[#^QM&.L:CJ5T+2VM_/$0WE2V2Q[?+0!!X;^+/@W
MQ1(+>RU>.VO<X:RO@8)E/IM;&3]":[.O#=;^%_BCX@ ZG\3M1T;0K* &5X=,
MM4::-1R=T[9(P.O)%;?A#POK/A3QAHO_  AVL7NM>"-0M'>X-Y=)*ML0N8VB
M/!PQQP!CK^ !ZO1110!B>+?"6E>-?#TVC:["TEM(0ZLC;7C<='4]B*Y2P^#M
MFNJV%YXC\1:UXD33'#V5KJ4X:*)AT8J -S#'4UZ-10!QGBSX:V7B77K?7K+5
M-0T+6H(S"+[3I K21_W7!!#"KG@KP'IO@>UNQ937-[>W\OG7M_>2;YKA^Q8^
M@R>/<UT]% &?K.H7FG6:S:?I-QJLI<*8+>2-& _O9=E&/QKF?AK<37<7B6>Z
MLY+&:379R]O*ZLT9V1\$J2I_ FNON[ZTT^$2W]U#;1D[0\T@0$^F37*_#V>&
MZD\436TL<T3Z].5DC8,K#RX^A'6@#L:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** (I+J"%]DL\:-M+[6< [1U/T]ZC34K&6T:ZCO;
M=[=?O3+*I0?5LXKQ[XB>';/Q5^T/X5TK5?,:QDTJ9[B%)"GG*K,VQB/X20,C
MVK)L/AQX>?\ :"U7PR+5T\.IID>H-I2S.('FRJ LN><;F/U- 'N=QK.G6NC3
MZM+>0_8+>-I9+A7#(%49)R/I7F.F^//B1XWMVU3P-X:TJST1F(MI]9F<27(!
MP6"H>!D?_7KS[4M-;1?#OQB\-^'T:/3;)[6:&V#%A$K'=)C/L/R%>]^ ;BSN
MOAWH$NF,K6IT^$)LZ#" $?4$$4 8/@;XD76M^(;SPKXMTG^Q/$MFGFM LF^*
MXC_OQMZ>W/UZXQ8?B%XY\9ZIJ:_#C1-)_LO3;IK5K[5IG'GR+][:J\@=.OK^
M%5?%DT<_[4?A%+%@9K+3IY+\H>5B*OM#?GG\15?3O @UB>]\4?!CQU<:5;WU
MT[7%HT)>V:8'YOE8 K^1Z\<4 =9X!^(.I:[K^J>&/%VDQZ5X@TM%ED2"3?#-
M&W1T)Y'4<9/7ZUW<-Q#<Q^9;RI*F<;HV##/U%>7^"/%_B9/B#>>!OB#;6,NI
M"R^U6^HV(VK/%G&&'8_@.AXZ&N[\+>%-)\&:*-*T"%X;02-+M>0N=S')Y/-
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M9S);^8)/+.R/C<.#74ZEJVG:-;"XU>^MK&%FV"2YE6-2WIDGK7,?#F[MK_\
MX2>ZL9X[FWEUV=HY8G#*X\N/D$<&@#LZ*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,OC=)I,NBZ%INM
M6]T/[0U6*&VU"VE$3:?-SMEW$8XSTXR,\C%>FU\__$SQWHWCR*[TA/"GB/6M
M#T:Z+7FH:9)Y<8=00?X6# 9)YQTSTH Z2;X2^+=;M_[.\3?$N_O]%? EMH;5
M8GF3^ZS@G.?QKU33["VTK3;;3["(0VMK$L,,:]%11@#\A7D'ACX.^!_$GAFR
MU?0M:\1FQNH]\0&HE=O8J1C@@@@CVKUO2=-BT;1K33;:262&TA6%'F?>[!1@
M%CW/O0!<HHHH **** "BN'\6?$DZ'XEA\-Z!H-WXBUR2'[1):VTBQK!'V9W;
M@9[#_$5>\#^/+3QI%?1"RN=,U/39?)OM/NP!) QS@\=0<'!]J .FGMX;E-ES
M#',N<[9%##/XURG@"-(9O%,<2*B+KTX"J, ?NX^U;^LZ4VKV:VZ:E?:<0X;S
M;&14<^V2IX_"N:^&MH;&+Q+:M<SW9BUV=3/<L&D?Y(^6( !/X4 =K1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M (.4_P#C==910!R?]O>-/^A*M_\ P<I_\;H_M[QI_P!"5;_^#E/_ (W7644
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M'875C:)!<M&1'*RHH8*W0D8KF]6\!:MXE\8_%*T-K+;0:Q96:V-U*A$4LD:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img134051827_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_16.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Q\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '&"^<F0X0DE-! 0      $P< 5H  QLE1QP"   "EKL< E  "')R,CDS
M.3DX' (% "M-:6-R;W-O9G0@5V]R9" M($E/($)I;W1E8V@@5')A8VME9"!#
M:&%N9V5S.$))300E       0U3)B1FTG*:>-]BZ8"8K)USA"24T$.@
MY0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!R#-TP        "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _@
M.$))300-       $    >#A"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          CA"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #-0    8              5L   %G
M          $                          0             !9P   5L
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   5L
M    4F=H=&QO;F<   %G    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
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MZG(])E+_ .;73=&QF8O2L7'9C'";76T?92X6&L\N8^YI?ZS]WP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MVK73E53A)3C'!G#?P:H2BW%QC3/VLW%N$LBZ^<'N2BE)/+&L. . . . . .
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MCD&HZ9$!R6!LKZ:/X$?TX_VX ]-O^!']./P\/P_#Z. /3;^WR(_IQ_K^'X\
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2X57A#%S)'HT%AE &S7 ' /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img134051827_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_17.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1S64&AO=&]S:&]P(#,N,  X0DE-! 0
M    '+J^<U0X0DE-! 0       << @   @   #A"24T$)0      $.CQ7/,O
MP1BAHGMGK<5DU;HX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q >0            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0    >.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      -!    !@             #T   !&
M   & &< ,  R &$ ,0 Q     0                         !
M      1@   #T                      !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   #T     !29VAT;&]N9P  !&     &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ]
M4F=H=&QO;F<   1@     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    &.$))300,     !*$     0   *    "+   !X  !!*
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MN]'U?3R_6_1OX?"*EZ,CZWTBGU?5?!8Z][J0\$678GK;::MMK?0IMROHV/\
MT;+/[!?VO];'.I8_$%,LQ[<BQN.]P9ZEM'KT5Q?9Z_I8UUS;O;7;OQK;/3V>
MDI],SOK+D=4KQ\MMM6*_&?\ I?0V>[<[[-E/+]U=5]M/IOLQ_5_17?H']/\
M^U*E1U+ZQ8_3<!]U#\K*R'6G(W5%I:6!WV?$]/'#?LWVJ/Z;D_J^/_AOYRI(
M^45?:AJZM];_ $C6,(>JRIDNMK<8=Z;;-[WUV4593LBSUF>GCMH^Q/K_ $V_
MUJU/J_4?K1:+<;!Q74&S&:]EC6%[FO>TFU[;R]E'J4V;<;[)Z7K_ *3[;O\
M2J]-5W=:^M@K&6,5VE&\X[:+-A?-XCTW5#,;;[:?T&_9ZO\ VI9CV^LKG4NI
M=?LSC@X6/9301CDY1I)+=]V,W(:U^ZVBS]6ON]3\_']"[_C$JU&D5?:SS^I_
M6.OJ&3B8.&'T5M9Z.196\C<0Q[_<VYGVAON>SV^@^NROWK/ROK#]8< "[+K%
M;;+G5-]2EWIL#G675Z5.]7)?7C-9^FI?_P ']EMRF(V'USZUW-JK?@-98]E
M?:^F]@#['UMR;?3/M]/&:^ZM]/KLL_0?:?Z+?^C/E]6^LM&3G5TX8R*Z'6.I
M(JL$UBO$]!M;P[;DVNNRLBQ_I?\ <*['_G7^P 5H1'[5+8_5OK58]ALP*V-%
MQ;:S98'!GJ44>GZCG"O=6VVZ_P"UU?:<:^JG]'Z:=W6/K1]KL@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M <5%4R6C*=17H]6=4AY&4?M5J+SK.8;,.DVN3 +%-MW:_&T=Z"#<$[8PQ-L
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ME>VG:MH;BVIML-N<3O KLB[$:%&,VZQUS3MDT95Z^?%T_7]7K;%0KE%M!+R
M^NA@15\[G!8D;G8=EQ9'FN.TEU-;R6<-I8V=D]@^GI:VZW)CABEOXM1FEC>>
MYFF,\MS"FYI9)$$>46-<*PN1Z;$CK*\T\TZSK<&:0Q!G=8'MT5ECB2,(L;G
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M<4JE+Y^X>Y_BI8O[(F<N0_.Q>\3[0JE_,;]5OJ->/BGX8_!C]'/IRN8UG_\
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M\)\/;/?MX,9SXN_;M]CMW_BY54UQ_P#*/VH7^E__ /'%*_?\H?:A=_\ I/\
M]W[7;BE?G^4?M0OY3_\ =XI3_*/VH7\I_P#N\4JE;W[0^0]R[XA]ODI8N_;+
M_?M[(F?#NGER'YV+WB?:%4OYK?JGZC7C^I^&/P8_1SZ<KF-9^_H:[UO^$Q#^
MI]7X_I(;8_Y7*L([>I ]_P#B8SGO]K['-+[>^@#\9;?Q*S>@?GY]Q)]:5Z&:
M//\ B3X\1/!WQXO!E[Q>'O[_  ]\=N_;X=_=W^/.)UNM<OBE.*4XI3BE.*4X
MI4>MQ!;Z6M%.S4HFQ5"5US90>R$Z7:J\'BBO;E2F0P,SV,<NE825LD8^D?(K
MQ'R<Q(20VIW!(/'DSW7K>&ZDI).QK*6->?\ M!N+5XV09!5A%'<(7RGSB+NP
M6*75*"-<@&07$3C(XZ0CF$@;((*EVB(7#9VL2IP 8JO:[ZKWHXU#$38$!P>J
M0QE4/;C[#9#6T9W:L4G4YT4MN.VRF-OW!)"B&A=QS8#$.M/9C1AVPJK# I"Q
M[JGO!G /])C9U0@*;,-9YBCRH*RCIW+R$A6(<QBXD!!-)*@87U6[A2ZY(NB+
M@]1^\P,/>ACC4;L;.H84)(J<>GQ=I#4 8/N&2J2[96VOQ8IXSBQ'A=8G7 ].
MI ,\>P3-X,G %+D@ A@G[;-YFDH$I_)HME>2,D?!/ D11*Q'K=8D5SYJY)<,
M2VT;CEO75L>+>S>Y'CYI=BN,DD#;C"DG:,+ZJKIQ)C+B\LO#<->+/J\.1I2G
M,([Y\.%J3*2G*L8[=\I3C&<]^R<<BIKX\)S[N*_FLS]<XI3PG/NXK^:S/USB
ME/"<^[BN_P#\+,_3YS_Z<CGZ/W_]*4\)S[N*_FLS]<Y-*BYUO),8Z.>J/USP
MU37T@]K>LPW&E)<RCY%&/%X%*E+3A7VLJ2K&/CG&?AS#=HO0&L_LR^_#R?HK
M':OZ)U/X"[^XDK13U9W^F?KCP]O%\O*AV[XSG'?Y0CNW?&,XSG'?XXQG&>WV
M>?+VF>DM/^.M/Q$=<=@^?A][']M:V=M^;RW2"WGL.O MGW>&/C6J9 &"!)ZW
MNC\Q)%H0.]5 %#'AY">RNR0(E69;J\H:4G.)=UC1H^+!$VOMR%W_ %&^O8[^
MXBBN;A5$@6-%>X*E6E*C:B;7D#3(( (6C>0@VMJ%9;Z^7H=Y=W27<R17$NWJ
MLJ(&E8;3.%(VH49P9E$ Z)1R,V5N#,M[>IE/Z3;%;+AT]ZYLQ:Q8L9(Q$/2I
MIHU/DV$E.?\ E6=:6N298;%CI^&LM^78=!0T5E,=IEJK/S*ZV+F2-ITB5YM.
MM97D:5Y$9FD>3J,Q,KY)<(B-CP!C40X $):'8QV'3)&EL8)'=I&<2%G9MY)Z
MLF<N JMCP!C'1P!T28MA,EXV)6&\XEKCK=\6>V8S;C;?@[)[8REUQU7B[^+O
MG"NV<>'MC&<9[Y*O?7(XI3BE.*4XI3BE.*4XI3BE.*4XI3BE4I?/W#W/\5+%
M_9$SER'YV+WB?:%4OYC?JM]1KQ\4_#'X,?HY].5S&L__ -#4_OF8?\A^V?ZD
M#S2^WOH _&6W\2LWH'Y^?<2?:2O0ZYQ.MUIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2G%*<4IQ2G%*BSUQ?6:]4WY =K_,HSS#=HO0.L_LR]_#R5CM7]$ZG\!=_<25
MHA:J^JAK?\?:?\X1W/E[3/26G_'6GXB.N.P?/P^]C^VM;%75"PX_U#[:;=B>
M:Q+O,EM<=<(A.23>G1IPMB,Y")D!C)I9FN#"0+,:60KQ0^-KN:H*E5G0=3N^
MP+GW75%)U&[!3(:8#;L9NH71U */(BR=2!&4K(\33)!TMUOI,$\]SO6H F^N
M<@'=.V05+;RR-&N0Y0R[X4>(@O$\B1>3Q&+3X;F[FS-]&2WG>F75#S[BWU/B
MC,A$IQ\K+7-CR+2=?B3\SC$4?*(^?BN,S,$XPT4%))?Q/KHD57Y P?&W+1B3
MIEH2228V.29&W R.0^Z549]X(;>$C1\[HHXXRB+M6EY-A;DDG*L0Q+$L#(Y5
MMSJA;<,-O5$C?.Z)$B**)/<R=>^G%*<4IQ2G%*BW8MZF!EYM501[!!MBC08+
M )'1[$V"/C2Y>O&2%EL3\2]CB$>$K-Z;C!QTH$$B3W$L246ASU<B#RECM('C
MD@#@^O'.0#@#)!R,%N-P\:@'=_P\L#NXY4D8&,\L &7.,JP)]E<[3VYK%L,V
M-@E6*VRT1K18K*%B6)K9>OR@[5#S$E$WI!B<EP9<&[9-*U]I8P<ZP,A1\8F&
M%*D26V>< J<,5) ;G SN&5  _22#D%68>($G:=I&Y=Q!QW#QW'P?/\? $<')
M!QF2+SR&$X6O#JL95A/9EA^0KOG&<]\HCMNKPGW9[JRG"<9[8SG&<XQFJIKC
M>T8_W.=_1A+]4XI3VC'^YSOZ,)?JG%*>T8_W.=_1A+]4XI3VC'^YSOZ,)?JG
M%*I6]D&,TBY8PW-[YJMAQ[QA+&/>(F?'.8F,8Q]O.<XQCXYSVY<B^=B]XGVA
M5+^:WZI^HUX_R?AC\&/T<^G*YC6?KZ&N=2SZ3 .M>'<X^DAMC'9IEY]?O9 _
M\VPVXOM]O/A[8^SG'-+[>^@#\9;?Q*S>@?GY]Q)]I*]#-,YA:DHPB9C*E83C
M*AQ!"<9SGMCQ+7%2A"?MJ6I*4X]^<XQC.><3K=:YG%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4J+/7%]9KU3?D!VO\RC/,-VB] ZS^S+W\/)6.U?T3J?P
M%W]Q)6B%JKZJ&M_Q]I_SA'<^7M+]):=\=:?B(ZX[!\_#[V/[:UL2]4$=K_9#
M;=]8TEEK-T*,R5280YIEMJ4^T2FLS$V&<\(<4_&&"[0[!N/A8+509\L;7.%=
M/M3IM(MG<=5 &I79/ ZQ#92$  GJ.&ZK&(9"1W#+==UX$%U=NFEV]I:3[[?
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M=KG*];""QT:NGQ Y+ 1Z;&K2X4 D=1*@0ID%4^?.<.2FJ[<EPIF"[@%D=4.
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MC''MJ 0? @_HJP5YUSL&R["'$TUO5AT4*O=(M51V!9GVWKQK$ *?J2[U5:J
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M3(P7),5M@G#1*S,$$!A6/#(1O'>V4-_$L,QD55D64&-@KAE#+PQ5MN5=EW*
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MMH#1V4Y6V/G-1'W,J&I>F4XY)."2Q;S5&"0 0"!D#Q\.3QN)(R0  4=X[%V
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MBC^I80&:::7'N5B8<;3% 9<%C_ XVI*A;,PJ^*7A0V<</3XLHU/W+1L?DRT
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M\:L7433VT\*D!I8G12V=H+*0"< G&3S@$_0:QQ8Z"]U_?.@_YSIC_P#7._\
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M644A0H;'BTW6)]9.VV79GU1GR6)B!AMXW[MRQF.2<D$@<1=(# QC,Y#X.1U
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M#KF>_;Q=L8QB0,?ZS]=*YW)I7YG'?&<9^&<9Q_IXI5K0.E]<5X:#&PZZS(P
M:@MQ)TY^1((R?(1@\9G!*0EQM,Z-G%?"/*%O->QD2!0YZ..9S!B88A5"@ 9.
MT8!/CCGU_P!Y_>?;0\G) S[<<_ZX'[A54B*15P122;%"DQ"TW$A,XAB7.>DS
MDR/)XRF:Y(E.YF)CMP(D<>F3ZU(N(SB&-Q$BJ6RJ:8\?I\?]?Z]7LJJN*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.
B*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img134051827_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_18.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2#L4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (-"^A  X0DE-! 0       << @   @   #A"24T$)0      $.CQ7/,O
MP1BAHGMGK<5DU;HX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q >0            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-
M!"8       X             /X   #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M T$    &              /1   $:0    8 9P P #( 8@ R #(    !
M                      $             !&D   /1
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   /1     %)G:'1L;VYG
M   $:0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   #T0    !29VAT;&]N9P  !&D    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     8X0DE-! P
M%K     !    GP   (H   '@  $"P   %I0 &  !_]C_[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( (H GP,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M+LLS<.RUM-=S'V/;O8QK@26P';P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ ZP$/ P$1  (1 0,1 ?_$ !X   $$ P$! 0             #! 8' @4(
M"0$*_\0 <!    8! @,# P81% \&! <  0(#! 4&!P 1"!(A$Q0Q"15!%A@B
M,E%A%QDC)#,T-4)24UB!D92AL](F-D-$5'%R<W23E9:7L;+3U-76\"4G1557
M8F-D=8*2M,'1US=&1U9GHX:BM?%E=H.%QN'D_\0 '0$!  $% 0$!
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MQ:&]NS:J6*VQN9C "SB5B(=_1C=(JR'"\Y '/C#-3T$ DZ40Q"4XS)T:=(<
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MVW?O$DW+I-58A3A?;4=0985:^O&6W9'MU:ZG*P/&"L;P@N1$R*2J,FTJ"0I
MJV+> %R((09 1(1&@+ACE@Y"^,">9#9!/,\Z3I?#_@C&\='Q&/<*XGHL5%6(
M+A%QM0QW4:XQC;:#!U%%M#!K#Q#-%I8BQ;Y[&EFFY$Y(L>[=,BN0;+JI'F?4
MM1NF9[F_O+AWBZ%WGNIY6>'<'Z%B[L6BWJK]&<IN4-C(!HEM;Q +'!#&%;>
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MI2C2E&E*-*4:4HTI1I2C2E&E*-*4:4J"9*R/5\34][>[HZ78UJ,DJS&R3Y!
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MW;I19RZ6%-,O:N'"JJZY^9590ZAC&&IF+LS'&68L<  9)R< <@.?(#D.H5;
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M8EL-(MQ=7,=G?ZC+=/'TL<6(8YM(@C9]T@Y/-&,9.[( /6Z4_;4" FBDDBF
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MHNE><53Z-@:TU*-C;'*S$<270\P>IZ8G9)-FZ?=HX!9FS=3"[!!E+M5G*@N
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M-_=\-*4V[!G^;P^UEM*5(JXBV+.0PD=@H8IS<I.P5+S^R<_/&Z%]/C[GOZ5
M[?2?BY#E5XZ5-&E*JBZW_'L!/(05G9E>RQ6#"42YX9%^5!O)+S,:S$'+@H$3
M54;,K.N)4S#V4<QE"JF(J\9MI"!@L5'NB#V=:@$M\"@Y.?XV%!.0)P0N[L!
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MB*1P#Y[W=M*'T>C\O/\ %2?<7?TD?]HGX6E*='9.NY-P[(=P=/!$.8G@*+$
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MV+G_ ":XQU]!+_\ MM60TC_E;3,XQ]L;+.>K'?,>?@]?I^#QNX)0DPSW"^<
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M ,Z?X>E,CRCXQ3H[-SW)N'9]0=/!'V:?@*+$ ^>]X?L:4R/*/CIKW)S]*_\
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M4!6)N'M?3I2FW?G?TX?]E/\ !TI4BKCMP><A2'4W*8YN8.4@;^R<^D"@/H]
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M/8/5Y15/4,]@4L3Y%7K/J'E^"M!:;56K%%=V@IV+EG#6=<,'#=B\0<+I/8M
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MABO-P/+"1 #O\ &1Z#N']LMM[O\ ^1=<[\+L'WBE^<$^AU\]^VVLO,6ZQ_\
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M+,D%@>L]T5?EIO\ D9_II/>TID>4?'37L%_I*OZV?_EI4U)*TDJ6=A1,FH
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MPA<'1>$5*]';9)7O?P2$:HN<!JH53S0%3<VYN4OQ.S6'S@+[SX8XB/<^Z]V
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MMUV'J'I#2E(FCGHD3#L?#G_)$OHOT>E*Y0XRLV73AMPF_P CU&(KTG+A8J_
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MW&4R!G!'D'\,0X7_ *CVN]?'^Q&//N?B9_Y:Y5X0^&/-2/\  Z?^RKY0\/\
MW-?>@TSY-H'[JK+X8APO<H!ZSRN[@81$?-&.]Q 0+L&_J9WZ;#[W4>GCIX0^
M&/-2/\#I_P"RI[8#N:XQX(=,QY.]] Q__%5\^&(<+_U'M=_8C'GH_P#AK[/N
M^G3PA\,>:D?X'3_V5/#_ -S7WH-,^3:!^ZJ57\HGPN*JG.3@YKB9#;;$"(QW
ML78H%';:L '40WZ 'B/IZZ>$/ACS4C_ Z?\ L:>'_N:^]#IGR;0/5]ZO)RK
MGE$>%XHB(\'E=, E.  ,1COH)B"4!ZUD?:B(&V]T-/"'PQYJ1_@=/_94\/\
MW-?>ATSY-H'ESC_DJMA$>4LX=ZW((34!PIL8*79 L9I*0K>C1<DU!9!5NOW=
M\QKZ#E$5FRJJ"O9JEYT554C\R:A@&[#W2>'H)%E@X9Z"5<A98DL8Y%W J<.D
M889!(.#S!(/(UZ+7[(W@'39TO;#N5VUC=VXD:*ZLQHMM<Q;XVCDZ*>'34D0O
M&SQOM8;D9D;*L0?<EF!W\'%/2=W3*\!1X5,[]ES$*Z9QRI2&,*X )R ;8X!L
M("&X@7F#?LD;B1$<# =%< ]8# '!]6:^TH91-#%,!@2Q1RA3U@2*& /5U9QU
M#JH[DM]&T^WV/\IU75VE%62PJ''G:=3#^7V(?<%P&WV-*5M8!HJ622,8[80
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MEV&Q5?YXIB[_ /9SXEWW#WP#3PFZ3YKC\);?1*'[);A#WJ--ZQ_UCI?E!/\
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MDGR8KJW<N[M%EW3M3U+3;70;K26TVP2^:6>^BNEE5[A+?HU6.WA*D%PVXDC
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M]4U'P^KXO7S[3_NI/>+^A?\ ^VW_ (O2G/T?%_?3I\,9WUYS%?<W>G'-L=N
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M<#\?DK#X:3BST<*L1^V2NA__  (=/"=I/FNGX:V^AU(^R<X6]ZZQ^#4M./\
M_@BE1\J;BL44TO6IQ "15903^J2N;F!4J!2D'\06^Q.R$P=1ZG'8/$1>$[2?
M-=/PUM]#I[9SA;WKK'K^^>G<O]@]?+T=7Q/8WRL5#AE%%H?AJ2BEEB=DLK&W
M*&8**I 8#@FH=K1TC'(!PYN0QA+S !@#<-7(^ZIIT))AX=,18 $QW,$9(!S@
ME;0$C/4#U&O3;?94Z%9LSV?<YBM'==KM;:U9P,RYR%9HM#0E<X.#D9[,@5ZV
M8-R.7..**9E=M%(5M"Z1[F13A'4VR?+QX-Y-]&BDH[[*/[<3&9"J!^YH;%4
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MOV[0?_2W7*/"C8>;$/RJ'MZ_^@U\H>V@X>]ZK3/GRQ_LO7WX:?COE  X2:\
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MU4"(N'3.(E7:*9S':QC]<J;1:"0H))Y#_<!Z23R ZR3@<ZD*6.T=9_WDD]@
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):4HTI1I2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img134051827_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_19.jpg
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ML\'P(S1S=+'A,D)#8F/Q)&06-7*"@__:  P# 0 "$0,1 #\ I'S]H#Q<, &
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M(VK8*]_N21.?#.QU!+G%#7XP+XE*"DK4\G-)BFSG.76B7(=OR1N4HWLU<C<
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M0=]99V;)VE@=)@2R@1NXW>'*G M]DS@7'(+#FMV>7\V1FC*(3=(GX1755_\
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MR4;9S1:\&E-90VP%Z1'8]=VHX5Y)W=2[M\GJB46'49^H1)'R/+63:OEA@2M
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M(?!>4VIYU3230TIUQ32#RH;-9FA)Y;4I,BRGD&@YLC&& # !@ P 8 , & #
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M"$*LYE>7:.NY!9L5:?0>V/K$M;GEI7$#T$Y*O;5R56F.  PDX(@^G.$G_O\
M-_FY/XRQ]YBUAG^$WD__  D:B5PG54:T3END*F>3=PL2/-T0DDJG4\D,HE>X
MDT.(W=MC+2[N2HS;&SIW0TYQ-3-1"03BN-$L=3%RD!1I>K?'ZJ:"+12OZ]@O
M>EGJ?K/-6M!(LKI:NIP]2=\EK%I].F5:FU))$*U4IVUN4'/<W%V.;1HRC"]$
MJ!K'16/3BG&2N*T(K9!Y1A)0PJF777VB3(CRZ*>P:5'N&"MF,,B&M73V9N,B
M@;K6 GN?3V1S!Y98 ]@"%TC$<6.ZP[D9(O&4D/<%J<O;NZ*&]L-=7%<)N1>P
M5.S(5-!4M+.84*W+;7*=:$>C]>L;3+J.@TS@,2KMPYP-K3 E44<86ZQ^0.3)
M)HTZ0M*%"P.C8^HC0*@KDR+VR,\9^CRE:=4J+4DF:-WZ!&9'73EZ=(&1&1%;
M92AY[!\EU#U\Y-5NLZ].\K$UXQA)$;$/4OC@>N=FA%"A0 K9*TTP:A(O''1"
M+4+RQ[4J%HA+S1B4"V+:IV=&0*%;TY>J@Q,BX=(,^R(4K;WFPX.^K(^RQ:0+
MJ[G\CAHI6Q1P"DI@2R,#0L*+6+6<E:M3MS\F"CD21*J,2%.P4H"22A&9%2P]
M%2K3U"+TLQF5E+#ID'N?*#ADEF33,7YXL!V ROT;E;?#W"?R=9 R95#TR,B-
M2'484N!J4*]J-;T;F6068!K5/Q&I$O;U;X:>X&JT*E"]=+;>D29$9UMLS5LK
MZA](A1$.B$TU/PNT[E,E1LSS'(ZJG<YD,Q+B,?D3BUNCZTQHI[6*=HRG98Q,
MFUJU6-<[&IFA ATX!1$>[B&==!>HJ>T"*FD_6=?8,38'#975BR5VE;BLG,==
M90P(HK.=06>2:%HY_&FW:[3>SS!(PKTA;F!$0Z.:%,Y$>YO93:X*6T#II ("
M< C,ORJ1'3U"#21G6TK*'3/Z_P!>L;TTU3!V&6LTS96@+4ZQZNB*I9$R$T:=
MG;8.E<T3JD:$C47O20D*12WI"TQH0:&2E*TF!O17Z8J=*=-?:)H5:]%.B@U6
MR* A%FRIEG3JXS>.S2.1]SC#%*()-7Z&O#:SO2Y$O=D@#F5404K*7F(2 'DN
M)*Q-Z %GED 7)42M*(S+1;E(\X&1'ILR&64A[8M0]9PI36*F,,AS5T01680Z
M$D%N2]04D9YXKC3A*3'(2L]0H>G1U<(HUKU+NYGJ7 Y<-P5G'FJ%ZDP:IG7I
MM"A%2F8C+KI[AC!\/<**FKK-V5\L:)GR*1(Y=*8W$+"D\<ATGDZ,M 3M[=X^
MVKB4X5CBG:V]._ ;3&Y+)"4V@OZ=RV<I$<J=*6>NEM-%0O2J9VVYB.A>NP8$
MWA3JHZ5\Z=F3< 06>GN9)%2IW)"H0ALXMW*?5DM318"W3:):[.99RMP3*@*6
MWVZYQ4(D2)2N4'#7Q]&0RR9LGT4L"]+IRURYZU^FMH]SKPR5D\;MLA4*7!9;
MLV:IG46(E[T7%E#PJ+92G"1-3'[P)(SO[F5'FHM<X(P@$8$@[V996UJW:A?'
M9T9#H5?4(O2MRVY;>FOT_P#0E(,"C@;#-M#2=1SN.AB>!#5>]G>Z;CB9\4R$
MI/I#Z?8:4:<U9Q@E?J^V$5L).]^H'6L5.E,U:^T32VN>E!N>0)# !@ P 8 ,
M & # !@ P 8 , & # !@ P 8 , & &+VR,NWK4DVT->Y$%K$R!?MMZ3EH+*-
M6%>-HTZ>Q]^TUB7  M$WZ/\ =!*P!4;)V<'0] &IEU/5A,T'9!5:0 JPS/7]
MI/"X;'03,?M"-IC/7E 6[3V+9B;>TX]B7;V(C>R1>DO^W%3R5LT!0LM+=(D#
M !@ P 8 4#W)_EZU?]D3G_IW3/1H/[E#_E8_X*!SC_R[W\5S[ZA;%354Q<^H
M*I.&Z62$9U;08T82;EM].5H1D7:QBT401.2R""];WO0"22RRBP^@!8  #H.N
M.G3'BG3")$6A2I!6P8)G8\O*9QS,STF9F9Y3.H^RPRC LVN_)-_Z[VH7_())
MZ)(KUK9O?7<OCW-7'7M2)W"#Y89<"C2[QW^8'1)%>M;-[Z[E\>XQU[4B=P@^
M6# HTN\=_F!T217K6S>^NY?'N,=>U(G<(/E@P*-+O'?Y@=$D5ZULWOKN7Q[C
M'7M2)W"#Y8,"C2[QW^8'1)%>M;-[Z[E\>XQU[4B=P@^6# HTN\=_F!T217K6
MS>^NY?'N,=>U(G<(/E@P*-+O'?Y@=$D5ZULWOKN7Q[C'7M2)W"#Y8,"C2[QW
M^8'1)%>M;-[Z[E\>XQU[4B=P@^6# HTN\=_F!T217K6S>^NY?'N,=>U(G<(/
ME@P*-+O'?Y@=$D5ZULWOKN7Q[C'7M2)W"#Y8,"C2[QW^8'1)%>M;-[Z[E\>X
MQU[4B=P@^6# HTN\=_F!T217K6S>^NY?'N,=>U(G<(/E@P*-+O'?Y@=$D5ZU
MLWOKN7Q[C'7M2)W"#Y8,"C2[QW^8'1)%>M;-[Z[E\>XQU[4B=P@^6# HTN\=
M_F!T217K6S>^NY?'N,=>U(G<(/E@P*-+O'?Y@=$D5ZULWOKN7Q[C'7M2)W"#
MY8,"C2[QW^8'1)%>M;-[Z[E\>XQU[4B=P@^6# HTN\=_F!T217K6S>^NY?'N
M,=>U(G<(/E@P*-+O'?Y@=$D5ZULWOKN7Q[C'7M2)W"#Y8,"C2[QW^8'1)%>M
M;-[Z[E\>XQU[4B=P@^6# HTN\=_F!T217K6S>^NY?'N,=>U(G<(/E@P*-+O'
M?Y@=$D5ZULWOKN7Q[C'7M2)W"#Y8,"C2[QW^8'1)%>M;-[Z[E\>XQU[4B=P@
M^6# HTN\=_F!T217K6S>^NY?'N,=>U(G<(/E@P*-+O'?Y@=$D5ZULWOKN7Q[
MC'7M2)W"#Y8,"C2[QW^8'1)%>M;-[Z[E\>XQU[4B=P@^6# HTN\=_F!T217K
M6S>^NY?'N,=>U(G<(/E@P*-+O'?Y@=$D5ZULWOKN7Q[C'7M2)W"#Y8,"C2[Q
MW^8'1)%>M;-[Z[E\>XQU[4B=P@^6# HTN\=_F!T217K6S>^NY?'N,=>U(G<(
M/E@P*-+O'?Y@=$D5ZULWOKN7Q[C'7M2)W"#Y8,"C2[QW^8'1)%>M;-[Z[E\>
MXQU[4B=P@^6# HTN\=_F!T217K6S>^NY?'N,=>U(G<(/E@P*-+O'?Y@=$D5Z
MULWOKN7Q[C'7M2)W"#Y8,"C2[QW^8'1)%>M;-[Z[E\>XQU[4B=P@^6# HTN\
M=_F!T217K6S>^NY?'N,=>U(G<(/E@P*-+O'?Y@=$D5ZULWOKN7Q[C'7M2)W"
M#Y8,"C2[QW^8'1)%>M;-[Z[E\>XQU[4B=P@^6# HTN\=_F!T217K6S>^NY?'
MN,=>U(G<(/E@P*-+O'?Y@=$D5ZULWOKN7Q[C'7M2)W"#Y8,"C2[QW^8'1)%>
MM;-[Z[E\>XQU[4B=P@^6# HTN\=_F"B&WX&QDVS:!(%TSV JQ)L6'9MC6$>;
ML)<E<PAV8>?*##CC-ZUK8S3C##3!>D9@Q#WL6_0X4EPX<0[V/;%8.R+%(K6D
M9")DB(N@B(BS#G7VDX9ZUSY5S_6=UU?[Q<(X6(KJ/@MZ4$"(IQ<*_P"&U%+F
MY ?H>TRQQ8JX3N#>G5^R$ S2,U800%8(L01@3;-&#>A!UGGLZV?,+3,D?C+'
M0LG2.T>AIO[A#'PFN%E7Q=KNF?7K<DK=8]"W.9V>!SE@'&!28OFHM<GO3?7X
MT&V",-30J&)TC9$,)8' D+8@1.#DZ)#G$M=JF=;"(K3LLMZ^G/6HR$5"J9F=
M*F>CJ/1[!YH3Q%V(N?Z6#9%4L$+A_$.6L+KAT9+ 5RJ1,;N"&N5A-##8K&HA
M<=;6M<^Q)F=E):B-/\F1MKT@,95!J@HXAV,@R*VAY,ME,]-)@1G94J5R9S]M
MGZSYQD(=Q-FRN)<)\G%"RT(N)IX4-1R+4@$IU#-)ZQG=A^W+4;9B-O\ L9D+
M T^R$2S>J!Q$M]H(27250I:?1[R+\POK".F4Z>H:/6?%E-;)L"JF-'7D 2PZ
MW$]DN[2M*M9S<+!BK!6RXEM6'S*$):X$WMKRZ*UB(O37J5^Y,ZP:EF<7K;J2
ME(72::$?0=,EGL,_=]%H@E&9E85#KZR(O[UIIZ!''!]>5FMU:\(43L""( 12
MWXDJBT1GO2"JD,S5R6*09[FWO\OC1\:)1(&J4L<9?CF=2CF;ZZ)Q)$.GQ"WJ
M'(Q(VC(JJMM(ZTITZ:YJ@DS*]*A4,M-NFOM_[,;7 .(6:\V*"A];5X=,9#;Z
M+B"<DBVT+B>%!<8!5%AMS6H52:8*8C(9(]MK@7(S0MJ=N95*YI]W98^0E$T>
M\/32,BJ=3I2F0M/14",Z%2VM<IY*'GLM&RI.+60O\7J$;# 8HT3VS76XV-T;
M+ L8Z-P:(.]$/KA&9V@%,V^'OBU]4K7MO-U%B$\:0F.+*6XOBW3>6T*D9BF6
MVPJ9"TY-%!-]DR6URG99E]?1UB>N'VSGFYJ>@]HOD:;(BJFS5RVG86F0JY2D
M2MJA0<%M,T]K([%Q+#%:0!2H0TS6)!O1P1H%[BC&2L.@RH9EH$D=2(](F7($
MA@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P K-N
M2<O6K9XB)3+X;+II5G#=&8&Y'-\;N-\K04?9U$1-L"7S%GC<>7-8YQ+AD*!I
MD^WYV:DJ1OC!;;'%Q3BYO)2JY%85M#.N8CZ*=!=>44,[3J5233(9E3IIIMZ+
M"&^VU745D=ZTU'H2Y6"VS.82?=T3YW06Q:Y+<T5;7ZAO7+$W-'<SU%6\J?3!
MPBD*(;@L2=-MD62P]"G+4-0A%060S.E,A6%E/IIFRY= &17Q4*VM3.NCHKG.
MP=ZY47# !@ P H'N3_+UJ_[(G/\ T[IGHT']RA_RL?\ !0.<?^7>_BN??4+D
MJWCS++N'J!121MY#M'I-3,5C[ZUJ?7]V<F9YA"!N<T!_LQ '[%8B4GIS?4&
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MENBAY?UELH.P(IPV1F)1WAMCB.0/JI-PTK%"V,J%(6_1\A&IKJ7UP,#[HI*
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M8GV%0_:.E\J+!@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
M& # !@ P 8 , .=["X:(18\@D[TYO\Z94%@LC-'+1B4:?4;;%[/8V'2PEO;I
M:0H:%SL0 3<O5LC@IBKQ&5SPQ&!:'94M0DD$E21F7LR5S>K^X@TUK:95RTI;
M] ^*SAA@*R6+W_;S-D\<>)VR6@]U8E>D!5:/%AQX;0I:92M:=LXWP)Q#FP,C
MX>R(Y&DBSB^M:9W<F%6MV>:<J=*69*5SD6@1>ETD6@LA^LAT=D"P8 , & %
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MU2GDATV8"Q#+#35:%HTG"EV>--N9*R&_;J &VW2<6W#WGW,(CM*']%?92O\
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MEM+-6@FC($A@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , &
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M+ERG_P!B(ZD9YJYZUZ?;^0[^RHN& # !@ P 8 , & # !@ P 8 , & # !@
MP 8 , & # !@ P 8 , & # !@ P YVMZEI=<!3[$'FT0MU02L+6GDT(10AM'
M)%;6C$B,<V1MG9KOK3:V2 Q&/E$P^+N3RF*7+"FEX;O_ +,:.2,BS6Z:_33H
MS"ID9UML.EE/S'XFM)R^PY*S\[;5VNK5AL2*V8VPI)!FAOD('F$/B*41AH/G
M9+D+UXX@D#<A5G%)XPED"]$0)L6R,Y.I5B4*D6:VE,MG5_>G0%#,[3L(ZD5/
MS'1F0+!@ P 8 4#W)_EZU?\ 9$Y_Z=TST:#^Y0_Y6/\ @H'./_+O?Q7/OJ%L
M5-.EOAJ"J0D0:MC"-5M!M$F'6M*"#3"M1=KT6,TD%-* $F#!Z!#* >>$L6]@
M"<9K6ABXZ<B#CTRLB41XU(J10V3(CPRZD1G.(S*N0Z%7060?98-[ L_LVODF
M_P#67J%_P"2>5;E^0JR[VY5Y*9JWD'>9?<F?/C+5_9M<9?(#E6Y?D*LN]N5>
M2F+R#O,ON3/GPJ_LVN,OD!RK<OR%67>W*O)3%Y!WF7W)GSX5?V;7&7R Y5N7
MY"K+O;E7DIB\@[S+[DSY\*O[-KC+Y <JW+\A5EWMRKR4Q>0=YE]R9\^%7]FU
MQE\@.5;E^0JR[VY5Y*8O(.\R^Y,^?"K^S:XR^0'*MR_(59=[<J\E,7D'>9?<
MF?/A5_9M<9?(#E6Y?D*LN]N5>2F+R#O,ON3/GPJ_LVN,OD!RK<OR%67>W*O)
M3%Y!WF7W)GSX5?V;7&7R Y5N7Y"K+O;E7DIB\@[S+[DSY\*O[-KC+Y <JW+\
MA5EWMRKR4Q>0=YE]R9\^%7]FUQE\@.5;E^0JR[VY5Y*8O(.\R^Y,^?"K^S:X
MR^0'*MR_(59=[<J\E,7D'>9?<F?/A5_9M<9?(#E6Y?D*LN]N5>2F+R#O,ON3
M/GPJ_LVN,OD!RK<OR%67>W*O)3%Y!WF7W)GSX5?V;7&7R Y5N7Y"K+O;E7DI
MB\@[S+[DSY\*O[-KC+Y <JW+\A5EWMRKR4Q>0=YE]R9\^%7]FUQE\@.5;E^0
MJR[VY5Y*8O(.\R^Y,^?"K^S:XR^0'*MR_(59=[<J\E,7D'>9?<F?/A5_9M<9
M?(#E6Y?D*LN]N5>2F+R#O,ON3/GPJ_LVN,OD!RK<OR%67>W*O)3%Y!WF7W)G
MSX5?V;7&7R Y5N7Y"K+O;E7DIB\@[S+[DSY\*O[-KC+Y <JW+\A5EWMRKR4Q
M>0=YE]R9\^%7]FUQE\@.5;E^0JR[VY5Y*8O(.\R^Y,^?"K^S:XR^0'*MR_(5
M9=[<J\E,7D'>9?<F?/A5_9M<9?(#E6Y?D*LN]N5>2F+R#O,ON3/GPJ_LVN,O
MD!RK<OR%67>W*O)3%Y!WF7W)GSX5?V;7&7R Y5N7Y"K+O;E7DIB\@[S+[DSY
M\*O[-KC+Y <JW+\A5EWMRKR4Q>0=YE]R9\^%7]FUQE\@.5;E^0JR[VY5Y*8O
M(.\R^Y,^?"K^S:XR^0'*MR_(59=[<J\E,7D'>9?<F?/A5_9M<9?(#E6Y?D*L
MN]N5>2F+R#O,ON3/GPJ_LVN,OD!RK<OR%67>W*O)3%Y!WF7W)GSX5?V;7&7R
M Y5N7Y"K+O;E7DIB\@[S+[DSY\*O[-KC+Y <JW+\A5EWMRKR4Q>0=YE]R9\^
M%7]FUQE\@.5;E^0JR[VY5Y*8O(.\R^Y,^?"K^S:XR^0'*MR_(59=[<J\E,7D
M'>9?<F?/A5_9M<9?(#E6Y?D*LN]N5>2F+R#O,ON3/GPJ_LVN,OD!RK<OR%67
M>W*O)3%Y!WF7W)GSX5?V;7&7R Y5N7Y"K+O;E7DIB\@[S+[DSY\*O[-KC+Y
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MM(CTC9\ & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
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MTTUR4_5ABVW*#(& # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@
MP 8 , & # "N;B4I2_G^6.LYBG,*7E.=I<,Q46;UC?)MR"$PFO[;@<N<D^])
M586S;0.4)7B9SMR3!+<G*/HVY%KTCC3/HFY&5*6U^-ZCJ1_E85@H9*J9E0\F
MFMAUS=-IC$R."V:?'+IH ==2E:\6KQ%MEA,MAMZ),.N$\&D$R@DWD$@<9&>O
M":V.,/*9I S$1M4EV_N*]N9--*96A<-+DRI?%/05*9ZD1_UKER!0[4T.TZUS
M4J7N%E^4%PP 8 , *![D_P O6K_LB<_].Z9Z-!_<H?\ *Q_P4#G'_EWOXKGW
MU"V&F[DI\BGZJ3J+5K4DXFM8,2>0=.8N68487%VLLTDTHQTT( P#T(!A8PZ$
M$6MA%K6];UG'3H,XYTPRARC(Y4@R,H[QD9&\LR,C)%#(RR&/LL/LX%G]LU\D
MW_J(U"Z1)'313'H#KI8K#T WK8-<^XIZ [UKT:V'7*O]N]:_36]>CT:_36:N
M(3MRE]V>\ RX=C;-<1'O'XW<=)[/TIW:E6;4A+V3I1N<1+V^BMB];96C>5/:
M:+V+^[8-"]78OU]'I_7&(3MRE]V>\ 8=C;-<1'O#5R4H$P9P;5JT)INP;,-U
M.8EHPS98=@+V,>G3UA[+ (0 ;%O>P!%L(?1K>]8Q"=N4ONSW@##L;9KB(]X:
MN2E-&&&ZM6K=&F^SV:;J<Q+1AFR?3HK9@].GK#]EK>_9^MO?J>G?J^CTXQ"=
MN4ONSW@##L;9KB(]X:N2E F#.#:M6Z.,V#9ANIS$M&&;+#L!>QCTZ>L+98!"
M"#8M[]4(MA#Z-;WK&(3MRE]V>\ 8=C;-<1'O#5R4IHT9^K5JW1Y@ EF':G,3
MT:86#8M@ ,S3IZXP V(6PA%O80[$+T:UZ=XQ"=N4ONSW@##L;9KB(]X_>KHI
MC7J^BV*PUZFO5!Z)W%->H'>M:WH/_P"5_MUZ-:UZ->C7HUK7_C&(3MRE]V>\
M 8=C;-<1'O'X!<=)EFFGEVI5@#C_ %/;G G$2":=[/7JE^U,"Z:&9Z@?[0>O
MO?JZ_0/HUC$)VY2^[/> ,.QMFN(CWCZ]-=-=K=9??L5_*XQ"=N4ONSW@##L;
M9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]X=-=-=K=9??L5_*XQ"=N
M4ONSW@##L;9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]X=-=-=K=9?
M?L5_*XQ"=N4ONSW@##L;9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]
MX=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW
M@##L;9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]X=-=-=K=9??L5_*
MXQ"=N4ONSW@##L;9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]X=-=-
M=K=9??L5_*XQ"=N4ONSW@##L;9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW@##L;
M9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]X=-=-=K=9??L5_*XQ"=N
M4ONSW@##L;9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]X=-=-=K=9?
M?L5_*XQ"=N4ONSW@##L;9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]
MX=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW
M@##L;9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]X=-=-=K=9??L5_*
MXQ"=N4ONSW@##L;9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]X=-=-
M=K=9??L5_*XQ"=N4ONSW@##L;9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW@##L;
M9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]X=-=-=K=9??L5_*XQ"=N
M4ONSW@##L;9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]X=-=-=K=9?
M?L5_*XQ"=N4ONSW@##L;9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]
MX=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW
M@##L;9KB(]X=-=-=K=9??L5_*XQ"=N4ONSW@##L;9KB(]XHAM^QJ]/MFT#R)
MY##B3K$FQI)Q4H8S"C2C)*YC+,+, NV PLP&]" ,.]A$'>A!WO6];ST.%%E%
M#B$<:01E%8(R-EPC(R:14C*]L,ASK[S6&>_:M_*N?YTZZND7L4XH(24G5:I4
M>2F2IJL@ZA2I4& )(3D$Q)K,.//.,$$LHDHL(C###!! 6 (A"%H.M[SSR?\
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ME;C"%9PQN8 P969"(R.EE>JW.5,QB2,ZTJ9V5M(M.4J?T,6"Y46# !@ P 8
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M$:E&6+>Q[_O%0\I_GE]HN60ORR>P;/@ P 8 , & # !@ P 8 , & # !@ P
M8 , & # !@ P 8 , & # !@!P]Q*0N,RF<0YBA'+@^(V02"#/K(_MDKE(-U?
M7D1EC4LELU<6\EXTQ,$96LZ1UC933R>058LF>"68Y,Y!TZK6NQ'9;_AMLTGH
M]>3U$**(J_[K*=!%GIDI_4S$&2THQ;%KEO<;F]!N>$<8['!(8Z%2!X*-:(XU
M7'7E?LE=(&8I>!KYNS&&.AIKPQ;;QDOJF6K'E6!0N-3JRIT%D(TU//6RM>LO
MHL$:3RF2J%IRY"]E>OH%JF4&0, & # "@>Y/\O6K_LB<_P#3NF>C0?W*'_*Q
M_P % YQ_Y=[^*Y]]0N+@,:03/APA4/=3%1+7*Z2CD:<C4)A12TI ^P1&UK#$
M9IY*DDI4!.J,$G,.3GE .T 1A)H-; +A)]D^:>B7(_&6/O,VL,EI:;^X0]3A
M2$1<HQ3L34+'\+92$@@\DB)I2Q"%8L7P!B61]E+?S1M@REB4]$M-,<2T)#8:
M>I"6-.<D*T(D>K4ZF>FM?:,E"H1:*4]@P4;X?TL,DZUVA]HVE&H@XS%VGBZI
MF]9!SJ_-DD@=3WZ0FISW*"+Y\UM3Z^JUKPY1YGG3>Q#7KEHD[>G(4G$#5Z"R
M4K;7Z#I9ZA%[TGEK2MG_ $/H+AS@HF$V/;<)/[B=?9'$6,S2]M]ZU.2+'3V>
M!O"/;/LK48W($Q:42#9.W+;1L:?3P%9O2\*O]*?13^@FA6=!U]M3/\QY9?PT
M5]-%-DN#FOEB)VLF3UW-C7EF=TK<ZPZ7U8VM;=#)%"%8&PP38XMW)"56=IT"
M])%IXU2=4E,:U1S>)?'9T5]M<I&%Z5O33V4R&0B"V^%)6ZU!;S,Q26:6;:EK
MFU@@?IO.WZ/-,C5QR"SEH>$;(V*8BQP>,Q=M8&TZ3.;<3'V1J5'.[DK7'J%C
MHH*.#)':5:$15R=)>TQ!IL/.9TRTTY,Q"3F[A<ANT=H$S27V+:3G;5>FU-(I
M'/7AB.>V^MAI'Q*"(Q\<8C47;FY($4A=%RES.;EC^[.AQ;@]NSDH3IQ%1?'9
MD*AUH62OZ_L%Z5MIG4J5,[:"-+RX6U]B5C2M1FO<HL5!%[>B[M)YU-7B--\I
M;ZW0MDB1RUN/'%F**('DJ2Q5:?60VU&R:-6-LD&YO@EPT2Q6=)*H9GDJ1Y-/
M7[_4!IJ1%:=N<RJ19_6)LM&AV^VEA9$DL&Q4<(/%'!O]7LZF'%0F3F19\)D#
M6-R/<88YS1KV-P2H^4-1*81L#@G1IR5(1Z"8(R".F0BKIM]]/H$FFN<_56RS
M]9A\3:$3HD\L#"[/L^NG"9V4]V>]N\54058J-=I"S-C(Y,X4$S@<L83(_M,T
M(U"0E8SJG9$O"-2F>"];T6%721'0J9_R,@IH,RM,^OUV?KUB1*UKV-U1 XM7
M,1*5DQR(M)#0V:7JA+5QI16QF'*ERH02]'K%JDT]6J&6401L\\S2=.G(T626
M,ZG4\X$5"H68;QD"0P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
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MZ4% ) $A>21LO9A(S!P>;H+\S/\ ,26?I/\ (B_(2[D"0P 8 , & # !@ P
M8 , & # !@ P 8 , & # !@ P 8 , .<I;P[<YK456\W7-;\+DQ\<1Q1(CCF
MZI<F1D8TYH%2Q''DT\JN:+F33\O+)7R,;>XD#?%*5NTOV:G:6HA#-;*4+3G_
M ",12VM3T9OS(?%?PP1!PE;J]F2V?DQ%_L-FMB0U(0OC6JY?+%85#.X()(N
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MZ-F<JN^2DR*F2M;:D9^JE!4R4=E#I0J4,B*M"K73;_;HM+R@R!@ P 8 , &
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M1QY16Q&J1" G*UH8P[V8>,(@D@U_<:((@@T+>MZT >G !@ P 8 , & # !@
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M'[6!4!T>%1[31NM&:%K*GE.FDQ<LA>HA)&0)# !@ P 8 , & # !@ P 8 ,
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M4F_AK'H6Z>[?;1^:&.QMK]1SP!\7/#UV@_Q2;^&L>A;I[M]M'YH8[&VOU'/
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..)=ANN&7Q5Y#6?^T?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img134051827_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_20.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI8VAA96P@
M4F%I8FQE    !9 #  (    4   0J) $  (    4   0O)*1  (    #-#
M )*2  (    #-#   .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,30@,3(Z-3DZ-#$ ,C R,SHP
M,SHQ-" Q,CHU.3HT,0   $T :0!C &@ 80!E &P ( !2 &$ :0!B &P 90
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" 6Z!MX# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M$+\:7V@?\(W]M^Q^7^_^W>7OWQJ_W?+.,;L=>U:4Z<ZCM!$RDHJ[/8**^?\
M_AJ/_J3_ /RI_P#VJC_AJ/\ ZD__ ,J?_P!JK?ZG7_E_%&?MZ?<^@**^?_\
MAJ/_ *D__P J?_VJC_AJ/_J3_P#RI_\ VJCZG7_E_%![>GW/H"BOG_\ X:C_
M .I/_P#*G_\ :J/^&H_^I/\ _*G_ /:J/J=?^7\4'MZ?<^@**^?_ /AJ/_J3
M_P#RI_\ VJC_ (:C_P"I/_\ *G_]JH^IU_Y?Q0>WI]SZ HKY_P#^&H_^I/\
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M_J3_ /RI_P#VJCZG7_E_%![>GW/H"BOG_P#X:C_ZD_\ \J?_ -JH_P"&H_\
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M?_\ AJ/_ *D__P J?_VJC_AJ/_J3_P#RI_\ VJCZG7_E_%![>GW/H"BOG_\
MX:C_ .I/_P#*G_\ :J/^&H_^I/\ _*G_ /:J/J=?^7\4'MZ?<^@**^?_ /AJ
M/_J3_P#RI_\ VJC_ (:C_P"I/_\ *G_]JH^IU_Y?Q0>WI]SZ HKY_P#^&H_^
MI/\ _*G_ /:J/^&H_P#J3_\ RI__ &JCZG7_ )?Q0>WI]SZ HKY__P"&H_\
MJ3__ "I__:J/^&H_^I/_ /*G_P#:J/J=?^7\4'MZ?<^@**^?_P#AJ/\ ZD__
M ,J?_P!JH_X:C_ZD_P#\J?\ ]JH^IU_Y?Q0>WI]SZ HKY_\ ^&H_^I/_ /*G
M_P#:J/\ AJ/_ *D__P J?_VJCZG7_E_%![>GW/H"BOG_ /X:C_ZD_P#\J?\
M]JH_X:C_ .I/_P#*G_\ :J/J=?\ E_%![>GW/H"BOG__ (:C_P"I/_\ *G_]
MJH_X:C_ZD_\ \J?_ -JH^IU_Y?Q0>WI]SZ HKY__ .&H_P#J3_\ RI__ &JC
M_AJ/_J3_ /RI_P#VJCZG7_E_%![>GW/H"BOG_P#X:C_ZD_\ \J?_ -JH_P"&
MH_\ J3__ "I__:J/J=?^7\4'MZ?<^@**^?\ _AJ/_J3_ /RI_P#VJC_AJ/\
MZD__ ,J?_P!JH^IU_P"7\4'MZ?<^@**^?_\ AJ/_ *D__P J?_VJC_AJ/_J3
M_P#RI_\ VJCZG7_E_%![>GW/H"BOG_\ X:C_ .I/_P#*G_\ :J/^&H_^I/\
M_*G_ /:J/J=?^7\4'MZ?<^@**^?_ /AJ/_J3_P#RI_\ VJC_ (:C_P"I/_\
M*G_]JH^IU_Y?Q0>WI]SZ HKY_P#^&H_^I/\ _*G_ /:J/^&H_P#J3_\ RI__
M &JCZG7_ )?Q0>WI]SZ HKY__P"&H_\ J3__ "I__:J/^&H_^I/_ /*G_P#:
MJ/J=?^7\4'MZ?<^@**^?_P#AJ/\ ZD__ ,J?_P!JH_X:C_ZD_P#\J?\ ]JH^
MIU_Y?Q0>WI]SZ HKY_\ ^&H_^I/_ /*G_P#:J/\ AJ/_ *D__P J?_VJCZG7
M_E_%![>GW/H"BOG_ /X:C_ZD_P#\J?\ ]JH_X:C_ .I/_P#*G_\ :J/J=?\
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MH_\ J3__ "I__:J/^&H_^I/_ /*G_P#:J/J=?^7\4'MZ?<^@**^?_P#AJ/\
MZD__ ,J?_P!JH_X:C_ZD_P#\J?\ ]JH^IU_Y?Q0>WI]SZ HKY_\ ^&H_^I/_
M /*G_P#:J/\ AJ/_ *D__P J?_VJCZG7_E_%![>GW/H"BOG_ /X:C_ZD_P#\
MJ?\ ]JH_X:C_ .I/_P#*G_\ :J/J=?\ E_%![>GW/H"BOG__ (:C_P"I/_\
M*G_]JH_X:C_ZD_\ \J?_ -JH^IU_Y?Q0>WI]SZ HKY__ .&H_P#J3_\ RI__
M &JC_AJ/_J3_ /RI_P#VJCZG7_E_%![>GW/H"BOG_P#X:C_ZD_\ \J?_ -JH
M_P"&H_\ J3__ "I__:J/J=?^7\4'MZ?<^@**^?\ _AJ/_J3_ /RI_P#VJC_A
MJ/\ ZD__ ,J?_P!JH^IU_P"7\4'MZ?<^@**^?_\ AJ/_ *D__P J?_VJC_AJ
M/_J3_P#RI_\ VJCZG7_E_%![>GW/H"BOG_\ X:C_ .I/_P#*G_\ :J/^&H_^
MI/\ _*G_ /:J/J=?^7\4'MZ?<^@**^?_ /AJ/_J3_P#RI_\ VJC_ (:C_P"I
M/_\ *G_]JH^IU_Y?Q0>WI]SZ HKY_P#^&H_^I/\ _*G_ /:J/^&H_P#J3_\
MRI__ &JCZG7_ )?Q0>WI]SZ HKY__P"&H_\ J3__ "I__:J/^&H_^I/_ /*G
M_P#:J/J=?^7\4'MZ?<^@**^?_P#AJ/\ ZD__ ,J?_P!JH_X:C_ZD_P#\J?\
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M/_\ *G_]JH_X:C_ZD_\ \J?_ -JH^IU_Y?Q0>WI]SZ HKY__ .&H_P#J3_\
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M?_VJCZG7_E_%![>GW/H"BOG_ /X:C_ZD_P#\J?\ ]JH_X:C_ .I/_P#*G_\
M:J/J=?\ E_%![>GW/H"BOG__ (:C_P"I/_\ *G_]JH_X:C_ZD_\ \J?_ -JH
M^IU_Y?Q0>WI]SZ HKY__ .&H_P#J3_\ RI__ &JGQ?M11$GSO";H.VS4 W_M
M,4OJ=?\ E_(/;T^Y[[17@_\ PU!9_P#0KS_^!H_^(H_X:@L_^A7G_P# T?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^$[L1XW!8X;PG?$C/4_)S^IKCE\1:TNK2:HNL7XU"5=LEV+I_-<8 P7SDC
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M>\Y%:O4M%_Y-A\1_]AJ+^45>6U934KZ/39-.CO;A;&5Q)):K*PB=QT8IG!/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*\GK:G*4FV^Y$DE:P4445J0%%%% !1110 4444 %%%% !1110 4444 %%%%
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MDLO$$M_#/9A(V)*@IN.[!7H&X/6N4\2^./$?B\0+XBU22[2WSY481(T4^NU
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M8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC5[?33:R*2YM6</$<9 .[@\\<5E>'O$/B+Q!*TD-KI\5I;W)BFDDW@NH;D(
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M'ZQ)9W$5P@LYU+1.& /EGC(^M &M#-%<0I-;R)+$XRKHP96'J".M/K$\&_\
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M;<"?-N;0QH,#/)S6!HL][X.^UZ9=:-?WEL;AY;:XLH?-#*W9AG@\?YZUW%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=J<UI'$HCMH[92Z-GESSG:>W/X5O:CXDMK#4/L,5M=W]V$\QX;.+>8U[%LD
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU'49K&QO$N+B%=TBQ@D*,X^]C'X9IFJ^(])T21(]3O%AD<;E0*SL1ZX4$XH
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MY@5&61@/0,!F@#8HJGI.J6^LZ7#?V>[R9AD!QAE(."#[@BKE !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YN^
M_P"2IZ%_V!=2_P#1]C725S=]_P E3T+_ + NI?\ H^QKI* "N;\+_P#(Q>,_
M^PU'_P"F^SKI*YOPO_R,7C/_ +#4?_IOLZ .DKEOB%(__",I:H<"\NXH'/L3
MG_V6NIKE_B%!))X5-S#RUE<1W.!W"G!_GG\* '^.[@6/@>\CA&TRJMO&J_[1
M Q^6:CANKO2?%FC:()0;)M-V>6%&/,0?>!QGH.G2I?$=C<:^NB"RB$UC]KCN
M;A]P&(P,C@G)SGM4/C+2]7O+O2KS0(U:YM6E4LSA?+$B[=W/I[<TP(QXHGCO
MM?U*60MH^F*((HPH'FS<;L-C/7 ZXY!K&N/%&JK96]W;:_:76H7#H4TBUA20
M8)^Z6&6! ]^U;FI^$2? 1T3374S)MD#2<><X;<=WU.?TJSHLVJ+=1QS^%K?3
M488EGCN8R.G95&3SV- %37-3UJ7QG;:-H5Q'$&M3+.[1AQ&"V-Q[Y&.!QR1F
MHM8U74]*OM)T>YUE+<W"NTVJ26Z#<0?E4+]U>PS]*T]*TRZ3QAK.J7D/EI,L
M4-L=X.Y%'S'CID@=:K:^=;O5N]._X1VVU"UDX@G:Y50N1U96YR#GI0 FK:W>
M>&O#\7VR\M[Z^N9_*MIG B0@]&?'  '4C Z5GV>N:BOB73K.VUZ'75G)^UQP
M6Z!(%Q]X.O\ 4]J6\\*ZE;:'H"VT<.HW&E,3+;R, LH;J 6XXZ#-=!HDU\S/
M'=:#'I,(&5V7"/N;/3"C'XYH Q(=1\0:WXIU>RTR]CL["TD6/SVA61D8+@JH
M/4DY)SG&!6GX+U6\U;0Y)-1D6::&YD@\Y5"^8%Q\V!QW[5%X:TW4M+\.W[W,
M.W4KJ>:Y\O>I^=ONC.<=AW[U;\(:5-HWA6SL[M-EPH9I1N!^9F)ZCKUH U9D
MM^)[A8_W(+"20#]WQR<GI7&://\ :_$6M>+TB*Z?':M#"3P9PF"S?3Y,9_PI
M?$MMXBU76O(;1WN=$A(/DQ7<<7VD\'+DG.,]L5MP17NJ^'KW3[S2AI >!K>)
M!,D@PRD9^7H!0!2\#6:)X:.IWFUKK4F>XN)7'4$G ^F/YU4\#:?#J/@1X+I&
M^RW5Q(P56*Y3=TR.<9!%106OBP^&H_#RZ9!:XB^SOJ!N59?+Z$A!SG'%;SI>
M>'=+L;'0M(;48XD*-BX2+;C')W=222>* ,GP3:P?V[XAN[6%(X%N5M(1&N%"
MQC!QCZ@_K6AKGB"VT&XFF_L:]N9A$"US!:Y0CL&D[8_2J?@:TUC2[-K'5-)^
MSAG>=[DW"-O<D<;5R>G?VJ6;4?%_V>2V70;5ISE5NTNU\H?[6P_-^% "^ [)
M8-#EO1+#(VHW#W+" _)'DXV#Z8_SBNGKC(Q<>"/#&GZ3IPCO=4N9L)&<X8DY
M9N,':!CFNSI >?\ CW5I+#Q-IDD=N;C^SH)+LH.@+'8K-[!@*Z+PUHJVL1U2
M[N!?:C?*'ENNVTC(5/1>E00:'/<^,M9O=2MQ]BGM4M8=S ^8A&7X!R.1WQUK
M/MUU'POX+UJTU%2;:S1UL;C>I,B-D*" <C!(Z^O'2F VU\8W5MX+N=;OBLSW
M%X\=DC (NTG"C([##')YX/-0PZ]J4>M:7!;^(+?69;F=5N;6V@0I%&?O,'7G
MCW-22^&KR3P/H":?%'/<6#1W)MIN%ER,LISQU;O[UO:)-J!F:.X\.Q:3!MR6
M6X1RS=AM0?7G- &9!<(_Q"UK49R#;Z58)"6'.W/[QL>_!_E52/4?$UYX?G\2
M)J-O9VZJT\-@]N&#1KG[S]02!V]O6K=CX=OI]'\2)>)]ENM5GE,8+A@$QA,D
M?4Y]JS+W3_%M_P"#(]$33(K000I"[_:59KA5P!M[*,#)R>V* &6VH77ASP)H
M,<,JV9U"7,][)'O$*N2V[!XS@CKZ5O7&K7/ASPW=ZEJ.I1:M'\IM76-4+D\8
M.W@C/<=LU)J']JV<2:=9Z%!JNG"W2,;KA8R"!C#!N".!TK$/@W4D\"I8QB$W
MB7HO%MRV8QS_ *O)[?Y]Z (I?$6JPRV#6WB"TU.]N)D$FFVD*.BJ3R-ZY(QZ
MDUJ:MJNM7'C=-&T*>.*-;3S)WDC#"(EOO>I.,8&<<UH:+-J7VD1S^&8=+A8'
M?*ES&W../E4<TFBZ9=P^)]<U.^A$8N9(X[<[@<QHN,\'C/'6@"'POJ&HRZMK
M.FZG>+??8)(Q'<"(1EMRDD$#CC'\ZZ*6&*=0LT:2!2& =0<$=ZPO"FEW=C_:
MEUJ4/DW%]?/-MWAL)_#T)]ZH^,(O$5_<QV.F6$DFEE0;AX;F.-YO5 6/ _#F
MD!%;D>(OB-%J5B ;'2(GA:X'261@PVJ>X&[_ #D5+X.5=6U35_$$ZAY9+EK>
MW+#F.)  ,?7//TK3\.O>11?8Y?#XTBUA3]UBY20$YZ87GWR:PM*L_$_ARQNM
M*T_2H;I&F=[>]:Y554-T+(>3BF!8\*Q)/KWBL1Y2&2[$64.,, P;'H<FH-(T
MNRM_B7-!86ZPP:;8!<+U,CG.YB>2=I[^@K5T[3;OPKX:C@L+,ZK>/*9)PLJQ
M;W;[S9;TP!6=X;AU^T\1:C<W^A&--2G5WE-W&?)10<# )+=: &^-IQ:^(=#N
MH@M]-;2.?[-4%GD##&\  ],=3Z?6E\,R?\)-XGG\0S[+=[2/[+'9C/F1Y)^:
M3(')YP/\*D^QZYHWBO4]1M-*35HK[9LD^T+$\0 ^[\W;Z>@J[X<TB_AU74=:
MUA8H;J_VJ+>%MPB51@9/<_Y^@!6\%,(-0\0Z='Q%;:@SQK_=#YX^G%=97)^!
ME^TR:UJR_P"KOK]_*XZHO /ZG\JZRD 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLW4O#VEZO=0W.I6@N)(/N;G;:.<\J#@_B*TJ* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ IDT23PO%("4D4JP!(X(P>1R*?10!!965OIUE%:640B@A
M7:B DX'XU/110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 <W??\E3T+_L"ZE_Z/L:Z2N;OO^2IZ%_V!=2_]'V-=)0 5S?A?_D8O&?\
MV&H__3?9UTE<WX7_ .1B\9_]AJ/_ --]G0!TE%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 <W??\E3T+_L"ZE_Z/L:Z2N;OO^2IZ%_V!=2_]'V-=)0 5Y:_
MB+QCI'C?Q=!X8\"_\)#:-J<3O=?VO#:['^PVH*;'!)P IST^;':O4JYOPO\
M\C%XS_[#4?\ Z;[.@#FO^$V^)W_1(_\ RY;;_P")H_X3;XG?]$C_ /+EMO\
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MO2:* /-O^$V^)W_1(_\ RY;;_P")H_X3;XG?]$C_ /+EMO\ XFO2:* /-O\
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M (3;XG?]$C_\N6V_^)H_X3;XG?\ 1(__ "Y;;_XFO2:* /-O^$V^)W_1(_\
MRY;;_P")H_X3;XG?]$C_ /+EMO\ XFO2:* /-O\ A-OB=_T2/_RY;;_XFC_A
M-OB=_P!$C_\ +EMO_B:])HH \V_X3;XG?]$C_P#+EMO_ (FC_A-OB=_T2/\
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M;XG?]$C_ /+EMO\ XFO2:* /-O\ A-OB=_T2/_RY;;_XFC_A-OB=_P!$C_\
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MMO\ XFO2:* /-O\ A-OB=_T2/_RY;;_XFC_A-OB=_P!$C_\ +EMO_B:])HH
M\V_X3;XG?]$C_P#+EMO_ (FC_A-OB=_T2/\ \N6V_P#B:])HH \V_P"$V^)W
M_1(__+EMO_B:/^$V^)W_ $2/_P N6V_^)KTFB@#S;_A-OB=_T2/_ ,N6V_\
MB:/^$V^)W_1(_P#RY;;_ .)KTFB@#S;_ (3;XG?]$C_\N6V_^)H_X3;XG?\
M1(__ "Y;;_XFO2:* /-O^$V^)W_1(_\ RY;;_P")H_X3;XG?]$C_ /+EMO\
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MTVCW"64$UN9YYB-TBC:"JI[G)Y[8IW@BYGN_!>GSW4TD\SJVZ21BS-\[=2:
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 9^O_\ (MZE_P!>DO\
MZ :Y+PMX2M=5\*Z=-J-]J$\#+O-FUQB#(8_P@9_6N[DC26-HY55T<%65AD,#
MU!%-@@AM8%AMHDAB086.-0JJ/8"@#D_%"*OC3PBBJH599@J@<#"IBI-0_P"2
MJ:3_ ->,O]:Z>6TMYYXIIK>*26$DQ2.@+1YZ[3V_"AK6W>Z2Y>")KB-2J2E
M74'J >H% $&L?\@.^_Z]I/\ T$UYU?\ _)#;/_?'_HUJ]0=%D1DD4,K##*PR
M"/2JS:98-8BR:RMC:KT@,2^6.<_=QCK0!:HHHH **** "BBB@ HHHH ****
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M6NI:SMFGBF:WB,L (BD*#=&",$*>W'I2S6MO<21/<012O"V^-G0,4;U&>AI
M<"8HHO'VM1:IK-YI#7'ERP/%.L:S(%QR6!SCH!]:Z+PM9:5;RZC-I.IS:D\T
MJ_:)9)%?Y@.Q50#P?>MB[TZRU!5%_9V]T%^Z)HE?'YBI+>U@M(1%:01P1CHD
M2!0/P% %+5[_ $BW2.SUN6!([O*JEP/D?&,@D\#J.M<GHJ6>G?$)++PO=--I
MTMNTEW#')YD43<[2#V.<?G7<75G;7L7E7MO%<1]=DJ!Q^1IMI86=@A2QM(+9
M6Y*PQA ?RH \VU)IM-NM6\(VP(_M2\C>UP.%CD.7_ ;0/SKI];U:XTG4-,T'
M2Y;6PCE@.+JZ&5C5!@*HR 3QWKHWL;26\CNY+6%[F,;4F:,%T'H&ZCJ?SI+N
MPL[^,)?6L%R@.0LT8<#\#3 XSPK,\OQ"U8OJ,6HM]E0-<0QA%8@@= 2..F<T
M>"0/^%67/'5+C/OP:[.WT^SM)-]K:00OL";HX@IVCG&0.GM2PV5K;6IMK>VA
MB@.<Q1QA5.>O XYH \WND<?#KPQ<M)-%:V]TCSR0'YHQN8!QVR/7WK;BL-!N
M-5TUW\4W>H3I,)+:%KJ.3+#GHJY X]JZZ.TMHK06L5O$EN!M$*H @'ICI4-K
MI&FV,IELM/M;>0]7B@5#^8%(!8M5LYM5GTV*;==VZ!Y(]I^4'H<XP>H[U;K+
MTG1%TZ\OKV:;[3>7LN^28IMPH^Z@&3@ >]:E !1110 5XAJ_A'Q'+XKN56RN
M)GEN"Z7*J=A!.0V_H/Z5[?10 R)62%%D;>X4!F]3ZT^BB@ HHHH **** .,E
ML8-2^)&JV5VNZ&?251QWP7'(]ZP%O+B*_P!$T'4CNN]*U:.,.?\ EI$?N-S[
M<?3%>A1Z-;Q^(9=85Y/M$L @921LV@YSC&<\>M5M2\+Z?J>N66K3^:EU9L"A
MC8 /@Y ;(.>?3'6F!BQVMOJ_Q0U*/5(4N$LK6,6T4H#*-P!9L'CJ<4_2K:#3
M/B;?V>FA8K6;3UGE@C&$27> ..@X.?QK7U;PO9ZM?1WWG75E>1KL%Q9R^6Y7
MT/!S4NC>'K/1#,]N9I[BX.9KFX??))]30 GB?5?[%\-7MZ#B1(]L?/\ &>%_
M4Y_"O/;V=K/P7IL-MH^KPWVERK=?:)K)E3=G+Y;TYZGT%>C:QHEMK<=M'>M)
MY5O.L_EH0!(5Z!LCIST&*O3PI<V\D$R[HY4*./4$8-(#B/&4T>L6_A:6WEDB
MCO+Z(K)$V'0-CD'L1G\ZZ;2M#.ESO(=5U*]WKMV7DX=5YZ@ #FJ$G@FQDT6Q
MTW[9?(EA+YMO*DBB13DGKM[$\<9JUIWAUM/O5N#K6K7>T$>5<W =#D=QM% '
M,6\'_"'2&+7M)M[ZQENRR:FJJSJ6.1O4C.<]Q^M>@5S*>!=.5HDDO-1FM(7#
MQV4MSNA4CI\N,X_&NFH X#P/H.F:C!K-S?V<5S(VH30YE7=M7 /&>AY/(YK.
M#LWP/NT9BPCFV+D] )UXKO\ 1M$MM#AN8K1Y76XN&N'\P@X9L9 P!QQ5(>$-
M/'A>;0?-N?LLS[V?<N\'>&X.,=1Z4P.?U66-/%NB-<V4VI0PZ;O:VAA\TQYX
M$FWOZ?A4VC:8T%KXEU(Z:;"&[1_LT<D8214V'=QU4$X./:F>(]-N5\4VT\L6
MJ+80V?E0S:2N9MV>0Y'.,?A^M6?#EIJ5Q?ZA#-)JIT:6W\M/[4/[[S#P2N>0
M,9ZT 9.D>']+D^$MQ>26<3W+VDTQF9<N&3=MP>WW1P*DUN2YN]$\&68\J47:
MQLZ7+$1RN(UVAB.<9)X[UV%KX?M;3PR="C>8VK0O"79AOVOG/.,9^8]J9=^&
M=/OM!MM)N1(T-JB+#(&Q(A08# COB@#&M?#NLKXFL-3>#2+)+<,DPLF<&5".
MA!4 X-5/"VDV%_XH\2SWUK%<O'?,B"90X4$DG /&3@<^U=#I_AB&POX[N74M
M2OI8@1']LN=X3(P<  <XJSIFB6VE7=_<6S2L]_-YTH<@@-[8'3GWI 7Y(TEC
M:.5%='!5E89# ]017'_#ZQM/L=_<"U@\^+49D23RQN0<< ]0,']:[*L:T\,V
MUCKDVI6EU>Q^=(TLEJLW[EW8$%BN.3SGKUH YGP/H.F:C!K-S?V<5S(VH30Y
ME7=M7 /&>AY/(YI- O-/M_A>!KJ27%FMPT2PKDL^),JHY'<>N*Z_1M$MM#AN
M8K1Y76XN&N'\P@X9L9 P!QQ5)/!^FKX=.C,T[VYE,H<N ZMG.00!_*F!R]SO
MA\6^';B+P]_8F^X,896C'FJ1T*ITQGOZU=LM,LM1^*>O-?V\=P(8H"BRC<H)
MC49P>":V$\&VG]H6M[<ZAJ-W<6D@>)[B<-C';&W&/ISQUK0MM$MK37KW5HWE
M-Q>JBR*Q&T!0 ,#&>WK0!A>"8DM-5\16=N-EM#??NXA]U,@YP/P'Y4?$!@;;
M28F1KE6U!"]FBY:X4 D@>OT]ZWM.T:WTR]O[JW>5GOI?-E#D$ ^V!T_.L/QU
M97=XNF&"&YDM8;C?<-9*#.@QP4[COTH KZ5IZ:AXX75;717T^R@M?+/VFV$3
M/+NR"JGT'>H/"VDV%_XH\2SWUK%<O'?,B"90X4$DG /&3@<^U+I,6IGQ%9G2
MY=>^Q+N-Y_;&=A7' 7=SG_/K74Z9HEMI5W?W%LTK/?S>=*'((#>V!TY]Z .?
MOI],O->U"'3_  R=9O%(2\F?8JJ=N H9SP<#H,5S27,R?"5K?>\49U VS9.2
MD9;)&?K7<7'A&TFU"YNX+W4+,W9S<1VT^Q)3C&2,$_D13[;PGI=MX?GT;9)+
M9SNSLLC9*DG/! '3 Q0!SGCK0=)T_1K&:RLH+::.ZBC1HUVEESR#_>Z9YR:?
MK2WFH?$E+6""QN/LUCYD,5^6$>2WS,  <MV^@]JTF\ :=+%&EU?:E=>25\EI
M[@-Y(!!PHQ@ X Z=*T]9\-V>M307$LEQ;74&1'<VLFR11Z9]* ,WP[H.IZ;X
M@O;Z[6PM[>ZB4&WLF;;Y@/WL%1CC-=)<)));2I!+Y,K(0DA7=L;'!QWQZ5GZ
M3H,.DS2S"[O+R>8!6ENYC(V!T Z =:GU;2K?6;'[+=F15W!U>)RC(PZ$$4@.
M+U:#4M!\1Z5JOB"[36;?SQ;Q8C\IH'8?>5 2#T_3MQ7H)&1@\BN>M_!ME'J$
M%Y>WNH:E);G="+V?S%C/J!@<UT- 'F2[[71M0\(J=KMJR6T6X\B&0[P<?13^
M=$3O>Z)I7A.7F:/5'MYQGDQ1'<3CZ%?RKM)?"]A+XHCUYC+]JC7:$##RR<%0
MQ&,YP?6BW\+Z?;>)IM=C\W[5,I!0L-BD@ L!C.3CU[FF!S=]'?:C\2KZ.WM]
M/NFM+6,11WY;:BL 25 !R<GK5BVT+4=)T[Q)/>"Q@M[NU=UMK-F*(X1@2 P&
M,UN:MX8L]6O8KTS75G>1+L6YLY?+<KZ$X.13K/PW;6EC>V[7-Y<M?)LFFN9M
M\A&".#C P">U &'X0TZTL? <.IV]K$;[[/)*)V0,^[! Y/., # K&T#1-2U;
MP>ODV.B3I>*[/<7#R&8L206)"G!!]#VKT'2M-AT?2X+"U9VB@7:ID(+'G/.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M117*W?Q%T&SUEM.EDF+(_EO.J QH>AR<YX]A0!U5% .1D<BB@ HHHH ****
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MC)Y2.LD;,US)MX*+DYSD\\5KZ;XKM-0U0:=):7UA=,ADCCO(?+,BCJ1R??\
M*@#<HKB]-\87DWBC5+:;3-4DMU:!885M5W6V5^8OSD GD<GCTK4L;NQ7QAK2
M+<7GVB&*)KA9G'D(-@(*#J..N: .@HKE9_B!80VRW0TW5);21_+CN4MU\N0Y
MQP2P]*UEU^W.JV.G/!<17%[;_:%61 /+&,E6YX;VYH U**H_VM!_PD']C[9/
MM'V7[5NP-FS?MQG.<Y]JS;GQA9PW%S';66H7RVK%9YK6#<D;#J"21G'?&: .
M@HJO87UOJ=A%>64GF03+N1@,9KGO%;_;]:T30@08[J<SW"YQNCC&[:?8G^5
M'4T5A>)TUB6S==,NDLK=(7DFG S*2!D*OIGN>W:G>#;B:Z\':=-<RR32O&2T
MDC%F;YCU)H VZ*\Y\-PPZQ:S2:GXHU*"Z-U(BPIJ6SY0>,*>:W_$+O!>Z%IC
M:A<6UI.[K-.LI21]B?*"_8D]?6@#IZ*XG3_$5Q9:%<PQ2OJ-VVH36>FF1]S3
M 8PQ;N%R<GVKI+#2FAT'[!J-S)>O*C+<2RN3O+?>QGH.< >E &E17->!;J5]
M!DL+I]T^F7#V;$GDA3\OZ''X5TM !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-WW_)4]"_[
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M@>.,GI[5FR>%/$3^%&T!)M*AM@H'F1A]\N#D;N,#H,D9/%=W10!A7MKXBA:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<UTU% '*V^@:W-XJL-:U>[M&,"2(T%N&"QJ5P-N1DDDDG..V*ZJBB@ HHHH
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MIFM;3[#1&\36,Z>)+G4[Z%9#!&]RDH *X;.U>./>NI:UMWM?LSP1M;[0OE%
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MD'OC ]:UQHFE+<>>NF68FSGS!;INSZYQFK-Q;07<7E74$<\>0=DB!AD=#@T
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M9&DZA(-+N+G6-0TZ18YF'G6TO[M%XP&)Z,._X5KUY;;?\DEU_P#Z_G_]#CH
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M=M8WE^&OBI8@2W]HRMQZ QD_H#7?:!-%/X<TZ2!E:,VT>"O^Z./Z4P*GAOQ
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M]#GNM-N[0'RBT5Q*^81[EAVK+U#Q3#HMEI/VZ>TGN+QX8Y3'<!556'S3#/5
M1UX'/6N6A06OA[QM8VPVV=O,PA0'(3.<@?D*MZK:VTGA7P7+/!$S-<V,;NZ
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M 4444 %%%% !1110!S=]_P E3T+_ + NI?\ H^QKI*YN^_Y*GH7_ &!=2_\
M1]C724 %<WX7_P"1B\9_]AJ/_P!-]G725S?A?_D8O&?_ &&H_P#TWV= '244
M44 9VB:);:#9RVUF\KI+,TS&4@G<V,] ..*IZAX3L[W4WU""[OM/NI%"RR64
MWE^8!TW<'-;M% &-_P (Q9GP_<Z0TUT\5T2TLTDN^5F..=Q!YX':KZ:?"FD+
MIP+^2L'D D_-MV[>OKBK5% &1%X;LXO"QT!9)S:F-H]Y8;\$D]<8SSZ4^_\
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MY<2QW%];PW3[Y[2"?9#*>^5QGGZUTE% &?HNC6V@Z<+*R,AB#LX\P@D9.<<
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M6LJ212W$^]@%SA.F-N3GUXZU:U7PO9ZK?I?">ZL;Q%V?:+.7RW9?0\'-;5%
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MPQC/ YXKL** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2.RMK*?:LAMUD< YPH!XQP22>:([[5M9\"ZQ'=7BP7EA+/;SRQQ*1,$7D8/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3'J=E+.TUO(+E8FCW?PL#UQ[4R;PMJ2^!=6MV"7&K:G-]HE1&"J&+J=H)('
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?^OO_P!JQT@.R3QSICW<$;07L=O<R>7#>R0;8)#T&&)S^.*Z2N+\:@#P5IH
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M!=Q>6Q7^\.3QR/SKGIK=X/&W@Z"Y7]Y%92*X/.&$1_J*OW7_ "5BQ_[!C_\
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M7MHMO"C227$&WS21U0 G//\ ,4VV\96<^H6]G<6.HV+71VP/=V^Q9#Z Y/\
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M;OO^2IZ%_P!@74O_ $?8UTE<W??\E3T+_L"ZE_Z/L:Z2@ KF_"__ ",7C/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJZK;0S>&[J^FA1KO^S9%\TJ-P!0D@>G)H\&_\B7I7_7NM+XAMM<O+>2UT?\
ML_R)X6CE-TSAAN!'R[01T/>HO"UAK>E6,5AJOV!K:WB"1-;,Y<D?WMP _*D
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M^0+>>&[#%)5'0Y'(/ _+ZU-HVA7T>M3ZUKUQ#-?21>1'';@^7#'G.!GDG/\
M7UH Q]"L=1\5Z4VM76N:A9O<N_V>&TEV1Q*K%0"O\7(JZ;J\A^)EE8/=RO#_
M &5N=-V%=][#>5Z9XJ*QT'Q+H-O+I^AWFG-8F1FA:Z5_,A!.2 !P?QK1&A7A
M\:6NLRSQ/'#I_P!FDZAF?<23C& .?6@#G?$,]K9B^>7QI=KJB;WB@AEVQJ1]
MV,HN1[<GWJ+Q/OUGPGX?U2>YN4EGF@1TCDVIN.<OM'\6>A[5H6OA;7M/TN]T
MFRN--%M=,^;IU?SF5NQ&,9YQG)QFK=UX4N[CP/8:2EQ"E[9&.1).3&77\,XY
M]* (?$<]QX9T.TL;&]U">6]NQ%]HD/GS(I^]M]3Z#WJG97=_:^(-/_LQ/$4]
MM-)Y=VFIPNR*I_C#$?+BMG4]"U/7=$B749[6VU2VG$]O+:ABB,.F=W/^14UC
M%XJ>\@.J7&EQVT9S(+5'9Y>.GS<#\* ,FWBOO%/B#6/,U:]L+;3YOLT$5G)L
MRPZLW][Z>]/\ QS0W&OQ74WGS)J#*\N,;R!UQVS4[Z#KFF:Y?W?AVYLO(U!A
M)+'>*V8W[LNWK^-6O"N@7FA?VC]ONDNGNKCSA*,Y;CDD8X.>PS0!'XXFN['1
M(M2L9I8S8W,<LJHY DCS@J0.HY%8_B#Q!=0^,;&>RN)1IMGY(NPK'8PF) )'
M?Y<$9KL]1LDU'2[FSEQMN(FC.1G&1C-<IIW@N\C\):GIVIW,,M[>JJK*C$JH
MC51&#D \%: +,=Y=7OB[6Y8[F46FFV@@2-7(0RD;BV.A(Z9KFK\3ZG\%X-0O
M+Z[DFBW;LS$B;-QM^?/WL <>E=CX>T&YTS0+FWOYHYKZ\DDEGE0DJ6;CJ0#T
MQ^M4X/"-Q_PK?_A'+F>(7&UOWB9*;O-+CL#CH.E &;XYTH:5X"NHQ>WMYOGC
M;=>3F5EYZ GH*DUBVU3PVVF:G_;=Y=S2WB0W,,K_ +EP^<[4Z+TXJYJ^@^(-
M=\(RZ;J,VGB[,B%'B+[2J]2Q(SD^PK2\4:-<:W8VD-J\2-!>1SL9"0"JYR!@
M'GF@#;K@M+M-1\0:YK\,VN:A;6UK>.L26\I4@G..>RC'W17>UA>']#N-)U36
M;FXDB=+^Z\Z((22HYZY'7GMFD!S&BVVLZ_X;NKR\U^]CDL_,B@%L_E[F3G<_
M][/ I^IZ[J%Q\.=%U!;F6&YFNHTEDB8H7P6!SCUV]*Z'P]H-SI/AZ[L+B2)Y
M9I974H25 ;IG(%9DO@^_D\#Z9HPFMQ<6EPLLC[FV$!F/!QG/S>E,"6Y_Y+!:
M?]@D_P#HQJIZ):ZGXJM;G6'UN^LI&G=;6&!\11JIP-R]&K=ET2XD\>0:V'B^
MS1V)MRA)W[MQ.<8QCGUK,M/#GB'1_M5CHM_9)IMQ*9$>9&,T&[KM X/XT 2?
M#;/_  AR;N6\^7./]ZF^*O\ D=_"?_7:?^25I^$M%GT#05L;J1)765VW(200
M3D=0.:;K6B7&I>(M$OX7B6+3WD:57)W-N"@;>/;OB@#*B%YXJ\3:K$VJ7EC8
MZ;(($CLY?+9W_B)8>XZ5#:ZY?: GB*QOKE[]M+B6:VFEY9@XX#'O@D?K[5H3
M:%K.G:]>:CX;GLO+OMK3V]X'P' QN4KS_P#K^E/T_P */]BU4ZU<K<WVK+MN
M)(UPJ*!A0N>>/Z#TH KZ/H&H76GV.J7'B+4OM<P2=T$F8<'#;/+Z8QQ2>(VL
M(]2E.J^+;K3RR@06UK-Y?E<=6 R6R><G'I4FG:9XML+>VT\7VFFSMRJ"?8YF
M,8[;3\N<<4BZ!K6G:]J5[I$FG.M^X<R72OYD/'08'(]LB@#$EU2YU;X.7\M[
M-Y\T3>49?^>@$BX/Y&NZT?\ Y =C_P!>T?\ Z"*YF+PA?Q^ [_1&N+=[FYF:
M1)<D+@NIYXX/'85U=C UKIUM;R$%HHE1BO0D "D!/1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <W??\
ME3T+_L"ZE_Z/L:Z2N;OO^2IZ%_V!=2_]'V-=)0 5S?A?_D8O&?\ V&H__3?9
MUTE<WX7_ .1B\9_]AJ/_ --]G0!TE%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&@N)+=7 C)_U>"Q^N<CM5NXUJX_X3*TT:TCB:/[.UQ=NP)9!T4#!X.?7/!H
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MH [5[^UBOHK*2>-;F92T<1/S,!U(%6*YFXU&6+QQHUA<VED\TUH[27 C)=&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:W2SD5Y0A**3G )Z U@:]%+J4[/I_AO4K#7Q, EW"N(N&^\T@^5@1ZBO1:*
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M=)0 5S?A?_D8O&?_ &&H_P#TWV==)7-^%_\ D8O&?_8:C_\ 3?9T =)1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% '-WW_)4]"_[ NI?^C[&NDKF[[_ )*G
MH7_8%U+_ -'V-=)0 5S?A?\ Y&+QG_V&H_\ TWV==)7-^%_^1B\9_P#8:C_]
M-]G0!TE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $<]O#=0-#<Q)-
M$XPT<BAE;Z@U''86<5F;2*T@2V8$&!8P$(/4;>E1ZGJ]AH]MY^IW4=O&3@%S
MRQ]@.3^%4M.\6Z'JMT+:RU!'G/2-T:,M]-P&: -'^SK+[!]B^QV_V3&/L_E+
MY>,Y^[C'7FIHXTAB2*%%CC10JHHP% Z #L*=10!2CT;2X;K[3#IMI'/G/FK
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MD=S5N*030I*F=KJ&&?0B@!]%%% !115*/5[276IM*1V-W#$)77:<!3CO^(H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTA6MHFO(KZ*>X2*0!44!LX+'G&11?:=J^E>+I]:T:SCU"*\A6.XMS*(G5EP
MP)XZ ?K0!+H>I:I!XENM!UJ9+N2. 7,%TL8C+ID*05''4]O0UC>'[KQ;XC\-
MB_BUB&W=-RQJ+9&,[ G[Q/"]AP.V:VM#TS4YO$5UKVMQ):RR0"V@M4D\SRX\
M[CEAP3GT]ZY?P5=^(X/!WDZ1I<5W'*S^3/\ :%C,+9P=RG[WKQ0!JS>.9#X'
MT_44:&&\O9?LY>128X2"0SD>@ SCW[U#9>+)(/$&GVT>OQ:W!>2>3(GV<1-"
M3T88 R,^M69/!MW:^#]+M=/EC.I:;.+I"?NR/DDK^N,^U:UCJ/B.ZO(([K0H
M;&#/[Z5[M9,C'\(7W]: ,Y;W7?$&O:G#I.HQZ;::=)Y()MUE::3OG/0?2F^
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M1[FU\,VNDV]G<!I=DL;2,/4E>H&/<\UN:9I5Y;^/-;U&:';:W4<*PR;@=Q5
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M6^E:Y_;;I<3Z/(RF:-=OG#!(X'0Y'ZU;TS2KRW\>:WJ,T.VUNHX5ADW [BJ
M'C.1R.]5;/PY<S-XH@OD\F'4Y3Y,@8'((/S8![''!I@<^_C.[32QJ2^)K22[
MP)#I8M1LP3]S?C=D#OG_ !KT:RN1>V%O=*I59XED"GL",X_6N7TZX\6Z;I<.
MF_V'!<26Z")+LWBK&RC@$K][I76IN\M?,QOP-VWIGVI <987*6?Q#\57,N2D
M-K#(V.N!$"?Y5CCQG=SZ6^H_\)-:V]U@R)IGV4,F!T0OC.2.^>M='!H-U)XN
M\13W492RU&WCACE# EOW85N,Y&.>M5])/BG0M+325T2&^%OE(;M;M44KG@E3
MSQ_GUI@9WB^>[UCP]H>IPWAMX+F>#_1O*4[9#D[]QYXZ8Z&G^+-/U5+SPXDV
MMM+*;Q8UD^RH-LFXD28'' (&WI\N>];?BC3-1U;1]-CBA22YCO(9IU1P%4 '
M<1N/3)^M/\7:7>WT.GW6EQ+/<Z?>)<"%G"B11U&3T/3]: -C3X+FVL8XKZ[-
M[.N=TYC$>_DD?*.!@8'X5R]I(L7Q7U:20X5-.5F/H 5KJ;":YN+&.6^M/L<[
M9W0>8)-G)Q\PX/&#^-84.C79\?ZC?S0XL;BQ6%9-X^9OER,9R.A[4@.;7QG/
M?V<U^/$MMITI+&#3_LH<8'0.Q&<G'8]_PK6G\4WVH:/X?-@8[*?6)"CS,F\1
M;>#@'@DGIFC1XO$WAFQ.DP:1'J=O"[?9[D721?*23AE//>JWB[[3>WGAVSN[
M)+Z]?S));".4QQO\O7?G(*\X_&F!<TJ?6T\>3:7>ZV;RVM[83E?LT:[\\;20
M,@@D'CTKL*XWP]=0Z1KL>DS^'3I5Q?(SI(+H7'F;1G#-U'&:[*D 4444 %%%
M% !1110 4444 %%%% !1110 4444 <W??\E3T+_L"ZE_Z/L:Z2N;OO\ DJ>A
M?]@74O\ T?8UTE !7-^%_P#D8O&?_8:C_P#3?9UTE<WX7_Y&+QG_ -AJ/_TW
MV= '24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 5)-*LY=6BU-X<WD,9B27<>%/48SCN>U6ZJZAJ=II<,<M_-Y22RK$AVELNW
M0< U:H **** "BJ&N:I_8NAW6HF'SOLZ;O+W;=W..N#CK6?<>*!;R:"OV0M_
M;&,'S,>5E5/I\WWO:@#?HHHH **R=4UT:9K>DZ>;?S/[1>1?,WX\O: >F.<Y
M]JUJ "BBB@ HHK)M]=\_5]9L1:L3I:Q-E&W&;>A; 7'!XQU.: -:BJNF7C:A
MIL-U):S6C2 DPSKM=.<<C\*M4 %%%% !533-+L]'L5M--A\F!26";BW)Y/))
M-&HZG9Z3;+/J$WDQ,XC#;2V6/0< U;H **** "BBB@ HHHH **** "BBJDFI
MV<6J0Z=)-B[F0R1Q[3\RCJ<XQ0!;HHHH **K:=J-KJUA'>Z?+YUO+G8^TKG!
M(/! /4&H])U!]4T];F2RN+)F8@PW*;7&#UQ0!=HHHH **** "BBN>U7Q=%H\
MD_VG1]6:& _-<1VZF(CU#%AQ0!T-%<_:>+5O87ECT;5(8Q TZRW$ 2-@%W#Y
M@QZ]JOZ!JW]NZ#;:EY/D>>"?+W[MN&(ZX&>GI0!HT444 %%%% !1110 4444
M %%%5+34[.^N;J"UF\R6T?RYEVD;&].1S^% %NBBB@ HHHH **** "BBB@ H
MHHH **** "J&J:)IVLI&NI6RS>6<HVXJR_1@015^B@#+TWPYI.D7#3V%H$F9
M=ID=VD;'IEB2*U*** "BBLK2];_M+5]5L?L_E_V?(B;]^?,W G.,<=/>@#5H
MK,\1:Q_8&@7.I^1]H\C;^[W[=V6"]<'U]*OP2^?;QRXV^8@;'ID9H DHHHH
M**** "BBB@ HHHH **** .;OO^2IZ%_V!=2_]'V-=)7-WW_)4]"_[ NI?^C[
M&NDH *YOPO\ \C%XS_[#4?\ Z;[.NDKF_"__ ",7C/\ [#4?_IOLZ .DHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/#+)+ !I.//RQ^;"J/EXY^[WQ0!%I.IRZ3K_ (@T_5+B:6* &_@:1BY$)'S
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MF%?WC#(3L>,_4FLNP\1:G!\,K:=+J22_N[S[+'/,Q=EW,><GT -=+X7T;6-
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M/=WT.B;"+BZLV._?CY2S*,X[\=>:L:SI/B;4HKVP6YTN2PNBP5YXV\V)#V
MVDCL>O>K4VGZ]86]G!H-S92V\%JMNT-\C $J,;P5YR1VZ4 9>KZN-(\$)-H6
MI7%]]JN%ABNI'\YTW=<<9) ! !YR:H)=ZA9:A82Z2OB:X)G5+J/4(':-HSP6
M&1\I%:4?@=W\)W&G7-TBW<UV;U984PD4O& H_N\?K6A:0^+6N(%U"YTI+>-@
M97MT<R2@=1AN!GV_"@#.*7GB;Q=J=J=3O+"QTP)&J6<OEM([#)8GGC@\?3WI
MO@B">V\0>)(;JX-S+'/$K3,,%_E;!/OBK=SH6LV/B2ZU3P[/9!;Y5%Q!>!]N
MY1@,-O\ GDU/X9T"^T?4-4N=0NX[M[YXW\Q1M.X [LC& ,GC':@"+XB_\B#J
M/_;+_P!&I6-JUGJ?A_PU!K\.N7L]Q;^4\T$DG[AU8@;0@X'4?K73^*](GUWP
MQ=Z=:/&DTVS:TI(48=6.< ]A6+=^&O$.IVL.D:EJ%FVE1NN^2-6$\R*<J&'W
M1T'2@"PM_/9_$")99YGL-7M UNCL=L<B#D '@9'/'<U)X4NKG5M2UC5)+B5[
M1[CR+2(N=BJG!8+T&>.:K?$B(+X=M[N!_*O+:Y3[*5ZLQXVC\.?^ UO:!I@T
M;P_9Z>.L,0#>['EC^9- &C1112 **** "BBB@ HHHH YN^_Y*GH7_8%U+_T?
M8UTE<W??\E3T+_L"ZE_Z/L:Z2@ KF_"__(Q>,_\ L-1_^F^SKI*YOPO_ ,C%
MXS_[#4?_ *;[.@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5'<SK:VLMQ("4B0NP7K@#-5])U*'6-*@O[99%BG7<HD ##G'."?2@"Y1110
M4444 %%%% !1110 45A^(];N-'NM'BMXXW%]?);R&0$[5)P2,$<UN4 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2;!>I$#YG'.Y.F"><>YH RHM.B\,>/=+M-'9H;+4HI1-:^864,B[@P!SC/\
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M7J1@[84MEA5B1C+8SF@";Q)8VVH>';R*\B$J+$T@!)&&4$@\>]<SX6L+/1_
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M357TRYG0+./)$J2XZ$J2.??_ .O4FF^%TL;34//NY+N^U%2L]W(H!/!  4=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8C@GGKG/2NUFABN(6BN(DEC889'4,I^H-16FGV6GHRV%I!:JQRPAB" _7 H
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M2_\ 1]C724 %<WX7_P"1B\9_]AJ/_P!-]G725S?A?_D8O&?_ &&H_P#TWV=
M'24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 9KW%T/$\=NMU9"T-J
M7:W9O](+;C\P']WH,^N:EDUK2HDWRZE9HH<QY:=0-PZKUZCTKGKG_DL%I_V"
M3_Z,:L_P/H6F:C!K-S?V<5S(=0F@!E7=M7@\9Z'+'D<T =O)?6D0@,MU"@N&
M"PEI /-)Z!?4GVIT]S!;>7]HFCB\UQ''YCA=[GHHSU)]*\YL;&74?A&WE,QG
MT^=Y[<YY78Y./RW5J17Z>+?%FB&+:;>RM?MTP':5L!5^H//YTP.MN]4L-/95
MO[ZVMF;[HFF5,_3)J;[1"+?SS+'Y.W=YFX;<>N>F*\_TNUU'4]?\07$%II-X
MZWSP-_:!<LB+PH "D!<?GBKJ^#M4/@FYTB2>V64W9G@C1V:()D$1DD XSGMZ
M4 =3'K>E30RRPZG9R1PC,CK<*0@]SGBJ'AOQ79>(;56#P07+.P%K]H#O@'[V
M.#COTJGH=W:W>H7&DZGX?@T[4%MP\D8C1DFCSC(('(W=C_2JWPWL[7_A&TN1
M;0_:!/*OF^6-X&[IGK2 WM#N[B72GGU*]L;ADD?,UF^8U4=B3W'>GKXBT1Y!
M&FL6#.QVA1=(23Z8S7G%N6_X53+&C',NI[/*&<SY8?(,>O7\*Z""P@U;Q=I5
MS9>'I;"TLXY/M#75J(@^5PBA>Y!YS3 ZZ[U33[!U6_OK:V9AE1-,J$_3)JGK
MOB"VT30Y-19XIOES#'YP7SCZ*><\<\9K$OI],O->U"'3_#)UF\4A+R9]BJIV
MX"AG/!P.@Q6#:1K-\'M0$\2L;6618?, 8Q?..A[=3TH ]!TK5[/5[-)K.X@E
M;8K2)%*',9(S@XZ=_P J6/6=+FNOLT.I6DD^<>4LZEL_3.:Y;7U72OA=)-I=
MO'!)-;0K+)"H0D-M!)QUZD?C2^)?#NBV/@&:2TMH(WMH5DAND0!RP(P=PY.?
MZT@.NGOK2UD5+FZAA=E9E620*2!R3@]AWJ/^UM.^Q?;/M]K]ESCS_.79GTW9
MQ7$:G;)K7BKPC%J:F19[-GF4\;R(]V#[9'(K9\1>')9&TVYT2RLY%T^1Y#8.
MH2.;< ,],;AC()I@=':WEM?0^=97$-Q%G&^%PZY],BLKQ+XFM_#=I%)((Y99
M9%00M,$;:3RW0\"D\,:I9ZC:W*6NGC39[>8K<VNP+M?UR!@Y Z^U9?Q(MX'T
M&VEDBC:1;N)0[*"0I)R,^E(#J+:_L[RW:XM+N">%20TD4@91CDY(XJ.VU?3;
MV8PV>H6MQ*.J13JS#\ :YKQO;PVVCZ=I]M%':65[J,45R80$ 4]<@?3K[5!X
MWTG3](T>SOM*M8;.[MKN(0/ @5FR?NG'7\?2@#N*Y3PQXF$]A?S:]J-O$8]1
ME@A,S)$-BA2%'3.,_6NKK@/ VB:7J$>LW%]:0W,QU"6+]ZH;:G!X!Z9)//M0
M!WJ2I)$)(W5XV&0ZG((]<U6MM7TV\G,-IJ%K/*.L<4RLP_ &O-/M4]O\,;ZV
MAD(@756M4+-QY.0<9[#.?S-;ESX6UJY^PFWM-"L6M)4DCFM7D#@#M]SD$>M,
M#NJI+K.F.\2)J-HS3,5B43J2YSC YY.>*NUPGPVTFPET62^FM8I;G[6X6610
MQ0*<C;GIR2>*0'876JZ=8RK%>W]K;R-RJ33*A/X$UC>-M8N])\.QW>ESB.1K
MB-0X4,"ISZY%<UX=L]3UB/4[N.QT:\>>[D69[XOY@Q_#@*<  \4>(-*O=%^&
ML%CJ,L4CQWR[/*8LJH22%R0#QS3 ]"N[ZTL(Q)?74-LA. TT@0'\331J=@;$
MWHO;<VJ]9Q*NP?\  LX[U@^()]-_MZVMVT1M8U3R"T<6 5CCW8W$L=HYXSBL
M_P 'VR-KGB6QN=-2T@\R"0V,A614+*2>GRXX!XZ<>E(#<\-^*++Q#IT$RR00
MW4@8M9B</(@#$9(X/0 ].]7Y=7TV"Z^S3ZA:QW&<>4\ZAOR)S7*^!X;>W^'<
M6H6]O!]M2&<^<(P7)#O@$]>PXK)T#1-2U;P>ODV.B3I>*[/<7#R&8L206)"G
M!!]#VI@>D3SPVT+37,J0Q(,L\C!57ZDU@7>O>;XIT"WTN^AFL[PW(G\EE<,4
MC!7YAG&#Z5BZEI\PN/!^AZ[,L\9:7[1@DI*R*-@.<9ZXY]:L7^E:=IWQ*\/2
M:?!%;R3K<^:D0"CB(X.T=.IY[XH [*:>*VA>:XE2*)!EG=@JJ/4D]*Q/#GBR
MR\01-B2""Y\UT2W^T*SNJ_Q <'!'/2MN6*.>)HIXUDC889'7((]P:XKP);V\
M/AJ]OH;2![N&XG\M_+&[@<+GKC_&D!UEQK&F6EQY%WJ-I!-_SSEG56_(G-7
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MCS3*8R3U.T*.:WZ* "L;2/"VGZ+J%]=VGFL]Z<NLC J@R2548X&3WSTK9HH
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M;%;-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\
MU4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_
M (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S
M_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A
M3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\
M["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@
M?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HK
MS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X
M//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U
M4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH
M])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_
MB!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X
M4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_
M^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?
M_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^
MPH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('
M_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;
M_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\
M@\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5
M'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])
MHKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X
M@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W
M_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"P
MH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\
MU4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_
M (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S
M_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A
M3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\
M["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@
M?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HK
MS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X
M//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U
M4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH
M])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_
MB!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X
M4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_
M^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?
M_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^
MPH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('
M_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;
M_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\
M@\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5
M'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])
MHKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X
M@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W
M_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"P
MH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\
MU4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_
M (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S
M_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A
M3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\
M["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@
M?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HK
MS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X
M//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U
M4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH
M])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_
MB!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X
M4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_
M^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?
M_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^
MPH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('
M_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;
M_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\
M@\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5
M'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])
MHKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X
M@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W
M_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"P
MH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\
MU4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_
M (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S
M_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A
M3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\
M["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@
M?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH ])HK
MS;_A3?\ U4?X@?\ @\_^PH_X4W_U4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X
M//\ ["C_ (4W_P!5'^('_@\_^PH ])HKS;_A3?\ U4?X@?\ @\_^PH_X4W_U
M4?X@?^#S_P"PH ])HKS;_A3?_51_B!_X//\ ["C_ (4W_P!5'^('_@\_^PH
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M\-^(+W4-0U#2]9MHH+^Q9=Y@)V.K#@C//_ZZ .BHHHH **** "BBB@ HHHH
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MH **** "BBB@ HHHH **** "BBN6N_'<%@$-YH>M0J\@C1GME 9CT R_4XH
MZFBN;O/&!M?#]]J;:-?P_9/+_=7B"'S-S;?E(W=,\\>E=!!+Y]O'+C;YB!L>
MF1F@"2BBB@ HHHH **** "BJNIWC:?ILUU':S7;1@$0P+N=^<<#\:GAD,UO'
M(4:,NH;8XP5R.A]Z 'T444 %%4K?4'GU>[LFLKB);<(5N'3$<N1G"GOCH:?I
MNIVFK6?VK3YO.AW%=VTKR#@\$ T 6J*** "BBB@ HKGM"\2W6O7+/;Z0R:;O
M=%O&N%R2O^QC//U-=#0 4444 %%0WEY!I]E+=WDGEP0J6=\$X'T'-13ZBB:.
MVH6L4MVGD^;''"A+R C(P.O- %NBHK2<W-E!.T3PF6-7,4@PR9&=I'J.E2T
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M'GH:EH **** "BBB@ HHHH **RI=;\KQ7!HOV?/FVIN/.W],'&-N/;KFM6@
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M2/6B\OVF.W^SA01LVY)SC&<\^M5-2\)6.H:E_:$<]W87A&UY[*;RV<>_!!H
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M._O6[?\ A?3K[0H=(VR6]I RLBPD @CZ@^IS5K5-)@U;[']I:1?L=TEU'Y9
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M2+D*"1P3@\XK?I %%%% !1110 4444 %>(:OXN\1Q>*[EEO;B%X;AD2V5CL
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M_M:^O[?41)%.EU)O 95!#+_=Y/0>E2^(VL(]2E.J^+;K3RR@06UK-Y?E<=6
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M137GF:E;J]Q-:H9)V58U9MO?)W9S[&I-$NK^'Q5;06B:[+IMQ&XG.JPO^Z8
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M1Y)M5-M:6JO*=,B)EFD/<E>57^M6K'0?$N@V\NGZ'>:<UB9&:%KI7\R$$Y(
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M$*&ZC'/ !S^%9?A#5?,\47^FVFK3:KIXMUFAEN'+NAR 5W'![_RI =M1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $5W<I9V4]U*"8X
M8VD;:.< 9./RK-\/>);'Q-9R7&G^8OEOM>.90&7N#P3P:GU__D6]2_Z])?\
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MUJ\NY9KU(;N%W_<L'SG8G1<8XHUW5Y[GQA/IC/JR6=G"K,FE1L9'=AG+,O(
M!Z>M '<T5Q&E7^J)IOB"&4:F+:"V:6RN;^)HY1\AR,GJ0>AK-BMM5D^'Z^('
M\0:C]KCA\R.-9<1X4XPP_B)QG)I@>@7NHVNG?9_MDOE_:9UMXOE)W2-T' XZ
M=3Q5FN"\56S:K8>&+^6[NHGNKNUC9(92J*7!)=1V<9X;M79Z;8#3;,6XN;FZ
MP2?,NI?,<Y]Z0%JBN4\07-Y?^+;#P_:7LMC#) US<2P'$C*"0%![<BHHH[[0
M?%]EI9U*\O+#5(90INI=\D3HNXD-U]/S]J +_P#PDMU/XBN--TS27NXK1T2Y
MN//5/+W<\*1\V.>_:NAK@?"NB!?&&MG^T=1/V.XBQFY)\[*G_6?WJ[Z@ HHH
MH **** "BBB@ HHHH **** "BBB@ JNU_:IJ"6+SQBZD0ND1/S,H[XJQ7.W>
MH^7\1+&P^R6K>99M)]I:/,J\M\H;L..GO0!T5175U!96KW%W*L,,8R[N<!17
M)VGB'Q)J]]JEMI-GIZBPNY(?.N"X5P#A5P#G=P23P.E.?Q,VH_#J\U66Q@::
M$-'+;3KOB+!@#QW'.: .MBE2>%)86#QR*&5@>&!Y!IU<SJ'B-]/L-(MK**T2
M\OXE*"5_+A@4*"2?8= *32O$MVWB%-(U1K"=YXC)!<6#DJ<=58$D@XYZT =/
M17(VVO>(==-S=>'K73UL896CC-VS[YRO4C;P/QJEK[:\_C3PZT2Z?%,R3FW2
M3>P1O*'F!R#SWQC\: .TGOK6VNK>WN)XXYKDD0HQP9".N/SJ>N7U/4+FTUWP
MU;7]I83W-TTHDE$9/E$!>8R3E<YY^E$FNZSJFMWMCX<@LA%8,$FN+TN0S_W5
M"^E '07&G65W-'+=V=O/)%_JWEB5BGT)'%6*Y>R\4W4VBZV;NUC@U/1XW,L8
M):-B%+*1WP=M9Q\5>)1X<CU\Z?IXL JM)$7;S7' ++S@#/0')Q0!W-%1V\ZW
M-K%/'G9*@=<]<$9KG;G7-5NO%%YH^C#3XFLXT9VO=Y,NX9^4*1P.YYH WKF_
MM;.6".ZGCB>X?9$K'!=O058KF=?U&6ROO#D5U9V4\]S<JDC/&7\IN,F,GD<G
M@UC$>(#\3;_["VF^?]C&WSEDV^3O^7H<[NF>W6@#NHK2W@FEFA@BCEF(,KH@
M#2$=-Q[_ (U+7,ZMXDN8]?.D:6UC%)%$)9[B^<A%ST4 $$GOUJ?PYXAEU2[O
M;"^%M]KLRN7M7W12JPR&7_"@#?HK!\7Z]<>'=)@N[2%)F>Y2)D<$Y4YSC!'/
M%07&N:MH>A7.H^(8++?E!;6]J[9+-_"Q/&>G(XX- '2U%<6EO=JBW4$4ZHX=
M!(@;:PZ$9Z'WKD6\5ZEILUI)JLFD7%K<2K%(MC*3) 6[G).X#VK9U*7Q(U\T
M6C6VGQVZ*#Y]X['S#Z!4Y&/>@#:HKE[/Q@?^$2OM6U.U\J?3Y7@GAC/!D!
M&>F2PJ73KOQ9++:S7UEIJVLY!DCC=Q+"I[G/!/L* .CJ""^M;FZN+>WGCDFM
MB!,BG)C)Z9_*N'\,#Q!_PEVMX;3<_:8?MN5DY&#_ *OGTSU[XK8TO6HEUSQ.
M9K6V@BT_RW>:&/$DHVL27/\ $1CCZT =/17&QZ_XJN]&;6K6PTY;+894MI&?
MSFC'?(^7..:DU7QG-%HVBZAI%HMQ_:4PC\F3[W/&T'/!W<9Z4 ==17+0Z[KE
MAX@L+#Q!;60BU$,(7M&8F-P,[6W=?P]:!KNL:GKVH6&BC3H18,$87F\O(>Y
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M\7Z'<^(-%6SLWB203I)F4D# SGH#6[5/5-6LM%LC=ZG/Y$ 8+OVEN3TX )H
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M'IU[):7EXT<T1PZBWD;!Z]0I% &78Z#XET&WET_0[S3FL3(S0M=*_F0@G)
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MYNK<78M3/&+@IY@AWC>5SC=MZXSWI(KVUGCDD@N89$B8I(R2 A&'4$CH1Z4
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M&WB6>6"1(9OLOE2,A"R8C(.#WP>M=#5/5-._M2Q-L;NZM QR9+638_TS@\4
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M(I4L0^<<^HSC\*]#HH \^\3:GJOB/PZMK;>'M1A='CDN#-"5QAAP@ZOR<Y[
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M46^N([>0CKM+,3_Z"*Z?QIX?FUK2TET[ U&T8O!R!O!X9"3ZC^54U\*7%_\
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M1]I?&<C^\V.F>M=%H&DPZ-HT%K!$8CM#2J7+_.0-W))].W%,#2HHHI %%%%
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MFBN[)WP<JIRNX>HXS57PM_R._BS_ *[0?^@O6?9#_B4^//\ KM<_^BVH O\
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M6G_8)/\ Z,:LC19K:W\">)9;ZU^UP+J4Q>#S"F\?)QN'(K7N?^2OVG_8)/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!/86EBDVF.VJ7S%8K&.4-R.22_3 ').* -RBL+3O$4TNL_V5J^G-I]V\9EA
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M4VM6CV,'@NTEQYEO=01-CU50#_*NWHH Y'QI,MCK'A[4[@,+2UN7$T@4D(&
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M3X[&WA5;:-/+6,_,-OISU_&@#SSQ%?ZCJ?P_DN?[.TVQTIPA@C\T^:/F&"H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4)^525/R8Q2 ]&HH!#*"IR#R".]>?:=H-IK_ (Y\2+JGF2V\$L9%N'*JS%2
MQP0> #CZT >@T5Y]J4<VJ>-+^QDTF35K/3884BM1=+$B;DW;B&(W'MWZ?2I[
M.QU/3O"_B>*\LY+*Q-K(]E#)<+*8P8VW*""> <8SZT =U17ET^A6\'PU@U])
M;C^U88HI(KDS'* ,%" = H%7=;T:'0M+TK7+.6=M3^U1&:YDE8M,'Y8,.F/;
MTI@=O)<7ZZU#!'9*U@T1:2Y\P H_.%V]3VY]Z9IVLV^IWM_:VZ2J]C+Y4I<
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MM"\-7%A?02*QN6U"-S*O\0<;N<T@/1Z*X._TJ'6_BI/:7KR&V73UDDB5BHE
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MV[E+P7R)Y7) "*6!7&/3]*L>)=*G;P+I,WB&#.J0SI [-)N.PN>"0<'("\T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"I'I5G%JTNII#B\EC$3R[CRHQ@8SC
ML.U.GTZUN=0M;V>+=<6>_P A]Q&S>,-QG!R/6K-% &3JGA?1M:N%GU*R6691
MM$BNR-CT)4C-3P:)IEMI+:9!91+9N"&AQD-GKGN3[U?HH R-,\*Z+H]U]ITZ
MQ6*;;M#L[.5'H-Q./PK"T_P5!>:MK4WB#3U>.>\:6V?S<$J<YY4Y';@UVE%
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M[Z9)=X-Q&8%F21A_%@D8-='10!B/X<-YX=N=+U>_FOC<L6>=P%*G@C:!P "
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M_M'D;OWFS;NW,6Z9/KCK4?B#P_'KD5NRW$EI=VLGF6]S&,F,]^.X.!^5:]%
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MNQHH KV$-U;V,<5_="\N%SOG$0CW\G'RCIQ@?A5BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .;
MOO\ DJ>A?]@74O\ T?8UTE<W??\ )4]"_P"P+J7_ */L:Z2@ KF_"_\ R,7C
M/_L-1_\ IOLZZ2N;\+_\C%XS_P"PU'_Z;[.@#I**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ;(&:-@C;&((#8S@^M<%X2T_5/^$FUHC6F @O5^TC[,G^D]
M?^^?PKOZY73['5]&\6:D\.GK=6&I3I+]H%PJ&'^]E3R>O;TH I6EYXCUOQ)K
M-C9ZK'96UC/A9/LR2,,YPH![<$DGFC5_%9;Q)=Z<-<AT6WLPH,A@$CS.1D@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1; [+4WP1'7S<";D8![8Z^] ':^8GF>7N7?C=MSSCUQ3JYNUNK1_B%- =/\
M+O\ ^S0\ESYQ/R[U^3;TZD?-[5$OBZ^OGN)-!T&74+.W<HUP;A8MY'7:I!+4
M =317.3^,;8>"Y/$-I TR1[0T#-L96+A2I.#C&<U7?QI<6\EK/?:'/;:9=RB
M.*[>4;AG[I:,#(!Z]: .KHK!O_$5Q'KCZ3I&F_;[J*(2S;IQ"J ].2#DUL6D
MLTUI')=6YMIF&7A+A]A],C@T 35']I@^U?9?.C^T;/,\G>-^W.-V.N,\9K(U
MOQ$VF7]KIUC8OJ&H7(+) KA J#JS,>G_ -8UB:1J,^H_$Z1KNQDL9X=(,4D,
MC!N?.!R&'!&".: .VHKFO^$HOKN2Z;0]$>_M;60QM.;A8][+UV+@[OZUF^*_
M$EQ=_#_^TM"25(IP/,N%G\N2V(D48P.22<KP: .WHK#;7[FPT6YU#Q!IOV 0
MD!(H[A9FESP,8 YR<8JM_P )3>V<UJ=;T1["UNI%C2<7"R;&;H'4 ;: .EHK
MF=0\6W%OXEET2PTA[VZ6-73;,$!!&3DD84#U[T:GXMGTS4+"P;1Y9KN\M_-\
MF*4$H_\ <SC! YRV<<9H Z:BN1C\:WAOY=+E\/SKJRD%+99U9&4C.XR8P!^'
M>M#2O$(UBTU**\L7M+FQ)2YMFD#]B>&'4'!H W$D25 \;*ZGHRG(-.KB['Q-
M9:+\.[#4[+2S#:O*8UM1.6\O,C G<02>03^-7(_%UW'J%C%J>ASV-KJ$@BMY
MWF5FW'H&0?=S]: .HHK%U37Y+758]+TRP;4+YH_.9!*(UC3.,LQSC)[8I-+\
M2)=O?0:E;-IUW8+OGB=PX"8SN##J/PH V9)4AB>69UCC12SNQP% ZDGL*(Y4
MFB26%UDC=0R.IR&!Z$'N*X;5?%MYJ/A74+B/0+A=,N+>6*.[\U2W*E0QCZA<
M]\UU'AK_ )%/2/\ KQA_] % %X75N;LVHGB-P$\PP[QO"YQNV]<9[U+7!7NH
M3:?\5IVM+&6^GETY8XX8V"\[U.68\*, \_2M:#Q=/)#JD5QI+V^I:=%YS6;3
M B1,9RK@?T[B@#IZ*PKGQ3;P>#5\0+'O1HE=8=^"6) V9QV/&<=JV;:226UB
MDFB\F1T#/'G.PD<C/?% $E%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!S=]_R5/0O^P+J7_H^QKI*YN^_P"2IZ%_V!=2_P#1]C724 %<WX7_ .1B
M\9_]AJ/_ --]G725S?A?_D8O&?\ V&H__3?9T =)1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7":G\+;+4==EOEOY(89I#)) L0/).3AL\<^QKNZ* &11)!"D42[4C4*H] .!
M3Z** "BBB@ KD],17^)7B!'4,K6T ((R"-HKK** /+DLKC1?'VDZ*X8V<-W)
M/9N>?W;KRN?8BMF#48/"?C+63K9DAMM29)H+G860X!RI('!&?\YKN**8'(^&
M2VJ^+-5U^&)X[&:-((&D4J9=N,L >W%6O'6F7>I>'T;3D\RYL[A+E(QU?;D8
M'OS^E=)12 Y:/X@Z1-:KY"7,E^PP+!86\S=_=Z8_&I/';,_P_P!0:1-CF-"R
M9SM.]>,UTM% &*^GG5/ ZV(.UI[!44GL2@Q^M86@>,;+2-&@TOQ#YME?62"'
MRWA8^8%X4K@<\8KMZ* .$\2WMQXGM](T:WAELGU&9IG69<LD*$D,RY[]<>V*
MB\5Z/KUG80ZS<:TFH/I<JSI&+-8B!D9Y!/Y5Z!10!P6M:S8VWCS0-6N9O*LI
M+%W$C*3PP..F?45U.E>)-)UR62/2KQ;AXUW. C# _$"M2B@#D_B,RKX=MS*X
MBC^VQ;IART0Y^91GYB/3TS5'0[[2K[Q/;75[XD_M&_CC:*UC:T:V49Z\$<DU
MTFOZ"NN0VVVX:VN+28302A X5AZJ>"*I?\(S>WFHV=SKFL?;ELI?.ABCM5A&
M\="2"2?I0!3\( CQ5XJR/^7M/_9JIZIK#MXHOK36=9N]'M8-OV6*UCPUP".6
MW;3GGM7=T4 >9:?87.H?"W7;6VCFDG-\[!)!^\.UD8@C^]P>/6IO%?BZQUKP
M/-::='-).Z1M.BQ,HM@KJ3N)&.HP,>M>CT4P.%\96EM%XLT[4]9@FDTHP-!-
M)$SCRFR2"=A!QS_.KOAJ/PM/K+3>'H9Y9HX3FY9IF0 D?+ESU[\#UKK:*0%3
M5;V+3]+FN;F&2>%  \<4>]BI(!X[@9R?8&O/=:GT+4IK%? ]N%U@3KM:T@:(
M1KSG?P!C_"O3:* "N!\.:Y9>$(+[2=>:2VN([J22-C$S"=3C!4@<YKOJ* /-
M;FUN!\//$FI7$#V_]I77VF*)QA@A=<$_7G_)KOM(XT2QS_S[Q_\ H(JY10!@
M^(O#UUK5Y87%KJ8LC9.9$5K<2@OQAL$CD?CUKGX=.UI/B6D<NN+).NF"1IOL
M2C=%YW,>W/'/.[K7?44 5M2FGMM)NY[2/S9XX'>),9W,%) _.O*];U&/4?!T
MCS:]J-[J,BHTUFL82&([@2&7;P > <\G%>NT4 <=XBN%T3QSINM7R.-/-LUM
M),J%A$Q)()Q]?YU6LM6AUKXG6MU9QR?9A8/''*Z%1+ALDJ#SCG'X5W5% 'F/
MB&*ZL?$6HZ!:*?+\0R12HW]S+?O#^.#^%:GC+3+>TU+1+RZM99=(M$:WG6%F
M!B4@!3\IS@?T]Z[JBF!QWAY?"5QKL<F@0W$]S%&S"XW3,D8(P02YQDY]*?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .;OO\
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M.#CMVK1ILDB0Q/+,ZQQHI9G8X"@=23V% 'F</@^XCTO[-)X4\S4-I7^T!J0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/:LK33X(N]4LETR&ZN;L3*\:A[AO)8<[FW' QCWJ]HH/_"S_ !(<<>5;\_\
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M[SQ=!;6FEZ@D!DTR_8(]T7P8">FY<>N0>>,5*GB03ZCJL%M:F2WTR(F6X\S
M:4#/E@8[ ')[>E8FM26I\*V'AW0[-HWU4!8+>8$M#'G<SL"21CK_ /JJ+0F_
ML73=:\+W:JL]M#+-!)C'VB)E/S>Y'_UNU,"U!XZO[O1_[4M/#<\MG&FZ:0W"
MKMQUV@C+@>O'>M:\\4VL&CV5]:127;Z@56U@3 :1CV/ICN>U<AH7BW3[+X>#
M39UG%Z8)(X81$Q\\L6P5(&,<\_0TNI:'-8>%?#,FHVLLUO8.QO8XBP=%DY_A
MP>.G% '5VGB.Y&LP:;K6EG3YKI6:W<3B5)"O)&0!@X[53_X3&]N-9OM,TK0I
M+V>SD*L?M*HI4=R2, D]!5715\&W6N6IT2*XN;J/<ZR[IV6'CJV\X&>E3>$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M444 %%%% !1110 4444 %%%% !144MW;P310S3Q1RS$B)'<!I".NT=_PJ6@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4457O+^UT^)9+V>.!'<(K.<
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M_H^QKI*YN^_Y*GH7_8%U+_T?8UTE !7-^%_^1B\9_P#8:C_]-]G725S?A?\
MY&+QG_V&H_\ TWV= '24444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYJ,ES#=1Q9BVOS\S9P.@_.L[4M%OCXX>S@LY7TS4;J"\FE"DQKY8;<I/0;B
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ.>>&VA,MS*D,:]7
MD8*!^)H I/HEM)XCCUHO+]ICM_LX4$;-N2<XQG//K6C5*VUG3+V01V>HVEPY
MZ+%.K'\@:NT %%%% !15>^OK?3;&6\O9/*@A&YWVDX'T'-2PRI/ DT3;HY%#
M*<=01D4 /HHH)P,G@4 %%4X=8TRYN?L]OJ-I+/\ \\DG5F_('-7* "BBJ,6L
MZ?-;7EPERHALI7AN'8%1&Z_>'/IGM0!>ID\*7%O)!,"8Y%*, 2,@C!Y'(HAF
MCN+>.:!Q)%(H='4\,",@BGT 0VEI!8VD5K:1+%#$H5$7H!4U%% !152+5;.;
M59]-BFW7=N@>2/:?E4]#G&._K5N@ HHHH **** "BBB@ JCJ^CVNMV/V6]#[
M X=&C;:R,.C ^M6KFXBM+66YN&V0PH9)&P3M4#)/'M3;.\@U"RBN[.3S()E#
M(^",CZ'F@#&3PC;M<0R7^HZCJ*PN)$ANYPT88="0 ,D>];]5[B_M;6>"&YGC
MBEN&*PHQP7(["K% !152^U2STV2V2]F\IKJ80PC:3O<]!P./J>*MT %%%% !
M5+5]+@UK29]/NVD6&< ,8R PP0>,@^E7:* ([:!;6UBMXR2D2!%+=< 8J2BB
M@ HHHH **** "BJ^H:A;:782WE_+Y5O$ 7?:6QDXZ#GJ:FC=98U=#E6 (/J#
M0 ZBBB@ HJMIVHVNK6$=[I\OG6\N=C[2N<$@\$ ]0:LT %%%% !1110 4444
M %%%% &=!HEM;^(+K6$>4W%U&L;J2-@"XQ@8SGCUK1HHH **** "BBB@ HHH
MH **** "BBH+:^M;UIEM9XY6@D,4H0YV,.H- $]%1SSQVUO)/.VR*)"[MC.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KBX[6/Q7XYU%=3'G6&D;(X;9
MC\C2,#EB._0_I7:5R%]::EX=\5W&M:;92:A8WZJ+NWA_UB,HP&4=_P#ZYZ4
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MYL?!\,-[;RV\HED)CE0JP&[T-("JOBO4M2:ZFTB32(+6&1HXEO92))]O4C!
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MT@8G(&T <\C//M61H%YJ_AO26T$Z'>7-U!(ZVLR)^X<,Q(+/V&2: -7X=?\
M(@Z=_P!M?_1KU2\??VG]HT3[&;00_P!I0>7YH;=Y^6VYQQLQU[UI>!+2>Q\%
MV-M>0R0S1F0,DBE2/WC$<'VYIGC:VNY=-L+FQMI+I['4(;IHHQEF5<YP._44
M )J6NZKHVGV<%S!:76L7T_E0QP%EB^IW<\<9J,:[K>DZQ8VOB.WL7@OY/)BG
MLBXV2'H&#=<U7U[[;J:Z/K^G:9=E].N'+V<Z>7*R-@$A?PI+N>^\5ZQI4<&E
MWMC96-TMY-+?1>469/NJH[]30!UEW]I^QR_8/*%SM_=^<#LS[XYQ7%?#K^V/
ML3DM9?V?]JE\P8?S=_MSC&<5W=<?X-:ZTB2YT6]TV]5S=RR)="']P4/(._/?
M'3W%(!/#WB'Q%X@E:2&UT^*TM[DQ322;P74-R$ )Y"]SQDBGR>*+^_O[Q-'E
MTFWM[24P[[^4[IG'7: 1A>V>?\)? %G<V6B7<=Y;RP.U]*ZK*A4E3C!Y[5C6
MNG0Z!J6HV^L>%Y-6BFN6GM[N"R6<E6_A;/3'^-,#H--\17NL^&3>Z98I)?+(
M8'A:4!%<'!.[NN#GU[5%!K>MV'B*QTWQ!#8&._#B&:S+C:RC.#N_#\ZJZHE^
MW@L'0M(FTHO< RVMJJI-Y6<$@+T8X'3FLF#3$;Q5HEQI.BZK;P0RMY]Q>"3+
M';U(8G;]>,YH FTX>(O^%A:QY+:9]H\N'SMZR;-F.-O.<XZYXS6K=>(-<F\7
M7NB:1:V;^1''()K@L @*@DM@\\D  5'(]UHOQ OKU]-O;NUOX(E22UAWA67
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M#^;G#?>SQZ]/:JNBZOXBTOP);7]M96)TZUCR5E=C+*NXY88X'X^E:.@RW?\
MP@]SHEQI5_!=6]E,A:2#$<AYP$/\1.1T]Z?#878^$)LC:S"Z^QLOD&,[\Y/&
MWKF@#K;.Y6]L8+J,$)/&LB@]0",_UJ:J.B1O%X?T^.5&1TM8U96&"I"C((J]
M2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YN^_Y*GH7_
M &!=2_\ 1]C725S=]_R5/0O^P+J7_H^QKI* "N;\+_\ (Q>,_P#L-1_^F^SK
MI*YOPO\ \C%XS_[#4?\ Z;[.@#I**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*GH7_8%U+_T?8UTE !7-^%_^1B\9_P#8:C_]-]G725S?A?\ Y&+QG_V&H_\
MTWV= '24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B>,O^1+U7_KW:MNL
MCQ9!+<^$M2AMXGEE>!@J(I9F/H .M &0-=ET?P?X>@L;=;F^OK>"*WC9L+GR
MUR2?0<5*-=UO2=8L;7Q';V+P7\GDQ3V1<;)#T#!NN:H7^F:C%H?A74K6RDGG
MTF*/SK7&)"#&H8 'N-O2IKN>^\5ZQI4<&EWMC96-TMY-+?1>469/NJH[]33
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MO&?_ &&H_P#TWV= '24444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ],5RG]FV6I?%N]34(4G2*S21(Y.5+#:,D=^":[6VMX[2TAMH 1'"BQH"<D
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M2J]A-YT00@ M[Y'3CVJKJGA:SU+41J"7%Y8WFS8T]G-Y;.OH>#F@#G9M$O\
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M?*X>%MT4T3;7C/L:K:?X5M;*_CO9[R^U&XA!$3WL_F>7G@[1@#/O0!F^*O\
MD=_"?_7:?^24SQXP@OO#MW/Q:PZBIE8C(7I@G\C707^B6VHZII]_.\JRZ>SM
M$$("L6 !W<>PZ8JQJ.G6NJV$EG?Q"6"0893_ #![&@">21(HVDE=411EF8X
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MX1T>]T/29;2_>$YN'DB2!V98T.,*"P!X.:FUWP[!KS6C375S:O:2&2-[9PK
MD>I!QVJWI>EP:19?9K=Y9 6+M)-(7=V/4DFJVK^'X-7GAN&NKRTN(052:TF\
MML'J.XI 8=A+J.A^.8=%FU*?4K2[MVF7[209(2">_<<8_'VK4\;7,UIX+U*6
MV8I((@H8=0"P!_0FI=(\,V6CW4MVDEQ=7DPVO<W<GF2$>F>PK4N+>*[MI+>Y
MC62*52CHW1@>HH X ^%M7U#PY:V]G9:%;*$CD@NHGD$JG@AMVSDGO]:T]5#Z
M+XXT?592HCOH_L-TPX!?JI_/]!5J+P-911K NIZL;-3Q9F[/E8SG& ,X]LUJ
MZ[H=KXATPV-\9%C+AP\1 92.X)!_R:8'&0SSR>%?$_B>(E9;]F2W;'*PJ=@(
M/XG\J;%X7U74O"EK;VEEH4*-$DD-RCR"53P=V[;U]:[JTTNUL]'CTN./=:I%
MY.Q^=RXP<_7G/UK$3P)8QQ_9TU+55L\_\>8NR(L>F,9Q^- &5K6G1W_Q"T"S
MU95N ;)C,O\ "[*"?Q&1G%7;.PM;#XH3P6<$<,%QI'FR1(H"%O-"YP..@_G6
M]/HEM<>(+76'>47%K&T:*"-A#9SD8SW]:?\ V3!_PD/]L;I/M'V7[+MR-FS?
MNSC&<Y]Z0',>$=.L3XD\1'[';YM[U?)_=+^[X/W>./PKM:Q3X8M1KSZM;W=[
M;2RLKS10S;8YBO3<N.?SJ'0-)NHM7U36=23R;B_D"I &!\N)!M7)!QD@9H J
M_$ [](T^UDD,=O=ZE##<$'_EF<D_R%4?%6B:5I^H>'+BQM8;:?\ M6WBQ$ N
MY,YY ZX('/O75ZOI-IK>FR66H1EXGYX."I'0@]C6/'X&T\7%M<7%[J%W/:RQ
MRPRW,^\IL.0HXQM)Z]^.M,#'OH[[4?B5?1V]OI]TUI:QB*._+;45@"2H .3D
M]:NZ9X<O;"/6WU.'3UM+R,.MI;;FC1U!R<,HQV/U^E:^K>&+/5KV*],UU9WD
M2[%N;.7RW*^A.#D5/I&B0Z1YS1W-U=2SD&2:ZF,CMCH/;K0!SGA**&S^&JZC
M:00I>"TF/G+&-Y(+$ GJ>0/RK)T;0-2U7P9''!8Z))'=QLWVF9Y/.W$GYB0I
M^8'W[5V.C>%[70YI3975XUNX8+:2S;H8\G)VKCV[YZGUJF/ UC%YB6>HZI9V
MTC%FM;>ZVQ<]1C&0/QH Q/$>FR--X.TW6'6X?S#%.48XDX0'G@\BK7C_ $^T
MM]"TRVM;>.WADU6+<D"!!RK GCOCO7177AVRNI]+D8RI_99S JMP> ,-D$GH
M*DUG1+;7(;>*[>55M[A;A/+(&67. <@\<T <EXF\.:5%XD\.6UO9QP0W#O#,
ML(V>8B@$!L=?YU<-G;Z7\4;%-.@CMH[FP<2QQ*%5L$D' X[#\JZ*_P!&M]1U
M*PO9WD$E@[/$$( )88.>/;VHFT:WGU^WU=WE%Q;Q-$B@C80>N1C.>?6@#C;'
M_CR\?_[\_P#Z ]5Y=#TU/A#]L%G%]J-NLWGE<R;LC^+KC'&.E=E%X9LH8M71
M7G(U<N9\L/EW @[>..IZYIS^';1_"_\ 8)DF^R^4(MX8;\ YSG&,_A0!RVOR
M7=_J7A6S"VTXE@,VR]9A'+($'WL9SCJ!ZGWK2TSP]J\'BN'5)XM+LX1"T4\=
MBSCS1_#D%0.#BM?4?#5AJFFVUG<^:/L@7R)HWVR1D#&0P[\4S3/#<.G7PO'O
M]0OIU0HK7EQOV ]<# ':D!SO@[1],UKP_>WNL6T5S<75U+Y\LH^9<'H#U7'7
MBK_PU '@V,*<@3RX/K\U6)O ^FR7EQ+'<7UO#=/OGM()]D,I[Y7&>?K6IHNC
M6V@Z<+*R,AB#LX\P@D9.<< <4P.;^(D$5U)H%O<_ZF74423G'RG@\]N*9XCT
MVRT?Q!X9FTFVBM)FO5@;R5";XS@-G'7@_K71:[X=L?$4=O'J/F%+>3S J, &
MXQ@\=/IBJNG^#[&QU.*^ENKZ^F@4K!]LG\P0C_9&!0!BR:@GA#Q3KHEP+>\M
MC?P!LG,HX9>/4_TK;\%Z:VF^%;43?Z^XS<S$]V?G^6!^%9OC/1FU[7-#LQ:3
M/&LK23W 0[$CXRI;IDXZ5V &!@<"D 4444 <W??\E3T+_L"ZE_Z/L:Z2N;OO
M^2IZ%_V!=2_]'V-=)0 5S?A?_D8O&?\ V&H__3?9UTE<WX7_ .1B\9_]AJ/_
M --]G0!TE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZGY07[,WE")BQ.,,!QC)!X[ U)IUAXI26UN+[6H9E8@W%H;55"@]0K#G(]Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLFB^!;CRY)?*\EO+C&6;")P!ZT]/%5I_PK]]&6"<ZI'9-:R6BPL&3"%2Y.,
M <FGWW_'EX _WX/_ $!*!'06'B>ZDUZ#2]7T>33I;J-I+=O/64/M&2#@<' Z
M4^Y\1W4FJW-AH>E-J+VF!<2-<+$BL>=H)!R:@UW_ )'[PK_V]_\ HH5S4EMH
MNF>*=83Q='-"MS.9[6X5Y51U;J/D/4>] SJ1XNB;PM>ZLMHZS6+&.>TD<*R.
M" 5)P?7KBG:3XDN=1MY+ZYTI[+2U@:9;N28$MC&?DQD#&2#[>]8E_#I"_#C6
MIO#]M-#;RG):7?F4@K\PWDG'Y=#6S)8RZC\-TL[<?OI=-14![ML&!0!7?QA>
MQZ>NJR:!,NDMAOM!G7S!&3P_EXZ=^M3ZSXN72]0T^UMK&2_-_$7B,+8)_N@#
M'?/7(P*Y+3Y/!@T>&#5K6\744C$<UGON"[.!@X ..:W;^%(?B'X5C@C:.)+:
M941LY4"(X'X<4 :FE>))[O6Y-(U73'TV\6+SHU,PE61,XR& '/\ ]?TJ!O%=
M[=7=VF@Z')J5O:2&.6X^T+&"XZA00=V/\]145U_R5>Q_[!C_ /H9K+\-Z[8^
M$K:^TG7GDMKF.ZD>/,3-YZG&"I Y_P#U4 =%?>))+=K&UM--EN-1O(O.%HSB
M/REQR78],'CZ@T_2-?DOM3N-,U"Q:POX$$IB,@D5T/&Y6&,\US/B1;*3Q-IN
MMZS:W!T>ZL!$9 71H'W%QNV'(X.,?7TK6\+KX9EU6:?PY!.\BP['NF,K)M+
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MT*W_ .0E.TM[),C-;. #Y8R,D _Q CK6HGC*_O+:6^TGP]-=Z=&3_I!N%1G
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MHHH **** .;OO^2IZ%_V!=2_]'V-=)7-WW_)4]"_[ NI?^C[&NDH *YOPO\
M\C%XS_[#4?\ Z;[.NDKF_"__ ",7C/\ [#4?_IOLZ .DHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$+5\F)!T63T8=Q0!IT54MM7TV]G,-GJ%K<2CDQQ3*S#\ :MT %%%% !1110
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MXX'-(#2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH R)-=\OQA%H7V?/F6GVGS]_3YB-NW'MUS5
M6^\4NNL2:5HFFR:I=PC,^V41QQ>Q<YY]JI7/_)8+3_L$G_T8U)X!P6U\S?\
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MAB.N!GIZ5+K'_(#OO^O:3_T$UD> /^1$TW_<?_T-J0'1T444 %%%% !1110
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M^$PET^XLY5\2P:PLDJQW%J+41E0>K(0 >/>@#T6BBB@ HHHH **** "BBB@
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M9-0U&Y 62X=0@"C^$*. ./TK<HH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH KW]K]NTVYM-^SSXGBW8SMW C./QJ#0M+_L70[73O.\[[
M.FWS-NW=R3TR<=:OT4 9&J:%_:>MZ3J'VCRO[->1O+V9\S< .N>,8]Z6XT/S
M_%5IK/VC;]F@:'R=F=V[/.<\=?2M:B@"&\M_M=C/;[MGG1LF[&<9&,U4T#2?
M["T&VTWSO/\ (!'F;-N[+$],G'7UK1HH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#D=/\(ZSI$<T.E^)%@@EF:78VGJ^"?<M["KE]X7N)M1AU
M33]6>QU)81#/.L"NLX'<H3C_ "/2NBHH QK?1+W^S;^WU+5Y;Z6\B,?F-$$6
M(%2/E0<=_7G%1Q^&MG@H^'_M>?W!B\_R_4YSMS_6MVB@#!U#PK'?Z/IUL+J2
M"[TU4^SW<:\JR@ G;Z''2I--TC58+Y;C5->EOE12%A2W6%"3W8#.:VJ* *]_
M:_;M-N;3?L\^)XMV,[=P(SC\:Q9/"4<O@E/#TESDQH ESY>"K!LA@N?ZUT5%
M & ?"L2^"CX>AN-BM%L,YCR2V<EMN>Y[9IVJ>&(M2TRQ@%U);W6G[3;W48Y0
M@ 'CN#CI6[10!BZ;I&JP7RW&J:]+?*BD+"ENL*$GNP&<U2?PE=P:C>3Z-KDV
MGP7SF2>!8%?YCU*L3\I/KBNGHH X+7?#Q\/^ ;ZRL]]XDMYYP<H2T"DCYN#E
MBNWK[]*KCQ#J4<UJFC^)AKT[RJC6GV )E>Y+ <?C7HM% '.R^&;R+6+V^TC6
M&L1?%3/&;99<D#&5)/'ZU!'X'A7PS=Z/)?2R+/=&Y2<K\R'((SS\W3D\9]JZ
MFB@#F)?"NH7M]876J:ZURUC<+,B+:K&I Z@@'J>.>WIS6A:Z"+;Q5?:U]HW&
M[A2+R=F-FT#G.>>GI6O10!@ZSX;EO]6@U73=1?3K^&,Q&41"173.<%21FH=.
M\./HNK76MW%_<:A/):E)@8LL[ [LJ >.  % _&NDHH P_"5OJ4.C-+K,LK7%
MU,TXCE<L85;&$YZ8QT[9K<HHH **** "BBB@ K&G\):%<ZK_ &E/IL3W6X.7
M)."?4KG!/U%;-% !1110 4444 %<;8>#8]5U'4]3\46;&>XN#Y$8G(V1 87E
M&P<C^5=E10!R6G>&9/#_ (T6?1K8C2KJV*7&9=WEN.0?F;<<X []369%X8U=
M?ACJ&DFT_P!.FN-Z1>8G(\Q#G.<= >]>@44 0VD;164$;C#)&JD>X%<9+H6H
M1>(-4N+GP_;:T;J3=;W%S,A6%.RE6YX]A7<T4 <%;^$=3;X?)IS+'!J%O=FY
MA4L"K$,2!D'C(-2:S;>*?$,5BD^D1645M<QRR)]I1VD(/)!S@ #/'6NYHH Y
M?QII&I7@L=0\/INU&S=E7#A"4=2#R2.G'YFG-X4\SX>#P\L@CD,*Y<]/,W!S
MG';=^E=-10!S%IJ'BWR8;:;0H%E7:LEV]XI0CNVT?-^%2S:5>/\ $>WU58O]
M#33S"TFX??WL<8SGH?I7144 8.OMJC3""'0K;6+"2/YHWF5&5\GKNX(QCISU
MK#A\(:HO@J&T62.&_MK[[=;1;RR1D=(\_B?QKNJ* ,"RU+Q+<W4$=SH,-E%N
M_?S/=K)QWVJO.?K6_110!SG@G2;S1](NH-0B\J22\DE4;@V5.,'@^U4K.SU[
MPQ?7\.FZ8FJ6%U<-<1$7*Q-$S=0=W4<5V%% '*Z]I^N:YX26*6"&.[,ZR2VD
M<Q"R1@G]V6Z9/'MQ6;%H%]+XCT>[M_#=KI%K:2'S?+DC,C#;U8KU'IU/)KO*
M* .1%CK7A_Q%J5UI6FIJ=GJ+"4H+A8GB?G/WN"#D_I4NN6&MZMX<L)_LL*:I
M9WJ7?V991M.UFPNX\9P1^M=310!R?B&QU?Q!HVF9TW[-<Q:C'-+ ;A'V1J&&
M[=P#U' IU]IVKZ5XNGUK1K./4(KR%8[BW,HB=67 # GCH!^M=510!S>AZ9J<
MWB*ZU[6XDM99(!;06J2>9Y<>=QRPX)SZ>]0>%]$O]-\ S:;>0>7=LLP$>]3]
M[..0<5U=% '*:?:ZWI'@_3+2'2X+R2-2EW:2RJK$$G&UN5^N:=X2T6\L-1U.
M^N;./3(;QE\NPBD#A,#EN.!GVKJ:* ,+Q=I%WJ^DP_V:RK>6EREU"'. S+GC
M/XUCZC;^)]>N])>YTJ*QM[._AGDB^T+([X/+@C@*!GCJ<UVM% '*W^G:OI?B
MV76M&M$U"*[A6*XMC,(F4KT8$\=!_.M;3I-4U""Z&LV$=A&XV11),)'P0=Q)
M''IC%:E% ')>&=-U:VT*3P[J]@L5LD,L:WL<ZMY@9CC"=1PQY/I4>DGQ3H6E
MII*Z)#?"WRD-VMVJ*5SP2IYX_P ^M=C10!S&MZ5J6H:OX;NA"C&SF+W91P%3
M(7.,G)&0:E\9Z5>:M9:='81>:T.H132#<%P@#9/)]Q7144 <_KVEW=[XCT"Z
MMHM\-G-(T[;@-@*@#@G)Z=J+S2[R7Q]IVI1Q9M(;62.23<.&.<#&<_I7044
M<=::!J,5KXO1[<!M2:4VHWK^\W*P'?CDCKBII=$U!OA>-(6#-]]E6/RMZ_>!
M!QG./UKJZ* .3U/1-31=#U/2HT>_TV(1R6TC@"12H##=T!Z_G6GIE]KMY?#^
MT-'BTZU5#DM<K*[-VQMX Z]:V:* .*TNQ\2^'8;K2M.T^"ZMWF9[:]>X"B,-
M_>3J<>U:O@K2[S1_#BVFHQ[)UFD8@,#D%N#P3UKH** .8\9Z3J>J'27T>-&F
MM;Q9BTC *F.03D\C/IS5:2RU[Q#KFER:MIL>FVFG2_:&(G64S2#IC'09]:["
MB@#@/B%97(U;3Y=,DV7&I(VG2J#C>C$'\N3G\*[FSM8[&Q@M8!B."-8U^@&*
MBGTJRN=3M]0GAWW5L"L+EC\F>O&<9]\5;H YR[TF\E^(EAJB19LX;-HGDW#A
MB6P,9SW%+X5TJ\TV]UR2]B\M;O4))H3N!W(2<'@\?C7144 <SX6T*>V\,WFG
M:O!Y?VB>;*[E;*-QG(R*H>"O#NJV&HO<Z\@!M+<6=G\RME-Q);@G'8>N*[6B
M@#D8;37O#FL:DVFZ<NJV-_<&Y %PL31.WW@=W4?3VK3>Y\0_V*L_]FVCWAE^
M>S\[@Q>F_IN]^E;=% ')>&]&O8?$UWJLVEQ:/;S6XB%I%*'WONSO.W@<#'X_
M6G^%K'5]#N;C3)]/5[%[F29+X7"_=/(&SKG(_7VKJJ* /,[O3;S1/AI)9:C&
MT4\^H )"K!A+E@0I(/ .*NVDD7A:]M[N^\)?8%FD%NMRE_\ :#&6[!3T'T]Z
M[:_T^TU2S:UU"!)X6Y*.._K[&L^S\(Z)8W<=S;V7[Z(YC:25Y-A]0&) -,#
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MJ7BB::WAN=!AMAO43W#7:LNW/S%5'.<=,UT5% !1110 4444 %%%% !1110
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M#IM*\1:5K;2+IEXLSQC+H59& ]<, <55N?&?A^S:1;C445HIGA=1&Y977[W
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX=*Q\-S7!7:EU>RS1\8RI(']#3 ZNBBBD 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHKA?$6GQZK\3-.LKEY!;R6#>:B,5\Q0S':2.Q(&:
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M9R#G.0.]/U'0M-U:SCM=1M$GBB_U8)(*<8X(.1^=:%% &;I7A_2]$\PZ79K
MTGWWW%F;\6)-3V.EV>G27,EE#Y374IFF.XG>YZGD\?A5NB@"E::/86&FOI]I
M!Y=J^[='O8YW=>2<]ZAD\.:3-H\6ERV:M9P\QQEFRA]0V<YY/.:TZ* ,FR\+
M:-IUW%=6=D([B'=LE,CLWS#!R23G@=\X[5K444 %%%% !1110 4444 %%%%
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M(J2@"I::79V%U=7-I#Y<UXX>=MQ.\COR>.O:B+2K.'59]2BAVW=P@223<?F
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M+>-HM_DB4,A[8)'J:W:* .?U3PS+>WUKJ-EJ<EEJ<$7E-<K$&$J^C)P.O/\
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MO]8EO;N!75]T(164K@!5!PN.3WSFNEHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .;OO\ DJ>A?]@74O\
MT?8UTE<W??\ )4]"_P"P+J7_ */L:Z2@ KF_"_\ R,7C/_L-1_\ IOLZZ2N;
M\+_\C%XS_P"PU'_Z;[.@#I*Y'XDH)?"\<3$A9+R)6QZ$FNNKE/B+_P BY;_]
M?L/\S0!5T._GBT'5_#^I/NO=+@D56.?WL14[6Y]N/IBJ::M=:5\*-*_L]MEU
M=LMK$_\ <+,W/Y U>\>Z?-;(GB#3DS-;QM!=*O\ RTA<8/Y$Y_7M6>=+N]2^
M$^DMIZ>9<V;K=)&!R^TL,#\#3 VD\ :5':J8Y+E-149_M 3-YI?^]UQU[?\
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M<>%XY(M#-OB?Y66)Y<\; ?P_7UH /#WAZT\7:3-K6NK+-<7LLA@;S6'D("5
M4 X&"#UJYX7\0-:>!9[O6)6<Z=+) SM]Z3:1M'UY JAX;\1VGA/1Y=%UTS07
M=E*XBC\HGSE)+ J0,'))_.ETKP?J-_X9L_/O#I\YO'OFBD@\T%CC;N4D<C&<
M'/6@"#1[.[A^(>FWFJ,3>ZA;2W$J'_ED#PJ#Z "NJU3PGI.K7<UWJPFG+(
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MGWQQ75^%(K^'PK81ZMO^UK'\_F'+ 9.T'WQB@#7HHHI %%%% !1110 4444
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MCR!^&32 ZFL:+Q;HD]^MG#?"29I/*7;&Y4MG& ^-OZUJSB,V\@G8+'L.]B<
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MH Z33M:T[5K%KS3[M)8$)#ORNW')R#@C\:K6/BK1M2ODM+*\\V:3.P>4X5L
MDX8C!X![U@:1!;/JWC2VN9%M[:5U21RP4(&1@3D\#K4FFWVI>&+_ $O1-2:W
MO;&Y'DVES!\L@ 'R[EZ8QCD?F:0'945#%=VTUQ+!#<1230X\V-'!9,],CM^-
M34 8.OVFL[+B]T[76LX8H2XMQ:1R9*@G[S<\UG>$AK^K:98ZM>>(&>*4EGM?
ML<8# ,1C< #VKH]8_P"0'??]>TG_ *":R/ '_(B:;_N/_P"AM0!B^%?&-C8Z
M3<CQ!JK&<WLNP2%Y6"#&.@)"YS[5VG]HV?\ 9O\ :'VF+[)L\SSMWR[?7-<G
M\.;2WDT+4F>%&::]ECD)7EEP.#[<G\ZP)&?_ (4SI.'*Q&[Q,Q7< GFOU'<9
MQQ3 [RQ\5Z)J5XEK:7P:9QE%>-TW_P"Z6 !_"M2XN([2UEN+AML4*&1VP3A0
M,DX')XKE;SP[J%\VGRZAXDMFB@N(Y8"EDL99NP5@_<5UU(#E/"WC:VUR9[6Y
MD1+MKB18(XX9 &C49!).0#@'N/I6C?\ C#0=,O&M;S4$29/OJJ,^SZE0<?C6
M=X .-.U2,\.FJ3AE/5>G45!\.S ?#MXUR8_M1NI3>[L9S_M9[8SU]Z8&KKWB
M:VTSPNVK6DT4PD7%LVUG21\$@';TZ'TZ4[0_%&GZQI1N1<HKV\*/=DHT:1$C
M)Y8=,@]STKE--16^&?B7[(&-K]IN3;<?\L@%QCVX/ZUT@U&TT_X=6][=PBZM
MX[&(M%@$/E5 '/'4T 3V7C'0=1ODM+344>>0X161E#GT!( -4I[RY7XIVUFM
MQ*+9M,+F'>=A;>WS8Z9X'-8/B6ZU>:UT2YU"UTZTC^WPO;)#*S3)[= ,8QG'
MM6Q<_P#)8+3_ +!)_P#1C4 ==1112 **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#F[[_DJ>A?\ 8%U+_P!'V-=)7-WW_)4]"_[ NI?^C[&NDH *
MYOPO_P C%XS_ .PU'_Z;[.NDKF_"_P#R,7C/_L-1_P#IOLZ .DHHJKJ>H0Z5
MI=Q?7/\ JX(RY'KZ#\3Q0!:HJKIEU+?:7;74\'V>2:,2&+?NV9&<9P*ATC6K
M;6X[F2S60);W#6Y9P '9<9*\].>^* -"BH[BY@M(3-=31P1 @%Y'"J,\#DU)
M0 4444 %%%% !1110 4444 %%%% !161JGB*'3+P6JV-_?3[!(4LX/,VJ3@9
M.0!TJ31?$%CKNGO=V;/&L3%)4F&UHR.NX=J -.BN7D\?Z9&C3K::C+9*^PWT
M=OF$'.,[LYQ^%:NI:];:;;V\OE7%V;G_ %,=I$9&<8SD#TY'YT :=%8VC>)[
M/6KRXLXX+JTN[<!I+>[BV. >^,GU'YU!?>,K&TO+BV@M+_4'M?\ 7M9P;UB/
M<,<CF@#H**P'\6VGDZ1=VZ&6PU*7R3<;MODN?N@KCU!!Y&,=ZWZ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUN'4,/\ @6>WI6CHOB"PU^W>2PD;=&=LL4B[7C/H10!IT444 %%%% !1110
M4444 %%9$^O>1XMM=$^S[OM%NT_G;\;<$\;<<]/6M>@ HHHH **** "BBB@
MHHHH *J:EI5GJ]ND&HP^=&D@E5=Q7##H>"/6K=% %6[TRTOKBUGNH?,EM'\R
M%MQ&QO7@\_C1+IEI/J=OJ$L.ZZMU98I-Q^4-UXS@_C5JB@#&U'PEH>K7ANK^
MP62=AAG5V0L/?:1G\:MG1M..D'2_L<7V$KM,&/EQG/YYYSZU>HH RM+\,:/H
ML[3Z;9+%*PVER[.V/0%B<4O_  C6D?VU_:PLE%[NW>:K,,G&,[<XS[XK4HH
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M>M,#LM,&HBS U?[+]HW'_CT#!-O;[W.:H:E+XD:^:+1K;3X[=%!\^\=CYA]
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M$8]1^- 'H=<]J%SXK\ZY?3;+3DMX<^6MP[M). .HV\#/8&MVV$JVL0N6#3!
M)".A;'/ZUP5Q;2S:SJ?]OZ5K.HRFX86*P.ZP"+^#YE("GU)_G2 U9_&3_P#"
M&Z?J]O;Q+-?S+ HF<^7$Q+ LQ'.T;36YI1U<K)_;+6+@[3$UF'&>N<AB?;&#
MZUR^CQS:9\.].M-2T&XOXR\B7-N(\R1@R.0VP\GMZ=<U8\%V=S;:GJ+6UI>6
M&C.%^SVU[D,K]R <D#_ZU,#9\2:[_86GQR1QI+<W$JP01NX12Q[L>RCJ:R8/
M$]_::U96FJR:7=0WS^4DFGR,3$_8,"3D'IGBI_&^DW&I:?9W%G;+>26-RL[6
MK@$3)W7!Z_3ZU7TR73KC4K9;/P5+:.&R]Q/8)"(<#.0W4G/I0 MSXQET:\U6
MTUR*)9K=/-LO*4@7*$X4<D_-D@''OZ4:MXDUG1M)T62>RMYKZ^F$<UN@9>3T
M5<GAN@R<C.:S=8T;5/%.HWNIQQRV9TW":8DL91I74ABY!&<'&!_]8TSQ5J5W
M>Z;X8O?L$D5[_:"'[+,IC/F _=Y[$C@^AH UQKVNZ9K6GVWB&UL1;:@_E1O:
M%MT4G96W<'\*6]\37DVN76GZ1)IMNMGA99[^0@.YYVJH(/'<U3NY;[Q5KVC*
MFD7MC;V$XNIY;R/8-RXPJ_WN:@GTU-'\5:G/J?AU]9L[YQ-#-#:+.T38Y4@]
M!_GZ &G9^-$_X1W4K_4(4$^F2>7,D#[DD)("E3Z$FI;&[\7RFWFNK/3%@GY:
M-7<20@C@MDX/N!5*_P!'77?!&HV^FZ$-(EDD#0PM&L32[2"&(7H3\PP:OZ=X
MGO;R6UMI?#^I0SN0L\DL.R*/U(8]10!A^$AKW_"3:UAM.V_;5^VY63)ZY\OG
MTSUK2G\3WUYJU[;:1+I=M#92>2\FH2$&60=0H!& .F>:9I+76B^,-7AN--O9
M8M1N4DAN88=T:@CG<V>,9_G5!;"/1->U4:QX9?5X+RY:YM[F"S6X9=QR4.>1
MC_'UH TT\;J/!]QJTULOVFWF-JT"/E7E!' /ISFL7Q?/XD.CVBZY:V(@DNHF
M#6C-NB;/W6!Z]^1QQ6EJVE3:MX(D&DZ*-+E2X%Q%9[%0R;3U(7@$CM["J?B7
M4M3\1Z5;P6GA_48!'<1R3F>$@@@XPHZL.22<=!0!Z!7G]@-?_P"%F7^#IOG_
M &>/SB5DV^5D?=YSNQZ\5Z!7,V-I<)\2=4NG@E6W>SC5)2A",1C(!Z$T@(UU
MW7=9U"]3PY;V"VEE*8&GO"Y\UQU"[>@HA\6W$OA75;Q[:.'4M,+QS0,24WCH
M?7!^O:J6DSWO@^XU#3[C1[^]MY;E[BVGLH?,#!L?*W/!&.]1QZ/J1\(>([NZ
MM72\U5GE2T0;F1?X5XZGVI@;7AS4=>U>."^OK:RMK">(,B*7\XG PWI@\G'7
M&*SOB;]L_P"$;C^SF 6_G+YV\'>3N&W;CC'7.?:NA\/Q20>&=+BF1HY([.)7
M1A@J0@!!'K6?XYTZYU/PG<16,9EG1TE6-1DOM8$@?AFD!B^.?[4'P^N?[;-F
M9_M*;?L@8+MR,9W<YSG]*NW'B+Q!I=Q8W.L6%G%I]Y<+"8XG8S0%ON[CT/O@
M=JK^+I[KQ'X#F-GI6H13>>@^SS6Y$AP020HR<<]?8UH^.+2XN],L%M()9V34
M8781H6*J,Y)QV]Z8#];\13VNM1:1IALTN6B\^6>]DVQQ)G & 02Q/;-'A_Q%
M/?ZK=Z5J(M6NK=!*LUFY:*5#QQG)!!K-\0Z8UKXPCUB?1O[9L)K;R)85@$SQ
M,#D,%/7_ /76IX=:TENIY+'PTVD1A !-+;) \F3R-HYQP* .@HHHI %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% '-WW_ "5/0O\ L"ZE_P"C[&NDKF[[_DJ>A?\ 8%U+_P!'V-=)0 5S?A?_
M )&+QG_V&H__ $WV==)7-^%_^1B\9_\ 8:C_ /3?9T =)2,JNI5U#*PP01D$
M4M% $<$$-K L-M$D,2#"QQJ%51[ 5)110 4444 4;C1-*O+@SW>F6<\QQF26
MW5F..G)&:N1QI%&J1(J(HPJJ, #Z4ZB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH C>V@EGBGDAC>6'/ER,@+)D8.#VR*DHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M&R1I-$\4R+)&ZE61AD,#U!'<4D,,5O"D-O&D42#"HBA54>@ Z4^B@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***AO+R#3[*6[O)/+@A4L[X)P/H.: )J*P3XV\.K<)"=4CW28P=K;1D9
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F[[_DJ>A?\
M8%U+_P!'V-=)7-WW_)4]"_[ NI?^C[&NDH *YOPO_P C%XS_ .PU'_Z;[.ND
MKF_"_P#R,7C/_L-1_P#IOLZ .DHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K$\9?\B7JO_7NU;=9?B6RGU'PS?VEHF^>:%E1<@9/ID\4 <M<G3!\&1Y7D
M;#:)G;C_ %^!G_@6ZFSY_MSP6FK[1;BTS^\Z>?Y8Z^^=N*U])\$:/'8Z?-?Z
M7']NB@B\T%R5\P* 25!VDY'7'-;FIZ58ZQ:?9M3MDN(<[@K=CZ@CD'Z4P.;\
M2^6?'7AO[+C[:)7,FS[WE8YS[=?UJ#PG]E_X3KQ-YGE?:OM \O=C?MYW8]NF
M?PKH]*\-Z3HLKRZ;9K#(XPTA9G8CTRQ)K LO!<-[KNN3Z_IZR0SW(DM7\W!(
MP<\J<CMP: *&EJ'TOQU]C"FT9IA#L^Z6\MMV.WI5C4KZV;X-1'SD&ZQBA4%@
M-S@*"H]3P?RKL+'3;/3;%;.QMTAMUS^[4<'/7.>OXUDKX%\-J9"NEI^\!!'F
M/@9ZX&?E_#% &)K'_'_X&_WQ_P"@I6BVL7M[K.IVV@:;8*+9PEY=7DA42-MQ
MC"@DX QD]JW)M%T^XDL7EM]S:><VQWL/+X ]>>@ZYJK>^%-$U"]>[N[%7FDQ
MO99&4/\ [P! /XT@./T8,_PAU=% (1I\!.0 ,'CVZUN:DRO\)2R$$'3$Y'^X
M*W[+1[#3[&6SM+98[:5F9XLEE;=UZ]CZ=*J6OA31;*RN[2UL@D%XH6=/,<[@
M,X&2<CJ>F*8'*7YC^P^ Q>;?L16,R[_N[O+39GMZUJ^,O(.O>&A%C[?_ &@A
M7;C=Y/\ 'GOCI^M=!/HNG7.DIIEQ:I)9QHJ)$V3M"C P>O []:KZ7X6T;1K@
MSZ=8K%,5V^8SL[ >@+$X_"@##TB&-_BMX@E>-6DCA@V,1RN8USCTJ3P@$AUW
MQ0J[8XUO<XZ <'-='#I=G;ZI<ZC##MNKH*LTFXG<%&!QG X]*;!H]C;R7KPV
MX4WS;KC+$^8<8[GCKVI 6+:Z@O(%FM)XYXFSB2)PRGMU%2U4TW3+/1[%;/3H
M1# A)"!B>2<GDDFK= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% '-WW_)4]"_[ NI?^C[&NDKF[[_ )*G
MH7_8%U+_ -'V-=)0 5S?A?\ Y&+QG_V&H_\ TWV==)7-^%_^1B\9_P#8:C_]
M-]G0!TE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 <W??\ )4]"_P"P+J7_
M */L:Z2N;OO^2IZ%_P!@74O_ $?8UTE !7-^%_\ D8O&?_8:C_\ 3?9UTE<W
MX7_Y&+QG_P!AJ/\ ]-]G0!TE%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\
M["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3
M?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_[
M"C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X
M//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S
M;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^
M#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_
MB!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTF
MB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?
MX@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?
M_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^
MPKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_
M %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C
M_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\
M@\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\
MA3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_
M +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X
M@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /
M-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_
MX//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\
MU4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2
M:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51
M_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A
M3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\
M["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3
M?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_[
M"C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X
M//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S
M;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^
M#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_
MB!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTF
MB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?
MX@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?
M_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^
MPKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_
M %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C
M_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\
M@\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\
MA3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_
M +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X
M@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /
M-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_
MX//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\
MU4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2
M:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51
M_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A
M3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\
M["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3
M?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_[
M"C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X
M//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S
M;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^
M#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_
MB!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTF
MB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?
MX@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?
M_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^
MPKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_
M %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C
M_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\
M@\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\
MA3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_
M +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X
M@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /
M-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_
MX//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\
MU4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2
M:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51
M_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A
M3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\
M["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3
M?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_[
M"C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X
M//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S
M;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^
M#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_
MB!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PKTF
MB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O\ A3?_ %4?
MX@?^#S_["C_A3?\ U4?X@?\ @\_^PKTFB@#S;_A3?_51_B!_X//_ +"C_A3?
M_51_B!_X//\ ["O2:* /-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^
MPKTFB@#S;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["O2:* /-O#_ (-_
MX1+XIZ=_Q4?B#6_M6BWW_(:OOM/D[9[/[GRC;G=SZX'I7I-<W??\E3T+_L"Z
ME_Z/L:Z2@ KF_"__ ",7C/\ [#4?_IOLZZ2N;\+_ /(Q>,_^PU'_ .F^SH Z
M2LW7=<MO#VF_;;R.:2/>(PL*@L2>G4BM*N/^)I(\)H0,G[7'@>O6@#0M?&-I
M-J4%C=V.HZ=-<'$/VVWV+(?0$$\U>UG7K'0H8WO7<R2MMBAB7=)*?15KC_$&
MI7T^L:)-XBTB72;"UNUE,XE6?+_P@E?NCBM*("[^+L_VGYOL>G@P _PY(R?_
M !X\TP-;3?%%MJ&H+8RVE]87+J7CCO8/+,@'7;R0<4R_\6V5GJ3V%O;7FHW4
M0S+'8P^9Y7^\<@"MMHT=E9D5F0Y4D<J<8X_ UR/PT D\+R7;_-<7-U(\[GJ6
MSW_SWI ;MAXAT_4--FO5E,$=NQ6=;@>6T)'9@>E1:'XGL/$-Q>1:<)B+0IND
MD3:KALX*\YQ\O<#M6C/96MU')'<6\<B2E3(K*"'P01GUZ#K7/Z"H7QYXI50
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MEP:K<V=I]A66187P<!@/E[*22/FZXJSH$UYIOC2_T">^GOK<6RW4+W+[Y$Y
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MVMF:[M[0"2WD?*_.,@L5SC(.>N<5K6FGVMBT[6L0C:XE,TK9)+L>IR?Y=!2
MLT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% '-WW_ "5/0O\ L"ZE_P"C[&NDKF[[
M_DJ>A?\ 8%U+_P!'V-=)0 5S?A?_ )&+QG_V&H__ $WV==)7-^%_^1B\9_\
M8:C_ /3?9T =)6#XPT.Z\0:$+.Q>%)EF20&8D+QGT!K>JGJFK66BV1N]3G\B
M#<%W;2W)Z# !- '.:CH7B/Q'%'9:[/IEO8>8'E%F)&=\=OFP!5W7O#MU=ZM;
M:SHEU':ZE;J8SYJYCE0_PMCZFK&G^+M#U2\6TLK]6G896-XWC+?3<!FMJ@##
ML+7Q%+J45QK5Y9Q00@XMK%6(E)!&69N>,]!6?#X>UO0;^Z;PS<V365TYE-K>
MAP(G/7:5KK** ,:UM-=MM-NI);RWN]3F8,BN&6WB' V@#YL8SSW-9&GZ3XKL
M]?OM1?\ L8_V@T7GJ'E^4(-OR_+UP>]=A6=K.MVVAPVTMXLK+<7"6Z>6 <,V
M<$Y(XXH R)M"UK3O$5[J?AZ>R9+\(9X+T. &48!4KSW/Y_2BQ\*3SG5[CQ!/
M%-=:I&(G%LI"1(!@!<\D].OI7444 <7_ ,(YXHFT5=!N-0T_^S@!$UPBOY[1
M#^'!^7IQ707=OJ5EIMM;>'5L_P!RJQXO&< (!@8VCKP*U** .4\)Z-X@T+_1
M;PZ:]D\KRNT3R&0%NPR ,9Q75U@+XQTYO#%QKHBN?LMO)Y;)L7>3N"\#..K#
MO6[%(LT*2)]UU##/H: '4444 %%%% !115*]U>TT^\L[6Z=EEO7,<("DY(]?
M3K0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "N*T70O%F@Z?)8V4NCF)I6D$DAE9A
MGVP!7:T4 8&D>%H[+3;^*^N&N[G4PWVR?&W?D$8 [  G%4;'2?%NDV"Z;8WN
MER6L0*PW$Z/YJKV^4?*<5UM% &+J,'B)986TFZL9D$(2:*\C90S_ -\%>>?3
MI62G@>5O"<^GS7<:7LMX;U984Q''+Q@ ?W<#]:["B@##TV+Q0;Z$ZO/IHM8P
M=ZVJN7E.,#.X<<\\4GA+0[C0-,N+:[DBD>6Z>8&(D@*V,=0.>*W:* .6MO#%
MY#;^)XVE@)U=I#!@GY=RL!NXX^]VS5%/#/BA/#R:"NHV'V%HQ')-M?S54CYD
M7C!'4 G!(KMZ* .;U7PM*\.E2Z'<);7NDKL@:4$JZ;0"K8YZ#]35O3(_$;7P
MDUJ?3TMU0@0V:N=S>I9NF/:MFB@#C[3PYXAT?[58Z+?V2:;<2F1'F1C-!NZ[
M0.#^-:OA+19] T%;&ZD25UE=MR$D$$Y'4#FMNB@##\1Z)<:Q=:/+;R1H+&^2
MXD$A(W*#D@8!YI+;0[B'QS>:TTD1MY[5850$[PP(ZC&,<>M;M% &/IND3V?B
M?6M1E>,PW_D>4JD[EV(5.>,=3QC-;%%% !1110 5!?64.HV$]G=+NAG0HX]C
M_6IZ* .2L=(\6Z19C3K"_P!-GM(QLAFN4?S8U[# X./>I[WPU?7%WH$IO5N3
MILS23RSY#2YP>  1VZ9]*Z:B@#GH/#]S'XGUS47EB\G48(XXE!.Y2$"G/'MV
MS2:/X?NM/\!'1)I(6N?(FCWH24RY8CG&?XAVKHJ* .2NO"E[<>%-$TQ9K<3:
M?<Q2RL6;:P4,#MXSGGOBK&HZ%JL'B1]:\/3VHEGB$5Q!>!MC8Z,"O.>*Z6B@
M#EM3T'6M8T.&/4+JQ>^AO5ND41GR"%'$9[D<GK2QZ+KEUXETK4]3ET](; 2J
M+>VW<!DVY!(Y.<<<  5U%% &%H6AW.EZUK5Y.\31ZA.LD00DE0,]<CW[9JQX
MDT1?$&ARV/F^3(2'BDQG:X.0?\^M:M% '%:IX=\4Z[9P0ZG?:<HMY$<) ' F
M(/+,2.#C. !C)K3UC0=0;7H=;T"X@BO%B\B6.Y#>7*F<C.WG.?Z>E=%10!EZ
M3'K@FEEUR>S*L (X;1&VKZDLW)K#M/!EQ!XU?47GB;3%F>ZAMP3N69U )(QC
M''KV%=A10!SFJZ#J*^(5UOP_<6\=TT7DSPW0;RY5SD'(Y!_P_.S;6FN7&GZA
M'K-Q9F2XB,<,=LK!(_E())/)SD?E6U10!R2>#YW\"V6CRW20WUE)YT,\6659
M S$'D XPV*)]!\0:Z]K!XCN=/6Q@D$KI9A]T[#IN+=!]/_U=;10!P5]#J4OQ
M6G.C3PPW,>G*^)U)21=X!5L<CKG(]*W-!T*^MM8O-9UN>"6^N4$02V!\N*,=
MAGD]!6X+6W%V;H01"X*>69M@WE<YV[NN,]JEH YG0O#5WI?@>?1IY86N)$F4
M.A.P;P0.2,]_2G2^';M_AX-!$D/VK[.L6\L=F00>N,X_"NDHH YG4O#5[(ND
MWNE7,,&IZ;$(@903'*NW!4XYQU_.K^E1^(#>-+K<U@(?+VI!9JQRV1\Q9N>F
M1CWK7HH PO"6AW&@:9<6UW)%(\MT\RF(DC:V,=0.>*IVGA2=?AS_ ,([=31"
M<HX\R/)4$R%UZ@'TKJ:* ,O08=7M[$0ZVUFS1JJ1FUW\@#&6W=_I4/B70I=9
MM[:2RN!;7UE,)[>5AE01V(]#_2MJB@#E?["US6-1LI?$MQ8BULI!,D%D&/FR
M#H6+=O:M+^R)_P#A-_[9WQ_9_P"SOLNW)W[_ #-V<8QC'O6Q10 5RVB^$6M_
M \F@:L\;^:7W/"20,G((R!R#@UU-% ')VVG^,K"Q6PMK[2IHHUV1W,RR"4*.
M!D 8) _R:T]"T'^P-)EBAE%Q>S,TTL\HQYDA[G'./_KULT4 <7)H_BZ3Q'%K
M).B">*W, 0/-M()SG[N<\UI:UH6HWE[IVK:;/;P:I9J582 F*0$?,OKC.?SK
MHJ* .<TW0M2E\1?VUXAGMGN(HC#;PV@;RXP>IRW))_K4-Q9>,GMYK-;[2I8I
M 5%R\;K*%/\ L@;<UU-% &;X?T:+0-#M].A;S!$#N<C!=B<D_F?RQ6E110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% '-WW_)4]"_[ NI?^C[&NDKF[[_DJ>A?
M]@74O_1]C724 %<WX7_Y&+QG_P!AJ/\ ]-]G725S?A?_ )&+QG_V&H__ $WV
M= '25Q_Q-.WPFAP3B[C.!^-=A7-^.M*O=8\.BWTR#SYUG239O"Y SGDD"@#
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M9EE,FW^)B>F?;_\ 7V5<9IMIXA\+&\L=.TB/4K22=IK>47*Q% W\+ ]<>U(
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ME22WI;]Y(.H4+T_&M+PSKC:[ILDEQ"+>[MYF@N80?NNO7'M0!L4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.F1B0W%D3Y3@J3MYS@C'\_2@#J**X*/Q?XEF\*_VZMAI\=K",R>:7W3?-@E
M#P.W).<'Z5W%K/\ :K.&X"E?-C5]I[9&<4 1W>I6.G@&_O+>V#=/.E5,_F:E
MM[F"[A6:UFCFB;[KQL&4_B*S]4T_1E,NJZO:V\ABBPTMP@?:@R< '@=3TZYK
MC-&NIO#OP\U;5HT-NEW.TEC"?X%8A5('Z_1: .[EUC3+>Y^S3ZC:13YQY3SJ
M&S]"<U/<7,%I"9;J:.",'!>1PH_,UQNH>&-,TOX=WAO;6.2\%JTDMRZ@R&8C
M.=QY^]^E;>FZ9::KX9T8ZM;)=/%:Q.!,-PW;!DD="?K0!J6>HV6H*S6%Y;W2
MJ<,895<#ZX-.NKNVLH3->7$5O$#@O*X1?S-<=X8MX+CQ]JVI:/ D6F1PBU#1
M*%227*DE0..,'\_>H/'>B0SW5CYL\MQ=ZA?1PQ+(WR01_P 6U1T[9/7F@#L[
MK5+.S>U6YF"?:Y!' =I(=CT&0,#/O5NN=\>6XG\&WKCB2W"SQMW5E8'/Y9_.
MMG3KK[=I=I=D ?:(4EP.@W*#_6@"S1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH YN^_Y*GH7_8%U+_T?8UTE<W??
M\E3T+_L"ZE_Z/L:Z2@ KF_"__(Q>,_\ L-1_^F^SKI*YOPO_ ,C%XS_[#4?_
M *;[.@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P F5TE% '-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97244
M<W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,
M/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\ P0S_
M /R91]A\;_\ 0P^'_P#P0S__ "97244 <W]A\;_]##X?_P#!#/\ _)E'V'QO
M_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\
M\$,__P F5TE% '-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97
M244 <W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'Q
MO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\
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M'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97244 <W]A\;_]##X?_P#!#/\
M_)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__
M $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P
M0S__ "97244 <W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)
M10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE% '-_8?&_
M_0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97244 <W]A\;_]##X?_P#!
M#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8
M?&__ $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'
M_P#P0S__ "97244 <W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\
M)E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE% '-_
M8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97244 <W]A\;_]##X?
M_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\
MF4?8?&__ $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\ P0S_ /R91]A\;_\
M0P^'_P#P0S__ "97244 <W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#
M/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE%
M '-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97244 <W]A\;_]
M##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,/A__ ,$,
M_P#\F4?8?&__ $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\ P0S_ /R91]A\
M;_\ 0P^'_P#P0S__ "97244 <W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_
M /!#/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F
M5TE% '-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97244 <W]A
M\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,/A__
M ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\ P0S_ /R9
M1]A\;_\ 0P^'_P#P0S__ "97244 <W]A\;_]##X?_P#!#/\ _)E'V'QO_P!#
M#X?_ /!#/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,_
M_P F5TE% '-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97244
M<W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,
M/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\ P0S_
M /R91]A\;_\ 0P^'_P#P0S__ "97244 <W]A\;_]##X?_P#!#/\ _)E'V'QO
M_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\
M\$,__P F5TE% '-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97
M244 <W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'Q
MO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\
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M'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97244 <W]A\;_]##X?_P#!#/\
M_)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__
M $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P
M0S__ "97244 <W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)
M10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE% '-_8?&_
M_0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97244 <W]A\;_]##X?_P#!
M#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8
M?&__ $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'
M_P#P0S__ "97244 <W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\
M)E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE% '-_
M8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97244 <W]A\;_]##X?
M_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\
MF4?8?&__ $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\ P0S_ /R91]A\;_\
M0P^'_P#P0S__ "97244 <W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#
M/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE%
M '-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97244 <W]A\;_]
M##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,/A__ ,$,
M_P#\F4?8?&__ $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\ P0S_ /R91]A\
M;_\ 0P^'_P#P0S__ "97244 <W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_
M /!#/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F
M5TE% '-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97244 <W]A
M\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,/A__
M ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\ P0S_ /R9
M1]A\;_\ 0P^'_P#P0S__ "97244 <W]A\;_]##X?_P#!#/\ _)E'V'QO_P!#
M#X?_ /!#/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,_
M_P F5TE% '-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97244
M<W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,
M/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\ P0S_
M /R91]A\;_\ 0P^'_P#P0S__ "97244 <W]A\;_]##X?_P#!#/\ _)E'V'QO
M_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\
M\$,__P F5TE% '-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97
M244 <W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'Q
MO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\
MP0S_ /R91]A\;_\ 0P^'_P#P0S__ "97244 <WI^@ZY_PE5MK.O:OI]W]ELI
<[2*&RTU[;_6O"Y9F:>3./(   '4UTE%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img134051827_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_21.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI8VAA96P@
M4F%I8FQE    !9 #  (    4   0J) $  (    4   0O)*1  (    #,C<
M )*2  (    #,C<  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#,Z,30@,30Z,#<Z-#D ,C R,SHP
M,SHQ-" Q-#HP-SHT.0   $T :0!C &@ 80!E &P ( !2 &$ :0!B &P 90
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" 8D!FX# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M'R5Q8O#PI13B;T:DIMIG/?M/?\DQT[_L-0?^BY:^8Z^G/VGO^28Z=_V&H/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+.[??]/\A.5U:QU=HI\-?!6[O-VR\\478M8OFPPM8#ND88YYDPI'H*XW1_\
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M7-I9';_&153XO^( H 'GH>/4QJ37$445I"/+%1[$R=W<****H04444 %%%%
M!1110 4444 %%%% !116IIGAG7M:MVN-&T34=0A1]C26EI)*JM@'!*@C."#C
MWI-I;AN9=%:FI^&-?T6V6XUG0]2T^!G$:RW5I)$I8@G:"P S@$X]C670FGL&
MP4444P"BBIXK&[GL[B[@M9I+:UVB>=(R4BW'"[F'"Y((&>M $%%%% !1110
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MM=FFWLK103^8IWLN=PV@[AT/45F4)I[!L%%%% !1110 4444 %%%% !1110
M4444 %%%% !116EI?AS6];CDDT71]0U%(R%=K2U>4(3T!*@XH;2W#<S:*=+&
M\,KQ3(T<B,5='&"I'4$=C3: "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&*R];\62:@ND6NDVYTS3]%4_881+YDBNS!WE>3 W.S '@     8YOEG+9O\
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M 1&"^W&,DEPW+'& !5BXT3PU%:^/8V\)6MJWAORX[2>YNKHM(3(4S(/-4%G
MW+M"@>C"L:'Q3!XT^,V@:M=K#HT,4]JK--*)$7RL')8A1SM_#-==XAM]4\0_
M\)3'XYT>\T;2-/CN)["]N;R[V_:%8B%46:5HI-PW+B-1P?E*\5B^:/*I-_?Y
MEJSNT8=OX.TC1;7PTM]IFD:DFI6D-_?W6H:VEI+$DIR$BC\],!4&=S!]S$]
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MJ5B55;'RLK=#DG-326(TSX(>*; /O%KXE2$,1][:N,_I5&P^)MG!?>'-2O\
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MI>=Y^?*_V-NWGZY'TKJ_A-XAN_#?@7QEJ3J#:6D,;VK."0EX^Z.,J._WN?0
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M]\_X9:F_Z'2/_P %!_\ C]'_  RU-_T.D?\ X*#_ /'Z/KU$/J\SP.BO?/\
MAEJ;_H=(_P#P4'_X_1_PRU-_T.D?_@H/_P ?H^O40^KS/ Z*]\_X9:F_Z'2/
M_P %!_\ C]'_  RU-_T.D?\ X*#_ /'Z/KU$/J\SP.BO?/\ AEJ;_H=(_P#P
M4'_X_1_PRU-_T.D?_@H/_P ?H^O40^KS/ Z*]\_X9:F_Z'2/_P %!_\ C]'_
M  RU-_T.D?\ X*#_ /'Z/KU$/J\SP.BO?/\ AEJ;_H=(_P#P4'_X_1_PRU-_
MT.D?_@H/_P ?H^O40^KS/ Z*]\_X9:F_Z'2/_P %!_\ C]'_  RU-_T.D?\
MX*#_ /'Z/KU$/J\SP.BO?/\ AEJ;_H=(_P#P4'_X_1_PRU-_T.D?_@H/_P ?
MH^O40^KS/ Z*]\_X9:F_Z'2/_P %!_\ C]'_  RU-_T.D?\ X*#_ /'Z/KU$
M/J\SP.BO?/\ AEJ;_H=(_P#P4'_X_1_PRU-_T.D?_@H/_P ?H^O40^KS/ Z*
M]\_X9:F_Z'2/_P %!_\ C]'_  RU-_T.D?\ X*#_ /'Z/KU$/J\SP.BO?/\
MAEJ;_H=(_P#P4'_X_1_PRU-_T.D?_@H/_P ?H^O40^KS/ Z*]\_X9:F_Z'2/
M_P %!_\ C]'_  RU-_T.D?\ X*#_ /'Z/KU$/J\SP.BO?/\ AEJ;_H=(_P#P
M4'_X_1_PRU-_T.D?_@H/_P ?H^O40^KS/ Z*]\_X9:F_Z'2/_P %!_\ C]'_
M  RU-_T.D?\ X*#_ /'Z/KU$/J\SP.BO?/\ AEJ;_H=(_P#P4'_X_1_PRU-_
MT.D?_@H/_P ?H^O40^KS/ Z*]\_X9:F_Z'2/_P %!_\ C]'_  RU-_T.D?\
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M/_P4'_X_1_PRU-_T.D?_ (*#_P#'Z/KU$/J\SP.BO?/^&6IO^ATC_P#!0?\
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M_AEJ;_H=(_\ P4'_ ./T?\,M3?\ 0Z1_^"@__'Z/KU$/J\SP.BO?/^&6IO\
MH=(__!0?_C]'_#+4W_0Z1_\ @H/_ ,?H^O40^KS/ Z*]\_X9:F_Z'2/_ ,%!
M_P#C]'_#+4W_ $.D?_@H/_Q^CZ]1#ZO,\#HKWS_AEJ;_ *'2/_P4'_X_1_PR
MU-_T.D?_ (*#_P#'Z/KU$/J\SP.BO?/^&6IO^ATC_P#!0?\ X_1_PRU-_P!#
MI'_X*#_\?H^O40^KS/ Z*]\_X9:F_P"ATC_\%!_^/T?\,M3?]#I'_P""@_\
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M,M3?]#I'_P""@_\ Q^CZ]1#ZO,\#HKWS_AEJ;_H=(_\ P4'_ ./T?\,M3?\
M0Z1_^"@__'Z/KU$/J\SP.BO?/^&6IO\ H=(__!0?_C]'_#+4W_0Z1_\ @H/_
M ,?H^O40^KS/ Z*]\_X9:F_Z'2/_ ,%!_P#C]'_#+4W_ $.D?_@H/_Q^CZ]1
M#ZO,\#HKWS_AEJ;_ *'2/_P4'_X_1_PRU-_T.D?_ (*#_P#'Z/KU$/J\SP.B
MO?/^&6IO^ATC_P#!0?\ X_1_PRU-_P!#I'_X*#_\?H^O40^KS/ Z*]\_X9:F
M_P"ATC_\%!_^/T?\,M3?]#I'_P""@_\ Q^CZ]1#ZO,\#HKWS_AEJ;_H=(_\
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M3?\ 0Z1_^"@__'Z/KU$/J\SP.BO?/^&6IO\ H=(__!0?_C]'_#+4W_0Z1_\
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MTN^6T<),NTC82,@9(Y_"K5 !144-U!</*D$\<K0MLD5'!*-Z''0U+0 4444
M%%%5(M3LYM4GTZ.;==P(KR1[3\H/0YQ@_G0!;HHHH ***K?VA;?VI_9WF_Z7
MY/G^7M/W-VW.<8Z]LYH LT55O]2M=,A26^E\I))%B4[2V6;H.!5J@ HHI'=8
MXV>1@J*,LS'  ]: %HJG<ZM86FEG49KE/L8VGSDRZG<0!C;G/)%7* "BBB@
MHJIIVIV>K6IN=/F\Z(.4+;2O(ZC! JW0 4444 %%%1S7,%OY?VB:.+S7$<>]
M@N]CT49ZGCI0!)151]3LX]5BTUYL7<L9E2/:>5'4YQC]:MT %%%1374%N\23
MSQQ-,VR-7< NWH,]30!+1110 4444 %%1O<P13Q0R31I+-GRXV8!GP,G [X%
M24 %%%% !1110 4444 %<W\./^26>%/^P+9_^B$KI*YOX<?\DL\*?]@6S_\
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M;H@>9%)P0Q[,<CD\9R>E:UI;ZFDZO?ZA#,BJ0(X+7R@Q..6)9CQCC&.ISGC
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ME?F>'S%< 8(*Y!Q]"#P.>QK:-HQTR>^NI[@7%U?2B25TC\M!@8 5<G''J32
MQ_$%K-+XY\/[+^XA\P7.WRUC/E8C&=NY3U[YS[8JVMQJ&I>([S38+Z2TMM-B
MB$DL:1M+/(ZYR=RE0 !T ZG\*NZMH\E_?6%]:7*V]U8LYC,D7F(P==K J"I]
M.<U%)HMU%J[ZGIU[%!<7$2QW220&2.4K]UPH=2I R.I&/SH ;X;U*ZO%O[34
M'66XT^Y,!F5=OFK@$,0.A]0.*VZS]'TE-)MI%\UIYYY#-<3N #)(>IP.@]!V
M%:% !1110 4444 %<W\./^26>%/^P+9_^B$KI*YOX<?\DL\*?]@6S_\ 1"4
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M+59%_=I&5 !;.-V 2><5M:II]S<>*M"O(8MT%I]H\Y]P&S<@"\9R<GTK:HH
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MLMK-<%+>*"3:6)9P /D+#IGO7457NK"VO9+=[J/S#;2B6++$!7 P#@'!Z]Z
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M@X!).,NI!YYXS3;G6[CP]>>([>ZGFF(B%[8[SNP'.S:,]A(0,=.>E '9T5Q
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M2'N230!:HHHH **** "BBB@ HHHH *YOX<?\DL\*?]@6S_\ 1"5TE<W\./\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1?L=Y+'-)YTC[X\X(9LCL,&MFD 4444 %<KXRE6#4O#LKARJ7X)"(7;[IZ*
M2?PKJJQ]<TB?4]0TB>!XU6RNA-(')!*XQQ@=?RH Q=>U*"^\1>'%A2Z4K>DG
MS[26(?=[%U&?PJ6Z\6L]UJ26NH:59"Q=HDBOFS)<2*.<?.NU<\ X;N?:M36M
M(GU+5-(N8'C5+&X,L@<D$C&.,#K^516^FZII%]J#:6MK=6U[,;D)<3-$T4C?
M?Y"-N!(!'3'3WI@4G\4WUZWA_P#LBVA7^UTE9_/RWD[ N2,$9 RW'&<#I22N
M]O\ $2T>]EC9H])D:21$*KQ)R0N21^9K3N=*O+G7M%U"66 _84F$^T%=S.H
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MXM71PZR6[ $$=B""".>A!'X@5F2>$[*;3;ZTGGN9&OY5EN+AF7S'*L"O1=H
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MZMIRJFIQ^3-'>+_K9Y'(W;FZN&W-D$D?E771Z79Q7MQ=K"#-=(L<S,Q;>JC
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M0*7//)(ZGZU9O;R3PU?>)+:$-_ID2WEF V#YDA$;8]]Y4UU)T33S96=H;?\
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M?PJU10 4444 %%%% !1110 445Y_\6?M_P#9%G]F\S[)O;[1LSC.!MS[?>H
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M9[V:XE1;R>Z=)K9E;"A0(SMV\$ 'GO7=V,<\6G6T=XXDN$B5974Y#. ,G\Z
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M7=(@QT!QC Z9-5[O5%TWP[K=O9:8-$U6"&/S([=@4*%]HD4KQG#'G ;IUQP
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M[HJK=Q1PZ/-%"BQQQP,J(@P% 7  '85Y];Z=90_":/5H@!J$2"6*[SF1'$F
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M<GGG]:TO"]S:R?;;6'2SI-U;NOVFS5@40LN5*[?EY'H![^M &_1110 4444
M%<W\./\ DEGA3_L"V?\ Z(2NDKF_AQ_R2SPI_P!@6S_]$)0 >//^1=M?^PUI
M7_IPMZZ2N;\>?\B[:_\ 8:TK_P!.%O724 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !6#8>(+K4]9O;&UTU1'8W'E33R3X!''*@*<MUXX'
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MCKF_!?[ZUU2_"D)>ZE-+&3_$@(4?R-=)0 4444 %%%% !1110 4444 %%%%
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MATW$9'U'-31HL4:QQC"H JCT IU5-/N+NYBD:_L?L;K*RHGFB3>@Z-D=,^E
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M'&@4# )(#,&8 'J 1U]#6E;W$5U:Q7%NX>*9 Z,/XE(R#^5 $!TJR.H07OD
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M1110 52U'5[+2O)^W2.IN'\N)4B>1G;K@!035VN8\6?\AGPW_P!A$?\ H)H
MV+/6["_NGM8)F6Y1=Q@FB>*3;ZA7 )'N*OUS/BT*FI^'9HR1=+J2HA7KY; B
M0?3 &:S([G4-<&K3)#JTDD=S+;VCV=TD4<(0X7*F1=QSR2P/H* .YHKC+A]5
MNM=\-V>I7-Q:23VLIO(K>7:'90.,J<#ZCD9."*9/=75C:^+[*&\N6CL84DMG
MDF9I(]\98@.3NX(XYH [:BN$NX[VUM?#<T&KWXGU"2.&YD:<L'#IDD(<JI'8
M@>YR:T[*62P\8:CIOVV<67V%;E3<3&0PMG:2&<GCOSD4 =117#3:G!!JVB2Z
M+?ZE.MS=""=[@S-%.I')!<;,Y&1LQWQQ5S1HI]1\6ZY]KOKMK>TN$$-NL[HJ
MDJ#G@C(X^[TY/% '0:;JL&JBZ-NLB_9;E[9]X RR'!(P3Q5VO-]-N[BXUR]T
M07,FG6USJ]U(UTC%7F*N/W2,/NGH2>N.![^CJH50HS@#')R?SH 6BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** .7@M;?6?&NL1:M''=QV20
MI;6\ZAD177<S!3QDGC=UXQ7.:EYG_"+WUD))#:VFN+;VQWDF- 1\H.<X7.!Z
M8]J[V[T6QO;I;J:.1+A4*>=!,\+E<YVED()&1T--DT'3)-+ATYK11:0,KQQ*
M2H# Y!R#DG///7O3 PGLK;1_'^DQ:9"MM'=6LRSK&,"3: 06]3D]3S63IFFW
MOB'1;N[-G8S7\\\FV^FNG2>V=6PH4",[-N 0 W\Z[J73K6?4;>_EBW7-LK+$
M^XC:&Z\9P?QJI+X<TR:>>4PR(;@YG6*XDC24]#N16"MGOD<]Z0%E#=6VC*9<
M3W<5O\VT$AY O.._)KC+?3K*Y^&[ZU<D-J;6[W/]H%OWPE7.W#]1@J%P..U=
MZJJB!$4*JC 4#  K*_X1?1_,+?9#L,GFF#SG\DOZ^5G9^E '.7%G;:CXL\-2
MZE96\LMW8R/<B2%3YC"-?O CG';TKH/%M@=2\*WT$?$JQ^;&>X9#N&/RQ^-:
M$NG6L^HV]_+%NN;966)]Q&T-UXS@_C5F@#@6U-]1\2:?KT3 06BVT$HS\H^T
M*VXGTP7CJGJ<(N?!5YJC9#:IJBRJP/S",/M0?D,_C7:P^&M(M])GTR&T"V=P
M^^2,2-\S<<YSD?='0]JFFT33[C2H=-EM@;2'9Y<8=AMV_=Y!SVI@8<]A;:/X
MZT1=,B6V6[AN$N G'FA%#*6_O')/)YK#AF9/#5Q;^<T,-YXB:WN'1MI$3/\
M-SVSC&:[Z;3[:XO[:]FBW7%J'$+[B-N\ -QG!R .M0+H.F+IUU8_9%:VNW:2
M:-F+!F;DGD\<\\=.U(#'\3:/I^G>$]8ET^TBM6DM2KK NQ6 Y&5'&>3SC-9U
MQIUMI=KX5O;&,174MW!#+,#\\J.AW!FZMT'7IVKIO^$=TUH;B*6*69;F/RI3
M/<R2,4Z[0S,2!GT(J>;2K*XAM(I8=R64B2P#>PV,HPIZ\X![T 9WC;_D2=4_
MZX_U%8;V4%_XQT*"[3S8?[)W-&3\KX(P&'<9YP>.*[*^LK?4;&6TO8_,@F7:
MZ;B,CZCFHETFR2^@O%AQ/;P^1$^]OE3TQG!^IYH XM=,:]T_Q5I-DNU;2Z$U
ME$HXB?&_"CL"1TZ<U>M[_P#X237K&_@421:=IWVDH 2//E& GU !KJ+73;6S
MNKJXMHMDMVX>9MQ.\@8!P3Q^%1Z9HUAHZS+IMN(1,^^3YF;<?Q)_+I0!Q&F:
M/J.N^%8;VWMK'^TISYRZK)=OYZN&QVC.  -NW=C%:7B&QEL]4N-9U33HM7T\
MVZ*Z[\268 .]HPW!SP<@AL^F,UO?\(UI7F.1;NJ22>8\"SR+"S<<F,-L/0=N
M:?>>'M-OYY9;J%V,VWS56>1$EV]-R!@K= .0> *8'-W-AI=_\0M.8V=O<07.
MG-*?-B#>9R-K-N&2<8Y/-,O[B6TOO'$]O/\ 9Y4M[<K)D@J?*/3'0]A[UU=Y
MHUC?302SQ,LMN"L4D,KQ,@/490@X]JH>(-!^U:1J_P#94:+?ZA&BR,[G$@7C
M'.0#MR,X')_&@#"TS1K.?Q!H<]CHKVRV=LQO)+BT:++[1L^\!O<-D[AGZU6\
M33Z=-H%_J6CZ9</-!.&35_E!$@9<X9G\P@?=X&/3@5J1:([ZII<NF:"NABU?
M?<3;HP9$QCRAY;$OD]VQT]\5JS>$-$N$ECEM&,4KF1H1<2"/<>K! VT'W H
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M$H /'G_(NVO_ &&M*_\ 3A;UTE<WX\_Y%VU_[#6E?^G"WKI* "BBB@ HHHH
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MA&3F_8:1!I]]?7<+R-)?2"20.00"!CCC_&K]% &'-X2T^?3[JT=Y\7%XUZ)
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M75)9XX[%[J-%G=PJ91<'D\=2!75*RN@=&#*PR&!R"* %HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_A
MQ_R2SPI_V!;/_P!$)725S?PX_P"26>%/^P+9_P#HA* #QY_R+MK_ -AK2O\
MTX6]=)7-^//^1=M?^PUI7_IPMZZ2@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7=_:P&,JKB295VE@2 <GC(!(]<50\0>)K70M+AO-T,XG=1$OGA=ZDC+*><@
M@\4 ;5%4CK.F+9K>-J-H+9FV+.9UV%O3=G&>#Q5N*6.:%)8762.10R.AR&!Y
M!![B@!U%9=OJ+I<:BVHWFG+;6S@(8I<-$I_YZY. >E6H=4L+B[:UM[ZVEN$!
M+0I,K.N.N0#F@"U15+6-4@T;2;B^N60"*-F57<)YC $A 3W.,52T'6?MNBC4
M+_4M/D3RU>0VXV+;DKDJQ+MR,^WTH VJ*KV>HV6H*S6%Y!=*APQ@E5PI]\&D
M_M&R^P?;OMEO]DQG[1YJ^7UQ][..O% %FBJMSJ=A9,5O+ZVMV50Y$LRJ0I.
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MJW-S;1VWV.:RB:2Y2-OMC%0RG.53'5SV%27&K:=:%Q=ZA:P&-E5Q+,J[21D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ@D9'45M>(KN:P\-ZA=6K^7-#;NZ-@'! X.#Q0!=6U@2Z>Y6"-9W4*TH0;F
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M=6"Y&".F<56UZSL(_!^I76GWLU^MW?1-+-(%VNP=02I554CMD9&0>X->@T4
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MEA<F)4G3:!PTB')7I@&HI[&RLY_!]O8/)/:K=RO&\ZX9LY;.,#N>./2N[HH
MY'Q"IMO&>GWUU>36%F;5X%NXPFV.0MG#%U8*"._'UJEJ^G6UQX8URXT>]GU6
M6X>%[A]J%9 A!(4HJJ?EZXSTP:[NB@#B=;U?3]5\1^&CILZ706ZW-)%RJ;EX
M4GLQP?EZ\<UO>+?^1.U7_KU?^5;%% ' W5[::MX7T+2M-8&^\VW_ -' P\ 3
M&YV7JH'KWSD9IGB-;G3_ !!>Z59J4C\2+&$D&<(X8++^:')_"O0:S;C2/M/B
M2TU26X)2TA=(H-G1VX+YS_=XQC\: +UO EK;16\(Q'$@1!Z # KSRS4-X'\*
MA@"#K:Y!'_3:6O1Z* .9N0&^)ULK#*OI3JP/1AY@X-8ND6\CZO9>&9"QCT:\
MEN7R,$QK@PG/UD_\=KT"B@#A;3R;'4M=MM7UJ726FO'F",8%2>)Q\K*9$);@
M$$ \8]:GN=/TC3[/2_LNMS:3<VMNWV2ZND #HQ^8,KJ 3S]W@C(-=G10!PM_
MJ%S?:7X6UC58EM +X-.V"J1@[@K'/0$ 'GUJY=RQW/Q MY;=A<1R:/(4,+ [
MP7_A/3FNNJ*[MTO+.:VE+!)HVC8J<$ C!Q^= 'G6B7?VG0_#UM?R1V=E:W"3
M+<&*;]XP)*)N,8C')P3N.<<5JZ[XBFF76[![BSL%@B:%+>>)I)KK<I^9 &7
M.0!@-W)XK1_X1B\GT>WT>^U2.73H=BE8K7RY9$3E5+[R!R%R0H)QVS724P.$
MNF$&C^";R=A';P^3YLSG"IF(8)/;ZU?:]MK#QW)J%_<QQV5[8(MI=N_[HX))
M7=TY^\.>:ZRBD!YSK(%SX<\7:G;(5LKR2#R&(P)-NT,X'H3W[UU7B.VTU].M
M8;V[.FI%,KVTZ8589$!VY)&T#&1@X!Z#FMRB@#"\*:E>ZC9W/VV2.Z2"<Q0W
MT:;%NE'5@!QUR,CC\JIZ]+'9>-M"O;R1(+58[B-II6"HK%1@$G@9Q74T4 <I
M97UMI/B[6I-6N(K5+[R9+:>9PD<R*F"%8\$@GI[YJWX/B<6-_=>4T4%[?RW%
MNKKM)C; !P>F<$_C7044 <;!J-GIWQ(UE[^1;='@@59Y?E13MSM+G@$XR >N
MT^E93VUPVAQZDBW%O8OKK7^](\O' >!+M(/ ^]R.G->CT4 <YI<&FW?B%;ZW
MUR;5;J"W*94Q-&B,>A,: 9R. 3GK4/B]%DU;PVKJ&4ZB.",CI74T4 <EXF1X
M/%>D7UQ>2V5DL<L1NHPI$+MC&XNI4!NF?;M5'6H+#_A%?$=[8ZG-J4MQ'$L\
M[;"A*] I154G!YQGMFN[HH Y6Z\0RV%W96!N+/3H?L"SF[O5++(>!L0!EY'4
M\YY'%<Y''*_PKO3M8F+4"[@(5VJ)06.T\C'7':O3:* .0\17,-SJFA:I;:@4
MT^&2:.6^M61UA9U"J22&4#.02>F:K:CI=OJ6D:[<Z+J=QJU[-;+$[C84;!W;
M5*(%+8[#)Y&>HKN** .$U75].U*'PS%IS+,\=_;,_EC/D#IM8_PDGL>3M/I7
M9ZA&TNF74<8W.\+JH'<D&K%% 'GB,+[X66MM9L+B6R:)KRUC;,@59,E2HY!X
MS@^AK7U34++Q!J6B1:+/'>2PWB74DD)W"&(*<[B/NYR!@]:ZRB@#G/'_ /R(
MVH?]L_\ T8M9^D-_8L^JZ'J !O)4DN8KQCS>H0>I/\2],#MT]3V=% 'GDB@?
M!* @#(6(CCH?/'-;/VFWT?Q[J%QJ[I;17EM$+6YF;:GRYWIN/ .<'%=510!P
MJZ8VL:'XGNK=66"\F\^R)4@NR*"' /9F'7O5)-2$N/&Y0[4NDA9!T$/E;&_\
MB-_^NO1Z* ."GL?LOA3PVMPJM+<ZO;SSY&=S2,6.?SQ^%:UWQ\4-/QWTZ0'W
M^:NGHH **** "BBB@ HHHH **** "BBB@ KF_AQ_R2SPI_V!;/\ ]$)725S?
MPX_Y)9X4_P"P+9_^B$H /'G_ "+MK_V&M*_].%O725S?CS_D7;7_ +#6E?\
MIPMZZ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M $X6]=)7+?$6)Y_"4444\EL\FK:8JS1!2\9-_  R[@5R.HR"/4&I?^$7U?\
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MX1?5_P#H>_$'_?C3_P#Y%H Z2BN;_P"$7U?_ *'OQ!_WXT__ .1:/^$7U?\
MZ'OQ!_WXT_\ ^1: .DHKF_\ A%]7_P"A[\0?]^-/_P#D6C_A%]7_ .A[\0?]
M^-/_ /D6@#I**YO_ (1?5_\ H>_$'_?C3_\ Y%H_X1?5_P#H>_$'_?C3_P#Y
M%H Z2BN;_P"$7U?_ *'OQ!_WXT__ .1:/^$7U?\ Z'OQ!_WXT_\ ^1: .DHK
MF_\ A%]7_P"A[\0?]^-/_P#D6C_A%]7_ .A[\0?]^-/_ /D6@#I**YO_ (1?
M5_\ H>_$'_?C3_\ Y%H_X1?5_P#H>_$'_?C3_P#Y%H Z2BN;_P"$7U?_ *'O
MQ!_WXT__ .1:/^$7U?\ Z'OQ!_WXT_\ ^1: .DHKF_\ A%]7_P"A[\0?]^-/
M_P#D6C_A%]7_ .A[\0?]^-/_ /D6@#I**YO_ (1?5_\ H>_$'_?C3_\ Y%H_
MX1?5_P#H>_$'_?C3_P#Y%H Z2BN;_P"$7U?_ *'OQ!_WXT__ .1:/^$7U?\
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MX1?5_P#H>_$'_?C3_P#Y%H Z2BN;_P"$7U?_ *'OQ!_WXT__ .1:/^$7U?\
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MQ!_WXT__ .1:BBT"_GEECA^(6N220G;(B1Z<2A]"/LO% '4T5S?_  B^K_\
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ME%<W_P (OJ__ $/?B#_OQI__ ,BT?\(OJ_\ T/?B#_OQI_\ \BT =)17-_\
M"+ZO_P!#WX@_[\:?_P#(M'_"+ZO_ -#WX@_[\:?_ /(M '245S?_  B^K_\
M0]^(/^_&G_\ R+1_PB^K_P#0]^(/^_&G_P#R+0!TE%<W_P (OJ__ $/?B#_O
MQI__ ,BT?\(OJ_\ T/?B#_OQI_\ \BT =)17-_\ "+ZO_P!#WX@_[\:?_P#(
MM'_"+ZO_ -#WX@_[\:?_ /(M '245S?_  B^K_\ 0]^(/^_&G_\ R+1_PB^K
M_P#0]^(/^_&G_P#R+0!TE%<W_P (OJ__ $/?B#_OQI__ ,BT?\(OJ_\ T/?B
M#_OQI_\ \BT =)17-_\ "+ZO_P!#WX@_[\:?_P#(M'_"+ZO_ -#WX@_[\:?_
M /(M '245S?_  B^K_\ 0]^(/^_&G_\ R+1_PB^K_P#0]^(/^_&G_P#R+0!T
ME%<W_P (OJ__ $/?B#_OQI__ ,BT?\(OJ_\ T/?B#_OQI_\ \BT =)17-_\
M"+ZO_P!#WX@_[\:?_P#(M'_"+ZO_ -#WX@_[\:?_ /(M '245S?_  B^K_\
M0]^(/^_&G_\ R+4+:#?I=):O\0M;6X=2R1&/3@[ =2!]ER10!U5%<W_PB^K_
M /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^
M_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+
M1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]
M#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_
M&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0
M!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_P
MB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]
M^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_
M /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB
M^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@
M_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__
M "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%
M<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_
M /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^
M_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+
M1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]
M#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_
M&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0
M!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_P
MB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]
M^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_
M /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB
M^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@
M_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__
M "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%
M<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_
M /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^
M_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+
M1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]
M#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_
M&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0
M!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_P
MB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]
M^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_
M /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB
M^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@
M_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__
M "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%
M<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_
M /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^
M_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+
M1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]
M#WX@_P"_&G__ "+0!TE<W\./^26>%/\ L"V?_HA*/^$7U?\ Z'OQ!_WXT_\
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M OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM+/*ZO$K$G#*%._!)_B&?:N@7(4;B"V.2!@$T +1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%0W5W;64!FO;B*WB!P9)7"*#]34JLKH'1@RL,A
M@<@B@!:*B>Y@CN([=YHUFE!,<9<!G ZD#J<5+0 45'<7,%I TUU-'!$N-TDC
M!5&3@<GW.*DH **@OKVWTZQEN[V3RX(5W.^TG ^@YJ6*5)H4EB.Y'4,IQU!Z
M4 .HHJG?ZM9Z;)!'=._F7!811Q0O*[X&3A4!/% %RBD5@Z!AG##(R"#^1Z5"
MM[:O>O9I<PM=(N]X!("ZKQR5Z@<C\Z )Z*AN[J*QLIKJX;;%"AD<^@ R:2QN
MQ?6$%VD4D2S()%20 , 1D9P30!/14%I>VM_"9;&YAN8P=I>&0.N?3(J.UU;3
MKZ=H;*_M;B506:.&978 '&2 ?4B@"W16<FO::^I_8%N,W&\QC]VVPN!DJ'QM
M+ =0#D596_MGU&2P27=<QQB1T )VJ3@9/0$^G6@"Q15+2]4@U:U>:W61#'*\
M,D<JX9'4X(.,_7\:NT %%-=TBC:21E1%!9F8X  [DU5T[5;75H?.L3*T6 0[
MP/&&!Z%2P&X?3- %RBHTN8))Y8(YHWFAQYD:L"R9Z9';/:I* "BBB@ HHHH
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M+K[%I_C.X,$%QY=X6\JX3>C<#@CO6V^L7;WFF:5I45O%//:"YEDDC+1PQ@
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M49*LN]L@CH<CH>* .FHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_\
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M?9"8F#KCE"^<C ((;\.: .;O-8FU+P?XHMI;M+Y+-MD-TFW]XAY&=N%)'3(
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M;ZD&<S:7-;JBA/FV^6<!CT!SN;C/'.0_X@;_ .PK3RBH?[?#M+#(!SQFKO\
M8-U=:E87.K7\=TNGEGA6.W\IG<@#<YW$'UPH49]N*LZ]HW]MV<,'G^1Y5Q'/
MNV;L[3G'4=?6@#/BO+_3O&%IIEU>O?07EJ[YDC1#'(IY(V@?*1V.3[U0US79
M=&,<L7B&"[NUNE2:P B"["<$!1EP1D<ECT_"M^YT;[1XELM6\_;]EB>/RMF=
MV[OG/&/I6*W@J<Z*FD)JB)90S>='BT_>,=^X!VW8;CC("GH?8L"X]UJ&J^)M
M0T^SOFL(-/ACRT<:.TDD@W G<"-H Z#!.>M5_ /F?V3J'GE3+_:4^\H,*3D9
MQGM6C<Z)<+K,VI:3?+:2W,(BN%DA\U7V_=<#<,, 2.<CV]7^']$&@V4]L+E[
MD2W#S;Y!AOFQP?4\=>/H*0&5=:S?QZKXFA2?$=C8+-;C8OR.8V.>G/('7-5S
MJ>L6.E:'JUUJ/G_;9H(Y[80HL>V1>JG&[<.O7!/8#BM:?PYYU]K5Q]JV_P!J
M6HM]OE_ZK"E<YSSUZ<47?AS[5H>EZ=]JV?V?) _F>7GS/+&,8SQG\<4 4;OQ
M%=:?KNOB5_,MK"R2:*':!\Q![XSR<56@UG51_9MS%-J%Z]Q,@NK5M+=(HT?J
M4?RP?ESU+'-/L;>VUWQ9XA962YL)K6*V:6-@REMIR >F1^G%;-AI>J64=M;/
MJR26MO@ "UQ*Z#HK.6(Z8!(4$X[4P*=G/J6NW>J/!J+Z?#:7#6L"11H^YD'S
M.^Y22"2. 5X'XU3:SN7^)>TZG<(YTK>6C2(8'F_< *'Y>_.6]ZU%T*[L[V^E
MT?48[6*^?S9(I;<R[)",,Z'>,9X."&&1Z<5)<Z+.VNP:K97JQSI;?9I1/#Y@
MD3<&SPRX.<\].>E(#$E\3W]E!XCF9DG:SNT@M(W4!1NP #C!(R<\GM5Z]FU/
M0;C2Y)=2?4(KJY2TN(YHHTP7X#IM4$8(Z$MP?QJ0^$K>:/6(KNX>2+5)EF^1
M=K0D8Q@\Y.1G.*F&B7EW<V4FM:C'=I9.)8XX;;R?,D P'?YFSCD@# R?PI@9
M-M=ZSJ5UX@"ZJUM'83.EN(X(R<[<@,64Y4?GR>:WO#NI2:QX=LK^90LDT0+A
M>F[H<?B*BL=!^Q2:NWVG?_:4S2_ZO'EY7&.O/Z5/H6E_V+H=KIWG>?\ 9TV^
M9MV[N2>F3CK2 Q-/UBYF\0S6NIZD^GW(N6$%A+ HBF@&%!5R,LQY.0W7^' Q
M6=JU]>ZEX?\ %D5Q=N$LYV2)41!\@7[A^7ISUZ^]=!=Z#=ZC+;)J6HI/:6UR
M+E56VV2L5SM#.&Q@9[*,XIJ>%X_L^MP3W!=-6D9SM3:8LC'KSCK3 S[C4+K0
M_"^EI%>3337[0PI)) )# I3)*HB@L0!P#GGUJUI6HWY\1?9"]]>Z?) 7%Q=V
M+0-%(#]W.Q 01[9J:3P[/=:-;6=Y?(;BR=)+2Y@M]AC9!A2REFW>XXR..*T;
M.#4$N&DU"^BF7;M6*"W\I0<_>.68D]NH'7@]D!D^)[_4K;4]&M-+N5MS>SO'
M(S1AN-O7D=1U'OUXJ+5=4NK+6++1DO+O#0M<3W<=J)IBH;  5$*CD\G;Z=ZU
M=3T;^TM3TR\\_P O[!*TFS9GS,C&,YX_6FZEHKW>IVNI6-R+6]MU:,.T?F)(
MAZJRY!//(P10!1TJ_P!2N;;5(;B>2&.V8&WU&[LS$6C(R2RL$&5Y&< ="0>]
M?3M>V^+/[.BUE-6LY;0S>9F)FA=3R,Q@#!'8C/2M#4M!N=8T6YLM1U$,\SJZ
MM%;A8TVD$#822P)&2"Q]L4V'0+IO$46KZCJ$=P\<#0"&.V\M-IQZLQ]>I/7M
M0!!H4NJ:YIMOJYU-K87$F];184:)8PV-I)&\D@9SN')Z8&*I>%K28>*=?)U&
MY8172;U*QXF^3^+Y./\ @.*U--T*^TFW6RLM41=/CEW1HUMNE1"VXH'+8QU&
M2I.#]#4UIHLUCKUY?6MU&(+YE>:!X2S;E7&5?<,9Z\@T 8-GXCU.X\,:,!,I
MU#5+J2 W#1C$:AW!8*, D # Z>N:U5NK_2_%%EI]S>/?6NH12&-ID19(GC )
MY15!4@^F<]ZCB\(K#X=L=/2]*W-A.T]O=K$/E<LS<J3R/FP1GG%7K;1ISK"Z
MGJMXMU/#&8[=(H3%'$&^\<%F)8X'.>G:@#F(=8UT> E\1RZINEB.[[.($"2J
M)2I#\9R?52!@#C.2=/6M9N+?6X8KF]GTG3)+<&.\2!75YF; 5V96"@#GMWYJ
MP/"F/ S>'?MO52OVCRO63?\ =S^'6K=_I>H75O-;6^I116\\'DNDMKYA7@@E
M2&7&0?XMW(_"F!H?:!%I_P!HED655B\QGB'# #)*C)X/;D_6N"UF75=5^&EQ
MJ]QJ&!<*':S$*>6L>\ *#C=N'!R21VQW'=V5A!8:9#80@M!#$(E#\D@#'-<[
M/X-NI?#[Z''K'EZ=DF)1;YD49R%9MV&4'V!X'/:D 7FMS?VY#I,4]U:PPVB3
MRRVEH9Y&8\!<;'"KWR1[<57?Q)JMIH#BXCF^TOJ LK>ZELW1G1N1+Y6 20,\
M =0/I6U<:%*-4AU+3;M+:Z6 6\OF0^9'*@Y&5#*<@]\^U+>Z'+J>D_9[^_9K
MI9A/#<Q1!/(D!RNU>>!Z$DG)YZ8 *6FZC?CQ%':J^H7MA-"Q::\L6@:"0'CG
MRT!!';&<CKVK%CUG7U\!)XCDU,/+&X_T?R$$<J^;L.XXSGGJI P!QG)KL;2W
MU);GS+^_AE0+A8H+;RE)]269B?;!'?.>V5_PB7_%#?\ "._;?^WCRO\ IIO^
M[G\.M, -UJ>F^*-+M+N_^UQ:BDV]#$J+$Z*&^3 SMYQAB3[FLF/Q%J>H:;=:
MC:7%[',LC_9+.'37EAD5&P%9Q&22V""0PQGMBNHO=)^V:YIFH^=L^P>;^[V9
M\S>NWKGC&/>J=KH-[I:W$&D:G'!9S2-(L<MKYC0ENNQMX&,\@%3CWI 5O[3U
M#5-?M=-AGDTU18+>7)2-3)N8X$?S@@8ZGC/&*@\%I/'JWB)+N59IEO &D5=H
M?Y>N.U:UYHL[ZO!JEA>K!=QP&WD,T/F+*F<\@%<$'G(-)H.@MHT]_+)>O=R7
MLHE=G0*0V,'IQU^F.E &Q1110 4444 %%%% !7-_#C_DEGA3_L"V?_HA*Z2N
M;^''_)+/"G_8%L__ $0E !X\_P"1=M?^PUI7_IPMZZ2N;\>?\B[:_P#8:TK_
M -.%O724 %<G_P (E<OX9U+3Y)H5N9[V2[MI%)(C;<&3/'!XP<9Z]ZZRH+>^
MM+QI5M+J&=H6VR"*0,4/H<=#Q0!S,OA&Y_X1&UTR*:%KL7*75S*Y(61]VYR#
MC/L.!T[5HS:7?VGB*;5=)-O,MW$L=Q;W$C1C*?=96"MV)&,5L0W,%QYGV>:.
M7RG,<FQ@VQAU4XZ'GI5;^V=+^V?9/[2M/M.[9Y'GKOW>FW.<^U %'6-*OM<\
M+7=A=26\-S/RGE[BB88,JDGD] "<#Z5#K&E:IK%K9>?'9@P3[Y[(SNT-RHZ!
MFV9X(S@J15]O$>AHQ5]9T]64X(-T@(/YU.NJZ<]BUZE_:M:H<-.)E,:GI@MG
M'<4 8FBZ!?Z5=ZQ=0QZ;:/>K%]G@@5C%&4##!&%SG(Y&._%36&AW(\4/K-S#
M:V1,!B,-I(7\YBV2[L47..,<'ZULVE[:W\)EL;F&YC!VEX9 ZY],BHK;6-,O
M+@P6>HVD\P!)CBG5FXZ\ YH QM,T+5-/T"]T>.>&)'\TVUY%(WF*7)(RNWC&
M>H:J-KX1NX]2T>X%EI5F-/(\UK9F:2?Y<%BQ0=\<'/4\^O67=]::?");^ZAM
MHRVT/-($!/7&3WX-)'J%E+9&\BNX'M5!)G652@ Z_-G'% &;;:9>V/BC4+Z
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M)&0-@DJP8!L'MC&,51NO#%[=Z'K*S3P'4M6*ER"1%&%P%4'&3@#KCGTKJ:*
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MM2:'[5=*L:QPDLL,:YP Q +$]2<"MBBB@ HHHH **** "BBB@ HHHH ****
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MJ^DO/+<6UJ(I(&F<NZ!P24+'EN0<9)..*S]8L(;CXD:4)'N!YMM*6\NYD3&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%VX]@!0!G1/>7'Q"U:2WLX;J2RBABB:XG,:PJZ;CMPK'))]!P.M0:WJT>O\
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MGF?WSAUR1V]/QJ?4-%EUC1I+/5;J-I=XDBGMH3'Y3#E3@LV2#GOT/XT 9OB
M+9^+/#4MLBH[2R6YVC&8ROW?H.H]*ZFL>#1KF35K;4-6ODNI;1&6W2&#RE4L
M,,Q!9B21QU '/'-;% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4L]-$?VR7:TK;8XT1G>0_P"RJ@D_@*@77[!XY&0W+-&X22);.8RH2,@F/;N
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M,[26E_=[%>YD96"_WE+88_[1Y]ZW;7P]%;ZT-5FOKR[NQ$8=TS)MVD@XVJH
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M#K4^JEW-S<0K%(N1L 7T&,_K3 Q_$4]CNU!/[1U,WL5ON6.R:;;;':2NX1#
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MBWNM'MYK*[>\MV3Y)Y#EG ..>!SVY&>.>: &ZIK>G:*(3J=R(!.VR/*LV3^
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M$MVBNV)GM6; *_O#G/!(W$C)/.!@ ':U6U#4+72K&2\OY/*@CQN?:6QD@#@
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M,D@SCA3@U=BD\V%)-K)N4-M<8(SV(]:X*V1M/^$+7MG/<Q7#6JG>+F0[#O\
MX03A?^ XK7>6XU/Q%8:5)=30VJ:<+R7R9&1YF+!0"X(8 <G@C/>@#J**XR:\
MN[#_ (2G38[JXDBM; W%M+)*6DA+(QV[S\QY&02<BFM]IT_3/#6HIJ-[+<W=
MS;17'FSLR2K(O(V?=&.Q SZDGF@#M:*Y#6+B:RU^[GUMM2ATUA$+.[LY6$=O
M@?,9%4]V(Y96!X'2NHNXC>:=-%!,8VFB94E1L%21PP(^N<B@">BO.[C7]3G\
M/Z,]M/)]IL8VNK]5<Y=87",'[G.6)'?&:U;O5[F.[\1:M;3M);:=:K!;H&)C
M:7;O9L="1E1GTH Z^BN*MH]::/2[NRM]6:X:1'NY+F\C:&:-N7PGF$+U^7:H
MQ5NRAGU'QQKB7-]=_9;0P>5;QSNBAFC!S\I''!XZ'))H ZJBN*6XO]9NM98P
M:K*8;F2TMFL;I(8X=@QD@RJ6;)R=P(Z#VKI]&:_;1;4ZP@2^\L"8 C[WKQQS
MUXH O4444 %%%% !1110 4444 %%%% !1110 5S?PX_Y)9X4_P"P+9_^B$KI
M*YOX<?\ )+/"G_8%L_\ T0E !X\_Y%VU_P"PUI7_ *<+>NDKF_'G_(NVO_8:
MTK_TX6]=)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !65
MXD@B?P[J,SQ(TL=E.$<J"R@H<@'MG _*M6J>H:7;:I%Y5YYQCVLI2.XDB# ]
M0P1AN'US^M %#3;:2[\%:;!$;?Y[.$,+F#SD8;!D%=RY_.H[+PW)8/IDD%ZF
M^R66-]T!*R)(X8JHW?)C&!UP/6M33],MM+A\FS\X1X "R7$D@4 8 &XG ]A5
MN@#G?',LD?AEDA>0&:>*)HXL[YE9@"BXYR1_450TW3+9/%MWJNE:/]FM8;'8
MF^T,.Z;).41@"/EX) &?>M7Q9IMSJFDPPVUNETJ7,<LULS!?.C4Y*@G@'IZ=
MZJ:?I$B^)X;ZQTE=%LXH&2:,&-3<L>GRQL5PO7).>:8&#IFCZCKOA6&]M[:Q
M_M*<^<NJR7;^>KAL=HS@ #;MW8Q6Q<6$&H?$H1ZC$DZ+HZL8FYC9O.8<J>&Q
MGC/UZ@5L?\(UI7F.1;NJ22>8\"SR+"S<<F,-L/0=N:N?V?;?VH=1\K_2S#Y!
MDW'[F[=C&<=>_6D!PKW=SIG@W78=/D>%+?6&MHF5ROD1%DX#?PCYB,]LUM67
MAZ\M-<L+NRL-.TN"%62X2UN'8SH5X!'EJ"0><DYK<CT>PC@NX1;(T5Y*TUPC
MY82.V,G!SZ#CI4=GH5A8S1RP),S0J4B\ZXDE$8QCY0[$+QQQVXH PO".F6DU
M]K5]/"LTZ:M<+$TBAO*PV<IG[I.>2.N!Z5D:]<:?)HHU/1-+N(VCO$,>JD*"
MYWX/S%O,8')'(Q^ KO+/3[;3Q.+2+R_M$S3R?,3N=NIY/'TZ5G/X1T22,Q/:
M,83(91#]HD\M'SG<J;MJG.>@'4CH:8&1J6EV%S\3+-;BQMI5EL9'D#PJP=@V
M 3D<G'>FR7$MIXG\77-M_KH=/CDCXS\PC8CCZUTU]H]EJ-Q#/<QOYT (CEBF
M>)U!ZC<A!Q[4^/3;2+4+B]2'%Q=*J3.6)WA1@#&<4@.-O].L[+X>0ZQ9@#4X
MX8KA;]3^^>1B,Y?JV[<1@D\''I5MK"WU+XE3)J4"S*NEQL87Y0MO(Y7HV,G&
M<^O6MV'PUI4$L3Q6S!89#+%"9G,4;Y)W+&3L4@DXP..U6UTZU75'U%8L7;Q"
M%I-QY0'.,9QUH P/"BQKI.LV<A(M+;4+B"-2<^7$,?*/89-3^ RQ\#:9OZ^6
MWY;CC]*L:EIC6F@:I%H5MFZO2[E?,QNDDX9LL>,=<>U7M*L$TO2+6QCY6WB6
M/([D#D_B>: +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% ')I'/J/Q!U*TGOKM+."WBD%O%.\8+$=<J00.O
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M$H /'G_(NVO_ &&M*_\ 3A;UTE<WX\_Y%VU_[#6E?^G"WKI* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(U72
M)-4U?399'5+2QD-P0"=[RCA1TP%'))SSTQWK7K/UC6(M)ABS&T]Q<2"*WMT(
M#2N>V3P!ZGM0!/#I]M;W]S>PQ;;BZ""9]Q.[8"%XS@8!/2DBTVTAO+NZCA'G
M7@43L22'"C X/ X]*BMKG4S=+'?:=#'$P/[VWNO,"$=F#(IY]L^^*>=7TU;[
M[&VH6HNMP7R#.N_/IMSG- %>#PYIEM+&\,$BK%(9(X3/(8D;).5C+;!@G(P.
M.V*MP:?;6]]=7D,6VXN]GG/N)W[1A>,X&!Z4MQJ%E:,RW5W! RIYC"24*0F<
M;CD],D#/K3[:[M[V 3V<\5Q$V0)(G#*?Q% $$.E64$MY)';KNOCFXW$L).,<
M@\=.U06OAW3;-XF@BEQ =T4<EQ(\<9]51F*@\G&!QFK%KJNG7L[0V5_:W$J
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M +%%5(]7TV:Z2VBU"UDGD4.D2S*692-P(&<D8Y^G-6Z "BBB@ HHHH ****
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M717G<;WMM\.;37_[4OI+^-HW)DN&*,ID";"F=I&#U()SWKJ-9ETYM02"[O\
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M0E=)7-_#C_DEGA3_ + MG_Z(2@ \>?\ (NVO_8:TK_TX6]=)7-^//^1=M?\
ML-:5_P"G"WKI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5R >3^%:M,B@B@#"")(PS%V"*!EB<DG'<GO3Z "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;^''_)+/
M"G_8%L__ $0E=)7-_#C_ ))9X4_[ MG_ .B$H /'G_(NVO\ V&M*_P#3A;UT
ME<WX\_Y%VU_[#6E?^G"WKI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXC4$_OU4F-L#U^[0!>_X1?5_^A[\0?\ ?C3_ /Y%H_X1?5_^A[\0?]^-/_\
MD6C2?#]W;^&?LYO9+34+Q_/O;F-09"6.64$]#C@'MUJ+P#$L&CW\2%BL>I3J
M"QR< @<GO0!+_P (OJ__ $/?B#_OQI__ ,BT?\(OJ_\ T/?B#_OQI_\ \BUQ
ML\]NEI<Z?<VZ-K37^Q=<$B^6C%MRDS9RI"C&SVZ=:Z?5;A;'XA:1)<^;+ML9
M%8PP-(S'/7:@)H M_P#"+ZO_ -#WX@_[\:?_ /(M'_"+ZO\ ]#WX@_[\:?\
M_(M5/ML5]\3+!X4G4+82 ^=;R1'[W8. 34?C+3-.L='#6%LL>L7%ROV29.9V
ME+Y)W_>(P3U. ,#TH O_ /"+ZO\ ]#WX@_[\:?\ _(M'_"+ZO_T/?B#_ +\:
M?_\ (M=(,[1NY/? HH YO_A%]7_Z'OQ!_P!^-/\ _D6C_A%]7_Z'OQ!_WXT_
M_P"1:Z2B@#F_^$7U?_H>_$'_ 'XT_P#^1:/^$7U?_H>_$'_?C3__ )%KI**
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M_P"2B:!_UPN?_010 [_A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\
M_D6J^@VMMXEN-2U+5X5O=EY);VT-PH=(8UP/E4Y 8XY/TI^B%M-\7ZEH=JV+
M$0+=01MR("3AE7T4GG'0=J )?^$7U?\ Z'OQ!_WXT_\ ^1:/^$7U?_H>_$'_
M 'XT_P#^1:I:/ITFG?$65+B]FO9Y=*$DL\O&YC+CA1PJ\# '2I;&VM?$7BC7
M/[6MTNHK-TMK>*8;EB!7+%0> 6('/7@#- %C_A%]7_Z'OQ!_WXT__P"1:/\
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MPB^K_P#0]^(/^_&G_P#R+1_PB^K_ /0]^(/^_&G_ /R+7244 <W_ ,(OJ_\
MT/?B#_OQI_\ \BT?\(OJ_P#T/?B#_OQI_P#\BUTE% '-_P#"+ZO_ -#WX@_[
M\:?_ /(M'_"+ZO\ ]#WX@_[\:?\ _(M=)10!S?\ PB^K_P#0]^(/^_&G_P#R
M+1_PB^K_ /0]^(/^_&G_ /R+7244 <W_ ,(OJ_\ T/?B#_OQI_\ \BT?\(OJ
M_P#T/?B#_OQI_P#\BUTE% '-_P#"+ZO_ -#WX@_[\:?_ /(M'_"+ZO\ ]#WX
M@_[\:?\ _(M=)10!S?\ PB^K_P#0]^(/^_&G_P#R+1_PB^K_ /0]^(/^_&G_
M /R+7244 <W_ ,(OJ_\ T/?B#_OQI_\ \BT?\(OJ_P#T/?B#_OQI_P#\BUTE
M% '-_P#"+ZO_ -#WX@_[\:?_ /(M'_"+ZO\ ]#WX@_[\:?\ _(M=)10!S?\
MPB^K_P#0]^(/^_&G_P#R+1_PB^K_ /0]^(/^_&G_ /R+7244 <W_ ,(OJ_\
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M-8Q[8LO)+"[;W] H8;5]]S'G&.,FIH^KWNN>&K>\M([>&ZD8I*)"Q2,JQ5B
M.6Z9 R.O6@"M_P (OJ__ $/?B#_OQI__ ,BT?\(OJ_\ T/?B#_OQI_\ \BU+
M9:S>C6]0TK4!;R2VT"W$4T*,BNI'0J6;!!]^:KZ#KVIWOALZ[JBVL-LL+R&&
M&-BS!0?FW%L#H>,'ZT -N- O[2+S+KXA:Y!'D+ODCTY1D]!DVM2_\(OJ_P#T
M/?B#_OQI_P#\BUA^)KO6+[PC9WMXEHMM=3PR"&-6#P@N"F6)(?C@\+R:] H
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M'OQ!_P!^-/\ _D6NDHH YO\ X1?5_P#H>_$'_?C3_P#Y%H_X1?5_^A[\0?\
M?C3_ /Y%KI** .;_ .$7U?\ Z'OQ!_WXT_\ ^1:/^$7U?_H>_$'_ 'XT_P#^
M1:Z2B@#F_P#A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\ _D6NDHH
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M'OQ!_P!^-/\ _D6NDHH YO\ X1?5_P#H>_$'_?C3_P#Y%H_X1?5_^A[\0?\
M?C3_ /Y%KI** .;_ .$7U?\ Z'OQ!_WXT_\ ^1:/^$7U?_H>_$'_ 'XT_P#^
M1:Z2B@#F_P#A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\ _D6NDHH
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M'OQ!_P!^-/\ _D6NDHH YO\ X1?5_P#H>_$'_?C3_P#Y%H_X1?5_^A[\0?\
M?C3_ /Y%KI** .;_ .$7U?\ Z'OQ!_WXT_\ ^1:/^$7U?_H>_$'_ 'XT_P#^
M1:Z2B@#F_P#A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\ _D6NDHH
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M'OQ!_P!^-/\ _D6NDHH YO\ X1?5_P#H>_$'_?C3_P#Y%H_X1?5_^A[\0?\
M?C3_ /Y%KI** .;_ .$7U?\ Z'OQ!_WXT_\ ^1:/^$7U?_H>_$'_ 'XT_P#^
M1:Z2B@#F_P#A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\ _D6NDHH
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M'OQ!_P!^-/\ _D6NDHH YO\ X1?5_P#H>_$'_?C3_P#Y%H_X1?5_^A[\0?\
M?C3_ /Y%KI** .;_ .$7U?\ Z'OQ!_WXT_\ ^1:/^$7U?_H>_$'_ 'XT_P#^
M1:Z2B@#F_P#A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\ _D6NDHH
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MB*.\:)H=68&+:22F%P">.H.#WJG!X0OD\%:AI\]Q#+JE^=TLY8["00%&<9P
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M]MDUQ'<V)PN/NE67<V&!YZ]"*I:%JT]AX+\/V=A"DM[?[HXO,SL0 DLS8Y(
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M3:"ZBFMXVCXW;2I4LW.2.<UMUDG2YSXR75MT?D"P-MMR=V[S V<8QC ]:UJ
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M'(;&T,%C?7MN3</<>8CKG<W4$%2I'L0<=>M)_P (MI[Z3>6,YEF-[(99[AV
MD9\Y#9  &,#  QQTY.=FB@#%A\,P)K-MJL][>75Y;JRJ\SK@J5Q@JJ@<<G@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<W\./^26>%/^P+9_^B$KI*YOX<?\DL\*
M?]@6S_\ 1"4 'CS_ )%VU_[#6E?^G"WKI*YOQY_R+MK_ -AK2O\ TX6]=)0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7-_#C_DEGA3_L"V?_ *(2NDKF
M_AQ_R2SPI_V!;/\ ]$)0 >//^1=M?^PUI7_IPMZZ2N;\>?\ (NVO_8:TK_TX
M6]=)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML_\ T0E !X\_Y%VU_P"PUI7_ *<+>NDKF_'G_(NVO_8:TK_TX6]=)0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<QXL_Y#/AO_ +"(_P#0373U2U'2++5?)^W1NQMW\R)DE>-D;ID%2#0!C>+0
MLFI^'88U+71U))$ ZB-03(?I@BLRWLYM>U+73=:?8Z@4NFMD-W<E'@C"_+L7
MRVVYR3N!&3]*ZNST:QL+E[F")VN'78TTTKRR;>NW<Y) ]LXIMQH5A<WKW;)+
M%<2*%>2WN)(2X'3=L8;L>] '*:KI]UO\)6&MS_:)Q,\<\D<C?O!M_O<$Y'!]
M>:LVT4>G>+==L+&-+>T?3UG,$:A4#X*Y ' R.N.M=(VBZ>39?Z,J_8#FV"DJ
M(^,= <'CUIQTJR-_->F'_2)X?)D?>WS)Z8S@?6F!YT=.MK?X9Z5J,"F._P#/
MC(NE8B5<N5P&Z@8[#BND%I!H_P 0M.@TR);:*ZLI%G1!Q)M.0S>K?[1Y]ZVV
M\/Z8VCQ:6UMFSA(9(O,;@@Y'.<]?>K$FFVLVI0ZA)%FZ@1DCDW'Y0W48S@T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(_Z'+P__ .#2#_XJNDHH YO_ (6/X(_Z'+P__P"#2#_XJC_A8_@C_H<O#_\
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M)P"/YY[8ZYXZTS1-;MM?LGNK-)D1)6B(F7:V1UXS[T 9G_"Q_!'_ $.7A_\
M\&D'_P 51_PL?P1_T.7A_P#\&D'_ ,54K>+[-;<WGV6\;3EE\HWX1?*ZXW?>
MW;<\9VXK2N]1>WF2*WL+N]9DWDP! JCMEG91D^@)- &1_P +'\$?]#EX?_\
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MJL.B:5+J%TDDD414%8@"QW,%&,D#J1WH R/^%C^"/^AR\/\ _@T@_P#BJ/\
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M_P#P:0?_ !5'_"Q_!'_0Y>'_ /P:0?\ Q5=)5#4=7@TRYL8)TD9KV;R8R@!
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M$J7I:+<$:40R;(R6V@.VW"<_WB.QZ'-0:IXF.G^*K'3?)D:":.1IF6UE=L@
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MCM/'G E*)E4;U!)Z=\5KV]O'I7Q 2STJ)8+6XL6EGMXAMC5@P"N%' )Z>^*
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MU?3H]3TV01 2K)B:P"C!* ^K'.5(/>@#LZ*;'(LL:R1G*N RGU!IU !1110
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MM6SCRYBA;Z_*S#]:FH **** "BBB@ JCK.K0:'I,VH722R10[=RQ %CN8*,
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M;7$US:1)(RIL <-T"EF'/UQ56/Q.9=3ET]-%U$W4*"1X]T'"GH<^;BJNF_\
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MN[HH YB[X^*&GX[Z=(#[_-5'09K"+2=?TS59A&[7=T9H <R^4V,L%&6(P<Y
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M/!CP?"-A3]]-\I&-O[P\8JCKOB*:9=;L'N+.P6")H4MYXFDFNMRGYD 9< Y
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M=$"8Z9/(!Z\U>\,:G>WEU?6MQ=Q:G;6I01:C$@43%AN*_*2I*Y R/QYKHJ*
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MHT\K!4#&,$ D\ G]:[*B@!%8.H92&4C((/!%+110 4444 %<W\./^26>%/\
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M-Y%Y5PP"+,F[D?*Q(!'(# 9%=M7!ZK-=ZAX:T>QM]*O_ #[>>W-R&MG41;"
M>2,-S_=R,<G%=C%J'F:K-8_9+I/*0/\ :'CQ$^>RMW/M0!;HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+96MG=7\\"!YUM@G[H'H"691DCD 9-9-WXAU!/&%A:VUG=O:36C2F#;$K2'
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M<HAAO6C"Q,Y' Y.X<\9VXSWJS<:Y''J4EA9VES?W,*AIDMP@$0/W=S.RC)[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<R1")MR 'DD8R,5IVIDT+Q+K$EY:W4L%\R30SV]N\V<+@H0@)!';/!YKIZ*
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M&!M+#<V..,D]_:J?A.WTNPT>T&I:+,NI1R.S2MI,K.#YC%3O$9[8YSQ7<44
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M&9T0!%5&:9B!\PVL0H]V*@>U+;ZY%?2WUF8+BTO+6/<\,P7=M(R&!5B"/QH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M31,5/(##!Q[\U-10!#96J6-A;VD)8QV\2Q*6/)"C S[\5-110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:UL-8L8[5KQ3Y$L-QYJ%E&2C952#CIU!K&/AS4WTF6\$<2:DVJ#4TMFDRO'
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M$<IFV*!NQ\W!(&.<C)S@8[AB>+((](U*[OK=H9M,F,,\,;;\MD!=K8&0V1U
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<U]NL[7Q3KD
MD=A_I=M9)+)/YQ_? +D+MZ+TZU%_PF5Q'IMAJ5QHTBV5ZRQILG#2AV7CY, $
M%N =PXY('2@#JJ*Q['6YY=<;2M2LEM+@VXN(C'/YJNN<$$[1@@XXY^M94?C:
MY;P\FN/HS)IX<+*WVD&0?/MW*NWYAG'4J<YXP,D ZVLVY\/Z==74MR\4L<LZ
MA9FM[B2'S0,XW!& ;J>35>'7;E=:M+#4=.^RB^1WMG$P=OEY*NN!M;!SP6';
M)JNWBB=[*[U&RTT7&FVCLKRF?;(ZJ<.R)M(('/5AG% &Y:6EO8VD=M9Q+#!$
M-J(@P *FK%F\0-+J%I9:1:K=SW%L+LF67RDCB/ ).UCDGC %<G#=Q?V3XPN=
M5TUI$%TAFLVFVG/'&]??G(ZT >C45FRW%_%%"FEZ;'-&(0VZ:Y\M1Z(,*Q)^
MH Z<]<<WXA\0W5_X)M-3TH-;>;<(LO[\H\;!]I7Y1R"0><CC'!SB@#MJ*Q[K
M6;JTDM+-[*)]2O&;RX([@F,*N"S,Y0$  ]E//'O61KVL/?>&?$-A=VPM;RS@
M'F(LGF(RL,JRM@$]/08H Z^BN?T76#]LM-'FM_+_ .)=%<0S>9GS1@ C&."#
M[FKVB:Q_;5O<7$</EP1W#PQ/OW>:JG&_H, G/'- &E16-JVKZCIMM=7::4DM
MI:@LY>YVR.HY+*H4C&/5@>#QTSA^)IYM3U7PY'%:V]Q8W3M*D,\Q"S'R\@.N
MP@ 9X^]]!0!VM%<?8W.K1>/+FRB@MUMXK*/;:B[<11+NQN4>7C..,8'UK0E\
M1W,D=]<:9IRW5I8,R2R/<>6SLOWPB[3D =R1D]* .@HKG;CQ6?MVEVVFV)NS
MJ<'G1,TNP(.#\W!P,'D^W0UME[K[%N$,)NMN?+,QV;O3?MSCWV_A0!/65-X9
MTJ>6YD:"5/M1)G2&YDC24D8.Y58*<]\CGO7+65WJ5Y\*KV2_"R(;6XQ.UPSR
M.0[#!!7@#IG<> ./36T[7;JQT[0TO=.$5I>+%;1RB<&17*?+N3& #@]&/O@\
M4 =-%%'#"D4*+''&H5$08"@<  =A3JQ)-=NY[R^@T;3TO!8_+,\MP8MTF,[$
MPK9/UP.:T-*U*#6-+@O[3>(IUW*'&&'."#[Y% %NBN!TU'N]9\27>K:99W)@
M9E9FF+/$!&?DC)3.#ZY7KT-:-GXACT_1] @TO2&9=1C<06ZSD^40,@%B,D<\
MGL 3@]* .MHK$GUR\CU6VTJ*QMWOY8&N)%:[*QHH;'#;"6/MM%9NN:AK">(/
M#RP0+ )V?= UV5#MLR5?:I&!V/S9]!0!UM%0R-)]@9I $E\HE@C$A6QV.!GZ
MX%<!'/<6WPZL=:AU&^.JNZB/S+N219W+E=AC8E3E<]!GC- 'HM%<JT;:A\0K
MVSN+F[%O'91R)%#=R1*&+8)PC"K&DW%U8>*;K0KBXENK?[,MU:RS-ND1=VUD
M9NK<]"><>M '145@^-KF>T\'WDUK-)!*K1;9(V*L,RH#R/8XK:N?/^RR_8_+
M^T;#Y7FYV;L<;L<XSUQ0!)17+^%VU"/Q%KMIJ>H27KP_9R">$4LA)"KT4?SQ
MS6KKFL?V);V]P\'F027"0ROOQY2L<;\8.<'MQ0!IT5ESZPT?B)-*AM&F;[*U
MS(X< J =J@ ]23QU%5WUZ[L]2L+;5=.CMX[]S'$\5SYA1\9"N-H SST)Y'XT
M ;E%8O\ ;EW=WE[%H^GI=1V+^5))+<>5OD R40;2"1P,DJ,GTYITFM7,VK2:
M?I=BDTUO$LERUQ.8EB+<JF55LMC)]/>@#8JK'IMI%J<NH)%BZF01O)N/*CH,
M9Q6.ES!-XTLA=:8T.H/IS2>:T^3$-V#'M'RGD_>JK#XTN9/#RZX^C[-/5L3,
M;D%P-^TLB[?F XZE3G/'&2 =9163=:U(-773-+MH[NY\D3R&2;RXXT)P,L%8
MDD]L=.:ET75AJ]K,[0-;SV\[6\\1;=L=<9 /<<CF@#1HJ.X)6UE*G!"$@CMQ
M7(^'?$MC_P (/!]OUJW^W>0^[SKM?-W9;&<G.>E '945R.B^();7P?HIE66_
MU"_S'"CR<R-DDEG.< #J>3[5HGQ#<P7ES8WVGK'>QVK7-ND5QO2X"_PABH(;
M/&-OO0!NT5S=SXRMK?3-&O?(+)J;H& ?_4*<!F)QSM) [9JU=^)8;+4M0AGA
M86VGVJSSS@YPS'A N.I SG- &U16"GB"[@FL/[4TU;:#4'$<+QS^8R.1E5==
MHQD9Z%N1^--C\5I_PB]]JMQ:&*6QDDAEMA)G$BG 7=COE><=^] '045BC6[N
MXOA86.GH]W% DUT)IRD<!;HFX(Q9NO8# _"JDWC%(M$M[]=/F>5[T64UJ#^\
MCDR0P'9CD<=,Y'2@#I:*@LY+N2W#7]O%;RD_ZN*8R #ZE5Y_#\:H^)YKJW\,
M:C+8[1*EM(=YE,90!#\RD _,.PX^HH U:*X'7[B^E^'^G37\2%O-M60QS&1Y
M>AR=RKAC]3]:Z2#7+A==@TS4[!;62YA:6!HY_,!V]5;Y1A@.>,CWH VJ*YR3
MQ5,=,GU:VTX3:5 Y!E\_;+(JMM9U3;@@<]6!..U;C72?8#=Q?O$\KS5[;AC(
MH GHKE(?&-U)X>CUV71_+TXD>8?M.9%&<%E3;RH/J03Z8P3MW=YJ*M_Q+-/C
MND";_,ENA&K^@3"L2?KM'3D\X -"BN*USQ!=ZAX<T;4M)4P175Y$&S<-&V=Q
M!0[5.5)!R<_@:T[B>/\ X2[1DU#3HQJ$D,Y2:*Y9EA '( VC=D'N!B@#HJ*Y
MU_%$[:=<ZK::;Y^F6SL&E\_;+(JG#NB;<$#GJPSM/2I;CQ'*=;M]-TVQ^UM<
MV8NHY3+Y:!2V/F^4D#'< G) QW !NT5R.K>(;J\\':Q):P_9+VQ=X;A1<$&+
M'\2,%^;MC[O?TYW="FO)M'MGOXXU8Q(59)C(7&T<ME1@_G]: -&BBB@ HHHH
M **** "BBB@ HHHH **** "N;^''_)+/"G_8%L__ $0E=)7-_#C_ ))9X4_[
M MG_ .B$H /'G_(NVO\ V&M*_P#3A;UTE<WX\_Y%VU_[#6E?^G"WKI* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^.)-3CM)+FVNK1(2T3(#$P;N&89&.<C)]JS;3P\NF37T5UX:AU<23O-;W.V
MG:QSL?>01@]P".:[.B@#G9-(N1XLT>[@M(XK2UM)(Y!$PV1,1PH'!(^@_*NB
MHHH XZTTG4X/ M]H#V#^>L4ZQ3"2/RYMSL1CYLC[W<"KFH:3>SZ/X=@BAW26
M5W;23KO4;%12&/7G'M72T4 <B- 6RUO4I+OP_#K%O>3?:(I@D+21DCYD/F$<
M9&1@FNETZ'R-/AC%I#987FW@(*1D\X& !^E6:* .8L=(OH7\3F2# OI&-O\
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MVJU39$66-HY!E7!5AZ@T >?Z1#JNJ_#:UTB#3\"X38+SS5\M8]^22,[MW48
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[/MTJM:^)+FT\)V]Y8Z?8QR2ZG]F,$2&-&!<C/!X8XZ\_2MVVTR]L?%&H7T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5RWCGQ=+X5L[;[+!'-<7+-L\W.U0N,D@8S]X=ZZFLGQ!X;L/$MFD&HB0>6VZ
M.2)L,A[XR"/TH H^"O%+>*=+DEGA6&Y@?9($SM.1D$9Z?3VKI*S="T"Q\.Z?
M]CTY&"%MSNYRSGU)K2H **** "BBB@#D/&&CZ8KZ5,-.M!+<:O LSB!=T@9C
MN#''(/?/6H_%-E%IUWX?CT:SMH&.H[EC11&A;;C)VCV';M6[K^ESZJNG"W:-
M?LM_#<OO)&50DD# /--US2)]3U#2)X'C5;*Z$T@<D$KC'&!U_*@"O#KEW9:U
M?:?K'D2"WL_MJ36T93<@)# J6;G(]:RAXW=+&UU&2\TJ2.:1?,T^*0&XBC8X
M!W;_ )F&02NP=QQC-;5SH3W?B:XO9F3[)/IALF4,0^2Y)/3&,'U_"FZ7::[I
MVGV^G'[!+%;A8UNVD?<8U.!F(+C=M&/O]>>>E %W7A,WA^^%NZ1OY#\R(6&-
MIR, CG'?/YUS>C:K<Z'\/K&ZF\JZ\Q(HK2".,QG<QQAFW'/U '3WKK[N 75E
M/;EMHFC9"P'3(QFN:C\-7\WA&+1[I[>&:R*-:W,,C.&9#D%E*C'IU/4^E %J
M35-5TK4=.BU?[)<6]])Y'F6T31F*4C('S,VX'!&>*S?"<=^/$>O%[FV*K>#S
M@+=@7.W^$[_E_'=6H^F:IJFHV$VL"T@@L7\X16TK2&67! ))5=H&3QS]:2RT
M>_L-:U62%H3:ZB_F>;YA$L+;".%VX;G'\0H 9J&JZOH\MC/?_87MKJ[6WDAA
M1]T6_(!#D_-CO\HS2:+_ ,CSXF_[=/\ T6:R!X+U!K:PB>#2Q/;72SS7^YVG
MN</DY)3()!/4MSCI72:?I4]IXDUC4)&C,5]Y'EJI.X;$*G/'K]:8%76-8U*W
M\3:?I.FQVY%Y$[M),I/E[2.< C/&>._J*O7":V0JVLVGH5C^:22%V\Q_0*&&
MP>^YNO3CF&[TB>?Q=I^J(\8@M8)(W4D[B6Z8&,?K5+5= N[O7I+TP6&I6[0"
M.*"_9MMLW=E7:P.<#/0\8S2 Q?$.J7.N> ],U%?*M_-NT$L90O\ .)"N0<C
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH :Z)+&T<BJZ,"K*PR"#V(I(88[>%(8(TBB0;51%
M51Z #I3Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*XM8+N+R[J".
M>/(;9(@89'0X-2T44 %1/;027$=P\,;31 B.0H"R ]0#U&:EHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KF_AQ_R2SPI_V!;/\ ]$)725S?
MPX_Y)9X4_P"P+9_^B$H /'G_ "+MK_V&M*_].%O725S?CS_D7;7_ +#6E?\
MIPMZZ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N;^''_)+/"G_8%L__ $0E=)7-_#C_ ))9X4_[ MG_ .B$H B^(JSM
MX2B6SDCBN#JVF"*26,NBM]O@P64%2P!Z@$9]1UJ7[#XW_P"AA\/_ /@AG_\
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M,I='ETI+^"W6_P!2EOVC+K]M>XC$WJ0CX0]<X X_"NCH YO[#XW_ .AA\/\
M_@AG_P#DRC[#XW_Z&'P__P""&?\ ^3*Z2B@#F_L/C?\ Z&'P_P#^"&?_ .3*
M/L/C?_H8?#__ ((9_P#Y,KI** .;^P^-_P#H8?#_ /X(9_\ Y,H^P^-_^AA\
M/_\ @AG_ /DRNDHH YO[#XW_ .AA\/\ _@AG_P#DRC[#XW_Z&'P__P""&?\
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M-8;:X8[FEC61<<_Q<Y&[O0!TGV'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\
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MG_\ DRNDHH YO[#XW_Z&'P__ ."&?_Y,H^P^-_\ H8?#_P#X(9__ ),KI**
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MUG4-+M;F\&E))9VO+LUUMD=1C+*H4C'U8'@\"@"K]A\;_P#0P^'_ /P0S_\
MR91]A\;_ /0P^'__  0S_P#R94^H^)&M;K2(+&Q:[;559HCYFS9@*<MP>,-D
MGL!T-12SP_\ "::9'>Z>@U![21A/'<,RQ 'E0, -GU(% #?L/C?_ *&'P_\
M^"&?_P"3*/L/C?\ Z&'P_P#^"&?_ .3*<_BB=M.N=5M--\_3+9V#2^?MED53
MAW1-N"!SU89VGI6_#,EQ;QS0MNCD4.C8Z@C(- '/?8?&_P#T,/A__P $,_\
M\F4?8?&__0P^'_\ P0S_ /R97244 <W]A\;_ /0P^'__  0S_P#R91]A\;_]
M##X?_P#!#/\ _)E=)10!S?V'QO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,
M_P#\F5TE% '-_8?&_P#T,/A__P $,_\ \F4?8?&__0P^'_\ P0S_ /R97244
M <W]A\;_ /0P^'__  0S_P#R91]A\;_]##X?_P#!#/\ _)E=)10!S?V'QO\
M]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F5TE% '-_8?&_P#T,/A__P $
M,_\ \F4?8?&__0P^'_\ P0S_ /R97244 <W]A\;_ /0P^'__  0S_P#R91]A
M\;_]##X?_P#!#/\ _)E=)10!S?V'QO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__
M ,$,_P#\F5TE% '-_8?&_P#T,/A__P $,_\ \F4?8?&__0P^'_\ P0S_ /R9
M7244 <W]A\;_ /0P^'__  0S_P#R91]A\;_]##X?_P#!#/\ _)E=)10!S?V'
MQO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F5TE% '-_8?&_P#T,/A_
M_P $,_\ \F4?8?&__0P^'_\ P0S_ /R97244 <W]A\;_ /0P^'__  0S_P#R
M91]A\;_]##X?_P#!#/\ _)E=)10!S?V'QO\ ]##X?_\ !#/_ /)E'V'QO_T,
M/A__ ,$,_P#\F5TE% '-_8?&_P#T,/A__P $,_\ \F4?8?&__0P^'_\ P0S_
M /R97244 <W]A\;_ /0P^'__  0S_P#R91]A\;_]##X?_P#!#/\ _)E=)10!
MS?V'QO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F5TE% '-_8?&_P#T
M,/A__P $,_\ \F4?8?&__0P^'_\ P0S_ /R97244 <W]A\;_ /0P^'__  0S
M_P#R91]A\;_]##X?_P#!#/\ _)E=)10!S?V'QO\ ]##X?_\ !#/_ /)E'V'Q
MO_T,/A__ ,$,_P#\F5TE% '-_8?&_P#T,/A__P $,_\ \F4?8?&__0P^'_\
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M'_\ P0S_ /R97244 <W]A\;_ /0P^'__  0S_P#R91]A\;_]##X?_P#!#/\
M_)E=)10!S?V'QO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F5TE% '-
M_8?&_P#T,/A__P $,_\ \F4?8?&__0P^'_\ P0S_ /R97244 <W]A\;_ /0P
M^'__  0S_P#R91]A\;_]##X?_P#!#/\ _)E=)10!S?V'QO\ ]##X?_\ !#/_
M /)E'V'QO_T,/A__ ,$,_P#\F5TE% '-_8?&_P#T,/A__P $,_\ \F4?8?&_
M_0P^'_\ P0S_ /R97244 <W]A\;_ /0P^'__  0S_P#R91]A\;_]##X?_P#!
M#/\ _)E=)10!S?V'QO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F5TE
M% '-_8?&_P#T,/A__P $,_\ \F4?8?&__0P^'_\ P0S_ /R97244 <W]A\;_
M /0P^'__  0S_P#R91]A\;_]##X?_P#!#/\ _)E=)10!S?V'QO\ ]##X?_\
M!#/_ /)E'V'QO_T,/A__ ,$,_P#\F5TE% '-_8?&_P#T,/A__P $,_\ \F4?
M8?&__0P^'_\ P0S_ /R97244 <W]A\;_ /0P^'__  0S_P#R91]A\;_]##X?
M_P#!#/\ _)E=)10!S?V'QO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\
MF5TE% '-_8?&_P#T,/A__P $,_\ \F4?8?&__0P^'_\ P0S_ /R97244 <W]
MA\;_ /0P^'__  0S_P#R91]A\;_]##X?_P#!#/\ _)E=)10!S?V'QO\ ]##X
M?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F5TE% '-_8?&_P#T,/A__P $,_\
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M&(K&+?;Z:7\^3<!C*8W8)R<MD\>M4M8TG6KZ+68)K:]NY;AF%F\=\(K=8R.
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M2WM8;;[3<F%RCR$MA4##E1QDD$$@XK0T35SK-K/<+;F*)+F2*%]V1,BG D'
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M5% &!J7@S3-0EM9HWN;">TB$44UG+L<(. N2#TI$\&:;'<:7,LMUNTPLT69
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MZ9H)[Z*!I1,;-+C$)8'(RN,_K73T4 <G<?#K29VN0+K4(8+ES(]M%.!%N/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP!(/&0<&M2&Y@N/,^SS1R^6YC?8P;8PZJ<="/2I* ,.STJ_&J7NKWDENM]-
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M*?:I(!,L67.,99N./E/XFF>"KJYTSQEJFDZC:?8#>YNX;<R!PASD@,.#P?\
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MII5K<6UCJ]ND4\[S;C9%I$+')P3)MX]U/TH P(-4O=(\&W<=A='%CJYLX)"
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MK152TU;3K^5HK'4+6YD4;F2&97('K@&G#4[%K-[M;VW-LAP\PE78ISCELX%
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M_4KVV@LC%' @>&5Y?]<I) .,?*#C/>C6->U71-/-W=:99.N]46.*_<N[,<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU237?$.CBSF=+>.R-]<K'(0&+@*B-CT.3@^E '44444 %%%% !1110 4444
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M0V[YW11Q!5;/!R ,<T-86;VL=L]I UO'@I$8P53'3 Z#% ":D"VDW84$DP.
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M)GB4NF.1AB,CJ?SH P;[GXFZ7LZK8RE_]W.!^M=%;W5O=QE[2>.=%8J6B<,
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M>@1_VE#?7UY=7\UN"(/M&P+$3U(5%49]SFM6B@ HHHH **** "BBB@ HHHH
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M%I>6\\$9(>6*565<#)R0<#@YJEX@U&'3X;/S+-;R>>[2*V1R JRG.&+$';@
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MAQ_R2SPI_P!@6S_]$)725S?PX_Y)9X4_[ MG_P"B$H /'G_(NVO_ &&M*_\
M3A;UTE<WX\_Y%VU_[#6E?^G"WKI* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^E;%G=)>V,%U%_JYXUD7Z,,C^= &7K6A?VAI5MI=DD%M9"=&GC4;!Y2G<54
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M"XB72(?#TTMSKD%DW[^''SVX3!8]>K8V^Y]<5V=QH^F7=S]HN].M)YQC][+
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M%]!TX]*O5"UI;/=I=/;Q-<(I59B@+J/0'J!4U !1110 4444 %%%% !1110
M4444 %<W\./^26>%/^P+9_\ HA*Z2N;^''_)+/"G_8%L_P#T0E !X\_Y%VU_
M[#6E?^G"WKI*YOQY_P B[:_]AK2O_3A;UTE !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52U'2++5?)^W1NQMW\
MR)DE>-D;ID%2#5VB@"C9Z-8V%R]S!$[7#KL:::5Y9-O7;N<D@>V<4VXT*PN;
MU[MDEBN)%"O);W$D)<#INV,-V/>M"B@"BVBZ>39?Z,J_8#FV"DJ(^,= <'CU
MIQTJR-_->F'_ $B>'R9'WM\R>F,X'UJY10!FMX?TQM'BTMK;-G"0R1>8W!!R
M.<YZ^]6)--M9M2AU"2+-U C)')N/RANHQG!JU10!BR^$-$GCDCEM&,4CF0PB
MXD$88_Q! VT'W %:/]GVW]J#4?*_TL0^0)-Q^YNW8QG'7OUJS10!4.F69U&2
M^, -Q+#Y#L22&3.=N.GZ4NG:;:Z39K:6$9B@4DJA=F"YY.,DX'MTJU10 444
M4 %%%% !1110 4444 %%%% !45S=6]G"9KR>."(=7E<*H_$U+7"_%#1]2U33
M[%]-ADN$@=S+%$"S'(&#@=<8/YT =M!/#=0+-;2I-$XRLD;!E;Z$5)7&_#32
M=2TK09QJ:/")I=\4$@PR#&"2.V?3VKLJ "BBB@ HHHH PYM<O&\23:186$$K
MPP+.TDUT8P03C  1JLR7=]'?:='.^G6ZS"4W$+3,TC;1E?*)"[L=6R.!6']F
MEN?B9?K#>SV9%A&2T*QDM\W0[U858U.-H?&7A:.2:2=E%WF20*&;]V.NT ?D
M*8'0+?6CV/VQ+J%K7:6\\2 I@=3NZ8J.YU73K.**6[O[6".89C>695#CU!)Y
MZBN'EB>)+OP:A_X^-14Q8YVVK_O6Q]-K#\?QK4MX[M_'FLQ6]Q:0.L$"PI<V
MIE)AV\A,.N%WDY'KBD!UJ.DL:R1LKHP#*RG((/<&JD^M:7;%A<ZE9PE'V-YD
MZKM;&=IR>OM57PQIR:5HBVT5['>QB60H\2X1<L<J!N/ .1UK#\.?V?\ \)7X
MI^T^1YPF^?S,9\G'S=?X<]?PSVH ZR>^M+6U%S<W4,,!QB620*ISTY/%5+S7
M;"VT2?4XKNVF@C1BC+.NV1@#A0W3)(Q7+^'M0^P^'M!@6R2[N[J6?["9W$8B
MC#'G>02/E/0 DBFZ:[R+XW#)$C8;='!)YBA_*;=@X&3D<\#F@#<'B,:AX?@O
MM)O-+BG81&9+JXRD.\9*$KSN[#..16O>:C8Z<J'4+RWM0Y(4SRJF[Z9/-<;K
M+!OA7HY4@C;9C@]QMJ]$MZ_Q#U807-O!,+:'R!<V[2DPX^;9AUP-_7KSBF!T
MSWMK'%%+)<PK'.0(G:0 2$C("GOD<\5'!JVG74$LUK?VLT4(W2R1S*RQC&<L
M0>. >M<9?:/;V>BZ)8-=0ZA;MKR9")B-0=^8]NYN <C&:V@H3XH?( OF:02^
M/XB)@ 3^%("SX=\46?B"%_+>"*X61U%NLX=BJG&_'!P?I6E9ZE8ZCO\ [/O;
M>Z\O&_R)5?;GIG!XZ&N2\.6\-UX%U2TN[G[)'+<W$4DI8+Y>6QSGZ]/>M'0[
MBYM-=_L/4H;26>WL@\-Y;*5)A#!0KJ?NL2,X!Q^5 %KQ)J-Q:_V?9:?+Y5U?
MW:Q!]@8H@Y=@#QT&.?6HO$GBR+0,I':2WDZ*CR*GRK$C-M!9L$#)Z#K]*9K9
MV^./#);A<W0'^\8QC^M'C[_D2;W_ 'X?_1R4 ;=X]ZBK]@MX)VS\PGG:( >Q
M"-G]*PV\47<&H:A:76G09L+)KN5X+IG P,A.8UY(&?I6]>W<-A8S7=RVV*%"
M[GV S6#X0L6DT>?4M1C!N-8D-Q,C#("'A$YZC;_/% !8>(KB*X9-<>U2(Z>E
M^)H49!&I."I!)SVP1C/I5NWN-6U'PS<7)5;*ZF1WM$10S1KC*;P<@L>_UQUK
MFK^RM4;4)M)MF>QTB+]Z)9'D%Q+'DK%EB3Y<>,E00,X&.*V]!O[YM8-G=7QO
MXFL(;KS&1%,;L2"OR@#!QD9YH TM U/^V/#]G?\ 1IH@7 '1QPP_,&IKS5=.
MT]U2_O[6U9AE5GF5"1[9-8O@ -_PB,+'_5M-,8O9?,;^N:H:5;WEUX@\1Q"Y
MM(YGN-LD5U:M*S0E1LP1(ORX)XQ_.@#KVN[=;M;5IXA<.N]82XWLOJ!UQ4?]
MHV6XC[9;Y640$>:O$AZ)U^][=:XG5;/[#X?\/V6BWOV[6(93_9]Q#C!3G>3R
M1LVX!Y[#WJE>-II^&^E8W")=1C%]YOWO,R?-W=\]?PQ0!Z'::G8W[NEC>V]R
MT?WUAE5ROUP>*:^JZ='?"RDO[5;HD 0-,HD)/(&W.:P=0\K_ (3;0_[+"&1+
M.<N(ON^3M CSCC;NZ5C:1ILVJ_#XPW.J6%K SN;EY;4F6*4/DEG,H&[..2.F
M* .XN=5T^R=DO+ZVMV4!F6695(!. 3D]ZAM+JXGU>\B:>QDM8UC,20N3,NX9
MS(.@![8ZBL*WM4;XH.T_[V6WTM"DA_O;BI/X@G\ZH:J;@7GCC['N\W[+;8V=
M<;&S^F: .QM]6TZ[N6MK6_M9YUSNBCF5F&.N0#FFSZUI=L6%SJ5G"5<QMYDZ
MKAAU7D]>1Q7.V^EF\L-!G;5=.CMK:6*2U\FT,;/Q_JPQE/49R,=O:HM%MH)+
MOQA(\2,[7$D;,5Y*[/N_2@#KY[JWM;9KBYGCA@4 F61PJC/3D\=Z9#J-E<6;
MW5O>6\MN@):9)59%QR<L#@8KAM)EWVG@?[:S-;?O1\Y^7S0N(L^XY K3\9F'
M;9B!K6-6U.#[<[H&4?+\GF@$9'W>IZ 4 =+9ZC9:@K-I]Y;W2H<,8)5?;]<&
MLGQ'XGM]+TB]DTZ[LY[ZVVYMVD#%?G53E00>,U7N-*O4UF?4&U.V?4/[/DC2
MWMK<Q-(/X6.9&)PV!G'>N:U$:9_PIZSR(O/.SRLCYO.WC?\ CC=FF!Z96>WB
M#1EF,+:O8B4-M*&Y3<#TQC/6GZRVW0;]MS+BVD.Y1DCY3R/>N*T.:'5Y/#%K
M!]EM7TU"[D74+M)\F"$5&+?-RS9 Q@YR:0';MJVG+.(6O[42M)Y0C,R[B_'R
MXSUY''7D4-JVG)??8GO[5;O('D&91)DC(&W.>AKG_"4$7_"1>);C8/.-]LW]
M]N,X_.L?Q'JJW_@>[FL=/L[6P%T%A=IPLID$@RPC"8!)W?Q9QDT =U>:C8Z<
MJ'4+RWM0Y(4SRJF[Z9/-4-"UB34H]3DNO)1+.^EMT9. 43&"23UYZ]*SH!&?
MB1J7V_;Q81_9_,QCR\G?C/OUKEU\G_A"]1_L]E33CK_SL$+((,KR1D97[O&1
M3 ](L]3L-1W_ -GWMO=>7C?Y$JOMSTS@\=#^5+>S7,, -C:BYF9@H5I1&JCN
MS-@G ]@3TX[C&CTN9O$FGZA>:G9&6.&1(XK>W,1G0@<<R-D*<'@=ZV;QT,:V
MYO?L<LYVQ.I3>2.2%# @G /8\4@*&EZV]YJMYIE[:BVO+0*Y$<OF(Z,.&#8!
M^H('X]M>N1TZ*XL?&6J:?:7,=Q//:I<O?7,?F/&V[:(W"LHQC) &W />MOR-
M=_Z"6G?^"]__ (]0!'XDU]?#^G"<6YNIW)$=NK[2P4%F.>< *"2<>GK5[3KO
M[?I=K>;/+^T0I+LSG;N4'&>_6N0U>'4MVMW^IZ9/-ML9+:UEB:(1I'L.^3!D
MW#<><8) XYKHO"TKR^%M-\R"2';;1*!(5.\!!\PVD\'WP?84 6Y]7TVUNA;7
M6H6L,[8Q%),JL<]."<U)=WUI80B6^NH;:,MM#S2! 3Z9/?BN.\0ZFMYX=\11
M66G6D=I [Q7$TLXC9YAC+! IR<[<$D$\5-8'?XNT%KTDJ=%S:E^GG?+OQ[[.
MOM0!IZ;XECN=3U6.[GM(K2UEB2";?M$@=-P^8G!SVQ6U+=00211SSQQO,VV-
M7< N?0 ]37":=IEIK'_"8V.F^6(9I$\DQ8"API((]MXJSI-[/XEU*VO8<F32
M]-(Y '^ER#!'/H%/YTP.L.K:<+[[$;^U%WG'D><OF9QG&W.>E%SJVG6;NEW?
MVL#)C<)9E4KGIG)XSBN(TG2Y=5^'L,,NJV%K;$[I)'M#YD4H?))<R@;L]R!U
MK7LX(I/BGJ,KH&DBL8]C'^')YQ_G^=(#H9=3L(+Q+2>]MH[F3&R%Y5#MGIA2
M<FB\U33].9!J%];6I?)43S*F['ID\URNIYT"?4=6@>SU33KJY47EK)S*K@A0
MJ$9#$$YVD#&*=I\-]<>,/$,8N+..8M&NRZM3*6AV?+C$B_+ZCGGK0!V*L'4,
MI#*1D$'@BJMUJNG64ZPWM_:V\K@%8Y9E1F&<9 )]:K>&K&/3?#MK:0WB7L<6
MX+/&,*P+$X')Z9QU[5S6D6EWJ$7B.&6[L83)>S+=)<6ID=4Q\I+>8/EV].,#
M!H [1;JW:Z:V6>,W"*&:(.-Z@]"1U IHOK0K<$74.+;/GGS!^ZP,G=_=XYYK
MD9XD\,W&@:J]X;JU2V-C<7*XQ(FW=&PYZ9'J>HK/N;6Y@\-Z-/=-'%_:&J"\
MO&F3=&K29*;ER/E^[QGM0!WEKJ5C?1/)97MO<1Q_?>*57"_4@\5&FM:7+-'#
M'J5F\LH!C19U+.#TP,\UC2:7-%K5UJ%WJ5H]RVGO$UO!;F(NF<ASF1B<'C/O
MBN>-O##\%[>6*)4D5HI@RC!W^<!NSZXXS0!U<WBO3K?Q,=)GN+6-5MS*T[W*
M@*^X+Y9![X.>N?:M*34["*]6SEOK9+IL;8&F4.<],+G-8SD+\4(MQQNT=@N>
MY\X'%9U\6\/75W?Q-9ZGI5]?+]I@8 S1RY"X4\AL$9VG!&/J: .TJ"[OK2PA
M$M]=0VT9;:'FD" GTR>_%.6ZMWNI+9)XVGC +Q!P64'H2.HK*U/4E@U^SLK2
MPAN=1EB=TDF<1K'&/O?/M9LD@< >YZ4 :7]H67V$7OVN#[*>D_FC9UQ][..O
M%)!J5C<W4EM;7MO-/%GS(HY59DP<'(!R.>*\[E<2_#KQ1@1!?[5;"P/O0 O$
M<*<#(Y]!72:S!%9>*_"RVD20JKS1*$4#">7]WZ4 :^J:W9Z?#<)]LM5O8X6D
MCMY)0&8A21\N<GI3]#OI=3T&RO9U19;B%9&" A02.V:Y&Q^R#P;XG_M81>>;
MJX%SY@!._P#Y9_KC;[]*Z7PE_P B=I7_ %ZI_*@"Y<:OIMI<BWNM0M8)SC$4
MDZJQSTX)S4MS?6EF5%W=0P%E9E$L@7(7ECSV'?TKD= ^P_\ "%ZL=4V><9KC
M^T/.QN#;C@'\-N/?I5:PMY)+SP*FIQ[Y4M[A\2#)&$4H?J!CW!'K0!W%I>VM
M_#YUC<PW,6=N^&0.N?3(J*WU;3KNY:VM;^UGG7.Z*.9688ZY .:X[4Q/'<^.
M%L RO]GMW CXZHV\_7 -7;?2S>6&@SMJNG1VUM+%):^3:&-GX_U88RGJ,Y&.
MWM0!U]%%% !1110 4444 %%%% !7-_#C_DEGA3_L"V?_ *(2NDKF_AQ_R2SP
MI_V!;/\ ]$)0 >//^1=M?^PUI7_IPMZZ2N;\>?\ (NVO_8:TK_TX6]=)0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_AQ_R2SPI_V!;/\
M]$)725S?PX_Y)9X4_P"P+9_^B$H /'G_ "+MK_V&M*_].%O725S?CS_D7;7_
M +#6E?\ IPMZZ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ J*YNK>SA,UY/'!$.KRN%4?B:EKA?BAH^I:II]B^F
MPR7"0.YEBB!9CD#!P.N,'\Z .V@GANH%FMI4FB<962-@RM]"*DKC?AII.I:5
MH,XU-'A$TN^*"089!C!)';/I[5V5 !1110 4444 8.KZWJ>DR09TVTEBN;M+
M6%A>L&RYPI8>5P/7!/XTS4M<U'3;C2X[JWLX?MEWY,FV5I0J;<Y#$)@]>Q%-
M\8_ZO1/^PS;?^A&H/&4,5QJ?AV*>-9(VU !D<9!X[B@#>BU*UOK2:33+VUN#
M&I^=)0Z*<<;B#P*AL]42/0X+S6+[3T+C#3P38@8Y.-K,?\\UBW:B/Q]J&P;?
M-T/>^/XF$C $_AQ6=HVG2WWA7PY-I]Y;0ZC9QR2P07(W)*"2IR <C&1\PZ9H
M [F">*Y@6:VE2:)QE9(V#*P]B.M5I]:TNVW?:-2LXMKF-O,G5<,.2IR>O/2J
MOAC4UU;1_M*VJ6K^=(LBQ\HSACN93W!/.?7/UK"\-G3E\1>*FNO)\U;AC)Y@
M&?)QSU_ASU_#/:@#K;B]M;2V^T75S#!!Q^]DD"KSTY/%4[W7K"UT.?5(KJVG
MAC1BA6==LC@$A W(R2,5S6@:A]A\-^';<6*W5]<M,+0SN$$:!F.=Y!(^0C@
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M(QU(7.6P", D\4 =K9ZC9:@K-I]Y;W2H<,8)5?;]<&FVVJZ=>W#P6=_:W$R
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MH0:MIUS=-:VU_:S7"YW0QS*SC'7(!SQ7#7)7^UO&QT4+YGV5-WDC'SX;S/\
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M7'7(''Y]: -9K6W:X:=H(C,T?E&0H-Q3.=N>N,]J@ET?39K6.VFTZTDMXO\
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M2O\ TX6]=)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7-_#C_DEGA3_L"V?_HA*Z2N;^''
M_)+/"G_8%L__ $0E !X\_P"1=M?^PUI7_IPMZZ2N;\>?\B[:_P#8:TK_ -.%
MO724 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNSCDCIBO0(E9(41WWLJ@%C_$?6@!U%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*_\ 3A;UTE<WX\_Y%VU_[#6E?^G"WKI* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M [>W6@#L**IZ3J<.LZ5!J%JLBQ3J2HD ##DCG!/I5R@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YOX<?\DL\*?]@6
MS_\ 1"5TE<W\./\ DEGA3_L"V?\ Z(2@ \>?\B[:_P#8:TK_ -.%O725S?CS
M_D7;7_L-:5_Z<+>NDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7-_#C_DEGA3_L"V?_ *(2NDKF_AQ_R2SPI_V!;/\ ]$)0 >//
M^1=M?^PUI7_IPMZZ2N;\>?\ (NVO_8:TK_TX6]=)0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*>>%%*1L>V-VXXSSM4XK/GU'[)/XD:Q?4+BZMD1FC=T,<),98&,,1@=V'?'
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M97WV*-]D]P8U"PG?MY&[+#H3M#8!]<BA(I]:\7VFHBWF@L=-AD$3SQF-II)
M <(V&"@=R!D]/6L>VT^]7X47UHUG.+EC-MA,3;SF0D87&>E,#JKS6H;:ZAM8
M(9KVZF0R+#;;2?+_ +Y+$*!GCD\D\9I^E:M;ZO;R26XDC>&0Q30RKAXG'52.
M1^1(KF9=,>WUVRO[^#4&M)--CMBUFTH>&1?FPRQ'=M//8@'&:W]!M+*W@N)K
M"TNK<3REG:[9R\I'&_#DL/QP>.G2D!JT444 %%%% !1110 4444 %<W\./\
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MFTR% !EW+$*.H&2>2>,U!+XNT^#1KC494N%6UF$$\!0>9$^0,$9QWSD$\=*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<*MK,()X"@\R)\@8(SCOG()XZ58M]?BFU.&QGL[NSEN(VDMS<(H$H'7&&)!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD17&]P<D'^ #/' '7U% '3WEL+RQFMFD>-9HRA>,@,H(QD9!YJNNCVT?A_\
ML>/<MM]F-OD8W;2NTGIC/?..M,^U:K]C5CID7VEVP(Q=91%QG+OMR#U&%5N<
M=N12B\4)'#JQU6V^RRZ5@SK')YJLK+E2IP,Y]"!0!L65JEC86]I"6,=O$L2E
MCR0HP,^_%35Q&N:EJ%Z?#IO=+%K%-J=O+&Z3^9CK\KC:-IP<\9'7FMV37+JX
MU"\M=&L([LV6%F>6X\H%R,[%^5LG'K@4 7=2TN#51:BX:1?LMRERFP@99#D
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M_8:TK_TX6]=)7-^//^1=M?\ L-:5_P"G"WKI* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTEM[:X\L6&GRW"N8\'+G.XJH8\XW=J -JWU^>WNM,M=1T\6T5^I2"03;V#
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ME?\ IPMZZ2N;\>?\B[:_]AK2O_3A;UTE !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^:HC1"YW%@3NW#G@ CIS7HE4M,@T_3[?^S-,,:I:8#0K)N:+=\PSDDC.<\T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\
MR'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_
M /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__
M  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R
M'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W
M]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0
MO>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?
M3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]
MN\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O
M>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3
M_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!T
ME%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;
M_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_
M /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\
MR'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_
M /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__
M  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R
M'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W
M]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0
MO>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?
M3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]
MN\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O
M>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3
M_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!T
ME%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;
M_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_
M /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\
MR'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_
M /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__
M  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R
M'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W
M]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0
MO>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?
M3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]
MN\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O
M>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3
M_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!T
ME%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;
M_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_
M /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\
MR'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_
M /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__
M  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R
M'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W
M]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0
MO>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?
M3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]
MN\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O
M>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3
M_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!T
ME%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;
M_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_
M /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\
MR'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_
M /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__
M  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R
M'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W
M]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0
MO>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?
M3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]
MN\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O
M>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3
M_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!T
ME%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;
M_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_
M /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\
MR'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_
M /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__
M  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R
M'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W
M]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0
MO>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?
M3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]
MN\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O
M>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3
M_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!T
ME%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;
M_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_
M /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
J44 %%%% !1110 4444 %%%% !1110 5D>'O]5J'_ &$)_P#T*BB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img134051827_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_22.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0+X17AI9@  34T *@    @ ! $[  (
M   /   !2H=I  0    !   !6IR=  $    >   "TNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M36EC:&%E;"!286EB;&4    %D ,  @   !0   *HD 0  @   !0   *\DI$
M @    ,Y-P  DI(  @    ,Y-P  ZAP !P   0P   &<     !SJ     0
M
M
M
M
M
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
MM1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!
M"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=8
M65IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ
M_]H # ,!  (1 Q$ /P#V+XC^,[CP3H=K?6EK%<O-<B$K*Q  VL<\=^!7F_\
MPT!JO_0%L_\ OZU=)\??^1.T[_K_ !_Z+>O *]+#T:<Z=Y(YJDY*5D>M_P##
M0&J_] 6S_P"_K4?\- :K_P! 6S_[^M7DE%='U>EV,_:2[GK?_#0&J_\ 0%L_
M^_K4?\- :K_T!;/_ +^M7DE%'U>EV#VDNYZW_P - :K_ - 6S_[^M1_PT!JO
M_0%L_P#OZU>244?5Z78/:2[GK?\ PT!JO_0%L_\ OZU'_#0&J_\ 0%L_^_K5
MY)11]7I=@]I+N>M_\- :K_T!;/\ [^M1_P - :K_ - 6S_[^M7DE%'U>EV#V
MDNYZW_PT!JO_ $!;/_OZU'_#0&J_] 6S_P"_K5Y)11]7I=@]I+N>M_\ #0&J
M_P#0%L_^_K4?\- :K_T!;/\ [^M7DE%'U>EV#VDNYZW_ ,- :K_T!;/_ +^M
M1_PT!JO_ $!;/_OZU>244?5Z78/:2[GK?_#0&J_] 6S_ ._K4?\ #0&J_P#0
M%L_^_K5YMIN@:CJUO-<6<*"W@($EQ/,D$2D]%WR$+GGIG-66\):HEG>3RI$C
M6=Q#;O$9,L[2@E"I&5*D#.<X(((R*GV-!=!\\ST#_AH#5?\ H"V?_?UJ/^&@
M-5_Z MG_ -_6KR[4M-NM(U*>PU"+RKFW;9(FX-M/ID$BG6>DWNH65[=VD.^"
MQC$EPY=5V*3@'!.3SZ9I^PHVO8.>9Z?_ ,- :K_T!;/_ +^M1_PT!JO_ $!;
M/_OZU>244_J]+L+VDNYZW_PT!JO_ $!;/_OZU'_#0&J_] 6S_P"_K5YIKNC7
M'A_6[G2[UXGGMF"NT1)4Y /!(![^E5+JUN+*X:WO8);>9,;HY4*,N1D9!YZ$
M&DJ%%[(?M)]SU;_AH#5?^@+9_P#?UJ/^&@-5_P"@+9_]_6KS!=*O&T5]6$(^
MPI.+8R[U_P!85W!=N<G@$],57MX&N;J*",@-*X12W0$G%'U>CV#VD^YZO_PT
M!JO_ $!;/_OZU'_#0&J_] 6S_P"_K5YAJ^F3:+K-WIMTT;S6DK1.T9)4D'!Q
MD X_"I)-'N(O#L.L2O$D$]PUO%&Q(DD*J"S 8P5&X#.>IQ1["CV#GGW/2_\
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M!;/_ +^M1_PT!JO_ $!;/_OZU>244?5Z78/:2[GK?_#0&J_] 6S_ ._K4?\
M#0&J_P#0%L_^_K5Y)11]7I=@]I+N>M_\- :K_P! 6S_[^M1_PT!JO_0%L_\
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M_P#OZU>:ZMH5[HDOE:C]E64.R-'#>0S,C+U#!&)4_7%9U"H47JD'M)]SUO\
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M:^MOL#6R*C22'4[9?*#_ '=X,F4)Z8;!SQ2="BMT/GFSO_\ AH#5?^@+9_\
M?UJ/^&@-5_Z MG_W]:O+8K"XFU1-.@5);EYA BQR*RLY;: &!VD$]\X[YIEW
M:S6-[/:72;)[>1HI%R#M93@C(X/([4?5Z/8/:3[GJO\ PT!JO_0%L_\ OZU'
M_#0&J_\ 0%L_^_K5YH-&N#X;;6]\7V9;L6A3)W[RA?.,8Q@>OX5GT?5Z3Z![
M2?<];_X: U7_ * MG_W]:C_AH#5?^@+9_P#?UJ\UU[1;CP]K4^F7KQ//"$+-
M"25.Y PQD ]&':LZA4*35T@]I/N>M_\ #0&J_P#0%L_^_K4?\- :K_T!;/\
M[^M7F":3>R:++JR0YLH9E@>7>HPY&0,9R>!V%4Z/J]+L'M)]SUO_ (: U7_H
M"V?_ ']:C_AH#5?^@+9_]_6KR2BG]7I=A>TEW/6_^&@-5_Z MG_W]:C_ (:
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M U7_ * MG_W]:C_AH#5?^@+9_P#?UJ\DHH^KTNP>TEW/6_\ AH#5?^@+9_\
M?UJ/^&@-5_Z MG_W]:O)**/J]+L'M)=SUO\ X: U7_H"V?\ W]:C_AH#5?\
MH"V?_?UJ\DK8MO"FLWFG1WL%JODS*[0J\\:23!!EC'&S!W _V0>E)T**W0^>
M;/0_^&@-5_Z MG_W]:C_ (: U7_H"V?_ ']:O)**?U>EV%[27<];_P"&@-5_
MZ MG_P!_6H_X: U7_H"V?_?UJ\DHH^KTNP>TEW/6_P#AH#5?^@+9_P#?UJ/^
M&@-5_P"@+9_]_6KR2BCZO2[![27<];_X: U7_H"V?_?UJ/\ AH#5?^@+9_\
M?UJ\DHH^KTNP>TEW/6_^&@-5_P"@+9_]_6H_X: U7_H"V?\ W]:O)**/J]+L
M'M)=SUO_ (: U7_H"V?_ ']:C_AH#5?^@+9_]_6KR2BCZO2[![27<];_ .&@
M-5_Z MG_ -_6H_X: U7_ * MG_W]:O)**/J]+L'M)=SUO_AH#5?^@+9_]_6H
M_P"&@-5_Z MG_P!_6KR2BCZO2[![27<];_X: U7_ * MG_W]:C_AH#5?^@+9
M_P#?UJ\DHH^KTNP>TEW/6_\ AH#5?^@+9_\ ?UJ/^&@-5_Z MG_W]:O)**/J
M]+L'M)=SUO\ X: U7_H"V?\ W]:C_AH#5?\ H"V?_?UJ\DHH^KTNP>TEW/6_
M^&@-5_Z MG_W]:O0_AOXXN?'&G7MS=VD5J;:58U6)B<Y&<\U\PU[O^S_ /\
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ME,-U'+L<GE'V,2AQG@X-;>K> A+>>)[C3)[6UMM+O1#!;2W4:Y4NP^9GD!3
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5]C44?77_*'L?,^.?[(U+_H'W7_?AO\ "C^R-2_Z!]U_WX;_  K[&HH^NO\
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MQJ*?UU_RB]CYGQS_ &1J7_0/NO\ OPW^%']D:E_T#[K_ +\-_A7V-11]=?\
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M5]C44?77_*'L?,^.?[(U+_H'W7_?AO\ "C^R-2_Z!]U_WX;_  K[&HH^NO\
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M?[(U+_H'W7_?AO\ "C^R-2_Z!]U_WX;_  K[&HH^NO\ E#V/F?'/]D:E_P!
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M]CYGQS_9&I?] ^Z_[\-_A1_9&I?] ^Z_[\-_A7V-11]=?\H>Q\SXY_LC4O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT2^T*V2T:[LI;502PBLWCDD<]79S*V2>IXYK<H **** "BBB@ HHHH ****
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M/E^2%&W[W.=G7C&>]6%T&^M-0O)-(U1+6UOIA/-$]MYKI(0 [1N6 7( X96
M.3C!Q0!C-K4>D:SXKU58_/1([)E7=L!W*0"3CY1\P)..!DUU6E7DU_8K//%
MFXY1K:X\Z*12 0RO@9'/<#D'J,$TCH=S%J>IW]CJ @GOC 5W0!U3RP1@C/S!
ML]MI'8UGV6@:EHBP6^E3Q*+K4?M5]+%"L4,<8 S&D1+$;L 9!SG)ST% '4T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !699_P#(QZG_ -<X/_9Z
MTZS+/_D8]3_ZYP?^SU2V8@U'_D,:1_UWD_\ 13UIUF:C_P AC2/^N\G_ **>
MM.D]D!E6_B72KN^%K;W#N[2-$L@@D\IW4$E5DV[">#P#V/I23^*-)MKN6WDN
M7+0L$FDC@D>.$GL\BJ43WW$8[U@6K3>%;O38=+OX-1T35+PQPP'!E@WY8M&Z
M\.@.2<C@8YJWX&N;>V\(,+N6.&>UGG%\9&"E)/,8DN3[$')[8I#->^\0Z;I]
MV;6>662X5/,:*VMI)V1?5A&K;1Z9QFIK?6+"[O5M+:Y669[9;M0H)#1,2%8-
MT()![UC>%G5-;\207! OCJ)E8-]YH3&@C/\ NX! ],&J<K7=Y\2FET6]M$63
M1(7$LL!G21#-(05VNOUSDT ;=WXIT:QT^[OKJ\\NWLKC[-._E.=DG'RX R?O
M#D9%6WU:R2>QA,X+ZAG[+A21)A=YY P/E&>:\XNDD/AC5TO&CFD/BE!(R1E5
M8[XLX4DX'MDU9LUETGQ]H/AR?>T=C<7$EE(W\=N\#[5SW*$%?RH [V[U2"RU
M+3[*59#)?NZ1%0-JE4+G//HIZ9YJ[7)^+TBE\1^%XI[I[6.2[E0R1R^6QS"P
M"ANH+$[>,'YN"#@UB7^I:C90:CIMC>S2V::S#:)<SW+JT:.@9XS.0S##87=R
M1NZ]* .\U34K?1]+N-0O"PAMTWML&6/H /4GBI;2>2YMEEFM)K1R3F*8H6'_
M 'PS#]:\^\0:??1^$]?AU*Y7R8S;RP6T6IS7$D+$X;>[!6*MP0K9&<D=!6PM
MJEWXFU'2KS4+^VM=/LXGMD2_EC9@^XO,S[MSX("\DA<=.: .OHKSZPN;_6V\
M)Q7^H7B)=6]XTYMYFA-RJ,GEL2N",C!R,'D]B:B9M<U";6IK2]BMI;"],$,U
MSJTL26Z(1MW0A"CAAR2Q).[KQ0!Z-163XEBNKC1C;Z?>QV=Q++&J,\QB\P;@
M2@<9*E@" 0":YI-7=K+15@>_M&CUU;2[AN;KS61O+<M$9 3YB[B,9)R<>@
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M.XL<X(P,5UM !1110 4444 %%%% !1110 56U#4;32K-KK4)UAA4XW')))Z
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M MG'/ %>ET %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F6?\
MR,>I_P#7.#_V>M.LRS_Y&/4_^N<'_L]4MF(-1_Y#&D?]=Y/_ $4]:=9FH_\
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M #,23^-6:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6G2>R ****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?$C5)T^Y9V$%JW/5V9I/T4K^= '1T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5F6?_(QZG_US@_\ 9ZTZS+/_ )&/4_\ KG!_[/5+
M9B#4?^0QI'_7>3_T4]:=8VMVEO>ZEI$-Y!'/$9W)21 PSY3]C4W_  C>B?\
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M(L?_  '7_"C0-2_!;PVL(BMH8X8P20D:A0"3D\#U))_&I*S/^$;T3_H$6/\
MX#K_ (4?\(WHG_0(L?\ P'7_  HT#4TZ*S/^$;T3_H$6/_@.O^%'_"-Z)_T"
M+'_P'7_"C0-33J*WMH+2/R[6&.%"Q;;&@49)R3@=R3FJ/_"-Z)_T"+'_ ,!U
M_P */^$;T3_H$6/_ (#K_A1H&IIT5F?\(WHG_0(L?_ =?\*/^$;T3_H$6/\
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M:Q>V_A[3;_3C9QZ3(DMQ<M,CI,8D*((PI+?,3N^8+@#')KLJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L;Q-K%QHMA:SVJ1NTU
M[!;L) 2 KN%)&".<5LU@^+M-N]4TVSBL8O->/4+>9QN"X17!8\D=!0 R+5-5
MUC5+^'1GL[6TL)C;O/<PM,TLH"DA55TV@;L9).3Z8HT_7]2U'0IWMM-C?5;:
MZ:SFA\X"))%(!?<>=F"&P 6[8/6H;2'5/#VJ:H(=,EU.SOKDW<3V\L:M&[*
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M0<U-_P )!817D=E-.6NF6/?Y4$C(A?A0S %4W'H&()R/6N6_X1[6[SPEK?\
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M+&:>TCBC<>5*BA@K$M\X(8#("T =A17*Q^+9+I=.EM%M5ADTV2_O&N&*+%@
M*N[G;\^X$X/"GBH--\6:A<7EY;>4FH.FFF]MS%8S6AD8$C8%E)+ Y7##WXH
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M4=3_ !*1@BL,>#[=M+DTVYU+4;FS,'D10R2J!"N005*J"2I5<%MV,>YST%%
M'/\ _"(V\DFHR7FHW]W-J-F;*:29HP5C.?NA4 4_,>V.^,YJY+X>LY[K3YY3
M(WV""2WC0D;75U56W<<\*.F.]:E% &':>%;:VM#92WM[=Z>(&MX[*>13&D;<
M;?E4,V ,#<20.E36&@FQ18WU34+J*.'R8HIW3:BX _A52QP!R^X_F:UJ* *>
MDZ9#HVD6NG6K2/#;1B-&D(+$#UP /TK(CT"1M0\1V<ZNNF:Q&'$D;C*.T9CE
M !Z'"JP.".?;%='10!A:IX0TW5[;2X;HS Z6Z-!(C ,0N/E;CD':I/3H.E27
M7A>PO/[9%PTS#6%19QN'R;$VJ4XX/ /.>:V:* ,BV\-6-H-'$!E5=(5E@&X?
M-N382W')Y)XQS54^#;,:=!:07EY!]GOVOXID9"ZRG=_>0@CYSP1Z5T-% &+%
MX6L/*U :@TVHR:BJI<RW17<ZJ,*HV!0H'4;0#GG.>:?;Z5<:<GG?VGJ6J-!$
MPAM[B6-0QQQDJJ[B<8RY/7/7FM>B@#)\+Z9-H_AFRL[H@W"H7FQT\QV+N!_P
M)C6M110 50U?1[?6K:&"Z>1%AN([A3&0"61MP!R#QFK]% &-/X;C;4KB^T_4
M+W3)KH#[0+4QE92!@,0Z, V.,C%36^AQ6.D+8:7<W%BJL7,T91Y'8G+%C(K
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M'Y><M]1'XCTM-2UJX3Q1:WLT4=BB6<^FV+N&D.?,)V!B#D#".=N.N3S7?T4
M9OATZ@?#=A_;*+'?>2HF55"X/T' /J!QGI6E110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW-N]N6FW%D(5@#\G'.,=AG%6/ D]UK?VKQ%J431SSK':1JW98AAR,<8,I?\
M*NO90RE3G!&#@X/YBJ^GZ?:Z5I\-E81>3;PKMC0$G ^IY/XT <K?I<VOBXRZ
M5;W<LEY=PB\MKFR+V[JH7$Z3 80J%Z%CR/NYP3ANGVW1/$NDV>F7$E_>:O,(
MITMB8RPFX9I0,+LP3\Q!],YKT^JUGI]MIZS"SB\L3S//)\Q.YV.6/)[GMTH
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MT_78M1FCCAL=1B9DW.;FS>$1>Q+@ G/'R[ORYK3HHH **** "BBB@ K,L_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *S+/_D8]3_ZYP?^SUIUF6?_ ",>I_\ 7.#_ -GJ
MELQ!J/\ R&-(_P"N\G_HIZTZS-1_Y#&D?]=Y/_13UITGL@"BBBD,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW%UJ6D1F66+]^YW1.5;_ %3]Q4O]B)_S_P"H?^!34:60&G169_8B?\_^H?\
M@4U']B)_S_ZA_P"!3467<-33HK,_L1/^?_4/_ IJ/[$3_G_U#_P*:BR[AJ:=
M%9G]B)_S_P"H?^!34?V(G_/_ *A_X%-19=PU-.BLS^Q$_P"?_4/_  *:C^Q$
M_P"?_4/_  *:BR[AJ:=%9G]B)_S_ .H?^!34?V(G_/\ ZA_X%-19=PU-.BLS
M^Q$_Y_\ 4/\ P*:C^Q$_Y_\ 4/\ P*:BR[AJ:=%9G]B)_P _^H?^!34?V(G_
M #_ZA_X%-19=PU-.BLS^Q$_Y_P#4/_ IJ/[$3_G_ -0_\"FHLNX:FG169_8B
M?\_^H?\ @4U']B)_S_ZA_P"!3467<-33HK,_L1/^?_4/_ IJ/[$3_G_U#_P*
M:BR[AJ:=%9G]B)_S_P"H?^!34?V(G_/_ *A_X%-19=PU-.BLS^Q$_P"?_4/_
M  *:C^Q$_P"?_4/_  *:BR[AJ:=%9G]B)_S_ .H?^!34?V(G_/\ ZA_X%-19
M=PU-.BLS^Q$_Y_\ 4/\ P*:C^Q$_Y_\ 4/\ P*:BR[AJ:=%9G]B)_P _^H?^
M!34?V(G_ #_ZA_X%-19=PU-.BLS^Q$_Y_P#4/_ IJ/[$3_G_ -0_\"FHLNX:
MFG169_8B?\_^H?\ @4U']B)_S_ZA_P"!3467<-33HK,_L1/^?_4/_ IJ/[$3
M_G_U#_P*:BR[AJ:=%9G]B)_S_P"H?^!34?V(G_/_ *A_X%-19=PU-.BLS^Q$
M_P"?_4/_  *:C^Q$_P"?_4/_  *:BR[AJ:=%9G]B)_S_ .H?^!34?V(G_/\
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M .H?^!34?V(G_/\ ZA_X%-19=PU-.BLS^Q$_Y_\ 4/\ P*:C^Q$_Y_\ 4/\
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MBR[AJ:=%9G]B)_S_ .H?^!34?V(G_/\ ZA_X%-19=PU-.BLS^Q$_Y_\ 4/\
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MZS2$>+0[&.161UMXU96&""%'!% %RBBB@ HHHH **** "BBB@ HHHH ****
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M98W%Q+J=K*8(VD,,5PC2, <85=W)SQ]>*YOPUI/R:';7KZW'=Z823 UI''!
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M$C&0*<C(XPO.1P* .HHKE? LDTH\0/<P?9YFUB4O%O#;#Y<60".H]_T%/O\
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M;DD>5.4+#_OAF'ZUR+R_9/&NE6]A>ZF6DFG%ZVH22K#,-O"HKX1FW$%?*&
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M9>%K."YU&.>1)I?* @0,5^4L6.2. %.?Y4 ;-%9FNZ_9^']';4KOS)8LJ$6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5&B;*L>I' P#P,#&,5T?C:".YO\ PW!.@>*74MCJ?XE,3@BNLHH \MA6]O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV[QI8V>FS6+#D.=X0 @8Q_"<\U3A\.:ZZ>'K>[;3U@T29#YD<CE[A50H#@J
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MPD%E_<OO_!?/_P#$4?\ "067]R^_\%\__P 16G11H&IF?\)!9?W+[_P7S_\
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MR^_\%\__ ,11_P )!9?W+[_P7S__ !%:=%&@:F9_PD%E_<OO_!?/_P#$4?\
M"067]R^_\%\__P 16G11H&IF?\)!9?W+[_P7S_\ Q%'_  D%E_<OO_!?/_\
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MPD%E_<OO_!?/_P#$4?\ "067]R^_\%\__P 16G11H&IF?\)!9?W+[_P7S_\
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ML_M33OL.WRL^5PPWYSS][IQTZULV5M]CT^WMMV_R8ECW8QNP,9Q^% $]%%%
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M].>* /2Z*\_O)-:U35/$#P7,=I)ITP2"275);9+5%0.LC1",I(I.22Y((XX
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M[N"?2O1J "BBB@ JK?ZE::7#'+?2^4DDJ0H=I;+L<*. >IJU7+^/?^0/I_\
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M_(T^U@M8<EO+@C"+D]\#BFRZ;8S"X$UE;R"ZP9P\2GSL  ;N/FP ,9]*LT4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'_"06'_3U_X!3?\ Q%'*^P71IT5F?\)!8?\ 3U_X!3?_ !%'_"06'_3U_P"
M4W_Q%'*^P71IT5F?\)!8?]/7_@%-_P#$4?\ "06'_3U_X!3?_$4<K[!=&G16
M9_PD%A_T]?\ @%-_\11_PD%A_P!/7_@%-_\ $4<K[!=&G169_P )!8?]/7_@
M%-_\11_PD%A_T]?^ 4W_ ,11ROL%T:=%9G_"06'_ $]?^ 4W_P 11_PD%A_T
M]?\ @%-_\11ROL%T:=%9G_"06'_3U_X!3?\ Q%'_  D%A_T]?^ 4W_Q%'*^P
M71IT5F?\)!8?]/7_ (!3?_$4?\)!8?\ 3U_X!3?_ !%'*^P71IT5F?\ "06'
M_3U_X!3?_$4?\)!8?]/7_@%-_P#$4<K[!=&G169_PD%A_P!/7_@%-_\ $4?\
M)!8?]/7_ (!3?_$4<K[!=&G169_PD%A_T]?^ 4W_ ,11_P )!8?]/7_@%-_\
M11ROL%T:=%9G_"06'_3U_P" 4W_Q%'_"06'_ $]?^ 4W_P 11ROL%T:=%9G_
M  D%A_T]?^ 4W_Q%'_"06'_3U_X!3?\ Q%'*^P71IT5F?\)!8?\ 3U_X!3?_
M !%'_"06'_3U_P" 4W_Q%'*^P71IT5F?\)!8?]/7_@%-_P#$4?\ "06'_3U_
MX!3?_$4<K[!=&G169_PD%A_T]?\ @%-_\11_PD%A_P!/7_@%-_\ $4<K[!=&
MG169_P )!8?]/7_@%-_\11_PD%A_T]?^ 4W_ ,11ROL%T:=%9G_"06'_ $]?
M^ 4W_P 11_PD%A_T]?\ @%-_\11ROL%T:=%9G_"06'_3U_X!3?\ Q%'_  D%
MA_T]?^ 4W_Q%'*^P71IT5F?\)!8?]/7_ (!3?_$4?\)!8?\ 3U_X!3?_ !%'
M*^P71IT5F?\ "06'_3U_X!3?_$4?\)!8?]/7_@%-_P#$4<K[!=&G169_PD%A
M_P!/7_@%-_\ $4?\)!8?]/7_ (!3?_$4<K[!=&G169_PD%A_T]?^ 4W_ ,11
M_P )!8?]/7_@%-_\11ROL%T:=%9G_"06'_3U_P" 4W_Q%'_"06'_ $]?^ 4W
M_P 11ROL%T:=%9G_  D%A_T]?^ 4W_Q%'_"06'_3U_X!3?\ Q%'*^P71IT5F
M?\)!8?\ 3U_X!3?_ !%'_"06'_3U_P" 4W_Q%'*^P71IT5F?\)!8?]/7_@%-
M_P#$4?\ "06'_3U_X!3?_$4<K[!=&G169_PD%A_T]?\ @%-_\11_PD%A_P!/
M7_@%-_\ $4<K[!=&G169_P )!8?]/7_@%-_\11_PD%A_T]?^ 4W_ ,11ROL%
MT:=%9G_"06'_ $]?^ 4W_P 11_PD%A_T]?\ @%-_\11ROL%T:=%9G_"06'_3
MU_X!3?\ Q%'_  D%A_T]?^ 4W_Q%'*^P71IT5F?\)!8?]/7_ (!3?_$4?\)!
M8?\ 3U_X!3?_ !%'*^P71IT5F?\ "06'_3U_X!3?_$4?\)!8?]/7_@%-_P#$
M4<K[!=&G169_PD%A_P!/7_@%-_\ $4?\)!8?]/7_ (!3?_$4<K[!=&G169_P
MD%A_T]?^ 4W_ ,11_P )!8?]/7_@%-_\11ROL%T:=%9G_"06'_3U_P" 4W_Q
M%'_"06'_ $]?^ 4W_P 11ROL%T:=%9G_  D%A_T]?^ 4W_Q%'_"06'_3U_X!
M3?\ Q%'*^P71IT5F?\)!8?\ 3U_X!3?_ !%'_"06'_3U_P" 4W_Q%'*^P71I
MT5F?\)!8?]/7_@%-_P#$4?\ "06'_3U_X!3?_$4<K[!=&G169_PD%A_T]?\
M@%-_\11_PD%A_P!/7_@%-_\ $4<K[!=&G169_P )!8?]/7_@%-_\11_PD%A_
MT]?^ 4W_ ,11ROL%T:=%9G_"06'_ $]?^ 4W_P 11_PD%A_T]?\ @%-_\11R
MOL%T:=%9G_"06'_3U_X!3?\ Q%'_  D%A_T]?^ 4W_Q%'*^P71IT5F?\)!8?
M]/7_ (!3?_$4?\)!8?\ 3U_X!3?_ !%'*^P71IT5F?\ "06'_3U_X!3?_$4?
M\)!8?]/7_@%-_P#$4<K[!=&G169_PD%A_P!/7_@%-_\ $4?\)!8?]/7_ (!3
M?_$4<K[!=&G169_PD%A_T]?^ 4W_ ,11_P )!8?]/7_@%-_\11ROL%T:=%9G
M_"06'_3U_P" 4W_Q%'_"06'_ $]?^ 4W_P 11ROL%T:=%9G_  D%A_T]?^ 4
MW_Q%'_"06'_3U_X!3?\ Q%'*^P71IT5F?\)!8?\ 3U_X!3?_ !%'_"06'_3U
M_P" 4W_Q%'*^P71IT5F?\)!8?]/7_@%-_P#$4?\ "06'_3U_X!3?_$4<K[!=
M&G169_PD%A_T]?\ @%-_\11_PD%A_P!/7_@%-_\ $4<K[!=&G169_P )!8?]
M/7_@%-_\11_PD%A_T]?^ 4W_ ,11ROL%T:=%9G_"06'_ $]?^ 4W_P 11_PD
M%A_T]?\ @%-_\11ROL%T:=%9G_"06'_3U_X!3?\ Q%'_  D%A_T]?^ 4W_Q%
M'*^P71IT5F?\)!8?]/7_ (!3?_$4?\)!8?\ 3U_X!3?_ !%'*^P71IT5F?\
M"06'_3U_X!3?_$4?\)!8?]/7_@%-_P#$4<K[!=&G169_PD%A_P!/7_@%-_\
M$4?\)!8?]/7_ (!3?_$4<K[!=&G169_PD%A_T]?^ 4W_ ,11_P )!8?]/7_@
M%-_\11ROL%T:=9EG_P C'J?_ %S@_P#9Z/\ A(+#_IZ_\ IO_B*CTJ=;O6M1
MN(DF$3)"JM+"\>X@-G&X#/446:3N%S7HHHJ1A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
@0 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>img134051827_23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img134051827_23.jpg
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MX? E,T)DA]+4V4=38I6RP2E#1$525&6#DZ+Q_\0 '0$! 0 " @,!
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M0DR=J-WB<3)2K(4W<9*1DFS52>&%1J^2!1-)8BJ1#33HPG55WT)19"C & ,
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M?*O6=C;-9L& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M=F SI^Z!NFF#AZY,4IG#I;OKK"4!44,(!@'(8 P!@# & , 8 P!@# & , 8
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MP_V3I3G1_P"U6#/9[G@_ZWG'[M^=+Q_F1X?K\Z=M 6$[8[OJ==C<$^X(?UL
MH&W!$/LB'OD#R_;$W[>1S_4V3_%.E--OKFP=C;ETJMR6&H?NNV5A_-CQX^SP
MZBSU@WSVD^LY_6P739'"6\05JY 4W0-E8:XK6P%)RM6:VF<K>%*J/+2NA'N(
MUD@1=VP<-R/R Z:F!(2'[P^PL-V=!KYDWQ!=\OI#9[3=UR6Z]9<=HG6*9*;L
MG@_812X(5%$XO"4]O#"J.K5*$TYDN.1X2&"."9.AEQ*'3A:ABAB>E#%5U:HL
M&DJ//62N0L/.VT.IES5+/QRCXJ(GY6M'1FJC>W;P\A".19O%0.SG4""@LL45
M$"F*0Q4!*"AN_P!3#Q&3-Z*RY4"M4%\S9NC"XXY4RRR(-)JK2@CESFEKKI-8
MZLCE%BF]%([(G:Y5Y*UJ;'!%X..'P3T8FDJ-PM8+&*KU46HO-Q/VK>]NZJ]\
M>Q"UXEOBKSL:E3@UAJ[9PB[FDW:;K";E@V?N'3M%%RA&I*@59PHIWC#WO/KF
MB_K%9[#;5)L3F^ F6:Q6J5X=PQ3%!:K))M#ACB@AAA<2BF.&J25$G3$\?I#8
M;+=UX>!LGA/6T=CLMHEJ9$HXU%/EZ42<5%55I3!8[B3X=>@=>@C]</4.>H/2
M+?F?N , 8 P!@%M;CL9:H22$<GKW9-L!=F1V,A3J\TEHY$3K+)>B+N%Y9@<C
MPG@@J=($C%!%9$_B")Q*6TWI=OF3!;^@[BMLDT@XVXZCVK'V!\_49OY(M09M
M:\R3<RBZ3)VY<#/*+(-&T<=JH_5!!0R9B.#D34   QI8T:W9^A8^<%VMA76+
MUO1+C?YLBZL53*U-65ZW:D%1X\1AX]=]Z P1*!CN)%^9$K*/:I%.LZ>KH-T2
M'55(0T6+2VAX$$]4\A]SFBJQJZ;39V?=4KMEI47TULJJ6W5;4E8M^D]B;M8V
M=&IK5&#FW$-!637UWU+72%BF03S:E&D7DZJ].[DULFEGNU.JJG3;O3QVF";R
MUU5:IK!JN6&QH]%?Y-;7N<E7[")*M#TBS#PUL;2J1KU;W\1<9OU:"]U6/NFY
MC5F,U&MY:24CY!52.CC/(Y 6T>\AWSDSA!1?.79]G'$:3PRQ<.K;B^5"L=E7
M_?%GV[5ZWJAIL2JJ*4"-LYZ[)M-1,X%B\3V@TA925V<6RN):RKU=U6$'R*#/
M6SUS93>("K5)@].@\1J4-*O:UA797#?7;AGN#;;PJL*T>&NF.ZFPX376X;XC
M::*Z4V/.[3=W;97)B MVHT8_7J[^H4K6EDVHE5K96$X.#K=ACR1DA4J-KUR6
MUSTG&2SF]L5E%4)<$72T:6RF"H\=U=NVN K1YMXQ56;PK2G?R+"^X7JP?3):
MXKSBU.XZL7C1>U;,MJ^68UAD]A;)4[9H=K"OWKAL5[/JSJL?=[<V<LTYQ2",
MS12%I&&=1[F4=34^*QXU]&PRKBLU5/![FO226R%& , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & <2XAH]V+P'+)BNF_ A7J:S5)4KPB1>B970' Q7 )]T@)^(4?#(
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M7+4K0+A VU.NSR(&,I$S)X-^]+'O>Z4QB(.13,H4AS)]\I#" %T\ 8 P!@#
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MZBBJA]^E(FF0H"8YS"!2E 1,(  CCV?\WRBL&Q]^L\RZ/[5$Q2F+SZX[&*8
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M[O7S[O7KTZ^?3U^> ?N , 8 P!@# & , 8!C;X2_&>[53[L;7?Y%W&' ,DF
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M:!74:E0*FA/3JAW36J4BMH%B*S"I=$(YH90O>4,<3X#;??NWUD:(#]6XV/\
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MV=NS/\U6H/Z,X^_US_[G6+_F-M_QQ]][@_W9L_\ ;;?_ )D?2T<IOV=VS/\
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M;FKJ!LPE*GF]IJ!;W4H.U!6+&T$HMYR"":9/ BY-(4T^Z\9^"M_6R=3B!"]
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M;X+G$9+VL7Z/,S$$]9_W8_>+E,3SP!@# & , ]#@ [G40Z@ ]>OG]3]28.H
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M6DGCNI14H:&HX)D<N.%PN!T:B5&GL:;S5&GPWG(9D!@# & , 8 P!@# & ,
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ML3YG3&=)+F\<75\I6'ZU*.13/<YGO(OFLU+A_P V;]T;[XYWEAR7!<CC1?\
MXF_&FXV^WG47S_@,]9?GB:]ODVW?5IILD^ZROA(/G(VO^=&SD@P"/G*+CWKW
MD]I2Z:CV69=O7YV'E_1Y9O+S,0-=F%H*6BF%B5/"S4"H_0A@E%WBL2_?EB9
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M556DG"VJM554JIM.C55@U6J9QZ&M/95KOA</DBQZUA6J63*WRF0P!@# & ,
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M<9K[=HN:OD+3J99HVSZ9)'2MEE6;MW&NF;&Q7Z-FH@A"LWR7IDC',543HB(
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M#.8V[]X'1OY=OOZO=9I@]UF^]@^=-,A)/S(?X_OCG#(/:KKYLW'EF0& , 8
MP!@# & >"GY@W[6 1BT)\)'*GVX17XG-:X*\^J'DB4&"# & , 8 P!@# +5;
MTNVN-;:7VQL#<"+=QJFEZ[N%EV.V=Q/NZV=4F&@7SZS-5X3PE@EDG,0B[0/'
M&24*]*H+<Q1*H. LU3/48ENRHVOV;4[>+]4.&7&*>XV;#LM-<7BTL+34649,
M3=.JU\D:/Z 688W"[)1S2#G5&SM"H)R$<R9LIV.=-&)E2O$V(KKK:>+IBV\E
MCBEPY&;[!!@# ,4,!^K<;'_P9^M_RD[S@&O%Y(?&(WU[:-I?/B=SO7=OBV[O
MB%B^K2CC<[W6;\)'\YEF"^L/VP^_GG0YKBN9JBR?!\C;/:?^ #5WL>I/S*C,
MZ-WKX\O+Y5MGUN8<G@]I#[V'DC5#W;].5M^V6=_";K.\4.2X+D<:BS?%\S@&
MGY[:_P!\(_RA<I#;8E^"(/9P'S8SHK!XRA^/0_6$<F_(_1\QJ377YY<?W=;^
M4-G>HXR5SJ;X5-:>T"F_..-SQ+?^(VWXI:?H8S.7[I+]_#\Y&UEWS\!&YO9)
ML3YG3&=)+F\<75\I6'ZU*.13/<YGO(OFLU+A_P V;]T;[XYWEAR7!<CC1?\
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M-QQ,'%L8>+9;)[C6.C&23%DV*I4:TJ8J#5LDFBD!U#'.;N$ !$PF'\T'7+S
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MS^OT\_OYA#%#'##'"TX8X5$J:DZX/8\*TV-/)H1*C6]+E3S$H<R,1@# & ,
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MWC^X_EB[/KL@U>QO6/[8_?SK"?L 7UXN?&7X]>V[5?SY@\\R[O&%A^.67Z>
MX[TO_>ETH_H[??\ =EJ-G%G9P_(D8!2=FH5&NHM#7*EU.VFCP6!@-FKD//"R
M!P*8N :#*LW8M@7%)(5@1[@*BFGW^]W"] /VL4.CTGTWWFTRJ5+W2]']T?>Q
M78B!]/\ 1/&]%]-]RF;3TKT;TAQZ/X_B>#XZWA]WQ3]X"J\ 8!C;X2_&>[53
M[L;7?Y%W&' ,6W:$_JI,]]Q)IW\<NZLS@S?#SH%I,V@DIV77ZH=OG[C/4_X[
M=G9HC]T7O/\ \F9?D?I>8DWVVGP&\8?NW]*_-G9>(<UQ7,PUK@^<)C0S>4HQ
MU\8+@C]W3H'_ $BQYC'[3]*'E$%F_>OYT!VC>3/Q;^0/L1VO\PY[-(.FJO0)
M;9G"[4E3AV!9=9;7_'V9>P99T]3?S\-6!HUDFX*$N*3-^XIEAEHJ*=L8"W-&
MJCNO2RS23;';K-R.4=\2;A27YL&?!$A\[U5UO4<]3:!):XXX[9A9"'<5M"3+
MO2VPE8D;8ML&?K-=MSJS3\+ 6K8;IFQ>WZTQK)\FA.V]^DH]F7P*+N73Q0!=
M+2%-0Q)ZE'L>I[/M,U[9<5]M-U:L[7G9]?$1X:?<NZ(_%E6<TF)UZ+G\;WM
M/NLWWXC])9M@R?'S('VYF"??8@_H)SM^[%>?B6U-FB+-\7S*\H>'G9G-R$&
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MT_ B9_SV'_TLDUISL0>TZI5^U;M5"F<9Y5K5+92[^C%GWW8F2LDWA):-L*;
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M&1*Y/"CPQSJ\,$]G[,B2Y#D4(11,Y5$U"E.FH0P'(<AP Q3D,41*8IBB E,
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M:YY)0NQ:C$:D9631M[V34).'EG=Y>6SCDO?G%";U*20=)P[>$GSWU7WQ>Z)
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MYFF4/LO7TN\K,<,M96L7<:Z_<U^+*)BGD9Q!I)K*1#%,4EN^\D"H-@%-0/%
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M\\C](J;PJ,=!,7,''RL?)BLC)S3-\NJR8.VYTG*\%)1;II,5N?82*,+/1\[
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M6T081[%JD'1-NT9M4TF[=$@?F4TDR$#J/0/,<A3D, 8 P!@# & , 8 P!@#
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M%$"P<7(.6S8I,M/-Y._I(GC2N&U46+5-?-\<SM*0Q521,:5P!RN"L6H."J'
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MBSKOKDMNW5E3:2[J-;"IP+.#&<G[(HV%91Q-V5Z@\EG[APJ=9994K%I&Q#!
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M06?2$J\*P9 <K1NXE9=T^E'B;4JATVI'3Q8C1$P-VI46Y$TBXYF>16^ , 8
MP!@# & , 8 P!@# & , 8 P#P%,ANG4OJ'J'3J'GUZ_)Z_\ '@ $TP P 4
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MQS38";L4-7&\7"2=@9^[CI@K+*KO53;??OE4J5._#G3'>7 R%& , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MBW14.JS7*0#G< 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MRMWQ&TXV5"K-RS3B1?0K6MH&=-J\>>]^!E:XD)1T;I@L&3 P08 P!@# & ,
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MU]6XVNQ44+JII+];T<.SC6;OT3]\?L8I7_.WK;_XS!*+:O+Z"10=1 !$.@]
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M&)W#*'2<O3N7SEVX5!NKR2W*M%VMO?GF47V6R9$NSMX<I)$(FFGH:C)IIIE
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MO9%IY8PQC11D=BHK(G?@L6^$7)F5C!!@# & , 8 P!@# & , 8 P!@# & ,
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M*[M^(6/ZO+/AMJ_&;1\/.^DB).<,OCN<&?NWN('Y1>M\^;>K?_!GT@^$N?\
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M*S\\#[ , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M>0>3T?\ '-@^&?T<9MBL_/ ^P# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MJC?"'K+VI:Q^?M=ST?JJ_P 'G2OY,?T\@\GH_P".;!\,_HXS;%9^>!]@& ,
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M-3T'8&W>4.D[)-;"UOKRW+0$>ZH](3J4S8*VUFIV- H7*6>O$TW<D1DDB_\
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M[">7>;A7N<K=(U1)Q7-HRCMI'-)@9-USHM>#V[55O4E14IK,U6#$8! KLO\
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M\R1W98G64[.GAHHX1!LX/H.AG7;E5!<J"QHPIE42KE*0JP)'$Q 5 A 4 O?
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M+^Z[*?%KU\:7E\?MGUB87*HWPAZR]J6L?G[7<]'ZJO\ !YTK^3']/(/)Z/\
MCFP?#/Z.,VQ6?G@?8!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M_HXS;%9^>!]@& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M;!\,_HXS;%9^>!]@& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MWVD6UFW>JM0;+V0VA7QSI,I=Q1J7-6=&+>*)""B;5^I%E:.#IB!R)*G,0>\
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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@@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>35
<FILENAME>iobt-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-05T16:10:42.7998+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.iobiotech.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iobt="http://www.iobiotech.com/20231231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" namespace="http://xbrl.sec.gov/country/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" namespace="http://xbrl.sec.gov/stpr/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails2" id="DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails2">
        <link:definition>100020 - Disclosure - Income Taxes - Reconciliation of the Statutory Income Tax Rate to our Effective Income Tax Rate (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails2" id="DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails2">
        <link:definition>100030 - Disclosure - Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100040 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2">
        <link:definition>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100060 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>100070 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical">
        <link:definition>100080 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100090 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity" id="Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity">
        <link:definition>100100 - Disclosure - Description of Business, Organization and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100110 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100120 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements" id="Role_DisclosureLicenseAndCollaborationAgreements">
        <link:definition>100130 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>100140 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>100150 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100160 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>100170 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100180 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceShares" id="Role_DisclosureConvertiblePreferenceShares">
        <link:definition>100190 - Disclosure - Convertible Preference Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>100200 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensation" id="Role_DisclosureEquityBasedCompensation">
        <link:definition>100210 - Disclosure - Equity-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100220 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100230 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100240 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100260 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>100270 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100280 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>100300 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100310 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationTables" id="Role_DisclosureEquityBasedCompensationTables">
        <link:definition>100320 - Disclosure - Equity-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>100330 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTable" id="Role_DisclosureNetLossPerShareTable">
        <link:definition>100340 - Disclosure - Net Loss Per Share (Table)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails" id="Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Description of Business, Organization and Liquidity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails" id="DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails">
        <link:definition>100370 - Disclosure - Fair Value Measurements - Summary of Assets Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy" id="DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy">
        <link:definition>100380 - Disclosure - Fair Value Measurements - Roll-forward of Fair Value of Convertible Note and Preference Shares Tranche Obligations for Which Fair Value Determined by Level 3 Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100400 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100420 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100430 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails" id="DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails">
        <link:definition>100450 - Disclosure - Leases - Schedule of Quantitative information Regarding Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails" id="DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails">
        <link:definition>100460 - Disclosure - Leases - Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Convertible Preference Shares - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails" id="Role_DisclosureEquityBasedCompensationAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Equity-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails" id="DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails">
        <link:definition>100510 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails" id="DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails">
        <link:definition>100520 - Disclosure - Equity-Based Compensation - Summary of Assumptions for Estimated Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails" id="Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails">
        <link:definition>100530 - Disclosure - Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails">
        <link:definition>100550 - Disclosure - Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
        <link:definition>100560 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails" id="DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails">
        <link:definition>100570 - Disclosure - Income Taxes - Reconciliation of the Statutory Income Tax Rate to our Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails">
        <link:definition>100580 - Disclosure - Income Taxes - Schedule of Principal Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails" id="DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails">
        <link:definition>100590 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>100600 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100610 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="iobt-20231231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="iobt-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="iobt-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" xlink:href="iobt-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="iobt-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails" xlink:href="iobt-20231231.xsd#Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="iobt-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails" xlink:href="iobt-20231231.xsd#DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy" xlink:href="iobt-20231231.xsd#DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="iobt-20231231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="iobt-20231231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="iobt-20231231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails" xlink:href="iobt-20231231.xsd#DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="iobt-20231231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails" xlink:href="iobt-20231231.xsd#Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="iobt-20231231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails" xlink:href="iobt-20231231.xsd#Role_DisclosureEquityBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails" xlink:href="iobt-20231231.xsd#DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails" xlink:href="iobt-20231231.xsd#DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails" xlink:href="iobt-20231231.xsd#Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="iobt-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="iobt-20231231.xsd#Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="iobt-20231231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="iobt-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="iobt-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity" xlink:href="iobt-20231231.xsd#Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="iobt-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="iobt-20231231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements" xlink:href="iobt-20231231.xsd#Role_DisclosureLicenseAndCollaborationAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:href="iobt-20231231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:href="iobt-20231231.xsd#DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="iobt-20231231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeases" xlink:href="iobt-20231231.xsd#DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="iobt-20231231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceShares" xlink:href="iobt-20231231.xsd#Role_DisclosureConvertiblePreferenceShares" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="iobt-20231231.xsd#DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensation" xlink:href="iobt-20231231.xsd#Role_DisclosureEquityBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="iobt-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="iobt-20231231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="iobt-20231231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="iobt-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="iobt-20231231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="iobt-20231231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="iobt-20231231.xsd#DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="iobt-20231231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesTables" xlink:href="iobt-20231231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="iobt-20231231.xsd#DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationTables" xlink:href="iobt-20231231.xsd#Role_DisclosureEquityBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="iobt-20231231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTable" xlink:href="iobt-20231231.xsd#Role_DisclosureNetLossPerShareTable" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="iobt-20231231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="iobt-20231231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="iobt-20231231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails" xlink:href="iobt-20231231.xsd#DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails" xlink:href="iobt-20231231.xsd#DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:href="iobt-20231231.xsd#DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails" xlink:href="iobt-20231231.xsd#DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails" xlink:href="iobt-20231231.xsd#DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails" xlink:href="iobt-20231231.xsd#DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails2" xlink:href="iobt-20231231.xsd#DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails2" xlink:href="iobt-20231231.xsd#DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2" xlink:href="iobt-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_LaboratoryMember" xlink:label="iobt_LaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesMember" xlink:label="iobt_ConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OperatingLeaseRemainingLeaseTerm" xlink:label="iobt_OperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligation" xlink:label="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc" xlink:label="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember" xlink:label="iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferenceSharesTrancheObligationsMember" xlink:label="iobt_PreferenceSharesTrancheObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PrepaidContractResearchAndDevelopmentCostsCurrent" xlink:label="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncentiveFromLessor" xlink:label="us-gaap_IncentiveFromLessor"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuanceCost" xlink:label="iobt_TemporaryEquityStockIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MD" xlink:label="stpr_MD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc" xlink:label="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_SalesAgreementMember" xlink:label="iobt_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" xlink:label="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_NY" xlink:label="stpr_NY"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_WarrantsPolicyPolicyTextBlock" xlink:label="iobt_WarrantsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityDisclosureTextBlock" xlink:label="iobt_TemporaryEquityDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NonCashSettlementOfPreferenceShares" xlink:label="iobt_NonCashSettlementOfPreferenceShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquitySubscriptionPricePerShare" xlink:label="iobt_TemporaryEquitySubscriptionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TwoThousandTwentyThreeInducementIncentivePlanMember" xlink:label="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueOfPreferenceSharesTrancheObligation" xlink:label="iobt_FairValueOfPreferenceSharesTrancheObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PercentageOfAggregateCashAndCashEquivalentsDeposited" xlink:label="iobt_PercentageOfAggregateCashAndCashEquivalentsDeposited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:label="us-gaap_RelatedAndNonrelatedPartyStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfOperatingLease" xlink:label="iobt_NumberOfOperatingLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityAdjustedFairValueOfTrancheObligation" xlink:label="iobt_TemporaryEquityAdjustedFairValueOfTrancheObligation"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassBConvertiblePreferredStockMember" xlink:label="iobt_ClassBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations" xlink:label="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OperatingLeaseAmendedBaseRent" xlink:label="iobt_OperatingLeaseAmendedBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="iobt_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DeferredTaxAssetsRightOFuseLeaseLiability" xlink:label="iobt_DeferredTaxAssetsRightOFuseLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset" xlink:label="iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PercentageOfTotalCashAndCashEquivalents" xlink:label="iobt_PercentageOfTotalCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember" xlink:label="iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuanceCosts" xlink:label="iobt_TemporaryEquityStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfVotePerShare" xlink:label="iobt_NumberOfVotePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_EquitySecuritiesTerm" xlink:label="iobt_EquitySecuritiesTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesEquityValue" xlink:label="iobt_ConvertibleNotesEquityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ContractualObligationsTerminationNoticePeriod" xlink:label="iobt_ContractualObligationsTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_AccruedContractResearchAndDevelopmentCostsCurrent" xlink:label="iobt_AccruedContractResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:label="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders" xlink:label="iobt_NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_SecuritiesPurchaseAgreementMember" xlink:label="iobt_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_UndesignatedPreferredStockMember" xlink:label="iobt_UndesignatedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferredClassCMember" xlink:label="iobt_PreferredClassCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:label="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PaymentsOfStockAndWarrantIssuanceCosts" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_RefundableTaxCreditReceivable" xlink:label="iobt_RefundableTaxCreditReceivable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DeferredTaxAssetsAccruedCompensation" xlink:label="iobt_DeferredTaxAssetsAccruedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_EmployeeEquityPlanMember" xlink:label="iobt_EmployeeEquityPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:label="us-gaap_RelatedAndNonrelatedPartyStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesConversionCost" xlink:label="iobt_ConvertibleNotesConversionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendDeclaredMember" xlink:label="us-gaap_DividendDeclaredMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DeemedDividend" xlink:label="iobt_DeemedDividend"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc" xlink:label="iobt_ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesTerm" xlink:label="iobt_ConvertibleNotesTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OperatingLeaseAnnualBaseRent" xlink:label="iobt_OperatingLeaseAnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_LaboratoryEquipmentMember" xlink:label="iobt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DK" xlink:label="country_DK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_IncreaseDecreaseInLeaseLiability" xlink:label="iobt_IncreaseDecreaseInLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange" xlink:label="iobt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" xlink:label="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_AdjustmentsToAdditionalPaidInCapitalStockIssued" xlink:label="iobt_AdjustmentsToAdditionalPaidInCapitalStockIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfBoardDirectors" xlink:label="iobt_NumberOfBoardDirectors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferenceStockMeasurementInput" xlink:label="iobt_PreferenceStockMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertiblePreferenceSharesPoliciesTextBlock" xlink:label="iobt_ConvertiblePreferenceSharesPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_GrantIncomeCostReimbursement" xlink:label="iobt_GrantIncomeCostReimbursement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesRiskFreeRate" xlink:label="iobt_ConvertibleNotesRiskFreeRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueOfSharesIssued" xlink:label="iobt_FairValueOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_SiliconValleyBankMember" xlink:label="iobt_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassCConvertiblePreferredStockMember" xlink:label="iobt_ClassCConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FinancialAssetFairValueDisclosure" xlink:label="iobt_FinancialAssetFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquitySubscriptionAmount" xlink:label="iobt_TemporaryEquitySubscriptionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PurchasePricePerShareOfCommonStockAndWarrant" xlink:label="iobt_PurchasePricePerShareOfCommonStockAndWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TrancheObligationMember" xlink:label="iobt_TrancheObligationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_WarrantsExercisablePricePerShare" xlink:label="iobt_WarrantsExercisablePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_AccruedResearchAndDevelopmentCostsPoliciesTextBlock" xlink:label="iobt_AccruedResearchAndDevelopmentCostsPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_AtTheMarketEquityProgramMember" xlink:label="iobt_AtTheMarketEquityProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PercentageOfUncertainTaxPositions" xlink:label="iobt_PercentageOfUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_CommonStockMaximumAggregateOfferingAmount" xlink:label="iobt_CommonStockMaximumAggregateOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesVolatilityPercentage" xlink:label="iobt_ConvertibleNotesVolatilityPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NetProceedsFromIssuanceOfPrivatePlacement" xlink:label="iobt_NetProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_WarrantsIssued" xlink:label="iobt_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts" xlink:label="iobt_IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferenceStockMeasurementInputRemainingTerm" xlink:label="iobt_PreferenceStockMeasurementInputRemainingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PeriodExpireInTwentyTwentySixMember" xlink:label="iobt_PeriodExpireInTwentyTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease" xlink:label="iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017" xlink:label="iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts" xlink:label="iobt_IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_EmergingGrowthCompanyStatusPoliciesTextBlock" xlink:label="iobt_EmergingGrowthCompanyStatusPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OfficeAndLaboratoryMember" xlink:label="iobt_OfficeAndLaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" xlink:label="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendPaidMember" xlink:label="us-gaap_DividendPaidMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion" xlink:label="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PercentageOfInterestOnSubscriptionPrice" xlink:label="iobt_PercentageOfInterestOnSubscriptionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_SharesIssuedFairValuePerShare" xlink:label="iobt_SharesIssuedFairValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfSharesIssuedForAdjustedDownward" xlink:label="iobt_NumberOfSharesIssuedForAdjustedDownward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferredClassBAndPreferredClassCMember" xlink:label="iobt_PreferredClassBAndPreferredClassCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OfficeMember" xlink:label="iobt_OfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc" xlink:label="iobt_ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_RefundableTaxCredit" xlink:label="iobt_RefundableTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment" xlink:label="iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Issuance of class C preference shares, net of issuance costs of $340 and adjusted for settlement of tranche obligation of $28,276 of which $25,908 is non-cash, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary equity, Issuance of class C preference shares, net of issuance costs of $340 and adjusted for fair value of tranche obligation of $25,908 at non-cash settlement, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues and adjusted for fair value of tranche obligation of non cash settlement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized R&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease remaining lease term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining lease term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Roll-forward of Fair Value of Convertible Note and Preference Shares Tranche Obligations for Which Fair Value Determined by Level 3 Inputs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity adjusted for settlement of tranche obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Adjusted for Settlement of Tranche Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity adjusted for settlement of tranche obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Issuance of preference shares, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Temporary equity, Issuance of preference shares, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Dividends, Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Cumulative dividends on class B and C preference shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cumulative dividends on Class B and C preference shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Deduction, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Deduction, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preference shares, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, exchange of preferred and common stock shares of IO biotech ApS into common stock of IO biotech, inc, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Exchange of Preferred and Common Stock Shares of IO Biotech ApS into Common Stock of IO Biotech, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity Exchange of Preferred and Common Stock Shares of IO Biotech ApS into Common Stock of IO Biotech, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 through 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period Twenty Twenty Three Through Twenty Twenty Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period twenty twenty three through twenty twenty five.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares and warrants in private placement, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock And Warrant Issued During Period Value Issued For Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock and warrant issued during period value issued for private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferenceSharesTrancheObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preference shares tranche obligations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferenceSharesTrancheObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preference Shares Tranche Obligations [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferenceSharesTrancheObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preference Shares Tranche Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preference shares, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, liability, non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liability - noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities, convertible preference shares and stockholders' deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid contract research and development costs current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Contract Research And Development Costs Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid contract research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock split, conversion ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncentiveFromLessor_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease incentives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncentiveFromLessor_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incentive from Lessor</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issuance cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issuance Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol(s)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, issuance of shares upon conversion of securities, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares conversion of convertible securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares and warrants in private placement, net of issuance costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock And Warrant Issued During Period Shares Issued For Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock and warrant issued during period shares issued for private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MD_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maryland</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MD_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MARYLAND</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, exchange of preferred and common stock shares of IO biotech ApS into common stock of IO biotech, inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Exchange Of Preferred And Common Stock Of Io Biotech Aps Into Common Stock Of Io Biotech, Inc,</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity exchange of preferred and common stock of io biotech aps into common stock of io biotech, inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Liabilities Level1 To Level2 Transfers Amount1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level1 To Level2 Transfers Amount1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency and Currency Translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_NY_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NEW YORK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_NY_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New York, NY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock conversion basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Conversion Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options exercisable intrinsic value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued in Connection with Sale of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Policy .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Dividend Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expectation of Dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preference Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NonCashSettlementOfPreferenceShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash settlement of preference shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NonCashSettlementOfPreferenceShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Settlement of Preference Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NonCashSettlementOfPreferenceShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash portion of settlement of preference shares tranche obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquitySubscriptionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, subscription price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquitySubscriptionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Subscription Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquitySubscriptionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, subscription price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preference share per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liability - current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Inducement Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Inducement Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty three inducement incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock split, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueOfPreferenceSharesTrancheObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of preference shares tranche obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueOfPreferenceSharesTrancheObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Preference Shares Tranche Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueOfPreferenceSharesTrancheObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of preference shares tranche obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit at the statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual term (in years), Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets measured at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets measured at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfAggregateCashAndCashEquivalentsDeposited_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of aggregate cash and cash equivalents deposited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfAggregateCashAndCashEquivalentsDeposited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Aggregate Cash And Cash Equivalents Deposited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfAggregateCashAndCashEquivalentsDeposited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of total cash and cash equivalents in operating accounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preference shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion or settlement of preference shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Settlement of preference shares tranche obligation through issuance of preference shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options exercisable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Warrants, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Conversion Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, conversion basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedAndNonrelatedPartyStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Party Status [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of operating lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use lease asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityAdjustedFairValueOfTrancheObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary equity adjusted fair value of tranche obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityAdjustedFairValueOfTrancheObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity adjusted fair value of tranche obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ClassBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class B convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ClassBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ClassBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class B Convertible Preference Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A Ordinary Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers out of Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax benefits for stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value adjustments preference shares tranche obligations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustments Preference Shares Tranche Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fair value adjustments on preference shares tranche obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value adjustments preference shares tranche obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Warrants, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Warrants, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseAmendedBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease amended base rent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseAmendedBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Amended Base Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseAmendedBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease amended base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common shares and warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock And Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment to reconcile net loss to net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DeferredTaxAssetsRightOFuseLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets right of use lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DeferredTaxAssetsRightOFuseLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Right O fUse Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DeferredTaxAssetsRightOFuseLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ROU Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right of use lease asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right of Use Lease Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ROU Lease Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of preference shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross cash proceeds from issuance of convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Options Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting standards update [extensible enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfTotalCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of total cash and cash equivalents.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfTotalCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Total Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfTotalCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of total cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants available for future grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Term [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Sale of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 through 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period Twenty Twenty Through Twenty Twenty Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period twenty twenty through twenty twenty two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value of $0.001 per share; 300,000,000 shares authorized at December 31, 2023 and December 31, 2022; 65,880,914 and 28,815,267 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign currency gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Realized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid Expenses and Other Current Assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for deferred tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfVotePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of vote per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfVotePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Vote Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfVotePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of votes per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision or benefit for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preference Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total equity-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_EquitySecuritiesTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity securities term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_EquitySecuritiesTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_EquitySecuritiesTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity securities term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of cash, cash equivalents, and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesEquityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible notes equity value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesEquityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Equity Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesEquityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes equity value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value adjustments through statement of operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ContractualObligationsTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual obligations termination notice period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ContractualObligationsTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligations Termination Notice Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ContractualObligationsTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual obligations termination notice period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Basic [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Quantitative Information Regarding Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Minimum Rental Payments Under Noncancellable Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AccruedContractResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued contract research and development costs current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AccruedContractResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Contract Research And Development Costs Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AccruedContractResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued contract research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Regulatory Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of directors entitled to be elected by preference shareholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Directors Entitled to be Elected by Preference Shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of directors entitled to be elected by preference shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_UndesignatedPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undesignated Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_UndesignatedPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Undesignated Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_UndesignatedPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Undesignated preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferredClassCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred class c.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferredClassCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Class C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferredClassCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class C Preference Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credit receivable current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credit Receivable Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows paid for amounts included in the measurement of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares and warrants issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Common shares and warrants issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock And Warrant Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of stock and warrant issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open tax year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_RefundableTaxCreditReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Refundable tax credit receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_RefundableTaxCreditReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Refundable Tax Credit Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_RefundableTaxCreditReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Refundable tax credit receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DeferredTaxAssetsAccruedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DeferredTaxAssetsAccruedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Accrued Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DeferredTaxAssetsAccruedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets, Accrued Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_EmployeeEquityPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee equity plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_EmployeeEquityPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Equity Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_EmployeeEquityPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Equity Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset (liability)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency exchange gain, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Foreign Currency Transaction Gain (Loss), before Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Issuance of class C preference shares, net of issuance costs of $340 and adjusted for settlement of tranche obligation of $28,276 of which $25,908 is non-cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary equity, Issuance of class C preference shares, net of issuance costs of $340 and adjusted for fair value of tranche obligation of $25,908 at non-cash settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period value new issues and adjusted for fair value of tranche obligation of non cash settlement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior period adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, convertible preference shares and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Earnings Per Share Basic By Common Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedAndNonrelatedPartyStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Party Status [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesConversionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible notes conversion cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesConversionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Conversion Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesConversionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes conversion cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendDeclaredMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend Declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendDeclaredMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividend Declared [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Issuance of preference shares, net of issuance costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of warrants granted transferred to plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Warrants, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DeemedDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deemed dividend.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DeemedDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deemed Dividend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DeemedDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed dividend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of preferred and common stock of io biotech aps into common stock of io biotech, inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Of Preferred And Common Stock Of Io Biotech Aps Into Common Stock Of Io Biotech, Inc,</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange of preferred and common stock of io biotech aps into common stock of io biotech, inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible notes term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financial liabilities at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities fair value disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial Liabilities Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office furniture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease annual base rent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease annual base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease annual base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of preferred stock shares upon conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DK_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denmark</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DK_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DENMARK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of preference shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Comprehensive Income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_IncreaseDecreaseInLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_IncreaseDecreaseInLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) In Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_IncreaseDecreaseInLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost, recognition period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Collaboration Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation recurring basis liability currency exchange.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Currency Exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Currency exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Liabilities Level2 To Level1 Transfers Amount1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level2 To Level1 Transfers Amount1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preference shares, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business, Organization and Liquidity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers into Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AdjustmentsToAdditionalPaidInCapitalStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital stock issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AdjustmentsToAdditionalPaidInCapitalStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AdjustmentsToAdditionalPaidInCapitalStockIssued_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance of class B preference shares, net of issuance costs of $0</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfBoardDirectors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of board directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfBoardDirectors_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Board Directors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfBoardDirectors_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of directors on board</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of shares used in computing net loss per common share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Class B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class B Preference Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, issuance of shares upon conversion of securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period value conversion of convertible securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferenceStockMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preference stock measurement input.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferenceStockMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preference Stock Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferenceStockMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preference stock measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions for Estimated Fair Value of Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertiblePreferenceSharesPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preference Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertiblePreferenceSharesPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preference Shares Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertiblePreferenceSharesPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preference shares policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_GrantIncomeCostReimbursement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant income cost reimbursement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_GrantIncomeCostReimbursement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Income Cost Reimbursement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_GrantIncomeCostReimbursement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant Income Cost Reimbursement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding potentially dilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesRiskFreeRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible notes risk free rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesRiskFreeRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Risk Free Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesRiskFreeRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes risk free rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued in Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Warrants to Purchase Class A Ordinary Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual term (in years), Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Principal Components of Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity securities, measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of shares issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Equity-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Risk Free Interest Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Silicon Valley Bank.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Silicon Valley Bank</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ClassCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class C convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ClassCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class C Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ClassCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class C Convertible Preference Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Bankruptcy Proceedings, Reporting Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Bankruptcy Proceedings, Reporting Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of preferred and ordinary shares of IO Biotech ApS into common stock of IO Biotech, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Difference in tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FinancialAssetFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financial assets at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FinancialAssetFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets fair value disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FinancialAssetFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Asset Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FinancialAssetFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial asset fair value disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price per share, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquitySubscriptionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, subscription amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquitySubscriptionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Subscription Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquitySubscriptionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, subscription amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of each exchange on which registered</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique, Option Pricing Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Pricing Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Danish Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Standards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preference shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preference shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PurchasePricePerShareOfCommonStockAndWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per share of common stock and warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PurchasePricePerShareOfCommonStockAndWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Price Per Share of Common Stock and Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PurchasePricePerShareOfCommonStockAndWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase price per share of common stock and warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TrancheObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TrancheObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Obligation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TrancheObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assets Measured at Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities arising from obtaining right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsExercisablePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Price of Common Stock and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsExercisablePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercisable Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsExercisablePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercisable price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of convertible notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business, organization and liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business Organization And Liquidity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business Organization And Liquidity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business, organization and liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business Organization And Liquidity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business Organization And Liquidity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preference share issued upon conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of preferred and ordinary shares of IO Biotech ApS into common stock of IO Biotech, Inc. upon closing of initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits in U.S. provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity, fair value assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equity, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AccruedResearchAndDevelopmentCostsPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AccruedResearchAndDevelopmentCostsPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research and Development Costs Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AccruedResearchAndDevelopmentCostsPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AtTheMarketEquityProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Equity Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AtTheMarketEquityProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At-The-Market Equity Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AtTheMarketEquityProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market equity program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Uncertain Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of uncertain tax positions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CommonStockMaximumAggregateOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, maximum aggregate offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CommonStockMaximumAggregateOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Maximum Aggregate Offering Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CommonStockMaximumAggregateOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, maximum aggregate offering amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesVolatilityPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible notes volatility percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesVolatilityPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Volatility Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConvertibleNotesVolatilityPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes volatility percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-average exercise price per share, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-average exercise price per share, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets and valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NetProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Proceeds From Issuance Of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NetProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Issuance Of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NetProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds from issuance of private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value of $0.001 per share; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer hardware</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with initial public offering, net of issuance costs of $11,773, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock Shares in Connection with Initial Public Offering, Net of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock shares in connection with initial public offering, net of issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferenceStockMeasurementInputRemainingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preference stock measurement input remaining term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferenceStockMeasurementInputRemainingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preference Stock Measurement Input Remaining Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferenceStockMeasurementInputRemainingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Price Volatility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Stock Price Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PeriodExpireInTwentyTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period 2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PeriodExpireInTwentyTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period Expire In Twenty Twenty Six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PeriodExpireInTwentyTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period expire in twenty twenty six.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and Off-Balance Sheet Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Addition on issuance of class C preference shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Addition in cash on issuance of Class C preference shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares sold, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of each class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preference shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Value Added Tax Receivable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value-added tax refund receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease incremental borrowing rate on remaining lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease incremental borrowing rate on remaining lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Valuation allowance deferred tax asset change in amount due to tax cuts and jobs act of 2017.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount Due to Tax Cuts And Jobs Act Of 2017</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision increase deferred tax assets and valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with initial public offering, net of issuance costs of $11,773</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock in Connection with Initial Public Offering, Net of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in connection with initial public offering, net of issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_EmergingGrowthCompanyStatusPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_EmergingGrowthCompanyStatusPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_EmergingGrowthCompanyStatusPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price per share, Cancelled or forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OfficeAndLaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and Laboratory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OfficeAndLaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office and Laboratory [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OfficeAndLaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Laboratory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award equity instruments other than options exercisable in period weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Equity Instruments Other Than Options Exercisable In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price per share, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendPaidMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendPaidMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividend Paid [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of preferred and ordinary shares of IO Biotech ApS into common stock of IO Biotech, Inc., shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity adjusted for settlement of tranche obligation non cash portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Adjusted for Settlement of Tranche Obligation Non Cash Portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity adjusted for settlement of tranche obligation non cash portion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to class A ordinary shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfInterestOnSubscriptionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of interest on subscription price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfInterestOnSubscriptionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Interest On Subscription Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfInterestOnSubscriptionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of interest on subscription price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Warrants, Cancelled or forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Supplemental disclosures of non-cash financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of non-cash investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SharesIssuedFairValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued fair value per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SharesIssuedFairValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Fair Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SharesIssuedFairValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued fair value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Loss Before Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total other income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfSharesIssuedForAdjustedDownward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued for adjusted downward.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfSharesIssuedForAdjustedDownward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Issued For Adjusted Downward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfSharesIssuedForAdjustedDownward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued for adjusted downward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stockholders' deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferredClassBAndPreferredClassCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class B and Class C Preference Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferredClassBAndPreferredClassCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Class B And Preferred Class C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferredClassBAndPreferredClassCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred Class B and Preferred Class C.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents incorporated by reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from IPO, after deducting underwriting discounts, commissions and offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of preferred and common stock of io biotech aps into common stock of io biotech, inc, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Of Preferred And Common Stock Of Shares Io Biotech Aps Into Common Stock Of Io Biotech, Inc,</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">EExchange of preferred and common stock of shares io biotech aps into common stock of io biotech, inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of shares used in computing net loss per common share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of the Statutory Income Tax Rate to our Effective Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right of use lease asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_RefundableTaxCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Refundable tax credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_RefundableTaxCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Refundable Tax Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_RefundableTaxCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Refundable tax credit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation deductible expense research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Deductible Expense Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D Deduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Earnings Per Share, Basic and Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ManagementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Management</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ManagementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Management [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of shares that may be issued under the plan as a proportion of outstanding capital stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents, and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement" xlink:to="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_LaboratoryMember" xlink:to="iobt_LaboratoryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ConvertibleNotesMember" xlink:to="iobt_ConvertibleNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_OperatingLeaseRemainingLeaseTerm" xlink:to="iobt_OperatingLeaseRemainingLeaseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligation" xlink:to="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDividendsAdjustment" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc" xlink:to="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember" xlink:to="iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" xlink:to="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PreferenceSharesTrancheObligationsMember" xlink:to="iobt_PreferenceSharesTrancheObligationsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent" xlink:to="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncentiveFromLessor" xlink:to="us-gaap_IncentiveFromLessor_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TemporaryEquityStockIssuanceCost" xlink:to="iobt_TemporaryEquityStockIssuanceCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="iobt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" xlink:to="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MD" xlink:to="stpr_MD_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc" xlink:to="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_SalesAgreementMember" xlink:to="iobt_SalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" xlink:to="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NY" xlink:to="stpr_NY_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConversionBasis" xlink:to="us-gaap_CommonStockConversionBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_WarrantsPolicyPolicyTextBlock" xlink:to="iobt_WarrantsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TemporaryEquityDisclosureTextBlock" xlink:to="iobt_TemporaryEquityDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_NonCashSettlementOfPreferenceShares" xlink:to="iobt_NonCashSettlementOfPreferenceShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TemporaryEquitySubscriptionPricePerShare" xlink:to="iobt_TemporaryEquitySubscriptionPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember" xlink:to="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:to="iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_FairValueOfPreferenceSharesTrancheObligation" xlink:to="iobt_FairValueOfPreferenceSharesTrancheObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PercentageOfAggregateCashAndCashEquivalentsDeposited" xlink:to="iobt_PercentageOfAggregateCashAndCashEquivalentsDeposited_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionBasis" xlink:to="us-gaap_PreferredStockConversionBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:to="us-gaap_RelatedAndNonrelatedPartyStatusAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_NumberOfOperatingLease" xlink:to="iobt_NumberOfOperatingLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TemporaryEquityAdjustedFairValueOfTrancheObligation" xlink:to="iobt_TemporaryEquityAdjustedFairValueOfTrancheObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ClassBConvertiblePreferredStockMember" xlink:to="iobt_ClassBConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations" xlink:to="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_OperatingLeaseAmendedBaseRent" xlink:to="iobt_OperatingLeaseAmendedBaseRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="iobt_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_DeferredTaxAssetsRightOFuseLeaseLiability" xlink:to="iobt_DeferredTaxAssetsRightOFuseLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset" xlink:to="iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PercentageOfTotalCashAndCashEquivalents" xlink:to="iobt_PercentageOfTotalCashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember" xlink:to="iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TemporaryEquityStockIssuanceCosts" xlink:to="iobt_TemporaryEquityStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_NumberOfVotePerShare" xlink:to="iobt_NumberOfVotePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_EquitySecuritiesTerm" xlink:to="iobt_EquitySecuritiesTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ConvertibleNotesEquityValue" xlink:to="iobt_ConvertibleNotesEquityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:to="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ContractualObligationsTerminationNoticePeriod" xlink:to="iobt_ContractualObligationsTerminationNoticePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_AccruedContractResearchAndDevelopmentCostsCurrent" xlink:to="iobt_AccruedContractResearchAndDevelopmentCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:to="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders" xlink:to="iobt_NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_SecuritiesPurchaseAgreementMember" xlink:to="iobt_SecuritiesPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_UndesignatedPreferredStockMember" xlink:to="iobt_UndesignatedPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PreferredClassCMember" xlink:to="iobt_PreferredClassCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:to="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PaymentsOfStockAndWarrantIssuanceCosts" xlink:to="iobt_PaymentsOfStockAndWarrantIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_RefundableTaxCreditReceivable" xlink:to="iobt_RefundableTaxCreditReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_DeferredTaxAssetsAccruedCompensation" xlink:to="iobt_DeferredTaxAssetsAccruedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_EmployeeEquityPlanMember" xlink:to="iobt_EmployeeEquityPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement" xlink:to="iobt_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:to="us-gaap_RelatedAndNonrelatedPartyStatusDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ConvertibleNotesConversionCost" xlink:to="iobt_ConvertibleNotesConversionCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendDeclaredMember" xlink:to="us-gaap_DividendDeclaredMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_DeemedDividend" xlink:to="iobt_DeemedDividend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc" xlink:to="iobt_ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ConvertibleNotesTerm" xlink:to="iobt_ConvertibleNotesTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_OperatingLeaseAnnualBaseRent" xlink:to="iobt_OperatingLeaseAnnualBaseRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_LaboratoryEquipmentMember" xlink:to="iobt_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DK" xlink:to="country_DK_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_IncreaseDecreaseInLeaseLiability" xlink:to="iobt_IncreaseDecreaseInLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange" xlink:to="iobt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" xlink:to="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_AdjustmentsToAdditionalPaidInCapitalStockIssued" xlink:to="iobt_AdjustmentsToAdditionalPaidInCapitalStockIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_NumberOfBoardDirectors" xlink:to="iobt_NumberOfBoardDirectors_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassBMember" xlink:to="us-gaap_PreferredClassBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="iobt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PreferenceStockMeasurementInput" xlink:to="iobt_PreferenceStockMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ConvertiblePreferenceSharesPoliciesTextBlock" xlink:to="iobt_ConvertiblePreferenceSharesPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_GrantIncomeCostReimbursement" xlink:to="iobt_GrantIncomeCostReimbursement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ConvertibleNotesRiskFreeRate" xlink:to="iobt_ConvertibleNotesRiskFreeRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_FairValueOfSharesIssued" xlink:to="iobt_FairValueOfSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_SiliconValleyBankMember" xlink:to="iobt_SiliconValleyBankMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ClassCConvertiblePreferredStockMember" xlink:to="iobt_ClassCConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsDomain" xlink:to="us-gaap_DividendsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_FinancialAssetFairValueDisclosure" xlink:to="iobt_FinancialAssetFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TemporaryEquitySubscriptionAmount" xlink:to="iobt_TemporaryEquitySubscriptionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PurchasePricePerShareOfCommonStockAndWarrant" xlink:to="iobt_PurchasePricePerShareOfCommonStockAndWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TrancheObligationMember" xlink:to="iobt_TrancheObligationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_WarrantsExercisablePricePerShare" xlink:to="iobt_WarrantsExercisablePricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="us-gaap_EquityFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_AccruedResearchAndDevelopmentCostsPoliciesTextBlock" xlink:to="iobt_AccruedResearchAndDevelopmentCostsPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_AtTheMarketEquityProgramMember" xlink:to="iobt_AtTheMarketEquityProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PercentageOfUncertainTaxPositions" xlink:to="iobt_PercentageOfUncertainTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_CommonStockMaximumAggregateOfferingAmount" xlink:to="iobt_CommonStockMaximumAggregateOfferingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ConvertibleNotesVolatilityPercentage" xlink:to="iobt_ConvertibleNotesVolatilityPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_NetProceedsFromIssuanceOfPrivatePlacement" xlink:to="iobt_NetProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_WarrantsIssued" xlink:to="iobt_WarrantsIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts" xlink:to="iobt_IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PreferenceStockMeasurementInputRemainingTerm" xlink:to="iobt_PreferenceStockMeasurementInputRemainingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PeriodExpireInTwentyTwentySixMember" xlink:to="iobt_PeriodExpireInTwentyTwentySixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:to="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease" xlink:to="iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017" xlink:to="iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts" xlink:to="iobt_IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_EmergingGrowthCompanyStatusPoliciesTextBlock" xlink:to="iobt_EmergingGrowthCompanyStatusPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_OfficeAndLaboratoryMember" xlink:to="iobt_OfficeAndLaboratoryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" xlink:to="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendPaidMember" xlink:to="us-gaap_DividendPaidMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion" xlink:to="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PercentageOfInterestOnSubscriptionPrice" xlink:to="iobt_PercentageOfInterestOnSubscriptionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_SharesIssuedFairValuePerShare" xlink:to="iobt_SharesIssuedFairValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_NumberOfSharesIssuedForAdjustedDownward" xlink:to="iobt_NumberOfSharesIssuedForAdjustedDownward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PreferredClassBAndPreferredClassCMember" xlink:to="iobt_PreferredClassBAndPreferredClassCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_OfficeMember" xlink:to="iobt_OfficeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc" xlink:to="iobt_ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_RefundableTaxCredit" xlink:to="iobt_RefundableTaxCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment" xlink:to="iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ManagementMember" xlink:to="srt_ManagementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassBConvertiblePreferredStockMember" xlink:label="iobt_ClassBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_ClassBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations" xlink:label="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassBConvertiblePreferredStockMember" xlink:label="iobt_ClassBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassCConvertiblePreferredStockMember" xlink:label="iobt_ClassCConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc" xlink:label="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc" xlink:label="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc" xlink:label="iobt_ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc" xlink:label="iobt_ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts" xlink:label="iobt_IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts" xlink:label="iobt_IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_AdjustmentsToAdditionalPaidInCapitalStockIssued" xlink:label="iobt_AdjustmentsToAdditionalPaidInCapitalStockIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_26"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_27"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_28"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_29"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_ClassBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_ClassCConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_AdjustmentsToAdditionalPaidInCapitalStockIssued" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_28" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_29" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassBConvertiblePreferredStockMember" xlink:label="iobt_ClassBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PaymentsOfStockAndWarrantIssuanceCosts" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassCConvertiblePreferredStockMember" xlink:label="iobt_ClassCConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuanceCosts" xlink:label="iobt_TemporaryEquityStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuanceCost" xlink:label="iobt_TemporaryEquityStockIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityAdjustedFairValueOfTrancheObligation" xlink:label="iobt_TemporaryEquityAdjustedFairValueOfTrancheObligation"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligation" xlink:label="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligation"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion" xlink:label="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_ClassBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_PaymentsOfStockAndWarrantIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_ClassCConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityStockIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityStockIssuanceCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityAdjustedFairValueOfTrancheObligation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="iobt_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NonCashSettlementOfPreferenceShares" xlink:label="iobt_NonCashSettlementOfPreferenceShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations" xlink:label="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PaymentsOfStockAndWarrantIssuanceCosts" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_IncreaseDecreaseInLeaseLiability" xlink:label="iobt_IncreaseDecreaseInLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="iobt_ProceedsFromIssuanceOfCommonStockAndWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="iobt_NonCashSettlementOfPreferenceShares" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="iobt_PaymentsOfStockAndWarrantIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="iobt_IncreaseDecreaseInLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceShares" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityDisclosureTextBlock" xlink:label="iobt_TemporaryEquityDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="iobt_TemporaryEquityDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_AccruedResearchAndDevelopmentCostsPoliciesTextBlock" xlink:label="iobt_AccruedResearchAndDevelopmentCostsPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertiblePreferenceSharesPoliciesTextBlock" xlink:label="iobt_ConvertiblePreferenceSharesPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_WarrantsPolicyPolicyTextBlock" xlink:label="iobt_WarrantsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_EmergingGrowthCompanyStatusPoliciesTextBlock" xlink:label="iobt_EmergingGrowthCompanyStatusPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iobt_AccruedResearchAndDevelopmentCostsPoliciesTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iobt_ConvertiblePreferenceSharesPoliciesTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iobt_WarrantsPolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iobt_EmergingGrowthCompanyStatusPoliciesTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTable" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_SalesAgreementMember" xlink:label="iobt_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_CommonStockMaximumAggregateOfferingAmount" xlink:label="iobt_CommonStockMaximumAggregateOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferredClassCMember" xlink:label="iobt_PreferredClassCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PurchasePricePerShareOfCommonStockAndWarrant" xlink:label="iobt_PurchasePricePerShareOfCommonStockAndWarrant"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_UndesignatedPreferredStockMember" xlink:label="iobt_UndesignatedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_AtTheMarketEquityProgramMember" xlink:label="iobt_AtTheMarketEquityProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_WarrantsIssued" xlink:label="iobt_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="iobt_SalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_CommonStockMaximumAggregateOfferingAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_PreferredClassCMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_PurchasePricePerShareOfCommonStockAndWarrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_UndesignatedPreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iobt_AtTheMarketEquityProgramMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_WarrantsIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockConversionBasis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_SharePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_LaboratoryEquipmentMember" xlink:label="iobt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_GrantIncomeCostReimbursement" xlink:label="iobt_GrantIncomeCostReimbursement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_RefundableTaxCredit" xlink:label="iobt_RefundableTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_RefundableTaxCreditReceivable" xlink:label="iobt_RefundableTaxCreditReceivable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease" xlink:label="iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncentiveFromLessor" xlink:label="us-gaap_IncentiveFromLessor"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_LaboratoryEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="iobt_GrantIncomeCostReimbursement" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="iobt_RefundableTaxCredit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="iobt_RefundableTaxCreditReceivable" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DeferredRentCreditCurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_IncentiveFromLessor" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassBConvertiblePreferredStockMember" xlink:label="iobt_ClassBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferenceSharesTrancheObligationsMember" xlink:label="iobt_PreferenceSharesTrancheObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassCConvertiblePreferredStockMember" xlink:label="iobt_ClassCConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange" xlink:label="iobt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_ClassBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="iobt_PreferenceSharesTrancheObligationsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_ClassCConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="iobt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesMember" xlink:label="iobt_ConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassCConvertiblePreferredStockMember" xlink:label="iobt_ClassCConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FinancialAssetFairValueDisclosure" xlink:label="iobt_FinancialAssetFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferenceStockMeasurementInput" xlink:label="iobt_PreferenceStockMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferenceStockMeasurementInputRemainingTerm" xlink:label="iobt_PreferenceStockMeasurementInputRemainingTerm"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" xlink:label="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" xlink:label="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_ConvertibleNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_ClassCConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_FinancialAssetFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_PreferenceStockMeasurementInput" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_PreferenceStockMeasurementInputRemainingTerm" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:label="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PrepaidContractResearchAndDevelopmentCostsCurrent" xlink:label="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_LaboratoryEquipmentMember" xlink:label="iobt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_AccruedContractResearchAndDevelopmentCostsCurrent" xlink:label="iobt_AccruedContractResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="iobt_AccruedContractResearchAndDevelopmentCostsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DK" xlink:label="country_DK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OfficeAndLaboratoryMember" xlink:label="iobt_OfficeAndLaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_NY" xlink:label="stpr_NY"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OfficeMember" xlink:label="iobt_OfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MD" xlink:label="stpr_MD"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfOperatingLease" xlink:label="iobt_NumberOfOperatingLease"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_LaboratoryMember" xlink:label="iobt_LaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OperatingLeaseAnnualBaseRent" xlink:label="iobt_OperatingLeaseAnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OperatingLeaseAmendedBaseRent" xlink:label="iobt_OperatingLeaseAmendedBaseRent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DK" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_OfficeAndLaboratoryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NY" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_OfficeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MD" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_NumberOfOperatingLease" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_LaboratoryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_DeferredRentCredit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_OperatingLeaseAnnualBaseRent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_OperatingLeaseAmendedBaseRent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OperatingLeaseRemainingLeaseTerm" xlink:label="iobt_OperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_OperatingLeaseRemainingLeaseTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ContractualObligationsTerminationNoticePeriod" xlink:label="iobt_ContractualObligationsTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iobt_ContractualObligationsTerminationNoticePeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TrancheObligationMember" xlink:label="iobt_TrancheObligationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferredClassCMember" xlink:label="iobt_PreferredClassCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferredClassBAndPreferredClassCMember" xlink:label="iobt_PreferredClassBAndPreferredClassCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueOfSharesIssued" xlink:label="iobt_FairValueOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_SharesIssuedFairValuePerShare" xlink:label="iobt_SharesIssuedFairValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesEquityValue" xlink:label="iobt_ConvertibleNotesEquityValue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesTerm" xlink:label="iobt_ConvertibleNotesTerm"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesVolatilityPercentage" xlink:label="iobt_ConvertibleNotesVolatilityPercentage"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesRiskFreeRate" xlink:label="iobt_ConvertibleNotesRiskFreeRate"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesConversionCost" xlink:label="iobt_ConvertibleNotesConversionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquitySubscriptionPricePerShare" xlink:label="iobt_TemporaryEquitySubscriptionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DeemedDividend" xlink:label="iobt_DeemedDividend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_EquitySecuritiesTerm" xlink:label="iobt_EquitySecuritiesTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuanceCosts" xlink:label="iobt_TemporaryEquityStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquitySubscriptionAmount" xlink:label="iobt_TemporaryEquitySubscriptionAmount"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueOfPreferenceSharesTrancheObligation" xlink:label="iobt_FairValueOfPreferenceSharesTrancheObligation"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfSharesIssuedForAdjustedDownward" xlink:label="iobt_NumberOfSharesIssuedForAdjustedDownward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PercentageOfInterestOnSubscriptionPrice" xlink:label="iobt_PercentageOfInterestOnSubscriptionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfVotePerShare" xlink:label="iobt_NumberOfVotePerShare"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfBoardDirectors" xlink:label="iobt_NumberOfBoardDirectors"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders" xlink:label="iobt_NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="iobt_TrancheObligationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_PreferredClassCMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_PreferredClassBAndPreferredClassCMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_FairValueOfSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_SharesIssuedFairValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_ConvertibleNotesEquityValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_ConvertibleNotesTerm" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_ConvertibleNotesVolatilityPercentage" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_ConvertibleNotesRiskFreeRate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_ConvertibleNotesConversionCost" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_TemporaryEquitySubscriptionPricePerShare" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_DeemedDividend" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_EquitySecuritiesTerm" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_TemporaryEquityStockIssuanceCosts" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_TemporaryEquitySubscriptionAmount" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_FairValueOfPreferenceSharesTrancheObligation" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_NumberOfSharesIssuedForAdjustedDownward" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_PercentageOfInterestOnSubscriptionPrice" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_NumberOfVotePerShare" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_NumberOfBoardDirectors" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_SecuritiesPurchaseAgreementMember" xlink:label="iobt_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_UndesignatedPreferredStockMember" xlink:label="iobt_UndesignatedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:label="us-gaap_RelatedAndNonrelatedPartyStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:label="us-gaap_RelatedAndNonrelatedPartyStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendDeclaredMember" xlink:label="us-gaap_DividendDeclaredMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendPaidMember" xlink:label="us-gaap_DividendPaidMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfVotePerShare" xlink:label="iobt_NumberOfVotePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_WarrantsIssued" xlink:label="iobt_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PurchasePricePerShareOfCommonStockAndWarrant" xlink:label="iobt_PurchasePricePerShareOfCommonStockAndWarrant"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_WarrantsExercisablePricePerShare" xlink:label="iobt_WarrantsExercisablePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NetProceedsFromIssuanceOfPrivatePlacement" xlink:label="iobt_NetProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="iobt_SecuritiesPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ManagementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_UndesignatedPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_DividendsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:to="us-gaap_RelatedAndNonrelatedPartyStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsDomain" xlink:to="us-gaap_DividendDeclaredMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsDomain" xlink:to="us-gaap_DividendPaidMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_NumberOfVotePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_RelatedAndNonrelatedPartyStatusAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_Dividends" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_TitleOfIndividualAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_WarrantsIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_PurchasePricePerShareOfCommonStockAndWarrant" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_WarrantsExercisablePricePerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_NetProceedsFromIssuanceOfPrivatePlacement" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_EmployeeEquityPlanMember" xlink:label="iobt_EmployeeEquityPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TwoThousandTwentyThreeInducementIncentivePlanMember" xlink:label="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="iobt_EmployeeEquityPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" xlink:label="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017" xlink:label="iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember" xlink:label="iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember" xlink:label="iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PeriodExpireInTwentyTwentySixMember" xlink:label="iobt_PeriodExpireInTwentyTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PercentageOfUncertainTaxPositions" xlink:label="iobt_PercentageOfUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_RefundableTaxCredit" xlink:label="iobt_RefundableTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_RefundableTaxCreditReceivable" xlink:label="iobt_RefundableTaxCreditReceivable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="iobt_PeriodExpireInTwentyTwentySixMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="iobt_PercentageOfUncertainTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OpenTaxYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="iobt_RefundableTaxCredit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="iobt_RefundableTaxCreditReceivable" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment" xlink:label="iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:label="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset" xlink:label="iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DeferredTaxAssetsAccruedCompensation" xlink:label="iobt_DeferredTaxAssetsAccruedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DeferredTaxAssetsRightOFuseLeaseLiability" xlink:label="iobt_DeferredTaxAssetsRightOFuseLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:to="iobt_DeferredTaxAssetsAccruedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:to="iobt_DeferredTaxAssetsRightOFuseLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PercentageOfTotalCashAndCashEquivalents" xlink:label="iobt_PercentageOfTotalCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_SiliconValleyBankMember" xlink:label="iobt_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PercentageOfAggregateCashAndCashEquivalentsDeposited" xlink:label="iobt_PercentageOfAggregateCashAndCashEquivalentsDeposited"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="iobt_PercentageOfTotalCashAndCashEquivalents" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="iobt_SiliconValleyBankMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="iobt_PercentageOfAggregateCashAndCashEquivalentsDeposited" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassBConvertiblePreferredStockMember" xlink:label="iobt_ClassBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_ClassBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassBConvertiblePreferredStockMember" xlink:label="iobt_ClassBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassCConvertiblePreferredStockMember" xlink:label="iobt_ClassCConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="iobt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc" xlink:label="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc" xlink:label="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc" xlink:label="iobt_ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc" xlink:label="iobt_ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts" xlink:label="iobt_IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts" xlink:label="iobt_IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_AdjustmentsToAdditionalPaidInCapitalStockIssued" xlink:label="iobt_AdjustmentsToAdditionalPaidInCapitalStockIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_ClassBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_ClassCConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_AdjustmentsToAdditionalPaidInCapitalStockIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassBConvertiblePreferredStockMember" xlink:label="iobt_ClassBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PaymentsOfStockAndWarrantIssuanceCosts" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassCConvertiblePreferredStockMember" xlink:label="iobt_ClassCConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuanceCosts" xlink:label="iobt_TemporaryEquityStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuanceCost" xlink:label="iobt_TemporaryEquityStockIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityAdjustedFairValueOfTrancheObligation" xlink:label="iobt_TemporaryEquityAdjustedFairValueOfTrancheObligation"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligation" xlink:label="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligation"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion" xlink:label="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_ClassBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_PaymentsOfStockAndWarrantIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_ClassCConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityStockIssuanceCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityAdjustedFairValueOfTrancheObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="iobt_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NonCashSettlementOfPreferenceShares" xlink:label="iobt_NonCashSettlementOfPreferenceShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations" xlink:label="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PaymentsOfStockAndWarrantIssuanceCosts" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_IncreaseDecreaseInLeaseLiability" xlink:label="iobt_IncreaseDecreaseInLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="iobt_ProceedsFromIssuanceOfCommonStockAndWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="iobt_NonCashSettlementOfPreferenceShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="iobt_PaymentsOfStockAndWarrantIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="iobt_IncreaseDecreaseInLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_SalesAgreementMember" xlink:label="iobt_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_CommonStockMaximumAggregateOfferingAmount" xlink:label="iobt_CommonStockMaximumAggregateOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferredClassCMember" xlink:label="iobt_PreferredClassCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PurchasePricePerShareOfCommonStockAndWarrant" xlink:label="iobt_PurchasePricePerShareOfCommonStockAndWarrant"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_UndesignatedPreferredStockMember" xlink:label="iobt_UndesignatedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_AtTheMarketEquityProgramMember" xlink:label="iobt_AtTheMarketEquityProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_WarrantsIssued" xlink:label="iobt_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="iobt_SalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_CommonStockMaximumAggregateOfferingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_PreferredClassCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_PurchasePricePerShareOfCommonStockAndWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_UndesignatedPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iobt_AtTheMarketEquityProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_WarrantsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockConversionBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_LaboratoryEquipmentMember" xlink:label="iobt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_GrantIncomeCostReimbursement" xlink:label="iobt_GrantIncomeCostReimbursement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_RefundableTaxCredit" xlink:label="iobt_RefundableTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_RefundableTaxCreditReceivable" xlink:label="iobt_RefundableTaxCreditReceivable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease" xlink:label="iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncentiveFromLessor" xlink:label="us-gaap_IncentiveFromLessor"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="iobt_GrantIncomeCostReimbursement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="iobt_RefundableTaxCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="iobt_RefundableTaxCreditReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DeferredRentCreditCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_IncentiveFromLessor" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassBConvertiblePreferredStockMember" xlink:label="iobt_ClassBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferenceSharesTrancheObligationsMember" xlink:label="iobt_PreferenceSharesTrancheObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassCConvertiblePreferredStockMember" xlink:label="iobt_ClassCConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange" xlink:label="iobt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_ClassBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="iobt_PreferenceSharesTrancheObligationsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_ClassCConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="iobt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesMember" xlink:label="iobt_ConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ClassCConvertiblePreferredStockMember" xlink:label="iobt_ClassCConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FinancialAssetFairValueDisclosure" xlink:label="iobt_FinancialAssetFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferenceStockMeasurementInput" xlink:label="iobt_PreferenceStockMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferenceStockMeasurementInputRemainingTerm" xlink:label="iobt_PreferenceStockMeasurementInputRemainingTerm"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" xlink:label="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" xlink:label="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_ConvertibleNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_ClassCConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_FinancialAssetFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_PreferenceStockMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_PreferenceStockMeasurementInputRemainingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_LaboratoryEquipmentMember" xlink:label="iobt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DK" xlink:label="country_DK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OfficeAndLaboratoryMember" xlink:label="iobt_OfficeAndLaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_NY" xlink:label="stpr_NY"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OfficeMember" xlink:label="iobt_OfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MD" xlink:label="stpr_MD"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfOperatingLease" xlink:label="iobt_NumberOfOperatingLease"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_LaboratoryMember" xlink:label="iobt_LaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OperatingLeaseAnnualBaseRent" xlink:label="iobt_OperatingLeaseAnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OperatingLeaseAmendedBaseRent" xlink:label="iobt_OperatingLeaseAmendedBaseRent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DK" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_OfficeAndLaboratoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NY" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_OfficeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MD" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_NumberOfOperatingLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_LaboratoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_DeferredRentCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_OperatingLeaseAnnualBaseRent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_OperatingLeaseAmendedBaseRent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_OperatingLeaseRemainingLeaseTerm" xlink:label="iobt_OperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_OperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ContractualObligationsTerminationNoticePeriod" xlink:label="iobt_ContractualObligationsTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iobt_ContractualObligationsTerminationNoticePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TrancheObligationMember" xlink:label="iobt_TrancheObligationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferredClassCMember" xlink:label="iobt_PreferredClassCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PreferredClassBAndPreferredClassCMember" xlink:label="iobt_PreferredClassBAndPreferredClassCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueOfSharesIssued" xlink:label="iobt_FairValueOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_SharesIssuedFairValuePerShare" xlink:label="iobt_SharesIssuedFairValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesEquityValue" xlink:label="iobt_ConvertibleNotesEquityValue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesTerm" xlink:label="iobt_ConvertibleNotesTerm"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesVolatilityPercentage" xlink:label="iobt_ConvertibleNotesVolatilityPercentage"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesRiskFreeRate" xlink:label="iobt_ConvertibleNotesRiskFreeRate"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ConvertibleNotesConversionCost" xlink:label="iobt_ConvertibleNotesConversionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquitySubscriptionPricePerShare" xlink:label="iobt_TemporaryEquitySubscriptionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DeemedDividend" xlink:label="iobt_DeemedDividend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_EquitySecuritiesTerm" xlink:label="iobt_EquitySecuritiesTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquityStockIssuanceCosts" xlink:label="iobt_TemporaryEquityStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TemporaryEquitySubscriptionAmount" xlink:label="iobt_TemporaryEquitySubscriptionAmount"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueOfPreferenceSharesTrancheObligation" xlink:label="iobt_FairValueOfPreferenceSharesTrancheObligation"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfSharesIssuedForAdjustedDownward" xlink:label="iobt_NumberOfSharesIssuedForAdjustedDownward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PercentageOfInterestOnSubscriptionPrice" xlink:label="iobt_PercentageOfInterestOnSubscriptionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfVotePerShare" xlink:label="iobt_NumberOfVotePerShare"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfBoardDirectors" xlink:label="iobt_NumberOfBoardDirectors"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders" xlink:label="iobt_NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="iobt_TrancheObligationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ValuationTechniqueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_PreferredClassCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_PreferredClassBAndPreferredClassCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_FairValueOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_SharesIssuedFairValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_ConvertibleNotesEquityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_ConvertibleNotesTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_ConvertibleNotesVolatilityPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_ConvertibleNotesRiskFreeRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_ConvertibleNotesConversionCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_TemporaryEquitySubscriptionPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_DeemedDividend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_EquitySecuritiesTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_TemporaryEquityStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_TemporaryEquitySubscriptionAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_FairValueOfPreferenceSharesTrancheObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_NumberOfSharesIssuedForAdjustedDownward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_PercentageOfInterestOnSubscriptionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_NumberOfVotePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_NumberOfBoardDirectors" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iobt_NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_SecuritiesPurchaseAgreementMember" xlink:label="iobt_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_UndesignatedPreferredStockMember" xlink:label="iobt_UndesignatedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:label="us-gaap_RelatedAndNonrelatedPartyStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:label="us-gaap_RelatedAndNonrelatedPartyStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:label="us-gaap_RelatedAndNonrelatedPartyStatusDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendDeclaredMember" xlink:label="us-gaap_DividendDeclaredMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendPaidMember" xlink:label="us-gaap_DividendPaidMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NumberOfVotePerShare" xlink:label="iobt_NumberOfVotePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_WarrantsIssued" xlink:label="iobt_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PurchasePricePerShareOfCommonStockAndWarrant" xlink:label="iobt_PurchasePricePerShareOfCommonStockAndWarrant"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_WarrantsExercisablePricePerShare" xlink:label="iobt_WarrantsExercisablePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_NetProceedsFromIssuanceOfPrivatePlacement" xlink:label="iobt_NetProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="iobt_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ManagementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_UndesignatedPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_DividendsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:to="us-gaap_RelatedAndNonrelatedPartyStatusDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:to="us-gaap_RelatedAndNonrelatedPartyStatusDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DividendsDomain" xlink:to="us-gaap_DividendDeclaredMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DividendsDomain" xlink:to="us-gaap_DividendPaidMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_NumberOfVotePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_RelatedAndNonrelatedPartyStatusAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_Dividends" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_WarrantsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_PurchasePricePerShareOfCommonStockAndWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_WarrantsExercisablePricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_NetProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_EmployeeEquityPlanMember" xlink:label="iobt_EmployeeEquityPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_TwoThousandTwentyThreeInducementIncentivePlanMember" xlink:label="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iobt_EmployeeEquityPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" xlink:label="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017" xlink:label="iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember" xlink:label="iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember" xlink:label="iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PeriodExpireInTwentyTwentySixMember" xlink:label="iobt_PeriodExpireInTwentyTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PercentageOfUncertainTaxPositions" xlink:label="iobt_PercentageOfUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_RefundableTaxCredit" xlink:label="iobt_RefundableTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_RefundableTaxCreditReceivable" xlink:label="iobt_RefundableTaxCreditReceivable"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="iobt_PeriodExpireInTwentyTwentySixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="iobt_PercentageOfUncertainTaxPositions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="iobt_RefundableTaxCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="iobt_RefundableTaxCreditReceivable" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PercentageOfTotalCashAndCashEquivalents" xlink:label="iobt_PercentageOfTotalCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_SiliconValleyBankMember" xlink:label="iobt_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PercentageOfAggregateCashAndCashEquivalentsDeposited" xlink:label="iobt_PercentageOfAggregateCashAndCashEquivalentsDeposited"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="iobt_PercentageOfTotalCashAndCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="iobt_SiliconValleyBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="iobt_PercentageOfAggregateCashAndCashEquivalentsDeposited" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment" xlink:label="iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations" order="3" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations" xlink:label="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="iobt_ProceedsFromIssuanceOfCommonStockAndWarrants" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_RestrictedCash" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="iobt_PaymentsOfStockAndWarrantIssuanceCosts" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="iobt_IncreaseDecreaseInLeaseLiability" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="13" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="iobt_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PaymentsOfStockAndWarrantIssuanceCosts" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations" xlink:label="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_IncreaseDecreaseInLeaseLiability" xlink:label="iobt_IncreaseDecreaseInLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"/>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_PrepaidContractResearchAndDevelopmentCostsCurrent" xlink:label="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:label="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="iobt_AccruedContractResearchAndDevelopmentCostsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_AccruedContractResearchAndDevelopmentCostsCurrent" xlink:label="iobt_AccruedContractResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="iobt_DeferredTaxAssetsRightOFuseLeaseLiability" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="iobt_DeferredTaxAssetsAccruedCompensation" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset" xlink:label="iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DeferredTaxAssetsRightOFuseLeaseLiability" xlink:label="iobt_DeferredTaxAssetsRightOFuseLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20231231.xsd#iobt_DeferredTaxAssetsAccruedCompensation" xlink:label="iobt_DeferredTaxAssetsAccruedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20231231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017" name="ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_ConvertibleNotesTerm" name="ConvertibleNotesTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc" name="ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_AdjustmentsToAdditionalPaidInCapitalStockIssued" name="AdjustmentsToAdditionalPaidInCapitalStockIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_EmergingGrowthCompanyStatusPoliciesTextBlock" name="EmergingGrowthCompanyStatusPoliciesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders" name="NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_OperatingLeaseAmendedBaseRent" name="OperatingLeaseAmendedBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_EquitySecuritiesTerm" name="EquitySecuritiesTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_NumberOfOperatingLease" name="NumberOfOperatingLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_CommonStockMaximumAggregateOfferingAmount" name="CommonStockMaximumAggregateOfferingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_SharesIssuedFairValuePerShare" name="SharesIssuedFairValuePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="iobt_RefundableTaxCreditReceivable" name="RefundableTaxCreditReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_PreferenceStockMeasurementInputRemainingTerm" name="PreferenceStockMeasurementInputRemainingTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_WarrantsPolicyPolicyTextBlock" name="WarrantsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_PaymentsOfStockAndWarrantIssuanceCosts" name="PaymentsOfStockAndWarrantIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_ConvertibleNotesRiskFreeRate" name="ConvertibleNotesRiskFreeRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" name="StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc" name="TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_PreferredClassBAndPreferredClassCMember" name="PreferredClassBAndPreferredClassCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember" name="PeriodTwentyTwentyThroughTwentyTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_PreferredClassCMember" name="PreferredClassCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease" name="OperatingLeaseIncrementalBorrowingRateOnRemainingLease" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_FairValueOfPreferenceSharesTrancheObligation" name="FairValueOfPreferenceSharesTrancheObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_PercentageOfUncertainTaxPositions" name="PercentageOfUncertainTaxPositions" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_ClassBConvertiblePreferredStockMember" name="ClassBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_ClassCConvertiblePreferredStockMember" name="ClassCConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_PercentageOfInterestOnSubscriptionPrice" name="PercentageOfInterestOnSubscriptionPrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_NonCashSettlementOfPreferenceShares" name="NonCashSettlementOfPreferenceShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" name="TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset" name="DeferredTaxLiabilitiesRightOfUseLeaseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_ConvertiblePreferenceSharesPoliciesTextBlock" name="ConvertiblePreferenceSharesPoliciesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember" name="TwoThousandAndTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" name="DescriptionOfBusinessOrganizationAndLiquidityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_ConvertibleNotesConversionCost" name="ConvertibleNotesConversionCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_ProceedsFromIssuanceOfCommonStockAndWarrants" name="ProceedsFromIssuanceOfCommonStockAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_AccruedContractResearchAndDevelopmentCostsCurrent" name="AccruedContractResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_TemporaryEquitySubscriptionAmount" name="TemporaryEquitySubscriptionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="iobt_TrancheObligationMember" name="TrancheObligationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_TemporaryEquityDisclosureTextBlock" name="TemporaryEquityDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement" name="TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_EmployeeEquityPlanMember" name="EmployeeEquityPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_ConvertibleNotesMember" name="ConvertibleNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_GrantIncomeCostReimbursement" name="GrantIncomeCostReimbursement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts" name="IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_TemporaryEquityStockIssuanceCosts" name="TemporaryEquityStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent" name="PrepaidContractResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_NetProceedsFromIssuanceOfPrivatePlacement" name="NetProceedsFromIssuanceOfPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_PreferenceSharesTrancheObligationsMember" name="PreferenceSharesTrancheObligationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_DeemedDividend" name="DeemedDividend" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember" name="PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_PreferenceStockMeasurementInput" name="PreferenceStockMeasurementInput" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="iobt_TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc" name="TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_TemporaryEquityAdjustedFairValueOfTrancheObligation" name="TemporaryEquityAdjustedFairValueOfTrancheObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_OfficeMember" name="OfficeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_IncreaseDecreaseInLeaseLiability" name="IncreaseDecreaseInLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_TemporaryEquitySubscriptionPricePerShare" name="TemporaryEquitySubscriptionPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_PurchasePricePerShareOfCommonStockAndWarrant" name="PurchasePricePerShareOfCommonStockAndWarrant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" name="FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_AtTheMarketEquityProgramMember" name="AtTheMarketEquityProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_NumberOfVotePerShare" name="NumberOfVotePerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="iobt_NumberOfSharesIssuedForAdjustedDownward" name="NumberOfSharesIssuedForAdjustedDownward" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_OperatingLeaseAnnualBaseRent" name="OperatingLeaseAnnualBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember" name="TwoThousandTwentyThreeInducementIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_DeferredTaxAssetsAccruedCompensation" name="DeferredTaxAssetsAccruedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts" name="IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_DeferredTaxAssetsRightOFuseLeaseLiability" name="DeferredTaxAssetsRightOFuseLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligation" name="TemporaryEquityAdjustedForSettlementOfTrancheObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_SiliconValleyBankMember" name="SiliconValleyBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_WarrantsExercisablePricePerShare" name="WarrantsExercisablePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_PeriodExpireInTwentyTwentySixMember" name="PeriodExpireInTwentyTwentySixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_RefundableTaxCredit" name="RefundableTaxCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_ConvertibleNotesVolatilityPercentage" name="ConvertibleNotesVolatilityPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_FinancialAssetFairValueDisclosure" name="FinancialAssetFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_PercentageOfTotalCashAndCashEquivalents" name="PercentageOfTotalCashAndCashEquivalents" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_SalesAgreementMember" name="SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc" name="ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations" name="FairValueAdjustmentsPreferenceSharesTrancheObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_FairValueOfSharesIssued" name="FairValueOfSharesIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion" name="TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_LaboratoryMember" name="LaboratoryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_NumberOfBoardDirectors" name="NumberOfBoardDirectors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_AccruedResearchAndDevelopmentCostsPoliciesTextBlock" name="AccruedResearchAndDevelopmentCostsPoliciesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_TemporaryEquityStockIssuanceCost" name="TemporaryEquityStockIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_PercentageOfAggregateCashAndCashEquivalentsDeposited" name="PercentageOfAggregateCashAndCashEquivalentsDeposited" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="iobt_WarrantsIssued" name="WarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_ContractualObligationsTerminationNoticePeriod" name="ContractualObligationsTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_UndesignatedPreferredStockMember" name="UndesignatedPreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent" name="ResearchAndDevelopmentTaxCreditReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" name="DescriptionOfBusinessOrganizationAndLiquidityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_OperatingLeaseRemainingLeaseTerm" name="OperatingLeaseRemainingLeaseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="iobt_OfficeAndLaboratoryMember" name="OfficeAndLaboratoryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_ConvertibleNotesEquityValue" name="ConvertibleNotesEquityValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" name="FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" name="StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment" name="EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576713646896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IO BIOTECH, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001865494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0909276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Ole Maal&#248;es Vej 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Copenhagen N<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">DK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">DK-2200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">7070 2980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">IOBT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents incorporated by reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Portions of the registrant&#8217;s proxy statement relating to its 2024 Annual Meeting of Stockholders have been incorporated by reference herein in response to Part III, as specifically set forth in Part III.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">EY Godkendt Revisionspartnerselskab <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Copenhagen, Denmark<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576713651184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 143,193<span></span>
</td>
<td class="nump">$ 142,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,062<span></span>
</td>
<td class="nump">5,629<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">147,255<span></span>
</td>
<td class="nump">148,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">847<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use lease asset</a></td>
<td class="nump">2,259<span></span>
</td>
<td class="nump">2,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">3,463<span></span>
</td>
<td class="nump">3,586<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">150,718<span></span>
</td>
<td class="nump">151,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,878<span></span>
</td>
<td class="nump">4,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability - current</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">11,184<span></span>
</td>
<td class="nump">6,157<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">15,717<span></span>
</td>
<td class="nump">10,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability - noncurrent</a></td>
<td class="nump">1,839<span></span>
</td>
<td class="nump">2,275<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">1,839<span></span>
</td>
<td class="nump">2,275<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">17,556<span></span>
</td>
<td class="nump">12,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value of $0.001 per share; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value of $0.001 per share; 300,000,000 shares authorized at December 31, 2023 and December 31, 2022; 65,880,914 and 28,815,267 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">406,587<span></span>
</td>
<td class="nump">326,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(263,822)<span></span>
</td>
<td class="num">(177,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(9,669)<span></span>
</td>
<td class="num">(10,141)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">133,162<span></span>
</td>
<td class="nump">138,854<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 150,718<span></span>
</td>
<td class="nump">$ 151,805<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576717746576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576711401056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 67,829<span></span>
</td>
<td class="nump">$ 46,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">23,614<span></span>
</td>
<td class="nump">24,438<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">91,443<span></span>
</td>
<td class="nump">71,424<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(91,443)<span></span>
</td>
<td class="num">(71,424)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Currency exchange gain, net</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">5,881<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(302)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">6,212<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(85,231)<span></span>
</td>
<td class="num">(70,185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">852<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(86,083)<span></span>
</td>
<td class="num">(71,458)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (86,083)<span></span>
</td>
<td class="num">$ (71,458)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="num">$ (1.98)<span></span>
</td>
<td class="num">$ (2.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="num">$ (1.98)<span></span>
</td>
<td class="num">$ (2.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used in computing net loss per common share, basic</a></td>
<td class="nump">43,539,976<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used in computing net loss per common share, diluted</a></td>
<td class="nump">43,539,976<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (86,083)<span></span>
</td>
<td class="num">$ (71,458)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="nump">472<span></span>
</td>
<td class="num">(8,652)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (85,611)<span></span>
</td>
<td class="num">$ (80,110)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576710565136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 211,924<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 319,665<span></span>
</td>
<td class="num">$ (1,489)<span></span>
</td>
<td class="num">$ (106,281)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">7,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(8,652)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,652)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(71,458)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,458)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">138,854<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">326,705<span></span>
</td>
<td class="num">(10,141)<span></span>
</td>
<td class="num">(177,739)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement', window );">Issuance of common shares and warrants in private placement, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement', window );">Issuance of common shares and warrants in private placement, net of issuance costs</a></td>
<td class="nump">71,860<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">71,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">8,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(86,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,083)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 133,162<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 406,587<span></span>
</td>
<td class="num">$ (9,669)<span></span>
</td>
<td class="num">$ (263,822)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock and warrant issued during period shares issued for private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock and warrant issued during period value issued for private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576716233632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_PaymentsOfStockAndWarrantIssuanceCosts', window );">Common shares and warrants issuance costs</a></td>
<td class="nump">$ 3,198<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_PaymentsOfStockAndWarrantIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of stock and warrant issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_PaymentsOfStockAndWarrantIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576711255808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (86,083)<span></span>
</td>
<td class="num">$ (71,458)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">8,059<span></span>
</td>
<td class="nump">7,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right of use lease asset</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency gain</a></td>
<td class="num">(331)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Provision for deferred tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,568<span></span>
</td>
<td class="nump">4,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(126)<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_IncreaseDecreaseInLeaseLiability', window );">Lease liability</a></td>
<td class="num">(604)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">5,028<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(71,737)<span></span>
</td>
<td class="num">(59,729)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(323)<span></span>
</td>
<td class="num">(690)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(323)<span></span>
</td>
<td class="num">(690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common shares and warrants</a></td>
<td class="nump">75,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_PaymentsOfStockAndWarrantIssuanceCosts', window );">Common shares and warrants issuance costs</a></td>
<td class="num">(3,198)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">71,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(60,419)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">803<span></span>
</td>
<td class="num">(8,522)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">142,858<span></span>
</td>
<td class="nump">211,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">143,461<span></span>
</td>
<td class="nump">142,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Components of cash, cash equivalents, and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">143,193<span></span>
</td>
<td class="nump">142,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 143,461<span></span>
</td>
<td class="nump">$ 142,858<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_PaymentsOfStockAndWarrantIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of stock and warrant issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_PaymentsOfStockAndWarrantIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576711487872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Organization and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business, Organization and Liquidity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Description of Business, Organization and Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on our T-win&#174; platform. As used in these financial statements, unless the context otherwise requires, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to IO Biotech, Inc. and its subsidiaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Corporate reorganization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IO Biotech ApS was incorporated in Denmark in December 2014. In November 2021, we completed a corporate reorganization whereby IO Biotech ApS became a wholly-owned subsidiary of the Company. In connection with the corporate reorganization, each issued and outstanding Class A ordinary share ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value) was exchanged on a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one-for-one</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> basis into shares of common stock of the Company ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value). Each Class B and Class C preference share of IO Biotech ApS was exchanged on a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one-for-one</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> basis into shares of Class B and Class C preferred stock of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IO Bio US, Inc., a wholly owned subsidiary of IO Biotech ApS, was incorporated in Delaware in May 2021. IO Biotech Limited, a wholly owned subsidiary of IO Biotech ApS, was incorporated in the UK in August 2021. In November 2021, the Company engaged in a series of transactions, referred to collectively as the Corporate Reorganization. As a result of the Corporate Reorganization, IO Biotech ApS became a wholly-owned subsidiary of IO Biotech, Inc.  IO Biotech, Inc. is a holding company formed in October 2021, which, prior to our IPO, had nominal assets and no liabilities, contingencies, or commitments, and which has not conducted any operations prior to our IPO other than acquiring the entire issued and outstanding stock of IO Biotech ApS. The Company, IO Biotech ApS, and the holders of all of the issued and outstanding equity interests of IO Biotech ApS have entered into a Share Contribution and Exchange Agreement, dated as of October 29, 2021, pursuant to which the Corporate Reorganization was effected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial Public Offering (IPO)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, we completed our IPO, selling an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,222,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at a price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,072,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock sold pursuant to the underwriters&#8217; exercise of their option to purchase additional shares of common stock. We received net proceeds from the IPO, after deducting underwriting discounts and commissions and other offering costs, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">103.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately prior to the consummation of the IPO, all outstanding shares of our Class A ordinary shares and Class B and Class C convertible preference shares were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,592,413</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. Upon the closing of the IPO on November 9, 2021, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,815,267</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were issued and outstanding. Our common stock began trading on the Nasdaq Global Market on November 5, 2021 under the symbol &#8220;IOBT.&#8221;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 9, 2021, we amended and restated the certificate of incorporation of IO Biotech, Inc. to authorize the issuance of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">300,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock. The shares of preferred stock are currently undesignated.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">August 2023 Private Placement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 9, 2023, the Company completed a private placement transaction (the Private Placement), pursuant to which we sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37,065,647</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37,065,647</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37,065,647</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (the Warrants) to certain institutional investors and existing shareholders (the Purchasers). Each Purchaser&#8217;s Warrant is exercisable for a number of shares of common stock equal to one hundred percent of the aggregate number of shares of common stock purchased by such Purchaser. The purchase price per share of common stock and Warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the Purchase Price). The Company received net proceeds from the Private Placement, after deducting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in underwriting discounts and commissions and other offering costs, of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">71.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Refer to Note 2, &#8220;Summary of Significant Accounting Policies,&#8221; and Note 10, "Stockholders' Equity" in the accompanying notes to our consolidated financial statements for the years ended December 31, 2023 and 2022 for additional information on the Private Placement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">At-The-Market Equity Program</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 15, 2023, we filed a new prospectus supplement with the U.S. Securities and Exchange Commission (the SEC) with respect to the offer and sale of shares of our common stock, with an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19,500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, establishing an at-the-market equity program. On February 15, 2023, we also entered into a common stock sales agreement, dated February 15, 2023 (the &#8220;Sales Agreement&#8221;) by and between the Company and Cowen and Company, LLC for shares with an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through which we may, from time to time, sell shares through Cowen and Company, LLC, acting as agent and/or principal. Any shares offered and sold through the at-the-market equity program will be issued pursuant to the Company&#8217;s Registration Statement on Form S-3 (File No. 333-269569), which was declared effective on February 10, 2023, the prospectus supplement related to the offering that forms a part of the registration statement, and any applicable prospectus supplements that may form a part of the registration statement in the future. The aggregate market value of shares eligible for sale under the prospectus supplement and under the Sales Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3, to the extent required under such instruction. We have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t issued any shares pursuant to our at-the-market equity program as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance reporting capabilities.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are in preclinical research and clinical development. There can be no assurance that our research and development will be successfully completed, that adequate protection for our intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if our product development efforts are successful, it is uncertain when, if ever, we will generate significant revenue from product sales. We operate in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, we are dependent upon the services of our employees and consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity Considerations and Going Concern Basis of Accounting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, we have devoted substantially all of our efforts to business planning, conducting research and development, recruiting management and technical staff, and raising capital. We have financed our operations primarily through the issuance of convertible preference shares, convertible notes, our IPO and the Private Placement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our continued discovery and development of product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if our product development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">263.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. We have incurred losses and negative cash flows from operations since inception, including net losses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">86.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">71.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023 and 2022, respectively. We expect that our operating losses and negative cash flows will continue for the foreseeable future as we continue to develop our product candidates. We currently expect that our cash and cash equivalents of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">143.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 will be sufficient to fund our operating expenses and capital requirements for at least 12 months from the date the financial statements are issued. On this basis the financial statements are prepared on a going concern basis of accounting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. However, additional funding will be necessary to fund future discovery research, pre-clinical and clinical activities. We will seek additional funding through public financings, debt financings, collaboration agreements, strategic alliances and licensing arrangements. Although we have been successful in raising capital in the past, there is no assurance that we will be successful in obtaining such additional financing on acceptable terms, or at all, and we may not be able to enter into collaborations or other arrangements. If we are unable to obtain funding, we could be forced to delay, reduce or eliminate our research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect our business prospects, even our ability to continue operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576716689824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements include the accounts of its subsidiaries IO Biotech ApS, IO Bio US, Inc. and IO Biotech Limited. IO Bio US, Inc. is a wholly owned subsidiary of IO Biotech ApS. IO Biotech Limited is a wholly owned subsidiary of IO Biotech ApS. All intercompany transactions and balances have been eliminated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant items subject to such estimates and assumptions include contract research organization accruals, the fair value of stock-based compensation awards, the fair value of Warrants issued as part of the Private Placement and valuation of the Company&#8217;s deferred tax assets. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Currency and Currency Translation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The financial statements are presented in U.S. Dollars, our reporting currency. The functional currency of IO Biotech ApS and IO Biotech Limited is the Euro and the British Pound, respectively. The functional currency of IO Bio US, Inc. and IO Biotech, Inc. is the U.S. Dollar. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the functional currency are included in other income and expense in the consolidated statements of operations. Assets and liabilities recorded in our Euro and British Pound functional currencies are translated into the U.S. dollar reporting currency at the exchange rate on the balance sheet date. Our expenses in the Euro and the British Pound functional currencies are translated into the U.S. Dollar reporting currency at the average exchange rate prevailing each month. Resulting translation adjustments are recorded to other comprehensive income (loss) (OCI).</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents, which consist of money market accounts, are stated at fair value. As of December 31, 2023 and 2022 we had money market funds of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">131.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">88.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, which are included in cash and cash equivalents and reported at fair value (Note 3).</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain our cash in bank deposit and checking accounts that at times exceed insured limits. We have not experienced any losses in such accounts and believe we are not exposed to any significant credit risk, however, we are exposed to the potential loss of uninsured deposits should a financial institution we maintain our cash deposits with fail.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the price we would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The three levels of the fair value hierarchy are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">liabilities;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are observable, either directly or indirectly; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We monitor the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, our policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, the Company only held Level 1 financial instruments, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consists of laboratory equipment, computer hardware and office furniture and are recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset by asset basis, which generally consists of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for computer hardware, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for office furniture and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for laboratory equipment. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If circumstances require a long-lived asset to be tested for possible impairment, recoverability is measured by comparison of the carrying amount of the assets to estimated future undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset exceeds its estimated future cash flows, then impairment expense is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment expenses were recognized.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. The Company&#8217;s research and development expenses consist primarily of costs incurred for the development of its product candidates and include expenses incurred under agreements with contract manufacturing organizations, or CMOs, contract research organizations, or CROs, investigative sites and consultants to conduct clinical trials and preclinical and non-clinical studies, costs to acquire, develop and manufacture supplies for clinical trials and other studies, salaries and related costs, including equity-based compensation, depreciation and other allocated facility-related and overhead expenses and licensing fees and milestone payments incurred under product license agreements where no alternative future use exists.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may obtain grants from public and private funds for our research and development projects. The grant income for a given period is recognized as a cost reimbursement and is typically based on the time and the costs that we have spent on the specific project during that period. During the years ended December 31, 2023 and 2022, we had active cost reimbursement grants with Innovation Fund Denmark. The grants provided partial reimbursement of employment-related costs related to two employees pursuant to Business Ph.D. and Business post-doctoral programs. For the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, research and development expenses in the statements of operations include $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.02</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.03</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, of grant income cost reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have historically met the requirements to receive a tax credit in Denmark of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million Danish Kroner per year for tax losses resulting from research and development costs of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million Danish Kroner per year. The tax credit is reported as a reduction to research and development expense in the statements of operations. For the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, research and development expenses include refundable tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantial portions of our pre-clinical and clinical trials are performed by third-party laboratories, medical centers, CMOs, CROs and other vendors. These vendors generally bill monthly for services performed, or bill based upon milestone achievement. For preclinical studies, we accrue expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled, the duration of the study and other investigative costs. We monitor patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to us by the CROs, correspondence with the CROs and clinical site visits. Our estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. We periodically evaluate the estimates to determine if adjustments are necessary or appropriate based on information we receive.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2016, the FASB issued ASU No. 2016-02, Leases (&#8220;ASC 842&#8221;) to enhance the transparency and comparability of financial reporting related to leasing arrangements. Under this lease standard, most leases are required to be recognized on the balance sheet as right-of-use (ROU) assets and lease liabilities. The right-of-use model requires a lessee to recognize a ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement as well as the reduction of the right of use asset. In 2022, the Company adopted the standard effective January 1, 2022 and chose to use the effective date as date of initial application. The standard provides a number of optional practical expedients in transition. Upon adoption, the Company elected to apply the &#8216;package of practical expedients&#8217; which allowed the Company to not reassess (1) whether existing or expired arrangements contain a lease; (2) the lease classification of existing or expired leases; or (3) whether previous initial direct costs would qualify for capitalization under the new lease standard. The Company also elected to apply (1) the practical expedient which allows us to not separate lease and non-lease components, for new leases entered into after adoption and (2) the short-term lease exemption for all leases with an original term of less than 12 months, for purposes of applying the recognition and measurements requirements in the new standard.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company will utilize the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. As of January 1, 2022, the ASC 842 effective date, the Company&#8217;s incremental borrowing rate was approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% based on the remaining lease term of the applicable leases.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for stock options granted in accordance with ASC 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation-Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In accordance with ASC 718, compensation expense is measured at the estimated fair value of the stock options at grant date and is included as compensation expense over the vesting period during which an employee provides service in exchange for the award on a straight-line basis. Vesting of the awards depend solely on service conditions required of the employee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All share-based awards granted are measured based on the fair value on the date of the grant and compensation expense is recognized with respect to those awards over the requisite service period, which is generally the vesting period of the respective award. The Company reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity-based compensation expense is classified in the Company&#8217;s consolidated statements of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes model. The following summarizes the inputs used:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies because we lack company-specific historical and implied volatility information due in part to the limited time in which we have operated as a publicly traded company. We expect to continue to do so until such time as we have adequate historical data regarding the volatility of our traded stock price.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected term of the Company&#8217;s stock options has been determined based on the expected time to liquidity. The Company uses the simplified method prescribed by the SEC&#8217;s Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term of options granted because we lack company-specific historical and implied expected term information due in part to the limited time in which we have operated as a publicly traded company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk-free interest rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free interest rate is based on the implied yield on a U.S. Treasury security at a constant maturity with a remaining term equal to the expected term of the option granted.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividends</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected dividend yield is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> because the Company does not pay cash dividends on common shares and does not expect to pay any cash dividends in the foreseeable future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share Price</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The Company's common stock trades on the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nasdaq Global Market under the symbol &#8220;IOBT" and is utilized to determine the fair value of the Company's share price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are established when necessary, to reduce deferred tax assets to the amount expected to be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We follow the provisions of ASC 740-10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Uncertainty in Income Taxes. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not recognized a liability as a result of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unrecognized benefit since the date of adoption and we have not recognized interest expense or penalties as a result of ASC 740-10. If there were an unrecognized tax benefit, we would recognize interest accrued related to unrecognized tax benefits as income tax expense within our consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have identified Denmark and the U.S. as our major tax jurisdictions.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrants Issued in Connection with Sale of Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for warrants issued as a separable unit in connection with sale of common stock as either liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered liabilities if they are mandatorily redeemable and they require settlement in cash or other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as liability or equity. If warrants do not require liability classification under ASC 815-40 or other applicable U.S. GAAP the warrants should be classified as equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The proceeds received from the sale of equity classified warrants and sh</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ares of common stock in a bundled transaction are allocated based on the relative fair values of warrants and shares of common stock with no changes in fair value of warrants recognized after the issuance date. Based on our analysis of the foregoing, the Company's warrants issued in the Private Placement are classified as equity in our consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders  by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method and the as if-converted method, for convertible securities, if inclusion of these instruments is dilutive. Potentially dilutive securities include stock options and warrants to purchase common stock of the Company. In all periods presented, the Company&#8217;s outstanding stock options and warrants were excluded from the calculation of diluted net loss per share because their effects were anti-dilutive.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023 and 2022, both basic and diluted net loss per share are equivalent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (CODM), in deciding how to allocate resources to an individual segment and in assessing performance. Our CODM is our chief executive officer. The Company has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Comprehensive Income (Loss)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OCI is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our OCI includes currency translation from the Euro and the British Pound, the functional currency of IO Biotech ApS and IO Biotech Limited, respectively, to the U.S. Dollar, our reporting currency.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (1) are no longer an emerging growth company or (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently adopted accounting standards</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#8212;Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_50d1f921-ea74-4d65-b53b-2d642b4f270d;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASU 2019-04</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the standard effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The adoption of the standard has </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t had a material impact on our financial statements or financial statement disclosures.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued Accounting Standards</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity s Own Equity (Subtopic 815-40): Accounting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">being separately recognized from the host contract as compared with current U.S. GAAP. Convertible instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that continue to be subject to separation models are (1) those with embedded conversion features that are not</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the derivatives scope exception for contracts in an entity&#8217;s own equity to reduce form-over-substance-based</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">accounting conclusions. ASU 2020-06 will be effective for us in the interim periods in the fiscal year beginning after December 15, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">interim periods within those fiscal years. We are currently assessing the impact adoption of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASU 2020-06 will have on our financial statements and disclosures, but do not expect a material impact on the financial statements or disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, the FASB issued ASU 2023-06, Accounting Standards Update 2023-06&#8212;Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative. ASU 2023-06 will eliminate disclosure requirements that are redundant, duplicative, overlapping, outdated, or superseded as a result of subsequent changes to SEC disclosure requirements, U.S GAAP or technology. ASU 2023-06 is intended to better align U.S. GAAP requirements with those of the SEC and to facilitate the application of U.S. GAAP. The disclosure requirements would apply prospectively in the financial statements. ASU 2023-06 will be effective for us on the date on which the SEC&#8217;s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, if we are already subject to the SEC&#8217;s current disclosure requirements. For those current disclosure requirements we are not subject to, ASU 2023-06 will become effective two years after the date of such removal by the SEC. We are currently assessing the impact adoption of ASU 2023-06 will have on our financial statements and disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 will improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 will also enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment and contain other disclosure requirements. The enhanced segment disclosure requirements apply retrospectively to all prior periods presented in the financial statements. ASU 2023-07 will be effective for us in the annual periods beginning after December 15, 2023. We are currently assessing the impact adoption of ASU 2023-07 will have on our financial statements and disclosures, but do not expect a material impact on the financial statements or disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 will require disclosure of additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate (the rate reconciliation) for federal, state and foreign income taxes. ASU 2023-09 will also require information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold.  ASU 2023-09 will be effective for us in the annual periods beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. We are currently assessing the impact adoption of ASU 2020-06 will have on our financial statements and disclosures.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our consolidated financial statements</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576710555456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value are performed in a manner to maximize the use of observable inputs and minimize the use of unobservable inputs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classified its money market funds within Level 1 as the fair value of the funds are based on their quoted market prices in an active market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about our financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,971</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,971</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,971</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,971</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Money market funds with maturities of 90 days or less at the date of purchase are included within cash and cash equivalents in the accompanying consolidated balance sheets and are recognized at fair value.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company only held Level 1 financial instruments.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers among Level 1, Level 2 or Level 3 categories in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23 and 2</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576719321232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. License and Collaboration Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreements with MSD International GmbH</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2018, we entered into a clinical collaboration with MSD International GmbH (MSDIG) to evaluate IO102 in combination with KEYTRUDA&#174; (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer. Under the terms of the collaboration with MSDIG, we will conduct an international Phase 1/2 study to evaluate a combination therapy of IO102 and KEYTRUDA&#174;. We will sponsor the clinical trials and MSDIG will provide KEYTRUDA&#174; to be used in the clinical trials free of charge. We and MSDIG will be responsible for our own internal costs and expenses to support the study and we shall bear all other costs associated with conducting the study, including costs of providing IO102 for use in the study. The rights to the data from the clinical trials will be shared by us and MSDIG and we will maintain global commercial rights to IO102.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In September 2021, we entered into a clinical collaboration with MSDIG and MSD International Business GmbH (MSDIB), another affiliate of Merck (collectively, &#8220;MSD&#8221;) to evaluate IO102-IO103 in combination with KEYTRUDA&#174; versus KEYTRUDA&#174; alone in treatment of patients with metastatic (advanced) melanoma. Under the terms of the collaboration with MSD, we are conducting an international Phase 3 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA&#174;. We are the sponsor of the clinical trials and MSD will provide KEYTRUDA&#174; to be used in the clinical trials free of charge. We and MSD are responsible for our own internal costs and expenses to support the study and we will bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trials will be shared by us and MSD and we will maintain global commercial rights to IO102-IO103.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In December 2021, we entered into a clinical collaboration with MSD to evaluate IO102-IO103 in combination with KEYTRUDA&#174; in previously untreated patients with three different tumor types&#8212; metastatic non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and urothelial bladder cancer (UBC). Under the terms of the collaboration with MSD, we are conducting an international Phase 2 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA&#174;. We are the sponsor of the clinical trials and MSD will provide KEYTRUDA&#174; to be used in the clinical trials free of charge. We and MSD are responsible for our own internal costs and expenses to support the study and we will bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trials will be shared by us and MSD and we will maintain global commercial rights to IO102-IO103.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  In November 2022, we entered into a clinical collaboration with MSD to evaluate IO102-IO103 in combination with KEYTRUDA&#174; as a neo-adjuvant/adjuvant therapy for patients with metastatic melanoma and SCCHN. Under the terms of the collaboration with MSD, we will conduct an international Phase 2 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA&#174;. We will sponsor the clinical trials and MSD will provide KEYTRUDA&#174; to be used in the clinical trials free of charge. We and MSD will be responsible for our own internal costs and expenses to support the study and we shall bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trials will be shared by us and MSD and we will maintain global commercial rights to IO102-IO103.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576823535728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Prepaid Expenses and Other Current Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,352</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,716</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credit receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">814</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">792</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Value-added tax refund receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">313</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">741</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid contract research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,695</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">754</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">561</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,062</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,629</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses and Other Current Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576716774288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.527%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.057%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.057%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">836</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">544</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office furniture</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">238</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">233</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer hardware</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">330</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">847</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">741</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023 and 2022, the Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of depreciation expense in the consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576717529648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued contract research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,153</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,936</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee compensation costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,225</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,863</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">243</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">407</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,951</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,184</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576711461856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 1, 2022, the Company adopted ASC 842 using the modified retrospective transition approach allowed under ASU 2018-11 which releases companies from presenting comparative periods and related disclosures under ASC 842 and requires a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption (Note 2). The Company had an immaterial cumulative-effect adjustment to the opening balance of accumulated deficit as of January 1, 2022. The Company is party to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">five</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating leases for laboratory and office space. The Company&#8217;s finance leases are immaterial both individually and in the aggregate. The Company has elected to apply the short-term lease exception to all leases of one year or less. Further, the Company has applied the guidance in ASC 842 to our corporate office and laboratory leases and has determined that these should be classified as operating leases. Consequently, as a result of the adoption of ASC 842 on January 1, 2022, we recognized an ROU lease asset of approximately</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million with a corresponding lease liability of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million based on the present value of the minimum rental payments of such leases. In accordance with ASC 842, the beginning balance of the ROU lease asset was reduced by the existing deferred rent liability at inception of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In the consolidated balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Company has an ROU asset balance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and a current and non-current lease liability of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, relating to the ROU lease asset. The balance of both the ROU lease asset and the lease liabilities primarily consists of future payments under the Company&#8217;s office leased in New York, New York, Rockville, Maryland and Copenhagen, Denmark. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is party to an operating lease in Copenhagen, Denmark for office space that commenced in March 2021 with an initial term that expired in January 2025. Base rent for this initial lease was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million annually. The Company amended its operating lease in Copenhagen, Denmark on September 1, 2022 with a new term set to expire in December 2027. The base rent for the amended lease is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million annually. The Company is also party to an operating lease in Copenhagen, Denmark for laboratory space that commenced in January 2023 with the term set to expire in December 2027. The base rent for the lease is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.04</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million annually. The Company is party to an operating lease in New York, New York for office space that commenced in October 2021 with the initial term set to expire in January 2027. Base rent for this lease is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million annually. The Company is party to an operating lease in Rockville, Maryland for office and laboratory space that commenced in December 2021 with the initial term set to expire in May 2027. Base rent for this lease is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million annually. The Company is party to an immaterial operating lease in Newport, United Kingdom that commenced in June 2023. Rent expense for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Quantitative information regarding the Company&#8217;s leases for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2023 is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/><br/><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.974%;"></td>
        <td style="width:1.319%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.035%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.319%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.035%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.319%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">730</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">755</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating cash flows paid for amounts included in the measurement of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">723</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">419</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities arising from obtaining right&#8209;of&#8209;use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">235</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remaining lease term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future lease payments (undiscounted) under noncancelable leases are as follows as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Future Lease Payments</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">792</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">798</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">403</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,786</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s leases do not provide an implicit rate, therefore the Company used its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company used the incremental borrowing rate on January 1, 2022 for operating leases that commenced prior to that date, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576716338144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may be party to litigation arising in the ordinary course of its business. We were not subject to any material legal proceedings during the years ended December 31, 2023 and 2022, and, to our knowledge, no material legal proceedings are currently pending or threatened.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contractual Obligations and Commitments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enter into contracts in the ordinary course of business with third-party service providers for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days, and therefore, we believe that our noncancelable obligations under these agreements are not material and we cannot reasonably estimate whether they will occur. However, in the event of a termination of any contracts with CROs or other institutions and with respect to active patients enrolled in our clinical trials, we may be financially obligated for a period beyond the contractual termination notice periods. We may also enter into additional research, manufacturing, supplier, lease and other agreements in the future, which may require up-front payments and even long-term commitments of cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enter into certain types of contracts that contingently requires us to indemnify various parties against claims from third parties. These contracts primarily relate to procurement, service, consultancy or license agreements under which we may be required to indemnify vendors, service providers or licensees for certain claims, including claims that may be brought against them arising from our acts or omissions with respect to our products, technology, intellectual property or services. The Company, as permitted under Delaware law and in accordance with its amended and restated certificate of incorporation and amended and restated bylaws and pursuant to indemnification agreements with certain of its officers and directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, which the officer or director is or was serving at the Company&#8217;s request in such capacity.  At the 2023 Annual Meeting of Stockholders, the Company&#8217;s stockholders approved an amendment to, and the Company subsequently amended, its amended and restated certificate of incorporation to extend the indemnification of officers pursuant to recent amendments to the General Corporation Law of the State of Delaware.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may receive indemnification claims under existing contracts in the normal course of business. In the event that one or more of these matters were to result in a claim against us, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on our future business, operating results or financial condition. It is not possible to estimate the maximum amount potentially payable under these contracts since we have no history of prior indemnification claims and the unique facts and circumstances involved in each particular claim will be determinative.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576719432288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Class of Stock Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Stockholders' Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common and Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the closing of our IPO in November 2021, we filed an amended and restated certificate of incorporation, which authorized us to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">300,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock. The shares of preferred stock are currently undesignated. Common stockholders are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings. Common stockholders are entitled to receive dividends, if and when declared by the Company's board of directors (Board). </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends have been declared or paid by us through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Private Placement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 7, 2023, the Company entered into the Purchase Agreement, pursuant to which the Company agreed to sell and issue (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37,065,647</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37,065,647</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Warrants in the Private Placement. Each Purchaser&#8217;s Warrant is exercisable for a number of shares of common stock equal to one hundred percent of the aggregate number of shares of common stock purchased by such Purchaser. The Purchase Price for each common stock and Warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Warrants are exercisable at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.47</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, subject to adjustment as set forth therein. The Warrants are exercisable until the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an acquisition, as defined in the Warrants. The Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the Warrants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Private Placement closed on August 9, 2023. The Company received </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in gross proceeds from the Private Placement, before deducting offering expenses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Of the total proceeds, legal entities of certain related parties contributed $33</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and members of management contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company intends to use the net proceeds of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">71.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the Private Placement for general corporate purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in-capital and were recorded at the issuance date using a relative fair value allocation method. The Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. In addition, such Warrants do not provide any guarantee of value or return. The Company valued the Warrants at issuance using the Black-Scholes valuation model and allocated proceeds from the sale proportionately to the common stock and Warrants, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">29.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was allocated to the Warrants and recorded as a component of additional paid-in-capital. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37,065,647</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants issued and outstanding at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.47</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share to purchase shares of the Company's common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the execution of the Purchase Agreement, the Company also entered into a registration rights agreement (the Registration Rights Agreement) with the Purchasers. Under the terms of the Registration Rights Agreement, the Company has filed the Registration Statement with the SEC to register for resale the common stock issued under the Purchase Agreement and the shares of common stock issuable upon conversion of the Warrants issued pursuant to the Purchase Agreement (the Registrable Securities), which Registration Statement was declared effective on September 8, 2023. The Company may be required to pay certain liquidated damages under the terms of the Registration Rights Agreement in the event sales cannot be made pursuant to the Registration Statement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">65,880,914</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,815,267</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares outstanding, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576711461856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Equity-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Equity Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, our Board adopted, and our stockholders approved, the 2021 Equity Incentive Plan (2021 Equity Plan), which became effective on November 4, 2021. The 2021 Equity Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, awards of restricted stock, restricted stock units and other stock-based awards. The number of shares of our common stock reserved for issuance under the 2021 Equity Plan is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,496,934</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, subject to an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022 and continuing until, and including, the fiscal year ending December 31, 2031, equal to the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of common stock outstanding on the first day of such fiscal year or (ii) such other amount determined by our Board.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">593,468</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options available for future grant under the 2021 Equity Plan.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, our Board adopted and our stockholders approved the 2021 IO Biotech, Inc. Employee Stock Purchase Plan (2021 ESPP), which became effective on November 4, 2021. The number of shares of our common stock reserved for issuance under the 2021 ESPP is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">257,272</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, subject to an annual increase, to be added on the first day of each fiscal year, beginning January 1, 2023, equal to the lesser of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of common stock outstanding on the first day of such fiscal year; (2) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">257,272</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock; or (3) such other amount as determined by our Board. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Board had not yet approved any offering under the 2021 ESPP.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Inducement Award Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, our Board adopted the 2023 Inducement Award Plan (2023 Inducement Plan), which became effective on September 28, 2023. The 2023 Inducement Plan provides for the grant of non-statutory stock options, stock appreciation rights, awards of restricted stock, restricted stock units and other stock-based awards to eligible employees who satisfy the standards for inducement grants under Nasdaq Global Market rules. The number of shares of our common stock reserved for issuance under the 2023 Inducement Plan is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,976,427</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,976,427</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for future grant under the 2023 Inducement Plan.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our stock options activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Options<br/>&#160;and <br/>Warrants</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>average<br/>exercise<br/>price<br/>per share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,071,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,211,155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled or forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">362,596</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.51</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,920,172</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.77</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,519,994</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.99</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled or forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">588,243</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.74</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,851,923</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,902,547</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All share-based awards granted are measured based on the fair value on the date of the grant and compensation expense is recognized with respect to those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures related to equity-based compensation awards are recognized as they occur, and we reverse any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023 and 2022, we recorded equity-based compensation expense of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, related to the issuance of stock options and warrants. As of December 31, 2023, there was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized compensation cost related to unvested stock-based compensation arrangements that is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of the options granted were estimated based on the Black-Scholes model, using the following assumptions:<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.553%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:16.683%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:16.683%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.62</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">- </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">- </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,859</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,855</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,181</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total equity-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,040</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize any tax benefits for stock-based compensation during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576719350688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to U.S. federal, state and foreign corporate income taxes. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our loss before provision for income taxes for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022 consisted of the following (in thousands): </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,885</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,596</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,300</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,231</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,185</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our provision for income taxes consists of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">439</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">374</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">852</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,197</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">852</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,273</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reconciliation of Effective Tax Rate</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our effective tax rate for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is different from the statutory rate in the U.S. primarily due to the valuation allowance against deferred tax assets as a result of insufficient sources of income. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The reconciliation of the statutory income tax rate to our effective income tax rate is as follows: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.358%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.358%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax benefit at the statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Difference in tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">R&amp;D Deduction</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prior period adjustments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is recorded when it is more likely than not</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">some or all of the deferred tax assets will not be realized. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets consisted of the following (in thousands): </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,343</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,338</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,602</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,828</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ROU Lease Liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">526</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">618</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized R&amp;D</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,348</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,231</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">529</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">529</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,381</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,565</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,984</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">479</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">581</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ROU Lease Asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">441</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">567</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed Assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other Liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">479</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">581</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax asset (liability)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2017, the U.S. enacted the Tax Cuts and Jobs Act (the 2017 Tax Act), which contained a provision that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022. Previously, these expenses could be deducted in the year incurred. The implementation of this provision increased our deferred tax asset and valuation allowance by approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When realization of a deferred tax asset is more likely than not to occur, the benefit related to the deductible temporary differences attributable to operations is recognized as a reduction of income tax expense. Valuation allowances are provided against deferred tax assets when, based on all available evidence, it is considered more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. We cannot be certain that future income in Denmark will be sufficient to realize the Company&#8217;s deferred tax assets. Accordingly, a full valuation allowance has been provided against our net deferred tax assets in Denmark. We have also provided a full valuation allowance against our net deferred tax assets in the U.S. for IO Bio US, Inc. The Company's valuation allowance increased by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023 and 2022, respectively. The increase for the years ended December 31, 2023 and 2022 is primarily the result of an increase in net operating loss carryforwards (NOL carryforwards) in Denmark.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Available Carryforward Tax Losses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had NOL carryforwards of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">228.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> that can be carried forward indefinitely according to Danish Tax Authority regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Uncertain Tax Positions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We determine our uncertain tax positions based on whether and how much of a tax benefit taken by us in our tax filings is more likely than not to be sustained upon examination by the relevant income tax authorities. We determine whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not recognition threshold is calculated as the largest amount that is more than 50%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by the Danish Tax Authority. As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recorded an uncertain tax position liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tax filings in Denmark remain subject to examination by the Danish Tax Authority. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, tax years </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and forward were generally open to examination by the Danish Tax Authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Tax Credits</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023, we have elected to claim a research and development tax credit on the federal income tax return filed for the year ended December 31, 2022. We plan to continue to make this election on the federal income tax return filed for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> based on law currently enacted, and will continue to monitor impacts of proposed or enacted law changes on the cost to benefit of making this election. The Company included $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in research and development tax credits in the U.S. provision for income taxes for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2023.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Tax Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes accrued interest related to unrecognized tax benefits and penalties as income tax expense in the statements of operations. The Company does not have any material unrecognized tax benefits which would affect the effective tax rate, if recognized. The Company does not have any unrecognized tax benefits which would reverse within the next twelve months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is eligible for the Danish enhanced research and development tax allowance, providing for an increase in the deductible value of the amount of certain R&amp;D expenditur</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">es. For 2019, the deduction is set at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">101.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. Furthermore, the deduction for R&amp;D expenditures is set at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for 2020 through 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for 2023 through 2025, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax allowance is reported as a reduction to research and development expense in the statements of operations. For the years ended December 31, 2023 and 2022, we applied for refundable tax credit of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million DKK for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and a receivable was recorded for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in each year, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576710431296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted net loss per common share is calculated as follows (in thousands except share and per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.389%;"></td>
        <td style="width:1.401%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.904%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.401%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.904%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86,083</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,458</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to common shareholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86,083</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,458</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.98</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of shares used in computing net loss per common share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,539,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,815,267</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per common share, as their effect is anti-dilutive:</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,851,923</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,920,172</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants issued in Private Placement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,065,647</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576716095280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have evaluated subsequent events through the date on which the consolidated financial statements were issued. The Company has concluded that no subsequent events have occurred that require disclosure to the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576710531424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements include the accounts of its subsidiaries IO Biotech ApS, IO Bio US, Inc. and IO Biotech Limited. IO Bio US, Inc. is a wholly owned subsidiary of IO Biotech ApS. IO Biotech Limited is a wholly owned subsidiary of IO Biotech ApS. All intercompany transactions and balances have been eliminated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant items subject to such estimates and assumptions include contract research organization accruals, the fair value of stock-based compensation awards, the fair value of Warrants issued as part of the Private Placement and valuation of the Company&#8217;s deferred tax assets. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Currency and Currency Translation</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Currency and Currency Translation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The financial statements are presented in U.S. Dollars, our reporting currency. The functional currency of IO Biotech ApS and IO Biotech Limited is the Euro and the British Pound, respectively. The functional currency of IO Bio US, Inc. and IO Biotech, Inc. is the U.S. Dollar. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the functional currency are included in other income and expense in the consolidated statements of operations. Assets and liabilities recorded in our Euro and British Pound functional currencies are translated into the U.S. dollar reporting currency at the exchange rate on the balance sheet date. Our expenses in the Euro and the British Pound functional currencies are translated into the U.S. Dollar reporting currency at the average exchange rate prevailing each month. Resulting translation adjustments are recorded to other comprehensive income (loss) (OCI).</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents, which consist of money market accounts, are stated at fair value. As of December 31, 2023 and 2022 we had money market funds of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">131.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">88.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, which are included in cash and cash equivalents and reported at fair value (Note 3).</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock', window );">Concentrations of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain our cash in bank deposit and checking accounts that at times exceed insured limits. We have not experienced any losses in such accounts and believe we are not exposed to any significant credit risk, however, we are exposed to the potential loss of uninsured deposits should a financial institution we maintain our cash deposits with fail.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the price we would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The three levels of the fair value hierarchy are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">liabilities;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are observable, either directly or indirectly; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We monitor the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, our policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consists of laboratory equipment, computer hardware and office furniture and are recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset by asset basis, which generally consists of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for computer hardware, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for office furniture and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for laboratory equipment. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If circumstances require a long-lived asset to be tested for possible impairment, recoverability is measured by comparison of the carrying amount of the assets to estimated future undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset exceeds its estimated future cash flows, then impairment expense is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment expenses were recognized.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. The Company&#8217;s research and development expenses consist primarily of costs incurred for the development of its product candidates and include expenses incurred under agreements with contract manufacturing organizations, or CMOs, contract research organizations, or CROs, investigative sites and consultants to conduct clinical trials and preclinical and non-clinical studies, costs to acquire, develop and manufacture supplies for clinical trials and other studies, salaries and related costs, including equity-based compensation, depreciation and other allocated facility-related and overhead expenses and licensing fees and milestone payments incurred under product license agreements where no alternative future use exists.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may obtain grants from public and private funds for our research and development projects. The grant income for a given period is recognized as a cost reimbursement and is typically based on the time and the costs that we have spent on the specific project during that period. During the years ended December 31, 2023 and 2022, we had active cost reimbursement grants with Innovation Fund Denmark. The grants provided partial reimbursement of employment-related costs related to two employees pursuant to Business Ph.D. and Business post-doctoral programs. For the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, research and development expenses in the statements of operations include $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.02</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.03</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, of grant income cost reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have historically met the requirements to receive a tax credit in Denmark of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million Danish Kroner per year for tax losses resulting from research and development costs of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million Danish Kroner per year. The tax credit is reported as a reduction to research and development expense in the statements of operations. For the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, research and development expenses include refundable tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_AccruedResearchAndDevelopmentCostsPoliciesTextBlock', window );">Accrued Research and Development Costs</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantial portions of our pre-clinical and clinical trials are performed by third-party laboratories, medical centers, CMOs, CROs and other vendors. These vendors generally bill monthly for services performed, or bill based upon milestone achievement. For preclinical studies, we accrue expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled, the duration of the study and other investigative costs. We monitor patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to us by the CROs, correspondence with the CROs and clinical site visits. Our estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. We periodically evaluate the estimates to determine if adjustments are necessary or appropriate based on information we receive.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2016, the FASB issued ASU No. 2016-02, Leases (&#8220;ASC 842&#8221;) to enhance the transparency and comparability of financial reporting related to leasing arrangements. Under this lease standard, most leases are required to be recognized on the balance sheet as right-of-use (ROU) assets and lease liabilities. The right-of-use model requires a lessee to recognize a ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement as well as the reduction of the right of use asset. In 2022, the Company adopted the standard effective January 1, 2022 and chose to use the effective date as date of initial application. The standard provides a number of optional practical expedients in transition. Upon adoption, the Company elected to apply the &#8216;package of practical expedients&#8217; which allowed the Company to not reassess (1) whether existing or expired arrangements contain a lease; (2) the lease classification of existing or expired leases; or (3) whether previous initial direct costs would qualify for capitalization under the new lease standard. The Company also elected to apply (1) the practical expedient which allows us to not separate lease and non-lease components, for new leases entered into after adoption and (2) the short-term lease exemption for all leases with an original term of less than 12 months, for purposes of applying the recognition and measurements requirements in the new standard.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company will utilize the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. As of January 1, 2022, the ASC 842 effective date, the Company&#8217;s incremental borrowing rate was approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% based on the remaining lease term of the applicable leases.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-Based Compensation</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for stock options granted in accordance with ASC 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation-Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In accordance with ASC 718, compensation expense is measured at the estimated fair value of the stock options at grant date and is included as compensation expense over the vesting period during which an employee provides service in exchange for the award on a straight-line basis. Vesting of the awards depend solely on service conditions required of the employee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All share-based awards granted are measured based on the fair value on the date of the grant and compensation expense is recognized with respect to those awards over the requisite service period, which is generally the vesting period of the respective award. The Company reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity-based compensation expense is classified in the Company&#8217;s consolidated statements of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes model. The following summarizes the inputs used:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies because we lack company-specific historical and implied volatility information due in part to the limited time in which we have operated as a publicly traded company. We expect to continue to do so until such time as we have adequate historical data regarding the volatility of our traded stock price.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected term of the Company&#8217;s stock options has been determined based on the expected time to liquidity. The Company uses the simplified method prescribed by the SEC&#8217;s Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term of options granted because we lack company-specific historical and implied expected term information due in part to the limited time in which we have operated as a publicly traded company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk-free interest rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free interest rate is based on the implied yield on a U.S. Treasury security at a constant maturity with a remaining term equal to the expected term of the option granted.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividends</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected dividend yield is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> because the Company does not pay cash dividends on common shares and does not expect to pay any cash dividends in the foreseeable future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share Price</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The Company's common stock trades on the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nasdaq Global Market under the symbol &#8220;IOBT" and is utilized to determine the fair value of the Company's share price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are established when necessary, to reduce deferred tax assets to the amount expected to be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We follow the provisions of ASC 740-10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Uncertainty in Income Taxes. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not recognized a liability as a result of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unrecognized benefit since the date of adoption and we have not recognized interest expense or penalties as a result of ASC 740-10. If there were an unrecognized tax benefit, we would recognize interest accrued related to unrecognized tax benefits as income tax expense within our consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have identified Denmark and the U.S. as our major tax jurisdictions.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_WarrantsPolicyPolicyTextBlock', window );">Warrants Issued in Connection with Sale of Common Stock</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrants Issued in Connection with Sale of Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for warrants issued as a separable unit in connection with sale of common stock as either liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered liabilities if they are mandatorily redeemable and they require settlement in cash or other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as liability or equity. If warrants do not require liability classification under ASC 815-40 or other applicable U.S. GAAP the warrants should be classified as equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The proceeds received from the sale of equity classified warrants and sh</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ares of common stock in a bundled transaction are allocated based on the relative fair values of warrants and shares of common stock with no changes in fair value of warrants recognized after the issuance date. Based on our analysis of the foregoing, the Company's warrants issued in the Private Placement are classified as equity in our consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders  by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method and the as if-converted method, for convertible securities, if inclusion of these instruments is dilutive. Potentially dilutive securities include stock options and warrants to purchase common stock of the Company. In all periods presented, the Company&#8217;s outstanding stock options and warrants were excluded from the calculation of diluted net loss per share because their effects were anti-dilutive.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (CODM), in deciding how to allocate resources to an individual segment and in assessing performance. Our CODM is our chief executive officer. The Company has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Income (loss)</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Comprehensive Income (Loss)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OCI is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our OCI includes currency translation from the Euro and the British Pound, the functional currency of IO Biotech ApS and IO Biotech Limited, respectively, to the U.S. Dollar, our reporting currency.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_EmergingGrowthCompanyStatusPoliciesTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (1) are no longer an emerging growth company or (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently adopted accounting standards</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#8212;Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_50d1f921-ea74-4d65-b53b-2d642b4f270d;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASU 2019-04</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the standard effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The adoption of the standard has </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t had a material impact on our financial statements or financial statement disclosures.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued Accounting Standards</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity s Own Equity (Subtopic 815-40): Accounting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">being separately recognized from the host contract as compared with current U.S. GAAP. Convertible instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that continue to be subject to separation models are (1) those with embedded conversion features that are not</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the derivatives scope exception for contracts in an entity&#8217;s own equity to reduce form-over-substance-based</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">accounting conclusions. ASU 2020-06 will be effective for us in the interim periods in the fiscal year beginning after December 15, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">interim periods within those fiscal years. We are currently assessing the impact adoption of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASU 2020-06 will have on our financial statements and disclosures, but do not expect a material impact on the financial statements or disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, the FASB issued ASU 2023-06, Accounting Standards Update 2023-06&#8212;Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative. ASU 2023-06 will eliminate disclosure requirements that are redundant, duplicative, overlapping, outdated, or superseded as a result of subsequent changes to SEC disclosure requirements, U.S GAAP or technology. ASU 2023-06 is intended to better align U.S. GAAP requirements with those of the SEC and to facilitate the application of U.S. GAAP. The disclosure requirements would apply prospectively in the financial statements. ASU 2023-06 will be effective for us on the date on which the SEC&#8217;s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, if we are already subject to the SEC&#8217;s current disclosure requirements. For those current disclosure requirements we are not subject to, ASU 2023-06 will become effective two years after the date of such removal by the SEC. We are currently assessing the impact adoption of ASU 2023-06 will have on our financial statements and disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 will improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 will also enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment and contain other disclosure requirements. The enhanced segment disclosure requirements apply retrospectively to all prior periods presented in the financial statements. ASU 2023-07 will be effective for us in the annual periods beginning after December 15, 2023. We are currently assessing the impact adoption of ASU 2023-07 will have on our financial statements and disclosures, but do not expect a material impact on the financial statements or disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 will require disclosure of additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate (the rate reconciliation) for federal, state and foreign income taxes. ASU 2023-09 will also require information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold.  ASU 2023-09 will be effective for us in the annual periods beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. We are currently assessing the impact adoption of ASU 2020-06 will have on our financial statements and disclosures.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our consolidated financial statements</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_AccruedResearchAndDevelopmentCostsPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_AccruedResearchAndDevelopmentCostsPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_EmergingGrowthCompanyStatusPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_EmergingGrowthCompanyStatusPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_WarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Policy .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_WarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576716095280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Assets Measured at Fair Value</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about our financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,971</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,971</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,971</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,971</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Money market funds with maturities of 90 days or less at the date of purchase are included within cash and cash equivalents in the accompanying consolidated balance sheets and are recognized at fair value.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576710431296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,352</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,716</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credit receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">814</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">792</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Value-added tax refund receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">313</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">741</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid contract research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,695</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">754</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">561</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,062</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,629</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576716170464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.527%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.057%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.057%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">836</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">544</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office furniture</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">238</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">233</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer hardware</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">330</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">847</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">741</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576716110064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued contract research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,153</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,936</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee compensation costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,225</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,863</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">243</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">407</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,951</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,184</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576716052768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Quantitative Information Regarding Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Quantitative information regarding the Company&#8217;s leases for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2023 is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/><br/><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.974%;"></td>
        <td style="width:1.319%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.035%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.319%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.035%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.319%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">730</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">755</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating cash flows paid for amounts included in the measurement of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">723</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">419</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities arising from obtaining right&#8209;of&#8209;use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">235</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remaining lease term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future lease payments (undiscounted) under noncancelable leases are as follows as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Future Lease Payments</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">792</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">798</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">403</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,786</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576716095280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Rental Payments Under Noncancellable Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future lease payments (undiscounted) under noncancelable leases are as follows as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Future Lease Payments</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">792</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">798</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">403</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,786</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576712284048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our stock options activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Options<br/>&#160;and <br/>Warrants</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>average<br/>exercise<br/>price<br/>per share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,071,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,211,155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled or forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">362,596</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.51</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,920,172</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.77</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,519,994</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.99</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled or forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">588,243</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.74</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,851,923</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,902,547</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions for Estimated Fair Value of Options</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of the options granted were estimated based on the Black-Scholes model, using the following assumptions:<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.553%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:16.683%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:16.683%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.62</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">- </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">- </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Equity-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,859</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,855</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,181</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total equity-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,040</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576875060976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before Provision for Income Taxes</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our loss before provision for income taxes for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022 consisted of the following (in thousands): </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,885</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,596</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,300</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,231</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,185</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our provision for income taxes consists of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">439</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">374</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">852</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,197</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">852</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,273</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of the Statutory Income Tax Rate to our Effective Income Tax Rate</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The reconciliation of the statutory income tax rate to our effective income tax rate is as follows: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.358%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.358%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax benefit at the statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Difference in tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">R&amp;D Deduction</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prior period adjustments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Principal Components of Deferred Tax Assets</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets consisted of the following (in thousands): </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,343</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,338</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,602</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,828</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ROU Lease Liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">526</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">618</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized R&amp;D</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,348</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,231</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">529</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">529</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,381</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,565</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,984</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">479</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">581</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ROU Lease Asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">441</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">567</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed Assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other Liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">479</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">581</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax asset (liability)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2017, the U.S. enacted the Tax Cuts and Jobs Act (the 2017 Tax Act), which contained a provision that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022. Previously, these expenses could be deducted in the year incurred. The implementation of this provision increased our deferred tax asset and valuation allowance by approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576718349344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Table)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted net loss per common share is calculated as follows (in thousands except share and per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.389%;"></td>
        <td style="width:1.401%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.904%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.401%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.904%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86,083</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,458</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to common shareholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86,083</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,458</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.98</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of shares used in computing net loss per common share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,539,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,815,267</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,851,923</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,920,172</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants issued in Private Placement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,065,647</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576709736992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Organization and Liquidity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 09, 2023</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 15, 2023</div></th>
<th class="th"><div>Nov. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (263,822,000)<span></span>
</td>
<td class="num">$ (177,739,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="nump">$ 71,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (86,083,000)<span></span>
</td>
<td class="num">$ (71,458,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,193,000<span></span>
</td>
<td class="nump">$ 142,590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from IPO, after deducting underwriting discounts, commissions and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preference share issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,592,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Common stock conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember', window );">Class B Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Common stock conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=iobt_PreferredClassCMember', window );">Class C Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Common stock conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=iobt_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,072,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,222,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock shares sold, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_PurchasePricePerShareOfCommonStockAndWarrant', window );">Purchase price per share of common stock and warrant</a></td>
<td class="nump">$ 2.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_WarrantsIssued', window );">Warrants issued</a></td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Maximum | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iobt_AtTheMarketEquityProgramMember', window );">At-The-Market Equity Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_CommonStockMaximumAggregateOfferingAmount', window );">Common stock, maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iobt_AtTheMarketEquityProgramMember', window );">At-The-Market Equity Program | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_CommonStockMaximumAggregateOfferingAmount', window );">Common stock, maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_CommonStockMaximumAggregateOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, maximum aggregate offering amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_CommonStockMaximumAggregateOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of business, organization and liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_PurchasePricePerShareOfCommonStockAndWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price per share of common stock and warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_PurchasePricePerShareOfCommonStockAndWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of basis for conversion of convertible common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=iobt_PreferredClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=iobt_PreferredClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=iobt_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=iobt_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iobt_AtTheMarketEquityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iobt_AtTheMarketEquityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=iobt_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=iobt_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576710975280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> $ / shares in Units, kr in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>DKK (kr)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>DKK (kr)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>DKK (kr)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">$ 131,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease', window );">Operating lease incremental borrowing rate on remaining lease | $ / shares</a></td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting standards update [extensible enumeration]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201613Member<span></span>
</td>
<td class="text">us-gaap:AccountingStandardsUpdate201613Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_GrantIncomeCostReimbursement', window );">Grant income cost reimbursement</a></td>
<td class="nump">$ 20,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense | Danish Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_RefundableTaxCredit', window );">Refundable tax credit | kr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_RefundableTaxCreditReceivable', window );">Refundable tax credit receivable</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense | Maximum | Danish Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward | kr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_RefundableTaxCredit', window );">Refundable tax credit | kr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_GrantIncomeCostReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Income Cost Reimbursement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_GrantIncomeCostReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease incremental borrowing rate on remaining lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_RefundableTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refundable tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_RefundableTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_RefundableTaxCreditReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refundable tax credit receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_RefundableTaxCreditReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 72: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4<br><br>Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576717749568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assets Measured at Fair Value (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 131,613<span></span>
</td>
<td class="nump">$ 87,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">131,613<span></span>
</td>
<td class="nump">87,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">131,613<span></span>
</td>
<td class="nump">87,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 131,613<span></span>
</td>
<td class="nump">$ 87,971<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576717779568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1', window );">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1', window );">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Transfers into Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfers out of Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Liabilities Level1 To Level2 Transfers Amount1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Liabilities Level2 To Level1 Transfers Amount1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576710422960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">$ 1,352<span></span>
</td>
<td class="nump">$ 1,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent', window );">Research and development tax credit receivable</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid income taxes</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">Value-added tax refund receivable</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_PrepaidContractResearchAndDevelopmentCostsCurrent', window );">Prepaid contract research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">754<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 4,062<span></span>
</td>
<td class="nump">$ 5,629<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_PrepaidContractResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid contract research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_PrepaidContractResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credit receivable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576718362880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576711276848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">$ (330)<span></span>
</td>
<td class="num">$ (115)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">847<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">836<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576713926704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_AccruedContractResearchAndDevelopmentCostsCurrent', window );">Accrued contract research and development costs</a></td>
<td class="nump">$ 6,153<span></span>
</td>
<td class="nump">$ 1,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation costs</a></td>
<td class="nump">4,225<span></span>
</td>
<td class="nump">1,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">563<span></span>
</td>
<td class="nump">1,951<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 11,184<span></span>
</td>
<td class="nump">$ 6,157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_AccruedContractResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued contract research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_AccruedContractResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576710923648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_NumberOfOperatingLease', window );">Number of operating leases | Lease</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use lease asset</a></td>
<td class="nump">$ 2,259<span></span>
</td>
<td class="nump">2,493<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease, liability, non-current</a></td>
<td class="nump">1,839<span></span>
</td>
<td class="nump">$ 2,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_OfficeAndLaboratoryMember', window );">Office and Laboratory | Denmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseAmendedBaseRent', window );">Operating lease amended base rent</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_OfficeAndLaboratoryMember', window );">Office and Laboratory | New York, NY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseAnnualBaseRent', window );">Operating lease annual base rent</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_OfficeAndLaboratoryMember', window );">Office and Laboratory | Maryland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseAnnualBaseRent', window );">Operating lease annual base rent</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_OfficeMember', window );">Office | Denmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseAnnualBaseRent', window );">Operating lease annual base rent</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_LaboratoryMember', window );">Laboratory | Denmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseAnnualBaseRent', window );">Operating lease annual base rent</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_NumberOfOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_NumberOfOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_OperatingLeaseAmendedBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease amended base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_OperatingLeaseAmendedBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_OperatingLeaseAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease annual base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_OperatingLeaseAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481178/840-20-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479341/842-30-25-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_OfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_OfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_LaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_LaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576717779408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Quantitative information Regarding Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 730<span></span>
</td>
<td class="nump">$ 755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">723<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities arising from obtaining right-of-use assets</a></td>
<td class="nump">$ 235<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseRemainingLeaseTerm', window );">Remaining lease term (years)</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_OperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease remaining lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_OperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576711444464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 2,786<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576712173888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ContractualObligationsTerminationNoticePeriod', window );">Contractual obligations termination notice period</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ContractualObligationsTerminationNoticePeriod', window );">Contractual obligations termination notice period</a></td>
<td class="text">90 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_ContractualObligationsTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligations termination notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_ContractualObligationsTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576710410512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preference Shares - Additional information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 09, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preference shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preference shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference share per share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preference share issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,592,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_NumberOfVotePerShare', window );">Number of votes per share | Vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_NumberOfVotePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of vote per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_NumberOfVotePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576706316624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 09, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 07, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 09, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from IPO, after deducting underwriting discounts, commissions and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_NumberOfVotePerShare', window );">Number of votes per share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="nump">$ 71,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_WarrantsIssued', window );">Warrants issued | shares</a></td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_PurchasePricePerShareOfCommonStockAndWarrant', window );">Purchase price per share of common stock and warrant | $ / shares</a></td>
<td class="nump">$ 2.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_WarrantsIssued', window );">Warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_PurchasePricePerShareOfCommonStockAndWarrant', window );">Purchase price per share of common stock and warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_WarrantsExercisablePricePerShare', window );">Purchase Price of Common Stock and Warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="nump">75,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_NetProceedsFromIssuanceOfPrivatePlacement', window );">Net Proceeds From Issuance Of Private Placement</a></td>
<td class="nump">71,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Securities Purchase Agreement | Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Securities Purchase Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Securities Purchase Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,222,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock shares sold, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,072,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=iobt_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsAxis=us-gaap_DividendDeclaredMember', window );">Dividend Declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsAxis=us-gaap_DividendPaidMember', window );">Dividend Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_NetProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_NetProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_NumberOfVotePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of vote per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_NumberOfVotePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_PurchasePricePerShareOfCommonStockAndWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price per share of common stock and warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_PurchasePricePerShareOfCommonStockAndWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_WarrantsExercisablePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercisable price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_WarrantsExercisablePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=iobt_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=iobt_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=iobt_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=iobt_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAxis=us-gaap_DividendDeclaredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAxis=us-gaap_DividendDeclaredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAxis=us-gaap_DividendPaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAxis=us-gaap_DividendPaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576709621632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefits for stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,059,000<span></span>
</td>
<td class="nump">$ 7,040,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="nump">2,496,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum percentage of shares that may be issued under the plan as a proportion of outstanding capital stock</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of warrants available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">593,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="nump">257,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum percentage of shares that may be issued under the plan as a proportion of outstanding capital stock</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iobt_TwoThousandTwentyThreeInducementIncentivePlanMember', window );">2023 Inducement Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,976,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of warrants available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,976,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iobt_TwoThousandTwentyThreeInducementIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iobt_TwoThousandTwentyThreeInducementIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576712209136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Schedule of Stock Options Activity (Details) - Warrant - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Beginning balance</a></td>
<td class="nump">3,920,172<span></span>
</td>
<td class="nump">3,071,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Warrants, Granted</a></td>
<td class="nump">2,519,994<span></span>
</td>
<td class="nump">1,211,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Warrants, Cancelled or forfeited</a></td>
<td class="num">(588,243)<span></span>
</td>
<td class="num">(362,596)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Ending balance</a></td>
<td class="nump">5,851,923<span></span>
</td>
<td class="nump">3,920,172<span></span>
</td>
<td class="nump">3,071,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable', window );">Number of Warrants, Exercisable</a></td>
<td class="nump">1,902,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price per share, Beginning balance</a></td>
<td class="nump">$ 10.77<span></span>
</td>
<td class="nump">$ 13.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price per share, Granted</a></td>
<td class="nump">1.99<span></span>
</td>
<td class="nump">5.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price per share, Cancelled or forfeited</a></td>
<td class="nump">8.74<span></span>
</td>
<td class="nump">12.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price per share, Ending balance</a></td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">$ 10.77<span></span>
</td>
<td class="nump">$ 13.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, Exercisable</a></td>
<td class="nump">$ 11.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted-average remaining contractual term (in years), Outstanding</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm', window );">Weighted-average remaining contractual term (in years), Exercisable</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercisable intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award equity instruments other than options exercisable in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576712346000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Summary of Assumptions for Estimated Fair Value of Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility minimum</a></td>
<td class="nump">86.40%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility maximum</a></td>
<td class="nump">102.20%<span></span>
</td>
<td class="nump">77.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate minimum</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">1.62%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate maximum</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576713721152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">$ 8,059<span></span>
</td>
<td class="nump">$ 7,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">4,204<span></span>
</td>
<td class="nump">2,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">$ 3,855<span></span>
</td>
<td class="nump">$ 4,181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576712788224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details)<br> kr in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>DKK (kr)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>DKK (kr)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017', window );">Provision increase deferred tax assets and valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Deferred tax assets, credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits in U.S. provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Danish Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Danish Tax Authority | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Effective income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_RefundableTaxCredit', window );">Refundable tax credit | kr</a></td>
<td class="nump">kr 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_RefundableTaxCreditReceivable', window );">Refundable tax credit receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Danish Tax Authority | Research and Development Expense | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_RefundableTaxCredit', window );">Refundable tax credit | kr</a></td>
<td class="nump">kr 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Danish Tax Authority | 2020 through 2022 | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Effective income tax rate</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Danish Tax Authority | 2023 through 2025 | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Effective income tax rate</a></td>
<td class="nump">108.00%<span></span>
</td>
<td class="nump">108.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Danish Tax Authority | Period 2026 | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Effective income tax rate</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_RefundableTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refundable tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_RefundableTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_RefundableTaxCreditReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refundable tax credit receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_RefundableTaxCreditReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance deferred tax asset change in amount due to tax cuts and jobs act of 2017.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=iobt_PeriodExpireInTwentyTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=iobt_PeriodExpireInTwentyTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576711189952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 2,365<span></span>
</td>
<td class="num">$ (1,885)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(87,596)<span></span>
</td>
<td class="num">(68,300)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">$ (85,231)<span></span>
</td>
<td class="num">$ (70,185)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576713483664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 439<span></span>
</td>
<td class="nump">$ 1,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">852<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 852<span></span>
</td>
<td class="nump">$ 1,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576712203536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Statutory Income Tax Rate to our Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at the statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Permanent differences</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Difference in tax rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment', window );">R&amp;D Deduction</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(24.70%)<span></span>
</td>
<td class="num">(27.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Prior period adjustments</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation deductible expense research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576713713920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Principal Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 50,343<span></span>
</td>
<td class="nump">$ 31,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Equity-based compensation expense</a></td>
<td class="nump">3,602<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DeferredTaxAssetsAccruedCompensation', window );">Accrued compensation</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DeferredTaxAssetsRightOFuseLeaseLiability', window );">ROU Lease Liability</a></td>
<td class="nump">526<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized R&amp;D</a></td>
<td class="nump">3,348<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">58,381<span></span>
</td>
<td class="nump">35,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(57,902)<span></span>
</td>
<td class="num">(34,984)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset', window );">ROU Lease Asset</a></td>
<td class="nump">441<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed Assets</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other Liabilities</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">$ 479<span></span>
</td>
<td class="nump">$ 581<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_DeferredTaxAssetsAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Accrued Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_DeferredTaxAssetsAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_DeferredTaxAssetsRightOFuseLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_DeferredTaxAssetsRightOFuseLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use lease asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576716511456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Basic and Diluted Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (86,083)<span></span>
</td>
<td class="num">$ (71,458)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (86,083)<span></span>
</td>
<td class="num">$ (71,458)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="num">$ (1.98)<span></span>
</td>
<td class="num">$ (2.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="num">$ (1.98)<span></span>
</td>
<td class="num">$ (2.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used in computing net loss per common share, basic</a></td>
<td class="nump">43,539,976<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used in computing net loss per common share, diluted</a></td>
<td class="nump">43,539,976<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140576719144640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding potentially dilutive securities</a></td>
<td class="nump">5,851,923<span></span>
</td>
<td class="nump">3,920,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants issued in Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding potentially dilutive securities</a></td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>93
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M7Z:, FPM -_O!+03[8T^&^Y^"]C\"U!+ P04    "  FBF58?B9U"=D"  !
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M$H05;(@'KCAYL#5'MMPU5E7H_">X?6HEO<)DA;4L)9W"9"T<IS9(LA3J%$Y
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MYGB=BT]T^RNI#0J5OH3F7/\%VTHVDL+)F@M:U(LE@B(KJ__XI7;$P0(XZEF
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MC7J(2 +(EIKD8"=OK;19)%Y'LEIT.6E7G @U2$(:I]%A+ROK+9^6@M4A\5"
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MB,*%!PNZTY IV:E;Z#WQZX:+[D,_=ZSZU'.?>*MES^&)*FW/!DSYJXOL!Q*
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M+I(;R%!EM$,.8]"?T[0LDUP\C"&%"V\YJM^!QPJ);VR\/,XIJO01@0C$1#5
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MG]<T/DG]D*1_1&9H@@\[,Z%+B\=_J;RN,/*RI%Q&[9&*R0330LVY,J<#YK8
M2UKO1;OKG:)LXWP\^CC";<5^+7F.02N3A"-'I,ZFR3/\-^.)54 ;S7@T.CGW
MFU'*2D/M(HG26/*4M-R 7PU'F\^G[\<?T[_U_5O?J.]S/6OU'?W/^N98!XI(
M;_/TGQ+/0A<V@[9;B<)[3]#FV*S^)) ,GR*P=9Z#?[:\UGT6?CYA_<+/P;^(
MNE;]+P\77KV@]]2_8,)S1N/A5KV%:6?;=U@'U:N;[^;5"[ S7%*A+),P0==N
MY\VKH$JDN7"Z\"]R8NV<SOV03BXP9(#W)UJ[YH("M&_V!O\"4$L#!!0    (
M ":*95@)% ['^@(  +T&   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;*5536_:0!"]\RM&3A2U$L78F(\00"(D57.(BI(V/50]+/: 5[%WW=TUT/[Z
MSJ[!I1*@2+UXOV;>O)F=?1YMI'K5*:*!;9X)/?928XJA[^LXQ9SIEBQ0T,E2
MJIP96JJ5KPN%+'%.>>:'[7;/SQD7WF3D]N9J,I*ER;C N0)=YCE3OVXQDYNQ
M%WC[C2>^2HW=\">C@JWP&<W78JYHY=<H"<]1:"X%*%R.O6DPO(VLO3-XX;C1
M!W.PF2RD?+6+AV3LM2TAS# V%H'1L,899ID%(AH_=YA>'=(Z'L[WZ!]=[I3+
M@FF<R>P;3TPZ]@8>)+AD96:>Y.83[O+I6KQ89MI]85/9]OL>Q*4V,M\Y$X.<
MBVIDVUT=#AP&[1,.X<XA=+RK0([E'3-L,E)R \I:$YJ=N%2=-Y'CPE[*LU%T
MRLG/3.8*"\83N-_2-6O4P$0"GTV*"F:E4B@,3+5&HT>^H7#6R8]WT+<5='@"
M.@CA40J3:K@7"2;_ OC$LR8;[LG>AF<1[S!N02=H0M@..V?P.G7R'8?7.8FW
M1,HQ@9G41C=AQ@IN6,9_8]*$766:!Q6I*@%W7,>9U*5"^#Y=:*.HM7X<JT\5
M/3H>W3ZWH2Y8C&./WI-&M49O<G41]-HW9W*+ZMRB<^C_=[%GH8\3[[;@S2%K
M2SRTE,XRWEFRRC*6]/ZU ;D$.H:ES$A&N%C!.RYH1Y::7/7[88-Z _,% 5!_
M-&Q_V"8)&P^"[HF)&.$2@F:G&[JQ'_0:3\2<J3AUL1-<DSX5N8ULV!9BZ@IN
M2'5BY&NVR! &003]Z["QI\Y%+'.TQD1_$%Y#$$:-%Y:5^($EU.X.AA2F)/0#
MF$[0@7X4U#"4G^L?4*?HQ+8WX>IB$ ;A#7'O77<;55'[W0BZO:#Q15+30O'F
MFEY"U&SW;"6ZS1XQ/]9M_H&DY*A63CCM=93"5.I2[];:/*TDZ:]Y)>R/3*VX
MT)#ADES;K7[7 U6)9;4PLG "M9"&Y,Y-4_J_H+(&=+Z4TNP7-D#]QYK\ 5!+
M P04    "  FBF58K/*%\@ #  "J!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q,RYX;6R55=N.VS80??=7#-0@R *&==U+'-O [B9!"R2MD;3I0Y$'6AI9
M1"A2(4?K=;^^0\JK]0(;%WFP2 YG#N=P.,>+G;'?7(-(<-\J[9910]3-X]B5
M#;;"S4R'FG=J8UM!O+3;V'46116"6A5G27(1MT+J:+4(MK5=+4Q/2FI<6W!]
MVPJ[OT%E=LLHC1X,G^2V(6^(5XM.;/$STE_=VO(J'E$JV:)VTFBP6"^CZW1^
M4WC_X/!%XLX=S<$SV1CSS2]^JY91XA-"A25Y!,'#'=ZB4AZ(T_A^P(S&(WW@
M\?P!_7W@SEPVPN&M47_+BIIE=!5!A;7H%7TRNU_QP.?<XY5&N?"%W>!;\(EE
M[\BTAV!>MU(/H[@_W,-1P%7R@X#L$)"%O(>#0I9O!8G5PIH=6._-:'X2J(9H
M3DYJ7Y3/9'E7<ARMUI;K:VD/0E?P[GLO.[YQFL+O2(N8^ #O%I<'L)L!+/L!
M6)K!1Z.I<?!.5U@]!8@YLS&]["&]F^PDXELL9Y"G4\B2+#^!EX]T\X"7_P_=
M*:R5T/24-?QSO7%D^:%\?8[[@%P\C^R;9^XZ4>(RXNYP:.\P6KW\);U(WIS(
MNQCS+DZA_VR93H(]G^K%#$X<\G0/'_<T[Y6&>]01F!JH0:B-XE:7>@NOI&:+
MZ1T'N;/YA*N)[0:MK^C$5]27-9M\$!MC!1F[?T2&%W"57_#WO"@F?]2U+!FX
MMUI2;Q&R_(I_^>36M%U/#-@(6^T$[Z1)#I>O)Q_0N3FW?-FWO1*$%7<J<RVE
M"%KP"O(\@3,>T_0<SB9_&A(*NA,<.9WBDK^710HL!X'H'H5U@/ZIPS&U\%@#
MB*<W#;X^4Z'WK&.EV6KY+X>\@&26<4\K%>1)#Y9TM$S9V7489$OQB^7K?4("
M[UF9'4*X9 Q5,$I6@:TC'GSVSH=Y6B'&S>"YQQ@?Z4>+=AM4TC%BKVF0DM$Z
M"O'UH#^/[H.*?Q1V*[4#A36')K/+\PCLH(S#@DP7U&ACB+4M3!O^,T'K'7B_
M-H8>%OZ \>]I]1]02P,$%     @ )HIE6('LQE"^ @  908  !D   !X;"]W
M;W)K<VAE971S+W-H965T,30N>&ULK579;M- %'W/5XP,0B!%\9J%D$1*2Q%(
M5$0MRP/B86)?QZ/.8F;&3?OWW!D[)DAII$J\>+9SSSUWEN/%7ND[4P%8\B"X
M-,N@LK:>AZ')*Q#4C%0-$E=*I06U.-2[T-0::.&#! ^3*)J$@C(9K!9^;J-7
M"]58SB1L-#&-$%0_7@!7^V40!X>)&[:KK)L(5XN:[N 6[+=ZHW$4]BP%$R -
M4Y)H*)?!.IY?9 [O =\9[,U1G[A*MDK=N<&G8AE$3A!PR*UCH-C<PR5P[HA0
MQN^.,^A3NL#C_H']@Z\=:]E2 Y>*_V"%K9;!+" %E+3A]D;M/T)7S]CQY8H;
M_R7[%IM- Y(WQBK1!:,"P63;TH=N'XX"9M$3 4D7D'C=;2*O\CVU=+70:D^T
M0R.;Z_A2?32*8](=RJW5N,HPSJ[6>:X;*,C5 QZS 4.H+,@76X$FEXW6("WY
MS.B6<689F$5H,:>+#/.._Z+E3Y[@CQ-RK:2M#+F2!13_$H0HME><'!1?)&<9
MWT,^(FD\)$F4I&?XTGX'4L^7/L&WH8]TR[O*_790;LC/]=98C7?FUZF:6\;L
M-*-[1W-3TQR6 3X4 _H>@M6K%_$D>G=&;];KS<ZQ_X<3.\M_6OUT1)Z7MX?#
M,5QY>-[!^1$\5_C.C26J)(@AI>)H%TSNR&LF<48U!N/-F_D CQ_$%EGP"@S<
M%7#W(!D<TB&//S;BI%.=5SYO ?=H/[5P67-EK"$OR608CU-LX^';=#*X$C57
MCP"X+)Q@ZCVCQ6;#)!DC;C9)!QNM2C#.DB@G):#R)$M)%DT'[58<US2>I(Y]
M' ^^*HMP^KPM06GQ,)YEG=8I.75YPJ.G+T#OO,&Y[6RD;5V@G^T]=-U:QU]X
M:\#75.^8-(1#B:'1:#H.B&Y-K1U857LCV2J+MN2[%?X'0#L KI=*V</ )>C_
M+*L_4$L#!!0    ( ":*95AB%[AI[ <  '\5   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;*U8:W/;-A;][E^!4=-.,J/H04FVDMB>L=UFMMM-DSK-
M=CH[^P$B(0D-";  :-G]]7ON!<E0+R?=]H-E/G#O/>>^<,'SC74?_5JI(.Z+
MW/B+WCJ$\N5PZ-.U*J0?V%(9O%E:5\B 6[<:^M(IF;%0D0^3T>AT6$AM>I?G
M_.R=NSRW5<BU4>^<\%512/=PK7*[N>B->\V#6[U:!WHPO#POY4J]5^%#^<[A
M;MAJR72AC-?6"*>6%[VK\<OK*:WG!?_6:N,[UX*8+*S]2#??9Q>]$0%2N4H#
M:9#X=Z=N5)Z3(L#XO=;9:TV28/>ZT?Z:N8/+0GIU8_-?=!;6%[UY3V1J*:L\
MW-K-/U3-9T;Z4IM[_A6;N':,Q6GE@RUJ82 HM(G_Y7WMAX[ ?'1$(*D%$L8=
M#3'*;V60E^?.;H2CU=!&%TR5I0%.&PK*^^#P5D,N7/Y+@9(_'P;HHB?#M):[
MCG+)$;EQ(MY8$]9>?&<RE6TK& )$BR1ID%PGCVK\5J4#,1GW13)*)H_HF[3,
M)JQO\B@S\9^KA0\.P?_O(9)1Q?2P"BJ(E[Z4J;KH(>.]<G>J=_G-5^/3T:M'
M $Y;@-/'M#_B^L?EY@-1<WMKQ#^EJ5!,(OHMZ8NP5N+&%J4T#T)FM@PJ$U?O
M;\1\FHC*:[/B%87-]%+CE5/!65\J+@X!1Z'<8KF4I;,R70N9HW"QLD*<'51]
M@*'Q_/EX+#9KC?<.%<9H4K:J<;5TMA#L,1/((K]QDDV4RFF;>2$-&<\EX<NT
M3W/K*TBT9B+BN.KW2M,KB8(HJISU/%?+)4"#XF\H$G2)(()E:M2OR.A"YM*D
MN%^B]&M!LJ66.M5!:,.K(QQ>1,XBYD]_M$&)Y-E _-SQY5IF0",T>E> C,S_
M3C#2TYN=6&[;UU[ A^&!-"_)D5!-+H7RVO_HT"*7"XNG%EK(=78)_4IP#F^I
M^^:K>3(^>P4A;1A8K4,ZU:6XL&$-3V7Z3F<5$B%JK5TG5RNG5EBZZR@ON.F"
M'[ BCR!&Z_W:NO <FHMH3:C[5$67T[H\;T# %=8H\:"D$\1)>3\0KRL')6X[
MP<D6&:!,IN>K2F=,!Q";%()N6SGDH"O)-:IQ"C'IN*MQ )Z2UDP14%0>*9:!
MM'NF4.696"B1YM+[6$(4O)U8#(#0>.0M4B%_Z-,2B3SVV"J('7NO23?<-U#M
M@7K>* BF=F7T'XHS\/;MA]I_0*!8']?JO::PP==/1#*88*_(<U*_T0BA)/JP
M7UK$LD$I<BT7.M?(J8,ZIJT.VO8R0L<5$^M:W,F\4@T;>$H750&H)B!O2OE
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MB1;@_=+:T-R0@?:;Z^7_ %!+ P04    "  FBF588]1APA<'   H$0  &0
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MA!5[\U-S5>->R*BK^PXW.6PS@ #3G@KVM-J&M9%.O!+3X7AZRG[%@Z.M#K-
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M;M1J$E*E(JKM&-#K_!+!/@*0IRK?5N5&ZCSOM46E\1?J?XS]\6=]KR$_^3X
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M7CD#"RQ'!P-X4^8IZD[!I68KGI6BGDF!E+KW>*#[$]N.-/%,8T&IAJJDY@4
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M=)9@FLI"#).)K.]^P\XPJC[QNY5$!T-<C@KOG7,TB0&(AD!9/>IMB5-)IR)
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MSH#V"T72]1,78'BBU_\"4$L#!!0    ( ":*95A8]&^ :0(  *T%   9
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M2&>#TZI*Y)6RPDHE- M( 9/X'7A@*H06JA'[3I1+9QIA7^CD$.E2M_3;D)A
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MBRSAY4 J<EJJ,(E/8S&J&,<:X1PFB<W9$LMRXO$6022PDOOTG,]3S\CMX:T
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M$K\AT:SXT487-O#WTEJZFX0 P]^ ^7]02P,$%     @ )HIE6*OM,#,# P
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MU][Y:."!JF=BO3&R='-H(0U--;?,Z&\$E36@^U1*L]U8@O:/:?874$L#!!0
M   ( ":*95C[MGS!L (  .,%   9    >&PO=V]R:W-H965T<R]S:&5E=#(U
M+GAM;(54VV[;, Q]SU<(WC T0%%?TV198J"7#1O0;D';;0_#'A2;CH7*DBO1
M3?OWH^S$38$T>[ L4N3AH2ARMM;FWI8 R)XJJ>S<*Q'KJ>_;K(2*VQ-=@Z*3
M0IN*(XEFY=O: ,];ITKZ41"<^A47RDMGK6YATIEN4 H%"\-L4U7</)^#U.NY
M%WI;Q8U8E>@4?CJK^0IN 7_6"T.2WZ/DH@)EA5;,0#'WSL+I>>+L6X-? M9V
M9\]<)DNM[YWP+9][@2,$$C)T")Q^CW !4CH@HO&PP?3ZD,YQ=[]%_]+F3KDL
MN84++7^+',NY-_%8#@5O)-[H]5?8Y#-R>)F6MEW9NK--*&+66-35QIGD2JCN
MSY\V][#C, G><(@V#E'+NPO4LKSDR-.9T6MFG#6AN4V;:NM-Y(1R1;E%0Z>"
M_#!=&*JOP6?&5<X^/S2BIAO'8_:=WL/1'5]*L,.9CQ3)V?O9!O6\0XW>0 TC
M=JT5EI9]5CGDKP%\HMCSC+8\SZ.#B)>0G; X/&91$,4'\.(^[[C%B_^3]S%;
M2*[P=?KLS]G2HJ$7\W=?[AURLA_9=='4UCR#N4=M8L$\@I=^>!>>!I\.\$YZ
MWLDA]/26NC)O)#!=L .UVT?[(/!^VJ\BP$L$1:\CT]29%AT1+($56E*#"[5B
M1T*11C>6G.QP.J#20;4$X\HW<.5S-8P&5WRI#4=MGE^0V7LVB4]I'27)X$=1
MB(R &Z,$-@98%$_HBP<7NJH;),"2FWS-Z20,8C;^.+@":Z?4Z%E3-9(CY-2?
ME$PF>#L!CE@<!VQ(_S <L>'@3B.7K#Z0(]%)QK2.DY#M*YZ_TW@5F%4[7BQ=
M3:.PZ\%>VT^PLZYQ7\R[\7?-S4HHRR04Y!J<C$<>,]U(Z034==O&2XTT%-IM
M25,8C#.@\T)KW HN0#_7TW]02P,$%     @ )HIE6)>7')') @  1P8  !D
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MMRUQTH.R!OA>2&D.!TO0_W>D?P!02P,$%     @ )HIE6*2&F^^, P  0P@
M !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULC59M;]LV$/[N7W%07]
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MT&@\IZ,P7<OJ)DXWODULM*.FX\V2NCP:=J#U0FOW,.$$P_^&]0]02P,$%
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MD[D]-2;NQ)D>:P!JGT)I/I1&H32&HJD:D/:ITW]>;,<\HX;4,3/H4=_@8"%
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M4!IIW4%UM3?L 6=/M6FEZZQ2FV[/%?I'H[9Q",QAH\SVX'_2]!"AGG[^+!Y
M&Q6W$EHK#DG#H#3R,WU5%]^MQ'??3GR>)/I3<KVF95&DET*[;WI[:[;>]-9J
MK8< ) V#TDCK#JKK7IDSCM4-&(Y$,LNU=D@_8X1S_9S1J!:H"P-*\T%I&)1&
MH&AU;2LKQCEZ0^?-@31!1J T'Y2&06D$BE87O3)\'+OCLQ*]4)NMU#Y ><:B
M/$8QCYIO<3O50PM&9:-;;J_96EE(&@:ED=?T45W%RC5R=MA&4<0#/8'F,N4J
MWY*5(?V3$2C-!Z5A4!J!HM6EK;PBY_@MLS*0:;,4'9+F@](P*(U T>JB5VZ7
M8[>[7IN5[=2^)2N#.F*@- Q*(Z_IH[J*E5GFV(VF+W0L)%5"+BH-&V6#](!&
MH#0?E(9!:02*5M\I4-E=;N\-,[,+:?J,0&D^* V#T@@4K2YZY7JY=C/EE9EY
M!]62F>TU6RL+:F.!TLAK^JBN8F5?N78_Y%:WALI@6JCHLT<6B_*NQ>5?O1LE
MA#1L1J T'Y2&06D$BE:7NG*LW+?<3^2"6EF@-!^4AD%I!(I6%[VRLES[MJ+?
MI9&:IX%(& I$II!D/!GG,F/;%F'NR]T^;L,&(WO@UA*6M,%&4*]A?Q%H4 )%
MJVM3.4ZNW??8E7O1#^33E&=3])4^H8M<387D:M&H&:1?,P*E^: T#$HC4+3Z
M"*C<*G?PEBD9U,<"I?F@- Q*(U"TNNB5C^7:-SW=,K.]DYK=(6;_3B!9R)6^
MUQ^:MEA<VF&M15[N;G(VD_NSC6\^:$B\3T@"%;(N2>4RN7:OHUD2R0+&'\W9
M1F%>[G8Z:=J(:P_=^K[:+RH&C4J@:'5Y*OO(M=M'>TR4U_2))WG29LH$]9I
M:3XH#8/2"!2M_DY$Y35Y;^DU>:!>$RC-!Z5A4!J!HM5%K[PFS^YX?*V2<D"E
M7$1"SJD,MTZ:=EQKF4&-)U :!J61)<UQ-Z:7_L;&^+I\E<GD[3*9VJQX[+#6
MXKE[K'A 0V)0&H&BE=IU-UZ#3)B<%"^L9JC8HU:^'+@^NWXI]J)X%?39^4OG
M%)>OME:8\DW;:RHG/,U0S"*-[!T>ZV<L6;Z\6AXH,2M>MAP+I412?)TR&C)I
M"NC?(R'4ZL $6+]"//P?4$L#!!0    ( ":*95@X1T^0Z (  ,\,   9
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M+:7!8G;#$MLM*!N ^RLIS6%B#V@;>/8;4$L#!!0    ( ":*95B5Y_Z'.0,
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M%'4);RL$05):C73)65=&G;*:LS6ON>4X6@L=CW2?O,O1 X$_VTPG+\<%IH/
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M=#0U+GAM;+6=76_B2!J%_TJ)'>W.2-F /_CJ39"2U,=$VIY&'?7,Q6HO'%R
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M?!EG.ZC7YU&4[C>R .5-I";_ U!+ P04    "  FBF58KS*53R4%  !T'@
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MP7F%\JT'YZP/&1PJ(;2,2&N.,6)=2IQ-,,\26(/#2<GAY)6/RXE-WFV">9;
M&KR[3E4_.L;5"VS#MLJ/250X"/3)&0J1$5C/;6P6H/5$C_N3X:37;V:ZA=G[
MI5390FMR5:NU72-7#^0YC+-8I46US4%7(;9&0JU)@>262*CL#U!^:.J Q0Q*
M8PX=%*60#1 1B*"4LY1QO;;!%I2<D"0)PF2#?)*&$FIU_2E:22^D@%.O&*Z=
M$\J-05Q,N26T)N6XHAP;*?^8Q2O@$*B"70ZI *HZL@/U0E81U:MTG<D,4L)&
M];629L2_=.,7:/5U/X!%/QP?'?"VO#99J\2':ZRQBR,I3B-VH!0]ZKV]S+B_
MA<1Y]F0R8U[,E%5)80NMR6<E*MS^*Q]/KE7M817-LX76)+\2-:Y9U7SG"74J
M1?!@A$?X.%O:U#^>+;0F597\<<WZYZO['OV#BD.LE3.K:L@JFF<+K<EL)9K<
MT6MG *N2RBJ:9PNM27XEL%RSPGKMNFO<6G>YQYG$JAJSA=:DO-)CKE%VJ$S2
M S4;9'Z^M+\N;,V %Z]?JQ++%EKS']N5QL+.*R</;%-F+:RB>;;0FN17H@V;
M1=OWE0]FT(L)=4^*$7<R&O;QZ$@WV'+;Y*I26_A_5EMF_(MI.U5;9VBS*K>Z
MM>NXF/*-OM84R&=9(O/[K+*UO#J]U1>&1^T+]\;++T KF/P^]H'P39@(%-$U
M0#K7(Z@;>7[%F;](ENI+OQ63DL7Z<4L)'&MJ /2O&9,O+\I!>=$\_Q=02P,$
M%     @ )HIE6/N,D'_:!   Z!4  !D   !X;"]W;W)K<VAE971S+W-H965T
M-#<N>&ULM5A=DZ(X%/TK*79JJ[NJ6P@(:*]:I3*S.U4[,UWC]/;#UCZDX:I4
M W&2H.V_WP1H5$3\*.=%0[CWY)Z3Y'*3WHJR5SX'$.@MCA+>U^9"+!YTG?MS
MB EOT04D\LV4LI@(^<AF.E\P($'F%$>Z:1B.'I,PT0:]K.^1#7HT%5&8P"-#
M/(UCPM8CB.BJKV'MO>-[.)L+U:$/>@LR@PF(I\4CDT]ZB1*$,20\I EB,.UK
M0_S@85<Y9!;_A+#B6VVDJ+Q0^JH>/@=]S5 1002^4!!$_BUA#%&DD&0</PM0
MK1Q3.6ZWW]$_9>0EF1?"84RCYS 0\[[6T5  4Y)&XCM=_04%(5OA^33BV2]:
M%;:&AOR4"QH7SC*".$SR?_)6"+'E8-H'',S"P:PZ6 <<K,+!JCA(*>L=VH5#
M.U,FIY+IX!%!!CU&5X@I:XFF&IF8F;>D'R9JWB>"R;>A]!.#CS_34*SO1U*Z
M (UI+-<3)]F,W*.)7&1!&@&B4S01U']%WQ;J%4=#-5O2#]UX($@8\5MI_DP8
M(XF0K:>)AVX^W*(/2$=\3AAP%";H*0D%OY.=LOUC3E-.DH#W="%9J%ATOXAX
ME$=L'H@8F^@+3<2<HX]) ,$N@"[IEQJ8[QJ,S$9$#_P6LO =,@W3J@EH?+J[
M6>/NG>Z.&]A8Y8Q:&9YU &^B!$<U$SI4TS,#N6D%&JW1MMTC66?=PQ5A ?KW
M;PF)/@N(^7]U\Y./WZX?7R6J![X@/O0UF8DXL"5H@]]_PX[Q1YVVUP3SK@2V
MHWN[U+W=A#[XFL8OP-1>*3:"7.LCF(5)$B8SF9LBDOA0)V<.ZV2P*DTO!U;7
M-+ KU])R6ZD:.\/%#K9V[;S&,"\4P2Y%L,\6X4_U7]VH.75[CY)IXVZWVZY0
MW[?#)L;8MBO4&X.[D+I34G?.ICY6<QY%<H=1AN1'>@KA 26</8;W=J=CMBN3
M.ZZQLQS3[CH5)1ICO5 )MU3"/5L)F:N/; -WCYG=D8O!K"JP;U>[7;P:N\IV
MV2'7*<EUSB?W!LP/.7F):IEU]E=OUS#MMEMAUCCPN:GP2F [&G5+C;J-&CUG
MU18$]V0)3%:/"'*! "U8Z,M?*6!6%YR8(?/1NML"&BVW*E^-E=7"U671&/F%
MNF!C4VT9UU*F(6T6@^#V-M=6MUL1I,[,;EF5Y.HUAWRI)%L%*+Z6)*>GTV+,
M'>J=EEO]KM298;-EXZI$C10NE<C<2&1>2Z+C>;882YZ$-IS=5K78**R.[#FO
MSFQGT^TRWM2PN+%4.XMQ<_(M!MJ)$+=,I\KWJG7HM=!VU=M4HKBY%-U3CX&Z
M E +PY=')R8/VRF)D  6HQMY&EL#8?SV#GU+!1<D6T&U4C:/VLEQ4!O%^?G,
M;*. K.N.>.,3H7 .A9Q#0-Z)0$X14Y.\FQH7-Q>YE\I[;*4VC^H65#KO\LJ#
M\$%YKU0(%QK_BK(:;^IJW%Q8#V<S!C,B (52W##AH8^6)$KA^(+-@=V=)+:7
MZ:Y4*A=:_8K"&V\J;]Q<>C=H=6SUN7M:[2G5./;92ET)+5=*W[H"BX'-LJM$
M+O=CFHC\)JCL+:\KA]DE7:5_I*XQLZNU#4Q^!_J%,%FK<A3!5$+*CZ'<%BR_
M5LP?!%UD%VTO5 @:9\TYD "8,I#OIY2*]P<U0'FY._@?4$L#!!0    ( ":*
M95BRPS=0CP,  *,.   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;,57
M;6_B.!#^*U9.6NU)U^8- MN#2$"[VDI;;=5J=S^<[H-+!K":Q%G;0/GW.W;2
M0%@GHG=(^P5B9^;Q\XS'SLQHR\6S7 $H\I*EN1P[*Z6**]>5\Q5D5%[R G)\
ML^ BHPJ'8NG*0@!-C%.6NH'G16Y&6>[$(S-W+^(17ZN4Y7 OB%QG&16[*:1\
M.W9\YW7B@2U72D^X\:B@2W@$];6X%SAR:Y2$99!+QG,B8#%V)O[5S.]I!V/Q
MC<%6'CP3+>6)\V<]N$W&CJ<900ISI2$H_FU@!FFJD9#'CPK4J=?4CH?/K^@?
MC7@4\T0ES'CZG25J-7:&#DE@0=>I>N#;3U )ZFN\.4^E^27;RM9SR'PM%<\J
M9V20L;S\IR]5( X<@K#%(:@<@B,'?]#B$%8.H1%:,C.RKJFB\4CP+1':&M'T
M@XF-\48U+-?;^*@$OF7HI^*;'VNF=A=3C$1"9CS#])#4!/B"/)9;2_B"3"3N
M<Z'G)<'<(3=2,8PA^GRD3)!O-%V#MOM2V;R_!D59*O\<N0I9ZK7<><5H6C(*
M6ACY ;GCN5I)<I,GD#0!7)17:PQ>-4Z#3L1KF%^2T/^+!%X06@C-3G</.NB$
M=<A#@Q>VX#VNJ !BB?A$")HO 0^)(M,=.;2[ISLS/=E2D9!_/B,DN560R7]M
M 2[7[]G7UQ?#E2SH',8.GGP)8@-._.X//_+^M@7G3&"-4/7J4/6ZT..;EP*/
M.^K?\!1CE&*JZD/ LG5FTUV"^67@]06VB;W+8=0;N9M#1969US ;[*T:5/LU
MU?[;J=*7-JK]7ZGZER:_&E0M9DAU$-JY1C77J)/K Y//%PL!0%BN +=-$8&'
MN2NTD8V(%_:/^-K-_"BP$Q[4A ?_C7![@ =6)KUCPBUF+7R'-=_A:<F0L U+
M($_(CD&:V'@.+<EXQ+'3I,'O0\WO0R>_N_:-[G1\Z]UQ)K"&1M_;?]J\WWS1
M5@3.%*USH37#=5 )^*<E+9ZPC+QG.=D!%2V?\&ZH?NE*(I*93[E5[?^!:$H,
M]A*#[KQOOR^Z/=^\E6=":^K<5QC^[RXQ_+/6&.=":X9K7V7X)Y89IV1^-U14
MI:U?IBVF;T)W]OP_"<BFSSTH]S,02],%23+GZUR557$]6W=:$]-?',U/=0=F
MVH@]3-F^W5&Q9%C'I[! 2"PYL! 194=4#A0O3%/QQ!6V*.9QA5TD"&V [Q><
MJ]>!7J#N2^.?4$L#!!0    ( ":*95CG<]T_- ,  .X+   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0Y+GAM;,U676_3,!3]*U9 :$AL^>CW:".M[8!)(*9U
M@P?$@YO<-M:<.-ANN_'KN7;2+.VZ"J0\\-+8SKW'YQS?N'>X$?)>)0":/*0\
M4R,GT3H_=UT5)9!2=29RR/#-0LB4:IS*I:MR"32V22EW \_KNBEEF1,.[=JU
M#(=BI3G+X%H2M4I3*A_'P,5FY/C.=N&&+1-M%MQPF-,ES$#?Y=<29VZ%$K,4
M,L5$1B0L1LZ%?S[Q/9-@([XQV*C:F!@I<R'NS>0J'CF>800<(FT@*#[6, '.
M#1+R^%6".M6>)K$^WJ)_L.)1S)PJF C^G<4Z&3E]A\2PH"NN;\3F$Y2".@8O
M$ES97[(I8SV'1"NE15HF(X.49<63/I1&U!+\[@L)09D0[">T7TAHE0DM*[1@
M9F5-J:;A4(H-D28:T<S >F.S40W+S#'.M,2W#/-T>/EKQ?3CZ1B=B,E$I%@>
MBEJ#3\D,:R9><2!B0<JX^?.XRP<S!G(R!4T95V\Q\VXV)2>OWY+7A&7D-A$K
M1;-8#5V-C,V^;E2R&Q?L@A?8^0'Y(C*=*'*9Q1#O K@HM=(;;/6.@Z.(4XC.
M2,M_1P(O:!T@-/G[]. (G59E?\OBM5ZR/\VY> 0@,Y!K%N$SH1+(@>.XX%Q$
MQ?#K@MQ ))89^XU1UR"9,,%**_+C,VY KC2DZN<ANPLV[<-LS)5QKG(:P<C!
M.T$A)7#"-Z_\KO?^D%4-@>T8UZZ,:Q]##V^%IIQ O2JCFEV'M!> /0MH;K=U
MV/<Z@Z&[KFMZ'M3SVEX5M,.U4W'M'.5Z@^JIC!*"'P&9PAKOSAQO0KW]= Z1
M/8KXKP?5$-B.^&XEOOM?57BW2>,: MLQKE<9UVNZP@O ;JUXVX'7WJOPYT%!
MO_89['#M5US[1[E^A PDLC4%?A'CWQ136E+S!WVLQH]B_NM1-02V(W]0R1_\
M5S4^:-*XAL!VC/.]I_;#:[K*2\3Z'=WJ=SI[97X@JNWW_;TZ=VN=4PIR:1M*
MA116F2Z:BFJU:EHO;*NVMSXVS:SMR)Y@BD[X"Y5+EBG"88&0WED/;V-9-)?%
M1(O<]F=SH;';L\,$&W*0)@#?+X30VXG9H&KQPS]02P,$%     @ )HIE6)&"
MW\,X!@  W#0  !D   !X;"]W;W)K<VAE971S+W-H965T-3 N>&ULM9MM3^LV
M%,>_BM5-TYUT1Q/W$58J 4DT="\:@G'W8MH+D[AM1!XZVVUAVH>?G80D+JYO
M@P[WQ:5)<W['R=\^CO_@V2YG3WQ%J4#/:9+Q\]Y*B/59O\_#%4T)/\G7-)/?
M+'*6$B$/V;+/UXR2J A*DSYVG'$_)7'6F\^*<[=L/LLW(HDS>LL0WZ0I82^7
M-,EWYSVW]WKB+EZNA#K1G\_69$GOJ7A8WS)YU*\I49S2C,=YAAA=G/<NW+,
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MNLRSMZRS*J#&%!1-5Z4QIO!W_AS)7)]O*8OS2%7F\7LK,ZA[!4KS0&D^*"V
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M2.E=]3"3LNJ_U42+E6UA<Z&Q(=IAAE<62!. WQ="Z-W$;-!<@O$?4$L#!!0
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MVD/1P.EN#XL]T-+(XI8BM>3(3O]]24I6[(26>^C%(JEYC^^-1^1,=U)]UP4
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M;(!YGTN)^XG=H&MVYS\!4$L#!!0    ( ":*95A\00W.PP,  -,,   9
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MD2/>RC&)3R+.,+F =NL5Q%'</D!H^O?N\0DZ[69WVAZO<P1O855R#S>%T].
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MHD]'4%=E1]6QJO O]YVR5 ?X9D:5&FIG0/-+16K6';= 4_N-?P-02P,$%
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ML_SK-_GM-:UUV1SR6?>YQ.034$L! A0#%     @ )HIE6 =!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  FBF58O@AE>.\    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  FBF58F5R<(Q &  "<)P  $P
M    @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ":*95@-
M$8E(=@@  'HU   8              " @0X(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  FBF58AGSZ#*8%   7&   &
M    @(&Z$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M)HIE6'XF=0G9 @  0 L  !@              ("!EA8  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ":*95B(/YPV\@0  $04   8
M          " @:49  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    "  FBF58SGCAZM4$  !P&@  &               @('-'@  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ )HIE6,J8-*@@ @  .P0
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M!CP  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ":*95B
ML/!]H 0  #,+   9              " @6U@  !X;"]W;W)K<VAE971S+W-H
M965T,3 N>&UL4$L! A0#%     @ )HIE6)B@EK8O!0  Y1,  !D
M     ("!1&4  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ":*95ACU&'"%P<  "@1   9              "
M@2I\  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ )HIE
M6,_$W%0>"   V!0  !D              ("!>(,  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    "  FBF58[:E1HRH(   J%P  &0
M        @('-BP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( ":*95C#2Q%V40L   P@   9              " @2Z4  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ )HIE6*9\N$QO P  K@<
M !D              ("!MI\  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    "  FBF586/1O@&D"  "M!0  &0              @(%<HP
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ":*95BY7G"0
M624  )%[   9              " @?RE  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ )HIE6"6!2I%F P  $@@  !D
M ("!C,L  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  F
MBF58J^TP,P,#  "D!@  &0              @($ISP  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( ":*95C[MGS!L (  .,%   9
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M970R.2YX;6Q02P$"% ,4    "  FBF58]A4EF^D%   3#P  &0
M    @(' XP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M ":*95C/%!I2< ,   $(   9              " @>#I  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ )HIE6 8,KSUK"@  /'(  !D
M             ("!A^T  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    "  FBF58/>90HW('  !./   &0              @($I^   >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( ":*95@X1T^0Z (
M ,\,   9              " @=+_  !X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ )HIE6*\3/77* @  $@@  !D              ("!
M\0(! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  FBF58
M?[ZGLS0#  "C"0  &0              @('R!0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( ":*95CV[O@): (  ,P%   9
M      " @5T) 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ )HIE6)7G_H<Y P  W T  !D              ("!_ L! 'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  FBF58Z.KG@M\"   6"
M&0              @(%L#P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( ":*95C8EG$7Z00  +8?   9              " @8(2 0!X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ )HIE6*)3'0Q+
M P  &PD  !D              ("!HA<! 'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    "  FBF58=J#@GZX"   "!P  &0
M@($D&P$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( ":*
M95B6&>3[=P(  &X'   9              " @0D> 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ )HIE6!:8\Y8( P  A@L  !D
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M=#0X+GAM;%!+ 0(4 Q0    ( ":*95CG<]T_- ,  .X+   9
M  " @>H[ 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M)HIE6)&"W\,X!@  W#0  !D              ("!53\! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    "  FBF58E-7*WK4"   0!P  &0
M            @('$10$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( ":*95CV?]LV! ,  &0*   9              " @;!( 0!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ )HIE6 >N !%1 P
M^ H  !D              ("!ZTL! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    "  FBF58?$$-SL,#  #3#   &0              @(%S
M3P$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( ":*95@%
M3XK,* ,  ,X)   9              " @6U3 0!X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ )HIE6 ]0X:P3 P  !PH  !D
M     ("!S%8! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
M"  FBF58=H3>AF8#  #&%@  #0              @ $66@$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( ":*95B7BKL<P    !,"   +              "
M :== 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ":*95@K&*0/K00  (0E   /
M              "  9!> 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  F
MBF58##^0_.4!  !_(0  &@              @ %J8P$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  FBF58C^&W:=,!   V(0  $P
M            @ &'90$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     0 !
+ '<1  "+9P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>106</ContextCount>
  <ElementCount>289</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100090 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Description of Business, Organization and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity</Role>
      <ShortName>Description of Business, Organization and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100130 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Equity-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensation</Role>
      <ShortName>Equity-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Equity-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationTables</Role>
      <ShortName>Equity-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Net Loss Per Share (Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTable</Role>
      <ShortName>Net Loss Per Share (Table)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Description of Business, Organization and Liquidity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails</Role>
      <ShortName>Description of Business, Organization and Liquidity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Fair Value Measurements - Summary of Assets Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Assets Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Leases - Schedule of Quantitative information Regarding Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails</Role>
      <ShortName>Leases - Schedule of Quantitative information Regarding Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Leases - Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails</Role>
      <ShortName>Leases - Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Convertible Preference Shares - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails</Role>
      <ShortName>Convertible Preference Shares - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Equity-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Equity-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails</Role>
      <ShortName>Equity-Based Compensation - Schedule of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Equity-Based Compensation - Summary of Assumptions for Estimated Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails</Role>
      <ShortName>Equity-Based Compensation - Summary of Assumptions for Estimated Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails</Role>
      <ShortName>Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Income Taxes - Reconciliation of the Statutory Income Tax Rate to our Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the Statutory Income Tax Rate to our Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Income Taxes - Schedule of Principal Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Principal Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Share - Basic and Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="iobt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="iobt-20231231.htm">iobt-20231231.htm</File>
    <File>iobt-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img134051827_0.jpg</File>
    <File>img134051827_1.jpg</File>
    <File>img134051827_10.jpg</File>
    <File>img134051827_11.jpg</File>
    <File>img134051827_12.jpg</File>
    <File>img134051827_13.jpg</File>
    <File>img134051827_14.jpg</File>
    <File>img134051827_15.jpg</File>
    <File>img134051827_16.jpg</File>
    <File>img134051827_17.jpg</File>
    <File>img134051827_18.jpg</File>
    <File>img134051827_19.jpg</File>
    <File>img134051827_2.jpg</File>
    <File>img134051827_20.jpg</File>
    <File>img134051827_21.jpg</File>
    <File>img134051827_22.jpg</File>
    <File>img134051827_23.jpg</File>
    <File>img134051827_3.jpg</File>
    <File>img134051827_4.jpg</File>
    <File>img134051827_5.jpg</File>
    <File>img134051827_6.jpg</File>
    <File>img134051827_7.jpg</File>
    <File>img134051827_8.jpg</File>
    <File>img134051827_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="461">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "iobt-20231231.htm": {
   "nsprefix": "iobt",
   "nsuri": "http://www.iobiotech.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "iobt-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "iobt-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "keyStandard": 251,
   "keyCustom": 38,
   "axisStandard": 18,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 15,
   "hidden": {
    "total": 8,
    "http://fasb.org/us-gaap/2023": 5,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 106,
   "entityCount": 1,
   "segmentCount": 44,
   "elementCount": 552,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 461,
    "http://xbrl.sec.gov/dei/2023": 39
   },
   "report": {
    "R1": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100040 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100060 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit",
     "longName": "100070 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_203b870a-e8de-4c48-bb69-1f143a5d1919",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_203b870a-e8de-4c48-bb69-1f143a5d1919",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical",
     "longName": "100080 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "iobt:PaymentsOfStockAndWarrantIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "100090 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity",
     "longName": "100100 - Disclosure - Description of Business, Organization and Liquidity",
     "shortName": "Description of Business, Organization and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "100110 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "100120 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements",
     "longName": "100130 - Disclosure - License and Collaboration Agreements",
     "shortName": "License and Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "longName": "100140 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet",
     "longName": "100150 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "100160 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeases",
     "longName": "100170 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "100180 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquity",
     "longName": "100200 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensation",
     "longName": "100210 - Disclosure - Equity-Based Compensation",
     "shortName": "Equity-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "100220 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "longName": "100230 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents",
     "longName": "100240 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "100260 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "100270 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "longName": "100280 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesTables",
     "longName": "100300 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "100310 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationTables",
     "longName": "100320 - Disclosure - Equity-Based Compensation (Tables)",
     "shortName": "Equity-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables",
     "longName": "100330 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTable",
     "longName": "100340 - Disclosure - Net Loss Per Share (Table)",
     "shortName": "Net Loss Per Share (Table)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
     "longName": "100350 - Disclosure - Description of Business, Organization and Liquidity - Additional Information (Details)",
     "shortName": "Description of Business, Organization and Liquidity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ce55bd70-3918-4ae0-9cad-0dfde777548f",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails",
     "longName": "100370 - Disclosure - Fair Value Measurements - Summary of Assets Measured at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Summary of Assets Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_735c9fc1-57ba-400b-99d6-3730bae07801",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_735c9fc1-57ba-400b-99d6-3730bae07801",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "100390 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "iobt:FairValueLiabilitiesLevel1ToLevel2TransfersAmount1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "iobt:FairValueLiabilitiesLevel1ToLevel2TransfersAmount1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "100400 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "100410 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "longName": "100420 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "100430 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "iobt:AccruedContractResearchAndDevelopmentCostsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "iobt:AccruedContractResearchAndDevelopmentCostsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "100440 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails",
     "longName": "100450 - Disclosure - Leases - Schedule of Quantitative information Regarding Leases (Details)",
     "shortName": "Leases - Schedule of Quantitative information Regarding Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails",
     "longName": "100460 - Disclosure - Leases - Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases (Details)",
     "shortName": "Leases - Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "100470 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_b343bb6c-f4f5-4b19-844e-c92494b10a7e",
      "name": "iobt:ContractualObligationsTerminationNoticePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b343bb6c-f4f5-4b19-844e-c92494b10a7e",
      "name": "iobt:ContractualObligationsTerminationNoticePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
     "longName": "100480 - Disclosure - Convertible Preference Shares - Additional information (Details)",
     "shortName": "Convertible Preference Shares - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "100490 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_1dcc1f3e-ab3f-4d97-8c1b-44559a31ab42",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7888a195-a9c8-438b-8292-c9c9a460c8d3",
      "name": "iobt:WarrantsIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails",
     "longName": "100500 - Disclosure - Equity-Based Compensation - Additional Information (Details)",
     "shortName": "Equity-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails",
     "longName": "100510 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Activity (Details)",
     "shortName": "Equity-Based Compensation - Schedule of Stock Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_229bed5d-8df9-47a3-bf23-b8454739ccb1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
     "longName": "100520 - Disclosure - Equity-Based Compensation - Summary of Assumptions for Estimated Fair Value of Options (Details)",
     "shortName": "Equity-Based Compensation - Summary of Assumptions for Estimated Fair Value of Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails",
     "longName": "100530 - Disclosure - Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Details)",
     "shortName": "Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_77b4e90b-4f57-4362-beca-0e8dcbcfba19",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "100540 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "iobt:ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "iobt:ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails",
     "longName": "100550 - Disclosure - Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails",
     "longName": "100560 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails",
     "longName": "100570 - Disclosure - Income Taxes - Reconciliation of the Statutory Income Tax Rate to our Effective Income Tax Rate (Details)",
     "shortName": "Income Taxes - Reconciliation of the Statutory Income Tax Rate to our Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails",
     "longName": "100580 - Disclosure - Income Taxes - Schedule of Principal Components of Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Schedule of Principal Components of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails",
     "longName": "100590 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Common Share (Details)",
     "shortName": "Net Loss Per Share - Basic and Diluted Net Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_2445c1c9-369b-4c39-93fc-0bb73e29ab07",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "longName": "100600 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_0d4b831b-94cf-4ac9-aae8-23f925e98a73",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0d4b831b-94cf-4ac9-aae8-23f925e98a73",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting standards update [extensible enumeration]",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r206",
      "r207",
      "r208",
      "r253",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r270",
      "r369",
      "r370",
      "r371",
      "r400",
      "r401",
      "r412",
      "r413",
      "r414",
      "r424",
      "r425",
      "r426",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r456",
      "r457",
      "r460",
      "r461",
      "r462",
      "r463",
      "r476",
      "r477",
      "r480",
      "r481",
      "r482",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r749"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r700"
     ]
    },
    "iobt_AccruedContractResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "AccruedContractResearchAndDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued contract research and development costs current.",
        "label": "Accrued Contract Research And Development Costs Current",
        "terseLabel": "Accrued contract research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "iobt_AccruedResearchAndDevelopmentCostsPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "AccruedResearchAndDevelopmentCostsPoliciesTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Research and Development Costs",
        "label": "Accrued Research and Development Costs Policies [Text Block]",
        "documentation": "Accrued research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r171",
      "r540"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r95",
      "r177",
      "r536",
      "r556",
      "r560"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Other Comprehensive Loss",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13",
      "r35",
      "r428",
      "r431",
      "r499",
      "r551",
      "r552",
      "r736",
      "r737",
      "r738",
      "r746",
      "r747",
      "r748"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r700",
      "r820"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r572",
      "r746",
      "r747",
      "r748",
      "r795",
      "r823"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "terseLabel": "Equity-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r332"
     ]
    },
    "iobt_AdjustmentsToAdditionalPaidInCapitalStockIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssued",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital stock issued.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued",
        "negatedLabel": "Issuance of class B preference shares, net of issuance costs of $0"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total equity-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r377"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Outstanding potentially dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r173",
      "r196",
      "r236",
      "r247",
      "r249",
      "r255",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r417",
      "r421",
      "r458",
      "r531",
      "r609",
      "r700",
      "r712",
      "r757",
      "r758",
      "r807"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "terseLabel": "Total current assets",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r178",
      "r196",
      "r255",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r417",
      "r421",
      "r458",
      "r700",
      "r757",
      "r758",
      "r807"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total assets measured at fair value",
        "totalLabel": "Total assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r255",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r417",
      "r421",
      "r458",
      "r757",
      "r758",
      "r807"
     ]
    },
    "iobt_AtTheMarketEquityProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "AtTheMarketEquityProgramMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Equity Program",
        "label": "At-The-Market Equity Program [Member]",
        "documentation": "At-the-market equity program."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r169",
      "r674"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r104",
      "r193"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r104"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r817"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Supplemental disclosures of non-cash financing activities:",
        "terseLabel": "Supplemental disclosures of non-cash investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, accounting standards update, adopted [true false]",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r161",
      "r162",
      "r205",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r264",
      "r265",
      "r270",
      "r399",
      "r412",
      "r413",
      "r423",
      "r424",
      "r425",
      "r434",
      "r435",
      "r445",
      "r456",
      "r457",
      "r459",
      "r460",
      "r461",
      "r476",
      "r480",
      "r481",
      "r482",
      "r495",
      "r513",
      "r514",
      "r549",
      "r550"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r161",
      "r162",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r264",
      "r265",
      "r266",
      "r270",
      "r399",
      "r412",
      "r413",
      "r414",
      "r423",
      "r424",
      "r425",
      "r426",
      "r434",
      "r435",
      "r436",
      "r439",
      "r445",
      "r456",
      "r457",
      "r459",
      "r460",
      "r461",
      "r476",
      "r480",
      "r481",
      "r482",
      "r495",
      "r513",
      "r514",
      "r549",
      "r550",
      "r728"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect [true false]",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r206",
      "r217",
      "r261",
      "r402"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ClassBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ClassBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class B convertible preferred stock.",
        "label": "Class B Convertible Preferred Stock [Member]",
        "terseLabel": "Class B Convertible Preference Stock"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ClassCConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ClassCConvertiblePreferredStockMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class C convertible preferred stock.",
        "label": "Class C Convertible Preferred Stock [Member]",
        "terseLabel": "Class C Convertible Preference Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r174",
      "r175",
      "r176",
      "r196",
      "r222",
      "r223",
      "r226",
      "r228",
      "r234",
      "r235",
      "r255",
      "r278",
      "r280",
      "r281",
      "r282",
      "r285",
      "r286",
      "r304",
      "r305",
      "r308",
      "r311",
      "r319",
      "r458",
      "r565",
      "r566",
      "r567",
      "r568",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r597",
      "r619",
      "r639",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r726",
      "r742",
      "r750"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r234",
      "r304",
      "r305",
      "r306",
      "r308",
      "r311",
      "r317",
      "r319",
      "r565",
      "r566",
      "r567",
      "r568",
      "r690",
      "r726",
      "r742"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r146",
      "r159"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r76",
      "r532",
      "r596"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r272",
      "r273",
      "r661",
      "r756"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Ordinary Shares",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_CommonStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockConversionBasis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock conversion basis",
        "label": "Common Stock, Conversion Basis",
        "documentation": "Description of basis for conversion of convertible common stock."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "iobt_CommonStockMaximumAggregateOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "CommonStockMaximumAggregateOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, maximum aggregate offering price",
        "label": "Common Stock, Maximum Aggregate Offering Amount",
        "documentation": "Common stock, maximum aggregate offering amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r703",
      "r704",
      "r706",
      "r707",
      "r708",
      "r709",
      "r746",
      "r747",
      "r795",
      "r819",
      "r823"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r597"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock shares issued",
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "verboseLabel": "Common stock shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r89",
      "r597",
      "r615",
      "r823",
      "r824"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value of $0.001 per share; 300,000,000 shares authorized at December 31, 2023 and December 31, 2022; 65,880,914 and 28,815,267 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r534",
      "r700"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Total comprehensive loss",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r180",
      "r182",
      "r188",
      "r527",
      "r545"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income (loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r677"
     ]
    },
    "iobt_ContractualObligationsTerminationNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ContractualObligationsTerminationNoticePeriod",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligations termination notice period.",
        "label": "Contractual Obligations Termination Notice Period",
        "terseLabel": "Contractual obligations termination notice period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Exchange of preferred and ordinary shares of IO Biotech ApS into common stock of IO Biotech, Inc. upon closing of initial public offering",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Note",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r287",
      "r288",
      "r293",
      "r294",
      "r295",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible Preference Shares",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "iobt_ConvertibleNotesConversionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ConvertibleNotesConversionCost",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes conversion cost.",
        "label": "Convertible Notes Conversion Cost",
        "terseLabel": "Convertible notes conversion cost"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ConvertibleNotesEquityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ConvertibleNotesEquityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes equity value.",
        "label": "Convertible Notes Equity Value",
        "terseLabel": "Convertible notes equity value"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ConvertibleNotesMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes.",
        "label": "Convertible Notes [Member]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ConvertibleNotesRiskFreeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ConvertibleNotesRiskFreeRate",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes risk free rate.",
        "label": "Convertible Notes Risk Free Rate",
        "terseLabel": "Convertible notes risk free rate"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ConvertibleNotesTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ConvertibleNotesTerm",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes term.",
        "label": "Convertible Notes Term",
        "terseLabel": "Convertible notes term"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ConvertibleNotesVolatilityPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ConvertibleNotesVolatilityPercentage",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes volatility percentage.",
        "label": "Convertible Notes Volatility Percentage",
        "terseLabel": "Convertible notes volatility percentage"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ConvertiblePreferenceSharesPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ConvertiblePreferenceSharesPoliciesTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preference Shares",
        "label": "Convertible Preference Shares Policies [Text Block]",
        "documentation": "Convertible preference shares policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Convertible preference share issued upon conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r59",
      "r88",
      "r116",
      "r314"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r745",
      "r793"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r745"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r398",
      "r406",
      "r745"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r745",
      "r793"
     ]
    },
    "country_DK": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "DK",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denmark",
        "label": "DENMARK"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Convertible notes converted",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r43"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Number of preferred stock shares upon conversion",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r43"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r82",
      "r83",
      "r131",
      "r133",
      "r201",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r479",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r743"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Convertible notes interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r288"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r201",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r479",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r743"
     ]
    },
    "iobt_DeemedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "DeemedDividend",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend.",
        "label": "Deemed Dividend",
        "terseLabel": "Deemed dividend"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Summary of Prepaid Expenses and Other Current Assets",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r745",
      "r792",
      "r793"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Deferred",
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r745",
      "r792"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Provision for deferred tax",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r125",
      "r153",
      "r405",
      "r406",
      "r745"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r132",
      "r392"
     ]
    },
    "us-gaap_DeferredRentCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRentCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Rent Credit",
        "terseLabel": "Deferred rent",
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r804"
     ]
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRentCreditCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred rent liability",
        "label": "Deferred Rent Credit, Current",
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as current."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r732",
      "r804"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r745",
      "r792",
      "r793"
     ]
    },
    "iobt_DeferredTaxAssetsAccruedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "DeferredTaxAssetsAccruedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Accrued Compensation",
        "documentation": "Deferred Tax Assets, Accrued Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized R&amp;D",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r791"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset (liability)",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred tax assets",
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r791"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r791"
     ]
    },
    "us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsRegulatoryAssetsAndLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Regulatory Assets and Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences derived regulatory assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r791"
     ]
    },
    "iobt_DeferredTaxAssetsRightOFuseLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "DeferredTaxAssetsRightOFuseLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets right of use lease liability.",
        "label": "Deferred Tax Assets Right O fUse Lease Liability",
        "terseLabel": "ROU Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r791"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Equity-based compensation expense",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r791"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "terseLabel": "Deferred tax assets and valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Other Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r791"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Assets",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r791"
     ]
    },
    "iobt_DeferredTaxLiabilitiesRightOfUseLeaseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "DeferredTaxLiabilitiesRightOfUseLeaseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use lease asset.",
        "label": "Deferred Tax Liabilities Right of Use Lease Asset",
        "terseLabel": "ROU Lease Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Total",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r53"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation expense",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r238"
     ]
    },
    "iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "DescriptionOfBusinessOrganizationAndLiquidityLineItems",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business, organization and liquidity.",
        "label": "Description Of Business Organization And Liquidity [Line Items]",
        "terseLabel": "Description Of Business Organization And Liquidity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_DescriptionOfBusinessOrganizationAndLiquidityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "DescriptionOfBusinessOrganizationAndLiquidityTable",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business, organization and liquidity.",
        "label": "Description Of Business Organization And Liquidity [Table]",
        "terseLabel": "Description Of Business Organization And Liquidity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r334",
      "r365",
      "r366",
      "r368",
      "r696"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendDeclaredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendDeclaredMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend Declared",
        "label": "Dividend Declared [Member]",
        "documentation": "Distribution of earnings in the form of cash, property or capital stock declared by the board of directors to be distributed to shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendPaidMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendPaidMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend Paid",
        "label": "Dividend Paid [Member]",
        "documentation": "Distribution of earnings to shareholders either in cash, property, or capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends",
        "totalLabel": "Dividends, Total",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r118"
     ]
    },
    "us-gaap_DividendsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends [Axis]",
        "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends [Domain]",
        "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720",
      "r722"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents incorporated by reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Danish Tax Authority",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r219",
      "r222",
      "r226",
      "r227",
      "r228",
      "r232",
      "r443",
      "r444",
      "r528",
      "r546",
      "r678"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share Basic [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r226"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r222",
      "r226",
      "r227",
      "r228",
      "r232",
      "r443",
      "r444",
      "r528",
      "r546",
      "r678"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r229",
      "r230",
      "r231"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax benefit at the statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r385",
      "r408"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r794"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r789"
     ]
    },
    "iobt_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation deductible expense research and development.",
        "label": "Effective Income Tax Rate Reconciliation Deductible Expense Research And Development",
        "terseLabel": "R&amp;D Deduction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationDeductions",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Deduction, Percent, Total",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r794"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior period adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r794"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheStatutoryIncomeTaxRateToOurEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Difference in tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r794"
     ]
    },
    "iobt_EmergingGrowthCompanyStatusPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "EmergingGrowthCompanyStatusPoliciesTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Emerging Growth Company Status",
        "label": "Emerging Growth Company Status Policies [Text Block]",
        "documentation": "Emerging growth company status policies."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_EmployeeEquityPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "EmployeeEquityPlanMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee equity plan.",
        "label": "Employee Equity Plan [Member]",
        "terseLabel": "Employee Equity Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation costs",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost, recognition period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefits for stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options to Purchase Common Stock",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "terseLabel": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r163",
      "r184",
      "r185",
      "r186",
      "r202",
      "r203",
      "r204",
      "r207",
      "r214",
      "r216",
      "r233",
      "r260",
      "r267",
      "r320",
      "r369",
      "r370",
      "r371",
      "r400",
      "r401",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r442",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r499",
      "r551",
      "r552",
      "r553",
      "r572",
      "r639"
     ]
    },
    "us-gaap_EquityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Fair Value Disclosure",
        "terseLabel": "Equity, fair value assumed",
        "totalLabel": "Equity, Fair Value Disclosure, Total",
        "documentation": "Fair value of the entity's equity."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Measurement Input",
        "terseLabel": "Equity securities, measurement input",
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "iobt_EquitySecuritiesTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "EquitySecuritiesTerm",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity securities term.",
        "label": "Equity Securities Term",
        "terseLabel": "Equity securities term"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of preferred and common stock of io biotech aps into common stock of io biotech, inc.",
        "label": "Exchange Of Preferred And Common Stock Of Io Biotech Aps Into Common Stock Of Io Biotech, Inc,",
        "documentation": "Exchange of preferred and common stock of io biotech aps into common stock of io biotech, inc."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ExchangeOfPreferredAndCommonStockOfSharesIoBiotechApsIntoCommonStockOfIoBiotechInc",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of preferred and common stock of io biotech aps into common stock of io biotech, inc, shares",
        "label": "Exchange Of Preferred And Common Stock Of Shares Io Biotech Aps Into Common Stock Of Io Biotech, Inc,",
        "documentation": "EExchange of preferred and common stock of shares io biotech aps into common stock of io biotech, inc."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_FairValueAdjustmentsPreferenceSharesTrancheObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "FairValueAdjustmentsPreferenceSharesTrancheObligations",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value adjustments preference shares tranche obligations.",
        "label": "Fair Value Adjustments Preference Shares Tranche Obligations",
        "negatedLabel": "Fair value adjustments on preference shares tranche obligations",
        "terseLabel": "Fair value adjustments preference shares tranche obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r454"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r454"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assets Measured at Fair Value",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r129"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r448",
      "r507",
      "r508",
      "r509",
      "r686",
      "r687",
      "r692",
      "r693",
      "r694"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r128"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r450",
      "r451",
      "r455"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r322",
      "r327",
      "r448",
      "r507",
      "r692",
      "r693",
      "r694"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r322",
      "r327",
      "r448",
      "r508",
      "r686",
      "r687",
      "r692",
      "r693",
      "r694"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r448",
      "r509",
      "r686",
      "r687",
      "r692",
      "r693",
      "r694"
     ]
    },
    "iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount1",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Liabilities Level1 To Level2 Transfers Amount1",
        "label": "Fair Value Liabilities Level1 To Level2 Transfers Amount1",
        "verboseLabel": "Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount1",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Liabilities Level2 To Level1 Transfers Amount1",
        "label": "Fair Value Liabilities Level2 To Level1 Transfers Amount1",
        "verboseLabel": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Roll-forward of Fair Value of Convertible Note and Preference Shares Tranche Obligations for Which Fair Value Determined by Level 3 Inputs",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r74"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers into Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3",
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "terseLabel": "Transfers out of Level 3",
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "iobt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyExchange",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability currency exchange.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Currency Exchange",
        "negatedLabel": "Currency exchange"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value adjustments through statement of operations",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Fair value adjustments",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Addition on issuance of class C preference shares",
        "verboseLabel": "Addition in cash on issuance of Class C preference shares",
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Conversion or settlement of preference shares",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "verboseLabel": "Settlement of preference shares tranche obligation through issuance of preference shares",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r507",
      "r508",
      "r509",
      "r686",
      "r687",
      "r692",
      "r693",
      "r694"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r455"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r19"
     ]
    },
    "iobt_FairValueOfPreferenceSharesTrancheObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "FairValueOfPreferenceSharesTrancheObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of preference shares tranche obligation.",
        "label": "Fair Value Of Preference Shares Tranche Obligation",
        "terseLabel": "Fair value of preference shares tranche obligation"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_FairValueOfSharesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "FairValueOfSharesIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of shares issued.",
        "label": "Fair Value Of Shares Issued",
        "terseLabel": "Fair value of shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_FinancialAssetFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "FinancialAssetFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial assets at fair value",
        "terseLabel": "Financial assets fair value disclosure",
        "label": "Financial Asset Fair Value Disclosure",
        "documentation": "Financial asset fair value disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial liabilities at fair value",
        "terseLabel": "Financial liabilities fair value disclosure",
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Financial Liabilities Fair Value Disclosure, Total",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency exchange gain, net",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r466",
      "r467",
      "r468",
      "r636"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign currency gain",
        "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax",
        "terseLabel": "Foreign currency gain",
        "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r710",
      "r798",
      "r799",
      "r822"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency and Currency Translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r621"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "iobt_GrantIncomeCostReimbursement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "GrantIncomeCostReimbursement",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant income cost reimbursement",
        "label": "Grant Income Cost Reimbursement",
        "documentation": "Grant Income Cost Reimbursement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment expenses",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r52",
      "r111"
     ]
    },
    "us-gaap_IncentiveFromLessor": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncentiveFromLessor",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease incentives",
        "label": "Incentive from Lessor",
        "documentation": "Amount of incentive received by lessee from lessor."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r140",
      "r141",
      "r727"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails2": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r407"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax expense",
        "terseLabel": "Loss before income tax expense",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r96",
      "r135",
      "r236",
      "r246",
      "r248",
      "r250",
      "r529",
      "r542",
      "r680"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails2": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r407"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r271",
      "r622"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r622"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r380",
      "r386",
      "r389",
      "r396",
      "r403",
      "r409",
      "r410",
      "r411",
      "r570"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax expense",
        "totalLabel": "Total provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision or benefit for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r158",
      "r215",
      "r216",
      "r239",
      "r384",
      "r404",
      "r547"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r382",
      "r383",
      "r389",
      "r390",
      "r395",
      "r397",
      "r564"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits in U.S. provision for income taxes",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "iobt_IncreaseDecreaseInLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "IncreaseDecreaseInLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in lease liability",
        "label": "Increase (Decrease) In Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-current assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "totalLabel": "Interest Expense, Total",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r137",
      "r187",
      "r237",
      "r478",
      "r623",
      "r710",
      "r821"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investment Income, Net, Total",
        "label": "Investment Income, Net",
        "terseLabel": "Interest income",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r102"
     ]
    },
    "iobt_IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with initial public offering, net of issuance costs of $11,773",
        "label": "Issuance of Common Stock in Connection with Initial Public Offering, Net of Issuance Costs",
        "documentation": "Issuance of common stock in connection with initial public offering, net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "IssuanceOfCommonStockSharesInConnectionWithInitialPublicOfferingNetOfIssuanceCosts",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with initial public offering, net of issuance costs of $11,773, shares",
        "label": "Issuance of Common Stock Shares in Connection with Initial Public Offering, Net of Issuance Costs",
        "documentation": "Issuance of common stock shares in connection with initial public offering, net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_LaboratoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "LaboratoryMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory",
        "label": "Laboratory [Member]",
        "documentation": "Laboratory [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Quantitative Information Regarding Leases",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease description",
        "label": "Lessee, Operating Lease, Description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Minimum Rental Payments Under Noncancellable Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "verboseLabel": "Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r196",
      "r255",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r418",
      "r421",
      "r422",
      "r458",
      "r595",
      "r679",
      "r712",
      "r757",
      "r807",
      "r808"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "terseLabel": "Total liabilities, convertible preference shares and stockholders' deficit",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r134",
      "r538",
      "r700",
      "r744",
      "r753",
      "r797"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, convertible preference shares and stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r168",
      "r196",
      "r255",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r418",
      "r421",
      "r422",
      "r458",
      "r700",
      "r757",
      "r807",
      "r808"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r79",
      "r80",
      "r81",
      "r84",
      "r196",
      "r255",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r418",
      "r421",
      "r422",
      "r458",
      "r757",
      "r807",
      "r808"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r55"
     ]
    },
    "stpr_MD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "MD",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maryland",
        "label": "MARYLAND"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ManagementMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management",
        "label": "Management [Member]"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r805"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r329",
      "r511",
      "r548",
      "r587",
      "r588",
      "r645",
      "r647",
      "r649",
      "r650",
      "r652",
      "r671",
      "r672",
      "r682",
      "r690",
      "r695",
      "r701",
      "r759",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Expectation of Dividends",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Remaining Term",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected Stock Price Volatility",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-Free Interest Rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r329",
      "r511",
      "r548",
      "r587",
      "r588",
      "r645",
      "r647",
      "r649",
      "r650",
      "r652",
      "r671",
      "r672",
      "r682",
      "r690",
      "r695",
      "r701",
      "r759",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ]
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds, at Carrying Value",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "stpr_NY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "NY",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK",
        "terseLabel": "New York, NY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net losses",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r106",
      "r136",
      "r166",
      "r179",
      "r181",
      "r186",
      "r196",
      "r206",
      "r209",
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r224",
      "r236",
      "r246",
      "r248",
      "r250",
      "r255",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r444",
      "r458",
      "r544",
      "r618",
      "r637",
      "r638",
      "r680",
      "r710",
      "r757"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to common shareholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to class A ordinary shareholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r209",
      "r210",
      "r211",
      "r212",
      "r219",
      "r220",
      "r225",
      "r228",
      "r236",
      "r246",
      "r248",
      "r250",
      "r680"
     ]
    },
    "iobt_NetProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "NetProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Proceeds From Issuance Of Private Placement",
        "label": "Net Proceeds From Issuance Of Private Placement",
        "documentation": "Net proceeds from issuance of private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_NonCashSettlementOfPreferenceShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "NonCashSettlementOfPreferenceShares",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash settlement of preference shares.",
        "label": "Non Cash Settlement of Preference Shares",
        "terseLabel": "Non-cash portion of settlement of preference shares tranche obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Total other income",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_NumberOfBoardDirectors": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "NumberOfBoardDirectors",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of board directors.",
        "label": "Number of Board Directors",
        "terseLabel": "Number of directors on board"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "NumberOfDirectorsEntitledToBeElectedByPreferenceShareholders",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of directors entitled to be elected by preference shareholders.",
        "label": "Number of Directors Entitled to be Elected by Preference Shareholders",
        "terseLabel": "Number of directors entitled to be elected by preference shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_NumberOfOperatingLease": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "NumberOfOperatingLease",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating lease.",
        "label": "Number Of Operating Lease",
        "terseLabel": "Number of operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_NumberOfSharesIssuedForAdjustedDownward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "NumberOfSharesIssuedForAdjustedDownward",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for adjusted downward.",
        "label": "Number Of Shares Issued For Adjusted Downward",
        "terseLabel": "Number of shares issued for adjusted downward"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_NumberOfVotePerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "NumberOfVotePerShare",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of vote per share.",
        "label": "Number Of Vote Per Share",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OffBalanceSheetCreditExposurePolicyPolicyTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk and Off-Balance Sheet Risk",
        "label": "Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]",
        "documentation": "Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r268"
     ]
    },
    "iobt_OfficeAndLaboratoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "OfficeAndLaboratoryMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Laboratory.",
        "label": "Office and Laboratory [Member]",
        "terseLabel": "Office and Laboratory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "terseLabel": "Office furniture",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_OfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "OfficeMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office",
        "label": "Office [Member]",
        "documentation": "Office [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open tax year",
        "label": "Open Tax Year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "verboseLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations",
        "negatedLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r246",
      "r248",
      "r250",
      "r680"
     ]
    },
    "iobt_OperatingLeaseAmendedBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "OperatingLeaseAmendedBaseRent",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease amended base rent.",
        "label": "Operating Lease Amended Base Rent",
        "terseLabel": "Operating lease amended base rent"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_OperatingLeaseAnnualBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "OperatingLeaseAnnualBaseRent",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease annual base rent.",
        "label": "Operating lease annual base rent",
        "terseLabel": "Operating lease annual base rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r699"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "iobt_OperatingLeaseIncrementalBorrowingRateOnRemainingLease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "OperatingLeaseIncrementalBorrowingRateOnRemainingLease",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease incremental borrowing rate on remaining lease.",
        "label": "Operating lease incremental borrowing rate on remaining lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Lease, Liability, Total",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current",
        "verboseLabel": "Lease liability - current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease, liability, non-current",
        "verboseLabel": "Lease liability - noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows paid for amounts included in the measurement of lease liabilities",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r491"
     ]
    },
    "iobt_OperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "OperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease remaining lease term.",
        "label": "Operating Lease Remaining Lease Term",
        "terseLabel": "Remaining lease term (years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use lease asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Amortization of right of use lease asset",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r699"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business, Organization and Liquidity",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r126",
      "r561",
      "r562"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Other Assets, Noncurrent, Total",
        "terseLabel": "Other non-current assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r12",
      "r127"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total",
        "terseLabel": "Foreign currency translation",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "totalLabel": "Other Liabilities, Noncurrent, Total",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r754"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PaymentsOfStockAndWarrantIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "PaymentsOfStockAndWarrantIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares and warrants issuance costs",
        "negatedLabel": "Common shares and warrants issuance costs",
        "label": "Payments Of Stock And Warrant Issuance Costs",
        "documentation": "Payments of stock and warrant issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering expenses",
        "negatedLabel": "Issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "iobt_PercentageOfAggregateCashAndCashEquivalentsDeposited": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "PercentageOfAggregateCashAndCashEquivalentsDeposited",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate cash and cash equivalents deposited.",
        "label": "Percentage Of Aggregate Cash And Cash Equivalents Deposited",
        "terseLabel": "Percentage of total cash and cash equivalents in operating accounts"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PercentageOfInterestOnSubscriptionPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "PercentageOfInterestOnSubscriptionPrice",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of interest on subscription price.",
        "label": "Percentage Of Interest On Subscription Price",
        "terseLabel": "Percentage of interest on subscription price"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PercentageOfTotalCashAndCashEquivalents": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "PercentageOfTotalCashAndCashEquivalents",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of total cash and cash equivalents.",
        "label": "Percentage of Total Cash and Cash Equivalents",
        "terseLabel": "Percentage of total cash and cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PercentageOfUncertainTaxPositions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "PercentageOfUncertainTaxPositions",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of uncertain tax positions",
        "label": "Percentage Of Uncertain Tax Positions",
        "documentation": "Percentage of uncertain tax positions."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PeriodExpireInTwentyTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "PeriodExpireInTwentyTwentySixMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period 2026",
        "label": "Period Expire In Twenty Twenty Six [Member]",
        "documentation": "Period expire in twenty twenty six."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 through 2025",
        "label": "Period Twenty Twenty Three Through Twenty Twenty Five [Member]",
        "documentation": "Period twenty twenty three through twenty twenty five."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PeriodTwentyTwentyThroughTwentyTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "PeriodTwentyTwentyThroughTwentyTwentyTwoMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 through 2022",
        "label": "Period Twenty Twenty Through Twenty Twenty Two [Member]",
        "documentation": "Period twenty twenty through twenty twenty two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787"
     ]
    },
    "iobt_PreferenceSharesTrancheObligationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "PreferenceSharesTrancheObligationsMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preference shares tranche obligations.",
        "label": "Preference Shares Tranche Obligations [Member]",
        "terseLabel": "Preference Shares Tranche Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PreferenceStockMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "PreferenceStockMeasurementInput",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preference stock measurement input.",
        "label": "Preference Stock Measurement Input",
        "terseLabel": "Preference stock measurement input"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PreferenceStockMeasurementInputRemainingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "PreferenceStockMeasurementInputRemainingTerm",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preference stock measurement input remaining term.",
        "label": "Preference Stock Measurement Input Remaining Term",
        "terseLabel": "Remaining term"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PreferredClassBAndPreferredClassCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "PreferredClassBAndPreferredClassCMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class B and Class C Preference Shares",
        "label": "Preferred Class B And Preferred Class C [Member]",
        "documentation": "Preferred Class B and Preferred Class C."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredClassBMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Class B [Member]",
        "terseLabel": "Class B Preference Shares",
        "documentation": "Outstanding nonredeemable preferred class B stock or outstanding preferred class B stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PreferredClassCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "PreferredClassCMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred class c.",
        "label": "Preferred Class C [Member]",
        "terseLabel": "Class C Preference Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConversionBasis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Conversion Basis",
        "terseLabel": "Preferred stock, conversion basis",
        "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r88"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r703",
      "r706",
      "r707",
      "r708",
      "r709",
      "r819",
      "r823"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preference share per share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r304"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "terseLabel": "Preference shares authorized",
        "verboseLabel": "Preferred stock shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r597"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preference shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r304"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preference shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r597",
      "r615",
      "r823",
      "r824"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value of $0.001 per share; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 2022",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r533",
      "r700"
     ]
    },
    "iobt_PrepaidContractResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "PrepaidContractResearchAndDevelopmentCostsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid contract research and development costs current.",
        "label": "Prepaid Contract Research And Development Costs Current",
        "terseLabel": "Prepaid contract research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses and Other Current Assets.",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r683",
      "r754"
     ]
    },
    "us-gaap_PrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid income taxes",
        "label": "Prepaid Taxes",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r684",
      "r754"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Convertible Debt",
        "verboseLabel": "Proceeds from issuance of convertible notes",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds from IPO, after deducting underwriting discounts, commissions and offering costs",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "iobt_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common shares and warrants",
        "label": "Proceeds From Issuance Of Common Stock And Warrants",
        "documentation": "Proceeds from issuance of common stock and warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of preference shares",
        "verboseLabel": "Gross cash proceeds from issuance of convertible preferred stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Proceeds from issuance of preference shares",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from private placement",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Issuance of Warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r179",
      "r181",
      "r191",
      "r196",
      "r206",
      "r215",
      "r216",
      "r236",
      "r246",
      "r248",
      "r250",
      "r255",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r416",
      "r419",
      "r420",
      "r444",
      "r458",
      "r529",
      "r543",
      "r571",
      "r618",
      "r637",
      "r638",
      "r680",
      "r697",
      "r698",
      "r711",
      "r738",
      "r757"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r148",
      "r151",
      "r152"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and Equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r170",
      "r541"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r530",
      "r541",
      "r700"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r148",
      "r151",
      "r539"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PurchasePricePerShareOfCommonStockAndWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "PurchasePricePerShareOfCommonStockAndWarrant",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share of common stock and warrant",
        "label": "Purchase Price Per Share of Common Stock and Warrant",
        "documentation": "Purchase price per share of common stock and warrant."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r321",
      "r329",
      "r360",
      "r361",
      "r362",
      "r510",
      "r511",
      "r548",
      "r587",
      "r588",
      "r645",
      "r647",
      "r649",
      "r650",
      "r652",
      "r671",
      "r672",
      "r682",
      "r690",
      "r695",
      "r701",
      "r704",
      "r755",
      "r759",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r321",
      "r329",
      "r360",
      "r361",
      "r362",
      "r510",
      "r511",
      "r548",
      "r587",
      "r588",
      "r645",
      "r647",
      "r649",
      "r650",
      "r652",
      "r671",
      "r672",
      "r682",
      "r690",
      "r695",
      "r701",
      "r704",
      "r755",
      "r759",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ]
    },
    "iobt_RefundableTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "RefundableTaxCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refundable tax credit",
        "label": "Refundable Tax Credit",
        "documentation": "Refundable tax credit."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_RefundableTaxCreditReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "RefundableTaxCreditReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refundable tax credit receivable",
        "label": "Refundable Tax Credit Receivable",
        "documentation": "Refundable tax credit receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedAndNonrelatedPartyStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedAndNonrelatedPartyStatusAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Party Status [Axis]",
        "documentation": "Information by related and nonrelated party status."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r500",
      "r501",
      "r502",
      "r503",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r614",
      "r616",
      "r705"
     ]
    },
    "us-gaap_RelatedAndNonrelatedPartyStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedAndNonrelatedPartyStatusDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Party Status [Domain]",
        "documentation": "Related and nonrelated party status."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r500",
      "r501",
      "r502",
      "r503",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r614",
      "r616",
      "r705"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r500",
      "r501",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r614",
      "r616",
      "r644"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r500",
      "r501",
      "r502",
      "r503",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r614",
      "r616",
      "r644"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r500",
      "r501",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r614",
      "r616",
      "r644",
      "r806"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development expense",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r379",
      "r815"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ResearchAndDevelopmentTaxCreditReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credit receivable current.",
        "label": "Research And Development Tax Credit Receivable Current",
        "terseLabel": "Research and development tax credit receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "totalLabel": "Restricted Cash, Total",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r741",
      "r816",
      "r817"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r731",
      "r741"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r118",
      "r537",
      "r555",
      "r560",
      "r569",
      "r598",
      "r700"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r202",
      "r203",
      "r204",
      "r207",
      "r214",
      "r216",
      "r260",
      "r267",
      "r369",
      "r370",
      "r371",
      "r400",
      "r401",
      "r427",
      "r429",
      "r430",
      "r432",
      "r442",
      "r551",
      "r553",
      "r572",
      "r823"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r699"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement",
        "label": "Sales Agreement [Member]",
        "documentation": "Sales agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Provision for Income Taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Principal Components of Deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule Of Earnings Per Share Basic By Common Class [Table]",
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r47",
      "r222",
      "r223",
      "r226"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of the Statutory Income Tax Rate to our Effective Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Equity-based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Loss Before Provision for Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r64"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r333",
      "r335",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assumptions for Estimated Fair Value of Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r115",
      "r117",
      "r118",
      "r174",
      "r175",
      "r176",
      "r234",
      "r304",
      "r305",
      "r306",
      "r308",
      "r311",
      "r317",
      "r319",
      "r565",
      "r566",
      "r567",
      "r568",
      "r690",
      "r726",
      "r742"
     ]
    },
    "iobt_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Purchase Agreement",
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r584",
      "r585",
      "r586",
      "r646",
      "r648",
      "r651",
      "r653",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r673",
      "r691",
      "r704",
      "r760",
      "r818"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r251",
      "r681"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercisable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable",
        "terseLabel": "Number of Warrants, Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercisable intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term (in years), Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Number of Warrants, Cancelled or forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average exercise price per share, Cancelled or forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of warrants granted transferred to plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Warrants, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average exercise price per share, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Warrants, Ending balance",
        "periodStartLabel": "Number of Warrants, Beginning balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-average exercise price per share, Ending balance",
        "periodStartLabel": "Weighted-average exercise price per share, Beginning balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted-average remaining contractual term (in years), Outstanding",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r333",
      "r335",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants available for future grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of shares that may be issued under the plan as a proportion of outstanding capital stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award equity instruments other than options exercisable in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Equity Instruments Other Than Options Exercisable In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price per share, Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r338",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r372",
      "r373",
      "r374",
      "r375"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Temporary equity, share price",
        "verboseLabel": "Common stock shares sold, price per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate intrinsic value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "iobt_SharesIssuedFairValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "SharesIssuedFairValuePerShare",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued fair value per share.",
        "label": "Shares Issued Fair Value Per Share",
        "terseLabel": "Shares issued fair value per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r194"
     ]
    },
    "iobt_SiliconValleyBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "SiliconValleyBankMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Valley Bank.",
        "label": "Silicon Valley Bank [Member]",
        "terseLabel": "Silicon Valley Bank"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfFairValueOfConvertibleNoteAndPreferenceSharesTrancheObligationsForWhichFairValueDeterminedBy",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r174",
      "r175",
      "r176",
      "r196",
      "r222",
      "r223",
      "r226",
      "r228",
      "r234",
      "r235",
      "r255",
      "r278",
      "r280",
      "r281",
      "r282",
      "r285",
      "r286",
      "r304",
      "r305",
      "r308",
      "r311",
      "r319",
      "r458",
      "r565",
      "r566",
      "r567",
      "r568",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r597",
      "r619",
      "r639",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r726",
      "r742",
      "r750"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r33",
      "r163",
      "r184",
      "r185",
      "r186",
      "r202",
      "r203",
      "r204",
      "r207",
      "r214",
      "r216",
      "r233",
      "r260",
      "r267",
      "r320",
      "r369",
      "r370",
      "r371",
      "r400",
      "r401",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r442",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r499",
      "r551",
      "r552",
      "r553",
      "r572",
      "r639"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r584",
      "r585",
      "r586",
      "r646",
      "r648",
      "r651",
      "r653",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r673",
      "r691",
      "r704",
      "r760",
      "r818"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r233",
      "r512",
      "r563",
      "r583",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r616",
      "r620",
      "r621",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r639",
      "r705"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r233",
      "r512",
      "r563",
      "r583",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r616",
      "r620",
      "r621",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r639",
      "r705"
     ]
    },
    "iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares and warrants in private placement, net of issuance costs, shares",
        "label": "Stock And Warrant Issued During Period Shares Issued For Private Placement",
        "documentation": "Stock and warrant issued during period shares issued for private placement."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares and warrants in private placement, net of issuance costs",
        "label": "Stock And Warrant Issued During Period Value Issued For Private Placement",
        "documentation": "Stock and warrant issued during period value issued for private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of preferred and ordinary shares of IO Biotech ApS into common stock of IO Biotech, Inc., shares",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r32",
      "r59",
      "r118",
      "r297"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock, shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r88",
      "r89",
      "r118",
      "r565",
      "r639",
      "r655"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of preferred and ordinary shares of IO Biotech ApS into common stock of IO Biotech, Inc.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r33",
      "r118"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "verboseLabel": "Issuance of shares",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r88",
      "r89",
      "r118",
      "r572",
      "r639",
      "r655",
      "r711"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Total stockholders' deficit",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r92",
      "r93",
      "r108",
      "r599",
      "r615",
      "r640",
      "r641",
      "r700",
      "r712",
      "r744",
      "r753",
      "r797",
      "r823"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r195",
      "r303",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r318",
      "r320",
      "r433",
      "r642",
      "r643",
      "r659"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split, description",
        "label": "Stockholders' Equity Note, Stock Split",
        "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split, conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r505"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Events",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r505"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r505"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r505"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r505"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r506"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TemporaryEquityAdjustedFairValueOfTrancheObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TemporaryEquityAdjustedFairValueOfTrancheObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity adjusted fair value of tranche obligation",
        "documentation": "Temporary equity adjusted fair value of tranche obligation."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TemporaryEquityAdjustedForSettlementOfTrancheObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity adjusted for settlement of tranche obligation",
        "label": "Temporary Equity Adjusted for Settlement of Tranche Obligation",
        "documentation": "Temporary equity adjusted for settlement of tranche obligation."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TemporaryEquityAdjustedForSettlementOfTrancheObligationNonCashPortion",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity adjusted for settlement of tranche obligation non cash portion",
        "label": "Temporary Equity Adjusted for Settlement of Tranche Obligation Non Cash Portion",
        "documentation": "Temporary equity adjusted for settlement of tranche obligation non cash portion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Temporary equity, Balance",
        "periodStartLabel": "Temporary equity, Balance",
        "terseLabel": "Convertible preference shares",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r280",
      "r281",
      "r282",
      "r285",
      "r286",
      "r376",
      "r535"
     ]
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TemporaryEquityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TemporaryEquityDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity disclosure.",
        "label": "Temporary Equity Disclosure [Text Block]",
        "terseLabel": "Convertible Preference Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityDividendsAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityDividendsAdjustment",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Dividends, Adjustment",
        "negatedTerseLabel": "Cumulative dividends on class B and C preference shares",
        "negatedLabel": "Cumulative dividends on Class B and C preference shares",
        "documentation": "Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends)."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TemporaryEquityExchangeOfPreferredAndCommonStockOfIoBiotechApsIntoCommonStockOfIoBiotechInc",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, exchange of preferred and common stock shares of IO biotech ApS into common stock of IO biotech, inc",
        "label": "Temporary Equity Exchange Of Preferred And Common Stock Of Io Biotech Aps Into Common Stock Of Io Biotech, Inc,",
        "documentation": "Temporary equity exchange of preferred and common stock of io biotech aps into common stock of io biotech, inc."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TemporaryEquityExchangeOfPreferredAndCommonStockSharesOfIoBiotechApsIntoCommonStockOfIoBiotechInc",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, exchange of preferred and common stock shares of IO biotech ApS into common stock of IO biotech, inc, shares",
        "label": "Temporary Equity Exchange of Preferred and Common Stock Shares of IO Biotech ApS into Common Stock of IO Biotech, Inc.",
        "documentation": "Temporary Equity Exchange of Preferred and Common Stock Shares of IO Biotech ApS into Common Stock of IO Biotech, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Convertible preference shares, shares authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible preference shares, shares issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary equity, Balance, shares",
        "periodStartLabel": "Temporary equity, Balance, shares",
        "terseLabel": "Convertible preference shares, shares outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "iobt_TemporaryEquityStockIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TemporaryEquityStockIssuanceCost",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issuance cost.",
        "label": "Temporary Equity Stock Issuance Cost",
        "terseLabel": "Temporary equity, issuance cost"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TemporaryEquityStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TemporaryEquityStockIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issuance costs.",
        "label": "Temporary Equity Stock Issuance Costs",
        "terseLabel": "Temporary equity, issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, issuance of shares upon conversion of securities, shares",
        "documentation": "Temporary equity stock issued during period shares conversion of convertible securities.",
        "label": "Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Temporary equity, Issuance of preference shares, net of issuance costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, Issuance of class C preference shares, net of issuance costs of $340 and adjusted for settlement of tranche obligation of $28,276 of which $25,908 is non-cash, shares",
        "label": "Temporary equity, Issuance of class C preference shares, net of issuance costs of $340 and adjusted for fair value of tranche obligation of $25,908 at non-cash settlement, shares",
        "documentation": "Temporary equity stock issued during period shares new issues and adjusted for fair value of tranche obligation of non cash settlement."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, issuance of shares upon conversion of securities",
        "documentation": "Temporary equity stock issued during period value conversion of convertible securities.",
        "label": "Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Temporary equity, Issuance of preference shares, net of issuance costs",
        "verboseLabel": "Temporary equity, Issuance of preference shares, net of issuance costs",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssuesAndAdjustedForFairValueOfTrancheObligationOfNonCashSettlement",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, Issuance of class C preference shares, net of issuance costs of $340 and adjusted for settlement of tranche obligation of $28,276 of which $25,908 is non-cash",
        "label": "Temporary equity, Issuance of class C preference shares, net of issuance costs of $340 and adjusted for fair value of tranche obligation of $25,908 at non-cash settlement",
        "documentation": "Temporary equity stock issued during period value new issues and adjusted for fair value of tranche obligation of non cash settlement."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TemporaryEquitySubscriptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TemporaryEquitySubscriptionAmount",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, subscription amount.",
        "label": "Temporary Equity Subscription Amount",
        "terseLabel": "Temporary equity, subscription amount"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TemporaryEquitySubscriptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TemporaryEquitySubscriptionPricePerShare",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, subscription price per share.",
        "label": "Temporary Equity Subscription Price Per Share",
        "terseLabel": "Temporary equity, subscription price per share"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r805"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol(s)",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TrancheObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TrancheObligationMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche obligation.",
        "label": "Tranche Obligation [Member]",
        "terseLabel": "Tranche Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Employee Stock Purchase Plan",
        "label": "Two Thousand And Twenty One Employee Stock Purchase Plan [Member]",
        "documentation": "Two thousand and twenty one employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TwoThousandAndTwentyOneEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TwoThousandAndTwentyOneEquityIncentivePlanMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Equity Incentive Plan",
        "label": "Two Thousand And Twenty One Equity Incentive Plan [Member]",
        "documentation": "Two thousand and twenty one equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TwoThousandTwentyThreeInducementIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "TwoThousandTwentyThreeInducementIncentivePlanMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Inducement Incentive Plan",
        "label": "Two Thousand Twenty Three Inducement Incentive Plan [Member]",
        "documentation": "Two thousand twenty three inducement incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "iobt_UndesignatedPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "UndesignatedPreferredStockMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undesignated Preferred Stock",
        "label": "Undesignated Preferred Stock [Member]",
        "documentation": "Undesignated preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r388"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r145",
      "r147",
      "r149",
      "r150"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "iobt_ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance deferred tax asset change in amount due to tax cuts and jobs act of 2017.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount Due to Tax Cuts And Jobs Act Of 2017",
        "terseLabel": "Provision increase deferred tax assets and valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ValuationTechniqueOptionPricingModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueOptionPricingModelMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferenceSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Technique, Option Pricing Model [Member]",
        "terseLabel": "Option Pricing Model",
        "documentation": "Valuation technique calculating price of option."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValueAddedTaxReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value Added Tax Receivable, Current",
        "terseLabel": "Value-added tax refund receivable",
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued in Private Placement",
        "label": "Stock Warrants to Purchase Class A Ordinary Shares",
        "verboseLabel": "Warrant",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r703",
      "r706",
      "r707",
      "r708",
      "r709"
     ]
    },
    "iobt_WarrantsExercisablePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "WarrantsExercisablePricePerShare",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Price of Common Stock and Warrants",
        "label": "Warrants Exercisable Price Per Share",
        "documentation": "Warrants exercisable price per share."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_WarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "WarrantsIssued",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued",
        "label": "Warrants Issued",
        "documentation": "Warrants issued"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_WarrantsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.iobiotech.com/20231231",
     "localname": "WarrantsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Issued in Connection with Sale of Common Stock",
        "label": "Warrants Policy [Policy Text Block]",
        "documentation": "Warrants Policy ."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average number of shares used in computing net loss per common share, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r228"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.iobiotech.com/20231231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.iobiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of shares used in computing net loss per common share, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r228"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-2"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-6"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481475/840-20-55-3"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-21"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-5"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479924/842-10-30-5"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479341/842-30-25-11"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0000950170-24-026275-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-026275-xbrl.zip
M4$L#!!0    ( ":*95C,>IX/UUL! #ZT 0 2    :6UG,3,T,#4Q.#(W7S N
M:G!G[+L%6)1AMRCZ$=(A*IT2@M(A#0,B)2*AM( T PP=0Y> = DH2$A+2B/=
MB A(P] ,G3.40\X9_]KG_&?O_YR[[WW.O<]S]SNSGEG?.^_WKG?U6A/H&?0R
M</N9DJH2@(6%!21@'@!Z!1NE" 5; X"Z.O (   " !=+"L#&8.0 @/4L @S@
M8G LS-/P4^:?5X ) +#'=A@ ?,P<">9:%@, P\Y?5_W7P$@2;&%K9N7 HFT&
M-G>PPDS<2L#YBT3O8217G(#[#[PE*?$O.(Z@*  D)?T;_F_2Q?KT9\?_DNZ_
M#2$!(1%) 2%)(6$604%)07%)(<%_=PZC!P ,6 "V@!E@!3@ +( V!@,#YAC\
MCU+0*[CW;=W=G27Y^1W=^,PLG<RM^"R<(/Q0,V=^03X!?D :!'4VL["W<F<Q
MM[(!.\IP'C:W<[* +64X]1ZK"Z@[*UC9@E5\7*U>^KQX9>%C;R%AR0F2)262
MADI"(<X0*W<S%BC$P=%-$BK#^I?=)3'XGVE^5EEI5TMK2>VG2G];@;F28?W;
M6;R\O/B\A/F<7&WX!24D)/@%A/B%A'@Q*WC=O!W=S:"\CFYL?]O@J96;A2O8
MV1WLY,CRY]K,W,G#78;5PP-L*6EM9OW8W-+R,:^YF; EKZ"@I1FOF:6P(*^E
ML+"EV&-!<2%K07/6OY&WM/@'=6</5X>_T+:TX+=RL()8.;J[8:0AR,_*__\L
M38R(_D'TWQ4_AD?,&DD%5RLS=ZNG&)#]HV1> 2%>(>%7?U<RG^!C46G^?UHG
MS?]/!_U_05JRTI86DA9_SN3D^E?R+ZU<_N]IVP$L^S\&EK_RB9G^*X(A@+$^
M0D)":?[_GO;_+ S^OQD?!ON'J6+N9/D_,/Z_3.3?W-W*$>/C7AAG1L\!"@#^
MK5MXMW#Q\6[A$>#C$Q!1$&-D3$1)?IN$@H:2CI:&DH::GHGS/CTC!R,U#2L?
M*P?70VX>;CH6?F'^1T*<C[@?_=D$"Y^ @(B0Z!XQ\;U'##0,C_XO#W0'0$&
M[85[BH/%"F!38.%08*%[ &9,4KB%]9?Q]^B(A8V#>PL/GX"0B!BSH.XV@(V%
M@X.-BW/K%BXFCV/Y8]X'<"ENW;DO*(]W5\L,G]7EGE!PXF<"MB=5G93:HPAV
M87/7$$(B*FH:6CJ.!YQ<#Q^)/!85$Y>05'BJJ*2LHOKLY2L=73U] T,+2RMK
M&UNPG9N[AZ<7U-LG]&U8>,2[R*BDY/<IJ6D?/J;GYN47%!85?RFIKJFMJV]H
M_-;4U=W3V]?_?>#'V/C$Y-3TS"QL916^MKZQN;6]@SPZ/CD]^XTZO_C#%Q:
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MK@T-Q'M+1S('#C;G?F&+?ZV7&/"+;B$M2I8"Y6LTQG[L4.$TF=+\11#TPY^
M)40F5O[R2>" $,)K,O!$)8?\"1H(0R*6;L)!5XG?T #<8W%VH3/0XM9ZWGG"
M:Z7J'A2;Z]?OXM)QY#Y'1H$T?@3-35&+BX-/O*V=W[4CXK\.W@T2,CNM- ZG
M*5^.HX>.<>5I1M)QZ2CB ( D(*5-^]W(3^Y2N7>P'0<-6$,N'W]HNG2""3??
M)UO(@%Y>>WF6+U&@,E0160FPHG=\-P/6%<561PN(_IRND,!GQZ1B-R\V=='
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M<[9T3+$NE;O3%+13/Q858RUB&)R2%+I(3N!'<!:JTT":0"L_.<3O<-GN#30
MX>B^+AJ>6SM7,3W8EZJ)\:#Y7:IKPE/5ABPL6/E@WDC=Y$ Q(A)3NE[=B'M+
M8D#Z.('[I_4TQB7@(\'4QHC]J5!?)TJ$K56*=6QG\%=MQ94FAI-^IKJM)J_H
MFR4DM3ZB<L:O?6_0UN92+S-;^"< MUX4S/J&<<+IQRN5U!A;4EC5H-@&F5V"
MSAA_R&^<SUU=_WCA4@O9'G_PE0.5_<7.IW6],OB*V6.56UW6XM80HB4.Q@L_
MY+%" U,4^_&#>#4!MTWKB^ @9A.9@M[DH4"<QZT_($EL5=5E,O(YY+JY+6A
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M38DA!#+RC"4%61'YVS"'](#L@EG#6;7FG_4A"W?$Y@5F-05<Q65KL9;1 $X
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M-A=.(G(I=HPY[.*@;MG_Q:!6<W6L7-+8J\;;!QXD_6"V^VIBLEDI:UEB$*P
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MO/^G\$K)($T+6@*-Y1=_WN6_W#PG E+_8O!_H'^J12<?%7#T8UP[%;XOMJH
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M1K"X6A]U0IOL/'DROS\[)L?B\F_!<$3DX2X!5\VCM$\K.SW6363?R7[#,:F
M%U4U/<XO7?5?+6->0L!R"NV--T&F-/7!E-.P<4,9.9A57"AMY=D5H5D+\K"S
MT3S;!H6IB/-<C;(H&4VNN^W1<0]_>\CQ=@HG*XJT,^?M(6Y>@L$N!]F,DIP@
M6S4 0$=CSZ]I>%(\Y,,]K%S)+UF;EU#R :,N&R_NSCDU^"UQIHS>\1)!;,/)
MTGHS!JM4Q63B+^ $0=N"X[4;8C-?G&;?-DVHD'^_* "^_/\G)(/HCTH'<*%-
MV9%\!@B]>;K# =R]RW0V/)\4.<Z6SL!_N%"\_Z6$\"O?8])O_#=8;@LB^RM3
M%.O'WP?]C0L0#K/\ZRCE_V\B?ZB9!KG031 !7/X7KU;@0MHWCLZ?FEB?_&LM
M2G3]^I=W'IT-'^&L1__S N1ODMIYI&7++%ZR+%?T^^7W,B['Z2F>8/RDGO#.
MZQF@.-SR[5^*'O\)J2FE#XKP]60V]@\)C5_<N;%#E4D&>?BZ[W[']L:G+(7-
M_P3Z_I6B_@AEW9FW_0A+OR?+DU7N<C3;$>$[SE)T$L7^I_-J]'-7DNS0\XTY
M]9<IGG,Q:]9GBE1+IV@*2#FN/CH]C *T?MNT][=-5?]PTZG?N-J_NBD+_^'R
M+V[Z5^X?;O(V/)_YPTU_9?[%3?\ZB.ROS+^XZ?\ED0S#Q-RXT"Q1*SCH'^64
ML7U?"FAIBVS!KR;N%)"7@P=8:-"K>;9>0@O&1;45)BY[CFP\U<2P6?L,>/EA
M'8L,B*]3%@\JW'6MPU<>8-F(4I/57WMWQNW1U4[A<#.!5 V: 'IZ.]Y4[<M-
M[IA;FO'\[,-YKQ?B(BZE#W<KA0:W9 $4E/S172*=-UJJ)5WX$2YJLBSFX^VF
M,4=\5I[IT@V0ZK0]V+;FD7N%F>=C=6ND=ZZ$KF7\(,IK+W,-L012=BP#>RY6
M+)!BMGMXM_VO8,M9+M0RDYF>2103;%[SV$YCNI17 'HUD;V-;LQB.-B*>YKX
M]+'&V#- 9QIBF]$#0IRSBAH3S\B6';,?<GB:N,2E"6[.W:O7Q(-9%)E["!4M
M"FI<HU*).TH1P'\\0]F9F*,IOM%5:JRZ^5JIS10/TOC!2,OD/R:9'"G&=^M
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M9U2_F^+EF]%G (V3SC.@COSN+?]:B4ME+^UM2N,S +4][!GPRW+6[\28]1F
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M!S,+7#GA'\69NM7&5+;OK(Z1$H$=JY4_ -W6'IUTFZ UMYN-M=550*9L:,L
M<AI?]+5QCAXW ;:B'EP?AZX;.9;S_?Q15$ZA-7X2OCS2?E&F")L*/F9L9"$.
MRUI\WQ^E"/G2FS>?9H]=T$H:CR8O42#KWR3VX+^:8[,L%6W&CCGU%^B8L)6W
M45GK6.^'NZW->R^C&J=>2!<>&3)(#GVC?:_]=*7F+VS8.FH ]?;!2UD/)V4Q
MGZ:)NMIC--?B>C_G0/B&_MA6R=BI!IODI.-\JLQ:&&G:1?H404_1M:#G53?&
M;+]RI0DBRT@Y\C;?F-_+TG9,Y\TV[1PH%V* "_6,<!\1*],2O7)+%JL?I0=Q
MY6 'B1%\9'V/;B/G(MA@YT/8JG22$C>V7MKZE(1W-T&\430Q#X#/R-'3-+[$
M?$/&\F2[NGP)QLEOD,&TCU-X#]M].V"IWM&G]1Y!J"FL '(C6]I&N&= .@'.
M4O)JYWRK-Y #DJ>T</15#F+2,LWZY@)95,0 UK6]#N\& Y(4= VK6L#]R6GV
M3E$[\;%+$\A$6?A&3Z/M&:7,MI8UP3 'O*PBYJXF>?8>M;8)/$GFH4Q^I\^I
M+:NO60[SVBJ@SJ^1RNV<@&",4K= F6U0S">/>*/%2$CS%F\_X2AP^&="\\E%
M*DM>N?7<K TEVDXR3_\6?]-:(H4L#8"F.O9X5$#YA#NMR)H_Z*)ZN=_%\ZHJ
MU,0%:47.9T6W/X%7A&WLX/.N* DD),(E@U%]-N@RIKFY8>[[]/>:>R\"R' '
M"FQ+^$A* <=GW5X1V43DJZJL:ZKX[NMG@%U=-DWT_.@*Y2T5=HK@<LK"5HSO
MME.?P(R\V]K%3QWN> \_)P>'LL75E659)G&90*D!,\-OK.3O%@,Y%DDT!DXP
M,RMR\@[/]H#NU]WJ6.0P]%+N2A&ZI, LVN4T>W[+5$!G4K_X?@^1F!>HV:L$
MZ,((*M$J]W.D"<1U)+!Y_$416+#5YQ3U>ZNLO 2-LM!&BT7UZ<O))BE-Y\;=
MB"R]U'5_G='"O;6?";<87P\6)@.^8T[O\^K+7"C+]4B57':@&;*)W;SUX.UC
M\W_/VX\K2(8TE:U/*;<TE"K_)=5;YJ@ACDY=8]6?W3XG-BK?G_RGO)S:K.";
MO-7]<"R8+7-._$B8_(H5/>85,0X5MH*:&9:JM@'K32QH#:RABT4[JPTN?5K@
M;6S3-1F,@Q=_F<7]H39J!5G!T4'6<LW'4&;.FZ\ >!>5PQV0+\DX3#TMT5P1
M%BLN82Q'?YNVC;ROZQD=K'*N2]2:6."39Y L/,Z4Z*O\A@(\1&@FK5<TA@)X
MZ+'$@0OQ.L5<7]3Z_+%^8F7]7%DK=\J![_5RSU)S\X&P1N^@<; 0VVRL+Z4^
M<\^YGE4H61*XE/0M**]E^6W;8Z 86<=+LS)?(RD%N'X>NS8R8&IBCG"!AY<?
M;>'QF\Y".S'FY(BX(KPWUN7,,6++#3M<*6O/ +BQN:8(V,-UX-+^M/4KK=M8
M LO;:A)($!.FO>L1 @-[JR-@D35<QWREFK2YWR;12:C'H<D E46I"Y56SKY1
MTBBZ9C,^((9#R3VI+Y-&!'WSE"RA +8[J0#>K$TX>AC\HO+Q.UY$EQ*>A@$/
M"1(=GQ*6<L&-%"G;5MB<2AN163DC][<G5=VG<P%_6I'W+%KIR'T^#<7M)P$Z
M(L%T)Q=W^7G"B;]B.Q$AK^\9<I!$([>.!&3T[)@[X/W96SZ<"GES>3!G/&9\
M;:JNDTL;B,I_%3,B*N<S@#Y>@RWUIF*<ZT/O$P>4BQ3OL44$3<S8O @&DRN$
M+$J^<Z+^-%09M&6_)LO$T7 BZ0)>@^?".D0#^ZG7M;OCH:4E![79)LC2Z^N\
M3='O@2\N0$Z?\?FP=I55*.^JJP2EJ&]MC#I;G\*/D#C/UI,=PD,\T/.W=Y@6
MG'AA1P#*I)@6-%U+(\46T*QO3S1/Y-M9V,&-3 ,*JWY#  3KQ;E38 +)U]]0
MQQD\ \R+)M9G1*JI6^\5CR72 CT"F1O8;K^PN!WU*:STN^F?;!(=W/D,-C=5
M-D_G R%E8%<\E0'E8%)M&8H[5]RL9P *7KI=1/#1Q0+7]=7GW;SI@V.'.8];
MMPU[K!KNY:6-6H!\D7OJWEP?WMV+J#32X6&+N2I%YO%OE5)EN TH/9E2@#U%
MXU'C7^0X!Y>/*FBZ[J4S=D:9('&N%Q[XPSOX*/C7 DG;)/6$Q[TN=MDZ[6%O
M#"R_+>7%:Z.<"583\S=2F_(-1=WT6P_7G0A!ZF(=<GYC+A\B*W-_X-@DP;KT
M^%#YUFTR(87Y&!*R-:#',&QVLKLX%%Q:ME,93/CV:0@J">6H*=\J]@C"-UZ-
MV+3']"F^#N+",-A?QPJ#7,90W@MRTPI8E<'<39>JXI2JRC@"LKXY"IP GP$G
M$.=!DR;=PP_*K:!P^M(O<34?)W+!;=SRL87HD$!4Y.\#@K-UH6M?G<&:2M#(
MQ\/'[1^5S#WU4L+>D$[[PK"2[HV *+C].-'WAVUO.4_GK;'R&*R:,C:TM9?#
M2X>FX#OE).M?EBK[4X;N_OYA]Y_B;=]+G6Q>$7T".:RCV!IP)1X$U;-)C0^C
MC!T<7I!'@K1OL.2K6^J<FUKCAL:VR@Z=%T@Q6K#K?,UOW=+Q3.!,X$P#IE+R
MO$6F.=.&^53VKM97%;6GNL;</N 6C_C:-ZMQ.)Q%'LPCGWY'?P9@@)K:BDY\
M+B.=/PL IS[2U6:9Q?E'N#D0O*XG,7I/0FX]7G<3[@/*+JR8R(5B=XO7SK#0
M-D+]_9C7F3KJ1EJR6)S\B;?I[ "7.H9?P#7E:(IK-\?EEA5Q>(%<R?U-*/.O
MU#]^'S> -,R _$+NU&N#MG[H&1 <<WZM"45U&0CF-$,7-FP/YA/B@/GS,PH4
M'I<R'ZVA4S6$FLMW(Z.S<]S._,YS[Q7[;]6)&24JI@\/UI@F%WLJ*4T'7[[G
M..XU^-=R*L!:61*7YH4C;'DEVV-#@!1I6B->.ECN'<O([&G/M!Y[55GON?HW
M +&3=^Y9 X6ED+S*#*<^JUZ]#!>$>UPYB-RSWPU^J'B^3]1(E)<NRQ.P[@U:
MQY!6P#_YI7FW5)_*DEK/(X52ZCO6B*F\?1Y8N;Q5)R%AA G@+4'S*G,/Z0WN
MF]-/DZE[ZJII6P39H=5G4(U@L>=X-XC%1IR\EQ9H I6CN?O>P-*6T3XU<%M1
MU7%H]SV)1X6ED-.3^I=,:L'$''8Z0>A.'G)8R;'^*SIQZNPB7_!X29$4(0#[
M)N'64G>(MX"MB^7DZ'8(69Y@7:R$64/,H8;:N3KT[0[=%MVV@33?YR[^VJW,
MZ+5"YNW[3YITJAX:7(87@7$<+%B\@T+1OI>PY1N0>/MO"[+6Z/-OCT'A7K3,
M?CWM#@BHE>DZ[<>UP&#IFA=E+@5GX]VWQ)(PM&D<Z=HB$QY'U<#M:)Q;$T5D
MPLVZD/J4ZZI A2=L$ND3"0A+CU!?)RC=?#H06(@NPY!%#N=ZYZV:*U^P#'IC
M==>6(_2C]<)5'#Z;AJ)[:]U(_4?'.=P+ITR'S!4L="ONIIP]#1AM&L;]@#FH
M\)!*6WO,L;=CD,YA<-QI7\* 8,)HAECEL\1T3KL'.L0Y,3;T+_PQ#\&=QN]8
M@M.VM2(OW8E[B2!U16X^@CJ]/6BD0[I?(E,/*)/73&\K%K]:H#[]*FON8K^)
M/IP[V:^[2YH7[[NJ)RI80-P:6WO[VJ;W900EHK_C"*8](]"9F9*UK%SS8Y5N
M2<_9D27>+S*7W=I%0N..GW>JSN585C"LM,>07"U@FZO@:N4BM; %1^2BZ!B[
M0Y:J*(EOT3J&35N!G67A8\I<SQ7,AOT6Y4D-6PSA/2#B39,417JF#Q*C6[<F
MT1>=H_K</?YOL%1M3JP7O3T.N=EFGQ+LF-457L9A3GATCC$":X:1+"PJZYC.
M(<-O7F[E*0%B3J_]U>&:_)'S/B5.2#LPG783R7,+#N("+/L1Z(KZK0'GK7(]
M_%-6!F]/J?D7@BY\Q$%6-0'H4H02MKBFCFJ#VQ]1&-3[[P9."G*(5B#K3#<[
M2C5S^=7AW=_E@%:)$^S"3!LI<>)#6D4FOKLJ/&2*<%X>+2(Y>M:G>]6[>-A[
M;!OF&XM4GQIV0ZCL^V=+A=-,WQI0)VH<U7?C6T^^PT>P4LR*3MN"\QA'(*5'
M^#QW^0QXL^*>^@Q0/#GP#&Q-2%<5(XVI,D^417AE<?\AY.PLV\\5Y_$9D,:+
MT%[CD5L5<+1^9FD%'2:@.+!Q9.?_.2.DVNU)5F?"/QM9L(?T2H/*S3KNUN@2
MK8'$F52(4?+?OUW\Q1^G+,JDFO8VG72FV4HFEFN? 3&HSX RNX=14XW1@@=_
MK$<GOVT04;J;V; 9CK*D]C^\@?GWP^SJUG\[LP(4"B&=&,=UWY _";J*!!9U
M>C&E]D[4UG-7> 1H)1#:2I.__VF6:8_)F/,C;(<_\(_WDU"IGK+DY3]H!?;)
M=DZL#,'X3.C;FS,]+-627#F&Q6,W>$<^AXW4WX2X@/S625654\AE9 X7Y8*&
MQ),]-NLQIUYW-?<W.Y$@4@3LSUFO8$]?IM3RV9']Y,XS)8W(U W8*K6CRBD@
MQ"12<1IG:'$84;VA^YB('\8A5/48!9LBIPQ\3-9M%F1)MQ\:S7045D+I$P-T
M5YXF/5"[W6$MT-5KA.O'31T YU:!]<D^@1Z:V(#FN2,27 +SW0[.R%-A7I$Z
M;"OGYL&+14)6=4Z(EC[2ZPH-6=3(3_*)>NBO?&VE^';?='L]=;D(Z3P#5./Z
M#LM^Q/T4#V%&ZZ[XNB&J:1/A:2ETVFO:?S+; 3PT%2XOUEMD2;[3>STP$6!G
MNRBLODA '<TLRMQPM^U/+A+)>D#;7 6MT<J!?M/UB5I!6V5CP>B))D)R(CI@
M,#59>H\0VW JWW!:EPUBO?*^HZ;3PJ_4(78_#OT2:NHFBYC_WO7A"\\ 2K<1
M#W%MK=U+K;UK-Q[580><\VY$$#4+7$!V[&:4Q "OT9CGYBL 1<1G1#*,FBBK
M(]OR<CL[C4M6@SW7",&RV.1)&0GUE[C1+TO&A62IX8/*(RXU,ZF\LG47864_
M.(=3-)58!MG V3F&3'81B0I:.8ZK+ "F14,BV6+WL./NBN$\YMU MT!]'G7=
M_- <HV:+#Z_8R)-=';HQNP7DU\)I@S;8QT.@FBHB[Y\!6F6ER(K-"20NU\6I
M/(&0"[#4[+:0JG)CU- [X^K:]-ZMQ=P@.;@Z+HO[DL"1'M-R.@HB&%?&3'#L
M"\CEXHHB]B%P:;.!%/5XFM311W9?L_ ?WVH25O]SD739V^,DQ/#4+[I6WE"^
M>=JD/N&'NFZHF2:QL:@[BK2=SLXS8"VS1?,9((9!_/0,&'X&].V;TYC&*<7'
M3YP5,\[X_9G[ZQD0['EJ^(C(:7?_#&!]!A 7C(1>.1YXJ./NM9^,&S ^ [X'
M1SX#_+:> 1O.?MU"[N5/@40\OQ_XI&= Y.3(YX7ARBTUS>)GP)]9SP#TR_7V
M.Q2KU>LGPR<>:78L2Y;^!&6#DC\S'CCF_JB/4>;XK=[ZW2R3# BE-Y.I2WJ6
M_XE!_A_4<:+XWZIIOI_E*BXJKD@-ITT%M>^3P>K56,;__:OZ;Z?IM.J5SZEJ
M=4"AU2H56*0]:8+\=N?X7]1-_&^H[O]MACWJR\[QAGR^_[L*VO^GC94"O/.9
M+2D4,RWHF%X:6Z.*1&8"[=D%KV*!O3%R+$2KK>L9,* ;Z7X5[0?1T/-?+Q2#
M#=$I3H2JE_<P,&8KWS-,2\?%TOKNF2&,.T5;'UZBW=0,H[(<437$\9XV@B$K
M'I@R)&_A1^<J!)VTAS0G5C($K,<\R<E@^4VI"K6Y>SHT/;-5RUUS*Q^H*WLC
M;]@^WE"0K%7V.GY6/A4)%R8VO!F^MY7'0V4V:YZ^&("LN?>P'9ES5.=P<+Q
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MF>(IT+PPSS(@AVV[M$_85,IDBV@(?'9279 9[)E8AY7@H)(E[UJ3FG<L/!$
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M2A/M27[9*KH0CN;XE.%B-JMZ8SLE)-/+:O%=H.QQ'0G+?(XO)F1ED>]U,6I
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MU9*BLWOK3O@HPO:+%;TCK3:5^3P)O5EISP_Y ;Z0)]GQ\R_(O(P_1^95ZU
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MU0RK%7=:N$!"4G39RW5>CF1>%]W&E&\%*MRUTY)RM,FKU=YCCX D\V]TL_D
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MKKCU>;L*%G7E=I:QR GF+U5L$1\B/U:M/(PKKUR1G+^"'&&9L4(!(Y"5V?B
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MV@G&@.+O1_J$3FTXL6ZI+TN>K?\2$!3\K1G3T7:TX4H<4N D8-DJ 6F50:^
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MY7FO;@UI_W[W:C[(#G_\.( MMCHNCF)Y48G2E$$WU8(?H:$BV+=F_?2)3\7
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MGF7QBEW,@Z>N[TK([PX46:*X/_L]25JQ'UYV>+WZ@\PKYQ%(UZ3XN?8(=,3
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M=:TS$!;B7"N/I44/KP 74(KOZ1777L=I=)+\1Q/T<-'")EH1H_"<G,$0 7#
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M>8VX>(% +EZ0P$5:_%7]'Z8E(""'\]D%T?9]]C:!@!#F?XXR03"7,8C+Q$B
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MI;2A.[VPS]\T(P9';G0_IS)X:1BI=]=(G50!HO/TD:K&,$/[S7JT7G\RV]+
M<&V93+ &GLU;Z2C\_7XJ,T&?N?Z>Q" 6@FM35GV9]!#SI*>VLM&)FXE7HVZ,
MX,E_KFYKC14A>E*\&,JHM%QX*J\KHIP<I"UF;/'";>N-<N%L=8&/P"1]T=?Y
M0\SC?O[1>+E-NAS.+D\#MC?IZ$$[7[M/-0N@[K+B?6A5L;%?-PIE-8N""KD%
MOU[52:@P!E;?BB7CY71A1 ;)''<R4'8$9!D:O7KXJMX$5FKI]X',;$0YP35H
M*9)J<?G^N*IU^54]S*BU-I% '2,'C:7<_/91M,8[3"#C0><BES5S&(;V8_]/
M<A,X=;T*.)S>&LSW7A=,B6:?BE8GO-E:$C[PGB_F/0.0';:M\BZZ9KKO,"1
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MH!1V(&1@<.X36.]J;O;=S-@"[2QV[R8.=\,'&B=+;W$6,J30#Q@7)+>'LQ#
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M?AVZCB?NU]BT*L]'.)B%8P[,U':CUWK=$BF1X;LI%H#)*QQC1BFP[_KQ6-'
M'0UI/K9VE,YH==2:NKM2?^S%NZK$K _2'[RQ<#'E'B>F!7F7FW>79]P!QCQL
M.C)>UH]9LZ-("5*;>D3OJA4>]:RT&_1H-)I2K9K]M6$;O2G_(@^E='/WD>3]
MH!3I*'/K47?XU)O=XJ%=/06'MRL'P^];F'@GD"MTD"MSY3&#M2R/@Y5EX^3C
M0T7S'M4<B!(Z^74/?\W?\%_Q:QJE2^512TL-/(VGL#D5$?2+-WBZ(!)?$K7>
M+#?G\#5]]]3!H=NGJ7<(:^7@1&C')M FJQG3-VQJ/WP\ MO=X,-._\<E<N'.
MSDB*$-$@?2<=ZT>MQ9^#1<M9N@?3Y[DY YKIOAZ<BGBJHQMP'M0>]P=5B$8*
M]K]PQB$VZ UP<X?@C70)Y5 7H^IX:HDW!:9!3S9 90SJ4K4,$_[&0CQ-TB$R
M*<59X?<(BE4MD^03BXI=IB2XC]W. )(B9?S44C5Q^J2CN0_*G,7$1]=298Y$
MU]L>XX8#63%7F<;&959:@EOR9>D2!P0\II82.9J!SM!1$YG=7<;$X3?<C>GI
M+!4M4F\6YE_2];>;F#=_ADWOS"_L*N5-]J&+)I+#-F?5XL1ZI#7(J+,"IK.$
M#:3NCW.O+9EE'I%UR*OG\PSPO9$?&)=8GHAX/^T&0\MK_[:85S[F54W70TK%
M$Z9D4K(_>Y#?5A]'1__^%;K+,?R$RD"2JS<UV(?K:]7!NFAYCJ#T@F<:JT&?
MF'Q%I-'7TN0KCY6.I(O9&IKLV^.BIR(?SISHV=HHYMOA@ (SW**^Z:C+W@L1
MKZAHRHR]R_QJY+9""Z\=Y9W 0X?CH4.T,P")F<#BGN@8LJB FQ5_3+2?_8/_
MK\L2:VZZN39%).^K3-+;&1A=T8Y(J5R/<I4#]=-GMHV9PPFG1Z<[63YYL]1*
M^_+G#+V/,/WJPQ?R$?\AM39*:BR\<XA?G"S70UUJ(+56=QE R]A<TEQ114W]
M@G^OVX/L:+EB[D:U7]?!K1-BU?MO"3[1NZS3^YC<,3::?A"T^QH=D[ "@Y9'
M/1<4-N7GE]YIZ 7$E50%%G!*JV0E^6B0T 09>G^JRI&W3R7Z43(\)IF;TK"N
MZ4WT]Y.)ZZ]CP6N:[V@U2I6MD%(,"KR<E<KL%GY<9<D.5YM'@\O9Y^ENMC8Z
MB4-$FB0X6MDX\)"Y  IVF"B &,K,PIR"IQ!L7N+06D'L9[#$MH#MV]@#(NVP
M9U+'@T54@WRM&=GJDBN9G7>]D-!I-D5Y!A9:&BD?%,0 8U^*HL)%Z9+=/T9/
M*]SY7@Q8%CBR;\IE%[ZXWE1>=^>KXE-!?G!=+*Y2'*;R+<E7=<ARVC?=ZISG
MR!N,1*;I*)J9F,*GJJJNR&&H.]@E: QH- 0CEY=7<1C5/$4CT::BOZU,EV<_
MU>"'%( _#0!A(#=ARUF1#22\V=_1'&SD5'LV[OYD:-9A>-P'_Z5B)Q.=*+$"
MF(\L.3R\OYXQ,IV@@E:85J<N0)'OP(N[%G/"=M/X@-V!*7?JS7XK(H1'SH@]
MLECNSLG$'87_4M%ZL'P&&(&SA;B&I/=*1?"OYO?UE6W>=.,AMBZ0\XI2I\AR
M:E1)_!+;K5EP@CFN23Y0E-QKYG?=%G?S5H@L.C0+B1)I:$48MD3N/S,_\\6Q
M2ZZZ$E Q,M%LJT;X*ONJ# 7 Y3J%*"DZ*-J[F&K\LU1% U.],4&.>*AZ;QGI
MU&G'6U$*=?45'@G)O:!)8L6ZM?$#RQ=%LO2?ZYL;>N5" MCL,,=B*//S6H=,
M3#1@:8]?7A7A4JYRN,VR,AMS0YB^G$U=T[Y!X<@93Y_W-?G'H>8SP-;0H.>^
MC/_IA!G/W(.]J==_E/![-I21/A;9L+<V-B]@Y%1U/+M\-N&S-X 3@=AD?N;/
MHFZ_]$M+%B#C1M5:6=-6\2.IM?JDP>,L2RM.WD9W1::O@G/AG4G\\$ &*ZM9
M59E7YS!VY U@$L>[4]666C6S=ZVM(@#&9,/@)';+4YO!7)7W?>6NI:\_,-CX
M:'JRUL*??BU?2I"Y?Q 6]$[J^E3CG+<F7JL6G>Y022$!O1.=?:R0GF#1=*-5
MW!Q=I <!0+D$:!_1='<R7G"L,NN [\,*NQE-5?]\D(W*"NWH*-J5. LD,PJF
MB0 EMO9FZ+T:>D*=J_E5V"#B3M>B;,NRMO'.#0E%1O:!V=5QS65U?; 8-46F
M[&,;_3&5F'];BG:/7^$I"0P\&7!GTS'LB> ."(;K]8W0DKS?>8^"%W;'6_U&
MHR?ORLSFFN]HM:UQ979%Q*>Z.\:B(:7J=.ZUY$^],$31/96SAS=O)&E;Z:57
M%%8&R));A &M\5#23'&\<#WF49%34;_$23\2'AP1J6H.'!:^SD2;6O&N]5M!
M9/,G&;*,ER_[#XD]J.3WV3V6MV'ZHM4N =@H#0#Z?/+832#>S:=5+EOS^KF*
M83E=S5%D;!P9T 1NU !<.6<?J%.+T&833*?^B&?K8:SO9T79LDX)=9$YY:3U
M-G]QYK@S@(9)^;:+P=R.9D7K)-6:_LEIN/I^SI=>O:2\#XX"IEY A>-/P63K
MC)93050]RR$-L6,/TW5?]J[?^,AO8#AJR+O !($6YQ_^F%[?[YHV-/)<K^C8
MC7 R9;+FTC<N*8M0-K>=N&:^L31\/8)1*J.D/3"0).Y5R&,_=<.HK;B8+VOY
MB3+S&'[:P4]0Z <=BCZ6.%U[5),\5QI^TQ=],TX**U'89\;62C8N6K!DJ6*D
M9!4GI\'X89BWU7'.D@?X]?V<\-MK@V34A!%X@BU0PAZ4-;!4E'8P<FTMB?QK
M$]Q"I5*9+RGE>7WL/"<6_5H,K^4;:NQM,.B98O=A-)32;$]B!C-Y3J[>/^ X
M$'K6:C/IZ'7*MDH/C>(+8R1LK2/*NX:FDD$-V+"]VPBA5-5&CL@IC\NY_5ZC
MOR[0 )GF42"1>0ARC31&[Y)Y0U.1T)[ZZKBZNKI+?@T6<AH  $!YA?(JE['B
M0\ZF ,LFEQ#GG+8O?3Q0EF<(:A7XX_)=*,&=>?3G_?'_7M$(%@NE.N&T%MJ]
M\]5SF=IP2VMW:W_VQ3;P#."LF>\),YM@^^QI4'(&B+"Z\NP,@,MCUCNZ6=.D
M^27V#+ YJ[FC6-$NK7#TU>P$Z.EBY>Q8XWG(E1U\E3SX0 7GF'E'#7WOR1F@
M ^\TT:6:>4X')EJX,\A.3/1C_LC0G'E]6!:I+9UQ>*N1M7)(H$75=NT;E&OX
MSAM;+M.!+V]F2GA.0\4K6FBT9Z"TKR7<9J8^0!21J,O6/4:6;&Q,(Y2*Z<L9
M/S9!:?5!=.N^6%(8D[!72-N,+7@FQOT[%4&?]1L;;1+9; J#"*%##"UTZ!6Z
M>5\-%5'8U C:V,\ =/T].%*^"YUH^\7I6D?,&9B*[:8/7HOV+/,D2SY_;EOZ
M/FC>]QG%G?6W[%RT!V(3!J'>?6HR[PUS8B-[->KE?*/L15J^I= ;'AI J]Z]
M<SO<X@]NP[,T^.">6QET!ZEWNYA7X^6S-Z<##:TTC*2MQD IJ1,\'+/1* ;+
MZ/_;5F, ;U/!\]V>=/7T,MT9X%X2[.IJ\T2I9S9C<V3-LLX98$_P#)!20KW6
M>A+G?[2L+#QZ3)9G4$LJYBCA,1E\$F_0VZ$R+C9"K>!X!B#;[3T#H)X!5OC.
M */!B<2';$>WS@ /#1+BATZ>G@'>AKU=?G T"C[19U\+?CIK *PP.GUM5?V-
M.?Y;=(L!&W%@[X]$*:8.E5F"C@(6]S2VR_R&&=PC54AY GW@AB$Z+(^J=4,3
MZJR)-<J(.+]M6C'=B^JR&F:JBAXAR-<RSN3$'5JZU:5P36H,J%?B*#-'5SM%
M1R+T1.H>JCNZT_&S77U6MR)_=_CS53C\!L#0KJA6S J=)L [P/K>U(YFQP$Y
M5;2E/5N<HZ)ZL1+56*$K^'G=1FB+%>6F:5[_)KVF!"4T+5J)=5>5:6&W\_Y'
MU1?2$C.& ]1=CKR--A]J[>Y]LQVJ(&RG&;XKBNHN[HEYX+Q*'UUM-2DGBZ*]
MT/T2A.7(Q>M6-W[U#K:FX=U7 0!)Z_SVJ@_NY^-+:?_413/$Y$"?F4RX1K&A
M@T3%]Z;W73EKGUQHHX9(E]3+P.TQ'_.Q;><6L5L"CPVOR5)14^MI*()9*RNS
MVUYSCF=^>,S(PH^+8?2YW[XU0]#^@=^XI>UX2&^NO)L8U++#4S9_,P"/,MYC
M23>8]>D+%<V^P?HPIJZ;^7EQB0\QMM]CR3I@W^%DR0E7P2:]]TI*P)9,/;ER
MYZ0RNZ-^5)H+=3KH1E24+P5G1H[SPYD@WBN:;ZV!@FPFSD:A,GU"3*$H',K+
M]/O.#FDN*PE+$/=O@7QYA52Y#]K%;,:^/2X(\D8M2^"M/B"G3*[)R\Q3GAHJ
MFAZU.VQ19M#2$^[!L^!X%T+[R60KL!.H=R29//IHK*E<#F)O@1/#+M*@J_K<
MXE8HCYLOOK/ZC"VQY$TD>J8@[:3\<HMK;U.T9D,MKO,/K5]74VJ@+;YZ13?T
M+C^*:ZLC0Y%#A!N;G@=^WOKCNL?7^<.,0*1ZQ-LM7E:?;>G3^F&S5$+7_ (T
M7]L8B\T=N#P6,*WHV1%"U6;_L+S,_=A.I#]KG7G&Y(H%Z&Y#X#K?>H=:K9L9
M5-LF)WO>A!Y8SPTEIC,FH2/@<!28<9PW@*ZP8 )G:F[P-/0*P T\;,G*B.^#
MV5Y,SW^3O5LHJJYU2MFZ=)3[(L5O6QW2'"-JY+ZE&'_\:6%H8\]T:V[SN$^V
MZTE7_;B]B[V9"'-(>3&A/\@>K_/!QA[EDM.8D*O>Y TJOOGZ ,BG3%P53??_
MSGU7_F3SK8.;WWJOUU<;Q]TXS=_%XPF&B 5I>8JS[SUWN[''ZSZUBKYSY'E@
MFJ=U!EB?UC@#!&";'1^I[WA\FUK==WFY./F8!3$#*'YCM3T=\DPDFSC.8A.I
MMO30;Q]<2L/[AG0&B*8^D=KRT&QOFG,W6\[19_I^&^5VYNCB:77PFOV#X\F3
MI.'L+@VJ7MR$*YKT$0RM3B?H<EI,+^- #XX5UM *_)A.VZ8XY(HR1;PR\<E4
M1F3$PF+,RD;\=5\MB21K<37XVN,4/($B^TP]_@+KBIK#8QDL%56T42V8I.<3
MC-*?<XL573H8?S*-0UO^GK3I0>@83=Y\X!L4@P2?ROH[19U7GBVO.-*\4S(L
MC1!ZT7,?1?FIKVJ@FD1*;@!OZN>:!I^;J0-5(OWJZIIO+:[1TB(]R2#"*<>&
MU^QI^MK>LO+W7:.8G8N0U8IM!0K REKG7*.S!#K++?YO]Y"TQ%H%3KW'J3PH
M]T)2SP O"SQR_4[GC]S8;HP&5]I37WTM1EV,6.G6',X \K9BXV'Q9X#D8SOT
MG"+"CNK:3+P7IS;[9X!].<^9PS- QI8:Y^Q,VT'GQ,G&ZJ+^B.>7R1.?P_OQ
M708)WPH@VT6'=TZ"AZ@/R@2JMG,KBPWZ$TX7]K?F_\WTZB46BC:Z68S^0=%8
M2?!1='SJ*JOW<L90(/0V[=B,G8FU4)EYX#[],.;;NN<WES+FT7)(-)N[)>35
M1RU&W%4F/E.\?*^+M _CT.MZ.=G'&910&7L4M[W=ZW8STZK@)@Y,.$?;!^,A
MM^FVT[BSA)D(IJC)FL#*8E][#^75[<QL#2&0?$*/,W=F"D]:HX?XJUYOAA:Y
MW03&N93RDACI@\<SL'!BS1)>^6>T$YTC^'E!1"3+,2C5\8-?F%MCDZK"5 :+
MK(9U?.>J8F(W =*<:>B,-*@D @+$+ 5R<?'$7F%K]+>E]@[O7AN::@F%$'NF
MX',*E2D'PN+VF-&:4ITJ*WLK'[;DYQ+&X"5MSGXCMO C9;3%Z,MO4KR+[LMH
MR)R5V+7Q<#\G[/H(MQD.14J@L7+M:R)C)U@,5V7:1H*C@1;[[:I<,7HH/7UW
MZ:>\+=0GTE5E;5;"K'7=^>MW%M.7.#3I&&N^'&BZJ[HHNQ*TI,63U=  GW0%
M;;MBI[VL8CLD%DI(C%Z;8(=T6F8\=FG5UF&0X>?G7[#*D$EZ^3P$BP"(M(1'
M=RC](#BB-S=S5TK9RCNHRB'\B"FOI7^+[.E+JT]I)F5EI0+BBY7K&TO-/J2=
M4ZF9%I8MN*ZOD?%IO'"E<.TXYY>6\PYE-S(_L$(88HLJY]W(Q.FW/K0\Y/?3
M)PYB$,\#EF^8&#*ETY$VZ@:@8[3DMQ;O:8L:B-$75=QS[5;?E%34#X3YS0W6
M<8<%/'CFE-3LFS\TM&)U35_!+98&/Z88UHN"TC^0#K']4BI#6_PA:.0V"L".
MS((D=D(6ZX4 R4U9&@++!5BXDH:@:Y24 W/UCI-T>*@!XY4&#\FE&QD:TII9
MJE^W;[#JB66P4?1+";N)\6;%>EKISF[QLC]1(/*AMS)\GQOM 3]B#E2/)'Q
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MY%."!W4D4]B!T.DWVS. O3VET+?G\=NM)[/9TZ,X1YS99LD(T<TQ2 !A_J'
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MDAJSU"^O.4H/_Z=<!!NN-D9[?\?9>8^5[[6%Q_+H![1.BR-/M'6R1.%MYOC
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M+7WO1&5&?E04UT=GNDBUF&SZF)H6F.*^%4IXTI8GH_S$JCJG<EDHZTML2L-
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M;4&2)2C1F1)ZH8$/Q1S66^C._E.,4X^:.4)AWX7PS<XI5&3QI-[&A14S?!T
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M2H6C?9<X-LUN2OA/,$ @ZOX^;;G="<:)9/L8NMW3FGIY$1&$@@A&B-R>+@_
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M-4'(CX*AUVU))Y-'OVK'=13D]/A*O QQRN<(XM]T*^B1U?CZ")E1L L5N_]
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M4O3SAA-C)W.TAI\Q$S&[EW+QV)-@3:!2<5*U'$58KF]K_.@KC-T&E"1Z7"!
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M[SU&67S\]EBQBZO&3G&0'^P"7P<+'.B/SJK0Y5I'KIA_Q(]B%?M9B@[BHU%
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MJO6/.=C*5;5&)<U9WSK'<1#$.V1H)<^0AKX!!4NITO-\'2+.I:EL3([P$F
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MZ*7WE5$">$ I,R0P+Z#1\WE"LV=/ON/L^ORR@'AHC^WA#H:^<'H76[%^!<Z
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M\HDFG@[P[2L0'R=802;7<E"Q2CF,?-VU_HSVTYM[&"$[:D,U'K:ZE+9X4"5
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M@O4,];=65"9?"JK69SIAV9!ADP7*.L.*@C15TZ[>]_L1M=2X*MV 4R@Q/(C
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M4E4U_G[L+>FK94JI+- @<FG>5HH/&X<0T*H6_VBT[J>0GHRDYB^D\@3;7KB
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MJ9$K3,9<JEQGH/&DU$G#L>0?B#Q_&!.(&,<R33GS>]<TK+[8& 'W\F.YW1G
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M6 )GYB/T/"YA9F8BH89/51Q%.[G3AAC$S  0KFN+$WB5-YW,\FUNT_C[N!M
M(=\6_7?;@YB&%!^L?!CCI8*4U@3YG3GO06UZ9G>CS(Z JFZB4#Q^*((_\RN5
MQ+YAK(8M$">;SGHBGG/N,'8Z,I67''VX3LSNVKG\DXC)=((9:A:^?A:K&T^"
M[51G)(:=+KX;@Z429X3!P057$F=?MC?)01)J,W[AJ+5#V-8X07?D $/!2#M.
M]HO==&\E]W0#RE"F1P_VI%>C9$7$87.Q,0AF;>>;:HK&'(+EY (6)$<QUU_Q
M(4@18G0R7J*ZJ5I1(\9 X1E@G4 ,5[+Y6K\W>O3#?D\0',M+<E62MJP5J7&J
MD*!"P7SYQO&1R$IF")="IL;Q][JJNW6@%U.PBFU[3\+RY<:?0C^AR#N-KLZV
M!,JTG^'CG"TP13T%5K=3(_-'FY,^M]NNT0K;X 0A CG44TEY,"7V4$F .'6I
M<H,WX7R "[2$^K;_V1F7BI4/!9='V\)/8A*7DS.PMN7F$^F3LW/)>)C/\@7?
M]K9EXWNQ3D*$'"!O66D)+O6!UCR_+1<:Y3@N.\7_:2OKZ9&]D*4SJV](4L@I
MOLOE*(JF./T5ZM1]?$9#H\_9U..+T:E*1T2_0;9*^20(13U;R@YRL#MXIEYD
M'L7&8O7R[,1ZV]L@3!>2!3UZQB4<I;U'B4H1C3L,<2:[W2<A.Q+NDX5@Z*GQ
M#$J+M-]GR4KR^&_,SXA"4#T0I@/Q+.<N?7 ,KM0[9)&].EM"")D;_=R_JM6M
ML$:GUTS5QS+ZP[/.YPP#J7>]-EFLT[D&T&Y;^<LQ"518HS[I^,BIT-IT+Z&/
MKLFRRE]IU]B+I+!2;$9I+-''T+F+LGWKT<%.Q<^'X4O2GQR$O\O"511:-OD'
M<+#O[A3.PF2 :- \,ODJ<I08]L@>&GZIJ;9CL([%WXPP@..>U JWM+Q;<[$&
MM0RPOV<U%R->F\])OKP>IL(@'(3WDF@?I2H*N.I[&SGXN;-="B;:@I^X[-+B
M,1%%]$4V.VF)&@&$N/N%2\Y-YW7WZ4C!%*:#G5RJ<(YD5+XFJ,8^,YG-5 <5
M3)$=Q&WOUM#$Y9MVOE3C8Z9$/F)O+>!E)D"E\JY-US&%3=)_ +^NN@IJ-&_!
M5!WYR@LW_#W$ H]V(D0B)8^ &,O'DH^;-7M2W7,H(MSW$BHC@W_''GQ5SCA]
M)_;=RV!B?D:5C$%T:$N50>+C5S>K]MA(62%=%HM )"Y*<0>KW][H7:NO-!>\
M4_PT)HL=G2:OJO(Q;8\_6,Z^-SI:&ZV]_\G)L:N@Z1?CKJYYFKT F# P8?^\
M5#_3U7$"M_SAD/W8'8;8IFZ'+B2Z1,J:!>I4U$^2YM*DQ F9#+$OG5?H#3$*
M9,BH*0QL B40-WY,H3N7L$FJ,5QR7-((KZ^L'1]H::P]5_Q91=>3F+-/KB&>
MNA=OG&#;D<R8-L'Y8-Z2\!B9?"54FN1)5QGB](77_-,GMT\Y=E(2;S]#)8(,
MU7-\O\X_HBB89A^*=YOW#]33@MI(1 ]<:B#[>"VXAH6&9R9,*V;S,TU41Q-3
M'&7+8]G$=G50_&,CDYEH1-BHO"&;OISQ$K,FJ<!2)]&38GUM\1C?JP0E47?'
M:HX:9OX*_;=4=)B5=9;F=Q^.C%F)5&S>TUF@<Z$![XWB4VM-U='M\].2NW:'
M()=,[NP*L;B2N?DY6[%&NF/$HOWJ4I:#*46]T_+:6%'B4+/@)L^*46E_H3&^
MXIAW6).MB,-+ON[^_CY\L*Y^Z?2U4IW3LE!]M7O(1'MRV</9A1_LVAF-_0=.
MC3*=:2[X82+@"_DM'XNJH[._)BK]X0H TU3D"VLT68+?-T/$29_3($PU2MJ)
M1RFTF.7S+#TF;)=:H>%O(YFJ/?$4KG9^PCPK&G7CS!/('9=@CB#7ZB.!,@ZB
MC\E:.> 4"CW_RL<XGV"(RZI)%-56A]W/8'&!&0_I!?F>JI1=7^@:UOEU99H#
M""!7#R]?58A<"UTYC['L;28DE6:;U!G4#4.:%'W^!\#L_0=P2=$X R\>Q?>U
M#.ZNO& UL7$T"<7@=RPMZRT:BI/7]*K.0LZ]4%M)9BKC698YY2^;TD2JFM=V
M_Y*H[A58W]=]E5&E\JXVE^.B$V)2_0;JLO=/T:7P&QMN8-IOSPEU4?VV-'_!
MA>0(.(^DN%;YC]XHM%4P1JL]\Y>SGFW4/_C=]*;7-[-#TRF'^<^YV<8:]]NX
MS.62#@7\LT5:JJ9A=;8NR3"8S[<6"#5(W1VAI!E9AV.]EJ5ZVP*[)%[M^*R.
M_?M_PVG;_PVGH?UI-F+.8DC/=1:IU[A(*P -Z%W=_UXA*=7[$UITWS!T\T8U
M=/_ &?9)PB&EGD?N&_GMQM#&;H^XU29U[K*1E<WH =)9_,#=IG 'YIM^*2\Y
M*3^!.#V M/0S,J7NUV<7P'5#KH.79KP@C3":]NIE?FMC73L<)MZF[;S1^S5M
MLI(3/]<0O*C, 1#B4'4..EEIR_(#,FBMS"OF/;LZ,QCUD>&1P*NR=N0W);"?
MP6.;C%[O1,S8>3B,VP:C!E%-R0''DIGGN&7KW9^X.+G/77$N>QW7IJ786WO=
M\T^%>>.W>[*6EP-<ZNHN5I47MGID[:<\,(P9+L\K.9?:K#-=_MSAJ;&0'6KP
MU_/WC/9QR1%.2.EL<"C1+/EYEIHF,0NQR11PB[8$B1#83#!Z.)F_)?AFI529
MPAWM-*Z^,.@H]QCO3<"Q )YM_'0S\-0SXYAOMY85)Z$%<X*Z4-4PW^K'*/GY
M2LBH\GMUYU"=?X"6Y5M5I[?Q]+X83L(UGOF/B5Y/'^7CJDF75H.E+X_GELQW
MGZ=-X<* (@B-D(JY%*_.\E>*4PH%2%,3GVT1(IW7-$/F;GEW37U/E(8C(7-:
M,Q0465GP(+<ET*24ROG3BE*$(VVKC0]77]44(6;715CM"";R6>Z"\_*R3M#U
MXXD)M1LE<C#YKL]+W<^25;TVE,.%[OA*"DL7@\,K3N;"&>?,9)'L[NCUH]W$
M!K!]WK?;6Z@P*VUIUG*7@:H11U [C>\]Q5>7@DQG7#AGD;LYE5&O7B+&DW?>
M:<YELK[G:(J+U6.22D! 'O/N?;^''JNM06K]1>:K">F>5(K:L5/3]['""G\O
MF_F'4$'5NKIA@W?<89Y!;?QF)B=7?@[M\R4M!5^UNY+)./;8?6G3O/)IE=]F
MEGN%M7Q#F6VF*YI+1X5F9AM6C>N%4SD,5I7[']S$_8N&JQNIR/E $J0O%9^1
M=9L@%O0KDC<3/X\]YMWP9J(S0A@8[CA@902%ERA\U_F$Z'QQ TBBY%"=!<VW
M7T[4;9S!KJ'!Q8ZW)T*&;9)7'KXX!GLX8L:[CF4)^B^]^7D)[#D+1&Q\19WV
MA3A.@@3:XMRV5P^?3T.I.D-#0Z:=T\9 V1]O>U^YW:O:AQ(,>K8\SYRID*HY
MZL>:XL34XQ[M6W1#+)IFC*V1S9+9R$V2?%:S!].XU/PD)VD86T%+%)"8Q)"V
MS[?H?X]_( J-AM+@RQYX3W*ACT[)4 T@35FRF*AUN3M>,;(HM%7#M=H\R Y@
MP*TJ@HTDMX #-JE#.W!:)'_L5L-"7>^EG#CCX#3"N(O_9)&NF.R0AP/YQ D?
ML&#*@X8_36^8P.P=QA5S9"\)V$T55%NN#=6-H:+' H9/Z"N2!/A92?>O@L(^
M)R^]\DH\\9D[7A 0\0;297;PLE-U*K+IAA?T,^"K'*<Z[?]Z8Z>W%)-_58(M
ML'=(KR@E&O%-N%CG#]WOR&BJX GYO#@A/))I6]QC>P@D/$EDY,64W/61E>HT
M1I+=.##4AS*)T +XAMN(K7Q_UJ^CAO_V=&3<S?J]P\"2YBD"%J_>T0XW/[3I
MI 7PD'@/>[<=JW7]73#\E>0>O=5J[&NLJ)(-<"J%FJJ>L782/[-=14HZ'YKD
M8782-;]MF2545_<,<Y43SM)S;QZP_0/ :HA#+:0"3RR6SK-RN=+6MK@&/>/W
M(@I]5SU4/06R-<D'Z'D%1OFCH@8#P09H754=C;VGW)[JS:R8 6NM!0QAVC-Z
M.&Y2T HH>EIP&6+J3OC8\I\EU@2]RWW)P, (Z4A:5(1X#52-<RRB,\Z8QXCE
MGL,-K'BW;MUZB2E5IA))&$!FV.#+AKSHQ6,++IHLW&490PC<S;J!Q\M9%@?+
M#;6CAG)GIX(4(=)R1 1CA72V?CBH<=LD3B] ;LB=:+.>JA%BJFZW+#HE;S_S
M)*AI9@=L6"CHR)BNVQN8LB'ER1;QO31BUJ_X?2>B%!6 1VC$/#F;=&#M(CSB
ME-/Y%V-%]<+D#XMY>@9!YC^6NDO>O1\8#-FI+(G/:W\FFMB]P/+#]_19TQ;2
M]YG%_P=A;\$4!]1T"0\2'(+KH#.XNQ,(.F@@N,,@P2TX!">X#.X)$""X!'<?
M/"2XP^ NP6V?=[>^JJW]5JK_P*U;MV_WJ3Y]SDX@ 1P*[33U9[ 22_WF1M[E
M1)?ZMH5B4:09.TG%%<\\I;].=%6QN'+TK^3!LNYVLSQ'[/O?(Z59+-67X+ZM
M>2&?[J[D]3=N-O5Y]<H[ZJ?TIN7EY143WEXA7-8?>$3"H#WU%4!'H1'XPY38
M;8UE3<E,.V?1ZJ2*JE/^FJ*EBKB!L9KM&J$WDXPSL G"V) R66S+>L3Z_YL'
MF;\"P </;S_[OTA=OOM'JO'<V>V2:>LL=3WX;"W9'K.^WCK_+-CR"O#2./YG
M%I18W4@T,2LU5$G4[*D3_9\*?J<:]/@*.-[]*8X8CJ)U!3]*=&@$USA)37?Q
MWZ*[/+6^4P]XT-OO/LZGQ%ZLFU;1%&?X=Q],U/QT8H15\5ACUG_KV_6KIG/.
M;+;P9;\F2[)*]$2H]>6B=:I2%'W%XT%#++_9G7&PM"$%\*7X]_LD_7&%>[:T
M,/=&S<Z,B8F3[3DO,T8Y%^NSY;3_%!U@#]C_#70?R1H]V?QMA90.\FDM!RU#
M)Y-:DB7YSIHLO:::FP/$3*KGS-(+FLB@ZBZ10*59107ODH62#XE2S@ERXA**
MDR639!*D6^3G7H5U+3 'V/ZP2EXQEJ<<)+XL5KEE@?&5 6\ \8D2[I?E(*:9
MMC\ZJ3@P!>P$O%/B.D+P_KDB60.BIIP!GDB 1*B)>L/;][E'R4<GJM##.'J!
M\[NMXNGO^MI>[#A\10YS<SPKI"U?/?/N#OVU=[DJJUT^2:UT>UG@4W4^!_2<
MT_PIB04*E#B%OH1V%(8\-^"$=YD0VI ^(LY2?7573@'L*C*VA=QJ+5K-$AF=
MV-FCDC-D/0998PA[2F?^"I)H.N0-YI^"-HI+>I.F?0(T)>S\^"OE1"3:)W?%
M4)G"A5[R/H."BA2$3B%H=<NY$N5V6 $X4[O$,1BAK[)72H#O\SZ8\X&BAC+#
M/>*W*J\IAZ+W-]F:4\W1T:-LOT\-K=S[^\XK^D!%44,AHL!(#:Y6[/BO!>5E
MCL[/Z9;Z5TI,&M@IO:\ '@B+L[Q"DM.=\)Q]4:9F/(&XCV25'"B9=2?N.QBY
M?\#E_)V\\;<L&]5+BPE?Q)+O-B+@;CY@#YF"\KLC/A\DWZ[&%QU8XQ=;3TU0
M>4*W[8$JW%)C:\' )CH:;RO6>H?(1]!(- ';"+H<VM'!25[+R2C0>4F9BYWD
MA+1_OP"BT*QOP&BL,^\H!=P(\72CR"D%5@+@RZ52J&WP[*@>W=)NIV89#%U:
M6!SI:%O,![?IJHBOS 8:\4'_#M#*[-'40WT[:$Q.SE@+CG;*'T4HI.;?ZVX0
MIR"?D^#_+B8P)1U*7DW B2S"^N:=8KC76G9]IN_:'Y4;9P4]51I9!SF&'0T)
MK97E[XL]D+-LX"_"S7WQ _@37;ZRE5]B"'I]BZ:9 V/*R%('X_SFKBQQ?<I-
MANR">"4 [\7_Z G"U]]]+S_UVDF%EBQ2[,!=FA.Y7<1^;&JY2T^IGM2B%VC@
M03WB!P,$[B88+3.O?WG.;K_'K=L6'!2 O=F$CI_I2J]8>'F,OE.59Z>9\W8S
M+-\5@DPQG;\S]=MSMC*_!%Y]  "_9O CNH<;[$_UD7')0PFC8_8ZC[T]O=U]
MD_=C$K0=.O7N18,$Y._A!?F*I0:3WJBYGO#K>T0!AS_:S/F=1"*'YW,CCR=:
MP:+(L\!)0F;C%XB!=_2"'A.6 ]U@TQB+.Q*:Z/*1E.B@(;J\[A)2)=NBAI6,
M-+G!6=GNZK'33GRZI;16#JLQC.J+_\;5D"_1[Q-=W[-*Z[:8.95^*XM6".X5
M2$#H<K!O>@]/F+M/I$4YP6JKT+YHH)=W>KP+#+2M,]XB1E8DJ4JX_H<@F$29
M1=90%_@RP(J3''9?R'=<[/:-G#D6<+U,/FS:,F7RY. J&[;:7#@^H$3. G0^
MK!J.@W))NWKW)0EA9__@=XH(ELM,JG8G=RK0A\3?2S4BZOF2AO$-2#_MSD$J
MD2N]?ETN,AKZ_* : O.GP56&O%%$I-!I)LT4_[:2P):75UPO&(1QPCB,41>"
M6%R5ZG'N@K4O!1<H,WU?J%UB".=Z>.OU/\RI9:*3BD$&F?)0I,KKIJE)/Q3I
MSZ$%*NVJQA,7WDO??+!D&6"IJJAO%?+^L%K.D8C$][XF 4D,1 YVU0F+VF&E
M>R]BD,2.7YQ=YQ4+>>0M-3EP5Y]+M@>29L1C>(@;_JJCVD?QCEW-659_F"V!
M8/<UM#,#H[XAQJS_[?DG[/XM5G":;=2LQYPG7YD;RO$:"'C4%ZHW'X/]D;2!
M .'U2SZ70U_?JWR,)U% YIRXOL\"ZS;%\O?4KG0HUU&0DCM7%?*6<S$DT[?$
M^8'9<P*4?*Q32!W>I72*C-E)^%7!U82NSWX]^M??JMB";Q_42[UQ)@3_Q![Y
MQXYACTBG2[%,%AO2P1:-1AE? 2IMEL-F,;6MDUK*]D;<'J6):)\A)32B$*$_
M31(Y%3$%J:FZI)]G"6:"J1WM?]K&,WPV8(-\)-C<[YJ9>V!"F[7,=RCI:,GE
M$Y>HCDL #;C!D\4;5*<A$IM6H/8-G4U)K\#\MM^,OB>-K)Z?/J\2?UI2SP7!
MYCM"%XKG--?4&*\'BV]K*S%M28Y)A>13.GRU[,!\N.4/]H6';]^"*V6A5B()
MO;.-"R=VGDV#9>(HOA8$A#P5]GMZM:INF_5Y'Q"U, @LNPA9[/3:.JF.4[9F
M2*HF[M3AO5<AHL%[=?4FQ<&_Q+Y^9530A,M%?8F51S5%GA5<01%(<_">2X7F
M$/^;0,M6'=;_,"7]GZ/.:+FT*G &343,L8^@<&G^86#8O>T'!O?%/9K<-2GK
M* C9F$**$](HA)1BQMZ LY&@SS":N(ISAD+8PN9EY33[==<%C2IFV%]^,9[_
M5U/AVH,0I&BDJ2,LPMDIJQ93P=KJLPC0=;2&:H,&_S"AI7(T,+N]OM[7('J[
MA49/9U6;L)+9<.OF"]OI"Q^[;M,ID5ZS2SZ5)4/[B+:3.OP(MFY4N]X1=_=F
MB^*20:9): I/:24NQ=#]:KO(+%*!5,_0Z1@,@ZF FU*0\M7P0[4_ACU%9Q)B
M(LE@L.$&'4\NS)&:<TV.U^4Z1UD3%<OU3_"]/'PR/&, \!V7'QZQY6_+.3"*
MD&&L"W.W>3OH6-1L??!!A=6!$][)R!R,1(N()WE)Q&L?%("7BE.*[.=OTIL.
M>]KT,UI:DFP]#1@C6;:8WWF-O8,A(U5V;_K8\-?4E>>^>UL2+9LP/:34F%8[
M/<H3_Y^?(IS5U(#PAQ+_"(/5HK7$2'V,G=:D'1J]F;VW'7D[;'P87! ?O"^*
MU.B"386M)O0'FXJ<<&UN$=5UD)R.91U<Q[BZ OL# 0G 1+F.)PWBOQVV0Q8]
MB;Y==8I_]$>GK!V;)_M@HC^8+ 3DKGL:HQG%/AR*D0'&T@D4Q[Q3C3]G7;CE
M#C/.1>BDQ:_<+DI:9"#P6;9VLR^[+,[\X'7C')@1Y+$9<]>2W;6XO1 ]WX/.
MB&8\5K5((NI?)!4[BOF^!!!BRRCT:-E_E]=/MI/A!5Q&_D*W[L^-IFN/(GPZ
M2X_\4 2%;CVN@D&R\U,*L*?Z_.!L<)/(X>WW>P(VK@T](*^:+KMSJKN!+XJY
M(E5IMU@$6#8@4Y?FFEHQ8_Z%HB2(YP8GK]-W?78SIE&K,\V?04?7][-)2%F&
MR"0G>GY@?")N.VG5<$/R=46$ITWF-0>M;V"9:^C<YEEOZ>2G" ^HM;='&F$'
M;BTG/_GR<NZCQ\>""EH%*<G9B1Q_CB:U@?@&<=KQ?W8%'2QB13WN8HYC9J9&
MB.QULD,]\-#E^YVV)E2#BS]"WM&DZ7(,BME)%?7Z1<._;SQ5(,\9@C3 ![^;
MBLV2Y[R/@DPSL_Y,0K;Q^A,]8HF'1AXF2R5BG^Z=+>)<)!U5"8NHFCHL\/^<
ML%HIEC2TI CNA;S;+JN* < $=+!*I4PDAUUJ_!K$^1>M\X_M;F?X^)V$:;$2
M6VY-CX;X4C:$+F]VY9TZO!QQ0QR^'OO#U U',N?HJ>>T__VI>-Y2@]N=@S/0
M?F0NZCH&!-+4)!86W;C_Q)X+DOEZ"+5P")BK7' \E##3/E9C#ZKV,'INC[8<
M&A2B[J)R8#@L4<@<KQTS('(8CFHJL>&V^5S259%%'5]7E*9#^G$/L>%_>^WQ
M<U)RX[%\;._+*('M9X,UB:<SBJ'!')FCM4ZN UX[.W]MKIH,?%6YHO0&A%IZ
MVW/F\>^5Z!L+SA454?R-R9 S/BMWWCW$X?J_ ,NL80V4)C&\'*2SFWD\@N.5
MA:5'L9Z;&WZJ4OK=F= EGQN+<.NSM66HH96GD3#PC\BE(\8?(6>7I.T/0NJ\
MV)!YS;F!&FLUG$J:EV'29%Z8PN-]BN9?X-/#=4T8Z,;VI(+:]S\-OZ[&WR.W
MU:H43T5#B00$Z@CCMD]DUZ&16[=K"L./2$R+X';%-VETF3L:X?#4AGZ]>).V
M(21[*8@$P*^ ^W?@%TG)F<F74__+I[5N/0Y=Z0?5@VHRU3M3[X3*;*/VE2.O
MTZH:CS3IGT!L_Y9'=ANKQ01)*J;\W<KEBDI_FI;*X>*%45XT^:J7/G/Z!SJK
M)_\#PZ0O2O[_!L_/%DHC7@&5@1$3T.4IA!?M[['G3=/!YXD@G^NGR_OGKB F
M!S0<TV64CVS/F'5NUF8#&=? @<\GU]@\OM[[@>/MC^S>-^.(^H=)T:<A!-7)
M$\'%SF^<RZ/.+^4,IEN4I7-"W*^ I=SUM"NNGT>Y_ 3PW7D#*_*N=[X6ZB/]
M/_/<-,QLN2J]DI__C'O^81H6_8XWQ.WS=Y$"X0@__)X43FM3BA9/"_P4GV"L
M3$53&:9SDUU=6CHH04J9]IPJK$#:%OGG=&N)/;W9@[$U7\1*/K67_HR>#XU7
MR@ +IA:@0WD$&!X*_=['RR8#1IFE.^0=]9O^8?5=#B=[VTK$PJ4%3HP!DE!?
M"\G"8U<6;A+1C$@0',9B0UCT?3-W2N(10D<!932U.S=.V%^WU'C&:YVT;[=N
MM<UPG5+M$0A4 >_3;27_.0F,PYZ7!.K3S*T<SU]T#?=FDLQJ.81GTX=B#*2&
M6/%AX0L>#DNL;Y6D%"CU%O6E%0B,9R+$K+3E4%/B$@XEA[TR+<+VXWM1\;T.
M*4(NF8=: POF?32_3-BO\ H3.]PH7T4*G16VC.(]8OG?T>6PH2];1+\<"H!*
M1W]U58^['2P,SI')7IJ$#/)T,^L-E653;&C_XV#0J"*V2[;%)/H+0>(W53H3
MD'VHPW,EBI4E^JD@T^?=0[X>D!P'%14=YG$;K1"8G/-*A'1]U6R8/8L8QYAF
MS=]2R<Q&'_%AC-PLCE$R2*3UVM>QPF9S'8TZ<KC$]4BTC\Z3FNJWIS**.JHL
MWR,NH,#Y&) A4V_GQ&[R"<(7]9'@=)(ZG@-!<AC%3N%.LXNA/', XZ4RK _K
M):JG:3$ 6>-H!'\!IB!TAHV[3[!O"DVTME?L#2>J.O?\>Z+7C>T^RC#TU V4
MQU24,O9$ZWAD0DW&2']*Q:X2?#EDN*RN?;@:9)MWJA(/.>TPSJSVUVK"SS;S
MJ\XA[SIR4C$/\\FQT)2L\M]2EB$.\6-7H9%6.E=)<&U5Z$Q6/:^SDABB4%>N
M/3<7?12FQC44K'JK/G\\D?X#D,ZSXJ;48G"RTXNL#^YEV0 "(Q6-*RJX9N.,
M7@$V:$KB[P-CG?P\_N"7?W.6C9\@^24M.GEA,69@KJ2K !7W)38OI3!;I00T
M:FIM-%]LN W=4Q.'=M7!,(YF]O)GRZJ[E)P?]^[S&YU_DS+BSE:&?II)"5Z=
MB4OAB[,* 4#S,HJ+?TMB.U0).Z%PP3F*CX%++=%,U4,!=+.__XS(:5NU9:-!
M\E\!J7()[@F>\?%A/:\ HCX@B$$\C\BT(P8J3S D@]META"WT]0#H@M&4QAF
M:,";",BS,R2>7EL972KYCHT>:6")OVS4@A*QT<3)CDF\70E3HU<0E:[\%EUR
M5*X+4<)KKK2:U89:5(4KC.J8A0J"?@;JF/TDZN_^HN4JQ=^S<+$I<KO5\-?-
M9;#W*DH6IOC6+]?W$+ U*7,07X'Y\MN$P"WZ&.(?DTZPLYGUI]_H@'?@,I9Z
M=&L@T50CR&<Z<.[-TZ=IJ[Y4[4\FCLOD._QJ3(!$KX:<!*DC$1AO@G\J.BC<
M TQ($KQ=%)NT+/U4<N/N+ZFEYK[&[(\K#3(>H=QQ<B'196#L882VF5(0:KVG
MT-6VP8'71'%&%-91AT@Z@PD]!4?PG9*E6GLOLGL;J^S'XMPZP_DPRX: +@0!
MFF7R;"!-;J_LM,%ZC!GV(6S\FL&($9SWR2U41'$;GTF*/;FF# [=O4^M0IW"
M1@B,I<3@<?&1VSCA<<%DF21>O]YI;#-.F+;-$5^>7$JDFT<:N)-HT$\H@E1L
MG5WC+"-4M(3;5.N_#6!L*%;@URL/,$JN;F<P=[98:R>"V2Y<RW&L<(XGE0#.
MD'6*GHIU6W&!*0^\M&+I*^-5I>^KETI[63:>TC]=\-_D-30SCN%3V9MHU%1<
MZ[;T-^Y8F# PL4-(&ZTER^;'TZ,0"U/^F@24]S=H:8(G&I,=I^I'R]V\T<5\
MHY<$": D"<"B8BV ?[Y:_?K8A$HU4?%/Y6=X(J&!4;&$#ZC#+3U=E5")3WER
MV]9RUK5U7D_L?^VEY]Y>JA=\NU7L1IR!7@$R5AXX)\-K+=V5I7-2PE6O@,>\
MH+]&B;=6+U/R1YH2RT^4M=IGKX"85P X\Q5 NW3:,8NZ$??9^L'C]TE\F[]W
MC>/($Q'B7.,5L%C@+/S<KK<_>/S=.Z/!H3#B,4_B:.@5<$>,L'T%'%V<7-_N
M/OYYN34(THU]+.RR\FIX9II_MR;,_*4U(.6,F48GR5EO3O+#*X")""79!!4J
M'9_.-QWJ8E-$4.)>R! TJ!'32M3<2W8>P%F_P3LD==#A"SP[>29?JG&%64;E
MEPE?T+VU\=W]:3=MP()%XJ^?Z*'M?/*/JJWB2^(/8(+I*P#ON4MR?G.2;?@G
M*!\ABD(.7W;YX]'$W@S=3/SV"DCDCIL#/W3T;2&H!/C-(^H@J9HQ6_[H%]B5
M!EQ6H#'H%XSY$2M74EE-HO']]S63?.4+@OHSZO4LBS,9*"D\0X]0U/A$D^@#
M@RE;6YB1L*($!#5OQ2JW/E)K--P3$.H;'WU>&7#"\7[T!4=4YR*1*Y"G6UBA
M+O[V[I*HM?,W]#\G"@Y^WX$U=VNAB5KLKUG]S:0)-$7[B]9+^F9C]B(UW_C>
M]N9MZ2&*FSG;D0U^!*%,DI;7N;00JY*6:(+I_K1@C*(H26<[2$=SM$KN['SG
M_0;7W=#]%LKW]0(.(L2&%U,;%6,JE[LH01*:+S!1XC3(&I+G$9L>63M0E\#2
M1,KD6-KO(%><2.SH6A0U.N,=#;SM^"K3*F&Z3=@Z.NQ=G!2Z%@7 ;;7RA:(Z
MU8'F==SBN(L'<FW!I_QU5 6T-*;&A_M;2TM>$,N9(=X,(P-<0U:A]\$"5MI)
M"5!<6ZOI! &FSIB;GPD7'1.7YMFV-<602$QG(,;O7+Z=8!'R83ZTA0O1=7 B
M7GL.W G$9'='C$PBDIHAGON&^2<J/G\B?PS\1K["+;<I4_/TZ#N7W!*Y9X%5
M\OODO7I'Y8L!DA ,LC=_5_BB(_[MB<!M"E$+^-OXF?Q9K./8&6Y#I/G,(Q><
M#LQM:<I[+6=*0VU\MCW#1R\%1-\HMY,N !^,=NIFDA26Y5X!C6..+,SIC)*!
MA7KEM]2!Q;:0=%KFHK>$K#.H?IU59_NMQV)L=]]6=M1O? 4>4]$QXOC<PM+I
MG%I0\A\)ICP,! Q7XW*1\G[7 G;>8D"GHN(V\'Q%X)-L8YQO:D\)<QN)J*PH
M,, 5'*#Z4<$0ZM,3% MBIU16^8]T^L24)(?R5 ;;G7FRJVVUZJ3<K1N](Z)#
M*T^B&TC-Y=4VGUIP\K:(-^'F8_W!_+"5X![Q_)9#>SO+53*K*5S'O @G9F*!
M[\A6'5:>;P+AA7E=3@2EJB+0@509-L%]%ET43(GL1+9&?Q,B%8O^]10:'Z-@
MG :7?$(E.-C1UV.(SX$FYY<F#:]]J(YQPFT\5EBN;3A1$MZ:/XT.R+L$1:@9
MM1I8&6MAGEDB:D1#':' *@<1RJ+6S,$J+\<&FKF)$,U^D ?6JSA]-.+Y44<@
M-U3APMNC4GA>_PT%1SM4KX0_";(W)K6TN9CS*U!)GKHJXF2U5W+\MAD;J%N=
M_Y_LH$!OES;#23C6+C:'R4/Y$)BU0\6$):=AX"';;'ZG__0A(O453C)Z(N&>
MX.:H6KM &S^W5,LD2CA!2:4OWJU,W0NVFQ+H/3E.[;;2$"_\+9?B_$G56>F4
MK2>6AH.'@Q^(B<*VT=K?PS6,B $)_/U].GHX_$D4P ]$$!M(OID4])8J/.7M
M-<>T<7C6;']D-5:LL XYS"M&4X01*UK6E"4JLMVSYTSJ]X)/FN>\))JVQ3PG
MA^VG&&"B!%;1]>$XA*[:GU5M'3T.SJC4$W+.<4I<>95%F_ OF*SFOE>25&N
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MG.B AF\\8VBB%57BO]2#U=>'E' M$^["GBT8S?%#VD!9&3#F'6 L[2G!43Z
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M'HWY]P,V2V?6&%P7RO,M-ZR;#P*_OK_7Z<-55QEY-^J3O_%SO#0<#0L3$ Q
MGZV]7,"V/.,F5FB%[WF9"356'\=KZPEJPJLT!#1H]M?VNXF/J^3W%$WS$?GF
M!=0)OO]NG$PN3ID1LR<51DW\<49:FS>B+S*R%@YH32;:E@.%T5CRR=LKBX-E
M->:R8M8![R7F/EHJ'!]PNDL<^Q4VC'RL-E!UV$E#19E=X J4SMVC6)[5:2+E
ML]>#V&$7*NT?XWR_$X%JG:50MB,3&#0#\$O=6LF4\TZZK*'E0_5?/CH*SQ51
M1L&H1-X'Z&$W3_R#]_-2GH5]8;]FX!:E0VQB84[AB3TO;.TD0$&9$I%L,>_I
MSU!@XO6CB^2@,*!BP,99/<PC5(PRQX>FNZ8/(5%VG>'"@P(\B'T^J;(O6J4$
M21@6)43(N5>DS/#5)3"4AE$N5_)PR Y.K8KN!GQ-&GH#U=/3<%^D8^->*:/*
M]^'P:\*3:%Z9[=L+U/J_F1=]C-&I6%GVH/HC\F:H9Y2*[KQ"5T#?\_?,EV<7
M)XD1FK9JVLI=S!^IUJ=7!'"6Z0@&S2!^[/:;?B+533*G:.8"K/B1J^&OICHV
M\XWMIE,'*8=Z%ED,&TI;<3:0O=3S04(<1_WM='$&]G;'DL:A0Z*JP!0KR+V7
M2^UE.=O/%"4Q8V&\YMK2$*"&QQA-.:I8PYS8B"5F641#"SV>!@DXFE,+0P+N
M>*Q:M6HTD*4E WO/IT?U*Z[G//??!R0Z/W&]='^-Y1/#CYS/+S_]'8AAKLL+
M"RL05$@Z1U*QVR\&&7)&0]]8<>K%6FE2%RU_=7[@6\9JP[AYBTA,:PS%B#QE
MXU+B)#)1\<@AXK%V"E<Y'6VJ$NU*B-NTYMJ-D%^5X?TO3$-F+WPEY LD,D(X
M^B:[]R?R^*81W"ET^_K];G;#R!Q/(IF@GQB+,P*&8;$53*@)7!>4AP8@7> :
M%W(6'A:=8/TK0(U:$1$HOWG)Q4X/RZ'_SB%BH(:DVE\L^I&A.//O$9A7QT93
MOQ4V;,8QGD@/P?I@I4#4E_"%T<-Y[A@)7(&L$]6[D,:VL,"7W').=UVCYZ71
MJ)M75F>WI;YUNC"4D5Y\X2H01<T8D7"YK"P7"RQF)XN1MWX#$?:V<,0QT]O2
M$^VR-A\=_P+CH]%.)"/?8<7X+1^!Q3*MPO7Y (RC[Q:Q\C7)AE?":/OF6I%*
M^8@2IP&(D_N6#[( $%ZK\2LIM2U:6+$7OHQR<DKB[Q:R'&!3I-PF2U=D2_ZV
MFA6\8!6GOO=E)K:%KV1DX/I&4#-!T3OSV*,]BUT46OB$*2"H\!49"=B9+#<F
MCL;[<1"F<N[-Y79PN&QC0"4!5OCFVOQ!!K=V'3?I[5?EOV(9H\\#3J"%@Z8D
M0Y 3UW=Q@0C(X@Y^O0RI7_D$[Z3K $!-I32P0H3)@-YB+Q4?^9U/ LCT:,S"
M2I-]2(MNBF\I'?+&'L,MI=7TX:^Q"LBP,A$P=?^3_X!/(9" P:-O_+LL/G\P
M8GKK'!4I+O>8K53NWN9O#6W[C!,4)5Y[Y2#E1Y]<<1F?A@M[\6$4ILVIE!L]
M"B814<SH#N..KJ*.D;^\%&.58 >/1E5]J)=2M! P^=?TMB++[ 1=C+#@A/=G
M[=.RLIB8:#MK-N5:MIZ-4![%&H3?RLTM_JHLR6!'M  1PPAQ7:U5,CER9;$'
M*DT+71Q!]DDKR:HZZ_\:AA(O_R=FX,[_HG*'C?D"M%^_"(M[!12PW4<=K =P
M_*?L:IQQ.K\LI#PNSOF^O<1.4'P%8,*WO8<3N_V>=9">-]Y=R;X"RM9<1N\S
M5Z8JGSW'!N4M;9<\@Q?@:$V+==):<S-MR[AM/@O5CHHKA)QIX+ *S4 Z\G-'
M^N\%"U]N&8!!8(X0G@QQ3'34I!-8GV:^+> GR@R>6]-:I6[ZO?%?Z\]_/+5U
M>=_;UF6&I,F*)AAY6:))VR1HHV[Z+.J)6J,#_)?5)Q=4:SJ&X:3KLT,!PG))
M"L&ZKKEZY):.7[FCP,/L\$(WDD)VY8MDA&[C&.S >\1A !8W2(]3#X#H3KVE
M;]7"A ^YY:*8.IZ@13,5@[+GPTW>E_#%*4?_;I+&42?)^(.=A((VTO.O?,CA
M-+?^8/Y\VX9'45,632F1XVT:J6J. ";E*\ =?ROUQ!ROZM^DI619F$>G4.?A
MK-/DF4Z(9=)R_J6N5OD*5P6-!J94.B:=.PH=39'C@L#DN&GG:.,_AS<=JC32
M^N+*^*>QJW5(1BF$[GIT.$D*<)I)$ZB%+YG;3DI1/I>X=QR_D=ZH!Y!''Y)?
MSVCJWY#6G<VH9*#+(-H%O6:64"J7SHKOJ['>Q$]P!!,AO0(\?8+W8"@T1L[H
MU9V02X.B,??LD^WOZ9.[<#M-8<;DW3.:[>_H;EC8G^D<*P<5#MUB5?=P%+$Y
MYN<G>$;(T^\:BTS)%&&8']3]$)T];+Z #=@;-HSH;>$Z@B\)3S4QNC'ZNYHM
M%@Q[Z&S>Z-6RK,OIPX*EC=@X 8]JK3C* G,IH2(FIL*?1JSW=>5P0YK),';T
M]YL.^JU[FP*P'O:;?N=;*\WUYN%)V$:8+&+2::FS\N8/W6B]_<OM\DV#S4MG
M%#'',1Z@:LC?RAHYZ9M4B:2%QYM.=[536P7EMA'4W^,=QIJB '.4[9=K7W)0
MW\T@) Q04V!OV0HDA?>-Y(3X*U@Z*B]S=U\D[/X@XK6E.=95/1B%VP2-C.2U
MB2;$X3]7>*UI&R2FXX?/7"+&5^^!/'WAP>JNY0/E>9/'"SW BVUVZ(U1 RS%
MH<AHU[]388=4JQQ#:X5M)^C\6Q2%R0B=M^,SKU$@;I208%1><EF\_(..9EE4
M3,5UC=7#_=<K<+[5]EGR<8T+4C!Z,(J4"'#"TJB*)IXOMB-]W?70L'D5=J#E
M;!?Y_KBIFY5'E: >Y\N[_AUF=:B^D6$RFUI 4_YGTC%PWQ#UY-P.5B5?/F%1
M!!A\GOR4ZH)'?>[6Y:KNH.SU6*N7(>QQU :TV:Q^2_U20$Y]D8%%L[O,@1KZ
M060O['0\QCHQOMCGB. >K=MJ&5PYRA,*;XF4QW:HX4V1^OU&T<L5!EXPO1LN
MF@[BE_GB2T+2^7C;5IQ!4+.T^IM0779376,5F9SK&4_]I4,WK?6O^(AX13N:
M77*+>$6LXVA54H<$'S-A/F<,0B(235Z=*]L/-.FELR.?X!:_L+'4]:MN0L K
M*5;-+GD0._/FS_1,IGD&*7%OZ0^NC6^HY@KN3:W@$>94/];3=+KA#L+QY<0=
M\[-(F\E!K[XKB1N2VG;&R\"RPV;2RT,AF-V2' >E7$O$M_1# ;I;H=_-*(60
MI"I1]6,Z9SPFB[A[V:\T71P^/'TLT_3!O)9#@ 5\Q7B@$P8R 2YE;]1[*/D0
M;]F<8-E<(8/[* 0,<X> 4\936IGG39,3!*()16; ;N6%#,$DF@ ='11KG0_(
M(<$  -)H5[Z\Q_\>H_S/^Z%++YM6+WLKNQ3+0?^EWI]X1-+=[5'SX/#NL2GH
MM-.>.2<H3)<V1KC_%; +>@68]2[_!Y[XUCZ] DH1R)U->[S",)Z7DR^Q72/=
M?^;W2V_>F0?M;N\^_.FZ60S22SRLR3*I?04H"Z[?IDW=3EAQ9V -_=? AVWZ
M])GSZ]FSOVWEU; )$Z\;5[G5S8<E6+Y;@0:49I+%A#64WX3B$HH+1@T%*4W%
M:D:8CTYR?)_YN>UV]$PK;R+@9'DK,T,W*W!%N+H<C:HFP"K&"A.*JX4@F?*0
MGPL-JF_,V!Q6E,!4#Y@4?AZ<X90F)F]XZ=,H5K$1T!='I>M[&6A^\L6OY,+Z
M37JJ(UTU8*='B#-FG<7%&3:> J_H_7MB_0&@@)60A>Z2R-9]8VNF]&A 6K5$
M-5;:U$5V;O]W:&I-A>0Y;;#=#6-ZN9U0*4Z3^ T6%B)<^Z#ZMB9EX_'2*^?4
M+?!$G%=<^1_%&>9"4%:IY7VIQ=/4B\O$R>12?T&X^+ESKEJ/]ZJ[C^_9&/"V
MFLHOYF@!O?)7W*)K,2CP0^N4K2<T^=C#E)DGSA\8M=N:Z)!R>J.SS1?Y1M^*
M$O3+D8*\ F<CP?_J[F8VLW4Z[2_'\U;AA#V[Z1PK7:6[JD_4W%TKE+P^\TRU
M,_G4+C7!@N2%2[.UR!JT6"%,6"?3U>,LM!^D0=]H#)W9UM[\3"BLR-FG* E'
M09^-O]C3G/?_?. 4F( 7#:$9IO0RJN:J/([9B+"81?@3D<)/:/DHU+;EB-E^
M<I^B)^,(5?A'3"HTY3LP2%/@A"3!U#&0]3.W'3&PJKJ?-UI ?NT'8J.R(BDX
M*0%+-^ /%&$C@L6_AT.1^FVTR$0 U[V"WF*0_H-O^WF2+DP,HR,1U1>&CP97
MIJ5)5/;9/C,WE=@ZE"RGCG=:V:\ )/KD@,S+[C2A9 99@EXNT(?!AMRR3?!>
M\FC!5!?;5[-\A5E/EC!+%'_7BV] 4#M,%R:18#OMJN#5NV#YXQW;X; 98_B=
MX >F)8/Q6!,C$T*Y1VS,4N G5PLY[&WE+"Y(;L]P+#D*?3&PQCR422+<7W]6
M.PD;OQS3AEX;"6:0 $#) B<!J%(:9>B0(3T F(8T&F2]1]OSX&OY\[O9->X\
MFS:MBT4FQM#CIT2=D2X% ==39[?L!W$*KS3J_+ULF"MW(66)P]) ;51E-ND#
M.F&5U_=2$SN8/.Z2*X2#8 5UG:V>GP4W"1V?Q2<8#FS(C3D,]3DER>9/TV4M
M(!1[2-1PB8"8?M#S%/GQ?PHH]Y+OV2L@K:11TZ^ *;  <KM."W[;Q23H<.F>
M4>]3D63&4O:?RZ(5M&<KO&DY6/>40O^Q^I/FVP)=?C AGCI 9 @R:&^6MG9U
MK)Z6P+5WG.+=(DXFU. M77,9;7I7/1!:'#(>#_6KKZGSJ,/6_958BLWQG>#$
MOBS$W%:1)S4F;[HZF1PL4_X$3%Z+ZGS!SOJD6MJMZF<=QD*^Q2;RM5!F2,:4
M@Y#GA[IP#:/7*"ND+A?90B>;(0@&XP>A@H_)XT)RT>B#P56R+1]V],=BD3',
M&!S[8P3T^Z"YLL!)!0Q5>VY//?'Z ++AYL$OM#1FBZ$_DVM)W,>' 0 T"(<Z
M1&08!%-:T24A=E=A4*1,]S:/[@]5(40C=E;'&[;D>:MV](G6>O.T[.80X<2J
M1JA0FDSYK&F\2:F#.NZ9=CGZ<[5<&I[%(^V?ID,EI6)TSG9E?&AME6" UK\G
M 8FO![:*W$"C''G[T)6O:T90C(V.;&;JK%,44O9D ]":8=-0&XEH ^HB!7!*
MQM"XA_]S&873UU&QTC<$,6QI7Y.L&WKF1=_P]7Z-T-2Z;)1ZZ^E#ZW3@?2<X
MAW4VY</V\0"!R7Y7:WSW1NN.VEL$A[^%VH'NWJ0SHVOZU\:.^6EUC0D2J"/+
M@#X\"0\CVG\+B6++M?]4WD%MEA1BQ\P;'2=20BVIXR@:EC O693"UYM(ST00
M=48H E)0P&H%%IWS,30.F-JT";#5"O0@GX&"73&Q>*0_Q@7[-)O13Z'3?#SQ
MG*GYTE2<C$,PS%#RQ"=17FWEB$CJPTTX5)>!YI"$&R_]WOE,*O"#9Z]^#F.H
MIV*6D>>/'(,<.\6B*H6J>WBHMK:[J(2_).6_5N-A8/IEY3=7\I7<#><R)?JZ
MY+ $V2!"S$J_/M^J&LX?(:-*3/$*>ZCB$5;F&*.UEA3JP^)SFZ;CG2%0MXB]
MMETW99\%G1\ZJ^Q1MY+T\]83]1#!D$N=<T"5G<T4E&CW5Y.M;HWU\:I3&1..
MNSOG0+C/K0]=RDR:1<'T?Z/N+=_BX+XM00@$"!HT>' "!22XD^ 6($CA3A4$
M"B_<)1"T@,+=M;#"/;A+< H/&MP]Y.W?O;?[>;I[IN<^W3-?9J\/YQ\XY^RU
M;>T0_Q^7JN5C4KEE!^H&A;-[X5NK2/80FO6'SX!6=%TC6U8T>_$9WB8(^VK3
MPMK_*PEM/)P?:X.5&O^@>5&._MW=-;OTGS_-_D$TE ;+ONN=>@3]O5PX/XGX
M!^W:QN@*V7*U3WIYU"5I8Y4%_9^BC)3_%F5HHW0!<7LM-TW<27/][?D=$?="
M[HF*AXK)M%'SNNV_H?1#C6&OPO?(L"DGW]066LW"Q9FQM<.UXP-"B"*8+0G[
M20CG5;UM' (=!(M7.20[^ZU%+1-/#92Q2S;+T9/#J?2QM'"PD/S(Y_3TUR=@
ME7FJ ;D*V>3^6,4LEB5=P1@?1 J_4X6E/FQ)%JB 5EI1#>]&QL8;E%PEJ6:8
M%1(U(0 VK(GXI:F7KRAWA#!A-J,-78A+5=>Z^M]M,7S= U%&AY([4+F/\%RQ
M8!:#.;K0#N*V:I&82JJ5T!>WUCL:R-CW$)OKQCF7X5FUBM[O//[)009769B=
M+=%Z%-G9LTC"Y6A+";O;2*8$(\;O73$.^/:GZ@/=P,MK;1:XO_Y*>K68TPCW
M=#)HP1WPU2&1@$OHA3)+\J>U !>Q_GBKAQ[\;S&_='(X1[%PVFKPRA"+7I)-
M'%@$^#IA6.%MIPV7_8.B4_P[+^$C7#,[E'$)/,K+!R2@I!+Q=2W1R;QX-6:!
M.F:X-U(!C5"?QAR]]A9WI0WRM>F#;(GM+$J>O.U<WH&\GVL3(X4+(]73@W5M
MA6M\(&UG9S"@2(RIKSDL*6N,MNGIY1([A*1W)/G 0CXA+[PGT@F S42,DBS
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M1HVDIB"IE8[%DF^NMP)*N9%/?Q#EPVT;Y%VC5<$V$8<.KBEO9.?N>V7-AV+
MXO1N^=@@<+BP=ZJP.^4DKRRA4?2+'*[?G\FV."[&TE<";.@I)[36#$>7F_1O
ML:O<PSD"G;F1M2ZKXI;@)"TC_.4K_39G>_[H#3]?8\I$+I?[^@, RX@.C JJ
M^<5UMU*$KXJZ;SV"*6H4=4J_!8)IP;D4WF&7,F.; TUZ[[[VORYNJ?TDF.5!
M38?N>..@9SKGP(WUO=#4CEHM;([ N6VPZ4M/,<I31?IK85LRS_[0,WDK9L4;
MM\9L+FW'57;+O?MQPU;^-L>6AG$^:F]14VD3V[0C_PBCB+#A<T.4)LM=5Z^&
M"]NC/&#-B#:Y^I6D0;&RFJWS9/=MM.'BA@ZD>FKMZZ-#U7A3SUDC /  J\&?
M&4 L&S46(N&3HY="X52[,,(GUBV94/NX9@3**)9&I0UV\S'@@[R%+90BLU3-
MIMBNC1J54'HXRU(HU-8:[+!PHZNL]2OK@WZ.,'<\S+YB+IFP,P_H\[A2R%/P
MO2'3G_G5]\HZ&G&Q52>FAH$3I^)%>0,W_<TJVU&JG!S9>-SJK%K?%,%H:Q8.
MS9TA4335G!@;ZN*XB:A7L;V<#1'5432<IZ/=,2S@E6@J&8P0W!".TY8 )V%Z
M+QG2("66:MR8V#MS[!R7+T/Y76GES\F2W,-UDN$#*/[;W87$AN'&<:4EI/U!
M,YL?OI/9TIQE8K&^E3NX--,7HO'J!_<X5;Y"Q4VT+?_<L43(H4$[N#(:!)_I
M-UPY=,5#30Q!KVAPV#L]DYE@WK)<'T9'D8-_Y&O?G,H;X;%%VVR0903<&BG)
M$:<]];E 63Q^(QOBJ%_RC1;.@C'2P:9:,RO5$@HQ'D!AZF;'>?NVCBFC7UAS
M4(3SIK46VTG!FD(/-\2F!/29<Q!V:"KI1+1+^6"5B0LB'<P2Z9>3EU]"C(7#
ME 35F$S$5"45;MQ!*>>H"ENFM9JM9"GPU=)^L&->P/%R#DN"@;)QPC3[U_Q(
M$U!=EVI#2WTSY(T2B>O=Y(']\)9'L]=:0D_ $P;-=M7S7'LA_8KLR)9LZ2@O
M?CUV0[1RYJ9WH[W=>"EE;3::4')U&N?#PCP44744,](H3+:PX"Z$)O/4,40A
MD8 U4/'[3DRSR9NMJ;V^*W*_]D==0G%#>Y0H-8<*_Q!M)!<?!^RK-4S4RMZ%
M ;]HC:MFJ_,L64N?O0D,VUO^!;0.6\,H?8,A85]=RGG1#C#?#,&IJ3$^.89:
M6WDK )4IUEE-63..N:@GFH@I#[XU+CP0I A[,Y'97:FSI"EFZK',=[TZ<[5J
MD=+$]/21^%5N*RP&GJAJ."%5]@27;BAVWTM3%#K1C:.O?XJ**7]'DL)('GQ=
MRZ?K>6$Z(#$-^!:RMS??DCKS'L(LS\Q9;CEJH/Q)DHURB33XYP'!<Z13\#ZX
M_Z#>T/KH3ZV(_S!_I:4CXU?(*Y$U>B"]L9TJD&[<BX33E7HKV,%<3S4PH]6R
M,6I1K-#PIY, LR7/;EWF<1C"I/=66-GS=:PC6Q/8=@N+(L$Z1-Z"%OZ.X=&
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MI1=9Z\R?^%^8>\NHN+9M:[0(A !! L$]:' +;B&X.X6[! _N$$)("%9HX9
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M(I:R;&[GUO?&Z71#DZ-/EKN=$!3)SK*CZ_()LG>F+_:*#8BP]%99C6"KMVQ
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M06%K@DNI(Z'KM7@IX+6 ZCJ1-N1I=I>WJGRQR3CN.HFFSQ4%]73<L=L>__L
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MN^EJRE-(/,TB Y?7;JGN+J1WLTJ)=XY/$G?].*,P#H\7<T+C':]'%RD9/3T
MT)3,=ZN/_BW4!T.[]CM^IY/?">!X>#XC[)'0;/;N+%WI]&RT'9TPM&BOK"C(
MEM5']BG#RS[+DA(NSSW+:/6\";5?NQH2.05N1/9>% )K>@&^Y=R!XB2U[GQU
M^]:('@O=QSX^5;M(!#6/PF9\=&)C;Y; P-4CTQ\!IL-T(:ZP<IO'/[,&5+;8
MLT6X>AKS')T-;#>N17.OP;$ZE_J3YUS2]ACP;PYZ+KAOF)[.U>\SMT0UH5TH
M=,8/LZ7#?\8SUFR&)ECA#S;7C7BOCU2A'%!$;D$'X8H[[.KT[=[60HA.]ZT
M; _6;@$]1E>@E)^B,V5<Z99S9[R>/"3#1()%D5H!2PO03I^^[D$U7##*3^M&
MR>)1=Z/ERVD$]N@DC.Z1H$3U&+ R@1099KN3W@&^RD<]ZN1$OPEQUB&3$\QO
M?-M1!KLU,2BO/7WH0OJSOLN90CIE]8B,,"\>WWI:?-SR"YT"1KZ,8)@JX0K9
M6ZDX9W=-57LOYU O9_$&>@LQ7ND<C7BYX/3BV-<V2RQ6B5167H'^YXKM$#O1
M7&H0>U4I#5[.N%Q22I2CO9[6O@B?XX[;R4QS1MJ[RH8@#6*\B&#]2@#3/,Z2
M574JH"^S,U4ZP%^2WUMW]NO890I%7WC:#\=,B0QVM,%&7W?RN>=/D.&"$OPO
MHN<T-MZR\ZDFY5#E<JR.]M;B%;^%BMW,F/+4B;<*W"25BR 9BQQX*ZHC6YP_
M?!M\RC#@00/5K^%&]4S3"U)5CMUHP&NK9*%?=RJ(HOA2U)R%V)Z9'I_NBCN+
M?)[^H_O\X-+>1)59+9V>_'-4Y.HE"%#8_7/10IA21&3' <IA[8AT)LXE1G'!
ML$1])7P>J(2E/W,,AF'JL=:S1R[GNYVFZY+PY>XFE+I4[D2&J!EZ.^^V@A2?
M8L*2WVDH9$3+=".937[(%/%8-(S2C2_,JM65QXX,6AKT,>Q709N5)EGS:C=]
M"I4WSV^^#B=.U7KKEYNE(686+NJS%-?';#,('&80?OR>[^2TNNH'2DG@4,PP
M=X(Q*WDFK;@.BKFO@>J;7 6\MJ34WSC?3Z(-P;S$<24K>!,L7J@W=A:[:2;I
MMWAA(Z2UI6)BL#=<)$:;^C,FZ2%99"/N)<GNK+#LIFYD,2^Y&!]5<5-WE3(V
M^;NIU@)VO^-SYZPLK_58'A-:Z5?=!5FNFD ;NGK6'^0V@=K"D2^KM'!G3A&]
MOJOEYZA4JO)O*?OFQ4#QXN)!PH?H-<>G=7N+5A/,VOP-Q&5-*7[ R)]Q^T:=
M X4U7QE4$J*8^_6&GUH9R7RD+8M-D)Z31O^)W[]1M;4A_'3H#O#<$ 8N*Y/E
MB"YC\#X=L.>Q]HT<HCP3,V>/_/H6F[>3UMJ]=V0B9&%Q!AE0U1*6/6X&BYU:
MU9R$Z];HNY3M)BA3#%#@HQ4H^WAIJ6C9D'X<48VQPYN9;?,"6XW=XN?R7#5H
MG:H5%?8B/2+MQ@WEHX"/F68:;,*%'[K2L;$QM>K85_7F?F3OHLE(/^67,</)
M.O2"Z"^^]IXSYJU>LC]0.-/T<2'FS]Y=7KFR,$5G5+@"BZZYZ*SVP1M]JN9N
M4PY#2TYK#Z>$CCE'%PVD\A<?1U KKE>..CUKQ'&"9D2\4WS\=DRNI//].VGL
M#9(,W.;)_]PP[;^'/M5I[\]!D%N!@)COKXD,L_AE/7?RK*8$S-S%L9A==9 /
MKC,BLF)L]/Q:LZ4! 0<CQ1Z-\O-K;G[M>A\3:XR=\F3M1")I9L-MB^AKL)[3
MNX%\!U9N$V:H.RZO[DHVK1S/&9-;@EH/ -<+)RBC7ME#K<QK=9"(746&)"TS
M_ #(;5U8QKV=?7)),3=GC??0[/Q6O%62VKR-$2PIC@1G=DDS)OF05.2LI>:R
M/<7C>1&_4D63."^9[9W]/;G?L'3:.FO?,@;,USK[5)&&W=6($B$NM$6545.%
MTU!YH&#0JABZ;."-^6G*1BHF(&)\$J%W#AM6MZ$AKHYA*G87?6J1>OVBE=9,
MA-_ZU;?(_7?6-8(5/-.=1],%8BUM9IO\YOOJ=I)J_DV,34U3;6"]A_+)M>U\
MSLZ?G*(_@/0W]L"#Z>PD:^?1!)$ONC6TU[4/MEZ[@7!;DKAY+J\PP!P]]CDX
M2A>O;S*R!'4L2/QONP0DK*2#QDGF0I^G%039!SB2R,DU-#7F]4#8EX0.'7>J
M#$C>HW.%4!G9JY,W?GGIH_P^(>)^GGXR+G2&F*_[132]1CT8FU*Q9J$4+X!#
M98M?YKE;%",5BP GZTS/?'@_R(AHA$JH$6-4LZ];75A?3!,,DU7VQ/<FM%E_
MJW?R=8XN"#+QQP/9-1&=S09(B!@_,&CCON)LZ&+:".@1Q*5/=6)[NOS"FTI6
M>SU9U+TVLJ8BZM"&22FM5M7VEW3J2CLL4]B-$;/2')WK1:RB/KMF<VE((CE?
MK;@2YL*JZZBQP2@*9W]8&ONKF(_B!YE87[A-TT1>335TTU=6#5"5P01J22K;
MH5\03Z%B;;8V0,'D=%?^'_J+:M)Q 7F;^59"Y=4C[B(J+A%01_-O*?S34!JZ
M'^,(I0;.J"+\+@;-N6*RH;7]^3BQ@&*&IY2^#-8Y!B5Z$QP?7C4IN?4_7U+9
M&XC@0O=8Z21=B&R=LPQM%#30VBH3+W5ZO=_L[:UMH7^3EM%QMJPP"-U>6/K5
M?8$F;-V'ZK4K;_U&/N&U-;9=)+UQ]T/J+$B!04_-95SR!UZP '1@$#7V<!-)
M4B[TUJVJV[&XPL8B%1FY9DV6+[4:UHZ9%M$+9_2;MG'-,?.'4-\!7*P\&<U
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M:_97FH*(B*6^1?+R2]'$1+]<TP2>*(AG;1QJ[9XXK)+CQ_X"\8AFF'%3 QT
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M]NY6/V_@L&&B G<K*9QHTFYHYW\GYA<1FW4'.>NTCYJ]KZC%3CW8H>3NS)R
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M9<_S1.G.'(&UH1<ZT%T81!FF'35/6PH_!X\1+B,FJ;F 9EB7/%?Q7FTYWGC
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M+(PG?*L[CKE>]GEF.3YUCXZ1B;K]LX3%<ZKX/*<2$:B 4/R8K*<7 ^H'+11
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M(_Q''WBZI7=QGS4?U;E$_C CN")#\7+GYL4?[G+]H[C#Y__@G+?KC5E)R);
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M/F2TTE^9(I6? QWTVJ.:@*2KO;T\KAZU1DI[A[_SGDIQI"+2L7@8I%"&+V_
M0E]<56DO*\^?0/JNF&%L(J(N/<#I4BS3EY7Y04L8C"8E5ZYD7VM7ST?Q_HZH
M>*CUF9<9TQV!"??'CWS+^:V<[>YEK; &UJQF$?EB&5/KB \9;+$PF[?E7;T.
MH"2JH:%:MI7/:0X[<*. 0TMC1N5C9+]MFYW%Q J7EL/[TM7T3^1R<"<K-$+5
M=%8HS9P+BV\D6%K8=359FTREA2."^O4-OKZ"JRN^X%?,0M9SS?2=BNH08V]6
MD.V?"(PX6XED.YVP_G 90)RQ(BE<\ZD824B[!ST^D <M@*MZ.1+@(RXH8H4,
M/E#++FDYX2=#LEWC?$'C:+W+HZU>ZA8\0*VN2_!;6D5;1U4OD;%SCB,&.] !
MI3L0 V>47N9.HH%JQ#OUUDF+U[R]'06VJ_IQ30_2L"J)@WROQ%UARPQSX1^]
M7-Z4(JL+[ Z;OJ_XBB&K+3XT=$"M+O.'20XNFQ)5ROCXM0K3*605OV^[3Y18
MECLR4'0P'@VXT[PE4G"%A)J/['O96JE7S&JE)EDKNT*4M@XV376P&L_3^I L
M)G+AO1&\G<U>Y[=HP(WCR)3U*IL)-;5]KD$LK%RS7#O-;S.%:SO!!3*K_'-.
M> "+VC3^AZ=>/ R1V!:SA\/J7HKS),-.*UR!6C#JHJP;G9XO,1X%%-[;W'?>
M^7)X> ;-Y$VC,9E644LR%M?VLA0Z)HM^6"MB2_WFH'XY2-6HD/M6^CT%2Z1A
M7E:<,W%E@X-':<=HMN?CV3BL!0'K:[U#(5<U$Y@/#P];^1^.6"*Z1I<G]GKD
M@?&E[ N#KKCZAC78IFHF;P5[#)'5Y<VL7;:76CH1MI:G\=7#V9ET; '=*M?+
MC%4+B@B'D* 9[0VR;*Q7'U^FR(5EG)S1E&?\>0+E0^F\3$S%G=6?OM6R6FA+
M:;LI)W%=@2WTB1$+N=>U[WP[8X<\@>H,WK$/[<A^%.L0XWVHE'=A@0))+O$E
MCZ_X* +E< ;[Y!>FE ]/L D3OE@EL-D0GPAY$CBU%?6\901'*1F3A2B+<X74
MD=[AX82GJ1,OI(=>KI,FOF'Y#40)[2MW]SA%\IE4(THF1?67<'O(,UR$QT.J
M.W)-YPU. FV,'A;([U9+\Z868T73ER^]D^U:^^SLZ#GI?>]4:!5R4U\MS:11
M?8/8QVOKQ*V^@"+LT<3N=M\ 0J0H:4>)/G6B(LM\4KD2KGRH;^!:HSY!>:6+
M.][+_\V+:J'V<'R%<LXK[]>EE(R&(E([2K+"'G[CF@AS)"ZFQRJZ.H3AV;?U
M'$1Y5@%WL&KQ5JX>7;YLV'?R8$:1R+KIB>AM!'61CV+$V:ITX'J7R-89Q/E2
MZK&.3J&?&*/@LQ8\J[#J]8X']J46&Y;S.*%*QJ/1VB;;[/#4@BBO^ BX8[_9
M!W,CK]"K'XMD\XLG&%-I_1C"WNW.T4\POWRY1$-U"H/#,XM44M>$]X/9NM>7
MRLLV=X)C?$ !Q\<EH,;OKW8ZJV[-M'.;3>Q<MV(Q-IKOHC4)R^&JFJ$4E[3G
MW-^?>VV>L P")=7!@"1,75W+TTN').HE:1NOK8BL2_(XV7IG](WX&]VX5"V#
M%%/9'M:=?,%];LIUFH&\76'%YZUWQ.B8:;6-=T-"2:(B%VXKPZM_-ZTGI2,3
M>6H&"BU8@<.%DI/85T!YG,$^$9,;>3$"0I\[6<II,QKN3;[M]DA@N+7>F;;B
M^'WP45X@#T4J?US24V!3;8GQ0SO]MN!73T8EV"*^[%IN)?6B 9<S(?^8W?_[
M25OG_/H%\#M,]8 V^%3L))E&:(\HZ?'IX=0DS>'&__^0D#4['JN!<#*2Z'C6
M.>%JJ8ID^MQN)'A%A0U*]L[%/W9BZ?T6GGK)]VC1*-W<_5N:DFSTCKD,>MST
MN&9"U)_*E![T1M[[.J'YJ3MC;%DR6OBCCE7V3.I']J4?A-<9 M7LRP89-]RO
M%Z@P!J@TB+/=5T@U9AHPUN*>>W7\B""('*_#1F?0SO"2QI=)DAM\DI+')"14
M65DPQ90=FAE(H]Z*(GX->0Z4\##4J<#:.?1@$W7<MVC3-.T]A5S>W!J+ ])/
M,6]PH5 TT^JGZP\U-S4G()+<(M*U2E/T9Z=B]25'$R&D\TUV,S[/0PDVB ]B
MT0 (_D8NRI'I/0RK#KZK1-_BVBHZ*S;=?+(BE@3'!3Z#CYB&SXK.)F_1;,R<
M[4%[Y]Y4?(?>DH:^_QG5X+>H;RJ\#B@,G4*=,FNE3PXA[B8[52+XAP_0@(^H
M@)]_AO_V9ZH'ATP3?XNY6?&]HO+;Q=X+O^W=/F/="*(*%;OQUT>+/#A\L,[;
MO@7<TBE@>\RG]ACNJEJ< ]P2S)G-RLI&L*3LV])E-G_/"MS=1[Z';ZNYXO_8
MS%#%!'9U;8' ? ^&(<+A#=/>D.UDMU,1@8O__"JW [.EM4V&M-]!P!^+,="Z
MM_V$E> W6.5QK7^43^P+NRQ=5+'S6Q5(#(2USD =D2]1F/3D_]J<8^:_K+U
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MGF;GDJUJ-):!WIE3!$L<$P@ZG>V8U]GCX&QQ-3S=86AY*NI1N_[BSDC.K<<
M[$?%SP#; ! HM$>^+%/FS(F-[]1!%;):(B?F-K:(W#ABA0P.4K,TH ']!,O1
MUGVT!6+F<A%GCYM1A#5G?8?R*#2@&;Z1H'WJ#KMG?0P=.*;1SQ6+%8$E)4R?
M,HFE=M:ZYPG)[N$2'3[;.)O'+-2Z6 @K6&-"IH-:U0P.KZQL&/<-W#T/&[Z&
MNMQ\"F'6@=2>N(G=H:FWM-LZ.(V"5:!\D9U0_5Q(G%A4#!K0^UM,?!CBK*0&
M#7!VUU4=^)E#-1HPH'DB]@/2W)NY"O;=H=DR/C.!RT4MKIE]%<N2@30Y0C=
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MLPH*:E85]=<?Z_N;6;A?N#G@R@,U#34 #P\/> U^ ;CY*RC5 &=' -#2 O@
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MX 9B7'\0S.(F 16 F(CH$A$A\26B2R3$Q"1DU.0@QB"CI;I"0<U R\3(0,M
M?YV5A^,Z"S<+/<,-P1O<O+?X;_,SL0N)"?&)\O#Q\UTL@D=,0D)&2D9#3D[#
MQ\S S/?_N>!^ -0D>/KXQ@1X-P!\:CP":CQ<&\ & 'A$>'^4?\D.\/ )"(DN
M$9.0DI&#$RJO /AX! 3XA 1$1(2$X&@H. X04A-=Y1"Y<^F:G@WQ#4\:T>=)
M.22<=\N::?6']KC$;+W"2<GHZ!D8F;AO\O#>XA.7D)22EI%5N:>JIGY?XX&!
MH9&QB:F9N9V]@Z/38^<GWCZ^?OX!@4$1+R*C7D:_BDE.>9.:EO[V749NWL?\
M3P6?"[]\+Z^HK*JNJ:UK:6UK[^CLZOXY/#(Z-H[X]7MB?F%Q:7EE=6U] [E_
M<'AT?()"GU[PA0<0X/U+^5.^J$&^\ D)"0B)+_C"P_>_F$!-2,0A<NGJ'3UB
M&\]K-T2?D]#<3<HI:R;E%-/?H[7U&B*CXQ*?YT9>L/8'9__O& O__\79OS+V
M;WQ- !0$>*#R"*@!)>!4+8;W _X?E2^[^*OIXR#+TX127]K\CV3F&@Y/ :7.
MR4; ,K?V50,TKWT^7LCB7D--HLGD\753=B%/&0>!9Q%#=WB^X>>F+ZB]J%.-
M//H^:]V4PY4T^=M\HGPJ+5'QD<B1U5NY\A$D#=ZXGJ&/JVUG&Y-"56&^UJJY
MY:>U66?B$A+V?1+V<*J[?$< C9[J_QG5)!8>$Z)5A!HL"N.-O5^>L6GP35,U
M7/1VTP#C;_'\VMLZ?1'/P_F',$0ETP'O?YBKE7V^(= W5N,L7Q9I2WK]31"S
M?3 3L.8B9S52=,1RTQ!>&;5N<^GQN#TE;4NF,''-P*6*QQ^H&(=*<H?DI?9*
MK<9,FS^9FVD2];5&5!&G =3O!Z_F>X6J&@Y*\%M=[TAK$AJS*A:_K+UK?"8Q
MU65$WQOP0&1QF?*&%^DF"E&(@K4=-[%HRCF6U8Z62I!2&%?111?MIUKUAMG2
M\#(G:_/S0:(G##.T8B><TT\0U2,]KJPIS'R"5^_#Q[]&/?I:SISLV=7AQ8L7
M1MM^ \7HQO5J7G-RLK[FJBI?RRT>?Y6($;X[&!<#E6Q4P$OSLL:FX*[B"?H7
MW4RWE#<T(&\HGB=@Q@:H7,;#N(<XQL1W16S>?'^[HO7]WD:[&6.P\*,[K&.:
M&C@@::2-;<<<!ZQ=5KY^:"S?Q#N\D+H8:"DJ8G!6/FK4J&1<,28_4%8OE1[_
M6U_VW"5;.D,LG<OQ_9%4&FL%9Q]O12-YA9ZJ#P,1C9[R?U\U8G'<P?9H.5<4
MRYT]6)+%<U\M,M/_(3(UY2'J.4N#M\CT,GPWC!N5;HAXBE&8OY]7!4_KDOP@
M^/" (:%EF&3:)-.#I%_$NB]G<L;\L;'?:?+O_%$]PJ2GNA_)$P!5^<@.Z5*6
M\8;+85C>,??;&-(BS>/Z@J228HRI0'NGO&+SB9=(IUOJIN*URK2>EJ#0RO:/
MX_J=))?=%1 3UF+949!%Q4.\,E4:76(BI##WQU/*HFK_#(?VK-Y8U@(BV$1>
M-14CQ?<.&=Y?!)PY[1Y8AO#-5J9/20O; 9#N3].S3]RY1\>+5SIX]AL*K248
ME;$:B\QNNBYC#08+$?-#!<TN!3V%3YA2FZLK*A-4$X.)!-OJ/3[PI9@6(D4$
M#Z?ESH3NU=6/[>X("J0_%,T5U\&[X3I\K8(O:=1)AN$#.81B+DL>S*.]W06^
MC5;RUZ_EO".K4^7J[4Z5#S<A9CVR:ZTJ=5[  =0?T[VGZ21WF$)K=8V:]"HH
MB=VP1_GSI5<L4+"[L?I5,:928NVWKP&LC-0Q=9+278]4C8:A2SY(XK,T^"F!
M+O%U* [@X(>=;LSV(C3FH.@0'/ ,:KZRBP.6N+UQ@)4%.F-=G@H'",'VJ#8A
M].DX "YD@A;;])S=T1D*>[SY.#?F3&4I_%_CX7]#+3_J(]=!LJ;<?%>D[%3Q
M)GR-R[Z?4IWOSH:"R]T8 +W@2JQ2C]08.:0B4%=XDVQM_GO L\B2<]K2@N,V
M<#E2J]5-QY+I& +,.".P>,."/A9FM[>RIP+]AF7\7H2K<-AJ2#]2<^G &+FZ
M2KW*;]R+'WAE4Y-N5EM1^:W\L9&;&X73MK[R+K8X3)\!!P0GQ1SK )H?^_9P
M@!J4LI6+R?VWH0I-I^#;N2B%7\(RBK4?*&/ /5,IH?(^5>5XSB]^-IVU7I,\
M<;_Y(<-+3#O^6_3;I^CC*!ZYP"6_$I/6C+#\^<!#%C>KZP:RW*D=>:[N;@)Q
MZ<;'Y32/L^]W]H;9/]+HL4F7V%"\,5;I>I,!HCYH/RY%=W#72IWX#;"AF>V]
MO6Y9E85\X&JA.KQS.T3"^V;.UP%Q/^.;*\+<,1SI[WO7KGU30'6: ^,H3[M
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MG<,!5[H7(%2Q/5]MG ,I]B>F?Y36VF7P\,ZQ+G)R_HIQ_$\]P=2$HN%+-F"
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MQS7T1K_SF<LS)4J)$&AI!0YHFL3P#[GO-+7;2/3W8?73)C,=:TM1VDKKK3@
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MB._9[Y(1C@,,D42P9^*28[O%UPR&S4^Q&Q.NZ=<8%A+)5WP9G45U#&* '8S
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MQ&:E^P 3I'^TH#@YN="W9@I$4.26GVYHSL]["6AT9H('?C8QUYQ_08!.V]6
M"*U:E[?S"3L=^Q;\202[<=V,2X7R<^%4\@E9A2$6.7T++'A; C.#(DG,^=O?
MLAGO9K[QG9L[#2>1OI&WYQYUK27CNAG_W>$^3^[>CADV/O:=H!OVV[H 07+
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M]5APC+ C@& D1C;5(&6S_^R@M'=346'Z/%R./%=L:;)W[MJS^Y/M@:O/A6;
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ME!YT!#^=TT.=<]*O8O-PS!L!L?/5B]L ,-U"<#&EL\ P)SUD*5:I(O%TE>?
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MB%7Y>@J(/S)<&PRP_]DL\5N9ZZA@5A3G 1'T-NA.@. ?S:P!=:?GA!K]H0=
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M^#N[^-U^M]_M=_O=?K?_MYO8.3%QN7/@?S$>42DY22DY"9E_\3,P#P&L 7/
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MTEC3[M2'@"*%]"CO%6I_KT;#205MM*W\-P5%+X'')[KMBC]T"BNL!5\^E>C
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MG?/Y-OD42L#,UILZPM&5#G*Q:TT8IM7)&QE+ C1+>@_?4Z6F.?I4]<DCYV_
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MDH!'4#AXS1]R6?W2);:VP)[[S2AF\A']H 0*K:/S8(+I*_NFR<LM[<+R0]X
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M X5YRR(DN6=40-(7B@SW00=)UOR@Q*^^#RS.#R65+V7-.)LO_+QY?:FW9H#
M:%QAN<'ZA"]^37$XWV;9U$79V;'>/>0-:Z7]U8SD7B\OSRQLGB&=ZTXHP\-[
MDL67A>TU0WB__DCO +=!*4OGB+9>Z&@8Y2V3 ]9"9 L-',XHO.12N?-P5MJ/
MD<G#7/I;A>B2\>:MU'WDW5:,!D&(D[H8,@KVS0?Z!B/^EFNOY$5SJ-X!KH@,
M_99"[N'Q1)*ELQYJ$FUC9EF?NH?B\CKJ^H)C9-:\M#_C=WPJ?7,CO:HX5W'/
M,7?\KJ_\>J&I!).FH.,[@,#(^\]#MG[AY1 T=2NL=K=%]=H$CO&YHX[J>]TR
MQ@S+1*7@8>"F;LTU,'4E$K]?I,KCEX*QV_,.:IP?0@-HQ2FT/$- -/^*0]7+
MI_L3P$7*R9LE;2.'+LY]WR7#EUM'2EQZ05\*!WMQ((P]V[L:-WKY#I&FN[^W
MHB4$2Z 9V>'[C,A<WCO EACX'O1H_U;_^)'?'4!VR.$:N;2JZ0/=O?7]NPP"
M4)!PM!RX%%^O5G4.)(^Q2J(^2+>:&.<AV5(ZVK=6\UG'I]0-MN#W>V_P,Y7W
M*-D>"X,Q;9-#[M;9O7?@S6N,49CA[@=B!6!ZWH#$5\_<IX4H6J>$8DE\(-W.
M;ZL,=DHY^\X^9+O@MM_F4U'UBIWX?847599YBU<VH3#<&BQ=E3\Q"E8&'56>
M7IWW@FHJ7@@B<!?QG<>O,EZZLJE(,JY9;=&XP#5"[02O2Q/=)&NA\MP=1AYE
MV/CF=>IJUIKR]N_^)_KTWNL.<(D]?P>8>7:K4*9Y6I+0;$!GG&:5A+O$Z-CV
MX@#]%&^+Z;'LL>&/<MY]6NG+O;;XDMRLYU,U7%2801&H7V+>+Z<]IE6W;UPE
M"=1!!#J2::J'C9NF)"=#P[HK[ %,DX<'-;,B2WY%!KUEX[[K?LUXQY/Q^M*/
MO;&ATEVQ%#OG-%F%%;LBXIYS/D7(DD]A2N65).0 @8&5%O9N$_:)9LYB[H-:
MY[4^UD".>)*"!!OB-V_>J?*=/*@2O .$BS^\ \SE)^[#?::#2TW4K'[H-Y-1
MZ7R"EA)_<YP3VL]R['4?ZDFSZB;&E4,PXN*7J[Z;>E:OZ%J=S%+S)IY^S<T5
M\.%YG_?,+PQ_G,)[' SJ>CI!._2C-O+5H\#DEL:)8J67?^ ]9\N8\:,J!\E!
M/RR8DZ("B35E\.6UIUV]Z)_T&^\XAS'Q%\B&L?/L42C@E#Y^L0X@UQ%)_6QS
M)K!HHO)K;JYW8HC%Y8UF@L88'E?%\A07]R$WX^_ %;84]@[:Y!#9CC-!#*&_
MOBWV[USF[I!.J$/4R2-!L-U;F)-X4QG_MX$73F+TU89"W6A]&&^- U99'>5H
M46'/:4LM+)]FO6S9#>\H]C4.]7X:(+!K^3RT9FX(% G:=Q.>X(K/MYTD'\SP
MUQ5EB4E>G FWK?.T"CP4Y+P#/+R8T9JJY6Q16)S?/M[)MOOKD*MWL6AGPEP(
MH,<+#*"@0\J[.K"U_%86Y,]59HF7XRRA8@J:(H$7Y/F+9M/NI-&7I7BR'0:'
MAM%S%[08:A*P<2,B,3(\OA*@VP%BTBH[+J!=-8W7E6V3V%P'X-64>;NYL%E9
MS9AYDI[/;8_1;,X0]S38P7'7X8H:F^ E]VI5S/X'D%>(PVE!-8^L$8^34I]<
MVJXW;Y'I'W?VMY-"L]WGOV8+1$B[NRT"EQ$AQ/3\?+LR%-Y^K"\O^%=4DY;P
MC QJ(J/6Y;L]J*Z BFA67Z)[_J5QJU)\,2GA@7CU!NG349WXSN/W6:=0JF;F
M5&5#%$&($['):9@WX0K!': O[9[-K-V#WNG1Q;LDBWVKH>/*37,V(+_)B,BE
MT>(]2XCM6#IY= <8T+EOM'KJ<$^1B4]&R0RW@^3)#-?*I^&=WP*:"/PHVXI;
M3-/;Q4^0S1I6P?$JF?5X1,2Y.!&H!=UEWJAR;S7L[(_%M3VUX]STXZZ<I#&M
M'W$ =P"IZ1V%&+P[0,]]_U$<*F7I9W'U-U ?0.LSY%MDB!KWIPCY_J?3N!_\
M&.2!DPYHC'RX3[K:&!!7-?5%W4\GY0&Q9XW#Q(@O];G6R&VDX7<@WU#SCC([
MQ!>GUMJODW"%^/+8]!J=O:J]]]GO^/ROY(>KX_-9.0UD^AT F> N<AL@??DB
M>U7'52-,FEBPU"52LR:6ZSIE?I;SUQW @<Y?\@JEOX0,<@^Z]9ZYO0.P7\QP
MKC@$9K%/'V+G?N).4>R4('N+ 2"B(HF/M6_6S?S^.NKE>:Z4E6NQT!T <V:@
M7/=)?L0YBU5Y.00BM^"B9JX^X^+E(Z>0R5Z=[/>EGR_*,>H+2]&+&Z=L0C0S
M>Z W+5&RL_BHTX3@)+^5M64??E8[QM6,K@F7_43CG,'+:/T7]JC6J'M2F/_X
M?ZI_5N  ]4VJ>8?#ZIDV-RZ]"M.XGWRAX35%/1H9>WM)P>JH2!I/^@)S &#6
M8(TH5/<>SK)GQ'GQ7FQ.XK#ON*/ ^RU2O:E<O"??L':A.974K[0^2ZD]^ML)
M=1=!5M(2C7MIET'V659ZL2)V>4E?KJG*3%TNFR$5.K]+B7BH&0G8C0'5S0AQ
M$PV.R:VH#DOA>\7IL*'#2GC$HZ1Q:K4FUI"N=>%N/%%P5@,37*B7W.-0+/--
MSJ,3R=V&DUB&:3MO;1 RM*MJ-^VR"0D>3LZSC=/[P^KV!#9,LQS*5L^QS >@
M<S9)1CU1PNEL[$TO[RLP[/_%2CF7/?3'6$9K^_C%RTO5F(#JM+DJ%$ZPD.B,
MRN0IF&&?1OJY':(AO.L97PV3)%\OWT2M5(?53?898U7'F626Z2RZ<GU_N][A
MK=<[G!$#R!\+Y!FDT/;EL,T9H:)J8SP3;/&HE]6C4T"1F3DN/N%]>!\!'Q#M
M]E-_OBWB0' H''=\50\,X?660=):Z<G*@K&\!Q)DYS<W6(\CSMU/Z+'[U'RD
MN#G5ZZL:/C#,@L?-X[+\*UZJ$2+*'QUH(6J,Q8IC^$A5P-I..51X1/S8HGV%
M />>Q5C&R),EJAWH]/[-[Q1QPC+8N*+'TS>L7O1[/>3^LZ++J,N9$K1(3*]T
M"!1W8ET_1YB/?H@O=?,%/F%W5G36*Y=5BB;ZF.R/!"&<AB#KB(>)=K81F@H
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M?[FZR3J!D<]WE[\WLHE>09TS#\4;VA=V4E-K_/I8+8TZ806_5$RXV;Y%5(Q
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MN"'K2,NLJ"UNO/"#&/11=-M9^%$^(F6B\NX1.,:8<?!-/ICNT+?U(U^\77!
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MND"#.L]GWQ&J:G80Q7L]+1 I]0D %2#E2G+QX-^%-7O,(.=15VQW'-SXV25
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MF)K*-#T<]8)*9DOV]#A(B?:C=UE-HY%2G"@G\D@CWM0S;\<GM&&1QZKT/CA
MT^VU\\- ZQ]' %Y;CAV31;DP4!^: "7B0AM2?\T6&;Y!MVT_)R7RWFD >*+E
M@@FQ;^WDH_HKLY@"N2I@]]3$B-@E6V[0$OX#6H?-&(L_5")")X)\39CF1I;7
M DYN$9@E^]=ZN:(C__NOP_\!_$=?_P-02P,$%     @ )HIE6"E9.(I+60
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MT /%O5-TVYT_:BVX3$Q@CV+,Q$J "Z?S%,/ J.Z@F5=YZ>7].^G%S@-F,=U
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MY?_V_%G!9U3,O*W^*Y@ZOKG4ZDGFIXJ^LK<=MU!\#_'B[--0N46.*NQP)PG
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MB.SW4TL\)U4<$C3.6W]"#XINS$R[C7U,PM5M;#RHI\1N0;DK\S_IC<&T<4_
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MQ($T.JU[]EM^ HO('YNJC4M2$1(3;H6,'"2 K"D+H\8K4Q'#N7_15$P*["3
M*I\!;_-B!BJFF^4PACS]ZL"O]DOV3I#?.9-F83B-^MLQMT*0$&Z^>QOD[H!-
M3=686P/5>4Y.OM]LRUE.C-FR=WC148G\QRE-(A,)*G-"*AK3Z30'WJ\9?G[T
MWJ4*;[O9XAIB/?M+AY&<JR"R#IFU?JU6YW[JYU72(4J(4"NUV=(0M4?#I1@[
M^H*S:L+?K\QJ8%1ORD3\OLQ+R,N\C1)O5SP#Y33(ZLD.PDX(\,TD)P],='NK
MZVPI]<KU@>EJGL'?M;^K6<>T6]4;#HMN!9, '=7ZK9\-]L\5UFINT9 CT]GB
M+O >J( $4):2@,7UO&J\W4O%'B]3WE25XV/^!Y)37VN7B ZY5H<+6TL+4MIA
M9+Y]X%@!IBF_TIE $E#P;][90DF.4@U8@:>*B8'KZ#<M(G\_DU]COMO+D EW
MR$MO2*K@LR:]GNP.-.>UCR3ZR(4,=NT-5"+^Q6JU*R5'L381CUO&9+TX2>51
MVF2$0K*6.2/PJHU*=+V!#M@W:N=(@.9/$H!5@1.EFB^2XV4;F" U*@6C+#%:
M]%+!>R"9%846MX(R@C'CWEP8-F@_.CCCU(KKU3%D8L3];])J.8W3)UP9/WZ%
M,"?15O,D  -'WX9J$1_NDH %LGP$._\Z. BF*MU;8:8?'E[L=#K#1\WWI.G!
MI521ASG;RX^+6OW?;1)4OD!WCGL<W.GKS9F^_>15=I"<K7=56X;?""ZDC\$6
M=W$IC6U!?I_D_]7+F4=#_7]_?&3--B%D5Q1]D,@ZC#4D?%"AB,G6D#1D9QB1
M)6L(I4)V%3Y9DWT;E66L,S*VF;%/PPR&=TS\?'[G_,[Y_?'[_I;O^9[?'_?O
M>\]YG=>]C^=]W==MW@0A_PZ0O73@WP.L^H\ M_\.4'#]A0U[-H [3K1LN6YS
M4N,U*91*)\4YD\6?R"QI?OCR6I,V],-?HPPFPBS[32MCR[H<A9==G$-!"M$<
M7827:=EC_[,6/!WTUL>:NION_]Y'V-P'_JBE)!L#0MVDW&5[2SOHRMW;';$,
MXN)X-._9L+3T+DW$^N!W0IO[X<CBO%.HF4&(J^][LK^)7R'I\2(WBC0YCG0=
M>:@<Q47.*9L^GX8>''IX@FGI#-IT_D\VK9]>S!TLIS@6)>.32(?\ZR&B'=TP
MWCD7[;#\(=N7=!US ]3YZNY_R/?:4B(,2^K*D_M-C=A'YS-WR;^MWGXTO7,W
MG"+!%OH^7P!H)A0(D<U,&WT^\-RZ1("CF.*FW'7A->+$&D/JGD4RT:X_M33'
MFW[2MWTX8R#F>1K;S938)^F]^[B70-D^GLA.X2,DZY\TK>M(D+WR(#S%>,F.
MFW=HEA:C5VU6!0J'I^J=!R(Z:_%.#[:&U.GSE^\X7O5\U6_YM_>]$BJB=YX7
M(!*)X^9Y7@B*Z?W:EL2^/]*=RROV'9@7;N-<?I<A?=_#W@]<R.5WG-X0V4K@
MRMXA6/_>.1;,?'QJRM/"G>%M,8GE$Y8YN9YLNI,+_\[P-NSU_VC0Q][Z6:M%
M&6#6@W/$-NEG>3]L=M.^#\TV>VS]8#+D-@F>$5.44J?2R8QM#Z8U#/6CS[0:
MO^_=,EO8Y'8<]N5<C&RGV#".0!LU0'@>:,^:"T@;Z&L7J<,%?CHW[7+1J_=#
M0S3WK<5(PVIE>V![@:)L]Z76&!75:&F_OOQ]8H!;-F@@,O0CBFW]IK=4[?7Y
MZ4_F"V.7\N0D[)K,8P'1*8"OZ,<=I/!8L*&()JT5)_9"ZG(='Z8&Q G:"%2*
ML*)I)"/>K^::A\#]FLT%Z"S!,I_5BUU4J&(0^+-6%*'B3\7Z65N7.;UOK5\Y
M)&/YJB*@_W7?A)5":7SMKDYAT/!X@[BE'--C6"O)RV_UV7TU:570,ZO75>I5
M1>>YKM;LN<D?TQOE:DTP$(511^8XMV/=;QXP97T_'#D0"!.K2V\[ F%K#-MI
M0EGEH4$-^ ' ?5SHK.9TB.=UON>FD!5=MU8G.^ 9)W#*T1EY90+7B0 U"=^Y
MA5 H^BH@XM(K,-]F2+OFM8U4I?+&$IXM1C+;312F7CGK-HH*S,*P?@GN P7G
MH8[U..L\S*GGR@.AR\YZ Q$# Z9I)\%_7Z9PO[/1THN2AA+D6*"!<, U'PN9
MS6A\YE9;JXJO,& Q5<G&KW7VCTRF/Q5]BZZA)O3DYJ9YO)P.>]A?.=7'I!^3
M!*+\;]JP6XAI=O..UST0L\3 EN#FW)[I%R$U_-R9T5M1T4_N2/'KJ8:Z]\*X
M-M0P7"X:Q1_(&5RW%=U24RKN1G?%:TE[1.2_$L=]/L4AG1([(3I83\7&N2(1
MBO4^7!'%1R"EHD83U"#W""LX89^E71B(*%K%29$I2H*>(L/B6SU469S)?S.I
MMKV"1B2A8<+@$][[TZL:,EP?'K0[M4C+7%#CX K<6?]3E<VG" @@I3_5$ZZK
MIZX\;<CV2:X44J7 M3*7;W8JHB_KT$8X=P[2>59#0L#0N=1RC%J"LFQCQ6#_
M3$:654*/*$_K-T71"Z]/)QK+E):XOMB/83_-1"J8SIGG/ )YI3[:[HVC!%H+
M&-0:(F^]Q-K&&/.-/^^AL9="5N[4 Y4'!J%!C,M#826A]S7SUW_=2OR!+ZJ$
MAG'15\;::H] 5I\F?=LQE3_P<\9O?@7T2@208ZW&=]KTKS5MJ7U0B- *R,RA
M_7$BTH\5Y/0/&O+,8'0XR]Q%:G!QD1-,_6GNIS"8E]TW@VL8$0DSB0A<JD\'
MIZX303D>4MK6T2OR9X:[ZQ4QEMI;#E8EM2O:*_F1Y%51CY$^?ZX>?U&+TTEV
MHQ.J?T$-V8]QC >P6*# [0'A(%9L^YZ]Z'"V>EMV[-43/YJ]V4*"M'7'& I
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M:W%U=65UY6*U=3!GXQ 0$&!CYV3CY&2!C6!Q=+=Q,G1CL7&D_?L$[TP=C1U
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MX4;E@)>98?^]7*K618GMU(9I.9RW],OIK) YEJ2 2$Q-\>0JZGP4US+]4V7
M)OW9X-9'97:.':421V^;$+&JK1DK,E_]3D\ETY&&,BOW5 7\;1+K)<;3Q9XJ
MWSRW& 74D8%'*U)23T_-C=_HTE:RK^QD$:O.PC]AUHSH7P]^J#@U?4Q=-R#U
M[>"ACXLH^EY>(VOH3JXS]&F4%)L3;V6]Q"DUI$9%-[T3K*,)::9AO3@\D[U,
M5(5NR?M2EY9T^ARI49[$DZV?'NN9 G@JDO^.\;>? &POV4*+VR'L-P6RV9H/
M 3JA1ZJ#AY2@!E7>=C=^HFUXA$M:_!W\D+)KQ<$NU>P$#;[+(1HWRH,$!>QX
MAIZ-3X*!D2W2QN(4/EZ>:Q@2TBVG+#5#+BZ-"C6?)T =^*8-7#2R+\W$V-N_
M(?8(D&VU@),M"7[Q$[<3\PPM>8F.E1['>"=@2]8BQ$\\#WMC1RT0*I-ZN>(M
M#FQH*(D3D007D _5XI2TK+UPIQQFJ<J\.I*TA=A43?0^MAD]FE7G YEA+^&Y
MNJ)?/Y(U!WW%XN%EG1Q9$Z<LP#>6FYR4FUBI^++T+L@EV"<O94H[X=BFF*5)
M^-'8&]OF"1BKA009$N5]'"U4?_#MV_F^D2^5>@YNF[SO"'M9,F('FQ?X;V)X
MT=]O)IS1 D4N4\'VKP#"&*I>^(6)N1UM]53[[5D0!'*V4GJ=B6J_&ZT;%2;*
MZ:;3(4J5+#T]O-,8]#%](-#AOAUGQ!M#:>4)^$I!>MI3?FL6;#/<\=9,U$F(
MT(**PG%F"Q]Z%JZ:<Y$@>0:]A^PN;9%5NQ^;VL=<,W<)ZF<5B@4V2]KF:5E6
MU0Q!KM1%W>L2'^^Z?LT0T_)_DK+T1;L7JCO9A.1M+_47ZE@2N%Q6TJ\L'6^&
MH(]TI<[7I;%S3-23+E/HY?2&46ROT8!<;UVR'!'COUNO)@Q]> +4>0^7YJ/(
M2 (&U^@OIAJSTYA/FQ\)F@(TI[EWSL^_2S>B+$0JQ[A6H9L+:^ T["UAG"SV
M?C[_XI0PI7W;\VIV]CEV2-WG,QJ6V"9;*@K^]D,]#,='Q"F>"(WV6]/C+RS#
MK7G<6HGH/EK"WXCR3F+J^0^3=OZ=?Y^5YA5H[=R:]F05+-#7Y%02T\>-HF:6
MG[.%4E">8FP0U!*^>'U%HX;N2G",X_NJ?,4&/GJ&W'Z$R8!"!S2CCSP5JS4E
M5L6"0Z#>W'-,'1U(:WQ=_LOM>++%O;>S._*N1WTT__K+!3%M0V-K;0 YYMHX
M">C[L6O,FW#$U\\"!*_6_$0RFY?7U-M*-?<)+D4IX^\K076$403)9&":QCB<
MYK1/M ,C*V_ON\Z'/22-K%IQ)KPD[,F[;W7I=E^\V9K7;7Y]RK<4$8;3H"A(
M JRP>>F5+&CN01_2*A$$Z0BPR&N:K3;TW?.C:'DW%X.Q@GX1=7L,\DZS!-AQ
M^0F4NJRWBY+7-P>L%B=QH$I01N.-?!NH<,1V^P6]$S(AV=F!1U:94E^31^DN
M67!OB=J*>9;A?*PSG5Q\7O$$E,VV)98P_5GY1I66W<*D]FHAJ\AW(PZ^D@8C
MU<Q(\D5?P6@?IPZF25RCEZ@>4'2I'@@O2D1>'9M,K'BK\X0=)G!F.B'SC,IE
M.FP>EZW_G-9.5MEJK)P<N9S9=%C$4]%#?JDBB0?\-S'<B.43@-7\JLQ2U9*D
M)\3*U94*;NL;63D\?%M& ;<8O)MYI^NP^T\+"$3C=3 7G?A& 57TS*RZ>M,I
MAI."Y;J2H-5[0]KM%\8"P'EOB\Y)781&5^-G2$?7O+N]>W)X4U4?T8Z(%4_J
M[\&]PNHFAR7UR3SC5BUU!FZ?\M4CZ-6D;>MF&?JUGK HM$J62;?U9\&H#^D
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MX?JK!KJ^=61J/"[/PUZ/(Z822**YI[NYJ_.S?I&OU?%'L@_SG'%TONVRE!&
M>W!#OI6@E5OP$8O+=5M0? ^IA5;/?,M !.W[^IO!(^9YHO6DBV"A#RDO_%,P
M<RMJL%!VM',K* I\\[+K[ ^$KLJQRH\4]C!GH(I2*_;0VOP_$H["_35.,>LJ
MTIE8FJ1R5ED6R=+_!'&4#72]8Y7JZY^ -)4J+ =$):W;WF/JNIHG(/WK9U6Q
M.61'GS!+)MX,*'<._JOL2TZ>=?L\-W7HQ!BS;I Z]2UYH/WHE)\8R<)$TLUY
M/>G'=_(=;2T?=C ]-7C6.EDNNFIK)ZIM<(RD]']^0;>_OI$X+8V5JT[JE N
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MTK,&,<2WK*P\"II8\>[WH6+[*5Y8OP_U3.T_&=_5J3SD75NW(3J.#^7=32N
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MVVI'?/4'5I"<_E$7*,-.(&;%]KK);[YG-.%NJ:7(!K9EV+!Y*9G2'W8/U\9
M5&B(>!48?_1>PTI%[WNCV*'3LDO2NKEJML/WJ47;"AOKKL1"CE>^VN.-;1/'
M/(QC]$WA2_TVYE:FMBGOB#!ZQTPB:S#CUA;1=*?,*B9J7MK8&"(FOA#.%Y*'
M;6UP*W%]2'[$0M<9!MIH;MRQUJ[>V<V5MF1>3:*ZSOMI4^5M81@78_6!L@19
MMG-A\@R_>X>;8(#F1TGA2_B4W\)6#Y]++L%H=QJTS']>2.G"PS*DEGNP@<WI
M/,WDP[<J9B9<J8]A)TH3R07[)#Y1>)R6"?;:Q;_I<-PC NDB[0J1'62+M;Q
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M>ZZP?@Z;U_CPQ_3U5C:KW W@$9ET/&!0ZZCLH\#^%-8,;#3)Z3C;B/SB($Q
MP9HH(QZKD>YN+&T;+D8J;8=4>1>&KY26FE4] U:PEQX;;=WL0<2LFRW;@H2A
M!5\R40-)<PHX0 I)F(01A18A"X*F%2UBH$O=,_&@Z@3OZHQ&I&BT%]6:&.02
MTRW^C"\/%0"*&3HREXOV;>4S77I].Q=^VK."W0,3[[^7@7H2M,HQ8V4E57
M,VL?K).#R;RLDF%EZM#Y8A^CT4CNEXW\M^3C=D3')8/"O(5(CA$D0O5$15MB
MMJ_2S]'K3LNS0B)_'.#^L%O ,:03!&'L;( B8</PTLR@SL$Y8 &:I:5!(!3-
M;9-6*IHA+(9,9>O>,YQF\/EX(/8C?DE!L='0L-.C8*ZRDB2V_OC#BPN6++')
MUAS[J<%F7DF\$@CJ.L<!FF/4S4K!SE\7-)8"\.+ O?!:H!L=(^OR3"&_'-L?
M<VI02X11S&'H?,0\MFZ+O95[/>9@<9]6=3'Y2J$S=SDT0J9 [T'=H]O18?HQ
MFE!OL8$Y>=H(I+T8X^_X((Z1:G$AY5_Q/M>5KU\LQQ0VS\<>WYVZ-R?!4Z8P
MUW]&1(P#B*"!/=Z1!8[^025E/(9-B#]ACFEAB?,!F1\ C3P?J$C.J%T.YCMT
ME5AFR_:=9Y3S*EP&$X=9V>$%JSPL*$6&EJ2CQ5_B:4/! TO-M7*+)BS)6 "H
M<#=8J.&HJ5%S-9K9@[&OXEZ3(/WJ.F;3G(DH^'- JDY[_<G%N_6E7LS2.J>Z
M\9CK(0[ RQCL745^U6]B$K='U4F^WA([]1'2"#Z^R%]LWWWU]@6^+C] %Y\]
M:/=R29A735!X<J#"^J:O?8)B*K<T6(4_[T3%66#OZE2*%3)CY#O&^,-%_\WD
MDQ-^ZE;UA$=\C-]F6'GK5,Z-]RBF%$BBZ#5?DBG8^H:K8F='2ITFB@?ZF(DL
MO\47_8E&"5++JU6,U2#([DU6T<1KTE-^(?Z:_<W:[/WO=4'6(Z@M@OVV+%,U
M8F=I?%U@L;L*#1S8MBN)M""=FS-6<$GV_V@XP<5QK@%FC4B^)EO"!KOB $?B
M%EB><ITB9X,U' ! 53QO6 ;'WLA3L,&GP#P.,#R( V )^W& 3BU/-3=AE[(6
MO,">!:.*?;)<N[& RV(PSS4.L,R@#UK3*Z^1_-WX21R[IWP##4DY0C/P0XIV
M(ZE\8(12'[WK?]NSNN3P#K-N')JI-T7G%:#]Y^7),1Y1 B<E.Q.)AJ>*4WA#
M/77M%$3]DH5PDROO;3WL'U@"5O9- YZHE((0L0,?@,:W#PHDKJ*?OI)A3/L
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M=0-[J(@6.BL\LY7N57?P78\V4IUK?;+<T72/ K.)-;PH\N*_!$6%@P[CI?&
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MVZ][VL,MW%$?QVJ*,PMR9QUIFA703Q2(W@NRFXOO][4GRJVE+LUQ[^@>[N$
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MUB$MH#_P0_.XHE1%R:_([.$H6A;4U&)7]F@GIFM:$4J=B ,0*W[$ 5X,2N
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MX2D+>D4"9)7WE'Y1>G6X5:$^>' @R_1.:[2R,C-4XT4!B-%7XL7IO7G#>YS
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M*0J6\%B_)Q0F'-%<66*>%""*R%*Z (YUO2\ J?WMY514MO=+8AY/V'\5 ;G
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M9S0];S+!+],(2==.WA-KS.CNH[J4C+Y1)RF3Y]I_-%-5A /D6,PLD45RSFX
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M[0%UT. (:C56>"Q)0+"!SX_*=_CMS<.KAG,X6MTA3ZY"7#?-N/M8,9HZ Y/
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M=VGTZ/3\KH,_GS,\]T(1B&8M^F\[L2@E7>RGU#(LH9B3MN9L>SDF5*[K/\Z
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M2A^?8\GX'"O WDZ=SH[_I<[+=H]<A9?M';CM&?R,:A)X]/3O?943'&!$%T\
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M/N >*>4 /"*E?X&2$Q3-.7M/3U<%,3%G#U$K&Y='MJ+6+DYB,"M7,0E1<3%
M$0ISM;)VM/7D>V1KY^"L)+15WRS$YV"C)&0@HR.NXZIF:^]PT\_=]K[?G0?6
M?H[6\C9"4&4Z:D68 LS)U<G6TXH/YO34V4,!IL3_6^T*I/2O;#%^945WF\<*
M]VYH_+D$Z4F)_\]M\?'Q$?61$G5QMQ.3D)>7%Q.7%).4%"&5$/'P=?:T@HDX
M>PC\N8(;MA[6[@ZNG@XNSGR_GJT>N7AY*O%[>3G8*#RV>BSSR,9&1N21E92-
MB(2$C96(E8V4A(B-E)2-G(S$5<G'$H_X_RS>QOJOTEV]W)_^)MO&6LSVJ:V3
MK;.G!ZDW),3XQ?Y[99*ZZ*]"_VGWDW0DE5%0<[>U\K2]06+E7X,L(D[Z2#[X
MRR"+RHI+*8K]KIRBV.\:^O]";RDKVE@K6/]JDXO[G\3?MW7[KXWV4P?E?P36
M?]*3E/VG!$D R?JHJ*@4Q?Y>]G_L#+$_&Q\I]5=3)7V3[W^ _A#RAY _A/PA
MY \A?PCY0\C_MX3\#>[:.I,PK@\)S)Y, FH Z/1IRM,4(,K3E&= H#/4C#0D
MC$'- F:@961GX>1@9V%GX^(5.L?%<YZ'C9U?E/_\Q4O"5X0Y^<2DQ"Y+"ET6
MOORK$C+0F3/45-3,-#3,E[G9N2__I^FD!6 \0Y9XBH^<C!\XQ4A&SDAVT@%
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M;#<:FY[W>;A9,R?W3!M%G](!G.^J,P,D)MM9#'5R\CJRA(5?ZWF4#OV44O6
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MA9+$RU^\Q9\&9[_DG4OT4.$!MV='^DD1>&IQ9N,IUJ@^V6$'GTG#'*JDX!;
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M+48X.'9OV1=4PS?/N4>-[6%SV4CR60CBJ @)+/AJG/B#.-B\<YQS F":"3J
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M1Z 1<)N1P2'#*^+D'@[O\1BSBP5V\VT;RKKWN WZ]%G@81(D*$5:'0<5P,?
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MJ%I@D'I/>'+23.&+R=>CR)*2-V;#.E)A-WC?90&E""*K1? )L.PR!,5:L9T
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MQ8G^,BUFLJ&A/P.OTQLOJO*L93()C%,F=\+.1S^<*BTHY*]UPV:W6%K"#.X
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M2Z18@C>6M='B Q6\ .T ?<[?D//XE:18*O+RL;"& OES<>#-,>2L6J<:TU[
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MS)DY9^9W9B:7,Y<KP(T'ZEKJ !X>'O :]P=<(FY@U<#.SP! 1P>X P  ,4"
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MB9TOQ%LQZ17P^IU+X&EMRO=>(2Y;X/4:MWADGH=5)[L:_"9&J7_O3 %]?^Z
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M[\"_X$;>>K FB5O&M >1F#LNWGU>?LT_+UP_]=JIRW&M\G%#OHX2N?U5N$!
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M:A<E!AM,$LS9N<1L?B-ZT*POT)U)74#WYT]]67CAW^SJTGX#C_31AU)/<'3
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M4ACL],M97&B?D(?CC>H3_/LEF "E<(VL4Y5@K134>3#(/GFM+*'?&^).EU.
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MK[+-C&L@9]=HK9+7" .-0)@IVVUT?Q:*@F+D_5;R9YXWWQ^^8BDF=;L9P[5
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MFF0?'$IN//D'P/ I%@<(V3$P6%O'J[K#MKC9H=X2=<NB!.J]9/-)?:)7(&M
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M473)LU>G)&]I*AH=6Y<T)7&RLK7'&W>O::3M1*$E9OY_$P!02P,$%     @
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M,D<'=D &K.8N"3!HO:5?"RRZ3F6L5E?Z75]'Z8]@-!?(:#(&^0<'##'DOW*
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M\^5MUE?K7@SDZ+?@0(5\>R\;_CY54<N; ;MM-$QMM#]\]4L-9R.$I<\9EBT
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M'WP+[M=95E3@\[ZE^I!GE( 37X?TR5<%LL/M[CFO5#%)9B-IHDX:NX7':MT
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M=8JS0H.#!NR?BUDI?+,1I6,T3,D=FYUQH6*X3>\/>C][YLGI3N% \[B+$4J
MD/*7N MW(K\TH*O??_%ZR-^2^JKZ6=V-%!E)3N6N>%^HRT!J7X! ?_/^%N=(
ME;=OKZ0?ZAM_\%'N=-O7ULFFQL'0^?#D5^AW$[JGU>8PE_MV1(I,";Y'Y:=_
M/9 B'-[0TI!YT%?P=NW>S:?"A3Q#;H+7?GER9ASI<QW2J=ZM]?*^R+?X8XUW
M3T6B;!\%\[M2HN-\]-QCQ_VQ_1+H9F66T.)4RGA_M/NH+N[#SKV:E.Y-N<:X
MC)?<4N_Z+4H>2Y]5-_BV?BW3KK+3V\H[G0UX.D29D:>V<#74)P24:!ATZ0$Y
M.F>'\K'?)$'=ZMPM@2P2W)$Q9/#';ZY6BB9">!:="ZS.PS7&LD^W"LU_Y#6M
M99Y7C^%!*:N''!OK1R8>$N;XD.("S.!!"!<?N[)G[4'L4432L&>F3*XC]Z1E
MNT?1+4ZGQ@]JE$GG)\9Y+_S<6C!HD?E"WSLL!SF??M6K[F'&[3_VY'OT]_ @
ML::OX0J$=;KJX4SZ>6(CW\<7 &% ]U<)HZ/G+_9,X3VF(+Z],:V.KO:!,C5Q
MQZ;2=)WS<>W3[IBAXZ$O-XZ[N);;^_B7 N_XK!=LNG1]8PG;2<!)E"(VBN?J
MU52ERLTAPQ&9\):)N=[U[KCL)!&V^\5-1:Y#I@6M%\^6.:=P'-VI:<^S#[%)
M1J,-4&A&&(XW96H\:7AI,![8N =3DAOWQGRB;ZZ*N14_PS>G^5U'GZ?VPQL>
MR)W*!W&##;/S8G& DNZ!&J'+E.)O%8/;/6T:/T"'[WY<O\F4Q#>2PYI8^A&V
M"5KMYEM57*;W.37B4-^;<@)S=@/?&7_\;G_RH7O>^]]9I#/G/?<<_JCKZM94
MW/7E_A5<A=M[L,9%Q#IPQ"@X\EJGD13E4O0-UCZPY4M>U2/"<:--1T/6UHJK
MO^3B>,EN_;$]@7>/@C_-OYFP4?W6L>^:(NB!N@$.(Q+U^YWPV-CGFH#8F; M
MF@V==W6JE@KT'N1DV!V]QX-'P(;2KIU7]IRXLT,B*5_CDI3X5@^.G/VBMH5M
M]A\=S:[$R4*;B>D#6K/![+66K5VM'IE5G8-@B<F^E+>@I')(Y'#_Q:.=K(]?
M^()T+%0S#V].6&\%3FZVW+BK-BNA[$7<BX&&4YA&^2\&"31D%H*_W9 5[TBD
M=+NZ%L<FK_U,-]:DN%&VE:WG7W?'G=?+(S(#9TWLK6W?;G\D\>"$Q=L,%A#A
M*U]>K0\4<)R-W%UX*&[--:XV\ MG7A!G@FBMZDD?PEM)FX[A1BVA?B%G]]*-
M6C8%3RI=;Z>Q]CKU<GLT;CG!&FG']IBZ&5CH_#]02P,$%     @ )HIE6)FF
M]OE(F   ).X  !,   !I;6<Q,S0P-3$X,C=?,3<N:G!G[+P%6%1=US<^=",@
M7=)(U]"A-$AW#" P,]04#,-0HH("DM(I*-T-0ZLH'2K=6(BTBH"W6'_ 6V_O
M>-[X/^_W?==[7:SAG#E[U6_MM=?>LV?.Q?DV\^T9@.:"CKX.  \/'R\0+Q
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MCWH&^$&Z:.3?>!KPO^MIH"&65DB,#J\Y' /XA33@$*Y_XIO[PC''?-, ^/G
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M/S)UZGOG]7ZPC[(+@;JY^!VO8618*!KS#^K6/]A_5J=P===$P5'H7Y)+^]U
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MX>&?"N=_GDY 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y
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ME6 _LO^6^D!G*XGDM EDWD9]VG]^W-O<;-!*?!P!=UUVXR&M;J'VN=[ET-C
M;98L9OJ.PUR*XW-#I/0*B[_06Q$"V*F411 H;78ZE]G_)7:I,CH;M^R.W'S)
MJ]"K&Q>\DEQ$7_]256')T)UEIJCN%KL[\R-JU8BZ]_J[A6L/]K94>18-9L/@
M(/R;8Z^*/_+46*:[3]M'7+0F" ?;U2$Z59YA@D53;V6)4!I$"*MK7^@54&-5
MV%^Y$%/_>)9M.>DW3=6"/H1OI3J\P9"GK9-5YEQJAMC]Y+L)>1EE"0+*^1H]
M5G6CZT_J0>GQ4$]P8R"YCM-9JA5"#7V%9_U!8 !.C__\2H5&;A*"5;P)UNF6
M?%=OX[XRM5Q%Y=,'ZZT]&VQNOWW9MFYP#+9L)4PN@H^S=&H&=<RYD9_:\B2S
M+/\&P)$ /_?"!:%-)&EL5\Z.)ZT86 2*-:9')\W.4[A@^3L60GDLX \LFI9G
M%-*+NX4JUW'/.8US!J*@JX4Q9) L34%=N +_K3WE FY_3AMALC.I3_7=3;"J
M[6P7I-G@U*T# S2_P5-9&FL?#9!5)3?!61$SID8F=5]DSD_6"87QVN%OA6#-
MNH4+-AMN]@X3\6]6ES DWI.V Q+ <^:O)7OR/TW4O<Q28-N1I(]+]>5*T!J2
MT:KCF#"RGEVA063HH5L\^AY5.KI=PXMA295)H"_>@U#;NI;!#ZR4@LYK2!=:
MR,-! 5^J[,=;)VLL183O#N- 99%R1"&FG=K/UV$)_58P73=9CHUK))UW%/T6
MKG_4^ZQ.)W%%9D\M/U0M]XGLK>8E6\'T@>N2CSD:,T=:;J-'1+WTKO;5M74:
M)XB?_5R#:,Q)CCPMRL$1-2'^KK$B5@_<I06^Q@6/:_=/**X27)->PS ^JUU[
MV8,$K%BEPUG1V^;U&;L*C(,"+5?@#AZ/A[L89ED:;$J?O$[.25_? E@^?U\Q
M2CU0IVM;;6<\Z+5CVQ/"JLXS,NJQ->8X3475\Z0^[-E9I\0(4)JE@R%T;HA7
MBT=Y'3>)8,2&9DX4OQV3=I5\U^V6I/+Z\FXLH^+Y5B)-1L)3S\=J0,D'!4_9
MO%)$G&97LU[D%0'EGA2_!ENZ6^)HFQ!C;$+#J2F/1(DUC$J3JJ=$B& 25)Z9
M=3FY]GC3K!)TIJ%4X/..O";U.=LN+6VYWP#FC;<'W.VVP#L,C6STNTG:.= L
M2(:BL(;..P(VT23MW#LH<?=8K=$>=L8&'8A&4K/#L#ZOKY!&%!LW,Z\O\1O\
M"ICPY=0<#7G[C0W.QRQ(\4M?6\L0L-9._>K*Y+T1IHM.<EOMQM=:<VZ[<=.4
M7JW=DKW"XTI1Q@U^G*W/]3R:,EY_]/) ^YF@#S92]BI"]#86=J"^8#^Z10='
MT*QZ"'^')UUJ("M+L\Y#N)WC39[6\_OIMJ'@N&+JX5&^,:"4LC:[N>';REC;
M""OJ#-ZTU]QZ)(Q+S6O,\RNXKPNT2NT7*\T ?DZ^Q=&DRO%5G>0RYX!53+7[
MGO7,G5VM1M1N$[8]QGR9SI#)C6M>LDQ:*FN:?$A):=Y)">@FN+[>+TV_FF\T
MV;HUB:+=/R[H(+7I%FQY"[]-(TJ&*,%(9$0A@3#.V7G?QC)C1$&XC-5)MM#K
M;7_E!="(".>=Q-2<+)67KJ*>S?PQ<9W%:;NX,%E[/IN =5".EM_I0J=LI;09
M9>F<B])."9N=+QWW$]6Y0SNB(!'$[$;PF^5#V![G;$@ZXR.9B=Y$*ZRZO<0G
M%CYTON>'6N-II:6*PKFYQSS\O8MJ+NPHOFM>*O&MGBG:=-V4)DD">"+-4U:C
M62^88K6AGOY\I12Z7[@I),G15I:QW$NO/CT$E 3IT^Q&>[V5RW$WPZUS%GKR
M8\=88TRT[]GH4/!8Y7I?6PDSSR'>RAFZL.G^8KJPC[WN&:G-C)!D0-CK\.20
MF5C7Z08FM*:_BGR;U0,[]D<N'=)X= /T: <R0AY:>H1P^E.>05-@8N\JP1FS
MB1<VX9QLI<.?!<VY2@(IAU@</WV0&R.F+WY!7PN.KFM[.%9DW3JZ9_UR!K@6
M9., PE1_G</=L3:3JZ!JO:A?H5-5W9-</4S-*&E5?M?)N,?9X,(E=NEBT:'S
M5S?!^/VJO-S^,Q_OM'34XG)0VW<F@/-G(>'/H_%>C3KI:4\@M]\.ADVT4O#R
M^4 7<M9)<L4<.<^ZIU)UF*!\92I(_#^2A.OJAY6WY99R>H@N"[^$N;T'CYD5
MS<5M[BB]+N5FDU^[(V'R6L=DBLSZJ=%23^4PHBW6ZFJH\RW:.NR<GN(R80ZZ
M/U%R:KRLSH!X6-KDP=LKLC4#U.GVL#DV^;N?\YL#ZG<"JL<&?2<"IHS>.NB5
MOMMMQJE'043S:KY:7NO*;[4+&B))SK@+*GV;^01A+1(9IT_5[K$LY<#N2'(P
M-^:Q5AP^"91U,!B5NQZ=$!)B1VL;Y-:/<]CN2[:NV7AG90*<8V_NKP]Z1\?3
MII_HO1BN!$G:BHY>_AQ(''K9#Q3'T4:[,$>VM&*30F'KW'QC1&QHF#[W:@P=
M,:GC->'K2QJ3XU>08KP=;'.*L3 ZX16;)!W2NNN/Y-]L)X \NOAK9<S.]Q4Z
M5_<L?>%==V0RQ>&'-\G%+Y:A3(K%"X#VDS50CS6N_(6]6Z%YVUWATZ);E?.G
M;R[4&\\1YSG>PA_L;P>:*X95#H>D&S@JVW=.N$?H-#369QOO@";B1?)*HUB7
MMNP- CEM30PKL9^XTCSI;&,T^ED[W"VD%^PTD?'YGB4&\96B3KRHYC):"I[R
M>P&,E_IO%#F04$6G?MAN]+M<_[1Q^[:X7U4&^^)NH_V6_>Z>$Z-L5S!P/4\D
M5I+F0ND+48O<2Z9)M/7.(?:.]D(M-:&W+@MY[/#(1N*>(+=W9_<4^!N3E"'2
M(T@!E+">-32T$+*VFT+BI\SJ(A5W/89%@VQ?/X321@B^=M:365B_%I,YR$1.
MO=7'K;?8X.QL6:MBJ=-^X )LJ3)RF[7D,&A'O-<>E;6>*+?9Q'RTU/M$8KM%
M%7D*E/_>4;)X$\U"<K&NDTNE>>!:5%(D/:ND@S%I$$<<2ZDR[>4/=?8.2VMO
M11:<9D=$+6)N"[0W-,$*4,+4"=(&-'1G]:G[NR.,ZG5&;:+V6@@E@*:/7H$C
M(#;&&6DL4%H_VOB732"1);.T.8#P?'A?ZAI[B27UEIY\5M$#W[V*^UE[!D[C
MGGSV<P6:4N.._J6?-JNBY1:\Q;!"PF*F4>8"+R,DTK-<@5Z_/5^I_&BI^SEF
M-O!U_$C52J@6[HWHM T3Q3**>Q(ZMI4VF1>O;R<NH*4WU!=F<.$-N^JK-C^]
MEX%IVFAS;<MXA<>V$DE5$Q&FFS3,3QHDK1\!K*POG_)F&@L?9QE)UIHR!+L^
M%+P$=JQCGQ5.";!:WRJ!C;+,*GV-=+<?@2P;.$:42$(F@B5IO59GH3T4,B[L
M%V!FOEHY29,%C:WM:A<&X--:O<F,:;;P;:.BD6$NW7%);>FV#\OZCF9+"IGT
M399M515&[+P5;<8)"Z9$NEE20)][P=[8V+)^Z_-VEBW@Z$J@;J%$2>=G'2V:
M:D>_3;_U@\NO:U@7K'IEGR@7-[0Q9X-88!4THE8!28HQ*F0,:RP"3TKXC7=V
MPN0<5/K#S]25[KM;C%L"PRB27_G.7$B3SB[C:F^.@P8(6*I'2K:DP,49T'QG
MU_M%<!-5U?H4$S<P!3GVF#711+WAZ%7;'?DRI[?FQN3;YF0E5 >&07#:%C$E
M>V$YJK0>V\O+M,1>30$Z%7*@10K'_CFL$<PB:6""6<KWIE&DN /?,I_7<]?$
MW&J*NJ':$@(&K-J@5PV8ZN..1WZ*NJ"Q9Y:B:W-K&Z./HR%E"/#J@G2%JTXF
M3903?\P]2UR%EV  B=6B4DSK:;1*8K=;0,+VPB->POA5':[R5F=M']X@XP-4
MK4WYE"-2!+GU&],G?27K%ICM1F;D"ESDO)B;#,RVQRHS6^4"YX@KSLATTW>@
M3=061%-PY[6QFZGG1S=0?5"A^0C5_*QM9Z.(ZG3JHB@,1IF.<C\]; 7IL[=<
MI"O^D"08K6U>+^[L-55=^HZLA*XUGIM>.S:^3G28GDZEVYD9-TG)HC]XR\]C
MMQJ3>+:WF%FR::&#HYK VK8.&FJE ]B8:2_\-&GD<PHL[&(+#:=7AL1Q:65P
M$<Y:X_5V?(G2N*[*'#-]+G/N2?S>D@)MY7)'3/Y8;M% ;:P19JK=K  3S\-G
MG:375M#.^(%(^UR:: ,I%2]9&M/2Z7;F%E]V#8>$^PUAI%8A=WU=] 3CSHP9
M5<&G5'WEZH@?VDR\>O,)6X2<43:X.+?QXF;7^$&#Y]*V;Y-^ .H>:0.FWKZ[
M4ME'H_9+1H3M)>_*0>'WPFXFT.K\Z#6HQTJG 8SE&:ZA-4(WKJ9&=.L9J-N9
MA7(-&T?._32)TZ@NS&"GT' TE3(A4U WR6-1\X9+EJXDSEO+C8?/C<V;O!K$
M\,EBMW)WU+>ZM/^\<N;[4XM-330,9&V$@1^RU54'[%KMF[3>NEZS)3_5G]TM
MS)'&KAN=QB#784Q>X'C':LY@C,5H9LN:+ BM[\S+^,&&SB$["?>V*/:)9D"]
M<G?<W<5J5SX>I<&X;&SV5?U*>[WL5'=12#0P5H<RWEV?DR[/+F*6$!4V7$3:
M':I8OI^Z1C/6+N!TFZ5ZG:UX$X:8=@,M7ZN!]5P0*2N_)F>XJ.'TL+F@PU5)
MY%KWIHL@S#>)=EZEN[S#NYWV(D#Q1<=[!ZS;UTF4TWHP1<!FD2VC/K(VO4&U
MW*G06HM;NF%N@'UH@E:</XZ"S('?\:9YF 5Y#_L.<-"AO"<MG+"8;CSLH;.=
MIA!%RP>[J\)D%7"VL:=C9N^F\S5R9BU8RZ-ID"6LLG(J#]CN0*]!;XX_NS@!
M?LZ>?+:A5X[[ZGFN4TU-Q@(O=;4Y' 0VDA@=:QQR8J;R81@?CV+W),4A8RLX
MIXC.W02G!AT&?/O"))GS[N?! <U^-B76-O;U+MS$YK16R;3+CVJ$[T?0,*<M
MB@B?]8[U)^Y]V%93HJ-ZP4XIIVI[0RP^_PLOZYLRJN12P/0% E[')O6:<=U)
M2+?76_% ,%6#STW1A=_<'!B$N#DMK1WH(UV%3O.#FQ:%Q00<U<Z6,'%:%<T]
MU1?6JW\P9CR.CU@T([M:Z37ZQNG.@N;S]H)Q,&8:YCT<H98ZD2!<G^I=6G<[
MA3#WJ^VUQBT%-K1R+_@]B=.<SX7OKU"V>Z,-8T_-ID:&@A?VT/(5\4]+  4:
M]2S>]$D'<'XXF3K^=&%QZT70Q M2 4A<K]:8<)VX5=/N2* (&Z=D&E;U7)/]
MW72JN,[8(111RHX#4(^/+(2OOC!>8N("X5H]\*HP)NR!I/*K0H6-..%':Z^3
M,-(J[PI=YET\&!A2+]U*$9 ;DDGRIWNMYD$N\9LJ%0WBG+NY\>:7ULNTC:%U
M3CRO5OKI*]ON3VSDV:\$6U:>KXR^>HIXAGFOL5V\ZS:=]LQH_69O'+4745U<
MLIE[[M@+90,1]X:$P?PE(5JW*\+!1?)LQ=CD8@>-Z]*)*':?)#O_VQ?FKR;S
M&@!CI,-5=2UJ,6F\XP_..MY'(4FE9>0 "K0M)@4VFI$E)H7:]5LVA E5NX'6
M(1\>3UJI\A[PR0)62@-+0(5-'#+4@^P/07@]VA;\!4(3-@63.>:<.F:?K$H[
M-A0CAI6,J@WQ>^06YSXC.%:Y%D[C)+OG >JQGY]G^#A!Q\4F*5V*N@SH!R"/
M@!_6U?O5ASCY^KDCLVC>7W0.X<C:I51HPB Y7LM83_LW@4N-_$N7TZ>O\/J-
M3#4W-[1;JA!.[=6+:\&TMV-"RFK%& L:G*^F\CG3N?*IU+-$*1OY\@)[^TQ
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M??:A8BLAI/A#M-L3-J_(X$D(T;I%*-5(VP;#>@RW#I9LQ$DW(!R3P<#7> .
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MKM&:O0FSJU)8OK^U'%E3KY[@F;C#LA^C;/):Y4 9&S2F+*;8I X?H9I-6T,
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MZX3Q0U^"KJ#^MX-N(-]:\ -'[H6KK=V-]\]<#\B9SN,JDXKPR^/Y)_EG0/L
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MR#65HM/D^W(8:HDE@X*I>.COQ$M2L)Y#S"%A0'0^)FOQRPIP\CJ!*(P?@6C
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M-,U;KS/U5CIZ!ELR*\CF5L@'CGJU$Y54RW"9Y$=O++]I=(W+(IY)#+-2(/-
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MLW"TPMSKR\1_3PQIY]O2N*^_[]JQBZOG(-56W;1HZO X3JUI*"<_72.?JEJ
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MH3"^B5.8T-B5[W2;"F3)?W,NZ1EPSE+MPK# LYTZD7>0K3W[#)#(&E5Q.J[
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M''F[X^/4/WZM\.3^?_S]&:#^IO+ <]75=G'_?\3I_@UQ\-],.XTB<Z+ZQ"J
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MG&-K1D?Q?+FWXQRW4UFY&+!A)]+,:CDI+F"58-F 84 [:9OY%)P?CJ(7HGE
M3V/WY2G.KH#V'J*CO/4_.C/<V.=%(1&Z*=LT<'.O:2KO"K!ESY(Z$M"J#%%]
M1Y&_RH'.S3J=0:NQ+R2I!>KP(5GMH<9N?N)4</:[$P5N;*U=WRXPZ0GYUG"E
M!1Z>HPC-[\MF[BI'$><5STJL;MV5B*P0,"07[*='K5UW8Z"M=E X*%BC,:IV
MD/D)YS<R1<$_%\"7<'>L.GW^'7_I:K]5</;[!+[RMOY7]*WB/W*);VG7=*-G
M[AF38*9?U83X>=4?H9E3"&[/ZF3*@_J'K"OH&\@Q&V7U-M33S61;=IJ4O;M+
MM[&L1/HP=5U%) >M3<4]\F!"L,]/J,TQ-=\6KB?'AF%=92Y<<)1(0"E1YDS%
MT\&J&W;3'GB7SC/=9U_$9DUT$KD/,G86X,5K18)]&&%H+8I:>KP&T>"J^TLB
M$/;(IS72*T*'RRTI<\<G]J!^R4\>;B3_(W;;=1;@'@0.O9U:^6?W,;<</6$(
MVE+UH;9OY"Q&0[C1N5+YSK"A];GS5DZV-!(!LSLN.3Q97#93G'#_J;W:+R<F
MPRZMMSU7Q(GPA*H_;6ZSP"AIKOLTBD?%Y8Y+M;1(ITTCP._,)OX#C?0/BOC_
MT$A%:1.__YE&BI,M#+EW3-\TO=":G/,3O'=G]G"";=8E%DY=8X /I_^+WX"D
MD\UG/XJ%\;%(=(PF*4Y,=KYEM0G]["ME.V2N*;/ AP>3^ T$F"5)I4H-[' W
MDG/&FW%+Y)NUD,X\?3^:O9CBMP+OHDQLMV:GT+81V;M#23M0/_)9-]WM4&!^
MW;VT6JHHQ]?8LW&8WYDD7JG"GB#/%8UMM<A!-/819),D_Y"93ROQ&!$X17]5
M@[,J* J]-/YYCX4C_1Y H*S)8J(!<$,)".Q'7".H$="_7&>H3N);5VO7DU7
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MPE6]C[O"\<^N#.#V_SNNCIO_.4 G8W3<#1EE%-P6C409(9&N"C\*Z,\?[8!
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M;3&_VL7V_)A1(DK,VU;7&X#G<64!N]EI<643U#V@1Y?C^,281YF +.Q5ZOC
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M>\1BPWQX"W$^ZZ TFWL1K*I!0.')%L<F.J:<8+<U-J0)*8V)M.)(&RIX45.
MZM:<1( S ]QVIA9?S63D6[19"W8Z3'&\[,- 7AFOO2D6*4])I35FGS$HSOJ8
MZU]Z9S>_QIP0LVII4A<0H7GY<^O+\^2E:"W<$#K21T/I"B^:^8OZZ&@NXKA.
M)O*(N:V"8;YI?H$<")-07S-,KYE)L'SO8#754O7Y> %CWJ5N)JX8I]@GT9P5
M,$R <D)*NJ[ML+2]O7VN7WJ=SL6'94)Y58VH%H,M$5QE,\OASQ%U-E\M)9M3
M?:J]6N^F\5V+='^0Q5@CL;4OM#$7YL>XJIC9T&#J86\7)';C&JB$T\[=+@9O
MM!L,S^2I:7S_C:>V3(#^[J7(FGB&FMD[NY+51[2M'%"M("9\6$KIDI3?@+1^
M/H*O*00ZPKU%^R0$;O%\V7^N)B.0+ULQ:Y(">'_!HG$"_8KA#=(-3-T8@+WU
M;:G+-TR .N.<[L*3^G6F63US-A%!7,O=N*NTVI)\YPRLEQZ8V:9^&!!9:TSR
MG<RP5Z_'V#Z1Q4$8O\7@",_:.&OP..[&B?EV=+B'A@"-[C+JFS!G"<672S@Q
MSMA%8=+:S!;L8FZQV+>6\KL*SL=)AV0B2I.)/.L:[\3E=PT,<!=HXO<-=GN?
MJV*DC70KWZ*+9/,MIWQ!C[&D,VJ,K$18,+D'?<W8U1C [212;THD?[>O,C02
M,-M88]Y)I'?!)'*I['DZO3*YS_(3+,H&=Y9@7!/;:C-R/#TDWP5SH9WH [LE
MUSA&TD7US@GL^IH N9BZ(Y65<T74%)Z\PJOBY0K\E&V5OF5#PA\=7+18]W@&
M\W IM"Y8SDE9C"S6O-\8?_B&)%;1@]1^3MVEO"%A/(%Y;%\3R(^W0%YL 'LJ
MH>?%%]*QFOM29>_1O#?E+F80T7V>[IHQCRU!)L[=BF>,V84?U3TO&);8EM5"
MBXMHXIYY$$7?AR[;U8L8-:;1\$@Y##='LZY]])4+)=R8GN /%3A/ I%+EDDT
M_CR:$[@M6CDGYFR6+U_[MCWV[OL9?9T):^%T/PZA9_ZZ582'+@),+LF8&>LJ
M^2ZY-";8>:XZG7&-LM&VCY,&V; @>YWJS#O):&M.^+"%#CBQ9JC9*R;TLBD1
MQ[FMRP##9V$=*?>W$O;3KE>0PAY">K^(V5^'9V?R)(AX+5W56;UPP&?F:3,D
M[NN]XMYBX[A'H<O=)QQ$X6(>\53OI;J*:)CO6Z<C%@?."4XJ9U(AI+@+T6J6
M4/EZVSWM1HB))23?%J^]O;LI/F#0@U:/UMO+(J QQ5@[$B%CYN:@'C/,WY,&
MHN;CYWW&&8'_G /G)A, X&RIOY_@<04Z,(<*JCQ'\SPYH_!YZZY5B/WJ!"1B
MH>_&H,10G4JHVTA)XH[ S=SBZ2.3YH99_,?6NKIR_EJ*Q%^BL5L\[-="WT6X
M52+42KE[FJ;<RO)MB=0S=>K#[,V5$*#W/?M@8!VGH$?)DKVQ6^[Z]93%06*?
M&EB_F^!P<R-N<\H3:AXL;<><.:EA('"%<%3%RL_L0/YZH'RBD!F228C%KM.0
MP9):U:3,NU_$#-+IH6R\XM=ME;#W!47(1[YKL\;B\Z)"4M%W+N+]$\W6ZZ_0
M7!-M;4Q0H1'O)\^L\:/UXL;V7D31F$# D?7N,R45&@F<YQ"X^>'>YJ+WJ4O(
M*F5Z)MJ MO=!733/6*/SZ]D-+J]K1<KIB6)95>^53$7O!WI<9!+H/A L#2OV
M'6L.&#;P'6:_"C=HE($9M@]0+WA+6M!F$7_SGH\=Q5@L7"@B$+^A=+-DZ#59
MJ";*@B^YQ=O$1G*E76AM*F/HT^JNI0M7:T.#;B 3B8O<>R5( 46WU]-8RG2.
MAI<O7'S$^N(&Q\7''RP++):]5:>$ *,@NJM$3AP:#;EB=0&\*)K\I=S+%%'!
M32Z^FFN9/'-NS)QK+OF6M+[OQ:%%T;WKT5.C8>_]VM9[9H8-'A?S+;AXC-QW
M,2'4X-=6:>6FVUKGIR->;$ZC^;BO,6L0?:?2?.6S1NX,HGPYXT77AO+"8K[)
M6\L%NT':Y]T"Z?91$&$6AIV"A$Y>W53YFK2X3'DE!W^I=6*.IIB=5#4G3HR>
MO7T\"E"R]: ,-R+G2;7)D!O2T2MW!O67S>/?=I/@ L.CIQ?><GVJQ-%H6Q&$
M>!0:9V4=VA4X]HL3+4Q[;!7)1+4&!26%>S&0KQB6Y$R;!YML\</)>( A+YXM
MDA4]6-3AZFW_NDTU@CT,EC3L%RP!!G)&K"R1DN)SDJ)*1=R0[((H19)<YERP
MXU#1/7$#0L.1 X#A._>;M$A?CR2]'K->YK@=B4CIC@*E4LJ7*Q(49*7;&O7W
MJQ4E<BPN/_0GG"/]H$@?CH :;L!J(AB3;MUTZ\UI;Y4H,2NO;K[SB$0J)2+\
MEIJD1BE;UT$"@8+HZ!5%0%(!>0^7U$@6(SH<\&!OKQ6#R;O'JK'UX,"&WM<5
M:G@OIV;E/9%8OL6$8VQN]B3->*:)H&/_8$=FO*8W$3V[FE9AE[V)KGGDQ09W
M$XR!2'8C[E*KM:IPEJ6Q4VZ3VQ4]EPB(Z!A2F'2<5C4V!L4@F>,X3A&5V$QC
MM'$9.]#%F2*/]BWA$N#5./<,5C1@N)$41TQT0,I.XX4.@N*1F5!;'E&=:!^?
MFCU_HU5AGV9!/+]*8MR#R8*\HA)Q;Q$2<C)&TZW)1 HQFCDTM:X"I8&PC))X
MJX-V)G\*@?X4,=C^T]N^_6'9G.8[I3HR8$_MH:OG!,=;^P42+%2\3;G,@DW]
M%X,(@\B-C;%>)K%1!+/C-++IIY@;H4ST+N,2ZZ2=;V*4,3B0O!@*%."[>Y=
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M05/)E#X\RH9)*,H]EM%-Z_Y&V+<WOD?_GGCUNJ"1<80PA4<]J8]^!3"V(9A
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M @$\%K5<_=(R^YR5<EI\DJ7'A*L?94)*<^=V0%]ZU@>WEB#%+DQXW66\06O
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MJ]8:DFO01_C+U1[63G=,*N/>59P]P&R'OE2U_D4NR<[5.WN9W8,@?8)?VP
MF#@PO1K61WBV7]P6>=C0T$_(>NHW>H4D ^9]_-*4#-G-1FK!O7R#H!?K5KF(
MKVN7]UQ>H">6\BL?+R3:43C_R[R@3;1S:GB@JSH[X2P(;N</^[TW2S';">Z;
M'4IS"B29M(9TL3&N7TP_/\+),;%.N?-M='H:+]^'C^^@IUC@]"8W,FY/+2:9
MQ4*R@K[UQ0N*)Q@K.UUW'"OHLW#[5KRO,M[H3^9O$X+C@0$8*J(35<?A2@QW
M"A,F".5AE<,V1<3Z]0IG8;S9EE _+J@Y.=_8,#'BJ&#ISWH%CD_);?;VJ'#
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MW6C%[QK&RO:\]:N$L/;A.&?+[1(JGPS> <%<-_/2+@C.YWON/;.T?K<T!+1
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M?13].%YZ<A+/Z'D'NY=L7ER36?Z=9+E1;C5H!94&\N.SKQB(A %U%PSN"ML
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M?7SP0P^+TVEG=5F6\OPCD]@(+QP6O12MN1U=%CU/#R&YGU_T"C)=J_V84%:
M+T@T%[E#3]S\&QGQJK.VS'%YJMM*GR?'#-2']^YDO24I .RE$$*^NZ2KIW>
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MNH6'N<@A*S^##"KDO ?'+G73'^Z5*4:NB!TG/&3VJFVF0M9W"AQIV'?\= A
M8XC2,(B]T^5-71/>:HPJ60@@(2CQ9H2B<4):.9U&5,IY]2"'AMFEQ?+?U($4
M2,/O:/(-?C4D@4GH=L76#&O5_%<I(K9.G'OD>^T@%27DNE\U""5.YL9^MD"8
M:63F;LA@]O\T9//4# 4RC'5>=(L IV=0T?L\0=<CEB<OP-U;K=/N(U*7O+LN
M_B!=O@?+TM:^YH$7 +UO_P5H>DQ^5+U\_O+%GZC_%A@,8@ZS;$>T;+;2)WT,
MOVH_;2OXL<!_+OW'SQ,U8]F<B?EU?;816K'K57P<@='8:]W7K1Y3/1#QV@XH
MP*R0GD$#T>A/0W$#^QXELSL>GL[V2FN_'1[*6LN *PC(642@:[))?$N#XUFY
M:#"GO;G6M&I# W$_;+<-$\8=2S_Q#F]Q_K;F&=0DX-C(4^39\7%?:3]'F%OG
M)%%!^OGNX1L;LJ%E>H'PY%,%UX1D1Q[)GO[J8J^0E:@7>44=XUKGN@S-ZTWT
M\FH@.,(_&(#</XF^'X+U/>2;4@?GOP#1F9#<F]I\\3@/A_E*70C]<[WWG:FR
MDM2T5((3MDR*#V!O12X,P*L+SXJPHV:<Q(,:YN]\'CNT?I_FR2K$E5+O%B59
M+1J#QRZWZ@N=T3]DSTG9LDV&Z(P>3 ^5+B?6#WU'%"QJ\J9X(ZG6H93/A//%
MJU7KH#Y(LB[6FMXIAX:BZ6:/Z 4(\I$<(8(#7+H$=:0^ 46I3NLX@@I )_X-
M;4'2 #5#JQ]:F"0,YG+2 F?0K]]E-:Q-!ZO%?(^?LNQY6(U P46 3:E+UGG(
M,<T*)[U<R[DVL09<&/9W?XZ(/*0A5B1'.ATCJ,%M"DZB9K$@K@.07147!<*;
M-%I*?"D?21AFBL1/[-D2=LP90O-X\/8N);%A[42_U%OGI_\0<L6U'D&8S7:F
M/I]\L,L^,&9VJ@N!U7#;_O8F!>KNBQ1?TF=N16562[SC[8:RY0Q!<$L-F0<U
M;=ZMAX:"D9$1^B> &H%LXPZ5']Z(OP)?GBDR0]1T]EL%YP-[.^QCZ\B^L/<(
MU)/G.C$]?>:$NM3U^YZ;D:OARN'3K^6]E%MJI=E1$Y+O8YMPF0LIOU430U+:
M5I=[22Q:')$4K>"9Z(:5$S$J=#5-FT6/K\"5K?4-X03F!E6-\5^_3-)I"(5M
M)FLB,V]=_&-Y6C.WU@&.;=:J,UA?9BX?7/*:9XC)HAFG3LHV,:JU<J/0251B
M3X([+08)?=AVG'LP-W4/Q'_>O !8M]MWJ<]?P3KHG/)CG,^2^<]Y'D7'OB?&
MI[+&%_RD][">I+292(]94-VL<AO4Q(]=$=P^OH*@78Z<./&9[0V2Q !4K#]R
M C&0CB)Y"S1[)C=SINBS%V"2@320JGM@-A+C 2I"(+GVS+?;RW3@0I;CBNZ_
M&W_?$:?YPUB5.V 3D_A3DJ"@+U0$7T0?0(H@B)H-S4^2SDMFDYD2_9@H^R3E
MKN>>[#ZCX1$9].RK1* >)QP(MOQ=/\G+R.*7[,E&2DCXJ9_>;VC%O(F#;B#W
M_*W,5K2#3S:CZZ@#CJP0&5[>1WOK"M5$TK,1G:]Y'<BAKCL9M-G)'RXO73+4
M,8)00XAM6S*F43_QF%/D/$413Q"JSN14G1C"_EB9KY_47--<WH^6M:3J+8$>
MCA$VBBF2BZ7),3;X!+6G,^O,YA5>L3SZ:FU5ZHO8^\<X)[(]Z?^V-JO"JC.2
M=7T2_[_90S""@+ C786]^O[24^O(G5A<'NZW!K."&O/CH+X_'YX[!DBXE>HK
M450H8\28EX\'"^J<)K=?P<A,=-2Z$I2'MG]P]62_7W+S+Y0:<5%_\[40WS^8
M*-Y0K=GA8N5(^%KGNT-JHED.3.T,PAX3(95B:0*Q0DE*#=%=<8S: -IZ?_&F
MJR'M@NZ82@$&#)^>GVUZ7F7? K0<J.6MR@N0\GZC]<<-4JX=^),D1@GY"5<W
M+G(Q' !CC]KS^ T[0+"1@S@6V] \S"^FOEC6J8N\Q.O 1*EJL%6Y"I,Z^@Y*
MCQE+527:+.4$BTY=FQVCJ+0X("P2;C9"8^!]-<?=5/K@6AUOUQ,./B<%#:P&
MPA']-G*N([KXEZL[6=-C'+,G-Q2?GC[V[S7JO9+P?DA<T>_>1DBF^N!SF.@(
M;H%K90P897)BDX<H%J^WLAHDI*E^]LO91O$1)J=W3#M]HRFMP72-5?&!LV&.
M0;S<@"7%+%3< : &56 BB.Q*SAW;LKRDO/-IGMFS"X:NC@1P]->(//FLY^5O
MORJE=]@T\KL S9W <2< '00 L)&5@+T#,!WGF\:Y([]UZ/$"[!3<,TUY:U_F
MV0]@):&[)/<QG>>$AEQN(?=^\*&&QK,P@ MQH(1KM^0=)4.S0H/?>KJ%992/
MIAOE??6UR<3@VH89@ITE^!1\F1'TI(@?H; +1L$N:]HKK8%--P[C,,13C?JW
M%@<%XNN>IN[KV;UF>.SYPE,W52W5$Y+3AMYR[(8\FL6MO]$H>IC1T;1X,CKN
MY1*?I.9Y^ :S@,R&ZHL7H&4&$O^GH0Z?[TSSOE"@MB[Z,>)HT/[M//J.JXS!
MZ1FU= 5ML/4+8*ISG8&0]?# - :Y''97C%V'[2CV?Y#6;NI^"R^ZB<,PM6P4
M?^H-$V 6F@97C"//"BL[UM0D?<[#%C0._3 1R!E\PW^XZI.%RF.+W<"(N8F]
MJ5M/R)1RT_$PSU/62_S6[6:<^6?>>D<[VKG3\?'J2/4-Q8E8VP@\.E0OO/:#
MBT-I;!X*2YO7'(HX'DAIEMLJ\S@R@3'RUPN0!N&5FZ'X<8=SV[Q\D6@=DEG0
MAWCZD+)B7GTG0-IK^DWN[=LR0/V+H#8'%)3" X)3[C[_B)2RSMDVY-"KV;M[
M.IZR['U5@;Z4L2JSC+T5G$(WZ"CMUB>B9X.$?^-?9Z,</=W^J-?'L^57R;&6
M=HY^T8UVQ/\LUAKG)-899/7M*(K[P!<9XE2&2?(9[=.I=JW12NM(F]/O8K/R
M-*PP-PG2-^@YE!<@FE1,'#%I="@V,J/M2?E.*!K *-9W$-"(@/:3P)&JWQ(F
MXO(:J][Q)$%-KXED38MM#G7I#2?[N)%R;,2G0AOOQ_PNR4P#7RIJ@<)@UN*<
MCD,6UXPN7,A."YI79H\L++T7@ )VHES1$89Q!Z1Q;RGPQGGUHT=)!*$E+PSY
M/$4"D23%EZOB!R?9X43]3?"-#,YWHA?9WZK.;^.I&J[(@7(&Q\2HGS';%W#*
MASDL#@;>H2^)GK%%1*BNA.Z6X?J."3N":J)W/%P,THR\CV1\7@")CT=#)"+7
M&\T[]C>8O"(1TQQB"WQ9_LLC(KGNOIR1WT<ZVS_9MCPHW&C[/'G+1\3C7SV*
M7ZIR9!['EQH&,36TC"FQWZE4])*W]LG:=TI1?8QMHF8^GE8,B,Y@MD%9X[6X
MB>\QEA*R7 *P=^A&@N<KRAQ6J:_OKY<[/EANBR4L6UA/!R9P=L<GGE@&.EH(
M,/W=PBFTO:[+M[E!,'<;K\H3+X,DX)X-.>?)XK1.K5&L:797M3K;#EEM&D53
M]A8.(\&!WLFZ@@Z?-]\<L)5ZS529_,%M,@D@P?JCZO5J8&4>OS:7FP1:3^+_
MJ",_GU;DO"[W$'BSH+KR#&VP4)]SJDP4T!F[_KQ9(ZTI^(^(E^>&YB9]NMUL
M,W.UYW"G(J/C!-TKY^O ,0^N-[/I)GS XV_=&-..$GG4IZ&G/8>*E$:3&\=7
M_X+WOU+C&NJ*U_]$F&@ RX/S@ [M@[HL!+CX1.8,R"/PTNP6/\;*/GUU<3Z1
M/^7),WD!',\FP _:=R6&H($!1.FQ7@[CKB?;V'E,F=0:MWAI//(2&O-&6>H)
M3%7:S_0IX>K<YM$B$:((1IU#204 >@L\J4W)!))X]T'$17_PTV%^>,0X=+W@
MX)($%U'_)X8ID]69)J/$A"(TNP^,B!D'J^3IK..$ZB%B\=!2I<UNU;46PG1J
MR @P'\D(;B@-TX!@I[!FA!? (<>_)_])^_+^.2.#^ZCNN@F<T:[C#QZ(9=TY
M>HLK.S(^8N-PYF4J#EC0,0,+W8=QXEDG #D9-#098!!<S')X&_GPW'B8WVZM
MY4UI^$!#0-I^*F5"HAN<.23%0-+QW3ODT_46*6N._\F;+/3[#0)E_O;2*T_7
M>P9SZ#X#24I#XBP?#+D KRYA1]KC(RP[0T^_B%6.94^Z3%W=^8K#L*V*]']Q
MW*3&D>T5K7CLM$]5<@T/JR@[6$)=8S1T=RI,,Y\1UV*1A<OCO)JXI>%#<@,L
MK+.59KVLZD\8GT]N35XL(5&(G,2OSW/TB=WB=HI@+5,NUC!"1!H3NUK?K9#J
M\%C92@G_/5L(*\I*:'P8>-3!5_/]8O6Q"H52,4-<# 9U5 D^&:I1R<=^N<]P
MJ[YA%_1B @$2RXU$,_"P53YY0C0@PNOCPXM ^'LRXH4^LQ6PF]5GO37N9LA^
MA^*]>?WW9ZX9'&TVJ09X_IK<L")8RFFA].9W.!(0L1.A%\#SFPIR";QV&B@>
MF?LGQ8A?XR"ED0ER*=?51WXMH4%.,G^?3A(-M7%4[O,H<5Y[Y<-\HPC7X4(G
M/E> 7R(Q\GO2$VDCZ,3+.TOEPM,=;;[A3QCORHUG"^E3;X=WIK5<7(%\SAK^
M81>,,XC;YMVYB+\-CMR[23EH4(-V4*&;L)02=80;I0P/*:KW$.:KU4&DP*B?
M:HQG E>H7P"*60.&:;M-@XI.D"8WVIJ8LZDX/;$C+-Y/ER#/C?31])\/>T8*
M6']R\\'@W[<=FLV;3[BR4N,\KM^D0UW\M$K#,32T2C#)$]ZNP"NN1]*RC;14
MG+<7K3SX[VP1DRQU'YP[,A RH^81]];W,\321H=\75F2TG9""9#!QG1F<%2/
MZ@);;.&Q/PKKI_>\ )VO,'<%TLKL[N]X[!%_1#F=*0'+6YJ0/NULO *.N6Y'
M":2UK%4XJ?_C5&7_[L<D[TKU\.;@2,%;LH?GDPQ<MA=@EUM@P]HK\W^)BD1Y
MRWE%Z$40S!C? E91V4((#/U;RHPUOEC64>*V>UJ=A!9$60H+XO9O_L8=^"<N
MY+AD^P5H32.=>.XK\WJNF&13E:1K;B6:28!0;^G D<@Z3'[$@69\RE&7BL8L
MK"[&(4\WA#96%$Y#@ 41[5X+KY7MF)9M)/N@O&>6Z+*O9<FN E&F0;L:Q494
MFY\\<8-/61_>-.&H29?P:/[$@4*HX$5D@$$>[0(Q([UA@0J+L3,3&>;:X/VN
M+Y[%)2CB+M(*I>0>8G;E[E;4D)KQ1-,SL%5X^0*L3,>_*_]DE[;R*4C: 'UW
ME\1AP*I<O!.9G ^&%_#:@"A.9%8DEH#^[%80_SVD,=ZP1DV;=#_"I)SPLZ8]
M.0BN0+'6P+&*9T>K<^B+3*VAJ_1[PP&]U=RO9:.13K(S#8<UUGBKMXRJT&_[
M];B0JXLH?=[:8R.O9L'A6XF;X4171N0%Z$L[;C!WPL366G4>44:48L7@"ZV4
M_BJ1V9,=BC8;$!Q866K2T:YU-Z8RG1GL*X8-5;/0;:ID^7[?\@:7KU\)@V,.
M\7M VE?R##5-I!GRJ=3B2J<21S@0*$%H*4R(^(>TA=78<"<F0.G*K/N.@J)P
M,UD(OL%&8;O!\!<9IJ"&Q!ZT+;IBD*]W<[3OA@(:E"ODH9T[)&Q[Y)QTE#Y]
MH@&/2#FH(AEZ^TM$R]QA-$)C7 GQ+-;T2/Z%9)@9XAN3?+??.B>0 S1VC>H\
ML@:0#WH?W4C0_.GQY1CY]?W)@H[F<G_XARJ$;H49<3PE2N0@Y,U6/?'0D0P&
MQ>TQ>[G-<8RYNC9U&6U#^9GCS81#69=-QQ;QEH8?"GG#O##O8W(S'<1 W\3#
MH$B$'YEU\/ASOWLOA+D_]I2K;J(%>LR$GGWU/F( >UN\?<6I4/E_<*J$*?!#
M]PM "U^&2VJ#A1"9PGRJ@$X+>'1=6I"39D,* OCQ_\@Q=9F^ )4%]6^:$MM$
M"P8;O?=5(WMP-OT/Q(*>@@<Z1KE=A#<S6;<><3,?D-SU6I+=9[_^Q:D?TDQ@
M_$U'5;E?G,*!,OG+!C!BO LMV(#3$O W#T$0C9CWW=E$BJW7&_FG'WR5VJ-M
M!Q_XQ5__DI\K@N_$&@V$E-YG(F)0*C)CY6;;?KD-H2X$KLW0P7X@=$AFW ZS
M"+(R-@P,#$B))]MFDBP".PQ="$94#X$BB2SX$P)O%[$JP[70#:N:F@Z8O7BX
M*SYA1A"Y-!?'F'R$S \*1L]_%-V\I-'](GBV,6"$K54>+?P(9_$-.4LH!1.#
M &H);A<\B(JW\/UG:M\ =2G6XQF2V1;Z(AA7'RYQL\WG??8TH6+A?.$"+<W6
M(9:?1BDTJNB]TU&J*IA?&.'0WN]<X,RZ8!T%3'.>AK">O*W;7)7J]A2UUF L
M9SS.#^&_J&IJUYOJ]5UVTV0U]Q]*PAHDN&P\/PRE!A_CG:!F( 0/]?LZ82?Y
M6.@[#U,<B=M 80 +(@"R(LD/W<\F\^>D0_.R'DO;D# !8X,7(,'T7WMHM*7V
MO@K;2Q\/],_CPJ >H(]@^!M-9>Z?*>X93&&Z'':4F"-&!9$*/DL,T%N;[Y-;
M1>C?]+Z9Y#B;3IY(+'7T$Q#O1+/4Y?Y7S2"_G_G5)I(J@\52Z$.%*3_H9A2"
MH.B"[?!@"MZ%D,/1^0@*BL# P$LI.^)]5+?Z'2O*Y2K2EF,D/TS)+84NG.3?
M0!Y,9G=\+!<BAA*6#$.Z>EL3&4I#4B-_^NCI36J=\"MQ)T8*A4R2<AHTS,'<
M]0D[;1?."A-$& =*ZDPQS8?F"48/($.CDP+R5"C_E0$A+^7*WQ9T.!X['7?\
M HQ,>*LV/9Q?YI%91Q<\=YSY2ZE*IE1Z,@738SUZ>ZA9XF%XXK/35+1;$[];
MI]".*NLD:C8D2S0@@^A,IJ_(Z(,7P O.O8=?V3+:#)8\SY,T6Z.'W> QAIHI
MFFSZB SY#*T%/IAIF7>Y"9#LAV>9A[LE?'"T=OK:[7)\PJUIL/N1,H$P8,&Y
M?L.0\J(+KYP)C4H=F9R,^ 6@=R3N(*[LF.(SW6OR1O:1.Y9.?"H7R)DGNZYP
M9GNV[2/E7O0ZJ"BX4#GK5D[+>KT> ;N?%F%9WWD!1KAB2UX>=H7ET5(:;/M$
MDN49NCKFG68KKKZNR326Y^T<DZ@[)-E]+\G"9?2I,#1PX,O#LKX3"&<[%WAS
M&W.V(^C'<WH4T+-!!IQI]PCTS[:KDT[M\_>=[+:^ -V<.=$/A\:_?5^7AVY>
M;:K[N;SV+BZ!MBBPBN9O"?K9"DL-TO6M^E@)R1F(\M[)9>5&B^S2(<#Q;\'2
MHG9-9H?KAW F\AB$4VBEI1?^$I, L'P^V7!=JT_.S9TO:6I^[6OL,X=1.T\D
MZQ!'-L?$)0,TS<)[ <2ASH.R$M)$C>=BZYMI,[#N_\Z$4 1?7=S^.Q,BN7F/
M( ^W>ZGA?;]&SYX21E51>DYSJIW?15C:('GAIY1:$1G&P6#V3P9/N8:!5KIX
M4[8C;;&F9&-IOAF3'[OLY. T\88.0)1&581BVI4^E6DD)A4(NL2-*+4^W"-&
M=@#FBA\X6!DO?(Q-JT!;((GBJ S6,0>6.39$4@SR)FZ'V)=RYQW)F)CZ[#OR
M]*BBA;5>XLVX<"564HZ40.U'5#/"JE"H0?^M-*(+<$8E]_D<G*C03I^[.GX7
MC#W^CKAN16%&MJU$X92.[<*QTT)'8K(G@GLYX#4>5^S.KZ-?Q4[2;L3 IQ^_
MA-2 'OL3J3DB6Y6RVIKR2S]E=/ YQW$8R@J?Z%[?U_<*N!MDL!^QP;WF2P$$
M:K'NA5K+;QH_Y(C'K!P]%)H:AC&M@FC(-UN-^;2:MNI0^>8M&DT"'-N<%6>P
MOE3/E&TE>+++!1DOM:VVTH?/]+%^48\W.M^RC=L!Z462M^,+H'4HB=#(GYN2
M3O%WZ&I5=(NCN99F[B\\=[<K7_?9O&UC"WH@O!$UXE>*(.42Y/M^EHZLCP'.
M.2$C4P >OU\NQ[E='5!,LIY%]ZR9T]RS"[S: (V/)Z24G^_MC0"DU.O? 1Y8
M(_<3,C YW<>,7@"Q@6OL_VJ;OB.N(JA.E?O')B[*IR1A ZCO6[ +623O%-$P
M4!Y! _*(1/QNMQIH=_6ZKXTS^+1!2@46UIL9H%VE.#UH@R,1SOR/Y+2;3$FH
MZ4) <[G\T#P/;;S"KRJ^W6KO',-7RS%H?+.6TO,4_I!=P4_0N-J+[\TZ4S4F
M'Q1<3'05.[%C;"9RQ:H2CC \VSL3X[O0*<X-W69.4(,!LT8)6G/B)&;^]&W<
M9H_P^WU[A7G!TG<&0]XMST2RK_YX$8A4^C>TJH^.G].2W,L]:C0;[,N/M2CZ
MM(QS;)X35ZYG/K?/RMX+%XLX=%YW+\NTM<42GQ9HCHI,:?+"4)8,:]6#8>7+
MX+]7V%D1'3? R\.#Y]P=12.6T5P6Q L4_O54A^& 7%U]8#LQ>R+4;4CVIIV.
MRQ[#Q9'C/79+\F;ZA+9NF\==8@DL*DE2DG_;(@J!KW*:W#[V"@A-6M?57YXY
M@2AX<SZ1*%X=L7F9_KN$*T/:W,1)-(/0[5N=B36)E &%:#OHU4;ZVBP"+E6_
MCR(TBU0$(9BV!LD*YBS,*+AAH;4KC5[3MEM[?%D8X$'>><Y!&..?2-#H*W>%
M&=-01S2__0!X_/,(&V!H!>D"9&O3+B%UN7B(^]M=1%@,5_Q]ZMB(6'HIRR5>
MCY@$V=7;$">/(>D\3N7>&R5>40>-9H9$%$H%9X*I"(WGV,++'YPK MGK733X
M[RJ1?,:(LQS!BDU&/EHFIN"AQ**@;T(3_#+!DURJM\>92BY./?N*S/>H&<1\
MY/PWVJ)"O /D-FZ/R8.WGOQ2/<WPN_G>%6@;WD_NV:_0UU$Q/[\#E]9N!GVU
M<9/PJZ4 5%FLA[YJ&-%-E X_^>X$HBR)GV5'<SXCD/D8M^J9"/'NJ#15S!1Z
MU.H@%?"G;NR()"KS[EH1&-0^+_N12Q7[6]:,C!3&0VM\E)*(T43BABL!+?E1
M09/B7*=3E89Q**VU?UUA.USM06R2JGTF'UVK;*S60)A(R2>&2YV06A(KZ7@Y
M>D'4]OF$5[W\S 1ZI,SF>&OA@*$8,I?M5%_7 OW&GT.J#6>%I6?;0K%QH,EV
M*SHV$]T+;P\/Z@4(^2#\ O@ROP"7AEK*W31O/?_H1BUX$K2S7/?<?"6]EWW;
M\VN?MTW@PM*3E/84CQKC(Y@ZFYR<G/\7\XTBQHKX><4)9!,KM/V>:;"4/US>
M0L"Q@DO_+O(S^'GLJ'0"3+:-\CE7&<R>K:*,/8.FX'++)4%?6!FXJ0Y%&D+_
MJX%X8-&RO1- 0TC3OIGR$M:_-,O\GQ;VGL<K)ID0;QCXY3>7\=>M[%$HCW&_
MWE=\T[UQLET%#]M;+\7+@0E^E^"^ !@6/UT)LZ+AK?29N,(HUCEU[O>4)EE;
M#H>X-5-3/?](8%"LK5*4.XD5APZ)4RGPX8]YKJYT:,TVQOJXF&C-,>(>*L]:
MY*:<;.H'KDC3KZ[TX@E;$RGD4X2K!(2K1*=A2O)A#V6!^OW74E#'%8A]%5><
M5-)!"X 5?T2;!Z]C1MD-O__BQ/S5WCW7C-4^:4KR<[/UUA/I4\-T\B5I!>0%
M\*(7U;* 20L4<+&P4DY=B!;"2K7GNOXU2'@,.2 A4.8='+#6[>1^YF[]FV&D
M2N,U7I?FRA_O]I6@^VGZ)ZMZ;:A:66/TC.E;P0_;5!;G3HCH](K%6;Y;F^LT
M=/0U;I=T.Z4TO$I6HR^ _#=XEO1?-;ZQ842@)6<]]%(UVU'D"/,.FBB0K18N
MK^\@9=@%H63_)0I^V-AOK3PMFJ3-D^CB=ENTU1$>U6BK22Q/E+VM)D?63LJ2
MJ:,I%E=:6!*)D5J+O.QWCV]$M=I/ IRI)( +LBN]/=ZX6'#G:H- OQJ(<TPY
MLV_^< CO:@/N!5@TIDDF0_JDF>;$(UO/N$Y:A9KV:_\4JK"HV%Y Z_"V!G7=
M>AZIUG.W03M8TE4J>^1SJY0^AYV,893$\7K\'U&HEH)@7M35XCS:>E <DEW<
MJT?-7]]_BW;W=+9@^G"\+9:P$+P@5<;Z'?NGL)C-."$RPKGK/X=LRB"/7-T$
M:PW%IK:'7[TRK9$;N+5*0 ,ND<[62/TC]D23Z!7DDC<2*\:?X&S$H[R1A7^\
M (77+?,##QB1_'M;)O_L'-T:CDF\ *""Y^%VA5=869E?\Y>Y8_=]**Z^-2!B
MLO-QFV!H\0T0\9B*N$%'9^SJ*$J_M^"_481LOV(+WA\E@<[7FUU=4 ]J*F?>
M")(9B&V[1/9^5/7X*WX2KUM?"'/=?P$V*VI.[AW.@GI(S,1OB06N5?Y7I'C=
M89KNK>*TG8W=QF24^EZ$,.<J)UILIZ5*J%EA+Q\2"LCA?P6K*@AZWFV_Y#89
MJD537ZN@H>_,4"1Y&T).T05VZ*3B!)#%>/:IR>+@RXP\"X,)K1U8_W]A@_Z&
M!8\+[!0OB+A*<SJ7#;YC@^I.Q:-S$JQ*D?K<D",ZQ 8;I=K\M/J'X!Y5$2>5
MOACIVBPQ'4=5XG&H4(^P\D9R<Y]20V\SPT]U4,- &F]'N[.H)U<_4(ALXP^,
M_^!\]OQ1^ 8QNT-;Y8FZI:&S%>7W\M+^4$M[W-LE+FZZS1DE$29"7NNZP)UO
M8L-5\"L)>LYGMO*2JS,,G8J;RCS76KT,^;;#<8$?RP$:,D)#'PNR=XV^KOY>
M0X0_,8B0X45MT+X@0W5=?6N?#E1D99:!@ZD2IU6>@PG! _W^G>:(6LP3LRXV
M<WPM,.RHK9V'8U19:+MG.MMSYQGLV65#Z!E.I_D%+B1!D@+O.  (<6"8,R&^
M\X0EW_WXI ?9;H^'Y\M0/#=)UTU1F?J_UJ63BUTJN?_B>?6!'LVD8GO'E(_>
M=/D%2,QX+K&_V89(":Y3R#]Y;YI*^>YHJ0J..HI?'L5J2TUHXB0-(QM,Y!G^
M7%]H%2G3<DYRGIH %&%_ V1<,)'C?+]0*BTW9QU&B+\N+!ZP']I;C,?@)>\(
MZGR2PC1PL,9.VW;BS9J##[XU_+RURE8;03XSHSSSU:6<8$ZR7$^9E3!,R2$A
M=GD4"=<"BDPY$P]#:X-$?ASM!NV8F73[!4BU0[ML^'J^(8<)9-9.7L _>_V!
ML&6YP)U([SHVC*><GNH&/32IO?+/+3]]"/;'7J\^KDX!G&3X+*@ ]D>G9^>%
MV0?0)E/KY#/)JXX$JB7F+MTR\PE2?G'EW1VW.1"[[=\[I6>PZ7+V:0PUV_^@
M@2R2N>O/K.!ZQ%HJ=8SQ CN:86/@%D^;[UGBVG=O--?+E+^A8U\ K++FYWOS
M=J$7P,W-//_[97$_3U'?=%&T9-<<P^A#&J^2G$XK!?6 @S.U1+F15JM;_6%Y
ML9\)JBK_'CK(SE>*\$-Z>GVF)4IZVN<WYHZ+R%+C76^I*O$7T_Y0WH[*<T/<
MV,/SSYZ337*^7Y<8YW\1TZ^MTZ".UP]K&521M*6LX60\6G0EKEX8!Z"U!L!S
MWL6I3[<IEW-R*1"IF#DOZ\]>8>O=CGGB_%[M.J5H$RGMET5E;"&F2"O(O0_Y
M)^GL@1'.E"W?!'V:-:B_$]OG!S=KEXB,&T0)USM!2EA!CNE<5BLA[R5H\"[C
M200Y/FI5'2"Q)!@.J>#R_I# Y[S$.H=^7>U0;B-E8?;^ &)@E8Y=P@L8KTK$
M%7'Q K3XOHU)<CF:C69'4TP% S%69W.&F&8XO_*QI*0,FK&0*8A8/%8O!FE]
MA:2Z]VP&8>6X=C#M>@!#KD&B"(1U$MMI:KV+ <5!FL1O (T %&>_T-(.)D:P
MZ+AN0&,)A[*E3K.H9+\<>Q#/3ZF# V'\18)!27IGELD1Z9[/;.08<ABBX/!+
M%HVW)97ZV#4WU2CH:A^=<NS.?Q/B#VF?#U 35G[$A-5/"X2_I=+(X1V\P,4G
M;C%RN> "^2E4I]DKH26BS.HUICDI)BR_?<@COGSW; >Z8<-AD]L;Z96CZ)D?
M#?U6]K&Y:\Y T>:YW/GL /=+I%%2/V52]!"E LG)Y@$3/_V8#905-" ,T,KP
M=WC#)>:LZZXLA2Y\V!:+^5UOH#<CCJ<\S5! ;;/V*7KKR@2G\'RWS:2'B*K,
M?"DPI;DM(]4:N092-@7;K-[2X*MP.26+BP/6X'5)<TD7W(@D]\+_!KJ/V1+0
MR?<681OVH-@G,>UYSKO\>F>X_*ZSIZ3)N/(%$!!_^JV!%M<"=>'C-IW- <(3
M$34ST;'2\;^-NK0[O;HBP6CT'N/T8F#4/8B7KQ?P;3O\X#TS]<J^GIXXD3T?
M.KTR,+?XUF-?EXQ/DP_-F0B/ KMI CB)4_2>58\HIQKF:=ZDXE>>!P='>6FN
M,C:8P^F?SZ)1DV7(R 2_)KX^]X%;Y4[N8"L^/FX7\<T7@/7UJW3_@>]5N[A2
M/?_T@?1&E5*7S@N:]H272C@"_!%PNIS BI("W4Y<(IP0<Q]?DV!<HOU;)5XO
M_+=[+",D_)$/)0V9)@)#?S83] 3D$15)*Y3Y&[U87H"*IH( 3] 8I_=L>ZCR
M<>2&A=X-0]W1,TEDQ,H+\%L7X^JB0LY%88N?)\3#GMGV1U&)M.779HG9,6(:
M'H++$^S/T'7OU27HU<YSR?G2?A'ZD47?(?N&T0-$>:C1W2N2;[&^3+BBY"R6
MOI4UGVHMH;.L[&'<4$2G[6UQVDY8V8,'[9>#5Z<_N.=_;[AORX]GCR;)+.:/
ML]QMBMAO$3<Q<9XN&4"F+ZD_-ERLC3*D<4( Y3_XO0 RQ@]4Q(\EFFP.PXK?
MWH04D$Q%G>B3IC!W\GE.GFK#KZ+0"K1LE96^H8J-D>CG$4(5Y<9XP$&9S29&
M$H?CF ?.+N]9\W3_S]M\5"6=FM<W5HN'"\(I/_1+#B&;F Y611A(Y&6MIG/D
M:1P&\"S/6G3V\_4*RTUMB+Q9%-"CJY.<M+]TV<$*V[3%1XFH'S+]!*\N'E&O
M*,]D'8QPV6X$*WF@ %T09A]+HX83')0P$U5J:QEJ/[ I;V "23M53;1JZ3^
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M_K_?+9=_ZO#F*65TS:HFWKA(<=1\L,H4II^MII]^05K/XLEU465>(2_6JI3
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M;G8DU6,F\'0/68 W@#FHW.ODI0 -F!;X,+KG3#)XF]MT+=4/JU*#,CDGH7/
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M!ZY15B-J*Q[;RHJID.G4Y8[A9]B*3?V%$VT,J$<6+3^Q#*>:3&:"W,E'EAD
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ME$1@)*?0PX4(YA)BE+RZY].K%6\[Z1$-'SE*#1@WIF_%7;L\S98X#Z%# !,
M0/-X)0A 2XAF;V'I;,H*#Y +*/?53W47KAZYHT+W=NEA4=23%BL$F[K;&JD<
MSGNP*O,PWIG;:;Y0^<=#C6+.N:>84 56KV1Q];R]SUQB#KF-L:C[W>(^=+P-
MIJ9I%N]H:*4U3T7PU>"T)L/R3/2DD?$T>BWXED&,2\D=^;=YG\T1GN,7>57V
MH<A"5V2B"O_N7LLB[5J%S_M[ _H=[6J3:L! N)M[]X?-[V9D))&"@FX'&PJ_
M OBPG@ ?AA]';X/N]%P$U/NK)S9Y"R3WQ>V!'@/RW*%':4\#*XEGT:W :ZF*
MZCQ/ U4P=;AW7W=9@D ?1(VA] W(^%NZZK?RZD+-*@V#.H,': :A\/GQ%5;7
M0FV4W7C][NC*<BIL<Z99?)3V.!BHN;Q8Z.VD]RBMA SZ!L11";CN/B!5/=RD
M9X"LHUXE]VUX-]M[\&?-;Z_*UPHYI/]MJ^CU')P5\'2[,C"(G<B,ZE_\H"I,
M9I9:&LUT!O*]T2$;D[IW9P!"+!?Z\2M!.W7%]=5F0[;&6;;9^UK<-I?M:83/
MMJ:?4\Y@A?ZG '?U^V.*R@P93?(YA7><IDR#.>_G/ ,?_'S0N:0B)PB@I!0!
MRP]:/(\]J:52[_NHH^D=D^/?8E, <=XW]ZB6 ,",DZHN=S6\/0R+I9B],RN4
M.UIP[9Z>HSAO2NZ%P#P<&;S*4 P;\2G(N_[)QN4P^:4N/]A(0L=OR=!8A^XX
M<?!A%B.AL_%N1U8DU=G%".OY^)Z613;.VR]MG+T@*_9CAFTMB%/6I^+3.EFQ
M[PXLT4D&"T'LCYGO/KPHAYEQ\K1*1B,3P^%Z&#BS30M/-#I_1TP\[H);>BX:
M/=(T YDUE:+6=$O2"(8;)/BK.Y3U(-;UB_+T8H1Z'BG"-K(?C5A:H$7J')_V
MI\_MQ \Y.A*RO]2Z.2XP*2BQ;>[.P:-R>;ES[PB/\[I;[QCY@Z)MC4]+1S(Z
M7UF?HBVRA$2P!0Z 9F1J3T9"577@B'D79 :6:7Z^3()O"I8[/_[+CCZ;^K\^
M*.\L6\W=E(1_"''VVM!;R;_^:)"@G-2DE["9J#HF%'?U-&<GWU0Y$J>#$ZV"
MIYS,QP!:F'TW9U@1;VVMPQ[TF<T*N_=V-=N:\<AK,(S6PTPE"JEU-W.9V(DS
M/&CXDB0T!KET-#W-!UG2%06HD',I( %PKA5]91 " GD+X9Y/3%ZC;&&3"3F_
M=ABL(\,7GNK7('YH_)>@9 W9:/-ZY1N K:Q$Q0KY8XD(MGW+W;:MTE]I-66_
M\3!-6A@>$<.7<HBBN,.)4.W1F?@F1;,L6N1SM-%)ED\2@Y8V<7 Q  V19)]G
M -BXG(:'9S<)-94AVZE-%IIC'CJS_E1=D>_#5\V"G-RE\WG<03QM7QP<TGMP
MR%<7^A]>9J3KD">OGDION,O^KF;5F:V[(B0Z-_OBV)^X%'ODDI<TN_!3[Y7L
MN&L)>$7 $.)5S=$W_<M:E#]MG,TJ+N&U(/)Y/S4@QYE2Z6XZTT!_L/FS%U]Y
M@H4S9Z&O7_O;K7?.;70!+*6]&?WLV]IWL%\9UAU)*JAGWD1BT7 Q$*#*[E0V
MJ_ U+5>UN+T$/GA/PX9F59UI.[YO=BTZ$JO+O;B=I:F?YP(U?%E'2;8T\@>O
MJIWI:G5--QT[/U#%D(]_4,15S;^L9JT31_N<USG,IKZ"HH:$V6;6$%S1%:O"
MW/?E.9;#.5\&%.+EI^EC.WPD?('\)N+ER$/W??=ZUMR))A/B%^=(?\C3MH[I
M6T=L.D,'V54F6IF8E^'Y</+$J3TEQ%GY#<4^UZ8Z+UI:NV$->L0,1**\,#"5
MX?4W;O7Q[75,?..).-NJ#D12V>_J=:K5RSS*COJ2$(37CMVXH]]HK*'.45W$
M9J8C%6U% BBNBSDU)J=TL,(D0Y2D^4D<O_ZH.=O-+O#JTS&KL(V)_4((Y3=E
M2H793!ZUH:XTTR3Y<ODX'^&0L4HV;W.#_7+%3.G5HN3J7!I.QJASP0=Z)2_K
MQN\5),ZYC\4?)XM&J.1ZJ(J::^'@Q$E$,(3>%J)5PLJ^1>\3HT'.7KM?'T!B
MC:XVBID_*2[U&#]_J_<!^4STID%J!\F(W#A?50BG5G\Z/V]6QR'I>]ZL8'K^
M:5[448EX4S?#ML83.A)2<_[S0BE6KS+=KNJN*>'S<DL6S_P+P*HY1#P=IL_$
MEZ1>G*A:6'!DE;I".RX;#C>(3*$KY:C/\ =)!:[@8&,A:'\N(%?36'/+L>_T
M^=WW*7?%N5'A745D*D9:% D+[8Z4]R9/CF]Y9G2BW?D[Z3;BCK_&Z(V^%S,4
ML0M:>$$K 4AJSIB-TLLW8E8D8FTRFNBT(O9(7PIV2\"*<E\-,QJ6O>^LEY'>
M:;WSD%++Z=UTG+!4@CQ<X!(9_S.VY\<$$SS;MPQX5V@0_?E^&'_'208HW-NS
M()$Y,RP($6BH]]E)(]A!FJ3_A0=S*N.[A2>#C^FS8JA#S P6!BY.:9X7ZI8F
MB2M_,'-T&%DU9>,A:'K!TK&Q-5I %IHNS<@:WI^W460UD98'B=69Y=VB7S#Y
M@\>9T=PQ(VP_4"C\B?,0)*/;R8D=>E?[_J$'<UK@=^XU9YZ3F,7H-9[AQ*G]
MPLEXRV1GZ9U9AX;Y=-5 ?#@*82Z!Y=D[I0^)D-O+Y6RAR:N?XE[>^R4H[?E)
MR.[18_GFM0,38;K XNW@R80AMU')\X:YRJTP]63(+[HZ]]O6%L.?F8:%KG/Z
MN/FLR3>BO27!KL%7,JDOHVL)0AYV=?![)XNK6=!9Y*?Y .5/M$I\=YCK7L.#
MVK&].35!&4T9@HE)SOU6DA6_^<N7&@+8^7'9L*%X2,EXUA'U21!E%D^32NK<
M225>LUE554!E(+K4J#R@V6TL8I0L_OXS(KSDM[I ^4?S5G/;>SV/A>VXJUU?
M*ZHO3P4+N+C'/5H!J,17;U=<_*P!29L]=H^PYGS1HIMOK5XR'7WU5E%AO<N$
M\\<;#PFV'Y526^(L>:9$%;#8N63S"^0'%P%U7W9!%GJH^E*4%(-F'U^JBW$
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M.D!H^G[Q[_7B0=,?X\C^1WV>9]33-NN2<AK4P)BWFVV)-U5.-OX)DL9-A@U
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MW6Z\ZM5271M^TZJLN==JU\=D9%*E^_"<@,J5B-^>'S%C<$:?EY5!+SEB7XO
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M7=S?D^['$NESU]IN1/7J&5E/,55N^G 3R<3"LL>.JW^PA/!V0ME0V?*BIYZ
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M=AC0]EN6$#=-9Y&HRXQ5Q0/_3*B>\9.,?8O8' M%;F=2]J78EU>1Z/+7@SI
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MY9R*1(BAG@HX[:<SN7"(9!X_,=6A9E4N\J\; 7-8] Q_7A: ]CAL1-/TJ**
M*8D./69?7-G?-O=4?I:F"F"[W^:"H=4'B^<:0UCK]Z@CO!TX98R6KDXM#\[O
M30_07%;K/M3*/3A8G:-9[&L>(!/8HQTKACOYW^VGHWJ]PP=92M,HR,T!:H<;
M]!7^A/0_E"HJ\!'D(=:!FQ#=[R?1FD,-31JS2? TTPHE)6KMW;YP-.R[26;0
M>M3K9/#*(7J X97[%8*W2.;J+.5MAM2*9ZW/-Y<!\(E7@NTBQ<!R06%R)DB
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M*I$N#71!2N6#*AHD%KJ2BOJ$AHY4(U"G-#+UK"J$^;Z!&#(7,G(0O=TP>@2
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ML_Q!K+*$Q[^E7:UM)'6N*_T!=\S)L/XQ+R\O+SXO83XG5UM^00D)B1,W0D+
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MK,HIZV<N1NQ0;EQ"CEO"I.H88^V#0(S*!E[FWH-[O5@P8BLDM?+ <+.=77R
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M?K6J\2W9CPCZ3"VC/)Z[8QYJGQJ;,66"DQWB@=CU9EKI#E2JS:H'1*5D*?Y
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M<%O:F9X4!N8-:#+N/#T"M.OLD<\/J(;Y&DXR4CHS?YBQ.5@_+)SLSN9A+GU
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ME,;<.U<>%UJP+5^S_6BW1E:"DM\Y#Y#SF5Z-:W7TR=9&6YA+LYCW9J9;5^"
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M;-JZO@2QYK#G#B!3F3;"*MW:0A^4H)8.71\RE"ZI"*(6^G;6B/U01P!2BR-
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MW]& %H,H7BW2SD33(&VU%XY^Y?FBET8&5CH<\;*!B_+=$/C9L.'"38%1:,U
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MI+X[)C"5YS\?T\ HPDIOR*S7&R/>KRRD&*'D>HBE'4DQ?@Q9^N&!_A:Q.,U
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MJ_WWV(]0P"_=VY$QY%$ B?R5$%;&-?X1"EBT1@'+G!<YMU2"9E_N^723+Z*
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M6+GKV/8E'X019OC>KEC^.F/]F/MP_V>&W;4T[*S@=,QAX)21N;9OW=4T&"Z
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M@B2$JRWL]UK&5VT(;9E3AUX%GQ;9LWEBKE"=Y>RNL7F6[+02G.-4*LMYY:"
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M;TFK7"NF:2E89T+GOO\O_;V3WZJ(>60P)R]9579G])M%O/##OLZOF,Z$\K*
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MOR<"Y0;)P;*$2ZPH$P@'GU$_3%5:C*H#"3C+@*8E9.4K@_<M= 4;/SMTEI&
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M)I==G>K6\!L^!,6'"_NRDGZA[(]'+ KF,=][SZ"<W,B4U5]9/SM5*-X-\6R
MEV+H0?Z<MUF;U[UU])B""Q.=[+N2/,Y; K/ 6M:,I&8A*<[- YMQ^#;CW9[F
M[-J/O<]I\%[R?Y,PAP\ /?)B&PPG1R?D:0<'J:WGY#3QX=4<4+?[F;<)69/
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M]%&9H]"C)L4B,(SP)@+L5JLZH92:ZAY%;U0P$%='FDWG_-B3(;$<@I#O23+
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M4[LUG 1I'XBV/A7N+[7C^CO%2#"GLV8=03+.#2-771/':JZK)2'$5&MF[PN
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M]U_-6/.CD]:&(4I=\!:-6^H:YRZ:D[2.SCH*UR:=?RH^KJ&2Z^];^^&!,'D
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M2:(U*OSK!N5-U-QRJ66+V_#8!V!JWFBR\3IX?6SVG)/U&,D6>DSUL9#\H[/
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M.(3Q(;<B5H\?8!MQ?0T6NH)".5^WFQA;4MK6XN2L/?OLOBM;L8"-MVH[.3@
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MS*+%U"(C^,#K7M3QQTVVFY:31[OZTKRIBT8B$L.=%N:(7ST?Z95$,MR1*79
MGY6;$:"6GM4$G'VB>'PU'3+QI/(EMARS2X9XCVS&(*A"ZQ>ZTNOAW7N>ZD#%
M2Q6BV .=]EA_3WFZTSV0"96<799N37S 6K_OA&B@0/;$E4$:BO]FNI8?K9SM
MFBD?D_LF\S2E?DQX >=,?A)15S1UU11DS_;$Y\/K^G0Y7O'E6__,71?$7IPP
MU/*(IW@B[V>TVJ'TU]^% LIX:+\O_"H.(3-*T@;\Y5.GK%7B_0W\-I;[R@;)
M>E4)FFE_  <OV,J9T].8%C'B6WUDN"(0L$T&05-"ONNTA^I5XXQ,E:</N?:#
MO^06K$:(_ Z$MQ'U7GJ(<4;<?0I\9L65E%B+V/C[LXM"[!GV^,U%B66WD]??
M1C^?_"-((%L?]+FF\=IDKM>'CBZ#)^0"L!ZT;5CQ+P<C:P*R\-:51#1F99L'
M!/U .J_E;?P!<U3>3%W8'!KV;E1:VD7$G]-8VS_$U96B)BE9X*X$)K_78_;O
M$?1Z.GA0I^13T#PT JWE3[-A6.@D>+?,,Y(S3W)>*L)$O,?23?1MA]*[.K>&
M.U\]!H-)NL;B5!(?(QN&P)C4,0'G1C9I^7\WW3[9F7KQW:CUZ- TMQ=/Q0#S
MR/K!\3)U5:-LF- Q74Q;F?);L?#H(&V2=@.OA]3R@[\V4%W9+69UB8R)H*<R
M1TZ+\B5Y'XWM&;T==GHVY[!5LCYOP+N*&33(<1I%Z>Y@(/C#UWAF*'J!.K=Q
M/%L;:/>_("'WWS_ _Y&[7>%R]_@:%OX'8&&J\0>@.C.M+H_]WV^#0,;^A[V2
MOVN47$>>9HX]"IPW.P"V/6W0$'K3K8L[/S,L+[Y:NLM(5M,\L:0=>GBGU9"H
M.,"6LFC^%:@Y3S]U0(X1]P?PI"OC^&'HR[BIM,$K1(TZ[XU1O,2\PE;(7&5Q
M+I[#TY)_'E^WK?^C-5CKLMA25_9>&^>5&5U-3'N/O!&':+%H@J]E*U;R-/6P
M;,K='P#1W"XCW6-GQJ:Q*Z_X%0O@6O')%O4CR1R2,P]_#TXZ=V1:/5GHH-R5
MU-#]0V6,VF+=:FE"QS+?V&&NXEL0YFN;"1I:/0^\T+R0V@3/:9$"98!5283P
M1>WDLR!1PPMUD-'DC)O6E1N.'.@;1PBW702G"Y+A[:HXWE=]X^!74!9J.G<T
M_5;TSG8>/MRIXW)NS5A=^$IT?*[*W@Z9;%6L\F2(R 3/I6BEC$>_>VKQ4"-7
M<(2(?<>FLU\>4ZKY+8Z3632@=ZQ)BC(=.FU[^WCIG3! Y"O[4/;%#0= '_*^
M^%@VBVVCLVK>W+C#ZVX+$1KXI=]_PQWV$3GVU_JWO''@O)WV_M[>#X1#TNVX
M-!(] '=MQT7ZVDE7JZ8[TX/4WPX;4<Y;,Z_7LQF?R&@ZC<K3@.0^<WM927_)
MJ.#E#9HV,6G-8(5UWNJ['8O$FGTPVI4LRD'$&L'!AZBN89U8:Z+N!D=.S+B3
M^$^NQ<<'*:(UFG84O^+-N05.UW[1L'HM0T3*2J J UH3?VOBW<O;5=873\TT
M-WV51J$4C<J #TM0LZDK(]I\T\79^13<9\@LBU2%93'@K?[DWU@4\EV.Y#NB
MW%P#33WM>9;$;<+[G..NE8^BV<KADH[Z(*[S2M90KKDN<&A^*SDDLTH98-=7
M8-RW2HV,\)4=)<?!UE89+-P2[_8<AMN3)(;U_JN]"@Q&( 55:JGV[%C2G4C<
M(X4>#^4J'9L6*<=S.W#S!C?['&A7C+ZZ B6 S)![+MN_(U:/94)-00M:OM]-
MYT']2<H\G7<SV$-DQ:+K6]/Q2">]XV98V<?T=O\RND[37/N:] %O<Z6V0?"_
MH:\2@Y- W_+^2DSP35MAYNX[%A0.4(2]JG!N+],Z3:PM5M=B@Y!&30*+"?37
M%%:Y^'.:WP:*=LD6'(E[T;'I'D>)6M0=%E;4CQ^1H/&V-&TSXWE3,T?:$*1$
M"!_'&2G+3$C(H)>P-H;)^B-NE7]9%)@/28=5_V%<P<&]6HRCE 4(]_+2QGD-
M]1B2^3"LH_I5PPY\:9_N]O(=K,D:%NAH?^X$O5?B_5G),<<6+-^O-HN@WZ(>
M@E[ _STE_0?PB4R+LMH(?EF(XE6_HYW_P#8LC6]7*<X:.[D3(&0C#'H%9EUV
MP,:GMCP# PCF/4>\NIQUY,E=SO\6?H%R.JF%9(:^,-U2NK<7<YX])6\^U+WZ
M65\["9$04;M7=I6^>K/W$%^HN'?/L;$;Z/DHLB.L#13XYN#C5_*IJ.I$=T!P
MD,77R4TUDV7-954N1D)$IN03SX$+<Y+F.[T&#6\B<BHJXP)=23? D,Q>WE]P
M;]-ZXG!R[7>F8N0B.^C[(DUEL;&-E9%0("'%^U_" 9_N\4-QZ;>>(A/I 2Q_
MT6I^@E,K^B^JKJ\G_C>E>^-7L1J0:8N67S<48V44J$4^+]=5[)\3[:.OK>.-
M:6#8MHI8I=EE+V14B'9,L<DQ<ISRC4%.TPT(UQ=US>^-*"+G_@G&P1%"3XSR
M1H'%(O.FC#:H^!4M];"<7WI.6$EL32'L\_ _'4_!8)R!4."=5<_/V+BP6)=N
MH6Q\2"EAF#/$?_"5AN2PKPO/$CY CV$Z-@SDI0WD<5@6Y^;II 0=(EV)63_%
M;[RWOEAF$^H$*4_<ZF>LW/DT-47_/\2]=51<7[<M6(0$$AP"!"D@08)K<"<$
M=PA:6( $2^'N@4""!P@2W+WPHG#7X!04H0H*=W<-/'ZOQ^CN\7WOOGYWW.[7
M8YSUYSEGRUIS[[5ESN55ZK22T6-ZG98#<\"8])L9,H26-%X2Q3K,R\JX;ULK
MN5"&@CZONAH&_VQ16Q/[.Y@8^IQQT5]#0((4XU?^IF"J!&2ZM3'>8+_(>_4Y
MT5P5("8D1E3/_)#S)[WBKOL#<*'EF2"0BOK^,=.G4J,/B/ H,S%_=K/)9W9K
MPEN+=7"#*=9%P]5 VXN$TI&A*<$$D;K\\IU+6N)<T!E@=[DIE0630?MP.A-2
MA$29JKA,&H%YYCE2?AD A!SZ=:(R1>%NE7B&6_J3IK_V*QUI//QSC\UXI_VQ
M,1_5VV03N.H>6E'U#JEXEFWGJ.;JAC*;<0G2X 0744"B^3JVZ@-D6II:KB*]
M8=J. ;[6F!&P_ROE-E_PDNPZT/:]L3W@WRF10@Q9"B5974<1ZVS>4=5..%@W
MAJFDI95TD!B;*)O\(4 G5LH!7,T.0PSZ&=LMI@3$*%Y;C('M76OX-$QY^S?T
M]UM$/KK_36PLE"D0A3;H[]0!,*U(?' 0N4$L\UL\IG;7 7GLBJ^K3L0+M 4S
M=NHV8M53>G7:#ELA^S4"[YI;:QM92&3M!3O90CH<"$\AI2R8SW4.(9D%)?@R
M7(X<W(*?;<O7CV=GQ@]=]=S .&-O@]_5GM"L^Y^HO3F(USNS1-<59^/]?2$/
M&W>;^/CI6/S#[ GKDQIU#6FVBN@E7Q,"6[7$Z150@WE]_$@3Q;&+1X5$\T;)
MV3^_^46+51TYK"*A\+ZV/BY2 -**^-.XS1OUY7)&[O$S,)B4*$J!Y+&FNA.@
MH^1AO%R=X,P[8DP=]PZ ,[7/_HX7! ^(]+W)E+!U/+7W5]"N:LU8)3$0$Y=Y
MBJ."!SS:0Y'E/*"\70!9[13T53'3R%KH^DBT0#H:)'I-2V"+"""#?SXM*R,S
M_ @:_IMK:_5:26G?Z*%3\7#IL&>1=D2F:MZ!@4SU?E^\)<\BY_!PNN!^'!=W
MK#/[#EE:\+0]AMT+P7T+/M91)\5N@D2TEC3%N)>^>OWA7E_TTT3S!OSUP78^
M$0F#>-$[TITQ?(,%KX %A8Q"(A"'!2OQ$3TIA=XH;[JO7BLI1JCSDABHC-K
MNFV*UMX0[P>:_^J7TLZ))<5Y+U?6DHH8_D=W#:BI\?SW83!33\Y%2$R+1_]G
MG+G<()'F>8S3OW0&:@0B7%Q06\-TY6TRO'3>O8['Z2[V9O)P'84)B-OE7!.J
M[[GS'</<G;O'_QA95F_9"W\S'_'KG]<HX*-S!!=X<<*):P?&-&5V##+QJYO3
M>KHF+S9"NB,Y>(4^>5J&W /\[@&O3&,-D9+AX%Q949!X36O/B'C-<&?&G^L?
M3P!6MH*>O'[R,_OYL$3.]0@,8/E7]A]!0-IO%$67ZI/+*.TCS#D91A7!W -*
M-S8:?WF?6)^M?U2#?%4BI;XBASV=5##3DLQK<K1EXIR<?-]?P*X+FY<H^*G!
M!.?LX2L10AGP"YP06S1=SJBHOGW9EI.]D>JU/TJQ:A1@28D1]E3<BDZY%OP(
MB>QUI&2BEXX 50!Z>41 T7Q> 2]MN/%(6B'0A![X8R9]G(Y'/IB3%7^3 B\-
MV^V.&6^DSJ62-SZ+"5W-HC)_]0M7A$5(.S7ASU]\Y:C@CX0\UVPF'MYS%$@W
MM5 LBDNXE=J8+-E.!:]G'58:)NMHT4R?_6F.YW%=2TZ2E%(^M<N#V/+8-[V[
M=D<I_AB!N;Z3_A"&Q_O#-\+<N:E@O619"K\S6R;7%#4BE50[QA'8**=-L!9P
MU5$FNA]W3D@F4ZJ41V.I[JL%9F0'_%IF\S(OJ@0&N"/E*,)(P]] 25G&LDFO
MI5U%->L;(VZWT)3^K'[!D1Q)@[B_%:6X)D:%R4#=]?J:?JR"KB UFK%9!_U!
MKP&_)#_\5N^!VYW*W"#QNWN :EM"1P E3$4L+)-Z@,J@1\'-'&OPPQ^\&*BU
M:=BR&;G*WUKK4O26J?+?)';\7J% \K]?@1OB"28/+CO@A=6WW.L>*-GE2QI_
MX*>E%O]V)3;E[Z[;F(!4CZ)50A>)&M$@-%5DX RC*C S$&>;C3W-JY*3J;[!
M9$(UE,9?AH(?P_3@?0Q*!72YM^^P8EY>8D\<]T?H[1,74XHIZ_HC@E+X)K+.
MML2DK.?@4Z>FVU "'.)!]3'8UL>*G%>%H[HCC;C '(29S8@Q[GRI6PKH:#X2
MZ(U>/3^Y#'R?;&G!ROGA1%OKSZK_0LZ6[BU=X;SM>5-,3G'GN:T[;E+##1]^
M'],NC]BQ%^TT?$(:6-"6YE]><%?K^[S34Z#EA^WY)'[A_%,&9@G*6#.9]_S4
MK&8ZAYO?E!IJP(+(=ZU)H$ .$987&.VQG DFTZ08@UMEYY41HJW#?OWVUC2U
M/%N-WS\')$*6YEUO OI\<\"K"C3=W90+#<IEL>E  @*--8WJ<3 'V/&##L>"
M0]QJ0[S\U1SL\4?ICGY5M[+ZI!\&2#E[6Y)>/&4R8A\,:>!%]'/-./ZS>I59
M#O&5\ZGJL51]H"5PI<+9D(H\8^WRG+H9G_:NKWLWIGG_(GXDL\A9+.#77KJ^
MOQS Y8Z@MA$Z)?YV1O"XJ];.1?S3._96)>$/F7GHJKU;J6)3/^$ICB2D047O
MS@BI=H[VI;GO==1R*TD$X.3@N9U/Y?=;T?IZ-.W4!S>OU88W;_4I/G015 Z.
M^F*8ALB18G3/VGAZUE[^1BI:!9DI/B91_,I^^.?E!66_<ED1-4B-B_HA7WND
M(IF'\W0V04,6F._</"SN.I5ZRL:"&7>$WSH=!LNQ%_1Q@Q'-EG5+0$L=;*:3
M,>UB&C:.R?"C4L-*C@@6M-.4FFKJ0,P1@AD\&B/IL NE,<!)K\=/36S\G#GT
MY5NQ>:X-N2G'%WO<G'4(IZMP>IBT>H#.G:]NM*X KB.QK>GK6)5,-\%,N>ER
M*?&J#<Z..PX2A263Z ?W15$?$%WV]>N )=>[NE5CU++LU6+9!YK57\ I;LL8
MNI%3U^JURSS\::A-,^V4;[6QPVQ+L;\5S!5\3HU&)^M4P/3V6^!,/?N=L(:$
MX9=+L9H\V'09/,*GAQ4%@8O1^F-?98NW7X2=2O<7#3^5/9@YH2S32[ ]2:&G
M?13'-?M3T4PCFEXV4_U8E "*FE D,,452[PL<O5 '$=^@C]Z5D\3"JL<RORU
M>*0!Y^1BN/P&F1M\7/:XZBW#SQR<598![)R*I(<NBA;M-ZZ]_(#?6M"Z^H+.
M[K77BG:"-RC&(V34QRT7GY>ZUXBI+R%WN_Y0EMW[XD6P:C5J*HS9<29JO94V
MPIRL[Y)+9*;KNB*9-)@=!?JUA"WE_OT*="+A7U932MXDT9I9[5W<,<F1_.5=
M]>IG)B_\*&NIZ)?"&:+658=1J30'H0+/*GXW-8(TCWYO"+LRK\S4"U=\4[L;
M/SP(VK-,18*&+BW^5/7A9O1DE"IN EX^'\<P82+%Z-F6!#;6'9Z2B&L4HR5N
MA5)_R,W! 0$?,1MH ! Z_)ZALAV?Y%G&ZNI&FY;\3&Z6V^^R]?!Q$I\;?17=
M@]T93?A&K;=5.//;J",B"LS./IEL J$NY+=S[B!W&@=%&"-,>RZ7'-5"0HIW
M$A5GDA':;6J+F.%[9^Z=:TA%[Z+Y@V#NQIH,=(.K >:;[%)Q.D>$4C$R?DG<
M5!>]/ND4R)$&^H^W'-X#8K@%M KGS0SMB.BK'WK>:QX K"S$WI%O2(W][B8&
MEA]3R43OJ+>!OH,K O037Z"J1;;V#DQ"'ZIG+Z2/YH%!)R%NX+>#5%;QZ[X#
M?M!H_?@7-_VW?[D[K5W:2?<=D&BMSTAS&<'NJOJS*U>X."U[\<-(OD>%\&H!
M+RNMA;T+"ZRYTN8CJK'@(R#THQJ!?^::'.O#.:]E;<QT!=@,G,C(!K<UGE>,
M1@"6I6H/I)8T_"-W$_Z6[?XY%J]M%SN);K4+)/TS/^<G":V'U:<:SNQ>A3-P
M=%.,86:R5_W/>>W_(Q/YE[O;_WIV%?"O;'H5\?_&N ?88L\\"H.ZY_U!,H4H
MD%[ E!RX7E,JRFSWWU[/R+YW!YD(:=53!92_<FN08M06Q"7^B[ZBG<+04:V>
M*3^X!RQ_*.LM1O(!]V'$BM$H:B^&2J,'?*&P$?VX8H2V>YK O* K[Y^EG;UR
M5,XIRAZ+YX7LEZV=^M@,/Z"/BV[9< 6!M>4)S15[50YW._S$O&9>2T&I2]3V
M=ZVE]JSKW\R@4ZBOP]JM+9<:W?/=&^H5+W*B&_S2,;)*,)'5G_=:S(H-7F>[
MI_DJ?3+C$^.N89?//L:40M^6I0A^.E@*@_W-+$=,;+NH./ BB(;@9U)?*N6K
MIG?/\&DEE%E7R/>_S$9&,0.#?2V".)!U!]:X)GW5HQ,EB:2K[)8_" /LC"*0
MZ]1#!OO@="6\4AI@()$$OHKB?U4VX[]L#;&4ER%&D^XWBG7?\$E0T)YQBF[O
M",B):U3,&S@9:H:YA"4P0E2["J^P3U,&2#P"4%K6(!JB"_T,52-?,6_,? DL
MEF)W?PP\0<(JW,5P61][)M<C]N47:WZ7*IYU2DZO4UTK+=T#A+IC$VPNXDS^
M5.\6M%G=/KNS;O6X>PE+-9&AXL8QW&'XC;GW?(BJYCC F"\AYAX0S2/("17#
MG<7S\*R_(,!:KE8NES[K$/@]9V_Z2H/,]IE+W)\_:/4C2!7&JKM6QK!SGXLP
M7;3M90#:IG+5UH_5.H^0)5;RF>4G!X6A4$WGA</2-I9[0%Q[U\+9$?==,"L&
MK,S03BB2""Z@!X](:(ET2PXL0F_%[AA/N7H%+_2=&RG-1-\&&#8T8TWR/\T
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MO/#FCS%_U?]X5VWY'@^W,4 >9Y$_U(M ZMJ7\4V3VXY4RHLG.(\' $?UB%:
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MC5*711656SK(FN=&<S0_/#!.?H_T<6/?@4SP2X<YF;&'I\9,;<^G#VY5?X"
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M;I_^W!A2_,M^BQE:GB#Z$AX!61#G<>)-B-E]?--]V/H%NPX,5D*(2K8H>U6
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MR'NB)?/%,$HNYAXNW6!3>VWWTQZ3UJ8C_B^GM!"70)6GT8ZW[7*=D"E#6QM
MUQW:CS%3_)X89G9/WE94$)AZ)Q:0Q^KN%_WK*FIVQ'V,X4RLX"T: M:,5FA"
M+-?7S4>[?TPJY8GX3 R7.^1X$,R_[5^75WR92$^JT!0W^=3=P]W;EH1<SXW<
MX&A$\18D,JQIB+@UO0N#6; =CV)!%]=MB.OQDJTE=H,&\B=/83I:1S+^BY]
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M<\TVJ9^@<$07A#=%%@\PU?3?W_9OY8=ZR6S/#Z4B=3&^#256]SUYH;@BB1Z
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MZ\A"2 ,7)7P9+]-<\7F I463ATP1)XK87W(#$G?17!\=D=!:C(NNE>05K<:
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M=CH/F?I3-FIV9^;"%_[GQ&LID!-JJE9R:)/??>D0*.&.2;^L+S+W>.L1!8A
M^\5CBS.[LU;&"5C<=S.^B9<@X5&1HGK]/P-D.;Z"_U(.]Z]M)H!_'4U;'O=O
MXVL!._^KN-)_*2E1M//F[?:S3JPY0]ML/$/34'A8:'%WN2JM^0^A0O/MQI'6
MED*,.9Y$&O:!4 ETJN5S>E\>QA(=Q9Z'D=]>&@/6A8OMTE7H@Y>"^,[/RU/B
M7IZ/'9VOY&-?/B'1]$L:R7A48("B!DE8!]@RJ=O2K&A'Q!R7\&**(HLB)[_H
MH!!8JE5.@TI;1"[I!(B82OBW$+[JD1RL8E[T(1 RA.0+^U0NL\GLX6'!9HBK
MTT7&&15*$HARC$_W/RXWO-8$UL^ ;?,;HWCXKB:!61&XB<IY;^/<-GWY&7.*
MG@"@CB? *YQ+L5FQB4N#6IOVV6KO>7/!4:\BY(MW*O^--)TE7(OZ/Y"F?SM2
MG1;5/SA_P+L]?0.A:VF.RS+L8,Z+N+.3CG6^#0HU=ON@'K>Z**C+N$R@_%6T
M(0LC0<.KM]H67*Z]HTH;Y%'C$IF E<4X,##J\V4\"SF,F;0IH:HJ8U>YARHR
M[WMN'&"@;T/BK8JVSQR+W8HE;SCM]X+IPD@ZLN,\7PFQQ9I6TJF"9S_2W,>^
MZ-F/_&V,RBA($Q&_(T'B^$_5HYH+-P12!L5#5J5E[W!?QISV8E -UIK,:JO3
M)F":L0\%8 KV"3!,^K+_6W)$RYL&?LCC :%@<5VS\_),.B5&$E9+P_L@P]OP
MWTL?U5G"P\^G#]Y#J[19\[!MV#%]B4(H&3&FUL=?(!C+]%"TZZ=MG5QM\'B!
MI+W^7+[^:BZ"HA8H5O]SY@YS4--_"_E'QV]YI?.[>=0=KF/7"^Q)$&Z7>;3A
MZ5@^D@9HMFA\SN Q"14S,S.,R2U0NM:P7F2&@]F\Y[Q6+%>K5!H6;&+SI"Z8
M(IX @0 G-0V'O;I769&&!<\^-B.9@*K<0#O1Q4"OJ%5FL,@7I[O4ZY1.((U9
M/R>+YS 1'E?]C1(YE_LXV@&^7_%UD@5OYGXZC:+7EPOC,U,5QE#J;S!6A[%:
M^6S7*%$]]LG5A7V;?0/P2',$J7DVJA,9A5?1\[ML6HM88A>N"O#LR3.UCHC8
MG"ST.[]"OE*GH;6;"=LI^A^!5&2F [9#'?H&?Z840ASB6!1KP_&(<[$+MG_/
MGJ#_^VSM\G^;3"3QXE^;X)PF-?^U4TZ"G.[_(W/8_U^$++)#_!AZ\(PB!\1O
M.4LI.S.(*V<.+BQKC7EV&W].]%&FJ!N+X"WCK&ZUY3OC67Q2(NPI?\A%$Y8$
MK^_OG;UM<O:Z-8KO0KP99SNB)J1P;6CR2-N?@_Y L?V69@SY(% _>:1RK?UB
M.W:C>9(=<[S?#5P)K:AZ KP'\KN$KMJ^<_5>G-I$$ 45\Y$*B)\.4_[P20=;
MB%$J$GX"<VD'3EF/:H>!^XW[>Q75C@M_TAQWZ4(1(_/Q8'7G:,O/Q)T78C5(
M(ZS?]FX/*T4/ ]EKDJZB06_NC+ICF.U\\_T&]C(?6_3T:+JCETE3T>2,Z^7C
MUSNO7NL=7 OS%^]-.1WHG%WK[)+K;SX!)."4"OS!3MW2"V8RMD< V8Y2Q>RE
M=')PLEX383A_^F5GUOH3P+%0L6U_'$T\&-+,7>15_35 +JES(P=Y=]!^M\=>
M<*]_5'#O9MHGZ)8^K5'$/:L.^<(T$;4IRGF+J-=N$EH3C:-D6J98LNN>NLM?
M]8E*\_3SE]"T9<8Q]VC)XX710#>JNFGM\\W8=2"?GWU^V]R>WWD6-OOH[NK2
MBBCL([=,XWU>(!!;^0\J1\.C=JE&HU)0K3BQ)4U77:^'19Q,\W<RYAAQ9SF1
MPP4-IP5D)1Q7:A8!4W[*$R[ME.U/L[6H6\.(5Z,?T-?DP:M8GW?AN);ZU'H^
MHVFLQUX_9:K$CIJQ.24(:J^;>=W*=?M\L+-+]9?1_&=-8G0B6_R7,2\.'5)Z
M< N*C\,VY8_/A@K[]VQ.XQM^M&,^HI/-:#T2M@2HM39..A5613UTC1%#M;'W
MC9F[3VY(O#-7B*SO.5QR%.W/>NQ/.6/*B5T<#^VEA<;11,\)'M]=.XA>!B/5
M-33XDY^^9\#\2]H@XK4&:\"G:%C!P"+LK-K5P),G*+8D&;J<X+:)]2,>_?K!
MIQ,*$>'E'#>?Y(7(U9)JTVCE(K\(Z2Z%Q:9E!#-,%F6B+<W/]A3N>E-G["E$
M1,R%.TD[D>.GD<5*$.L,*U9<IW96Z@[1RKN9'?$G.,>]MC&]1">Z)6E9Y< .
M9U'D8^-03-J3K4N1:8*M)$+EZC%QX^,#XL/F&XYOE59%.=2B;)D<MQ=Y?1DP
MB;]$.?1R;UO>MB;[>(AP[Z1T-SK&^N=[5K+:X)3$"5YEO11A$ MG3Z8ZO@>C
MRC.=??<,BCQ&0L6S&W=<N\@_ >Y(RD<Z#?W.AEH&4?O]XNWHZ#1THVE%$T1)
MB9<8EPXE'Y)SO'+1M+^I'MTE]/!@W&:<.7];]A"E98,8W1TTX"/^A ZX*]Z3
MQ5;J.@(9KUVSG0/E#\1&=R<BDF94&I&[8@9)=V;V%.(00XIPF_63NG0[SI3M
M&I(L,\Z2MZ?%S-X*1HW"2IAZ?:O"7N;*TXA35V.+2S<D0E0[7QSR!X<4_[-.
MH<![)5.75>%0QP':>?C1Z]^OMX0]Y[<H S\(94DR,MOC4$5=#'J*"T[6<MR]
M&GM@*?FLM:;V,5 90.'?$'0<.*4Y,U8 JI[57AHTS5@44*M;NPIK$&?W3O#=
M2,B\5G6Y?P(,]3W.Z#25;]?=4L07@)RYQAX*+W]%0)68S))]6(DH. ^  1U6
MK2\SNTH]/PW1GX@GIK<)>((7QA2<2F^7@I\ =3Q +_$#,:586MM--X_JZCHN
M(1A*Q@E!)D7I"??7J@:W%\U)6)LYG :<DIS/<$:6N, U"J?:ZE8\Z'R/V!P&
M9_A=EE-_>K\H!ZBF\%U?XX4I987> T&0AUQ+*-1")#W3@_:L2>R!4W&F6:BQ
MNPZJ<65K[&/1W>5 $D1%D14PI8S&$.S8HO3U1/PW.'<@WU*U4\."9(=.>2UF
M$ 4/QPJR\LU:A&'UK8\+73KT,F'1Y*05KO)SV^O6FQ=FJ:-?"'*=(2F TF<I
M>!"\1^X.[Q=L'U4B]QHQ[UFN3^YR+X@571.R(E2TVV3U4#!)I#)F$&!^-G9#
ME9/6M1#LHRYGG<3,5"\R/"56>U:7EUOHF\8#E[>W&NDS08X>2Z&G<_.SK+&*
M!:F%JOO\7\PZ;' *;1)+^0.=6/;"7SDI>I5+10Z[O RWJBS%%UQ'&1#EGF.(
MLAJM7!D*/[!:TH#Q\L&.J'^VCZRS9H^GK:%&K8^CBT)N$-&10/G'X>1O594U
M&D">!EPFANLY.^)V@1[%?,G2;8+&_36E>"78Y$1AK3_P9^I0K%H<VJOE"PCD
M6Q?7HI6R58ISWB5)A)V;DE!W>55%+E/[$T"LL^ROQ97*W$)?V6Z<E8^51 0)
M)PGSLC^^C,)6_#XC2LP3X*?JJ$'PY!X.ST'QD-&5JE[HK^H-C'<T C1D)/O-
MO$\ ZHS8)X#^AR? -O*?8+_R)T UY1?;-_/D')@TT#=%IN<OSN*RSJ*X#_3$
M?IL_I.<AM&W/Q$:0)=N(%FHE1H4=L[#YNTFP4[U.6.3E2]5C;=\G%K[X9<O\
M2S\XXKMC<6VXP%&S7MZU:43LCO+L[Q14^QR)!G55]QB^,,2,ISA]J9NIE[&G
M-8=UN)O#RY^^0414_M(^MYNYTR+<]#EP0CLK5:!5G=P?_3R)FS2'!J'O&7:'
M%BC,;$(<F*Y7\C43L]E54SD)BJ!- N7^I@" P[.#%FGC6M*+> )T$0ZXO(DU
M\MN0D"-R4OVXF@T3X65K_>,$-E#U^GIC?+KJ\";42/]:V3U3!]'@QPXQA?XR
M$U3.1=J6QJ(2@&!(P_8?R16+@,"7A^6. R*S*&_;-A@*[+2.76WZ[SE)AGBV
ME*-06+^YE8F4\;_.(D/2<TY>"1\1EVF8W("3;([*N_BC\@T6L,VNQ]@O>)58
MW/-6=\AT/3O^8X>8^C[)NP[I#8\U[1TG]-D>#GFN5B,:VD^ &O_:;KLO-)9_
MPK[8" #PW/(G:]*_]'7#-4G,_-CC323I5DF[8\F,-X0EW\: 7)2/:W2"@@U-
M;$R"UI1>77K4]Q(32Q#W9?<IP,X?:#3]'X4COW7CZ>=]/PAD2\(WDN;Z.VJ!
M;(NG-6=%0=X<=OJ>F561"C4V2%E6Q&.&>P6$(4K9CE4^"V0V>/#7M'1YVV0C
MVS\J5%2^:!'GJL\DK2K%W#6%&Z"E0QE4.&F]#CMTXO8H($(('.B_4,V.^JI+
MEI'G_&Q,^>:D6]N.SUV47;UWP5]<NR=VVQ",9 WK?/P_1-L@5M=)B[M7ZL=.
M==FL25=O:8OM#3T_T+T10'4_%;B "-N^LJHCV!Q2/.&YO 2DQY*:F$LH2:QO
MG4-(GP X7DWJ$Q58<]'[55O831%SOF1I$93)L)8/@MJ>O.;@M?X:D" [V_E0
MDU*-KDX?-SBF%-??(8WB_G9Z >M;UR+KC.,>G<^?+JMDE8[F=$B4Q%BY3Z(C
MUW:&;=@RO'4BFGEJ[D98:'U+N/H(]B[&XA/E.WT0EMB)$W+G=\Z'>9=1MQW8
M.Z1A5X<N C'ZX]/=VS5Y!Q]WO>8C7K]@3(G72.V]S'JX^Q>9P1O-ZN%%/#>9
M7,(Q0#,)0523Y;7%<IGEO3NBK=J)9DG>I$P6 H(G@+DFYU:1)@-U_E0S(?E8
M$-A14>AX=JZ#*G9(:M/M[\!-D(RJ@P0Q!>F?QX[CNHI51K!B3;)R#1S>Q3 8
M^9$I[6),U8O)^I[2T&-Y>IJ#-D51U<.@YJ%F="XV[)#\Q ]V5I[4)3<5RQ"L
M,QVO6I=$0QG'1O &:?D4IY"H+.%8/QLKP#+ID;8^6MZZ8O9QM$ BN"24.\W[
M'5*X@X]888XK_>$!=/@VPO#OA1&EC7<A?@&<T[6T3PA25[$I9UI *X=?;%\R
MO$;73^[NPSS3>EQ&^&9['"%_J>68^O/W6[.#%0]S&N*+S=1B5S/+B^I2B]O4
MG>0X:9I?(3^+&<FY\J*\'@(!QCMVY(3=B,50<Y8'7ZV' L;?0VZLTB]1SZ)\
M$HUVQ(BKFZ^-;ENZ1J]B@2-L33=Y;A1 /F1?N]%%[]HY2WT2( Y4R<6-[N#A
M]"!E5PJC]P-RT3+2CESA-6A?[+4/SD/I\ +JGYM'?;$;X_2&@Z:96H"]3D8H
MF1A2=#?$P8Z]=D/2D8-"8QX#_\8N[3M*=&<=+_&SY<!M9GN_-@S]7;=58$Q?
M>^0I?#F&QNYW"4D%KP6,G9Y=\9U!12]OK_*3NW+T/.2F'B<_PHQ<[ULR]_C9
MY[=$G*ZRL+V[9.M.S$-Y!R[:N)RJZ^]X:SYIJ+RA[/[@_@2XV!-7RO!"Z=+G
M\-!.WZQKYLR;)(/2LJ]ZN8W!&X&9KQ?H*YU\<D!<EFU@P'SW>VU)_JL@I4%+
MA&8 V/&!_]N?C%7Y)J^/5_R_/G1%V,^N;Z6=2) 5CSN]S>_@BUX9*N+E?45M
MA:X241/L+X\U[\_=XZXK-<QHJERN9@,X%]W[77?<6@VV)4^Y+EC6E@E4 YK@
MO2 G'![U^;++A-3=8X@>[FE:1E^]*6]9D!"$H;I?&H>MNQSE^N!5PB9**CLM
M(I<-'#PRQD_.1!9.^A"75L0 %<\'&UP;N<#7IQT5U<^'?H^SK@W@Y=5O?WGV
MW9X >U,IMH&3O3#EL\/UIM8IM;(K>T;48PDD&0GNR5]$;3C-XB:.HN+::2(S
M<\"AV/1*O(UX"^)>SLQN>%^4S[K,U/,=GH^N\4#]<9[,?;;7<XIGS4\ *MQ-
M\%P3JY)"FE,AJ-'@$A[L5.BVJ(1X:_L;ZKSX<2<V(\%W[4+Y]?4;N6&IU7Y1
M?FO%VH5YHL":-HN^^#\WJ8W@/L%[%OJ[+K[&Y*"#\U2H\:7KN(R09UEYJ6_7
MO>B>F.WK/<*ZSC&5D\]GVKBU:U'3-"X&GY:W"J&BVTAM6!-C?F#4H<0SLBQ;
MQ6<P(S+Y3WWF$^#=$V"FV^#V%6269RM BH"$9Z^PQJ(8,T,YA@K5Y]5>;.88
M;W"!JZ8FS,FM(CA$0ZGV2YP>P]]W;MD>YBY#L;&Q"FC7YNB]BTP<PZW6E![E
M"X64SZZ93FH!HVV8SN%$XATM]<<Y 5WO1 _5X^$S4+#F1*T,S&8]0H;S]',I
M(_DK51E1<>;*'%=/B_$%P4:/U+W>)='Y,"3G@]-S@'D^P'3)M^U=C6\N0&L0
M0-XXHZW[,P-OAFXZ>VK]1"BUB(8S]]D:<;QVC[#IL5[<T81&YS?NPB3@]BSS
M;J :/6-B5)1V 1$'> S)U/_AU_G?+_:(X&Y%#$4XY=?T0O/(2SEFZ=<T+JA;
M(AXH$N2*[\(&=XE?FAK&?.RG3OJ?0>?7++XG7I>5H#7:^"\-J4.5L*13>>4M
MDT$ZYO8*R=/,R5JG@^_S.XMD+3!V$]D*7GE38]+8!E)GE<HI9QJ$KU )"XW6
M"5U&M -66:SN@MXPOPP81'#S^G;-+[HW6?J$/*-6Y/)$Q@[L9!M 5SOE0:NR
M%_T% ,\IL4I)+X\NE/?PO'L?X> 7)[<,$(ZS:OT-(?_B'%K3(MU?<HCE I"R
M<4=^M87PY=DNMU$B_<L\Q,/G'MB3QJHAWP\^PULK'K67N$"N: LI^Z8**WL"
MN':I1K0T+^.P_>&.V!+L%79YAU0J93X" 795S&UOT(%^KUKZJ9.JR#@+CM$:
MYYL.K'F\T#8+&E.NKPX,&W##:C72=1(<E:7(4D:7DS+:762!\7B 6,*38Y=;
MG@#JM/+UQL0#6Z)WRB(J%BFLC>D7M1L_508V0@ZSYVB# 9$EKT8=_,[%$I!J
MI8RTKPO@6ZIAO9NC=TH9/Q2H3]_XZSH!_-TN!2"- ,9RRG;WQ+K$XPU;IU>>
M]=1QGX;='ME]W3=KOY^T!,P#^UQ,B_[*V'<89APNF=@H?;5WOQM'EY$RV:.@
MJ9XH]%_4.F0O+^<RKJN-]HQ _Q81Q4QTKVV$4+N"?70#7[JA*J'"U^6;UP",
MHPXI@/F</S5/  (= ZOB0GES'T,G9L)0#JK3^W:AM?AM'^;1XTJ&WD?6@;&C
M[\^V4=]7:)>Y/+\(L2/D"86>AF2%F*82WP,.020XI']%>YI=G'4B?[JP$A ?
M'EQ*KY]O,52T !P=-2@@JT/DE.IZ0JNDQ39Y/Q7?_9!I'DA"X+O=S;_=\8/7
M6MNTSIGB]\7RMOWBWM"E[S,P$E9&/=? 7&2% N?"/13%55KO>#+4)A%S1Y_M
MIMW]92_1RGL@<W*KQ#7@N/QAY="J=K"3B&>AX#\!7QZ+,LMFE<*Y9_2BN%FR
M4\F:_!;\ NTP[*4@VT$8JX@TQQ!XDE=6[;.I3,K\BQCL=G\W4;\>@/6$KGE0
M,]"CR.KJ<B9)*"+$%O-'9C4CT/1Q_R?%RWN0_E&/<]T5##&G;;"+!_S^U7IY
ML9+RDQS9'>8XV@9^J-WJ"!<.-GL=B1R8V/_Q0'I9KO<EK3$ZY-LS%GH"R,KE
M$G(N(N:^$'6YB#9HY:/<%1;?%Z$4YOQQ7"+4MA+*<T:#7TY:YG))7A;QO4IP
M2%R_W(R7::RTQ06MDH;W)A&&'R!O]"52#OX]?4!#&O5Z ;"=T)WR%H)M?C^>
MM5)%$(M4NB=U=WZUFQ'L6]%C [S3Y'=:"R?]QAU._@6DI9N7; <THZ-:ON^.
M"D;4\'+@6B+TXPER1<J.QZ#]N.R;"7_Z7XOV *Q4=+%S*R1+KX>Z8MEJ-]*.
MYV7U2>L]ZP!%';L?R4CV'--MYK0\^@\FM?*JTSI8[8M0<9?\745;$Y!RI0S[
M5@\XS\/3Y5+4ZJ#UH!_#:<-==[[F5%M1F8%LF6%@&R?&,AOKHYJ;+=1.CO<O
MZ?J47S)D&H<!YG(:AC))M3Z6Z.Y,:"\MZ,W5:X0A !M!7%H.XXY;Y!Y35][,
M4&@K2("5%V,N9$+?XN [IB$F%XI)!)ES%M8@"]<SC*R!\?QE/X0[\9-^UECE
M,G4V3&_R\O)B9A/NKINYC?Y+5]M<V<2T2<L?B\K%85]/2P+XFQ/[BSK)"%]B
M@/;XA8-YGY!KR#PD(P>.5)>Z 7T8TS47'.5>>H<T.:$=7H'@:Z&(0\UPA#\!
M+,(4<-BE+@5'/<[S'Q=J'N<SY6^ZZRZ?_TCYA)X4GO%SJUQP)\(E"XN9)?5Y
MV=>4<,,#S(LPT, Y]W./6^7<:5O$1V'59:X57R?8(5G-9[_+8S/X OD#H@+*
MY037WB%!I8PL,YAKIH[867L@&Y!UW)L"Q"YYU-!N+H-HFU#O\55XA6WMPB?$
M89=*'(UC9>>+*C^KPIJ?%.(Z@ /&,N)F;1LHE. RQ3O7Z])2I#B_%KH8LE9R
M@1J[CV6KC"3UW>"ZLW=(-660!;2W Y[B[:@.&-;R612D++ *]CN";,!J]TX8
M[[BM9MZ^(O6K?NUPHXRN)^5@W$?BW;\5-Z8<UBN-@([9AGS]BC3J$.VIKN?3
MP^]N&^XX).PAO /^]<5,]KO&G5+_ZQN3M/2\]?-["Y3RG"H.$3F0L;&EZ$@+
M8L35#NM7.#?G(=^6OUB-I3=-[32':=4'/>U%Z=21EGD/HHJKH%>HWCQ(%5(.
M&H\"?YJ;02 6-NE-K4U.V?>^_,D!D2,!G?'7QZ[YF7TDGCJ!TQ$:+E>:&E7O
M7"'+V++D6@ZPO3# #F.YEJ?$I&G=6VW@TJ)OD%S2XI*=G\_<.M+X%:]86XDE
M-.-%JDJ<1Z4A,XU;D@EK%J$R9T;:L0\)8+NHC%R^Q]TFZ%+CRL?2P0'[^O<W
M-VLD7[<!XXPNB'R>:P9,8XJ^DN#*V<6.*J;#A3"IQZ=94,1>7 @PF_/'IAEH
M^6*CIZ4V\>&F5MC<0Y:_3*:>-K;_<D1'C 9&V+4T)[WL%6YS<"TX:@>E:'A>
MZV(IMZ4P3R7;4IU_>+V]S%D,NEB-#K$RC$Q."QE$I=SIGO=PNJM\=XRE!J(&
MR]++0_PR B:D\W'SG0+C?!^5_<?[TB);PIT N:JIF"$ZR/H>P$GEKD!\"77=
MF.(<J4G*?-=]NBY1-(&[+$[>2R"(-@+9WKUR@ S[V<L;_^])JG\7[']+Q^C^
M"QN+[^M_;278R_NW?@-?H2__(6/]7T+.1 U63!>N0@H;ZUK]V-CIN.H>YF!V
M P!C](JB"H4<7QJH'QABY"^R'XK,[KZ,J9;P'U(Y78P^83U::-^RE_T%:,;*
M51^)'2EQ+1<IWT>F@OBNZA1GE2LQV_QH;JXJ%.]X*$%WFO'_T!QY.W>TF3E
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M6R(.O2"\6R^N,_VI][![+J?4GO<<]%YA)<[+C.8B9-@!^ &6)"/''LION\O
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MVKWGYX.L6:F1J<8TFX#6:72[6WN6;[T&IW2[;1>'4TA6;.K&Q\/NM8?3E";
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M[87,/=%HW*]U75&K-:KFOP#J&&YRR%] C0'('%2IU"S?:([K%'VC]I!ZG%W
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M"F&-I8;+RCX^$,EJ=/B\8AD\8RM9XF;R6N>K:W/1]UUDYL'ZW,;B,(T"_3H
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MPM+#NL7B9AT%!&Y8ZGJ0@MBH10F?:'UI+TFJI0 Q=HYOK<>XM4NO&T;/HI1
M$@T:LIP; =&TA95>NP" ]C(N6!<9LEE8O'OTEN0@FY&C%FO?[?/[A"QOO.D
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MS @0\UFUTN5R2[=5'=@E]]922@)NL*/T.!;NWW_12\A)R(0Z.M78H"_\OH*
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MVZK/TU4XLY.W/*-<X6<M]B\ EVK ,SY]V88A[><4FND3+6(#.PV4T?FK[J"
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M7@#%E!FNOU60/JQ57;:.@#0.&K5A)+C+6%\I9Z.);KM<B&FF8"FT[<V&W<"
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M O8 7N>6B(F)E0AM3C?K)G;%<LM;U AF^-C;F[+,#^$"(@KK6@$$7$F*.##
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M)0LR;5?VH$OB*UH06QJN ;>]27-#G5?"Z-2=YCR/K]BJW/-P^()?7P@BP?L
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M1;JZR"]*/OS+Y-7\G;S<?YT\L)?>EK[@K.OG3WVYX*J7;#B,GB4N:O<J"\4
M8<$JTV:.DG<$]]M<@=8&C-4_E[O?0$"#WX$;MX@]0T<%?,V7FZ ?(]L8NIV#
M;ZU#Q@<'3?H#]!73F[+ER"#0G[4=!]7LW\Y/N##V=<<P^2MJ%.TAFAUZZ;=M
M(@ ANR*U#2U2JM':?"%_L#B=2F[OW7BRT$XBQCRO'3<E-V0DY>,-EV\)GARI
M%' GY#,ZB.?R)/]7;WC_=<4?_S>:!/]_*\H_J-[EF!=85R^\0Z:*0$9QDJ<
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M^=*C6P,3H;CZA=GKZY8*N)*FF_"Q<JFXD[^*VT3Q#3ZJV'DAYY<Q+1.ZZL^
M$-*S?D9&?OJB14I3IFOXG;\N!&/SKH6U#/0K8P2C?;V.7S-,G"?5O]P5:"B\
MU]K7 !%K$A_NH-]L&[XG^?6X*DD(98>;G=(M>*#B:L ?NTG)LU#6GS G4Q>R
M5%7.::(PQ/1Z.SGKFJ'^;I_AJNV5]7:XB"?(-029G%M99$68P)6H;_1CTK'
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M=$G9)/5=1DCL.F$1J8.X_[AU8_8OPIA0&:MV^CG7.R./([-HTL!<Y7R]QA&
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M11YW=UWN1\2GK1!N2=B\.<2['R2>=B3-);;K3+Q\/L'7/.\K!E"?S0<M2;6
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M4@9U1)G0AD%[5*6\J^11*EA&+"28ZGV1DV, 8&O>=*/B#]95S/UYV#- &+M
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M<ON#7]5%0'V\6T!09L@>(\J(JVN9EY%E^5J@[?!WN80VTM-'_]!Q[HMRGF=
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MI];BKZXQ]V,NX-)N:R=?3$TF/>[DPR5^Q9=$B#AI66OU>RY^"EB\@P6'>3J
MZ#9F[<F,XY3$/[$E9D8' # K60I.)KI!&X&BA_+S#+F>Y%S40T[)O [Q0^R0
M!)&:>Y#HH<;-.RT$1HH!MY'-)UMW=/<DWK7\F2\TY@_,KYO<C7*=W_IC&U>2
M"N28<&13M&%J8,#'VV""-UT,*NA-7V:+%FG2RVX81&];B-QX\!P]KZO2;7N:
MS^%](&=OB;&4 GSG%DLJVVKKKX!C!P6#.= %=Q3L+J+,B%WDHL^IT=$&I3^[
MOD>B_G8*H_0ZRNG%W.:LP*I@7=U#LL#T[3>!</7J)-])1\WRFXPCK[N854.)
MTN.LTG*H+<[@3$\$C0QJ+?L7&/ABU)Q:/1 I7/8XWM4<U^L6SU#5%L*S_%0J
M'VH/=/4)O #;;/9YG:\O$_M'/P^WOC5&4<G)"0X'&)]<QS@'O)E2Q8@Z->AZ
MFZ'JTB(/R$'OX>#_F*]]I,/YX.OO7S8>:+DQ4AZQV)SW&V#WC!CU0<3\RV8*
M  D)0!GZ*+!V3?<;(&L_=&(@=5+K^2+!>^4W8$\ Q4F=5AGN.\\I()8)*1G*
M=#NKXMG#):H&J/'GZ(+=?@/418<B*1VXH8)C_<NJ.Y_/W(B/>^Z7AM=A.HR/
M'(7#OP$9++\!4_'\&IB3)V1TJW\^$X8(<048NW4Q=$Y['%$:+U>__T3RA:&A
MP8DYFHZ+#S-@'DS5?W+@YWDTL()GR94WUJPQ[.WK+Z\T?,"#MVW8QB-U A%7
M^@TP ?T&7*#7W*M0>#*?=N:VC#6JZ:(<>^4\ \S]AYW1\ZOF_8>6G/%-V79W
M:=MW/T/)5^A?Q1US^.$]=KIF!>0]IQ3GL8<UQU:4?!"IN5XALT7%!%"[&XOV
M)]WX#[0)58L3RI6"DR'<D.8D7S:JROVA76F")7LRRL@!;,O \A$+5]*\O5,Q
M3,P=5K:^4)%#T]S?@(<PI^##V#\9F@DH'8P+/16%'4R(2(YQT IO>[ Q]UFE
M8>:X)WYK9_\-N,7X<^(++(_R(<)X3V]B-68?\)RO.)\Y+/OSOL@+%K&D"_QR
MA$:XB)FUGQC[GL\ND1C]QZ6;INU:&-&55LLN:T)GO%L7Y:EU1-HZVM=.P^(V
M D7ZQ%'6(ZK,*#;I(>W$;Q"JOF:5DW1L)<WBKD99;W(I7VK>@$ 7Q0+<K%V3
MLP!-ZV(Y)VO_*#.@U=I'0ER4/VDX^9&F3Y>_<3#6FDHP\&K44W<-\XOEVOGS
M@+[D"1PK'P9#P=%?*OT9!)]>,W-N:#ZPA3@-S?T&L'5N/@9@50:WY-]13J$*
MXA$/%<D6]>%F<QQ6O FH0 8T@.3@+8PYZ:CBEF#5,I\LY*:IJ'Q=:5>VQ[3O
MUT1AY0;N(.GUWX"/-::*=$>33TZGZ:2NCT6[*_X$_QFIP^_FA]*4HG11F_.0
MV.SE*,G!JQ0EFGZYZUMK$?%UKZLJUYO^UY$<4-;9K7NYAS(Q8X$D?D4W:9&>
MGDW)^;&;3"[()(&]J&I,;A>C04>#*.,Q_#?@RT10$30 6#( <B@<O3*TF?58
M$F^=(92ML4+)S\",\RK B54G6(FWP7EM-#.1+SC3:-SR)]*1;,6%\+C"BR+[
M%^[B!X:NA&*<.3EW>02./.K3K0=_O*(1.9:SM:M>7P:[S>TEFYBL*K3"3&<;
M^H;T$"[\,PV"( 75T&.'.NP5\\7#.F&\\J?9CD?MF&X>N[4RCQXHE=6'E#_H
M\,&@(PY:@WZ\[67LJ6@7J2Z?'L:IW5*@B9DQ';7=M.G^ESEFB)=AQUE  NY6
MST9[W#Q-T)%'(M5>6VWE?;9YPPAQ2CA'Q191 LIEN=GW#"DB"-8&<U'*=P6]
M7@IT@X1N(T"C._*^[U<A5W*1X&59WH^4":>W_IE!5]-A.;K5Y@1F)C=..*H>
M0*NLC9 (.-:G3"T^\B: YF%>6A_<GH?UJC-W,BJXH:BU(WL2&C,V44 4JB63
MQ"<U7)NJ/[>@>I*7+O[:>WM_G$V&^8PURR*VT-&R;D.:TL\[VLEF(4-Q_J)L
MMK8D:A27E; FQ',+)6SAK,8<]U"2/G^ $J(-K.,(MHNV5NA"=_R(*29#]YKZ
M-"%-134=X1SE)[9D[PTO,=/I.R(S]_;J2XJTNZ0XG-/+RZPPWNN2A($%6>VL
MYFP^@M4&&4SBWN-+J$F(WFE@I"W$<)D;M,Q".%]<BH  ][*9,.(WP9%,U%F>
M&;$,'=."['U )C*C#R(MD.16K2JUUW[4GC6F8GK0D_RHRV'!3>8&,U.J;-\Q
MQU&&)A\TU#^^C=*Z(OU:^32]^<H[=%FCR<*)QBM#)WK!2^+\80_54NG4=*+<
MGGM9/F5-!9_";'_')+0Z'84WA3\)+\"CTB,P6'O^<=(EBRZM?,6M&>-(!?V'
MLN4MD=)&)2%>9)/6./:[:.O6(IV5"0 KP)O)J]96I;.Q^90V%R^,VVF[*4_[
MJAV+9,R%U?T<[W-BY?YMB!]-WRA-39TS62Y?(>] N]/5$';>DKA-RQJJ/7QU
MHR7A;&2G^75#9%O*">^GC]=/DE-0>C83')IJN7NSPKMR@ROV]!.F#W J5)E<
M/SOG/IU8=XU[3]N%@(2T_@9@@8Z.!A:N,,)9BD$.+^)W7V/CV]"\"<4]6)B"
M5@<&JZ@LZWI0Q2A1Q0DXB5;6RO91_DK\!%F.IS/C6S9=GMB6B<Z>1-LBH7?_
M#3@ =Z,:K<@6KZZL+F=;5IB->B4EA\8L]@PY?>Z9.!V8;CA5C^ BQ.*B8,IW
MU'S>F$,/T*O-1SI$>V[-".:^@BQG%O/)W%^F6:%6#%-3H][JF<?7!@T@\Y^O
MDI=F6OA'>D9["TU5* U]'7EX!:Y8OJD;$A7/$DEQ,.6U3O$/"=?G & /4Y](
M\>]+4\[<I%SY'[8(2%!<HC6Z$\\*?NOO>G]0G>1-<*.7$%W36[L/]'6LHQO3
M4EP)F&XY*&O!5C%%59R#LJN3*8@3496G8WU*95.A<N/!WY3:/#+M#D?.,DY?
MVZ7/&L-'V86)G%9V"YV_I(;% ,!(/!(:/-W&KXGJ*6?&_9;D\2?>N+%QWA+J
MSGZ>DU''C@+WEH&EHO;Z;E\*ZA,\W;:\UZ:>NQ_I"!8$;]C>.&XFLFWFWZ#J
M!$E ]#JFH53M0">!>R4FXT*"]]]KB3%N%871O!XA*)662/8(6/$,-)YG_YI_
MT"JD!JGS&;>8_CG!OB$M4<L]$X*]!7]4)%$[\Y-&[6Z0.L!O%H*R@1WOMWKQ
MM):+JTC?.M]C+/D)CYO)9I*KCD=[^[B4ZFDN+)LLTY.V]%6\U_$CEYK8NM4C
M,0I$7#_8(=":MK%@Q,+9_V7$J\>9!HOE FO4Q,F%F48HIZ59))+)Q6C_IX"#
M/<*T;OD-TVC+X\EIB/_[<Y/'2E]G?X=2B-%Q8=5*]K"9A^<3\H1 H3CJ')1\
MHWW/^T4/\R@CK]**])CQFCPZ,8OW=*["ZW2:TE24D5&LT';H[(^+A?:Y\L@)
M!]>7NM&BA!,*=:@)=C,=\ES'SAR7[/*S=1Q32ARJ])XO@Z-X#M@S3XDI X+X
M(O5@&UFJ#&?CFK9QPUW:8<GM-GCJYN;VG:5&/OX:8;KFV+W\JLS9TDY60&6A
M=9>"UDMB%)+?@-@Z03K<-9/E/3),E70*2Y5N06]+-*>ST]S6GUFK__V]L%N3
M&2NTZ81J+Q%]Z JB-V,L^"6Z&344FR@.@,G25H?Q&S"<41J\T#:%P=)9[>"U
MAB]P[T_%FL7-)DO]Y$2^68I+B9&<2LUO5Q@<K]Z? EQ[#S4558G7NWS-^=DM
M,>EC^NA%CPC%D/WXJ=R8GT(<A-/HYG/#VZQ7S,\4X](VA6G.[R@C#3MCU4\C
M4I%*>@HS90T\F3"^M[[,801Q<6'2E'>VT67Y1H\C,(&A66<S*3X2ONB_S;P)
MOKOL-K%Z?>J3/^1GO9,4SYF>25QF7$RA:^,))[:ME1IL%Y7^3VTO\UX[T[G@
MOG]R8'XG.=BF_'?#_#\#]%]O!-^2=]C^!EA4_$G9UFQ-F=V#R'X#DF,'@Z\H
M$W\#5*\\4&;^DR# _T]%OZ,;.HLTY+9-0/-^6K,+J-][^63@KP5Y)+FL40(M
MD&A/^<[XFD)0'=^3=>J/<<_S2G3#*I; \YWM)O(L;5I3@^ICZ\]3,&="./X!
M4-&ETFE4-15HRB9+),NI!XF7N>9LTLC\U/N+]E+G&^Q0WM]@-DG]])C < +%
M<DH#/>9?8**J^"K#VMHV8]78H<@)@S_11GC"-:&XS%V:=.^O81A5;0GEP)+E
MFKM/B'?OD#S+*M:),CT".]U051D.,Y^!N2A3!M8=:YI3:=+_=\<#6U,IB/,X
MTQ7D['H%9(DK&F_T&CO-L=+->ODD/;Y,KMCN"AZ Z69<MMIOZ7J@CE02]/I[
M G=!0Q=T#J2''/0Y?O%!VF="7L$H+T3$7_V9O9$.G[$=_'JI!B'O2IRNPLCE
M]] ?]\@ O9"@7).9*:Z'VKB4-+9?>DFH-\] [/XUXE=DW^1F/[,?+>3,$*=\
M"A)_]3/'LN7G?U/R[Z6"ZR?8D52H,T^8U!!-T633G3;LHG+OW_[)ZF"[/QFE
M0[#-;?=^D )<O+/\E]E1ZP3O0IRMH$W(,[92&+C<X#M#9S>T.;F-J9&-Z(9(
MR;T&F&XLN50!-[Z-;15?FO?&TTP=+L#^K&?O$_LV14[Q,EYB->I9M<>GU#V1
M:F_OJW2"R*ZVT"6L'F#)4SRDW1._OP&7;YM2A\1MB_LW/C\R9#F#T?<:7VO$
M%K5_HGV/4*A%M!1@[54XU7'6O.<W6Y%SQA?F>[=!)J6M6[  B:V$48'T!H$F
M&Y8)VQ1?[@%V3W[]<UGC?Y&03-PL:#Z.SW!:WS.#$??#FTONM)<FNSNH"PDX
M'KJC/H\3.]=O(0D3",-5YR(O@Z3Z9_RI0_8 4\M^2FAS;-&T0+4*$.[/R]<Q
MIB._/,P<)5Z!/?5\:ZZ-J[52*HI+0-4/V^YX\Y,Z<=- DW+F$$KK1'#R14V@
MUQ5("IE;VD^JA3B:Y3F5YKM_EYA2W$J;YBT?<VYP"H%?CH</Q-<(%<%6N;2M
M$KRMZLW['S]\(<^ )U[E?Z/1"FXP@G]8Y\YPH.U'ZNS20KM9BK=NRON\I*R:
M4H](:X.F3G<,3FE=XI>%=V&M-Y!<N2"" SV;P2U3"=AVV'?0#_$Y$>RX/!3!
M9G=++X30R<"W966+4+ANNG2DH^TH/89$J\0>2KU/9+]1>FL5$"Y7&L%AL[R[
M0O8,\[VT"-/Z'8JF@4]Q?QLL5^#.*],:V_#8.*+%BT&)K*J %E'>:7H"S1UO
MC@Y0X1SHJ%>0F!%0VY-."E@)6ZNS3^VYRB#U<RK(<%%"E2SFKTA^EJX=1Y"'
MN$!!WXW=I45M6J@IB%+A9_BR-<J6>V]<2-,+YB9V>$W)G%8"JZ2"+"3W?)-6
M?+8T0LZ8Q_XE[,T<5Q">[(>FF:%  J >%G$U(8O-(%[%5A#Q4;#FW(.<0[F<
M\\:O-V@QQQ2VOAOLD+"XEP<*3,=[O'_"\%"4H$,PF5P14"A]5N#J@[5OM":5
M,WTZ_5D!MS1_JBXH0 [ID*NU^]94LL=>J%\@@WEYF" YR?4Z6N2R6GMII7E
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M!;$(!-HZ_[6NG LIP F5=JP?DIDTFH0)K'WUF0G4NI8%V7P[0]=B:#;,(]/
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M9>\_:,F=?WS>NH7K&K9O:E;M!:,4/$+BC#L[,Q70;NOD[YO DNX2"D^Q+L7
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M>134%-=4_]VL8V$S](TU&== J35%X)=!P#48#]-P!7Y ^\(AV]?"$"I"R\]
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MB*DH@@K0%)YQV&&- )[C.L2UG6P>=!-RV[88+]OI35-BC[IIX_+P4)%/\ \
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M>Y5*V/'*L&#[CJBL;&*E*6[GZLJ<K(C!*G7@:<2Y%!; L#>/];NP2G&0+>@
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MG47W;:O8>:/AI9%>V6%<HEWF;I>69;W;7-Y[+K>E)+\L0MCMUY:Y^"[GQ<-
MN14\2Y?(CZU,U<[3?==^L:PX.7L31*O@$#>06=/()F*<?9VXT_DXK%W,L5+?
M&#@%=[B(JW[O^7J*W1H^6*&W< M_P8A%G!T!I*M3ZP[[<:/D[G+KJ36"O5]8
ML$,1KS0+<>=&^9?;F)U\4LH;>E]SL9HMF7$9)Z(\=@6N=RY-5+"/5Q*R/C[D
M2@K/]/^K)A;D!$D_$G;FN\JZ$HT_MWLYC GC'C/;/VCMPC)SM9XO23L*:ZR,
MYTK\Z2?)/-(1;1UV'M.R&^E.^%Z<PDF/8L%"E'R"G7&$G?)+377<J_V;25!?
M++[1#J7(R=>JPHAR\R:LFN.U^+YCK?Y0D\3'21B["@KDFK"V9B]J_:2=J!F>
MHK@0/.PO+Y375@$8O;F+L.YX'[%%_WN ^&=,1PIZUKH877_PY*D;][9U)@0T
M._Q- DW]?,G65E!E_Z'2L!0Z&*1OR^4UYF!UA-F6O2S;-&>B3?#7>8B)Z[;F
M\XM[0$: @[*6>9U9L-/W(T>'C]5<?]#6Y.M?G:PSUT2D&X&"42M;B6U3=>4H
MP4'#+@$TDVU1^&,LV=:SW6#GF!5PLM0">#?Y]5YEE6^.5BT+)N)]:@PUD/KY
MM0>2^4;PXPT_,N?PMG)DML]>4^?O+[_F=PNRW>LCR($XSATQ@K&A.>\K'1YR
MC/U9;"R ^O_MC-&)J^&0>/ $][66)37'X(WDRCL$[MT6D.YDBO%1+4A4 9N
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M*76#BZAWQM-8ET&RN[-ZG=R<K)AEQO3?_6U5M@O%)]%"Y>U>E&XU/ZU$@Y5
MY(G?A$6=VUI$5^Q:1#.2'5X.'ZG+)+S]O2AGJN+'B6MSE$8@U$P\-S,[W<[^
M"UVP$(=K&),_6YW/,8+OD*12.?QTT*Z(-[9@&YV[\%?7T7(CB.3K$"X^8'.6
M_,>J)3_C$4M\@44IF#>NK(&/ -?6D#6RVYJ0$_:Y8KGFYK4=_&\30Z";]8N@
M"!3X2T]:)._Z$*?#]O0(5L@]@,PB+FI.1WJY\$=I-:@)PJHQ5W!F0(_;#<M6
M/(JKA]W&9,V;'\F BG,"/PAJNUG-EG_Z1&@KK3)69LT3Q$,GI'PW@W3"\Y*^
M*.O.UNRNQ.@!A.4R3D3S#_/8*$HSX'&S!80E@TS\(+RAD?X"8@\==HC*D>1"
M2+IDG@5*(8HIG@W7EQVX+.]MY3LLT?DUM9M2T*OC=>&E]_XD^Z_;7T5^TE'U
MKQ5%E>WYA]US5W64A[\=9L<B$SE2B<Y_@1M>Z(J+IKE/W@,H83V=R["K.[$>
M12PX7\<4UVZF[&1E[K@UT\]!0M-OGX(%CW%P4,D.*T+Y/%J)!$2?H9+H=^Q,
ME@%!Y!%"'YZO38I\A74.C2C<"@W? ](2-M<0HX[#9+NX*UL; =9F7*@YMKZ\
MG7GI'O<(=\#V;-=[HB<+.[NF*Y:LQ[F546WE_/J/AXA*M%75CQH'B&=U%\Q5
M9K=="/.JY3CWJ;>ZA,WHSY(+VC-+VG5,;8AFY0@:BK,JZT]>$_Y?B6@R@C+B
M$H& @6VVQ8F.= N+4*XE4H%MHRA2QCW5^FGV\-%8@UGZO\6(/JV@O<SH\VG-
MH7:.QY&B[=LU3L5&73&@\+)EM/S2N\JJ6CMN7]G'5 #<[I$I!1,W['0SNLG$
MOY%]G&&5_WD[;R25BRYK/53^>/C3Z*P2[W/<N;G'/H9<5?:$JZJD72?W@#;F
MVWK>:,:P;(V54!WL!3PHJY!K*TZH<Q$N#W?ID5I3K@Z-$-@6*$V>7DN8;DOU
M;@BYF^J [@K,-S$1:ZO "<SA&_E67O,&U_3%A:BT42__:0Z.T@J!S?43),K(
M9O/OA:Q-V+7S_K (H5UX[&?+Q!='- LS12ZZR<)U\W]SU^70QU;;.PY3"9N>
M"BLA!-[]7T+ I'(A6TRQ-^44C-&\T; 0UK13'K@MT0WH6B)<K%SA+M0"$']'
MBE?X9S]59B2WN:PRLAO4]Z5 ([S^:40B@^;PH34<FGDC"/VX:Q?$&AF@=/*>
MPP=PQC1!3SV%;N#(U3%'9:D49V*U_T:/L8#L:M:=H[IY4J&Y.A8,N,%:+6-@
MK-TO(Z'[^L7VV$(G5XHXZO< 7#ET$C)7:Y2^#;DC&<9*B<?29>T[@8$HF(;U
M:D^*[=&G#EIR#EQ2W'EH0.'[F[717Q\17. ;69U9(0!T@Y '2NN_4>:/Z%@[
M> 75?:S/H'R?CU_X+?E#S_UF?]?E"_WDOY[I$E+-/<KN;(BK6#1WF(7$V_]<
MJ7>36DZMTWS'B;&+K-7XP(!UIDMT\]!_HK\6AW2UW[UJ%+IK FT!;52GLLHG
MTL<==RF;F^.X.'XQ$1=($?)QT:ZF"'[5A 4A(1SH,S#?^/X>XTGV]YI(JJ/D
MOG:X0Q-K15GE49L%_7,_L[%]T"==1[F7/[-P+A&TJPS#J)(MZ+(3]./)A_+:
M6F(M8N[?L1V%4_UZ[XY=M\5I:$2;\W?N 68U<D1]X_L"6O[.V7[GS.]O@N#]
M/^*$ONDN< B:?#0*<9Y'AU.*E+L.NFW$>YC9K(@(,F#KSO=#A7/1SB1LOY?D
M-S<87C.HC)^<NHN[W0/\*2S#C%1KFT;@]X U9B&P!U//H-42<#TT-)+HZ)$@
M,L.U[^X8I85F;1_7V1Z-N8NT)J=NV5%])TNV2*!5M?!G)=$8"N<M=*$IVY,!
M\DBT+["/GQ+A=^980(0%8W^;#^;^FLV"=C^3H=I$_GXF^",4;77SWJQ8JV6*
MXD*YR,,%:CSD,+T6EF5T!@?1WP,4F\.E)QSCQN/]G[K%SK2> ?>CNG&0-2 )
M<.W8'<WV.UTIH^0SIMC,[KDY#=^_AHVBD;3[C0XF1,&>(N23$2C6.-E/I'^S
M/?T>K:%I>5UWQ\F!EVT[.O;7LN..LC;L4%K\H+87VL9QAJ)ZX@*#DBN1"F$W
MK+ZI"_])1]DFVW6W*0&K)23)X(%@W.R?;LMX;Y["?>S&!?BO:/2M)5; 7D;M
M@OT+&L+*,Y)O=#4:D@Z_1]4X/R=.:)]8KTX%'WY!.-\#3'U+EEX3'E]C2S^+
M8-T%YQ;%)W"$GL4&RZ"K'AM?BYZU.LG,67<W632T1!!>DC[T=@REL/?B="+9
M@S&>GYJJP]M-=F8*1183Y,_Z;NH%">>NU:#-$1PVCC,E19X"W(>S%">+:(R/
M/K ?;">T]N*T7Q& AX0R.S'$?S>LL%&ET*K_\+%V(E!@T>%A3R-8M<)N;)#-
MKY4C^Z9C,?0F_7UY[6G\\D48_$-V6I0++\ Z$M+5P40"/%+ZY3:SI5B8M$9)
MFZC:'NF;;Q)1]P!VN7M .HUUZ4:[W*$W_(V0YLP;M[W"9-],I9B_BCA*+O#;
M^ XDC?3,A5>Y ,/@8EBBE%VH0RK<.)5J0:%0;QNE&P#:.[<G-V1]'"!MWV&K
M8#!D\>.\$U%]Q"B9JD#26" A"&J74C46XORX&1,:>FNQ^!U;6'VEZ!XPC(+M
M30#B%@1K)ZQ2O%C%:VIY=^1&W+X;OA3,8_+L!O(_0C >/9EW-:73;>M;.1A6
M*E]X$3>?I'\.H%U#FOE0"LKG4!G3R=M^H'-78_^3MPB!/7;</AU3&AB(_L*X
M8!#:]]?3P^[O"(ZTV8KE,'K6BT-S-%4^&OT-/J?]MN!:2H8)PS]B>U>#QC37
MQ>C!(]IS(=$6E*1@XB=,Q!EO"HTKZ).E<+PMTE*0JUWT#+R"G7=%A5PV<:NW
MFF6Z(<?AK@*TJ\'5N9:(!*)P89FKU#_D#2=2HB-/RQG?Q/B'2SETC_D(IA*Y
M^CI-6P-G19+GBYI4.^L1*S]VYYQN"A1(^FUP IUP;4!WXX_:.I<75%Q/YP08
M-#<]N<Q8JEA_.I%%[_=-J22+#G/+K?>H<IVP2U,/B0E6%9NCLR^Y-.\!07'I
ML VM>T#_6IO<[^'Y%JHAMZLG *U4LM9T<T$\K>UR8;Z1C$Y,>PKSKA95*>D!
M-V#5M](CD8F$4QK=DLS>7+#3,UGK!?<^!O->'*"_[UCM]9)WYQ*AH###U2.U
MC?I[ .-%  Q]< ^0? )P6@PNEB]S,,@P/[: FN*@C$G?6GR_!SSN^1M19>RJ
MH'I<Y*E:<)O<'>\ :O53B TD0XQON7;2>)=9+NN16"*N%O_@H/:]QZU66 PX
M4]JI-^\!)4J7;J:3W#"J-[.]^%/V@PA*!L[XT"4&;TF XY3N\VL^?W7=:]Z]
M6>;NJ VC X!=/?VMG=*.+JL6'D@DO2)ZYT(),(N2:B%M8?V/?*"J>_XR8VAS
M.??\$T3(@EBSB*3MI<V\5<O;CD-LRC,XG>RL[(3P^^)AV@@3K)(8H9=QQ]4L
MP*="#@]5Z(/-"EX>O,1TJO(/=T=EQ"#'1E'>:@H0WP%]\%6O\P*!M+,0#/0'
M-?UYH3WGE?YM5.-PX/>2O="$9E<^=)4(?P<IB!&]C636O_OVU9"*+BW)^":G
M%,UT*-*5BJ^N5AWAV5?('.GA=WT=:MVM"=BMBB 1"<R&YFPC"/+UYJ1,B-]F
M\&C< QHT-ND(#+<HQ_5NP$T/=@>_GE+ 9>)\.BMC-Q+^^"+7@N^=JU'W=MYB
MH72N]C2>4](+@V=L0/_0<^!)UD@5YJ0WLZ[N![)\&Y8DX?C8)W\+F("V.$DD
MA**_,&:5),E\_KW?_G_Q,JZ0QI1[>_S6+J]?J!3@)9N&,ZI:=,9&)^$RS0'=
M1]P>L*AZ>DMEQGP;6ZF[YJZ+S5!(<I,3#!S.X4H U$LZ-'%.VG"'@ 3!N)XY
MB8K!U+B*LY&!/6L>1.X--JP1'2K2(FB_Z6[(!A5XQ41@?=KYBUD"8"*CU%&!
M8OMJX$(Q")T>QU9='2A66<B]4],1S+]T,BXB.-G(LK$#<<)P<S$1E+3O?UKE
M^3O2\9L(E0L91J[D5\3DZ>S, *][ +PC,X96A>W=#4:AX__H+&:,P9) F[V2
M$M-1IY*R3@\A;3!97 @[75WD#*V'6J!_NF2ZIAS-P/B@'9><\$"Z2^V.+3\0
M5?7?\9=X.7?C8TC"!CPO)(+K6G+5AL-4N#$MO'93X!SN_C]MMW^ZA?]%N@4B
MFKQZ9(-0KO:)B8-CE_$0,!9H+O:GN*FB"DXXK%NAY;%N5];>S02M6C685[
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M7!T^'-F$@IP&8>!Q:P:U8,G@XW-^G5_3FH"6]SC4F&;3(S@ND@ZPP[(;XGN
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M<"=S<9%V1:D BOQS[&9$XR+/R!1P)>P%-GP)S3H4:R093<3)515<("5XWL,
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M0#T*9*H"B"8%I;O=2?GC1F3!^HC9P<=),Q%GUF6C1<9*BK[W+3N)DFB&R[^
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M&T8Y4VW&*)U+B@ >Q)3GW2 T)9=W,J]PZA.YM-2.E+Z N ^8SN3C>DC2E:H
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M35B#)\M- -+KH3-J[.Q!V04F"8<]68%*IJMF9??6[6=S(G8;O\;A-;CZW1"
MV3&O_U.2TB2_+F?*AN9L4;NF.@D13%<U:2EP%&3[?W^R(!*5%_*<P1K=DX:;
M?8&,8ZG!E11O@G=N9V6?O(L&JZ<=2X(Z;,.LW@!G6RQQ?M"^Z<C'*JO<TXQ=
M\7--H)&"HUL)4N!:+58U$&6C46COGQCDR"BT_6G"WE=6K>A;6LCVUN%G'G,+
M2N8,\TGR(GG,YJU DT#.L_,TYB!3G3]QZI4J0RI5K"7Y@4+L'MW]W8\H[;5U
M*YZ)RUZ=0Z_&W])OKVY%(@^.)ROB7NZKC=BF2T:$M8D.E<)S3%\D'RFB]&\8
M1\D"7&IOK,[8S:[N/L+)>TR(>?OL4PSCN9,93F^G"6ZHB4]&EN,8+VK9KN6V
MF%G/WPS0B]TO"8M9(YK36=!^I'8UAR(O0^%E5=!AW46V@2C;FC*T4EKJDE@?
M;Q=]DN;G#:=:5]"KF+XCHJC!^9@,J1WAG9(BT(04J<A8V-:OF=P9UR79BX,;
M<VZR#^]E74>=-!/2PY5/-G:;H7 8. !<JL)8IA 4Q7:(=UB*&0M D;H'%>8'
M<MTS.I;)%/ U_ZZ%]DZ/",7JL'W1[B/,_M&O/ \9^K]<;JXI.4D)=7FJAH$J
MQ3W7!B&I#*LYZDV=DFH&?/]G=6]H'QYB/N-&I:)Q*IM!=L2!GT":&9. $KI%
M@4G_1\=2%N"L[Q%F<?(7$$/B1SX7\VY_KJC/<FFK<9,F#4:YBO>@9"6[%F/D
M3[I/KE#_%Z"<ON$MN\U,_ULF<X<*Y=@X2!8@ Z20M41WX!HD+Z->U2'C""V5
M7<=57]_IOD),-">YM?7^'M F.BPRR!8/]>!3Q7SFN$:EU$[#E#E,21[:-M\4
MJHA:*?,*0WJ#=CI]!!;I*T,<J5(H:TD,_>T\D .4!SX7BW<)!(Q1@9J>D#^
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M9('"$ZU:?_X)S2$<_3WM5&$'GZ;J;S@@RU8^H-E&+'K<A\U],%*_'6ORF"\
MC[VX@'H0#B0-[-@D63U1T=]ER<4S[_-6+BFG8KSPG"B&MNI%?>QX9QZOK$(O
MD3D#9(,>OSQ(-TQOR/A',D?Q*HS.[?L([5ZT*]EE55<D8%7BC9YAC(%*ZN<D
MR[["F))/N1O>W)AGFSLG5=NC<%$*4G93TMCG</Y;E,A(OW=#.QJP:>9POYF?
MK-@IDDS>IYG6*\0.@<+#;4QG)M]2R/-E,X3L$,Q)3FL1=CC6XKV<H:X5(P+7
MAHE7G.P.ER^8OAYA.K]R\A3SY__'*&.A]6^1K;Q>);8G7@$VV7956W8%X,SH
MR+S5:KS]!O*HQ8,!E'H8B7L 3X,&F+&1F2J\BA7ZA':D_]V(^/KEG1[)N0K)
M*_N"93)_'TG1D-?%CQEMM]I+1"B#GHYR;>$]L]Z5"$-]\5;X^AL@4=YU^^&Q
MJ"<ECK^D?D!HI9L?WO;&YQP5G1J?-";%-:=?KF<8HTT##WX5Y?F!8J/'2JT3
M$N0*EJ5]$RH2N:CO*TD54]#?TI[@O4,6)GCJ7RT?W769F.H5DAPXI_X%V'"G
M'!)=T*AX(ZLO[I341R!NSU]Y&B3&BM[>D8_5G<1&F'M0C;2E'N<+QQ0F;\[Y
M29E)\75T-(Y7;YQR%'FXY!H<1+EV+"B*#380]R^]6VH/SBFZ,5$U"4?$QKA1
M.AF.,11S56)=/O.V!JRWZ+]%&11(+KL)Z72Q04""]Z;D<8 X89;?13DD'%./
MHDNO._F?[7O6&4P$U!S5E]KC=,B#?1VTOE<[EPH/_C-4?.N(C^+'O=':090N
M;!YX=2;#$-JG<VVI$ULBY@K!=5=2PP%:%B[L-R2^)>QD"*(0;[\>DH?:/5EQ
M)<05-$('OZQ^HRC;W,C3:TV9 4?9R\Y)+=(]#4N0@*UE1"FR^94X#[XT#_ST
M4T@R#/3$:;?<["5U3ZF#<&IU^XOW4W04P8X4OVLQWTFVMO$H;,Q95>R39+\Y
M_828L]77]#9*_U2[.'R5_'T0=J/)^?GN+^#V[AT+H(KP _14)5Q'59?/LYJN
MN3G19@K)$OUU%8-9Z)T4I=MZ2S,+6D1<IX?CJIX=8SK_='&38%'XHIZSA$DQ
MA@2TS+K,,Q\(66L:_]) ,:WB-&L[#)/DUJ+<H>(U(OY?G*#S[\=;L/ZG8O*)
M9?Q':5#7Y/\@'SJ.J6"X$@LU6*+I#M[XG#&05?*Q^Q WT"7[.5WSITT)IH"!
M,IH'O]X'&S3%+I&V/DA^#A+_YB\ FHP\"@/\F;[L=^"^A6.4K,<HM8(=@26+
MSR_FCNGJOGO9^LZ*_6*P,"\A NG'W;_Q9VUO12@U5-A82,=*C(<$W6Q:/^Q#
M.+[?RL9]S6\<0UA-PWV"O=-HDG+ '?=O@Y:J2FQNZ_8J!!SIOWV>0(J]$1H%
MQ[9?R)8A5,H6@:=*S?OS6D5Q0 H99^$^_#7#0[8W-U"GVJQB/V[?ITJ FB;3
M7_ZLV,;CY>*]PNSRLFPR.E?5IC 9&KJ_:^# 9*N)1/+)!.>1@_Z.JI>1Z=U'
M+\'X#=J$77QGUMR,GA21ZE"'([M+JQJN?*_9]_-CB3VQD5+,4W'Z6VPHDFB.
M7+SG.0_DT,F;II![KD9+80S$J^?'YXQ<_%NSKDB>Y5XW*FGBJB_LE%5%'_(T
M21RE.T?QJYZ1ZT34^]FNK4XY:@-5'5C4XC>F,=#H]PRSVZX<D31H#RW#9P("
MQX(4_IN>HWZG^OK;W:><W5U3CHBO+A3!(G]\/,<>Q2,!&5VILX0'$@P&+6D,
ML<L7E6;R#'*M)[SC8)V"TY0@]LF%XL+0M"M6(M-HEVC,OJD_L[3%7XH]3Q8<
MSB4F5URJ%K-6BFT/18B7JU=+Z9)ZW!/VXE I_8*DXD@E?0+0J2]0EN&RUY$7
M2@+KZ]@+EY$@Y^"/0]RFNA:F*&/4:?W>4PT1N=!(YOB!B5SUG8J7W.F;KM_,
M R*7:9,WM!.%3.=ZG)MB7.(^2=D.;JC@RUH33^TGD!:/CI3_7G0;"DJXB6Q\
MI)W<J*]K!D'/."T(I%FTWQUZXP3UR\Q2L6:?:"77@J@976'1@@O+M.]C":M6
M2J"60'*U&?_7*X@/^&G/IJOM8\L'/  2K7%]/ZBVKDJL2_B;EY6VH+_S276
M9D?>."BW%^7-<1$7?DP'A]>S04S8304?$>\+ID,Q:6)<R 4*Q<S78S@V[\?W
M4MX#Y83N9$[DJ7\,W&KP8?M].NBAIB,1Z='6P2Z5N-FL>U7'Y"^3V!T-CCO-
MQ0T@M>U2"9]-CXWS[" @B_6D+"-+D.ZDC%V'6L,/7;/H$#O:+;K:'PQ)!CG
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MA8^6A9DV'\W;58)ATT=B"![DH?K$?5M;.(5".UCE.A7MDE0RAHO?KE5FG>+
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MAEQ JU0 I36*IE-!=C))0NY?@*5M,^08(;:")/O:(F!_=IK-FY3=/O,$#E]
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MAD6O/O):10(&(3YT^0A8*.*QY\\R13([CXGK6VA^6F$N"XZ-=^FJ&[C$:_M
M?..8]>BY(];@%0D8G;GG+-BM!]W:)@XP8Q>-U3>*(AD[_C'6Y]"$AX:'2I;O
MAD=+VQ4<(X/<30*3G<P:D0"FD-"P$DOW5&TMH@HLF&WK5RR5C40O_, 144YM
M!"8<;BLTH=2VIT7\EL3=+CC+7PA04V3AY19!7E8$QW1-OVK&&D^Z3KK1-)#N
M%2(J\X!IMWJU'UYE&\0WP2Q)[JV6DROGK-W&Q=(==P9CZF('-7"XIP-$$1>
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MDE@U6B<2534D$3_B/U]="^HK8$N$AE\R<M2VL* +(CPG.ZVE?C:(X^_>\LX
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M/%-@O2]D[S?^9,FS1J:BZE1S,U]W3UN<D>,7Z2N.PJ-!Z"BKKJ+,5(_XA$^
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MS)-UJ/B_Q>YQMV4=V>5 XD&:L!)Z'7XO1^"F=W!KUA&61JG^E=;<Q^VF%M4
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M9>,UW.2T6I/U<))=XPBG?A_L381K.US1H?R])&+&&EJ-5$SBED4HGWT0$*>
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MM>O9>[_ZO-5=/$P]+ (O9"2D)0 8&!@@\O$/>%AZ<2GN"C(! #DY@!X  "0
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M='Z[)-@MUXY&]J-I7J?9R".X"(Y=>U82CJ%66OTULQU8'LC8L240UYUP]'@
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M_H]XX7K3$3U@SL0NU:/Z(@B7%PO\D#;&PK'9]=F+Z_HAQ(R&DS]!^;0QR3T
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M8QE:]I]P)R9N MBI=\&K=M4IS4GHIS"IV9 RO(CZ,-T'8(@=%,83A:Z*'Y$
M( LDF:X+GJAH<;@&MB?4<\SIB%OE?O?'W]LP\S:H,37(PN7#)UA$GQWQ:>^^
M'';2VQ48*@^!M8C@1H.&^I5'<.0@3LYD!8\\ .^.$ J<0+G2/E9YEC&>\8:J
MX>+XKZI*%\^Z!X7H_/3$Z^]_'[9G:HVM^G'>=%7%KID>OT]'QW,XE+#G?R$-
MFR)O?-C07KY#^&M&1]8ELW.3*3M!-8XE(HD"(DLKO %MD,W4,"<E&WE!Q (9
M<G"@O)"UH<\/;53H:X(I\\6@F$S089&OM<'5W6&?\3%MXZIM)C=1/B[E.R'2
M9[CO7DU"'_,U#=,:+!L]'9C2D;BGI<3?(77AN?<7X8_X@.&T<D-$P&P-GMY-
MD0@GBG\-'V KWTIWS_$,Z31,W&_:.*_]N'0S;UK9AYW.20AN6Y>KO*ZN[.MV
MJX!D6'^+AEAL]Y7"20<KJPV7P*8GS;(CI+$Z%H7HBZQL$^N5+ZY.7U.!%0W!
MSI#FS!%:Q3S9B-'X:4A?&54>&B4>'KL"<4^UT8O5/>$OMN[7XR786U@ZE^P'
M[T>8% 5>%RIV56+KMS1O(HHI6;!NZ[XNM6+BO'*\I*'8>[Q30NJ-*'UPZ+3A
M@5\PL$D>;\VTDB"X%P5;[+X8.H'XM3@W5?L(U6&(,@AM47U\-C+ Y@V&J*95
MIB9G'[E'Q10VO:0'.SDR &OVJ:&![T!]1IL_/*K(0KDQRLD.9ZT[EL9?RE8-
M?Y73-_B-VE%[0D=#[6R+S[D6[WJ0LH!G(9B#%='#&;:4Q&%(IF$EQOBPHBK*
M2,Z0T84-<SHF\)0ZX\B3,+P@FRDY/,:!XJI,1KL'.:^E1U>/[Y;M0#+4>C6Q
M^<+\? 2J8-\#9]O[H<S$5N1SZ5;TQ \22O;"PZRRXU^TQM>8"5Z2-DA5E<$X
M?)AI;[QLV925_^$K\&+V";8\\WD:_J^97G"J8!BB+C=&BV>[/>0(L.'UP;L[
M/T8%N8A< S3KQD_[0+$>7SQ U.\B]U &^:.&1GS9B)3'F#,/K>YFF>P\*/J=
M@9?]O4M:OY^Q.FS-U YP:'HT*)^\;X!H6?0IAK^SC\<<#D3%_YE2 X=Y-<8_
MD>SDLLR$O#W/=#@CR_ >ZCN%_,E67D'X.U2.>Y^%Q)PPH"-$H\@PC'*6[Y,;
M_J#9,Q%,'07$;_4"Q!P]Q [:M=W?5A&)W#'G'^>*24=HW8#+VVI(B*=J'/H)
M]R+WLVI$N)-+U;W__9?Y!B]3MCV\M-JVX([?E>O!12EUHU<+$COA#*L)+7L0
M01,'"-<[Q_>_)"\DTU-D0&:=9]^() -6NG)VJ,#TS%V.ZJ?T]WXX7E,GOD)^
MPN/1>-]F97]JSD\7\B0X"KM)K<^#T[7]\?,H(D6[;[>%],_")%I?&1I[F.&N
MH;5[.THSEIY44S!$8LAO>Z&9:&RZ^XZ=%:26#L'Q)+A]A:^N>RFE%?65*I&T
M0:J%^ R E2##D?'DHFYPROG!& OSFB4YGJ0:'UH!U-"@)44%^"6,CQ:7%$O8
M%&;X:> ,+]6<Q)1#!3YL;")M%"F/6C$7>N)8@+B"9V<ES<OZS/:KO5G[4CX<
MI=23QI.8EP1R)H:)J#?&HDASSC%_T&/NU?CX '@DE?L6MDCR-HL$/O.EN]S<
M5M;;PIT17^NH& D)?(;'L(X=X:J,J!T5T5FL=QDZL.CJ1"(8X.0=A%9;[#,I
MTN>WG^MR=Z)Z)B>\OM'!C[/*9NT_G,LAO,AM'8'2:6_OQ4#Q_K!CKR1DMK_@
M+LR",4[U$^;]KS<P^$/B5V4= (_H!)GXX7[&=<S 8-KY3%9L9)S!L8PH\D]V
MCU3W2L00YHC@])&2/?+*L$9),-_[YMX/[%UU*!4K?$NU?AVFYH0Z\ZE+#:K[
MMJ6R-H6-V=;X^UB^BWDKO'._,;1-<0QE?Y\1Q9^.YFD*54T7ZU[O:Y"@* C
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M8]-8D6.WLM:69Q98/$A^9-IDDQ?'W!>9-LM%?<4TRC\CM)RM&7;"%S<XUZ%
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M[E$BYG$J:"3JAC<E_MG/;)#^>@=6>E\W4Z/?A^7W.=YCX U_F^$PA5;^:PW
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M%8QUMS3:NM'C<$D_7+M-XMD+@0N<#W9^>&GB:ORHZ[CR;Y1H=QLX!6(A4_U
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MB_+\Y@2]$E'S[]B#)/<O-+<TN0XG:3Q-]1G?\85:S)N7,P][QS$,#8$#O_[
MI4Q(-5SJ,C6H'QN@KK,F$"!Q%ZF'"AU\-?Z6K2THB7E)HADBCGQU&5-1<<L#
M9?! 5\>^:A'V38:71*A)<A9K@7\S3&BLY'"K0<!!,5:)T %]PY^P&U*YU&::
M+&?\ F@H%=C-S<#0:%Y[N5URA&!%HV0'D6'>JFCS.)5>1MT(ZE(CQ0EWQ/JU
MYUOR8MI=+-Z^4XQ/6ID._#Z%TAB/EEZQL].:5/?=)'(MEGB4WC^<,YXC2I-0
M0X-*N)&.X<EB3A?*;N@0.";S $BA\3ASE8O6<J. P)F)X-4(]U"@:[GT1]1[
MJ/6NMSY<JV^3>,Q&D@JK$X4W<4?>%UK<Q=BPWE_*/OF"_/RSAX:'"++#"=WP
M&X.I;+#RL;(J<80J?FRBF>'O]68+ZQHT2PH8D*IH-2?0KHLP9FZ4AZ2S5*PG
M9_-2PK&%N/$UMO'8L]^5S&I1):D).1C96O@,P:.CA(X_6#].D,3T &QOE>C;
MGC[#+17Y*2R=N$A4MJI)A70]S1)YV1##=RA (Y-DW,LO6$+,]A5X<)BDT3?=
M$J^LW3#E^K#BUL*%_1WUO%&2IQ0N4W[<'[F9U_7.SI>&#I^V")C?S49($<Q[
M*="*2[]$:9<$?-7!R_Y<U/#E0<5^B2]]Y^CGL+AZ3/]:=FJ\QWGR[EO&]@G1
MF-.-;(S-C28W5U/\AR.K.(0'J5G01>6O)=4:A*.)34"&_O%"I7W @,[!QL!:
M=A9WN07U^$J0/3B %B7H'"J\:?0H^<_8D(>TAZ0D4T28\.D78K[05S-VTRP)
MQPZ'IBBQ3SCKW=_$]P^:!Z1H!ZY?TZLA<U;?I/+%MY7^2=U,!BI>R'^)7\^N
M2%P%36,6PTLLS#6AHGJ\=<P:, F*Y^PXS 2$/R1P$[SZJ&[B:7YNKCY8I$D
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M$:LWTKMR]^%,)41I;YXN0R_'\"G]Y32\_S@].!,0-C<N 'U7P!8&C. ?J)6
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M>7Q8[/0DK*%M?&.J:GI6=/R9'F*E!CED^4WG1EYB<%31K.<G^^%/S!/G_ND
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MIL*"+SZ>>*)JX^0+RG96X( 2RY?&R9 IHDJ7'#A?'=7[I1MNE"-UCJ<-4FR
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M2F[Z4%+'M%K5L2YFXS?!4+'N>"K7@5^]8(?>_TK\9)3K18*GVY3%ZW'A8+,
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M2T#]"@L>\"/@/6#?B^K/'-55L.C9_[6N-MJ7KBO+UX/*#5%GBX[YF?!-&(.
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MS8G Z0;QY:A"]XN+FH[L:!;^8?R>7DTEM$Z6( @[^DQ;'452--P2@MO%PN)
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M_2O,28S'9:);)5CX5%G<EUI4?KQ_3Q.8BBPZCLKU*KET-3Q\,PH58\ZTN@?
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M.%S=>1W>8H\E*O?\*@#?H;7IM3GTJLZNS^NR>?EQ,BW.:.GF4*7A@G:Q723
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M;0^52\RT;.FN"8_"T#Y#".C7_Z2.^>PU^ORA0_>Y QXH<% #G'%@FO[-7WY
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MTGMR+'BR'WFR0];%9F&M5*VY23>^CS>VQ>EJN&,:*)>,Z*Q-WAL^A K#^R6
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M.Q/!U*@\SH=)0.8:U:1E5#N)<JHYMI\G=6::,,G9.!$..;+ZIAF&04=.-JL
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MH*+%6J1_Q==PW=G7B4/O/6%0*+=W,UW@F%&G86P(>3[.)!GXYQ$-09IZ!]A
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MW5CK;XI\=T!S\N20 ]P@##QTG3\M]G@Z*$1YS7^8-"3([#^?SW)Y,]MDKTF
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M3"[3'T\WJFZE6T$:@2X+F-J_.8=,'0Y2$P;S7RV[?NQ:8H8&';^.9$K^_O'
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M-FIQ$+/<Z5H^S6J;*:#$B23[>#97IY;Y/&;*%/MF2DB-W=QL>?VE68A04G;
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MJ7:UQQ4%!3RGHXZ\>4VQ#JD%CIA<G*])H;-X-YRX#KJHY4D$WB7.DD<T)71
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M?$[DG[K>=$V=*U+G_@:3\2TA)FLKJ[Y3[KY!NE9#8V=#39IZ(XW\V/.Z3 R
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M77NXJZ@D4JH,HC4R8G]U!R!K1 "\] RY5[XZ=*+J_<LPU\TZ&-TTSJ>G"]H
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M4I=\G/-;N#'$?[L@VN(3",D(I4W><4]93P>,_X\F7UP. ATROER4HSVF+^'
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M"_U4;>IMG5W5+7??W)/$?2R9!1%1),WMXI1SD%@L);!ZQR"=%MPMH8#(R4\
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MBFGJW&@UI.>WJE[CTNT,U")L(425=HUY\XQAG"<6['Z,K=U,!+'-760D&^(
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MR,?9.Y&)E^(ZDX3'H5 0(B98!<_N&8BL&V7'YB_$ULOT'()SG /WZ,Z#F^1
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M)1*"Y-'23N\A.&M_W6 NT'33+\2@4<*=8].4;3W*S+Q,R=Y?<^Z_P=?'/X%
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MZ?^)-C2NVK$7K'C<ZN9M.6,7,^+%,@\)D!('\0FXF):;ZB #4VN53<V-W"\
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M_S(<[ 53:TT<+[6IV"9J Y K>>T$4]LC<4K[$-?JL>#-V4@FZ\  +^RI7QY
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MTQN3U0EGW@$E;@;9RSEE=L8U75C&2E.E40OYH:6UXQ$J*3U XGAW23P!M\]
M?35L6R:LPHW%O@@1&YD<1I(\2\\MHELE]M[ ,92<3WK&2&<_4$_.;6H.<UM8
M8SXGW:1XY2"P:J0,?X63(BB>ETZJ__'(<#>:3=O0U"[B2R=RPR*J]&JH+LA/
MH:4E<FYYM28VV"HD8I8&Z::.C\B0X!G38_N/:0WQ4<_INJ&;5QRW&:DN=9#>
M9FJ5@_L8M'-"RG_169*D4Y:07JK)H<>2P*:"$8[''C=!KI<X;@"S\5M92ZC6
MS#&R9(&EF0&X/2$]Q:96#>,CI3 &0A)&^V"F &W.[Y?>=2BN?F^X;PE\%K2B
MH7(5E+Q;7H[CG#"SD^JN*++SLK5X>.=W*GAJ*S5UKWD).GAW6IGZ<FQM/6UM
M!5,MFQG?BN0F0=B]4%D%4@#5$N;]ZPKTNC^,Y!)'N^.#)8/F^'0GS2AMO8TN
M(!F>%=;7>$SV@E6< V#37%:9=Q)7H%"WJ'(ZH&3H>,.\RX.I':%;3/G'D1#R
MD&U+I1.0B*+0O;K%S'KC;$U2S6R J%ML%23,=\4:TO+8'\\ %NT\$B'BU&!Y
MI+ZG&=0SX*!BJ=+4]7S3XQR5%M1UL;C!Y76A7EVII="3FSSV5CHFUY.5W:TX
M0!&!#Q@*:)2P+&_.KTOBSKK.T[5U,T].E_VQ0(QC3NE@EX81%[-/;\LD"U6^
M@*N6)J0 ]C,J895+BD)^6Y=^?-[W\3 VH26D.;;<>5Q?G;;W835CA7*-=;/&
M6/W>E((IIG(GS69C#[G"S8+C*1U$^^4M*VH!UI-ZC_>-M8US%G@G3DS&$7,#
MVG6@X;?DL?!:W.Q^S2LXJ:[K)47/)'(ENKAU;=+K%O;5[)F,JR1Y??BF0J][
M 6YJ&J[E[?G+ADQYK9T<_$E1+I]*Z"/S\/V)O8O>UZJNZ-965<_879'HZ8FB
M7'3I0>,?A,D1&\BX7S\L78@0Q6NXYK<6&!H@Z7I"QZP>>[0I7"ZP'H:T -V+
M%F7ZRZ*F".FNY!\&5#JI?UPJ(U"!.YRL7GG11T16FQ8NRL'55.QTP<02F'BD
MB^ZZ-2"07FEJS>[4S7(^,2AIM<W[Z(58P.9*!S+*!B!A\@(IP9<PE1(F>_RM
M,TU+US%%I33;OS34$N'HJ_J6KF.ER<]F9I^DU*JG0!)C.;P!F&L\/ZE>>;GL
M764BN6B(G&E$FK$]%<TI%.\1=5*T%/<#LA.& _R:4^I!)0OZ"X.>*$/?WUIH
MZXB8GB<KXK-^PJ%<P89Q"AVI/4--]71$9E.@:.U*^C86(/VUP_083YDH (U@
M(R72$,?JM'6(:[H:4LUX0(S)%V:OVJFVYOG0']ER:@4T".V8?Y3FK,Y+5;^8
M.M_GM-0BE6!CI:4;[K2#1Z"*["LQN(V&>C1UX8&E#YD9E\61='^Z^R[@JS9?
M'"*LB9!(X&@JS92Y2I/JOD,JEI[D-3,S<YS5UGJ%5HD35>217"JH;9V/;V9%
M%;*LH:NM?PXON92S3?I[$F=@)E6T8SW"Y$/O#L//N:9 2Z]$*1L6V5$G<C=(
ME$1CTLQ4EVWO7;].]3IR!JV*7'@JR] %20\PJTL;P'OV$T_ )^#([FA6U48B
M>(8'K%K@?"'4B#;E4Q>1P:>,9ANX*AW5[675O=78T9A*T\,?_ "/]U;/%37S
M57ND@%<H8)>NU*-%SBA%O78[BT&'<23&#OR:0O^P<<.!C,4PM:"5WJ- VLT%
MC_UUG/TQX;)$0KT+E$!_M%\0V,\)4R&A\DUGNIPS?R:G.>HP+'VJ?@B/&%UT
MD\QTE'M8?_KDN&T4MHIQ2[ WTHJ4QO7Y_!O0X08;)DO"I""L1H82,V_/JA[6
M^@/[I_!$"+!ND59XF;)RUUG9!DS#[Q=:ZK)"(QE@M6F=##)W&P"4C^9L$U_X
M._Y>Y(E)Z5(2(/):L*0HPKG0.ZM_-MT]\,_'P!)&;R^>):"&#RC6AO<.]>6Q
M_F]Z)Q_5C<MLDA)Q!P6=(5@-LID(,*&Q#;3D&"LD$B#-Y(7 _+=GR*9A0A;K
M1&#^;DJ TJJ#!,#-:R7T$R=1LZYM;8J,G=+06V4WY*!ALW#DE%\5G/^W[:Q/
M-DT!'DJ]FO61;/9%VIS%;)W@M]-G'^^F@=6%]LSO!TV%^I:>Y3\].(>O6A*4
MXQPRUSP)=.O(Q_2_;4V1.:%($2=4H%E:(ZFK)^#M0W7[HA.S>]/D=(!UAYO(
MC?6+YYZDM'=&%CMB%5NYT0"5?R/##/XYHO %8+M;5_^L&7?]O?O.NQXT_FG5
MHGP>QCRLC+(38CX<8^H2.=V?]EJ61IUH!M/+O=<6"NW/\Q&1$Z*G#IA;[\T#
M+[^MXS+J8 @B?N7EO>[/'\HP<GG$W>%#QY_O[(LL?Z:7.-PQM&.3]8P![G[H
MGZLC'.6*(EY@+@0;/?=JYP5]&Z3T# PV^/K*.4I9B Y84WJ";K.RH(,REK=Y
M]RR",+Q2[Z:%VL![L*=59 DJ]EB^'E<)Y2O[Q&3\0)WV'=G402"-19&71&".
M-)\0#=&CJ@NSKV]J"W,!4SJ*&HG\O3\XO5J$9&-1/T*;::[?-?6#=OGC!'?;
MY^.Q@GFNC_)SM+/V%;A(TG-C<UM'*98_[L)WX:45&OH4W]]\6J^VFZ2^3081
MAY9'Y$F7EK(CLKM05+D,F$P+"JRG/O%/X1\?G3!O!&NMP^2HA -$5E$;]GH!
M[C.:&*:9A@J@W.4%[;WKZIQ^P?IAMR.F+E(]X>.^HU_CC#9CZ?DZAAXO@!X.
M@ZYZ4IGZ\XT$<8HX=(&??F%;J]>#5YFH386&^Z?6-W/<<501U)?!O$, $7)+
ML%]?HQ+6^V3/_ /57]8<BXN08[3"-3]'^HL@=Z/5=\"O^"1-DR40J.&*AY@M
MU,HR=N>512QKG^A68/"X2JPB"L -Q=&-R[P>5[N:]83GL]7:140J_^4.ETVC
M>\V7MK=E!;$!B[L@O/B<-UBC0"M@9C]."$*R>]:"AZ*)CM45;EU#Y\/$!_>X
MPS?QP,=0P"4_0\@Y,U<[CJW*DG6=5ZA.E02V9G45HGH<5?:AG2[!4N=ZDS#J
M+X.])FS<E+1ASC,[HMGAQ^;(R5@87GP2 658X=-XZXU>ELS![7Z78D0WE:U&
M<E9EY[2-&3<N&Q*#U[70B'>JHD(M<@QL0&N4:02^\36]O.-(2'^(CWS=Z-8R
M-(SOB)I$0T*2,D-\^JR04\'ZBLE/:V8U/*]C*K[F@U-LN:B>7XLPXT?@A%6%
M\+2+@KCJZ5+$5E#K5Z_ PP;"K&9G 39A[I,ELTW,/'?3\S*/,M!5!M'^Q/YD
MWHP;FUC=W 6=F?*^W/OI3KX-X2!R_A2&,2[,,P^RGCJ;HVL!(5&*.NJ0\QD9
MLH'7AP4%>;;[W-Q-W,UK=S4.E"G;:]G),UOEI@R-R>-G:?Y.SH.C /O=^_KK
M$AO@X'E;O\=UNY_;4R;)$CS_91GA!B<TE4&!LN=\/UBIVL]VA,24D> <'8[(
M<W/5= 7,H?"3P?H,?HJ!B5F!@BB5]L*(@;"T65&]KJ_'S"P<[/G;\M=H8A7H
MHJ$=N)W:)KYFG-=4NO8UH1T>.FI^3?[0O;5!7*$D/ZOE$L9PQ-([K^EP-]7K
M[;J%QX>!_J6>[ADKS2Q2$0[@!8?3*92KT20<Y&IU0R*Y?SP_WFQ!(_,A[(*!
M;3/< <&(?J[=QF7)Y$9K]G+W2HA;%!VS]$=*!UTG'5H)\9:TT"ZP.CN5.(S1
MELJ2?I4]0]EZYF_[4.HH4IJ!\HV5 2XQ*=?V-.S^Z$0$.[0%.YH'/\XL'X-]
M>%X QA@O@,P4P$S+_-NZ&4VE@-<G]F].K)BZMO >1K2"R,"^11"W6O@L5Z&L
M4%O=81\"IG( *O:E<8 XFH."F8=+E4=_3^4BV4K-SZ8 3[;#.^EK$KI&>/M0
M7$-+\A^<-SSX0MCU0VCKSJ& =KQ0E^$H=.8HFQ/!339V29@(V?"$); 29;[C
M<MZ\H$3![6?H:'MTDI&L*/H2Y4:LR"7 21'.S$ 4I[U' 9/!(Y:NMZP3,10;
M^=R#=#.E>8.7X@7P54DM8TB)5Z?J-7=$IQ,JQSP!"1U0I6+"6LXG>I2^QI:B
ME] NI@H> &P7%EW<2"FQ+N]U+$[G7I];[SL9NE 5\,]HT5M-H!M!%0C?SI_:
ME&X1MJ0J+PRQ"1_IAQ$1C54PL5I[%%V7/'LM3A+18K'<30EOI#3Z;ES$"VU/
MA 0^SY<T.6]Q>?2&:=T:<8SC2]IG(7H2]G-/3B3OI8]#D1K^"BR)B&JPEHVT
M7[0_OW\!Q) I7[[7LB_XT?CT#LS?QMU&@HO;^?@D)E$G$2+'^O%F0)G]LUXX
MF@Y@<L)'W'J=R-JB6B;[_ >#%'^0<30^\2L/\KDR1VZ>Q'OWJ/7(.8'",BX&
MB6]/%,O24JGH=XZMDI]%HXI*2'&GF>RX].VNM]]R3NQ/,[XW0J;HFVX4W>VG
MI*T8^JW?RXN7?>>OZW\]]S]_V[1_,$P1GK/K&TWW<@:GEXRU]9(V9\NW_SI?
MWK\AC&'PN1[_F3T8L6R,OX C>S2^IB_OF&N(A<L;HX(E\:8X!T8DU1\.X%*C
MF:R[5U=TFG>E0FJ_P4+% QM[FI"V^O898P782-.4>A#!?WP^MGPC%Z?9YJW"
M$XVA32G^:";="4-+*>3MDHD:&[KJ8HNT9-^ANJ SO/6#Y1<NPS<!'6J_*WE-
M0=-(CFGL^J8JB(>29I3"],J']@ MU6W$39BWRYK;&@;PF@V FTS4Z] M)A\!
M;]LR+7TM+6N(GK(Y,USM<&4ZXBKK^3P5J9.B;5XS6,[#O=N::]J25(\:Z/O9
M3>5^ G9&C;MZT!'UKLRB]M/&\(\L^XJA$6&=E+]31N24[D]8><E#@J;DJ)2/
M%BL!6L=&.8"8Q=G]'4'?%P"%PLG#Z6\W9C,3*6I=%^ZT_?K>,_;7G?%I*,]5
M)SXM 4+@N,UL1$],284D('P^S:-2Z=NGJP@._.FK#P\2Y0@80P1R!3\IHQDF
MF=HWILAN\.Z486LTV4&>PF<T9VC/*.T/^4UP(>:5Z$T#H9-']$>-_I3XM+2T
M*S3^;*E]N&+S1^T6S?SVJ5M/+11W^H[-1+]=!P)H^-R3 W];1M&N'QKS95%0
M?%UE423#%X;7^'A#42QV/)B.-ZUW?6CVQEC=!;H2//<#Z^I^A0!" /B?W7PM
MM/'J(31+G*CYJ*>WQ"?-M IH7C4#2P-@!JE"V[7YMX-=G4%"M9N)/'.?=);7
MN5#J';I?%03#NF4BU6E&N$5MZ^CI"()J<](EO8#1:@F4X)Y[UQ*N'H/!(MLF
MFMH\&[;.IX+<&F<)KC:W9E.O:#3R58S;V1*BGC.RD,.*3L.JO;E7;CM!*<;3
MI\J?XV'F)@W<BQ>UPA1XU"=JFL-\]E]O[2O4<.YKE9@E7N#S"'LX,2BX'"A(
MK1OD)ITR]5A;8B'F$D6#D^D]>'<(?LMP!,[V@:NS_:HGB&G;+,0USNQU=/F
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M<_0J6U)_-P*96*Y+!;:-(X*KEI9>6;S6FLW_/FH*Y9M@^E7W-$UTFR3+^ ^
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MO1=K-?M<$KUZHZ@>9>G@_5'>][%-Q0\L?=5"XS[W !P/&]F]  &:H.#C+:+
MLT19FZJ_(5JNZM?D\?&YC5$)08;EJNO;AQ[OI8<&.IP9$DB=TO750=]E"<S5
M0<\<R-1Z&.NM,+:=AR2>IM[_SD -W"Z7S0X012T?1X-,Y!:UT!+(:F!N/\+P
M#:+R#\!^S>EK +/[<I5<_/+U\9;T/O02'<;1/E7I0_CYQ(W-VI,\53T_%9TH
M6+S-NK4L5;+HY!MH,W0MY2N&:%&G^]CV?BXGYLW1RERZ=ZQ$LLHK9=R,SQL
MV10=DT-#F0_0DK7E59S^"YSR.^B,E)P.+IV<<+&F/U*/L,<C+RH%<W&B$QCF
M]UT^RGA6S(Q?CXSJ>Y-_HPLW4N_+7X+MR M8ASDKS]7O==R1OT8UK*F=XPS;
M#=*QNT$G]:O%>9FD'L\*NF*>[UG##307C^+@C@\J_(.T4EZF:*9R)4]KN,'
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MWP0(MEC&6VY=K>!JA7#\;7\S;Y=]@N>'!/O.#&-<6K,@HV]?&UI\: TSJ;R
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M_&Q2/>Y!>-SOAK?-EW-5^OTM4=FU:77(&I-YH8+'=4,3EO#+Q6 G>_&H]C^
MQ>J"KW#E. MU^G<J7(SQRS5P$2RZ4T4F*BK8@L3!%CNAN45EC]8%D?+ 4D3
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M)M4( ;1/!%G<?6NT)/733K6G+Z?.XNMO#&4"EY^#1C/C2+K%^!N4I+F8WB,
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M;@GT(79MH3'=<\01+.(\R\%W1(L[DU-JZ:YK&=M.U+XM@R4QGM9[+)TI#PL
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M)K]0W+P5G&Z@7'C);B\HV 3\3CM(]OB09Q-TUEDH8<G P;GQ9-A_0TPKV)1
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M^;J3H[PK&0DJ)O#HD?MH$/"_<'C<D'Y?M!MUI]NM 25==#SA'F4TF\2R;A:
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MG8Q5F*Q/NZ<2 GPL/:X0J14EP/6:UP--3E5^JZ!Q+!M;_$BN?I8XO]WQK=:
M#K\TTZE#[F%U%Y&VI<7!08U^>1J5KB--_VBE<<CA_\'>6T;%U73KHDW0!$N
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MP^PU1_V P)+A_#J:298&N3)/_$O:BULYP)D.10]!U?FI&$ 9=3E9@V!U1=Q
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M=:-7O"E!2R[6<:']^;)_9D)Z >\9@&^GO7%GMGCH>31:)UM'QQRDHT_.$PA
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M>OEQA>YD;32>_5ID;A99S'NB'6"<TPOZ16QSXX?I!BJO/K9-"\;,D^81<6L
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MO6+%SD_&)MRVO=DK9!_5FR706]3MV&#C/.[(HM-0]2L4Y:;?>]];M&\$Z*J
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MJY,J#>J*;9+[@AM%C9GI4:IZ.99:\>.W>/L2<YF\A2'SW#*.I&:?+?G<"4/
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M*<&Z/4\WA6BJ'%[*,+9\-BD->T"'O(X)1-W/T$GO;BX_##'"GN%9<,8F"DI
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M$[-2NC![6_D$SG. @=&?\C>D?J&$L/IO9\:64!F6^QU:%I&W(VU\W0!:!36
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MRYH=_/B0-CY7]OV*5+TQ)1%LG4OFT5)-BH<'4]D[X22%*0(BIM=/,WJN^]B
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M;9S!S//FV&4>A:GMY/NQ0CFJHJS,P=FY8J5+>WKB/M%FRQATAD"=&F?)C<>
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M2N?61>8)(-<!XI<64<,<J1>&'# !4CIKY7Y9SA$D-^X]6GS[C_Z2Q!:D?"D
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MCP#L7Q4RJ-QKUZ=QKN7ORI)9 U8D(2;]KD'3.#2;Q)EHJ01+TFX6=.-?!1.
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M$(I6]$]:34OK-T^ZD0[X R$SKT?6UL8\2JX4+.L::J,5 Z!#1..7^+6_8,\
MW-&?HX-:6<5>*<]L ]GX;O6U31K^4E:D/DE%"\M?XK(%\8P38U.2PJ?D3#*H
MT=42)IISL!V>/@(&NS<=;AYH;G"DJ@SQ<*[R;LT"47>^Q<GA.EI$DJCT11;?
M:*L3E3^39XN5HG3@M8^+ W#XRE,I,<YE5ORRI8+7"V"44VGI] ;TYG:?2%*V
M1XN*%/[0\ZH./]1LX3B8KHZ4V;:/3>ZFW:CI8@C4B1]Q=IV@N'Y:PI2(55 >
M*FTDX17:-8%4UW5B%.)A!O3'"+^!4J3TVF/RF72)-XE=?X<-3(]X+,!-P,L
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M_0CH27:HQVB#0T2ZUA Q7'MK[KPG,3;0SF9JRCF[AD: _@IP +-N<C"L78(
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M&&N.O@[!SC$!!M0+H/V-%OL/JK\VL(:97M^Z'DHA8BX6 OU]QOWLA?:RK)_
MA!7)ARA8\P##P\X88MU%ZFH$3%#!.37"/S;(@"-4X8"G3-__\_$OA:^VO,%:
M;\PU8Q;A(Z":/?OAJP) ]%\J7X.U&(EMPX;?SZ&)CX B+._]?[B<_I\>Q97V
M%4<;O$8JE/BX5:PA:E=I24T?P\G%"TJ!",["7L8>R6.+<%K=:,GNKL-(FO$
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M%5@/F;9KA['."/X=0U96UNS%K%T6!%[FA:QGG%V/J3W2)2C![S0?OE-_]F6
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M>A%PX=1#OAN2E95LU"L6.U(/=XK(9DWU^.!)ZBO3Q_SNVP 6*(SN>NH#X,-
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MQ.'UT)70Y2J=)\I286T;36JA\\.-U!V<;!JC5-USU;B#B[!D05^+C.Q3A-7
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M[4UQ:QNCSL4'7K]5('G5JHWUU3U_4P2P[E4)/U&OF?3^8&=@M.#G-[?U]]Z
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MI'<;PT#]&U"U]AN0 VMSIJ[P;(C^;/2F\5&VPB#8H)Z 8=,V;4VY)D5/U#;
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M3_J\^@TXAHMF=IP_S%;8&-9Q#B%4F80-KFRB34QA8QF<X\4R2>&?#,JCV[Z
M7,CRM76Q=\R?CA*1:_;ZQU9^RVN[@.0A\<H*.#&I!Z_<-0&V6)(MTT_K+PB.
M9#%^Z%:K>4(-*!8]N!4.%5:UE:0C50#;YE/UN]\2:0-N#*P35/,4^>OX3P8
MQR+2R8]V6CQGBD8Y;O1:=&1#;'260?G.'GWN'>3!B%O.-"=17),1C-Z0I /!
MX-K2Z]N<]V3#],_/>'!^?9VJOP'JIU$VVB%QF^+IG/"MH:ON1-2L@B@PWVCM
M=*5#Y,9=;;XJ>L 7)1P=CR7T-][7X?/PV"CJ"@IJ)'KM2_W/P_YEIP@M7\3]
MJ\S7]TV_ =H&V&\#K?.I'P_+YM78C@J#1,<< #NO=6$%67;,G0WV9O@PA;KG
M=M^74ZC7Z$\,KA]'<7HU5YI' 3W3:+\Q@82:].P3_)6P<F_?-R3E7W4PM$\(
MVD_#M.LRE!RY5XQ5PC"^5J\3RUFZ)_2;UK?(9@:*K];9-AF#[[:C;1>)8BHE
MK[6P5/]2W49G?L>;PJ.?8 /91C)XP9SR5M?9[3MK%C"A9B);YS#K<ZR1)J3A
M<VZ -VB\_#,*=!QJ[,S*>)3HH>M954O@TZ=H>%Q+'S@F@A^4;4O_(2)8.)"O
M; SLZ[UXOVVI;&V/AMV%*]S*MJ-IK@F9-.$6HIAT$=R 0%R)^[AIGO;?-@Q^
ME^007SG'"G$4#IH?CBM..QM[]QO0'PGJW,W[\(OI*_WD7Y604#27]^3^.EG2
MT+IR4%$X1C^AI<;%V7<S7BQ&UZWV%=_[66'$O?IVEB]X\(2HOQ/L?%FCZBO]
M%A='VCHI6'JN (-VB8+U7#@[H' 0*#!O(HL_P'(B ;Z3A2M0!=R_;;8OF5VJ
M#X4>+Z[WRL3+L7?\>%B;]$0;QG&?+$%K70P,('DBNE0*A^_'5.3EC3E=1X\U
M*,K((.GL3J8H@ V]7P0 EX[R8L5 SH+.!J,\&6+!(1:68\SY3?!,UC:-([RJ
M9XU@M-0<B":>GIHR^<WBBY2R+7](J\@ZZ&N5S&>#)Z]\%H=R**1[@^Q0)O^E
M*_-?EKLN]JFRG];3=)% ;KX*V7C4?8S]Y<(]YR.=+1=(M!2FTY#T)DE#V<.+
MS$(OSGY%^;LHE W5I:[KO*K^BN_J1J+SA=U"X]^2UR)E:XHPB@MD=+$A'AC1
M=H1Z,%:Y9RN$WL$TD5N7M6-476TTGVY@G!]8BQ;:+JEIFG6ZJ_Y!O:/5".B'
M&/$\829Y]>OINX,G9FA$;FF 5+WZ)*WQ@XH5]EICHT$22A% ;;P <D2VT"XE
M+:B]O"&S"I$7PASP\9.S!=GSJYH,-ZT/W29YCLG3R$QSBSI^HX%N)D(I=\H-
M:JRD8%<'\06=%0GS?$,C#8+,>5+QLF"Y%=G76>TW- !8VT0]4G;J8(_K 5F2
M%X<;AR 3-)NKZ]H:]7FX&+/(&2O<H=2R]"(2;T7;% N-1IA4W;_+,T89O.*V
MB!U$ RIA]HDRTF4)C"C[/0PB9??0CCMW&A_[RP3QUE*1JY>A^NL,6"+HI]0Y
M..]48.NUJJ*<7%E3A+J8X2K/SXW-O 0/]A"/@/15L^#[,5),$,]S[R=8HFA4
M6$*9OP$XWI'GYJZ-K:M0XP+N1:U1*5?*YV,7-5D.9YM@:TLZ'K<7UR>?=%GL
M:30$CLM"->D.V5"<!<%B>P/.%5RV_.3<5N%&?EHODQ)&441.!TL9AJ:5F")4
M[0S95+[FVW6]X;A0HJ]!T+/G'A&F"#:?4;0@G)P1S[AH,3_7Q?!;NHKN*7:J
M&)E\4&]K5S4*")T8J/CI'#MEC3>93TS>?U-P- +0_(M&^PHF%NT*M[(\-MRR
M? #*+.[6:1P9O9SII*-UQ%L0CC8CASV;"$=26T+X5I&;7E*OO]&\/'&3R]+@
MAOSS\%X=:6GV 85N#4)>/Z0,Q3JLHK!=== 1N;B-2>+]6;7J9TW"=$$C)'3B
M$7D%7Q<5R\=8U)@LY>]EKR_#U!LG66K\%BK7$"W8*WZ/-]%#4<,20@;I" 5B
MHE*6]&I:ZIN;(P)['/:3ZIAY4@8O0M!MHP#:^=O1 >=],##&-'+1-\1G:\9;
M((UU0A!1GNOA40P?$8$^3<2P62MFL2FJ;XVX'N4HU^7!'V 09M=SSXI$1],7
M2P%7_ +:>I7<10#]*G6IS1MC>_I;@^52>BSOIL8: $Z#Q0;J5A#W.41[63 %
MYF<5?,_N-;)?CDY<Z\J,#1&L(.GGU,R ,EMQ67K, ,_20=R"FN]TB0&Z;]X_
MF[!.%%+-K[7'UU8;;XI0V K_$AN9"R62+$&]GH,7>"BDC)<9\]E_40#$)X3J
M^[!XC0B;2 T%"-5GC>(XQ0.JVU2T9;;#F>GT) / (R]B296C-L\G%L5=^&(H
MY-.4\=/]N&@#@XG:>$5W^]X=F38_"\D9\7-Y_$V$G9F M"5HF7"U7825FCD-
M,*[.HPD:K%BK@:CJ;>3HOV$.TJ,J9:F'?.FV;OS\ \O3*/XQYW55\8KQ?NNJ
MG+W7 T8X-C+4]/PY[W>.I+;&RP+EW#.#G68=S@V_P.2!S%?CEB-1^EFL:C&A
M;[^+2-6C<+8$?;E(6!BQ14_EBV$9(TF5W9L=V/D@EJ:?GT89967 G*#2(C)@
MYLL(6JVS/&)(YCQ22.5\-7&EK6+N1A8W-E3[J#HC5$0B(6J\J2EB JX:_8V"
MS5)G=,^53 LMD6TMW.+5VU@]AQPJ+3%+AF1#F!+,\XI&E4!J>FK6B>OO^@E:
MLE7;,,2(F#I3 ?'5P687B^UPEWBP-48D5D):HI---QZMT: M @/!U'U#=<!S
MX0M5"/J%^KIH-EV92SVYN3&Y49GH2RO=EB@S%2NS8$J+=7BT<VUM8Z-3JP"^
M2C:W!PA+[40__C+&Z+).OZ:SR1M$BC5G%H7&?$)M^T1;]5&&5186O8"ANV^D
M<K0Z9)*EX[,3=P;+:SHDIT>7=,_XE@A4M ]@&*91"VE.686/+E)OL@QRNK'7
MK6\E8FH*T5?&%>F/VM3"P%P;C&$L6NQ\6!"9LL^KF4_FQHT'GJEW-@']*'07
M8([6/B_H#HGH)@U3ZEP\5KX)$8CK4VA%:I_7.%NS^82S:\6L)X$4J4< =L/_
M03*(Y+ 7G]OBJ.BY5KXBHN6>6]5]6_JQB$6%]3QL$M^VTT'P-X TJ+P7#LID
M$<#.X:W AW@X#Z.U^D')K/!)0^(, ; @(N44^V=)JK5^UF-?D<[AV9+N;B.J
M?L7Z.^QA6G6-+=C*VA(J-^^_T;U5OE4N--)D>6U<?6RLR!F-5^_&QVB^CN9P
M1J_4[Y]V85!3G495^<R2<_GK:L2SY%G" G94MX.)8"XY)PS(;T!=#YVII<L'
M+M1]YV\B.[YT-Z^=')&.YL>.X%Q(M.@<OCFE5!-YY(J)@XG#EIZ'.S=7;LN<
MXUL9%.%0++3L_K2)MIGZ7;P5:R]12G6JY"=*F0N3&8&YLISN1&@9J/[XX^@)
M#R!'#WK,)37%'4TA4('[F+5T(69]_=Y+PGM<3K"V!]]MD ]3[PV@F0Y5T_\/
M@V^KW UOD]'"D26W#J4+F^UC$;PO6S>S8T+^N[IU=<<?:^OJ\SW=NFC5]CH7
M<8,S.R[[F:>#R1]\.L>:'WUXF0F)<J:YUGI6L;? R-._:41]=CF],2HE]XY,
MPW#'*E+:'I$)5"R(?7RCM<A61T@\W-"A.\JKP$\8)"\&,X5556& VY!;@N\M
M.!/$_#[?;7 "S/<%9&B$-/Y0P;11>FQ/)\Z'8G];_L/<M"H ?5Z]*TPZNV J
M+_6+BWK:=K;'7+,=RN^&5$LWA>5&3"A\6T)^[EA@"E_WHZ0>D,>HB7-F0UWX
M*U45C:;&T'W,T!VJK?#[T[_WSVHX>6B$CBYN[PO0#Z(2?QH]?BP33,$Z:0DZ
M(^MX-L%8:]2\?_M5[3? ]IE^)NY@J'=M0O*R;;RT(: 1,[48#A]T<K)TPB>U
M4B9S+2M?-UM'">LG9S: MVE!S\?K7?GKE2S1%?3VD^D_(4')J1ZE%?"(U'4'
M_CG.B9:[-" K@4=(1N R6;_Q1?'P*ICA.3?Q@GA[G=AHC2SS5\C=:M>;E0_P
M[9DL L"[;,W:EJ:HU<U1G**/862)KRH&9,?08T!!SQ.V#3U?%!USX+UIL?B_
M)\4*V,%Z_Z-M0F<J\-*ED'9=B4'+DIDQUQ3GG%H$:73XHZX[,<>UDA\M5^'V
M;3#S40YZ%G:EF9VSA?+?&1XJ)+MVM0S_6N'"*"^8N;$Q= (C8IIJ^;,'1&22
M/2;C$*M=+TX)9M'Q(L'^O-13OR;33.M*4F//EI7UI/S+ P+\IR9L^[S164VZ
M[L4GG/8;!2&8&^_VPV8#WDQJ8:B:<&C4?"MZ>"XD&4J]$J[]U:N+\34TVZIQ
MQ!_BB@>A>H'Z] 0;*G4N,&Y1H2U#MC8A.%L5NVX85&9"P6FK3R;U1WAF</!V
M^X+&.G:AUV-ASFA,4/]X/?&IC1I=# F_:+F@%KJK40\0.PK.$L&KC$,3CL;*
M&K*O7(+0J/7*-!U="!_\L=Q;//(;$ #Z0%,C#WAY[CWQZ57*D4A(F'PSRO'
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MTTLU+,(SI.?J:*K[\>6\!UCA5;[2O767T>H&W!6VH6;-]H&)U8,GCXY)--Q
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MW3[9 J,QRI@V.<'X@03U<Q=N!1WR(VHLK X"*\3VD?T%O,VP#U+1'=#,;1[
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MN%D=<ZTF%F+D',(]H?GWY"]L8=\:_YXP39VM7N @R/GL.%2KI1_/>PPCXRZ
M,O)9?N$2U-(>%S#%3LCK &3,>4@JR4$\2:"J;/,'T*T./$!(*S?E+O?-P6>X
MXUG_!9RM!D8E#^8!&PE*O9Y.E7SS$K3=X_2X7F8_G,D#@))\3&5<9;IRH@J,
M5 ;@(P1)\06-=I<<=FG0S@C<O<GZ6^2?4KGOO@M13^LM?;!R2-G2!'-QQV#W
MDMLH.U/-RH"LI7\^Z;?8(<0IL:X%^B]:-%O0\"G.OWN53V%IFY3^U\MU=55>
M)R]IN6^AEGZECQ /LY-V>8_CK#WR(I4C 6@I>R-I$?#?(GFJS1TNN_*] @;J
MY-0;X#N_W-![9.:9U=GHB;K>*O@\K0"VR29,1/V:(U+GJ)>L/Y1/QTCW)FYB
MQE>K'F6F&F)9I.[^.!\R9%H9@BWR7X/E/OU-.7MT:4&&6K+H$1F>XJ5?'2$2
MEAK2+DWJ)6W$:5+V?GN0]<%<^O>$!F\Y6#DF;5B+BV_%DL62,ZQ?LHOUSK\"
MR3 WRL)]2OR$"*N@Q.&:W!-%+C#NV1)*_[R;5.M+5SYI:^R@/.?,>(I3V0O;
M3$$U$*30=(C]T3K@FDYJJ'/ )*O'..KV*H@KW$5CD$H&-$[KJ305IJL7?]JU
MEN@(5"E3+5*DZ9"HJN7*$^,E>LKNJ.W=V>]],_VM&C?P(E"C*D[V*SW&"[\?
ML%8F-7[T2UJ/J+:++Z,<[.+O@?2N;CDK&$Q](?(B9\U&%MK)THA3J6QO=("\
M]O?W:U 63Q\K^ CES2V\KZ+D9L"CBND3&>@E+ L0 2U8,&I$\5(O)O@],V7"
M7\G'E&M+!T[B-U&GD$47M/B[R#".9.ME#SWS*&@,JL=A=5OII Q_D=(EA^_\
M07HK,=.E9K6]-:'7+\/.7CW3PL:6^*5H]\^>" 5F\7^YXNU9_FK.IE;XG4F#
MR8@TGC'\?( S;$#2DO2I.!EY7TE5@^F"!9&D+?F0_U:9\B;QVE>O?-@7M8LQ
M@*N.:7]IS2H:,MT]C$)MN!A;IJ D?]:N/L0A+O[\D*#E48()XGMC4J])@X9W
M8 +8G:EA0"8"5P,AI2#-!,P"+!?4T?9)=()&Y'*W.G)GPR7=.97)ZY[[I+1Y
M11T:J^KDO"T^Y7A:N;0'O3+,,/3K,IZF,J6V&U<2Q1D XH:KK[%XX#0HZTU?
MRH!M-&-O1^MB=::BZ-76RIFC9?65-NA VLU-\(:V5IJ:<D\Q[F)K&S0C0D(Z
M-__O'2^K<=O1IKG]&&T^=$EX5&T9W\BW:YW$_:K1*GK@-3SP:DS@XP:7^_V^
M\@,GL5?)A7(]'WI[<X(K/L":Z5A]J7"FIHP-4#^]G846S8S-%K0\(M=H>3Y_
M(E7#,_ZJL!D1H9);.U A(EZ=OMB4OLC>QOT-E#XA*[$F_S9<CW2Y#^ \]5]]
MR?]C8W+UWQC8,*B8!BUI4**ZZ==BBK@]^_4575D"@+&N1%4+CH;/_) S(/G"
MBNR8>SW;8^[ -;>S'R,>(D)J0YC8/<MIU@C3UCGR3=%EE9365(G0#B'A/&3M
M) %;OJ+/BN2W]F1G"O20?0SSV%9S= O)#([AHQ<XQS/X95WN/GG$@F(&]6VT
M)ZJ/&]\[!#\_5F<$T;F16;MT%(1*HG.EUN?%#N[00=N-8'%^LRJ4?BH]#O\Y
MGZHG0>D+'* X"Z)8B>O#,:/*3&UO!JVG*&%O$A_:[%U(C4;8?!E!/(9.'*VC
M0,?0T7YV,](SHTJ<1/7<Z9Q#G_.M<*A(D.VL/+.ZJ_BR,VI_99UA_[(T2HLS
MWBU2]32LD46:THR?"F?B)G'%=\['3)>.98.7?DF+R=$L?+#-/Y(IM\-#)*12
MZDL;LMVP[!74GP8^LXMU(3[O':1'P-38>8=D63Q$$UWJ_JXA5Z1[Z *D^5Q_
MQK>D-9Y#%TWO]IKS4UBSQ#&O.^-'23I,SH/W,8UW-Y>9?P#UZYDS( 3(&";.
M:66Y_^P; 7#$GOZJ9CP6L-DDQ^;:KF[C,VDNGP5_;CT6-\Q"4>J5^E@F-F6
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M! OS$3"?0,:%QUPA-2M!GZ9^3Q"G_@BL;D^JTP!KOS'"Y+,TXECO6"3RHN-
M&KP=+T#Z)))->H]EX\/.1393%FQGG['PSU@VS=2P4RX-E*7"M^]?4RCLJOZ%
M% ?SU"DTL*SWT4TV%4H5 8;>A&NPOAJ)KZSWJMAD'X8HR^^\/JMIYVNUS_7&
MJZ*ED%%9J_L@Q+4C)3DD-\;ZS+4)'=26W>94 !W>&-/?CMW,9[L_:*D?S;XJ
MZU]B=+!7%D"A6+H: EV/CMWM;Z/SCNJTWB>5Y,OWDG-AN=9H:S\U:*WKWL\P
M44VA&BUB\TY)6):9^T6IZS?MZO/#U3V_S>@#!="UZS%/,W][:)%G/R'7XU!F
MKC@^3%A-7Q-Z;X@+.K\?MP7,H4Q QT;TO\#$U@75=H'+^!,ZFL9^3<6-.V)?
MY,8LI(X2R$5YN7R>;LP&F>'YY+IH(3E;XC_#[MLV"XT2V5+S=+/>9Y=B)Y"J
M?LY_\8C.;$6N>!1IZ)=2Y XF&M4IQ%@](*1GVCP]?DW83E^F7FZRW] ^\RH/
MY7V_?<,K)I+-(P#@4.I<_:O:V_WTP>\YW;-3^2'Z1!3%@_*C5>$'WW55G.<C
MOK3%KNH'':CS<^2]S;)BRHW DV7Y$)0H63",]+GY6+[42,%'YD!154R*9#W#
MV=4$:-+&\7$VU36K'4F8+_WZ9 <0&LD!OX/LS(A;7_?2P)_-H&2]U:ZNP %/
MX^]1XT,VDSYCPDRW:CYZ!ZPM>TVK<42MU^[ T,&VPI9=R?&W*?%WLR:*&6]/
MWD?+*D*:\[3A*89);0PJ>C:G8P!WI8V#IU9-+2Z@YJJ:(B-,6SJ5:L='P$]T
MZ 1C'4+N=,RD>=XF21LZ/#V]_WL#CT0:7;'!JL";>EC(P11**&LH9-N"_$E9
MO#OI-/_4\S&:(&5#WM2S!GF.^QGE!5AC.H^W;SQ$:0)[I4?,4&8C)(=QGO^P
MEP6.,_!(.]58+\9Q\HG2(&T:'Y7A<T2OD3/CK#]L?A1ZYT29MUMN$N>]GHN3
M"^3-579U:&JI:TD5E.9HT6=QWB%@-#J3B8B8>-,TN$^#@#(PIX\B/Y@NW\0(
M4LQ B)\)\WRX( B[&'-WRS Y=<L,P"ONE6@-%FE,->V>HC@#? %8$K+3<]@&
M30-E>M[QT'RC",?H)MYN/4Z9WKA(&&&QLQ0Q1@@!:GE("5CF9I2J0&,UFL4?
M4AQBJ7-$<>I?<M&_A7E :G3EY"^"'T$'46\$8D>B94M6O$7)SS!R4J60QF7'
MJT"#%MN/V(<OP!RF#]5\NG^_(=AP"H/+@JQ/*Q7Q1B<XT2@E!IZCS(QCD:U0
M])':GN;LY7U;31Y0'E:&)D21S<B&C>BYI+$46Z'D;PKO/KT,I:]U)RN9I19H
M\Y8P=5 ;AU\J833'UT4H/4=*%SU0KD%U""EP44VUJNPKJE1=J#*M'*/<3$R]
M"? (41]PG0:J])C-VI^6%%OQYXZ 7GX]U%I*XI(:26OC8&FWO2/]U.K78F-5
M9&9*V,3[Y5?^U7X&KCK[L!HC90YXXG6*AFOJPLV=3M;&"F;H6Q1>E-&ZP^L:
M16*]A]\3>9]KSFRPL'R/ ,T(<D29F1C>D[0()%DT!CR2$)&N";RU_\QLEXXQ
MJ_P!S:!)8K0LVA>!C"OJZB5]J23NTJL;!TP N<YJM%[/N37*4;YMFTNX[,]U
M$8E3%[#I&XU6>YN,5O^11-_UB[<T2_U='P=TZBA[A)_)O1_$!-P;8Q75BMY(
M/$+R5A*AC8ZVSO)ACK/L"$L%Z^$WDL3YMQO0G5X/Q?>>3GC%RQB3,A<H7-GN
MH^S:9O@;J>YPEXS,)C.M.\*:]TWVS9HOZ&N^!.%02=S8Y#"')HN&^@MU<F!B
M9^M=$H!FR)\'C)4I03Q+(-F'#54?XEWY\!]&_#HD]GY]7TR0LJ_DAO+UK+B3
M@)OF6&]R#+ZME\90_.9FO( ,+/V[?#/T:]=5'&]1:XM7LO'/!+X/ONS$>@ I
MCJ_W6D#,TC]D.=>C;>MS[2.,*#0?0;T9CC\=R7I(,5UL&GR/:?S!B;S(52YH
MS9I&CR;Z-OI3J+8#F'#9H@?I@3F!DW@]&]F2AY>$-:PMX6922J8@M<IM@(HB
MG771(VTGUE/-Q@9C0KYC_O7O,N#23"J.C_1 QCCBJT'ZJEQ5S<:\GM:E5LVH
M@GE14'3[2)X4S-6[R>"%15(^TRG,TT:_L27MU4FKJCNO&"UR@J>"PD8[GM!=
M06X7J*4S/Z^9&% T4UL$1_P!@#Q2RO0O)>V).QTJPN5NQ%7.?JO+NN17-_7F
MV;4@8"]B>_DB''G4CN<[[ \,&3J6I+>J!ZY2*6I)<IMRDR';+]I%U?1;=U):
MU :89J^N##5J(+HJ\,^<WV![HG3C[.[\*G174H=..%/.K54,RA5C'O5JMBG6
ML=P9WH,[!6$'EWVV9I#D9=2!A*?1JO&R,4JF;=C&[,,7'D5#CHM]GN=,8BLJ
MR="<I5P5B6ANXA\/EB(Y%:^'@/CEW55GD'"9A:/W\%H^HN@L:GW'[G3M,.:N
MS7/HN-K?7$W:O%C,G'YJN;KF^$B _['-%D!=!H=O?)/[8&GS:D+L$;5139AO
MI:PA$7-.%&_T*QP.-[I[10[,76L7XM"T?;B)P\?J>RLFQK]B\&:1R!*G%*30
M/6H46B4PM[1$LLIOYI(PF';#1R)C0GQN+94SBUB#)_6CC)[-&9.W O,'%G9$
MMC:\$8K<1V.=QUSX=JGMT1-,4 *F]5#)BJS2&&N:P )CM/DHW/%TQ/\!28IZ
M8AY$&-W_*B*Q$1*+#/BIO+[(%J[.'K6%4GW)P8J>A<UE.PHTAO":3N=IM<,V
MG+:#[&/Q;3-MF2@P6Z;^0RR+>PJ,,$H8*(_0J<'TU=GPR5,'/[[1$'4YY\AO
M'5:%N[>YAPW.SX30^X+$)7ZDPW?AR3F_NF $YDWONSTTP.O\$HS1L*>Z>,2)
MQ<9:7PB*O:Y;P><W;T&1KD<,QKX#4#%RB1TM\3=KPH,#@8!][.5-R>QZ'6S\
M:!P4C=+P]HC%S??MITM6D.H!J!9S)D5;S=K_ ;QL: ^RX7TAT/TT_NM!/W9A
ML/\59J72^>I\!"-(ILDD(JO]JW0T12_]=3]@")MF[-'%6=/AN,*$F*WJG2?
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M-WA-(IE;J_G06.M7\3$Q5OT%?)8)2Y5UJ'BOUT/..:NXC),_D^ON:D+OGT\
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MZ3BDF9WQ\@M;$PFMP%D?$6W1):6BI2D:4W0;JJ8X;T=S6]'0=V&AHBDZWF<
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M7_N?F(-?X(U)P6^ '?&?O>?ER:?XO? ?4$L#!!0    ( ":*95A1(?E+ .\
M "8U 0 3    :6UG,3,T,#4Q.#(W7S(R+FIP9^R[!5A<S9(_?'#7X!XD$&!P
M"*[!@P9WAP$&=Y<0@CLD6 @2+$"0P36XN[N[6X  '^^5O>_*?>]^NY_\=Y_;
M0SU4]_3IJOIU59VN\\QYG'E< ;#EI&2E !@8&"#VZ0,\KL+^E/0 6P" @@+
M"   ,@ /(P# /G%8   C%PH&X)]XF*<_G?2,W_X#%   .[9'!B ]C:$_]86?
M""#;^_.L?[8G),&F5L;FME2JQF 36_.G 818N#\ABO>$7$$L_+_PC?%Q?^+A
M^%X!0'S\W_B_H0N3_MN*_T3W;XV#C8.+GXV#GX.#BIV-GX.=GXWK/QQ[V@<
M#)@"5H Q8 [8 E2 ZA,'!DR>^-\VY7$5_KF5BXL#/RNKG3.+L9F]B3F+J3V$
MU</8@96=A8T5$!3Q<# VM3%WH3(QMP3;"=$?-[304X'-A.@UN178%!PDS*W
M,EY.YF^]%-5,O6Q,^<SH180Q4 4]^#T@#A!S%V,J#XBMG3._AQ#UGU;G?^)_
M&V:E%A9T,K/@5WTM]9<93STAZK_HXN[NSN+.R6+O9,G*SL?'Q\K&P<K! 7J:
M 7+VM',Q]@#9.=/\98'7YLZF3F '%["]'=5O?6,3>U<7(6I75[ 9OX6Q!;>)
MF1DWR,28TPS$SFYF##(VXV0'F7%RFKWB9N?EL& WH?Z+>#/3?Y'NX.ID^R?9
M9J:LYK;F$',[%^<G--A9J5G_GY7Y!-&_"/T/X7^R\6D.OX23N;&+^>LG$OYM
MDT%L'" .#K6_;C(+'P^W(.N_F2?(^F\4_?\!+6%!,U-^T]]TLG?ZL_BWYH[_
MO=VV!0O_Z\3R9SN?AO_,/ EX\CX4%!1!UM_+_O=@L/[%^9ZX?W'5IRNI_C]H
M_R<+^5NXF]L]Q;C[4S _S@,2 !(" B("/!(B B(R$A(R*@[:$\:H^%C8Z#A$
M^"3$1/A$A*04],])R>G("8FH6:CI&%XR,3.14+%RLC)RT#,R,?ZV" P2,C(J
M"BH>&AH>(QD1&>/_[?;8"N @P_R 5X2#H09@<6#@<& >.P#*IYL" LR?VE^S
M(PPL'#P"(A(R"BK:TP0H-@ + P<'"P^'@ #_=!^'\7WZ'H#'0<!]SBZ&^$S%
M&(G:$8\C,.X+,HUX>1N^ZN@)+:>)4Q **@$A$3$)W0MZAI>,7-P\KWCY^"5>
M2TI)R\C*O553U]#4TM8Q-3.WL+0"6SN[N+JY>WAZ!;\+>1_Z(2P\/B$Q*3GE
MXZ?4[)S<O*_Y!85%%955T.J:VKKZ'^T=G5W=/;U]8^,3DU/3,[-SJVOK&YM;
MVSN[>Z=GYQ>75]<_;VY_LPL&@(/Y:_L/[<)YL@L6'AX.'NDWNV!@W7^;@ ./
M\)P=$5=,!<G8\1DU1R RGGC<E_(V%!I.U1-\$Z=15 ):KE6ZT]],^Y-E_SG#
M@OY+EOV+87^S:PY AX-YVCPX'$ $N&+]\,!9>Z(8:N,+ML'O'W1ZSL2$#<QU
M"[JO:*8] NVBUBT7")6/0$N)/GWW\LVSJN/;1X#R%K3?RC36/IK/[Q[/5Z0H
MIR%=\J_F2O_B0BQ^!$1U1>YN)S<2-:4G=]TXK^*/O)9_]\6$_^^N,)"5I-3,
MFQ'*;<BL>00P8(H>@1&"X8<'*.7)"$G9/8SM(W"\KQFO\MM*6&"6[3^4IW+I
MI1\\)U^W[_^[BU7^U;*>='B^!BE&_V?I5)V69<T/;9PF<,BJ"0BDZSBGQ7DI
M1.CSCL5S-WTR^22Y(-D]H2^.1GM!PNZ4F&-H+$BYD%@U%WV;ERJ(@]$W"F'$
MYUP([H$$3OT1R )]OK^W%EG-XC:\A9U]!):GRE@FJN9+:%0SVY4C^NIJ(/$O
M5N:5OHI19UCF+NT1:-:XQ1X'=;'3M:>HS^2ND#U+&/X*OD/E:0K.M,S_([O>
MWC:Q_/AC&,&E.],4E%-'+@W38=O51J6CN&H;<&U4% ])JGM3:WVK)<=&R4MF
M73N;XI%UQ,1(F>](Y$((*RBK/CM/MOS.@)S?6W:.,%9&*NFK)2[\(R'"E.7R
M$=#2=-"OZUUY-HYOL(185Q^.W(/!]$YU$8;^::-CC*X2CKQ:_JZ&QL6["5;U
M@TMI+J.-4_%5BJ/Q:K$.CK&8(JCQ"A1KK)CMW^1.:9\M<#>JE%/+HA8PMYHB
M2*UP9N;C>:,*!6?Z#LL_ N\#)OUWT"P? 7^=F)]6&)H/ =7^UY?%_4]6]POQ
M]SVLD2=/MPTV'+]MI('8P?2TK:>KRPF7R5Y@@87_R'&VIOCQIW*RE_<T#@F3
MC$YR/PQ(L"?&-GATJ_/UXB,6?M7?F4N_]<LC3'"%@\0+K5:G6Q;%"XP>,"Q-
M87IF?OD#KU5K,:^](VXXH[MC2^CCM!5XM2[@[C+$URE2/'9 ,>8[K/%W31IP
M5:"^EJR7]Y6C?*$99J&^5))HG"3R4DC:#BH7WS[F3?4;UG\45+^)8/W?&L/_
M8W72O,@@.-?YV&X$B6Q($E=PQZ/K)P.RI4ACO@_;ZRAA25J/W.?>97[Z^PJG
M[LWA'X6Q)A7<)YEC]HRV>Z(/1#9)P)NHW3MJ3S#B&10B/47TU"/P]T+Z3.[E
MO4&*L;>LNY#]WTUB+WEJ8 ?T/]+>L<=VO)AQ(P1P&^HMX<F\)]2>3#2^D[W^
M@VMILV/^AWI>4AUXY=#@6LEFW_X[=P4C5SRYXJQ/UB/@[L%ACK+[OFT8+P.5
MR478L[+E[R<BD^^U:6H*_ BR=@;&L,Q.3$Q\D"Q$)##\]9# UB=W&^ZH@ZL4
MV0IO3Y*7A%2'YKPT-,$]A]*3.U>_):BB/TA0P5*UPJ00>Q]#"]URJ[?T?F<A
MYY&F1!0M(9:CEUY*6=Y_N"7<TU6Z,5@V;W=3RIX-(XL/HM I;J"SQV))D1?S
MAX@G:,H(/?G<'\#W\46"]XL(EF^Q6WW$R4@I7I%\Q'#$O2MN^(HQ?\ECNG\7
MD5Z&_*>=#CFD6[AL^=MPP;^:WQ@?+EPF__V/??+/?D4QIO^'PG+V+AJ0JE+^
M. (8GNZF;?_4Z \UFJD^^5KIF2_MC5!TP\E4Q7C>%?\&VSS2L1+)0606*8]>
M/'P1*]/V0N0/]/5_"DR#_YWH_,_0J'CD@?3GVG8WB>OAX&*NQM<Y]2B-%_1\
MQ,/<YQC>+0>/P"- A6'XT)SP"(A]8\<#_TASE$K<IF?BZ/XW1<CR@_ CT).1
M[S_]\Q$8M3> T3'V?Z=@^($A.WR/ Y4A.^#O$?^A(D_:JF((W8<7:-[]<;Z5
MV0/S@A4/FX@P5]3YHR4;$:M#Y>0#S"%04L19ZG7&MADRB@YLZ0+J.HB(YD15
MBOL8%*V8(-9X;LXB\ON%@,P@C\);Y93A<_M2PT-<%(M%3DKN;BD[3QKZA&'N
M%!IHXR.@6EHC1-KA,&M5W<Q45SYVL<K=7(/'<TB7;D<E'BFC3E7*NR-&?AJ+
M;%>3#:X^\RC2LH6,N\6!W7&9);!E::0;+*^=$\;+N^7.ZR[E[W(_V=F76FAO
MX [0?OHHLV+$:7;F*9@)-IN\?-FX+*!<GS 499+@,N">?3\I>(:(B"06GJ10
MVC(5O"5MN98F2W7Z9HEXC,N;\GOV?"X'-&L)CNB44S''CS@-3+N^W4K<Q?(S
M^,UW>V2/&!P)4%>"+SH*%[^<#JU27=*ZI@:(@<SWP8O".74E;^I2NVIR_.O$
M,6WY&TBU]WMV%GYCYW#?[0_0$JF%^3V2SOL)>N)H[WQ7W@T'Q9=W?. "9QKW
M-<$2I$X,53-D';YU<UPJ5UKJ3/5 >&]LL=(&];KP_;7HAON<_!D#B?Q=W 5)
MO.2X@ -0W/LM@-.)ES8=\V,90WU];5.==\3L9FVF1$JR)LO@?+PG-_AR44?&
M-%Q!]3(GG* FBF2U1^8CH(Q^D@L@[XCB\7O1S6KQ0?F]T90.'P'DW$-+(U>T
M,AQ=G>+[#".%DF<8H?UH4!0@H_9R?Q"RY\;O4_]LH9U,R=%XC>CP]2E899:!
M["C2UD1?"F^SV;C+:SH5M-FG<_^)A4Y+L(TUD2QD"1'.]*LHK649M]UQA\Y2
M5J#]9<1=G@8F_+3B"ML0%GU!;_=4J,*R%%E?5TQTCJ<?C8UC1^31]1EC460R
M72V@]B 0!W(E%<&:YZ\BH:NM-@G=! \/<OHOF\7\Q##5LM'4$*8*U4Z '"Z\
M13EWTVZOY4-?"/+<+GE;FZE;_,F.A:R7N51_X=*"GO;!50[$O<&4&;.:P:J8
MT8AU%24\9>R,F#T-*Q-X7GV3YN[.V]K]E??K3C6)?037(.:^5F5E-9C[W)1^
M9D77D5:*;15SP'+K1FP_>%IP&HZ@N$#LRI_Z=DNDXCVV[:?01%*!H)5?=;U#
M_%O9A"GR5B"-+6.[BIL?.,]G*(F6:[X>.&9"6=*.[ZV%S=P/?=U]3Y8[!SWS
M=&8\W:=&8RJUOP$X-!8T5< \[_ZYST)"G,8O36/++Z_"H$(T"I4V'URM#GX(
M?7/J!,/$N&V&)3X561@=;JU=BCX/YQTD0SFDW076T],R*XC:1_KM@!,,_'F0
M;#:YOU9U2^KMLD9S^)%CF!WNYI0LTMT;3"6QZ;&42O>6R_%?P9_(ET.YAEFV
MAO8UQDL@I.J3C4GE,5*$S.*'2^_D9@(1CU=OZNAC<W#VKNEE3Q#+C4TQ"FIJ
M3FF3R[\EE_=H",6;;IG3NY/Q"000(>%WS'N$ZE1J=V:6^0.U3N?(I?H^4T+:
MWSWI)R94;$C2*6W.7$EK'Q:0ZV<%L*HL^9:'!S.Z2[T^ZPBE-<TX,U&$%H#=
M"%3VO)*2T\"@S>@(8V9L+M0=]'#X2J+34"JRS4 @/3.Q7N-SOJ&AA]^=\MA!
MR.)1DC=H,BM FBR(VQ&O66?=;@6+*3*II]-SPVNH$./"/<Y:TW'Q=1#OMO8,
M/Q41*BD?')GI6-REKYR"V/'&!$OJF23C-88 ,1%D/FBVE]3CUE&Z,JG$?_]V
M@B]N=#^,(._D^LW4!K2JIO'.9ZH4 HI'B.,I9E$'B(EI>'<\!YWPV1OK;+@K
M;<(4*OCBC%C<F'""VKPLR?=(IAC[.FH<LL,9W^&I2 +_B/ +5_UO2"_\;Q^"
M'P$ID/EX=K+,"UDCMVB9&0Y^,HZX'JHKKM3Z[S0C)*.:'7Z<DY8\NPBEV:/$
M)&WVYABTAP%Q O!M<TZ#/:UH$U/19>;Y5JDU4=LU8[8SLW.SLO;XG45)0;(^
M30/8&ZPLBDL9WZ7QMS7JMTI,W;DGDPL][1T=9%.M[,@IQ!45MY#H,SV_*A3M
M$2*N#/L[OZQ7U[X>Z!Y$B_I2X6?$QI[Y$3^F,NGZH8KU$T5.UNYH9];.7%6]
M$'2"4\+5U1_5ZC/8<Z'RPQ5_ARH;:EEO'6QTUE;EX?O0O%UALOBMX4-3#<WD
M3:K1U=I73EPA.K3.U%624@!.8)#81CHZ*27QK$X&P1:$1+IYU.3L,)5TF1'Q
M^:?@1F\4>E!R>]3B/HZ@]+?VJR\V10:ZTNXTLES*BJ,YE:YT8FW#<DF*"BW[
MM3=Q$\O6D9]1?1IXC73M#^L.UY]I_S#3^I7(E%#S_-Y0H':_T\'5;EE] L3\
MM1+:4A<TM7[O@C/0%^]VDTA&V56D,1H#ZK%;E<13_^WN"/R>F$I.KG\E^!,]
M O,I#]'<O6KEBPL2$.Y&3=S<9X?GV9K/S>:<&D(E@GN&Y3XQ%6,(D%^NZTKX
MKI2PD',J:ME#;+<:_,N[QA0'63#U(@-##B,WMJG+=NLEFS*;')FGIB(@[FLO
MF0]78F2C3S?4_)1#GQN+(F]*K2?,2GH6&RX)5I\U+1S2%16U;HF_$5-4>_F
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M$#^=EV,2MFJ.;Q;/S\^=AX5VKNR+,<VD'046%F2Y@K@]B<IQNLH+A/NR *&
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M=:%#GF<Q"V;!KC4+\Z'0^C:7A"5!^(M+A:!R@+8I4-X+%QFWKR=T5.8.SED
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MC)D1&'NN-A4[-,,%73M^3[6+TQOF/KL.>Q.""N&MOLY6QOV='W9ISI%0_@C
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M?VF,HGQ8\<-@R(HWV/F^03]_*L%<^0BP7<:8<^*<[D>_)#T!S9PZC6/LV8@
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M#,WOV1VMK-#/:'8'QS')GC56%7IOVETO"5S:;2\V%C8V]@YUZG#2UI-REK4
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MTI2+(%;(.B.7?:9/+%2$EEIPQ1/J2@_Z1[,L*@&>Y'>Q*:NC-S=PZ.6$DZN
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M<5K#ID7R77>4HR@Y2-9$7D(&<:7H0LF&!S:7N%/5H%...E0"2SRGU!M1G'H
M]I,]YXGFYR$_8.SXPGT9H7T[._"O&2%%&<Z.HSK\!E24)$+/OB9U[;CTK$7]
ML[$)-19H/IRQY#/?']R%_)C$=H12F=F:CFEH@49.*9D8MFUFT+(Y)IZO(7HJ
M#7\3T2G,G[ YS(#)4JP'OJJ+CJO84-X70<3*XC8W<4'O%MXKXBE+\3 ]TTP.
M&KH&XFR>?+(JPXV^J6T0?F7AYMC78. X&N^F =E6_L[HW?6RU<VW4CWB67BP
MLQ# <#0$D(7ZZ>I4BHZT;@"=1^""TU6A,'MEXP.!$O"*E*F@MB*QKO4U7D4Q
M0\@*]59C]OOW<0L&4]?Q=:!IV^35/JXROF==[(.RO!-((V&JO2!-I ]T3VFJ
M<JL6MC *GY[>&A1R7VG;>!LQ$(1S!K >=_.A\04<'XK[I_%PS?LKY</(QY<8
M789=7%P4.]Q#3&8;C=5H),D<N29N/+RG&Z<%TOE>0'D;JL1HX9+-%:;8A_ I
M'_>>#+7,&Y\3'I)=?99L:OE8$MDI::W>>I19,S0INI_"KXU^Y]ADB'XJYAW:
M:7:,$2L=D)%D5[[,YC!IGZHX_<C;CPB]^>Y*;)N;Y!&/0[6HD"..AP;A74B&
M@!4"R8^$[C@O_H92[XKO.^9!_?4K\UN4*/&^!*:#Q@F15%1[A0"O!FWLJN+I
M*X[H,350E65CZ*Z[,W&D'ALKBHJ0"'UC*D9I14^>4&7I6*$B&L)W Y3$BT9+
MAK?DN(6^#2EF,*,]0YF:,OI@\OH[J+$A05X"*O;Q._SKXI@]3?AO U&"3;[\
M!!<_SW)>GU2MVO;ZAV5#17AG;<;QLP('ZA><'&3,:>&_#:LH_JDR&>9(BS:>
MJVP7>7@Y1SZX1,/21CY97E%KB2&'5"( B;#:KU].YTZW*Y6OF/30K99FO*I$
M*"0*C$1;-;FT( S4GC@6$YV8NQ2=I^)-A.H0G&1@[PL))1R_6ZG+P;-?FNJF
MPA3KT*"J/F_9/B.O7KXUTD3$<=/L_4JM1=9U/X:8Y74%1[BP@6(O[JZ(2[T!
MV\-AGP/OQ-SB@P#*ZI2)"N?T02=%T]GUEHW56,I.=/+MNJ\NQ[4B, !G/J6W
MLO"3QNQU>PZC>#18O,J'>(P$,K H8CHZB5F@:>*3)%1ZSO]NGG*7L-%HR>"R
M&_3-952<ML4I<(DLC1AXUODU6?]OJ]"Y7%YE3?@85>9.3\+W]#Z 7Z.0OA8E
M3#_;(I:TOBWK&5HI:TVU$'BI(9:BMVE>B27^94>01;T1FA7I\O-1K8*2%96<
MKPG%:U''%7_XOQU<<"P>3!HVQ_2/4:\/%YB%/P)@V6^C)2[G(0)3TWKSH"5C
M2@R=]PG2)_AB+1,HPZ;=-Y.UUD))*O:X@5ZB5+J/ #J KN(38?CWQ@2(6!1'
MXK3 ,@^Q/6)UM\61(/=FX=0.79<-"&+2EKTH=\%F!=YN)O<TL6I.7DO2^R_7
MVEF5#CE2Q9G3Y1E7,/+<-EWH,H0$Q4QBFLK[=L0D!?XH/IO[!IKJ"_1TMA.5
M#;;PQ;*:<(A[2[T8KU)?=YY]DF)ESSAS*I C!N9P7N4027:20G_&68Q9Y,+_
M9+IT6^XI<L W$_6_.S_>"V?"O?X6G]ATKJZ*]H.3SWYJ('P.[]@\3G^R[=3&
M#!0?RU\.UZX*,3%C\%$ DE<V&YQHCM^2_%Q/R(;Z6:82Q]\@Y=\] M88XOLA
M8F(<PQ[^H%-.W7M6M=1[#[";R"S)7((\9=HIE]!J19OP*]4!T7Y\IWT$1FKE
M(?*56$H,O\K? DU6-HG% 6@:XJ_N/QT,=&,*36>%O<D%FA73H?I '#01H_7G
MLUNL+]X;382VRZB'-LR49BYG1I(EC\>-VX6$)B;P\[T").1>7I=^HGF ]YK>
M4.<\ J25 0?V(DXOFPD<=^(TXBS<8FC :,'%=%B2Y4DU,]">S8KCF^CH2&Z!
M?([VT^:8B1^0UZA!78#/C=ZRC&O],&!#/".+T*VTHM1XJ-[#&SV!)^_XWS)?
MKJ;$/PT_Q,O4*!F0YVC^ !73T,K=&YY)3&*"Y5VHZ:M9:K<JN0T+B)'=12N&
M2+FWP9:):(1YZ_'F'/D+$K)_$SUIWWC%TE^MQLJ^O^>_9@J]6&:*:\G%'V:/
MBR\)M+<;<>\<N^6EJFN]E_M$/]'H%HBS)[ JZO$(B/+V:6YN]KW*XQARN8][
M=]S5#_CG\?ACBU;[K7G,765F\UPHD2#>OKQBY!./37/\7_LN[$O<[\:Q;69:
MKN. WZ[&V?_IW^>2:AIU0)@VXZH3%]3@ W^OKE!F-4W<9I2;[AH+W(90[>G9
MR>N&:,@^T@#](4QY(OT!1TTS5_@<2FDCA8NRUJ/!PD3<?2YB3FAA3+6B3*PP
M58#M/Y3"*JS\7.%:4(7#?S9>Y<NW%;FZ9W^WKO (GARD3H["]+4XVTFB>?U<
M;$I6J@IS#SI[!=,'4Y@.%0/>-H%[Z#9:RQ._>=MW>UE8D4KTXR-UO1V<SY=$
M9H C+8LIJYBS3-8F6=/HL,[>8#Q5<*RP ;IEF(08.]L(?C*4[\*ZF><@6Y0O
M8@%>5[J">3[!IQKS-O6SP(8F&#^+QTWD%DR00.:UM4@*B&H8@J'(DEZZ&OV6
M6H73:[+AW-9=N5[H>(TSRLM"9!GF9X/\1X>3I]MERR7G@_Z6<,88K.#M0\];
M&_"82/!JS2F)8:]?NPX=6I][I7K[NQ<9]Q0/E!OHMV5F"REJL*R@AJ-TZEC^
MCL"D\]F%B-ES)$3W"B7LBYG_\@/]_)9>$.MXPL72 F-,7Z4,YF_;$1U:#:61
M&F1Z%A]UC6_0(Q,WSN'#X\DKFJ1D81W'BXWH9=%N$>D"6D@D1P&.]JM,MK3/
M4<%W7C'AJDHG7%89X!#2N/+:KF?O722"^0K.U-_'@4U^-9W,&(5A[30V!S52
M_K2,HU'*M-ZD8-GZJV<&8GX-.LBZE**+)>LS]<DWA#<N"&)9S(P5Q?MN^W+'
M[ZKEOOS8YD6T\4O$X0[/W<F49&W_%O&%>A,QRM704Y+7H/,. .+-[MW+^MA\
MAP,X+*F253H7JG;W=4@5*M)SXD(J>LPX<<W/_3C!,5$#8B8FPA-G,J)5SM7J
M!9N"?$NB49PK7[RR"&9=Q4T;X7#B"D,O'5ZWD%3CDQ)7Y@B9:1RS4)EJ]&\;
M*1'$QBAG+FS@HBD^-="(OJ1PK(W9<Q)!JW0V.,R(K8[\-G7MU=A\KUJO_JRO
M@8L<YXFK5!PO?0W)T8P"(/\?%6[_AY#.P#/=YA' 1%_\"#!:?P0L'4)'I?^M
MU6WT7ZH/6>O0,MY@-]@Z<9EJ?G=\L[M3Q5S+11D[(K19&.R\#%LN^SL/2;:/
M+]$W-3Z \^4J(6;[Y;H"5D<8:P:W40$B(A/*HU-_G,DK72L,&]/AJ6I\ O;3
M-L?$^7RIM*[#ZW&NB?-%T7VQWD4'^!8?]^RI*U!]CF.6M8  <IM/)*1._3))
M:AB21"/>]#3!^ERL81<7B)MY?A*3 38[8T+M@(V4;HF-H.YM\^+I!MN&4NXB
MBN>K1D@0$.8?W)85BB.B408 $ #*O%N;X%:%*\9#^0CK.7HEZ5F">6V-KGXY
M.=AZ&&ZP>$A&]2, 6_+*@+GP&IF..E0BP+O8C;_ASC2(C3(4ZP7 4*)I?:$F
M)<AU)0YBF5TY_6H?W[D!9*A>P0X*FD%#?IN^0BFDU!:4E-E$KN)(.PM$U_%.
M$J;("F&BN3H$^%8L?Z=4*5XZW+Q5BW6^ZHM2"!;/GAI.HN7@^(I9)?W;APG9
ML/:^8^:J[>BOVS@68\.7L6CQL.ST#R0K G9Q(72!>!KH&K\,ANEXU&KUG? ,
M B9;(Z#&H\MI&\T'E_1IQYJ'G21-<ZR=@7!3 Y9\DCYOLOI<_>!@%.:OB=W=
MW8"@08$Q_MY47;'&RK#"XAZ'6VC8"0:\]3)L4D'6B@)SEXZ/4&(*O-G;<1Z3
MP=Q1:JLE2HCX,TX-&@Z7:OYIA+=7PD2K@3[SRP2C625:_&@9NW.TJ6[(81!O
MJGIUM44-:P^O6>+Z(/+[Q@L(F+!$T=4ES%8'-X*OFNY'B5G;[2N'V($$!?_=
M,J5-FB-)DQ_+[Z?SX2$:V>O!<JV70"T4C@Y4"!^FM8-FN4^EP!J1WH$&@@8*
MT]N":;),.;<GI*]O9U>X#J"M:*!52K Z@IG3P,O+T888:W8V_*5Q:%,N,F&.
MN1O>_&:?/?.*#H3NC(1YI8SG=W<-4R^QW@K$Z$.Z:"WGG:,D=#KI+DC$97TE
MOO#W Y=V%%O>^XJ\[1T&#$C<41N_[_46:JT<"\O\B#\+A>: LXM;7P,*$E#_
MQ#;_*9XD$+T"])_=?N'Y*2'ZK QTYP&G> 38M;WBO;2(5!\BJ=M^D:*I+@*
M&QQ>2W+CZXA[--N1&J[TN<'TT;AH, #;]'RBQ0?>YX>MJD5Y.*V*GCCORK;0
M,0"00+%&*<J%SQ0SIU77KT[^++UMR(W#SN<*1>'[4(4A/33NOJCIO-&<W\R/
M7$/:\T=0(U]QI_/C"",1Q!\LUZTB6(/&'*:D*&N?]@6',?DSZ)93C#2<.97K
M"\>EZP1F$_MN=4%WI5ZT87$BD0IM2PS$+8;2$S,FJD,>8*V4BQ@JL:>(!2*M
M\QR:IB$*9+I>..<+NY+NB#+XEV,HG8C^FLG26+'!WR31=0_DN1E^90OHK0=]
M"&9BU.HWR&O'3Z_(<XKDK8KL,U(R%*:;?NTH6),(;1)<F[GX"0D3^&[O4'3?
M>!TY_DWU]BT:<@;?\'+5O[2)%@6<ZE!ALC*@#>W"]W/QE-I?%1MU'+3PC\*;
M:@V5ZY1RH!(I9I]O?F9M)P^2.:M-;]>X71ZF+AS7,/XMG<'!K&,/#AAD7:NT
MU92BTD72-\SR\'!;)UGYMZ%]9%  8 U9) X@?\?#&\7O,1:.,[0GTH7^<K-&
M$2>&X>6IG8B*:,Z0%<L#S.375[G%C746?T\0E":R\T.8M$:7WP/,,+R8J@T,
M W$4R7XN)!^V9L^-SO<OC"=9Z<@-,CGU&1$IN*^QBE8>LJ'E)'??I)+?'OC[
M^WH*/@*^LK0D]--RVKB5X 1)C?M;[AU$>\/HZCO.GQ75\BNS-AJQ<P#B8Y=5
M\"R/D;UN8O.5I"C1CP"L6:4 5\FBO  [LMEOX&A;H"9M_,IVJ2<KFKB>=158
M3+6SI6"D&"E0BE>(2YD)_E1!:7:S(V_RM/2I/Z"C\+"+FYL+<)NLI4WVS">7
M!+?R1JG3K 0E!LN,J*-N:"JJ=M3#PQPW5WYCBQY0>N\;*H4K.T@$: 4:K(J*
M O0F_YC?-;1S=*YVV F>U!=($+/6"V<0VA%A>%)D)M:,*![,)<13H*"WBC08
M*DI_,^$6%\N@C\U=[)9BYB86\R<_8Y\ME\"/!\/N;#&-J;F=)+HG@&XJ06!J
M5 H]6!J=2!0/2_3-G'4@@;RO>=/"PBU<SFC S2IQP=62H:1+(^^S9I<F3/U]
MQN(W"!,,Z\1Q.]B#D+1$<_810)(8S('G\V:UH45@.5M%LZ7^M2^Q++ ,G2-!
M6JL,FUW;Q="+]\1]4E.*]A'PAU'H0JEDR+=D;76L9"GS54%Z_C,+T?L\C6=O
M>8_C?HW;;W?2U\..U&'OF0*"L;FV9!06=+5U5@<DV [BKDOE 1\1/CH(Q.22
MBK^_=_&3:HF_VGY/K;#B^/L#OQD>?F^"V(=Y:NQ:^=AK59E#MHT+\RAOU9)F
MM%_:*K0H(R=OTROMV5!AR46R^7;DK9[EH+-E!2:%A.!>0B/ 6^7!>*G$1D+B
MI?&J5NM:2E>@$U_<5-H.@#X<IX( :V^9;.I):0V*OPBLFBRKA.V/$D#W)T$Q
M:$3-OPWCI!$%5_MB'U)-*&K:'Y8H\/GQ/VK:T(0/U0J5JHE(H(W[5F:PH3$N
M]^@(A2@246E[A%I!G%X(;2^JN YMPWC'M-_@UU-[D">8F$C?^-]\C[*TY*[+
M7D/*8/V>0/?3E94'F/=M@ DY-*A#5$N&2LH*1^'RWF(E/TH62=GH%"8)?,=]
MBY</=*G=?-<0?M"22;D?-/Z1%AH#M)9E59NN,2V2[@L9"]\@?)]XBE3S?UD/
MC^^'N)28.'A<TD4WOSAC$:Q\"B&T\4T5X?.5><$'V_)AF^*AO G8EHY=M"']
M]G])46+?AFTY*F_>J\_R> Q50>ZE&GE3O@9!>L5>X\?Q\;XWW'?5.\#]6+BR
MHE=6ZRY@1:]H[M87$]65I*;$)/BDNN[SG00-\+.E2>3-S>:4S&\,A1C)EO<M
M^E0:M"$AXWY^EMH1[<(DN$O,LSS%[>VQ%N#Y1!V]N<^'17W:&MBL-+[ /::H
MI2?\%1Z4QYX*LU7.W(VX$QR#2DY>A%S\2:2,)=O7(A-H&5&W:BVFE':(RF\4
M\8/0Z:-=-'M:L2;L)^788MVM+&-##8O/7]Z'JCO:7HA)3+][5_"\9;%V'Y-*
M,.N!)&;%M)VZ*=^1/(\GTQV=BTA'! !9%BYA\/IH_(P4!;^P@)S<!:'?6].-
M@QY+\2UH4L>X.OQ-3XF1T9+]PN2 NX=341/J<YJ6?H5W5A &E)X #OLH0(\I
M/M\O"!A3?Y9ZG?6K1@4-GN&MKP^Q#=5I-O+JF$*]-=Q@OI%F\4]1>_.'4&&T
M^Y(%>SAF"Z?KLF#C_W9IEZSFU/&U>";V";T\&#>^08X(@NO($9(X@W[59_H-
MPKMYUI]#& T\QY.1:X<2,L^^OEA.O-RB6@U%$^W'5+NN_:<ZA?8SM>4Y8)Z@
MOD1R /J2?02C/T;H..T)A*1[CM_*/R[A#_=\1NC.3E5+J2+S-M)AC:O-:0#%
M;8H<@0FPB0M0=?Y/@[,GH*DEMKS(0]?#UR;&>B8%)DH9BT4F$GM@CO)7@"1%
M*JI*Y=V33R9-G2+A/1=+B;0EQ<>?;5 6>3\LQ]T3BAY)D0\\!<^Y0X6@NB':
MZMTA?M"GA5312^_ 0 ;:&)1)/%<=!X$AAUV^%?LGEU)O'@V5*A$_B\I-#AJQ
MC'&-R=JS?^ PYN]%>,73I3>#X=I04W[;$->7(MU#XJ9Q;XY-&N?SP89'V7++
M^K)V;F?IU =47J4 ?N(?SW-:?9\^[5JXW-W6X7QKRG'H: )7V]\LN>'A"M"F
MG--GISF:7PI=>@:&B!%W,'/![JYXR8I D<[XGOE&"/F*>X+]/3A#>6G "Y&=
MUO25-\[")?.%LY&0B^O:=%* /ZC)]MEXN15VL\99)#?QISE)G.T+PI)<'*)?
MRN-<)/>J_IDMT#L+5\Z+UG3T')Y1@A6TK^BN,?>N[UG#'/(;IQD4TUB2&9*>
M-ULMVVF9QKDW/UD)TUG/?VY'@]W=R$=A$=77OWX1IH:AM.Z?46BUF4U^KQRN
M$:_5&$?UX?FN&B1OJ3W?'=+M!CH.D<)VW%C,FWO9^33Q_/A+M$,J044-9O\3
M_W("4+D-O,A6\<Y;-K'7,AF^B+2L\V<DC6VC#%97:P^0+&WR6_'.2!G5I+&N
M#T//YLYO4T322!S3EL4$;'4?3W_K/"?+.T.6EMK"F[PG+!R!^<-?07DIN(!E
M=7A)+N; QC)H69X#N';.(@/]_?$2[47J$[^A3]NM,#VH,U&EK;'7A?(QIK"L
M)H1A8J9X6DW0N<+:+S56P9IV#Q1B'9<*08Y?>OF_X/6YD3Y?@6'.YYXAFUIA
M*6!!9&&QD=$J]U7<S YNJ-90\$^]4B=U.D54R$MZO-HP<=F/WKX6K@Y)/(@\
M#SZ57=H6M\.N) 7WH) 9NE?F9YXIG3G%RPAC$VGNK O)CNG6AO)=$B.Z8>V@
M"1<_@C^SB*J.&[N&OIEM>+-A]CM]-5FGI0O1C]T;05*B!Q.D:P1'CP $]/3F
M@&NS1=B;J(>D:8:Q=\<-!9B$P1]O,HLB"0]?A\]6.B,/#S<W$=@,A )!\'"S
M4<.X%EJ+IV#FX(-AMY>C1Q7/Z?0J3UAN4]0^HSX\?&)E15IT/<O--8ZW-15:
M!SRF&^5L^JEE7H?*:,8GZT>$)7&W(+ZQ1MY3J>XMT K+:#IRFS\SS"<4^'.O
MF0Y?/QT L(TK8.?BSCPQRJUW<PXFAD'DY:(P-RIO#J)\W &T;3IW9(71OI!N
M1@5\X>6V745&/RB2AIIO2<)"=(_.3SO=DX.2V@IV@12":UQBIDC'JLLL2: =
MVG$)BN/+*.77=#2U^! LZ5!IC]K *-$&9!<F)Y]QO>UY!)C)Q1QFA(X2]YI'
M46VKUI92/I ]BT #M-C'\> L]ECD(SCA&)+TTLPMG"WFI-5C Q+/9\CP'MCA
MR;T9:MF%QDLFS+-U YX[RD#;IM[Q[QYG2B8/U^7TU45/4?47@]!R)+>W(>>A
M)>51RK@MFI ZUI(*1KXS5]\,8FUXIH'F*U8A4#@MAL)%E&HGXJ;<2XS:P%Z]
MQ,ADU10I8"(SYE[C$"\>!8G*3PY6XW,1W2SYE=.G<R>4X\)9];-@-L]'NB%)
MPP@SD30)$G9?G3-<Z9.IDR,_37XXQ^0M_+HO$H6)D+%T7U%$ *5:7B/:>)J;
M"[F)KS6LI]GKS&CT4MO<A33!!?NJW-0NY#C0ZC+_7EJ=?P@I_'-<V***O]\6
MU8"](J/PBT&PGDJ 0VH27F']NV\*M!<4HI*$.YI-+065"(.F8FMNNE$[[&;5
MGUWK)51#HEOT#2A^4<6^%789 ;TNIH="T'H07^*$6/Y;D?7G$P(FAW=.68NS
M@KB&LI!%F*<:=I=$CD8@.Z!%_GWKW-4RC6T5CR>NH2W+0"KG3!G'.0Q;1,)=
M);#<#F&0-WMZ[-";CN7$HG=K4<6GX#?YK)6]<+Z\6*\W";F&6!Y@/%7,L)(:
M&6!('OP=OBMIW]E2P9*\T5:IQ57OZW(:@9;(1$]D,YGT5@PP\ZW.;&[W$? E
M2I)\EY0_T":ZA34V0FOYA@S'M]]WW+X=R0%OR#2^MR1(V-]ET">X26OE %"@
M87*2XET$L*'Y18W6M,\SPWA+#EXORS.2K^+O94S!WN@^^R=%S<DG*5HI]G_4
M%/_'2W[FL__UH+NPGLC^[07E]-NC]IR[5T=J]8(O?N/9O;A&JO\EO2Y6^@FY
M5/^)+R\A[%VJOS3:F@++]SEXKB!K9#C8*X:RQC%\'Q37Z ^J[YC<.ILOETP9
M361)XG3:C,+P=1QB&^[#'/5%)\)0+"[VEW^9UAJ[-/>'HSP@:?K8VU"%5L:6
M6NAKVL2J DIKEAL&:(L)H_;TIU-R#SUYJZ'^=O+_PMY;!\75=0F_32"X!((&
M#QHTN%L('C2X!X>F@<9= PEN 8*[NS2-!G>W!AKW((T$"<Z7YYE[OWG?J;IS
MY]9\W]Q;M^:/7;6J3O7NL\Y>9^^USE[[MY025O768[@M,'8([9DT9(^VJM$B
MCDIR<(50/+S':RO6]@5<]NMZ'*WBE"Q&SP&]]3=L D3/!TZWU^-P- Q8FZSF
MJT5I"]LSTQ?8U V4[#[I'3L['V(%3:&3T:"*M\W[R0"\CL/S(Y7-F._?4.5:
M$M[Z]/F(74;2Q'SP1\P*?FQUX6+^8EU3+NP?5&XK_G8J3P&T70^I2>;A=>=F
M66\A*(R*/J\=FI@/,1HC1.I5$5_:%./X+5\[E]]AD'\5'T!8Q$SK>-GZ(56&
M"8#'?#Y3*%WFZ6+0D#!46<U>M0JRY+#\9CMNI#H6YLS0)4-J"&A#&CQ9G9*D
M8(IH$ZK D=!N:6P)/E9:S&'DJW'_]EH^75U7(;I\A#HE SHKMRG&SL=NMR&J
M#O3A55_(TYLH6F@-B]L;93(UPY7L%EJ*:1:=#_@3X%Z['J#UN%,O,=>N>;$P
M:JDU24AUBN> LY(*_XO83?\I[A-:M8U.6DHXWS[[>A*] 9:7??&">^JFNQOF
M:C/ GV]579(JX'E8O@]N:L7JPA@EXA%*-'IZ VJ!$T9/$84) IP5CB]PQ*]6
M]QV+:YN3IY=Z=4A>OJOELI+5*&7)(7.JD%JGWC,.D@$X"VB?'62]/D7L_$@2
M=9]:61ZA39L=./=ZSQ958.G<:5J#1N.CY377<%?]LJMDW\.CS@[4LK+>Z*7M
M.2I%S#V,KEP@L$IW8M5JQXQ,/*/2]J6SUK8>FN[9XAD4X]V1 JV>;W<IM;N-
MB5T?3%=MD?C4'.Z0GS4U,VP1^$N:>9U?W"'U)[ M+U PTVY)7=FZ=YY?']S"
M;0L[1$_&V:?%O@M$^T)#@;@<J+16 /IX@#=MS8ST+ZTF]='WVFI_Z=MR,0V7
MX6/<=6)'/<BR3OW,P3889'1$FG"H%?J^7Q'\MACLR$HZ8+@7I2T:/U&\?*WX
MZ*-4% P;EN<03?=(VK2.$6N6>5[[C4YP?4L,6)<7*'K5/?PH;U_H)WQ,L/HF
M;3\_X?4KP53+'GYNP#;V'L5E22&T>:J-Q:V9W4(IFDFWJ67A0#T++2FI<\(L
M.LXOU%M,:];UT$A[J))S\]S42MMB64=$GDZ0+BJH#V!]+=MOP(FSE%X;V9HW
MKT.?Y3N$NY5=)'G/FFHD?LN)<<(OP';U@T8@&K/7=R#<P8.@?.Z'L:SP?,Z?
M<0952OF4"T0>@WA'SBAAF2CNCY;E^1\T&]U+R>[1T7Z\E0$>>FLM7:</3X/T
MF;.EFB!R,6*U^9:^#1-2,3V'1DF$2)T+<E>9P#^3G]64(WM'?7Z"2"I#G4TR
MQ5+-4E-0?),;F6'\N++T!N*53.,,+T)?V1'A+I#E(]D87]D4KQ>;NN<ES2(E
M=#-"V6O63A !.!<Y5 K:P&I_I4QUM:5II+E,ECR5:D@>^.B42"K1*N+)T!+,
ME>%&)=J0=M>]B^4CQ*F[8I"(8MO4$JX9']+/E;$7J[_/G(-+943OF:\]1[4Z
MO#D^[,< $EA>:F^VA1*_(PJ48*+8H@P#:XMBB,&@5]7X=NJ\+N.U<-G*13-2
M9ZY^[,(G ,OAHO2;CQGX(2$A-Q'5Q?M7+=K9.$F?C97;6!MY43+P2K<?>9&&
MUPK'JB.C6K3:E^N,C;HYV:OL(Y=:2@Q5$I$^LY#DF@_>-7<).F2#ID25"A;W
M4PA,5NW.T8N5S,S9&#?2U-ZVOE4=E;H8!\X<0+*R0<45W>.<;*H\$TRC*GOF
MR:)9>U!%P':Q]LQQFRIJ?N'*ZE!IXZ%'\.*.WA87BNX(,RU_W)IG;'M:BO24
M0Z6O4G& K:25C]$S$?<FF]_,<>)DTMY;9Z];7S$CCU6R'=O[,N6-3]JYMV1&
M\7Q]ILO7:X^=T4-OZD">)(FVLW7=J@TI;9IV6^2$M#.:0?4-\64;M<><:KB1
M=Z4@2' ,4[G3#+?-5F%FY)"I"]968#5Z(2)R<XK3PO2C4^.JM&S!!0IRT,4F
MY)&&E1IU61YC"7ORP[J'5A*6OZ3U:55R?A,TXAAF /Q&(,U-NBU]KRB+?E^"
MG#6+DN81#8(40YN::M.Z*LD0GVS3!%8I%=X_;XR/C\-%)^L'OCZ4GN7+E.C5
MN;J:($R!QAGJ=3GQ\T8")+G)CT\6G,A)!\=9FX+1$95;P2_>@VG>/P_O1$9.
M'+JW4P2,SEPN0,CR8\@I91DMEG=WQS;P?0C6G[D,C+3^VFWX^0]8UG^&(A3_
M([ZOU+[W5>Q]&&_L[0G38X3W3,78/V6I3?O0_.DAKOM_!]/GOZ(UDT!!.IM4
MA=9N'K[)I[K=9P../FRT>JF_G**X/2F!5158F6AJ)@2&![?&A8X.O_GWD0?
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MM[__LC8G?\.4A<%FT,Z])IDU8?"X/,M)< STT?GLESPHPW;8];"![=M_(PO
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M'$8(=).W37&:QARF)$D;O2D'YSL:^8 +50[F4/[3RO;F4'PE!S,I=_H,W&N
MZXFZ,7S"<:M21#V"*8$\4L^^F.7SUV8".@+A9]*XGMM_C57*Q@/)'99*POS$
M^>]E)7%$.K@]TIQ,C"<*YNSIJ EIFZ-6@7UJ_*+1=+[&+U/X-0G372(U:MU)
M,4-'20:@-<-[Z$>G!*VIQZ:%2D8V;6<[^R1X\:44VW@GIY08*]B6ZJ<;C,!:
M$][8?Q\4,"7"94#..W7/[H>6Y.!ZN;)K>E8 5<OTLI<?OG>S&5JQWYVUCMVM
MU$?Y?+Q@M5WJU;\J%.7$5.5U/PTG#!XBV/(0B^0Q_4W4_G_"/LI_KL&A:8:/
M 4D/V:X<[D<KN[X5K=Y1?L=ML$)"I''XM2R6!(7J)KE/F$P6L0YD<>![GX<\
MKL]G"O-J(81^"IPQJ72X[D#?,G,[HE7KF'WZ'5H.O6OYK!H*L;MVFE\3M*8Q
M#/9" ;^+5 ;E<AVL.[;Q('NUVWDHW*;C?L43^5FWXKXX0>:N<,D+C8P)LSP1
MT>=*J(;&]HC[K8<_(RVA*%ILL=G'I/[Q/!G7G,"A\]V6A(>@X)@;K_J_(-/_
MO69N8I/"65557; F9^LZB>65[./"ZYS#D!(X+/U,5>BGM_:8I<GAE+Z=0K&!
MON$!225UVJ3^YU';#%0K=RTR.H UTW0@3<.DPP6"=Z#XX).C9;. CL!+@R\*
M*V&DA"@@X^](0>1R3!D3^3831<LFQD8K6.5+-T1[\:]_33XW*BMK%@1X)ZA6
M&M<WWUEFN-SP2!JZ$.Y#)B]H8JO!<=[!LC@?9R]CCQ!*2@V_1"<0&'#*N[.=
M#;+Z*)??8'@@[\^*,63=Q^49_9/!7_P3;"("QW<Q.D*=AU%398?4BRDM1AWQ
MNT\ &\.';/=[KP Z?N\_/XL1GD3-_%MY+6#[.W@?(OE E;VJZ,4[_L3F07I<
M-(HWVV=] +V\<BF?O;45^,-?6>.$5']GC7/X2Z]1XN66\P+49;0CU1JSU9IK
M(Y3G^<MBN4%T-KZ(/5(AN+>WVO,TEJI\OX=L^WJ_Y-U#UTCJ%!#5%7D,3U0,
MFH8/)D3R.5&F>;D?5'^.330S>_&$X";]?-=1\H&KGR?F,O_/50/U]L?QFH3#
MHWD2 \Q81IC8+WY=7#1*GL0C'($[E<6J:G8SO]_\X(I$N8;HW"#6<:[QF9GI
M0/8IO5O<T@=HCIZ=OVK\5<GG+&/$DLN2(-E]&31<5-5R RC(X4:Z%\^8,OP,
M!5MGATUW.P;P,7M'DIQ7VZJU>O$Z0 ZD>#*:S%8B$XAJB[$/C1.VN/R)8U3?
MK+1$RI&'3> )D\$60@J3#1 &I/T="(U/N3DB/!W6AG[YCWGQ50D<K^PT&ZV@
M\D1M06PF_^<4]V_;?SHZ^C9@RU<4Y+=)3FB5//UXB]5@<F-K_XMRS>@+KGA8
M@ZO01UD33#MX/+ZN0MY#W/@]/0&7K,9 7A@R8#YO2MZ*N+QTT2[K!<QRIHI@
ME[XA]4,MY># "-..0_1\K: 0I<RG ^JFT^*02PP%XD8>_1&G!<'W;Y-6_0!L
M0K^K=B, &U1&Y-KS?"NRC[K;DZNK\+%CK04YNA.FUS)'6#3L&;B[WVOT[<X/
M&XEO>V<\04<?Q]J2CT;C#"T2"'28:)BUZ>B?^5BU'C C?YE..]0]ZPN=G*OD
M _H)3VLE'(ROC<3Z()"4T$Q'P0E( &]L6$R8+&1SY:.^!%][ZN-XO=@/8TOP
MI3V''W&+-S/R=Z@C8H)Z3% (,IG_5N[G/ %V\Q,@L(CD$068";,/7EBY]G@_
M;W_R?#6/U/:LE[XI,%6ZR1KO5UY<;_*'F-0AHGU>-;1GM]%583\X:V8+=(^/
M][P09HX=KG6]9<%<<X^6K/U.=N.EA!VG4=<!W>^3FCLBF!W>>LF;R7!G#Y '
MK&O!IR31O];F%=@1:7[2D@50?6OX#TPV_V\W9UL_4([GGDZB7I:((!]IC@\P
M?)D>M%.JK3P0V)FQ-;G;,LR,'#%7[9I^\M+V]ZO#[EOL1@?8A">7_6_RL\36
M'28KQ<0NE*1Q((^JG%(VKOW:%3',026+6N(,L2,^:IW9[KYW#5XBVO\S.7\W
M,#2H"BHV,&&(,% M77-LF9UM;Y Q&L1.3])+SW 0-8T?^PA-F%;%^HFLX7>%
M?^B!OB GHRN9$MW,H(:;<TI"<Y9VV<*,/+K]*WE"3Y@_8(-,.!J: 0J8\Q*D
MMEV$7O-$+WGV/RZ6.NJH+&Y:G78L/@'J FJ*2*C-!A;'^F>@Y/Y&2SP9 ?5I
M%W^,9>*2W(CUPTP#N2QDACVW73O99TP!JV<7O6LTLOE] A?3\_0H?E8J&([X
M5M<J1<N<&21Y=4TO@21M\T59G,/WYR(WFN-KW[($*<MAS#EXXFTU=Z#Y")5O
M+\?J^77<C76P6@2AS(;@8-2UW+*TC.B*?9W5UXTB;-75ID';"?QN!LS7SEVZ
M!*$CQ(#8;SI%ZI(4U2&5[#DMLXPS$"7R5CW1VFW;Y")6FPSDA Z1-V9<<7B?
MLB#&PQ/RD.O<,O)6('/57MBJ 0^]#>72[Q_FM**),_0N?_,"=AK30)G0;A#+
M+W)/V,$FD(=WVW+M91620Q, @"85X1A139.H-FOY! CWR\H%E4A38-"K,IP'
M#OKV^FV-1 4[/4LZ7)XO^W,_NZ%/ +KB"(G#2NCC5_V=-JGB9=5*.W'B1FNI
M (FK"K;V+]]Z8^_N(P?NM/;_^.W?5U8H?;J%3[ZN8$;FVSIBUNP0"+SKM"X^
MH;R^JK2HGV;W?PV4/88/LS8C/B6/#KU"<^_]U_O^XV_NOF+(_)%>Z/GJ<9@H
MXOC@$^%YC+&F33K+0"D%-G)G9S^7$75T3LR?E:O'225H,T5CX2 @_(,*>E5=
M!.#7@O;5'[_XQ_0E $$=>N1@;NV?.#QX^-(?W^)!O[C]O0\"QPT8S;^F\M@?
M.0C27QASL'JD#?Z9>X7H$A(<9YW^^6?X8N4:FV9]:3_]40U2!U]]ZY5GJ?>-
M=/A9E *+N*&U$!Q'N3@:P^U!0?0=K9$6'Y$!0QP^=S?FS>L7XJ!,%VAL>VO4
MO(<,P*LH[+WQF_C+ N[]B0JCPO G0++3RLW82,R1'/I*C"RWBW'*OY?Y^H];
MQ97"_WRR2<F*YI]2DZW^"7R3N/A7#V'_]P3M_V\VHH&#5>;6:;Z.%R3B;HW9
M17U@;'*YVWXVX<LN&H^J[F8_N6[5LH/;V12-/+B=-CZ\JELI_XUY*^D > T"
MD"D?J?+TD0(Y;VD#F]DC1MPL3*,_6;"'O:?U*%7S9$@__H4+E.OWCH8EKB/>
MW7:;,&X2/J>'DSOH8J\'"U-=*I[+SU]64O+ZF2XPE"<9E)<PN">X?DQ L02\
M6R 322<3I>(JW*QD]'/I_MT"RN]/5 FD4Y17DT8> F2M?D/Z8EXU?)M5#C*O
MIC0>7E.YDULBHHVOW!D!-$>Q-$HRH<U4\Q4"-V4,*%G0-]KF'*LJS)M9L<']
M?9BQJ^*[Z,U,.0[MPEH^E5A:<Y<? _R3^55QHF"U# UC;[X-2D0/<Q YO06(
M)MBR\^+H*#3-.+*)#[CP"AOJ^XWR?)@J71QT=8KR3EZOIJ-D1N*\M_IC-5/'
MO'[BP)*3:O$Q[AH9SP76XTCLPW DXR< !])>?#K4GS5XZCA@T\2/UUVQTH=-
M,13D+/!B35PW=/L()TB3O'O^=%^;$0.T-TL[AULL&)\F6.".UZP9:@98Z^K:
M/U%7WL! K0QPY<U\J4YR7._8830!9)RL0#N>^)[Q#/5CQX?=0'X.465'RJVE
MA<55.U5"5M'^,:W/\LNE(M\MXC PFYDHA:W)?!5O3;ZV*<YKWX:N%%;$#7Y0
MQ-0?V*8U#_NTG/!N^Y)>.VB:#R2@W]XV1=PM7YT;_DHDS*87[Q7B^;O2Y:9'
MBFJ5AJ58W%5EDHA9)52$%4T<11SA0X;<.7A@E*??,P<']%&W<;I!P4WO<\*2
M;,31)T!F06QZ@B!@[R=+QSW]K=.\0T.1M5XE2'R>_C-.D. XKK,\"E4F>CG^
M?B33EX]*;3UT^EA>[A=T5C-1\^1/ '2J6L9H3&4?X$/.KP:/CZS\\U";Y-<Y
M6T+P"/",T&X@KZ.O%,.1@#-\V<A CO/+ZA6Y=3AAKD@MXVE?B#DUI]2\4"DO
M^4AIF[(UX3R/ KD-\3DW[^?@G7$#ZE7Q=KOQPHV1R$S%7T#M,$&KJ735<-(X
MK2'ZEP,K752/LP^L4BVU,,0)8\)+"OT/_&R$&2FR]%G9'MG5$(!^Q_Q6PZQ^
M-ZS_1+U%WG??#()Q5\ $2#C*9T(#$'B*:EF?A4;*%/$E07;.[8!T!@7XT8L?
M4'&: @NL.RBHO"V:9_B4.%^L'*0Q-S213-*[2'NPRM3.B.CIJ=>][27J_"E4
M!G<,=> ]S'P>VNM<]>>/-V(T6T>E"?*S!!P.O,T"Z6;Y3A"$D]8U/I&@V\G&
MYM#Q@><:1E--:&AQ@D.4K.\XB1:5"Q=7"P2H]U.RS>0QJ[_7'5O2AAUA@\R\
M?O+H37EJW]"'1S5>J[Y0*,W@"2BS=$)3;3_'%?:9^[,F>USGEGY+=(L.NM,8
MB&UV$;4CS_ZMF7U-W0YP3?O1BAL/MD1)GA?@,9&?ZJ)L064(3NX:(MV?/15.
M0%562^Q/?KLP) I+*643B+1D*$ZNY%9<\P@U0Q<BI<G8+;^N1ICWKI(*>WY>
MQDH=KMC^_&E;7(HN/CX^@X+*R9MTJ1L>.EIT>V!@V=8T!SJQBJ:, O<1 V1
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M_9.B#&P)>K",VBQ?2TAAFN!^S0,WR6OR%$U6;#N"IR>9.(.]>6.WO*563MM
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M=!$[1R9(3\6QY275MTHU3 M'P;7UJ=]T$^6-[Y!PX8R":?,9B(.+Q5B$L]Q
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M=$JL@O_K<AIY$$;ZFM-[W:V$;<HW8&OWL(MB9NM-9,/G_HT&ZFI2[7>6M40
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M%MH=YL/8^JJ3.4=CJ?9SJGG0M1:6W\.(2/+5UR7[DV"V&-HN/0PALR$563G
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MU[DE4BB@..8F4>UB1'@4E^4V)[Y@A6.BJ&<V@[YWN4X@9S0?;GAE,'L3UVM
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M8.Q@M-R6<!=,AVHP?+!G5/!9DR)>MAC:7S(/^4<9_S-VZFEOQNPY]4]\.?K
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MU67WFNKNJJYWU[NJ.R2BJJNJJ[K>SZXJA$A" @F*$OD5@@268B1$D"$DMH%
M)/)PC @2(K&=&.=I8P0XY"6"1/Z(E^I?_^[,G9D[,SOK-=Z(:<VOIV^=<[[G
MG._Y/C[?[SE]^DL__:6__<JO$5B>?>755S_QZO3J],HK7_K9P8V[KGH*@D7[
MIA>4?OCFJ<S!T:M ^$T(?.4+WS56WBD-NR=^>$Z*+[[^]_^;__;U)TGPQ=<=
M7(;D:A/&"3<WH3$KYFE.3U3P^G<]^]P7QJ=C7N5AYST9\ZQHGXY??/V!^-/E
M\^TQ^/J3ARI=^L77Z5O!$U=6GVS*)GR"OXF^<8)@^ E!O EC.$' O_4) L$(
M""W_$6_ V%.<>(JLGCR^7G_VN>7]"TT0/=6W[&-WR[^^^/KCO*[7ZYM7],VR
M.8,P15$W,@CRQE+CC78J.F]\HV@_?R?RG,XV;$]-4G5)63RY_=OSR[[[XNNO
M?^[)"Z_'>>756QV]E('OTVC'Y^</;G@&D_P,OC6PV]B6=D\W3>AUX7;Y>X9
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MGASSJC\51R)*ZWU:>5Y1BWE=$U/7U,  >HN@;6\2P=Q$;$O2*[=$"R?$2<I
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MP9F9=P#G(2J8P?>4:<4!1E'$1N@MPKIF]TFU*OAC#U7' VGIUUP=3RA@'K!
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M7%9UE2C.(DNNQ7"KVX@#,'</"%"YR@6(.SL'&B/,*"_I(&]CW/,V"''"%M/
M"8M#-WH[PA?,!\Q)(ZYK]AS$I]$&81ALDGJXR=?A"";N#&[Q#,[%%=E?Q]!>
M;= P'&$-O:M>8IS&>&-3BLXO%NJT!# 5/-H9V8W^-6.SS%"JK4[/:V/D#O;M
ML#D#K1410,1*"50\]9UFYR"V!05,?C_#63I-M8.@2[LF)'W:.$ELNNE&(6TS
M7.+WQ619 GCP,GV)X#>&NKCA%X^8O^OMGI!\6>F,VI&$M'-42&7?7SW?NQ@K
M9\[C03$D!^LW4&H55:Q9U E2;!ZWJGY+E8^Q'K$A3WYRJ7?<67<[<]$;=ZIK
M CR*Y::6C%6Y;M45LBBU?+(=(S_089KT(18D945MNJ1V"-\/#TV(#W=\./CU
MGHI[Z0)+(N=)1+<EO(90%[@S1;M&F?PH+/R'_6U< 4Y)#.ZYU&N;Q2R!CK[E
M?',&ZLA)N$I]/ =+C&,]BA=L<?;K%<>ZY:[WBJH%4F+T-/<D=^C6<[G&(0P1
M2JP+KPITJ!&7)>QC027"8R*NBISM]N?V<#\$9;6XS=4J/V4)-<S$VC2*^E 7
MIK?$:!E^:H]8XZEP9W9(NECVT]F*Q;/(NNFX,&Z9L$\H@3E+@6[JXST1M(-S
M1DQXN<[,+2>YR77M F1ELM;U(UH&1+Q;&W4QN;.%@O36A@9'.#1Q)[9\81^A
MRZ&^J![*R7MBHG?\*MH2ID(4')9QC%PW! R<P-0T56D3'NV^DE9WP79[MXTE
MGZ?1IF*@2I/VD!*D&+AU3^#B,EG BO9A"OASM3#7O075MZQ=HS<WE3TS_>%P
ML<[=SIPN*O*(#\7V/F!FF#%046<%MV#D"C4&)NT])._*53<&6FX/%C-?? QB
M11W8^5N=,/86DU,Y4UGS3%:J<H]&Z] ;>+AHG*IA.EP1]I>&K@QY(]JIDV3%
M2L+PBU<P<JB-G)XQ" L6CFGPW8$<=@!$^5-(]*.'6'%OQ_?LW%[+CAM]-X\;
M$V,.U S,)C8[L<C!*MF! G4)PD.DV-V1#4[P;N[9?E7.IC*M-47C75%:9K:@
MP>L\XW=-V8&%9&^(==*F@K6XW,4=[!+"'NUBR"3PD@"."BPV!C!#L0,.@TQ&
MF:^K,C(8#MZGK9\+0TVTC,1BDG<_1;!--5A!2;D=#\!>NZ#ELM* !>)P@R,P
M@4$6$4B^L;ARF%C"NZ.@QH:WEX71$;E.5D!?OEB>C)TWQOF^RAW1Y+OI TS(
M>]_"$#A@QZ8AKV?(:6>G[2Y56ID&^WB:Y>A?B)$];?;&'L=3D?3YD=<U4]?"
MQ8UR..?9G ?8/H"F761H1"'(J=6HBKL$).Q@;:<,4=5L0M7'_*%S,M[/MA@Y
M25X1M@N!E$)9CF6:[I2EQUZX8.FYW;"[^5 #X4#2A6C>TON/7QH"2;K+&Y"6
M"_R$1D<5FKSV G-@P46+4<W<6]ITG??@=5OSD1(UX(IP,4+&3IE)0H.ZKP$W
MDKF,,YO[""5E@.8HLF?AU [UN)\%IDWT BO<BWSUXW&/<;P],T>^L%1U7[I]
M%1Y J2)[=$%J1\>^3MY56WL3J3'EXQ82L:PJB5MKH506+]3@.(B;G!U1(0?6
MNV21G^C=\E.M 7\9,2Y%<[/,XKCRP40I\OL>?;6P3!UT*25OQS0BD%:%"UJ
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M@#.#W#9A@R68:104G"[@[<2+J*J >;S[91N[G6D6%L[UV>TLDN*"*2CEJY4
MY*:=AN6RBOO]PB]!',R%UQ<E "E]BS?4HE4<-(S0\8HK45Z$CXGQ 6_(/#8%
MUC?=,LG[O8(<SFZ>8,W499[B'L_TT-@N0K0]/YF2/4Q@V[CV($?Y(D&4ILPU
M&TNL4*W,>WC;,9M1Z-,CJYD$W0Q+/-_J) F2U:4>@.%VF%&#'+%=D55$GMQI
M7%;Y.M_.B RL=085\&;B!AP&L1EYW %G?%6^&!':1F'B"K@$SLDR=<#D!A5
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M'[JEJX7UH@6:X<S<L1_M4W<J3OW-(NV;N0W,5!6+>*6T$Q4.N8TT GY* ;>
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MM&]NN$ =1A)5A#;MZ?YDFC_\#H %$(&9I102Z"4U)36F.#TY! B;DEI@8L+
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MC&O$J?T*143N6=$F\KR-O/7<E7F)I&"&X2/#A$F=0H-"1H6*GM4JK6S[^?0
MW(O^&FY*8>28>?T D:6;+U5+;3/OCP&OYUSWP7ZIM855S4R0XHYE^A2'H& %
METXF5\@9SF?L"H_=3=R+?C_)7\%L'4DL;@$A!MPO.6<-.E<?54:RN:\SK4.1
M+,<R7Y+4F&9W'.E5I3[\4^P4:R0X<7J\+#R6O)*<7"F<\W1+.W!'&6Q8'A]L
M><KPSYEGFT:O5CR,C?HM:Z3?Q8J)V2;+WD0TI2B,S TJ[.LQC(H56HTO 1@N
M2/_1%&.X)?2C8!7],#E1^E'U[\2A #:0\2T \Q"Q'YU>M]+$@["BTQ7>(FT$
MRCD"-MF;5RT:B\D1K#?+;DG_R-5>_-NHB-J]U+WS7G&:'^91IG] ,GG&M-!L
M#_GI+()V(-9R(TTPWM.8H_3R1YM-4%B5@EIZ7W'[604-C*H$$@+,\'\7+(.Y
MK?H@-)G357+RDH]^[/'<,RU3=G]S?_?\RT/H0/=E3&O]ZX5!EY/!CN7"+''W
M3F9V]->8N!PH?['UV6!+P[(EU/UW?G)=(Z2!>EG==I;56$'&24TT2I$7/+=$
M8O9"&@!R6\@II%'@4M6JY,G!T"*1:M]#'S^$&V)NL5[<\5PO7K]9O17EL-!L
M%FA+R.4I.&SI:3C@YAJ\U_Z2K^=%F;-JIJ([)$"YG@),+/\2(V>,%Z.JQ=Q^
M6_B:HU0+HHW<&."J-B2^7M1_+<19'<^UD4$@O&@_0D]9C2E;3Q?.\-6 G)O.
MIDM3Z 43_7#".AWA3O"^[S=NIL:./TWFGOSA)G 5-X#ZJ(7KA=R@F_P. %YG
M C\B6^00P8VHE7@K\N+JJDZHBN=/N_#S4OH2*N2,QLI(,3M2K_:I%6HW/4"<
MV)=EA9?KLK:)< )-X^ZQWP']S!UF,#\I*86D1V'O.X)E2B^L*$._E=>#(\=F
MDW-(6VOX]X*J \/05NEZ:=A;^)PK,]A$W@'QMW?$S#'):QAFU?):V?:3&#P@
MBZ#A)71M->X7VO!FG_1I_I\;^/TN4CW8*KT)(;3>80#23HD.(HKL4YL@3Z6D
M_F2[MSGCT@2XQ;\*-CRWQ>\ 32:>%[>+*,A#;W_-SRBGNA;.0MGAPPH<U0D4
M)Z8#4PY'Z9.*'9.Z>U6WY"_\0Z>&SZ%LP8+/YFZ=BK8G%B<@\-@2-\*B.]C9
M37$G<US-<\7/W>P=4/$2B-'$T59M$-_S!4M$HWO_'>"(*/[5'0:F[BG\:_@]
M+)+'R7R W$ZGHH<.O\8?W:I[J>Y''LT;2$$?^5_6(_FW(N^COW])M<WTE7M"
M+J*/8Q6C>X3SY\%8>0Y34/2KN+"_9C?/U2(L5UM#H??<?:^)Q7PS[X!&;8Z5
M2V^1LZ]#EUO9K&2',F%GMZ4.,"8"9NVG'LOK.)=(W_0 >0X]F"^4I$^P8P_]
M6\WQ4_?<RK^5DN:<JNQ)HEO=(>LIA&&7[18F?Y=_[YU?GS+=!_D]))[QO=I_
M4HSOU>O'@\;A;L!:F%0QZL'(C2YDK%HQ>JM!!!NJ@GW#%V6QO.R)>:AN8$M*
MX(+#KC!J:C:R$;K,MS -;IXEK!HVEFC:[E-)"CPBS4O.<S"6I5B0-%1Y.VB$
M.KY ^!M!.$KF+?O>LL8Q'Q/S4['#E/#S(PERDMC "Q F0E"LD'F5>-_DFD1Y
M*I>\"''A;@'M@9V,M&VAK^?U#6:,5.: Z/F1"GE>W0 >)GVD!!X,'9WC/TX@
M!E8B3T'=@6BEBA&'Y7'O7HS&&%,X9P84A'0P:6-7E:A].GR 3]^)&S.<707>
MK[2U=Y;:W@OK$2+( $7W+J(00.Y5;5EY<!XJKQQ/J_U\,1MW]7:K!0B3>;E"
MJU9Z60X3/3,K@ =!5I<D E*?Z*2+RO"LD.DWOSQV/!]&/0]8U:QI9.)D;@-U
M*C3+#4GZ< ?@(2/ Z9T8.HK03]B19J'E-)+9;((!<<OVS1X[V_8Y.(LSR^=-
M$;;F(-YY]8,3R2P-,+CXB_8E]1^/8Q(?I%?G>W2?H%GFI]R6?]-)>GHQ@[KY
MU,&N/H_F:S">YI[LN*>W<M;[DF=,J04L.U\M$:EZO<G+9^%^JDB9*^\B98'T
M%$\\GQ+AN_,N&>T397G78@I7:Q\0I^8MWV0;$1SLQA/=Z-H4LEN=.4:9@J1G
MAFP+[\7@4=/#M_<510&PA-HSE2O/^,+.!I4A'E&+=_+1;_914#R%2D4=PV9;
M,=6]?I.])?]C5"PZ@DMJHW3LNEC;>*7Z4FC>!C8)6%9"*DK>VAM36>.&S"V#
MH19:,F=EM:'6;E$L=;<X"M'ST%/39'Y6-G5<Y':WM=,P/ER7$-/ANM]26Y+5
M+A$37$VR^90(Z11HY:JSL6I7AT#<USH%/=. -TM@W9(:VU:3VL(9H_W%I=81
MK7-*4(,0Y;@@5VT#1+I3;ZM?W_)5%V5#4_BD-5KGY[S=5QL:JGT\-7[>*:HX
M_)DKBBT^CF!<(SY/_RP70F746N?3M:@#\=H5K=??5FN-/IME-K4,$'K1Z/J<
M=N"<*L</T]]">;/X:EI6^*.[NJ.=!@LFB,-Y4WI";A8\X<B-<D%S>;\)DSBA
MJXMX*_H\2XZ?+]&:KB&]#=YV)0+E-3M<BSM=5#8%;>IFDQ<\7@[)(^$HGH72
M(H95;_F@Q13%LF3=%6TE=/1FDUAJ\Q!0=+5^RI(0[6>FPX<!"SQQ?2SW!AO[
M$N18DH6UIA;DF<---K#E=27]UG!-UXY/C3^[[F['[OPE?ZWWC*_F>%-UBIFV
M^0/^B'J3M6=-]6:+O5;]Z224S*N9VW6";X#\YP1N2)%)MDQKD@>7,",IUYT]
M>Q4CE\:U;\9=@AZ%]/_\'NF_&,S^EM!83U:8,2!CR5\DK?**!1K0=<2G @MW
M1%B\7[0;Y+2[N'[L@*1.@$0>J1GNW"SH=N8S2O_:YP*E@3;1 ^[#+UEZP!I,
M3<66+&3*>+P/2-_#4X>_H(J[IN6^I1J.W=R_ X[WT@Z>_((V'>Q%[/U-CI;V
MSVX.^;\,%!7.0D,C>G!5MC>5HH6T9Z[&5U#E)/ )=A1JO,U6?_8!<]U18:9]
M"'S"(]K"[S#JT^AMB2FTK<X+8V@-V20W>#1ZFFZ%LGN>!]YPOE6S!*U@V!LF
MH&^_FKX#/G8O12/6D2YWDGLAGGWZH_C682T4]S!P MLBHMW=ZW2_)W8>UL0J
M*_B]4\C8Z+<'67<ZG9IV\50ZB8=Z59<9JN_!8)BN91ZA"9:T"^E"M&#.#5M<
MNL3 VMN.1[I&6"J68^T'I/L;[[A>-J VNH9(563KQ#/V3BA+,A=R];;#(_*(
M9JV.9G.4XL$0[&"C0J1ZW>"L>R,((K>_$TG2!M4\K1L>,<QG"TG^<X!)+QRY
M=!O[I[A?0<(OS_@YCT=Y/$TH0*?'DHOXR]M1*8J&(T%!P"A!5E.#[2[4I@+[
MAT24/,=$I&Y*YT+#70DS(76B"V=FA&:$74_G$R-M3V,/L[(+O419S,L^F?<
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M6)K9RCN 9Y0186BKHHZ_M/XEJTU\IK&JK3J5V*A4U\N_YC&ZG(.DMQQ,HN\
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M$KRNEG5/5]7F!/1TM:R(%TNKP=Y?#UV<#K.E9,?9K2\ZS/7E(YX^,934%7U
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MGM;N##ZNY[\#A"S:7_".:*]1SUX#9M\^E_4-OW&@GU!>A.V_ ]!HJ79RC5J
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M=;2U+4BAMB06'@FI.6]Y?9\K"WPQR''FB!ZP0AN,V23EY='4PD?TU,"A92O
M<<-=?5:9^QUWSDH-*0U[%D(RJUU(T?C3F)&MU$6,+S>!U5.<6-%_U?>Y:4'J
M-_I\\]([X,_DPCL@(?, CGO[6GP'L[.CWI8U&[MEHZT)VN3>S_1#/<&Q9>.$
M=XOR<:SNXUW(6<CF)#_Q(N[8/)YBX*YMUNP[ $#8MG1'NZ]F[F)W=[6W=UU1
M=^*,I@A?'[+1-TR8Q]+[Q:G1!?.58^*EZQV@ZIJY'4+=X_1U3JN3-;6;"_.V
M:,/D<8LLX<=3[]Z7QNXN.-'3/\(V%I*&5PDBI"$G"+N;L4_")BK659,L(FT5
M+[EU'=*?&3-!EZ450CFJ?HX#!Z'V+U*K5W**4P,6K.O4SW_]G'AJ+[+](\=/
MXXU])E(FXG0WOK9VJE2_6BD/%7EG3'KBCYL7]KW9;+;R;A)?, P[2!.RO@.P
M_;C6;.]O2CI_=%N4=PF"O'W2[9[J9TVS7?]U#L:N[8^)R(P80P*6,_/Y%5J[
MTU9&T%9%AK[RS-JW?5::(W3*1O6^1:>(BJ>?C?5.O;BT:FTX<I*?EQ"9(.BD
M;<;W6M'^,?U\5F!]FGU!RW#P\FJ=V^E(F2[WUNJJV,V]=\]\P_[!2NM*1&.W
MLWKL=A6J^T]I([OQAN;-@4G;4A:QNJ2?81JF:S:QETK3S$>8IC8R"(?)T7-@
MHS2]1T)H(:EL(K2]SG5U\QZ/X6055S"#,6I;]QH_O(*W<6R'=) YL4'O@-0M
M8Z+?)96QPLQ ]S/P^"RD4JDR(F B/8F;X*YJ@E8)/ O\%9!OMA+AX.54%I?R
M<$*!COM,Q]V9KN.9[(X/NI ]WU;4DT!K#MU99]2R"J)HT!F5.^Z #%?LK$_,
MGQ)Y27J;Y*W81Q LK@"_?$:)\'6CJT#?'K'0M=Z<S=*B6&0 JZ*<'%Z(IY[N
M+JHQ*[8+*-(1#J1J+<Y9O0/8#DM[U.BG8N]6=OGMFST'2FF#(D/"[.8#.5IC
M/,YN_$7A>BSL-'1?]\!\OW9EF])+$VU@;W+0RP$_H/[\\ OH_X3H4\+5/P"&
M&&CV]0?!=\NK0G8&9I/<J66*6I 0ZUOJU;!B\X99-Q2%\OKYAINY[\?L2_=T
M1+LOU'X*I%'[GB<:6.4+RN3?<RJ5O]\4O?F%S$=)]"VTX>4VT<V/1TKX["L4
M6YFZ3YUO]LEK9*=RZ7TUWH._5,?#=(Y%3^W\?I2^]*BY;Z_=8@=AS!''$8=C
MS/IY%_@7%N""7D[VS[:1XVOX!N@F@3V!O_P$."33%/%G0U_[EQR$Q:U7W1/>
MH?*882(T:[6&D@%47U[N%]E8#&J?T,L]9!BUZB?KLGKB\9UGFK6ERBO&"G*=
MIZ</>]RDH4/$D0&#_#*MP6#OVF<W%4F;KUE,F22A^.TF^*X-;D&1@IX43[[G
M1[Y5!IK!4.#ZG@#EP8P\%<+4";O5V($DIS2'!;G44"EYDQ^KP+S"BVM(5GFB
MI:QZ>MO<L)T*RO^5UM/G7#K/U\OUT)!LY9HT\ 2=I;-]@&%+4ELB'<K Y @M
M#TO40Q&Y^A&/J6WO;-/Y]8S9HLT:KP(ZUG%XH:-GRNUSHJ=L:FV5D-@D&B=@
MR ='00*YIF"1'+&LO^H7A?5'>)#_<KL1HQO/ZEW9X[O>.-HX2W%T6#A2A<S5
MIHNI8]J" :Q3"%V>8XD93>5!:B*T50^%!EZ:32CQHEAQ'2B&RJGU/#,SZ7@8
M(4,9#./74ZAE2:9(?^XM5B4OPDRFD5J:?CUW0 5_,D+SQW+K/IH3J5V>K)NM
M$D4+)@WX,IOC^4OBN*R^0KFANE-/H&_C_#$DQKV]U?^63"-[]!I]A,P 59 ^
MS6NU.":D0H6@9S;'Y9B$'\$_9.$.7C]3R.^'29&)5(VM\;R*6IGW M]KZU+/
MP49FD-Z^%IQ'PY!"[MV7XJK .>D20 1V#JLR&3O&4PY:AQ>\?N ^WUFK '@&
M.0TGWTO]6>!>F5>J>*3(+G3[KQOEYJUQ= &^I$'-W1H;%)4A#USFT>XPMR 4
M_&>!T</K."PN&(./ ?SVV-X/$!JV7+^YP;Y%\Z?XQA8R>CQI8!N%;]- <_EK
MEIN?+M.:@V$W&X6MLJZ[_0AWRRX,/Z!>OD^R:#9TMS3JQ0?:+[^'A?.-'Q!2
M5@+_^H%<V*^+#64A3C;\XU'_W4&VA\@E]3M@8P3^/Q^Z2?Z\ [J3WP'>@+L/
M?ZAA85 /%DL0$N!@)\?$J\K>LD7423\W;.KS=WPUE-&/"YZNH)4T$&+<+3VG
M]^_^0,;Z2F9"L25O<$;_G/#?FCKP6C+;%'.;MQK.'33.E$67]_-T4RVEB<*.
M5//GBAN7&6:Q<$8>=UE4E=@N= 5BC<&_^(!P+^85:W35L1 YB*A*V6)G.HKB
MO8PS?FI[VD:Z*.H[H/Y.:%27%3+;K'XXSPA/2FU+N %LN)U[FD$?+3QW&P[!
M<FOMUSF)?&R_OB"WYFA$ZA?RTL@[J:72OEYI=A\<+JFA*I546'.:NQX[14[H
M-T2!Q6$C*W.L>0?T9%>\ ^@%)F"J\./(""+OSO(M??YF3MRM=S*W=7XQ?JK/
MCYQXT.I"))LP2V$M%[$1?O.<VF^N-"^I]2&CM+G/_@N8WQ@L%>'(Y\QWKXIF
M94VTS=9)<?(0*A"^)Y691W=[Y=/Q6[;X@=@Z<24>]Z>%V(II$W_L#Z&?M_7K
M9?1U\(BX;:@?0N!RM\_21%C/#IV?$/H"YG 7Y:W/0,&B09;N#W>=1W$+KR@.
M#?[T+55M[V]%+SN1DUB;?R.;MI.R<R,F#%KE'BY?=FW--D5@B-*7:?H?,]DS
MJ5K:'5U]"HV>YO)CY1_XLJY9T\;E0EZ6NUSL._DV-)UT\2DC\=\!H5V$=CS/
MGG,&(G\X%PRR:#HZ04V^VI:UBJTC?V6$G7BZ#J0F9-A0Z.\K%!VWD(L*3;K^
MO@Z>M6D76-H![=-1]A_,CU9O+0DK&;+27RV*E475QQ>7B?#F34MI1!/T//8=
MIA5Q!77#&U8^(#UY(\7[,+2650V'WKC)@S6/VQ:>YE6TB<*U XW*(%^'6RJL
M'=UR!93,<(D:5\\L, C=+3BJE\JC]?1<G1*/7-/DJ+:Y$9N]59Q@87%R@_2@
M=5W4O[KO+ZSY]^2]3J)>JCW,%^D_P41V8KU8M(&%3VW='_$=0P##-#"6=F7V
MIOM(>LY$I7J+KYB8'$U:;1$^@\7N";<!B0@,+^E?OG^\;,<.C]$<P 4<)0#R
M*+8J.^IO.&)N*[7> 6,^;N\ !C>-6P%8U.@&+_A"I\DWDYVF1]7:KMPE AO?
MLBD3'1,W"UM0."SRI^L?6H-)'R:'D4TX&9GP4A8G6WA;MIM<5_BAFFV6C"3Z
M4!@BHU I/%(*E2^FD_I:+H6X/QC49RKV\ 1F]0HK^>],C^**>O4<^X#7TA%/
M*J'Y$).B\L0G;'H>QUF>U<RKN9V\4479I0R:$LF3OR5%\I_;DO4BJ 3EK1%*
MODI-3TU7*)M"/WRDM#S^9U;Z[P#9O>R7P4'[ZV*S'^+5;$O/&CFOC)6:#^&;
M03M=[B7N;8V9<33_JMO[SW;#_>,+/I"3^)K\/'43GC^DHA!F#4HN^&#8]4N1
M !/[,[E&*RDYE4E",8>AWR6&@DJ*W)2\$FEN .D8[-2>I(K-EAHF/F-! (1B
M#4T-VEL@/P#"4-I4$57[@_AS_(X:VSUD"![0GVUAS\+G/*276W]"'+ PI,%8
MG8CP_+5D5=Z66=96M#ISW<8![1:GX![JM,WH-,)6!AW0COZ1%UO_1?;/&X5?
M)#M:&D6KLNV.?GMUY;@:U-AL$H[@$^JS-L]]?$I(^;$W$TU^?$W?VI35L^&9
MNC>45IM"6[L>N"1@BWU(J:5R)F+F2:@*629<'RB9KUFAVC#V_(A#:3RX.;[Z
M[, !/%Z.XH(,=&@:@[(F/FJ1A=6;IESS[XP4: EF&]T:=*A;,*@ZT5A3&:-\
M4,8SM[4QPM6"85(S&=[;H]ZH!W)OR@TQF3#@1 O&_3G9*Z/U0V!#X7=*O]-[
M9GW-=*;<][6@:>IQ_CWLK=DEG9H2X#7Y7/,,'3'V_(\:!<Q5)VPJ##WLC=2A
MT?4U74(WA9!?]>T[X,W3O*55%F<K1"&6%H>[T#!_)A\"+><^B$U B^V[2**A
MYI444\]L;+8)ZASSK$O(.D/N6,G/Y%,+868A]=8\DV9_.LJ)O0UQC&3'1)C#
M9%_-**3W/],.;:>XJ?S%9^#5ZHQ2,!.>I^W0Q-Z?P;;1Y((X"FK(VP*K]4 Z
M$BXK,+Y+FUHC9!8Q4U=8TD>36'HS,59]#!]DL8+7/_)Y*Y'@]T=X"3S!@ &<
MW/6+3\XOCG$&96F1=B8?UYM8  =TW$SE#)6?ZY>D#(H_L]G503,$=8D:9&3#
MZ%/[@A7@R $ HEPO '[!= \#;R*CGB*8K[R9 ;._IDSG2L?U+E$A*-:7N>1[
MU1Y96UR</J:(O->K2;/7EL0ZOPRD54^4?5YS5QYND.V.-^;V:)8%U'L91F:3
M9=F@EM:S>PF!PLV"0=P-QN&MQ?I_?KMBLLX#<. DO'S\8?:%_ :09>O+Y-6%
M5OIL'?9U4.NJ5L] ]CX+59D"D69>D'%P1I=5JIK#,&(2<HU /;9F)U98 ^-/
MS2"E;O%4CABO$*7Q>T8;=2+?N$6X8@Y&YCRU0U5E.@JGO%_F$<I41R@@Y?XL
MPJ3\R3;F']YGZM;:LG3ELPE09%M+ZG!-_NE9J5(CW0534-1V%TT^04VDR41F
MW'2"M]2I5HX>N"1"_4R[2 U#!L5K><*00N++-XD!=G_^E%Z_/,%? D\'84)?
M6VE-PNCV)7$<&7LW#4S7%&B?*^@V*D"S<-[#R>O#'/2QT.E1+N6Q ;J\QM7C
M;4]H<"[#R3##\4BV5O/DB"$FX,!M# -=Z1=D#F;Q]"WIQ]7U/LM;2[S+H6\H
MI%6DD^>T]2"%<6,KKTJJ?'P:7&;;A:\8P=(E;'$P,SUB_T_D(S*NGO,6L?O\
MZOP.:%E@?8QL>G%\V/@'(-QLW@&KMN^ ?>G_[<V=B[O)MP/-KGV>S:O!3>_
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MPIO/M0\V6^Z8^!5*R]R?+BB,4T0>1 W<8R@U_%XW/Q242?_R!=GV,7?8G!)
MEPUJS?^65*Y5$3:YJ9_'X^B1:R#$&DJ.4%#0L\00(]0:4]"7J.)(EQB&S/L;
MO0,:VF2M*X85YNAL2(JA0NJR\[5N*DB*"6=VC%!AGVV,B$6%I 9>NV/ITWU,
MB3U$>*0A8,QG)I6<0#/O8WI"R.W#[@*U0JK[1&NJNIM NVD7!BH^Z:H^+'_6
M[IK+OC-_(J.'M8"W]EF+.8(NO<(%7GC$2P3QM66L2S:SX!9L"VC4;?<#]T5*
M:0FW-)2VMZ5BC0?_(4NP/^C/?6#<1GRB.[[I=(M*R;1K$%/LW0>1Y):)QM]
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MRQP<G& 0G&"W^) XX/7?JYE$RK/-9T^#ZE&O.4?KXGBAJ?0*/>8^K#$SW+Z
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M2;08P (A"\=L?8/Z'%V"(&,TEBY"BRBFU>(9DLP$.?7(!)=F"C&&/\-(Q11
M' 5R_=1A^W!PT?*4790VLWKH?<N5@?LM)JA^(I5'Y%/YHDXR4I2I\B#H:]X]
M"X.X9MJ8;(!:2SP7MJ(4TK2RM^<2Y/M.(IN6L6E[5RHZ.7HU:?F?F)FPL'"C
M-A)O T%TIJ'_O,6F609,_PU)U07S6#7Z&]9O3_]']*H<P*Y#2;Q")->L6H6J
M6I%5Z,E85#,SJ(*VA>MZX9YF$7LFC3&A XWJ9%=(EO($K4-\#':/M,,+/GN(
MM#S!U=6AH1A7*)(>=E@5^,S</!.XS(V6:)7[JW/T:\/BTEXRR7*715#5XCO@
MM8Z90*"W@Y(DO.$)/>,LD=7C&]:Y/X*_OPM[D%>TZ#6IOY"73X?@^,%BCN&6
MI]@<(U!2&BT.8E>U*AZN)F<"EK*B#71UI-,.(<%)MS>H78_DK"0 #[Q^^* 7
M/A(7K1A"T'-]C2[$5R$R?_PHW+RO!!%E5L'%"L E#;/"Q[)MDMIPG43!ZE&*
M;-RN< QMT*SO" ="^!E8]W>D-31TJ?%4_F=1=-#=\M3\RAIJ/3$[]9+F"GVF
M":TTN&_?*]LPW-BRF4\1LG#^_M3&]^GGJR#"='^@G 3C/;.9FI&Q?ZA3.5,M
M?6;NSOIFW=D?L.Q._+4]!:]9-%N+6>N]VD;%7C_D2EUIJD&HJXIA)DVJ3#R^
M:7J?AG(+6#O;HL([L!GF(*D+2:<GS#B5%/.$5XG<+)I3EEPUA^Y=#/*SS<Q/
MM%B4VFI]'AD1XV'LBZ)G;2IN.HD2L#P@RILFHL0T65;X#C[ :VG$QMC23Y%5
M )G3*J_$S5\^("G/=%LXL?6RV^-KA4;XAVLT=?G96S. B :R1*[2T,P;!M<%
MJEQ.<<-TUI</QW]H150TIB0SNBP7W$O4'%)96#6:Q]DL)YJ0\("P*=6#1#\$
M&'Z!(Q=1WS%Y!P2*Z+RIN&? ZK-2";,3G:Q*S3Q>"62>M/GHN/N(0>\LI8DR
MS^O\L$0R1MD,-/V6?%]N<L<==<>53?\*2RV?B5S"E'5$J_B925E(71B0ZALP
MK HWL>U>>LOXG@K&0DC/GIP:7VLGWK#_'UUJ+_>+SUMD>\@)OU:Q7C#AZ_P?
M:S)Q P>47KS(RBGC_:0/'R.!E5V"S6_G3=>_)NZ(32M=>7N+ZN]_@AX'B;*H
MNZZ([*',(N*?,[I<DB^V'H=61CO]/O#RUH)";_A-^('.'MO'C[)]=Z72%*GG
MSD*[!MQIR>B/=7Z'FS[.[=7_SD'^OV]1ZSJS+5 ]:"XXWS,/2T^,76R#5^TL
M1_8=K[UMX,?3=[>9VHIM.!U^M:8;?DJP"CANJ!UOU2M+GHK(6QO^)E(UDLA7
M%%#IG:1],XIZ&.H;@9^_>I&1)CNHMU#3AI@IIQ <^2KB;.][9!^AP'+297G>
ML#]0>P$*]$J$R*K:<EM3#H4%?9.L=20Q)1()I<#:5>!A>;IK-=GX>7RK;%JK
MY7JR'.]Y.R(>'A88'  <P8BY<AAJ]V@/[S?.7Y&F.A:=2M 3=DJ74*:X( Z5
M96Q50VGM50D+8?,W)+C88AWP;E ]'UC\$>M.X( 2]V]W@Y#=U#1?K+^4D[OI
MF/;L%I[6*39;FO1]53B5RJ4B"9S>Y%B96E-CD&^>AR!6YY-<)#/(#L;.HP#
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M*A)<U,:<"O_"U:2 9?:B#7Y'QH8-.OC8=C+&)!U'UAME4.E-EB=,<]TNWQO
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MQ%OEQMH+",^ZG6[LGSC0JJ/A4?1M6J54D</%T'"3IY[CT6-YRG3R+:BH<\C
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MHQ1_QIV!-"X0J2"\0T[8<89,A6NU1G%072=(IF [88T&Y85>:;1%FUI9@4\
M91]<!<D?_ Z? &2V+-N9<U':-*XS./!)$>*SS9NU/PW4:4I.4IEH$$\4P9O
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MX[?$AO"3I@'I$B?M*))6-?KI=*VNP />MX'[O(!T%=JX!^4) KR$>MP9'-H
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M:MNZGVI(V2).;?[T"8:I 2%@'5D#G5]@/PPT8%"HE388X>*D;F$'.F$3 #0
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MG4KX1@/1$_8UEE_-J!1H?/\0__GN'<$+@V9E@._^BRB[Y?RVU1!1\F:#;)Z
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M!(W?N>@]8[[R1 8N\/8:;@E6NAW?WFRZS=5 ARE$4E_]J.FE!LJQZM=JIL>
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MSBZ;L;M7H$LU:F]-:#N0)"3S$W"AG*_C4,;T;D*%(:]RB=C#"])[JZ0%@_U
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MM?_D#25^+6WY=&<#:9W^@-9L+E-??/?46[XUY)HJR6S!^$#YR-H!C?$D/J?
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M>4:/5(O'VS@WQ/B+V&?VD/%$VY]4%'?DXW8^^RP]P&L1SK"6H.][QAH*GCW
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MGRL@+@P2/FG[<X&")ZL0EHH6'T;[?CA*\2C;_O29*5:SP(8G,VY/DPC47.S
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MU"M"#5)3+_G>CM_&Q+)[<XLAH3N54N!TXAKJS<$LN$7G1J](>B^0J9=4SW^
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M9-W+5'< /HU[T+WI=-_1''=*QEQ=(0WG8EWIX).\,*FG2-)EIHA?8/J;^'I
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M-6:(Y!:/)A@/R4,M[0%G@3F/QVI*L7 #6)8.^!+"K7HU43<<2?NX2^G8M$1
M%Y/@G+#A&D^&U<JU+MK0N<SL3L5.7\(D&N+OG^#>*&#J&DV*W+U3&S\)2^11
M2*PHM44%BC4.UB#VZ[VRQK>?E;UI=L%I 5W=#R>Y4",8R>WTK27)[>WM] CB
M(?@,S/4($QR!PPHB1-OV4^7OG=DCN4QI=7]$=@/>&Z<?>CBV+16VKQH2)A!A
MLK@UVLHKE BA+WG)%&KYS5I?K&[W<*\9%>U_R+J%&$'OIMJGQ!,2SJ@."F!4
M%],%]4PFUW,K'>)B&V/Z*C%IJZ>?%U!FB6-,\6O,*84_-=D/\I5_P#M>JOM.
MY+<2'4I;JU/U]D#6X,"<3R#[@=#<Y,]<=:O7_A)$C4)+3:O24*'Y[E9Z7 FW
M=4'?\+C<A.W62PY=]JN=VK4+OM$KAV$%;,^KFL]EB>%'!XW=B/3YXM<B<7^V
M2C:<5/6MVQE.Y3D.O.+#2S5^G76QJBDR_+4&];ATL.*-]:T^& Y_6)G*S/SO
M$STC/3X](\'A7[L$6FL"ZCL:W,ER']S5$M<Y"U0KL*5TJSJRQ UB0$DT!PGK
M5OV7!ISF1E]0+ 2[A(0^4/S '7VT3"Y'][P);DWH4;<-H>R;U D_F/?C6<5L
M6<@KI/G4K6!VKWVN1,WTNF;BXPQ8L;L\5OML=U#-<,9L:9NFQL_>D%\ <C_R
M4K#'Q9^1>O_361/8",^!=//VKR3 )<?E['4>0RJ-H:2U7.-$=WV(O?F68".C
M8_K0F<#T^K(G\'USJZ-BM[^U384.V''/CCJ#CWYIV*7CO?_C3\2\'2*;8[AN
MR\'8,ED.D2P^V,N[%>A6$-><(&;42,F<#CC#FK<W(&58)6L 6$RTQRB=91Y!
M$DB3?=O XEAJ([%G[+<09:Z\5C!/1??\QONI[)F:-JEL+TZN]G.SGL*WS://
M2-2C6AQVHOYR"QRO/WU[?::(3_76K=U'7^XGBE:>[S'I)H4\K2'A;V&\3=!D
MTIW=#^N!6']]G-FO(ECO6?((]289G8<$AV@XTLA)A?TF;_U7U>AETEE'Z)DW
M0&AK!;Z;(.#1YU90!*M>-J-9NI-L.5TRV;UR-[X+/1_X7A;GRLF%* >09_E2
M'.?)]HSA+=;GU6]X(Z[]7\4W2!0V>>:[,@\*\$XYX'TZ(4Q5V+9KC=<8B1K1
M=+! E>Y--J7F\VL\B=L%!Q0G!99I^T?&NBB+%[Y-:<EUUJ7$7QP=/LR<26P:
MG?C5>D W_F\OJ[.3L2$TTR=*:5(RD\O5AIO[7Q.7YBI5;'"Y^,5(G@_3$C +
M;H)N_C!QOU* +TWADS[41_7-5QPU>T^^%-P)]1686CN)\[Q=$_^@$]D9AY<G
MZ9_JT#OL Q<7#-B'OEVJ%J.;//B8(XLD\2:</0G86V/E+(Z6"] [5! 3UJY7
M,8KJ/N7GYOL2W/)G-?UV$*77?FZI>5Y8--[GPVLIG3&MJC@.8;7"+;<DW\R!
MVD7D>5KC=4($7&8TJ=A>;\("]+I?KLXKVXZZ$0L$BQ8RSQ?=R6;BA?CL1BN[
MER:-E=^L&5]N*<&,+]=((0#W//?_01K+:$&+>))+B%SQO!XTP=@3HLP[3P)1
MYOO?K50C2S(H"9CKO[W4['<'9P7<6F_G]'Y>/%7;7+,&#;A^I_Y>D6WNE2\3
M7_X#4$M&=OI.MYBLK%=ZR;N/QGJ1IJ&^Q@CT,7; [BNMESQY?75KES%,L3!A
M+DI 6"NPW&+4+Y2P+LR*?ZKCJ]U;C[;;F&:<-!5_3?U* 4ROL)2WG@&ST5?E
MDXI^D\P97$1LNB$!4O0V,012[]OCC49HQ=U5.\JW0E1!K(U/HN(X6R'RO%/!
M./>6HO4O$ ,/]3L?ZX.NP81NP&+B&S?/2-[B@E/!&[?3X.!<2Z&I/D'P%E6,
ML7O"@NL(D7L>USD\UE(<@D@X@HE3"4T_>$VY/\!@XE,!N^<P X6&L=:UD_K[
M-2C4"0I]/ ZB&GQX@(H+/8B/3 6YQP5O@-WJISH*A<4;'2G&*^ F2DJD%S6B
M8DD7U#68[1DH^*$ZM>CE"AN'L>Q(*\ICY7LL8^@M9CAHY1%"K:-YW@^]K32#
MHB"IZ!*4I^\HX\D::/,NW[*]*/=?4:>GNP%IC>6<NW3SN'LW%K11\&DS?^*9
MU: A2ZMU.3\0EE2X\YDA]Q9O%N>S?S7^4&&B'CKLH.(.YVB4H%_W&[=Y1QA^
M(%A#R&#OX@:F]QA6UY"(4WNU!H"'?=>N\MCH85G,%Z5+$%R3Y_K)MZ5D?][+
M#Q%^$L\]*"@8+G>OG[[.<W]&2LA;MWSY_N(UEE"JW<?@\1=#CH_DBN@F *ZV
M7K2H?T  X,$QU_8&0C(-KWNQK'$0SS,25G"YF""B B<+[ F!O@ 1SWG="SV;
M#L8^0(UL82] S@.')PRWNN4&W*[^+W3ZPITLG6Q);U] Y;_)E&>DS[YZL3L!
MWZE_*_WIB&9,YP)"M4;R2.H^_(Q6^#.JS<SD5\4,^M1AQ/9:B]&DFINII8*P
MFK=\B<)%!VOD,];[+]M%V]^QBDD8JQO521BM]>SBJ52PW4H)[35K2SV/=".5
M+/7^(\_Y%^<^B@W^8/4 SL2A"Y/G9(B8Y<9:Q+2(16/2P1S$B.E[D^823R,S
ME;S4]06A;UW[K2SJ;\BDKU6$W75"(&A".CC-79O9C)&UF/E'<96[A2+O4"C5
MEZ9;[!_K!IO_[%@D*:0 H[T2W^V=M)9(R\G]=N6]-\DU#[KY84U&,A%YJ(Z!
M6!1\MSK7G_9UKB8GJUA^"T]<C@T&'7L* +MW:K3:\!40-HV<&U7K#\>N%F6Q
M(V:A^TRL/R0;(FVQK:0^WEE+&FX>:STC:5+(&%,7?0/Y=]0ZVCDKLZI!UNSX
M)IH5*0PLN5WJ.OK1V,8ZRY'YP[O33VYD4VI:P6*C*:8>?"&*PPI_7QG<3]]^
MOXI^K=OWS7Q>7F:R7[(B(W"W2I-K[\"]E N$A/LAOT,FI%;MO4[E KX,AAE3
MM>2WIDDSA$6D'IK$ZP[R?VCQY8F'8N3I%K51T&QEKZR;BS2Z(^_Z<C- M6'T
MMP$^4Z5E"V^@)Z'SL W\ZE2+QFZ>]5W\*HTT:U*1RL/UZ)'%1%OATN:%#7AM
M#)3,)F]$N3$::8K'_9 :K+1YPDP(7%UV?FO*%4V:SXA(N3!(8Y2+3PLF7IG;
MO??BFW^GEP$H%?OL.YQG?3O]9XL$'.2>4' &@U&1/"-UY5J:Q@;8BD\%YSX$
M9XRPBP5QP1]@T-O_^4'UOWZWR2ZXXPC^:=Z=LSBEH1+2IT:*SS;%0BZME!>M
M<SI'K6]VXV?+I&SG*4)2_JV#;%89%QK!>+5I= ;N'_(5T5LS7\'_0D8:T+^$
MV1(E+1H%(+=1X)G2>SL95_&@8< 9/P"P><@!%$Q@,3BPG>==/_B4.]R1'F(S
MMU>9AC,>X?[])A+8EGE\Q0#D:CJF=7/XN_NWS=E]*"%G4'J<9]RMP=P"*<N)
M$,W9?.VDV^V *'OD0^?!ATQPIWV=V$MB#M8#<SU8OKPDJ^7-2$'?_W?>EG1D
MBB<!,3*2[4,\_][,5H3+H [;<.Z4-E^A%37).VD8I.B"(&<A7M>T9K?5+%*,
M-A0B2N4XFD*](J?:)L59P6:;7=H1^Q4HZC/=Z*_=L/GKX4V>6G>9NZ8"L?9^
MUCKQIS6@'):*/+&6@ ,SO<U1Q3%WOX$>+[69QG%:HRPO8#L2%_O.Z]P$Z2+U
M+MEMZ1NZ!08**F_+YV<D9,\*;^\\QI&>Q%')968(CG@Q=\*"74JH5,-)(C@/
MC8>;/8Q/-O#A_^_A9'@E;J<MDL'1;F>B.;]&1XAN%Z7!PGX1ALPXAFIU[Z^\
MO]#^ =X<4K())7 ZL3-%EQ_3+\UNKT6_]^$Q%1_FQK'9SB#J#=O-U2.UJC3O
M&1+2?EJ9'M+\@1D37%.97#D7U$NRQ<[ 4429V'& 917XK38&/ 1E[J^J?FN3
MTT2/L?X\6\^/FPQT3ZDA-%&T<0"N]*SMS4-*E%:W28?]QJ36>3 $2HJXECX1
MCE)6'24/HWX^-AD&'%.*!#CQTCR*A4OC.OJ[J0P9+E5#;Q;%4C%"R0%UY2K\
MOQ^J+]K?XYCL5H.)>$6I_U"**1HKV<@CI\V4X1L]2/<F_3S[&^Y)UHQ0]5V8
M*O;;W];,N6Q8.=WV37JM ]/E%"7((S_$<&1E^87AH9,TCEFCD48[K:[_;6?J
MKV.N58+T=#8;;3]'6DU:;T44FSN\T?*&N+$URT\PT9F&B'A!A^IW[)YM>CM4
MVR3*-LAU>^M+5/:@2(B7'&;V7J3]F=[4'.Z](#+34\Y9'QLD52B&^,-NF%D!
M"!O),/,9*2HM-4I;L')C\U$=NBU,N[@D?',?RC@NM<(FKR-AN6)??HO?'K7"
M6UU2]NAB%AAPE>!B]LW.8-5WG]: V"0'[0N-NIX! &W.$1.G)!6J_HR$/]:W
ML27-8)WBA3X+M/ZF-!:@0WKTOI;.IP0]?THD?H=>N$ ;@[!A?7.DZ^XXNV+L
MQRA(J.0H?[+%;ZB+#1B(5KB)KXLU BFT[[#YT^@I$4/-F,GIDR;<1/0][RY$
M1M;6W"[7I3*^,W:GM5!^NI#^K(*EQ?%!20+F4AV:1Y3)CO)QJ5MR;E?=%9?M
MV\^.M.58K,SD?X=M"N,:HF=:-&#A$74_.4_COH%;;EU5']-JLE8E 1R 2GN_
M7!N7<>;"W^BJ!F(\0*!H6%EU430!F9QG*!Z>L5T8G],N@KY8T%SMHX^I,3+$
M<C>6TI6;0\T$J\#F=W&;M/G>UYK5#_8] ;6^2ESAA&'['-LR$X4;&:O59X6<
M@:A:3UWU"WK?B5!\?IWO)2/XQ:QH+BBKU-!ZD%=89?L6\QOP"Q,,R*>C#4@V
M#J1KM.8,D^;3+"XA#IM, 0_:\Z=!N*?T(I90->H#@1T)U!#=8LW]>8">TMQL
M/:1S6JC\]=S7L)B\A[W0CG),JR$=WK&W+O)E:;MCC>B/A:B])8Y2FDO*]L/"
MGCKQ%>/N2SX*OLFY$'GA@76F<F'2JLHL0Q\[LK[45#_)K$U@[F8CON5*Z#Y9
M*$H,OBP_T\BAZ.O.I(%$5]GQ"7.PM)1"<C/\[HCHSLK(G*4O7:(_^MA;[TA"
M($,8P@=,*UU.9TLD]GCO;<G@^E[Z0A3YT'S"%X"*7$_15AVCBVQ9IAT7W=V]
MA- D<)L:Z#DZ4QE^=>Y!J30?Y]C4QEHMR?2GOT20-:Z"RU"EFJ1#.(.#_ JH
M IR-O[B+BH5G:#,>1=++-613VK/:375MW%H$BBPZ7[Y3BBW%?K<- -%_*J5-
M4RX=;1:099]E</Z.8<^RU:V%-G.*N/QB/E%S21D>\0YH1/_O=^[(,9K;]@'7
MF!]T5GQIA<ET^SABO6[0V"O64R%NAE._)=I^=XKI_HGKC/\-RS\54(;?Q\RL
M&"8*GE%I)RRD?.\!/XFF(67I>8ZHGK>_GL!P@^7B1O.PT;4;ZUI79SH*<AE&
M3I<JB>C?33P=WW0!;+J[;MZHTF5"&F>CX>,2%Q^8%H1I*%N158L_^OU^$.TP
M5+?0D5)S%*"X8L35[K*SNJHU'0OZ6PF*/:./*OI,^W/[L,Q$+LFQ9]IQSD7C
M'6P-KXR[R\F]GPQ*DQ<:(KPG2&FMG?W*"U*_N53N8E+''EN/D-PCJHTJHV(X
M\JSYW7 YLVBT((_IK7Y S>U/EJUZC11!_"J21=*Z><EK>%].A;N6S'I#R"YD
M'I<7^B.TC_BIK#J5\7=0W\<C6X=1G,F),BW4W/;CCD#Q#YLK!X:<2F>S$-DS
MO.C\X@Z)S_PM,F1SCPU)JF4=."8U)0[U]Q7(P<Z:T)C<O*:WF&*]#-P$CHPH
M9DTW:=K%-2PN"ZD5'7;]+;UQ2-Q7*5@CT:#QJ!*+#>,]&J5"MY8555^_0"^<
M-(=H/YQ#(Z<L8P-D_8U(MKKBG6OBYKM?PB'J<G)F=GNWTM]6E;Z$)+YV0+T:
M=&/2:069^"A)?9*^&E_&":W@:2J:$N*AJ[O];20BP*>5U1%G5/QICD'U[V^9
M#+^DR>$F2._(IWJMF?#[5TCA/^PWU'9T9!N/>BQ%C)4^+!R7'7/%TXY-14L0
M%?:B) 6BNVVW[J]:G$;XXT6'RH6U?=RA"4==2\*?PI+-2=[,GDB4XT_X4]3!
MYE./4(1EV,V:E0S<AR^L,>YT$HZ@T_T5QGX'XB#?[IE-GVQL[2RS422H+/%_
MEU![./C:-+&QLP*MWJR4=[O+80+M; #(TU1-@B.RA$ZRCSWPJW#R-M[2((9[
M!??\S!%W35Y<:LYS)I3E;N\^:)G?;X?2ILKN#?*2,VGJMBMI?M;9NS9^SE.6
MSQGU@OLE"Q+G7-<:PS5Y68-566K:04TMO8W:)=X%XRBJ3G46YSL8H#?*/^B9
M9QH=?'40%N45=Y'X;WZO>.:D@$:F!["6IP:W#5JH2NA^Y@5#2E:8%O<IQ?&&
M9L=F//>P.[77U$?TOWQTU6-BHQ[$3H$[^T<:6"NR#;U+I-9-*NB\O%C?EV)Q
MYMC2U!TX8S^@U*H]*AY() P,2_M-L;K_2N(P%[,-)C=J\(U<YZV9YPG5_I9Z
M! A\9B:T:E AY.@*JS9WN/AI)?8-!7):^"HAL0KQIUQNQ/1I7 MG?.,]9*&\
M!)2B&T6-\)7KKW4EA+=2)"RB0M^H[OHV:2PX/B/]V?I8/XKN\<X:16YPW4\$
MCU/9\23IY]PF$[W;/;8;UOY:]-#$]TS?8"M\AVY-=EUP(,$?R@.!Y?>TL):[
M&A S/_S2^4?TGK:^]$*1]E\*5,?PV?B;:""]ZNMD^:'FZ-=&:8L#" 8*Y_9[
MGR6*C?^F3_;R+O[6ZVV2WQW.U.F^6A(3@A1\$I0%%CK+;-N<+MXZ-UTS"##>
MB(U%O2,;:UMFZMWN8ZS1F 1^0Q[>-L0%L>E8=OM53#N+?'OZ<=3CK#ZEN:'3
MP<.#&:*+3CCBQ=A/OT'(GH\(ZR8 )=H$"P!_.6UIU]9:M$$G.U/):YQ$!-KX
MYA<U^-C.:5N=[>=@M=:PNDWU3S.XY:1KHNT_(]OX#\P87">KT/@EUTX,LO4:
M;]$7A.5^S-J_'A?,OO8\K;>[9'Q&HMJ;Q?C;/1:3+J2COT^=B.:^*?'5+X6E
M]V$4$*CJ?HPW(;EQJ'D2G673R:O]B#S/X)#%P[76S?W3T2,X$(%;<S;IY<PP
MCMJ4V"WN_!6MW!B&WS7H,U,6<WE2.M.?0BM!L.7N."".(B2=%79V$ HWU:]%
M7KU"RYR_\^=PD_3R[19K7=WIUKJ13,T\6)#E[VTZU_?5*0R9:YPVV=HKB*Y?
M5BO0":PSL#8'NO*=1&T.5S>[I+8MB6)*?.85U7CJ4;=T#-0. 1$B5>TJ& <<
M:M1>TKG3\FJ1>_E=KSDQT73)S"AR#MN,>NBP?#WG=13@64=9#I3&-U8%UFO_
M-5\C?5-%I]%$[*RN_6!PQ%?GI$,8(SV4/>$>BE9A!%,*^\'10%IE@;K;%>.1
M8&)I'-:2A0ST2SNF$D*6Y)RF#X#EV5RUH=$;OR/GS59I"VU;/Q[01_IW=^5E
MS?Y)0Y2UAT:2AH.UKY(S.0;>N=(8RVRH6P$;XNFIYW#++I5VWX7$AR/],OH+
ME'O?K_A'7X<;(NPU IS&\YQU1)'4#JMB9,:J:?10V4I99ET;\2UPOJRLH&V;
MKY0&^VIXJ[P6E^U7QOLV#/226=%$\HO"*4!_;2VAG\YKDEBGZ[JKF#P7 O\U
M"; WX%Z#K-*#CG'G>_MW:;4W;M16]TA,EXC8?N?G5@.!$"%K;7G.8F9+Y- C
MZ]0B,6@-"U=(A5_5(6HVK"KX>"-#0T>_->%K 4.<??0S$O T7<DC>BP1B<<T
MFUO)L-K@XZ5SI1RJ<<CI$'DY8__\Q&"IFG*PX[ ?*9OW_149PT3LECX"N:"E
M@?#S^:_4/-\E5G0+.H]BP?0TUDL=:AV7J YO0!$KOZ[,W'<;6IYW!TQ+&D7\
M/2C)I9&!=YX\17[(+B4;C^6:/X%-_[;9:)'G\0/I?/TN7)QA#XJE/ @4SH_U
M^TRI! K-5,*$S7N#/,[@)<5P*@OULHK4TD)#E_FYVB.IL/>(#W$[W2%#Q$?S
M"2GJZ<](&'&VURA)D*=USIT@Z[#SY*Q4Y9KCCK29MC.;.MFP'CJQ#08JB>IU
M9H,?+EJ5B?0577]VU [&[3;:"YO01^U)5(SN.:<_(A!YF>%G3$SB>(GB=1IK
M!E 0]8=/R*(_+ST4ZMFNT"XH0$)R;<8G1ASYB!W%!X2/P]IKZ=,M@2_4TM-P
MKGT4T=XSZGW^[4_<3W26F;_NZ<"0Q$;1*@.EX1[%WH_U$DUH/\56=V.,Y7=Z
MLBU]DS0E(EAXLR,KUW&,CA=DZL_N'^0[V=ZPYZ +L"'D3@-2B8Y,FK$"IG4N
M^=-*]B;X[P;O^MX#0AJ[=$[@HG'ND1N\*?D+M=VM/#&.@.S!\5*%2&%YI5@^
MW]-?<%J/!3C2P[N2C"(&(5,A_P6J>@PF\2(.SS2\$Q:*R2 /?_RPO8OXOL*
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M$Z("9(9R);BX?F8X)SLNFU7-NQUVWV]9K(UX ,LURA&.014UMDL7JXS(7?J
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MV7#B6AB)U!R(KA3[$0UIK"6T,T]L?2M4M 86[=S9^(\:;0TC[]<!FTWB22C
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M,B).?K<[W,B:PQY_LGNP[3:3G1\FT&YY8V>1;^S7.SF.<O"2!5CQ"W=]BON
M )?S:11ITH^,YVXR_<4H3<4IH4J)UW"IM@Q#I[!I561/S9!M=_U$<D"L(77W
MA?+CB4NIW3-0F!=Q(ZKO(FJ.*Y3ULPK?W0_VB7Y6"0\)MODM0R]Y40F16'+Y
M[":8=<&>F]F@\/CI*WWIA8'%C4_W[\M<]RV1HZO:L>"^*#R4$*;N_EK<GKA'
M&\G!IUWWED%W6YV+-YOO>@<-W!;-@!19&69V*H\!!RQPV"!=-IC6]%_NOV<C
M@B*"XEP#]3"N*VR@E:?%;H7;AMY2,IZWG0)B?,,>,]),7?Z$=;XI"\87*"E-
MJ*B+T'5\R KMU6*:\'B5T O[M0E[ETOA@'4-*@P>>>E;YO.S[NIQ[QQ7W%PA
MMVI%3\<W)0GP2GJ/%M56MV0P)UHKEOF@MO)10P.#3.R+8&Z6M\ L$9E:.PRX
M/=XJ+14#LIW3HI\A65U[HG^5EZ! ;3%?_O,@,6@EJA=) B*==;#@Z6CX7A?$
M3O<Y>TXG4:G7VC$1#*!(U'0\]M5)K>6+8E!;7<W#EV^*^B#0*^Y+7UVOWK)0
M8F2E"K]%ZQ9JP;ML28N]GZZ58H))*5$JPZ3K)*TWGWN]FB$'YA_F448H$I'&
MOQ]0LA@+\,O'JJ#P3,*!^0/#&_$;)G!4_;H&TX.MC_U*:Q+=6%Y,5.&V E-"
M-[MX4\+#:7$?)^_XT];")*D;%8S8-BJ9GR%X*B2BP.P;HUB+V? KP%"ABU"+
MU0YVUYV3;ER;M$$: ?$$.* ]9)_?E69;%Y-^DIVNT=+4%#:XI:'KF79$*T43
MPMAO[$Z;*!;?W>:CB<Z)_#5L?CS, /X\*31^4_9.09[.=;HK!V;Q%:WV<C.9
ML.%Y'##/@0-L<ZF??F\5R,7826E3[]#[P]X!WF'7*Y8]YQ? :(DDM'(/!RH]
M\,$4O'$B:#1U"^Q_6OJ3C\,,B@-"C< JMSX8]6@SJ%1C^2;J6G9"G)RLV=9R
M5APBF1(F*9?B/'*(D#Q3,[WLLI-< FZKY%M'!)=7KR<")R-&EX# *-;$*V@Y
M3K\?1'W\Y1V^[-+UNH(PMHBNK;_#\50RF.[PS"(*!US% 6&5QUJ<$0&RPK<9
M=M+)XP;F&WCWGJB15CM:$L,I[4[8_ 5O:#U<]4G;;GO?DJC>FS9$#"WF1B=%
M;UZR[3)+9J%7]YZ@V'-K?5V??9(2A-Z\R:I/U4B:*L<NSS)!Q]NY1(.Q[%%@
MF(3*:039%_B&"7P-7KCXR!D-D;%.VVA!28_X;O& *'W#U='"2&DZ'!#U0L#J
M(I4;(I6R4;&A03SIEI0M&E":2VG)<MIQ74'"&$.VN:H.%V#1#8)1:,'G&W0*
MSMQS,MD;!WP[* ,9&!N. D6*ND]&/JO<,USA-M1/]*EB/)+-^(D#6%H[J(.E
M?F .#A :GH(/)TTLS50+V[]=$'!-;"@?1A)EM^-Y$KE8ERI?EIQNX1>[YZ6L
M/OQ'-YX"/T1[CG*IJ/LO77NIXPP5")L:DP7)^B<M+7MN0J4$)^\J?"C>'*@2
M613NL23N%\3F4$ ^M=56)&G2-6K0O5UGVXN4B]]LQ0']A\(]2W$G"K(M]<GF
MY#IU]$8S-*6NM2!%]>-3G?.5D*UJ_([\#:4;S:M-"W%G>L>OQC;8^BHE1)+B
M$[:$*!QSB"_F>'L.SRFH+ZCXM1&/OLB)K/QT%5#FFYJPB9EBL7Z>\+'P7P>!
M(-2G]%A9'&#U"@\1S"$R>Z!7"N0-8]P3!W!CX?7WVCE!WNVVWRK\.S*";5_X
MG:I7.9UX30I5R5TK@?P6$Q^#-,<F@M.E!=BG9(/?<U]*['FMP6IAV)C@VWAN
MU(,O*<G5J91[%F50U&_D#,HQ*:M!9]I2B"<R%EE>3O=0<W,45F%EGY,#MAIY
M62=K,.5=S?;]HY26@?>;#>JG"NEE"E/;6A.5?WXND^PW8 .#A(GLG7\VH"9Z
M)6%D=5#KSD71MY :\NFFB6K[*RIRSL#Y BD9E;:[TKI1*1ASWNV345B?:;TJ
M*'-TM!/=0UG9_<TX1!MESTHT_8[=$AVVV4\=<TFO\$!CJ6O'^5N/M3C/EA#5
M<NL':@&NB3F)!8RE%L:US/&EXR)5_7?$R9<;R9#!I%:KMZ7SI>%?7BA88<NU
MS=':X<CJG$=HR>+"'@%5;B>H2JKNVRW2K5-M90ME^8[(JF!YS',LOSK1PY$S
M>(8]-N!J[<3&J9]Y3SR541L01&3!@-;49%Y"DBY?2%15"=Y8_9JT41^43/RM
M)<1EEHGI=[5G-0NZ _OA$!]W>WC">%)Y*X.#YI()HS"P8EAUYA)J:R\?D:]-
MW"M"P/^9(K9CT7F-E/M75<I*6K%D&RKS4>N4C:B&8$ZZ>/Q\HYX^]UEB$T_1
MOQ:M$MW;AHBXI?UWGQSR5%N#))_'T/N(GE8VJ<HDMT3*;U]O,&WH-!=O3Y*3
MN<;%-\P6\T3MHOX9*'LW9ED+J^.;TG?)/BY!%)1K8L:-@"RUWI8.C%!X1Z2P
MG%TPU1&I\ !%\@:5_S0ZR.C)IS26E\*5Z\]KY?(/;^3X'041K'$\'L;PEB#P
M%?%-K%?)3OTHU-[S>=K5;-"]5W=>RP;8>& FB#17,G)( Y^A[4.7UN%9_>7%
MPDHUGQBI<_E!RR0)M-58G@XX2?@*2FX8U/,RZS'*^^=3,GSQ_"60_=N45-^Q
M A-:.**=\V%E@V8S??J&JD9#"A<HTBS([%G.E7N;DYX7KOV(6%L7K%K@43^C
M>R+7]3+J(DWJE^6*C!P,@48%\X%/Q@/OKE8^!E-3S'6=##]2_<Q1)SWR9:03
M[ I<\C:2?%+@=.H@/6SEXO(579W3GJD8'+(2C,^1:$DW9*4_ZI2S3_9](%W5
M,# ^NLP1>V:4("2XD:[<##\GQM;<LG9Q?SG UK[S&]%3)=", R)RECUL3ZHQ
MCX]SA)GF3NJ6<$"@O<^.(H,<=:7F*HC0 ='VA3UHH<!5B)08'<F%)JEVFCXS
M7PSWHWX=F+/?'WM1/!KTYI.[#VLL60/$B_+76P;OA$TE-^:AFR&J&U:)?B<2
MFR"X5GVA!RI;>[\O*3_Z0%J8_OY3*X+:G.=SU\[L$K\%*3_#7"M%#.7;J]9[
MZS//*SU'B[)_X[E*,&#9JN(</&K:=E"*&C>N/LC8.P?I)(]<8UQ_U\U%D*/4
MNC9'6(W?/08Q3H6^HO3P2?&M&F/%J"<A H.^*W+9N2=;1)/3POMSHR$2L 6X
M)5HN\[?S??W?.B@U9WV:W>:X?7^7=*^@^SRRQA;V1(T&W#B 'WWX*INN!KV8
MY;-6S3*G7+$KD_HMAL('LJGB>N,#\3/G^*8S0/[G/G-A]&Z&_,:K*$=S153-
M,44AK-+W=Q<.H-^Y)!NOPE*O@4O$S34UFQ+S+=2YXGU_;+FW//<:D5Z_KD(D
M>GD'HZ:"ZNASC=+;IG_1)^P5(3K7V_N0R2Y\\]EV0617OQC<WW )28P#1'TN
M(AG.#!EZ$QBW%P4PM:@S#NKYBV9!6>,XN^8W&J]:AJGH+/.OW^1E=9??J\!<
M%"R:^RIK3>T+9JQO-X>9#S,3@@>! SE_MJ9C)OD2FMTZ/"_,P;X^6[J(*L8!
M8VY&FJ!^:J*^E9X*X=?WUBT%OH$-W@9]C!>].73>>;)NO?A)@70[H_T]*N,(
M_#JN<K/<2Q[Y^0%"1Y3_(^?QUR<)+^Y2F ?H801SG:0^[8TY)#LRW&QM4-D?
MG@]3Y:XW%H!*\\;&&DFA#G7&X(<)#*;V(;^(,WO\"T.;G!S>O5M]Y]4I5[J,
MWEY\5ZI @DGHOF1"M>=#5C7WY+EZ:2PT3PZ1UZ[H:TRP-@@NA8YX#$B+8)QZ
MF=7>P"!?JK&R-&#J_5(NC=8<07M^=:'\V%ATRH*6"'/'?_JO@(44FN/R*?G*
M;RPU#G@HL?^6 H4#XNKU'&&T<L16=.LGJKLFSZ7HD?6/C&P,$0&L-\3,U6(4
MZ'R%EE9&RHF+0NVOI-6+?J4<5Y7[Y?E0F4D!O4ZQ_M,8AB\%UN%823Q/JL>;
M,6FF$--S^2C(Y[)KAN-,L(3HFP*5K^93=%0X5$YK34*!LQTZ_5TH3^X'<C5V
MGZS$EQOY]86HQR\>>?;!N:X<^,Y8J_SUV@DOZ/UAB8) U2HBUK*3#1#E0)TG
M1^TA-JE-ZK)%&T_+36M^"9_*9O%>=B)Q0.Z08NQAM,6],5>%>\88ZWZ9V#0+
MI@EDW_"Z^N?[+>^.7G???_K]/@SDV(EYLTK]:L:"X5P[Y  */Z0QEG/_\=7*
M2J)6A$*4J?43-9,TKS11=M->JZT';T]UO&&[9%N8VG<OL/"GQ7G5B/:1SJIK
M1 U#3+]/:[Y4H=MY,6S.$6-HBY2-I*P\)#D.6&):.-,A%5G3?IW>[-JI:7ES
MEH:JL!0Q5^%"2J-Q.ZPW" @,6*W""*_P1HJ/4LRQ66O IR5DW[UJ2/=!W]L_
MNC_TO/ZEZ$N1T6H)WKY#RM&UG B?^]ME+D(,0VUU2HFV P_8-TP^R;_D!UW!
MFJ'J*U<R+9%0BU'UR<I5&G.$Y9-/HNKYE'&]-C9N\4%^!22;E1]WVMDP3I4[
M9X)Y)@C!B(D*D2W'-%5>IIVO.Q90E'"G#!4^B89,9I ,1N^^BGNC%A-$66QN
ML+Z*Q3;Q)JL/^ZM65D.R;V-<JRT=TI,6$1>1NR"9>\A[7,XA 1=.'RYR8.MQ
M.QV_$+ +YLG^YPXGAHN4%\69JJCCVZ-:4_!122=U3)P9"6<$<C"8)<Y'04Z!
M .ZDI;E*N//M>R38RK\=PKE<_Z-IX;NW1/^NY9&/C/9%Z!Q^+TPK\\W8'%"]
M*()*<+ PKHW;3'CO-#!HOGN1Z+6.NBI[BFS2?NE ,Q2H-J/ !K-%^":L!"&S
MLZIW9AR^U!LB'6V4$V'>!DK(;!D;=DI_T,";)SB Z)#'*IQK3H2HWD;?+'U@
ME-77R!3U9AP.+@\RTOVI9YC][9K>U:Y^4]W.KYS/V;$G5>5K"=C$@(1S+WPY
M-ATBA.%:28ADZ9:40DQG4C64[$HFC7KXE7)F_?A,%+&0%4(4&ON2V"J05K#
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M%"U@&%R:NWV&*-LS-8C/O7D0TV*3[CKQ4N*C"F#;MQ)$R"B8&Z4\81T][JJ
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MB,]"Y_0LTH2Q&'Z:$KR3#6%C'*PHO4N@[DQP1)7[N\JU$Q%9O)+P)B.])RA
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M;05/$UJP+^E1I3JK<*("CIYX]O F'/?8+@H[RKMBI<<<Z$2QVAK(?S*U9.H
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MBVQS#[!#5/Z\I-?*OLWWH9<(G1QY[;^U-.GWOD-/CLD;]0QX720KA0%TSF(
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M>1_S/@"WW!<WW!\+YD*KF@")5?YX\LJLE,]8 G"V_(G1SS8//OO!7V@5C@'
M8^PO+D"L\R=1K5$RA%6\L>\FR;8M:FE0@RL7M!:[YH.OEQ_!D\/7*JLP !>C
M@-(#(?Q##,!WM^HV4%=H\MM >9JB-/C""@-(L"F"SEF!;BF(G_= K\2?AZW
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MY:+4JN#B5VZXVI+>Y1W1P!.]0&H,8.X-!K"S[W@L?!R:]7#"^6PA4^Q%Z'P
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M0 9>9R\L=%.W>QTN*#;& L]'O4:[*8.V [&-S1;G((F]8N];\=>8=([>J#W
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MW)&?#]\XV(CK7&>K8ULVI,3_Z3)7'(57NH&_-C4G'%FS%^Y(8:EY>W-L=B:
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M'/T#?W?$CT2\8 =(*'PHI3S+6Y>^'VU[TT-@J-OQ];[/ SPLN0$Y057&BP,
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M%)#LD\@NR&^>RJ-Y+&4JW?_;+18V8X6ZX[[WYXMEWBB38U5A?+US_)C3%<I
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M"S<2!PKS;M]"ZG]?R7L_@:U<>32& '$#]/;ALOY2TV#]&C-1@,9N\XN'@X#
MJX5!-J\]^_1E]G%!,<I2N./?>OM#&%30HI)$TNG)-#L\Z_@0[8;2Q\@+K45T
MUM_@+5[9W(VU8MHN^E=Z0&8H8=\7&,+57\A[P(TDNKT*]";$;G719?[TJC78
MI3.Q?;34'W!-LM_;0AW7J+.\#PQJ2P\(GDA9>D(G052%U!I*GI2SAR=&_:4Z
M@W<S,WQ\@:AO'9.>R5?@HR-VA7 _ZLC(>C#9W92\0*+9Y.K4X\;:QG1)9\K
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M4+F5^<:+QFQJXXY1X<%ZB25N_.^_8%7/EOS /0N)Q$#?.ABM/'.V9ICR%_B
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M9 *">(?;E/-'UP[=US6;!T\6A#J$MA[?0-")LV):6NU-$^=T@I7@H;REGL*
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MQO.8E8(%9QY@42]6'_(C45LG\&UM?6X6*^/<SN^CN]J^6ETK^(%ZB$2TFJS
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MQASW !QW%<EJS8)029?H9:JFZ0[RO6 69%[VPZP7#QOKPZR?AN?^A8T\JY3
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M\J;'H<>9:<?IE29.C,8H^!0ZE(W:>V=S/%PPLOS\4"Z*C;6[QDF>U7A^5]Q
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M6O#P-?-T<P-TM<UL^?EO@5!;G6,3#+F]S&YW/X3S%-_\7Z],PF;("$JN#9<
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MA1O;_#?XD [:*97:=MH0D>5+,+L$%!FQFH-"%]):_,-Y\OC^N;ZL/O$X=DQ
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M7'$&1EGL6IC( IRS!/F=W(5T)/2/[TH!54PTK?B.3226K"-BW@0<U]I$[AR
MHI:GF89,P7[^WDM][JU,/"JR;DR"70\\@H0;"Y:/K=3?@T5Q1T^,O_)2']!W
MP(D;)K)$'B$RH8++JLR_9_@\34(*S2HJU=06P'(7:_:%WOT CX^PZU+ZJ#E#
MZ!OL^,[LJ1WHC8RA"CJ%Z$H4!!&$W;D85,S_:;E5HIOJ_%K#E]N7 .@7WG&>
M=-H'#1=)>#KN/>'O(JI<+JN<E77<5D>G93#P0&)K&J,,"RS+'6)@<G=38W^"
ML?DB7>"<,R7N$((C1]C_]!4#A2S>J5 ',I91<B46-=](>U-W^E%3 CVX0'S
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M(^)0I"DT3QZ0I#EV[E^KR3#^@>J_YOV94L/23/^#4]S]9@I%T"^&> O,OF"
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ME2Q=[_]!1^3<+@' ]:W'UL%[!.E93$[5 QBET!8:?E9Y-GZOSNR$;1O<:Y8
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MMUA:%J=5E]Q;,GKB\DY-#I1KVGD7U8!H9J,^7"0&]X*^G44C/0Y,K!-9>H6
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M>95!1_\X/Q) )JOV?Z<KO#');F?O*J853!VW<I+F-,>%S;7KB$\ZA\8ERC_
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M8?<(O:9ZEU&S6J7U:E>]-^$L=IH.]4]9M&E#5'/<(UH$%W%5J(6Z[*NCR32
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M7^_WHLGS,Z7^RJ5<'$:@5Q-G/8@$2F!5EB&AGJ#PK,:J<-[Y9R=J;T]TP%G
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MMC(V86+<BR\!_0$]$[;\Z**.M;FB>Z_)[?\/]MXZ*LYO61-N0A(< L$]2+
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M\!ZZ<[?LDLO7*'HC_TNH"5N^7,PA0)0E0;)F_!&P%A?PQ4H>[Q3#AG!OXZ4
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M53AJAL4RH;WSE"=]=OU[;"<LCFR3'HV*':=^R+\]R(TJW@_]U/4G:GQ,' #
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MZZ(Z\X7V8BA'3KW)$C-@'V):^YQV?$O^<"OY81FQ0G 7"F]R&<H;+J@&6XY
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M)<^8:)\, 4)^FPZ2_46%8JWD6[IO9Y8NJS!54%>=.@)>E%&W7VRN %F24&<
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M;*RGQ;MHU(P&&Z&/M4A2UN=;J^KMX7)8;\38/,NF14%KME[)F)I^4M)ZW.6
M9DO)'-F=K,=M5R+-J5S/\B[\KINZA$ +7>[7'H["GXD6^NQ=!DU>/2]&&(-W
MY$5<BG3ZLE"X%AW &41,.54I#7":,^YT0+9N&MQK<@B%KK7(+,6,'!4N%9?V
M:#R@$-3^![;-\O0:!\=]>/)VO$+R??/G/(D$\Y9\UV]BEH!G(\3?!#->OK =
MTS&B.9&N"T63GN>9QTFB]CMN]L+9_B^)-V.'D=3M(R",M89,Y'1UV^FN,& S
MMNBRG&&2!R-:X52QI!&C?SOSZ5O6$EU=D4;/+RS)F2>.TEU>4@:6T#FK</:@
M<_5OVSZ%7%^6B7QY=2.K:*/FXH,Z0F*+I@8YUC\#[Z((-&7IIJ$@LZY*:U(_
M,N#B(!=WYAWC)8%VIQ&!(1Y.S=(+[UT4D6[)N]SER6DE@]I]%^_*F:,NTQLB
M[GITQIQ&[#__W@"H_Z]2?%5GXXTDNQJZZ'"44BG-/><A[C0Q/V#')<W8Q;[_
M4=9Z _MK"5,_;:T;WR6:+R'.$,T##)&IL&45J.CYT85)BPKJ,5%8T/)KAWM1
MU7Y2EHW0](9OO 88^;SD65Z@(.Y<O>N#A?DSENK:6Y0#O[;$8 5>&#5P.NY:
MLL>#<$YCB0+^&W<9>$4*O0^V&$VP(IK+H_S2;;(^)C%$I5R[G[C]Y/O8/&2L
MK [<\T- ,3P]8T,#?<,W9O@50USR&TJ_Z%'M04+Z<<>_460=RFPQUG?N1=PN
M;6A)^5OCK=?-6=E3*U8(^0U<8E1:/2]B[^,S_^K<OY1YZQ+?^G)9<I*L;^PZ
M9/]@K-?5R8*.HW]$RYC/LX.9LV%=F,JVNP[^%H(3Z&I( :GA(R3=VU.K<)\9
MP^C-1'??=H<A/T?*N-X*($VF9&R-[#&BGB!DQ!2T3" X>*=9SU69_*:QPW@Q
MQI^R99I8](V/1&B'NQ]W\Y@K;K8GKI*; _EI*D32?YP!SKC]1IX..V_:RFG5
M>]9'<PU+R<)?LFB70_=#?JISTT]G_:@7#RL[\OL]5O\>LZ:  T%W(AMN<6(*
MGPYXQ[U;;G>8M'=ZK.'Q2KRLF\94]'.?C:B_9OD+4*CA5"VKA_()#S2X=BF!
M^WW<YZ.=^55=#(O&;0]D9 J!?8U[^=7,U_/7E?=**X:2'T.VMF99R^UX-%PP
MLS'P'0?.7I*%G?>H71LZ>7JO49$LVA(E)9_5WJ/1#T<0!*3;_>$LD+]K83=R
MRN 2QP5E..#)GH3PP'W+,GD.4EZ27#"1F(;[_?'[_'K+WO&]B,W)]7;/IYV,
M-W63-:GX)U2AZQ%[.EE6WM[-[@.L5$)!=K( \I6 :1[O'E'RDZ\9O*'=?IBM
MXY]!YR>6<%O@&WDPR&#;I+^/F/I.<QD%I*\QX>"F9-7C43<]-P+=S.N$<59(
MXIL$1R,[R_[N3ICF1GI;M#8-C,72!WGT-R8;?E<H9Z17&]/VB3?!'4$/F'\G
M>%[FL=Y^.7W/$MY>U=9QR2Z(4_<  ?]$M+&S#\WW+?<>7.X.2\.3)4Z/+WP_
M+9"5D#%MC;MJT1[IY?T>CE5M.1S-DZQCJ3B9#MD\\0ATPR)<6K4K:$ =4]A/
MU)8GE.X_'XP0=VKC:#@QA 2WB(F%0;F'%BW%<.>Y>6\5FYX\[8OA^"F:P,#.
M"Z"U$?U)<'TTU)6=S.;VHTV1OJ*3%6\R771%7[VS* *"+4 .EB<3/_&KS]M%
M[GEMW>Y0 5MM-3.QP"6FI1 UD7>6/Z=@L5+_4^;@XY8%5!6FF5>J;XXP_^Q1
M^5VZWKH7E0S;6=:^!FF;;YG$C2_C3&W\+3S'^E*M/_-SV]1SK^"Y7CE6TFV,
M-(KL$!7*G%8EZ'DY_@[OL:^9 ]C,C=2 CL^Q-$*"['NBB8QG^?N$59G&O&45
M[*#\:R+-B;STS1@E#T56%[QJPAE=E-&H%3P7?T%MZ&S7)9"8>A;33\,VE5JI
MLNSE^]RJ6QP%P%DLSC5+9[6/S(EOS1+)V$;@\H'11Q537)WZ#XIV9(Z<GOS[
MAB/UQ;,@E<YZK^\57ZLG["+#3#^U,\?@RDK,H!?E66OS4G*>$$*YNO_89EJ>
M:J(MM!E8Z#OVHC!$O=;VD<[1OT[H\KCE6>?L\D7^\+M5FS90I&,;GH7MTEG_
M",#E8;D#CK[:G7L1$NL8/-RB_G$Z[EE>(0,9V@C71-0#2V3#]521' .L9M>'
MY2'4@7:M<UT#H\A JE1FX^.AFGB_&B=H/^50F-7TA$AIDO7@7KIPA^A6&/73
M0@_^D"<C1C"=[R^7J(MUGGY9>*KAF"50Y+4"G+*H()RXA[<VG\N0AI".!9_8
M!SDJ(2%FLMNM7AMW\=X8/M7-P#&<8R1([O9BA:8QE8I@$22VZC-=]TI?7J0O
M[.A02W\ 77_^N"GY*KYB@[I7-$_;A3W47K]/4+2:I"X&UJ6<,;;VL6CAD,2P
M),H."0>L,%@#/XZH$7NI8IK5%LZ6S9OOXMBEBM>"A5G5''SC*.DS-!/3ZC5.
M4KXR= A6'3=:[TXFQ1JJ1FS98=O0!2<OM(.S><:TB>"/@([;Y%"VVFA%_00E
MQ6$]N0Q%I;>$,3"L"!D-/OI4#P;R%6U#-P^L-/WM+U[8V[O*T^[BHKIJQ'/R
M.LSL:L"D*1[M=M_P[P$J& _'+A\G>4@<-F[:=";O"W'V-4X,O^\Z[UTA-4"C
MB>3.9@P6RH\Z;C0> 43MXPD*8W.;2=[^6J^<B>X> 0^VN_[H &2 (Z"H1&OI
MX*^&2QO_\.WP7]M8BJE.$.Z0T'3^%GM;YB5MO9 ;6(J-*E)269P\YZI=-#I
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MAZZ-VT(5^YZOQK@'6P<@A:B=KM^:7NNX,SNHMZ)96N.W$F)6.E+&!OU0 W<
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MH<,N9A#NN5IHXMPO)./9'/3G:][3!62F_@-D1'< 9ZP!JA"K(YXK!&6JN ?
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MD.B;9/J^]H/FN.SNZR_+_&G/:9*$3]AR.?#.P)7!KU?(T03Q3^8%[7.F3>\
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M![WI0P:_KA/XR?HT9;R]7VA$+I5L=)B-=TIZYZ1\!6,Y=@?H\P"%.KG1SM!
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M2$1A7JIW+7\T:H3E=% 'N<JX)Y,29_42S193-NUNNK1L%M.N^2GG1:_.KV)
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MU'%2N>AQ<-8H_RL?M;CK0O&0'@I'!1:@09\_HWA>^USS!5S$@O.''@3%H,I
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M)";J$@348/6#V.CZBQQ7V I-<XYU-,?5H'E"N:TH>A$DG2./IT(4\RRB?$!
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M8JF[8*VZD5B=%!8 #1U^X(FG:& W6AG=#J%D4=/9& \JGM"<&(,9:6X;JM:
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M;+TWV'GJ3P5596MQ,]PB0)D:X0W@62."J2ZN#LE#IAM>5\?YYUZ%>*:=(Y)
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M9;NB;KXXJE#W&P'<0"'!M"41_('+!W*/[[ZKUOELN\F$:7:#?VV\:C0,@(7
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M9R9HZY);P)\W08C1DU]]^=&!P%B[\KS,/CO)WNTLQL<-(K< O%_&33MG+K>
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M"H!%GPF'"&.J#QV29(=SW=&V/2K#91T##U=W)=[<Z Q[YBQ#@^6#'+CLW'Q
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M=^TOP8]+[4UNC+/8K\9/+R)R%H?(I)>@P2@3(Z;4QP,0?AZ9@O44N:2/M+>
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MI.7O(S:GL%JFQZNTM!0?O:6$?6K];_GZ]J2*%(1+PG9X; FU=7==X(6)!?<
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MB88/"8I/^=&>K"T1M.&3C81&.2%,@)4%0=L#Q?< RT^F2IX"ZQE4BBCC&D;
MXR.YR"[8M=Y9/3&X>&!K04^V0_IDZU4G2A25%*1@_):Y9,=5UM9+SK=8N[>
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MW'>'W86WQY\W]47RL*)]CKWY("=>*&_'"EFA?]K)W\F\TV=CR71K4*ZX6G9
M*S&QUB2'*I'FSH 1,$A.<LUCY#8HQZK:K9X ?'R]IEO;*!87Q/#B41<7RLD:
MZ1:,D#H<VGF^Z8O1XTT<0;5+<X#N'8,Z+A?;I&'1R;<CZ6]2AV ,2Q?_4>]4
M!RH;:E3'\'1#G/*3KF<!5DO[5O4D1X_D:V%GR /].XTP&<ST>)+'DC+GCXL0
MU*&;,.X]WH"]_:;@KV7VF!VFSP"=3UPIH,31K,ZD0L^X!5J'WUJ^522#RYF3
MRL?H/J6E.^$:6Y/TTVQ$G%[9I/FDTT]-ZI/+T?4_]OXN)Z(H\;0*J49I?(%T
M*^OBVL.5 KX&IEFL. R^_RX,DMWJ5.$-S94H7$B7EY(57$V%.53S8J:'VLG+
MV:]X'FB??FJ&VBP#684Z7]:_+UV9JB2EN\P3>WM6&1Y9;'EA7UL.,O,6%'\2
M^?)M"!J@"=LO*ZE@Q99DP2WY^GU=G/B7=WYDMDLEJK&I@BA*2-?.E*:GW4HL
M:5872LW<5A?9.P \:?(^"G/27N %%4Z+(K%4A8&\10C)(D_,(#YU>D.,Z8!@
MV%R?0F$T8#]47 )@^"A-&Y6>H$;IL;*<!. _^4+PK>!/2^N_Y4?C31H;^>PL
M;*(P8=U]7;O/:Y<,K^0*QO1&!?J[$N3$0_)"+ Y?R1C&F\9(8,84O?(_9&;N
M$:&M/VX+9"NPBV9&Q>UY_GN'SK:I_7N.Y,!>@N]SQ4\N.P>Z\E\-<-DV @Y/
M]F1^2IJQ&[YR>:6HI..J]*9VL7EUX4,?/"8T9Z"P$RL(5U9^6*%G"(\SK@OB
M)WCB>(2<6!+>2SH.C6 _]_Z@"N'9T[0^E^?\*FT]<+*N/DIBFC@';2K]7Y<I
M^5.=R:R:K9OI\%4#PNTVO&JYRA?ZX'P5WIDAS$.1#D<Q<H+/O!K)UTE?W[FH
MY%],OG1;_Q WZ D31>!KMH[?HI18"I@NRD]Q$D5?!-9<+R/$*/F7S6M?O:0P
M3UNM 9/WJ/ DC8Q%#6]WFB;@@EXLHH_RZ4XZ@VWUH$)Z[*%"S$(N&.9D ][>
M-&A,#8]QQ?OI I%*:+:3E02FQHV>TNRWM 6[9,FME2.E6EW$:1]_Y!+TRFR(
MC7KOX<M6([(CN6?._PAA[2O;M9F!OW+0OF'::?E!EP8X>]F1H7)]HX&;XP:U
MJ $[B!*AK[8?7S$<K%'(^J,P^Q_F^_"HRM4BBB+W\=4;8:(_P!4BGB Y"]Q4
MC2KCCBSOURCCQ5N3/!J? G8G%4.PWF\OZN9T#7]F<MSS[[AE#DC8ZR&[[+9V
ME(6TB,'-"C,)/A6SYGDEC[FH>"JAY6W1TL9+>9SJ&%#L:?OXK^9/?WP'NZ-^
MD[M*^(AAWNXMFOU41./*@F@/67122-4]X%GN KE?PL@3%P3)^PP\O^!^OE4_
MP5NJUA*F2IH^#!FN(#7=YD0_3MV%T&Y%+,NTW)V+M!"SI(CN,7P6A_A9BF@P
M$E^,DH<Z6HJ[:JYC4I%&BL!2*W4F6$EPLW%!<)4ZI-9:01!#7KQE1P:7E,8"
M8N5KW_^H_;$%2F%!'U^%IRJBUS]/;\#,VZO,F;R4&SWJ!*\#-QB0P$\![8%^
M-S<QN6C>"P.#JQ).&R10*NDN+W(PJ L(DW+<TF40/#75VQHESA1L*E(2O>A@
M _O^\_\R7?Z_*HRD E%""[F;R#Y%N1ZZ#7:SW]-?NY&\!_P[MK6FC'F3_="=
M\.._GQICP&#JJ^2N\14 ['A9@^= VDE?FYP@)'D_8D@?\5V%.' J'F.7%0$%
MIM= Q%BV3T<BYU*5W[T8EK+M@+'["9@<$WB_%?FJZ=HXIZF+_/"+JZ*H<&E^
M+RT#A;>JM2'B=7HU?D-B3"MS5AU"I-:,=6C6$E_G=\G0,"W?O#>(N<Z.ZT""
M^5E*37I-'>)I],$D/H6&#'?T_$HG0]-OE['.M+9FUY)8PA%R/6E37.\@O"*4
MJ*,*C%N$U$;BP2<VE[LGZ5W:\K"+F)(*&<Q*@A_>&3HV3S@ZK.="-R(V>$ @
M9CWQE4G;M(MYG&03JN$;PH&=\U*?F>6S)YN)*#FWDO)$J&>"D9'W &RWT5&H
M-4@I11K*NO+BTYTZLH+ &Z(@CE9IHFQ!W,08W*+%\F-WQ-L"JM*S5:[C2/M*
M"4VD"&R??X*M. DF(5U#B55@TF3/^=F8.M\^=DKUC#%B^VR!N$OC E?1<]6U
MJM'*?4*X;17];L]FZZS"RH[#5^0L(Z9+)!]%(M2Q&#$69G7>O$?BE,=2EV96
M.D<WB2FT[HM+V2CR@,1%RV;A2!M!4P2%AU!^-G>7>9/4==O1CJ[HE''<64?N
MKSU'.>T(*/GF#5'Q=:[ ILP"+]%1E"E,;?FJA2E_I]VZ$?J);.XQ+9"UOJ"^
M@934UH<YL/.L#YI2J9]5U$KT9'12%NH420X&2;9-%35-.H>I:=\#!J\2Q#I"
MF+,R/*;("BX2\Y"\BCC;3?Y3FRV-^ NZZ'4T3WNG]15S1AP^\"W?->3E;,7V
M<6NZ/BP$I;\>/N+^;60!_OY0DP'KWQ]ZPI^!IG2[KD8\)8R'T@KD#+U *^&)
M+Y<G2-"DD2Y? J(!MI#:-39@FI;(H4Q7QD)[9?%"+?@/-^L\=?WH&O/3' S#
M<0L*SPDQC+]X<;&6VJ\?-5O O9FFE%#$:%)(CK+!K 2 3A),:13&=D>YFC72
MU4P) #<308-("V1"##=,U=XZ@AQ&,?Y*OJ?NM<G46J**LAC6'^_$E& :?;-]
M5#5&6R 2 3#\Y-1QK9(T(A !L%!Y@!QP9P* T_^_^O &1_;(M!41QEN>V%6V
M5*"5,RE+?FVB0X-\I_]>?+S>VA\91-_>OOO>MS*&K07$E9V4 KV(]3RW]=@2
M>2/Q=IN(+$BY96(''J3!U1N98/+(G^\H"F8KO;?Y2E))+70X_S'.BEC4'#6N
M15-PN0:O=F99U\NGZ'&86T5H6>>;VC'197NB!+=*0OS@D0+]#T4=JH/4+/DI
M';:VB I$&S52K3)X97P?HA8GC6D?_*@:AM)J_:%P5MR7=9YWHF!XL(2E-)OK
M]387<AR-^KA4\.DXFQZ1\S1<US)@XU)F"W.+<;*"N8E0'4L .J?4T!*RR'?(
M9K\EG8/"(&!.Z3%=D6GQ/]+7O[C^E"7?I^$HS #[K#TLS1E<6,0]+ER6$B,=
MUC_Z%IT6WDQ\,S4Y[Y*#N8 F47=\$0[,GT$C@L:7VQ_Q\Z&T.K83G?@0[;T\
M^<08Y5(Q!EL"O[4P;@CKL2<;('=6)T7U$^KK AU#?GF+;':I!1GD%HO!%)8X
M4:+PU7UKK6_Q$>\TTG6_!,I#D_E?MM*N:Z@!O@LWPQR:4..BRIO,<LSXGWSD
MXW'8A),W:#,7XUG,&)95B!,\&@*]:]*(OF4OVTXC*K!UM+>W['_,Z[).@:_5
M1H ,_#Z'U(?#]!X@O5)5U =G$#^\?Y"_X^A +S,DL0BH$Y)J8@ML/W+G#![;
M^-0\X=3Z?L.&W>G&??.3=8)T%VZL!^!44 _OM/?:-=HYW0(.9[7!MS7:Q"1]
MW$O ><$B^J81)\)+M,)-A))=9]IL_*A\G ZZ:O#FL_,3YY?K9&<;Y/8U)E1)
MLC<?(>?\*+MDSK5#_GZ0;I+843]^Q2 -U46W9W2-3<G;D240_B)^<_%7&-<F
M:5NYQ[7UX3[LR.P#5]>+(<P7AMJ#M)C8C@GB(Q[E+R1 Z"%PG@CZ[3 .M)7W
MG7B?3NDL?TH#7%&2K\=1">O"5X[0W%QV.2GL@#,C0\,]+</'<HDPL'ME6/L*
MZ:3YSV8DJ.3MGL/"1]KJZF\M#M\-R1VR DDK+=T@FL,.N4T<G>JD3]0$A?'E
M)HN Y=Q[(*!.6<\+%5]<,5(J@8#KTQ5H"58:E[YPG=J+Y<3>E=L]/UBM-XH6
MTC,'Z$-YLC&-"0V HT]>QOT42%F(^:8T6VERE%:"FE2DH]^ZT!J%JSN0>4IG
MR.4M#W"DQCNPK6@CV>700F'M\"/^*-2 LOFXT99HSX<2)L24![PCY1PI'G)^
M5!/RI#MN>2/\C 1-5/N\Q7G,IU8%)CM97K'16%T5\&SS'J#%8N\W=BZ\C1)^
M_#M#U<L0(53/P9(HA=44_MP\,W*29P9DG<^6? +:?&1"CNJ2?A@(KRC'91E[
MTYLK(W+S:,C;HJ$NY) H9)<NF7<EOE<\!X<;:5YI$;W*CJ<UJZ]CTSBE=;"B
M(-0#.&F;WKD'A'!]7H9PSVD%U4&)$-*ME+2 F&F'_S(P]R_B8@\76HC/1+OK
MA[\@"1N?I OBB%N<7&3WG*_-^Y/?WQ+\*2H-BB"-/4CJY9_2O(Y;=\UIT+<_
M^2U5'9)#ATFOE;,+O,7O <\%.PU]^[[VW<V1B1^+=GXTU1HYN#EQ5,S0[_4>
M^\9UEB<J>QUX1^ :< _8&O6]^2-G1C#E<EYG=?;=/2"-OVMFK/'DSN>K^8Z!
MDN^OV&.-VROYP'N _ CU<=XMX>2^JN_2J12?)^FEB,$8).HW\RX.4GD1XQZ0
MS=]^A,B[(_ -:-\:M7T@NX5C(K(U=/47MD1\T-U8?3<&?;)/9R;^PJ+F/2"6
MJ>]W/4.,W077H5=G=@'IM<;DVG)HP.D]@$J5^L8*Z+LBY<9^Y_5@T?;>O_9J
M_TNOJ0=.6HCO 2*.ODMK4K>OCY[> \8REBZ1$Z-4#R*FG/Z]B+;_)F+[U>D?
M(I+]643%[ "JY[W:HT;W .O^'"^<8V5;Y,D?O;)>_X7_/ZE5M%/J3O</9C9C
MD<IW&-0G&^]^WUD^$!OZ=V*^O^*/%=;NPM]1^OH ^QYD";UM''[K.0IT1/N1
MXKAQ^_OU&*0MY^^8$?V3D-G_B5K_0Y8_Z_6OYO8]W7I@A=OW5\RQP>W5R#W
M-YIB9=]\_LI75);KK++XS_\1^V>R&<)1-]GL6SN2/DGG:']6Y)_).H969?\3
M[^E_XQW)W)HQ<P^HV/R;&>/G87\);*4 YR__$LEZ,$-H@"+-J#%._F8S#LXV
MD3X9Q'B2N\;BX#NC936>I((O^%.!$U !FUU5IY9 62O]KQ7'5!W%L/^7"]A_
M 0[2CU2!NBNAL&S+4]\HIC7'[[/W@%]/)MT#;,]BJQLT4- H$OA&.(2I=Z!5
MMXJK(-'G%DMP#<0(B[YQ+][3^>$^OK7C@N.<Z91?:1[(L)"IEOBM>T KTK7"
M=77L-L+%3?04/S"QX^[-$^U:9$J>\"UO6E+K81)KEW5TY?>3Z;$<GD8P,E#Q
M^"(!'E)FOZ$3Z"=V]2W+SS-M#.EO:V*_+&]H648:;JTWWFZ.\95VR8535ZU:
MUP#4CF,"$[> 0F3R<&X= <V^%,9^ K\9>_LTIG+K]%#4:R.6,U.X.FN%W<_Z
M2]D1<I^(7:O$\W?K<6>')Q2%>&_B9<^W>.91!?T83RJ?3]R:5"#EO>1XLW.E
MG WAW1&7"7+!P>&]FM@N,?E^%BBSW-Z6?0:0M7:(.;Y.OUVY)]7R-=DX!0ZB
MPJ"#BMH6RTW/.&U3L(2MT+,H 3=H'KDB540X]7]4U/FON97E ?1_9#>0!/[5
M_7J:F_"W<RG _WFILW_ANSU<CP)7,R5W1S%T]/B"FMJ^O4^(CR<1UCD>D3 O
M* K-2U=NF3ZL4*9A^"#(ME0)<+SC<>S69H):*1ME[U]R2%>+<Y#"U^*1:NC[
M/+\E(9Z4=EH%+?&$IR\=AG6J.E&H,U7H@U,BHT=&\ET]G*#Q!B@70%,;NC7:
MG?C^:ZABR*VB<%WBE_HZ5ZPG]:BX+GW(GW:\YWVMNM7'%U4\T+2TX;I-V*=-
MVF>"A2^-9-9B J$%!IBZE2'E-9NIF,F7-%^,YA^[_09N2]93BT83,38FLXH
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MG(W7%BUZ5$YZX*\TR9)'RUBQF(\Y;:W80Y^V"OM4E7:>5W]*YS;WF$.*6O5
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M&!EI7V"NC=&83$)IUW9!8Z8*OU*.WV4><28?.J"1_[(XIMJ0QFP6'%?U-&^
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M(+5@O0S/(X4XN7Y0<=.CGZ42<5F#-UX7HWZ9@A(;JF;F,'8(:N!Q ;@#"Z;
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M%=4>[XY2\:2T"1^IB,G>H;VD+4JK*W#GZ5:>8F[U/]9,<N_"_]+BIGOY1IW
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M,ZFBY1F_,2ZD9+>EJTXQ3>PPZEY/;FIYZQ737?7:[(LMKZ2^*8"'N_T@:%D
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MP4T8S47!%W*EK/V;;W[TOR+?(4?$/_$+-KW<X9FP-9Z_'+&98OI/]C'\KI1
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M:?0]Z^O4G+<# IG@GM0U8?QAC %*?'6E-6N/P-\PPD"DFG2/YK)4.C-I7?)
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MX-K<4R.GJ P-5G9=&W0CCBT?P<0?7'PIL[#T]=7@OB:/DKVTPCP?QJH.E_J
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M5"Q@RW%=<H*W9YS#/7'4+J6DYN:W"7$GL(Q%-W*T 6D+.DMC[.)9I6LVK-"
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M*MHA E780>,@[*Q>2S;]GQU4VO[O%\^L5L "%- #5?:&-4\J5*GIE+7H+92
M/O'DL(2F]^4;GTSW+D+^/#I>ZL"3?C^_491%?R[BC88/UYC?5T:+#,89(<R(
MPTB@M8'J(/B1Y>G*@!6>W\UX?1K]6:5[[J85Q]LSQ-!UGBK3%))S)EJ\;2D3
MQ351-A<5Z:;W)XHED,H%]_Z*(?LL&LQ$[F#.!R-W'S@X!BT+GQJ3;BFJSZC
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MUI7B\XV&6UQ!8&@S+6L+XC(B= ]R%A=O,N(FC33WS5U)LPEE\2>S4!&\':F
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MWZ;NW,C503<CH\.<.#(I>)E-)T.IL)PUQ3UMU#?YV72\ *FG/+$DX%N) *2
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MBV>/\#FO&38Z'"M[;@=X#QT_&T:N7W;?Q0-%*LOC>C9!H-AQ4>'^]DH*$'G
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M:<V]%((_6,N&MN"?O=&4+-;OG].]BAAW5KO-.A'C#^ ;&DU:2WS=CU?\LA(
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MJCM+2\-NF8BM/> ]?>7%V#.ZB>30KJ%UH0)17UV4".W4$WNX2I!8>>S^56'
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M2?OXKM8=K\LF*HK#9:]#= >V7CU,OE*) !_X2I E^GP\)B6IZ?HJY+=;3ZC
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M;<)FMFB) &NSE:= <[OB[C.;B&O!O)0AU\5TZ:WFYP-'*DP4];$G/T)<LL;
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MJ?&9L-9TEP=T-EN"Z/X.!QIF,+Q\AWNG/ :V42HN,>L>5J+=Z \]'7JIGNF
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MK/T+ZD]I,L2QRSO+Y3")SZ=A4]I5.E4D+6^^K)1PI*K(/ 5Y:-EV1 ;:.ZC
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MPO6G]BF>]YS(#%/$V2X/JG&]L:J)@C[V[>N1']Q+F%>90DP*!!H][7-%BPW
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M5-&JYH!HL+G*#Y_2K^;(:/.-\KPP=4@;J8:K*GN$_K).5<+6H.E+"4>.,@N
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MC,=J(*'^?F[AK07\@B_2KJ)ZXF>H=G_GNX0Q3;$\/F4;B*3%60*57YOW8,;
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M\4)%A819'L 8ZUA9C8%6W "^O4MS%SB>R_%45R"J_:I:MQM ?.\JTN<&""B
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M#=F$T9MXTLF4C_S@)$!].KC;>H="@H7Q8GYZ>D.Q]L/K G7.D,\<C*6846K
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M>U7A+/B=3S-T_<6,Q3 KW6-9 /;!B;B1!3;7Q-?'E]+<HEGP-4UWPU$-S.P
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MMSRAL-/:\+0H4#+F1\[RL5%C'V?(X<NP:6XA[_(C>8PYR(5(<;9&MU78QJ/
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MV*'^F'S5'!_RY4J?TO=$]*%,[O3F7:/]G\5@"-A^BKI[WB7O!GA"3R,"-BC
M>:.&K1PY7,N6:VX[)VU]3_%9XF:,K!.4H,CW2QC^5Q*7KO!0\]SL#:+JUQTQ
M^[YXK&?I<% $O]HHK9**OX&WC3AZ&*1FR'K'';002KE)VO-CXI6'AQ%GV:/
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M1[F+IIJ[+C\JEJPI?90FV$B=4SOT[ JW4[;!OL^YP.\!*=AY.8+(:P:%2XF
M^5-HM6,$AX"-U-&SRO[[,YW0_6'9BOW>W@38:IQ5]+B-]A17VZS4L$5X-7.
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M/^"^[?0H;U60"60 ' NJ;8?=ZMM;G@JP@1S*C69%ZU3&05=>680?0PCB0G<
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MRHGK5[>/O"_.1&X>\YNJP;[RR56; ^,@VD'S4@FTMWE1XCUL('D-:(GYE\A
MQBKMB&3D&K"W<@VXM*Q"1NX:HUW^82+C2,LOUR+^'CP3\J;6_052<"WX"/S+
M%1113MTU0,P3B$(I7@.Z\M"@U'V>$7P9312_7OJ'$0EE"026IQG_4Z/]U^?3
M7X/]KPR6HA7ULGP?Y0>U8IPNH9;7[I@5?:?VLCB S#K*YQ _H23X!-K( _'^
MM!2'%T6?Y'I[,I\&+\D/]VV#%SB)YJ&S<;*G9<WE"WE[E.^YR-5EVC4@3.D:
M<%=%]QJ0WAQQ#?!FN ; U)*0H/G$[EEQ+8Q3OVR*""J1F3TV*!V>Q0%#SX=%
M[S78'GY"81R0>,=AP+C=V6G265DRU[P_1Q_[;I$""3.0CI(8RXP,6>"]G\TU
M=(ZW<0TX.?!&<4G^O5CE*GK.;>:6DNPADDO9L48Q*S,0=CY4FD9G(Z=6"UH9
MFF4I34\?]@:'TC F0KL4!OZLS=*R_"1KAKXP3_=L^^FBY28@FAC8EL,VZ'FE
MR 7\W9Q4GTEKSV//F[D7]T-:.EKP!V!"/%WD>@$Y7)_UU-?P D+%5EUM0A^$
M5N]]-4SEW51C\0 M4S%*3\6T:=L4L%;U))(E7HWU^P,%?$%TJ;EDEQ<J_V A
M?W^S,\8;_+>%_4P0J+CS$]]2\:;U^'2M]MO#SQM2(@$R'G/A M#*2RZ$9;_D
MN. ?,=UY8F8%6^R+8K:F4630A?F[O5\V(W0ICXOV?F-"EC'J[Q3*G<5[4706
M&EZ<$6JU$Y>J-+Y#O0'FT2,,<[IQZFIO_>_,3C'0;NI.=8@06RPP3<)W*POY
MC*1 DR\8:E6U;#2]*3Z=V1]= [;5AWZK1M@.=->?%?3,-#RM/8VL42C3'&)2
MH649=PUX7Z-I4ED5C(GY?9M^3:#?>8O_,+6J8_%T2+%^G[XBH_O^<%WS%% I
M:(;$,-3GH\+.+BP=RWWB&O"_GV#^,VF!C*QM::V,Z=/<7#%8&*N&;]>6#J^#
MZN@N+/)EW6K0^W;"JX4LYTW5*N!CE]=3RZC2Y99[VMN,R(O/ZQK-!Y^5B[(B
MOJS<8Z52+!;X[2H3<9[3*#HG325#B,>%+.T16? H*1QN(5Y'<EIFJWZS<WXH
M!G1QP*Y^<AIA983C2]TW:L$BR%]1W-=WJRA#/G.%)F:86HH25BSR6T&@,9N]
M\PVZ@NSW+85S$PCO3GF>#O[[JV$YV=#G PL3Y@S5%:\R;"@"^WA2.2*^VH<F
MJQF<:C:3HSJ%"?G5]BZ?+II,TYUY3:WOSJ_!G!:;9D5RB55^*_1+_K-WR84\
M3L'GBL&-3"B,:\ GXXZX\XI.L-=4W*'FY_&6/E%\TLL6EY5[5U; '_5K:<MP
M&]EYF3W-RJL1S951.9U>NO>O(@U+J81$2_Q^*ZYAK$)C+D2MWFFZT>N%^8B'
MW-BE&"A'-TG'_0U(,+RLN+.5!H7P7;8?"Q?!CR7Q%Z9QL6K5[OI&[8]=SEEX
M2DO V2Q=%ZYJMBHY1TL0[OGR]WZ+.]N*Q&VJ*3Q&$A%;$^+%[**QXPQI@FA7
M#2KD$M<3,Q->-,M$[!XF'Y'N:;KMA7CP?9MQ29/?7XW+<A1ZYQR,U%E_0RDJ
M8$,(7PG7(2-;%RJ3-ML/[(!X0O0T7?SDJFHC!.@#W#\Y]K2V$K[_()6W>LH!
MQ5US-9VL3*"+"A%HK(CN.) 6UJ"/5AU;%*M1*ZZZ!OB\0X?6P';XDM7 0P+X
MO+9T<<>KDN_,,\P1)Q/C-CU;'!O\&G$:F=YM7Z9$-E@SKP&+O>@5,0'\>]>I
M0:82_G/0ME!H9)WS]XWA3^:&9A3+_HFFDI6!']!1F^L \<;B_]99*Z$QA;Y<
M4-N+N_'\UD6@\QX"$^'NY!']L'^\^.N(J$>IVO\:[']ML(Q+:6?/J6^*0[)K
M4&':%_C-;OM3;<QF\@C3&$_N_&Q!IYKO/S<I!NI\:]]A&V,*.C]M]B^A5/V2
M6+9I"(61?,@(9HR$"[Y!HF><8(]::$'&NGAZ<B&,EY&%L):=M)V0$%ZOSG77
M-$MGW;V94) Z:OD(KF]_#;AW!BT]OV..GLBY 8I'/XS\>QAGDF"R.'ET 40R
M=D0__]<FDI<<Z\$M&T]NM+3I?3H/@N>?O#IO,E@5+ D^5CPU&R+V'GYSXRY&
MT>ZB7F0Y35#MIHH#B+H&R*(]R@9R_")P8NL:\&+50:/ NUW8I1#E2RYRA8I'
MJV?D'X15Y\X)EVJ<*3)F-*F@R X[#8X>W#R<CUHN;2)^E254);Q\[-;2YZI'
MO)6V/Y3Z\J:PY$;/V6@]._PJ"CUL@L()E$K?1JGJ-2#  Z%QA<7I?7'%>@V@
MR/Q5%$BQUE._]"!50]PM]Y?Y _]!DKNE9_O6L?>7@WK&B7^<_S_(FE79!6H4
M7N;^,\JFAJ1]^+]&UWK>[6E$%JG$DZ6[7'DE*]6-8RL53T=4:UEZ[ \?\+^X
MXBV)_]TPE0ME9 9BR;DR=C/L>0Y/\2= NX*\@G_80&O#>EH.!,L_KC:O\QV5
M!,]"U2,(NNZK=,J#/*S!S'^P==$J<O+$DQ_P&).]61S-^MV@O_7%+(CGJ>O\
MT5>% /L[@F];N/&$6CNJUX[>\YT$\<$P1CX_TW%6^/@!%\:W,F65>5HH@P '
M"5H4,3=!-P?2B5+I(>5?U)X@#R1LDS5$?KTSZLQ>V*<+77RC_3ICQ=%0#J+^
M^W,;S]Y,Z! >"(7)I3!4A@07I9:Q[39Z9YJ?ZX?DG+)TG>I80"+'L^*5WQ\^
MB[S5\*$.0$QG%C[G7(R!P&L]5\\O. ULAZ@7<,W+\&'(UKP!/^JQ^_G*F=JU
M]?R>TN^,4&!D5Y'9>Y4#?NF=W=%\^S[8Q7N9RD)^@=#+LU-JYM#^1%%7E9N:
M?XS9IM&1+E(O"OKLJS9(_(RG(JH%G6:$)^QI+_[.8L;6,A?/YW2K+KS5RV)L
MH2UX5L*W1CE3[*;4]=Y(!FC"(2.9!\EUE&4VWI\<@"D6IQ%0;K\\EY?;$M6H
MV0FSKS0!( M#^EF</4::.44;[V[6W]V_<$NA[G[]1=Q_9IUHH]?W3Z__20OE
M+Z?T?YVN>;VQK@&]HOLG5_[,+4>64]..2\U4IQ10/=I.<OUL>\]L3F[GR*&G
MW9S^P9D!-*:O.'RV]8]U-1.ZY.TJAMM>OPU9DQ0JO09TGWM//;D<,%$O:;D&
M #>O ;J!AURQ?P@3\5W*%5OE:R[V<CKQ5)^P8EHG&,7J=BV$8BQ=D%?H:OB@
M*'1.&=3&68W&31MX_"QI<Q:9.9(?Q=1>((Y*)O,-\EFFAE<O=:!ZSNT+H*Z4
MY0BXO#">L:W0%-+WS2I\3M.:)L8?L.(X^"+U(4*A :KX%'K2=@V8J0=U4#MH
MI$%PN2]AF(88 6)"GHR276D'-*=^J-;XF_W5AP1EX,"=^5Q!:Z7)A>'"%ZTX
M=@<O=2R^1)L?;5\#X-XUFM< 4\^0G52C"S"$YRR)K3L^G"/YN/!XC7POT&'O
MODM%JWJBG"*EW9:]_)-H]:B4G^9X#SL.7D=8'J:16Z:"/U=9S<KSW^=0J6EX
M1_&S@2>8N&5R7?BMRN:LH!.=W?=Q&_?&5(89!#;K/<\88=,TY&+E69.P79(3
M;)9O:%EG8KT SM -$II;36HWC-GR6"LP>'@_]Y)>V^"2'FB)SLP4=XH;>@\%
M6RIW1;:Y[<-JNUM@XIW]3FZ>Q,L\7F:7+\%D% 15$02>.;,7#'"=&M"ABM?\
M''QPSDOH4#N5 M4C0LAIO$3KY>W,BMR,&9SVTN<Y:^EL&(.$&ZX(!0>?92IY
M2KD$(^6-E2K&'%<;F:DZ>YHN7@/FL @+)2LPPPFPFTA0A W 1Y?:".+PQFC%
M6S/:#>*4>^0<GS!M[TK8QH2>CPS8UFH>OUQUN :0SF^AF!K&.)ON2A]M4P14
M-XPG;A))TE#Z -77P^^;>= YCS<3:W5[[?'7I. N=*0D31L+V88S1NZ7^AM6
M5R"*3P*M9QQ3N,]WQ^0=8OLE/CX@EOB@@-O*Q]?-J;=!%U<C5!"\#V+:&'!<
MWCM]+5)Y#5AFO)"35&4G<Y7S.AF</X )IQ06#CO@W0=#%X/7QZ.U%)*<+83*
M<5.4Z*85#M(_*O8TF:_5\DX?;3'V>W%69ZYN+#MY&X,C%\X6G*-U, WC^\Z0
M5SO&379E@H7[DIU/F14F=P=LF <JG=+,9\ 7*WWY"6^,<^T7 AD%;H5-#'ED
M-)8P/QQJ]WXL^-PA1E"^8%:7"^$>&#E'_/D[<VWJ)8HX;9D9HT3P"?2^O8QT
MUA2\!/RDS)8#M4'][9& G3./36WF5S[%]R7<>U"<&8/.D*N$%A1A9U +# 8T
M7\!%[?6'ND\E6YA)6)42>+<17N5> W -(._XOT7V]QF?-#OMQ9,=P;7K:\[W
M0H#'?6/7 %%+W?95R>+-^!8(OWC*2?SJ50Y6DND.?"X=)G0^D7A /\KLN$CA
MHJ$P_D>Q%4] S$ X7Z+(*WRGZ*R'[!C=5<9BRY[\L%84IWM$E8R'B*?CXZ_%
MCO2SALDE)+Q#=;D_653=JXB7]#GKQDO@EZS<570/+1YN1$JO60(M7@FU/V?2
M;#T$;[C"B&UL;5G12_->IVT!WCCXX1M*GL<#[*#0PN4W4@67[Y?.C;'#C0ZH
M5U4Y]<"*"/QXZLS,.<^,T=>O>\MBZ"BI23''-9(M4(]&X%XO+9M)@Q<,=JP&
MB'05S:<>/CAP[3U\7[V#$AIXLR\C=&N2C#F:["F"7Y*F25)+3+/##["^@A.[
M.4 Y"%U5K]N.?:,^>72%+V VP2+H7U\KJZG0!1KE=BKMP^?PZX4VQD!7YTBH
M7\DR%M./]U,5A+B'=#?0VTF?O=-4F/^16L1_#-=RB_6O+MX/:=-_,IF9N.L"
M%J^:'S%[5^VK)8:%.>9/MCUL&O@DSWK(*T=^[2I5L6+GL#J-]>?@_#2,%YZX
MSMG+R;$_/]ONS#ZS 1VUO=UA\<1%U69NBV*=CC)J#EG*OH\[]F2<BY>SUFA\
M]H+=F*4"A,Q:!SK]$;\ZYZEQ:3$GPU!44NW@*2*G^'A.NSUO4:&Z@&E4(FCU
MG5/!RD/>;F8?';7#8V1@MD@[&,O*+26S4=HN[F0L/]*_ZO"]*=8+6/[*O<.I
M;!W$3MP>,+ KFH;Z_F/)G6L B,3;C-TU5!C,>I+0-5IWDK\&?+([KA'@0]2"
M\RU0$R'WPISKS0K_&X?]7E*Y,X(O6MPK-4+\]JDIW6U:H*S]+&BWK)[PO,VL
ML3C= -507^9/19ZUNQ^PA9KLY65V%+@EC<V$QKM@<*<TTX.U]R$GWR['2=L1
M)_9#.%'!%?IF[G?G+#3VI73IFE_YDV9^L29[AW,OZ\$'-[_$Q;*QHDIPT-,I
MJ4K?K@68M,6S  @;N4!1'W%P";:H$]GV@$!PMXZXK=<3U UEZZ3(J9Q\"U)D
M.G"Z$RD\@ P;:$&O"*_YVB'>^?!C_"('VI)-$4C+.V'B"[RK"*>A[V<7 3S>
MV$YFIBX7IVLA_N%;P8=X/7+-Q%-)$M)TP^GC\-SR.]F1$A$4"D:81:(!M&!*
M;L@\:KAB\M+S]F"8X_VKIIR8#S%#()IHWID%H0)-V]H=X_!:LHSE/B<U;:K7
MDU#45A^9LZXV%@?]*#<8JY2WM0<GV[4X(,;(>'^]K;ZSN,AVR]3]W@*,X\'H
M4_8]03A$!C[(UL6FPP\*#*S<"X*4ZT(LJFNB0RRLL:(DPE<* \W+V:5IUL'"
ME;I\:$<D_:T\54=3>(Q?8H!2H,TU% >O=I_=9<C2@6D/3#$ C*5]SDH-GU7@
M(]N+T#X<8)0M-_#GK\Y&OK=:KQQ_,%<[3R-_$.83\;*1X(NA&0,9??K$%^E"
M"^GB>0LGB 923L04]&YXR'KLL-'^Z?,8<UUTDVXW%F&5,?-2@<8QA^-]FRCB
M[N C:7CQ>BP<<HI=7F_PE4E'KN55! U!0EGE!ZO<?="*1C.IKRR(>U'^DV 0
M)7?F"=.WH3W:,XWGBRZ4]]9"@C)5%%.WH+TF+947E*M?.87-8P!L@%U*.X#P
M3*=6*6M99< U0'S?L1CB&BE;N% 45/MQ.R0YO_NM&^&PKU@/G5I_ ]]1[Z59
M[JDV=H5:>64BHSO6M%+23RUR+OUP)6RVWI<"([8'*0NY[E<I6?H&KEYF,^FN
MU39=\ (%CMELEC1'))Q[<L\L'OE962]A</X'I5F+]LH;%]Y3170$\$END]XX
MN^_]Q1-%WIQV5 501-?,F6][0,S"&93I$B(V7F7UN6@G9_AVN>[@,NVA,^T.
MDPM6'MTMU]9N&19&*KBI\/?VCM*L9]5K.L"J(,&?-@)].UU"]>O[)51?I9>1
M#6G>2.+USR:INZ*D3-5A#5; \_>:+-)+I66%V@9(0D1UN@<KDL.44[G(VG9E
M[Q"7!G1F[\L1H92(O@7UWQ.A,,6:Q/.IG7AVB6+FEJ]T!U_#-3XL+2&B5*82
M-LD]2W*![=N@U\2U-?Q,J]^\E/:K3^\UD3JW]BRY*<]U(<DU@IDXIU?]Y*HG
MX!W?M?*Q*=2EM&U)]45;[?V/WSVOK5.4+9KWUD!UC*PT2 F/L3D$XWVXD!MM
MN*V*D_P^M7;I/;)$IA]%6'JJ"6&]?.H]@]*J:#B\!E14GVE=37)4K,Y/+9(.
MD19"?C1-73J"C;/U=-H2B=YM.:5B)]P[N%7V[>UFC_S U&E<B'\5OSR%2H36
M",CQCE*FSN=VTMDBT*6,9VN/,+1D*H6K^9L)"#IT=ZY1@X<_[-/)I(C9IX[P
M]^I:A*H5#]XLP1CVQC<+IK>=A?&K1FTR&FHKO\K;WY./KQ&O<3"FV?IJJM9N
MN (-"7RQJ&;%_'I*22MQT."5&$<K0Y_$U)L RO#N%IG#*SZ'0E8223#NL(<L
M\_%XF^SG*/WS<>X#N;#X.1^I"!%Z;&Q\6[E1.">5B"3",^OQN6-),86!ST.)
M(/X?8HP?A4%?7TK:?-'UR,U1 RF<7 A(-38?7 Y5B!Y:SX?-JB:;U<C ;(J/
MX!3+5\GY.9I27(065/"!2V%K0THOI)V"[@M!&Z/0<-$B3^:EH$9CBYSYS;'I
M%"I33)F:5SJN_B;*?0WSTFUY3+DXYCBQ&5 EH;O=2O5-5B]N!\S*)K%]F*+^
M(*P;:$,[&YH<8-R0V[^GS=5N<5!)_6SD63A] FR_,K2L5./)$B]0>]VAH9"V
MY-3T1#9)K*:^OA[/WB)S^JN)/SD#,^4@I5_ W5<]6;$]77<R8*M"-N5'*587
M*LH3Q5Y#J]ZF<R&>LR>N"6$&O#^Z%[KX-M5WCO'T1.<\HPTX=L8X'UYF@1R[
M)&F3S?*@=>[W9=K;]1FG8%,VRV-QJ%668I-Z6TI[FB!"WP;#Q_?X]#-ICCA[
MI5I80[ ,9F?*G$'T+DOBTM@VU.*O,R-O70[BT)U/AGTZGXLG'3^Z$EZ@REVO
M:7%-$DZ2>\ZVE]96UT0MQ(]<["3/*3&6?Z12KT)9P[Q*%\4DE6IH'/K"T*F&
M"H,J3$2RN5+QT:SV*;B#PXI;)8AZ;;[$'ZK],=,*U]7Q6<"MBDAG;AQ*QO!N
M$W'ULG&0X_/LZ#X#KJ<)2TX04?RPJD#:Y <2DL2F"4_$B51NOE6[U1EQ^8GY
M&K"=<0W@WRZ,*KL&1/JW7#D8K.LYVD_,;696W'V>4<Y-QD$LJ@I+#!STWO.*
MI;L&;'5/UJ8178J7[U>W@#*%(XJV:FJXUY9I1^'JQM\?XDLLN;NIO#8S61<Y
M:9$17$>=;.HN?KJTRG;IPHO)\<S "^$AG->:[WB7B"V$R;KD3:MQ7#BOT,4H
M,7(4 9>(VWR:XC7Z_8R0<C>>^:3,YR!<P>+SQ&':Q6(VM?TUP/TH1TF4X+]]
MJOXL+;BHM-$X[]3R><GMM91[]K*T+\^L2S H%.Q3W7U$*1;^;)=Y,],O?<\Q
M4/]Q&AN;K[_E!(E+P4_+\JR'0"5T&B(JB[S?O^4%Y<8/I1\5OP1X)U\#%JZ>
M_RE0I7:\",3*7,Q2RKQ<U\#$O!RMIO$UK]]:V6X:RXR*0]W\;[%_$?5_]O26
M>&S_1T5OF3*U1U?OKL1ULKI\@Y]GL477B?<<[RFYPC=>H+U;(5"[8ZI1.O/4
M0/'"IB7OC3&&@%J68-F1&F7,SFU.>FMTL^>'L\,:K,LMGX4?(QSV< *K/MNL
MB]6VJ65ZN/E_P*6&ULN\HT,W45JO22]*P>L@-PMR&//.T+W*F98: 1_,")OP
MTM[#0&LI9@@L)IFZX)N9\?'?VN=MI.,*(H^(T%)>\C^_I2C4=)O:W>UN>/"_
M-RX'7XKE6+AU)64OZIYIU&=*5=NZ6B]8B.+986 "PK/48P'2:)Q,=&NE$=&'
M_SI:58>W6*EH'#0T,141!@,:)P(-_7[3BV:,J[#I]:Q<W6'.F!GWB>QJ^9F=
MMS,=P"OS:67>?\BOT-&:A;X?::FHPJR?@HO8//#.B/A:&O=^:!$F8#L<#)C\
MI\>/GNPSK:_?22D34PL8SCO/@VNDPRB1?_M.0;O^&G#IG7ME!_PYJ>;0OBQ)
MAZ(G4A+7PA"W/T?EY\]:0;CCLWHM<,?O7:S6^63/KJ8;^6LHM&B/5+K/\@XA
M=[\9OX@6ETJD<*HA$[Q]EN41[69,5") LE%4@Q#VH?KB'&WE9JDCUVF<4@*[
ML^*(4>$KKDV>XE,1O&.@XYEHAZ7BVE\N=P29:=V$?&164CV"&\M/C"Q*CX-8
MX]@QJRJW:93=J;*@2>"231ZW3W&/Z[._G$0]?J@C^2'L*3&O=1X?J9#G\UMI
MH8("Z+3-[-,>IT&59PQ<1\1S=6^V:@*U*^&URW]2[&+,)D9I4D/TMJ'I _^$
MCB=8IGZ<[GO5^,Y:8XBP2:7SW5%Z?'Q5RE#R!E&K[TJZB(DJ/0/UQHK]<\CL
M[+3,D]3S ^XO@@UV2K3JNC#&.":^'L!QL3N;\^T$_JJ)RM'\9]F^F'=OGW/4
MK"?>ZBQX&1M0E;U5UD\?GZ^UD"6R3;[@&,DPGL^[85%8LHD_F%^@Q28N:<CR
M *[1U>:ZQ+WLMTA+97[KBC@!&%3YPK VE=E*P:78=KVGQER=,OE^MPB+(N4X
M3'.,0@8UIB<QO'DZ!.G87G6</3D,;W3<%B5Y7J#N-AB?!^FWS]U2CU??7_\9
MASLQ\HK=3NP'+-&:'!GEZ(EDU%/OLFIJ:!ZBZN/\VF5?20FC'+Y]_A*KI2*Z
ML]2XP0=.Q,&Y3</VL6Y.U@&&(_R52T=C(EYN?W6M&,O 6L?=M%8*"CY.9Y&X
M,X0SE0@8SJ@# 0W&LQ#W<Y*\A=/RF.<#9_^8?%#I)=J#^<',LV^V61VVFTH
M\GZP96=^?G]@!Y>BGU1-C!$D^K-5[!W_<P:&:7*6QYQY1=MWN&IW.?*WR#T[
M!!1[P8;[U9[.9,G&L\"P)PCJSZS*/[?YO2'O/8-P(#'NW-!:O.286L*(M^(
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MTMU.^IFX8@LD[9K8GDJ."MXVQUR%4W0M<(T[6GDJ<6D]>FLU)PURA%)H@OK
MK2$[-FH^\.1U1.GKALH)#WG$FVYR+81$38Z6Q3!D $N=1%]_\A5F*TVL[DID
M;:_@5+;\,IA@SM( PD/^.(EY%[YHX<X+D3O?I>4KM/U?WX]T@OO4').E*(I3
M7$>#![H6ZI"!SI_\J1446%&/7Y 9ZUT#VC0)FE"#BFY)[?)@$Q@06!T$I2BV
MY.4D9K.TTRLZ>$P8@ZIBB\X-/88VQ:,(KR@NJ!S2=D* .Q.#3*B?J5*]=)=?
M9\=CQO(+-!:(QP+\\[7-ZT'^80/SH7$A=&^9/(B?J,:207 '160 "'F.#A[U
M1*"_8PI'-R0\'XHWF\>\ZZ!5JN[P7&$2^TE?,L8A#P/?H&OQ@(8F:@I1$[2$
MD(Q@O7S.F?!Z<S)NZO7\>_FZAP\D]^Q;(7QK37BMU+B5^U.!1SU[UIQ3DR#0
M)_9%L5OQUK8=_F\(0_&MK-[N(T,*YR2%"[,T#>1)SNM80-$2BM\,I=()Z,8$
M-:#,RD/+CI.YSO98Y_[S;7IWYKIJI!II^4-OW6E=#[?CGR +J"O82'O@: ^%
M.TU4WM<_V5%'3KD;8^"_KJ$(1N)%XF2[?SHW\?\Y6:$[/2O/G#!O??"Z:)C2
M^+G4F0M5 =<(9U9-HX]#/U? &42VMK/^=JWIQ4\8Z3OWF.1A''^7\A$N*OOE
MDIJ2TS25L:Z*=^_KZG0F?)BF=3ID_Y#J,.GW6&C4*-9LS:H)^G_*>\NHN+IM
M0;0(E@0/[@0))+B[)6@(%.X:7(K"*9Q <(< P=V"6^'N[E:X!RG<(="<[]S;
MX^L>/6Z?[A[OOG[C_5A_]MAKKCGGVFOZGHNK.,R'0&]I"8.9 $.X%M_B:'V7
MD)E2XUE:":.B4LQ4.V=:7,.<!+RNXHP=36WQ/H&XJX3L?=E>%!$1D:&KY$PX
MU8,-F\/DJ^6*(<C-G"6O*1B"9&8JHYLS?M@_JX#_H$F,ZA- LTU)?3_;I\2@
ML-CIY_BS; _\IS2D.07//P'6,SVYGPT-BM7#U<,!D9ZK<#<#ZY6%4<CH<OWU
MHG[#/]XLD??H<A<-Y7H"5%K?>?*.(S:HBP]FJ!GUBZS-4&OM9N"JS[320=XZ
MF:N>OIH6B\D"]$/K*8SL]\(WA>L\9L%=S/3=[)Y?3G5T(86?$UPGRC*#@!$^
M-40YR/QC1Q4>K-H7!A@/(B=UW\W='H1SNBP%(_*_CM!LCG/&BEWA5=T@=IY#
M*H6^W'TQUI#"9%&7-OB);E(H*-OGP(#8\\#KL8F!N$Y^'<+%[#([V:?0&A^9
M/LOXMGXXDV?OU>#E&@.YP)ST9E3PXSN1]U43GES) =G0-/+#*LM&Y7U<0;Y^
MO?!V),J5@^2+X >,]?EF9OOU[JG*W&5^M]*'6Y&OFNR"=;9DOA!N@I:3\\Y6
M^L!984?IT-_:4M0!#WW2$N2$[A5?A4,R,5&N^RAXP,@WGV5I!%AJBZP9\Y?0
MFIBS9JI^[? 0(\8+X?1?;+004YUB)JTE;?!.6+M?J)_5J R\6,R=].Q!D.0#
MF&J4\PW0<*.+()P,D]@F&F'^+++.748;8NB>]-XW=* 4K%I*CXC1T8[,L"ZV
MK"/QSGJ9/KO#B5<9*V9*@V3B*$8AO3Y&=A,G*V\&)-JOB]MW<?]2-Y2];(FS
M"-! =?@2[II)5<['QP]7]<39?#:4K;RI)^E::F9J,3B5HIG[O5Z*@ZU*)S;3
M9%ERJ+8K^W;U4]:/@_1Q3XI'[PC",)J6WD:JN[K)O=UO<( (]WU2JUD-T'\]
M<=E_&<'[,7+ECGZ5+(PK1?'N.W.-MRK"*,1 \]0UBGOYDV+5*7-91+XE+$[[
M"6":%PJD+?QNTC_L$!!$3/$8+_D@OTF)(QKJ#*+OAI)@) :5[=3IB7APQ>3C
MH!_%SV\C.B&Y]L.3X>6M)!!1I=,WUG7:M/3*6A(K[C*G.V(.1+\JE!TX8S$M
M&\>ZL%!N_+4$RLJSQ(4/L+7%CE+ZCP9+$)V., #V49L9>)# ^W;H'?,AB5 Z
M366#AS]=89(Q9$YP1@'K!(IB?XZ^D_D$" C;,,"XT>CM4F\(TIP6$G7&KVU9
M@&('G2L@"K ",.LIOUR7*\9UD7 U0A.+:D-+9V-(>[[V#Q>_X#C\@(>="]J,
MMH?E&+RT^ !K$'"RY<['*&0*'ZV.9N-X1>4,#P6<+2Y28FM[JMZXT8=XRH/+
MN<[T!E[YC;S5E/[1@/#C81_20>5TO<G92XDO))Y[0!*9LPZWO;N7KVYF"]81
MC["I(D6A<6QSHW)M'R,ZT,_)]60Z,?,OTC'8$R!SF7.IXHKY0A^?)$LDK+EE
MF(Z%C_&L#UA?[&M'S%SN!F5YA&5_&:Z6\8UUD%$S1!BS0S@X$"-R+ZO>6 9O
MI$"LNV 7VMS%%I7[*-)5<H'AMRD*2YNT1^20S6^JSAG!C:O?RYK5LJRF2$=T
M'.36=\^BB6/-YL," .Q2EV1K<[E=ZRWO5KL-%BM@\.G6?J;F)P#[V-$G%+0Z
M0?=OHYS'NK-YZ];+/ILH:256/.\I8K*T$VI_5A$TU#O^QEPKY"=&W"$FMT#4
MWE2<;F8]60%):R7>RZE,75REK_M]>&6JRB2%!R 4LA-X?8Z%!'D"],$R@FM"
MP"!NT*<OTR9H#I0?L75@Q4Z0766YPGY^&_O;N7I9$GG<'@ZFF,9X$Z/H]DLD
M5_R!O;;7S?@Y!S$')+8!Y"T7P%9^ DN>K,N7.A8/A8A^]:>\D<<U8R3["11T
M?J.K7>YY2_9B3K^W+'/"MZ0T3P!DYLA1CMJ)WNRGK,&7X->_!=X56&?J6L%H
MM6M'SG68%IA$9WJC.OB1SD<%3\=<*?V=B&K^?!T41-<Y<)05OG.;]+[=NM\5
MK&JXT/50 ^FLKP9P+],#IYSU* 3#0#QT@>/$Y-JTB@#%=7\<7X&XU.>#+&=9
M<J"/=V+>O?QY3$6+VUK>[.W53)T8>7AAR8K64@Y5.G^O=7GUG*=6YC-'NAIM
MF\JUK1/2J2/5L?O,H,=F:KQ^3;),+55]E<44W#<@2ZS.90_)DW>1,7I6K(A_
MTM[!:-\SF:0V@70_9'SY8YUY,M8UA@[Y>GPO+3MA6#U-%_5&ACBUB&8'K3XZ
MY\^2(FHJ?800Z!>$5>ETNR#XX@!-D#_W5=: 242\>N\ +3W$01"SV6G$"?K(
M-7/<2F,Y&S,(NK@?>\U2"$*W^JPP[+8D=82"PADIH+Z]VEF.M&H=4;Q\XPZ3
MZ_-AGZ_^[G+TQ?!0-'@'FG<R&\,;C-) E^^,8V8CT2E%]+T2E"*^.)UNG^$.
M.*T7LMS\_4AJT<J7T:U>+<X]N#B4_P0PISJ73IY(L$2EBFW!0]"H]:+I=GB<
M"",O#T/.G;2 VZ/O*D0\I("%VR:NX@*W<)O/1]R!#U3ZI$^ [\JK708+;:<,
MT+B1T,6QN&W0]GF3R^8YNU R\,VSMGED:_3;[=;^XAJW6-:_=4Y.Q.)8$V\4
M$POAW_>R0/P^TRR[R<RZ@1:%;55'0O =YB=N9C1)TPBM#\_X(;18UWLH7"_Z
M^2*%%$-[56^:I=PYHW9>U^:>+FI!6;1JS7.UF:P5*'118G_2U)%Q$MO:"B,#
M%@GMK.>YF9ARX,8NHH%&W?9FH4R>O+E[R4=9)5K:MQIW"6.U(SO\YSSAK(,*
M**B9> C%_]:0ZD7!7_&/_QJ-BO0P> )$73P!RC[=)@^6ZOD\BDX]-F#M6']H
M-#K)B?WKIMT2__A3D2B*\HUCC-*=U+I9I90<O@0L#JYA8]M#/U2:\.M\2$X7
M5#9S?N]./^H%K+74DO9J=K:X,FY$[W PAPC&3U^QTPC[8".8.A=2SLWHI=S)
M9S;-S#47^4EX-,WT*DG"W[:;L?*J"#G2)5V,F/PVC)EB?[,+>G6M[;4UT1;R
M'4Z^7(@^GC!Z+:F82;9U@DJ?YVZ*I^DYR\]L_*6M\52]Z$]Z%-K2;PPP_K@R
MGGS+U<,R!Z]9[B3++!"M+*1 <]528T*+BR%V08[,KI^03*[.Z+8!B7U,W[HH
M.\UO-QWB^"7,+,BR4!?BAU;*GFB:F_R5"4?FEYIO,A_/#WZAVPPV&GKN1<O&
M$I*BYGL.&>2\*5@U'T"0@31T[6*@CV^+I$G5R>L=!JX\@<L8;=B.+*/L>^3E
MM*%*6H! )5R6$=&5_T9H#$O/ZHHD+>TAV27+D6ZF9?N[<G_7< =D7C()Q]_V
MK6\O>[^0.NE>8UG1VA, >U&;I9BNR<J^I48C'R@@9WJ6-"/9"^3S1"&BI]K"
MU8^7), TCIR$EQY=RD6(@R\/FB8,3T#33JO5+)WBO1(X@8;NZ.FED?F%(F$?
M'MY43.'*V[/[38W68)/W-,_#Y ?"=X]Q8Y[ME]<,%8YD(X\)M#<16<NEP1:E
M)2P:H]C;7VUZ\6S[4)%/X4TK56K.:2R+W6=[LW-L2;5Y=J>+B?9HM!]EOWYD
MV_+LRQI ]9]L&F2HT#UOTM%IB@ ;U(?=?STCOC"@8V$]E,!@\FT;_%69Q8>Q
M[#C01U1\G">'%>A)BE'KWWM5YU+.9-\I'G0-:HY&'1K@IY]+AEMD=PR[7>49
M.7AJB 90AT.32KYPOT_%"=Y O3Y-?P((?G\"M$7MZ0'#1&O:U@E:'KO/O1=J
M76[YSGEL2:_,(^YY0=<]VG635'6SQ\YZ9P..+C'=GITO0W#Y5#>_)9@).P#'
MT:8U6=PD$C1(,$KA&5U_1%7E.?Y(+Y(?FH5:$_2K<,E3:='1.;A@=.-$:_")
M)#HS_[(XNK:7%RZ6# I?%"K;EV(S?JVY*Q3NOE.F]%$=Y<B^4;CTAP@]%/QZ
M[RX@(.45R2,_<P$4VJ%(:*.,K+?M=Q8VS@,46M?6E71<\\&QJ-CC371-G)N;
MZ"XR&\&+G.(H3K*O=$EU&'ZY<#%6,$-.+^LO59NP,K/E%+NAXV="E3;)[T*&
MT"O;\[S=2=,%,VO3WET^KL62%@E*+W.GF AVX0YGM)@CN &_ZT<GSM\ \X!8
M>W4G6A <%J8CI9+NC34A$R(?AS7;QV-#QK;L,%3V76".;D&G ;9.3_Y@W1PO
M86QPP@NZ^.8KAOE>V79=2C%V_3!)O,F*?UXY_/]D1V'-OZ<Z''A$S[#KG@50
MV,-!69E[4QJ7BY$DGKI4M\I?@?&-RU7R=_Z;I31B]17,X,),5J]=0['A'D6\
MOK<IB/Q$2XPU_XC S"5#BB6 ;SPEZB>VH[M9FCFI9!'X(\4= L@\B@'2DT5O
M1GR"*02BVF%Z-0>&SJ3%29_[;*IN?:B+S*.A6*_9%XL15AIA)W_40=+=*RBG
M]*'<BV;0AJI*^7=$FNBTQ=1_BMKAC< ?'M+'>I01!9/E#UK.!0>5-V;=.@N]
MAO6S%\>U\A"R5G5TF:!M&B+ED89ZQ'!?=_R1GBWM@!_J5R)>S<,;&YNC:%=V
M>/&"0.:$SM,I_F+G;0'\F9%#RM<LK/FQUD$Z_K2QE4Q]AP[HL6[OBN2> "^/
M'ZCOQAYH4WS6><_+7,P?/^I[GV]Y)=Y<&0\M5&_W^L RL8RSF\_F9*(T;A*W
M;[)G20<V3[;C1M!S/$5<TT1TS)=IR=:B[>/"S<H\@=9T4TXTO^#W6%?3E!;+
M::WZ<\M-E%WANT+&_)M<"(L3^D;6KGGSULGP8]]#YEJ,-ZL2,4<@I_8VT_HF
M5(:P.@;=ONA%<3[&U!-&QJZ@+V *B!=7RAB&[B<OL%WB["/E5#A./+OM*QY:
M9UOQ=D/2P.M,+* /ME9K1-$^ <95_%3XW@?#@F/JT:T!BAQB8DKMZMQGM6/U
M.T$@*'';JVR%_Z%E$6JK.#]&W.O^O)7>0UWN9HF;<HS6>BQC.J$@B9?&D7Q'
M!/,/ [X ,*NE,OO919X>H<+$!3BH,3_)G+PUR][-'.\Z5-2+0[CI2-KQG..$
MC]87@$B$A[ _$R/2M 7I'/IX+W)<JS7BO'O<N\J\J==D/^HY_$S]2OU[GW7\
M>W!PV[J1&^6B@77B8895'\Q[*.[*IW)W9V]J:'=X>:7D]^JBZ$DL!'BO([I(
M>1*N>]OJ:L#KW+9R/6;@.8Z:-Z'/U#;O<^*O_<??_(')AE[7Q_)/W:,V^ F0
MD*ZQ.NH-9%W$']?-P!2-N+R\\6-Z> )PO,W#D":Z%_W1=GK<=/,P<@_U7%A\
M' &X/I_+&"L")9WYVZMSSK"P*#[6A79E5;@05 >M[\M.Z5S<S9==^1M]!P7O
MN2%ST=-C>MW9(/^H@)[^9S,EK:9K4]R+(>->H@#6G3?:0? $2!F:5S$;2[1E
M7_$5I@[=%/*RQK\J72>UCAY!;VS0PM<MN[SG6E#QX\#Z*( MPX\4NMNL8V1I
MOLDH1RY^0<[856DYR&0\4W/,TPUL&?9E32*S?K=</ZJ !NH;B<92S6ZNNI>=
M(FQW)^/5YSSY,U):VCUF PLMGM=G'2W&[.(=IED"W"[:=D3+_%+9)Z&[+/?+
MF^4J%96=D(0?@E]@7="+DVZ(QRM^=0P:8B#;NAM'K5#2_]P)K( T/PB_B2 T
M_5GW.(AJ%.=VKU2[T.M9XC6VN3=J!4]\H'X"G,1#'!_Q,^9=;R/^Y/R)KQN\
MI_^Q>GI:?5-WN-BV,WKL#KB ,?;L3#C-W(AO8'@<VO.46[IZ<=>>1TSI<+DZ
M<+C9NH6_X QH'S .CTL#4J31RY]RKQ0[\@9Q'U3BR;12S.#K_S;DF8'R?RW9
MGH:?C6XNV?O^@^"H[O%%@YM=]:B>.AA&0$X7]A1AM_H[57:BN>$SW3&2XI!7
MRW4[]\UKKR\R,*7&;\P5(BZ52O"@DH_CNC@.[-U)2+LTJ5N[L[Y<O_^EB$N9
MN>JIS-2#.$&8=<X^2=IA0OXQ*.O;QUZRM[1#U(ZQ?,0'>ES_3 D'/0%B%U#_
MA$WZ['U6H]:JS86$3JDWI@\-UE=-@Z:%KG@M"#2G8Q'M/C>F4B81!]GLA@Y-
M/(!X6HQ 7ODW.MJQ@[M_]+J$L\/-D=;&FL@H%JX*3=.%-39JOTTNR?Z),W:D
MR.'R_)5$PLKR1OK4E!B:[HNX9,ZZKA_COH(X?M07[$SG;P2N? EO+@&#$]^1
MWX@>[Z[X"LAZJM!8$:HWZG_[M1]F21_/=;7R48JVG4X\X=E3DY)!,@_?(EF)
M".LMZ9]( /RP,?6*?$494V:L,EY>4\3*#4+M%ET(GA1>GJE]>"6<0LF*WG?4
MGX9?10M[26\Y4"I/JA.F-.'D45Q-GC=;9!675UR/%4?DHHA%;^N6B0()ZU:"
MN*R,;%<WML1>P9FI N?,=F+\<8:J"BG?[W)!DY>'*W7EO#*MM&WL)$Q6':[@
M;>1B9]N.&66H+88/L@%'N)VGGQR9BUO;; D@'Q,_;0_U8Y8TW/DQFEX<E(I^
MFNY9J?;Z!:[SRH=3&;"^=G=3*M"]'E-@%\-W A,N64.AO G>A+,$@Y?*,D>Y
ML>,,4AV88JE0-D??W'OST!A/+>:1GLX]??*96E((O07&$LHRC>NGH,6=X7 Q
M0PU!N\^IYJ7&#]R38)7V1](F,/:^LOB?##2OD!SHF2][5"(U]@WE\6ZD;%%M
MJ<"SYRY@FU/RV_VFKMH7Z,:25M@9JY-@T_!RTR;FR,&]&J 3\)L!L:8DS=A
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MVU".JN6-3U5V/9ZEWS@@'4N8_'G#08/'QHW9%2Q"CNM->G86Y_O!R=_JY8S
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M8WF S1.@UD ]4;7BV[>6P"L&_Q(M0#/H#16R8RP1CUC[!_>]?6^ZR8L0&.F
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M)+Y$JN3<=\R"4RN0BOHDJ-S)/S<8ITR='^\++>H16;3+;JHW-VNH$*?076(
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MT\F+J9SF7VVP2<V<D5T&5(:]N#I7BHS/%T5/@)FH4D?YK*6,X)B#CHW[#WM
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MZ0G0^1[0R"N^>2\N3IPX0#KH']TP:A^K(/SOB\G^)Q*;[=_I<K5BOI#.Y[F
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M>/;;W*8F7&;/S&S,;)T<46AP<S%R_;\[)PJBWR?]3^%'R8CJ(R+M8&;D9/8
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M'"@-LHEF$(:"!@[R#;85=UP#$6U=$?:>S&J\LI3?>/;>I;XY>L=8X-[N+(
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MJ%U/U,0?+5:PP4FIBYVCQ>U8>N:T,4;+9BE&P&.M:U.^E?'4!AJY6!6T &+
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M\9DA\;,QM#^VF:NJ*95_#&6VD\J_9%>?W;00LINLB$9&E%X#+:9].P]0&>Q
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MRBRY_)!6F!\+'W>U'XB,1+,X[<X"P6=Z2,_8VCLR%3XZV0Q5=KY%<7L)( $
MRI%+ 0!T0M/^#VS3#_HX<VWT.[JT,*\0R>3"I*8O;S?U'JH:4QE)*>;#SHDB
M?U4<@BI!B-+7\)N00^SR@.>V=#7% "TGC$7QE( 24D?_S./M #I'X[ZWS*/!
M%[]72J\%3[6LSYYEI5?1'K5]\HPK8RAUP"NX^/"]GC6SWI+;K'XG[G9GF\)2
MK;^M<ZCN=P5PE*S7J70<[*!.42__T6+EPK^79IL":9VO^EMI<5:8-BDP"_ &
M!>VR%QYP$E4*2A"; P5X.F%/CQ#I6;-3\$+B.<<P1L3OBEO/LBN602Z'S>F^
M[]JT&-9FMD:^[GPL+XNMJ*!C6HQXIO:FR)+03>F<*JJZ,:8 3/:AZ'N0%9&7
M(I.DKRU(<!)'>-QT^EKD.(9-0*>NO0T*5$,E9@(FO73V>B-DXKW?"="K@Z;-
MC FR<]AV)?&T;6VJBUSF2#/7-#\7UHX>F^W0W/QM.ODXNN"^?-I0\D5@J88N
M9=STE'_&66Q"0O6<(:+RK6B;:D/)NKP#4C:B.EDVDB*K3L/E^_45+U*Q+#^3
M90Y!&K$^7=);NOP1,Q]4JJWL?Y"+/2,<//@@,,^'PR@W?RV&/S.K B,#AB&N
MB3+TX*:MG61 DDDDYH$0>9)12LX%WC28H8*QQLB1?7M<8HN:(+:M"$\[B=#A
M3!#'>WV)LU1O/T3?^+W?N_OWZY'B2]2?/8E>7.Q+,,E-?9W-"2\]6N.HIR)H
M@8D*!98<@7 &.'D3OS7(%1?)FBD)J-=DV;;DX29'?VOX,ZS2Q0F_DF.#@/E*
M;"+]C39YA=$?WW"1=CR^*F]-X?:6Q!Q>_V87X6$*,A+;L>"A.<J,&MH,'38
MP KJ'#UF^!"X\-&\G"G->!#VF)>CMJSUFYYM="\35^:F[MA&/QR6/V[R8^:
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M38)08B=[]0FP,)_[F"IK'.;R!/C+%4G*OY5#*/YN'W_8=. .BOD3P&3Z"7!
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M]L:YHNBU;S6TBN;X'\ZPDZ4'7YNUT!5KGNM\02OV*#(\]/U:F1'>S-P-9_,
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MYO/$M/KGV+WEUF@2X2J.H+J,M0NNI+M!6["T@,%&8R@-#%+WO>GRQ)0S(Z/
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M1V66D_#)L<N'O*ZI,DQVIAJECD4:Y&0FSVN,24Z/]3$RM-T_6L-I:P^83A!
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M0YME[*02Z_5WU:7>D@93,OMSUL4 Q$;M6QG5,)W8145=#T^).;E\HED'RQ>
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MP^Q\;.^N."61T3H#Q2@CKP^L;__KE/8R,M/94YS%]8\R<5NA-1K? P><"(0
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M3FU?G<C\&!@R9!T9H-_[Y?ZK[M<LCR_^5!68#IHYU3#B=C=].0%T!+X KJ>
M&AA1T<*JO$!G>DJRTX7P5BFPE9_9G8U7E+QB>S!IVH@\@T684:);>?>2X:@Y
M,9J*WK; =63 K+N7RO/<)+A*> GS,,'>*J?!RX6I7"V&>2D%A3*PW!%%B%_=
M]"(X#NN[\Z-+&S2HB(<#A)3G0#8]*(T.XFB,N]_>,^E4>:(AX;=-L\JWFM(Z
MG/S%?6EA?<8$ L;WA='^B <9_]$#T?DS_\]!A>K,!O*A]26[]6WUU>X+'DUM
MH4-XUGS&P^2\G8)G1,>:U@TYM#>N7V#JD+:Q<>G%,UL2/!K!W3FR:)$ED2"
MDPY26Z4-3&A;2SC1^6*-U)U+$H0[OR64G6(2XT0(ZRU$2-,J^SP@-GP\XK>M
M%/) &%KEO.S5FR#3%&^9)!G.*!]F+$$^;FJ7: )[ ;#1+OB*<BU891(T9D"\
M*KPKRF$5O4Z") HWERBM]2@BWNVZ=:\Y% FKN_H5CM\B':2Z?N.T\?)85M24
MT;4ZITO1_(RH9N?T;3@FX2QS.T&43.R2ZS:SA*"C^+#PU'A&H=?*@3VH@JDG
MM[6+F]TJ?_RTR!9'W1'+Z<@EN<S=3FZ!!5PT>QI9J_LVMGP\('C7.!K/_T".
MX=W2IX ^Z[^[/XTD$UK445?-D^39D%:PO%PF- J+RON8X]XU/$*QXK3 -WBX
MCG6M=TGB3K'>ZZA4=$CZ!;%OKF \@[GGUS<+ZRW+P7%1-+4&1?Y+W=2?03<=
M;YB+YVD:8[6'Z;X.M:9BQF/%/$+UXA8ST[>)N>1> #VX>MQ115T?N&.L'&TK
MY\^.M/<R$O;">&2U:L-0G)*V1Y1YZ0%DBF56E5I'\Q3 2Z1$/%@>*8]\&4=6
MHU$EL"Y*?S0E+LVR7^V?G??):=:T1^L7@,(E02+B^EW;P0Q$H,ZA$76L*IUY
MGJ.U.RXC /I*JPY,&E8EEJ58W]Q>W]KX#224XF3;F[6:I%\N>IC11'P$1^G"
M5^S-5?#V==076!8T6N+71)WK6-I3Z\EZ=>)ZU++[.&\VEMUF<%BQEN6,-<EE
M'(3X#L:01!W=</<KFBGP0U*/K)(?1[FWV@L@WLWM!6"HX?>@CN^*/_#T9PG@
MGWC= $Y9?X>,*&];2/A8XX*NI<CJTF-!T]/Y0H)BHV4USR@/Z,\GI/!9RSVB
M;S[5!5+G+=1A'DP;&5<"<_)'?KK)QB17[']>[J\Y(O'=2$W*A'DGA'IWV;PG
MB"<F=N3($LR^XH-]N#:UZ.C.PO;K?M_L \E()ZFW?Q>C2V!I*]6]$3;BL[7<
MO\7C-#BF] ) U8P0.<@T? %LC$^\ *)5_IU$&0$JC-4X*ZAM5F&H9V4LST<@
MF;H@SZY?C2;=PY?8+M&XZWJ%]6$M?[J5O>20W^O@TOIN^B"7@3J0F$GW%(?1
MPOI7KGXY(>];2EZ A>"<W;U<J_8+0/+J!? "0'+U>W*,^7<2?P:#)S9HICSJ
M]O- <^:R8G"WX:D/N1U.K\2N,^E<GJVN"#N"2?0'?:R,3<C,[>WLM):*IGR(
M$L'\W;.:)8W%E^(5UZH)_S;_(QO69]PJ K\IP8X70%=&U@N +.]O!=D(,9T_
M'0Y^\AO;X.2C>L*"TZAU<)C+^UW3]FF'AUM^1+6H)0(M!*,4WHJU-LS;ND0Y
M*0>_ )13\1LBEW5)W7."0. <]"8FK7BMFH-LN*_I$_^5\6$*=#H<&K!EZ=21
M2(2=Y3=;L7!F_RPV?<M?,!C[V5$13L)?=D>C(2#7P!*JDY7AASD'V5U)5LEN
M8&#Z<@+">!RT1\+[K G V*OUVWQ_:?'[S<@+X(EXZ05P.2SRMP) E8B_"S'Y
M9H1!&.<+X#3FU+3!"[,OG^-7 ="/S4YYI?)57+\;7/A"]<593I%P[OQ#<TG[
MG-0C&P3QFX?H9'H-\OLT"0 *>1B^Q#\V)68,ULH13]P1#TEL$J?7KZ1I!N.K
M)2IQ&@,V5 R5]#=#6 +&M3L7XQT\D<DZ6?K5F6N$?YBE+NVCTYV:('?_FX ]
MCGB,R/S(6 !"2<P_OANB(8(^=0:;]>$+ .6RG:?#^)'^O(OCUYIA1@>%8=HX
MM^WRU=FY4NO%>)O;UL&M%=<R*IAYA:L@\L&DNF$CV,PL0RRVA,:+H5]Q$L[(
MY _GMJPOZT:)]05P86'Q AAX]^\EKWK;R1?,+OO:V[DR!"40.'0JJNY,DM@$
MXUI>/?OR/)\ EAV&?BDH;)+J!G*!C>]0F0OFSJ.Z)=Z]O^PMCI,F5EJE-<&0
M439$CE/[+TS;R;M*D7]L ZSN\.T7P%]H?Z']A?87VE]H?Z']A?87VE]H?Z']
M7;1_%^WU[W3Z+LWV(YZ4-I<XBY]0O;Z89:Z.5A7#V%3(AJ@V0 G=)']<] \*
M@_U_ND7O;0G(:]O2@VO$@V6$_3%2XZM;P5;%1Q3(<^7ULM['RV7F@9PK91DO
M $:R&L!GD$@0HA0],$5\9(L[HOA>8\*@7KZ$LK55'NA/_:N,47@RWW; WO.F
MXG;>&3J7)J\O-P7!(TT=56QWC(2/3YD0QU8,;OW=3K&^Z/X"D.$W1KHX$M1T
M,^2O2G9"8"9YW32T^GT<;H?$$/->7D?[201<LD@J-77.4F5[_K$&NES@N"D'
M-EZDJI4/X@7XP.>J'>I<^BW<_LHP:-I&9X;OU3%/\[V[D/+ FQYQ<7"LH6TN
MG/R0B;5GA$S39F5@TRR=WG!:;)VD4>;R J#8\_HFQJ/4DG#M0BXDY2A,<_%<
M5>P>T4M2T)Z9P&]I:#0-E?5OK;5CZ:'?[5<SW:8)6*OQVS1<ZRN+\)%>4&V=
M+IAA*@?,[#4HTT3\-E5-08E3JU[QSAM7\E9&R^!.7#KXF4DY57_<955L/<\-
MI94(M6B2=,S?(,_?)][F2MNJ(CY\)I[9I]:U:9-C?YM<^+M 59NG.7L['DFW
M$EMNVZZ5H7*HU$ 2QJC7Y;#%R[K;HKT)=[*-0A,E9K2D]UH,'IYW-56[E;EJ
MJ)S3Z:!P"U50E4L^HH/_S9YN%<[[P,Y-4;@ >/*OII.\TX6IX,RH<NL['8($
MX;Q2Q5A=T:"4C,#]*6G9(2' F7545J0S:0>6CDV\M6M2$H^8N-#8J"7^X$22
MXA9/)%FE(YL/(T\_/U*%ST:%ZXA21_-LI=TD$_?U+Q1JU76.'#6E3:#WS@U9
M-&AT[J;-"O+HH]@CEKHE<O)_=&?F7TD@" #&S2(KHT,G5#SQR@LQ#\RK+!-U
M'(_$-4%W=FTSQ)L4&\]TQ,FC&4W)(3PF4;1$E$16Q2PKD$I+"0U$5/ VQ?M:
MT]G]*_:]_>'[%[[WO?<Y6L30I\B :%JD[H6][5?^2J8A$TB>K0;W5()PGC#0
M6\)E7IV?';=A4HC /XZT*TYL"_Q6#!]94]L^87AXVP!T>D/XC8BB=SN="+TS
M(,90S<">8WT*_G5P\A"Y5OB!I)F2&]W3HT_VSZ.42FU&7>,O1G8EDL+_,O1C
MR_)4+0<NXO^=*K5ENWOLQ-$*31"3<@L"P%/7&PB^CAW=S3!Y@L;]A)H2]K'J
M:)$N;^L\W@1@H,X(A--+1\SI!UA2N,% DKZ^@%5PO 62@2NW*MXT1DKB4S2
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MTV9YY]K/F2/-[[\+8FIB+C'3[C*O4MZ##U5[AQW%:KK="GG^_CO (U\8* G
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M:Y)E8+OAL->FD>XG,%U=LEAO<,>M]<PS/%WN;>\7JV^ T6L-X2;ZW).LH<C
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M1&A7:.SST+O!4$-$99*"HIJ_]ZH%;I+Y"AZPON;"E0BIIS0YDF=1XIWM=30
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M$&:2@_;%S O5\MPF1/TKRWC)+];%^7J9W*!F18HH+0FK!:,2Z1XE.7=U.PF
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MR<Y #KW^'OY!UV*,:_F6J9;T+('3/K,DSV?D\ZW<NA$/[=4C;)GBWX_$D!/
MA$,M(TV(>U7P@>Y;L\U:(T%I(J_4 D418M4<S:X5>?1K^G:WH4B3XEWGZ</>
M$G7CGPM&KA0+N8=(1*Q@5ZSEZT Y3SD"W'@$,$=3B$ST2;@??P6Z?K:L7=I.
MC=9##L3.:LL<6['1Z0S'9K'P>$;GH(_H)+'<.5=3?__.,:5IZ-?^68;Z/+BV
M=STM3=;TB^9.C%GTLMEE?#]#EEK\8JSIW.!5U+F@*Q*8A\8G$4PT/BT'*8^P
M0:M2CTZ389JTNN9ILVJ[(AG@+(3.F4.H.A%Q1[]'D'\N;[F(\^A]27+],G7U
MH]J[G9R[C[$*4F/6.9JEQC^):<G:U"A(W$3<W91C)3W%M9J;)M^8)J#86);K
M5+S%W8@M#UPR'+E]6?<71$4TA@-EFT+;W<#1&[$5O.F55&UG%,;\B* VO/DA
M/I7;ZE1'T"K/_DJH8^LI6Y+W78E_'0TAP'SXGJ*>^0%F7_@8ZQD.3<I!_Q9N
MQFN%SLL?YG-@T'GA7M]J K#5-=,"F+. 2/;YA;4GBQOH3#5<2C;N @USMET@
ME#?8@X4 9X".[^+@.1#%GP'5 L0=3P 8Y;_AP#E+0'6<8. C;.ZU C8YN'_U
M7M?,K7QKB5^&PF2!YW._2(]>=X+^^+*B;]\;A!\2[J@EQ6$(:&?$GI5*7G]-
MC%%W5L*MH))C%W/#E1L=X_X#1F*O"W/5@[)B_%Q;:693.!<&^7U888W%(>F!
MH#V;VXFZURK1J-=O=(,G@'?^(^:?R*.PPU[V*(X7._QN'F:<K$XP,CHS=* X
M@)&&#_SDE-='2)Q1 BQ8TG$1&D?>R3/'Z(&7N+S_M??+F[858&V]R/=R_(_\
M*?YQK-)TBFI,++#"OW-5[U6_4R!'_T1G'C#5/]5-@157Q34:OZ"$VP[K:<M_
M3&<N\4]%#:#7RW\_'$W^L'J1[741?L$!F'OW?*KYC:'V"6+2:G:':'2>.=37
M^FAHLY@.M1D5A#*XL22U@?->P=CJ4\18]1'M[ZP-P&O8$(D8F2S_QH-FT\_"
M3EW!!/6V%N5 ;9>2[+H0Y!C7]F!C%9@LE)3T2.6P9),<6: (L6/F[NUATEIO
MK-+QY)K.7HVR8&<X8P-\" LVE1CU7=X/QN@8X.L7G+\A!/-ME"?RE*R-9=L#
MT=^Q/UZT'23&_#VGUS@#@A[@N#K]?D+JH5[F&=3OOP<R;$:?57E4OR(Q/"!;
MQ-=2J$EMN\UB_<EH1U6I*T][AA'X0V0N#3;+>OCD#>8ZT>'>$^!+"+VGN\1D
M)O72]OZ475KL9@BE;"8:[DT=PRP/?^TP9X)C[G7]Y1(/LQ5G0Y!A=^]FB+IJ
M:P\@[!5=W8C ^T^O4VA46.EQ,!X29=.# ,F&)<]YC.H<$ZXJ>O/SPX\OADW/
M0+P$?>N8U?7NCG5QGRWT:8^*,I ?K4?@R#U\%"555:Q6?]97TR=,,5-,<!;.
M]U*<9M36NBJBJZ)V^MQ./ '^T+O(:TG'Y5O87>%KY"? JN:0:@&]C'!M+9V"
M\\>.6CQEO:6IS#6I#NT7!U0:G,BOL> WD/3C?"[Y+?KU._!W2$[A_T&FB;VM
M7O<Q957[#?RE.G#+6DJI2-AEIC_51NO<?M?:6J6 $9^G?!)3Q5QT]V=PKH?P
MB?'@VKPYAH09H/OF?F2=N-61\[=6H:B5C4GF'%'[ M.AJP(B0&B;MZ 85-P/
MUEXJ4YXHH*O90@ :Y-SH5,L(Q+@E7K+4TFFH+7";) 1U379JRJ?GFB*'F8P5
MC5/H%LJ7C$?]Y?GLX?98C;F]D\5=;E:1ZMZQ]B]21F8B#S/\,*36;0(.Q.<'
M7C(U%1.VB57<C%1%Z@Q#5 R')YG1,7Y'V)0F-4ND)PJI*"[>CB,0LB> M;V7
M/Y_^*Y<8$S2NR(+>-E51=\T7+], ? X @""@-+ZJCM?5BWUL[*JNH<"B7BW7
MT!'D2)4<8$$902!1@6('OXOEC.>+U@L;>S4D"F>3<]5F<Q/N-8_^D*^#?D_^
M^'RZ@#@;JA5BO/S=Y-L%F17&O2!/@"I+:RN!81J35!3J?9LA-MY=8;Z]#MX!
M#!RJY=,OJ@QI8X+D4/?/9>T_Z_X) 3,@P]\:)?E^XZ<] 6IXGQ7N^T:IYT+#
M\M#]&6K1OMROYV$8N-5N?X29_EP=8IHC:D/UJX+K>I/8&DL%P,7]"YVJ JN\
M.KLE8NZNK1ZHU7+IF>Q<V2FQ7E6DD\'.8ZS?X)UI*H=.F7R"6>\581* G LY
M@8^>9ZM"/AEZ+^&BE/8PQF^8+>&5>3VL&DTY<?Y@?S)BI58;8/8R4D2:)Y]>
M^ZV+QXX3']7!^!Y7N7F"0I]Y_)F4T$RFK>J/[^%^K'@ (YCD6#!] F<Y5+LE
M!$'-/YC\YQ+1J:M2]^1ZSZGWB%!CTQLZ6((()C-#HQ?J(QX2!@597PTJ4XQI
MDZT!I^R';/1+C8:KKAZ&-L9KZ"C#;WN/?;'F37\B]Y_-G"TU2LHCNP1%./R[
M0"Z7T37-^4P"JT:M&*8J0J6_19?];D,455YP#UGO&LG5(XR=V6]72\$[>S]X
MG.M]T><H;=TH$FQA Q=XVA%@AGRP3U_6U"@KKC'8@!2"4<8BP'HH=7I/EU5<
ML,R<X.C4S3ZI*+:]YS.H7U[^^AU G0GGA3P*#KZG7*,D=0ZYS'#Z5S+_?%K,
M3TK3FK_^$K#TY(\%>TX++O3G"!X_4*4^^%% +<^*Z3@EH224>]RDKR^> -%/
M .B><_FV^AE%0/_3=,_2/_\Y+K _L![<>NU^1S>N?\)!GVTNUKZ%.]L\GJW+
M4H<<1C7 ]Y:"<!T^9K%2]9XSUVP._+.( ]\Z<[7!E2;@$ 77H8YQ;C*C31-+
MBS&2'I,@#BX,@83;2S+#KU^@^JI=:_N2T7\Q6<M/-TM9 OZU'C(UY%56]RG7
M!BIP=5,Q2D8!*P[!:9H-:,* @W[6* $\6'<NML;/=;2F4D).>V72H_>ZX80R
M_G8XT#A"IM,=G_I3ABCXE3O&LE#<SU5F6(O(@@[G-7AM#<8%GC">+U$1*7PO
M?W\=]C0DX\)A$V-/2=OTHNABR%5MT:<[/ @S.@U)%[U= >DY?JSV_[ T!52N
MQ]T=R=Z?ZFH8@$QPIHR\'GW/A8A$%@EZ]*17(O,OP.8B1P"\'%/TT0MN9_R+
M6EC$>+P2S<IT":)E%0%M%' 4@H6.]Q:.7,6.G)WV,KD+G2/5J=M10?Y.X8V?
M,+Q!D?I:Y28KC,I:E:$*$/ H^<^OJM$S+#T#0YA76-Q_""!BG6*57<],)^7B
MF% _ 7 >3684.C]E!^84R.A*,,OBW.#6<]58I _5.,4K0W:[5002Q <HPXS2
M1*0O%V4?YVKJQZR*'"UHF83ZHN%'ALAM<V-RZ5HCY1#I07\=?"W")B#,[$_/
MS3A] E!:G_ @,9D(>NI?3/Z0*=(&9E.GY&GV"38U%ET.$JY2AG$O*74A?Y)#
M%P'=J.#G%#CJBO'F?)."ER[K@K>*9*+ZG1[A>B4X+#<Y]J=@J-0?0Z79_CT?
M!$K0CW?*%;M6#)F,.:^:&[XS"6CC/P%,4NBZ@62Y9::?N6'6:*Y#F5IE*,(.
M;U5P\!^^CTJ9<_0A),S-'9J&3VFI4P"LY[CR"!V&6]R@[_+7AKJ)PY.!#_=>
MSVEDJO7+]P\:7LL]3X U>BDI%O>>8TGS:KWJA+5?#0^JD ,MO'W&-8@IQ5RT
MKOP+_]>V6.(%I7@"A*G]/]?V@JPA06#:S$1%*_P% <9Z88Y73N ?.^,ATW_Y
M%EH@6EBRUG>B^9;S0$*YEV]"PR9C:LZ')8^/[D-N]1]<H:LP[26=%=WDOH,%
MO4S(3\:#]> 0\ M5P/I\"/T^+75^EU!/]Z391*SN@.,_%3S-S]O1^EJ*:KM;
MK: G07 32G@2J#!#P2/@8*C=KE/QL1N8R$A"-*JO!=W-"58C;W$X(N]AH$9B
M<.;CZV54KY&Z+*\55/U[60=WQYF-V\I#C[@_%JAJJOEC.PH7[H[U)%VFI;:[
MOL^^B[WG##\HW1U6W%3Z*V(@(?Y(>#3VFUA2CZ\?N!_=EI\+VB[?JY(<!^ZT
MG$T]^^EP6\\%:7_L3C1)0,W5;\*R3P P= I>DW _ ;"D[LEN;>XOGC\@W+1<
M%\ I7?PK2GEHP E5DFOQ\^6;O>>O F=>)RI>[20YT)'0?@+<HR<] 4+2.)D5
M5;Q6T<>]MJ$C](@T^/=3'LA?H3<%H8[VL9#-(YWW_\_0_\8,[?U[8<DIK[\_
M/R'\MW= K24.*)]Y7G][$B;?+23SSVQ$_K$KB-F[=)%_Y$'XCQU1P$_(*Q#^
M,Q/_U!$1<[T,Z+]_DDSF'_L"DY_)?-OQ$4HNR"RWJ#[P?[ZH.K_\,$0L^/.
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M^H HJGIL[&%N@L[7IY(]I,,&WFH/F]C7V,X/('2:[PL,U]N7UL [PZ\C14S
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MJEJ:'R\WP3^R41+'5/ALA@*CHRA3_>C9QNVC96+VN_N?7/;()W8?PX0@V3:
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M#45A_36!H8[N_C1L1]C0A)WNXX<NOM1Z*I=;/)%#-3)$6*I"KA\Z 9UZBZ/
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M"F;XU:X)EO=HS^_^"U!!B1JD%P!:YN[')?E2S\;W-3;=3 .''(3/R14OQ\U
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M\Q7$_%7N+)TEWP/^HN.=7R)\K3S(A.>]LPE%/^^?\0,N[W\+V(.S>89?+@
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M<GY=S\3JOJ""@8UG2$I!?>_DVB<\ "(BW%KD<YO04%$$SDV@Y<%'AEO@0D>
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MGY+LO]\N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y
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M;'F';\W.H<+BOC^PUK4PJ/MYRLMC2:D#&S'&DS$/KNSTWFT-\N[G!0S*.Z>
MZ'>]^PVK)S(&K*FZ9I?\VO_.E9=L+UM>K^$)K3$Z\ ?!N4Q_XQ*>X QBK]9Z
M?=SDV^SWP'Y%!R,BFZM!DGWM;MM,=/='/L/C_E, E$0(SB9,9S!;T#S$_J5-
MEKQ1MR/GC<KVS:E?.)<-FPA?A]UP?+\K5/WA.\_EGP/A!=<##'CYH3(DK3<F
M!#HD<.YBTC)\Y2R= FZ0?JF^CW\*L!<E>3X(^G0URO*-3CPCZ++PI]Z/&O@T
MXT_SB4BD;SC[&PU?"JBEC'AC77F4T/&&1#KB%*"0--FL(ISI7Q=E6F3AXL9X
MW*KP]#=DN ?7WPGM&!W.VL)UD?RFJZ?2C:4/;EO$8<..O[^H_-D\'>(W_SI/
M F'9ZHI)D:)#DC?&_ABO17[,;-E30*[RC3K?EN7#@[/I?O3;= M$9*N?&;U[
M#!I>VL7^:O4GM)7,]RE'6E.MP0[4C6(.)-*9,6RDWIE>IP NHCO_-,WP9-B8
M.VBM7#V^:2_P+6=.0']":QGB.%B4U2I.4N7DO-NZN)N%-7FWC56YE3!9U5MX
MZ*9A@0/[50DQ&^J.'A8)1A"5)!5/UHO(S]5?O'HO/3##8&S;]C81XYLK%WQ'
M07P0?!:=UH$PLX$ OHW?P!23X/-)^<IE>>?S>;JWD3*> M E;O[)K$BQM7GJ
M_-Y4>#1M/ITMC*QGOTU+/WY+P'(S/.=35ZO:X?:SPNU?&T[] U_3)^_>=?/O
MN3)M]XHX"V.ULP8I5TOP^,.\<S6NE9Y_M=FDSV9E-<.-G8-'H!#IG,=,.F^5
M=5OR\L=? X,:6O)J. P_N#P81 ,F\72&.]CA,W14#F;P#*0RMF,X=E_1$I*5
MG5%+FC:[.VU"TM(T>!WB/)"\9.7252>#S+L0SIQR&X^FUNMF?W6-FKQO\^)(
MN2/Y?B*?W2MGC]H*@W('0@/^8R*;F,!.USGGJ=#-YR^=O&P'GV06!H%$7J,;
M!O&-O.9+'5[$E;IV"K"I-AH,X%238'(%C>0W* QIFQ8F=X1Q"A@ .WD9PPF#
M450>E<6O$*]S? K;#Z6]AQ6:XYSP4.41>)W;3 X[ J+TD=U0N[M6"Z("U ,J
M%EMYZ;1P&ON\4K]=\\F_YX&9C"5OV(2CS^QU5"Z\PLJ,- SI)=6<NJ6EP=!=
MWNP!AX$H3K[2-LI)<F.]#/(W,E(:N==6[HD7I^'-,1!8-;E?P:@HZL0WHT\Z
MU"QB96>KBJA+SEX&EAK%D0_<DX \&ADPCS9MT,/ST((8 I/$?)4SY"-^25SF
MLP5)I<^].[S<RB&V]RUOJ9-AW^N]_^L=>-6\>DQE<'TGP(!:;/^L'LK!>=BA
M&BWL_KA1&;,X-0[-]5;LJ(634;N%176Q T4.#5$IY92/D<C-057FH\NJ%O&X
M#(JANW$,/+0<(BU5N^K>;.IF,*DF,COY8A&H<A*GKX_#](@UPYJ*"]#$.ZZ=
M7(9P+TB?-(Y.5M?042U1.U\O/'$R"JP*(]14S6(E'5E%;@IF?D$$/U%X:(]-
MF6ALO\L:1GN#]KY\.@;CZMU$-)?Z_,2QY@\+FU+W@J9$-DQ'94?V#EPQP1D[
MUXA\IKK:U!)E[R:!<(/;9<H5$P^_C! NEQ6S#G_DN"HM0I0A7=#FJQ8;IZ *
M61\-?2D<2*CGB#4]"JKLD,* =!,JAX:&+:D )5#&]0LQU[!?"T5I75%-837E
MOE9LJ1I.:J%BKJ<W):N65#]47)GOQ(6N$-Q<'HT&]=RD'"SFL?C8@N"_\>C-
MD^PT4Q1:OADR$3 *[IHD&F=M6-QRZ_+.S0TCO[KW2[SEUB+DSXG4M^RV4L5&
M2HS":#?"XJ[%%;PP7%1@(^3NMGQ9E$.W^;(<+?$PRKUV<(?W9D:S-E&T+FY.
MD>-4,4IXH;UQ!M 9SW 8<SCHVAB]U1T/\GU#=WM,.798CT-4@ 01O !,4?43
MN.8\OV>N2U+P-.I2(>REI6C\:QXR'/!:AG1IC)3QY13"!OJ\ND"62E/E8$%U
MBW"(;01^.Z+L"ETT6Z)A,JFC2:+>C)Q8=LGXDF(R"0&=(OY; 25G5AF,TN2N
M0I38O*(P^ZGD(L:Z#)2CCKQ%F_'77:BM^_CCIDP^A88ME\*8"A^]+@/KOV:\
MD_00W10CMR[#]E$ANXI=2/++'NU5BB3*D/C\RM?S4H=8WLCPZ53*0"X<S>@I
M%/XHR)<K7[4Z8%+XOJ@$+R>GR#B\$,+#2IFOMX&O1YNZ)&09CFXM'8%5FDJO
M\LAR*L1.NUMV5G=V>O9%V\_;P\K7BMU#%8!&7;![GOAG2<V'W\)UG?"-E)P1
MDP?5'GZ3AY*0U&7E29%#(1T^Q%4F+%E"K1ERFKCXJPPTYAEXU-Y39!D$^+&3
MN=4K'T.DC''#A59D5*"$TW;(.HP/"U1X3?DXR^BBD6'NB HPHHZNT#C3TL%Z
M-AMPR7@\*<B #Y^T5#8,_"2VJZ+(C$ZVPK#..+2.L[M9@O[R+VM4=(-$.CG
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M)P5GA]GE-\I3<'6',[^QP<FPIQMSF\=M+5?@RP,3KJMQ=_5/"4'R>7N?_13
ML[PSZ_CP'\]S]&?*3@$OO4\@4F?S)'&W[-?,83L%4)V?LA+OB\_-[SBW]%=\
M2\.Y?YB!W:$_Y*G+*6"S#*Y'A7T,GCK-?@\_5MBO:,]](I$V#CB1#*.SG\=
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M/ E^PS650%,61D@&TZ6W%>WDRH=L]L?,)3M=&1*\7HH>9M303W<J33!-R8)
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M'J8OWI,P3=%]6L+3RX3&PDL1#BL,K2AQH@^>?81'/$7$KC<SJTY\:SS3]<I
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MH5J6&BHS-%_&L9:!<!AU:'Z8[;37=XED$QX20B77F\E =PG\L)74L%3\W(I
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MS+ \,#*I"/<Y[0(OMVU/Q>$K]QYZJ>BQF^!/E.Y=#Y]Z]U[13G[ 0SYK/"*
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M.=)VJ)@]V$.M5391M#:"L$R,_;/GW82HY?2=V\.\0'3<_*;-D_7&*6!M+O%
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M:%CBP#(W]R1 4<C%S&ZKR+IC=8?RPYLJY@X)&YO NX.5:::?Y>W=DU+Y%UF
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M:^M$:UE]^8L2766P'D PAAYC5P!F^1\7HX N&[JGKIAM?^1D68.+[2YW1_S
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MW_YL99$(QW006/6A:(*!]TJ\@4YD<"P($:/C8GF,+\HK-U1ZZ:Z]^K2RRYA
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MZ=6%1 OZDU]HR[>3(JR2P*%[J-8@)%@"V"H]I:;(2#(-6MH].LA02"#L]]A
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M>&HZBBG-A7KIN%3R^*SU(,D9!SX+KCT9?:58')]*ZC"^$S3C+J5UF6.)-]E
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MO<2HO"'I>":=ZQ@@ECHU?K[:@6J9@D&1*GK 2;-D* ;_A$.O(,\NM7,M'\0
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M'UCAQ?HO'JZJ'=F _HDE_O Q%'NP#F@\*KC]D^"^_CT7_2/V;OA^P#FR@'[
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M>;S"H%4T4=3JHNJZ9H/\N?3L'?91ZQSFA+7*4S@7*4/WMW>PBW$+S2SN^9'
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M@62B7D/KGQ@(&2[X-U@6FO.2.K]9GG^#OR*BB:)')H6=P/D /J)OAR09]:+
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M*O?JA^\8'>],7J@-&W$ZEJWC@-=1J;,:N@K>QX25\GC &S=NFW<),^MJDSN
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M>K[.?VSS^$J?M<&PPQW?]N4Z3""^1HAG;U=/(0UYS2D=A^UB\YYMHI1D6O9
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MEVK[D27@WDTW(BX'"*=AXA,1VY9KQ4D4N5ZS5$T"W^T7XW%:XRE7>SE'D <
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M*V."NA'[V.(,M&&7V:!K>!MK0=R<$F0;@(LNI5Z *7^N!WJC&]. 4,%B8H6
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M79:+T2PAD-> AD$8!J:(-[9LUS/'L)P(*?-\ ?HR.X,U5)2AQ%M]F/5_612
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M_#1H,8#AQH#ALN3<:B2RK%$9C:TE^;@K W*WKZ</?BX>A^TD)DTP%H$ LXA
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M*R&>H"YQ(YJ0T DH"4S/=0,.0HO[X*I C>&KZGJ9"OYA!J.)4H"V?P9#?\B
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MF>;BJ,\#PW\7QHABR<462@I5\Q7 ;)16=5'.=M03 %K3LH0'<@$@5518,Q]
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ME6E% A1[C * -4T5LK046 %])JA4!^:CY% $D^/WC-P)B/[BLBB_:2^N#C<
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M\<]E*Y%G-T:/[?598U , 1RO?8_NI?&R%W2.U/7O&[FX^1X@NC<_)N_V?D$
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MJ!;>@)Q-L+N&Y0%\!_!5X-L'-2T%+J8VK4@MTE&\O0#:QL/2!CDMC^4=@&\
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MK1"\=2>2!5$8SD0LEX1W=.$+].PUDJMVB/>L .BA;O5M(#_34MG0YZ-%>I:
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M9DM>)0."LJ9^^O*0G#:J1EN_5+R1(@DVVF,P*D?SJA8D[<9:M860Z83;K3:
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MJ=!!<Y]T6<I6YM@Z//UTO"U-"5J\&(E,ZM3'K"YZN4L*(N#@VSM98B38VS&
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MR<L-YN,KM ==&LN;5<<P,8"INCD9QH&XZC<!,&TED(8 8K1=O^1"N/#D>5D
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M;R\%6O:=<)N?YS"^C6?^3+M+Q9X_<,53SY\':/A3PV\>\D;9@&Y0$Q"P)&^
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MT8$V<#RF0D6=C?.D#DHI,]7YA0E8Y5[N)XT1U.LY(Q,S51H<QCO,R+:YT36
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MC2QT*!>($2(F6QQ&1@\"\;R,_,6"$C\MMVE[P5;3P1GRZ6.XO3"1DUB3>*'
M2 XD(\UA ;29828A7<=H(<;&^$#3P_:&JS(^R'JPAOYV$\#Z%+8$OM*H9XAH
MP;(OF1U> M)3D@4COIH+J'#A<Y!('IJJF42(6IX)V'G4&5Y ]4'.X3(<G_X-
MNSXM:4T_I\' :?-G2L(=CJO@&A&[:!+LL;HSSCC)4)A-$:M)+E+LKV#;\<@3
MHTD*PM#:.'A&T;$+C[78$^7E^$PMZ#?2?)BL*XCXS3JC5:TT1.\X!(A:*2U5
M&B[G.!D244HN,[[$8H'A3TZKC*J<)M7*D^*)\$#"&N%I4:@RC:D.DA->A7@
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M2HN90J(LC&\:7HB-A$Y--]_IEJ%F^6R&O:]-#P3]FHP[4]_T?"[-B))KA9P
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MG*-K,.+H2FT]U<>L6*SRZ=TYB6$?MMIMAV([L2"5MA;#"28JC"Q62E@M8+6
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MY#_]=#5/><T;@R[^)0C]-)TK\]\QAE#@OV#;\?N+=42ER +,@+_SKU+P9K[
M3!I]>J[>9?W?87R99TRJ(+"T1H\^^*I2V*)D@0/ OS"*4L2 _K)#3M!^*;\Q
M2"Z*(,C=)<:[;<Z:-LH]MS[YY6T6PH+>\1K\QT%[U'P-NB]/W><,2L]Q97G0
M'J(LMRC2H%WUXDOEBW#JIW"ZECZZ\2F)>_%7&*^PW_:#5,64)3>!]ZD$^=WC
M7_J1.2AP[IQ'!R&,I.&.>]34ISX'T59+# ]8#H&VT/S 04;@$3&5,'O(?+U,
M8A_TS +? 3</.G%"1S4OSJ6@,C4S :T5GWD,I.J!@ZS 4^ C_D/?6\8JA\O)
M_:,[/?O%*S^#9<7OT3#UGQU6%X/2DL,-UY$"69Z:4\XJVQUZMEXL0<RY;_TZ
MF2+#"KUA9>#X 6C:N8WV@,)3D>*^]JLT@44"-?,>H[L!LB)Y:CKGQR0PPN5\
M31$LKG=0^JH@"(5$;GJC%SK4ZSM1.8S\''1?\(C=D5%("+?(J4B &<UU*4.$
M?"]11)N$NC=2OHED6]H:<Y=(G EWW.%UFJSEPK-%'/B B7)O+;/R/$BD^J*X
MURV<CNZ(RN. GQ.[EMU4':+6"1N</ISW7=3"^^HK?-88VL^4K(R-UUX[#KMR
M=WZ6K&HE9%\0+CY2FK632S3K^"27BD):CBIS2[>.1R]8%P5X!2!"!U'Z$5Q#
M[^&./>AW#MO'W<X(3"<R:"7*WQ]685R_N62+<K+T?<Z-N<5:J#,.!YV!C/7D
M_6MO-.ST7J &.CKL'-+(X%>VF*O3=;X[Z.%/X;L'1YW=,@#K*/BC1\&'=12\
MCH(_211\\,K[:, ]Q3L6S#.WOA8^Q>SNL[AN=U)^'RH&7NB0Y$JOGZ^2UP_7
M,DD>G9+JH&=_7Q.E4:<'ON_V/DH]IXU2Q:<W? 9WY_#HIA9-O;OV9YKXTR^S
M-,GCH"V;>TG_]Z#-!':>5?^:%V221,'VXA QWPA4)#;=LVDO4#GU.Q.D%Z<&
MBXJ?_.-O_;_=/,V*,3WBM+_/GKF+!)0,]V_;^UU8E >2AAM4"]U"F[IE>GG9
MO9S^.-WRU)?A+?P"7(/=SI</J48>=<Y/K4>L/#_FS,D">,#M=JA'OEMI/.$*
M/)G:T";)'35$Y3COW-]H5W7&6T()HR6LHSJWR=)=UN'G4"45CXR3W9KNP\WL
MEJW<#5WQ'8(^Z.[7/N^$&?7\]"'';L"3S[R&38CFL0U2FSXVS=J^VGWKXCM$
MX8@S"Q^\?WC]X3=N]FXL0FUB/:5*.2FI#E0NM9'U4U^^^VIDE>AZ?_I]KHVL
M;Q*3-]B[YZ,TJ6H8TZI9RIPU3J)DN52I]PF+<I/8>_O5GZX\3O77UM<S,#R^
M0T8$ _+A'_W^RT&W60*!U-;8=UAC>ZU[3H00J-8UM:[1"R$8L@__Z(U(UQ1!
M9+6NJ>V<;Y.K3WY*O1IK55.K&E.I+V;-(6F:X\XQ*9IA'_Y<*YK:J/D.ARJI
M<*@*O=T1BLA<*MR*U6O0?_T]6KT&T_H*J=@.>@>]8_BO6@WMSYFK5<P/L&7<
MRA5ZS2TZQP6DTO?=!W1O@%;OBDIB1;-,LG!5+ "MK9]GKG:^)Z5VU.EK1ZMW
MV/0.!IT#LG^.CSJCVOYY*OMG3Y63:1I9*Z=:.?WM_XP&G2-QS7J#)K;GDH!S
M%_Y>ZR:CF^!_$3#X)*5"CU4<M#'K;Z]MV_6RX[O7A;T'A;Y4I-5!$8+T(O/%
M9RGK73^G0K:]J!N_2*C\>H6<KY;WUZD\]+.,B[6%&EA('#1%=\NR=INP 94E
M89DU_(+HB(EN8@+?0^H.*QY*BP=SUV*)MM!?P&UZF1#Z!1MI(I=[&H5(B.'6
MKS><S@S=IG>-]>%.Y?KA0>?P!9:HO_)&F/W#$O7>BR8]/U5(M*PYO3F2[T_G
MH:(FTB>?6UZ??KV46*R96N/3YZ8026%(+N-Z0*&/W:&Z\;VOL#VA=N(AFF/8
M#\ [P4\6L.LH,);@^$)HXPTON>%/^$"BCMTCL+_AW#NS;,%GFO_X% 1]0J14
MI^.SL[>GS5JO[9!>\X, >2:\98)_PV/,?'J3D#3 S!<">,.9(QSKJSGX2K,Y
MM=-JSY,ILA_!D'UJB>2#2*PS9#)RFQ1O<JL3%YR_H@:LI&26&Q)F!&N;-&G6
M(&0K<CBCV]P\,]!?)RZW5*W2Q!+!H06.Y-&9(9XO]M&I8O.V39QV2)'5[:'V
MK3T4'@/G>!X/CAS9G2<5[3Y\UN6+)$YT3]"I4?>Q2O(,#H1C+6"/B<3[.%TE
M$[ IX+^/V2J _272X:#C]7M'#L-[L5$52$"(MS[R:D[M-4,\@GCB<=0-S*E@
M+3\<-"P+\*_\,$);H=GQ#KH>'_#2@R\Q0H,CHZ?4[?OJ$V$0 :Z8Z%L%16X&
ME\7#Z^K_/E\O)DGTWZU,I>'E#>[O ?B_MI/XCU^8PV[+^_ML]=H[[,)E.2.>
MTQ8V:_ :,;@/2'REF?S@\S/<^1DU>?#AOWH3_']3^.#-Y_$[D]W\(XR"U7J)
MS>3R%?W2Z;2BOT39SY;WM$O?.W["I?=ZH,G&X)E1K-/H/3^:8?>.^8(4:HYV
M"OMEWV4MB;HTK;CXI1DHUT*/'%#85Z",4<W6K71K]6G0,\<5QO<M\F>ES!&P
M3#/;9>%7*VE%>M9IDD<!=729F$=V/(RRJ"GQKWH3/\)FE?I94S^:BF$/3@7U
M64K*S<V8$:2J;56<+]"&<4G!T2RA[DPR1?F@X[V%S5Q00QKJ]5-R>^15>C@<
MLS$O1DH^ZFX#AIGNN\6ND&*R5O/-D^0K4OQA?(7]Y[G_'S#EP#H+5 0JPWX3
MEQ7LL:I'TY>M"G$L+9AZ 9YB% I2Z>HME*Z U':VU@.U'A"F$R,==,9$X)'3
M$B87BIBYRD(ZVIF XK$03'H84SSH=;H84AR^:'K)!*[K*^FG5=5FS9CV$^7V
M0@2W! F'X0 WEFA2=#O=;J_?%%FWS/&+XL@]3.8N-P*>PQX%/#GO^ KQR%U*
M18TP5*GCGCXKI'=YBJX2-M-J&;[.XQMOZ18UA73'[@SZL*EGLE0I9JW0T.(Q
M#24(VQ]A&A_'<]PY@/'89:; *ZJ.S]7O=9>CUY?''0C:NM^CI\D/]4K-0:6
M(3+5K>OTHG6VJ8,]BXZ)5*-,5,JC+.<M]^9J#@.7KVZN.%QG63Z;82J!6C)+
MCP5JJ%:$&.J#AJTNL>>CM"5! 3)?-&?,W,^NZ:?]?FKCB)<?=CW+8VG$P =/
M2-+U36V[JV% <(="7GL?N[_(02]YYW.X[;^@'D'Z==N*\I.CH\H\U'L9ZJ:
M&1(W\S%36@5C)\"8EX\[A'I@K9(9:TZS(:,/,WH"G>9WX0PMU0.F3):@.&H*
M-MBHXZ!1#"JDGB"Z2#WP&OVAE^34J12QZFB,.LT#=*-%MW]K \UI^Y..]\%I
MBB"$U,5$F]<X/Q5&YQ Y[;&%Z30-T>+6P>PTS+[H5HP=[]=4*3CGOFW+R'D^
MUDJH*]!BAW^BL>*M2/[@PLE9/^#G83F"'JT7RSG\+#"M,3/%W1CM)S"PA%NL
MAAEH)NQ@.X%Y<FP"&S2',35J[GAOHEQ)TP,S4CT<W4B2=LP\R?@0A:UML56
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ME;9D*=IPRP\$(HC@G7"U;IE,PPKA5+?\=@JW#$*NX/C'"E: +H2BL3=7H)W
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M"MYPK.!9'+*]L-).2E$<<NL#^%>L*"S_\3/>C.>GE,+P/7A,N,BI%1XBS35
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MM.A1SMW'PRV:IXPR@@$[.)\R$F6'+JO]4&K:CJG$M:%TZ:U;E7:N\?GE6=/
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MNK]" D&2C;Q,0[()MUWE<&,[ENGV(HY[/)) [6VS<]N,!7IKQ_M4E(P;*G#
ML C(F)!:)5/P(DMJ5A#_EG*=#AF]O4-"-PQ>5.V8_'@P:@\.7A2V I== NCP
M(I"L';IG]TPC%0K+0.@G[+V*/VQTQZ4/PK_27 [DV3#8=I$$>'J)%6(F ),9
MF+B1P$7*=1A4YY"A?!"LP]0],RTI?!2B)3?%H"16A(79(C.8U)!9L/W5RI]^
M*1<';U.G*ZF))G<.5$NQJL0>4E>L!T<O2*X/7UA)%;6!PDK5()H>A][PH 6
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M?I&5ZW)9KG[K-23C1)J0KD$_'OQX\OWAXVRZK&<?Q2<2'KT'HY?N$</YC["
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MV=-#YOII-^@"MT])E08#QXI _-)N*V1#RC8V&F"1[&M7O=4KM&N36W=6SB_
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M^.S)HX</GS^-CUY66/PA[\ 53_P__C?;C6?!;KB-E7L</WS8O^I=B<29B?^
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M-7:+S8)-\?EA2QJ='%^-43U^?G5TPADBT.3NB$BPH&>L%Y[W(Y.]@=\;^,3
M/_NL*./9;S+QR;=O8.3'8XPP1G40;!C#1BLWW#+1GH>AM'+H?I_E1VPU@L&\
M%G8RA&+2:Z2+"-"DQ_KG%Z?-.^'V-T;QC#E)"4SHNMU(J%%W 45U05=LFJ&1
MKD OI9"J %^ZZ9-^=@ T(E=#_*<#?%JH-U(ODBF^G\I9?91]C_V&;)8K.F^Z
MY:&@E%2//KA#8IY:H%0D\Q"LW:-]=6BOL4<T]O,;:>SWQ9I>([3NHR>LM#^W
MX:!_@<?7-QU\;D SHN&S5V]_Z6=>1HZCX;!'CJ4<23F>X00J!_U(-<J/3'?>
M&;[-=5RV.O5B7U[Z=XI3?C]M()/6Z\@;E%M[X8!7Z,)B#YO%-E&Z6_^\U^O_
M1GK]"\>]'U[^<I<JA?^"LN7.(J4&W6CS]F=L^SD&\/@I&\"GZGN5H6[WS6\V
MB7+)QT^_>+F$7GU$0,3Q.#=TM'MU$O0[2*'DV8UZ])Y]\[MZ]#A0 #)W5LY=
MJ(#/7_%8XPB28PT5;[#LIX^>?HGZSDXO8]#@]5NZ$33.T:2/ZYGP^6KI;&MG
MO+J(;]FQK^-[NB,6<0UK1YG+(OD4TB <V>.>;P_W_&2/>][CGO>NU[_:]4+)
M\-'>^?J]SE> E81FS9[K];G9B/2"-\@AW] 7&.=*U'+JE\@NJI/!:0U<.F0;
M=X)CE5;(\P\.LQ%?TH3OE=T]57:GIS\^VBN[+QEI2GWLV4#=T;'ZS:'F,XW@
MOI;&ZP="+NH),=&7UX468[GJBXM1)B-!UUY=[M7EK:K+6)F[LS"4-.]<MGHZ
M]/B63;MQ2NF9PY#(P+4AX$;.B8[=P'CEN==JQY/KM>//X-ME1?;;ZE"][U];
MAOJ]L#JOI'Y3 :I7>/I=>@O/(NRXL6)LF__$;?[FLM;7*]S@&-4Z+WI/^!?Z
MPYQVFCX?$VV\J8^DE.^,CG24,>*A_UHO26KZ#6A/[E@#VA-I0+O69NYX-SXI
M]X7MRQYDO3<Q5U1^OG_]7__Q[9.X]C^VA4$E_5H#(0APT2"?ZR;'KSYY^+4;
MR=4P.(?UM]N('2"%WVLJAA;ZV>=8Z+O11OPX+NA?K<:CN75;^/P&6VCIJ4?/
M[\06ILOY[1LXH#0(^FFXGX+"Y#D5M.KS8O9Q79=<?#HOIR4X^J55 *C#/@]"
M@C=,@9*\.W3B;*[;18'A'_QV[2JQ&AH>4Y>A7Y(Y#&'M1S>UUD?9KG#P?O',
M_TJ;*%#,M32F#2<.\L3TG/&V7;5IMC(($B():4[%'VQW-QH_\J=KAX_DK9\&
M;4!YJ:]B]C+YP-U:A,7#=9ZR[+=R89:S</\^;SP_%-]['O(H$VB6<\;G!U!R
M56=GY'OB<!9A^(:=:)Z&$4>%\#G09_A=XRZR-PLWPUZO/KIIX[ENB?KP^Q_R
MS>S\\&_Y)Y*#[$1'0<F$8O)P*GVM9?A.6Y($Y:#0/RO;I:Z9-V.**398@<Q]
MDJTS'(!M>)0@-Y@F\/*/C>#QHW]XJ,D4**QF5<S[TSQNMYR8: ?OQW_502*W
M,_;MYHG=#QBA@Y>^GR9R9[6\34/F<VKO*_M GZW^ZS^.GS]Y83HD</N2,B'-
M<O ..F##$T.J^BA[>/S\F^?'%,8]F(RHG/ZGGSY_^N39\Z</U+\>_/WQX^.G
MCYY\\^R!T0OV/_#L^.'SXT>X@/52]](=@_4]_#:L4%V^\+1P<?# T.A-_!K]
M8K;,2?$\S0XB+B=MW4C'' E\*IB[%?R8G$$_ZYK\$1D@(M=\\LA?M)V5T)T+
M9CB<_\E]%]S:#.G"P*IR1A>YFS-&]HB@KX,(>KI'!-W%8:U_.*N]:PN^!XJS
MXCB*-&8G3MU^6.L=L<ZP4Z]?GC@CT\A+ C5NWE$XTLC828H\%@6=UWR)L9.
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M+@?PW$(BVV)GK\:F#KG%[WX\:7NM.2&R11)]LUWK5+8>XA>L=-J;5QJ_5AL
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MLBQHWIB_+&.#^*QL9MTJ-(E[-)Y<;,3WX.>UB'U1-NW&V1C>E78%-W':M:5
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M(R)Y^$0;07'1(W!H57=:5N>\&B^IR>7_ AZ_ $'>++0PI4[F$%- 8H>\58\
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MRDVR81)9Y*I9YUL0*S$],+0R5X3*%<\\J1'B5)J/8S\);8YN4@\<K+5GU4G
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MV4^)H56P['FQ! D_ZTNADN3:Q.D)4W>B6L1Z<6OJ5W!J]GZ#OT^WC;>R%(\
MJ+;\HA6L0I]35PTO+SAIVC#G1HCO?"LPA'.;M^::;DQS%^H8<BY'5AFQ=;F
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M2CW?!B^E7H;*U^[G?+%[8U?3XI__M!1'N]%TAX:G5UTQ7@,]K,&1FTH3*/]
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MU^2^/"J.8&0X"E!Y"^%%J[UQ3Q\]2WALF,'MDV)$PK"@Y%P-@R!EHK-(,C8
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MM\6S0\8IJ"13(%S =GUQ:6Q.IF0'ANP>/#2D*Q2UFB"$V6 H_\T@RK_?:<5
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M2&6>NA@#BD_;/F13%ZH5$(7N%<,XV,:IY/NL=C%O -X H9.9\4Q\'**/&$4
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M2;+UUL8)_S.N%/=O&K06(_.P;$R)JUAH<B$Y,'5N\X3.<MZ)GX7QYL5/68*
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MT40013K;A""+O5+])M]J>I<IH<;DILH6S_6ZA?*]\K,: C+:_R"(R26OH@9
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M6$UP./4Z*71'<OC!GGT77+%11S:@2@]<:(B%M $B' WNQF7^N*<8^ZX$ML4
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M1/=$Q6)BNRNJP&TKFB-YV]:K(D_DV4/$\R[-V%L =2 'Z_MN=M%3XV@L1H?
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MLV=#8-D!B%_%TF3>)4>9C$0/M\BN:YBWH\&1QR8>)*9S_="EPUXHTF#\/.2
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M<J0Z?JCW?F@QWR!W)V@S<M-0O6236VES/6&FQ1DLQ%92>YDT5(@H<007OZ_
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M9599F^T?!,*=$[3Y+_5!9^=R7I$_<T6&U9>6H*?2.FE*A\#[O6"*6P1VJBN
MKTS@.4>^.2B%S:MU7JUCJQ4VSOMZS?H$R_$0,<4$XQ$,)/< 2%MR;YE2J@CE
M*F;#N'$-<VN02@E=><%7#A@OJ:?-*W)>D8,5V8]>_/HA<V<PP\3<7#GMO*D0
MD.?4B*ZH*Q>A3D,\4%B_!KNN,=2\).<E:98DQ!&+7<>'^NC)J\T(]$WJPH-W
M*7*WMA4OV-HCE9YB$[KYYH4X+\2>;631WC[ R1BQ.X NS0JSO4]#&*61>^QC
M*-E0SPMT7J!F@3J_+*^(2(U7Z8YM)=R]?*<9'?;^M =4NH$,AF]>5/.BLHO*
M-&B%3G_!J4M_%C7HNRL"8)=EOA1*Q2SJ$<:H(V^H&S15^HOT0<QAB^01J2L&
M":-Y3<YKTAJZ#YVS[*FW@ N=\'*CIJ=\Q7A47G0AFJ8%ISP:Q1S\SLLJ-774
M(L6KA!/:$B[L\D.@9AN1\"9.&LOIFS0L!#2RKL_9K,WK[TCRI:B@Z.Y,0IEB
M@DU1BK*O2(PR+T%0K=<.:/KGVFT<-ZDR(0_Z0ZG.EY/A7)5YL4V(%]!@=I7'
MR"*<S5+B"6=R_.*\>.?%*XN7.8.$M-QV]+/8W7MW,-J5S&N$T[DE+ Z:#3,^
MECE;&-D?MF[-'TE?D4;#(?LXK\%Y#9HU6 #8@#46^LY,RIHD#_&/]M#B%4K1
M;M/D/H#9(SF=Z!>&GFBLOQ"A#)(R9EU;VEBYQ[P^Y_5IUN=X=26<VTQ&& 5D
M0)NY+TKY$[>V2GP-# 2-<5YA\PJSD3%QN@4I%#^L9J]=G#49+.]<YEV0SB.W
MTX<Q0O(6,S&<&&SU.XG4G_+!E>M;=$8R=2&WX%^[O,22EDQDH;TS5Z[>U5C6
MS/I9;?R7N\4C3O/077YZWX!G.ZKI%>MUZ4@3\/%W].F\TN>5/H*=.,X%,;5H
M'A8S@Q(<Q3[ML;9^93Q+.;2"5/CIXJ+/;6*9T$+/-C&=0>.Y/#"Y68:/-OF-
M/[B"4!E)QP"S4HI[3Z: KDH5,J(B6&?3_ >.:9*8=3!A3%,GL*][K4\D^>I#
MX"')QIG(1B9)DC]2/2%VFEV^$AV;2,#K;6/KB'CPJJR75A$@\./'"!M5ZZK[
M74SU,9HI,[O#!\]BGW["-K7R$^A?.Y<ZP6R<D,^&1Z3<6-%I4?2JJ6]!,*GO
M86Z@?T -]-_.#?2?3>9G)OQ3E0WA7I\P\4SUN"Y*QEI(1M_2/A+E==<40I-F
M;)YA0^&SJ8'OZ#]HKQ<-'JO5Z]E*E*'?_:WX<6;VO4^ZU7[R1WTI^-H"/1"!
MS)P)P*&(%^AR+:62OF9!K?4(T/A8[].5!BHGK"R@>$50DNAMEYTZ _Z#6&K7
M!2U 7YO;"IZ*]V"N&L VL[1VWVKQWID+MH6?H#RMX9\NWC'?E99DI65]TH/2
M!R&EAKRDPH(^%+'K^"GL"G@F]& H=31"$SW%4@[!R::]+G:<XO/[,K![T1:&
M&ZF>2  8,.51O#SM>YXA5.K\B*3=.3S^+N@4*MPZ>($Y,ZF3-\=;W-]!"6)'
MQ(X23SI]@0P/4U\ZDV%11<@4#H5W688+O'=%X-L-.[0L3R' "S54FF R?FZ'
MPB51+6Z@5K625Z]1>7(U-6]5_R(#RCX\4,9%T1&^-&FY795P0OT)!0F+]1^?
M">R/:L8X(.#M*GR5*DV0& 1B]0YXG@3&(SIEVF-0&-9PXAA+ST"2:L'^GCX,
M,ZV8*[#7+V"7;_G091IHRUD[PIQ1-VS7C!6K9.\',C.)*DU<6OL3^UB(-*#V
MG&#CM=@ X>.E+61I>3&8X[2\$3@P0L/)K-?Q.>-DCG!]'Z$68>YN,G"W!7&6
MP\A-7,>/U)N[F_O)VW?$D?V?*PZ'$^=Y)#IZWJ-B?!,;)B\4,.^/(S#D7<J:
M>!;6Q"P1][E?^]U=[XNHA3VRN7/221_7/R*!@BG5HW'C]RND;%2#8U*S!UP;
MX)P<")-,:GHP)W53$,[9DA5'*I U];2W=99F,M4I5+'+$N=3LW7K.<RZO_[)
MNVL(4)%R.'&2-D+7#<WQ(7V;(5_C!'/H'=>C].Z4;Y$A.,C90. %GX:X;D>Z
MFS?FNO['N1*;JI<A?4FC'-U)'_ROX6$*<<I(E_R=&E.B3IF*V]F-ME_ZSVCL
M+__^O-6SQX^:6-X;IPKPP]<DW^.9V\'MZ>Q Y,7@JC9$Q3?\9TJI=W8.Y=S%
M5<T,RR)=59A*PQ;9YR96%?SC>+\497,_,+W2B+"8H7)GAY"'* >L\+:,M84/
M<^V*D1O<XS[Z2P_">GP_4!NP9R%D=R+G4T:U(N*R<"?4T;I56"4K"HADT HZ
MBJR LR*4&DO2E#EE,%0T!]N!I9AS7NXL@9GV'_96%8OUN0\Y*EA1RB%NPS4-
M4=F/@PI<Z7)"+-^%M&J"*BCTF ]&%$6 CASET_J0LNTIDNN0$26SU=>BBD'&
M-%L#RTFHNJ=LP)ZZQ+$Q3%$^WW,BYQG2\# @#7R*225<'0ZE:F(PXPB/[0S_
MFE=0X/B2 OXJ^E8!(Q [/R.3?E_(H7)8=GESN"MA\KSXYL6GZ-8@M6E;0V/+
MB7>KFGSM<,9S+0;_A?)+P_G)CF$60N<0' SWP9_-+7KK#\=\C+"Z)8?)EQ-/
M0E*CXN!\1(YZ7M+SD@[V=*DQ.#(+B'JQSIZ]N]!@>FVY27S(6=]RU%MS;!#$
MJ@PX:I!_:([F)^;E."_'P##+>@@4DBJE<=9S&%-VSVF661$F12=?W9S(I<>6
M)T1_0X]UDAP2(9QYA<XK=. #A+2HBG)0T-^C!3OF67+FL-WO<# C2>.V=45X
M43''#KYNOCJ *V?CH,M,69A]$^26-YHDG/8;YK4[KUU9NYRBMZGY=IS!\TB6
MB5G'=J0]3@"'T43\O.CF17<'"F6BNW-\CIN%E"C9!3X>[C_X3<I(-E$P+]]Y
M^1Y9OF'Y4;5=E7]#B7/ 6&>4C(=N:YGOJQ5=:8RST5A<(=!#A17HJ\BDY_^3
M*:;*NG*"<T@P;!*-X4OS,IZ7L2YCFZS*0R?9>I&O(*I.)[GZF%U=NN!A$K.*
MN*%8G)NB#/4]795AT<[K;5YOFE=RC*,PZVO7%"N!:%C?DL[B$%01R \U9-:M
M]XX $"B-*[9+X#*I!"J'N2$2SP_UW:S=W._V:?K=_C3WN\V"L;--_;3K0&RI
M4-_>Q5M$OS:C8%K6GQ&N*7(_]Y4>\+_,ELZK[D&LNKMHS##\RQ[VB.Z9T&1>
M2/-"&H8@8,MIZEO^MX]CK_+*Y!Z%,Z_M(CU>FD!').(HYX,<)OX4 /#IGVZO
M:T(IVD:?20Q^CSOW<#K)QO.P *:O!,W)[:2"*:3^B:4[U/#?J?632F6V_D:]
MJ/X>*M9+;1;LTL<:GBT'HUI'Z-3K)+%LBM2"1V6 9Z BZ:Z]:QG;[,;A#PR1
M.%V\)$SLKO87I-X/%&$JRJ8<AU:B[_D(/#3#%RH<Q-+J3,F?V!%-$R$:[H)-
M4O$X;D65ZVA[RKHFK':@J^%TS[9NW/!5'(.(]UL$]"?$Z:)OR:#Q>F#3Y0!<
M')V.0)=RO%F%[N_':-IIDZR8[LW)'@4NS=*=>FTM2>_+?02@SV04L<4E%$K'
M49Z<:\H;F(9>H50UOSAJQ(_7!=$UX5*AC98N?KJXJ [#911Z0;7/:X A3Y #
M28N-=KCH5HS-M/I _F+H5AR3O*546<8MZE,-,G-KUOT]^V3=<D,V-T$D]G'=
M[*_$ RFHL]N:2!PT_CE0RBIQ +7OO4_QN@($>M%N<VX50N)&NB:F>I@IM3-H
M!="SD ZF(ZMK\;W;T+$1LFQ3/5I'NJHLE<6DH?:W]^\J]!,174:;=(XI\J$V
M: <G%T?Z.4TX"\'CR+3X'7>]]^]-&B8,@7??F\ ["/TLU/Z%_>R/071_8E[\
M*>QMP;5_&ZZZ<@%#.30A=NZ5UBO3-C@XF9A*<$7:]C#3A0XGPK2"IEUWVIHB
MA/I$?C;1S=?P)8_Y*J!OTZY^61@C+@O/W2^VRM/^DF$>2&UUE]Z/C.8)-PT=
M;Q,J.FZ/[/ NF61D,\Z*@,:Y#]?%LNCL^Y75A4OJXO(>Y=X)O0'6"I/1\ZKR
M[[K=H:?(WV#++$K&UMMI\G'+%H1*M7=VX%Q:K55R7?Q;,*<)U^NBQ"55ZQ Z
M>R?QY/+YR9F_4E6O2N)?P(?+>@U7I_5S">\R(-IXM/GBTO_-+<Z^.)=.*/_A
MTR<^:.KR%FPF*__/,J^\B0N9(/B%/[JF=#?H[ .["YRR'^N664S\:WGF/>;J
MVK^4*C.>Z/NJOEU<^__?/H[V.X(46M>PZFWST)[V>[7X\7NG[!TGPM]A4S0M
M*"^\/PS"C$X-L1SLZ^$#9W[X#9["/TMXB-26#(=]#E9'\$'0H#,_UN]/GIR?
M9W?]ZM-SJ<Y.[&([<>!HM#Y,?RNFV#$Q:\<[X_TMZD6)TT$[^=9,'$D]$/6-
M4U%!D"_>P!SM*]D$?F7N0Y#!ML)[/GJ_=_Z4K/[W_SK[YLOO@/?M>/POE08*
MW.'IZ]9>0=@$?C[!$/FSPAO##MP^\.)"**,^V*;,;^GEP!(A2D!HD?GW2)1&
M)9=PLK$VOY4_MQ EL!6-O7WVR(E.W(AI\%\IR)5L*3;+PD6&7N.1'DAY4_XR
MBVJ_72(HVPAE*RN!T@0/ RSO4OE3%%07!LJ*?*T[J:L592;B93(&K*(OAN1P
M6]<M\]7[<'G9%KI+^J.755'ZGUC$(<5LHIXF\R/%7]I-'78K(ELFVAJSD3@R
M"C@M;,WGT.S^AF:OI\U(P%.QR4C(_+COW3^VX_;W:S],(HOU*[4&JK5!&@[4
M2/LM,A?%JJE==5,T=<6L&1S7@T*KQ?D>>I2YMX#<!NLP*'I,A3(8/G;<3<,W
MR^*]*XOKNEZ3#0M.\)A#- =B]S804]X&_PDBIH9<(&I]FHK. G]4-;:\]ZW6
M,^A("X>9H ,C:8,V8W-K-9-L'4V9==?HN9=S\W0QL;W,SAG?(+(__+6F=E8D
MLX!_=G =#XIRK=RAQFZX?$JL,1%C[I\^F'M"JK&=5PJ-D2$':R#-/C1?J5$8
M.2#9#3H:?"(SZ0@8P+,/8E+U;T9OHT\FH2]Y%44EEQ:T"8?@(>(CC\@D*@V3
M#K\^AD:U?HWG1<6\A(WCRU"BF.;(/Q==/JV*:22.T,Q'?:T_BAM.K>8Q3.=.
M5$7](4JHB#FQ62080_(O;RO[W?1F%F(8C>AAC'Y >V1&2 \6/=RWTI&$U(4E
M..=(R^]'>G:A.T=JBTE([N'A_B!,HO>ZE:V/:R8]USO!48L_3]CIC^&? Y-H
M\*2YWA"^W=(6)9>:.?Z.YG!&"&D6-SD7=K0^@IS8:E4W7#CB.*4[[)QH$;D/
M!;")Y(;('5#EJ6#J,!1+X"=)HU =BJ;@W?5H'B1L4=@^]G1&K)\2AH(@4(F
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M3:?-KQKG8J"I?;,-F!/9TN56QF'@/8"?CP*\?1//S?"3 >2,#N498#PO8%G
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MN3"1^.#0.V.K >\.F [X>M5ANFU3BL4L0"L]>??H+)L;TL<QLW=#RMNR:(H
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M1_)7YK?978RV:%'FO<]$*D6ZBUS:A:Z<:%\":@A/B@NDB<QO9K<6&ZIGD"]
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M/_0J8BSYBH*S^[:^U[0_6FCL*%&A6F*M>?14 9"[$<@FGRQ=1XG$:V=+W/5
M0/%N2*Q:?X9-* EI1?GY73=4=B":"(=NT'B%'2#TU[:?(W_E&H'OPF"T AQ
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MB4RMAON8SCAWQ&%T=ML5/G0=HY*PMU&.G *Z?&A^;A'L]P'<U?X*9)5AOR4
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MQ)DW#L=S75]NTIZ;;!42Z51)^IP&!,J7_,,^::S:%I.)KXG^:[*1"&/8QA5
M7I'S?+FZ[799?LTTZ0+!&D[LYEC>&Z^PN6U9Y*ZN@[F#T?R4 F.PC@3&_]KM
M.DI&[UGS,+^U1^-HI#HB2?>D]HHZHIFB\1&D3;J<&&/ ,U,1]$I#!U6Q'4^5
MC6$JR+H,]]!UDU,$T<0_@/AR=B5JXTP74M",X#IEL;QN;E,>V8 ;9HZ?+JL,
MC$..\9"X[Q2P*(AOCQ]!49A9+*/Z:[TR?D@;2)Q@7-0_7S]2Q(+,R$G4P7%K
M7"BA$<[540$:1K<RNK?( ^Y"\G*CR<+]:96]8.]%R&;RP=#<4>OD[?3<8Y2
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MP8:U&QJA&BVI><WVC)J ;2C9_7#X3>KITBI ,A]QW,:LRK@7.DTSYU*_3#Q
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M4+;4HI:5^1>KY]-&*6=Z]=R[5BW@ 57DV[FC00S6#,@H1Q-9&X<]=2$$HD]
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M+8TUAIBE+=H1[@(=S;[,]#]6/N']BKQ^>G3M3OBX4K:5O$#HP#:7A'2E:KB
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M/!>E8/EKFN2CQ2%,U*8\M<')V_* ()7>,7= Q1+(QXQOR#?(+:]&<*R0<K#
MG:W2\AGL01*FR1T+Z+%/@MM"$W,*1J9<O%A%]/2#OAPJ7C58*UX?F,0MJ0.)
M.3'E-=5R^)A0$R:SD?1B[A>E$!&.N",9L-4%-D7+E&?S-WPCI X<,-W'*.>3
M.$WB?.2 ZTL53R:=9.S(3KU:JJM>7(3_G'=C(S.E@J7,$"G3RIT"%8+L@BC*
MT;(,/F.U:EF-XYE2 WWQZB448?JUC""MPO<O#D;+R+(O=N',AL8XF -0N#]T
MRM<N.'SK3(+8K5GF #]:\2J\6ZDG.@^V[UNHP6=3AL5^/@(3F@U)ET/ZJ2$P
M-?2#&!?>787W?Q6B7<)Y'IK+@C8&ZJ$-S-%H,_4LVW"BBN]!^9E@JC7V%PXG
MG$I??,9R$;5U /!Y*Q2%RUXWS K;W!#C\;/J< 6$II ,C6^)$ =E13WTU-&[
M*3],0]\]EZ%O]B[P@6X"3=5J_%6\8PTK]@?<LE>]>-3P)7G2NY+7\Z XNSS3
M/Z!JJ!WO3'01:AZ_%(C(0XH 9L(YE,GEB-Y39[X!L!27I@(5961H-%QYU\$E
M2?0PW)MXP/R-'?>R5^>/O]7G)^;UW([*-\'"GFT.#SD,TZ="WXH<CN*0)AY.
M>B]2 <W8_M*%RKLM3;",R:JX5860C5["K\_J%O_SZ_P/3KB+8@N7\1MX(53&
MV2S!T';A#JH'P6H1BSV,K2<!W</!"'_Y%W](?)>2F#] /^8"<:B<G%C\"ZY]
M5:L?95CR>8.=O3K_TU=?(D3/=R!"?HAL(Q;/PJ][O_8'X%S83H/KZ@[)?>AZ
MX<42U^I8V8.MFXI/2(2 J*8&(0K.JP>NS44[('B)"B"N==Z5W4,>\[$DTM!6
M>-;P%RX7',70%DPTY+4+'L'E?3R0C)FGE;6DU5CHC$5S(GIAG_-:?,Z3KQZK
MSZ'G[PD@+'":D+A@]H8<)J?CP,8C(BS5>.1\ZW U"/#"LZ5LYP8J-*(DB %=
M51'4N\>S7US,QRNG1P;E82B/$YI1#/*R)L_*@1F%3?BJ7Y^M_GZV.C__XM&?
MGF8A@L@W8F&//SM_:OP@31V<DVAV<5^9CK_GO8S#_[59=W08DI'A>P_>//_K
ML[ 1?X)IX_/A+[)!)#*;?O@!\CVES ?9=@S*4^"AIAUDF2O'YQT^^!5Y(?Z%
M<7*"?9"$!H./)/UJ:D^$X)_F14),I"?P>-T1,;@*9WE17: 47!5<@:%/]75/
M[O+N 1CU/\E1A[NJCO=HZRWHOP^._OMR0?\MZ+\/';,JFAG"AIE74N.>E<K?
MS1;Y)"4A61PK;0^[5Q0#MJ>JFH2F&L7%3M]MKIDZ+Z2[M%E_=VU6B4T<($[A
M;QY6HV4YQ@9M'+.34N(9-06UC" BF*\[)E4D<ON0PGL.[&5FZ1Y[J&]$7X?H
MX1L0_E.4P;Q!! R3/\E<IE70NE,FX7$GP[X59Z3>?G) C@O%4TJ9M^( #==6
MMP;7\^#Y]\\? BIV6S'@;'6WDL$(3(L<%J!6\"@JW95*R9>(/8?Q;)%+O(M_
ME.+ 9=6L\;,*L29'_4C1=_0]K1>D_3MZ5E;XEFN%AP: \/?J]$TO#5VFJ.99
M-^GV$P*?[;TL72WNV:MM3OE79H67?2AH%^?!Y^P;E$D#\/.:9/6N(A8T?&RJ
M.C,<L0(2%>DP!<&/&&@6,N Z$OM;TQ+U,WB(Q>O?7Z__#P.^*^>J#C@B]7?L
M\='W^ZD$[5[&B%"1K771LH_G8=<YH_8  .?\B_HRI%S29SBT^1;E5IN%F"PE
M0CW,7<Y;?(2;8)NX[4&7'>T&!QDNC7V/2HJ0TMI4Y-U1-\['=W6DS[M;61=T
M_/V2&[K;V38<1MF$9T]HXZY#';'I^0W0Y4<UY]<L8[AZ\.+'UP_CPV/[V&94
M#KK*]UTR59K=]D:IQO-+;E<HX]QK0YU[^,*$)9(&49WEAO\.CV(J4M"Y":%G
M:6QM-Q-S(7./F\M,]C?"H^@-UHF+;(@D!94]8TG6#870B=[&\)$D_">TU+&'
MEC5(%&"-.P+J!J^+J!O%/HL'^KI224W_/,J.,4V5@KHJTGSENG@^&DO&/1ZS
M. _CBG7<$ OV1B,#: <LD<4]CRQL"PZ2>,W_D-"[!@Q]X*K<RQQ'I$D#P\E5
MD5>D*),S]^<%=>7)R4*5U83\R&&4[?81!:U'(AUH6OW-+CQ#9<.379C-9!X0
M'M2="6:A ^9.L 2LX*+->^YCYVO*9&AP/V-\>_CIHMX<XRP_PVW<E^U?A&=7
ME!0GQ?]V>UI.6!VCE9O#2L;MP2I DR%1GH@785-H(TV6WV;<?(F2/JAK^4NT
M$T%]MLZ,()1T!!ZBW-'YWS:1B9W0CSMJY.8V84D E4U;[CTRT%B"Z<R/PU5S
MS,8.GQ(Q[O$XE$J>NZS,+_*5LN&@V8P#&-.13>[_R>T?MS82@^'^SR9*4-<Y
M!(O3,WARIT]M5E=KR*R+A!Z5C!];YUTO#5K%OY6;M^M\\Q9!2'\H)CZW"2<M
M+R2\-6+SK,(VKI@2FX;#;#7TS5<8J"Z#A;Y2=I77/;G0ND#/;N1BF, -UP"7
M-^;<,N&H$RZ8*Q[1PGBUO*8)/^ZK+0G#=VR=6ZL\4V)M"B*WT_)UE.X)A: Q
M<#&]5L=":% &L'5<N$)P8CG&,IJ>)5<G-Q73Y:$[R4QYMBGH*:D=@^,ZD=I+
M%)?OOIV&DKECZW0I1%QY!MOLF94]E?:4 :KX"(HZ+&;#A&'KXVVJ(F&=\T.7
M%DVZ _TL!//!_*@P]");O3@4N]5YIL'BGPDC4N.G?XS&AW\]#X$B,_O_&%?R
M0WXXT.M(/^#<X-^#O6J8>0'578?G)US<?0P$/XFSZKL0=PF:1[*T4K.^8=^&
MO;SMX+&[A]^VG<B!SX@PZ1:_K$"@:QFP]7)T'8UZO$ J)60\DEM=FKV2,_$D
M!BR8(@58N\4H64A:S,P.%)VAXN?'-[A7;]T1-X'*?3+N*_@!?(&I^P6SO)?'
M)WH&=1<)+3O.I=U@"'#?F1W/[O&I%V^,.I_]"*T[.=-"HDIQZV5?;G.!OVYR
M/B_DF8H?T[<Q#(*-/.$NL>XP+*"@FH>+D3N'1WA=-E7N Q?I!>"26\0U:TJ(
MUPT+M^ C^/WDE4X:BBE?T.T<]>E-.F,_=V01=/+*Z<S.XH'-Z@+AOX6$]+KP
MW]OFN_"@PW\03 \BJ>$Z4.\$J O10%P_,970ZTT/,!R0F9'0_U $SYW+*"S_
MH=PRT%D%X_505>%%-Z[?C(;EPP%WV;1LO!D$8,NNJ?E/JG3>0T-$;J4M]OU!
M1VN).9*N@0= #+*&@76..WRC:7$NCLZN!KKS(<60,8)Q]3E/>LZ'XK(EN!2(
M1G9BZ7KC\2_=Y#TQVERJZBJU+NI'0Y*V0XR4--J"BFD6\=<A>D-MPGA*@!3N
ME7)X1+% 7,,M \RIX<[4;(H:MHD=H3_3>7_R6R)80>C)1TAU=X@[5;Q5IZ>]
MG;KHJ'9ZL5ZY]8VVFF(/1]+/(7'IK6OU,C)K1% '^W OL:1Y3?D<Q9XD-P-?
MX#:W[&9"RZ(>RJGL4*QCB)-39HCDEY3G=!)-<!]CAJ5X-,Z!*^)RKMB+"M'
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M"3>&QCYA /P#X;W_(R<-B\N#<:A41S%+?$XP+3\<A9-E%?Z+'IF"6YYM#.P
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MSK/38-NH+V1-1@6#]:)/ZR4<C))IJOTXU( T31A'I,5-9D)N<P=WJ07>YRB
M0T:I22>.@GUHH5YN&G(0H3U_R0^;JT?_R-^%WX\-X=H2MXA&X.^HQ3CH=YS!
M\LA%K,":PNK8HRBMRKA2_^6BF5-"FW1.4!;]E6'J$HY\Z)[M1)A@1V947J34
M9O7]M\\>L9\.']ZV/7 LVILU 8%P5Z4*\.9#,]\6,A' R=VAT1 F@F5B0(/O
M8@UT%A/TQM<%VD(DZ<8'BA0(@!SHP8LJ+9AP![YMVN^%FNI =>S+C*X?.9<,
M=X!#.GS5;0M_7,UNB9JE+9O6^C=N&J";?&":!T\[B>@/OJ6G_PJ$6L_=F4_+
MELSC#7WU1SQBOB7R&F$9YW_ZZO,,<%D1/GPPY5\>FDX;T1L>'/9ML"029=LS
MF"N$&!(-,OYIC$XSX]''E3...UQ+0D:*$VTPP?^B?_WZ[2%V0-[PO$$0MF_Z
M-J2-Q]Y0ZB,[:=M8O&XS!<61BA+!N)L#F\#YYSX01OB3LYRCW:D8C+18B"Q/
M^IOV@)1CVNTO^39M21:%$UX!%'U08$G^(147+XU)AV]+\@(6.\E.R7$.K3)]
M6$YN?N*8P6\(6,*7EC+JC8XDRXUOK/9G85)H88U%J?:XE&A;Y-N* ]CTHSQ@
M@ACKE*!ORI2@ER!#["Z.28G/-Z^&0FV2<?'+LUO@O,*\B9*ZQ5N4IPS<:O!P
MG.F+@)-6FNCR?3U27)\T8&:)N$@.<2,O<$^VF_[)S#MAV64F@$OURK&$A\:R
M%TI=JK:D+70:_6-L%^+O0@/H(:L'N"'EYM2KHKX&YQ[U.F,TW 3/VG(I.]9
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M8PZM1 A%$@#AF5A\WW=%=LMUB?:8+EA;PO1+Z/%'8Z@153)X4M(B39[6>RA
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M_\6H0#L>$5=,^^% A(G3G9)U7Y)X: X"0HC0C9OC-KV#3%T/Y2%7V6],K[N
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M.X6(H@9P39B/7^[$XPOG6,M$:W2>63%:1\XG(J;! U"TJX$M26$I3^)<=QE
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M@P&>Q9H6:SIA38J!#)'A33A[PR>IPM2%+Z@"IYS1'>*\\3<[Z9<<\K>D\HB
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MZ.(S/\;.[DMKIZ@WBG'<,F6\;!79*N3/>;N86:-!MR.T+ P7F2+9.0D:' X
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MPW&*-UU8SY++<ZG] 5NN=&Q?M9N5GSA7_C7S?5$_@>!>PK3IH=CUP'W@F/K
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M2;W#9KJM.B$?K8CK7B6"JR)((0A88R:@21C+/I;E*AWL*J,24B15)>-DP00
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M=BI:E]HM5-0?57 GE^F&TRY(ERO1[!=I]6-97^;F)E&Q'EP,"E8 S!$W/8,
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M-VS@FBQZ.IH&8Y)7O;=ZP<F=9^BEA;""(?HN8*B2<H9?Q)]71S"N(TFRP!F
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ML\C5.ZLT8!I@(M7K1Y:2.3?KI'V JEE6GZCW>7Z8HD'=",LDD<PL&9\IHK8
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M$+.U"\KMB^$ZUTFD1_D.(SQ'HY8R!F8,S!AX4Y*&A@HIKX$R-!KGP2Z7 <D
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M,@RZK<(G$.?,O7UD[N5:_(?7XK?R_7(B0]9U6=<]5#<Q(RG%RH#221)T$S%
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MCT_[(5B".CB$E)3 *,V#FV@-T!)%VJ2 7$;[<@/!DN7>&,04H)P$UY($*RP
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M!OG_9[4HS<J=QTEWQ5740_)Q1,I9_3\[I,OJ?TG]*R$M4PR4/@JU\3X(M7$
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MKF$ -0N!-!("+HVB A'.U1I=]$.,\2<!0D2.BSPZ1[</W38/GN5XYF[-W7Y
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MD.7?YF(<__!J:)=_T?KD!S?NC^PJU?6;[V8PL\$6#C]<J.$7]YN:NC?>._.
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MM6I2)3S2@D.@J0XN!;<(Z*#H .:NQ%)QQBP_ H47M'>/<K0OA;=R[)Z7RLN
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M;3U!!LJZ"RFV&,04J]$'V'"#"PNGU64XPE\HATB=P0!\KNUQ32DP)%KJZ%+
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M<CU($&+^,$/(_SK2_/^H9A?6_*,%/JR&,TK#K"E98X5N2MVBPM)9ZY#+>['
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M N$S(4%?"_$_J<P+%HD@BZ+02V.Y%:^]5<JW.D,!^YO%D9^B!;>S"LP^3@F
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M Z,,!WJID\#!:&KX?*:)B@@4T7S1CNE[F^Q<+[%(N^CAVI8:1)XN3JV_3J$
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MH7?HWKK"+^#_6!)0?_28,QY'.4L2/XK\'/2WX"!@>5V;\X%LO'F#W>OG.*Z
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M4VA/U7>0*N%QGQ4YHD6$6<"$4H+%>1 *Y:DPC^Y4W6^]Q,;-V=V\ \$V>K,
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M+MQPXZ;*)]O3VRW&H:F_G4R:XI%#Y;BIL1F+VN9]5WBU@1^:LVC;Y1S^Z*X
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M@U.&7$C +I@E[SWCBNR<OSZY7W--N]^O2#>;X;>UOV\J3_GP9ZZ5Q5X7B_E
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M1K-@D:4NBRK)F1#:<;D3AOVH8H>!V#F<S?O0+'-#8<*7PS05*2M2OAZD# I
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MJ:]'BK\*T!6@*T _,D!3(@+5CB*B(P645@)990E2UGN*#=94[+2&?23;XX$
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MML!N5]:X[38,T$]TA_G?!LK7\KR(\WU2V\+6KS69/)3Q]'V>1[X<3>S%;+F
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MG2&;8*AO[.2CO6AS/\7M+5JO?Q'8!Q;_F#5^PN:BO5!VIQ#\:9O ;S'KYRI
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M5*A:X!/&V8NK:E'+\5= JX!V&-"PT9%;P+(DDT9<4X"I&!/"RF+FO%(!\^N
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MT@A#TB052>*2.WV,XEW:+^ZF"G4LN"U9^M*BJZ>Z(E?=TE> 7($ERSU@#V,
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M"*1+!#FCE;*::6]V:H4=4]EE701A'%?E$=+?5^41"A_VI9_SFNI5 :QNZ2L
ML"1\<!*47FI%]B9(CYR(&I& C:%:)*5VO G'E'9Y'  34E4 >UQO=M6*O_C+
MC^-/,70:<75XOQX>JQ+E2@<*EK#UWB$:C,SJK4:&AX"4"%RY8'RB.Q&:1_JG
MMX3*+_/<3G9Q\<O$3A=OIR%WQNJS#D(M>EAQK&[I:\"Q'&=N @\H<*X1YPIP
MC&J#(H_,4AQDQ'W'A#PBCI':SJ"ZC9^FF$NS1>95NM0HR!H%>4\)I86SCDJ+
M*"<!<4(CLIQ@A!7UG#*L)#ZJQ<[G)52?50S(ZPP5KYIWQ<:*C0^"C=9%FQ3Q
MR"OF$/>4(H,E18H2+I6.PA#Q<-I[K]A8H7%XWNZ7&;N]I[[+I.KJ51Y5>71\
MH(@/C$F/4<H^)!YB0)H[AI)+T0J&J5"X3UW]IZF?G<6K4NEY1F\_<Y%4T;&B
M8T7'FZ)0 -NXC@9 )F2D,Q+9"-HZM]J0P)R0J==P[0=$QT<.VW[FZ%@+NSQ
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ML%A\3OV27S3,*\%[E.*UP-6=)V&6#OG5*57M$G;W3/ATO9->=95NE%6%Z;$
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M>.R8K0P>,88ER5FR8T9O2<:.(#?$"(25,R,^V$:X3:"U:OF1+9:!![I&@+\
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MV.H\5#,=E1D@)0_[8&@J"]A(F=/@%C3,C!4X@B=TQ&RA"4)7]DQM#58F7P[
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MRA5+:\<R0(\I)D]J(7JE@WRD7E;B)0[Z2_Q/ I-VC$F&P"2!28LQ25,,4W<
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M/?H-^J9WTF]ISL.:JR.M^DRD_>(7*0*M9@F=\Q"0T13 *(#Q1<!H[NR40!
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MUU%(=W8PL'++S:-E5;E+4U?/R?E$(OD\BXI"^K^I[Y/.*I(B#>?@ =84 "L
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M(%P\U>K"2H5:YJFL&%$4$"/Q.DT6S P&S T=S0X?RHJ3[F8']$9\>C4@&[!
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MP%-!JAM!&:[R:K;$8C37FJ9EJ<4#M[WF%"(2.N;A::HQWKLEI'3QLEKV:#8
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M&;A740M(RM*P:K^#7?@FSG[%61$A_#).^%=0KNXMZ+@3T[OE3O<MP9Q=:D[
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MKVGNF7 @]V=Q&+(0_^ )(ZU-N@_TOZE/-\H>O0CE*_W&WHC_U]: Y.*>@>^
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M.;D[B A15$XFU)T\'>#!+1Q-/!%9J/N=,.J.8.JO,9EJG$>L2(<BUS*B,U3
M&4F=X&7;X2PGSU%2KAR@!RPSS6O;R6(:TF6G'ML,\I:^X!:K_!(9"E8LGX5Q
M'H?&,CJQ$5["W--VL2INX"-@H?J)7I@+:WLW3;+?[_ :UL//.%XGWO8Q\+UP
M4.B%3LA9] 43  ;Y4$VSBW5N>1/M;8VSG?V7!/CK<ZP5\O8>B/&DR/&W/,5
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M))>U%_Z*O80\S88$#?,[F-%#0! >>U;#@$VRD9/^1^"EV1PQS.WHKB91@ZN
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MN$F*:X*A6NT3Y^4HF"A&VX<0;0_8U#Y/9LX8>G#!4!%')COSDF1/6!R.U%$
MU3DN3D*-B1PDCD<>[)RP71052S.D)\IN9\[RV4 E"P4-)Z*SYNL$T^-X>'2>
MAG0G0](D^>-B*^S D9M(.^.L%=X(&HLR:,X3+5B/G&N(/;(1:71$[!1PU'(\
M^;GHJ3?@Y8]^<@2"?R> *@;J?7BHFR3G"LX,+$AIL(X )IB]H!*\I/Y PP]
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MX$DE( 9I_1;[,>E1R++IL12<=/$-]A8EK)+%RU>YIVA^"7P*E81H2LNMS-Y
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MCY(#6,R4<=/O<M0[DC%#ZB*@W7\70@X\@3V!2$=.A+Z9>!S 'CX_^^)C\,3
MKZUB]CGL&!HY8W1$RDOF>$PQ$<#<1U;X*ZO\,Z.Z:48GN(SYPR_BV&>Y2@;&
M8B\21WK9!&K+=4&1YKG4F*F,!*/0*?3)DJU:)73T8A$@2>$G4:::D_3%G*(C
MK5PXE-T3#VISOK)^SKQWIS+QD=TY+&,<^0B_'?P8W(4O'_!$',E_G_UO_<\!
M?91]_N'SG^=&1E"B@ P-!=>*#,O^@,-/ S4Q H7UY'Y$*2"4HJQ^0B+](_&_
MC:Y;PV<']<L^OP&0$NPV2#/.Q!V\T#Q\_Z DQ1C3CU^X%*KUR4](;1<XG^_H
MA%9X1OA7\^<"W=L<>=\1\B@#V,<N",02O)CIGU,"N6:O"?@U@PMT\P[_\P+[
M],('*\9;X0%7:,31H<(&IZ:,0BL@R=H\)%'8%SI.MS& $@W2!6\_!./X!>J[
M^ZR?U@R'_6X+QT4HHGC@58Q"!?=DZ*6R2&"E'CA.#DM.--L5FRXM-_IE&LX3
M1%!<QPY-E\7L]S"N4(S1?,@\#V B\\J %)4LQ3*RYG\V"'C(*.*##+U4%ID4
M']-P/F<@9R! MO&O801OVO@=P1!@@T%2AAI^*M59S0LOLNJ!764/7VN5-Y]@
MLS@_)V)026H R$_EXJL71;E*J-FQR2V%J27KL.?YI(Q16*YE%CA)LKJJU2]9
M#)/*67LYFY!;QDG>JNRZ,L6N044D,]9=HY K$'I]R]#GQC^/#K@Z^B 8/6+<
M.IZ,?U_DG&;3Q-?%Z-#N4;A#UGB$B8)>7#VT2S34=\A'@(M#7M WZ22*Y1!4
M\+L>DY*629F@VN763^^[0R8BCSQ5A7^/AOD#+BL19#@1XC&*R3Y-T]A_S5)\
MTZ81PEV!(CB%XP2H&5-5["6V&C<7C @).<!L.8OXD.LS$4+#/4@2 "2EN!E2
MX'4&_@6<^-9_[W73?/[A\U_G3@^3A/@S%]4"ZR65%:[M*X!W@P^O!/2Y%?K>
M!!D\!_C%NQ"J97WA-?)!;)\T<WZ085:3S3M718BN>X]P[C_W\M_P;R@R*-Q2
M:-C5Y\G<S0-25;IQ"1F3Z)78@]U' 20^<'OG6BH_"/:'*$;5J0 MCT**6(Z*
M+=R?A/+;[4H079=$ 12=%:2M\2&+X//0)<]5^/< T'JTZSVZOW_KA,U21F@J
MQK]8Y5_ #CS^&Y,A- U/;M".TCF26$:A*L9G8"9C9D30\,#CI\^O. .K;_;6
MI\^_?_T#"SH<-76N[\Q+4H]-'SCN&[&$C5[YB0E:@E&(2Z3FD.*\6O\2/3H]
M<'T+@<[J7;%/T;R+B]HC@GQO]@RH8@#4K[:)$N$GHI0' SA=6G7+;H]^@(G9
MT/,P(.$3<('_WA^%FQKZT*BDMF,^[F1XW,/2Q2\7'OD[!Q.'0!;ABF4A*N_%
MOC%Z[&L4@B.I670+OYRL4[8_>R/-X*%7M& 1(FOT_3<P,0%/!ZTKA<>]6#EI
M<6>,"J:,H_W*YI:[T"4>(2>XC.(X^H"_0(;N39B'A^-V/0, "]-+@$9#16/9
M9U>O[+O$$P[ULB*] +<>-[]@&G[0Y>_%AU'94 =[K>+!7N%ZRW<AN6NN,WC%
MH,*[68H0!_]7])JLW72S_?S#I[_TW"P"+&-! :45K?_LA[1RR\K+L'J%2Q9G
M%%WVWW!>*\?%V5QH:N/N)9-,Y&ZX"G[PJ@XTO"+S0$''-#OXFC /US5&S(/3
M6:'YK."$4#HLFM+)\JZ,:<:J6^/#B4ZIH'J7*>ABQI,G>%Q(1.T BD.^/THX
MGJ.GD@Q&2U A PV85^<>6:VKP1Y<H<T9]P3(R<$.Z&BVSUZ%US R"6PW/4 !
MX21O^/A"#?CR^#4!WEUXAPL0H"<2*NQ.\C_[U=)"CD/TI17[%(HP^#WZ&I08
M?UCE'UP57YRPS/KX;"B]$!$?ME#V,1#5G'@G_\[T6>BG"H]PLIP,ZDPL 2+,
M$ G!,@P$>\$/, MO]B#>P8__!%] Z1N%5D,1Y-FPI>[9=U;D0PS$;44^-5L2
M QWJ#-2T'Y/FRL[/:=\1VEU*>T)H/]#/C0_D#79H5D_@@!Q6X6[PU$+Z@?'C
M8,<@)"C1L,H'-YD-"%6E XC3XR,<((4OR1S>KW=>((Y;O/??\<L[W&$[.GE^
MF\H-1%;@H9(<_S\\VOBHBU#%A*N"_D K ]_<:/?W"(S%.BL!28-_X<:<#@^S
M#)>T*3#.>V))<H6.:5@&AY\^)[J"$DD4D)J,>K':S).FJK^TD;BI8=.')Y9W
MF6J0.SF$^I 4-X=(37@6M8N,\QD;O?7/QBKC$][J$W.@],C KGE!6HJU:3J-
M=3QOHW@+_!1R,YE_<5N.F-,O;SOFRI5P__6KKUXAT1X$D.=1O-J2^8T,O+_9
M;N$DUOCNC6(GC>*.2%Q5OS8>%VN3Q<@C^ZN'(H6YI$4D3 ,\-!@I_$84TF,(
M2J'7ZU$!#S'1ZW%0JHQ"1.#MUBADD\Y2]H8(.Y)*3="N*M*6MN@6?E^1.B3K
M 1<_PW:N_*IT.%K079EP#0_TKG00031L<>5S5V547)41H8K)<!RXZH<KHM2O
M/MB5*1;UXXJ_^2XBK^<(X<?YQ;L\EG#*2XJ.7,]YX?2<%4<.BO.@&&PU?8?1
M-&X6S<S7KJ.FP\UJ_/<.25-'*8S]+]$\Z1T-9__4 \&L1U=A4.S$-17,R%3<
M==)TB%&SVOO.M;0WIIAP_C#"OE1<X.HZ0^Y)<K:)M8;$IR<8_)N+52\@N?M!
M;=  0UP/EH46X9J4L>>'*/:?V76VJ[O-ZM*/4N"^K=:'9X3M%)7]KZ4V.-/\
M^[&+'9AA(;OE,-7DJROR67H#%;:_XMO$X5\D&XP/JIX#8J)[A.8BTPHJ_8+0
MR$7,LIOID),E%PQ'3NE)A48=53.HI+6LO7]G";QB;Z/X&:1I@)6#S?8%)8J_
M@<UKX.^PZO 0A3C8B: U#)F7NW+H%)"!8I7DDT [-2736$7Y/%9A1%&,#F0J
MI\>LH,HGJH2N>3X]E_A$9[ JIH#P,VCLW*GRJ?)4&WA?C1Z^D-L"&38&E,$4
M-\S;5"#!:@!B9?RPRV..KX'!O'H90SB8)OBNS0>F,&%3&42LXPXOPI0LLB?L
M=+JHV_G27,4IPB(@([1.&F/+D4IL=@@I:?WN^ '),>4<J&]1X,'=B/:^VY=>
MA"*U<BIITTR?1MHC_=C,R>:V=@F):I5_"M'-.\[IURXPZ*8[<_)%V&'U5<<"
M?EUY=(V\_JPL L+P=W:X!"\!^MJ$* S*C7UL=1K"EEM\!<?<,FQ:M-&Y+TUA
M61V)7KK).3HWVP*#=P,W-D_G^$;(D<BLE";17M.IDJQ>G&^<TH)?='W3K%"N
M(#?FQ6K4=^((!-7>N#PYLW?Y(UV$F%SF$I%!]!LRYP6SOW0O9LB&C<3(S]BY
MAS#FIHV?:-!V;^&M#%\UXVOX^8?,:_@#T"S4\ \<X=N<W/&U_"(+]-8/0'SE
MI& 7]4UAQ4.MV%B63UV0OSK-_/DH]]L@^D  L_"OQ1LR] 2[K0AN[)G+BL\;
M^N[%BGZ9>TDC7X?HU*V*ST^8V#HUA\KQO,_9X1 PI XO'QP[?\(H_ ZS3G1F
M_\>I\:5<)4J#*R)[Q6A<*>(,$N)\RDUVK"KP$+$W"4Z.1$9<9'-[QS:WW.T_
M0?S+4+3QBE["O'6<'1&.2[2[^9!4VIZ-:S5!!!V&$+D&Y,^[$&N+Z*P2MQQ.
M!]/7'OY&B S!#@6QEYXN^+R102E&R=R(JX4_$O25W[/Q_X!>!X38XALDH<X
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MT/TW9W_XG]>,+5/FA-\X,2J=FS#@' S)BR@C9H_A']#T>P5($$4EQF>%?M7
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M2>@+\'I'OJ"/7M2RBRY6Q;16I FZ]2L_+/?(Y[MB$U[A&5,;=3'G53'I)2]
M'9*(,!K7MP!<IA?B7UQPWL6M7L'.#Y%3 *MFDU2WLI^9!3!5&U8"G#1[9J(
MH,D5LO%"Q$<#X2\][=22D)XV9NIU[)9H<&*7303^M6$NM,4?D3L9'-+OR+1H
M=Y0'3E!QUG#%TRB^]>/]G9>S+!+\$O/ACX:F*JJ.KJ?MP_W+E5'/C32"*NJ;
M+:VC7M1:YQEB: I&V9Z#H((D :"L+>7ENIFYX#H##^!;^O(!@G?P!0J,MX3G
M7]^QK& $9^U'RPI7RRE^P@'ZT[QL$?TMAS!*-H^;A:>&L_B> '(2586%K)T5
MZU9#B+X+,?I&DH@C:D0+UW8,*PB'9P<<OSCQ?T!ZFX6>8E^*6YJ7^E!E0%!J
M47RLSUW8P J^,T%&L2J8$? *F2!$W%>U-[\&7(8R2E 6[")%,RO60R?:#@-E
MY3\*=W<IV"?4:RM:L[YC&F4,"I#)L[5_ M$N=@YOONM@'QQ/K;*A^:U92;X"
MR"?&_O4"XGUMDS9UL&*[YDHB9^"C;D!O R]65,P'3AHG87\-H]<$Q.\H./ N
M/&1I)0^1Q0N*MO 8WS&_)RI:.J=\%WJU0/MNTO9UQ[%B!V'!PZUJ47]0M _D
MK:T@IE[X[C$&!\?WF$[&X!)##U-"]#,1H=U&LH()^5G%AR_! 1.?Y/J<HKD5
MY.@]I3$%^4M:1&>7<8P_JDC%;H+R=QM$3NTU56M@XYI=^ZCX.WPK%!7K-%9(
MT,L*XG0-$_^";[W;*!,>NK9C6$%XBTR4*!2>P78C6$&T*#193U42=;""I*HD
MQ%9(&O+]&_!TA&>EBQ5DY7N*I/HJ%TG6U@I"I&%47Q.PS8)[?PM$-&ETLT[E
M;L3/H[ [6VW\O";E?/@O6K%G6,3',WQX^2X01\8_(+L+>IG@2/,$>]?XWR,K
MTD.4_@O@)]LNE$F#T3YF!2OSY*EU$$0?R+I6M>A>X1UT%Z[W"+1,Q*&V8QA7
M-._<;4S=>.LTA>N&9W\;.+NJQBEO:5ZZ$!W^Y0,*O2/][UL, /Q/E.W>^)_?
M0B5$8IWL,HAYTK%@@I+L9^PE2B4OF[Q*VF/LOT/5"]X5KMB#V7,\XS;+%S\E
M)90]](S(G.!G/WW#P79(M7SS#R\1>3N1\/BJ);-E=RL$UW/VFN"H__3F'<=E
MJS0@:6/S6[DH5$7NXIKA3.97T.UHQ6H)56IRGK0U<-+<"G(D;]D&<V)3)RM(
M*_+NL5"\/&(<>)QD+SQ9\N96D$-,E8)G*HLY$D8C-'6R@C0>]O_>#P'VHHG(
M$3:T@@3"Z"OYF2DUL&+*G#\ H0G72C0*#6 -?:P@K!;)@4W]6C$?N*551$CR
M8$7XA2I!T&,X*]C1V7]@O\. Z4#(3876 ?%<''*$PT4$,J;;"/:L:TF$H- 2
M8M$Y!'ACOL-?H7 SM"L_29>XQ1A6$ X/(EP#^!)%Y:&07R$22BA!,_.;5>:3
M8R%-3<:\6@<K5@19N6+P!J5B[NEX "@ P/DFU$7DS8V;A> +"@-C'/>O4<!/
MOO9+*SA?NX8A([6N:]C.WM,@"AHO1-%FRX73/:-('*Q5:1^=3J-;L=HUH[W\
M]2QI:G[-&\UL_'0'L=LU#&C%RA:N_TJ0H;"!%5.F6I,P+$CQFM/H9M:4FA[B
M7[Y<E\RCY$=6<)T)<J*.$NPIY$BB;"WS4\_2T7-(\R*EK<-S2N?JW-RJ+-_;
M)T_9:R@IA2\'43LK"*B5K1&^>X2U;4Q/O4V,%/;0]0VTPH-803IW**@$(DN$
MWN+Q.TD/S%(H==C;IT'GT1O$"M+7KIOM,XQ:@>6LX'6DR)G3[6Q>2C\[ 4C6
M.[CC"N#1NC(G:&1^ZJ)D !(V_!+A/S_CW#XH_Q,2W?"I1EC[(:S8G+)-!8\2
M\'<A4=C<(Y>=":\__"_B."XB6=D+_Y' :*[3-/9?LQ0#-T>/CC+^?JH)6,%R
M.65)F;1$(^RO\V#F=?"'?]5T\(=_6;%"G#&%.\W2:,0&>XS.$,;-8B3T8^UY
M\#I-KN!?-_%+]%$*(E$TLV+5>.T@M_;@_*TF7:+<V@IBROI=I9 CAB6!5P@*
M-5=D:;8=PPK"I4=$*0:;>YE7,CIC.Y.7Z%T(G^,9295&=^8+?)=N#EBTWWR#
M"^@G)#T1WGKP&G6Q+E)7OZ:?@WG&4\,AO0$5EVIS:RN.2"703?YX$#:TD807
M^#&98532U HR.'QBG&N(C)X(N8D9<Y%P5>!.:/<V?X9JF6RU6FE-EC19>373
M:PB5&8S9X@2/CN_=A=2RH'B2JSI805(1KX>D?!02> U)?$NYM([P!'8?SOS&
MK<%*,4MN$51;V[D:?:Q8YSK$JLH-(&]M!3$E#U%SX*9-) B]T?#:<F,?*T>/
ML>\"5MFJT8TMZVC%*N5>$/QR>G3B38PA4DC4F(C&=CVM(/)N?W#\F!S\^PB^
MG_QW^&["V^[O($!FYJ^)D$:MCE:0F./:T)#A4HR8ZO1I=;2"Q#P?S<4/710N
M )\EKG\(0/&C9^0?0ME\7P\>).QNCXKLQKX3D,1NH>5@@'&M8)#$AZ3P[:M[
M6$&4U!(@"9Q2M;?@4OF(7MZB+(&;B4O<NPN]S*7O!AH#B:8O<;ET&,.*E>0S
M&NHI;?)65DP^=P<1Z0\WEAIGBN!AQB78J7H5Q>1>E0(R]C>M8&Q31+/XSE+W
ML>J<K]DQW82 6=U:'7*M <R3S*$!-V8YRKVM&IVMV+8Z.#'K]!; +>H$2,?*
M$*QGJ;%H9P\PK!7L05:]S9:S0\NL@<*&EGC/K@#*+PG@S0J^_0.4DL2DC:S@
M/A(+#\X>R&_9<@LK)MU%#5][T2&5Q%-W'\X*=B"S@>_Y3GS<Q$3J?P'I6^3=
M$<P2@ )O\OS=>F/63)X#/.#X=C!L-%<8%W98<;KFF*LL%2US H2\*G9\V#1!
M*Y:,5I9Z=.)4 (DM;V7)Y/GJ(VH4 5E;*PB1)L[+C;6"QN854+YD\GJWBW&%
M1EHJIE(@YAH<HL2OW!R=![%B%<OF6*V@ZH8N5I EJD6+@&YJ$,Y)64DN S[G
MEJW"!:1^<0_^-2N82>UZ-,:PYNH3JE'J+E:057>$Z;G++'EF0*;>>>@]O_5=
M@DN75:_"QL;FI>\DD4AFXI^LV.3DC7\?)0E*CQ>!6%R"+3REN2T 0!*@RA?%
M4)9#Q1U;_)#F@13!* A0!8<P!:@ZF=#S-=[GK&!G^>[3B"]5=K""I#H@?.[>
MH2$M*C^@?F\KB*WEQZ.*=V7@^Y)$"#UZ8R5BD5'%<ACS.U8PD+ZJF,^@>&)A
MJZ(TK5FCFQ7DB;+JU'"#ZAY6$,6L=K+%X7]O7B,@FLEF6V9I/3A+V,PX.N<S
MV%7+!(EQ.*4-K=@R\OHA%M4#(<9$ZKLFX#+B*ZK6S(KI5^HP(0/<9OLU(6[;
MYK"+2@?S!U=6+$A1[K,I"$YG#/.$X]B#2PY.IJSTR6K%Z?2R8J.2'"D\W[7<
MWEIO9<E#^0GL?*2"ABFZY,3OXW(;*[C>U:B4FY'R1.--AN(04?+QCT-:KY0?
MLH*%1#>[)^^3/)KV7A4\T]#%"K)XSX;<5UMO9<GD4S@5^ IR8N1@2CAD _A
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M0FYDB41GO[9ENI(#?:\RK6IT,R_>G\ V"SWL4ZSKF +M5-':/#$U49R[%L6
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MJ)&K66]N!3E<MLM+) '&QX?MM:H9/@%X$A,_92\-\C[@'@=2F,.QOVD%8X>
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MXL5OJGH>UVOK/*[U;A>#'=P#4#&&5T_BNP0W0VW3,3D?*Q:$BU_A*R+"OP>
MVDG6^RA.J0U%ZK!JB(WI-;85C&K0CSNHU%:0]3/P=V_("_L.I[H#[$:K&3>E
MQ2]:#6 %R67H[4L5M(*@H2TD'."+!9<ZELP\_[T5$V:Q<0PR^%X)<BAK; 4I
MDIN7VH][WM^*4:P@7@PE3@4:"0$44:O1S0KR1-7RN+)<(M(:NIA_R[0 (2M2
M5#9;+F&R>,O57D!##F[%#LB]/_)PE5(+\^M;27^H%L:H+5E#>SM601 2Q&O?
M) ^9*-IH<Q&M'>Z[/?E9<UW,8;]@_,E?6*02E.A(X^3<K'1BE0VM6'?=BL&Z
M@EC4UPY".6A0I9-!V- .$C3YC2"W7SZB/DM&A["";(KD#!6W+9P]=A[< B J
M1*O7PPJB\CM-J9?76YF__3A-HE)G,V'E887W0.O.YDG%2$7$LHF"HY^ OW_-
MXD0,/:MJ;,66Z^DL( &!PN,VQ,!6L*BK^RV1^-^DT3"C?,C\@:EBOCSYR7]N
M8X 3>U2RH-;8BMV ,!+ KQEZ-[\W2FI)6RL(H4@U<KM;J8'Y;30>]MS--Q"[
M?H*.5\6,^@10'C$\6%>T@GWF!$)<(YLF9\7N*AYV]2(<I1BU-F_$5D-9P09J
MC\GOO]OW!U]E&FC3SPH"N5Q7N22I-;)BZE7[MM34)&QH7B!R10EXW)J:;)*T
MLV(-Q$",F@72&SM:02*'0Z^3D(F@G%VJ%%=3+G%A/4U9.?#'K&!E50(RY9!/
M!I9+(?W>QNV(!("5$YO*S!B]'N8%UC.\IUT<F1^ XZ43R@JX2]I9L04Y89JG
MJG#:F]SWIM71_!J1.M@UBPS#>9*LF%8O*]9/;)90UYALZF.)N$ G)<X.J7ND
M"8[(GD+05- C056"0ZNK%>M78/D0$Q(&[X!S+- [2.FK//00H#H54+J+PV9Z
M#&<%.P9S(P\RH!4LT2GO] AIBI$[@UM7X3.LXUC&)<)5A*J"" )?:K^T8LWR
MC%A%H=]R$RNF306C),Q9)$V42=N=1S.^W<KN;'08-+S>>3/S6D^ND6&S4@-$
MMEX/*S8H!^.+U!52O9"6BI0?M>9>5A#7I)FJVEE!@/A-3NR^ZQ!E:,&S B\?
M%(FM>%ET&,9B\H<O)E,QF^-?7L-K/#^T^DPU,#GSPK$:7)B]YF&5=?>O7@_C
M%Q;567,@'R3GJK>5J(T5!R</A'L![EOH_YH!LK6@)HIBEK]$'@CDXE"_MQ7$
MLN<6K3VD*+(F:F@%"0_@@]:O0^^I. KA7PG&4*(-WMQV#"L(+]^\,B=%<VMK
MB:& T[_I$U3T,"_8'[,82K8$H).?(].BIWUN1(;J XT"J,GX-ITM63])7MM/
M<92T@X7$/:P@2L= <85OK[OP)G00-BYMT]7<(1[-_&:NU667F*HE[:Q8S0J8
M3QOX'N7E,<2X5C"(FDA*2>9MRHFH.UI!XA-Z#VRV7Q.R6)O7%+ZW44X:4T-O
MHU@2JBTBO,=PYL\T*Z;&Q4"5KIO:X6[J8/S=0=PM-WL0[R"_X3WRD;ZA!Z83
MEE:OH:D5&Y5'T>2\ 0BF6W*9RIJ;WVA<IN!F>YDE\(@D"0]:B /-X/7O(>RO
M:IQ0QR%F1O:]*-*UQS!6;&*IRYI_?GP]L&)AB23[M,,PQD71&FJR'K;&"Z"5
M2K^T8J7@;7T%N>J3"*]M%"-CFSS]0-'<"G(XN":2E]0Q)+:IMQ7$WCUNY':;
M_)=63)7W<9-7+-XS5ZQ6H+#20F,G*T@K'G6E!UU^4A(&#R /E-#H; 6I6)%5
M.EO++:R8-#&6:];GE3:V@A2X+8A[0^YDK#0QKPQ122K&R,#!L,V9C!W&,*X'
MD'?&K1](:O96?V_!2J4O;^"+$_\'T"+W\&VQBQU!!0R-YN;)*0H7P7<Z;!JC
M)SHZ'E'BUZIDZ?6P0@C4LG6DAE9Q2_,KP^>MD#HJ.9S<9@NGC QG8@^H=D\[
M5BJ_/; !GP-9QZAQ6'#5\/>4UVN_$6U8^7(:ZC\C.&^&GBLH4J;=R8KUII[$
MA,)_JT$3!"VM(*)<#TY6VJO>RHK)CQ=>DA=TLRSL17]>5BQ0[4HJT(>"(/I
M)8.T;K)Z-RO(RTW^U ,B!@"L-C*NJZXS^-2,XGN:M%:S6I5_;06GZP8:^"K
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MHR<'#FH*+Q%*IL@PJ/W_@L^%M9MNMI]_^/27&E.&'-R* \"F_X2BY$G6EOQ
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MNPC$C8U-OOSLDTRZTFCH2$7);9\O<.&P%\<KMND_@UNW]VT[] +5$/589C6
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MG4!UTG7Q-N$3<+,X)G6''J(P9O_$[B2\9-HXZGV&-L\8#KQ,0 *>\]<P>DU
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MMN'UKPZCF%OB=Q C!S6.922A \I;3-[>Y%+ %P>X@WNC*C#ZC&2P^@]\8(7
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M_O "%9C0AX=5N3K2YA81L,%Z(N*S'^Z^1!X(E O48@!C1-XZ?HSF"2Z/!1
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M!EB]BBT](4,YBQ8EL0E#CCX[DWW-,5%#7AFPFWSAPBT+)EU= :>+/ :02QP
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M22[4[YGM#,WE*L&;ZR9,D8][,D\?3DM#\VD^<$MR%40H>$ZNT&V$_X:"J^-
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M89CQ%J616)935+$SB"W<O>]=';N_R,]$E0% $*DI7.V?#(W\&>QDD:(B[@/
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ML--K8GVB&BMM/U%(1W>_]M["W(O*.]X3RE#Z3FMKW!4YEM7UT<.A2W^<15/
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M62#KPH(/LJ=<;A7\2XZ_DYXH-[B.*L=?,4\W<;>.+\<K;4R$0,.IYGBIBXD
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MB8_S&@>E1,+YPDA.:]P-G,'SBXOSV["Q7,VJC*:;!'72E**Q2VU@^#QI:IF
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MJ<]%@YPCM,6<B[S(*O9$>\23.&&9V#80-X"!TV5!4&BJ-"CG:[8.0@@(,.G
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M=VT"XQQ!.P4G"L[K6F>*9CYT&XMDQQB_W5R,#42P15L$=1B)-_\VN]A)1F;
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M,*3_HP1M2%?BSS!Q8QL?<IFN%?)^S8R89=WM[K8_"DP#)!( I V@G(?LWR&
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MQM.CF<XWS_[P]&AI5\6S_P=02P,$%     @ )XIE6.VV,1$&!   4AH   \
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M$<=,)J/#\C6F+B,,3W.I)ASNCA/E8PI]P#'@Q N3NOHC:)V>1W%0$1G#YQ#
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M/?ABZ=#,X#G@(294:0+//J)R3"?6!X"C/?QZZ_%/1WO^B[%_ U!+ P04
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MG[$D6%.44$4!ZT?0YDM8( /T**)*LWA60=E8Y6-(1TA+M'2K-Z_]L_.P\"K
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MC\TN-P'&G*&B^$-@_SOF@PWK+@5IY>9Z/M2HC^94$6%>:&FNKX5R55'-6E.
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MVA#)>"&A+42#U.2#DV^\P#?HAXK30Y)=D@M%F@U4("<KIC^9 M%/89R M,%
M/!L;Q*VSV/##!7%<("^%$5"Z7&\ERX=-FSVASTX>/+RE3P+CC,-$<@4?WK:H
M%*N#F@K12>UL6UKAV/F\M'/U$P?KB"Z\O?*SV+C^?_A&TUV8O >G/%SM\]E/
M'N+.I)%(H(S-5#'(-5F@D)]E0E4(II.Z4H7SU5ZPE_4%-$Y:LHL5XKDN4,1E
M;0?83M8##2Q)91.?I5IR:!-*Z?%K VN1JJ0+FI_)E*8:N"1T(ZDQ9G1%SLF\
M).ZQU^(W. ,/'HU-8S<-1<022G+>CM@MB.0IBKE >DZQ7RB3$\7[<@F>YO-'
M=]T8,9E"P^PE J-F>[E).4D3C@C&CQWS9R#"M4&??65*61BZ#4/M)"I4T"\K
MM3V#W2;(AY]55"VI.&)2X2EYK&2$$0%(.4D#-984T/)U1MK/D]IYE ,#H\PG
M^.PX>HYGH[U$M9F@X/! &3I'/N#8'[P10ECL!R=FY1^?P6W/5V#@)-#2FU3*
M-6LHB$;8. 7$7E/'B9T&0YENN\-.=2%'-Q@W(5>2LP;U%9\N"1^#:V;YV#V;
M[T)R&RP@;)TBQ,;4<(S>YZ(M;>)8-Q@GMMZ6+#FXZ*XLUC@&;<-0#%3+8SF.
MG*B _4-VT6!"C#YSZ'$%#B5H&4, _[]C K-)91PFF\XP3.K2Q?!]*Y?(M41U
M#WG6OG8Y *7]VBV):)>D<DM"A]?>)'1ACH&J7.AUV> 5#J7X?E=AE)0+OFV(
MHU?'SUF1T*_:"Y-EG:>AHOFC&?1QB[3MLJZD!+GB K@WXIU_ 3X!:-T86<.Q
MGIW,3N:<P )/>0V"1;G219M'".IZ\&0V^R9Z^OCDZ/3DR>G7?;Y_KZ&-I@C?
M%S#Q[-N%3K??_>G9MZMZG7_W_U!+ P04    "  GBF58\Y2*WMX.  !]:
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M/ 1GWDI8[U,)Y[.D[3@PVM6EM.S$HIVA#MYF=,Q@U.W^&YR.B##O/FP3+.L
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M4$L! A0#%     @ )HIE6,QZG@_76P$ /K0! !(              ( !
M &EM9S$S-# U,3@R-U\P+FIP9U!+ 0(4 Q0    ( ":*95@<CMQ=N_@! +1;
M @ 2              "  0=< 0!I;6<Q,S0P-3$X,C=?,2YJ<&=02P$"% ,4
M    "  FBF580#PM_N5=  "_E@  $P              @ 'R5 , :6UG,3,T
M,#4Q.#(W7S$P+FIP9U!+ 0(4 Q0    ( ":*95B63I/G:H\  %#7   3
M          "  0BS P!I;6<Q,S0P-3$X,C=?,3$N:G!G4$L! A0#%     @
M)HIE6"E9.(I+60  HG\  !,              ( !HT($ &EM9S$S-# U,3@R
M-U\Q,BYJ<&=02P$"% ,4    "  FBF58/V>/XB5W  !"F@  $P
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M,#4Q.#(W7S$Y+FIP9U!+ 0(4 Q0    ( ":*95B):LK.)GH  )C.   2
M          "  >@." !I;6<Q,S0P-3$X,C=?,BYJ<&=02P$"% ,4    "  F
MBF58,FTF,<IC P!N7@0 $P              @ $^B0@ :6UG,3,T,#4Q.#(W
M7S(P+FIP9U!+ 0(4 Q0    ( ":*95@S+H#RI_H#  7S!  3
M  "  3GM"P!I;6<Q,S0P-3$X,C=?,C$N:G!G4$L! A0#%     @ )HIE6%$A
M^4L [P  )C4! !,              ( !$>@/ &EM9S$S-# U,3@R-U\R,BYJ
M<&=02P$"% ,4    "  FBF58PJRMV'9U 0"LS $ $P              @ %"
MUQ  :6UG,3,T,#4Q.#(W7S(S+FIP9U!+ 0(4 Q0    ( ":*95@%"?6:3I\
M +_P   2              "  >E,$@!I;6<Q,S0P-3$X,C=?,RYJ<&=02P$"
M% ,4    "  FBF58-F5P[4B/ 0#9N0$ $@              @ %G[!( :6UG
M,3,T,#4Q.#(W7S0N:G!G4$L! A0#%     @ )HIE6 X#2)9Q@@$ 7-<! !(
M             ( !WWL4 &EM9S$S-# U,3@R-U\U+FIP9U!+ 0(4 Q0    (
M ":*95B?\W5MO<P! +$^ @ 2              "  8#^%0!I;6<Q,S0P-3$X
M,C=?-BYJ<&=02P$"% ,4    "  FBF580E3\ZP<. 0#7B0$ $@
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M,#(S,3(S,2YX<V102P$"% ,4    "  GBF58KB7]$5D=  "(K0  $
M        @ 'VKR  :6]B="UE>#$P7S$Y+FAT;5!+ 0(4 Q0    ( ">*95CM
MMC$1!@0  %(:   /              "  7W-( !I;V)T+65X,C-?,2YH=&U0
M2P$"% ,4    "  GBF58H7&] LH(  "..P  #P              @ &PT2
M:6]B="UE>#,Q7S$N:'1M4$L! A0#%     @ )XIE6%,KS8>V"   'SL   \
M             ( !I]H@ &EO8G0M97@S,5\R+FAT;5!+ 0(4 Q0    ( ">*
M95CL)LD/304  $4@   /              "  8KC( !I;V)T+65X,S)?,2YH
M=&U02P$"% ,4    "  GBF58@$ZNRC<%  #:'P  #P              @ $$
MZ2  :6]B="UE>#,R7S(N:'1M4$L! A0#%     @ )XIE6%CX^\*-'@  )Q(!
M  X              ( !:.X@ &EO8G0M97@T7S(N:'1M4$L! A0#%     @
M)XIE6/.4BM[>#@  ?6@   \              ( !(0TA &EO8G0M97@Y-U\Q
:+FAT;5!+!08     (@ B '0(   L'"$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>iobt-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iobt="http://www.iobiotech.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="iobt-20231231.xsd" xlink:type="simple"/>
    <context id="C_f4208fa4-bfe6-48ee-94c0-37e910003209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="C_a0cd7c29-89c5-48ee-ae9e-0dbf0ed84a0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <instant>2021-11-09</instant>
        </period>
    </context>
    <context id="C_fc58b312-a405-4ae4-8b50-2ef63fe4fbd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:LaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5cfd6318-0a41-4064-a4cb-7e43fe8305a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b417c094-4b8b-413a-b777-f37fa824d616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1dcc1f3e-ab3f-4d97-8c1b-44559a31ab42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_2537fee5-7e0b-4dba-8a7b-1ae868729ba1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_49c77671-362e-4825-93e3-6d0010545188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-09</instant>
        </period>
    </context>
    <context id="C_fbedcb5d-67e0-47f1-96ac-c9bcc05daf23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0307f33c-16a4-4f72-98f6-13168e29e650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="C_7f69509c-a54b-452b-9c95-a1abe33fe007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4f734c8a-b5ea-4a27-879c-88db0c526af2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_37d816e8-ef70-4e8e-b59e-b1a42f867be6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a8dd0b70-be88-4ed9-9abb-fff49a8e9151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_921dd2b2-b1d9-4630-914d-9162f5d60817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0ea23d1e-bc0a-42c8-afab-71532c2b7804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e8a83503-acc7-4b7b-80a3-5d4810b2d5de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iobt:PreferredClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_57eb6f8c-679a-491b-8e02-004bcdd10820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d1bf34e5-9771-45f8-8bae-3cab72620d3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c4753ff1-8839-464e-bba4-852e1ac3dc55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">us-gaap:DividendPaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4f7c3011-7c33-440c-af08-6ace8d509cd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="C_1ae0c7b5-ef8e-4cb0-93ba-4ebe49f60bd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iobt:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_57a8bc27-67ad-49ea-8c7d-a4bc7bcdaabb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fe4a2a0a-b6ee-4598-80ca-db97232d35b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_43f3828a-2a64-44ee-9ffc-49729d49c629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f7a68159-256a-4ce2-b281-a534093c1329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iobt:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="C_b46bf404-a97b-4035-a273-403e9d7a9848">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eff12647-8a9c-4060-a740-40ce3f445548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_61743499-6fd4-4641-8e5f-157d373726ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_75385bc1-6f5b-43da-a2b7-ac643558b468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4610fd3b-ca44-4e94-a210-d0913cb10978">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_58193eaa-01f7-4f8a-933b-82502af9abe4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_589be980-c3a1-445b-9010-4a1c2db1e2ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cdcfe8ca-1864-4dc3-9e85-2db43b36cb88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1089e4d9-f1b0-4539-bd02-0c5b3cebf7f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-07</startDate>
            <endDate>2023-08-07</endDate>
        </period>
    </context>
    <context id="C_08166775-fe5a-4472-96b3-587d9d04a349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iobt:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="C_b343bb6c-f4f5-4b19-844e-c92494b10a7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cca131d2-c4bc-4848-b12f-0a7cefd61f16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_229bed5d-8df9-47a3-bf23-b8454739ccb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a0939c61-54dc-4cc6-bd3a-04cc2fcd2c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_ccc9ec90-8753-446d-ad46-4614b4157e4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iobt:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-09</instant>
        </period>
    </context>
    <context id="C_ea391396-42d3-4eff-9bdc-69880686eb48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_77688354-ad09-4f13-a478-c216dd6f48f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a0c8c506-94c5-4204-b3e9-4087e11e4d77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_58b5fcb9-88bf-4c8f-a0dc-fb732ca6c6a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_95e6310f-8da5-48b8-9242-a4b89a5ea523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_85d6429e-66de-40ef-8389-98da77aaac70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_735c9fc1-57ba-400b-99d6-3730bae07801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ed65f1e2-5595-4174-b58c-577f2a1fce62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c1c118ba-3d68-42c8-9af6-0389748a393e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d6fcc15a-463e-4377-ad07-b2311c2c2577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_deb3bb46-923f-471e-bc2a-d3f58a8d1640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_65b6ebb1-4040-4de5-b896-f3c903f4135b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2a3ed7cd-93dc-4db4-bb66-a7f11ce29791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_aba91903-9247-448c-a45a-f748af1aed15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">iobt:PeriodExpireInTwentyTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e7f56205-a6d1-42a7-bef6-62ddf1cf7159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">us-gaap:DividendDeclaredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ec32ec8b-699d-4395-8839-904cf311de78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_605c651a-ab13-4d27-8446-969fb0785085">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-04</instant>
        </period>
    </context>
    <context id="C_785d9f06-9d6a-47bd-8cd0-ef70f3e4eef7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2af36d65-e5e9-4e90-8479-0c3a9a9006ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_546c8f6d-7b20-49cd-8a0e-b394348d36fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a8883698-bb05-40fe-9155-b8dada03facc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandTwentyThreeInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ce55bd70-3918-4ae0-9cad-0dfde777548f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_a179b419-8f22-455d-a4ab-2a0aa92c018a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e2898211-1ef9-46ec-9a67-2298c6e5e1c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="C_6f628d94-953f-4311-9f9c-e89296efa0d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4193a798-b6e0-487a-bf56-e3158437f049">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_09c04cd1-1667-4969-a0bf-6219d9198637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_4842f3fa-8b43-4d85-86bd-f8d28ee08613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-04</instant>
        </period>
    </context>
    <context id="C_203b870a-e8de-4c48-bb69-1f143a5d1919">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_41282bac-d510-44e1-bcd8-e9ad005dc1b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6976c5c1-5909-47d1-9d43-69c889de3121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iobt:PreferredClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_5265fdb7-64e2-41ae-bedb-28fa9d99cc76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="C_83696999-4b34-4804-9e55-9bcb95f224d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a27d25f7-5479-49f8-a811-d80dec1dc3d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_62f128f9-8dcd-483d-9972-ffa3ab6dd713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_204fa06a-ebbb-41fd-82ba-760913723921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_86125bde-a241-4410-b61b-886b4c205d56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iobt:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4aa5700b-45ac-4ba7-aecb-189135584209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6bfe21b8-29be-4452-8c6e-25ec17762b3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eaf8786d-c5b6-4a4a-8524-1e92c7607db8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="C_7888a195-a9c8-438b-8292-c9c9a460c8d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-07</startDate>
            <endDate>2023-08-07</endDate>
        </period>
    </context>
    <context id="C_93ef2e83-0050-441a-9dc6-7635a9140a67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">iobt:PeriodTwentyTwentyThreeThroughTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_75c24bfc-711a-4d8f-a9f1-617a36085040">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c457cad7-3e0c-4a59-b4de-aa28ef642dbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1bdcb713-0037-4abc-ba55-93260da29f6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">iobt:PeriodTwentyTwentyThroughTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_856ab70f-a3ef-4cca-b917-88f71a19dda0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c6520b4d-f760-4dd3-8633-eeeaeb10c4af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_adf457e8-e0ad-4c0c-aaa7-41e091effa59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1525e770-dbb6-4a8a-b414-dae67b1c0c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_05adc53f-1ee4-4206-b227-537d28cde4b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_af6f9339-383a-4c92-83a8-eb2b5990df31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d68d18d7-93d7-49d5-ac79-3f37468692f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_77b4e90b-4f57-4362-beca-0e8dcbcfba19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8a8a956b-e82c-4de3-b66b-515c278c6057">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2bad730b-2375-4c64-b7fb-4fb30c1b1ef9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dd5861a4-c39b-4313-99f5-dd1a1dc0195b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="C_d7201268-1a27-4850-b9eb-b381cbd53051">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a06c72c9-9013-4145-a984-c7a878870eb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="C_6a5e0744-7a0e-42a8-87f6-2990329c4ad7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9b50e362-cf80-4463-9c3a-8766edfaa5cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="C_0d4b831b-94cf-4ac9-aae8-23f925e98a73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Lease">
        <measure>iobt:Lease</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Vote">
        <measure>iobt:Vote</measure>
    </unit>
    <unit id="U_DKK">
        <measure>iso4217:DKK</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_8d9f799b-97bc-4727-8d6f-a3a18ad85239">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_a5359254-18bb-4a55-aae0-90d76b590981">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_52e49ca8-9bcd-46f3-b15d-915a079cf977">0001865494</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      id="F_522691ef-a049-4d10-a8f6-eb2141bf9945"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      id="F_5e0b0588-b270-4242-937d-c044a120045f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      id="F_c1641a20-794d-4ed3-aacb-528b63397b4c"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      id="F_bcd4aa41-7f61-41fa-affb-30d04105e5e8"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_50d1f921-ea74-4d65-b53b-2d642b4f270d">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <dei:DocumentType
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_cbe2983a-89bc-455e-b4e6-084a64f2b15f">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_0d94e257-55b6-4526-935c-259e8abf4b58">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_c11307dc-e7fd-4847-9f6a-4b28c0762ecd">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_a285ca7b-57fd-4839-8b3b-a935d6bf1320">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_f927126a-4ca2-4619-8653-77144b43f59c">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_fc005415-4a02-4d97-93a8-069425a956e4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_25c03e7e-1147-4683-8bd2-3de3b9b706e8">001-41008</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_64db9e25-0013-4512-a89b-347679563501">IO BIOTECH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_f8966c0f-87b3-4cd3-ab1f-73667617016e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_36d54fd8-a985-44c6-9346-1772eb023353">87-0909276</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_5912c1bb-2d7b-4c40-9e53-d5f8c3b6abb3">Ole Maal&#xf8;es Vej 3</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_6a65f8c2-1f11-40c8-9e1f-dc96f1e373b4">DK-2200</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_c755f249-d301-4730-be7a-6784256381f5">Copenhagen N</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_42f9bcc3-56cc-4248-9e83-451fecd8b6dc">DK</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_7345082b-78c9-4a93-8f12-793d9acae192">+45</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_d9bb64d2-b51f-44c5-8c5d-18883dce2c01">7070 2980</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_dc9b1de5-1df6-4414-94df-b6256530b0c0">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_9ba12d4a-c1a7-4c64-8d2b-0c11a825e2ba">IOBT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_d2021763-5d3f-4cc4-be24-e8227718b256">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_67c5767e-bf1e-450c-bea2-dab242d74507">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_70288302-dd85-4135-8796-62e1843f2f36">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_52db3cc7-3b17-46fb-b70c-c3ef13848972">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_2ef0c796-320f-40cf-8c37-b5bff887c308">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_e77f18c5-a6bc-4720-81d4-3129ead0ff0a">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_429cad14-acde-47f5-af88-3c90f4f88773">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_61b35504-9a27-4b5a-9dfb-3b379eb0514a">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_a0508648-4b93-4b16-a103-efc324e55dc2">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_3d882888-20f2-47e7-9f3a-c2e2ed49cf9a">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_c98e3421-6651-4638-8107-f65716fd141a">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_f0afead0-9ab9-4b0a-bd8d-a06915b4668b">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_eff12647-8a9c-4060-a740-40ce3f445548"
      decimals="-5"
      id="F_abf25739-a82c-4f09-9f16-2cc925df2438"
      unitRef="U_USD">31100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_9b50e362-cf80-4463-9c3a-8766edfaa5cf"
      decimals="0"
      id="F_8b8c1b9a-d8a2-4c4e-9d64-d85e27418239"
      unitRef="U_shares">65880914</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_7ad46f1f-5ea4-49af-837a-705447d57347">&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s proxy statement relating to its 2024 Annual Meeting of Stockholders have been incorporated by reference herein in response to Part III, as specifically set forth in Part III.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_557963e3-43e8-4504-98f7-db8643c54d94">1757</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_f46650b0-c57e-4fcc-b144-9abc2128382f">EY Godkendt Revisionspartnerselskab</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_6a386937-fd15-4b8e-92c4-884f02391865">Copenhagen, Denmark</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_b50542f7-464a-49a6-bd2b-696b327a455b"
      unitRef="U_USD">143193000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_2af1651d-0c9d-4cb4-969e-5e05ec68a2dc"
      unitRef="U_USD">142590000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_f5e5c760-adcc-4fd1-b7f4-1c4d5be72ce7"
      unitRef="U_USD">4062000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_bc231335-a2be-4da4-ad08-f39e7920ce60"
      unitRef="U_USD">5629000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_a6c9048f-8476-4e0e-9b29-444d2d172edc"
      unitRef="U_USD">147255000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_50285101-f9e5-4f05-a997-28c140d93325"
      unitRef="U_USD">148219000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_9e818f17-8ac7-4842-8bac-fbd0276ebbc2"
      unitRef="U_USD">268000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_dec3a5f0-f739-4105-bb53-c438b6a113f2"
      unitRef="U_USD">268000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_070ca81a-cfcd-43ef-82fd-744a0256eabc"
      unitRef="U_USD">847000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_dfd471f2-0add-49a0-99fd-ed4ea4f80889"
      unitRef="U_USD">741000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_a8496d72-a362-4573-af67-3e4f30bb7b2e"
      unitRef="U_USD">2259000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_638578a7-e024-44ca-b207-86826e0f2f5d"
      unitRef="U_USD">2493000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_40149936-5e92-4702-b3cb-bdac2fead226"
      unitRef="U_USD">89000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_b6af1eef-d5a5-447d-bf8e-dd5b49f95957"
      unitRef="U_USD">84000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_aec8394c-bfb6-4a70-a3b5-f79d9f020259"
      unitRef="U_USD">3463000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_db0a1afb-ac45-448e-9e72-32fc6f3b40dc"
      unitRef="U_USD">3586000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_20075a61-6952-4be0-b3ad-315af7e63f70"
      unitRef="U_USD">150718000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_4302ac14-cd96-4432-aaac-864c5b690f8c"
      unitRef="U_USD">151805000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_d28ba28d-7c15-4b85-b16d-82564a4cf522"
      unitRef="U_USD">3878000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_9f04bda4-5eae-482b-88d1-3a1d4a374120"
      unitRef="U_USD">4004000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_80f130f6-66b5-46ee-b8dd-9b49c106bf24"
      unitRef="U_USD">655000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_91df7cf0-2bb2-4dfa-af34-f63a247fab17"
      unitRef="U_USD">515000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_27278b3f-5acd-4918-9d37-c6e285fab65c"
      unitRef="U_USD">11184000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_5c94c28e-6532-4d00-851b-b160108b06d6"
      unitRef="U_USD">6157000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_66210287-c28d-46e5-85d3-f15ffe114ddd"
      unitRef="U_USD">15717000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_29aed86c-44e8-45be-ba1f-cf3fcdeea527"
      unitRef="U_USD">10676000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_712b108c-248f-4182-ab29-0f47cf680e98"
      unitRef="U_USD">1839000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_764e4dfe-f4b3-4599-b88d-9bf558a9de4e"
      unitRef="U_USD">2275000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_b1a9cee1-4023-460e-a444-df1a0cf6795f"
      unitRef="U_USD">1839000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_e33d759a-5b85-476b-b88f-a8e2382faafe"
      unitRef="U_USD">2275000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_b6fca4f4-3bbc-492f-b41d-0b18337cc186"
      unitRef="U_USD">17556000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_722688e1-cdeb-4f44-ae08-5ee26aec6314"
      unitRef="U_USD">12951000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="INF"
      id="F_78407ba2-b9d3-4c84-8f70-62d60493c5d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="INF"
      id="F_e0a6fc11-752b-451e-8cfb-a5d174cdbdfd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="INF"
      id="F_8a239d80-1568-4acc-9196-18646044760c"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="INF"
      id="F_6b2f2439-3711-4411-a6e4-70eb91dbeeb4"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="INF"
      id="F_9936a930-57e7-4b5e-b73b-2d0932b7457c"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="INF"
      id="F_d1d87d13-4526-4c2d-be38-e918a514881e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="INF"
      id="F_d34bf874-532a-4587-a6ec-8dc4d9b6abc5"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="INF"
      id="F_716d9865-072c-4a8d-8a37-a6c3982ebc89"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="INF"
      id="F_5c90c96d-9646-48e6-a528-e15a241f6bd8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="INF"
      id="F_bd0dbce2-ce77-428f-971f-630ff5020ace"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="INF"
      id="F_1f5c68f4-5364-4a89-96fb-0a8b100bbfd5"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="INF"
      id="F_ca3ec0ee-34bb-431b-9c4d-fbd9d248bc46"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="INF"
      id="F_8f8387ee-56f5-4ce5-aaf6-8a5bfb3edacc"
      unitRef="U_shares">65880914</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="INF"
      id="F_af9078af-0501-400e-b330-0103137280ec"
      unitRef="U_shares">65880914</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="INF"
      id="F_5b34d6a2-88d7-4d2c-a10b-65c4ae5fd395"
      unitRef="U_shares">28815267</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="INF"
      id="F_0f6ad70f-e07d-49a9-b9c7-979f81344d61"
      unitRef="U_shares">28815267</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_6f577b68-7616-4253-a33d-0dc11605c2cc"
      unitRef="U_USD">66000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_05c18bf9-4aef-417e-ad57-e82178fa3cb2"
      unitRef="U_USD">29000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_7c68cc6e-7779-450d-8a33-165d6c42a280"
      unitRef="U_USD">406587000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_4e48b28b-c91d-4704-b6ee-236ecba3f59b"
      unitRef="U_USD">326705000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_feef3c00-3c22-486a-8a64-b2327906a7c3"
      unitRef="U_USD">-263822000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_0b3cefaf-b622-4675-85fd-5172f5baaab5"
      unitRef="U_USD">-177739000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_8a444eea-600a-4970-aa4f-f8f22112f6a6"
      unitRef="U_USD">-9669000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_90eb34b9-0ed2-49b1-acbd-6f097ae8d6a4"
      unitRef="U_USD">-10141000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_41504297-7d16-4940-a7a9-f4c8347eb461"
      unitRef="U_USD">133162000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_d22112c4-7aee-42ec-b5df-4d72e16595ff"
      unitRef="U_USD">138854000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_ffc1be2e-bb14-4f8c-8b9f-4ef0efb755af"
      unitRef="U_USD">150718000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_2a6fee04-d7fe-404f-9231-838fb50b7b67"
      unitRef="U_USD">151805000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_e599c28d-3a55-4acf-b258-7d33051a44c8"
      unitRef="U_USD">67829000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_8e8be449-fa1a-4d49-89cb-cc5347436b40"
      unitRef="U_USD">46986000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_41b121f2-fe2e-413d-a860-33bcc1c396f3"
      unitRef="U_USD">23614000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_ebaef840-11fb-44e6-a17b-7695bc0cf69c"
      unitRef="U_USD">24438000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_293e027e-3513-4d38-94d5-513ccf07be00"
      unitRef="U_USD">91443000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_268216a6-9a09-453e-9e2f-ab5b0efc3c30"
      unitRef="U_USD">71424000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_802df391-4e39-45ec-bd68-43f285abaefc"
      unitRef="U_USD">-91443000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_6402ba3d-7359-4ed2-b511-00845eade1bc"
      unitRef="U_USD">-71424000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_3c504422-e3ba-43cf-a652-7db367ea9cb1"
      unitRef="U_USD">331000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_a8812a9b-a432-4a4c-a5de-59d1bf8efe77"
      unitRef="U_USD">130000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_ab4fb823-b965-4e46-b56c-e18507e23cc3"
      unitRef="U_USD">5881000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_bf794e5e-2fc8-4e9c-8517-40535b225cc7"
      unitRef="U_USD">1411000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_0c6db8ed-4042-465e-8e58-33dbe20b1f33"
      unitRef="U_USD">302000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_5c9442ac-7e93-463c-a677-6ab4b3af0c1c"
      unitRef="U_USD">6212000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_5484512a-d3f7-4313-b982-3bad1b9b90e3"
      unitRef="U_USD">1239000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_8626d2be-28e6-4e13-8f7f-9704d19b6b37"
      unitRef="U_USD">-85231000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_58a8afa0-f5fc-445c-900e-20f993b2d64e"
      unitRef="U_USD">-70185000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_de820c4d-2587-4b12-8807-913474b67ee6"
      unitRef="U_USD">852000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_a8052753-01d5-4b15-bfcf-33f31f57200f"
      unitRef="U_USD">1273000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_a73d8b68-20e7-46a4-9652-4631bc0286e8"
      unitRef="U_USD">-86083000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_191a1eda-587f-466a-81f3-17c7bfe0e761"
      unitRef="U_USD">-71458000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_50dea70e-bd78-402b-ae8f-eeedfb4e13e9"
      unitRef="U_USD">-86083000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_7c5bf734-2927-4309-be19-cef0d72677cc"
      unitRef="U_USD">-71458000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="2"
      id="F_c8532c0b-1780-4aea-99e2-e8942c570158"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="2"
      id="F_0e5ebd78-2e47-45ac-9fac-4e69aa1a6d41"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="2"
      id="F_ec6c9257-c781-4db4-8421-433125882836"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="2"
      id="F_a4c28836-7b21-464b-b6fa-a1c920cf103c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="0"
      id="F_b85ad78c-1945-4124-9a08-f19187ede66f"
      unitRef="U_shares">43539976</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="0"
      id="F_b07622ca-4041-4ac0-9b75-469189c97d15"
      unitRef="U_shares">43539976</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="0"
      id="F_38968f9a-9994-4102-ba46-dbaa6663738b"
      unitRef="U_shares">28815267</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="0"
      id="F_0c308d94-9f46-45e7-afaa-0fc4cc796cac"
      unitRef="U_shares">28815267</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_e8d9ad01-1e64-47ca-8fc5-3c0facbadb50"
      unitRef="U_USD">-86083000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_7181e693-6f2d-48cb-bbe3-91aad70f34b7"
      unitRef="U_USD">-71458000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_6ce33051-aae7-4ae5-aa36-fd408a2155f8"
      unitRef="U_USD">472000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_f7695dde-d5d7-4b07-8c96-27d28ae13b0e"
      unitRef="U_USD">-8652000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_5b4167ef-72ec-44d3-bdef-1dab8cb2d9f1"
      unitRef="U_USD">-85611000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_dbaa94af-6212-4973-89ed-7b2df5c0cb3a"
      unitRef="U_USD">-80110000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_b417c094-4b8b-413a-b777-f37fa824d616"
      decimals="INF"
      id="F_b7a33282-432e-4e68-b56f-f1ee0f2717c6"
      unitRef="U_shares">28815267</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b417c094-4b8b-413a-b777-f37fa824d616"
      decimals="-3"
      id="F_28769005-1b80-47b2-8988-bea541aba61c"
      unitRef="U_USD">29000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_41282bac-d510-44e1-bcd8-e9ad005dc1b8"
      decimals="-3"
      id="F_9fc9bfb1-f151-4197-a595-e0633189fe18"
      unitRef="U_USD">319665000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d6fcc15a-463e-4377-ad07-b2311c2c2577"
      decimals="-3"
      id="F_0bf1e437-cab6-4edc-b915-4e005cbf7b3a"
      unitRef="U_USD">-1489000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2af36d65-e5e9-4e90-8479-0c3a9a9006ed"
      decimals="-3"
      id="F_bc43b766-df5c-4228-bdad-10a569131534"
      unitRef="U_USD">-106281000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_203b870a-e8de-4c48-bb69-1f143a5d1919"
      decimals="-3"
      id="F_39897e10-3bdc-4fda-9e2a-e773556fedcd"
      unitRef="U_USD">211924000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_58193eaa-01f7-4f8a-933b-82502af9abe4"
      decimals="-3"
      id="F_c794076e-b430-4d0f-bc8f-67a09683d1a1"
      unitRef="U_USD">7040000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_dc875605-eb30-4245-8716-ae10bac8c49a"
      unitRef="U_USD">7040000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_4193a798-b6e0-487a-bf56-e3158437f049"
      decimals="-3"
      id="F_fa03c31c-ba82-49de-b42a-6a6d875e4918"
      unitRef="U_USD">-8652000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_c302390a-9959-4ac8-8be9-70c5db3e00c9"
      unitRef="U_USD">-8652000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_a27d25f7-5479-49f8-a811-d80dec1dc3d7"
      decimals="-3"
      id="F_bbbec681-0c42-42d5-86fd-b92d76c53b3a"
      unitRef="U_USD">-71458000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_d2134c7d-2700-401e-bc39-e84ce22a17c4"
      unitRef="U_USD">-71458000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_83696999-4b34-4804-9e55-9bcb95f224d2"
      decimals="INF"
      id="F_6c62058f-401d-4568-adb4-1af787041dd3"
      unitRef="U_shares">28815267</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_83696999-4b34-4804-9e55-9bcb95f224d2"
      decimals="-3"
      id="F_f548597d-82a2-4a57-b17f-955cbac11120"
      unitRef="U_USD">29000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_af6f9339-383a-4c92-83a8-eb2b5990df31"
      decimals="-3"
      id="F_507bcec1-62aa-45ae-95a1-5a00250ec35a"
      unitRef="U_USD">326705000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4aa5700b-45ac-4ba7-aecb-189135584209"
      decimals="-3"
      id="F_f7ae6289-dd47-4a7d-b2e7-4ff7284a2721"
      unitRef="U_USD">-10141000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fe4a2a0a-b6ee-4598-80ca-db97232d35b5"
      decimals="-3"
      id="F_efe3f25b-8e65-4466-b27a-f4ba5b115cd1"
      unitRef="U_USD">-177739000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_db194839-3793-46bb-9cd9-07a407d79643"
      unitRef="U_USD">138854000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_546c8f6d-7b20-49cd-8a0e-b394348d36fc"
      decimals="-3"
      id="F_5ed645ed-cae3-41a3-bf82-4d4bf3dc07b9"
      unitRef="U_USD">8059000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_ebc94958-5f4c-420f-8b8c-17a284ed86f2"
      unitRef="U_USD">8059000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_b46bf404-a97b-4035-a273-403e9d7a9848"
      decimals="-3"
      id="F_24a7aa6b-68b9-4146-82e0-cb1f63020835"
      unitRef="U_USD">472000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_f44845bd-ad1b-495f-a599-19049fdbb15b"
      unitRef="U_USD">472000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <iobt:PaymentsOfStockAndWarrantIssuanceCosts
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_2c8fdf4c-54f4-42a6-bf38-36bcb5e667ec"
      unitRef="U_USD">3198000</iobt:PaymentsOfStockAndWarrantIssuanceCosts>
    <iobt:StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement
      contextRef="C_4610fd3b-ca44-4e94-a210-d0913cb10978"
      decimals="INF"
      id="F_fa89d5a5-7ff4-4cff-bfce-2922f15af1de"
      unitRef="U_shares">37065647</iobt:StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement>
    <iobt:StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement
      contextRef="C_4610fd3b-ca44-4e94-a210-d0913cb10978"
      decimals="-3"
      id="F_0a912b45-8dec-4e84-ab08-7302e7a2b2a6"
      unitRef="U_USD">37000</iobt:StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement>
    <iobt:StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement
      contextRef="C_546c8f6d-7b20-49cd-8a0e-b394348d36fc"
      decimals="-3"
      id="F_41dac33e-3a8c-459d-b011-fe8bb8eec6ab"
      unitRef="U_USD">71823000</iobt:StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement>
    <iobt:StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_937ca690-97d1-4af6-ad2d-d175df0ff596"
      unitRef="U_USD">71860000</iobt:StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement>
    <us-gaap:NetIncomeLoss
      contextRef="C_6bfe21b8-29be-4452-8c6e-25ec17762b3a"
      decimals="-3"
      id="F_11d6d1ec-1d0f-4171-8af9-4c4046ea5129"
      unitRef="U_USD">-86083000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_5598bfa3-1f27-44ef-971f-137dee31a0ac"
      unitRef="U_USD">-86083000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_785d9f06-9d6a-47bd-8cd0-ef70f3e4eef7"
      decimals="INF"
      id="F_03f5f6ed-e088-4c33-8099-44986d590cc7"
      unitRef="U_shares">65880914</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_785d9f06-9d6a-47bd-8cd0-ef70f3e4eef7"
      decimals="-3"
      id="F_3df412ed-0195-4081-a365-abb6744a8c16"
      unitRef="U_USD">66000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d68d18d7-93d7-49d5-ac79-3f37468692f2"
      decimals="-3"
      id="F_561330f4-a0c9-44f4-993a-3fe9a5dc4300"
      unitRef="U_USD">406587000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8a8a956b-e82c-4de3-b66b-515c278c6057"
      decimals="-3"
      id="F_62efd84b-05e5-407c-aecc-c98e8a7d0fad"
      unitRef="U_USD">-9669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cca131d2-c4bc-4848-b12f-0a7cefd61f16"
      decimals="-3"
      id="F_0ddec3d2-6c6f-47fe-b25c-c6b25939ca63"
      unitRef="U_USD">-263822000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_8d9c3d31-d2d1-485c-81fc-b61f4ae2ff58"
      unitRef="U_USD">133162000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_0ce1484f-81d5-42cd-87ac-fa0c470223d5"
      unitRef="U_USD">-86083000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_10b3b84a-3f94-484a-832d-cec5a700604c"
      unitRef="U_USD">-71458000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_8c269b96-f005-49a2-8ece-daceff7be8e8"
      unitRef="U_USD">215000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_39e079d7-58f7-48fa-9f76-72a1e7efbca2"
      unitRef="U_USD">104000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_867e51ba-aaac-4113-bcfd-270f18e30ed0"
      unitRef="U_USD">8059000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_8eb29c5d-6835-467f-8ab6-d62d21686872"
      unitRef="U_USD">7040000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_cf1b005a-615a-4f7a-b466-210bf7ace20d"
      unitRef="U_USD">541000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_7cae8798-5c9a-4118-80fa-721d451efc9b"
      unitRef="U_USD">436000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_95dd0a2f-7fec-4a33-8f9c-56dee8291d26"
      unitRef="U_USD">331000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_5db59ee2-78b3-4c1b-bd16-d607ee644177"
      unitRef="U_USD">130000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_f19f7b58-873f-4454-a172-7439a4cfff68"
      unitRef="U_USD">87000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_0cee8e88-1d25-46a3-bc87-ee571e0d5c14"
      unitRef="U_USD">-1568000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_7dae1bbd-820c-4ee7-a03c-d7647d28d471"
      unitRef="U_USD">-4578000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_0e6b77db-219b-4273-920f-1f86413f9274"
      unitRef="U_USD">4000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_56008a38-82ff-41bc-af15-6a1eb9c1bdfa"
      unitRef="U_USD">44000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_e8de3d88-21ec-4888-8fd8-31a153eda914"
      unitRef="U_USD">-126000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_f89936df-5459-45f2-9d4b-9ec586e46da4"
      unitRef="U_USD">77000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <iobt:IncreaseDecreaseInLeaseLiability
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_ff69b4a6-a73a-4055-a6cc-8e5b0b11bcc4"
      unitRef="U_USD">-604000</iobt:IncreaseDecreaseInLeaseLiability>
    <iobt:IncreaseDecreaseInLeaseLiability
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_2327f35e-16b0-4cd0-9c90-69ca481366a0"
      unitRef="U_USD">-139000</iobt:IncreaseDecreaseInLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_eb417c1e-b403-44e5-b72e-4331b34159ee"
      unitRef="U_USD">5028000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_29bc10f4-691b-4111-8a9d-96eec860ea39"
      unitRef="U_USD">-280000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_0c53a4de-923f-430e-88db-7eaf92656a1b"
      unitRef="U_USD">-71737000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_283b291a-f5dc-4758-95a8-c97bb2d2f987"
      unitRef="U_USD">-59729000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_d2b4b34e-bc17-4985-9afb-cdfec7696380"
      unitRef="U_USD">323000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_c5b7f14b-27bf-499b-95d7-549180e4cff2"
      unitRef="U_USD">690000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_a00672f0-19d7-452a-ad3e-2f3a4fd82141"
      unitRef="U_USD">-323000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_d0bc1b9f-06e7-4c08-92be-86f62c30ab5c"
      unitRef="U_USD">-690000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <iobt:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_5ed7f53f-2efa-415b-a589-dece5a54494b"
      unitRef="U_USD">75058000</iobt:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <iobt:PaymentsOfStockAndWarrantIssuanceCosts
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_5de0fd86-640a-4953-ab1e-7b8c3a86ef9e"
      unitRef="U_USD">3198000</iobt:PaymentsOfStockAndWarrantIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_909c609e-1855-44fc-88f6-197500ac028f"
      unitRef="U_USD">71860000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_66308c1e-3da4-4cd7-81dd-19f53952047d"
      unitRef="U_USD">-200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_13080fed-d48e-4c71-a691-657209ef0fb4"
      unitRef="U_USD">-60419000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_58036804-0283-44a1-9722-7b8e5efece37"
      unitRef="U_USD">803000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_a47f7446-5a94-4cfc-80c4-a6ad9c3fdf83"
      unitRef="U_USD">-8522000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_ae426bfb-a51c-4979-882a-ca6fafaa519a"
      unitRef="U_USD">142858000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_203b870a-e8de-4c48-bb69-1f143a5d1919"
      decimals="-3"
      id="F_31552093-2984-4043-91b4-6aea147ad6d2"
      unitRef="U_USD">211799000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_81fdabb0-f19e-42c2-905f-92f4a1cc0cae"
      unitRef="U_USD">143461000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_3ed39c3b-82f2-4d37-8566-3a4e8a75ac45"
      unitRef="U_USD">142858000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_0d65acc5-1cca-4b6b-9d8b-e41ef67fffe9"
      unitRef="U_USD">143193000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_4f8a25f4-b71c-49b4-8ee5-b75ea5525e16"
      unitRef="U_USD">142590000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_24e6560a-7d9c-41a1-9f1e-7939887fdcbd"
      unitRef="U_USD">268000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_862d43c4-e338-4456-908d-544ea7426c24"
      unitRef="U_USD">268000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_ce361ff0-9a26-4b01-8ec5-0a5564e151bc"
      unitRef="U_USD">143461000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_52c352e7-3399-424d-847c-809cdbc35bc1"
      unitRef="U_USD">142858000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_0566469f-20a8-4148-835c-5ceee5e6bb55">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. Description of Business, Organization and Liquidity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on our T-win&#xae; platform. As used in these financial statements, unless the context otherwise requires, references to the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; refer to IO Biotech, Inc. and its subsidiaries.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Corporate reorganization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;IO Biotech ApS was incorporated in Denmark in December 2014. In November 2021, we completed a corporate reorganization whereby IO Biotech ApS became a wholly-owned subsidiary of the Company. In connection with the corporate reorganization, each issued and outstanding Class A ordinary share ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; par value) was exchanged on a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one-for-one&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; basis into shares of common stock of the Company ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; par value). Each Class B and Class C preference share of IO Biotech ApS was exchanged on a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one-for-one&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; basis into shares of Class B and Class C preferred stock of the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;IO Bio US, Inc., a wholly owned subsidiary of IO Biotech ApS, was incorporated in Delaware in May 2021. IO Biotech Limited, a wholly owned subsidiary of IO Biotech ApS, was incorporated in the UK in August 2021. In November 2021, the Company engaged in a series of transactions, referred to collectively as the Corporate Reorganization. As a result of the Corporate Reorganization, IO Biotech ApS became a wholly-owned subsidiary of IO Biotech, Inc.  IO Biotech, Inc. is a holding company formed in October 2021, which, prior to our IPO, had nominal assets and no liabilities, contingencies, or commitments, and which has not conducted any operations prior to our IPO other than acquiring the entire issued and outstanding stock of IO Biotech ApS. The Company, IO Biotech ApS, and the holders of all of the issued and outstanding equity interests of IO Biotech ApS have entered into a Share Contribution and Exchange Agreement, dated as of October 29, 2021, pursuant to which the Corporate Reorganization was effected.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Initial Public Offering (IPO)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2021, we completed our IPO, selling an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,222,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock at a price to the public of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,072,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock sold pursuant to the underwriters&#x2019; exercise of their option to purchase additional shares of common stock. We received net proceeds from the IPO, after deducting underwriting discounts and commissions and other offering costs, of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Immediately prior to the consummation of the IPO, all outstanding shares of our Class A ordinary shares and Class B and Class C convertible preference shares were converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,592,413&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. Upon the closing of the IPO on November 9, 2021, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,815,267&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock were issued and outstanding. Our common stock began trading on the Nasdaq Global Market on November 5, 2021 under the symbol &#x201c;IOBT.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 9, 2021, we amended and restated the certificate of incorporation of IO Biotech, Inc. to authorize the issuance of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;300,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of preferred stock. The shares of preferred stock are currently undesignated.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;August 2023 Private Placement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 9, 2023, the Company completed a private placement transaction (the Private Placement), pursuant to which we sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock (the Warrants) to certain institutional investors and existing shareholders (the Purchasers). Each Purchaser&#x2019;s Warrant is exercisable for a number of shares of common stock equal to one hundred percent of the aggregate number of shares of common stock purchased by such Purchaser. The purchase price per share of common stock and Warrant was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (the Purchase Price). The Company received net proceeds from the Private Placement, after deducting &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in underwriting discounts and commissions and other offering costs, of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Refer to Note 2, &#x201c;Summary of Significant Accounting Policies,&#x201d; and Note 10, "Stockholders' Equity" in the accompanying notes to our consolidated financial statements for the years ended December 31, 2023 and 2022 for additional information on the Private Placement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;At-The-Market Equity Program&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 15, 2023, we filed a new prospectus supplement with the U.S. Securities and Exchange Commission (the SEC) with respect to the offer and sale of shares of our common stock, with an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, establishing an at-the-market equity program. On February 15, 2023, we also entered into a common stock sales agreement, dated February 15, 2023 (the &#x201c;Sales Agreement&#x201d;) by and between the Company and Cowen and Company, LLC for shares with an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; through which we may, from time to time, sell shares through Cowen and Company, LLC, acting as agent and/or principal. Any shares offered and sold through the at-the-market equity program will be issued pursuant to the Company&#x2019;s Registration Statement on Form S-3 (File No. 333-269569), which was declared effective on February 10, 2023, the prospectus supplement related to the offering that forms a part of the registration statement, and any applicable prospectus supplements that may form a part of the registration statement in the future. The aggregate market value of shares eligible for sale under the prospectus supplement and under the Sales Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3, to the extent required under such instruction. We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t issued any shares pursuant to our at-the-market equity program as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We are subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance reporting capabilities.&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our product candidates are in preclinical research and clinical development. There can be no assurance that our research and development will be successfully completed, that adequate protection for our intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if our product development efforts are successful, it is uncertain when, if ever, we will generate significant revenue from product sales. We operate in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, we are dependent upon the services of our employees and consultants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity Considerations and Going Concern Basis of Accounting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since inception, we have devoted substantially all of our efforts to business planning, conducting research and development, recruiting management and technical staff, and raising capital. We have financed our operations primarily through the issuance of convertible preference shares, convertible notes, our IPO and the Private Placement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our continued discovery and development of product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if our product development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, we had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. We have incurred losses and negative cash flows from operations since inception, including net losses of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended December 31, 2023 and 2022, respectively. We expect that our operating losses and negative cash flows will continue for the foreseeable future as we continue to develop our product candidates. We currently expect that our cash and cash equivalents of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023 will be sufficient to fund our operating expenses and capital requirements for at least 12 months from the date the financial statements are issued. On this basis the financial statements are prepared on a going concern basis of accounting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. However, additional funding will be necessary to fund future discovery research, pre-clinical and clinical activities. We will seek additional funding through public financings, debt financings, collaboration agreements, strategic alliances and licensing arrangements. Although we have been successful in raising capital in the past, there is no assurance that we will be successful in obtaining such additional financing on acceptable terms, or at all, and we may not be able to enter into collaborations or other arrangements. If we are unable to obtain funding, we could be forced to delay, reduce or eliminate our research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect our business prospects, even our ability to continue operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_ce55bd70-3918-4ae0-9cad-0dfde777548f"
      decimals="INF"
      id="F_39243a8f-6f0d-45f7-8c37-30589dcefbcb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.16</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockConversionBasis
      contextRef="C_deb3bb46-923f-471e-bc2a-d3f58a8d1640"
      id="F_f9eb2d5b-c0e7-4de3-a872-0f97159cc2eb">one-for-one</us-gaap:CommonStockConversionBasis>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_6976c5c1-5909-47d1-9d43-69c889de3121"
      decimals="INF"
      id="F_d0fe3949-ec3d-4c9b-bee3-c6a5698bffdb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_1525e770-dbb6-4a8a-b414-dae67b1c0c72"
      decimals="INF"
      id="F_271c1361-70c9-4291-83f8-7bc86ca36240"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockConversionBasis
      contextRef="C_204fa06a-ebbb-41fd-82ba-760913723921"
      id="F_8fafe75b-7666-46ab-a506-611ad0145f42">one-for-one</us-gaap:CommonStockConversionBasis>
    <us-gaap:CommonStockConversionBasis
      contextRef="C_e8a83503-acc7-4b7b-80a3-5d4810b2d5de"
      id="F_ab1bf50e-5af6-41ff-b532-b35619d14aab">one-for-one</us-gaap:CommonStockConversionBasis>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_58b5fcb9-88bf-4c8f-a0dc-fb732ca6c6a9"
      decimals="INF"
      id="F_9137bbdd-0811-4fec-87b4-fe8596be9773"
      unitRef="U_shares">8222500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_09c04cd1-1667-4969-a0bf-6219d9198637"
      decimals="INF"
      id="F_34b223a3-187f-43bd-b07d-fd5a013a4750"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.00</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a0939c61-54dc-4cc6-bd3a-04cc2fcd2c13"
      decimals="INF"
      id="F_53dcc3e8-3480-4d9b-abce-ddee9a45e3d2"
      unitRef="U_shares">1072500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_1dcc1f3e-ab3f-4d97-8c1b-44559a31ab42"
      decimals="-5"
      id="F_f47554fb-f914-487c-9a1d-fa52d7e353f1"
      unitRef="U_USD">103300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_a0cd7c29-89c5-48ee-ae9e-0dbf0ed84a0c"
      decimals="INF"
      id="F_d40b09ba-b701-4000-bb75-39ae9801c93d"
      unitRef="U_shares">20592413</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a0cd7c29-89c5-48ee-ae9e-0dbf0ed84a0c"
      decimals="INF"
      id="F_8790969e-b5a2-4fee-a5c9-92d0121f78a4"
      unitRef="U_shares">28815267</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_a0cd7c29-89c5-48ee-ae9e-0dbf0ed84a0c"
      decimals="INF"
      id="F_94c786a3-f51b-41b5-8d58-b3ae5c970aad"
      unitRef="U_shares">28815267</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a0cd7c29-89c5-48ee-ae9e-0dbf0ed84a0c"
      decimals="INF"
      id="F_e550a670-8d34-4a89-82f0-a745e857a90b"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_ccc9ec90-8753-446d-ad46-4614b4157e4b"
      decimals="INF"
      id="F_1ffea1b6-caaa-4fa9-837b-1c17e93f6471"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e2898211-1ef9-46ec-9a67-2298c6e5e1c8"
      decimals="INF"
      id="F_c3858e6a-cd85-4170-a3f5-67e53ce0eff2"
      unitRef="U_shares">37065647</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_49c77671-362e-4825-93e3-6d0010545188"
      decimals="INF"
      id="F_bc6d2eb7-0d3d-4b79-8ef8-779afd1438e8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <iobt:WarrantsIssued
      contextRef="C_e2898211-1ef9-46ec-9a67-2298c6e5e1c8"
      decimals="INF"
      id="F_e79eb01e-d9f7-4fe4-84c7-2ec74d74411b"
      unitRef="U_shares">37065647</iobt:WarrantsIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_dd5861a4-c39b-4313-99f5-dd1a1dc0195b"
      decimals="INF"
      id="F_24330d7f-547b-4aae-b99a-0402fe05a737"
      unitRef="U_shares">37065647</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <iobt:PurchasePricePerShareOfCommonStockAndWarrant
      contextRef="C_e2898211-1ef9-46ec-9a67-2298c6e5e1c8"
      decimals="INF"
      id="F_8ce58918-dc95-4c64-8564-cd49cf52ea99"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.025</iobt:PurchasePricePerShareOfCommonStockAndWarrant>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_e2898211-1ef9-46ec-9a67-2298c6e5e1c8"
      decimals="-5"
      id="F_f56a5044-64b9-4250-b296-3787a926b474"
      unitRef="U_USD">3200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_5265fdb7-64e2-41ae-bedb-28fa9d99cc76"
      decimals="-5"
      id="F_d6f90595-ecde-474e-b61b-ca8a8c30abfa"
      unitRef="U_USD">71900000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <iobt:CommonStockMaximumAggregateOfferingAmount
      contextRef="C_08166775-fe5a-4472-96b3-587d9d04a349"
      decimals="INF"
      id="F_b1ea159a-b2fd-45ac-85d5-cc8c7dbb54e5"
      unitRef="U_USD">19500000</iobt:CommonStockMaximumAggregateOfferingAmount>
    <iobt:CommonStockMaximumAggregateOfferingAmount
      contextRef="C_f7a68159-256a-4ce2-b281-a534093c1329"
      decimals="INF"
      id="F_e1d7abc8-59cc-4e42-a9a2-b742abcb16f4"
      unitRef="U_USD">75000000</iobt:CommonStockMaximumAggregateOfferingAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_86125bde-a241-4410-b61b-886b4c205d56"
      decimals="INF"
      id="F_4be51fb2-3972-416e-ae90-7fdeaa3f3e39"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-5"
      id="F_de53d405-1482-4e6c-9916-dfbbb18ac87f"
      unitRef="U_USD">-263800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-5"
      id="F_5efab89b-3e15-4383-a524-652ad78f09e9"
      unitRef="U_USD">-86100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-5"
      id="F_f9e3d1fa-fc44-4907-abff-584f370050cf"
      unitRef="U_USD">-71500000</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-5"
      id="F_b2b96b36-9c8c-4fd0-bb08-7b130a15d73d"
      unitRef="U_USD">143200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_495d6598-26f6-4bfd-9e30-89acdaea1561">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements include the accounts of its subsidiaries IO Biotech ApS, IO Bio US, Inc. and IO Biotech Limited. IO Bio US, Inc. is a wholly owned subsidiary of IO Biotech ApS. IO Biotech Limited is a wholly owned subsidiary of IO Biotech ApS. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant items subject to such estimates and assumptions include contract research organization accruals, the fair value of stock-based compensation awards, the fair value of Warrants issued as part of the Private Placement and valuation of the Company&#x2019;s deferred tax assets. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Currency and Currency Translation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The financial statements are presented in U.S. Dollars, our reporting currency. The functional currency of IO Biotech ApS and IO Biotech Limited is the Euro and the British Pound, respectively. The functional currency of IO Bio US, Inc. and IO Biotech, Inc. is the U.S. Dollar. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the functional currency are included in other income and expense in the consolidated statements of operations. Assets and liabilities recorded in our Euro and British Pound functional currencies are translated into the U.S. dollar reporting currency at the exchange rate on the balance sheet date. Our expenses in the Euro and the British Pound functional currencies are translated into the U.S. Dollar reporting currency at the average exchange rate prevailing each month. Resulting translation adjustments are recorded to other comprehensive income (loss) (OCI).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents, which consist of money market accounts, are stated at fair value. As of December 31, 2023 and 2022 we had money market funds of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, which are included in cash and cash equivalents and reported at fair value (Note 3).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We maintain our cash in bank deposit and checking accounts that at times exceed insured limits. We have not experienced any losses in such accounts and believe we are not exposed to any significant credit risk, however, we are exposed to the potential loss of uninsured deposits should a financial institution we maintain our cash deposits with fail.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value is defined as the price we would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;liabilities;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;are observable, either directly or indirectly; and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We monitor the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, our policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, the Company only held Level 1 financial instruments, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment consists of laboratory equipment, computer hardware and office furniture and are recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset by asset basis, which generally consists of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for computer hardware, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for office furniture and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for laboratory equipment. &lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If circumstances require a long-lived asset to be tested for possible impairment, recoverability is measured by comparison of the carrying amount of the assets to estimated future undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset exceeds its estimated future cash flows, then impairment expense is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairment expenses were recognized.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. The Company&#x2019;s research and development expenses consist primarily of costs incurred for the development of its product candidates and include expenses incurred under agreements with contract manufacturing organizations, or CMOs, contract research organizations, or CROs, investigative sites and consultants to conduct clinical trials and preclinical and non-clinical studies, costs to acquire, develop and manufacture supplies for clinical trials and other studies, salaries and related costs, including equity-based compensation, depreciation and other allocated facility-related and overhead expenses and licensing fees and milestone payments incurred under product license agreements where no alternative future use exists.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We may obtain grants from public and private funds for our research and development projects. The grant income for a given period is recognized as a cost reimbursement and is typically based on the time and the costs that we have spent on the specific project during that period. During the years ended December 31, 2023 and 2022, we had active cost reimbursement grants with Innovation Fund Denmark. The grants provided partial reimbursement of employment-related costs related to two employees pursuant to Business Ph.D. and Business post-doctoral programs. For the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, research and development expenses in the statements of operations include $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.02&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.03&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, of grant income cost reimbursement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have historically met the requirements to receive a tax credit in Denmark of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million Danish Kroner per year for tax losses resulting from research and development costs of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million Danish Kroner per year. The tax credit is reported as a reduction to research and development expense in the statements of operations. For the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, research and development expenses include refundable tax credits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accrued Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Substantial portions of our pre-clinical and clinical trials are performed by third-party laboratories, medical centers, CMOs, CROs and other vendors. These vendors generally bill monthly for services performed, or bill based upon milestone achievement. For preclinical studies, we accrue expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled, the duration of the study and other investigative costs. We monitor patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to us by the CROs, correspondence with the CROs and clinical site visits. Our estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. We periodically evaluate the estimates to determine if adjustments are necessary or appropriate based on information we receive.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (&#x201c;ASC 842&#x201d;) to enhance the transparency and comparability of financial reporting related to leasing arrangements. Under this lease standard, most leases are required to be recognized on the balance sheet as right-of-use (ROU) assets and lease liabilities. The right-of-use model requires a lessee to recognize a ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement as well as the reduction of the right of use asset. In 2022, the Company adopted the standard effective January 1, 2022 and chose to use the effective date as date of initial application. The standard provides a number of optional practical expedients in transition. Upon adoption, the Company elected to apply the &#x2018;package of practical expedients&#x2019; which allowed the Company to not reassess (1) whether existing or expired arrangements contain a lease; (2) the lease classification of existing or expired leases; or (3) whether previous initial direct costs would qualify for capitalization under the new lease standard. The Company also elected to apply (1) the practical expedient which allows us to not separate lease and non-lease components, for new leases entered into after adoption and (2) the short-term lease exemption for all leases with an original term of less than 12 months, for purposes of applying the recognition and measurements requirements in the new standard.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#x2019;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company will utilize the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. As of January 1, 2022, the ASC 842 effective date, the Company&#x2019;s incremental borrowing rate was approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% based on the remaining lease term of the applicable leases.&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We account for stock options granted in accordance with ASC 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In accordance with ASC 718, compensation expense is measured at the estimated fair value of the stock options at grant date and is included as compensation expense over the vesting period during which an employee provides service in exchange for the award on a straight-line basis. Vesting of the awards depend solely on service conditions required of the employee.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All share-based awards granted are measured based on the fair value on the date of the grant and compensation expense is recognized with respect to those awards over the requisite service period, which is generally the vesting period of the respective award. The Company reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equity-based compensation expense is classified in the Company&#x2019;s consolidated statements of operations in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes model. The following summarizes the inputs used:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies because we lack company-specific historical and implied volatility information due in part to the limited time in which we have operated as a publicly traded company. We expect to continue to do so until such time as we have adequate historical data regarding the volatility of our traded stock price.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The expected term of the Company&#x2019;s stock options has been determined based on the expected time to liquidity. The Company uses the simplified method prescribed by the SEC&#x2019;s Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term of options granted because we lack company-specific historical and implied expected term information due in part to the limited time in which we have operated as a publicly traded company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The risk-free interest rate is based on the implied yield on a U.S. Treasury security at a constant maturity with a remaining term equal to the expected term of the option granted.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Dividends&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expected dividend yield is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; because the Company does not pay cash dividends on common shares and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Share Price&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: The Company's common stock trades on the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nasdaq Global Market under the symbol &#x201c;IOBT" and is utilized to determine the fair value of the Company's share price.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are established when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We follow the provisions of ASC 740-10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Uncertainty in Income Taxes. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have not recognized a liability as a result of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; unrecognized benefit since the date of adoption and we have not recognized interest expense or penalties as a result of ASC 740-10. If there were an unrecognized tax benefit, we would recognize interest accrued related to unrecognized tax benefits as income tax expense within our consolidated statements of operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have identified Denmark and the U.S. as our major tax jurisdictions.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Warrants Issued in Connection with Sale of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for warrants issued as a separable unit in connection with sale of common stock as either liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#x201c;ASC 480-10&#x201d;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock (&#x201c;ASC 815-40&#x201d;). Under ASC 480-10, warrants are considered liabilities if they are mandatorily redeemable and they require settlement in cash or other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as liability or equity. If warrants do not require liability classification under ASC 815-40 or other applicable U.S. GAAP the warrants should be classified as equity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The proceeds received from the sale of equity classified warrants and sh&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ares of common stock in a bundled transaction are allocated based on the relative fair values of warrants and shares of common stock with no changes in fair value of warrants recognized after the issuance date. Based on our analysis of the foregoing, the Company's warrants issued in the Private Placement are classified as equity in our consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders  by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method and the as if-converted method, for convertible securities, if inclusion of these instruments is dilutive. Potentially dilutive securities include stock options and warrants to purchase common stock of the Company. In all periods presented, the Company&#x2019;s outstanding stock options and warrants were excluded from the calculation of diluted net loss per share because their effects were anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the years ended December 31, 2023 and 2022, both basic and diluted net loss per share are equivalent.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (CODM), in deciding how to allocate resources to an individual segment and in assessing performance. Our CODM is our chief executive officer. The Company has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Other Comprehensive Income (Loss)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;OCI is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our OCI includes currency translation from the Euro and the British Pound, the functional currency of IO Biotech ApS and IO Biotech Limited, respectively, to the U.S. Dollar, our reporting currency.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (1) are no longer an emerging growth company or (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently adopted accounting standards&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#x2014;Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_50d1f921-ea74-4d65-b53b-2d642b4f270d;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ASU 2019-04&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; the standard effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The adoption of the standard has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t had a material impact on our financial statements or financial statement disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity s Own Equity (Subtopic 815-40): Accounting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;being separately recognized from the host contract as compared with current U.S. GAAP. Convertible instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;that continue to be subject to separation models are (1) those with embedded conversion features that are not&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the derivatives scope exception for contracts in an entity&#x2019;s own equity to reduce form-over-substance-based&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;accounting conclusions. ASU 2020-06 will be effective for us in the interim periods in the fiscal year beginning after December 15, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;interim periods within those fiscal years. We are currently assessing the impact adoption of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ASU 2020-06 will have on our financial statements and disclosures, but do not expect a material impact on the financial statements or disclosures.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2023, the FASB issued ASU 2023-06, Accounting Standards Update 2023-06&#x2014;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative. ASU 2023-06 will eliminate disclosure requirements that are redundant, duplicative, overlapping, outdated, or superseded as a result of subsequent changes to SEC disclosure requirements, U.S GAAP or technology. ASU 2023-06 is intended to better align U.S. GAAP requirements with those of the SEC and to facilitate the application of U.S. GAAP. The disclosure requirements would apply prospectively in the financial statements. ASU 2023-06 will be effective for us on the date on which the SEC&#x2019;s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, if we are already subject to the SEC&#x2019;s current disclosure requirements. For those current disclosure requirements we are not subject to, ASU 2023-06 will become effective two years after the date of such removal by the SEC. We are currently assessing the impact adoption of ASU 2023-06 will have on our financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 will improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 will also enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment and contain other disclosure requirements. The enhanced segment disclosure requirements apply retrospectively to all prior periods presented in the financial statements. ASU 2023-07 will be effective for us in the annual periods beginning after December 15, 2023. We are currently assessing the impact adoption of ASU 2023-07 will have on our financial statements and disclosures, but do not expect a material impact on the financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 will require disclosure of additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate (the rate reconciliation) for federal, state and foreign income taxes. ASU 2023-09 will also require information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold.  ASU 2023-09 will be effective for us in the annual periods beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. We are currently assessing the impact adoption of ASU 2020-06 will have on our financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our consolidated financial statements&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_0b32e0bf-410e-44b0-9c21-003dd5b02a5f">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_e90741b1-8ebc-454a-bc14-4921473b5bbd">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements include the accounts of its subsidiaries IO Biotech ApS, IO Bio US, Inc. and IO Biotech Limited. IO Bio US, Inc. is a wholly owned subsidiary of IO Biotech ApS. IO Biotech Limited is a wholly owned subsidiary of IO Biotech ApS. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_66bcb947-5797-4ba8-b081-697fcb5cef3d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant items subject to such estimates and assumptions include contract research organization accruals, the fair value of stock-based compensation awards, the fair value of Warrants issued as part of the Private Placement and valuation of the Company&#x2019;s deferred tax assets. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_8cc4a8f7-d309-43b2-8395-d5b716eebd61">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Currency and Currency Translation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The financial statements are presented in U.S. Dollars, our reporting currency. The functional currency of IO Biotech ApS and IO Biotech Limited is the Euro and the British Pound, respectively. The functional currency of IO Bio US, Inc. and IO Biotech, Inc. is the U.S. Dollar. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the functional currency are included in other income and expense in the consolidated statements of operations. Assets and liabilities recorded in our Euro and British Pound functional currencies are translated into the U.S. dollar reporting currency at the exchange rate on the balance sheet date. Our expenses in the Euro and the British Pound functional currencies are translated into the U.S. Dollar reporting currency at the average exchange rate prevailing each month. Resulting translation adjustments are recorded to other comprehensive income (loss) (OCI).&lt;/span&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_eb455bd7-a8b5-4013-8afc-4a87d22d7e11">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents, which consist of money market accounts, are stated at fair value. As of December 31, 2023 and 2022 we had money market funds of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, which are included in cash and cash equivalents and reported at fair value (Note 3).&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-5"
      id="F_0a5ec556-952d-4085-a9ee-9cc9283e9b48"
      unitRef="U_USD">131600000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-5"
      id="F_25629bb1-65c1-491e-8d98-16c4d24e4a64"
      unitRef="U_USD">88000000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_37a0f9f1-7517-42c8-8ec6-62cc9a443b9a">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We maintain our cash in bank deposit and checking accounts that at times exceed insured limits. We have not experienced any losses in such accounts and believe we are not exposed to any significant credit risk, however, we are exposed to the potential loss of uninsured deposits should a financial institution we maintain our cash deposits with fail.&lt;/span&gt;&lt;/p&gt;</us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_79e8f6d3-ef92-487a-8997-b35b39ef4ee1">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value is defined as the price we would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;liabilities;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;are observable, either directly or indirectly; and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We monitor the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, our policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets.&lt;/span&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_933976ff-0867-4b14-b824-4b507dc1a18c">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment consists of laboratory equipment, computer hardware and office furniture and are recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset by asset basis, which generally consists of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for computer hardware, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for office furniture and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for laboratory equipment. &lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If circumstances require a long-lived asset to be tested for possible impairment, recoverability is measured by comparison of the carrying amount of the assets to estimated future undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset exceeds its estimated future cash flows, then impairment expense is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairment expenses were recognized.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_a179b419-8f22-455d-a4ab-2a0aa92c018a"
      id="F_b331dba7-d4e7-4cd2-b9d4-9a1aba3b4027">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_c457cad7-3e0c-4a59-b4de-aa28ef642dbf"
      id="F_a279fa7c-0505-47dd-92b2-24df9fa809b7">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_a0c8c506-94c5-4204-b3e9-4087e11e4d77"
      id="F_1992e3c0-7279-4ec9-bd14-d116f7ca7380">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="INF"
      id="F_a1fec080-17dc-49d3-9d4b-51d954dfee2c"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="INF"
      id="F_65821b11-8a0d-4991-8640-dc5c8d1d9c92"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_672de337-3a00-446b-9079-9622c8861064">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. The Company&#x2019;s research and development expenses consist primarily of costs incurred for the development of its product candidates and include expenses incurred under agreements with contract manufacturing organizations, or CMOs, contract research organizations, or CROs, investigative sites and consultants to conduct clinical trials and preclinical and non-clinical studies, costs to acquire, develop and manufacture supplies for clinical trials and other studies, salaries and related costs, including equity-based compensation, depreciation and other allocated facility-related and overhead expenses and licensing fees and milestone payments incurred under product license agreements where no alternative future use exists.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We may obtain grants from public and private funds for our research and development projects. The grant income for a given period is recognized as a cost reimbursement and is typically based on the time and the costs that we have spent on the specific project during that period. During the years ended December 31, 2023 and 2022, we had active cost reimbursement grants with Innovation Fund Denmark. The grants provided partial reimbursement of employment-related costs related to two employees pursuant to Business Ph.D. and Business post-doctoral programs. For the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, research and development expenses in the statements of operations include $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.02&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.03&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, of grant income cost reimbursement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have historically met the requirements to receive a tax credit in Denmark of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million Danish Kroner per year for tax losses resulting from research and development costs of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million Danish Kroner per year. The tax credit is reported as a reduction to research and development expense in the statements of operations. For the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, research and development expenses include refundable tax credits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <iobt:GrantIncomeCostReimbursement
      contextRef="C_77b4e90b-4f57-4362-beca-0e8dcbcfba19"
      decimals="-4"
      id="F_2efc2c14-5ffc-48be-bcc1-db5df1daf5b1"
      unitRef="U_USD">20000.00</iobt:GrantIncomeCostReimbursement>
    <iobt:GrantIncomeCostReimbursement
      contextRef="C_c1c118ba-3d68-42c8-9af6-0389748a393e"
      decimals="-4"
      id="F_5d4be2c2-6983-4c21-816f-cfaa01d3fb7c"
      unitRef="U_USD">30000.00</iobt:GrantIncomeCostReimbursement>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_2537fee5-7e0b-4dba-8a7b-1ae868729ba1"
      decimals="-5"
      id="F_e82267e8-b3dd-406f-9492-93db1ad22eef"
      unitRef="U_DKK">5500000</us-gaap:TaxCreditCarryforwardAmount>
    <iobt:RefundableTaxCredit
      contextRef="C_65b6ebb1-4040-4de5-b896-f3c903f4135b"
      decimals="-5"
      id="F_f4e0be7c-bd61-4be5-b748-4e08fa1c4537"
      unitRef="U_DKK">25000000</iobt:RefundableTaxCredit>
    <iobt:RefundableTaxCreditReceivable
      contextRef="C_61743499-6fd4-4641-8e5f-157d373726ff"
      decimals="-5"
      id="F_8737624c-6bd9-4d05-9f28-2b3263fca278"
      unitRef="U_USD">800000</iobt:RefundableTaxCreditReceivable>
    <iobt:RefundableTaxCreditReceivable
      contextRef="C_0ea23d1e-bc0a-42c8-afab-71532c2b7804"
      decimals="-5"
      id="F_ccfeffea-9c01-4f52-8c7b-2b46b2208fc0"
      unitRef="U_USD">800000</iobt:RefundableTaxCreditReceivable>
    <iobt:AccruedResearchAndDevelopmentCostsPoliciesTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_56e1a531-e38a-4db2-a257-973b14b9863b">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accrued Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Substantial portions of our pre-clinical and clinical trials are performed by third-party laboratories, medical centers, CMOs, CROs and other vendors. These vendors generally bill monthly for services performed, or bill based upon milestone achievement. For preclinical studies, we accrue expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled, the duration of the study and other investigative costs. We monitor patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to us by the CROs, correspondence with the CROs and clinical site visits. Our estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. We periodically evaluate the estimates to determine if adjustments are necessary or appropriate based on information we receive.&lt;/span&gt;</iobt:AccruedResearchAndDevelopmentCostsPoliciesTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_dd8c77a1-5c17-4eed-946c-7d106b9a25e8">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (&#x201c;ASC 842&#x201d;) to enhance the transparency and comparability of financial reporting related to leasing arrangements. Under this lease standard, most leases are required to be recognized on the balance sheet as right-of-use (ROU) assets and lease liabilities. The right-of-use model requires a lessee to recognize a ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement as well as the reduction of the right of use asset. In 2022, the Company adopted the standard effective January 1, 2022 and chose to use the effective date as date of initial application. The standard provides a number of optional practical expedients in transition. Upon adoption, the Company elected to apply the &#x2018;package of practical expedients&#x2019; which allowed the Company to not reassess (1) whether existing or expired arrangements contain a lease; (2) the lease classification of existing or expired leases; or (3) whether previous initial direct costs would qualify for capitalization under the new lease standard. The Company also elected to apply (1) the practical expedient which allows us to not separate lease and non-lease components, for new leases entered into after adoption and (2) the short-term lease exemption for all leases with an original term of less than 12 months, for purposes of applying the recognition and measurements requirements in the new standard.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#x2019;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company will utilize the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. As of January 1, 2022, the ASC 842 effective date, the Company&#x2019;s incremental borrowing rate was approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% based on the remaining lease term of the applicable leases.&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <iobt:OperatingLeaseIncrementalBorrowingRateOnRemainingLease
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="1"
      id="F_249bfc8b-1560-4135-a3fc-ed10c71696f6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.5</iobt:OperatingLeaseIncrementalBorrowingRateOnRemainingLease>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_f2ee48e3-6c29-4840-b94f-b40ee0c8131b">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We account for stock options granted in accordance with ASC 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In accordance with ASC 718, compensation expense is measured at the estimated fair value of the stock options at grant date and is included as compensation expense over the vesting period during which an employee provides service in exchange for the award on a straight-line basis. Vesting of the awards depend solely on service conditions required of the employee.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All share-based awards granted are measured based on the fair value on the date of the grant and compensation expense is recognized with respect to those awards over the requisite service period, which is generally the vesting period of the respective award. The Company reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equity-based compensation expense is classified in the Company&#x2019;s consolidated statements of operations in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes model. The following summarizes the inputs used:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies because we lack company-specific historical and implied volatility information due in part to the limited time in which we have operated as a publicly traded company. We expect to continue to do so until such time as we have adequate historical data regarding the volatility of our traded stock price.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The expected term of the Company&#x2019;s stock options has been determined based on the expected time to liquidity. The Company uses the simplified method prescribed by the SEC&#x2019;s Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term of options granted because we lack company-specific historical and implied expected term information due in part to the limited time in which we have operated as a publicly traded company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The risk-free interest rate is based on the implied yield on a U.S. Treasury security at a constant maturity with a remaining term equal to the expected term of the option granted.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Dividends&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expected dividend yield is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; because the Company does not pay cash dividends on common shares and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Share Price&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: The Company's common stock trades on the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nasdaq Global Market under the symbol &#x201c;IOBT" and is utilized to determine the fair value of the Company's share price.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="2"
      id="F_db0e5d9c-87f6-4af0-83fb-97621707894c"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_a1dfb2c6-dea7-4174-a9d4-232e9bef6752">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are established when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We follow the provisions of ASC 740-10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Uncertainty in Income Taxes. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have not recognized a liability as a result of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; unrecognized benefit since the date of adoption and we have not recognized interest expense or penalties as a result of ASC 740-10. If there were an unrecognized tax benefit, we would recognize interest accrued related to unrecognized tax benefits as income tax expense within our consolidated statements of operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have identified Denmark and the U.S. as our major tax jurisdictions.&lt;/span&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="INF"
      id="F_ae77d6f9-a477-4658-8e27-281df5b02395"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <iobt:WarrantsPolicyPolicyTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_5197b6f2-d80c-4355-8fdb-7ebfe6a3995a">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Warrants Issued in Connection with Sale of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for warrants issued as a separable unit in connection with sale of common stock as either liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#x201c;ASC 480-10&#x201d;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock (&#x201c;ASC 815-40&#x201d;). Under ASC 480-10, warrants are considered liabilities if they are mandatorily redeemable and they require settlement in cash or other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as liability or equity. If warrants do not require liability classification under ASC 815-40 or other applicable U.S. GAAP the warrants should be classified as equity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The proceeds received from the sale of equity classified warrants and sh&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ares of common stock in a bundled transaction are allocated based on the relative fair values of warrants and shares of common stock with no changes in fair value of warrants recognized after the issuance date. Based on our analysis of the foregoing, the Company's warrants issued in the Private Placement are classified as equity in our consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</iobt:WarrantsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_826b38b4-5ff5-4931-8e78-4c636eeaf6fc">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders  by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method and the as if-converted method, for convertible securities, if inclusion of these instruments is dilutive. Potentially dilutive securities include stock options and warrants to purchase common stock of the Company. In all periods presented, the Company&#x2019;s outstanding stock options and warrants were excluded from the calculation of diluted net loss per share because their effects were anti-dilutive.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_119d73b2-bdb4-4db4-8dcf-5b39554186d5">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (CODM), in deciding how to allocate resources to an individual segment and in assessing performance. Our CODM is our chief executive officer. The Company has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_7d75fc19-07a9-4dd2-aa03-6ce39b5aee66">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Other Comprehensive Income (Loss)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;OCI is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our OCI includes currency translation from the Euro and the British Pound, the functional currency of IO Biotech ApS and IO Biotech Limited, respectively, to the U.S. Dollar, our reporting currency.&lt;/span&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <iobt:EmergingGrowthCompanyStatusPoliciesTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_e31fbf31-239b-4d32-90f8-1bc1f6ff70f1">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (1) are no longer an emerging growth company or (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;</iobt:EmergingGrowthCompanyStatusPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_92794b0f-205f-4de0-8dc3-749b638aeb5d">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently adopted accounting standards&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#x2014;Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_50d1f921-ea74-4d65-b53b-2d642b4f270d;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ASU 2019-04&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; the standard effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The adoption of the standard has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t had a material impact on our financial statements or financial statement disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity s Own Equity (Subtopic 815-40): Accounting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;being separately recognized from the host contract as compared with current U.S. GAAP. Convertible instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;that continue to be subject to separation models are (1) those with embedded conversion features that are not&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the derivatives scope exception for contracts in an entity&#x2019;s own equity to reduce form-over-substance-based&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;accounting conclusions. ASU 2020-06 will be effective for us in the interim periods in the fiscal year beginning after December 15, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;interim periods within those fiscal years. We are currently assessing the impact adoption of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ASU 2020-06 will have on our financial statements and disclosures, but do not expect a material impact on the financial statements or disclosures.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2023, the FASB issued ASU 2023-06, Accounting Standards Update 2023-06&#x2014;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative. ASU 2023-06 will eliminate disclosure requirements that are redundant, duplicative, overlapping, outdated, or superseded as a result of subsequent changes to SEC disclosure requirements, U.S GAAP or technology. ASU 2023-06 is intended to better align U.S. GAAP requirements with those of the SEC and to facilitate the application of U.S. GAAP. The disclosure requirements would apply prospectively in the financial statements. ASU 2023-06 will be effective for us on the date on which the SEC&#x2019;s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, if we are already subject to the SEC&#x2019;s current disclosure requirements. For those current disclosure requirements we are not subject to, ASU 2023-06 will become effective two years after the date of such removal by the SEC. We are currently assessing the impact adoption of ASU 2023-06 will have on our financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 will improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 will also enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment and contain other disclosure requirements. The enhanced segment disclosure requirements apply retrospectively to all prior periods presented in the financial statements. ASU 2023-07 will be effective for us in the annual periods beginning after December 15, 2023. We are currently assessing the impact adoption of ASU 2023-07 will have on our financial statements and disclosures, but do not expect a material impact on the financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 will require disclosure of additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate (the rate reconciliation) for federal, state and foreign income taxes. ASU 2023-09 will also require information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold.  ASU 2023-09 will be effective for us in the annual periods beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. We are currently assessing the impact adoption of ASU 2020-06 will have on our financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our consolidated financial statements&lt;/span&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      id="F_fbd59a99-de54-420d-aa86-1aed79344f1b">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      id="F_464c5d34-9e07-4ab9-b842-5f7ee5e4633d">2023-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      id="F_7927560a-b601-49fa-b29f-07ae81b86e67">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_a1b2fb2f-73f6-4a6a-a65c-772552cced35">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value are performed in a manner to maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classified its money market funds within Level 1 as the fair value of the funds are based on their quoted market prices in an active market.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables present information about our financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1) Money market funds with maturities of 90 days or less at the date of purchase are included within cash and cash equivalents in the accompanying consolidated balance sheets and are recognized at fair value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, the Company only held Level 1 financial instruments.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; transfers among Level 1, Level 2 or Level 3 categories in the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;23 and 2&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_67ec19b0-6e02-44b0-900e-36da532b1844">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables present information about our financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1) Money market funds with maturities of 90 days or less at the date of purchase are included within cash and cash equivalents in the accompanying consolidated balance sheets and are recognized at fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_adf457e8-e0ad-4c0c-aaa7-41e091effa59"
      decimals="-3"
      id="F_0af8c9b5-c9b7-4458-bc1d-b4c297735afc"
      unitRef="U_USD">131613000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_85d6429e-66de-40ef-8389-98da77aaac70"
      decimals="-3"
      id="F_c7ab0217-001f-4dc4-9622-63e6bde1a776"
      unitRef="U_USD">131613000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_735c9fc1-57ba-400b-99d6-3730bae07801"
      decimals="-3"
      id="F_2a8dfd89-4902-4a79-86e0-482de63a21b5"
      unitRef="U_USD">131613000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_856ab70f-a3ef-4cca-b917-88f71a19dda0"
      decimals="-3"
      id="F_914e95b9-d693-41e5-8852-4ac9dd46af71"
      unitRef="U_USD">131613000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_589be980-c3a1-445b-9010-4a1c2db1e2ba"
      decimals="-3"
      id="F_90a4a485-8f58-40ef-abc3-1b0e2dc85bd7"
      unitRef="U_USD">87971000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d7201268-1a27-4850-b9eb-b381cbd53051"
      decimals="-3"
      id="F_43eb5e64-dd5c-4fcb-9254-81d034c04abd"
      unitRef="U_USD">87971000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_cdcfe8ca-1864-4dc3-9e85-2db43b36cb88"
      decimals="-3"
      id="F_92c9b7d5-2d39-4aa8-a609-2fa81995d825"
      unitRef="U_USD">87971000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_77688354-ad09-4f13-a478-c216dd6f48f9"
      decimals="-3"
      id="F_bde634ce-5761-457c-bbcc-c9bb53229031"
      unitRef="U_USD">87971000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="INF"
      id="F_97586331-a9cb-4d20-9c53-f21fc9aefd8d"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <iobt:FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="INF"
      id="F_f4e1663f-4627-44b6-98fb-3d3f9c7256ba"
      unitRef="U_USD">0</iobt:FairValueLiabilitiesLevel1ToLevel2TransfersAmount1>
    <iobt:FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="INF"
      id="F_44c82a4c-525b-4ab6-bcb1-a242519e6b97"
      unitRef="U_USD">0</iobt:FairValueLiabilitiesLevel2ToLevel1TransfersAmount1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="INF"
      id="F_0a47edea-5d4b-4422-aae5-f3f96901f84d"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <iobt:FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="INF"
      id="F_1af21924-417a-43b0-962f-8c850214cbf2"
      unitRef="U_USD">0</iobt:FairValueLiabilitiesLevel2ToLevel1TransfersAmount1>
    <iobt:FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="INF"
      id="F_70291045-524f-442d-a7a5-0be955bbdd88"
      unitRef="U_USD">0</iobt:FairValueLiabilitiesLevel1ToLevel2TransfersAmount1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="INF"
      id="F_969e7053-7b1e-47dd-bf37-fd87ea439870"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="INF"
      id="F_58a166e8-43af-425f-a0d0-89ab03b88b54"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_f27642b1-1099-47e5-a8d9-a8123dfd7026">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. License and Collaboration Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Clinical Trial Collaboration and Supply Agreements with MSD International GmbH&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2018, we entered into a clinical collaboration with MSD International GmbH (MSDIG) to evaluate IO102 in combination with KEYTRUDA&#xae; (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer. Under the terms of the collaboration with MSDIG, we will conduct an international Phase 1/2 study to evaluate a combination therapy of IO102 and KEYTRUDA&#xae;. We will sponsor the clinical trials and MSDIG will provide KEYTRUDA&#xae; to be used in the clinical trials free of charge. We and MSDIG will be responsible for our own internal costs and expenses to support the study and we shall bear all other costs associated with conducting the study, including costs of providing IO102 for use in the study. The rights to the data from the clinical trials will be shared by us and MSDIG and we will maintain global commercial rights to IO102.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; In September 2021, we entered into a clinical collaboration with MSDIG and MSD International Business GmbH (MSDIB), another affiliate of Merck (collectively, &#x201c;MSD&#x201d;) to evaluate IO102-IO103 in combination with KEYTRUDA&#xae; versus KEYTRUDA&#xae; alone in treatment of patients with metastatic (advanced) melanoma. Under the terms of the collaboration with MSD, we are conducting an international Phase 3 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA&#xae;. We are the sponsor of the clinical trials and MSD will provide KEYTRUDA&#xae; to be used in the clinical trials free of charge. We and MSD are responsible for our own internal costs and expenses to support the study and we will bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trials will be shared by us and MSD and we will maintain global commercial rights to IO102-IO103.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; In December 2021, we entered into a clinical collaboration with MSD to evaluate IO102-IO103 in combination with KEYTRUDA&#xae; in previously untreated patients with three different tumor types&#x2014; metastatic non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and urothelial bladder cancer (UBC). Under the terms of the collaboration with MSD, we are conducting an international Phase 2 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA&#xae;. We are the sponsor of the clinical trials and MSD will provide KEYTRUDA&#xae; to be used in the clinical trials free of charge. We and MSD are responsible for our own internal costs and expenses to support the study and we will bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trials will be shared by us and MSD and we will maintain global commercial rights to IO102-IO103.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  In November 2022, we entered into a clinical collaboration with MSD to evaluate IO102-IO103 in combination with KEYTRUDA&#xae; as a neo-adjuvant/adjuvant therapy for patients with metastatic melanoma and SCCHN. Under the terms of the collaboration with MSD, we will conduct an international Phase 2 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA&#xae;. We will sponsor the clinical trials and MSD will provide KEYTRUDA&#xae; to be used in the clinical trials free of charge. We and MSD will be responsible for our own internal costs and expenses to support the study and we shall bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trials will be shared by us and MSD and we will maintain global commercial rights to IO102-IO103.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_c186f951-afcc-47af-9ce3-9a1e1df8257f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development tax credit receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Value-added tax refund receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid contract research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_498b5976-22b5-4e72-943b-dda9d5d1cbe6">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development tax credit receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Value-added tax refund receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid contract research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_038eb1a2-fcf6-4493-beeb-6c34be1e4c5a"
      unitRef="U_USD">1352000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_3bb3278a-33cc-4d6f-a9cd-23280bfb378c"
      unitRef="U_USD">1716000</us-gaap:PrepaidInsurance>
    <iobt:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_17be1b04-b59d-45aa-be0d-1ccdc45ed4b0"
      unitRef="U_USD">814000</iobt:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <iobt:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_0af6859b-072b-418b-a08b-141bfd6cd211"
      unitRef="U_USD">792000</iobt:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <us-gaap:PrepaidTaxes
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_b2c2afaa-400c-4ad8-ae07-c2ba95a24a2a"
      unitRef="U_USD">829000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_b2406986-66a5-435c-9f1b-15abdb657559"
      unitRef="U_USD">124000</us-gaap:PrepaidTaxes>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_3cf079fb-50ee-48c1-9ad2-5f86c4b1ba11"
      unitRef="U_USD">313000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_1aad2203-039b-413b-820f-2d55de6a6485"
      unitRef="U_USD">741000</us-gaap:ValueAddedTaxReceivableCurrent>
    <iobt:PrepaidContractResearchAndDevelopmentCostsCurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_a0aa3130-1472-4790-b288-751f08982c5c"
      unitRef="U_USD">1695000</iobt:PrepaidContractResearchAndDevelopmentCostsCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_0e62e451-4b42-4baa-ac01-04ac0ae463c8"
      unitRef="U_USD">754000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_0bfb164e-ea37-467f-9f0f-c08e4de762e5"
      unitRef="U_USD">561000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_13acb106-18fe-4633-b2e2-b684c7a5dc07"
      unitRef="U_USD">4062000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_c8dd6ceb-0026-4284-803e-b309c5db10a1"
      unitRef="U_USD">5629000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_9e236b9c-8b1d-4fa9-aa7d-985f315367d0">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.527%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.057%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.057%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer hardware&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the years ended December 31, 2023 and 2022, the Company recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, of depreciation expense in the consolidated statements of operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_389dc251-8e6b-42ad-b1f6-927bd538f87c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.527%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.057%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.057%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer hardware&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a0c8c506-94c5-4204-b3e9-4087e11e4d77"
      decimals="-3"
      id="F_5a243de8-ff95-4fc7-a811-9c033a1bad8f"
      unitRef="U_USD">836000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ed65f1e2-5595-4174-b58c-577f2a1fce62"
      decimals="-3"
      id="F_741c291e-e0f2-4b0f-abc3-119d6de69db0"
      unitRef="U_USD">544000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c457cad7-3e0c-4a59-b4de-aa28ef642dbf"
      decimals="-3"
      id="F_cf646ba5-3c00-4707-a4a1-df2ffeb4fdfa"
      unitRef="U_USD">238000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c6520b4d-f760-4dd3-8633-eeeaeb10c4af"
      decimals="-3"
      id="F_741cfd48-5fa2-4c74-a67e-3a138ef6015d"
      unitRef="U_USD">233000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a179b419-8f22-455d-a4ab-2a0aa92c018a"
      decimals="-3"
      id="F_be7c0658-b204-4f15-8d0e-7b32b1255976"
      unitRef="U_USD">103000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2bad730b-2375-4c64-b7fb-4fb30c1b1ef9"
      decimals="-3"
      id="F_ccb5145d-58ea-4b99-817a-6bae61a5e63f"
      unitRef="U_USD">79000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_94893afa-d77d-48c3-9f18-a4d5c63213f1"
      unitRef="U_USD">330000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_e5fe87f0-03ee-450a-9c24-5a58bc475eb7"
      unitRef="U_USD">115000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_9c751cef-8825-47f1-aec4-f03ca63fde8a"
      unitRef="U_USD">847000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_2ef14a23-7ec5-4666-a2e6-f2aa065384b5"
      unitRef="U_USD">741000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-5"
      id="F_f5e06159-052b-4e72-9737-caf9954de131"
      unitRef="U_USD">200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-5"
      id="F_bcbfc4ab-d743-418f-aca3-5938984b7c0a"
      unitRef="U_USD">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_32e00243-f331-44f3-8d86-20576208c568">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued contract research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee compensation costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_7b8411d4-d75f-411a-b64c-999666ea7212">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued contract research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee compensation costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <iobt:AccruedContractResearchAndDevelopmentCostsCurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_fa886c44-88a8-4fd1-938e-5e46d637480a"
      unitRef="U_USD">6153000</iobt:AccruedContractResearchAndDevelopmentCostsCurrent>
    <iobt:AccruedContractResearchAndDevelopmentCostsCurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_e485d5be-9933-4f1b-8e11-4d31b03afbfe"
      unitRef="U_USD">1936000</iobt:AccruedContractResearchAndDevelopmentCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_559cb8d4-7bb0-4002-894f-5d38f469e605"
      unitRef="U_USD">4225000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_ed51369d-d849-49c7-9c5e-f395c55abae7"
      unitRef="U_USD">1863000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_d00365ba-113c-4b25-9555-17e091a60526"
      unitRef="U_USD">243000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_9abda506-3fec-4ba4-baa7-557c939a46ae"
      unitRef="U_USD">407000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_f621ac6c-d6d7-4234-9b67-4c34b9996b63"
      unitRef="U_USD">563000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_4cc3413e-66fb-4abd-84fb-dceca8069c50"
      unitRef="U_USD">1951000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_4bea18b3-9747-4222-abea-9b0fb3aa4c13"
      unitRef="U_USD">11184000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_bf6cb09a-beef-43db-be54-4eac3af5698d"
      unitRef="U_USD">6157000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_2420de48-a142-4c16-8efa-ba5d886ebadc">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 1, 2022, the Company adopted ASC 842 using the modified retrospective transition approach allowed under ASU 2018-11 which releases companies from presenting comparative periods and related disclosures under ASC 842 and requires a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption (Note 2). The Company had an immaterial cumulative-effect adjustment to the opening balance of accumulated deficit as of January 1, 2022. The Company is party to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating leases for laboratory and office space. The Company&#x2019;s finance leases are immaterial both individually and in the aggregate. The Company has elected to apply the short-term lease exception to all leases of one year or less. Further, the Company has applied the guidance in ASC 842 to our corporate office and laboratory leases and has determined that these should be classified as operating leases. Consequently, as a result of the adoption of ASC 842 on January 1, 2022, we recognized an ROU lease asset of approximately&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million with a corresponding lease liability of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million based on the present value of the minimum rental payments of such leases. In accordance with ASC 842, the beginning balance of the ROU lease asset was reduced by the existing deferred rent liability at inception of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. In the consolidated balance sheet as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, the Company has an ROU asset balance of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and a current and non-current lease liability of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, relating to the ROU lease asset. The balance of both the ROU lease asset and the lease liabilities primarily consists of future payments under the Company&#x2019;s office leased in New York, New York, Rockville, Maryland and Copenhagen, Denmark. &lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is party to an operating lease in Copenhagen, Denmark for office space that commenced in March 2021 with an initial term that expired in January 2025. Base rent for this initial lease was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million annually. The Company amended its operating lease in Copenhagen, Denmark on September 1, 2022 with a new term set to expire in December 2027. The base rent for the amended lease is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million annually. The Company is also party to an operating lease in Copenhagen, Denmark for laboratory space that commenced in January 2023 with the term set to expire in December 2027. The base rent for the lease is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.04&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million annually. The Company is party to an operating lease in New York, New York for office space that commenced in October 2021 with the initial term set to expire in January 2027. Base rent for this lease is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million annually. The Company is party to an operating lease in Rockville, Maryland for office and laboratory space that commenced in December 2021 with the initial term set to expire in May 2027. Base rent for this lease is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million annually. The Company is party to an immaterial operating lease in Newport, United Kingdom that commenced in June 2023. Rent expense for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively. &lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Quantitative information regarding the Company&#x2019;s leases for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;year ended December 31, 2023 is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.974%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.319%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.035%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.319%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.035%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.319%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Lease Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating cash flows paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liabilities arising from obtaining right&#x2011;of&#x2011;use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future lease payments (undiscounted) under noncancelable leases are as follows as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Future Lease Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s leases do not provide an implicit rate, therefore the Company used its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company used the incremental borrowing rate on January 1, 2022 for operating leases that commenced prior to that date, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <iobt:NumberOfOperatingLease
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="INF"
      id="F_3f762881-5d5e-4f75-bd7a-6798a3992cd0"
      unitRef="U_Lease">5</iobt:NumberOfOperatingLease>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_37d816e8-ef70-4e8e-b59e-b1a42f867be6"
      decimals="-5"
      id="F_359ae5e5-a48d-4f8f-8f46-9035f2e64650"
      unitRef="U_USD">2300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_37d816e8-ef70-4e8e-b59e-b1a42f867be6"
      decimals="-5"
      id="F_129638e4-c0fb-4749-bb15-b655f468d3f7"
      unitRef="U_USD">2400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DeferredRentCredit
      contextRef="C_37d816e8-ef70-4e8e-b59e-b1a42f867be6"
      decimals="-5"
      id="F_33f128c0-faf4-4a18-b142-7d5340eb4abe"
      unitRef="U_USD">100000</us-gaap:DeferredRentCredit>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-5"
      id="F_073e5c4c-2dab-42de-a589-19f3e478c2e2"
      unitRef="U_USD">2300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-5"
      id="F_9bbb86be-30ce-47f6-8611-ea53f486b2c1"
      unitRef="U_USD">700000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-5"
      id="F_a87b2a14-b611-4277-bded-8ec45bbf825d"
      unitRef="U_USD">1800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <iobt:OperatingLeaseAnnualBaseRent
      contextRef="C_d1bf34e5-9771-45f8-8bae-3cab72620d3b"
      decimals="-5"
      id="F_5fd81edc-3af5-4b26-b740-8b497ef5593b"
      unitRef="U_USD">100000</iobt:OperatingLeaseAnnualBaseRent>
    <iobt:OperatingLeaseAmendedBaseRent
      contextRef="C_ec32ec8b-699d-4395-8839-904cf311de78"
      decimals="-5"
      id="F_cf810669-3e51-4214-8e66-38eb81e5690b"
      unitRef="U_USD">200000</iobt:OperatingLeaseAmendedBaseRent>
    <iobt:OperatingLeaseAnnualBaseRent
      contextRef="C_fc58b312-a405-4ae4-8b50-2ef63fe4fbd2"
      decimals="-4"
      id="F_64b3732f-38a7-48e6-89aa-5605adc99321"
      unitRef="U_USD">40000.00</iobt:OperatingLeaseAnnualBaseRent>
    <iobt:OperatingLeaseAnnualBaseRent
      contextRef="C_7f69509c-a54b-452b-9c95-a1abe33fe007"
      decimals="-5"
      id="F_59cc8263-0865-4e6a-8e8d-6bc6b147cca4"
      unitRef="U_USD">200000</iobt:OperatingLeaseAnnualBaseRent>
    <iobt:OperatingLeaseAnnualBaseRent
      contextRef="C_4f734c8a-b5ea-4a27-879c-88db0c526af2"
      decimals="-5"
      id="F_1573b6d7-3ef9-4ee8-973b-0937c37374c0"
      unitRef="U_USD">300000</iobt:OperatingLeaseAnnualBaseRent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-5"
      id="F_428c0fc0-6887-4ba3-972d-3b56a8b45787"
      unitRef="U_USD">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-5"
      id="F_cb509a54-4c11-4331-b06a-99ee64b136fa"
      unitRef="U_USD">800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_acdaf063-0dc8-403c-8f4e-d4ac5a13ca65">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Quantitative information regarding the Company&#x2019;s leases for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;year ended December 31, 2023 is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.974%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.319%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.035%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.319%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.035%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.319%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Lease Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating cash flows paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liabilities arising from obtaining right&#x2011;of&#x2011;use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_5d8cab44-6f5c-4ff0-bce0-f5db80dc4ac6"
      unitRef="U_USD">730000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_fb5e0a29-563a-4775-ab08-d3f5ccf9dd5f"
      unitRef="U_USD">755000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_0a778271-69de-4127-b2b9-30ad3bbc9956"
      unitRef="U_USD">723000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_6f32e24e-631f-464e-b093-6b977710182b"
      unitRef="U_USD">419000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_822dbe46-9638-4c4a-9a9d-668b80aee624"
      unitRef="U_USD">235000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_63db5dbe-3caa-4018-98fe-421cb28cd42b"
      unitRef="U_USD">2600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <iobt:OperatingLeaseRemainingLeaseTerm
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      id="F_f4ec0d25-df05-4554-a771-f373a008a783">P3Y6M</iobt:OperatingLeaseRemainingLeaseTerm>
    <iobt:OperatingLeaseRemainingLeaseTerm
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      id="F_c46c16fb-b0c5-402c-a143-7ce5131079c9">P4Y6M</iobt:OperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="3"
      id="F_cc461f6c-69cd-4959-8beb-378ab2de9af0"
      unitRef="U_pure">0.063</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="3"
      id="F_4b319240-9815-4e32-8c84-3147ef122a43"
      unitRef="U_pure">0.065</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_3fb7fbf8-5689-41d4-bfa7-f08b87dd47d1">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future lease payments (undiscounted) under noncancelable leases are as follows as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Future Lease Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_5e89589e-36ec-4312-b1c9-716e6c448f0e"
      unitRef="U_USD">793000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_de8b9a8a-c65e-46be-aa6c-b07538a6fc37"
      unitRef="U_USD">792000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_78b0ee58-a93b-4fe5-bf57-e032cd22b0e1"
      unitRef="U_USD">798000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_25e0d9df-0ef0-43c9-9a83-9c32169a3d67"
      unitRef="U_USD">403000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_f2fc7e7c-cb32-4bf7-8798-a1c2ebcf2fb5"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_b47026c5-9c39-46f9-b0ae-3109cf5fd227"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_24e89747-30f6-4576-bd36-403d6d567cc5"
      unitRef="U_USD">2786000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_fb1f8d95-31f0-417b-a328-c5a9b045d286">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, we may be party to litigation arising in the ordinary course of its business. We were not subject to any material legal proceedings during the years ended December 31, 2023 and 2022, and, to our knowledge, no material legal proceedings are currently pending or threatened.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Contractual Obligations and Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We enter into contracts in the ordinary course of business with third-party service providers for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; days, and therefore, we believe that our noncancelable obligations under these agreements are not material and we cannot reasonably estimate whether they will occur. However, in the event of a termination of any contracts with CROs or other institutions and with respect to active patients enrolled in our clinical trials, we may be financially obligated for a period beyond the contractual termination notice periods. We may also enter into additional research, manufacturing, supplier, lease and other agreements in the future, which may require up-front payments and even long-term commitments of cash.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Indemnification Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We enter into certain types of contracts that contingently requires us to indemnify various parties against claims from third parties. These contracts primarily relate to procurement, service, consultancy or license agreements under which we may be required to indemnify vendors, service providers or licensees for certain claims, including claims that may be brought against them arising from our acts or omissions with respect to our products, technology, intellectual property or services. The Company, as permitted under Delaware law and in accordance with its amended and restated certificate of incorporation and amended and restated bylaws and pursuant to indemnification agreements with certain of its officers and directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, which the officer or director is or was serving at the Company&#x2019;s request in such capacity.  At the 2023 Annual Meeting of Stockholders, the Company&#x2019;s stockholders approved an amendment to, and the Company subsequently amended, its amended and restated certificate of incorporation to extend the indemnification of officers pursuant to recent amendments to the General Corporation Law of the State of Delaware.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, we may receive indemnification claims under existing contracts in the normal course of business. In the event that one or more of these matters were to result in a claim against us, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on our future business, operating results or financial condition. It is not possible to estimate the maximum amount potentially payable under these contracts since we have no history of prior indemnification claims and the unique facts and circumstances involved in each particular claim will be determinative.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <iobt:ContractualObligationsTerminationNoticePeriod
      contextRef="C_b343bb6c-f4f5-4b19-844e-c92494b10a7e"
      id="F_e42f194b-ea27-45c3-9ef9-50c839f76eaa">P30D</iobt:ContractualObligationsTerminationNoticePeriod>
    <iobt:ContractualObligationsTerminationNoticePeriod
      contextRef="C_fbedcb5d-67e0-47f1-96ac-c9bcc05daf23"
      id="F_90a210a8-6a18-4275-87e0-c1b5b3e93bdf">P90D</iobt:ContractualObligationsTerminationNoticePeriod>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_5cf7f29a-3323-4097-ba2d-3a097911b92d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10. Stockholders' Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Common and Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Upon the closing of our IPO in November 2021, we filed an amended and restated certificate of incorporation, which authorized us to issue &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;300,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of preferred stock. The shares of preferred stock are currently undesignated. Common stockholders are entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings. Common stockholders are entitled to receive dividends, if and when declared by the Company's board of directors (Board). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; dividends have been declared or paid by us through &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;The Private Placement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 7, 2023, the Company entered into the Purchase Agreement, pursuant to which the Company agreed to sell and issue (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, and (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Warrants in the Private Placement. Each Purchaser&#x2019;s Warrant is exercisable for a number of shares of common stock equal to one hundred percent of the aggregate number of shares of common stock purchased by such Purchaser. The Purchase Price for each common stock and Warrant was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Warrants are exercisable at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.47&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, subject to adjustment as set forth therein. The Warrants are exercisable until the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an acquisition, as defined in the Warrants. The Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the Warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Private Placement closed on August 9, 2023. The Company received &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in gross proceeds from the Private Placement, before deducting offering expenses of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Of the total proceeds, legal entities of certain related parties contributed $33&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and members of management contributed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company intends to use the net proceeds of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the Private Placement for general corporate purposes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Warrants were classified as a component of permanent stockholders&#x2019; equity within additional paid-in-capital and were recorded at the issuance date using a relative fair value allocation method. The Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company&#x2019;s common stock and meet the equity classification criteria. In addition, such Warrants do not provide any guarantee of value or return. The Company valued the Warrants at issuance using the Black-Scholes valuation model and allocated proceeds from the sale proportionately to the common stock and Warrants, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was allocated to the Warrants and recorded as a component of additional paid-in-capital. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; warrants issued and outstanding at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.47&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share to purchase shares of the Company's common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the execution of the Purchase Agreement, the Company also entered into a registration rights agreement (the Registration Rights Agreement) with the Purchasers. Under the terms of the Registration Rights Agreement, the Company has filed the Registration Statement with the SEC to register for resale the common stock issued under the Purchase Agreement and the shares of common stock issuable upon conversion of the Warrants issued pursuant to the Purchase Agreement (the Registrable Securities), which Registration Statement was declared effective on September 8, 2023. The Company may be required to pay certain liquidated damages under the terms of the Registration Rights Agreement in the event sales cannot be made pursuant to the Registration Statement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,880,914&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,815,267&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; common shares outstanding, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="INF"
      id="F_85d373fa-4c93-4485-aed3-9041f5e2340d"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_1ae0c7b5-ef8e-4cb0-93ba-4ebe49f60bd5"
      decimals="INF"
      id="F_289f6d5d-4711-4875-9974-bfa724f8d473"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <iobt:NumberOfVotePerShare
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="INF"
      id="F_5d60fc88-41eb-4489-867c-abb13e119600"
      unitRef="U_Vote">1</iobt:NumberOfVotePerShare>
    <us-gaap:Dividends
      contextRef="C_e7f56205-a6d1-42a7-bef6-62ddf1cf7159"
      decimals="INF"
      id="F_562388c7-807d-44f7-9e84-b0b3b9caa151"
      unitRef="U_USD">0</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="C_c4753ff1-8839-464e-bba4-852e1ac3dc55"
      decimals="INF"
      id="F_d05c9d9a-fb26-4f43-84f1-2ed94730b3d2"
      unitRef="U_USD">0</us-gaap:Dividends>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1089e4d9-f1b0-4539-bd02-0c5b3cebf7f8"
      decimals="INF"
      id="F_7b18acab-a048-4ba1-8a99-274cfb78d77c"
      unitRef="U_shares">37065647</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <iobt:WarrantsIssued
      contextRef="C_7888a195-a9c8-438b-8292-c9c9a460c8d3"
      decimals="INF"
      id="F_7f332518-9077-4a7b-abab-861fda985c4b"
      unitRef="U_shares">37065647</iobt:WarrantsIssued>
    <iobt:PurchasePricePerShareOfCommonStockAndWarrant
      contextRef="C_7888a195-a9c8-438b-8292-c9c9a460c8d3"
      decimals="INF"
      id="F_c69a1133-e337-44ef-addb-79a2a7e76aee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.025</iobt:PurchasePricePerShareOfCommonStockAndWarrant>
    <iobt:WarrantsExercisablePricePerShare
      contextRef="C_7888a195-a9c8-438b-8292-c9c9a460c8d3"
      decimals="INF"
      id="F_18c1592b-53f5-4bad-bf60-256e62542524"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.47</iobt:WarrantsExercisablePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_0307f33c-16a4-4f72-98f6-13168e29e650"
      decimals="-5"
      id="F_512f5fcc-047e-4366-8835-170736ed8f8c"
      unitRef="U_USD">75100000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0307f33c-16a4-4f72-98f6-13168e29e650"
      decimals="-5"
      id="F_a12c7c1a-b8ef-4d19-a983-837de65b0899"
      unitRef="U_USD">3200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_a06c72c9-9013-4145-a984-c7a878870eb5"
      decimals="-5"
      id="F_dc6d530d-1c00-491b-abb1-e30a752441e2"
      unitRef="U_USD">400000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_f4208fa4-bfe6-48ee-94c0-37e910003209"
      decimals="-5"
      id="F_23f3badb-d123-4131-ba36-206a476e6017"
      unitRef="U_USD">200000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <iobt:NetProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_0307f33c-16a4-4f72-98f6-13168e29e650"
      decimals="-5"
      id="F_2ce4b024-6542-4342-96bc-19b31b8bc371"
      unitRef="U_USD">71900000</iobt:NetProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_921dd2b2-b1d9-4630-914d-9162f5d60817"
      decimals="-5"
      id="F_64c17818-280a-449e-9c07-5cdb3e8413a6"
      unitRef="U_USD">29600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <iobt:WarrantsIssued
      contextRef="C_921dd2b2-b1d9-4630-914d-9162f5d60817"
      decimals="INF"
      id="F_1f506c67-530d-4ddc-b51f-481f03c8cef2"
      unitRef="U_shares">37065647</iobt:WarrantsIssued>
    <iobt:WarrantsExercisablePricePerShare
      contextRef="C_921dd2b2-b1d9-4630-914d-9162f5d60817"
      decimals="INF"
      id="F_12ec9be6-9065-47ec-a59d-5656c1376c3b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.47</iobt:WarrantsExercisablePricePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="INF"
      id="F_41fd596f-8900-4ab9-a10b-8fdb975ecf8f"
      unitRef="U_shares">65880914</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="INF"
      id="F_629b0a50-f279-40cf-a3f1-dd93e9feb07b"
      unitRef="U_shares">28815267</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_793610c1-d477-48e8-91b9-58ea208cbec5">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11. Equity-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2021, our Board adopted, and our stockholders approved, the 2021 Equity Incentive Plan (2021 Equity Plan), which became effective on November 4, 2021. The 2021 Equity Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, awards of restricted stock, restricted stock units and other stock-based awards. The number of shares of our common stock reserved for issuance under the 2021 Equity Plan is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,496,934&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, subject to an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022 and continuing until, and including, the fiscal year ending December 31, 2031, equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the number of shares of common stock outstanding on the first day of such fiscal year or (ii) such other amount determined by our Board.  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, we had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;593,468&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; options available for future grant under the 2021 Equity Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2021, our Board adopted and our stockholders approved the 2021 IO Biotech, Inc. Employee Stock Purchase Plan (2021 ESPP), which became effective on November 4, 2021. The number of shares of our common stock reserved for issuance under the 2021 ESPP is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;257,272&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, subject to an annual increase, to be added on the first day of each fiscal year, beginning January 1, 2023, equal to the lesser of (1) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the number of shares of common stock outstanding on the first day of such fiscal year; (2) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;257,272&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock; or (3) such other amount as determined by our Board. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, the Board had not yet approved any offering under the 2021 ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2023 Inducement Award Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2023, our Board adopted the 2023 Inducement Award Plan (2023 Inducement Plan), which became effective on September 28, 2023. The 2023 Inducement Plan provides for the grant of non-statutory stock options, stock appreciation rights, awards of restricted stock, restricted stock units and other stock-based awards to eligible employees who satisfy the standards for inducement grants under Nasdaq Global Market rules. The number of shares of our common stock reserved for issuance under the 2023 Inducement Plan is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,976,427&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,976,427&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares available for future grant under the 2023 Inducement Plan.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes our stock options activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;br/&gt;&#160;and &lt;br/&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;br/&gt;per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,071,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,211,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;362,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,920,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,519,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;588,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,851,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,902,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All share-based awards granted are measured based on the fair value on the date of the grant and compensation expense is recognized with respect to those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures related to equity-based compensation awards are recognized as they occur, and we reverse any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the years ended December 31, 2023 and 2022, we recorded equity-based compensation expense of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, related to the issuance of stock options and warrants. As of December 31, 2023, there was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of unrecognized compensation cost related to unvested stock-based compensation arrangements that is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair values of the options granted were estimated based on the Black-Scholes model, using the following assumptions:&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.553%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.683%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.683%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.62&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equity-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total equity-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognize any tax benefits for stock-based compensation during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4842f3fa-8b43-4d85-86bd-f8d28ee08613"
      decimals="INF"
      id="F_7d468d50-b7f8-4a92-b86e-b91eb39b8fc4"
      unitRef="U_shares">2496934</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_4f7c3011-7c33-440c-af08-6ace8d509cd4"
      decimals="2"
      id="F_efc8afa7-c929-4670-9883-3df3fa88311d"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_75c24bfc-711a-4d8f-a9f1-617a36085040"
      decimals="INF"
      id="F_6206ddac-3c44-4319-b31d-891b29024666"
      unitRef="U_shares">593468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_605c651a-ab13-4d27-8446-969fb0785085"
      decimals="INF"
      id="F_c88bc158-50f1-49d0-bb36-87fc18f2656e"
      unitRef="U_shares">257272</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_eaf8786d-c5b6-4a4a-8524-1e92c7607db8"
      decimals="2"
      id="F_c3029f9f-8ea1-4f6b-9e0f-b7c752ee108e"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_605c651a-ab13-4d27-8446-969fb0785085"
      decimals="INF"
      id="F_635d54c6-c0e4-4092-a08b-07bf345d7afb"
      unitRef="U_shares">257272</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a8883698-bb05-40fe-9155-b8dada03facc"
      decimals="INF"
      id="F_7756ca39-af68-4693-83a1-4bd3406584d1"
      unitRef="U_shares">1976427</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_a8883698-bb05-40fe-9155-b8dada03facc"
      decimals="INF"
      id="F_22876125-f53d-4ff6-ba86-40c47b89a1c7"
      unitRef="U_shares">1976427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_0c9be312-a964-432e-9302-36bd91f1a48a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes our stock options activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;br/&gt;&#160;and &lt;br/&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;br/&gt;per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,071,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,211,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;362,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,920,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,519,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;588,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,851,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,902,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_43f3828a-2a64-44ee-9ffc-49729d49c629"
      decimals="INF"
      id="F_75d4ba43-d8c5-4f13-866e-8a9b77d0f5a4"
      unitRef="U_shares">3071613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_43f3828a-2a64-44ee-9ffc-49729d49c629"
      decimals="2"
      id="F_8220f459-8a4b-48d1-8585-eea811fe93c8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_a8dd0b70-be88-4ed9-9abb-fff49a8e9151"
      id="F_8c045dc7-1029-413c-8c19-95358eee5216">P8Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_57a8bc27-67ad-49ea-8c7d-a4bc7bcdaabb"
      decimals="INF"
      id="F_c59aa5da-4ee8-4442-b1e3-a99de02c0db3"
      unitRef="U_shares">1211155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_57a8bc27-67ad-49ea-8c7d-a4bc7bcdaabb"
      decimals="2"
      id="F_84ce89dc-ad7e-4fc5-a1f4-9a7a387580fa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_57a8bc27-67ad-49ea-8c7d-a4bc7bcdaabb"
      decimals="INF"
      id="F_07ff4320-5ec2-416b-95c4-ffc03815dff4"
      unitRef="U_shares">-362596</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_57a8bc27-67ad-49ea-8c7d-a4bc7bcdaabb"
      decimals="2"
      id="F_af765631-19da-4bf5-b442-7c5387f9ee4e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_229bed5d-8df9-47a3-bf23-b8454739ccb1"
      decimals="INF"
      id="F_9ef49c6a-c04c-440d-9df0-1a6dab26c245"
      unitRef="U_shares">3920172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_229bed5d-8df9-47a3-bf23-b8454739ccb1"
      decimals="2"
      id="F_0b465f7d-56e4-4ea7-a38d-3d2806bc2c63"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_57a8bc27-67ad-49ea-8c7d-a4bc7bcdaabb"
      id="F_93527b25-9067-46cf-a6fc-3f6e6f0b4b59">P8Y1M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba"
      decimals="INF"
      id="F_e24df5fe-6bfe-4262-b6d0-494339f404c0"
      unitRef="U_shares">2519994</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba"
      decimals="2"
      id="F_2213174e-2d98-401a-8ed5-6b75f8473bbe"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba"
      decimals="INF"
      id="F_e5a6268b-b065-4339-bc50-e3d5bc5271ec"
      unitRef="U_shares">-588243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba"
      decimals="2"
      id="F_107c6fb8-f5e9-4e67-9b7a-415fe585781d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_95e6310f-8da5-48b8-9242-a4b89a5ea523"
      decimals="INF"
      id="F_6cea26d5-9148-4153-880c-7f646f1c9139"
      unitRef="U_shares">5851923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_95e6310f-8da5-48b8-9242-a4b89a5ea523"
      decimals="2"
      id="F_0c66e49d-816a-4295-9ad1-e6425c8a6690"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba"
      id="F_90cd56c1-a4d9-4e03-813e-9aac00b36e2d">P8Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_95e6310f-8da5-48b8-9242-a4b89a5ea523"
      decimals="-3"
      id="F_c3b5fa44-0056-48b5-b0a6-3ae2fa4ec5fb"
      unitRef="U_USD">102000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable
      contextRef="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba"
      decimals="INF"
      id="F_50f3396b-9ddc-4841-bfa8-28d70637d784"
      unitRef="U_shares">1902547</iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable>
    <iobt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice
      contextRef="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba"
      decimals="2"
      id="F_03c589ee-c304-4df5-9976-a25eca5be13d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.26</iobt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice>
    <iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm
      contextRef="C_2597ab6d-8323-49a8-8a5e-7c0fdd5e78ba"
      id="F_56459260-fd32-4d5c-a18f-a55076c1e81c">P7Y8M12D</iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm>
    <iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue
      contextRef="C_95e6310f-8da5-48b8-9242-a4b89a5ea523"
      decimals="-3"
      id="F_ea665edd-12fc-417a-a06f-314889e74abc"
      unitRef="U_USD">2000</iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-5"
      id="F_40f690af-37ea-464e-bd71-83bf4ac7c3aa"
      unitRef="U_USD">8100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-5"
      id="F_74e5896e-e696-421b-8d41-30015514413a"
      unitRef="U_USD">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-5"
      id="F_57d4e7a2-a939-4c11-98fe-f1b7b74f128a"
      unitRef="U_USD">11200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_38ef42a9-fd51-4e34-a7fe-964d34d919ff">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_7ddf26e9-4e11-4077-b37f-e739ad7dd786">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair values of the options granted were estimated based on the Black-Scholes model, using the following assumptions:&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.553%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.683%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.683%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.62&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="3"
      id="F_66fb5b28-70d8-4fe4-acc7-e943aa6e144f"
      unitRef="U_pure">0.864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="3"
      id="F_03238426-cff6-4a80-88d4-c27db584e339"
      unitRef="U_pure">1.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="3"
      id="F_7a22a916-0ed6-4359-9b9d-ab3e0ab5a191"
      unitRef="U_pure">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="3"
      id="F_6871d9ca-5fcf-49e1-9303-f255a15badbc"
      unitRef="U_pure">0.773</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="3"
      id="F_28bd7b09-c07b-48e6-909a-ea96c933a907"
      unitRef="U_pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="3"
      id="F_e6e4bf85-c462-4def-9597-8d449a9c93ea"
      unitRef="U_pure">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="4"
      id="F_a8274448-3ce8-4832-8f40-3c4dc383cb2f"
      unitRef="U_pure">0.0162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="3"
      id="F_33896bdd-c98d-490c-ab6c-9f12d79644f6"
      unitRef="U_pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_b343bb6c-f4f5-4b19-844e-c92494b10a7e"
      id="F_b18a5fbd-9b01-4046-b791-f52f7c3216c3">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_fbedcb5d-67e0-47f1-96ac-c9bcc05daf23"
      id="F_f179b075-fa8b-47f7-a7b7-ff3ed4ea7484">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ea391396-42d3-4eff-9bdc-69880686eb48"
      id="F_1de6c0d2-23dc-4c3f-ba18-899508c7c323">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_2a3ed7cd-93dc-4db4-bb66-a7f11ce29791"
      id="F_c1601c78-9901-4e31-948d-7876601e05a3">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="2"
      id="F_6fd26216-a4d9-4423-bdfd-c03fccc34711"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="2"
      id="F_cd273477-d393-4479-948d-a51533dee5aa"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_510670c5-ebae-4694-9c4d-4d5a9e788cb9">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equity-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total equity-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_77b4e90b-4f57-4362-beca-0e8dcbcfba19"
      decimals="-3"
      id="F_dd79ce97-fd65-45d4-812f-ce3f4ee41f5a"
      unitRef="U_USD">4204000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c1c118ba-3d68-42c8-9af6-0389748a393e"
      decimals="-3"
      id="F_b8139d46-7678-4169-a837-ac0e974db9f8"
      unitRef="U_USD">2859000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_75385bc1-6f5b-43da-a2b7-ac643558b468"
      decimals="-3"
      id="F_4783e6d2-6968-47ea-8b9c-911251476826"
      unitRef="U_USD">3855000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6f628d94-953f-4311-9f9c-e89296efa0d6"
      decimals="-3"
      id="F_d7855e05-80a6-4556-8363-fc90fec0a540"
      unitRef="U_USD">4181000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_52e00b28-4380-4ce1-b1a7-78eb2f1b1161"
      unitRef="U_USD">8059000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_75a2e161-2f0f-45b1-b15d-c4c695f52071"
      unitRef="U_USD">7040000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="INF"
      id="F_c08dcced-0ee9-4c95-b6e7-e2a1514bf58b"
      unitRef="U_USD">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="INF"
      id="F_a4954dd8-3f3a-4012-8f4a-8e99bde2d1c1"
      unitRef="U_USD">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_7021b10c-a4f2-4097-ad0f-c3aa6d9b4a22">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We are subject to U.S. federal, state and foreign corporate income taxes. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our loss before provision for income taxes for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022 consisted of the following (in thousands): &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reconciliation of Effective Tax Rate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our effective tax rate for the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; is different from the statutory rate in the U.S. primarily due to the valuation allowance against deferred tax assets as a result of insufficient sources of income. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The reconciliation of the statutory income tax rate to our effective income tax rate is as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.358%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.358%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax benefit at the statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Difference in tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;R&amp;amp;D Deduction&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prior period adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Deferred Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is recorded when it is more likely than not&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;that &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;some or all of the deferred tax assets will not be realized. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The principal components of the Company&#x2019;s deferred tax assets consisted of the following (in thousands): &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ROU Lease Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ROU Lease Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax asset (liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2017, the U.S. enacted the Tax Cuts and Jobs Act (the 2017 Tax Act), which contained a provision that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022. Previously, these expenses could be deducted in the year incurred. The implementation of this provision increased our deferred tax asset and valuation allowance by approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;When realization of a deferred tax asset is more likely than not to occur, the benefit related to the deductible temporary differences attributable to operations is recognized as a reduction of income tax expense. Valuation allowances are provided against deferred tax assets when, based on all available evidence, it is considered more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. We cannot be certain that future income in Denmark will be sufficient to realize the Company&#x2019;s deferred tax assets. Accordingly, a full valuation allowance has been provided against our net deferred tax assets in Denmark. We have also provided a full valuation allowance against our net deferred tax assets in the U.S. for IO Bio US, Inc. The Company's valuation allowance increased by &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended December 31, 2023 and 2022, respectively. The increase for the years ended December 31, 2023 and 2022 is primarily the result of an increase in net operating loss carryforwards (NOL carryforwards) in Denmark.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Available Carryforward Tax Losses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, we had NOL carryforwards of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;228.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; that can be carried forward indefinitely according to Danish Tax Authority regulations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We determine our uncertain tax positions based on whether and how much of a tax benefit taken by us in our tax filings is more likely than not to be sustained upon examination by the relevant income tax authorities. We determine whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not recognition threshold is calculated as the largest amount that is more than 50%.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by the Danish Tax Authority. As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, we have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recorded an uncertain tax position liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Tax filings in Denmark remain subject to examination by the Danish Tax Authority. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, tax years &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and forward were generally open to examination by the Danish Tax Authority.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Tax Credits&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of September 30, 2023, we have elected to claim a research and development tax credit on the federal income tax return filed for the year ended December 31, 2022. We plan to continue to make this election on the federal income tax return filed for the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; based on law currently enacted, and will continue to monitor impacts of proposed or enacted law changes on the cost to benefit of making this election. The Company included $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in research and development tax credits in the U.S. provision for income taxes for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Other Tax Matters&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes accrued interest related to unrecognized tax benefits and penalties as income tax expense in the statements of operations. The Company does not have any material unrecognized tax benefits which would affect the effective tax rate, if recognized. The Company does not have any unrecognized tax benefits which would reverse within the next twelve months.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is eligible for the Danish enhanced research and development tax allowance, providing for an increase in the deductible value of the amount of certain R&amp;amp;D expenditur&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;es. For 2019, the deduction is set at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;101.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. Furthermore, the deduction for R&amp;amp;D expenditures is set at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% for 2020 through 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% for 2023 through 2025, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% for 2026.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The tax allowance is reported as a reduction to research and development expense in the statements of operations. For the years ended December 31, 2023 and 2022, we applied for refundable tax credit of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million DKK for the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and a receivable was recorded for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in each year, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_4cade335-6889-4442-bd28-14fa9010205b">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our loss before provision for income taxes for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022 consisted of the following (in thousands): &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_2f319ece-38b4-4ee4-be60-85e8c01555df"
      unitRef="U_USD">2365000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_0488ffd4-c610-4193-86b9-653d096d668c"
      unitRef="U_USD">-1885000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_47445d03-4eff-47c8-b6b7-646c360e697d"
      unitRef="U_USD">-87596000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_215d28b2-18e2-4e75-a7a1-7acc20908254"
      unitRef="U_USD">-68300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_134a4fc0-a125-4692-9e22-184ec1bb05d8"
      unitRef="U_USD">-85231000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_7d7c122a-9eac-4c51-89f7-4ddef77174b6"
      unitRef="U_USD">-70185000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_ed782164-a249-4a7c-ae75-580c412c266f">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_312eeaa7-1d54-49b8-ba21-e580592e0bbf"
      unitRef="U_USD">439000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_5068468d-25d0-4e28-976c-f8fcba473410"
      unitRef="U_USD">1059000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_b6bacdae-a130-4461-b232-06be7969ee22"
      unitRef="U_USD">374000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_bbc94cb8-737e-4390-930e-18e53e6d87dc"
      unitRef="U_USD">86000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_58693a84-59eb-4d41-86c8-801ab9160439"
      unitRef="U_USD">39000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_0e90ae96-576b-44de-b498-72a954b435b1"
      unitRef="U_USD">52000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_c9cde8d5-de14-462e-a89f-1df8f8592fe7"
      unitRef="U_USD">852000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_4b27c451-a354-43b7-9472-e572ea912c6f"
      unitRef="U_USD">1197000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_e0ef86d9-c7db-432b-bcce-70eb78ce4865"
      unitRef="U_USD">76000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_2415e6ad-b1b1-4b3f-9ca9-caa93af575cc"
      unitRef="U_USD">76000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_27474a81-9b7c-4c4e-b307-2decfc286fb8"
      unitRef="U_USD">852000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_32a06260-589a-4422-be6a-a8dc0a7d3121"
      unitRef="U_USD">1273000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_428d1bea-30a0-48e4-a16b-dacd762db2f2">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The reconciliation of the statutory income tax rate to our effective income tax rate is as follows: &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.358%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.358%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax benefit at the statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Difference in tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;R&amp;amp;D Deduction&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prior period adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="3"
      id="F_9c0e4118-c5fd-4971-b4dd-b6823690452e"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="3"
      id="F_56e41415-ddb9-4548-bdd8-88972c6eca10"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="3"
      id="F_4abe14d9-8d5a-4d89-bc2c-17c045846015"
      unitRef="U_pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="3"
      id="F_6c429d5d-bb0a-417a-aa17-70bddd1afdf0"
      unitRef="U_pure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="3"
      id="F_2e75b193-f3b5-4f5a-b59d-a90d8700724d"
      unitRef="U_pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="3"
      id="F_1980029f-c101-4218-9065-0f49e5fde093"
      unitRef="U_pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <iobt:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="3"
      id="F_bc5df299-4233-4df7-866c-3a6f36a81cb3"
      unitRef="U_pure">0.011</iobt:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment>
    <iobt:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="3"
      id="F_d177e287-9742-45e1-b8a6-11ca9b7f7562"
      unitRef="U_pure">0.04</iobt:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="3"
      id="F_fda7427c-3acf-40ef-9c47-726c81d5651f"
      unitRef="U_pure">-0.247</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="3"
      id="F_ba7608a9-84ae-49e1-ac21-ce1e9e97edf1"
      unitRef="U_pure">-0.274</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="3"
      id="F_b23666a3-757b-47cb-b195-c621fd319b6e"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="3"
      id="F_1f90b3d9-c303-4f0b-8087-dde8d28c2597"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="3"
      id="F_44b37494-f6b0-441b-a3b0-3524e8be2daf"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="3"
      id="F_e7a02e15-39bf-40e8-b097-a5d585a6740c"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="3"
      id="F_af54fac7-7554-487f-9722-2f82d947028d"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="3"
      id="F_e5baa205-db05-4053-a317-426860c00cf0"
      unitRef="U_pure">-0.018</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_a36d631e-8a7a-4fac-b2d9-ef3e733d9f5c">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The principal components of the Company&#x2019;s deferred tax assets consisted of the following (in thousands): &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ROU Lease Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ROU Lease Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax asset (liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2017, the U.S. enacted the Tax Cuts and Jobs Act (the 2017 Tax Act), which contained a provision that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022. Previously, these expenses could be deducted in the year incurred. The implementation of this provision increased our deferred tax asset and valuation allowance by approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_3c3cd572-c90b-4464-8f42-f7dcc812857d"
      unitRef="U_USD">50343000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_098e4a0b-f6f8-4820-beef-07a03bc77d04"
      unitRef="U_USD">31338000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_50277603-138f-4cea-8b3e-718b1cb3fe44"
      unitRef="U_USD">3602000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_ec40f5ac-f071-4de0-b36f-451aa2665a44"
      unitRef="U_USD">1828000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <iobt:DeferredTaxAssetsAccruedCompensation
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_6bdd853f-8308-40a7-a513-69f7e1f464b8"
      unitRef="U_USD">33000</iobt:DeferredTaxAssetsAccruedCompensation>
    <iobt:DeferredTaxAssetsAccruedCompensation
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_d3fa4cd1-33a7-402c-9efe-bb56ad017f47"
      unitRef="U_USD">21000</iobt:DeferredTaxAssetsAccruedCompensation>
    <iobt:DeferredTaxAssetsRightOFuseLeaseLiability
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_cd10d748-255b-4a6f-9b26-643e564c18ed"
      unitRef="U_USD">526000</iobt:DeferredTaxAssetsRightOFuseLeaseLiability>
    <iobt:DeferredTaxAssetsRightOFuseLeaseLiability
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_ace9f87e-237c-479a-a13f-51dc64488d8f"
      unitRef="U_USD">618000</iobt:DeferredTaxAssetsRightOFuseLeaseLiability>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_5575cb3f-f49c-4aaa-b347-a022cf41605e"
      unitRef="U_USD">3348000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_2fdf3638-5a68-48f9-af16-bff372e37471"
      unitRef="U_USD">1231000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_fec60121-53c5-42b2-b35e-3b174908c129"
      unitRef="U_USD">529000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_4b567c62-dce1-4def-819f-9d4e2da76236"
      unitRef="U_USD">529000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_9a57de5b-db8b-4363-995b-b1752d5ce52f"
      unitRef="U_USD">58381000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_5d6dbfe5-1fe8-4380-a898-bbd3183ba246"
      unitRef="U_USD">35565000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_67e1de63-d2ab-4143-a33c-f0781bd895d2"
      unitRef="U_USD">57902000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_5e6c54d5-2ab1-4970-8977-f07d61d4f2fe"
      unitRef="U_USD">34984000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_fb822042-1f92-421a-b27d-b187b930ba9b"
      unitRef="U_USD">479000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_c943043a-51a8-42e7-80dd-56ada93b3e09"
      unitRef="U_USD">581000</us-gaap:DeferredTaxAssetsNet>
    <iobt:DeferredTaxLiabilitiesRightOfUseLeaseAsset
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_1be31fb7-d64f-4247-93be-56877a838c97"
      unitRef="U_USD">441000</iobt:DeferredTaxLiabilitiesRightOfUseLeaseAsset>
    <iobt:DeferredTaxLiabilitiesRightOfUseLeaseAsset
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_f5cdb68c-2a52-426c-b5e8-1d099285f77b"
      unitRef="U_USD">567000</iobt:DeferredTaxLiabilitiesRightOfUseLeaseAsset>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_e3f0accb-2d96-46d8-94dd-75d47bd9cf26"
      unitRef="U_USD">26000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_6dbf9d4d-d448-4478-9289-e4e3a20d6e0e"
      unitRef="U_USD">13000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_85bab26a-241d-412e-a410-072c42307608"
      unitRef="U_USD">12000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_abeaf71c-c73b-4c22-9062-7214678e5915"
      unitRef="U_USD">1000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-3"
      id="F_1cd336c0-f289-4ded-84b3-fbfea5302570"
      unitRef="U_USD">479000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="-3"
      id="F_f6d148e9-deda-4696-ae62-4a891d3b56f9"
      unitRef="U_USD">581000</us-gaap:DeferredIncomeTaxLiabilities>
    <iobt:ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-5"
      id="F_12b03a91-6726-410c-8ae8-ffaabf939007"
      unitRef="U_USD">2100000</iobt:ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017>
    <iobt:ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-5"
      id="F_c2f1989d-5bde-488e-beae-941007207642"
      unitRef="U_USD">1200000</iobt:ValuationAllowanceDeferredTaxAssetChangeInAmountDueToTaxCutsAndJobsActOf2017>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-5"
      id="F_5e31360c-6ca3-4597-b460-5d9d66073a9b"
      unitRef="U_USD">22900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-5"
      id="F_5fc03aee-c179-4080-b1bf-1069e1630762"
      unitRef="U_USD">19900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="-5"
      id="F_9dde44f7-063c-418b-8a59-e7e161c3fcc5"
      unitRef="U_USD">228500000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_57eb6f8c-679a-491b-8e02-004bcdd10820"
      decimals="INF"
      id="F_0e7295d9-0ec2-4df3-bd3b-588a0702e18b"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_a8f1b860-b4ba-46d1-b3a5-26e729a655d6"
      decimals="INF"
      id="F_852c9b4a-5026-40e1-8339-e127780d5a63"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:OpenTaxYear
      contextRef="C_62f128f9-8dcd-483d-9972-ffa3ab6dd713"
      id="F_3e227eb0-9ecd-4ca9-a554-d71d28ccb093">2020</us-gaap:OpenTaxYear>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-5"
      id="F_3d61b573-4630-4ff4-96f9-1325fa4be992"
      unitRef="U_USD">1000000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="C_05adc53f-1ee4-4206-b227-537d28cde4b2"
      decimals="3"
      id="F_06ded1ee-a17c-4500-abf8-ad48d841095d"
      unitRef="U_pure">1.015</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="C_1bdcb713-0037-4abc-ba55-93260da29f6f"
      decimals="2"
      id="F_fcb8b67c-7acb-44f4-8985-a071b345189a"
      unitRef="U_pure">1.30</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="C_93ef2e83-0050-441a-9dc6-7635a9140a67"
      decimals="2"
      id="F_c31542a1-a313-4f71-b576-d147ab13bee0"
      unitRef="U_pure">1.08</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="C_aba91903-9247-448c-a45a-f748af1aed15"
      decimals="2"
      id="F_25447d21-fd0e-45b3-b621-4bfde7f2e134"
      unitRef="U_pure">1.10</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <iobt:RefundableTaxCredit
      contextRef="C_61743499-6fd4-4641-8e5f-157d373726ff"
      decimals="-5"
      id="F_345f1e30-1bb1-428b-b015-e525e2ea2cb8"
      unitRef="U_DKK">25000000</iobt:RefundableTaxCredit>
    <iobt:RefundableTaxCredit
      contextRef="C_0ea23d1e-bc0a-42c8-afab-71532c2b7804"
      decimals="-5"
      id="F_3a0f76dc-8e9b-4a11-8884-e37ad97fccd8"
      unitRef="U_DKK">25000000</iobt:RefundableTaxCredit>
    <iobt:RefundableTaxCreditReceivable
      contextRef="C_0ea23d1e-bc0a-42c8-afab-71532c2b7804"
      decimals="-5"
      id="F_9e8bfa8a-64c6-411b-acc3-26d0c140ec90"
      unitRef="U_USD">800000</iobt:RefundableTaxCreditReceivable>
    <iobt:RefundableTaxCreditReceivable
      contextRef="C_61743499-6fd4-4641-8e5f-157d373726ff"
      decimals="-5"
      id="F_8cb3d96a-6970-4704-bb99-499c7f77c69e"
      unitRef="U_USD">800000</iobt:RefundableTaxCreditReceivable>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_c04074dd-970a-434e-ba88-3572720297d1">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;13. Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic and diluted net loss per common share is calculated as follows (in thousands except share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.389%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.401%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.904%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.401%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.904%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss attributable to common shareholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average number of shares used in computing net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,539,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,815,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per common share, as their effect is anti-dilutive:&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,851,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,920,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants issued in Private Placement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_f0cd0ccf-f91f-4dd8-9fe4-45087ce5eb0b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic and diluted net loss per common share is calculated as follows (in thousands except share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.389%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.401%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.904%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.401%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.904%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss attributable to common shareholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average number of shares used in computing net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,539,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,815,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_8995d2df-8f82-4177-b764-bda0421919c0"
      unitRef="U_USD">-86083000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_65cf6d85-e118-4768-b202-d3745b5ca186"
      unitRef="U_USD">-71458000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="-3"
      id="F_09e1dfe9-7d15-4957-b699-57cd50ec4c89"
      unitRef="U_USD">-86083000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="-3"
      id="F_fdf2ac06-7869-4713-a3f2-2ada396f4b0e"
      unitRef="U_USD">-71458000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="2"
      id="F_a9aaaa92-92b0-46f0-bcf0-f0efdbea5bb5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="2"
      id="F_888016a0-3c43-4b8e-981e-68a2f9c467e8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="2"
      id="F_f48e93d0-f034-46e5-b53d-b8c135f76311"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="2"
      id="F_0161d104-d2a8-4cff-98fd-0557ed0b4b4c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="0"
      id="F_ca09b15f-b5b4-4fb3-b478-2c4fe57eefa7"
      unitRef="U_shares">43539976</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      decimals="0"
      id="F_e82976c0-1555-404e-b042-7b5df2b5bcb3"
      unitRef="U_shares">43539976</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="0"
      id="F_a84592d8-b545-43dd-93f0-018c2a18f033"
      unitRef="U_shares">28815267</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_93ba4994-82a5-4ef1-9265-2fadebfc3ace"
      decimals="0"
      id="F_77d29725-fb38-4a1a-8819-2f8a56425dc1"
      unitRef="U_shares">28815267</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_26056ab7-d242-4edb-addd-0adcaa0b4db8">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,851,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,920,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants issued in Private Placement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0d4b831b-94cf-4ac9-aae8-23f925e98a73"
      decimals="0"
      id="F_34f6cbfb-0f54-4306-85d1-d486fadd3056"
      unitRef="U_shares">5851923</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6a5e0744-7a0e-42a8-87f6-2990329c4ad7"
      decimals="0"
      id="F_322a41fb-ea00-4177-b663-9242bb2b5dce"
      unitRef="U_shares">3920172</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5cfd6318-0a41-4064-a4cb-7e43fe8305a2"
      decimals="0"
      id="F_4e850832-54d6-4921-82a6-3c19693306a2"
      unitRef="U_shares">37065647</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_2445c1c9-369b-4c39-93fc-0bb73e29ab07"
      id="F_1b910fce-6b5e-4e95-b50a-9582cd6478a8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;14. Subsequent Events&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have evaluated subsequent events through the date on which the consolidated financial statements were issued. The Company has concluded that no subsequent events have occurred that require disclosure to the consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
